PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zielke, C; Kosik, O; Ainalem, ML; Lovegrove, A; Stradner, A; Nilsson, L				Zielke, Claudia; Kosik, Ondrej; Ainalem, Marie-Louise; Lovegrove, Alison; Stradner, Anna; Nilsson, Lars			Characterization of cereal beta-glucan extracts from oat and barley and quantification of proteinaceous matter	PLOS ONE			English	Article							FIELD-FLOW FRACTIONATION; MOLECULAR-WEIGHT; PHYSICOCHEMICAL PROPERTIES; PHYSICAL-PROPERTIES; SOLUTION BEHAVIOR; MOLAR-MASS; PART I.; WATER; MACROMOLECULES; SOLUBILITY	An extraction method for mixed-linkage beta-glucan from oat and barley was developed in order to minimize the effect of extraction on the beta-glucan structure. beta-Glucan were characterized in terms of molecular size and molar mass distributions using asymmetric flow field flow fractionation (AF4) coupled to multiangle light scattering (MALS), differential refractive index (dRI) and fluorescence (FL) detection. The carbohydrate composition of the extracts was analysed using polysaccharide analysis by carbohydrate gel electrophoresis (PACE) and high-performance anion-exchange chromatography (HPAEC). Whether there were any proteinaceous moieties linked to beta-glucan was also examined. Purified extracts contained 65% and 53% 6-glucan for oats and barley, respectively. The main impurities were degradation products of starch. The extracts contained high molecular weight beta-glucan (10(5)-10(8) g/ mol) and large sizes (root-mean-square radii from 20 to 140 nm). No proteins covalently bound to beta-glucan were detected; therefore, any suggested functionality of proteins regarding the health benefits of beta-glucan can be discounted.	[Zielke, Claudia; Nilsson, Lars] Lund Univ, Dept Food Technol Engn & Nutr, Lund, Sweden; [Kosik, Ondrej; Lovegrove, Alison] Rothamsted Res, Dept Plant Biol & Crop Sci, Harpenden, Herts, England; [Ainalem, Marie-Louise] European Spallat Source ESS AB, Lund, Sweden; [Stradner, Anna] Lund Univ, Dept Phys Chem, Lund, Sweden	Lund University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; European Spallation Source (ESS); Lund University	Zielke, C (corresponding author), Lund Univ, Dept Food Technol Engn & Nutr, Lund, Sweden.	claudia.zielke@food.lth.se	Stradner, Anna/B-5195-2015; Zielke, Claudia/I-5864-2019; Kosik, Ondrej/AAR-1206-2021	Stradner, Anna/0000-0003-3310-3412; Kosik, Ondrej/0000-0003-3117-0224; Zielke, Claudia/0000-0003-4654-4903	Swedish research council (VR), Stockholm, Sweden; Biotechnology and Biological Sciences Research Council of the United Kingdom; European Spallation Source ESS AB; BBSRC [BB/I00582X/1, BB/J019380/1, BBS/E/C/00005206, BBS/E/C/000I0250] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005206] Funding Source: researchfish	Swedish research council (VR), Stockholm, Sweden(Swedish Research Council); Biotechnology and Biological Sciences Research Council of the United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Spallation Source ESS AB; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Financial support was provided by the Swedish research council (VR), Stockholm, Sweden and from the Biotechnology and Biological Sciences Research Council of the United Kingdom. The sponsors had no influence on study design, collection, analysis and interpretation of data, nor in writing the manuscript and neither in the decision to submit the article for publication. European Spallation Source ESS AB, provided support in the form of salaries for author MLA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACKER L., 1955, Zeitschrift fur Lebensmittel-Untersuchung und -Forschung, V100, P180, DOI 10.1007/BF01713465; Ahmad A, 2012, CRIT REV FOOD SCI, V52, P201, DOI 10.1080/10408398.2010.499806; Ahmad A, 2010, INT J BIOL MACROMOL, V46, P304, DOI 10.1016/j.ijbiomac.2010.01.002; Ajayi AO, 2007, AFR J BIOTECHNOL, V6, P1181; Alftren J, 2012, FOOD HYDROCOLLOID, V26, P54, DOI 10.1016/j.foodhyd.2011.04.008; Alves LA, 2007, J CHEM ENG DATA, V52, P2166, DOI 10.1021/je700177n; Andersson M, 2003, ANAL CHEM, V75, P4279, DOI 10.1021/ac030128+; Andersson M, 2001, ANAL CHEM, V73, P4852, DOI 10.1021/ac0104734; AUTIO K, 1992, FOOD HYDROCOLLOID, V5, P513, DOI 10.1016/S0268-005X(09)80121-5; Beer MU, 1997, CEREAL CHEM, V74, P476, DOI 10.1094/CCHEM.1997.74.4.476; BERRY GC, 1966, J CHEM PHYS, V44, P4550, DOI 10.1063/1.1726673; CALDWELL KD, 1979, SEPAR SCI TECHNOL, V14, P935, DOI 10.1080/01496397908058103; Cui SW, 2009, STRUCT CHEM, V20, P291, DOI 10.1007/s11224-009-9441-0; DAWKINS NL, 1993, J FOOD SCI, V58, P562, DOI 10.1111/j.1365-2621.1993.tb04324.x; Food and Drug Administration S, 2008, FED REGISTER, V73, P47828; FORREST IS, 1977, J I BREWING, V83, P279, DOI 10.1002/j.2050-0416.1977.tb03809.x; GIDDINGS JC, 1993, SCIENCE, V260, P1456, DOI 10.1126/science.8502990; Gomez C, 1997, CARBOHYD POLYM, V34, P141, DOI 10.1016/S0144-8617(97)00134-3; Gong XC, 2012, J CHEM ENG DATA, V57, P3264, DOI 10.1021/je300885g; Goubet F, 2009, PLANT J, V60, P527, DOI 10.1111/j.1365-313X.2009.03977.x; Hakansson A, 2012, J CHROMATOGR A, V1253, P120, DOI 10.1016/j.chroma.2012.07.029; Hakansson A, 2012, CARBOHYD POLYM, V87, P518, DOI 10.1016/j.carbpol.2011.08.014; Immerstrand T, 2009, CEREAL CHEM, V86, P601, DOI 10.1094/CCHEM-86-6-0601; Izydorczyk MS, 2008, FOOD RES INT, V41, P850, DOI 10.1016/j.foodres.2008.04.001; JOHANSEN HN, 1993, J AGR FOOD CHEM, V41, P2347, DOI 10.1021/jf00036a025; Kim S, 2006, J FOOD COMPOS ANAL, V19, P466, DOI 10.1016/j.jfca.2005.11.006; Kosik O, 2012, METHOD ENZYMOL, V510, P51, DOI 10.1016/B978-0-12-415931-0.00004-5; Lazaridou A, 2007, J CEREAL SCI, V46, P101, DOI 10.1016/j.jcs.2007.05.003; Li W, 2011, FOOD HYDROCOLLOID, V25, P189, DOI 10.1016/j.foodhyd.2010.02.005; Nilsson L, 2013, FOOD HYDROCOLLOID, V30, P1, DOI 10.1016/j.foodhyd.2012.04.007; Papageorgiou M, 2005, J CEREAL SCI, V42, P213, DOI 10.1016/j.jcs.2005.03.002; Perez-Rea D, 2015, ANAL BIOANAL CHEM, V407, P4315, DOI 10.1007/s00216-015-8611-8; Robyt JF, 2009, FOOD SCI TECH-INT SE, P237, DOI 10.1016/B978-0-12-746275-2.00007-0; Tugel I, 2015, J I BREWING, V121, P44, DOI 10.1002/jib.195; U.S. Food and Drug Administration, 1992, FED REGISTER, V62, P15343; Ulmius M, 2012, FOOD CHEM, V130, P536, DOI 10.1016/j.foodchem.2011.07.066; Ulmius M, 2012, FOOD HYDROCOLLOID, V26, P175, DOI 10.1016/j.foodhyd.2011.05.004; VARUM KM, 1988, CARBOHYD POLYM, V9, P103, DOI 10.1016/0144-8617(88)90008-2; WAHLUND KG, 1987, ANAL CHEM, V59, P1332, DOI 10.1021/ac00136a016; Webster F. H., 2011, OATS CHEM TECHNOLOGY; Wolever TMS, 2010, AM J CLIN NUTR, V92, P723, DOI 10.3945/ajcn.2010.29174; Wood PJ, 2004, TRENDS FOOD SCI TECH, V15, P313, DOI 10.1016/j.tifs.2003.03.001; WOOD PJ, 1977, CEREAL CHEM, V54, P524; Zhou MX, 2000, J SCI FOOD AGR, V80, P1486, DOI 10.1002/1097-0010(200008)80:10<1486::AID-JSFA668>3.3.CO;2-R	44	24	26	0	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2017	12	2							e0172034	10.1371/journal.pone.0172034	http://dx.doi.org/10.1371/journal.pone.0172034			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BA	28196092	Green Published, Green Submitted, gold			2023-01-03	WOS:000394423900046
J	Hradilova, N; Sadilkova, L; Palata, O; Mysikova, D; Mrazkova, H; Lischke, R; Spisek, R; Adkins, I				Hradilova, Nada; Sadilkova, Lenka; Palata, Ondrej; Mysikova, Dagmar; Mrazkova, Hana; Lischke, Robert; Spisek, Radek; Adkins, Irena			Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy	PLOS ONE			English	Article							CARCINOEMBRYONIC ANTIGEN; TUMOR-CELLS; IMMUNE-RESPONSES; CLINICAL-TRIAL; PHASE-I; PEPTIDE; IMMUNIZATION; DEATH; THERAPY; GENES	High hydrostatic pressure (HHP) induces immunogenic death of tumor cells which confer protective anti-tumor immunity in vivo. Moreover, DC pulsed with HHP-treated tumor cells induced therapeutic effect in mouse cancer model. In this study, we tested the immunogenicity, stability and T cell stimulatory activity of human monocyte-derived dendritic cell (DC)based HHP lung cancer vaccine generated in GMP compliant serum free medium using HHP 250 MPa. DC pulsed with HHP-killed lung cancer cells and poly(I:C) enhanced DC maturation, chemotactic migration and production of pro-inflammatory cytokines after 24h. Moreover, DC-based HHP lung cancer vaccine showed functional plasticity after transfer into serum-containing media and stimulation with LPS or CD40L after additional 24h. LPS and CD40L stimulation further differentially enhanced the expression of costimulatory molecules and production of IL-12p70. DC-based HHP lung cancer vaccine decreased the number of CD4(+) CD25(+) Foxp3(+) T regulatory cells and stimulated IFN-gamma-producing tumor antigenspecific CD4(+) and CD8(+) T cells from non-small cell lung cancer (NSCLC) patients. Tumor antigen specific CD8(+) and CD4(+) T cell responses were detected in NSCLC patient's against a selected tumor antigens expressed by lung cancer cell lines used for the vaccine generation. We also showed for the first time that protein antigen from HHP-killed lung cancer cells is processed and presented by DC to CD8(+) T cells. Our results represent important preclinical data for ongoing NSCLC Phase I/II clinical trial using DC-based active cellular immunotherapy (DCVAC/LuCa) in combination with chemotherapy and immune enhancers.	[Hradilova, Nada; Sadilkova, Lenka; Palata, Ondrej; Spisek, Radek; Adkins, Irena] SOTIO, Prague, Czech Republic; [Hradilova, Nada; Palata, Ondrej; Spisek, Radek; Adkins, Irena] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic; [Hradilova, Nada; Palata, Ondrej; Mysikova, Dagmar; Mrazkova, Hana; Lischke, Robert; Spisek, Radek; Adkins, Irena] Univ Hosp Motol, Prague, Czech Republic; [Mysikova, Dagmar; Mrazkova, Hana; Lischke, Robert] Charles Univ Prague, Fac Med 1, Dept Surg 3, Thorac & Lung Transplantat Div, Prague, Czech Republic	Charles University Prague; Motol University Hospital; Charles University Prague	Adkins, I (corresponding author), SOTIO, Prague, Czech Republic.; Adkins, I (corresponding author), Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic.; Adkins, I (corresponding author), Univ Hosp Motol, Prague, Czech Republic.	adkins@sotio.com	Palata, Ondřej/N-2764-2017; Faltova, Hana/D-6279-2017; Lischke, Robert/E-6087-2017; Mysikova, Dagmar/D-7011-2017	Palata, Ondřej/0000-0003-3264-9384; Faltova, Hana/0000-0003-2221-4950; Lischke, Robert/0000-0002-0578-1833; Mysikova, Dagmar/0000-0002-0400-6253	Charles Universityin Prague, Czech Republic, project GAUK [458216]	Charles Universityin Prague, Czech Republic, project GAUK	The authors declare that this study was supported by Sotio a.s. This study was further supported by the Charles Universityin Prague, Czech Republic, project GAUK No.458216 granted to OP. This does not alterouradherence to PLOS ONE policies on sharing data and materials. The specific roles of these authors are articulated in the 'author contributions' section.	Abdi K, 2012, J IMMUNOL, V188, P5981, DOI 10.4049/jimmunol.1102868; Adkins I, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.968434; Alanio C, 2010, BLOOD, V115, P3718, DOI 10.1182/blood-2009-10-251124; Atanackovic D, 2004, J IMMUNOL, V172, P3289, DOI 10.4049/jimmunol.172.5.3289; Babatz J, 2006, CANCER IMMUNOL IMMUN, V55, P268, DOI 10.1007/s00262-005-0021-x; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Brunsvig PF, 2011, CLIN CANCER RES, V17, P6847, DOI 10.1158/1078-0432.CCR-11-1385; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chang GC, 2005, CANCER-AM CANCER SOC, V103, P763, DOI 10.1002/cncr.20843; Coulie PG, 2005, CURR OPIN IMMUNOL, V17, P320, DOI 10.1016/j.coi.2005.03.002; Datta Jashodeep, 2014, Yale Journal of Biology and Medicine, V87, P491; Delamarre L, 2003, J EXP MED, V198, P111, DOI 10.1084/jem.20021542; Engell-Noerregaard L, 2013, CANCER IMMUNOL IMMUN, V62, P17, DOI 10.1007/s00262-012-1306-5; Fucikova J, 2014, INT J CANCER, V135, P1165, DOI 10.1002/ijc.28766; Fucikova J, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-223; Grunwald C, 2006, INT J CANCER, V118, P2522, DOI 10.1002/ijc.21669; Gure AO, 2005, CLIN CANCER RES, V11, P8055, DOI 10.1158/1078-0432.CCR-05-1203; He XS, 2003, J INFECT DIS, V187, P1075, DOI 10.1086/368218; Hirschowitz EA, 2004, J CLIN ONCOL, V22, P2808, DOI 10.1200/JCO.2004.01.074; Hirschowitz EA, 2007, LUNG CANCER, V57, P365, DOI 10.1016/j.lungcan.2007.04.002; Hirschowitz EA, 2011, J THORAC ONCOL, V6, P169, DOI 10.1097/JTO.0b013e3181fb5c22; Karanikas V, 2008, CANCER BIOL THER, V7, P345, DOI 10.4161/cbt.7.3.5424; Kontani K, 2003, INT J MOL MED, V12, P493; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Mellstedt H, 2011, LUNG CANCER, V73, P11, DOI 10.1016/j.lungcan.2011.02.023; Mikyskova R, 2016, INT J ONCOL, V48, P953, DOI 10.3892/ijo.2015.3314; Morse MA, 2005, CLIN CANCER RES, V11, P3017, DOI 10.1158/1078-0432.CCR-04-2172; MUKHERJI B, 1995, P NATL ACAD SCI USA, V92, P8078, DOI 10.1073/pnas.92.17.8078; Perez-Diez A, 2007, BLOOD, V109, P5346, DOI 10.1182/blood-2006-10-051318; Perroud MW, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-65; Rouas R, 2004, INT IMMUNOL, V16, P767, DOI 10.1093/intimm/dxh077; Sheikh NA, 2013, CANCER IMMUNOL IMMUN, V62, P137, DOI 10.1007/s00262-012-1317-2; Skachkova O. V., 2013, Experimental Oncology, V35, P109; Tajima K, 2003, LUNG CANCER-J IASLC, V42, P23, DOI 10.1016/S0169-5002(03)00244-7; Takahashi H, 2013, EUR J CANCER, V49, P852, DOI 10.1016/j.ejca.2012.11.005; Takahashi N, 2012, CANCER SCI, V103, P150, DOI 10.1111/j.1349-7006.2011.02106.x; Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269; Truxova I, 2014, IMMUNOL LETT, V160, P39, DOI 10.1016/j.imlet.2014.03.010; Ueda Y, 2004, INT J ONCOL, V24, P909; Um SJ, 2010, LUNG CANCER, V70, P188, DOI 10.1016/j.lungcan.2010.02.006; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Yannelli JR, 2005, LUNG CANCER, V47, P337, DOI 10.1016/j.lungcan.2004.08.008	45	22	25	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2017	12	2							e0171539	10.1371/journal.pone.0171539	http://dx.doi.org/10.1371/journal.pone.0171539			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK9KV	28187172	Green Published, gold, Green Submitted			2023-01-03	WOS:000394244300028
J	Hyman, DM; Taylor, BS; Baselga, J				Hyman, David M.; Taylor, Barry S.; Baselga, Jose			Implementing Genome-Driven Oncology	CELL			English	Review							CELL LUNG-CANCER; CHRONIC MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; TARGETED THERAPY; PROSTATE-CANCER; OPEN-LABEL; ACQUIRED-RESISTANCE; PRECISION MEDICINE; COLORECTAL-CANCER; PD-1 BLOCKADE	Early successes in identifying and targeting individual oncogenic drivers, together with the increasing feasibility of sequencing tumor genomes, have brought forth the promise of genomedriven oncology care. As we expand the breadth and depth of genomic analyses, the biological and clinical complexity of its implementation will be unparalleled. Challenges include target credentialing and validation, implementing drug combinations, clinical trial designs, targeting tumor heterogeneity, and deploying technologies beyond DNA sequencing, among others. We review how contemporary approaches are tackling these challenges and will ultimately serve as an engine for biological discovery and increase our insight into cancer and its treatment.	[Hyman, David M.; Baselga, Jose] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA; [Taylor, Barry S.; Baselga, Jose] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA; [Taylor, Barry S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10065 USA; [Taylor, Barry S.] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10065 USA; [Hyman, David M.; Baselga, Jose] Weill Cornell Med Coll, 1300 York Ave, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Baselga, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.; Baselga, J (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA.; Baselga, J (corresponding author), Weill Cornell Med Coll, 1300 York Ave, New York, NY 10065 USA.	baselgaj@mskcc.org			Prostate Cancer Foundation; Sontag Foundation; Josie Robertson Foundation; Breast Cancer Research Foundation; Geoffrey Beene Cancer Research Center; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; Cycle for Survival; National Institutes of Health [R01 CA190642-01A1, P50 CA092629, R01 CA207244, U54 OD202355, P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA207244, R01CA190642, R01CA204749, P50CA092629] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U54OD020355] Funding Source: NIH RePORTER	Prostate Cancer Foundation; Sontag Foundation; Josie Robertson Foundation; Breast Cancer Research Foundation; Geoffrey Beene Cancer Research Center; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; Cycle for Survival; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Alison M. Schram and Maurizio Scaltriti for their critical reading of this manuscript, Jianjiong Gao and Nikolaus Schultz for clinical annotation of sequenced specimens, and Scott Johnson for assistance with medical graphics. The authors acknowledge support from the Prostate Cancer Foundation, the Sontag Foundation, the Josie Robertson Foundation, the Breast Cancer Research Foundation, the Geoffrey Beene Cancer Research Center, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Cycle for Survival, and National Institutes of Health awards R01 CA190642-01A1 (J.B.), P50 CA092629 (B.S.T.), R01 CA207244 (D.M.H. and B.S.T.), U54 OD202355 (B.S.T.), and P30 CA008748. J.B. is a member of the scientific advisory board of GRAIL.	Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beltran H, 2015, JAMA ONCOL, V1, P466, DOI 10.1001/jamaoncol.2015.1313; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Bower H, 2016, J CLIN ONCOL, V34, P2851, DOI 10.1200/JCO.2015.66.2866; Brenan L, 2016, CELL REP, V17, P1171, DOI 10.1016/j.celrep.2016.09.061; Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8; Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cunanan KM, 2017, J CLIN ONCOL, V35, P271, DOI 10.1200/JCO.2016.69.9751; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Drilon A, 2016, LANCET ONCOL, V17, P1653, DOI 10.1016/S1470-2045(16)30562-9; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Eubank MH, 2016, J AM MED INFORM ASSN, V23, P777, DOI 10.1093/jamia/ocw020; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hyman DM, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-PD5-05; Hyman D. M., 2015, AM ASS CANC RES S2, V14, pB109, DOI DOI 10.1158/1535-7163.TARG-15-B109; Hyman DM, 2015, DRUG DISCOV TODAY, V20, P1422, DOI 10.1016/j.drudis.2015.08.005; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kim E, 2016, CANCER DISCOV, V6, P714, DOI 10.1158/2159-8290.CD-16-0160; Kitzman JO, 2015, NAT METHODS, V12, P203, DOI [10.1038/NMETH.3223, 10.1038/nmeth.3223]; Kivioja T, 2012, NAT METHODS, V9, P72, DOI [10.1038/NMETH.1778, 10.1038/nmeth.1778]; LaFave LM, 2015, NAT MED, V21, P1344, DOI 10.1038/nm.3947; Lai A, 2015, J MED CHEM, V58, P4888, DOI 10.1021/acs.jmedchem.5b00054; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lanman RB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140712; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Melnikov A, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku511; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165; Milojkovic D, 2009, CLIN CANCER RES, V15, P7519, DOI 10.1158/1078-0432.CCR-09-1068; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161; Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283; Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056/NEJMoa0912614; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schrader KA, 2016, JAMA ONCOL, V2, P104, DOI 10.1001/jamaoncol.2015.5208; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Siu LL, 2016, NAT MED, V22, P464, DOI 10.1038/nm.4089; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Tabernero J, 2015, J CLIN ONCOL, V33, P3401, DOI 10.1200/JCO.2014.60.7341; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Tiacci E, 2015, NEW ENGL J MED, V373, P1733, DOI 10.1056/NEJMoa1506583; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Vaishnavi A, 2015, CANCER DISCOV, V5, P25, DOI 10.1158/2159-8290.CD-14-0765; Voest EE, 2016, CANCER DISCOV, V6, P130, DOI 10.1158/2159-8290.CD-15-1321; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yang JCH, 2015, LANCET ONCOL, V16, P830, DOI 10.1016/S1470-2045(15)00026-1; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054	87	281	286	6	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	2017	168	4					584	599		10.1016/j.cell.2016.12.015	http://dx.doi.org/10.1016/j.cell.2016.12.015			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN8VJ	28187282	Green Accepted, Bronze			2023-01-03	WOS:000396277600011
J	Sharma, P; Hu-Lieskovan, S; Wargo, JA; Ribas, A				Sharma, Padmanee; Hu-Lieskovan, Siwen; Wargo, Jennifer A.; Ribas, Antoni			Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy	CELL			English	Review							REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; ANTITUMOR IMMUNE-RESPONSES; PD-1 BLOCKADE; CHECKPOINT BLOCKADE; TGF-BETA; ADVANCED MELANOMA; BRAF INHIBITION; CTLA-4 BLOCKADE; INDOLEAMINE 2,3-DIOXYGENASE	Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.	[Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol & Immunol, Houston, TX 77030 USA; [Hu-Lieskovan, Siwen; Ribas, Antoni] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; [Hu-Lieskovan, Siwen; Ribas, Antoni] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol & Immunol, Houston, TX 77030 USA.; Ribas, A (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.; Ribas, A (corresponding author), Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.	padsharma@mdanderson.org; aribas@mednet.ucla.edu			Parker Institute for Cancer Immunotherapy; NIH/NCI [R01 CA1633793, R35 CA197633, P01 CA168585]; Cancer Prevention Research in Texas (CPRIT) [RP120108]; Ressler Family Fund; Garcia-Corsini Family Fund; Samuels Family Fund; Grimaldi Family Fund; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant [SU2C-AACR-DT1012]; American Society of Clinical Oncology (ASCO); Tower Cancer Research Foundation Grant; Hope Foundation; UCLA KL2 Award; NATIONAL CANCER INSTITUTE [R01CA163793, P30CA016672, K08CA160692] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001881, UL1TR000124] Funding Source: NIH RePORTER	Parker Institute for Cancer Immunotherapy; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research in Texas (CPRIT); Ressler Family Fund; Garcia-Corsini Family Fund; Samuels Family Fund; Grimaldi Family Fund; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant; American Society of Clinical Oncology (ASCO); Tower Cancer Research Foundation Grant; Hope Foundation; UCLA KL2 Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This research was supported by the Parker Institute for Cancer Immunotherapy, NIH/NCI grants R01 CA1633793 (P.S.), R35 CA197633, and P01 CA168585 (A.R.), Cancer Prevention Research in Texas (CPRIT) grant RP120108 (P.S.), the Ressler Family Fund, the Garcia-Corsini Family Fund, the Samuels Family Fund, and the Grimaldi Family Fund (A.R.), and a Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant (SU2C-AACR-DT1012; P.S. and A.R.). S.H.-L. was supported by a Career Development Award from the American Society of Clinical Oncology (ASCO), a Tower Cancer Research Foundation Grant, a Dr. Charles Coltman Fellowship Award from the Hope Foundation, and a UCLA KL2 Award.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Allard B, 2014, INT J CANCER, V134, P1466, DOI 10.1002/ijc.28456; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Beavis PA, 2015, ONCOIMMUNOLOGY, V4; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Berrien-Elliott MM, 2013, CANCER RES, V73, P605, DOI 10.1158/0008-5472.CAN-12-2179; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Bradley SD, 2015, CANCER IMMUNOL RES, V3, P602, DOI 10.1158/2326-6066.CIR-15-0030; Bronte V, 1998, J IMMUNOL, V161, P5313; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Burnet F M, 1971, Transplant Rev, V7, P3; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415; Chang DK, 2012, MOL CANCER THER, V11, P2451, DOI 10.1158/1535-7163.MCT-12-0278; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chaudhary B, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030028; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chodon T, 2014, CLIN CANCER RES, V20, P2457, DOI 10.1158/1078-0432.CCR-13-3017; Coley W. B., 1910, P ROY SOC MED, V3, P1, DOI DOI 10.1177/003591571000301601; Comin-Anduix B, 2010, CLIN CANCER RES, V16, P6040, DOI 10.1158/1078-0432.CCR-10-1911; Cooper ZA, 2014, CANCER IMMUNOL RES, V2, P643, DOI 10.1158/2326-6066.CIR-13-0215; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das R, 2015, J IMMUNOL, V194, P950, DOI 10.4049/jimmunol.1401686; De Henau O, 2016, NATURE, V539, P443, DOI 10.1038/nature20554; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Ehrlich P., 1956, COLLECTED PAPERS 4 V; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fritz JM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00587; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; GERSHON RK, 1970, IMMUNOLOGY, V18, P723; Gil M, 2014, J IMMUNOL, V193, P5327, DOI 10.4049/jimmunol.1400201; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hamid O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-204; Hanks B.A., 2014, ASCO ANN M P; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heninger E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00029; Hicklin DJ, 1998, J CLIN INVEST, V101, P2720, DOI 10.1172/JCI498; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066; Hu W, 2016, CLIN TRANSL ONCOL, V18, P251, DOI 10.1007/s12094-015-1373-0; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kaplan MH, 1998, J EXP MED, V188, P1191, DOI 10.1084/jem.188.6.1191; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kodumudi KN, 2012, J IMMUNOL, V189, P5147, DOI 10.4049/jimmunol.1200274; Koya RC, 2012, CANCER RES, V72, P3928, DOI 10.1158/0008-5472.CAN-11-2837; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Laborde RR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00147; Larkin J, 2015, JAMA ONCOL, V1, P433, DOI 10.1001/jamaoncol.2015.1184; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Le DT, 2013, J IMMUNOTHER, V36, P382, DOI 10.1097/CJI.0b013e31829fb7a2; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Leclerc BG, 2016, CLIN CANCER RES, V22, P158, DOI 10.1158/1078-0432.CCR-15-1181; Lin RL, 2015, CANCER BIOL MED, V12, P385, DOI 10.7497/j.issn.2095-3941.2015.0015; Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626; Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Ma C, 2013, CANCER DISCOV, V3, P418, DOI 10.1158/2159-8290.CD-12-0383; Ma C, 2011, NAT MED, V17, P738, DOI 10.1038/nm.2375; Madore J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12340; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Meyer C, 2014, CANCER IMMUNOL IMMUN, V63, P247, DOI 10.1007/s00262-013-1508-5; Miller JFAP, 2015, CANCER CELL, V27, P439, DOI 10.1016/j.ccell.2015.03.007; Miller RE, 2002, J IMMUNOL, V169, P1792, DOI 10.4049/jimmunol.169.4.1792; Mittal D., 2016, CANC RES, V76; Mok S, 2014, CANCER RES, V74, P153, DOI 10.1158/0008-5472.CAN-13-1816; Moon EK, 2014, CLIN CANCER RES, V20, P4262, DOI 10.1158/1078-0432.CCR-13-2627; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Ninomiya S, 2015, BLOOD, V125, P3905, DOI 10.1182/blood-2015-01-621474; Oida T, 2003, J IMMUNOL, V170, P2516, DOI 10.4049/jimmunol.170.5.2516; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Ormandy LA, 2005, CANCER RES, V65, P2457, DOI 10.1158/0008-5472.CAN-04-3232; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Puzanov I, 2016, J CLIN ONCOL, V34, P2619, DOI 10.1200/JCO.2016.67.1529; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Redmond WL, 2007, J IMMUNOL, V179, P7244, DOI 10.4049/jimmunol.179.11.7244; Redmond WL, 2014, CANCER IMMUNOL RES, V2, P142, DOI 10.1158/2326-6066.CIR-13-0031-T; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Roszik J, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0705-4; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; Ruella M, 2016, J CLIN INVEST, V126, P3814, DOI 10.1172/JCI87366; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Sadelain M, 2016, CURR OPIN IMMUNOL, V41, P68, DOI 10.1016/j.coi.2016.06.004; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schachter J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9504; Schadendorf D., 2015, J CLIN ONCOL, V33; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shin DS, 2015, CURR OPIN IMMUNOL, V33, P23, DOI 10.1016/j.coi.2015.01.006; Shin DS, 2016, CANC DISCOV; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Solito S, 2011, BLOOD, V118, P2254, DOI 10.1182/blood-2010-12-325753; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Spranger S, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-3; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Sucker A, 2014, CLIN CANCER RES, V20, P6593, DOI 10.1158/1078-0432.CCR-14-0567; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Sundstedt A, 2003, J IMMUNOL, V170, P1240, DOI 10.4049/jimmunol.170.3.1240; TAKAHASHI H, 1993, CANCER RES, V53, P1612; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Tang DYL, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00236; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Tham M, 2015, ONCOTARGET, V6, P22857, DOI 10.18632/oncotarget.3127; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Turcotte M, 2015, CANCER RES, V75, P4494, DOI 10.1158/0008-5472.CAN-14-3569; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Vanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viehl CT, 2006, ANN SURG ONCOL, V13, P1252, DOI 10.1245/s10434-006-9015-y; Vo DD, 2009, CANCER RES, V69, P8693, DOI 10.1158/0008-5472.CAN-09-1456; Wang LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062924; Wargo JA, 2016, CURR OPIN IMMUNOL, V41, P23, DOI 10.1016/j.coi.2016.05.006; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wesolowski R, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-10; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wu XS, 2014, J INVEST DERMATOL, V134, P2814, DOI 10.1038/jid.2014.206; Yang J.C., 2016, ADV IMMUNOL, P279; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yee C, 2015, CANCER J, V21, P492, DOI 10.1097/PPO.0000000000000158; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang H, 2004, J IMMUNOL, V173, P932, DOI 10.4049/jimmunol.173.2.932; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	178	2328	2433	57	741	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	2017	168	4					707	723		10.1016/j.cell.2017.01.017	http://dx.doi.org/10.1016/j.cell.2017.01.017			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN8VJ	28187290	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000396277600019
J	Zilverstand, A; Sorger, B; Slaats-Willemse, D; Kan, CC; Goebel, R; Buitelaar, JK				Zilverstand, Anna; Sorger, Bettina; Slaats-Willemse, Dorine; Kan, Cornelis C.; Goebel, Rainer; Buitelaar, Jan K.			fMRI Neurofeedback Training for Increasing Anterior Cingulate Cortex Activation in Adult Attention Deficit Hyperactivity Disorder. An Exploratory Randomized, Single-Blinded Study	PLOS ONE			English	Article							REAL-TIME FMRI; MULTISOURCE INTERFERENCE TASK; RESONANCE-IMAGING FMRI; DEFICIT/HYPERACTIVITY DISORDER; SUSTAINED ATTENTION; CONTROLLED-TRIAL; CLINICAL-TRIALS; WORKING-MEMORY; ADHD; METAANALYSIS	Attention Deficit Hyperactivity Disorder (ADHD) is characterized by poor cognitive control/ attention and hypofunctioning of the dorsal anterior cingulate cortex (dACC). In the current study, we investigated for the first time whether real-time fMRI neurofeedback (rt-fMRI) training targeted at increasing activation levels within dACC in adults with ADHD leads to a reduction of clinical symptoms and improved cognitive functioning. An exploratory randomized controlled treatment study with blinding of the participants was conducted. Participants with ADHD (n = 7 in the neurofeedback group, and n = 6 in the control group) attended four weekly MRI training sessions (60-min training time/session), during which they performed a mental calculation task at varying levels of difficulty, in order to learn how to up-regulate dACC activation. Only neurofeedback participants received continuous feedback information on actual brain activation levels within dACC. Before and after the training, ADHD symptoms and relevant cognitive functioning was assessed. Results showed that both groups achieved a significant increase in dACC activation levels over sessions. While there was no significant difference between the neurofeedback and control group in clinical outcome, neurofeedback participants showed stronger improvement on cognitive functioning. The current study demonstrates the general feasibility of the suggested rt-fMRI neurofeedback training approach as a potential novel treatment option for ADHD patients. Due to the study's small sample size, potential clinical benefits need to be further investigated in future studies.	[Zilverstand, Anna; Sorger, Bettina; Goebel, Rainer] Maastricht Univ, Dept Cognit Neurosci, Maastricht, Netherlands; [Zilverstand, Anna] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Slaats-Willemse, Dorine; Buitelaar, Jan K.] Karakter Univ, Ctr Child & Adolescent Psychiat, Nijmegen, Netherlands; [Slaats-Willemse, Dorine; Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands; [Kan, Cornelis C.] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, Nijmegen, Netherlands; [Goebel, Rainer] Netherlands Inst Neurosci, Dept Neuroimaging & Neuromodeling, Amsterdam, Netherlands; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, Nijmegen, Netherlands	Maastricht University; Icahn School of Medicine at Mount Sinai; Radboud University Nijmegen; Radboud University Nijmegen; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Radboud University Nijmegen	Zilverstand, A (corresponding author), Maastricht Univ, Dept Cognit Neurosci, Maastricht, Netherlands.	anna.zilverstand@gmail.com	Zilverstand, Anna/AFR-0554-2022; Buitelaar, J.K./AAY-7522-2020	Zilverstand, Anna/0000-0002-4889-9700; Goebel, Rainer/0000-0003-1780-2467; Sorger, Bettina/0000-0003-1393-3144	Netherlands Organisation for Scientific Research (Rubicon fellowship) [446-14-015]; BrainGain Smart Mix Program of The Netherlands Ministry of Economic Affairs; Netherlands Ministry of Education, Culture and Science [SSM06011]	Netherlands Organisation for Scientific Research (Rubicon fellowship); BrainGain Smart Mix Program of The Netherlands Ministry of Economic Affairs; Netherlands Ministry of Education, Culture and Science	The authors gratefully acknowledge the support of Netherlands Organisation for Scientific Research (Rubicon fellowship 446-14-015 to A.Z.; http://www.nwo.nl/en) and the BrainGain Smart Mix Program of The Netherlands Ministry of Economic Affairs and The Netherlands Ministry of Education, Culture and Science (grant number: SSM06011 to A.Z., R.G., J.K.B.; http://www.rvo.nl/subsidies-regelingen/smart-mix SSM06011).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; American Psychiatric Association, 2013, CAUT STAT FOR US DSM, V5th Edn; Borm GF, 2005, CONTEMP CLIN TRIALS, V26, P637, DOI 10.1016/j.cct.2005.09.002; Bray S, 2007, J NEUROSCI, V27, P7498, DOI 10.1523/JNEUROSCI.2118-07.2007; Bron TI, 2014, EUR NEUROPSYCHOPHARM, V24, P519, DOI 10.1016/j.euroneuro.2014.01.007; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 2003, MOL PSYCHIATR, V8, P60, DOI 10.1038/sj.mp.4001217; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Bush G, 2008, ARCH GEN PSYCHIAT, V65, P102, DOI 10.1001/archgenpsychiatry.2007.16; Bush G, 2006, NAT PROTOC, V1, P308, DOI 10.1038/nprot.2006.48; Bush G, 2011, BIOL PSYCHIAT, V69, P1160, DOI 10.1016/j.biopsych.2011.01.022; COHEN J, 1973, EDUC PSYCHOL MEAS, V33, P107, DOI 10.1177/001316447303300111; Cotan, 2012, WECHSLER ADULT INTEL; Cubillo A, 2010, J PSYCHIATR RES, V44, P629, DOI 10.1016/j.jpsychires.2009.11.016; DAUM I, 1993, J NEUROL NEUROSUR PS, V56, P94, DOI 10.1136/jnnp.56.1.94; De Sonneville L., 2005, TIJDSCHRIFT NEUROPSY, P27; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102; Delazer M, 2003, COGNITIVE BRAIN RES, V18, P76, DOI 10.1016/j.cogbrainres.2003.09.005; Dickstein SG, 2006, J CHILD PSYCHOL PSYC, V47, P1051, DOI 10.1111/j.1469-7610.2006.01671.x; DuPaul G. J., 1998, ADHD RATING SCALE 4; Faraone SV, 2010, J CLIN PSYCHIAT, V71, P754, DOI 10.4088/JCP.08m04902pur; Fehr T, 2007, BRAIN RES, V1172, P93, DOI 10.1016/j.brainres.2007.07.043; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Goebel R, 2006, HUM BRAIN MAPP, V27, P392, DOI 10.1002/hbm.20249; Goebel R., 2010, IMAGING MED, V2, P407; Graham J, 2011, EUR CHILD ADOLES PSY, V20, P17, DOI 10.1007/s00787-010-0140-6; Green CT, 2012, NEUROTHERAPEUTICS, V9, P639, DOI 10.1007/s13311-012-0124-y; Haller S, 2010, EUR RADIOL, V20, P696, DOI 10.1007/s00330-009-1595-z; Holzapfel S., 1998, PRADIKTOREN DER SELB; Hoogman M, 2012, DONDERS SERIES, P97; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Johnson KA, 2012, J NEUROIMAGING, V22, P58, DOI 10.1111/j.1552-6569.2010.00529.x; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kooij JJS, 2005, PSYCHOL MED, V35, P817, DOI 10.1017/S003329170400337X; Kooij JJS, 2003, INTRO DIAGNOSTIC ASS; Linden DEJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038115; Marchetta NDJ, 2008, J ATTEN DISORD, V11, P664, DOI 10.1177/1087054707305108; Murphy K, 1996, J ATTEN DISORD, P147; Murphy K, 2007, NEUROIMAGE, V34, P565, DOI 10.1016/j.neuroimage.2006.09.032; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; Rheinberg F, 2001, DIAGNOSTICA, V47, P57, DOI 10.1026//0012-1924.47.2.57; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rota G, 2009, HUMAN BRAIN MAPPING, V1605; Sattler, 2001, ASSESSMENT CHILDREN; Scheinost D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.24; Schneider MF, 2010, PSYCHIAT RES-NEUROIM, V183, P75, DOI 10.1016/j.pscychresns.2010.04.005; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Simon V, 2009, BRIT J PSYCHIAT, V194, P204, DOI 10.1192/bjp.bp.107.048827; Sitaram R, 2012, NEUROREHAB NEURAL RE, V26, P256, DOI 10.1177/1545968311418345; Slaats-Willemse D, 2005, J AM ACAD CHILD PSY, V44, P385, DOI 10.1097/01.chi.0000153227.34473.c7; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002; Sonuga-Barke EJS, 2013, AM J PSYCHIAT, V170, P275, DOI 10.1176/appi.ajp.2012.12070991; Sorger B, NEUROSCIENCE IN PRES; Spencer TJ, 2007, J PEDIATR PSYCHOL, V32, P631, DOI 10.1093/jpepsy/jsm005; Stevens M.C., 2015, BRAIN IMAGING BEHAV; Stoeckel LE, 2014, NEUROIMAGE-CLIN, V5, P245, DOI 10.1016/j.nicl.2014.07.002; Subramanian L, 2011, J NEUROSCI, V31, P16309, DOI 10.1523/JNEUROSCI.3498-11.2011; Talairach J., 1988, NEUROPSYCHOLOGIA; Van de Loo-Neus GHH, 2011, EUROPEAN NEUROPSYCHO, P584; van Dongen-Boomsma M, 2013, J CLIN PSYCHIAT, V74, P821, DOI 10.4088/JCP.12m08321; Van Veen MM, 2010, BIOL PSYCHIAT, V67, P1091, DOI 10.1016/j.biopsych.2009.12.032; Vollebregt MA, 2013, J CHILD PSYCHOL PSYC; Wechsler D., 2012, WAIS 4 KASIKIRJA; Weiskopf N, 2012, NEUROIMAGE, V62, P682, DOI 10.1016/j.neuroimage.2011.10.009; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Young KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088785; Zilverstand A, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00148	70	48	48	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2017	12	1							e0170795	10.1371/journal.pone.0170795	http://dx.doi.org/10.1371/journal.pone.0170795			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7IT	28125735	Green Submitted, Green Published, gold			2023-01-03	WOS:000396176100050
J	Song, K; Chang, SS; Roper, M; Kim, H; Lee, SJ				Song, Kahye; Chang, Shyr-Shea; Roper, Marcus; Kim, Hyejeong; Lee, Sang Joon			A Biologically-Inspired Symmetric Bidirectional Switch	PLOS ONE			English	Article							HYDROGELS; POLYMERS; SYSTEMS	Stimuli-sensitive hydrogels have been intensively studied because of their potential applications in drug delivery, cell culture, and actuator design. Although hydrogels with directed unidirectional response, i.e. capable of bending actuated by different chemical components reaction in response to several stimuli including water and electric fields, these hydrogels are capable of being actuated in one direction only by the stimulus. By contrast the challenge of building a device that is capable of responding to the same cue (in this case a temperature gradient) to bend in either direction remains unmet. Here, inspired by the structure of pine cone scales, we design a temperature-sensitive hydrogel with bending directed an imposed fishing line. The layers with same PNIPAAm always shrinks in response to the heat. Even the layers made with different chemical property, bends away from a warm surface, whether the warm surface is applied at its upper or lower boundary. To design the bending hydrogel we exploited the coupled responses of the hydrogel; a fishing line intercalating structure and change its construction. In addition to revealing a new capability of stimulus sensitive hydrogels, our study gives insight into the structural features of pine cone bending.	[Song, Kahye; Lee, Sang Joon] Pohang Univ Sci & Technol POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang, Gyeongbuk, South Korea; [Chang, Shyr-Shea; Roper, Marcus] Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90024 USA; [Roper, Marcus; Lee, Sang Joon] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA; [Kim, Hyejeong] Pohang Univ Sci & Technol POSTECH, Dept Mech Engn, Pohang, Gyeongbuk, South Korea	Pohang University of Science & Technology (POSTECH); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Pohang University of Science & Technology (POSTECH)	Lee, SJ (corresponding author), Pohang Univ Sci & Technol POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang, Gyeongbuk, South Korea.; Lee, SJ (corresponding author), Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA.	sjlee@postech.ac.kr	Lee, Sang Joon/AAG-2448-2019	Roper, Marcus/0000-0001-8756-0112	Creative Research Initiative (Diagnosis of Biofluid Flow Phenomena and Biomimic Research) of the Ministry of Science, ICT and Future Planning (MSIP); National Research Foundation (NRF) of Korea [2008-0061991]; National Institute of General Medical Sciences [T32GM008185]; National Science Foundation [DMS-1312543]	Creative Research Initiative (Diagnosis of Biofluid Flow Phenomena and Biomimic Research) of the Ministry of Science, ICT and Future Planning (MSIP); National Research Foundation (NRF) of Korea(National Research Foundation of Korea); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Science Foundation(National Science Foundation (NSF))	This research was financially supported by the Creative Research Initiative (Diagnosis of Biofluid Flow Phenomena and Biomimic Research) of the Ministry of Science, ICT and Future Planning (MSIP) and the National Research Foundation (NRF) of Korea (Contract grant number: 2008-0061991). Shyr-Shea Chang was supported by Grant Number T32GM008185 from the National Institute of General Medical Sciences. Marcus Roper acknowledges financial support from National Science Foundation grant DMS-1312543. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institute of Health. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alarcon CDH, 2005, CHEM SOC REV, V34, P276, DOI 10.1039/b406727d; Dawson J, 1997, NATURE, V390, P668, DOI 10.1038/37745; Fahn A., 1972, ANATOMICAL MECH SEED, P151; Fratzl P, 2009, NATURE, V462, P442, DOI 10.1038/nature08603; Harmon ME, 2003, POLYMER, V44, P4547, DOI 10.1016/S0032-3861(03)00463-4; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; Ionov L, 2014, MATER TODAY, V17, P494, DOI 10.1016/j.mattod.2014.07.002; Jeong B, 2002, TRENDS BIOTECHNOL, V20, P305, DOI 10.1016/S0167-7799(02)01962-5; Kabiri K, 2003, EUR POLYM J, V39, P1341, DOI 10.1016/S0014-3057(02)00391-9; Kim H, 2015, ADV FUNCT MATER, V25, P4496, DOI 10.1002/adfm.201501445; Lee H, 2010, SOFT MATTER, V6, P4342, DOI 10.1039/c0sm00092b; Mano JF, 2008, ADV ENG MATER, V10, P515, DOI 10.1002/adem.200700355; O'Grady ML, 2010, ACS APPL MATER INTER, V2, P343, DOI 10.1021/am900755w; Prabaharan M, 2006, MACROMOL BIOSCI, V6, P991, DOI 10.1002/mabi.200600164; Ren HY, 2011, MACROMOLECULES, V44, P8516, DOI 10.1021/ma201272j; Reyssat E, 2009, J R SOC INTERFACE, V6, P951, DOI 10.1098/rsif.2009.0184; Song K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09963; Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]; Timoshenko S, 1925, J OPT SOC AM REV SCI, V11, P233, DOI 10.1364/JOSA.11.000233	19	6	6	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2017	12	1							e0169856	10.1371/journal.pone.0169856	http://dx.doi.org/10.1371/journal.pone.0169856			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH5WO	28068391	gold, Green Published, Green Submitted			2023-01-03	WOS:000391843900075
J	Sagy, I; Vodonos, A; Novack, V; Rogachev, B; Haviv, YS; Barski, L				Sagy, Iftach; Vodonos, Alina; Novack, Victor; Rogachev, Boris; Haviv, Yosef S.; Barski, Leonid			The Combined Effect of High Ambient Temperature and Antihypertensive Treatment on Renal Function in Hospitalized Elderly Patients	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT VISITS; ACUTE KIDNEY INJURY; 2003 HEAT-WAVE; OLDER-ADULT; MORTALITY; DISEASE; OUTCOMES; IMPACT; DEATH; FLUID	Background The aging kidney manifests structural, functional as well as pharmacological changes, rendering elderly patients more susceptible to adverse environmental influences on their health, dehydration in particular. Hypothesis Higher temperature is associated with renal function impairment in patients 65 years and older who routinely take thiazide and/or ACE-inhibitors/ARBs. Methods We obtained health data of patients older than 65 who were admitted to a large tertiary center during the years 2006-011, with a previous diagnosis of hypertension, and treated with thiazide, ACE-inhibitors/ARBs or both. We collected environmental data of daily temperature, available from collaborative public and governmental institutions. In order to estimate the effect of daily temperature on renal function we performed linear mixed models, separately for each treatment group and creatinine change during hospital admission. Results We identified 26,286 admissions for 14, 268 patients with a mean age of 75.6 (+/- 6.9) years, of whom 53.6% were men. Increment in daily temperature on admission of 5 degrees C had significant effect on creatinine increase in the no treatment (baseline creatinine adjusted 0.824 mg/dL, % change 1.212, % change 95% C. I 0.082-2.354) and dual treatment groups (baseline creatinine adjusted 1.032mg/dL, % change 3.440, % change 95% C. I 1.227-5.700). Sub-analysis stratified by advanced age, chronic kidney disease and primary diagnosis on hospital admission, revealed a significant association within patients admitted due to acute infection and treated with dual therapy. Conclusion Whereas previous studies analyzed sporadic climate effects during heat waves and/or excluded older population taking anti-hypertensive medications, the present study is novel by showing a durable association of temperature and decreased renal function specifically in elderly patients taking anti-hypertensive medications.	[Sagy, Iftach; Vodonos, Alina; Novack, Victor] Soroka Univ, Med Ctr, Clin Res Ctr, Beer Sheva, Israel; [Sagy, Iftach; Novack, Victor; Rogachev, Boris; Haviv, Yosef S.; Barski, Leonid] Soroka Univ, Med Ctr, Div Internal Med, Beer Sheva, Israel; [Sagy, Iftach; Vodonos, Alina; Novack, Victor; Rogachev, Boris; Haviv, Yosef S.; Barski, Leonid] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel; [Rogachev, Boris; Haviv, Yosef S.] Soroka Univ, Med Ctr, Dept Nephrol, Beer Sheva, Israel	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Ben Gurion University; Soroka Medical Center	Sagy, I (corresponding author), Soroka Univ, Med Ctr, Clin Res Ctr, Beer Sheva, Israel.; Sagy, I (corresponding author), Soroka Univ, Med Ctr, Div Internal Med, Beer Sheva, Israel.; Sagy, I (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.	iftachsagy@gmail.com	sagy, iftach/AAS-3372-2020					Akaike H, 1998, 2 INT S INFORM THEOR, P199, DOI 10.1007/978-1-4612-1694-0; Alpert P, 2004, INT J CLIMATOL, V24, P1013, DOI 10.1002/joc.1037; Argaud L, 2007, ARCH INTERN MED, V167, P2177, DOI 10.1001/archinte.167.20.ioi70147; Berger JR, 2016, ADV CHRONIC KIDNEY D, V23, P36, DOI 10.1053/j.ackd.2015.08.005; Bi P, 2011, ASIA-PAC J PUBLIC HE, V23, p27S, DOI 10.1177/1010539510391644; Birnie K, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0606-x; CROSS NB, 2009, COCHRANE DATABASE SY, V3; El-Sharkawy AM, 2014, CLIN NUTR, V33, P6, DOI 10.1016/j.clnu.2013.11.010; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Glassock RJ, 2016, NEPHRON, V132; Hasegawa H, 2013, KIDNEY BLOOD PRESS R, V37, P521, DOI 10.1159/000355732; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Jamerson K, 2008, NEW ENGL J MED, V359, P2417, DOI 10.1056/NEJMoa0806182; Jerkic Mirjana, 2001, International Urology and Nephrology, V32, P539, DOI 10.1023/A:1014484101427; Joe L, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030299; Klenk J, 2010, AGE AGEING, V39, P245, DOI 10.1093/ageing/afp248; Lancaster KJ, 2003, ANN EPIDEMIOL, V13, P525, DOI 10.1016/S1047-2797(03)00004-8; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Li MM, 2015, INT J ENV RES PUB HE, V12, P5256, DOI 10.3390/ijerph120505256; Lindstrom SJ, 2013, INTERN MED J, V43, P1246, DOI 10.1111/imj.12275; Miller M, 1997, BAILLIERE CLIN ENDOC, V11, P367, DOI 10.1016/S0950-351X(97)80347-3; Nielsen SE, 2012, DIABETIC MED, V29, pE184, DOI 10.1111/j.1464-5491.2012.03585.x; Palevsky PM, 2013, AM J KIDNEY DIS, V61, P649, DOI 10.1053/j.ajkd.2013.02.349; Rey G, 2009, EUR J EPIDEMIOL, V24, P495, DOI 10.1007/s10654-009-9374-3; Roberts G, 2015, CLIN KIDNEY J, V8, P673, DOI 10.1093/ckj/sfv080; Siew ED, 2012, CLIN J AM SOC NEPHRO, V7, P712, DOI 10.2215/CJN.10821011; Singri N, 2003, JAMA-J AM MED ASSOC, V289, P747, DOI 10.1001/jama.289.6.747; Vandentorren S, 2006, EUR J PUBLIC HEALTH, V16, P583, DOI 10.1093/eurpub/ckl063; Velasquez KMR, 2014, PRIMARY CARE, V41, P857, DOI 10.1016/j.pop.2014.08.006; Westerterp KR, 2005, BRIT J NUTR, V93, P199, DOI 10.1079/BJN20041310; Winquist A, 2016, ENVIRON RES, V147, P314, DOI 10.1016/j.envres.2016.02.022; Zhang K, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/1476-069X-14-11	32	5	5	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2016	11	12							e0168504	10.1371/journal.pone.0168504	http://dx.doi.org/10.1371/journal.pone.0168504			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QC	27992525	gold, Green Published, Green Submitted			2023-01-03	WOS:000392842600070
J	Ikeda, M; Honda, H; Takahashi, K; Shishido, K; Shibata, T				Ikeda, Misa; Honda, Hirokazu; Takahashi, Keiko; Shishido, Kanji; Shibata, Takanori			N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for Loss of Muscle Mass in Prevalent Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; TOTAL-BODY WATER; HEART-FAILURE; SERUM-ALBUMIN; EXTRACELLULAR VOLUME; MORTALITY; MALNUTRITION; INFLAMMATION; PROTEIN; MARKER	Protein-energy wasting (PEW) is common in hemodialysis (HD) patients. A recent study demonstrated that a high level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be associated with PEW in those patients. This prospective study aimed to assess the association of NT-proBNP with body composition and muscle loss. A cohort of prevalent HD patients (n = 238) was examined. Blood samples were obtained at baseline to measure high-sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), adiponectin and NT-proBNP. Nutritional status and changes in muscle mass were assessed by subjective global assessment, percentage creatinine generation rate (% CGR), creatinine index (CI) and lean body mass (LBM) estimated by dual-energy X-ray absorptiometry (DXA). The % CGR and CI were calculated five times for one year, and DXA was performed at baseline and one year later. Cardiac function was estimated by ultrasonography at baseline. NT-proBNP was significantly higher in HD patients with PEW. High NT-proBNP was associated with cardiac dysfunction, increased levels of hsCRP and IL-6, and serially decreased levels of the indexes for muscle mass. Multiple regression analysis adjusted with confounders showed that NT-proBNP was an independent predictor for decrease in LBM and serial lower levels of % CGR and CI. In conclusion, the present study demonstrated a novel association between NT-proBNP and muscle loss. NT-proBNP may be an independent biomarker for malnutrition in HD patients, especially in patients with muscles loss, regardless of chronic inflammation, cardiac dysfunction, or overhydration.	[Ikeda, Misa; Shibata, Takanori] Showa Univ, Sch Med, Div Nephrol, Dept Med, Tokyo, Japan; [Honda, Hirokazu] Showa Univ, Koto Toyosu Hosp, Div Nephrol, Dept Med, Tokyo, Japan; [Takahashi, Keiko] Kitami Higashiyama Clin, Div Dialysis, Tokyo, Japan; [Shishido, Kanji] Kawasaki Clin, Dept Med, Kawasaki, Kanagawa, Japan	Showa University; Showa University	Honda, H (corresponding author), Showa Univ, Koto Toyosu Hosp, Div Nephrol, Dept Med, Tokyo, Japan.	hondah@med.showa-u.ac.jp		Honda, Hirokazu/0000-0002-5634-6145	Grants-in-Aid for Scientific Research [16K08975] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Arkouche W, 1997, J AM SOC NEPHROL, V8, P1906; Arques S, 2011, J CARD FAIL, V17, P451, DOI 10.1016/j.cardfail.2011.02.010; BALLMER PE, 1995, J CLIN INVEST, V95, P39, DOI 10.1172/JCI117668; Booth J, 2010, CLIN J AM SOC NEPHRO, V5, P1036, DOI 10.2215/CJN.09001209; Bordicchia M, 2012, J CLIN INVEST, V122, P1022, DOI 10.1172/JCI59701; Canaud B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093286; Carrero JJ, 2013, J RENAL NUTR, V23, P77, DOI 10.1053/j.jrn.2013.01.001; Christensen HM, 2013, ENDOCRINE, V43, P626, DOI 10.1007/s12020-012-9836-3; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Desmeules S, 2004, NEPHROL DIAL TRANSPL, V19, P1182, DOI 10.1093/ndt/gfh016; Engeli S, 2012, J CLIN INVEST, V122, P4675, DOI 10.1172/JCI64526; Fahim MA, 2015, CLIN J AM SOC NEPHRO, V10, P620, DOI 10.2215/CJN.09060914; Friedman AN, 2010, J AM SOC NEPHROL, V21, P223, DOI 10.1681/ASN.2009020213; Guo Q, 2009, AM J NEPHROL, V29, P516, DOI 10.1159/000185628; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Isoyama N, 2014, CLIN J AM SOC NEPHRO, V9, P1720, DOI 10.2215/CJN.10261013; Jacobs LH, 2010, NEPHROL DIAL TRANSPL, V25, P243, DOI 10.1093/ndt/gfp417; Johansson AC, 1997, KIDNEY INT, V51, P855, DOI 10.1038/ki.1997.120; Kaysen GA, 2004, KIDNEY INT, V65, P1408, DOI 10.1111/j.1523-1755.2004.00520.x; Kidney Disease Outcomes Quality Initiative (K/DOQI) Group, 2003, AM J KIDNEY DIS S, V41, pI; Kovesdy CP, 2012, SEMIN DIALYSIS, V25, P423, DOI 10.1111/j.1525-139X.2012.01097.x; Kuhn M, 2009, J CLIN INVEST, V119, P2019, DOI 10.1172/JCI37430; Lee SW, 2001, NEPHROL DIAL TRANSPL, V16, P91, DOI 10.1093/ndt/16.1.91; Madsen LH, 2007, KIDNEY INT, V71, P548, DOI 10.1038/sj.ki.5002087; Martins T, 2014, CLIN BIOCHEM, V47, P8, DOI 10.1016/j.clinbiochem.2013.10.025; McEntegart MB, 2007, EUR HEART J, V28, P829, DOI 10.1093/eurheartj/ehm033; Moro C, 2013, AM J PHYSIOL-HEART C, V304, pH358, DOI 10.1152/ajpheart.00704.2012; Nongnuch A, 2014, AM J NEPHROL, V40, P251, DOI 10.1159/000368376; Park SW, 2014, J KOREAN NEUROSURG S, V56, P79, DOI 10.3340/jkns.2014.56.2.79; Paulo Araujo J, 2009, EUR J HEART FAIL, V11, P567, DOI 10.1093/eurjhf/hfp046; Polak J, 2011, J AM COLL CARDIOL, V58, P1119, DOI 10.1016/j.jacc.2011.05.042; Prontera C, 2004, CLIN CHEM LAB MED, V42, P37, DOI 10.1515/CCLM.2004.008; Roberts TK, 2008, KIDNEY INT, V74, P143, DOI 10.1038/ki.2008.220; Satyan S, 2007, AM J KIDNEY DIS, V50, P1009, DOI 10.1053/j.ajkd.2007.08.017; Sengenes C, 2003, J BIOL CHEM, V278, P48617, DOI 10.1074/jbc.M303713200; Sengenes C, 2000, FASEB J, V14, P1345, DOI 10.1096/fj.14.10.1345; Shinzato T, 1997, ARTIF ORGANS, V21, P864; Snaedal S, 2014, BLOOD PURIFICAT, V37, P138, DOI 10.1159/000360267; Stenvinkel P, 2000, NEPHROL DIAL TRANSPL, V15, P953, DOI 10.1093/ndt/15.7.953; Tai R, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-189; ter Maaten JM, 2014, CLIN RES CARDIOL, V103, P976, DOI 10.1007/s00392-014-0738-7; Weber M, 2006, HEART, V92, P843, DOI 10.1136/hrt.2005.071233	42	16	17	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2016	11	11							e0166804	10.1371/journal.pone.0166804	http://dx.doi.org/10.1371/journal.pone.0166804			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED4UE	27870908	Green Published, gold, Green Submitted			2023-01-03	WOS:000388846400033
J	Johnson, DB; Balko, JM; Compton, ML; Chalkias, S; Gorham, J; Xu, YM; Hicks, M; Puzanov, I; Alexander, MR; Bloomer, TL; Becker, JR; Slosky, DA; Phillips, EJ; Pilkinton, MA; Craig-Owens, L; Kola, N; Plautz, G; Reshef, DS; Deutsch, JS; Deering, RP; Olenchock, BA; Lichtman, AH; Roden, DM; Seidman, CE; Koralnik, IJ; Seidman, JG; Hoffman, RD; Taube, JM; Diaz, LA; Anders, RA; Sosman, JA; Moslehi, JJ				Johnson, Douglas B. dbj; Balko, Justin M. jmb; Compton, Margaret L. mlc; Chalkias, Spyridon sc; Gorham, Joshua jc; Xu, Yaomin yx; Hicks, Mellissa mh; Puzanov, Igor ip; Alexander, Matthew R. mra; Bloomer, Tyler L. tlb; Becker, Jason R. jrb; Slosky, David A. das; Phillips, Elizabeth J. ejp; Pilkinton, Mark A. map; Craig-Owens, Laura lco; Kola, Nina nk; Plautz, Gregory gp; Reshef, Daniel S. dsr; Deutsch, Jonathan S. jsd; Deering, Raquel P. rpd; Olenchock, Benjamin A. bao; Lichtman, Andrew H. ahl; Roden, Dan M. dmr; Seidman, Christine E. ces; Koralnik, Igor J. ijk; Seidman, Jonathan G. jgs; Hoffman, Robert D. rdh; Taube, Janis M. jmt; Diaz, Luis A. Jr lad; Anders, Robert A. raa; Sosman, Jeffrey A. jas; Moslehi, Javid J. jjm			Fulminant Myocarditis with Combination Immune Checkpoint Blockade	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DILATED CARDIOMYOPATHY; UNTREATED MELANOMA; PD-1 BLOCKADE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; INFLAMMATION; AUTOPSY; HEART; RISK	Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab. In both patients, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with a robust presence of T-cell and macrophage infiltrates. Selective clonal T-cell populations infiltrating the myocardium were identical to those present in tumors and skeletal muscle. Pharmacovigilance studies show that myocarditis occurred in 0.27% of patients treated with a combination of ipilimumab and nivolumab, which suggests that our patients were having a rare, potentially fatal, T-cell-driven drug reaction. (Funded by Vanderbilt-Ingram Cancer Center Ambassadors and others.)	[Johnson, Douglas B. dbj; Balko, Justin M. jmb; Hicks, Mellissa mh; Puzanov, Igor ip; Alexander, Matthew R. mra; Bloomer, Tyler L. tlb; Becker, Jason R. jrb; Slosky, David A. das; Phillips, Elizabeth J. ejp; Pilkinton, Mark A. map; Roden, Dan M. dmr; Sosman, Jeffrey A. jas; Moslehi, Javid J. jjm] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Balko, Justin M. jmb; Moslehi, Javid J. jjm] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA; [Compton, Margaret L. mlc; Craig-Owens, Laura lco; Hoffman, Robert D. rdh] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Xu, Yaomin yx] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Roden, Dan M. dmr] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Xu, Yaomin yx; Roden, Dan M. dmr] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37232 USA; [Slosky, David A. das; Moslehi, Javid J. jjm] Vanderbilt Univ, Med Ctr, Cardiooncol Program, 2220 Pierce Ave, Nashville, TN 37232 USA; [Balko, Justin M. jmb] Vanderbilt Univ, Med Ctr, Breast Canc Res Program, Nashville, TN 37232 USA; [Xu, Yaomin yx] Vanderbilt Univ, Med Ctr, Ctr Quantitat Sci, Nashville, TN 37232 USA; [Chalkias, Spyridon sc] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Chalkias, Spyridon sc; Koralnik, Igor J. ijk] Beth Israel Deaconess Med Ctr, Div Neuroimmunol, Boston, MA 02215 USA; [Olenchock, Benjamin A. bao; Seidman, Christine E. ces; Seidman, Jonathan G. jgs] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Lichtman, Andrew H. ahl] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Gorham, Joshua jc; Seidman, Christine E. ces; Seidman, Jonathan G. jgs] Harvard Med Sch, Dept Genet, Boston, MA USA; [Seidman, Christine E. ces] Howard Hughes Med Inst, Chevy Chase, MD USA; [Kola, Nina nk; Plautz, Gregory gp; Reshef, Daniel S. dsr; Deutsch, Jonathan S. jsd] Bristol Myers Squibb, New York, NY USA; [Deering, Raquel P. rpd] Neon Therapeut, Cambridge, MA USA; [Taube, Janis M. jmt; Anders, Robert A. raa] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Taube, Janis M. jmt] Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21218 USA; [Diaz, Luis A. Jr lad] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Bristol-Myers Squibb; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Moslehi, JJ (corresponding author), Vanderbilt Univ, Med Ctr, Cardiooncol Program, 2220 Pierce Ave, Nashville, TN 37232 USA.	javid.moslehi@vanderbilt.edu	Bloomer, Tyler/S-9788-2019; Roden, Dan/ABD-5412-2021; PUZANOV, IGOR/AAP-2966-2020	PUZANOV, IGOR/0000-0002-9803-3497; Diaz, Luis/0000-0002-7079-8914; Compton, Margaret/0000-0002-0568-2309; Alexander, Matthew/0000-0003-4739-7204	Bready Family Foundation; National Cancer Institute [6R00CA181491]; Vanderbilt-Ingram Cancer Center Ambassadors; Breast Cancer Specialized Program of Research Excellence [P50 CA098131]; National Comprehensive Cancer Network Young Investigator Award; National Institutes of Health [K08 HL119355, P50 GM115305, U01-HL098188, U01-HL098147, U01-HL098153, U01-HL098163, U01-HL098123, U01-HL098162]; Howard Hughes Medical Institute; Gilead Life Sciences; NATIONAL CANCER INSTITUTE [P50CA098131, K23CA204726, R00CA181491] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL098163, U01HL098162, U01HL098147, U01HL098188, R01HL121363, U01HL098153, U01HL098123, K08HL119355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER	Bready Family Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt-Ingram Cancer Center Ambassadors; Breast Cancer Specialized Program of Research Excellence; National Comprehensive Cancer Network Young Investigator Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Gilead Life Sciences(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by funding from the Bready Family Foundation (to Drs. Johnson and Balko), the National Cancer Institute (grant 6R00CA181491, to Dr. Balko), the Vanderbilt-Ingram Cancer Center Ambassadors (to Drs. Balko and Moslehi), the Breast Cancer Specialized Program of Research Excellence (grant P50 CA098131, to Drs. Balko and Moslehi), the National Comprehensive Cancer Network Young Investigator Award (to Dr. Johnson), the National Institutes of Health (grant K08 HL119355, to Dr. Olenchock; grant P50 GM115305, to Drs. Phillips and Roden; and grants U01-HL098188, U01-HL098147, U01-HL098153, U01-HL098163, U01-HL098123, and U01-HL098162, to Dr. J. Seidman), the Howard Hughes Medical Institute (to Dr. C. Seidman), and Gilead Life Sciences (to Dr. Olenchock).	Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Cooper LT, 2009, NEW ENGL J MED, V360, P1526, DOI 10.1056/NEJMra0800028; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Eggermont AMM, 2015, LANCET ONCOL, V16, P522, DOI 10.1016/S1470-2045(15)70122-1; Grabie N, 2007, CIRCULATION, V116, P2062, DOI 10.1161/CIRCULATIONAHA.107.709360; GRIFFIN LD, 1995, CARDIOVASC PATHOL, V4, P3, DOI 10.1016/1054-8807(94)00025-M; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; Koelzer VH, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0117-1; Laubli H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0057-1; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishino M, 2015, NEW ENGL J MED, V373, P288, DOI 10.1056/NEJMc1505197; Okazaki T, 2003, NAT MED, V9, P1477, DOI 10.1038/nm955; Pham J, 2016, CLIN EXP ALLERGY, V46, P1194, DOI 10.1111/cea.12772; Pollack A, 2015, NAT REV CARDIOL, V12, P670, DOI 10.1038/nrcardio.2015.108; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Tarrio ML, 2012, J IMMUNOL, V188, P4876, DOI 10.4049/jimmunol.1200389; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Wolchok JD, 2015, CELL, V162, P937, DOI 10.1016/j.cell.2015.07.045	24	1133	1207	18	119	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2016	375	18					1749	1755		10.1056/NEJMoa1609214	http://dx.doi.org/10.1056/NEJMoa1609214			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB0BB	27806233	Bronze, Green Accepted			2023-01-03	WOS:000387007300008
J	Vogel, JP; Moore, JE; Timmings, C; Khan, S; Khan, DN; Defar, A; Hadush, A; Terefe, MM; Teshome, L; Ba-Thike, K; Than, KK; Makuwani, A; Mbaruku, G; Mrisho, M; Mugerwa, KY; Ritchie, LMP; Rashid, S; Straus, SE; Gulmezoglu, AM				Vogel, Joshua P.; Moore, Julia E.; Timmings, Caitlyn; Khan, Sobia; Khan, Dina N.; Defar, Atkure; Hadush, Azmach; Terefe, Marta Minwyelet; Teshome, Luwam; Ba-Thike, Katherine; Than, Kyu Kyu; Makuwani, Ahmad; Mbaruku, Godfrey; Mrisho, Mwifadhi; Mugerwa, Kidza Yvonne; Ritchie, Lisa M. Puchalski; Rashid, Shusmita; Straus, Sharon E.; Gulmezoglu, A. Metin			Barriers, Facilitators and Priorities for Implementation of WHO Maternal and Perinatal Health Guidelines in Four Lower-Income Countries: A GREAT Network Research Activity	PLOS ONE			English	Article								Background Health systems often fail to use evidence in clinical practice. In maternal and perinatal health, the majority of maternal, fetal and newborn mortality is preventable through implementing effective interventions. To meet this challenge, WHO's Department of Reproductive Health and Research partnered with the Knowledge Translation Program at St. Michael's Hospital (SMH), University of Toronto, Canada to establish a collaboration on knowledge translation (KT) in maternal and perinatal health, called the GREAT Network (Guideline-driven, Research priorities, Evidence synthesis, Application of evidence, and Transfer of knowledge). We applied a systematic approach incorporating evidence and theory to identifying barriers and facilitators to implementation of WHO maternal heath recommendations in four lower-income countries and to identifying implementation strategies to address these. Methods We conducted a mixed-methods study in Myanmar, Uganda, Tanzania and Ethiopia. In each country, stakeholder surveys, focus group discussions and prioritization exercises were used, involving multiple groups of health system stakeholders (including administrators, policymakers, NGOs, professional associations, frontline healthcare providers and researchers). Results Despite differences in guideline priorities and contexts, barriers identified across countries were often similar. Health system level factors, including health workforce shortages, and need for strengthened drug and equipment procurement, distribution and management systems, were consistently highlighted as limiting the capacity of providers to deliver high-quality care. Evidence-based health policies to support implementation, and improve the knowledge and skills of healthcare providers were also identified. Stakeholders identified a range of tailored strategies to address local barriers and leverage facilitators. Conclusion This approach to identifying barriers, facilitators and potential strategies for improving implementation proved feasible in these four lower-income country settings. Further evaluation of the impact of implementing these strategies is needed.	[Vogel, Joshua P.; Khan, Dina N.; Gulmezoglu, A. Metin] WHO, Dept Reprod Hlth & Res, UNDP UNFPA UNICEF WHO World Bank Special Programm, Geneva, Switzerland; [Moore, Julia E.; Timmings, Caitlyn; Khan, Sobia; Ritchie, Lisa M. Puchalski; Rashid, Shusmita; Straus, Sharon E.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Knowledge Translat Program, Toronto, ON, Canada; [Defar, Atkure] Ethiopian Publ Hlth Inst, Hlth Syst & Reprod Hlth Res Directorate, Addis Ababa, Ethiopia; [Hadush, Azmach; Teshome, Luwam] WHO Country Off, Addis Ababa, Ethiopia; [Terefe, Marta Minwyelet] Minist Hlth, Maternal & Child Hlth Directorate, Addis Ababa, Ethiopia; [Than, Kyu Kyu] Burnet Inst, Melbourne, Vic, Australia; [Than, Kyu Kyu] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Makuwani, Ahmad] Minist Hlth Community Dev Gender Elderly & Childr, Dar Es Salaam, Tanzania; [Mbaruku, Godfrey; Mrisho, Mwifadhi] Ifakara Hlth Inst, Dar Es Salaam, Tanzania; [Mugerwa, Kidza Yvonne] Makerere Univ, Kampala, Uganda; [Ritchie, Lisa M. Puchalski] Univ Hlth Network, Dept Emergency Med, Toronto, ON, Canada	The World Bank; United Nations Population Fund; World Health Organization; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; Burnet Institute; University of Melbourne; Ifakara Health Institute; Makerere University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Vogel, JP (corresponding author), WHO, Dept Reprod Hlth & Res, UNDP UNFPA UNICEF WHO World Bank Special Programm, Geneva, Switzerland.	vogeljo@who.int	Ritchie, Lisa Puchalski/AAI-3717-2021; Vogel, Joshua/K-7649-2019	Ritchie, Lisa Puchalski/0000-0002-1791-5368; Vogel, Joshua/0000-0002-3214-7096	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO; St Michael's Hospital, Toronto, Canada; Canadian Institutes of Health Research [NC1-122929]; UN Commission on Life Saving Commodities for Women and Children (Uganda, Tanzania, Ethiopia); Alliance for Health Policy and Systems Research, World Health Organization (Myanmar); KT Canada Strategic Training Initiative in Health Research Fellowship	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO; St Michael's Hospital, Toronto, Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); UN Commission on Life Saving Commodities for Women and Children (Uganda, Tanzania, Ethiopia); Alliance for Health Policy and Systems Research, World Health Organization (Myanmar); KT Canada Strategic Training Initiative in Health Research Fellowship	Financial support for these activities was provided by UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO (www.who.int/reproductivehealth); St Michael's Hospital, Toronto, Canada (www.stmichaelshospital.com/); Canadian Institutes of Health Research (grant number NC1-122929) (http://www.cihr-irsc.gc.ca/); the UN Commission on Life Saving Commodities for Women and Children (for activities in Uganda, Tanzania, Ethiopia) (http//www.lifesavingcommodities.org/); and the Alliance for Health Policy and Systems Research, World Health Organization (for activities in Myanmar) (http://www.who.int/alliance-hpsr/en/). LMPR was funded by a KT Canada Strategic Training Initiative in Health Research Fellowship Award in 2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker R, 2014, COCHRANE DB SYST REV, V4; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Cousens S, 2011, LANCET, V377, P1319, DOI 10.1016/S0140-6736(10)62310-0; DAD, 2011, MAIL INTERNET SURVEY; Fervers B, 2006, INT J QUAL HEALTH C, V18, P167, DOI 10.1093/intqhc/mzi108; Graham ID, 2007, ACAD EMERG MED, V14, P936, DOI 10.1197/j.aem.2007.07.004; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Jagosh J, 2012, MILBANK Q, V90, P311, DOI 10.1111/j.1468-0009.2012.00665.x; Kennedy J, 2004, CAN MED ASSOC J, V171, P455, DOI 10.1503/cmaj.1040170; Kiesler DJ, 2006, PATIENT EDUC COUNS, V61, P319, DOI 10.1016/j.pec.2005.08.002; Lassi ZS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub3; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; McDonnell J., 2001, RANDUCLA APPROPRIATE; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; O'Connor AM, 2007, MED DECIS MAKING, V27, P554, DOI 10.1177/0272989x07307319; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pimlott NJG, 2003, CAN MED ASSOC J, V168, P835; Saldaua, 2016, CODING MANUAL QUALIT; Shah BR, 2003, J POPUL THER CLIN PH, V11, pe239; Straus SE, 2013, BMJ BOOKS; Straus SE, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-108; Straus SE, 2009, CAN MED ASSOC J, V181, P165, DOI 10.1503/cmaj.081229; Tricco AC, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0370-1; Tuncalp O, 2015, BJOG; UNICEF World Health Organization, 2014, COUNTD 2015 FULF HLT; United Nations, 2014, MILL DEV GOALS REP 2; United Nations Population Division, 2018, WORLD POP PROSP; Wang ZC, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0440-4; WHO, 2014, WHO REC AUGM LAB; WHO UNICEF, 2013, TRENDS MAT MORT 1990; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; Wooding S, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-47; World Health Organization, 2014, WHO HDB GUID DEV, Vsecond; World Health Organization, 2012, OPTIMIZEMNH WHO REC; World Health Organization, 2012, WHO REC PREV TREATM; World Health Organization, 2011, WHO REC IND LAB; World Health Organization, 2011, WHO REC PREV TREATM	39	28	28	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2016	11	11							e0160020	10.1371/journal.pone.0160020	http://dx.doi.org/10.1371/journal.pone.0160020			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EA6DJ	27806041	gold, Green Submitted, Green Published			2023-01-03	WOS:000386715500004
J	Berrouiguet, S; Barrigon, ML; Brandt, SA; Ovejero-Garcia, S; Alvarez-Garcia, R; Carballo, JJ; Lenca, P; Courtet, P; Baca-Garcia, E				Berrouiguet, Sofian; Luisa Barrigon, Maria; Brandt, Sara A.; Ovejero-Garcia, Santiago; Alvarez-Garcia, Raquel; Jose Carballo, Juan; Lenca, Philippe; Courtet, Philippe; Baca-Garcia, Enrique		MEmind Study Grp	Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications	PLOS ONE			English	Article							ELECTRONIC HEALTH RECORDS; 2ND-GENERATION ANTIPSYCHOTICS; ATYPICAL ANTIPSYCHOTICS; POLYPHARMACY; SCHIZOPHRENIA; EFFICACY; QUETIAPINE; CARE; METAANALYSIS; INPATIENTS	Purpose The emergence of electronic prescribing devices with clinical decision support systems (CDSS) is able to significantly improve management pharmacological treatments. We developed a web application available on smartphones in order to help clinicians monitor prescription and further propose CDSS. Method A web application (www.MEmind.net) was developed to assess patients and collect data regarding gender, age, diagnosis and treatment. We analyzed antipsychotic prescriptions in 4345 patients attended in five Psychiatric Community Mental Health Centers from June 2014 to October 2014. The web-application reported average daily dose prescribed for antipsychotics, prescribed daily dose (PDD), and the PDD to defined daily dose (DDD) ratio. Results The MEmind web-application reported that antipsychotics were used in 1116 patients out of the total sample, mostly in 486 (44%) patients with schizophrenia related disorders but also in other diagnoses. Second generation antipsychotics (quetiapine, aripiprazole and long-acting paliperidone) were preferably employed. Low doses were more frequently used than high doses. Long acting paliperidone and ziprasidone however, were the only two anti psychotics used at excessive dosing. Antipsychotic polypharmacy was used in 287 (26%) patients with classic depot drugs, clotiapine, amisulpride and clozapine. Conclusions In this study we describe the first step of the development of a web application that is able to make polypharmacy, high dose usage and off label usage of antipsychotics visible to clinicians. Current development of the MEmind web application may help to improve prescription security via momentary feedback of prescription and clinical decision support system.	[Berrouiguet, Sofian] Brest Med Univ Hosp, Dept Psychiat & Emergency, Brest, France; [Berrouiguet, Sofian; Courtet, Philippe] Telecom Bretagne, Log Uses Social Sci & Informat Sci Dept, Plouzane, France; [Luisa Barrigon, Maria; Ovejero-Garcia, Santiago; Jose Carballo, Juan] Jimenez Diaz Hosp, Dept Psychiat Fdn, Madrid, Spain; [Brandt, Sara A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Alvarez-Garcia, Raquel] Univ Hosp Rey Juan Carlos, Dept Psychiat, Madrid, Spain; [Courtet, Philippe] Montpellier Univ Hosp, Dept Psychiat, U888, INSERM, Montpellier, France; [Baca-Garcia, Enrique] IIS Jimenez Diaz Fdn, Dept Psychiat, Madrid, Spain; [Baca-Garcia, Enrique] Univ Hosp Infanta Elena, Dept Psychiat, Valdemoro, Spain; [Baca-Garcia, Enrique] Univ Hosp Rey Juan Carlos, Dept Psychiat, Mostoles, Spain; [Baca-Garcia, Enrique] Univ Autonoma Madrid, Gen Hosp Villalba, Dept Psychiat, Madrid, Spain; [Baca-Garcia, Enrique] CIBERSAM, Madrid, Spain; [Baca-Garcia, Enrique] Columbia Univ, New York, NY USA	CHU Brest; IMT - Institut Mines-Telecom; IMT Atlantique; Icahn School of Medicine at Mount Sinai; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Fundacion Jimenez Diaz; Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Columbia University	Berrouiguet, S (corresponding author), Brest Med Univ Hosp, Dept Psychiat & Emergency, Brest, France.; Berrouiguet, S (corresponding author), Telecom Bretagne, Log Uses Social Sci & Informat Sci Dept, Plouzane, France.	sofian.berrouiguet@chu-brest.fr	Baca-García, Enrique/ABH-9371-2020; Vian Lains, Antonio/ABC-8519-2021; Baca-García, Enrique/F-4106-2015; Carballo, Juan J/A-1965-2014; Barrigón, Maria Luisa/ABI-6017-2020	Baca-García, Enrique/0000-0002-6963-6555; Vian Lains, Antonio/0000-0002-6246-9301; Baca-García, Enrique/0000-0002-6963-6555; Carballo, Juan J/0000-0001-8446-8820; Barrigón, Maria Luisa/0000-0002-2497-6353; Sanchez Pastor, Luis/0000-0002-5360-6351; Palomar-Ciria, Nora/0000-0002-2293-3106	French embassy in Madrid (Spain); Fondation de France; Fondo Europeo de Desarrollo Regional - FEDER [PI13/02200]; Institute de Salud Carlos III	French embassy in Madrid (Spain); Fondation de France(Fondation de France); Fondo Europeo de Desarrollo Regional - FEDER; Institute de Salud Carlos III(Instituto de Salud Carlos III)	The present study has been supported by the French embassy in Madrid (Spain), the Fondation de France and Institute de Salud Carlos III co-founded by Fondo Europeo de Desarrollo Regional - FEDER (PI13/02200 grant).	Alexander GC, 2011, PHARMACOEPIDEM DR S, V20, P177, DOI 10.1002/pds.2082; Anderson SL, 2014, AM J HEALTH-SYST PH, V71, P394, DOI 10.2146/ajhp130221; Baandrup L, 2012, EUR J HEALTH ECON, V13, P355, DOI 10.1007/s10198-011-0308-0; Ballard C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003476.pub2; Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Berk M, 1996, CLOTIAPINE ACUTE PSY; Bernardo M, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-42; Carney AC, 2013, J PSYCHOSOC NURS MEN, V51, P11, DOI 10.3928/02793695-20130709-01; Carton L, 2015, CURR PHARM DESIGN, V21, P3280, DOI 10.2174/1381612821666150619092903; Centorrino F, 2012, HUM PSYCHOPHARM CLIN, V27, P521, DOI 10.1002/hup.2257; Christian R., 2012, 13 AG HEALTHC RES QU; Classen DC, 2011, J PATIENT SAF, V7, P61, DOI 10.1097/PTS.0b013e31821d6f6e; Connolly A, 2014, THER ADV PSYCHOPHARM, V4, P247, DOI 10.1177/2045125314540298; Correll CU, 2012, PSYCHIAT CLIN N AM, V35, P661, DOI 10.1016/j.psc.2012.06.007; Davis JM, 2003, ARCH GEN PSYCHIAT, V60, P553, DOI 10.1001/archpsyc.60.6.553; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; Faries D, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-26; Gao KM, 2006, J CLIN PSYCHIAT, V67, P1327, DOI 10.4088/JCP.v67n0902; Gaviria AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139403; Gentile S, 2010, PSYCHOPHARMACOLOGY, V212, P119, DOI 10.1007/s00213-010-1939-z; Grupo de Trabajo de la Gufade Practica Clmicasobre la Esquizofreniay el Trastorno Psicotico Incipiente. Espanya. Ministerio de Sanidady Consumo. Plan de Calidad para el Sistema Nacional de Salud (Espanya) Catalunya. Departament de Salut, 2009, GUIA PRACT CLIN ESQ; Hartung DM, 2013, PSYCHIAT SERV, V64, P1236, DOI 10.1176/appi.ps.005482012; Hersh WR, 2013, MED CARE, V51, pS30, DOI 10.1097/MLR.0b013e31829b1dbd; Horsky J, 2012, J BIOMED INFORM, V45, P1202, DOI 10.1016/j.jbi.2012.09.002; Koppel R, 2010, STUD HEALTH TECHNOL, V157, P7, DOI 10.3233/978-1-60750-569-3-7; Kreys TJM, 2015, PHARMACOTHERAPY, V35, P175, DOI 10.1002/phar.1529; Lauriello J, 2015, J CLIN PSYCHIAT, V76, pE366, DOI 10.4088/JCP.14com09755; Leucht S, 1999, SCHIZOPHR RES, V35, P51, DOI 10.1016/S0920-9964(98)00105-4; Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3; Linden M, 2004, HUM PSYCHOPHARM CLIN, V19, P111, DOI 10.1002/hup.574; Maher Alicia R, 2012, J Manag Care Pharm, V18, pS1; McElroy SL, 2010, EXPERT OPIN INV DRUG, V19, P1527, DOI 10.1517/13543784.2010.538048; Menendez GF, 2004, ACTAS ESP PSIQUIATRI, V32, P333; Montejo AL, 2006, ACTAS ESP PSIQUIATRI, V34, P323; Novick D, 2012, J NERV MENT DIS, V200, P637, DOI 10.1097/NMD.0b013e31825bfd95; Pani L, 2008, CLIN DRUG INVEST, V28, P465, DOI 10.2165/00044011-200828080-00001; Procyshyn RM, 2010, J CLIN PSYCHIAT, V71, P566, DOI 10.4088/JCP.08m04912gre; Ranceva N, 2010, J CLIN PHARMACOL, V50, P699, DOI 10.1177/0091270009350625; Roh D, 2014, AUST NZ J PSYCHIAT, V48, P52, DOI 10.1177/0004867413488221; Runyan JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071325; Schiff GD, 2010, NEW ENGL J MED, V362, P1066, DOI 10.1056/NEJMp0911734; Schwartz T, 2012, DRUG TODAY, V48, P283, DOI 10.1358/dot.2012.48.4.1745225; SIEGEL C, 1984, COMPUT BIOMED RES, V17, P419, DOI 10.1016/0010-4809(84)90011-9; Sim K, 2004, PHARMACOPSYCHIATRY, V37, P175, DOI 10.1055/s-2004-827174; Stoffers JM, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-014-0534-0; Sun FF, 2014, AM J HEALTH-SYST PH, V71, P728, DOI 10.2146/ajhp130471; Taylor D.M., 2018, MAUDSLEY PRESCRIBING, V13th ed.); Wang SJ, 2003, AM J MED, V114, P397, DOI 10.1016/S0002-9343(03)00057-3; Weiner MG, 2009, ANN INTERN MED, V151, P359, DOI 10.7326/0003-4819-151-5-200909010-00141; Weiskopf NG, 2013, J AM MED INFORM ASSN, V20, P144, DOI 10.1136/amiajnl-2011-000681; Windfuhr K, 2011, J PSYCHOPHARMACOL, V25, P1533, DOI 10.1177/0269881110379288; World Health Organization, 1992, 10 REV INT CLASS DIS; Wright BM, 2013, PHARMACOTHERAPY, V33, P344, DOI 10.1002/phar.1204; Zhornitsky S, 2010, J CLIN PSYCHOPHARM, V30, P417, DOI 10.1097/JCP.0b013e3181e7810a	54	10	10	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0163796	10.1371/journal.pone.0163796	http://dx.doi.org/10.1371/journal.pone.0163796			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DZ9NZ	27764107	Green Published, gold, Green Submitted			2023-01-03	WOS:000386204500009
J	Hagen, S; Glazener, C; McClurg, D; Macarthur, C; Elders, A; Herbison, P; Wilson, D; Toozs-Hobson, P; Hemming, C; Hay-Smith, J; Collins, M; Dickson, S; Logan, J				Hagen, Suzanne; Glazener, Cathryn; McClurg, Doreen; Macarthur, Christine; Elders, Andrew; Herbison, Peter; Wilson, Don; Toozs-Hobson, Philip; Hemming, Christine; Hay-Smith, Jean; Collins, Marissa; Dickson, Sylvia; Logan, Janet			Pelvic floor muscle training for secondary prevention of pelvic organ prolapse (PREVPROL): a multicentre randomised controlled trial	LANCET			English	Article							SHORT-FORM; WOMEN; SYMPTOMS; URINARY; HEALTH; QUESTIONNAIRE; INCONTINENCE; TERMINOLOGY; ICIQ	Background Pelvic floor muscle training can reduce prolapse severity and symptoms in women seeking treatment. We aimed to assess whether this intervention could also be effective in secondary prevention of prolapse and the need for future treatment. Methods We did this multicentre, parallel-group, randomised controlled trial at three centres in New Zealand and the UK. Women from a longitudinal study of pelvic floor function after childbirth were potentially eligible for inclusion. Women of any age who had stage 1-3 prolapse, but had not sought treatment, were randomly assigned (1: 1), via remote computer allocation, to receive either one-to-one pelvic floor muscle training (five physiotherapy appointments over 16 weeks, and annual review) plus Pilates-based pelvic floor muscle training classes and a DVD for home use (intervention group), or a prolapse lifestyle advice leaflet (control group). Randomisation was minimised by centre, parity (three or less vs more than three deliveries), prolapse stage (above the hymen vs at or beyond the hymen), and delivery method (any vaginal vs all caesarean sections). Women and intervention physiotherapists could not be masked to group allocation, but allocation was masked from data entry researchers and from the trial statistician until after database lock. The primary outcome was self-reported prolapse symptoms (Pelvic Organ Prolapse Symptom Score [POP-SS]) at 2 years. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01171846. Findings Between Dec 21, 2008, and Feb 24, 2010, in New Zealand, and Oct 27, 2010, and Sept 5, 2011, in the UK, we randomly assigned 414 women to the intervention group (n=207) or the control group (n=207). One participant in each group was excluded after randomisation, leaving 412 women for analysis. At baseline, 399 (97%) women had prolapse above or at the level of the hymen. The mean POP-SS score at 2 years was 3.2 (SD 3.4) in the intervention group versus 4.2 (SD 4.4) in the control group (adjusted mean difference -1.01, 95% CI -1.70 to -0.33; p=0.004). The mean symptom score stayed similar across time points in the control group, but decreased in the intervention group. Three adverse events were reported, all of which were in the intervention group (one women had a fall, one woman had a pain in her tail bone, and one woman had chest pain and shortness of breath). Interpretation Our study shows that pelvic floor muscle training leads to a small, but probably important, reduction in prolapse symptoms. This finding will be important for women and caregivers considering preventive strategies.	[Hagen, Suzanne; McClurg, Doreen; Elders, Andrew; Logan, Janet] Glasgow Caledonian Univ, Nursing Midwifery & Allied Hlth Profess Res Unit, Glasgow G4 0BA, Lanark, Scotland; [Collins, Marissa] Glasgow Caledonian Univ, Yunus Ctr Social Business & Hlth, Glasgow, Lanark, Scotland; [Dickson, Sylvia] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland; [Glazener, Cathryn] Univ Aberdeen, Hlth Serv Res Unit, Hlth Sci Bldg, Aberdeen, Scotland; [Hemming, Christine] Univ Aberdeen, Aberdeen Royal Infirm, Foresterhill, Aberdeen, Scotland; [Macarthur, Christine] Univ Birmingham, Dept Epidemiol & Biostat, Birmingham, W Midlands, England; [Herbison, Peter] Dunedin Sch Med, Prevent & Social Med, Dunedin, New Zealand; [Wilson, Don] Dunedin Sch Med, Dept Womens & Childrens Hlth, Dunedin, New Zealand; [Toozs-Hobson, Philip] Birmingham Womens Hosp, Dept Urogynaecol, Birmingham, W Midlands, England; [Hay-Smith, Jean] Univ Otago, Dept Med, Rehabil Teaching & Res Unit, Wellington, New Zealand	Glasgow Caledonian University; Glasgow Caledonian University; Glasgow Caledonian University; University of Aberdeen; University of Aberdeen; University of Birmingham; University of Otago; University of Otago; Birmingham Women's Hospital; University of Otago	Hagen, S (corresponding author), Glasgow Caledonian Univ, Nursing Midwifery & Allied Hlth Profess Res Unit, Glasgow G4 0BA, Lanark, Scotland.	s.hagen@gcu.ac.uk	MacArthur, Christine/ABA-8601-2021; Elders, Andrew/N-4195-2015	MacArthur, Christine/0000-0003-0434-2158; Herbison, Graham Peter/0000-0002-5684-024X; Elders, Andrew/0000-0003-4172-4702; McClurg, Doreen/0000-0002-2872-1702; Collins, Marissa/0000-0002-0896-6673; Toozs-Hobson, Philip/0000-0002-1859-9934; HAGEN, SUZANNE/0000-0002-9741-9160	Wellbeing of Women charity; New Zealand Continence Association; Dean's Bequest Fund of Dunedin School of Medicine; Wellbeing of Women [RG1271] Funding Source: researchfish; Chief Scientist Office [NMAHP2] Funding Source: researchfish	Wellbeing of Women charity(Wellbeing of Women (WoW)); New Zealand Continence Association; Dean's Bequest Fund of Dunedin School of Medicine; Wellbeing of Women(Wellbeing of Women (WoW)); Chief Scientist Office	Wellbeing of Women charity, the New Zealand Continence Association, and the Dean's Bequest Fund of Dunedin School of Medicine.	Alves FK, 2015, MATURITAS, V81, P300, DOI 10.1016/j.maturitas.2015.03.006; [Anonymous], 2013, HOSP EP STAT ADM PAT; Avery K, 2004, NEUROUROL URODYNAM, V23, P322, DOI 10.1002/nau.20041; Bo K, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.06.049; Borello-France DF, 2007, PHYS THER, V87, P399, DOI 10.2522/ptj.20060160; Braekken IH, 2010, OBSTET GYNECOL, V115, P317, DOI 10.1097/AOG.0b013e3181cbd35f; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; Culligan PJ, 2010, INT UROGYNECOL J, V21, P401, DOI 10.1007/s00192-009-1046-z; Department of Health, 2012, REF COSTS GUID 2011; Due U, 2016, INT UROGYNECOL J, V27, P555, DOI 10.1007/s00192-015-2852-0; Giraudo D, 2011, NEUROUROL URODYNAM, V30, P1009; Hagen S, 2010, NEUROUROL URODYNAM, V29, P1055; Hagen S, 2009, BJOG-INT J OBSTET GY, V116, P25, DOI 10.1111/j.1471-0528.2008.01903.x; Hagen S, 2014, LANCET, V383, P796, DOI 10.1016/S0140-6736(13)61977-7; Hagen S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003882.pub4; Hagen S, 2009, INT UROGYNECOL J, V20, P45, DOI 10.1007/s00192-008-0726-4; Haylen BT, 2016, NEUROUROL URODYNAM, V35, P137, DOI 10.1002/nau.22922; Hendrix SL, 2002, AM J OBSTET GYNECOL, V186, P1160, DOI 10.1067/mob.2002.123819; Hensrud DD, 2000, MAYO CLIN PROC, V75, P165; Kashyap R, 2013, INT J GYNECOL OBSTET, V121, P69, DOI 10.1016/j.ijgo.2012.11.012; MacArthur C, 2011, BJOG-INT J OBSTET GY, V118, P1001, DOI 10.1111/j.1471-0528.2011.02964.x; Resende APM, 2012, NEUROUROL URODYNAM, V31, P121, DOI 10.1002/nau.21149; Miedel A, 2011, INT UROGYNECOL J, V22, P461, DOI 10.1007/s00192-010-1305-z; Miller JM, 1998, J AM GERIATR SOC, V46, P870, DOI 10.1111/j.1532-5415.1998.tb02721.x; Moore K., 2013, INCONTINENCE, P1101, DOI DOI 10.1183/13993003.00541-2019; National Institute for Health and Care Excellence, 2012, GUID MAN; Nygaard I, 2013, JAMA-J AM MED ASSOC, V309, P2016, DOI 10.1001/jama.2013.4919; Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6; Panman CMCR, 2017, BJOG-INT J OBSTET GY, V124, P511, DOI 10.1111/1471-0528.13992; Price N, 2006, BJOG-INT J OBSTET GY, V113, P700, DOI 10.1111/j.1471-0528.2006.00938.x; Rogers RG, 2003, INT UROGYNECOL J PEL, V14, P164, DOI 10.1007/s00192-003-1063-2; SCA Hygiene, COREWELLNESS PROGR; University of Sheffield, HLTH EC DEC SCI; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	35	39	44	2	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2017	389	10067					393	402		10.1016/S0140-6736(16)32109-2	http://dx.doi.org/10.1016/S0140-6736(16)32109-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EI9CK	28010994	Green Submitted, Green Accepted			2023-01-03	WOS:000392804700036
J	Spitzer, MH; Carmi, Y; Reticker-Flynn, NE; Kwek, SS; Madhireddy, D; Martins, MM; Gherardini, PF; Prestwood, TR; Chabon, J; Bendall, SC; Fong, L; Nolan, GP; Engleman, EG				Spitzer, Matthew H.; Carmi, Yaron; Reticker-Flynn, Nathan E.; Kwek, Serena S.; Madhireddy, Deepthi; Martins, Maria M.; Gherardini, Pier Federico; Prestwood, Tyler R.; Chabon, Jonathan; Bendall, Sean C.; Fong, Lawrence; Nolan, Garry P.; Engleman, Edgar G.			Systemic Immunity Is Required for Effective Cancer Immunotherapy	CELL			English	Article							REGULATORY T-CELLS; MASS CYTOMETRY; BREAST-CANCER; TUMOR; IDENTIFICATION; PATIENT	Immune responses involve coordination across cell types and tissues. However, studies in cancer immunotherapy have focused heavily on local immune responses in the tumor microenvironment. To investigate immune activity more broadly, we performed an organism-wide study in genetically engineered cancer models using mass cytometry. We analyzed immune responses in several tissues after immunotherapy by developing intuitive models for visualizing single-cell data with statistical inference. Immune activation was evident in the tumor and systemically shortly after effective therapy was administered. However, during tumor rejection, only peripheral immune cells sustained their proliferation. This systemic response was coordinated across tissues and required for tumor eradication in several immunotherapy models. An emergent population of peripheral CD4 T cells conferred protection against new tumors and was significantly expanded in patients responding to immunotherapy. These studies demonstrate the critical impact of systemic immune responses that drive tumor rejection.	[Spitzer, Matthew H.; Carmi, Yaron; Reticker-Flynn, Nathan E.; Martins, Maria M.; Prestwood, Tyler R.; Chabon, Jonathan; Bendall, Sean C.; Engleman, Edgar G.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Spitzer, Matthew H.; Madhireddy, Deepthi; Gherardini, Pier Federico; Nolan, Garry P.] Stanford Univ, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA; [Spitzer, Matthew H.; Nolan, Garry P.; Engleman, Edgar G.] Stanford Univ, Program Immunol, Stanford, CA 94305 USA; [Spitzer, Matthew H.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Kwek, Serena S.; Fong, Lawrence] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA; [Spitzer, Matthew H.; Fong, Lawrence] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Carmi, Yaron] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Ramat Aviv, Israel	Stanford University; Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Tel Aviv University; Sackler Faculty of Medicine	Spitzer, MH; Engleman, EG (corresponding author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.; Spitzer, MH; Nolan, GP (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA.; Spitzer, MH; Nolan, GP; Engleman, EG (corresponding author), Stanford Univ, Program Immunol, Stanford, CA 94305 USA.; Spitzer, MH (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.; Spitzer, MH (corresponding author), Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA.	matthew.spitzer@ucsf.edu; gnolan@stanford.edu; edengleman@stanford.edu	Nolan, Garry/AAE-7903-2019; Reticker-Flynn, Nathan/R-7226-2019; Bendall, Sean/AGG-0126-2022	Bendall, Sean/0000-0003-1341-2453; Reticker-Flynn, Nathan/0000-0002-9963-039X; Spitzer, Matthew/0000-0002-5291-3819; Nolan, Garry/0000-0002-8862-9043	NIH [F31CA189331, DP5OD023056, F32CA189408, U19AI057229, U19AI100627, R33CA183654, R01HL120724, R01CA196657, U54CA209971, R01AI118884]; DOD [OC110674, 11491122]; Gates Foundation [OPP1113682]; NIAID [HHSN272201200028C]; FDA [HHSF223201210194C BAA-12-00118]; NATIONAL CANCER INSTITUTE [T32CA009302, R33CA183654, F32CA189408, R01CA196657, F31CA189331, U54CA209971] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL120724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI100627, R01AI118884, U19AI057229] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD023056] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Gates Foundation(Bill & Melinda Gates Foundation); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FDA(United States Department of Health & Human Services); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank G.K. Fragiadakis and L.E. Sanman for helpful conversations and feedback and A. Trejo and A. Jager for CyTOF maintenance. M.H.S., P.F.G., L.F., and G.P.N. are investigators of the Parker Institute for Cancer Immunotherapy. G.P.N. has a personal financial interest in, and S.C.B. has been a paid consultant for, Fluidigm, manufacturer of the mass cytometer utilized. E.G.E. is a founder and board member of Bolt Biotherapeutics, licensee of the therapy with alloIgG. This work was supported by NIH grants F31CA189331 and DP5OD023056 to M.H.S.; NIH grant F32CA189408 to N.R.F.; NIH grants U19AI057229, U19AI100627, R33CA183654, and R01HL120724, DOD grants OC110674 and 11491122, Gates Foundation grant OPP1113682, NIAID grant HHSN272201200028C, and FDA grant HHSF223201210194C BAA-12-00118 to G.P.N.; NIH grants R01CA196657 and U54CA209971 to G.P.N. and E.G.E.; and NIH grant R01AI118884 to E.G.E.	Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Bastian M., 2009, INT AAAI C WEBL SOC; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111; Bulliard Y, 2013, J EXP MED, V210, P1685, DOI 10.1084/jem.20130573; Carmi Y, 2015, NATURE, V521, P99, DOI 10.1038/nature14424; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Cheng GY, 2012, J IMMUNOL, V189, P1780, DOI 10.4049/jimmunol.1103768; Cohen CJ, 2015, J CLIN INVEST, V125, P3981, DOI 10.1172/JCI82416; Coley W.B, 1893, AM J MED SCI, V105, P487, DOI [DOI 10.1097/00000441-189305000-00001, 10.1097/00000441-189305000-00001]; CORBETT TH, 1975, CANCER RES, V35, P2434; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Haeryfar SMM, 2004, J IMMUNOL, V173, P3581, DOI 10.4049/jimmunol.173.6.3581; Hanninen A, 2011, EUR J IMMUNOL, V41, P634, DOI 10.1002/eji.201040760; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hotson AN, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaa9303; Ideker T, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.99; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Kwek SS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1101204; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Pelletier N, 2010, NAT IMMUNOL, V11, P1110, DOI 10.1038/ni.1954; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Rosenberg SA, 2014, NAT REV CLIN ONCOL, V11, P630, DOI 10.1038/nrclinonc.2014.174; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Spranger S, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-3; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Xie Y, 2010, J EXP MED, V207, P651, DOI 10.1084/jem.20091921; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	41	485	499	11	108	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	2017	168	3					487	+		10.1016/j.cell.2016.12.022	http://dx.doi.org/10.1016/j.cell.2016.12.022			31	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FV5CU	28111070	Green Accepted, Bronze			2023-01-03	WOS:000424595700001
J	Esteruelas, NF; Cattet, M; Zedrosser, A; Stenhouse, GB; Kuker, S; Evans, AL; Arnemo, JM				Esteruelas, Nuria Fandos; Cattet, Marc; Zedrosser, Andreas; Stenhouse, Gordon B.; Kuker, Susanne; Evans, Alina L.; Arnemo, Jon M.			A Double-Blinded, Randomized Comparison of Medetomidine-Tiletamine-Zolazepamand Dexmedetomidine-Tiletamine-Zolazepam Anesthesia in Free-Ranging Brown Bears (Ursus Arctos)	PLOS ONE			English	Article							POLAR BEARS; GRIZZLY BEARS; PHYSIOLOGICAL-RESPONSES; KETAMINE ANESTHESIA; CLINICAL-EFFICACY; PLASMA-GLUCOSE; BLACK BEARS; IMMOBILIZATION; XYLAZINE; MAMMALS	We compared anesthetic features, blood parameters, and physiological responses to either medetomidine-tiletamine-zolazepam or dexmedetomidine-tiletamine-zolazepam using a double-blinded, randomized experimental design during 40 anesthetic events of free-ranging brown bears (Ursus arctos) either captured by helicopter in Sweden or by culvert trap in Canada. Induction was smooth and predictable with both anesthetic protocols. Induction time, the need for supplemental drugs to sustain anesthesia, and capture-related stress were analyzed using generalized linear models, but anesthetic protocol did not differentially affect these variables. Arterial blood gases and acid-base status, and physiological responses were examined using linear mixed models. We documented acidemia (pH of arterial blood < 7.35), hypoxemia (partial pressure of arterial oxygen < 80 mmHg), and hypercapnia (partial pressure of arterial carbon dioxide >= 45 mmHg) with both protocols. Arterial pH and oxygen partial pressure were similar between groups with the latter improving markedly after oxygen supplementation (p < 0.001). We documented dose-dependent effects of both anesthetic protocols on induction time and arterial oxygen partial pressure. The partial pressure of arterial carbon dioxide increased as respiratory rate increased with medetomidine-tiletamine-zolazepam, but not with dexmedetomidine-tiletamine-zolazepam, demonstrating a differential drug effect. Differences in heart rate, respiratory rate, and rectal temperature among bears could not be attributed to the anesthetic protocol. Heart rate increased with increasing rectal temperature (p < 0.001) and ordinal day of capture (p = 0.002). Respiratory rate was significantly higher in bears captured by helicopter in Sweden than in bears captured by culvert trap in Canada (p < 0.001). Rectal temperature significantly decreased over time (p <= 0.05). Overall, we did not find any benefit of using dexmedetomidine-tiletamine-zolazepam instead of medetomidine-tiletamine-zolazepam in the anesthesia of brown bears. Both drug combinations appeared to be safe and reliable for the anesthesia of free-ranging brown bears captured by helicopter or by culvert trap.	[Esteruelas, Nuria Fandos; Kuker, Susanne; Evans, Alina L.; Arnemo, Jon M.] Inland Norway Univ Appl Sci, Dept Forestry & Wildlife Management, Campus Evenstad, Elverum, Norway; [Cattet, Marc] RGL Recovery Wildlife Hlth & Vet Serv, Saskatoon, SK, Canada; [Cattet, Marc] Univ Saskatchewan, Dept Vet Pathol, Saskatoon, SK, Canada; [Zedrosser, Andreas] Univ Coll Southeast Norway, Dept Environm & Hlth Studies, Porsgrunn, Norway; [Zedrosser, Andreas] Univ Nat Resources & Appl Life Sci, Dept Integrat Biol & Biodivers Res, Vienna, Austria; [Stenhouse, Gordon B.] fRI Res, Hinton, AB, Canada; [Arnemo, Jon M.] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, Umea, Sweden	Inland Norway University of Applied Sciences; University of Saskatchewan; University College of Southeast Norway; University of Natural Resources & Life Sciences, Vienna; Swedish University of Agricultural Sciences	Esteruelas, NF (corresponding author), Inland Norway Univ Appl Sci, Dept Forestry & Wildlife Management, Campus Evenstad, Elverum, Norway.	nfanest@gmail.com	Evans, Alina/AAH-8881-2019		Swedish Environmental Protection Agency; Norwegian Environmental Agency; Swedish Association for Hunting and Wildlife Management; Research Council of Norway; Austrian Science Fund; Natural Sciences and Engineering Research Council of Canada (NSERC) Collaborative Research and Development Grant Program [CRDPJ 328937-05]; fRI Research Grizzly Bear Program; Alberta Innovates Bio-Solutions [VCS-11-008]; Fundacion Especial Caja Madrid	Swedish Environmental Protection Agency; Norwegian Environmental Agency; Swedish Association for Hunting and Wildlife Management; Research Council of Norway(Research Council of Norway); Austrian Science Fund(Austrian Science Fund (FWF)); Natural Sciences and Engineering Research Council of Canada (NSERC) Collaborative Research and Development Grant Program; fRI Research Grizzly Bear Program; Alberta Innovates Bio-Solutions; Fundacion Especial Caja Madrid	The Scandinavian Brown Bear Research Project is funded by the Swedish Environmental Protection Agency, the Norwegian Environmental Agency, the Swedish Association for Hunting and Wildlife Management, the Research Council of Norway, and the Austrian Science Fund. The research in Alberta, Canada, was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) Collaborative Research and Development Grant Program (grant number CRDPJ 328937-05), partners of the fRI Research Grizzly Bear Program, and Alberta Innovates Bio-Solutions (project number VCS-11-008). Fundacion Especial Caja Madrid provided stipend support for NFE during the first year of the study.	Ambrisko TD, 2002, CAN J VET RES, V66, P42; Ansah OB, 1998, J VET PHARMACOL THER, V21, P380, DOI 10.1046/j.1365-2885.1998.00155.x; Arnemo J. M., 2012, BIOMEDICAL PROTOCOLS; Arnemo Jon M., 2007, P103, DOI 10.1002/9780470376478.ch8; Arnemo Jon M., 1999, Rangifer, V19, P85; Barton K., 2015, CRAN VERSION 1 14 0; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Benson GJ, 2000, VET SURG, V29, P85, DOI 10.1111/j.1532-950X.2000.00085.x; Bouts T, 2011, VET ANAESTH ANALG, V38, P106, DOI 10.1111/j.1467-2995.2010.00591.x; Bouts T, 2010, VET ANAESTH ANALG, V37, P207, DOI 10.1111/j.1467-2995.2009.00523.x; Burnham K. P., 2002, TECHNOMETRICS, V2nd, DOI DOI 10.1007/B97636; Burnside WM, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-48; Butler PJ, 2004, FUNCT ECOL, V18, P168, DOI 10.1111/j.0269-8463.2004.00821.x; Canadian Council on Animal Care, 2003, GUID CAR US WILDL; Carroll GL, 2005, VET ANAESTH ANALG, V32, P147, DOI 10.1111/j.1467-2995.2005.00187.x; Cattet M, 2008, J MAMMAL, V89, P973, DOI 10.1644/08-MAMM-A-095.1; Cattet MRL, 2003, J WILDLIFE DIS, V39, P649, DOI 10.7589/0090-3558-39.3.649; Cattet MRL, 2004, J WILDLIFE DIS, V40, P562, DOI 10.7589/0090-3558-40.3.562; Cattet MRL, 2003, J WILDLIFE DIS, V39, P655, DOI 10.7589/0090-3558-39.3.655; Cattet MRL, 2003, URSUS-SERIES, V14, P88; Cattet MRL, 1997, J WILDLIFE DIS, V33, P611, DOI 10.7589/0090-3558-33.3.611; Cattet MRL, 1999, J WILDLIFE DIS, V35, P548, DOI 10.7589/0090-3558-35.3.548; Caulkett NA, 1997, J WILDLIFE DIS, V33, P618, DOI 10.7589/0090-3558-33.3.618; Caulkett NA, 1999, J ZOO WILDLIFE MED, V30, P504; Caulkett N, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P599; Coltrane JA, 2015, WILDLIFE SOC B, V39, P378, DOI 10.1002/wsb.538; Lima CFD, 2016, J ZOO WILDLIFE MED, V47, P17, DOI 10.1638/2013-0304.1; Delehanty B, 2009, GEN COMP ENDOCR, V160, P176, DOI 10.1016/j.ygcen.2008.11.011; Evans AL, 2016, FRONT ZOOL, V13, DOI 10.1186/s12983-016-0140-6; Fahlman A, 2008, J WILDLIFE DIS, V44, P133, DOI 10.7589/0090-3558-44.1.133; Fahlman A, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P69; Fahlman A, 2014, J WILDLIFE DIS, V50, P574, DOI 10.7589/2013-06-148; Fahlman A, 2011, J ZOO WILDLIFE MED, V42, P1, DOI 10.1638/2008-0117.1; Fahlman A, 2010, J ZOO WILDLIFE MED, V41, P161, DOI 10.1638/2009-0036.1; Friebe A, 2001, URSUS-SERIES, V12, P37; Gannon WL, 2007, J MAMMAL, V88, P809, DOI 10.1644/06-MAMM-F-185R1.1; Graesil AR, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0183-x; Granholm M, 2007, VET REC, V160, P891, DOI 10.1136/vr.160.26.891; Granholm M, 2006, VET ANAESTH ANALG, V33, P214, DOI 10.1111/j.1467-2995.2005.00259.x; Grimsrud KN, 2015, J VET PHARMACOL THER, V38, P24, DOI 10.1111/jvp.12139; JALANKA HH, 1990, J ZOO WILDLIFE MED, V21, P259; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; Jin YP, 2016, VET ANAESTH ANALG, V43, P333, DOI 10.1111/vaa.12301; Kanda T, 2008, CAN J VET RES, V72, P278; Ko JCH, 2000, J AM VET MED ASSOC, V216, P1578, DOI 10.2460/javma.2000.216.1578; Kreeger T.J., 1996, HDB WILDLIFE CHEM IM; Kuusela E, 2000, J VET PHARMACOL THER, V23, P15, DOI 10.1046/j.1365-2885.2000.00245.x; Kuusela E, 2001, AM J VET RES, V62, P1073, DOI 10.2460/ajvr.2001.62.1073; Lemke K.A., 2007, LUMB JONES VET ANEST, P203; MACDONALD E, 1991, J PHARMACOL EXP THER, V259, P848; McDonell W.N., 2007, LUMB JONES VET ANEST, P117; Mich PM, 2008, J ZOO WILDLIFE MED, V39, P480, DOI 10.1638/2007-0150.1; Osofsky SA, 2000, ORYX, V34, P27, DOI 10.1017/S0030605300030866; Ozeki LM, 2015, J ZOO WILDLIFE MED, V46, P279, DOI 10.1638/2014-0052R.1; Painer J, 2012, CAN J ZOOL, V90, P753, DOI [10.1139/Z2012-046, 10.1139/z2012-046]; Powell RA, 2003, ILAR J, V44, P259, DOI 10.1093/ilar.44.4.259; R Core Team, 2021, R LANG ENV STAT COMP; Ramsay E., 2003, ZOO WILD ANIMAL MED, P523; Ranheim B, 2000, J VET PHARMACOL THER, V23, P379, DOI 10.1046/j.1365-2885.2000.00291.x; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Reeder DM, 2005, J MAMMAL, V86, P225, DOI 10.1644/BHE-003.1; Restitutti F, 2012, VET J, V193, P481, DOI 10.1016/j.tvjl.2011.12.010; SAVOLA JM, 1991, EUR J PHARMACOL, V195, P193, DOI 10.1016/0014-2999(91)90535-X; Selmi AL, 2004, CAN VET J, V45, P481; STIRLING I, 1989, J WILDLIFE DIS, V25, P159, DOI 10.7589/0090-3558-25.2.159; STONEBERG RP, 1966, J WILDLIFE MANAGE, V30, P411, DOI 10.2307/3797828; TAYLOR WP, 1989, J WILDLIFE MANAGE, V53, P978, DOI 10.2307/3809598; Teisberg JE, 2014, J WILDLIFE DIS, V50, P74, DOI 10.7589/2012-11-273; Toien O, 2011, SCIENCE, V331, P906, DOI 10.1126/science.1199435; VAINIO O, 1989, ACTA VET SCAND, V30, P401; VAINIO O, 1989, ACTA VET SCAND, P85; Virtanen R, 1988, ACTA VET SCAND, V85, P29; West G, 2007, ZOO ANIMAL WILDLIFE; White TH, 1996, WILDLIFE SOC B, V24, P521; Zuur A.F., 2016, BEGINNERS GUIDE ZERO; Zuur Alain F., 2009, P1	76	5	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2017	12	1							e0170764	10.1371/journal.pone.0170764	http://dx.doi.org/10.1371/journal.pone.0170764			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7CU	28118413	Green Published, gold, Green Accepted			2023-01-03	WOS:000396160500006
J	Liu, FJ; Sun, YT; Xu, TH; Sun, L; Liu, LL; Sun, W; Feng, X; Ma, JF; Wang, LN; Yao, L				Liu, Fangjie; Sun, Yiting; Xu, Tianhua; Sun, Li; Liu, Linlin; Sun, Wei; Feng, Xin; Ma, Jianfei; Wang, Lining; Yao, Li			Effect of Nocturnal Hemodialysis versus Conventional Hemodialysis on End-Stage Renal Disease: A Meta-Analysis and Systematic Review	PLOS ONE			English	Review							LEFT-VENTRICULAR MASS; QUALITY-OF-LIFE; FREQUENT HEMODIALYSIS; HOME HEMODIALYSIS; PUBLICATION BIAS; RISK-FACTORS; DIALYSIS; SURVIVAL; HOSPITALIZATION; HYPERTROPHY	Objectives The purpose of this study is to assess the efficacy and safety of nocturnal hemodialysis on end-stage renal disease (ESRD) patients. Methods We searched Medline, EmBase, and the Cochrance Central Register of Controlled Trials for studies up to January 2016. Analysis was done to compare variant outcomes of different hemodialysis schedules, including mortality, cardiovascular-associated variables, uremia-associated variables, quality of life (QOL), side-effects, and drug usage. Results We collected and analyzed the results of 28 studies involving 22,508 patients in our meta-analysis. The mortality results in this meta-analysis indicated that the nocturnal hemodialysis (NHD) group was not significantly different from conventional hemodialysis (CHD) group (Mortality: OR: 0.75; 95% confidence intervals (CIs): 0.52 to 1.10; p = 0.145), but the CHD group had significantly fewer number of hospitalizations than the NHD group (OR: 1.54; 95% CI: 1.32 to 1.79; p<0.001). NHD was superior to CHD for cardiovascular-associated (left ventricular hypertrophy [LVH]: SMD: -0.39; 95% CI: -0.68 to -0.10; p = 0.009, left ventricular hypertrophy index [LVHI]: SMD: -0.64; 95% CI: -0.83 to -0.46; p<0.001) and uremia-associated intervention results (Serum albumin: SMD: 0.89; 95% CI: 0.41 to 1.36; p<0.001). For the assessment of quality of life, NHD treatment significantly improved the patients' QOL only for SF36-Physical Components Summary (SMD: 0.43; 95% CI: 0.26 to 0.60; p<0.001). NHD intervention was relatively better than CHD for anti-hypertensive drug usage (SMD: -0.48; 95% CI: -0.91 to -0.05; p = 0.005), and there was no difference between groups in our side-effects assessment. Conclusion NHD and CHD performed similarly in terms of ESRD patients' mortality and side-effects. NHD was superior to CHD for cardiovascular-associated and uremia-associated results, QOL, and drug usage; for number of hospitalizations, CHD was relatively better than NHD.	[Liu, Fangjie; Xu, Tianhua; Sun, Li; Liu, Linlin; Ma, Jianfei; Wang, Lining; Yao, Li] China Med Univ, Dept Nephrol, Hosp 1, Shenyang, Liaoning, Peoples R China; [Sun, Yiting] China Med Univ, Dept Clin Med, Shenyang, Liaoning, Peoples R China; [Sun, Wei] China Med Univ, Dept Gen Surg, Shengjing Hosp, Shenyang, Liaoning, Peoples R China; [Feng, Xin] Liaoning Elect Power Ctr Hosp, Blood Purificat Ctr, Shenyang, Liaoning, Peoples R China	China Medical University; China Medical University; China Medical University	Yao, L (corresponding author), China Med Univ, Dept Nephrol, Hosp 1, Shenyang, Liaoning, Peoples R China.	liyao_cmu@163.com			scientific research project for the Universities of Educational Commission of Liaoning Province of China [L2011134]; Key Social Development Program of Science and Technology Commission of Liaoning Province of China [2013225303, 201404046]; Key Social Development Program of Science and Technology Commission of Shenyang of China [F16-206-9-04]	scientific research project for the Universities of Educational Commission of Liaoning Province of China; Key Social Development Program of Science and Technology Commission of Liaoning Province of China; Key Social Development Program of Science and Technology Commission of Shenyang of China	This work was supported by a grant from the scientific research project for the Universities of Educational Commission of Liaoning Province of China (Grant No. L2011134), the Key Social Development Program of Science and Technology Commission of Liaoning Province of China (Grant No. 2013225303), the Key Social Development Program of Science and Technology Commission of Shenyang of China (Grant No. F16-206-9-04), the Key Social Development Program of Science and Technology Commission of Liaoning Province of China (Grant No. 201404046). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkhouli M, 2015, NEFROLOGIA, V35, P234, DOI 10.1016/j.nefro.2015.03.001; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Chan CT, 2013, CLIN J AM SOC NEPHRO, V8, P2106, DOI 10.2215/CJN.03280313; Chan CT, 2012, CIRC-CARDIOVASC IMAG, V5, P251, DOI 10.1161/CIRCIMAGING.111.969923; Chan CT, 2002, KIDNEY INT, V61, P2235, DOI 10.1046/j.1523-1755.2002.00362.x; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Demirci C, 2013, AM J NEPHROL, V37, P559, DOI 10.1159/000351182; Demirci MS, 2012, ATHEROSCLEROSIS, V220, P477, DOI 10.1016/j.atherosclerosis.2011.11.015; do Sameiro-Faria M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/175286; Friedman AN, 2002, J AM SOC NEPHROL, V13, P265, DOI 10.1681/ASN.V131265; HARNETT JD, 1994, J AM SOC NEPHROL, V4, P1486; Heidenheim AP, 2003, AM J KIDNEY DIS, V42, pS36, DOI 10.1016/S0272-6386(03)00536-5; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Jin HM, 2013, NEPHRON CLIN PRACT, V123, P220, DOI 10.1159/000354709; Jin XC, 2012, THER APHER DIAL, V16, P334, DOI 10.1111/j.1744-9987.2012.01070.x; Jin XC, 2011, HEMODIAL INT, V15, P200, DOI 10.1111/j.1542-4758.2011.00537.x; Johansen KL, 2009, KIDNEY INT, V76, P984, DOI 10.1038/ki.2009.291; Karkar A, 2015, SAUDI J KIDNEY DIS T, V26, P1095, DOI 10.4103/1319-2442.168556; Kotanko P, 2015, HEMODIAL INT, V19, P386, DOI 10.1111/hdi.12255; Kramann R, 2012, NEPHROL DIAL TRANSPL, V27, P4298, DOI 10.1093/ndt/gfs400; Lacson E, 2012, J AM SOC NEPHROL, V23, P687, DOI 10.1681/ASN.2011070674; Lacson E, 2010, CLIN J AM SOC NEPHRO, V5, P220, DOI 10.2215/CJN.06070809; Lewicki MC, 2015, SEMIN DIALYSIS, V28, P147, DOI 10.1111/sdi.12322; Lindsay RM, 2004, SEMIN DIALYSIS, V17, P85, DOI 10.1111/j.0894-0959.2004.17202.x; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Manns BJ, 2009, KIDNEY INT, V75, P542, DOI 10.1038/ki.2008.639; Moher David, 2009, Open Med, V3, pe123; Moradi H, 2013, AM J NEPHROL, V38, P136, DOI 10.1159/000351758; Nesrallah G, 2003, AM J KIDNEY DIS, V42, pS13, DOI 10.1016/S0272-6386(03)00532-8; Niakas D, 2009, HEALTH POLICY, V89, P329, DOI 10.1016/j.healthpol.2008.07.005; O'Lone E, 2016, AM J KIDNEY DIS; Ok E, 2011, NEPHROL DIAL TRANSPL, V26, P1287, DOI 10.1093/ndt/gfq724; Overgaard CB, 2011, CAN J CARDIOL, V27, pS114, DOI 10.1016/j.cjca.2011.07.102; Overgaard CB, 2013, CIRCULATION, V128; Papageorgiou SN, 2015, J EVID-BASED DENT PR, V15, P8, DOI 10.1016/j.jebdp.2014.09.001; Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889; Pierratos Andreas, 2004, Hemodial Int, V8, P45, DOI 10.1111/j.1492-7535.2004.00074.x; Powell JR, 2009, CLIN J AM SOC NEPHRO, V4, P1097, DOI 10.2215/CJN.06651208; Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213; Rocco MV, 2011, AM J KIDNEY DIS, V57, P90, DOI 10.1053/j.ajkd.2010.08.024; Salari A, 2012, TRANSPL P, V44, P3007, DOI 10.1016/j.transproceed.2012.03.060; Sawant A, 2014, PHYSIOTHER CAN, V66, P44, DOI 10.3138/ptc.2012-59; Schwartz DI, 2005, CLIN NEPHROL, V63, P202; Shantha GPS, 2015, PEERJ, V3, DOI 10.7717/peerj.835; Silva LSV, 2012, SAUDI J KIDNEY DIS T, V23, P262; Stenvinkel P, 2006, NEPHROLOGY, V11, P36, DOI 10.1111/j.1440-1797.2006.00541.x; Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P689, DOI 10.1053/j.ajkd.2011.12.020; Thumfart J, 2014, DTSCH ARZTEBL INT, V111, P237, DOI 10.3238/arztebl.2014.0237; Van Eps CL, 2010, HEMODIAL INT, V14, P451, DOI 10.1111/j.1542-4758.2010.00463.x; Wald R, 2016, CAN J CARDIOL, V32, P369, DOI 10.1016/j.cjca.2015.07.004; Walsh M, 2010, HEMODIAL INT, V14, P174, DOI 10.1111/j.1542-4758.2009.00418.x	52	13	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2017	12	1							e0169203	10.1371/journal.pone.0169203	http://dx.doi.org/10.1371/journal.pone.0169203			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3QC	28107451	Green Published, Green Submitted, gold			2023-01-03	WOS:000392405300021
J	Cui, JG; Zhu, BC; Fang, GZ; Smith, E; Brauth, SE; Tang, YZ				Cui, Jianguo; Zhu, Bicheng; Fang, Guangzhan; Smith, Ed; Brauth, Steven E.; Tang, Yezhong			Effect of the Level of Anesthesia on the Auditory Brainstem Response in the Emei Music Frog (Babina daunchina)	PLOS ONE			English	Article							EVOKED-POTENTIALS; XENOPUS-LAEVIS; HEARING; FREQUENCY; SIGNALS; MS222; CALLS	Anesthesia is known to affect the auditory brainstem response (ABR) in mice, rats, birds and lizards. The present study investigated how the level of anesthesia affects ABR recordings in an amphibian species, Babina daunchina. To do this, we compared ABRs evoked by tone pip stimuli recorded from 35 frogs when Tricaine methane sulphonate (MS-222) anesthetic immersion times varied from 0, 5 and 10 minutes after anesthesia induction at sound frequencies between 0.5 and 6 kHz. ABR thresholds increased significantly with immersion time across the 0.5 kHz to 2.5 kHz frequency range, which is the most sensitive frequency range for hearing and the main frequency range of male calls. There were no significant differences for anesthetic levels across the 3 kHz to 6 kHz range. ABR latency was significantly longer in the 10 min group than in the 0 and 5 min groups at frequencies of 0.5, 1.0, 1.5, 2.5 kHz, while ABR latency did not differ across the 3 kHz to 4 kHz range and at 2.0 kHz. Taken together, these results show that the level of anesthesia affects the amplitude, threshold and latency of ABRs in frogs.	[Cui, Jianguo; Zhu, Bicheng; Fang, Guangzhan; Tang, Yezhong] Chinese Acad Sci, Chengdu Inst Biol, Chengdu, Sichuan, Peoples R China; [Smith, Ed; Brauth, Steven E.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA	Chinese Academy of Sciences; Chengdu Institute of Biology, CAS; University System of Maryland; University of Maryland College Park	Cui, JG (corresponding author), Chinese Acad Sci, Chengdu Inst Biol, Chengdu, Sichuan, Peoples R China.	cuijg@cib.ac.cn	Zhu, Bicheng/AAU-3425-2020; fang, guangzhan/AAH-1098-2020	Fang, Guangzhan/0000-0003-1803-6610	Youth Innovation Promotion Association CAS, CAS "Light of West China" Program, National Natural Science Foundation of China [31270042]; Youth Professor Project of CIB [Y3B3011]	Youth Innovation Promotion Association CAS, CAS "Light of West China" Program, National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Professor Project of CIB	This work was supported by Youth Innovation Promotion Association CAS, CAS "Light of West China" Program, National Natural Science Foundation of China (31270042) and Youth Professor Project of CIB (Y3B3011) to JC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BORG E, 1983, ACTA OTO-LARYNGOL, V95, P19, DOI 10.3109/00016488309130911; Bradbury J. W., 2011, PRINCIPLES ANIMAL CO; Brittan-Powell EF, 2002, J ACOUST SOC AM, V112, P999, DOI 10.1121/1.1494807; Brittan-Powell EF, 2010, J ACOUST SOC AM, V128, P787, DOI 10.1121/1.3458813; Capranica RR, 1983, ADV VERTEBRATE NEURO, P701, DOI DOI 10.1007/978-1-4684-4412-4_36; Carter KM, 2011, REV FISH BIOL FISHER, V21, P51, DOI 10.1007/s11160-010-9188-0; CHEN J, 2016, PLOS ONE, V11; Chen Q, 2011, J HERPETOL, V45, P406; Christensen-Dalsgaard J, 2011, BIOL LETTERS, V7, P139, DOI 10.1098/rsbl.2010.0636; CHURCH MW, 1987, ELECTROEN CLIN NEURO, V67, P570, DOI 10.1016/0013-4694(87)90060-5; Cordova MS, 2007, BRAIN RES, V1153, P78, DOI 10.1016/j.brainres.2007.03.055; CORWIN JT, 1982, ELECTROEN CLIN NEURO, V54, P629, DOI 10.1016/0013-4694(82)90117-1; Cui JG, 2016, EVOLUTION, V70, P922, DOI 10.1111/evo.12889; Cui JG, 2012, BIOL LETTERS, V8, P337, DOI 10.1098/rsbl.2011.1091; Cui JG, 2011, ASIAN HERPETOL RES, V2, P149, DOI 10.3724/SP.J.1245.2011.00149; Cui JG, 2010, ANIM BEHAV, V80, P181, DOI 10.1016/j.anbehav.2010.05.012; Downes U., 1995, B ASS REPT AMPH VET, V5, P11; Feng AS, 2006, NATURE, V440, P333, DOI 10.1038/nature04416; Gerhardt H. C., 2002, ACOUSTIC COMMUNICATI; Gerhardt H. Carl, 2001, P73; Hall III J. W., 2007, NEW HDB AUDITORY EVO, P212; Henry KS, 2008, ANIM BEHAV, V76, P1659, DOI 10.1016/j.anbehav.2008.08.003; Higgs DM, 2004, J EXP BIOL, V207, P155, DOI 10.1242/jeb.00735; Katbamna B, 2006, J COMP PHYSIOL A, V192, P381, DOI 10.1007/s00359-005-0076-3; Lalonde-Robert V, 2012, J AM ASSOC LAB ANIM, V51, P464; Liu WR, 2014, J COMP PHYSIOL A, V200, P311, DOI 10.1007/s00359-014-0885-3; Lucas JR, 2002, J COMP PHYSIOL A, V188, P981, DOI 10.1007/s00359-002-0359-x; Mann DA, 2005, BIOL LETTERS, V1, P158, DOI 10.1098/rsbl.2004.0241; MATTSON NS, 1989, AQUACULTURE, V83, P89, DOI 10.1016/0044-8486(89)90063-X; Narins P., 2006, HEARING SOUND COMMUN, DOI [10.1007/978-0-387-47796-1, DOI 10.1007/978-0-387-47796-1, DOI 10.1007/978-0-387-47796-1_1]; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; Sanchez-Vazquez FJ, 2011, CHRONOBIOL INT, V28, P109, DOI 10.3109/07420528.2010.538105; Schrode KM, 2014, J COMP PHYSIOL A, V200, P221, DOI 10.1007/s00359-014-0880-8; SMITH DI, 1991, HEARING RES, V54, P1, DOI 10.1016/0378-5955(91)90130-2; SMITH DI, 1989, ELECTROEN CLIN NEURO, V72, P422, DOI 10.1016/0013-4694(89)90047-3; Stapells DR, 1997, AUDIOL NEURO-OTOL, V2, P257, DOI 10.1159/000259252; Stronks HC, 2010, HEARING RES, V260, P20, DOI 10.1016/j.heares.2009.10.015; van Looij MAJ, 2004, HEARING RES, V193, P75, DOI 10.1016/j.heares.2004.02.009; Wells KD., 2007, ECOLOGY BEHAV AMPHIB, DOI 10.7208/9780226893334; WENSTRUP JJ, 1984, J COMP PHYSIOL, V155, P75, DOI 10.1007/BF00610933; WILCZYNSKI W, 1984, PROG NEUROBIOL, V22, P1, DOI 10.1016/0301-0082(84)90016-9; Yang P, 2014, J COMP PHYSIOL A, V200, P117, DOI 10.1007/s00359-013-0866-y; Zhang DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039772	43	12	13	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2017	12	1							e0169449	10.1371/journal.pone.0169449	http://dx.doi.org/10.1371/journal.pone.0169449			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH3AE	28056042	Green Submitted, Green Published, gold			2023-01-03	WOS:000391639100043
J	Banatvala, J				Banatvala, Jangu			CHRISTMAS 2016: IN THE LITERATURE Thomas Dover: doctor, privateer, and rescuer of Robinson Crusoe	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Banatvala, Jangu] Kings Coll London, Clin Virol, St Thomass Campus, London, England	University of London; King's College London	Banatvala, J (corresponding author), Kings Coll London, Clin Virol, St Thomass Campus, London, England.	jangu@btopenworld.com						Beattie T., 2015, BRIT PRIVATEERING VO, DOI [10.1017/CBO9781782044727, DOI 10.1017/CBO9781782044727]; Cotterell D., 2009, CAMPDEN DISTRICT HIS, VVI; Dewhurst K., 1957, QUICKSILVER DOCTOR L; Macintyre D., 1972, THE PRIVATEERS; MORTON RS, 1968, BRIT J VENER DIS, V44, P342; PHEAR D N, 1954, J Hist Med Allied Sci, V9, P139	6	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	2016	355								i6516	10.1136/bmj.i6516	http://dx.doi.org/10.1136/bmj.i6516			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF2JS	27974348				2023-01-03	WOS:000390151300008
J	Manhica, H; Gauffin, K; Almqvist, YB; Rostila, M; Hjern, A				Manhica, Helio; Gauffin, Karl; Almqvist, Ylva B.; Rostila, Mikael; Hjern, Anders			Hospital Admission and Criminality Associated with Substance Misuse in Young Refugees - A Swedish National Cohort Study	PLOS ONE			English	Article							MENTAL-HEALTH; USE DISORDERS; DRUG-ABUSE; GENDER-DIFFERENCES; PUBLIC-HEALTH; UNITED-STATES; CHILDREN; CARE; NEIGHBORHOOD; EXPERIENCES	Background High rates of mental health problems have been described in young refugees, but few studies have been conducted on substance misuse. This study aimed to investigate the patterns of hospital care and criminality associated with substance misuse in refugees who settled in Sweden as teenagers. Methods Gender stratified Cox regression models were used to estimate the risks of criminal convictions and hospital care associated with substance misuse from national Swedish data for 2005-2012. We focused on 22,992 accompanied and 5,686 unaccompanied refugees who were aged 13-19 years when they settled in Sweden and compared them with 1 million native Swedish youths from the same birth cohort. Results The risks of criminal conviction associated with substance misuse increased with the length of residency in male refugees, after adjustment for age and domicile. The hazard ratios (HRs) were 5.21 (4.39-6.19) for unaccompanied and 3.85 (3.42-4.18) for accompanied refugees after more than 10 years of residency, compared with the native population. The risks were slightly lower for hospital care, at 2.88 (2.18-3.79) and 2.52(2.01-3.01) respectively. Risks were particularly pronounced for male refugees from the Horn of Africa and Iran. The risks for all male refugees decreased substantially when income was adjusted for. Young female refugees had similar risks to the general population. Conclusion The risks of criminality and hospital care associated with substance misuse in young male refugees increased with time of residency in Sweden and were associated with a low level of income compared with the native Swedish population. Risks were similar in accompanied and unaccompanied refugees.	[Manhica, Helio; Gauffin, Karl; Almqvist, Ylva B.; Rostila, Mikael; Hjern, Anders] Stockholm Univ, Karolinska Inst, Ctr Hlth Equ Studies CHESS, Stockholm, Sweden; [Hjern, Anders] Karolinska Inst, Dept Med, Clin Epidemiol, Stockholm, Sweden	Karolinska Institutet; Stockholm University; Karolinska Institutet	Manhica, H (corresponding author), Stockholm Univ, Karolinska Inst, Ctr Hlth Equ Studies CHESS, Stockholm, Sweden.	helio.manhica@chess.su.se	MANHICA, Helio/ABG-2029-2021	Gauffin, Karl/0000-0001-9349-9936	Swedish Research Council for Health, Working Life and Welfare (Forte); Nordforsk	Swedish Research Council for Health, Working Life and Welfare (Forte); Nordforsk	This work was supported by the Swedish Research Council for Health, Working Life and Welfare (Forte), and Nordforsk.	Bean T, 2007, J NERV MENT DIS, V195, P288, DOI 10.1097/01.nmd.0000243751.49499.93; Becker JB, 2008, FRONT NEUROENDOCRIN, V29, P36, DOI 10.1016/j.yfrne.2007.07.003; Beckett K, 2006, CRIMINOLOGY, V44, P105, DOI 10.1111/j.1745-9125.2006.00044.x; Bhugra D, 2011, WORLD PSYCHIATRY, V10, P2; Brady KT, 1999, PSYCHIAT CLIN N AM, V22, P241, DOI 10.1016/S0193-953X(05)70074-5; Brady KT, 2004, CURR DIR PSYCHOL SCI, V13, P206, DOI 10.1111/j.0963-7214.2004.00309.x; Brama A, 2010, J HOUS BUILT ENVIRON, V25, P331, DOI 10.1007/s10901-010-9179-4; Brendler-Lindqvist M, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0122-2; Byqvist S, 2006, J PSYCHOACTIVE DRUGS, V38, P427, DOI 10.1080/02791072.2006.10400582; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Crum RM, 1996, DRUG ALCOHOL DEPEN, V43, P155, DOI 10.1016/S0376-8716(96)01298-7; Dupont HJBHM, 2005, INT J DRUG POLICY, V16, P27, DOI 10.1016/j.drugpo.2004.06.002; Eide K, 2013, ACTA PAEDIATR, V102, P666, DOI 10.1111/apa.12258; Medina-Mora ME, 2008, ISSUES CHILD FAM LIV, P73, DOI 10.1007/978-0-387-78512-7_4; Fazel M, 2005, LANCET, V365, P1309, DOI 10.1016/S0140-6736(05)61027-6; Fazel M, 2012, LANCET, V379, P266, DOI 10.1016/S0140-6736(11)60051-2; Fellner, 2009, STANFORD LAW REV, V20, P257; Gauffin K, 2013, ADDICTION, V108, P1441, DOI 10.1111/add.12169; Grella CE, 1999, AM J DRUG ALCOHOL AB, V25, P385, DOI 10.1081/ADA-100101868; Hjern A, 2000, ACTA PAEDIATR, V89, P722, DOI 10.1080/080352500750044089; Hjern A, 2004, SCAND J PUBLIC HEALT, V32, P40, DOI 10.1080/14034940310001677; Hjern A, 2013, EUROPEAN J PUBLIC HL; Hjern A, 2012, SCAND J PUBLIC HEALT, V40, P255, DOI 10.1177/1403494812459610; Kirmayer LJ, 2011, CAN MED ASSOC J, V183, pE959, DOI 10.1503/cmaj.090292; Lappalainen Paul., 2005, BLAGULA GLASHUSET ST; Lindert J, 2009, SOC SCI MED, V69, P246, DOI 10.1016/j.socscimed.2009.04.032; Little M, 2006, J RES CRIME DELINQ, V43, P357, DOI 10.1177/0022427806291260; Manhica H, EPIDEMIOLOG IN PRESS; Manhica H, 2015, NORD J MIGR RES, V5, P194, DOI 10.1515/njmr-2015-0024; Marshall GN, 2005, JAMA-J AM MED ASSOC, V294, P571, DOI 10.1001/jama.294.5.571; Martinez R, 2008, URBAN AFF REV, V43, P846, DOI 10.1177/1078087408314774; Matheson K, 2008, J IMMIGR MINOR HEALT, V10, P291, DOI 10.1007/s10903-007-9086-2; Momtazi S, 2010, CURR OPIN PSYCHIATR, V23, P221, DOI 10.1097/YCO.0b013e328338630d; Montgomery E, 2011, ACTA PSYCHIAT SCAND, V124, P1, DOI 10.1111/j.1600-0447.2011.01740.x; Norredam ML, 2007, DAN MED BULL, V54, P48; PANTELIS C, 1989, PSYCHOL MED, V19, P657, DOI 10.1017/S0033291700024259; Pfeiffer-Gerschel T, 2013 NATL REPORT 20; Pickering S., 2014, ROUTLEDGE HDB CRIME; Rosen M, 2002, SCAND J PUBLIC HEALT, V30, P81, DOI 10.1080/140349401753683444; Salas-Wright CP, 2014, DRUG ALCOHOL DEPEN, V142, P345, DOI 10.1016/j.drugalcdep.2014.06.008; Samecki J, 2006, AR RETTVISAN RATTVIS; Sellstrom E, 2011, HEALTH PLACE, V17, P551, DOI 10.1016/j.healthplace.2010.12.013; Sellstrom E, 2008, HEALTH PLACE, V14, P155, DOI 10.1016/j.healthplace.2007.05.007; UBA L, 1992, PUBLIC HEALTH REP, V107, P544; Vega WA, 2003, AM J PUBLIC HEALTH, V93, P1057, DOI 10.2105/AJPH.93.7.1057; Weitoft GR, 1999, INT J EPIDEMIOL, V28, P756, DOI 10.1093/ije/28.4.756; YEE BWK, 1987, J PSYCHOACTIVE DRUGS, V19, P77, DOI 10.1080/02791072.1987.10472382; Zanchetta MS, 2006, CAN J PUBLIC HEALTH, V97, pS26	48	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2016	11	11							e0166066	10.1371/journal.pone.0166066	http://dx.doi.org/10.1371/journal.pone.0166066			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3FV	27902694	Green Published, Green Submitted, gold			2023-01-03	WOS:000389474100010
J	Dreher, C; Scholz, C; Pommer, M; Brons, S; Prokesch, H; Ecker, S; Debus, J; Jakel, O; Combs, SE; Habermehl, D				Dreher, Constantin; Scholz, Christian; Pommer, Mira; Brons, Stephan; Prokesch, Hannah; Ecker, Swantje; Debus, Jurgen; Jaekel, Oliver; Combs, Stephanie E.; Habermehl, Daniel			Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific alpha/beta-Values for Patients with Non-Resectable Pancreatic Cancer	PLOS ONE			English	Article							NEOADJUVANT CHEMORADIATION; DOSE DISTRIBUTION; RADIOTHERAPY; THERAPY; IMPACT; REPAIR; BEAMS; MODEL; TRIAL	Background The aim of the thesis is to improve treatment plans of carbon ion irradiation by integrating the tissues' specific alpha/beta-values for patients with locally advanced pancreatic cancer (LAPC). Material and Methods Five patients with LAPC were included in this study. By the use of the treatment planning system Syngo RT Planning (Siemens, Erlangen, Germany) treatment plans with carbon ion beams have been created. Dose calculation was based on alpha/beta-values for both organs at risk (OAR) and the tumor. Twenty-five treatment plans and thirty-five forward calculations were created. With reference to the anatomy five field configurations were included. Single Beam Optimization (SBO) and Intensity Modulated Particle Therapy (IMPT) were used for optimization. The plans were analyzed with respect to both dose distributions and individual anatomy. The plans were evaluated using a customized index. Results With regard to the target, a field setup with one single posterior field achieves the highest score in our index. Field setups made up of three fields achieve good results in OAR sparing. Nevertheless, the field setup with one field is superior in complex topographic conditions. But, allocating an alpha/beta-value of 2 Gy to the spinal cord leads to critical high maximum doses in the spinal cord. The evaluation of dose profiles showed significant dose peaks at borders of the alpha/beta-gradient, especially in case of a single posterior field. Conclusion Optimization with specific alpha=beta-values allows a more accurate view on dose distribution than previously. A field setup with one single posterior field achieves good results in case of difficult topographic conditions, but leads to high maximum doses to the spinal cord. So, field setups with multiple fields seem to be more adequate in case of LAPC, being surrounded by highly radiosensitive normal tissues.	[Dreher, Constantin; Debus, Jurgen; Jaekel, Oliver] Univ Heidelberg Hosp, Dept Radiat Oncol, Heidelberg, Germany; [Dreher, Constantin; Combs, Stephanie E.; Habermehl, Daniel] Klinikum Rechts Der Isar, Dept Radiooncol, Munich, Germany; [Scholz, Christian] Siemens AG, Healthcare Sect, Imaging & Therapy Div, Mannheim, Germany; [Pommer, Mira] Hottinger Baldwin Messtech GmbH, Darmstadt, Germany; [Brons, Stephan; Prokesch, Hannah; Ecker, Swantje] Univ Heidelberg Hosp, Heidelberg Ion Beam Therapy Ctr HIT, Heidelberg, Germany; [Combs, Stephanie E.; Habermehl, Daniel] Helmholtz Zentrum Munchen, Inst Innovat Radiotherapy, Munich, Germany	Ruprecht Karls University Heidelberg; Technical University of Munich; Siemens AG; Siemens Germany; Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dreher, C (corresponding author), Univ Heidelberg Hosp, Dept Radiat Oncol, Heidelberg, Germany.; Dreher, C (corresponding author), Klinikum Rechts Der Isar, Dept Radiooncol, Munich, Germany.	ConstantinDreher@gmail.com	Jäkel, Oliver/AAC-4379-2021	Jäkel, Oliver/0000-0002-6056-9747; Dreher, Constantin/0000-0001-5671-9389				Batista V, 2014, RADIOTHER ONCOL, V111, pS152; BENTZEN SM, 1991, RADIOTHER ONCOL, V20, P159, DOI 10.1016/0167-8140(91)90092-U; Cattaneo GM, 2010, RADIOTHER ONCOL, V97, P525, DOI 10.1016/j.radonc.2010.08.007; Combs SE, 2013, STRAHLENTHER ONKOL, V189, P738, DOI 10.1007/s00066-013-0391-5; Combs SE, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-419; Dreher C, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0538-x; El Shafie RA, 2013, J RADIAT RES, V54, P113, DOI 10.1093/jrr/rrt052; Grun R, 2012, PHYS MED BIOL, V57, P7261, DOI 10.1088/0031-9155/57/22/7261; HABERER T, 1993, NUCL INSTRUM METH A, V330, P296, DOI 10.1016/0168-9002(93)91335-K; Habermehl D, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-59; Habermehl D, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-28; Kirkpatrick JP, 2010, INT J RADIAT ONCOL, V76, pS42, DOI 10.1016/j.ijrobp.2009.04.095; Kramer M, 2000, PHYS MED BIOL, V45, P3319, DOI 10.1088/0031-9155/45/11/314; Kramer M, 2000, PHYS MED BIOL, V45, P3299, DOI 10.1088/0031-9155/45/11/313; Kumagai M, 2009, INT J RADIAT ONCOL, V73, P1276, DOI 10.1016/j.ijrobp.2008.10.055; LAWRENCE TS, 1992, INT J RADIAT ONCOL, V23, P781, DOI 10.1016/0360-3016(92)90651-W; Liu F, 2012, INT J RADIAT ONCOL, V83, pE423, DOI 10.1016/j.ijrobp.2011.12.073; Mori S, 2014, RADIOTHER ONCOL, V111, P258, DOI 10.1016/j.radonc.2014.02.014; Oonishi K, 2012, RADIOTHER ONCOL, V105, P258, DOI 10.1016/j.radonc.2012.08.009; Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177; Richter D, 2014, INT J RADIAT ONCOL, V89, P175, DOI 10.1016/j.ijrobp.2014.01.043; Shinoto M, 2013, CANCER-AM CANCER SOC, V119, P45, DOI 10.1002/cncr.27723; Suit H, 2010, RADIOTHER ONCOL, V95, P3, DOI 10.1016/j.radonc.2010.01.015; Taniguchi CM, 2013, INT J RADIAT ONCOL, V85, P1090, DOI 10.1016/j.ijrobp.2012.07.2366; TURESSON I, 1989, RADIOTHER ONCOL, V15, P169, DOI 10.1016/0167-8140(89)90131-X	25	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2016	11	10							e0164473	10.1371/journal.pone.0164473	http://dx.doi.org/10.1371/journal.pone.0164473			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CV	27736917	Green Published, Green Submitted, gold			2023-01-03	WOS:000385505800069
J	Neoptolemos, JP; Palmer, DH; Ghaneh, P; Psarelli, EE; Valle, JW; Halloran, CM; Faluyi, O; O'Reilly, DA; Cunningham, D; Wadsley, J; Darby, S; Meyer, T; Gillmore, R; Anthoney, A; Lind, P; Glimelius, B; Falk, S; Izbicki, JR; Middleton, GW; Cummins, S; Ross, PJ; Wasan, H; McDonald, A; Crosby, T; Ma, YT; Patel, K; Sherriff, D; Soomal, R; Borg, D; Sothi, S; Hammel, P; Hackert, T; Jackson, R; Buchler, MW				Neoptolemos, John P.; Palmer, Daniel H.; Ghaneh, Paula; Psarelli, Eftychia E.; Valle, Juan W.; Halloran, Christopher M.; Faluyi, Olusola; O'Reilly, Derek A.; Cunningham, David; Wadsley, Jonathan; Darby, Suzanne; Meyer, Tim; Gillmore, Roopinder; Anthoney, Alan; Lind, Pehr; Glimelius, Bengt; Falk, Stephen; Izbicki, Jakob R.; Middleton, Gary William; Cummins, Sebastian; Ross, Paul J.; Wasan, Harpreet; McDonald, Alec; Crosby, Tom; Ma, Yuk Ting; Patel, Kinnari; Sherriff, David; Soomal, Rubin; Borg, David; Sothi, Sharmila; Hammel, Pascal; Hackert, Thilo; Jackson, Richard; Buechler, Markus W.		European Study Grp Pancreat Canc	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial	LANCET			English	Article							FOLINIC ACID; CHEMOTHERAPY; THERAPY; CHEMORADIOTHERAPY; ADENOCARCINOMA; MODEL	Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer. Methods We did a phase 3, two-group, open-label, multicentre, randomised clinical trial at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden. Eligible patients were aged 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection). We randomly assigned patients (1: 1) within 12 weeks of surgery to receive six cycles of either 1000 mg/m(2) gemcitabine alone administered once a week for three of every 4 weeks (one cycle) or with 1660 mg/m(2) oral capecitabine administered for 21 days followed by 7 days' rest (one cycle). Randomisation was based on a minimisation routine, and country was used as a stratification factor. The primary endpoint was overall survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat population. Toxicity was analysed in all patients who received trial treatment. This trial was registered with the EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434. Findings Of 732 patients enrolled, 730 were included in the final analysis. Of these, 366 were randomly assigned to receive gemcitabine and 364 to gemcitabine plus capecitabine. The Independent Data and Safety Monitoring Committee requested reporting of the results after there were 458 (95%) of a target of 480 deaths. The median overall survival for patients in the gemcitabine plus capecitabine group was 28.0 months (95% CI 23.5-31.5) compared with 25.5 months (22.7-27.9) in the gemcitabine group (hazard ratio 0.82 [95% CI 0.68-0.98], p=0.032). 608 grade 3-4 adverse events were reported by 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse events in 196 of 366 patients in the gemcitabine group. Interpretation The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.	[Neoptolemos, John P.; Palmer, Daniel H.; Psarelli, Eftychia E.; Halloran, Christopher M.; Jackson, Richard] Univ Liverpool, Liverpool, Merseyside, England; [Neoptolemos, John P.; Ghaneh, Paula; Halloran, Christopher M.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England; [Palmer, Daniel H.; Faluyi, Olusola] Clatterbridge Canc Ctr, Wirral, Merseyside, England; [Valle, Juan W.] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England; [O'Reilly, Derek A.] Manchester Royal Infirm, Manchester, Lancs, England; [Cunningham, David] Royal Marsden Hosp, London, England; [Wadsley, Jonathan; Darby, Suzanne] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Meyer, Tim; Gillmore, Roopinder] Royal Free Hosp, London, England; [Anthoney, Alan] St James Univ Hosp, Leeds, W Yorkshire, England; [Lind, Pehr] Karolinska Inst, Stockholm, Sweden; [Lind, Pehr] Clin Res Sormland, Eskilstuna, Sweden; [Glimelius, Bengt] Uppsala Univ, Uppsala, Sweden; [Falk, Stephen] Bristol Haematol & Oncol Ctr, Bristol, Avon, England; [Izbicki, Jakob R.] Univ Hamburg, Med Inst UKE, Hamburg, Germany; [Middleton, Gary William; Cummins, Sebastian] Royal Surrey Cty Hosp, Guildford, Surrey, England; [Ross, Paul J.] Guys Hosp, London, England; [Wasan, Harpreet] Hammersmith Hosp, London, England; [McDonald, Alec] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Crosby, Tom] Velindre Hosp, Cardiff, S Glam, Wales; [Ma, Yuk Ting] Queen Elizabeth Hosp, Birmingham, W Midlands, England; [Patel, Kinnari] Churchill Hosp, Oxford, England; [Sherriff, David] Derriford Hosp, Plymouth, Devon, England; [Soomal, Rubin] Ipswich Hosp, Ipswich, Suffolk, England; [Borg, David] Skane Univ Hosp, Lund, Sweden; [Sothi, Sharmila] Univ Hosp Coventry, Coventry, W Midlands, England; [Hammel, Pascal] Hop Beaujon, Clichy, France; [Hackert, Thilo; Buechler, Markus W.] Heidelberg Univ, Heidelberg, Germany	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Clatterbridge Cancer Centre; Christie NHS Foundation Trust; University of Manchester; University of Manchester; Royal Marsden NHS Foundation Trust; Weston Park Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Saint James's University Hospital; Karolinska Institutet; Uppsala University; Bristol Haematology & Oncology Centre; University of Hamburg; Royal Surrey County Hospital; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; Beatson Oncology Centre; Velindre Hospital; University of Birmingham; University of Oxford; Derriford Hospital; Ipswich Hospital NHS Trust; Ipswich Hospital; Lund University; Skane University Hospital; University of Warwick; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg	Neoptolemos, JP (corresponding author), Univ Liverpool, Liverpool, Merseyside, England.; Neoptolemos, JP (corresponding author), Univ Liverpool, Liverpool Clin & Canc Res UK Trials Unit, Owen & Ellen Evans Chair Surg, Liverpool L69 3GL, Merseyside, England.	j.p.neoptolemos@liverpool.ac.uk	Neoptolemos, John/HGU-7742-2022	Middleton, Gary/0000-0001-5695-3474; Halloran, Christopher/0000-0002-5471-4178; Cunningham, David/0000-0001-5158-1069; wadsley, jonathan/0000-0002-1499-1277; Neoptolemos, John/0000-0002-6201-7399; Ma, Yuk Ting/0000-0001-7830-6091; Hammel, Pascal/0000-0002-4630-4996; Wasan, Harpreet/0000-0002-6268-2030	Cancer Research UK; Cancer Research UK [8968, 16186, 11883, 17680, 15957, 16791] Funding Source: researchfish; National Institute for Health Research [08/29/02, NF-SI-0510-10126] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	Cancer Research UK.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Campbell F, 2009, HISTOPATHOLOGY, V55, P277, DOI 10.1111/j.1365-2559.2009.03376.x; Capello M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv132; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; COX DR, 1972, J R STAT SOC B, V34, P187; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Greenhalf W, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt347; Henderson R, 2000, Biostatistics, V1, P465, DOI 10.1093/biostatistics/1.4.465; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Liao WC, 2013, LANCET ONCOL, V14, P1095, DOI 10.1016/S1470-2045(13)70388-7; Neoptolemos JP, 2009, BRIT J CANCER, V100, P246, DOI 10.1038/sj.bjc.6604838; Neoptolemos JP, 2013, LANCET ONCOL, V14, P1034, DOI 10.1016/S1470-2045(13)70403-0; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Reni M, 2012, CANCER CHEMOTH PHARM, V69, P115, DOI 10.1007/s00280-011-1680-2; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sinn M, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4007; Sobin LH, 2009, TNM CLASSIFICATION M, V7th, DOI DOI 10.1002/9780471420194.TNMC26.PUB2; Sultana A, 2007, J CLIN ONCOL, V25, P2607, DOI 10.1200/JCO.2006.09.2551; Trotti A, 2007, LANCET ONCOL, V8, P613, DOI 10.1016/S1470-2045(07)70144-4; Uesaka K, 2016, LANCET, V388, P248, DOI 10.1016/S0140-6736(16)30583-9; Valle JW, 2014, J CLIN ONCOL, V32, P504, DOI 10.1200/JCO.2013.50.7657; Vivaldi C, 2016, INT J CANCER, V139, P938, DOI 10.1002/ijc.30125; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067	30	1044	1085	6	85	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	2017	389	10073					1011	1024		10.1016/S0140-6736(16)32409-6	http://dx.doi.org/10.1016/S0140-6736(16)32409-6			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EN9UN	28129987	Green Published, Green Submitted, hybrid, Green Accepted			2023-01-03	WOS:000396345200023
J	Greenlee, MC; D'Angelo, L; Harms, SR; Kuo, AA; Landry, M; McManus, M; Talente, GM; White, P				Greenlee, M. Carol; D'Angelo, Lawrence; Harms, Stacey R.; Kuo, Alice A.; Landry, Michael; McManus, Margaret; Talente, Gregg M.; White, Patience		Amer Coll Phys Council Subspecialt	Enhancing the Role of Internists in the Transition From Pediatric to Adult Health Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PERSPECTIVES; YOUTH		Western Slope Endocrinol, Grand Junction, CO USA; Childrens Natl Med Ctr, Amer Coll Phys, Natl Alliance Adv Adolescent Hlth, Washington, DC 20010 USA; George Washington Univ, Sch Med, Washington, DC USA; Univ Calif Los Angeles, Los Angeles, CA USA; Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA; Southeast Louisiana Vet Healthcare Syst, New Orleans, LA USA; Univ South Carolina, Columbia, SC USA	American College of Physicians; Children's National Health System; George Washington University; University of California System; University of California Los Angeles; Tulane University; University of South Carolina System; University of South Carolina Columbia	Harms, SR (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave Northwest,Suite 700, Washington, DC 20001 USA.	sharms@acponline.org						American College of Physicians, 2016, PED AD CAR TRANS IN; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Bryden KS, 2003, DIABETES CARE, V26, P1052, DOI 10.2337/diacare.26.4.1052; Committee on Improving the Health, 2014, INV HLTH WELL BEING; Garvey KC, 2016, DIABETES CARE, V39, P190, DOI 10.2337/dc15-1775; Kirzinger W, 2012, HLTH CARE ACCESS UTI; Lotstein DS, 2008, J ADOLESCENT HEALTH, V43, P23, DOI 10.1016/j.jadohealth.2007.12.013; Peter NG, 2009, PEDIATRICS, V123, P417, DOI 10.1542/peds.2008-0740; Quinn CT, 2010, BLOOD, V115, P3447, DOI 10.1182/blood-2009-07-233700; Reiss JG, 2005, PEDIATRICS, V115, P112, DOI 10.1542/peds.2004-1321	10	8	8	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2017	166	4					299	+		10.7326/M16-0514	http://dx.doi.org/10.7326/M16-0514			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EL7FO	27894127				2023-01-03	WOS:000394786700021
J	Torjesen, I				Torjesen, Ingrid			Seeing same GP is linked to fewer hospital admissions	BMJ-BRITISH MEDICAL JOURNAL			English	News Item							CONTINUITY; CARE											Barker I, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j84; Tammes P, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j373	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	2017	356								j543	10.1136/bmj.j543	http://dx.doi.org/10.1136/bmj.j543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ8BT	28153827				2023-01-03	WOS:000393450100009
J	Craig, CE; Doumas, M				Craig, Chesney E.; Doumas, Michail			Anodal Transcranial Direct Current Stimulation Shows Minimal, Measure-Specific Effects on Dynamic Postural Control in Young and Older Adults: A Double Blind, Sham-Controlled Study	PLOS ONE			English	Article							SENSORIMOTOR INTEGRATION; LOCOMOTOR ADAPTATION; MAGNETIC STIMULATION; DC STIMULATION; TASK PRIORITY; MOTOR CORTEX; GAIT; INFORMATION; VARIABILITY; BALANCE	We investigated whether stimulating the cerebellum and primary motor cortex (M1) using transcranial direct current stimulation (tDCS) could affect postural control in young and older adults. tDCS was employed using a double-blind, sham-controlled design, in which young (aged 18-35) and older adults (aged 65+) were assessed over three sessions, one for each stimulatory condition M1, cerebellar and sham. The effect of tDCS on postural control was assessed using a sway-referencing paradigm, which induced platform rotations in proportion to the participant's body sway, thus assessing sensory reweighting processes. Task difficulty was manipulated so that young adults experienced a support surface that was twice as compliant as that of older adults, in order to minimise baseline age differences in postural sway. Effects of tDCS on postural control were assessed during, immediately after and 30 minutes after tDCS. Additionally, the effect of tDCS on corticospinal excitability was measured by evaluating motor evoked potentials using transcranial magnetic stimulation immediately after and 30 minutes after tDCS. Minimal effects of tDCS on postural control were found in the eyes open condition only, and this was dependent on the measure assessed and age group. For young adults, stimulation had only offline effects, as cerebellar stimulation showed higher mean power frequency (MPF) of sway 30 minutes after stimulation. For older adults, both stimulation conditions delayed the increase in sway amplitude witnessed between blocks one and two until stimulation was no longer active. In conclusion, despite tDCS' growing popularity, we would caution researchers to consider carefully the type of measures assessed and the groups targeted in tDCS studies of postural control.	[Craig, Chesney E.; Doumas, Michail] Queens Univ Belfast, Sch Psychol, Belfast, Antrim, North Ireland; [Craig, Chesney E.] Manchester Metropolitan Univ, Dept Exercise & Sport Sci, Res Ctr Hlth Exercise & Act Living, Crewe, Cheshire, England	Queens University Belfast; Manchester Metropolitan University	Craig, CE (corresponding author), Queens Univ Belfast, Sch Psychol, Belfast, Antrim, North Ireland.; Craig, CE (corresponding author), Manchester Metropolitan Univ, Dept Exercise & Sport Sci, Res Ctr Hlth Exercise & Act Living, Crewe, Cheshire, England.	c.craig@mmu.ac.uk	Doumas, M/A-4494-2009; Craig, Chesney Elizabeth/V-6388-2019	Doumas, M/0000-0002-5323-6258; Craig, Chesney Elizabeth/0000-0002-9492-1294	Department of Employment and Learning PhD studentship; British Academy/Leverhulme Small Research Grant [R1067PSY]	Department of Employment and Learning PhD studentship; British Academy/Leverhulme Small Research Grant	This work was supported by a Department of Employment and Learning PhD studentship to C. Craig and a British Academy/Leverhulme Small Research Grant R1067PSY to M. Doumas. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ben Taib Nordeyn Oulad, 2009, J Neurosurg, V111, P796, DOI 10.3171/2008.2.17679; Benninger DH, 2010, J NEUROL NEUROSUR PS, V81, P1105, DOI 10.1136/jnnp.2009.202556; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Carpenter MG, 2001, EXP BRAIN RES, V138, P210, DOI 10.1007/s002210100681; Carson RG, 2013, BRAIN STIMUL, V6, P760, DOI 10.1016/j.brs.2013.01.016; Duarte NDC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105777; Censor N, 2011, J PHYSIOL-LONDON, V589, P21, DOI 10.1113/jphysiol.2010.198077; Clark S, 2007, EXP BRAIN RES, V176, P299, DOI 10.1007/s00221-006-0620-6; de Berker AO, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00613; Demain A, 2014, J NEUROL, V261, P196, DOI 10.1007/s00415-013-7174-x; Dilda V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112131; Doumas M, 2008, EXP BRAIN RES, V187, P275, DOI 10.1007/s00221-008-1302-3; Doumas M, 2015, J GERONTOL B-PSYCHOL, V70, P377, DOI 10.1093/geronb/gbt105; Doumas M, 2010, J NEUROPHYSIOL, V104, P1969, DOI 10.1152/jn.00345.2010; Doumas M, 2009, J GERONTOL B-PSYCHOL, V64, P193, DOI 10.1093/geronb/gbp009; Dutta A, 2012, 2 IASTED INT C; Dutta A, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-13; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Ferrucci R, 2014, NEUROIMAGE, V85, P918, DOI 10.1016/j.neuroimage.2013.04.122; Galea JM, 2011, CEREB CORTEX, V21, P1761, DOI 10.1093/cercor/bhq246; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Goodwill AM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00087; Guo CC, 2010, J NEUROSCI, V30, P16241, DOI 10.1523/JNEUROSCI.3569-10.2010; Horak F., 1996, HDB PHYSL EXERCISE R, P255; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; HORAK FB, 1990, EXP BRAIN RES, V82, P167; HORAK FB, 1989, NEUROBIOL AGING, V10, P727, DOI 10.1016/0197-4580(89)90010-9; Horvath JC, 2014, NEUROPSYCHOLOGIA; Hummel FC, 2010, NEUROBIOL AGING, V31, P2160, DOI 10.1016/j.neurobiolaging.2008.12.008; Iyer MB, 2005, NEUROLOGY; Jayaram G, 2012, J NEUROPHYSIOL, V107, P2950, DOI 10.1152/jn.00645.2011; Kaski D, 2014, CLIN REHABIL, V28, P1115, DOI 10.1177/0269215514534277; Kaski D, 2012, J NEUROPHYSIOL, V107, P2493, DOI 10.1152/jn.00223.2011; Kaski D, 2013, NEUROREHAB NEURAL RE, V27, P864, DOI 10.1177/1545968313496328; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kurlowicz L, 1999, Director, V7, P62; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lindenberg R, 2010, NEUROLOGY, V75, P2176, DOI 10.1212/WNL.0b013e318202013a; LORD SR, 1991, J GERONTOL, V46, pM69, DOI 10.1093/geronj/46.3.M69; Lord SR, 1999, J AM GERIATR SOC, V47, P1077, DOI 10.1111/j.1532-5415.1999.tb05230.x; Manor B, 2016, J COGNITIVE NEUROSCI, V28, P275, DOI 10.1162/jocn_a_00897; Manto M, 2012, CEREBELLUM, V11, P457, DOI 10.1007/s12311-011-0331-9; McChesney JW, 2000, J GERONTOL A-BIOL, V55, pM658, DOI 10.1093/gerona/55.11.M658; Melzer I, 2004, AGE AGEING, V33, P602, DOI 10.1093/ageing/afh218; Montero-Odasso M, 2012, ARCH PHYS MED REHAB, V93, P293, DOI 10.1016/j.apmr.2011.08.026; NASHNER LM, 1982, J NEUROSCI, V2, P536; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2007, J NEUROPHYSIOL, P97; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Parazzini M, 2014, CLIN NEUROPHYSIOL, V125, P577, DOI 10.1016/j.clinph.2013.09.039; Peterka RJ, 2004, J NEUROPHYSIOL, V91, P410, DOI 10.1152/jn.00516.2003; Peterka RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/jn.2002.88.3.1097; Pijnenburg M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100666; Prado JM, 2007, GERONTOLOGY, V53, P274, DOI 10.1159/000102938; Rampersad SM, 2014, IEEE T NEUR SYS REH, V22, P441, DOI 10.1109/TNSRE.2014.2308997; Rankin JK, 2000, J GERONTOL A-BIOL, V55, pM112, DOI 10.1093/gerona/55.3.M112; Reis J, 2008, BRAIN STIMUL, V1, P363, DOI 10.1016/j.brs.2008.08.001; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 1994, ELECTROENCEPHALOGR C, V91, P2198; Ruffini G, 2014, NEUROIMAGE, V89, P216, DOI 10.1016/j.neuroimage.2013.12.002; STELMACH GE, 1989, INT J AGING HUM DEV, V29, P205, DOI 10.2190/KKP0-W3Q5-6RDN-RXYT; Vallence AM, 2014, J NEUROPHYSIOL, V111, P1, DOI 10.1152/jn.00088.2013; Wang Y, 2015, EUR J NEUROSCI, V42, P1933, DOI 10.1111/ejn.12953; Warnica MJ, 2014, GAIT POSTURE, V39, P1115, DOI 10.1016/j.gaitpost.2014.01.019; Wechsler D, 1997, WAIS 3 ADM SCOR MAN; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; WOOLLACOTT MH, 1986, INT J AGING HUM DEV, V23, P97, DOI 10.2190/VXN3-N3RT-54JB-X16X; Zhou JH, 2014, EUR J NEUROSCI, V39, P1343, DOI 10.1111/ejn.12492; Zimerman M, 2013, ANN NEUROL, V73, P10, DOI 10.1002/ana.23761; Zimerman M, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00149	72	22	24	1	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2017	12	1							e0170331	10.1371/journal.pone.0170331	http://dx.doi.org/10.1371/journal.pone.0170331			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3HH	28099522	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000392380100074
J	Li, Y; Zhang, J; Li, T; Liu, HG; Wang, YZ				Li, Yan; Zhang, Ji; Li, Tao; Liu, Honggao; Wang, Yuanzhong			A Comprehensive and Comparative Study of Wolfiporia extensa Cultivation Regions by Fourier Transform Infrared Spectroscopy and Ultra-Fast Liquid Chromatography	PLOS ONE			English	Article							DISCRIMINANT-ANALYSIS; CHEMICAL-COMPOSITION; PLEUROTUS-OSTREATUS; QUALITY-CONTROL; CANCER CELLS; FT-RAMAN; MUSHROOM; IDENTIFICATION; FINGERPRINTS; METABOLITES	Nowadays, Wolfiporia extensa as a popular raw material in food and medicine industry has received increasing interests. Due to supply shortage, this species of edible and medicinal mushroom has been cultivated in some provinces of China. In the present study, cultivated W. extensa collected from six regions in Yunnan Province of China were analyzed by an integrated method based on Fourier transform infrared (FT-IR) spectroscopy and ultra-fast liquid chromatography (UFLC) coupled with multivariate analysis including partial least squares discriminant analysis (PLS-DA) and hierarchical cluster analysis (HCA) in order to investigate the differences and similarities in different origins and parts. In the tested mushroom samples, characteristic FT-IR spectra were obtained for acquiring comprehensive fuzz chemical information and pachymic acid was determinated as a biomarker in the meantime. From the results, the comparison of samples was achieved successfully according to their geographical regions and different parts. All the samples displayed regional dependence and the inner parts showed better quality consistency. In addition, the chemical constituents of cultivated W. extensa could be also affected by the cultivation methods. Meanwhile, there was an interesting finding that the soil properties of cultivation regions may have a relationship with the chemical constituents of the epidermis of soil-cultured W. extensa, rather than the inner parts. Collectively, it demonstrated that the present study could provide comprehensive chemical evidence for the critical complement of quality evaluation on the cultivatedW. extensa. Moreover, it may be available for the further researches of complicated mushrooms in practice.	[Li, Yan; Zhang, Ji; Wang, Yuanzhong] Yunnan Acad Agr Sci, Inst Med Plants, Kunming, Yunnan, Peoples R China; [Li, Yan; Zhang, Ji; Wang, Yuanzhong] Yunnan Tech Ctr Qual Chinese Mat Med, Kunming, Yunnan, Peoples R China; [Li, Tao] Yuxi Normal Univ, Coll Resources & Environm, Yuxi, Yunnan, Peoples R China; [Liu, Honggao] Yunnan Agr Univ, Coll Agron & Biotechnol, Kunming, Yunnan, Peoples R China	Yunnan Academy of Agricultural Sciences; Yuxi Normal University; Yunnan Agricultural University	Wang, YZ (corresponding author), Yunnan Acad Agr Sci, Inst Med Plants, Kunming, Yunnan, Peoples R China.; Wang, YZ (corresponding author), Yunnan Tech Ctr Qual Chinese Mat Med, Kunming, Yunnan, Peoples R China.; Liu, HG (corresponding author), Yunnan Agr Univ, Coll Agron & Biotechnol, Kunming, Yunnan, Peoples R China.	honggaoliu@126.com; boletus@126.com	Lv, Yuanjie/AER-0767-2022; Wang, Yuan/HHC-1520-2022; Zhang, Ji/B-2830-2013	Zhang, Ji/0000-0002-7737-0785; Wang, Yuanzhong/0000-0001-5376-757X	National Natural Science Foundation of China [31460538, 31260496, 31660591]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was sponsored by the National Natural Science Foundation of China (31460538, 31260496 and 31660591).	Akinyele JB, 2012, MALAYS J MICROBIOL, V8, P135, DOI 10.21161/mjm.03912; Barbosa PCS, 2012, J BRAZIL CHEM SOC, V23, P1823, DOI 10.1590/S0103-50532012005000049; Briciu RD, 2012, FOOD CHEM, V130, P994; Casale M, 2016, TALANTA, V160, P729, DOI 10.1016/j.talanta.2016.08.004; Chen Y, 2008, ANAL CHIM ACTA, V623, P146, DOI 10.1016/j.aca.2008.06.018; Chen Y, 2012, J AGR FOOD CHEM, V60, P4243, DOI 10.1021/jf300076j; Choong YK, 2014, J MOL STRUCT, V1069, P188, DOI 10.1016/j.molstruc.2014.04.001; De Gussem K, 2005, SPECTROCHIM ACTA A, V61, P2896, DOI 10.1016/j.saa.2004.10.038; Dong JZ, 2013, FOOD CHEM, V137, P164, DOI 10.1016/j.foodchem.2012.10.021; Ezekiel CN, 2013, INT J FOOD MICROBIOL, V162, P231, DOI 10.1016/j.ijfoodmicro.2013.01.025; Gapter L, 2005, BIOCHEM BIOPH RES CO, V332, P1153, DOI 10.1016/j.bbrc.2005.05.044; Giner EM, 2000, PLANTA MED, V66, P221, DOI 10.1055/s-2000-8563; Gong F, 2004, J CHROMATOGR A, V1029, P173, DOI 10.1016/j.chroma.2003.12.049; Guo L., 2012, BIOMEDICINE PREVENTI, V2, P42, DOI [10.1016/j.bionut.2011.07.002, DOI 10.1016/J.BIONUT.2011.07.002]; Guo LP, 2013, SCI CHINA LIFE SCI, V56, P1047, DOI 10.1007/s11427-013-4562-5; Islam MT., 2016, WORLD APPL SCI J, V34, P1066; Jing J, 2013, TRAC-TREND ANAL CHEM, V44, P39, DOI 10.1016/j.trac.2012.11.006; Jing P, 2014, J AGR FOOD CHEM, V62, P12128, DOI 10.1021/jf504349r; KANEMATS.A, 1970, YAKUGA ZASSHI, V90, P475, DOI 10.1248/yakushi1947.90.4_475; Kim JK, 2013, J CEREAL SCI, V57, P14, DOI 10.1016/j.jcs.2012.09.012; Kizil R, 2002, J AGR FOOD CHEM, V50, P3912, DOI 10.1021/jf011652p; Li Y, 2016, SPECTROCHIM ACTA A, V165, P61, DOI 10.1016/j.saa.2016.04.012; [李妍 Li Yan], 2016, [食品科学, Food Science], V37, P222; Li YQ, 2016, FOOD ANAL METHOD, V9, P202, DOI 10.1007/s12161-015-0187-6; Ling Y, 2012, BIOMED CHROMATOGR, V26, P1109, DOI 10.1002/bmc.1756; Liu YC, 2016, RSC ADV, V6, P366, DOI 10.1039/c5ra21468h; Ma F, 2014, SPECTROSC SPECT ANAL, V34, P376, DOI 10.3964/j.issn.1000-0593(2014)02-0376-05; Maquelin K, 2002, J MICROBIOL METH, V51, P255, DOI 10.1016/S0167-7012(02)00127-6; Mohacek-Grosev V, 2001, SPECTROCHIM ACTA A, V57, P2815, DOI 10.1016/S1386-1425(01)00584-4; O'Gorman A, 2010, J AGR FOOD CHEM, V58, P7770, DOI 10.1021/jf101123a; Oyetayo V. O., 2013, Jordan Journal of Biological Sciences (JJBS), V6, P223; Pan Y, 2015, J LIQ CHROMATOGR R T, V38, P1407, DOI 10.1080/10826076.2015.1053912; Phan CW, 2015, CRIT REV BIOTECHNOL, V35, P355, DOI 10.3109/07388551.2014.887649; Rosmiza M.Z., 2016, MEDITERR J SOC SCI, V7, P406, DOI [DOI 10.5901/MJSS.2016.V7N1S1P406, 10.5901/mjss.2016.v7n1s1p406]; Roy S, 2015, AM J BIOSCIENCE, V3, P178, DOI [10.11648/j.ajbio.20150305.13, DOI 10.11648/J.AJBIO.20150305.13]; SEKKAL M, 1995, J MOL STRUCT, V349, P349, DOI 10.1016/0022-2860(95)08781-P; State Pharmacopoeia Commission, 2015, CHINESE PHARMACOPOEI, P240; Sun J, 2016, INT J MED MUSHROOMS, V18, P433, DOI 10.1615/IntJMedMushrooms.v18.i5.70; TAI T, 1995, PHYTOCHEMISTRY, V40, P225, DOI 10.1016/0031-9422(95)00182-7; TAI T, 1995, PHYTOCHEMISTRY, V39, P1165, DOI 10.1016/0031-9422(95)00110-S; TAI T, 1991, PHYTOCHEMISTRY, V30, P2796, DOI 10.1016/0031-9422(91)85149-T; TAI T, 1993, PHYTOCHEMISTRY, V32, P1239, DOI 10.1016/S0031-9422(00)95099-4; Vijaykumar G, 2014, INDIAN J TRADIT KNOW, V13, P434; Villares A, 2012, AGRICULTURE-BASEL, V2, P452, DOI 10.3390/agriculture2040452; Wang XM, 2014, FOOD CHEM, V151, P279, DOI 10.1016/j.foodchem.2013.11.062; Wang YF, 2004, CARBOHYD RES, V339, P327, DOI 10.1016/j.carres.2003.10.006; Wang YZ, 2013, J ETHNOPHARMACOL, V147, P265, DOI 10.1016/j.jep.2013.03.027; Wang YZ, 2012, INT J MED MUSHROOMS, V14, P79, DOI 10.1615/IntJMedMushr.v14.i1.80; Wong KH, 2013, J PHARMACEUT BIOMED, V84, P5, DOI 10.1016/j.jpba.2013.05.040; Wu X.L., 2013, MED FUNGI CHINA; Xu J, 2014, CHINESE J SPECTROSC, V31, P531; Yang Yong-Hong, 2012, Zhong Yao Cai, V35, P1557; Yu XW, 2013, CHIN J CHROMATOGR, V31, P691, DOI 10.3724/SP.J.1123.2012.12039; Zhang JS, 2015, J PHARMACEUT BIOMED, V115, P395, DOI 10.1016/j.jpba.2015.07.035; Zhao SQ, 2014, SPECTROSC SPECT ANAL, V34, P3401; Zhao YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089100; Zhao ZZ, 2012, J ETHNOPHARMACOL, V140, P476, DOI 10.1016/j.jep.2012.01.048; Zhbankov R. G., 1997, J MOL STRUCT, V436-437, P654; Zhu Y., 2015, AM J ANAL CHEM, V6, P480, DOI DOI 10.4236/AJAC.2015.65047; Zhu Y, 2016, SPECTROCHIM ACTA A, V159, P68, DOI 10.1016/j.saa.2016.01.018	60	15	17	0	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2016	11	12							e0168998	10.1371/journal.pone.0168998	http://dx.doi.org/10.1371/journal.pone.0168998			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7LN	28036354	Green Submitted, Green Published, gold			2023-01-03	WOS:000391229300046
J	Gavrilescu, G				Gavrilescu, Gabriel			Physiotherapy reduced recurrent headaches linked to neck pain and dysfunction in older adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LOW-BACK-PAIN; EXERCISE		[Gavrilescu, Gabriel] Cleveland Clin Florida, Weston, ACT 33331, Australia	Cleveland Clinic Foundation	Gavrilescu, G (corresponding author), Cleveland Clin Florida, Weston, ACT 33331, Australia.							Meng XG, 2015, AM J PHYS MED REHAB, V94, P358, DOI 10.1097/PHM.0000000000000188; Saper RB, 2009, ALTERN THER HEALTH M, V15, P18; Steffens D, 2014, EUR SPINE J, V23, P113, DOI 10.1007/s00586-013-2846-x	3	0	0	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 20	2016	165	12					JC68	JC68		10.7326/ACPJC-2016-165-12-068	http://dx.doi.org/10.7326/ACPJC-2016-165-12-068			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG7OJ	27992924				2023-01-03	WOS:000391236900007
J	Rizvi, W; Fayazuddin, M; Singh, O; Naeem, SS; Moin, S; Akhtar, K; Kumar, A				Rizvi, Waseeem; Fayazuddin, Mohd; Singh, Ompal; Naeem, Syed Shariq; Moin, Shagufta; Akhtar, Kafil; Kumar, Anil			Cytokine Attenuation and Free Radical Scavenging Activity of a New Flavanone7,4 '-Dihydroxy-3 '',3 ''-Dimethyl-(5,6-Pyrano-2 ''-One)-8-(3 ''',3 '''-Dimethyl Allyl)-Isolated from Mallotus philippensis: Possible Mechanism for Its Anti-Inflammatory Activity	PLoS One			English	Article							INDUCED PAW EDEMA; LIPID PEROXIDES; CARRAGEENAN; BIOLOGY; LEUKOTRIENES; INFLAMMATION; JAPONICUS; DISEASE; ASSAY; RATS	Mallotus philippensis L.(MP) commonly known as Kamala tree in Hindi, is a small to medium-sized monoecious tree. The objective of the study was to evaluate the anti-inflammatory activity of MPand a new flavanoneisolated from it by using in vivo models of inflammation. Albino wistar rats of either sex weighing 150-200g were used. Seven groups were made (n = 6), namely normal control group (normal saline, 1 ml/kg), standard control group (acetylsalicylic acid, 100 mg/kg), methanol crude extract (300 and 500 mg/kg), ethylacetate fraction (300 and 500 mg/kg) and active compound 4 (new flavanone, 50 mg/kg). The anti-inflammatory activity was studied using carrageenan induced paw edema method and cotton pellet granuloma method. Levels of cytokines (TNF-alpha, IL-1and IL-6) and activity of antioxidant enzymeslike catalase and glutathione peroxidase were estimated. It was found that the methanol extract, ethylacetate fraction and Flavanonedemonstrated significant reduction in paw edema in carrageenan induced paw edema method as compared to control. They also diminished the serum TNF-alpha, IL-6 and IL-1 levels. Significantly attenuated the malondialdehyde levels and increased the activities of catalase and glutathione peroxidase in paw tissue. Similarly there was asignificant decrease in granuloma formation in cotton pellet induced granuloma method. In conclusion, MP extracts and the newflavanone-possess anti-inflammatory activity and this might be due to the inhibition of various cytokines and increased free radical scavenging activity.	[Rizvi, Waseeem; Fayazuddin, Mohd; Naeem, Syed Shariq; Kumar, Anil] Aligarh Muslim Univ, Jawaharlal NehruMed Coll, Dept Pharmacol, Aligarh, Uttar Pradesh, India; [Singh, Ompal] Aligarh Muslim Univ, Chem Res Unit, Dept Res Unani Med, Aligarh, Uttar Pradesh, India; [Moin, Shagufta] Aligarh Muslim Univ, Jawaharlal NehruMed Coll, Dept Biochem, Aligarh, Uttar Pradesh, India; [Akhtar, Kafil] Aligarh Muslim Univ, Jawaharlal NehruMed Coll, Dept Pathol, Aligarh, Uttar Pradesh, India; [Fayazuddin, Mohd] Raichur Inst Med Sci, Dept Pharmacol, Raichur, India	Aligarh Muslim University; Aligarh Muslim University; Aligarh Muslim University; Aligarh Muslim University	Rizvi, W (corresponding author), Aligarh Muslim Univ, Jawaharlal NehruMed Coll, Dept Pharmacol, Aligarh, Uttar Pradesh, India.	waseemnakhat@gmail.com	Akhtar, Kafil/AAA-9467-2021	Akhtar, Kafil/0000-0002-3482-1195	University Grant Commission, New Delhi, India	University Grant Commission, New Delhi, India(University Grants Commission, India)	Funded by University Grant Commission, New Delhi, India (http//www.ugcnetonline.in/).	Arfan M, 2007, J FOOD LIPIDS, V14, P280, DOI 10.1111/j.1745-4522.2007.00086.x; ARMSTRONG D, 1994, ADV EXP MED BIOL, V366, P43; Bignotto L, 2009, BRIT J NUTR, V102, P126, DOI 10.1017/S0007114508137886; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Chang CT, 2011, FOOD CHEM, V127, P1131, DOI 10.1016/j.foodchem.2011.01.114; Chattopadhyay D, 2002, J ETHNOPHARMACOL, V82, P229, DOI 10.1016/S0378-8741(02)00165-4; Chaturvedi P, 2008, EVID-BASED COMPL ALT, V5, P55, DOI 10.1093/ecam/nel077; DAWSON J, 1991, INT J TISSUE REACT, V13, P171; Dmitrieva OS, 2016, BIOCHEMISTRY-MOSCOW+, V81, P80, DOI 10.1134/S0006297916020024; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gangwar M., 2012, INT J PHARM PHARM SC, V4, P643; Hewageegana H, 2014, J NATL SCI FOUND SRI, V42, P291; Huang GJ, 2012, J NAT PROD, V75, P54, DOI 10.1021/np200512a; Ishii R, 2003, BBA-GEN SUBJECTS, V1620, P108, DOI 10.1016/S0304-4165(02)00514-7; Jayweera D.M.A., 2006, MED PLANTS INDIGENOU, P225; Kim HS, 2000, J ETHNOPHARMACOL, V69, P79, DOI 10.1016/S0378-8741(99)00137-3; Kirtikar K.R., 1975, INDIAN MED PLANTS, VIII, P2266; Lee YM, 2009, J MOL MED, V87, P1251, DOI 10.1007/s00109-009-0532-6; Liao CH, 2011, FOOD CHEM, V125, P930, DOI 10.1016/j.foodchem.2010.09.082; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manandhar NP, 2000, PLANT PEOPLE NEPAL; Narayana K. Raj, 2001, Indian Journal of Pharmacology, V33, P2; OHISHI N, 1985, BIOCHEM INT, V10, P205; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pankajoudhia, 2001, MED HERBS CHHATTISGA; Sharma J. N., 2006, Inflammopharmacology, V14, P10, DOI 10.1007/s10787-006-1496-6; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SWINGLE KF, 1972, J PHARMACOL EXP THER, V183, P226; VINEGAR R, 1969, J PHARMACOL EXP THER, V166, P96; WINTER CA, 1957, J AM PHARM ASSOC, V46, P515, DOI 10.1002/jps.3030460902; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544	32	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0167294	10.1371/journal.pone.0167294	http://dx.doi.org/10.1371/journal.pone.0167294			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27941980	Green Published, gold, Green Submitted			2023-01-03	WOS:000392745600012
J	Benci, JL; Xu, BH; Qiu, Y; Wu, TJ; Dada, H; Twyman-Saint Victor, C; Cucolo, L; Lee, DSM; Pauken, KE; Huang, AC; Gangadhar, TC; Amaravadi, RK; Schuchter, LM; Feldman, MD; Ishwaran, H; Vonderheide, RH; Maity, A; Wherry, EJ; Minn, AJ				Benci, Joseph L.; Xu, Bihui; Qiu, Yu; Wu, Tony J.; Dada, Hannah; Twyman-Saint Victor, Christina; Cucolo, Lisa; Lee, David S. M.; Pauken, Kristen E.; Huang, Alexander C.; Gangadhar, Tara C.; Amaravadi, Ravi K.; Schuchter, Lynn M.; Feldman, Michael D.; Ishwaran, Hemant; Vonderheide, Robert H.; Maity, Amit; Wherry, E. John; Minn, Andy J.			Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade	CELL			English	Article							CD8(+) T-CELLS; CHRONIC VIRAL-INFECTION; PD-1 BLOCKADE; I INTERFERON; CANCER; THERAPY; EXHAUSTION; RADIATION; RECEPTORS; REJECTION	Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.	[Benci, Joseph L.; Xu, Bihui; Qiu, Yu; Wu, Tony J.; Dada, Hannah; Cucolo, Lisa; Lee, David S. M.; Maity, Amit; Minn, Andy J.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Twyman-Saint Victor, Christina; Huang, Alexander C.; Gangadhar, Tara C.; Amaravadi, Ravi K.; Schuchter, Lynn M.; Vonderheide, Robert H.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Pauken, Kristen E.; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; [Feldman, Michael D.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Pauken, Kristen E.; Huang, Alexander C.; Vonderheide, Robert H.; Wherry, E. John; Minn, Andy J.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA; [Vonderheide, Robert H.; Wherry, E. John; Minn, Andy J.] Univ Penn, Perelman Sch Med, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Benci, Joseph L.; Xu, Bihui; Qiu, Yu; Wu, Tony J.; Dada, Hannah; Twyman-Saint Victor, Christina; Cucolo, Lisa; Lee, David S. M.; Vonderheide, Robert H.; Minn, Andy J.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Ishwaran, Hemant] Univ Miami, Dept Epidemiol & Publ Hlth, Div Biostat, Miami, FL 33136 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Miami	Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.; Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.; Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.; Minn, AJ (corresponding author), Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	andyminn@mail.med.upenn.edu	Pauken, Kristen E./ABA-9363-2020; Wherry, John/ABI-1280-2020	Maity, Amit/0000-0001-7151-2845; Twyman-Saint Victor, Christina/0000-0001-7253-6179; Benci, Joseph/0000-0002-1759-4621; Wu, Tony James/0000-0002-5049-6986; Ishwaran, Hemant/0000-0003-2758-9647; Minn, Andy/0000-0003-1418-0906; Lee, David/0000-0002-8821-9028	Melanoma Research Alliance; Parker Institute for Cancer Immunotherapy; Robertson Foundation/Cancer Research Institute Irvington Fellowship; NIH [P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521]; Basser Research Center for BRCA; Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer; NIH/NCI [R01CA172651]; Merck; NATIONAL CANCER INSTITUTE [R01CA158186, R01CA163739, P30CA016520, P50CA174523, R01CA172651] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI082630, U01AI095608, R01AI105343, P01AI112521] Funding Source: NIH RePORTER	Melanoma Research Alliance; Parker Institute for Cancer Immunotherapy; Robertson Foundation/Cancer Research Institute Irvington Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Basser Research Center for BRCA; Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Merck(Merck & Company); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A.J.M., R.H.V., and E.J.W. were supported by the Melanoma Research Alliance and the Parker Institute for Cancer Immunotherapy; K.E.P. was supported by a Robertson Foundation/Cancer Research Institute Irvington Fellowship; and M.D.F was supported by a grant from the NIH (P50CA174523). A.J.M. and R.H.V. were supported by the Basser Research Center for BRCA. H.I. and A.J.M. were supported by a grant from the NIH (R01CA163739). R.H.V. was supported by grants from the NIH (R01CA158186, P30CA016520) and by the Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer. E.J.W. was supported by funding from NIH (U19AI082630, R01AI105343, U01AI095608, and P01AI112521). A.J.M. is a Department of Defense Era of Hope Scholar (W81XWH-09-1-0339) and was supported by funding from the NIH/NCI (R01CA172651). This work was partly supported by a grant from Merck.	Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Blackburn SD, 2008, P NATL ACAD SCI USA, V105, P15016, DOI 10.1073/pnas.0801497105; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Chen X, 2012, GENOMICS, V99, P323, DOI 10.1016/j.ygeno.2012.04.003; Cheon H, 2009, P NATL ACAD SCI USA, V106, P9373, DOI 10.1073/pnas.0903487106; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; Gajewski TF, 2011, CURR OPIN IMMUNOL, V23, P286, DOI 10.1016/j.coi.2010.11.013; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; He R, 2016, NATURE, V537, P412, DOI 10.1038/nature19317; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Ishwaran H, 2010, J AM STAT ASSOC, V105, P205, DOI 10.1198/jasa.2009.tm08622; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; McWilliams JA, 2006, J IMMUNOL, V177, P155, DOI 10.4049/jimmunol.177.1.155; Minn AJ, 2016, CELL, V165, P272, DOI 10.1016/j.cell.2016.03.031; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Ng CT, 2015, CELL HOST MICROBE, V17, P653, DOI 10.1016/j.chom.2015.04.005; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Pauken K. E., 2016, SCIENCE; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; Vanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wilson EB, 2013, SCIENCE, V340, P202, DOI 10.1126/science.1235208; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	40	565	588	7	143	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	2016	167	6					1540	+		10.1016/j.cell.2016.11.022	http://dx.doi.org/10.1016/j.cell.2016.11.022			27	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EE3EN	27912061	Green Accepted, Bronze			2023-01-03	WOS:000389470500016
J	Parand, A; Garfield, S; Vincent, C; Franklin, BD				Parand, Anam; Garfield, Sara; Vincent, Charles; Franklin, Bryony Dean			Carers' Medication Administration Errors in the Domiciliary Setting: A Systematic Review	PLOS ONE			English	Review							ADVERSE DRUG EVENTS; ACETAMINOPHEN OVERDOSE; RISK-FACTORS; CHILDREN; HOME; CAREGIVERS; HEALTH; MANAGEMENT; MEDICINES; PARENTS	Purpose Medications are mostly taken in patients' own homes, increasingly administered by carers, yet studies of medication safety have been largely conducted in the hospital setting. We aimed to review studies of how carers cause and/or prevent medication administration errors (MAEs) within the patient's home; to identify types, prevalence and causes of these MAEs and any interventions to prevent them. Methods A narrative systematic review of literature published between 1 Jan 1946 and 23 Sep 2013 was carried out across the databases EMBASE, MEDLINE, PSYCHINFO, COCHRANE and CINAHL. Empirical studies were included where carers were responsible for preventing/causing MAEs in the home and standardised tools used for data extraction and quality assessment. Results Thirty-six papers met the criteria for narrative review, 33 of which included parents caring for children, two predominantly comprised adult children and spouses caring for older parents/partners, and one focused on paid carers mostly looking after older adults. The carer administration error rate ranged from 1.9 to 33% of medications administered and from 12 to 92.7% of carers administering medication. These included dosage errors, omitted administration, wrong medication and wrong time or route of administration. Contributory factors included individual carer factors (e.g. carer age), environmental factors (e.g. storage), medication factors (e.g. number of medicines), prescription communication factors (e.g. comprehensibility of instructions), psychosocial factors (e.g. carer-to-carer communication), and care-recipient factors (e.g. recipient age). The few interventions effective in preventing MAEs involved carer training and tailored equipment. Conclusion This review shows that home medication administration errors made by carers are a potentially serious patient safety issue. Carers made similar errors to those made by professionals in other contexts and a wide variety of contributory factors were identified. The home care setting should be a priority for the development of patient safety interventions.	[Parand, Anam] London Sch Econ, Dept Social Psychol, London, England; [Parand, Anam] Imperial Coll London, Natl Inst Hlth Res, Imperial Patient Safety Translat Res Ctr, London, England; [Garfield, Sara] Imperial Coll Healthcare NHS Trust, UCL Sch Pharm London, Res Dept Practice & Policy, Ctr Medicat Safety & Serv Qual, London, England; [Vincent, Charles] Univ Oxford, Dept Expt Psychol, Oxford, England	University of London; London School Economics & Political Science; Imperial College London; Imperial College London; University of Oxford	Parand, A (corresponding author), London Sch Econ, Dept Social Psychol, London, England.; Parand, A (corresponding author), Imperial Coll London, Natl Inst Hlth Res, Imperial Patient Safety Translat Res Ctr, London, England.	a.parand@lse.ac.uk	; Garfield, Sara/F-9941-2019	Parand, Anam/0000-0003-2031-5416; Garfield, Sara/0000-0002-9980-0520	National Institute for Health Research (NIHR) Imperial Patient Safety Translational Research Centre; National Institute for Health Research [NF-SI-0510-10193] Funding Source: researchfish	National Institute for Health Research (NIHR) Imperial Patient Safety Translational Research Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	This paper represents independent research supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translational Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Absulem S, 2011, REHABIL NURS, V36, P98, DOI 10.1002/j.2048-7940.2011.tb00073.x; Alander SW, 2000, ARCH PEDIAT ADOL MED, V154, P346, DOI 10.1001/archpedi.154.4.346; Algahtani F, 2013, SAUDI PHARM J, V21, P165, DOI 10.1016/j.jsps.2012.05.008; Alomar M, 2011, ANN SAUDI MED, V31, P513, DOI 10.4103/0256-4947.84630; Alsulami Z, 2013, EUR J CLIN PHARMACOL, V69, P995, DOI 10.1007/s00228-012-1435-y; Axelsson Johan, 2002, Lakartidningen, V99, P1178; Azkunaga B, 2013, AN PEDIATR, V78, P355, DOI 10.1016/j.anpedi.2012.09.016; Barber ND, 2009, QUAL SAF HEALTH CARE, V18, P341, DOI 10.1136/qshc.2009.034231; Cameli D, 2013, JBI DATABASE SYSTEMA, V11, P1; Carers Trust, 2014, KEY FACTS CAR 2014; Cassidy N, 2011, CLIN TOXICOL, V49, P485, DOI 10.3109/15563650.2011.587193; Central Statistics Office, 2009, Q NAT HOUS SURV CAR; Choo J, 2010, J NURS MANAGE, V18, P853, DOI 10.1111/j.1365-2834.2010.01164.x; Cohen AL, 2008, J PEDIATR-US, V152, P416, DOI 10.1016/j.jpeds.2007.07.041; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CONROY S, 2003, PHARM J, V271, P209; Costa LL, 2011, J NURS CARE QUAL, V26, P243, DOI 10.1097/NCQ.0b013e31820e1543; Dean B, 2001, AM J HEALTH-SYST PH, V58, P54, DOI 10.1093/ajhp/58.1.54; Donelan K, 2002, HEALTH AFFAIR, V21, P222, DOI 10.1377/hlthaff.21.4.222; Ecker L, 2013, PEDIATRICS, V131, pE1771, DOI 10.1542/peds.2012-1970; Erlen JA, 2013, J GERONTOL NURS, V39, P30, DOI 10.3928/00989134-20130220-91; Family caregiver alliance, 2014, CAR 2014; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Frush KS, 2004, ARCH PEDIAT ADOL MED, V158, P620, DOI 10.1001/archpedi.158.7.620; Ghaleb MA, 2006, ANN PHARMACOTHER, V40, P1766, DOI 10.1345/aph.1G717; Godfrey C, 2013, JBI DATABASE SYSTEM, V11, P82, DOI DOI 10.11124/jbisrir-2013-959; Goldman RD, 2004, PEDIATR EMERG CARE, V20, P89, DOI 10.1097/01.pec.0000113877.10140.d2; GRIBETZ B, 1987, PEDIATRICS, V80, P630; Griffith R., 2011, NURSE PRESCRIBING, V9, P94; GUBERMAN D, 1990, Harefuah, V118, P17; Hain Debra J, 2012, Home Healthc Nurse, V30, P246, DOI 10.1097/NHH.0b013e31824c28bd; Health & Social Care Information Centre, 2010, SURV CAR HOUS ENGL 2; Heubi JE, 1998, J PEDIATR-US, V132, P22, DOI 10.1016/S0022-3476(98)70479-2; HYAM E, 1989, FAM PRACT, V6, P221, DOI 10.1093/fampra/6.3.221; International Alliance of Carer Organizations, 2015, GLOB CAR FACTS 2015; JONVILLE APE, 1991, DICP ANN PHARMAC, V25, P1113; Kaushal R, 2007, AMBUL PEDIATR, V7, P383, DOI 10.1016/j.ambp.2007.05.005; Keers RN, 2013, DRUG SAFETY, V36, P1045, DOI 10.1007/s40264-013-0090-2; Kmet L. M., 2004, STANDARD QUALITY ASS; Knudsen P, 2007, QUAL SAF HEALTH CARE, V16, P291, DOI 10.1136/qshc.2006.018770; Lemer Claire, 2009, J Patient Saf, V5, P168, DOI 10.1097/PTS.0b013e3181b3a9b0; Li SF, 2000, PEDIATR EMERG CARE, V16, P394, DOI 10.1097/00006565-200012000-00003; Lifshitz M, 2000, ISR MED ASSOC J, V2, P504; Lindquist LA, 2011, J GEN INTERN MED, V26, P474, DOI 10.1007/s11606-010-1596-2; Llewellyn G, 2003, RES DEV DISABIL, V24, P405, DOI 10.1016/j.ridd.2003.06.001; Loganathan M, 2011, AGE AGEING, V40, P150, DOI 10.1093/ageing/afq161; Madigan Elizabeth A, 2007, Home Healthc Nurse, V25, P191, DOI 10.1097/01.NHH.0000263437.08062.cc; Masotti Paul, 2009, Healthc Q, V12, P69; Masotti P, 2010, INT J QUAL HEALTH C, V22, P115, DOI 10.1093/intqhc/mzq003; MATTAR ME, 1975, J PEDIATR-US, V87, P137, DOI 10.1016/S0022-3476(75)80090-4; McCann JJ, 2000, J AM GERIATR SOC, V48, P1612, DOI 10.1111/j.1532-5415.2000.tb03872.x; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Mcerlean MA, 2001, PEDIATR EMERG CARE, V17, P249, DOI 10.1097/00006565-200108000-00005; McGraw Caroline, 2008, Qual Prim Care, V16, P239; McLeod MC, 2013, BMJ QUAL SAF, V22, P278, DOI 10.1136/bmjqs-2012-001330; McMahon SR, 1997, PEDIATRICS, V100, P330, DOI 10.1542/peds.100.3.330; Meredith S, 2001, J AM GERIATR SOC, V49, P719, DOI 10.1046/j.1532-5415.2001.49147.x; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Moretti R, 2013, ANN FR MED URGENCE, V3, P205, DOI 10.1007/s13341-013-0316-z; [倪韶青 Ni Shaoqing], 2013, [中国药学杂志, Chinese Pharmaceutical Journal], V48, P1419; Oshikoya KA, 2010, ANN AFR MED, V9, P203, DOI 10.4103/1596-3519.70954; Pelissier-Delour L, 2007, ARCH PEDIATRIE, V14, P1403, DOI 10.1016/j.arcped.2007.08.012; RANELLI PL, 1997, RES SOCIOL HEALTH CA, V14, P233; Reinhard S., 2012, HOME ALONE FAMILY CA; RiveraPenera T, 1997, J PEDIATR-US, V130, P300, DOI 10.1016/S0022-3476(97)70359-7; Ryu GS, 2012, J MANAGE CARE PHARM, V18, P439, DOI 10.18553/jmcp.2012.18.6.439; Sandars J, 2003, FAM PRACT, V20, P231, DOI 10.1093/fampra/cmg301; Schaefer MK, 2008, PEDIATRICS, V121, P783, DOI 10.1542/peds.2007-3638; Sears N, 2013, INT J QUAL HEALTH C, V25, P16, DOI 10.1093/intqhc/mzs075; Slatter Amanda, 2004, Br J Nurs, V13, P1135; Smith MD, 2014, PEDIATRICS, V134, P867, DOI 10.1542/peds.2014-0309; Sokol MC, 2005, MED CARE, V43, P521, DOI 10.1097/01.mlr.0000163641.86870.af; Statistics ABo, 2012, SURV DIS AG CAR SDAC; Taylor DM, 2009, J PAEDIATR CHILD H, V45, P304, DOI 10.1111/j.1440-1754.2008.01462.x; Taylor JA, 2006, CANCER-AM CANCER SOC, V107, P1400, DOI 10.1002/cncr.22131; Tomkvist L, 2006, NORDIC J NURSING RES, V26, P52; Travis SS, 2000, J GERONTOL A-BIOL, V55, pM412, DOI 10.1093/gerona/55.7.M412; Walsh D, 2005, J ADV NURS, V50, P204, DOI 10.1111/j.1365-2648.2005.03380.x; Walsh KE, 2013, PEDIATRICS, V131, pE1405, DOI 10.1542/peds.2012-2434; Walsh KE, 2011, ARCH DIS CHILD, V96, P581, DOI 10.1136/adc.2010.204479; Walsh KE, 2008, ADV PATIENT SAFETY N, V4; Woodward C, 2002, MEASURING CONSISTENC; Yin HS, 2014, PEDIATRICS, V134, pE354, DOI 10.1542/peds.2014-0395; Zandieh SO, 2008, J PEDIATR-US, V152, P225, DOI 10.1016/j.jpeds.2007.09.054	84	22	22	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167204	10.1371/journal.pone.0167204	http://dx.doi.org/10.1371/journal.pone.0167204			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3JC	27907072	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000389482700090
J	Robbie, N				Robbie, Neil			Douglas Stewart Robbie OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item									[Robbie, Neil] Royal Marsden Hosp, London, England	Royal Marsden NHS Foundation Trust	Robbie, N (corresponding author), Royal Marsden Hosp, London, England.							ROBBIE DS, PUBLICATION LIST	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 25	2016	355								i6276	10.1136/bmj.i6276	http://dx.doi.org/10.1136/bmj.i6276			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ED5UK	27887001				2023-01-03	WOS:000388917600001
J	Papp, B; Lazar, V				Papp, Balazs; Lazar, Viktoria			New recipe for targeting resistance	NATURE CHEMICAL BIOLOGY			English	News Item								The rapid spread of antibiotic-resistant bacteria demands novel treatment approaches that delay or even reverse the evolution of resistance. A new screening strategy identifies two compounds that select against a common tetracycline-resistance gene in Escherichia coli.	[Papp, Balazs; Lazar, Viktoria] Hungarian Acad Sci, Inst Biochem, Biol Res Ctr, Synthet & Syst Biol Unit, Szeged, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center	Papp, B (corresponding author), Hungarian Acad Sci, Inst Biochem, Biol Res Ctr, Synthet & Syst Biol Unit, Szeged, Hungary.	pappb@brc.hu		Papp, Balazs/0000-0003-3093-8852	Wellcome Trust [098016] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen JL, 2015, INT J ENV RES PUB HE, V12, P1487, DOI 10.3390/ijerph120201487; Chait R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015179; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Imamovic L, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006609; Lazar V, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.57; Lukens AK, 2014, P NATL ACAD SCI USA, V111, P799, DOI 10.1073/pnas.1320886110; Munck C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009940; Pal C, 2015, TRENDS MICROBIOL, V23, P401, DOI 10.1016/j.tim.2015.02.009; Stone LK, 2016, NAT CHEM BIOL, V12, P902, DOI [10.1038/NCHEMBIO.2176, 10.1038/nchembio.2176]; SZYBALSKI W, 1952, J BACTERIOL, V64, P489, DOI 10.1128/JB.64.4.489-499.1952	10	2	2	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2016	12	11					891	892		10.1038/nchembio.2215	http://dx.doi.org/10.1038/nchembio.2215			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EA7GP	27755526				2023-01-03	WOS:000386798800003
J	Rosenbaum, L				Rosenbaum, Lisa			Unlearning Our Helplessness - Coexisting Serious Mental and Medical Illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER											Baggett T., 2014, SGIM FORUM, V37, P1; Howard LM, 2010, LANCET ONCOL, V11, P797, DOI 10.1016/S1470-2045(10)70085-1; Kisely S, 2013, JAMA PSYCHIAT, V70, P209, DOI 10.1001/jamapsychiatry.2013.278; Maier SF, 2016, PSYCHOL REV, V123, P349, DOI 10.1037/rev0000033; Saks Elyn R., 2002, REFUSING CARE FORCED; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	6	1	1	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2016	375	17					1690	1694		10.1056/NEJMms1610127	http://dx.doi.org/10.1056/NEJMms1610127			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EB2DX	27783917				2023-01-03	WOS:000387168900018
J	Yang, CJ; Wu, LN; Cai, WF; Zhu, WW; Shen, Q; Li, ZJ; Fang, Y				Yang, Caijun; Wu, Lina; Cai, Wenfang; Zhu, Wenwen; Shen, Qian; Li, Zongjie; Fang, Yu			Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study	PLOS ONE			English	Article							IMPACT; MEDICINES	Objective Drug shortages were a complex global problem. The aim of this study was to analyze, characterize, and assess the drug shortages, and identify possible solutions in Shaanxi Province, western China. Methods A qualitative methodological approach was conducted during May-June 2015 and December 2015-January 2016. Semi-structured interviews were performed to gather information from representatives of hospital pharmacists, wholesalers, pharmaceutical producers, and local health authorities. Results Thirty participants took part in the study. Eight traditional Chinese medicines and 87 types of biologicals and chemicals were reported to be in short supply. Most were essential medicines. Five main determinants of drug shortages were detected: too low prices, too low market demands, Good Manufacturing Practice (GMP) issues, materials issues, and approval issues for imported drugs. Five different solutions were proposed by the participants: 1) let the market decide the drug price; 2) establish an information platform; 3) establish a reserve system; 4) enhance the communication among the three parties in the supply chain; and 5) improve hospital inventory management. Conclusions Western China was currently experiencing a serious drug shortage. Numerous reasons for the shortage were identified. Most drug shortages in China were currently because of "too low prices." To solve this problem, all of the stakeholders, especially the government, needed to participate in managing the drug shortages.	[Yang, Caijun; Wu, Lina; Cai, Wenfang; Zhu, Wenwen; Shen, Qian; Li, Zongjie; Fang, Yu] Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Peoples R China; [Yang, Caijun; Wu, Lina; Cai, Wenfang; Zhu, Wenwen; Shen, Qian; Li, Zongjie; Fang, Yu] Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University	Fang, Y (corresponding author), Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Peoples R China.; Fang, Y (corresponding author), Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian, Peoples R China.	yufang@mail.xjtu.edu.cn			National Natural Science Foundation of China [71503197, 71473192]; China Medical Board Open Competition Research Program [14-196]; "Young Talent Support Plan" of Xian Jiaotong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Medical Board Open Competition Research Program; "Young Talent Support Plan" of Xian Jiaotong University	This work is supported by National Natural Science Foundation of China (71503197 and 71473192) the China Medical Board Open Competition Research Program (14-196), and the "Young Talent Support Plan" of Xian Jiaotong University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASHP Expert Panel on Drug Product Shortages, 2009, Am J Health Syst Pharm, V66, P1399, DOI 10.2146/ajhp090026; Baumer AM, 2004, AM J HEALTH-SYST PH, V61, P2015, DOI 10.1093/ajhp/61.19.2015; Beerten E, 2011, ANN PHARM BELGES, V15, P11; Bogaert P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125691; Butler D, 2013, NATURE, V504, P15, DOI 10.1038/504015a; Canadian Medical Association (CMA), 2011, EPANEL SURV SUMM GEN; Canadian Pharmacists Association (CPA), 2010, CAN DRUG SHORT SURV; Casassus B, 2015, LANCET, V385, P1279, DOI 10.1016/S0140-6736(15)60667-5; Chabner BA, 2011, NEW ENGL J MED, V365, P2147, DOI 10.1056/NEJMp1112633; Dill S, 2014, EUR J CLIN PHARMACOL, V70, P1405, DOI 10.1007/s00228-014-1747-1; Ding, 2015, J TRADITIONAL CHINES, V23, P99; Dylst P, 2013, APPL HEALTH ECON HEA, V11, P437, DOI 10.1007/s40258-013-0043-z; Fang L., 2015, CHINESE HLTH SERVICE, V8, P610; Fang Y, 2013, LANCET GLOB HEALTH, V1, pE227, DOI 10.1016/S2214-109X(13)70072-X; Generics and Biosimilarrs Initiative, 2012, UK DRUG SHORT AR FAR; Gong SW, 2010, CHIN J HOSP ADM, V26, P126; Gray A, 2012, B WORLD HEALTH ORGAN, V90, P158, DOI 10.2471/BLT.11.101303; Gu JL, 2013, SOFT SCI HLTH, V27, P325; Haninger K, 2011, EC ANAL CAUSES DRUG; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210; Kaiser J, 2011, SCIENCE, V332, P523, DOI 10.1126/science.332.6029.523; Kaposy C, 2014, J BIOETHIC INQ, V11, P1; Kux L, 2011, PUBL WORKSH REQ COMM; Kweder SL, 2013, CLIN PHARMACOL THER, V93, P245, DOI 10.1038/clpt.2012.235; Liu B., 2007, CHINA PHARM, V18, P2481, DOI [10.1360/jos180001, DOI 10.1360/JOS180001]; [刘敏豪 Liu Minhao], 2012, [中国药房, China Pharmacy], V23, P673; Liu XK, 2013, J N PHARM, V10, P88; Meng QY, 2005, HEALTH POLICY PLANN, V20, P185, DOI 10.1093/heapol/czi018; National Development and Reform Commission. (NDRC), 2014, NOT IMPR MAN LOW PRI; National Health and Family Planning Commission of the People's Republic of China, 2013, NAT ESS MED LIST; Pauwels K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119322; Pauwels K, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-438; Printz C, 2012, CANCER-AM CANCER SOC, V118, P289, DOI 10.1002/cncr.27386; Rosoff PM, 2012, AM J BIOETHICS, V12, P1, DOI 10.1080/15265161.2011.634483; Schweitzer SO, 2013, AM J PUBLIC HEALTH, V103, pE10, DOI 10.2105/AJPH.2013.301239; Tang S., 2015, CHINESE GEN PRACTICE, V18, P243; Tucker ME, 2012, BRIT MED J, V345, P900; US Food and Drug Administration, 2011, REV FDAS APPR MED PR; Ventola C Lee, 2011, P T, V36, P740; Wang YG., 2005, DECISION INFORM FINA, V12, P36; WHO, 1988, DEV IMPL NAT DRUG PO; WHO, 2012, W AR HLTH IN; Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220; World Health Organisation, 2001, WHO TECHN REP SER; Zeng WJ, 2014, J COMP EFFECT RES, V3, P371, DOI [10.2217/CER.14.28, 10.2217/cer.14.28]	45	31	34	6	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0165183	10.1371/journal.pone.0165183	http://dx.doi.org/10.1371/journal.pone.0165183			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED7LQ	27780218	gold, Green Published, Green Submitted			2023-01-03	WOS:000389046900034
J	McCarthy, M				McCarthy, Michael			Therapeutic hypothermia has no benefit for in-hospital cardiac arrest, study finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item							ASSOCIATION											Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Chan PS, 2016, JAMA-J AM MED ASSOC, V316, P1375, DOI 10.1001/jama.2016.14380	2	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2016	355								i5409	10.1136/bmj.i5409	http://dx.doi.org/10.1136/bmj.i5409			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ4UM	27758780				2023-01-03	WOS:000385856000007
J	Morris, JK; Vidoni, ED; Johnson, DK; Van Sciver, A; Mahnken, JD; Honea, RA; Wilkins, HM; Brooks, WM; Billinger, SA; Swerdlow, RH; Burns, JM				Morris, Jill K.; Vidoni, Eric D.; Johnson, David K.; Van Sciver, Angela; Mahnken, Jonathan D.; Honea, Robyn A.; Wilkins, Heather M.; Brooks, William M.; Billinger, Sandra A.; Swerdlow, Russell H.; Burns, Jeffrey M.			Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; CARDIORESPIRATORY FITNESS; PHYSICAL-ACTIVITY; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; OLDER-ADULTS; DEMENTIA; WALKING; BRAIN	Background There is increasing interest in the role of physical exercise as a therapeutic strategy for individuals with Alzheimer's disease (AD). We assessed the effect of 26 weeks (6 months) of a supervised aerobic exercise program on memory, executive function, functional ability and depression in early AD. Methods and findings This study was a 26-week randomized controlled trial comparing the effects of 150 minutes per week of aerobic exercise vs. non-aerobic stretching and toning control intervention in individuals with early AD. A total of 76 well-characterized older adults with probable AD (mean age 72.9 [7.7]) were enrolled and 68 participants completed the study. Exercise was conducted with supervision and monitoring by trained exercise specialists. Neuropsychological tests and surveys were conducted at baseline,13, and 26 weeks to assess memory and executive function composite scores, functional ability (Disability Assessment for Dementia), and depressive symptoms (Cornell Scale for Depression in Dementia). Cardiorespiratory fitness testing and brain MRI was performed at baseline and 26 weeks. Aerobic exercise was associated with a modest gain in functional ability (Disability Assessment for Dementia) compared to individuals in the ST group (X2 = 8.2, p = 0.02). There was no clear effect of intervention on other primary outcome measures of Memory, Executive Function, or depressive symptoms. However, secondary analyses revealed that change in cardiorespiratory fitness was positively correlated with change in memory performance and bilateral hippocampal volume. Conclusions Aerobic exercise in early AD is associated with benefits in functional ability. Exercise-related gains in cardiorespiratory fitness were associated with improved memory performance and reduced hippocampal atrophy, suggesting cardiorespiratory fitness gains may be important in driving brain benefits.	[Morris, Jill K.; Vidoni, Eric D.; Van Sciver, Angela; Honea, Robyn A.; Wilkins, Heather M.; Brooks, William M.; Swerdlow, Russell H.; Burns, Jeffrey M.] Univ Kansas, Alzheimers Dis Ctr, Fairway, KS 66205 USA; [Johnson, David K.] Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA; [Mahnken, Jonathan D.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA; [Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA; [Billinger, Sandra A.] Univ Kansas, Med Ctr, Dept Phys Therapy & Rehabil Sci, Kansas City, KS 66103 USA	University of Kansas; University of Kansas; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Burns, JM (corresponding author), Univ Kansas, Alzheimers Dis Ctr, Fairway, KS 66205 USA.	jburns2@kumc.edu	Brooks, William/AAF-8299-2019	Brooks, William/0000-0001-6227-7636; Wilkins, Heather/0000-0003-4563-4544; Burns, Jeffrey/0000-0001-7609-8954; Johnson, David/0000-0003-3670-8054	National Institutes of Health [R01 AG033673, F32 AG044953, K99 AG050490, P30 AG035982, S10 RR29577, UL1 TR000001, KL2 TR000119, K01 AG035042, K01 HD067318]; Foundation for Physical Therapy New Investigator Fellowship Training Initiative; Hyndman Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000119, TL1TR000120] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR033177, M01RR023940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG035982, R01AG033673, K01AG035042, K99AG050490, F32AG044953] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for Physical Therapy New Investigator Fellowship Training Initiative; Hyndman Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Research reported in this publication was supported by the National Institutes of Health under award numbers R01 AG033673, F32 AG044953, K99 AG050490, P30 AG035982, S10 RR29577, UL1 TR000001, KL2 TR000119, K01 AG035042, and K01 HD067318. Additional support was provided by the Foundation for Physical Therapy New Investigator Fellowship Training Initiative and the Hyndman Foundation. The Hoglund Brain Imaging Center is supported by a generous gift from Forrest and Sally Hoglund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.	Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Baker LD, 2010, ARCH NEUROL-CHICAGO, V67, P71, DOI 10.1001/archneurol.2009.307; Bakken TE, 2012, P NATL ACAD SCI USA, V109, P3985, DOI 10.1073/pnas.1105829109; Billinger S.A., 2016, J AGING PHYS ACT, P1; Billinger SA, 2011, ARCH PHYS MED REHAB, V92, P2000, DOI 10.1016/j.apmr.2011.07.194; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Bossers WJR, 2016, J AM GERIATR SOC, V64, P1258, DOI 10.1111/jgs.14160; Burns JM, 2008, NEUROLOGY, V71, P210, DOI 10.1212/01.wnl.0000317094.86209.cb; Church TS, 2007, JAMA-J AM MED ASSOC, V297, P2081, DOI 10.1001/jama.297.19.2081; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Daviglus ML, 2010, ANN INTERN MED, V153, P176, DOI 10.7326/0003-4819-153-3-201008030-00260; Erickson KI, 2010, NEUROLOGY, V75, P1415, DOI 10.1212/WNL.0b013e3181f88359; Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Feldman H, 2001, ALZ DIS ASSOC DIS, V15, P89, DOI 10.1097/00002093-200104000-00008; Fleg JL, 2005, CIRCULATION, V112, P674, DOI 10.1161/CIRCULATIONAHA.105.545459; Forbes D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub4; Gaugler JE, 2003, GERONTOLOGIST, V43, P219, DOI 10.1093/geront/43.2.219; Harry A, 2014, CLIN NEUROPSYCHOL, V28, P486, DOI 10.1080/13854046.2014.892155; Hayes SM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00031; ISAACS KR, 1992, J CEREBR BLOOD F MET, V12, P110, DOI 10.1038/jcbfm.1992.14; Jedrziewski MK, 2010, ALZHEIMERS DEMENT, V6, P448, DOI 10.1016/j.jalz.2010.02.004; Johnson DK, 2008, NEUROLOGY, V71, P1783, DOI 10.1212/01.wnl.0000335972.35970.70; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Kryscio RJ, 2014, JAMA NEUROL, V71, P947, DOI 10.1001/jamaneurol.2014.1120; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nichol K, 2009, ALZHEIMERS DEMENT, V5, P287, DOI 10.1016/j.jalz.2009.02.006; Paillard T, 2015, J CLIN NEUROL, V11, P212, DOI 10.3988/jcn.2015.11.3.212; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; R Core Team, 2021, R LANG ENV STAT COMP; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Schultz SA, 2015, J INT NEUROPSYCH SOC, V21, P841, DOI 10.1017/S1355617715000843; Shirk SD, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt94; Tappen RM, 2000, ALZ DIS ASSOC DIS, V14, P196, DOI 10.1097/00002093-200010000-00002; ten Brinke LF, 2015, BRIT J SPORT MED, V49, P248, DOI 10.1136/bjsports-2013-093184; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; Tolppanen AM, 2015, ALZHEIMERS DEMENT, V11, P434, DOI 10.1016/j.jalz.2014.01.008; Topolski T. D., 2006, Preventing Chronic Disease, V3, pA118; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Uffelen JGZ, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.044735; Vidoni ED, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131647; Vidoni ED, 2012, CONTEMP CLIN TRIALS, V33, P1105, DOI 10.1016/j.cct.2012.08.002; Vidoni ED, 2012, NEUROBIOL AGING, V33, P1624, DOI 10.1016/j.neurobiolaging.2011.03.016; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; Wu CW, 2008, J APPL PHYSIOL, V105, P1585, DOI 10.1152/japplphysiol.90775.2008	53	137	142	1	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2017	12	2							e0170547	10.1371/journal.pone.0170547	http://dx.doi.org/10.1371/journal.pone.0170547			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK9KV	28187125	Green Published, Green Submitted, gold			2023-01-03	WOS:000394244300006
J	Thorpe, JM; Thorpe, CT; Gellad, WF; Good, CB; Hanlon, JT; Mor, MK; Pleis, JR; Schleiden, LJ; Van Houtven, CH				Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.; Good, Chester B.; Hanlon, Joseph T.; Mor, Maria K.; Pleis, John R.; Schleiden, Loren J.; Van Houtven, Courtney Harold			Dual Health Care System Use and High-Risk Prescribing in Patients With Dementia	ANNALS OF INTERNAL MEDICINE			English	Article							OF-VETERANS-AFFAIRS; INAPPROPRIATE MEDICATION USE; ANTIPSYCHOTIC-DRUG TREATMENT; OLDER-ADULTS; ANTICHOLINERGIC BURDEN; ALZHEIMER-DISEASE; CONTROLLED-TRIAL; VA; ASSOCIATION; INFORMATION	Background: Recent federal policy changes attempt to expand veterans' access to providers outside the Department of Veterans Affairs (VA). Receipt of prescription medications across unconnected systems of care may increase the risk for unsafe prescribing, particularly in persons with dementia. Objective: To investigate the association between dual health care system use and potentially unsafe medication (PUM) prescribing. Design: Retrospective cohort study. Setting: National VA outpatient care facilities in 2010. Participants: 75 829 veterans with dementia who were continuously enrolled in Medicare from 2007 to 2010; 80% were VA-only users, and 20% were VA-Medicare Part D (dual) users. Measurements: Augmented inverse propensity weighting was used to estimate the effect of dual-system versus VA-only prescribing on 4 indicators of PUM prescribing in 2010: any exposure to Healthcare Effectiveness Data and Information Set (HEDIS) high-risk medication in older adults (PUM-HEDIS), any daily exposure to prescriptions with a cumulative Anticholinergic Cognitive Burden (ACB) score of 3 or higher (PUM-ACB), any antipsychotic prescription (PUM-antipsychotic), and any PUM exposure (any-PUM). The annual number of days of each PUM exposure was also examined. Results: Compared with VA-only users, dual users had more than double the odds of exposure to any-PUM (odds ratio [OR], 2.2 [95% CI, 2.2 to 2.3]), PUM-HEDIS (OR, 2.4 [CI, 2.2 to 2.8]), and PUM-ACB (OR, 2.1 [CI, 2.0 to 2.2]). The odds of PUM-antipsychotic exposure were also greater in dual users (OR, 1.5 [CI, 1.4 to 1.6]). Dual users had an adjusted average of 44.1 additional days of any-PUM exposure (CI, 37.2 to 45.0 days). Limitation: Observational study design of veteran outpatients only. Conclusion: Among veterans with dementia, rates of PUM prescribing are significantly higher among dual-system users than with VA-only users.	Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA; Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA; [Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.; Good, Chester B.; Hanlon, Joseph T.; Pleis, John R.; Schleiden, Loren J.] Vet Affairs Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA; [Van Houtven, Courtney Harold] US Dept Vet Affairs, Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Thorpe, JM (corresponding author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA.	Joshua.Thorpe@va.gov	Good, Chester B/K-2818-2019	Good, Chester B/0000-0003-4388-4558; Pleis, John/0000-0002-0928-9192; Van Houtven, Courtney/0000-0002-0783-1611	U.S. Department of Veterans Affairs, Health Services Research & Development Merit Award [IIR 12-379]; NATIONAL INSTITUTE ON AGING [P30AG024827] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs, Health Services Research & Development Merit Award; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the U.S. Department of Veterans Affairs, Health Services Research & Development Merit Award (IIR 12-379; all authors).	Adams K, 2003, PRIOR AR NAT ACT TRA; Ajmera M, 2011, J GEN INTERN MED, V26, pS669, DOI 10.1007/s11606-011-1788-4; Atkins DC, 2013, HSR D FORUM TRANSLAT; Bang H, 2005, BIOMETRICS, V61, P962, DOI 10.1111/j.1541-0420.2005.00377.x; Blalock Susan J, 2005, Am J Geriatr Pharmacother, V3, P168, DOI 10.1016/S1543-5946(05)80023-6; Boustani M., 2008, AGING HLTH, V4, P311, DOI [10.2217/1745509X.4.3.311, DOI 10.2217/1745509X.4.3.311, 10.2217/1745509XA3.311]; Bynum JPW, 2004, J AM GERIATR SOC, V52, P187, DOI 10.1111/j.1532-5415.2004.52054.x; Byrne CM, 2014, INT J MED INFORM, V83, P537, DOI 10.1016/j.ijmedinf.2014.04.005; Byrne MM, 2006, MED CARE, V44, P768, DOI 10.1097/01.mlr.0000218786.44722.14; Callahan CM, 2006, JAMA-J AM MED ASSOC, V295, P2148, DOI 10.1001/jama.295.18.2148; Carey K, 2008, HEALTH SERV RES, V43, P1164, DOI 10.1111/j.1475-6773.2008.00840.x; Centers for Medicare and Medicaid Services, 2013, CHRON COND DAT WAR; Cooley SG, 2010, GENERATIONS, V34, P57; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fox C, 2011, J AM GERIATR SOC, V59, P1477, DOI 10.1111/j.1532-5415.2011.03491.x; Gellad WF, 2016, J GEN INTERN MED, V31, P153, DOI 10.1007/s11606-015-3492-2; Gellad WF, 2015, JAMA INTERN MED, V175, P26, DOI 10.1001/jamainternmed.2014.5405; Gellad WF, 2012, MED CARE, V50, P954, DOI 10.1097/MLR.0b013e31825fb21d; Gill SS, 2005, ARCH INTERN MED, V165, P808, DOI 10.1001/archinte.165.7.808; Good CB, 2007, AM J PUBLIC HEALTH, V97, P2129, DOI 10.2105/AJPH.2007.124008; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Holmes HM, 2013, PHARMACOEPIDEM DR S, V22, P728, DOI 10.1002/pds.3431; Hynes DM, 2007, MED CARE, V45, P214, DOI 10.1097/01.mlr.0000244657.90074.b7; Little R. J., 2019, STAT ANAL MISSING DA, V793; Lu CJ, 2003, AM J GERIAT PSYCHIAT, V11, P458, DOI 10.1176/appi.ajgp.11.4.458; Naples JG, 2015, J AM GERIATR SOC, V63, P2120, DOI 10.1111/jgs.13647; National Committee for Quality Assurance, 2010, HEDIS QUAL MEAS HEDI; Sarter M, 2014, EXP NEUROL, V257, P120, DOI 10.1016/j.expneurol.2014.04.032; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Schneider LS, 2005, JAMA-J AM MED ASSOC, V294, P1934, DOI 10.1001/jama.294.15.1934; Sturmer T, 2010, AM J EPIDEMIOL, V172, P843, DOI 10.1093/aje/kwq198; Tan L, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0102-9; Tarlov E, 2012, CANCER EPIDEM BIOMAR, V21, P2231, DOI 10.1158/1055-9965.EPI-12-0548; Taylor DH, 2002, J CLIN EPIDEMIOL, V55, P929, DOI 10.1016/S0895-4356(02)00452-3; Thorpe JM, 2012, AM J GERIATR PHARMAC, V10, P230, DOI 10.1016/j.amjopharm.2012.05.001; U. S. Department of Agriculture Economic Research Service, 2003, MEAS RUR URB INFL CO; U.S. Department of Health and Human Services, 2012, HLTH PEOPL 2020; Weeks WB, 2005, J RURAL HEALTH, V21, P167, DOI 10.1111/j.1748-0361.2005.tb00077.x; West T, 2013, J AM PHARM ASSOC, V53, P496, DOI 10.1331/JAPhA.2013.12138; Wolinsky FD, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-70; Wolinsky FD, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-131; World Health Organization, 2012, DEM PUBL HLTH POL	44	35	35	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2017	166	3					157	+		10.7326/M16-0551	http://dx.doi.org/10.7326/M16-0551			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EL7DL	27919104	Green Accepted			2023-01-03	WOS:000394781200004
J	Ellis, H; Schoenberger, E				Ellis, Hugh; Schoenberger, Erica			On the Identification of Associations between Five World Health Organization Water, Sanitation and Hygiene Phenotypes and Six Predictors in Low and Middle-Income Countries	PLOS ONE			English	Article							FALSE DISCOVERY RATE; DIARRHEAL DISEASE; DRINKING-WATER; IMPACT; INTERVENTIONS; SETTINGS; BURDEN; ACCESS	Background According to the most recent estimates, 842,000 deaths in low-to middle-income countries were attributable to inadequate water, sanitation and hygiene in 2012. Despite billions of dollars and decades of effort, we still lack a sound understanding of which kinds of WASH interventions are most effective in improving public health outcomes, and an important corollary-whether the right things are being measured. The World Health Organization (WHO) has made a concerted effort to compile comprehensive data on drinking water quality and sanitation in the developing world. A recent 2014 report provides information on three phenotypes (responses): Unsafe Water Deaths, Unsafe Sanitation Deaths, Unsafe Hygiene Deaths; two grouped phenotypes: Unsafe Water and Sanitation Deaths and Unsafe Water, Sanitation and Hygiene Deaths; and six explanatory variables (predictors): Improved Sanitation, Unimproved Water Source, Piped Water To Premises, Other Improved Water Source, Filtered and Bottled Water in the Household and Handwashing. Methods and Findings Regression analyses were performed to identify statistically significant associations between these mortality responses and predictors. Good fitted-model performance required: (1) the use of population-normalized death fractions as opposed to number of deaths; (2) transformed response (logit or power); and (3) square-root predictor transformation. Given the complexity and heterogeneity of the relationships and countries being studied, these models exhibited remarkable performance and explained, for example, about 85% of the observed variance in population-normalized Unsafe Sanitation Death fraction, with a high F-statistic and highly statistically significant predictor p-values. Similar performance was found for all other responses, which was an unexpected result (the expected associations between responses and predictors-i.e., water-related with water-related, etc. did not occur). The set of statistically significant predictors remains the same across all responses. That is, Unsafe Water Source (UWS), Improved Sanitation (IS) and Filtered and Bottled Water in the Household (FBH) were the only statistically significant predictors whether the response was Unsafe Sanitation Death Fraction, Unsafe Hygiene Death Fraction or Unsafe Water Death Fraction. Moreover, the fraction of variance explained for all fitted models remained relatively high (adjusted R-2 ranges from 0.7605 to 0.8533). We find that two of the statistically significant predictors-Improved Sanitation and Unimproved Water Sources-are particularly influential. We also find that some predictors (Piped Water to Premises, Other Improved Water Sources) have very little explanatory power for predicting mortality and one (Other Improved Water Sources) has a counterintuitive effect on response (Unsafe Sanitary Death Fraction increases with increases in OIWS) and one predictor (Hand Washing) to have essentially no explanatory usefulness. Conclusions Our results suggest that a higher priority may need to be given to improved sanitation than has been the case. Nevertheless, while our focus in this paper is mortality, morbidity is a staggering consequence of inadequate water, sanitation and hygiene, and lower impact on mortality may not mean a similarly low impact on morbidity. More specifically, those predictors that we found uninfluential for predicting mortality-related responses may indeed be important when morbidity is the response.	[Ellis, Hugh; Schoenberger, Erica] Johns Hopkins Univ, Dept Geog & Environm Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Ellis, H (corresponding author), Johns Hopkins Univ, Dept Geog & Environm Engn, Baltimore, MD 21218 USA.	hugh.ellis@jhu.edu						Bain R, 2014, TROP MED INT HEALTH, V19, P917, DOI 10.1111/tmi.12334; Bartram J, 2005, LANCET, V365, P810, DOI 10.1016/S0140-6736(05)71007-2; Bartram J., 2010, PLOS MED, V7; Bartram J, 2014, INT J ENV RES PUB HE, V11, P8137, DOI 10.3390/ijerph110808137; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLUM D, 1983, INT J EPIDEMIOL, V12, P357, DOI 10.1093/ije/12.3.357; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Clasen T, 2014, TROP MED INT HEALTH, V19, P884, DOI 10.1111/tmi.12330; Clasen TF, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004794.pub3; Cumming O, 2014, PLOS ONE, V9; Engell RE, 2013, LANCET, V381, P44; ESREY SA, 1985, B WORLD HEALTH ORGAN, V63, P757; ESREY SA, 1992, AM J EPIDEMIOL, V135, P659, DOI 10.1093/oxfordjournals.aje.a116345; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Esrey SA, 1996, AM J EPIDEMIOL, V143, P608, DOI 10.1093/oxfordjournals.aje.a008791; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Fox J, 2019, R COMPANION APPL REG, Vthird; Fox J., 2015, APPL REGRESSION ANAL; Freeman MC, 2014, TROP MED INT HEALTH, V19, P906, DOI 10.1111/tmi.12339; Fuller JA, 2015, TROP MED INT HEALTH, V20, P284, DOI 10.1111/tmi.12441; Godfrey S, 2011, ENVIRON MONIT ASSESS, V176, P561, DOI 10.1007/s10661-010-1604-3; HOLM S, 1979, SCAND J STAT, V6, P65; Hunter PR, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000361; Hutton G, 2007, J WATER HEALTH, V5, P481, DOI 10.2166/wh.2007.009; Jeuland MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074804; MacDonald L, 2016, HOUSEHOLD WATER TREA; Maindonald J. H., 2014, DAAG DATA ANAL GRAPH; Mosteller F., 1968, HDB SOC PSYCHOL, V2, P80; O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6; O'Hare BAM, 2007, J ROY SOC MED, V100, P564, DOI 10.1258/jrsm.100.12.564; Onda K, 2012, INT J ENV RES PUB HE, V9, P880, DOI 10.3390/ijerph9030880; Pruss-Ustun A, 2014, TROP MED INT HEALTH, V19, P894, DOI 10.1111/tmi.12329; Pruss A, 2002, ENVIRON HEALTH PERSP, V110, P537, DOI 10.1289/ehp.02110537; Rheingans R, 2014, TROP MED INT HEALTH, V19, P2, DOI 10.1111/tmi.12220; Saunders R. J., 1976, VILLAGE WATER SUPPLY; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Shaheed A, 2014, B WORLD HEALTH ORGAN, V92, P283, DOI 10.2471/BLT.13.119594; Stuart E., 2015, DATA REVOLUTION FIND; VANDERSLICE J, 1995, AM J EPIDEMIOL, V141, P135, DOI 10.1093/oxfordjournals.aje.a117401; Weisberg S, 2014, APPL LINEAR REGRESSI, V4th; Wolf J, 2014, TROP MED INT HEALTH, V19, P928, DOI 10.1111/tmi.12331; World Health Organization, 2014, PREVENTING DIARRHOEA; World Health Organization, 2015, PROGR SAN DRINK WAT	44	8	8	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2017	12	1							e0170451	10.1371/journal.pone.0170451	http://dx.doi.org/10.1371/journal.pone.0170451			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7IT	28125625	Green Published, Green Submitted, gold			2023-01-03	WOS:000396176100108
J	Wang, JJ; Wu, CC; Lee, CL; Hsieh, SL; Chen, JB; Lee, CI				Wang, Jyh-Jye; Wu, Chih-Chung; Lee, Chun-Lin; Hsieh, Shu-Ling; Chen, Jin-Bor; Lee, Chu-I			Antimelanogenic, Antioxidant and Antiproliferative Effects of Antrodia camphorata Fruiting Bodies on B16-F0 Melanoma Cells	PLOS ONE			English	Article							EXTRACT; BODY	Antrodia camphorata is a fungus that is endemic to Taiwan, and its fruiting body has been used as a folk medicine for the prevention or treatment of diverse diseases. The present study is aimed at investigating the antimelanogenesis and antioxidation effect of the ethanolic extract of Antrodia camphorata fruiting body (EE-AC), as well as its antiproliferation effects in B16-F0 melanoma cells. Regarding antimelanogenic effects, EE-AC had effective cupric ions reducing capacity and expressed more potent inhibitory effect than kojic acid on mushroom tyrosinase activity. Moreover, EE-AC significantly inhibited cellular tyrosinase activity and the melanin content in B16-F0 cells at 12.5 mu g/mL concentration without cell toxicities. Regarding antioxidant effects, EE-AC exhibited potent DPPH radical-and SOD-like-scavenging activities. Regarding antiproliferative effects, EE-AC exhibited a selective cytotoxic effect and markedly inhibited the migration ability of B16-F0 cells. EE-AC increased the population of B16-F0 cells at sub-G1 phase of the cell cycle. EE-AC also caused the increase of early apoptotic cells and chromatin condensation, which indicated the apoptotic effects in B16-F0 cells. We demonstrated that EE-AC possessed antimelanogenic, antioxidant and anti-skin cancer actions. The results would contribute to the development and application of cosmetics, healthy food and pharmaceuticals.	[Wang, Jyh-Jye] Fooyin Univ, Dept Nutr & Hlth Sci, Kaohsiung, Taiwan; [Wu, Chih-Chung] Chang Jung Christian Univ, Dept Nutr & Hlth Sci, Tainan, Taiwan; [Lee, Chun-Lin] Natl Taitung Univ, Dept Life Sci, Taitung, Taiwan; [Hsieh, Shu-Ling] Natl Kaohsiung Marine Univ, Dept Seafood Sci, Kaohsiung, Taiwan; [Chen, Jin-Bor] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Chen, Jin-Bor] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Lee, Chu-I] Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	Fooyin University; Chang Jung Christian University; National Kaohsiung University of Science & Technology; Chang Gung Memorial Hospital; Chang Gung University; Fooyin University	Lee, CI (corresponding author), Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan.	mt046@fy.edu.tw	Wu, Chih-Chung/AFB-8873-2022	Wu, Chih-Chung/0000-0002-6518-5312	Ministry of Education, Taiwan [99B-78-014]	Ministry of Education, Taiwan(Ministry of Education, Taiwan)	This research was supported by the grant 99B-78-014 from the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akanbi MHJ, 2013, APPL MICROBIOL BIOT, V97, P4385, DOI 10.1007/s00253-012-4311-x; Baurin N, 2002, J ETHNOPHARMACOL, V82, P155, DOI 10.1016/S0378-8741(02)00174-5; CHEN JS, 1991, J AGR FOOD CHEM, V39, P1897, DOI 10.1021/jf00011a001; Ding HY, 2011, PLANT FOOD HUM NUTR, V66, P275, DOI 10.1007/s11130-011-0235-3; Forni C, 2014, MOL BIOSYST, V10, P1255, DOI 10.1039/c3mb70316a; Galvan I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003335; Geethangili M, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep108; Hseu YC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/197309; Hsu YL, 2005, CANCER LETT, V221, P77, DOI 10.1016/j.canlet.2004.08.012; JAY D, 1991, ARCH BIOCHEM BIOPHYS, V290, P463, DOI 10.1016/0003-9861(91)90567-3; Kim YJ, 2005, BIOL PHARM BULL, V28, P323, DOI 10.1248/bpb.28.323; Lee CI, 2014, FOOD FUNCT, V5, P3224, DOI [10.1039/c4fo00720d, 10.1039/C4FO00720D]; Lee CI, 2013, APPL MICROBIOL BIOT, V97, P1269, DOI 10.1007/s00253-012-4279-6; Li YQ, 2011, J MED PLANTS RES, V5, P1066; Maity P, 2014, INT J BIOL MACROMOL, V63, P140, DOI 10.1016/j.ijbiomac.2013.10.040; Sapkota K, 2010, BIOSCI BIOTECH BIOCH, V74, P1527, DOI 10.1271/bbb.100058; Solano F, 2006, PIGM CELL RES, V19, P550, DOI 10.1111/j.1600-0749.2006.00334.x; Song TY, 2002, J AGR FOOD CHEM, V50, P3322, DOI 10.1021/jf011671z; Tsai Z-T., 1985, USE EFFECT GANODERMA, P116; Tu SH, 2012, J AGR FOOD CHEM, V60, P3612, DOI 10.1021/jf300221g; Wang LC, 2013, APPL MICROBIOL BIOT, V97, P9955, DOI 10.1007/s00253-013-5214-1; Wang LC, 2012, APPL MICROBIOL BIOT, V94, P1505, DOI 10.1007/s00253-012-3941-3; Wu MT, 2011, J AGR FOOD CHEM, V59, P4248, DOI 10.1021/jf104561h; Wu SH, 1997, BOT BULL ACAD SINICA, V38, P273; Yeh CT, 2009, CANCER LETT, V285, P73, DOI 10.1016/j.canlet.2009.05.002	25	9	9	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2017	12	1							e0170924	10.1371/journal.pone.0170924	http://dx.doi.org/10.1371/journal.pone.0170924			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7IT	28125738	Green Submitted, Green Published, gold			2023-01-03	WOS:000396176100023
J	Sandler, H; Fendel, U; Busse, P; Rose, M; Boesel, R; Klapp, BF				Sandler, Hubertus; Fendel, Uta; Busse, Petra; Rose, Matthias; Boesel, Rainer; Klapp, Burghard F.			Relaxation - Induced by Vibroacoustic Stimulation via a Body Monochord and via Relaxation Music - Is Associated with a Decrease in Tonic Electrodermal Activity and an Increase of the Salivary Cortisol Level in Patients with Psychosomatic Disorders	PLOS ONE			English	Article							PROGRESSIVE MUSCLE-RELAXATION; PHYSIOLOGICAL-RESPONSES; ANXIETY; STATES; CARE; EEG; MEDITATION; THERAPY; PATTERN; THETA	Vibroacoustic stimulation by a Body Monochord can induce relaxation states of various emotional valence. The skin conductance level (SCL) of the tonic electrodermal activity is an indicator of sympathetic arousal of the autonomic nervous system and thus an indicator of the relaxation response. Salivary cortisol is considered to be a stress indicator of the HPA-axis. The effects of the treatment with a Body Monochord and listening to relaxation music (randomized chronological presentation) on SCL and salivary cortisol in relation to the emotional valence of the experience were examined in patients with psychosomatic disorders (N = 42). Salivary cortisol samples were collected immediately before and after the expositions. Subjective experience was measured via self-rating scales. Overall, both the exposure to the Body Monochord as well as the exposure to the relaxation music induced an improvement of patients' mood and caused a highly significant reduction of SCL. A more emotionally positive experience of relaxation correlated with a slightly stronger reduction of the SCL. Both treatment conditions caused a slight increase in salivary cortisol, which was significant after exposure to the first treatment. The increase of salivary cortisol during a relaxation state is contrary to previous findings. It is possible that the relaxation state was experienced as an emotional challenge, due to inner images and uncommon sensations that might have occurred.	[Sandler, Hubertus; Fendel, Uta; Busse, Petra; Rose, Matthias; Klapp, Burghard F.] Charite, Dept Gen Internal & Psychosomat Med, Berlin, Germany; [Boesel, Rainer] Int Psychoanalyt Univ Berlin, Berlin, Germany; [Boesel, Rainer] Free Univ Berlin, Dept Cognit Neurosci, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Sandler, H (corresponding author), Charite, Dept Gen Internal & Psychosomat Med, Berlin, Germany.	hubertus.sandler@charite.de			Universitare Forschungsforderung Charite (Universitary Research Support Charite) [11/48720]	Universitare Forschungsforderung Charite (Universitary Research Support Charite)	The study was funded by Universitare Forschungsforderung Charite (Universitary Research Support Charite, Identification: 11/48720)) in the period from 1.1.2011 to 31.12.2011 with an amount of 3.800 (three thousand eight hundred). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENSON H, 1974, PSYCHIATRY, V37, P37, DOI 10.1080/00332747.1974.11023785; Bernardi L, 2006, HEART, V92, P445, DOI 10.1136/hrt.2005.064600; Bonny H., 2002, MUSIC CONSCIOUSNESS, P43; Booij SH, 2016, PSYCHONEUROENDOCRINO, V69, P16, DOI 10.1016/j.psyneuen.2016.03.012; Bosel R, 1993, KOGNITIONSWISSENSCHA, V3, P53; Boucsein W., 2007, ELECTRODERMAL ACTIVI; Bradt J., 2009, COCHRANE DB SYST REV, V12; Bradt J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006911.pub2, 10.1002/14651858.CD006911]; Buchanan TW, 1999, PSYCHONEUROENDOCRINO, V24, P227, DOI 10.1016/S0306-4530(98)00078-X; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Castro M, 2000, BRAZ J MED BIOL RES, V33, P1171, DOI 10.1590/S0100-879X2000001000006; Chan MF, 2009, J CLIN NURS, V18, P1250, DOI 10.1111/j.1365-2702.2008.02491.x; Chlan L L, 2000, AACN Clin Issues, V11, P128, DOI 10.1097/00044067-200002000-00014; Deiber MP, 2007, J COGNITIVE NEUROSCI, V19, P158, DOI 10.1162/jocn.2007.19.1.158; DUJARDIN K, 1993, ELECTROEN CLIN NEURO, V86, P353, DOI 10.1016/0013-4694(93)90049-2; Fendel U., UNPUB; Fendel U, 2017, UNPUB; Gingras B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102103; Han L, 2010, J CLIN NURS, V19, P978, DOI 10.1111/j.1365-2702.2009.02845.x; Harding S, 1996, Int J Nurs Pract, V2, P160, DOI 10.1111/j.1440-172X.1996.tb00043.x; Harthog T, 2001, Z MUSIK TANZ KUNSTTH, V12, P111; Hellhammer DH, 2009, PSYCHONEUROENDOCRINO, V34, P163, DOI 10.1016/j.psyneuen.2008.10.026; Horhold M., 1993, Z MED PSYCHOL, V2, P27; Hoyt LT, 2015, PSYCHOSOM MED, V77, P392, DOI 10.1097/PSY.0000000000000178; JEVNING R, 1978, HORM BEHAV, V10, P54, DOI 10.1016/0018-506X(78)90024-7; JIN P, 1989, J PSYCHOSOM RES, V33, P197, DOI 10.1016/0022-3999(89)90047-0; Jungaberle H, 2003, MUSIKTHER UMSCH, V24, P319; Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Koelsch S, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00110; Kreibig SD, 2010, BIOL PSYCHOL, V84, P394, DOI 10.1016/j.biopsycho.2010.03.010; KRIEGER DT, 1971, J CLIN ENDOCR METAB, V32, P266, DOI 10.1210/jcem-32-2-266; Labbe E, 2007, APPL PSYCHOPHYS BIOF, V32, P163, DOI 10.1007/s10484-007-9043-9; Lee EJ, 2012, COMPLEMENT THER MED, V20, P409, DOI 10.1016/j.ctim.2012.07.002; Lee MS, 2004, STRESS HEALTH, V20, P243, DOI 10.1002/smi.1023; Lee OKA, 2005, J CLIN NURS, V14, P609, DOI 10.1111/j.1365-2702.2004.01103.x; MILUKKOLASA B, 1994, EXP CLIN ENDOCRINOL, V102, P118, DOI 10.1055/s-0029-1211273; MOCKEL M, 1994, EUR J APPL PHYSIOL, V68, P451, DOI 10.1007/BF00599512; Nater UM, 2006, INT J PSYCHOPHYSIOL, V62, P300, DOI 10.1016/j.ijpsycho.2006.05.011; Pawlow LA, 2005, APPL PSYCHOPHYS BIOF, V30, P375, DOI 10.1007/s10484-005-8423-2; Peeters F, 2003, PSYCHOSOM MED, V65, P836, DOI 10.1097/01.PSY.0000088594.17747.2E; Pekala RJ, 1991, QUANTIFYING CONSCIOU; PENNEKAMP P, 1994, J PSYCHOPHYSIOL, V8, P131; Putignano P, 2001, EUR J ENDOCRINOL, V145, P165, DOI 10.1530/eje.0.1450165; Rodriguez ACI, 2015, PSYCHONEUROENDOCRINO, V62, P301, DOI 10.1016/j.psyneuen.2015.08.014; Rose JP, 2008, FORSCH KOMPLEMENTMED, V15, P335, DOI 10.1159/000164268; Rux M, 2002, ERPROBUNG DEUTSCHEN; Sandler, UNPUB; Sandler H, 2015, NORDIC J MUSIC THERA; Sandler H., 2008, MUSIK TANZ KUNSTTHER, V19, P110; Sandler H, 2016, BRAIN TOPOGRAPHY; Sandstrom G.M., 2010, MUSIC MED, V2, P137, DOI [10.1177/1943862110371486, DOI 10.1177/1943862110371486, 10.47513/mmd.v2i3.243]; Smith JC, 1996, BIOFEEDBACK SELF-REG, V21, P63, DOI 10.1007/BF02214150; Smyth J, 1998, PSYCHONEUROENDOCRINO, V23, P353, DOI 10.1016/S0306-4530(98)00008-0; Spitzer M, 2005, NERVENHEILKUNDE, V24, P198; SUDSUANG R, 1991, PHYSIOL BEHAV, V50, P543, DOI 10.1016/0031-9384(91)90543-W; Teut M, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-18; Uedo N, 2004, HEPATO-GASTROENTEROL, V51, P451; Vaitl D, 2005, PSYCHOL BULL, V131, P98, DOI 10.1037/0033-2909.131.1.98; Vaitl D, 2000, HDB ENTSPANNUNGSVERF, P206; Warth M, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0933-8; Weeks BP, 2011, EUR J CARDIOVASC NUR, V10, P88, DOI 10.1016/j.ejcnurse.2010.07.002; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; White J M, 1999, Am J Crit Care, V8, P220; Yamamoto M., 2007, PSYCHOL MUSIC, V35, P249, DOI [10.1177/0305735607070375, DOI 10.1177/0305735607070375]	65	10	10	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2017	12	1							e0170411	10.1371/journal.pone.0170411	http://dx.doi.org/10.1371/journal.pone.0170411			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN6QR	28114399	Green Submitted, gold, Green Published			2023-01-03	WOS:000396129000045
J	Hawkes, N				Hawkes, Nigel			Trolley waits in England rise sixfold in six years, show latest figures	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Gulland A, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j212; Kmietowicz Z, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j153; NHS England, 2017, COMB PERF SUMM	3	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2017	356								j222	10.1136/bmj.j222	http://dx.doi.org/10.1136/bmj.j222			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9DG	28087521				2023-01-03	WOS:000392071300014
J	Spooner, L; Fernandes, K; Martins, D; Juurlink, D; Mamdani, M; Paterson, JM; Singh, S; Gomes, T				Spooner, Luke; Fernandes, Kimberly; Martins, Diana; Juurlink, David; Mamdani, Muhammad; Paterson, J. Michael; Singh, Samantha; Gomes, Tara			High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study	PLOS ONE			English	Article							CHRONIC NONCANCER PAIN; GUIDELINE; MORTALITY; THERAPY; FLORIDA; DEATHS	Aims To examine the impact of national clinical practice guidelines and provincial drug policy interventions on prevalence of high-dose opioid prescribing and rates of hospitalization for opioid toxicity. Design Interventional time-series analysis. Setting Ontario, Canada, from 2003 to 2014. Participants Ontario Drug Benefit (ODB) beneficiaries aged 15 to 64 years from 2003 to 2014. Interventions Publication of Canadian clinical practice guidelines for use of opioids in chronic non-cancer pain (May 2010) and implementation of Ontario's Narcotics Safety and Awareness Act (NSAA; November 2011). Measurements Three outcomes were explored: the rate of opioid use among ODB beneficiaries, the prevalence of opioid prescriptions exceeding 200 mg and 400 mg morphine equivalents per day, and rates of opioid-related emergency department visits and hospital admissions. Findings Over the 12 year study period, the rate of opioid use declined 15.2%, from 2764 to 2342 users per 10,000 ODB eligible persons. The rate of opioid use was significantly impacted by the Canadian clinical practice guidelines (p-value =.03) which led to a decline in use, but no impact was observed by the enactment of the NSAA (p-value =.43). Among opioid users, the prevalence of high-dose prescribing doubled (from 4.2% to 8.7%) over the study period. By 2014, 40.9% of recipients of long-acting opioids exceeded daily doses of 200 mg morphine or equivalent, including 55.8% of long-acting oxycodone users and 76.3% of transdermal fentanyl users. Moreover, in the last period, 18.7% of long-acting opioid users exceeded daily doses of 400 mg morphine or equivalent. Rates of opioid-related emergency department visits and hospital admissions increased 55.0% over the study period from 9.0 to 14.0 per 10,000 ODB beneficiaries from 2003 to 2013. This rate was not significantly impacted by the Canadian clinical practice guidelines (p-value = .68) or enactment of the NSAA (p-value = .59). Conclusions Although the Canadian clinical practice guidelines for use of opioids in chronic non-cancer pain led to a decline in opioid prescribing rates among ODB beneficiaries these guidelines and subsequent Ontario legislation did not result in a significant change in rates of opioid-related hospitalizations. Given the prevalence of high dose opioid prescribing in this population, this suggests that improved strategies and programs for the safe prescribing of longacting opioids are needed.	[Spooner, Luke] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Fernandes, Kimberly; Martins, Diana; Juurlink, David; Mamdani, Muhammad; Paterson, J. Michael; Singh, Samantha; Gomes, Tara] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Juurlink, David] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Mamdani, Muhammad] St Michaels Hosp, Dept Med, Toronto, ON, Canada; [Mamdani, Muhammad; Paterson, J. Michael; Gomes, Tara] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Mamdani, Muhammad; Gomes, Tara] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Mamdani, Muhammad; Gomes, Tara] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Singh, Samantha] McMaster Univ, Dept Family Med, Hamilton, ON, Canada	University of British Columbia; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University	Gomes, T (corresponding author), Inst Clin Evaluat Sci, Toronto, ON, Canada.; Gomes, T (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Gomes, T (corresponding author), Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.; Gomes, T (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.	GomesT@smh.ca		Gomes, Tara/0000-0002-1468-1965	Ontario Ministry of Health and Long-Term Care (MOHLTC) Health System Research Fund; Institute for Clinical Evaluative Sciences (ICES) - MOHLTC; Ontario MOHLTC	Ontario Ministry of Health and Long-Term Care (MOHLTC) Health System Research Fund; Institute for Clinical Evaluative Sciences (ICES) - MOHLTC; Ontario MOHLTC(Ministry of Health and Long-Term Care, Ontario)	This study was supported by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC) Health System Research Fund. It also was supported by the Institute for Clinical Evaluative Sciences (ICES), an independent, non-profit research institute funded by an annual grant from the MOHLTC. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the authors and not necessarily those of CIHI. The Ontario MOHLTC provided support in the form of a research grant for MM, DJ, TG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Ms. Fernandes had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Barbera L, 2012, J CLIN ONCOL, V30, P1095, DOI 10.1200/JCO.2011.37.3068; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boscarino JA, 2011, J ADDICT DIS, V30, P185, DOI 10.1080/10550887.2011.581961; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Clarke EA, 1991, IARC SCI PUBL, P246; Delcher C, 2015, DRUG ALCOHOL DEPEN, V150, P63, DOI 10.1016/j.drugalcdep.2015.02.010; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998; Fulton-Kehoe D, 2013, AM J IND MED, V56, P1452, DOI 10.1002/ajim.22266; Gilmour Stuart, 2006, BMC Med Res Methodol, V6, P16, DOI 10.1186/1471-2288-6-16; Gomes T, 2013, JAMA INTERN MED, V173, P196, DOI 10.1001/2013.jamainternmed.733; Gomes Tara, 2011, Open Med, V5, pe13; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Kahan M, 2011, CAN FAM PHYSICIAN, V57, P1257; Kenan Kristen, 2012, Open Med, V6, pe41; National Opioid Use Guideline Group (NOUGG), 2010, CAN GUID SAT EFF US; Paone D, 2015, MMWR-MORBID MORTAL W, V64, P491; Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553	21	32	32	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2016	11	12							e0167479	10.1371/journal.pone.0167479	http://dx.doi.org/10.1371/journal.pone.0167479			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8KC	27973601	Green Submitted, Green Published, gold			2023-01-03	WOS:000392754300031
J	Hortobagyi, GN; Stemmer, SM; Burris, HA; Yap, YS; Sonke, GS; Paluch-Shimon, S; Campone, M; Blackwell, KL; Andre, F; Winer, EP; Janni, W; Verma, S; Conte, P; Arteaga, CL; Cameron, DA; Petrakova, K; Hart, LL; Villanueva, C; Chan, A; Jakobsen, E; Nusch, A; Burdaeva, O; Grischke, EM; Alba, E; Wist, E; Marschner, N; Favret, AM; Yardley, D; Bachelot, T; Tseng, LM; Blau, S; Xuan, F; Souami, F; Miller, M; Germa, C; Hirawat, S; O'Shaughnessy, J				Hortobagyi, G. N.; Stemmer, S. M.; Burris, H. A.; Yap, Y. -S.; Sonke, G. S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K. L.; Andre, F.; Winer, E. P.; Janni, W.; Verma, S.; Conte, P.; Arteaga, C. L.; Cameron, D. A.; Petrakova, K.; Hart, L. L.; Villanueva, C.; Chan, A.; Jakobsen, E.; Nusch, A.; Burdaeva, O.; Grischke, E. -M.; Alba, E.; Wist, E.; Marschner, N.; Favret, A. M.; Yardley, D.; Bachelot, T.; Tseng, L. -M.; Blau, S.; Xuan, F.; Souami, F.; Miller, M.; Germa, C.; Hirawat, S.; O'Shaughnessy, J.			Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; CONTROLLED-TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; ESTROGEN; PALBOCICLIB; CRITERIA; PLACEBO; CDK4/6	BACKGROUND The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). METHODS In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease. We randomly assigned the patients to receive either ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day) or placebo plus letrozole. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. A preplanned interim analysis was performed on January 29, 2016, after 243 patients had disease progression or died. Prespecified criteria for superiority required a hazard ratio of 0.56 or less with P < 1.29x10(-5). RESULTS The duration of progression-free survival was significantly longer in the ribociclib group than in the placebo group (hazard ratio, 0.56; 95% CI, 0.43 to 0.72; P = 3.29x10(-6) for superiority). The median duration of follow-up was 15.3 months. After 18 months, the progression-free survival rate was 63.0% (95% confidence interval [ CI], 54.6 to 70.3) in the ribociclib group and 42.2% (95% CI, 34.8 to 49.5) in the placebo group. In patients with measurable disease at baseline, the overall response rate was 52.7% and 37.1%, respectively (P < 0.001). Common grade 3 or 4 adverse events that were reported in more than 10% of the patients in either group were neutropenia (59.3% in the ribociclib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuation because of adverse events were 7.5% and 2.1%, respectively. CONCLUSIONS Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT01958021.)	[Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [O'Shaughnessy, J.] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Dallas, TX USA; [O'Shaughnessy, J.] US Oncol Network, Dallas, TX USA; [Stemmer, S. M.] Tel Aviv Univ, Rabin Med Ctr, Davidoff Ctr, Tel Aviv, Israel; [Paluch-Shimon, S.] Sheba Med Ctr, Ramat Gan, Israel; [Burris, H. A.; Yardley, D.] Sarah Cannon Res Inst, Nashville, TN USA; [Arteaga, C. L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Yardley, D.] Tennessee Oncol, Nashville, TN USA; [Yap, Y. -S.] Natl Canc Ctr Singapore, Singapore, Singapore; [Sonke, G. S.] Netherlands Canc Inst, Amsterdam, Netherlands; [Sonke, G. S.] BOOG Study Ctr, Amsterdam, Netherlands; [Campone, M.] Inst Cancerol Ouest Rene Gauducheau, St Herblain, France; [Andre, F.] Univ Paris 11, Inst Gustave Roussy, Villejuif, France; [Villanueva, C.] Univ Hosp Besancon, Besancon, France; [Bachelot, T.] Ctr Leon Berard, Lyon, France; [Blackwell, K. L.] Duke Univ, Med Ctr, Durham, NC USA; [Winer, E. P.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Janni, W.] Univ Ulm, Ulm, Germany; [Grischke, E. -M.] Univ Tubingen, Tubingen, Germany; [Marschner, N.] Joint Practice Interdisciplinary Oncol & Hematol, Freiburg, Germany; [Verma, S.] Tom Baker Canc Clin, Calgary, AB, Canada; [Conte, P.] Univ Padua, Padua, Italy; [Conte, P.] Ist Ricovero & Cura Carattere Sci, Ist Oncol Veneto, Padua, Italy; [Cameron, D. A.] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland; [Petrakova, K.] Masaryk Mem Canc Inst, Brno, Czech Republic; [Hart, L. L.] Florida Canc Specialists Sarah Cannon Res Inst, Ft Myers, WA, Australia; [Chan, A.] Breast Canc Res Ctr Western Australia, Perth, WA, Australia; [Chan, A.] Curtin Univ, Perth, WA, Australia; [Jakobsen, E.] Vejle Hosp, Dept Oncol, Vejle, Denmark; [Burdaeva, O.] Arkhangelsk Clin Oncol Dispensary, Arkhangelsk, Russia; [Alba, E.] Hosp Univ Virgen de la Victoria, Inst Biomed Res Malaga, Malaga, Spain; [Wist, E.] Oslo Univ Hosp, Oslo, Norway; [Favret, A. M.] Virginia Canc Specialists, Arlington, VA USA; [Tseng, L. -M.] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei, Taiwan; [Blau, S.] Northwest Med Specialties, Rainier Hematol Oncol, Puyallup, WA USA; [Xuan, F.; Miller, M.; Germa, C.; Hirawat, S.] Novartis Pharmaceut, E Hanover, NJ USA; [Souami, F.] Novartis Pharmaceut, Basel, Switzerland	University of Texas System; UTMD Anderson Cancer Center; Baylor University Medical Center; Texas Oncology; Texas Oncology-Baylor Charles A Sammons Cancer Center; Rabin Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Sarah Cannon Research Institute; Vanderbilt University; Tennessee Oncology; National Cancer Centre Singapore (NCCS); Netherlands Cancer Institute; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Universite de Franche-Comte; CHU Besancon; UNICANCER; Centre Leon Berard; Duke University; Harvard University; Dana-Farber Cancer Institute; Ulm University; Eberhard Karls University of Tubingen; Tom Baker Cancer Clinic; University of Calgary; University of Padua; IRCCS Istituto Oncologico Veneto (IOV); University of Edinburgh; Masaryk Memorial Cancer Institute; Curtin University; University of Southern Denmark; Lillebaelt Hospital; Universidad de Malaga; University of Oslo; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Novartis; Novartis	Hortobagyi, GN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Div Canc Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ghortoba@mdanderson.org	Alba, Emilio/S-1435-2019; ANDRE, Fabrice/AAL-2683-2020	Alba, Emilio/0000-0002-3364-2603; ANDRE, Fabrice/0000-0001-5795-8357; Sonke, Gabe/0000-0001-8088-9628; Yap, Yoon-Sim/0000-0002-0347-5066	Novartis Pharmaceuticals; Eli Lilly; Pfizer; Novartis; Roche; AstraZeneca; Amgen; Celgene; Genentech; Eisai; GE Healthcare; Hospira; Rockwell; spectrum; Incyte; Sandoz; Janssen; Bayer; Oncovis; GlaxoSmithKline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Novartis Pharmaceuticals(Novartis); Eli Lilly(Eli Lilly); Pfizer(Pfizer); Novartis(Novartis); Roche(Roche Holding); AstraZeneca(AstraZeneca); Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Genentech(Roche HoldingGenentech); Eisai(Eisai Co Ltd); GE Healthcare(General ElectricGE Healthcare); Hospira; Rockwell; spectrum; Incyte; Sandoz(Novartis); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Bayer(Bayer AG); Oncovis; GlaxoSmithKline(GlaxoSmithKline); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Novartis Pharmaceuticals.; Dr. Hortobagyi reports receiving consulting fees from Eli Lilly and Pfizer; Dr. Stemmer, Dr. Villanueva, and Dr. O'Shaughnessy, receiving fees for serving on advisory hoards from Novartis; Dr. Yap, receiving consulting fees and fees for serving on advisory boards from Novartis; Dr. Paluch-Shimon, receiving consulting lees from Novartis and Pfizer; Dr. Campone, receiving consulting fees from Novartis, Roche, Pfizer, and AstraZeneca and grant support from Novartis; Dr. Blackwell, receiving consulting lees from Amgen, AstraZeneca, Celgene, Genentech, Eli Lilly, Eisai, GE Healthcare, Hospira, Pfizer, Roche, Rockwell, spectrum, Incyte, Sandoz, Janssen, and Bayer and grant support to her institution from Celgene, Genentech, and Pfizer; Dr. Andre, receiving grant support from Novartis, AstraZeneca, Pfizer, and Eli Lilly; Dr. Winer, receiving grant support from Genentech; Drs. Janni and Hart, receiving grant support from Novartis; Dr. Verma, receiving fees for serving on advisory hoards from Amgen, Eli Lilly, AstraZeneca, Novartis, Pfizer, and Roche and being cofounder and medical director (uncompensated) of OncologyEducation.com; Dr. Cameron, receiving consulting fees from Pfizer and Novartis, fees for participating on a data monitoring committee from Eli Lilly, and clinical trial support from Novartis, all paid to his institution; Dr. Jakobsen, receiving travel support from Novartis; Dr. Alba, receiving consulting and lecture fees from Roche, Pfizer, Novartis, Celgene, and Eli Lilly; Dr. Marschner, receiving grant support from Novartis, Pfizer, Roche, Celgene, Oncovis, and GlaxoSmithKline and clinical trial support from Novartis; Dr. Bachelot, receiving consulting fees and grant support from Novartis, Roche, and AstraZeneca and honoraria and travel support from Novartis and Roche; and Drs. Xuan, Souami, Miller, Germa, and Hirawat, being employees or and having an equity interest in Novartis. No other potential conflict of interest relevant to this article was reported.	Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Cardoso F, 2014, BREAST, V23, P489, DOI 10.1016/j.breast.2014.08.009; Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Dhuria SV, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.e13577; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Finn RS, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.507; Finn RS, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0661-5; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Infante JR, 2016, CLIN CANC RES; Juric D, 2016, 2016 ANN M AM SOC CL; Kim S., 2013, MOL CANCER THER, V12, pPR02, DOI DOI 10.1158/1535-7163.TARG-13-PR02; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Ma CX, 2015, 2015 SAN ANT BREAST; National Cancer Institute, 2006, COMM TERM CRIT ADV E; National Comprehensive Cancer Network (NCCN), 2020, NCCN CLIN PRACT GUID; O'Brien NA, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-4756; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Setiawan VW, 2009, AM J EPIDEMIOL, V169, P1251, DOI 10.1093/aje/kwp036; Tolaney SM, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.522; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Vuppalanchi R, 2016, HEPATOLOGY; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29	29	801	820	3	115	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2016	375	18					1738	1748		10.1056/NEJMoa1609709	http://dx.doi.org/10.1056/NEJMoa1609709			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB0BB	27717303	Green Published, Bronze			2023-01-03	WOS:000387007300007
J	Ostroumov, A; Thomas, AM; Kimmey, BA; Karsch, JS; Doyon, WM; Dani, JA				Ostroumov, Alexey; Thomas, Alyse M.; Kimmey, Blake A.; Karsch, Jordan S.; Doyon, William M.; Dani, John A.			Stress Increases Ethanol Self-Administration via a Shift toward Excitatory GABA Signaling in the Ventral Tegmental Area	NEURON			English	Article							ALTERED CHLORIDE HOMEOSTASIS; ALCOHOL-DRINKING; DOPAMINERGIC-NEURONS; GABAERGIC NEURONS; MECHANISMS; MODULATION; PLASTICITY; RECEPTORS; DRUGS; ABUSE	Stress is a well-known risk factor for subsequent alcohol abuse, but the neural mechanisms underlying interactions between stress and alcohol remain largely unknown. Addictive drug reinforcement and stress signaling involve common neural circuitry, including the mesolimbic dopamine system. We demonstrate in rodents that pre-exposure to stress attenuates alcohol-induced dopamine responses and increases alcohol self-administration. The blunted dopamine signaling resulted from ethanol-induced excitation of GABA neurons in the ventral tegmental area. Excitation of GABA neurons was mediated by GABA(A) receptor activation and involved stress-induced functional downregulation of the K+, Cl- cotransporter, KCC2. Blocking stress hormone receptors, enhancing KCC2 function, or preventing excitatory GABA signaling by alternative methods all prevented the attenuated alcohol-induced dopamine response and prevented the increased alcohol self-administration. These results demonstrate that stress alters the neural and behavioral responses to alcohol through a neuroendocrine signal that shifts inhibitory GABA transmission toward excitation.	[Ostroumov, Alexey; Thomas, Alyse M.; Kimmey, Blake A.; Karsch, Jordan S.; Doyon, William M.; Dani, John A.] Univ Penn, Dept Neurosci, Mahoney Inst Neurosci, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Dani, JA (corresponding author), Univ Penn, Dept Neurosci, Mahoney Inst Neurosci, Perelman Sch Med, Philadelphia, PA 19104 USA.	johndani@upenn.edu		Thomas, Alyse/0000-0002-6070-4769; Kimmey, Blake/0000-0001-6559-8005	National Institutes of Health [NS21229, DA09411]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021229, R37NS021229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009411, R01DA036572, T32DA028874] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank Drs. Y. De Koninck and A. Castonguay from Laval University for the generous gift of CLP290 and technical assistance. We also thank Dr. Amber Alhadeff, Madison Taormina, Kevin Guan, and Natalie Neale for their help with experiments and Dr. David Connor for helpful discussions. This work was supported by grants from the National Institutes of Health NS21229, DA09411 (J.A.D.).	Astorga G, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00275; Ayer LA, 2011, DRUG ALCOHOL DEPEN, V115, P205, DOI 10.1016/j.drugalcdep.2010.10.022; Bass CE, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00173; Becker HC, 2011, PSYCHOPHARMACOLOGY, V218, P131, DOI 10.1007/s00213-011-2443-9; Brodie MS, 2000, ALCOHOL CLIN EXP RES, V24, P1120, DOI 10.1111/j.1530-0277.2000.tb04658.x; Cadepond F, 1997, ANNU REV MED, V48, P129; Chung L, 2012, ARCH PHARM RES, V35, P2035, DOI 10.1007/s12272-012-1202-8; Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868; Creed MC, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00008; De Koninck Y, 2007, CURR OPIN PHARMACOL, V7, P93, DOI 10.1016/j.coph.2006.11.005; Doyon WM, 2013, NEURON, V79, P530, DOI 10.1016/j.neuron.2013.06.006; Foddai M, 2004, NEUROPSYCHOPHARMACOL, V29, P530, DOI 10.1038/sj.npp.1300326; Gagnon M, 2013, NAT MED, V19, P1524, DOI 10.1038/nm.3356; Gonzales RA, 2004, PHARMACOL THERAPEUT, V103, P121, DOI 10.1016/j.pharmthera.2004.06.002; Gulacsi A, 2003, J NEUROSCI, V23, P8237; Hewitt SA, 2009, NAT NEUROSCI, V12, P438, DOI 10.1038/nn.2274; Hwa LS, 2016, PSYCHOPHARMACOLOGY, V233, P681, DOI 10.1007/s00213-015-4144-2; Kahle KT, 2013, TRENDS NEUROSCI, V36, P726, DOI 10.1016/j.tins.2013.08.006; Kaila K, 2014, NAT REV NEUROSCI, V15, P637, DOI 10.1038/nrn3819; Keyes KM, 2012, ALCOHOL RES-CURR REV, V34, P391; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Korotkova TM, 2006, EUR J NEUROSCI, V23, P2677, DOI 10.1111/j.1460-9568.2006.04792.x; Laviolette SR, 2004, NAT NEUROSCI, V7, P160, DOI 10.1038/nn1182; Lee HHC, 2011, NAT NEUROSCI, V14, P736, DOI 10.1038/nn.2806; Maguire J, 2014, FRONT CELL NEUROSCI, V8, P1, DOI 10.3389/fncel.2014.00157; Margolis EB, 2006, J PHYSIOL-LONDON, V577, P907, DOI 10.1113/jphysiol.2006.117069; Niehaus JL, 2010, EUR J NEUROSCI, V32, P108, DOI 10.1111/j.1460-9568.2010.07256.x; Noori HR, 2014, ADDICT BIOL, V19, P225, DOI 10.1111/adb.12125; Pfau ML, 2015, NEUROBIOL STRESS, V1, P66, DOI 10.1016/j.ynstr.2014.09.004; PITMAN DL, 1988, PHYSIOL BEHAV, V43, P47, DOI 10.1016/0031-9384(88)90097-2; Ramachandra V, 2007, ALCOHOL CLIN EXP RES, V31, P1669, DOI 10.1111/j.1530-0277.2007.00463.x; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7; Sarkar J, 2011, J NEUROSCI, V31, P18198, DOI 10.1523/JNEUROSCI.2560-11.2011; Spanagel R, 2014, TRENDS NEUROSCI, V37, P219, DOI 10.1016/j.tins.2014.02.006; Tamers SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087653; Taylor AMW, 2016, NEUROPSYCHOPHARMACOL, V41, P949, DOI 10.1038/npp.2015.221; Thomas S. E., 2011, PSYCHOPHARMACOLOGY B, V218, P19; Uhart M, 2009, ADDICT BIOL, V14, P43, DOI 10.1111/j.1369-1600.2008.00131.x; Ungless MA, 2003, NEURON, V39, P401, DOI 10.1016/S0896-6273(03)00461-6; WHO, 2013, WORLD MALARIA REPORT 2013, P1	40	53	54	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	OCT 19	2016	92	2					493	504		10.1016/j.neuron.2016.09.029	http://dx.doi.org/10.1016/j.neuron.2016.09.029			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA6TN	27720487	Green Accepted, Bronze			2023-01-03	WOS:000386762000029
J	Shahab, L; Goniewicz, ML; Blount, BC; Brown, J; McNeill, A; Alwis, KU; Feng, J; Wang, LQ; West, R				Shahab, Lion; Goniewicz, Maciej L.; Blount, Benjamin C.; Brown, Jamie; McNeill, Ann; Alwis, K. Udeni; Feng, June; Wang, Lanqing; West, Robert			Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users A Cross-sectional Study	ANNALS OF INTERNAL MEDICINE			English	Article							ELECTRONIC CIGARETTES; CARBON-MONOXIDE; RISK-ASSESSMENT; CANCER-RISK; TOBACCO; SMOKING; DELIVERY; SMOKERS; SAFETY; URINE	Background: Given the rapid increase in the popularity of e-cigarettes and the paucity of associated longitudinal healthrelated data, the need to assess the potential risks of long-term use is essential. Objective: To compare exposure to nicotine, tobacco-related carcinogens, and toxins among smokers of combustible cigarettes only, former smokers with long-term e-cigarette use only, former smokers with long-term nicotine replacement therapy (NRT) use only, long-term dual users of both combustible cigarettes and e-cigarettes, and long-term users of both combustible cigarettes and NRT. Design: Cross-sectional study. Setting: United Kingdom. Participants: The following 5 groups were purposively recruited: combustible cigarette-only users, former smokers with longterm (= 6 months) e-cigarette-only or NRT-only use, and longterm dual combustible cigarette-e-cigarette or combustible cigarette-NRT users (n = 36 to 37 per group; total n = 181). Measurements: Sociodemographic and smoking characteristics were assessed. Participants provided urine and saliva samples and were analyzed for biomarkers of nicotine, tobaccospecific N-nitrosamines (TSNAs), and volatile organic compounds (VOCs). Results: After confounders were controlled for, no clear between-group differences in salivary or urinary biomarkers of nicotine intake were found. The e-cigarette-only and NRT-only users had significantly lower metabolite levels for TSNAs (including the carcinogenic metabolite 4-(methylnitrosamino)-1-(3pyridyl)- 1-butanol [NNAL]) and VOCs (including metabolites of the toxins acrolein; acrylamide; acrylonitrile; 1,3-butadiene; and ethylene oxide) than combustible cigarette-only, dual combustible cigarette-e-cigarette, or dual combustible cigarette-NRT users. The e-cigarette-only users had significantly lower NNAL levels than all other groups. Combustible cigarette-only, dual combustible cigarette-NRT, and dual combustible cigarette-ecigarette users had largely similar levels of TSNA and VOC metabolites. Limitation: Cross-sectional design with self-selected sample. Conclusion: Former smokers with long-term e-cigarette-only or NRT-only use may obtain roughly similar levels of nicotine compared with smokers of combustible cigarettes only, but results varied. Long-term NRT-only and e-cigarette-only use, but not dual use of NRTs or e-cigarettes with combustible cigarettes, is associated with substantially reduced levels of measured carcinogens and toxins relative to smoking only combustible cigarettes.	[Shahab, Lion; West, Robert] UCL, Dept Epidemiol & Publ Hlth, 1-19 Torrington St, London WC1E 7HB, England; [McNeill, Ann] Kings Coll London, Inst Psychiat Psychol & Neurosci, Addict Dept, 4 Windsor Walk, London SE5 8AF, England; [Goniewicz, Maciej L.] Roswell Pk Canc Inst, Dept Hlth Behav, Elm & Carlton St, Buffalo, NY 14263 USA; [Blount, Benjamin C.; Alwis, K. Udeni; Feng, June; Wang, Lanqing] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA; [Brown, Jamie] UCL, Dept Clin Educ & Hlth Psychol, 1-19 Torrington St, London WC1E 7HB, England	University of London; University College London; University of London; King's College London; Roswell Park Cancer Institute; Centers for Disease Control & Prevention - USA; University of London; University College London	Shahab, L (corresponding author), UCL, Dept Epidemiol & Publ Hlth, 1-19 Torrington St, London WC1E 7HB, England.	lion.shahab@ucl.ac.uk	Goniewicz, Maciej Lukasz/Z-1604-2019; Goniewicz, Maciej L/D-8986-2012; Shahab, Lion/B-5835-2009; Brown, Jamie/F-4413-2011; West, Robert/B-5414-2009	Goniewicz, Maciej Lukasz/0000-0001-6748-3068; Shahab, Lion/0000-0003-4033-442X; Brown, Jamie/0000-0002-2797-5428; McNeill, Ann/0000-0002-6223-4000; West, Robert/0000-0001-6398-0921	Cancer Research UK [C27061/A16929, C1417/A14135, C36048/A11654, C1417/A7972, C44576/A19501]; Society for the Study of Addiction; Medical Research Council; British Heart Foundation; Economic and Social Research Council; National Institute for Health Research under UK Clinical Research Collaboration [MR/K023195/1]; National Institute on Drug Abuse of the National Institutes of Health [R01DA037446, P30 CA016056]; National Cancer Institute of the National Institutes of Health [R01DA037446, P30 CA016056]; Roswell Park Alliance Foundation; Cancer Research UK [14135, 16929, 22962] Funding Source: researchfish; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; Medical Research Council [MR/K023195/1] Funding Source: researchfish; Versus Arthritis [19501] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Society for the Study of Addiction; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research under UK Clinical Research Collaboration(National Institute for Health Research (NIHR)); National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Roswell Park Alliance Foundation; Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Versus Arthritis(Versus Arthritis)	This work was supported by Cancer Research UK (grant C27061/A16929, with additional funding from grants C1417/A14135 and C36048/A11654). Dr. Brown's post is funded by a fellowship from the Society for the Study of Addiction, and Cancer Research UK also provides support (grants C1417/A7972 and C44576/A19501). Drs. McNeill and West are part of the UK Centre for Tobacco and Alcohol Studies, which is a UK Clinical Research Collaboration Public Health Research Centre of Excellence. Funding from the Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council, and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged (grant MR/K023195/1). Dr. Goniewicz was supported by the National Institute on Drug Abuse and the National Cancer Institute of the National Institutes of Health (awards R01DA037446 and P30 CA016056, respectively) and by an award from Roswell Park Alliance Foundation.	Alwis KU, 2012, ANAL CHIM ACTA, V750, P152, DOI 10.1016/j.aca.2012.04.009; [Anonymous], 2004, TOB SMOK INV SMOK, V83; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brose LS, 2013, ADDICT BEHAV, V38, P2529, DOI 10.1016/j.addbeh.2013.04.006; Brown J, 2014, ADDICT BEHAV, V39, P1120, DOI 10.1016/j.addbeh.2014.03.009; Bullen C, 2010, TOB CONTROL, V19, P98, DOI 10.1136/tc.2009.031567; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Burns D M, 2008, Tob Control, V17, P132, DOI 10.1136/tc.2007.024158; Burstyn I, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-18; Cohen JT, 2002, J TOXICOL ENV HEAL B, V5, P1, DOI 10.1080/10937400252972162; Dawkins L, 2014, PSYCHOPHARMACOLOGY, V231, P401, DOI 10.1007/s00213-013-3249-8; Dillon MC, 2010, BIOMARK INSIGHTS, V5, P57; Etter JF, 2011, TOB CONTROL, V20, P243, DOI 10.1136/tc.2010.042168; Fagerstrom K O, 1997, Tob Control, V6, P311; Farsalinos KE, 2015, ADDICTION, V110, P1352, DOI 10.1111/add.12942; Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P3439, DOI 10.3390/ijerph120403439; Farsalinos KE, 2014, THER ADV DRUG SAF, V5, P67, DOI 10.1177/2042098614524430; Farsalinos KE, 2014, SCI REP-UK, V4, DOI 10.1038/srep04133; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424; Goniewicz ML, 2017, NICOTINE TOB RES, V19, P160, DOI 10.1093/ntr/ntw160; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Grana R, 2014, CIRCULATION, V129, P1972, DOI 10.1161/CIRCULATIONAHA.114.007667; Hajek P, 2014, ADDICTION, V109, P1801, DOI 10.1111/add.12659; Haussmann HJ, 2012, CHEM RES TOXICOL, V25, P794, DOI 10.1021/tx200536w; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hecht SS, 2015, NICOTINE TOB RES, V17, P704, DOI 10.1093/ntr/ntu218; Hornung R.W., 1990, APPL OCCUP ENVIRON H, V5, P46, DOI [10.1080/1047322X.1990.10389587, DOI 10.1080/1047322X.1990.10389587]; IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC MON EV CARC R B, V100B, P255; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V89, P1; International Agency for Research on Cancer, 1995, IARC MONOGRAPHS EVAL, V63; JACOB P, 1991, BIOL MASS SPECTROM, V20, P247, DOI 10.1002/bms.1200200503; Jacob P, 2002, CANCER EPIDEM BIOMAR, V11, P1668; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; Jain RB, 2015, ENVIRON TOXICOL PHAR, V40, P471, DOI 10.1016/j.etap.2015.07.018; Jensen RP, 2015, NEW ENGL J MED, V372, P392, DOI 10.1056/NEJMc1413069; Kampa M, 2008, ENVIRON POLLUT, V151, P362, DOI 10.1016/j.envpol.2007.06.012; Kim HJ, 2013, J CHROMATOGR A, V1291, P48, DOI 10.1016/j.chroma.2013.03.035; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; Le Houezec J, 2011, DRUG ALCOHOL REV, V30, P119, DOI 10.1111/j.1465-3362.2010.00264.x; Lee YH, 2015, ADDICT BEHAV, V48, P1, DOI 10.1016/j.addbeh.2015.04.003; Malaiyandi V, 2005, CLIN PHARMACOL THER, V77, P145, DOI 10.1016/j.clpt.2004.10.011; McGuffey JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101816; McMillen RC, 2015, NICOTINE TOB RES, V17, P1195, DOI 10.1093/ntr/ntu213; McNeill A BL, 2015, E CIGARETTES EVIDENC; McQueen A, 2011, NICOTINE TOB RES, V13, P860, DOI 10.1093/ntr/ntr088; McRobbie H, 2015, CANCER PREV RES, V8, P873, DOI 10.1158/1940-6207.CAPR-15-0058; MOORE D, 2009, BRIT MED J, V338, DOI DOI 10.1136/BMJ.B1024; Murray RP, 2009, NICOTINE TOB RES, V11, P1076, DOI 10.1093/ntr/ntp104; National Institute for Health and Care Excellence, 2013, SMOK HARM RED; Nelson VA, 2015, DRUG ALCOHOL DEPEN, V153, P300, DOI 10.1016/j.drugalcdep.2015.05.005; O'Brien KM, 2016, ENVIRON HEALTH PERSP, V124, P220, DOI 10.1289/ehp.1509693; Ouellet-Morin I, 2011, BRAIN BEHAV IMMUN, V25, P640, DOI 10.1016/j.bbi.2010.12.020; Rose JE, 2010, PSYCHOPHARMACOLOGY, V210, P1, DOI 10.1007/s00213-010-1810-2; Schraufnagel DE, 2014, AM J RESP CRIT CARE, V190, P611, DOI 10.1164/rccm.201407-1198PP; Shahab L, 2018, NICOTINE TOB RES, V20, P81, DOI 10.1093/ntr/ntw258; Shahab L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113045; Shahab L, 2012, DRUG ALCOHOL DEPEN, V121, P38, DOI 10.1016/j.drugalcdep.2011.08.011; Shields PG, 2011, CANCER PREV RES, V4, P1719, DOI 10.1158/1940-6207.CAPR-11-0453; Silla K, 2014, NICOTINE TOB RES, V16, P1050, DOI 10.1093/ntr/ntu019; Smith CJ, 1997, FOOD CHEM TOXICOL, V35, P1107, DOI 10.1016/S0278-6915(97)00063-X; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stepanov I, 2014, INT J CANCER, V134, P2278, DOI 10.1002/ijc.28575; Stepanov I, 2009, CANCER RES, V69, P8236, DOI 10.1158/0008-5472.CAN-09-1084; Sussan TE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116861; Vansickel AR, 2013, NICOTINE TOB RES, V15, P267, DOI 10.1093/ntr/ntr316; Vardavas CI, 2015, TOB CONTROL, V24, P442, DOI [10.1136/tobaccocontrol-2012-050857, 10.1136/tobaccocontrol-2013-051394]; Weaver VM, 2000, CANCER EPIDEM BIOMAR, V9, P749; Wei BNA, 2014, CLIN CHIM ACTA, V436, P290, DOI 10.1016/j.cca.2014.06.012; Xia BY, 2014, BIOMED CHROMATOGR, V28, P375, DOI 10.1002/bmc.3031	70	326	333	5	129	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2017	166	6					390	+		10.7326/M16-1107	http://dx.doi.org/10.7326/M16-1107			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO9RM	28166548	Green Accepted, Green Submitted			2023-01-03	WOS:000397025800014
J	Oehlke, K; Behsnilian, D; Mayer-Miebach, E; Weidler, PG; Greiner, R				Oehlke, Kathleen; Behsnilian, Diana; Mayer-Miebach, Esther; Weidler, Peter G.; Greiner, Ralf			Edible solid lipid nanoparticles (SLN) as carrier system for antioxidants of different lipophilicity	PLOS ONE			English	Article							DRUG-DELIVERY SYSTEMS; BETA-CAROTENE; PHYSICOCHEMICAL CHARACTERIZATION; ALPHA-TOCOPHEROL; VITAMIN-E; STABILITY; ACID; TRISTEARIN; LOCATION; IMPACT	Ferulic acid (FA) and tocopherol (Toc) loaded solid lipid nanoparticles (SLN) were prepared by a hot homogenisation method. The particle size distribution, zeta potential and melting behaviour of the SLN as well as the stability, encapsulation efficiency and radical scavenging activity of FA and Toc in the SLN were analysed. The different formulations containing up to 2.8 mg g(-1) of FA or Toc were stable during at least 15 weeks of storage at room temperature. Despite partial degradation and / or release of FA and Toc during storage, significant radical scavenging activity was maintained. DSC measurements and radical scavenging tests after different time periods revealed that the re-structuring of the lipid matrix was connected to the enhanced antioxidant activity of Toc but did not affect the activity of FA.	[Oehlke, Kathleen; Behsnilian, Diana; Mayer-Miebach, Esther; Greiner, Ralf] Max Rubner Inst, Inst Food Technol & Bioproc Engn, Karlsruhe, Germany; [Weidler, Peter G.] KIT, Inst Funct Interfaces, Div Oxid & Organ Interfaces, Hermann von Helmoltz Pl 1, D-76344 Eggenstein Leopoldshafen, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Oehlke, K (corresponding author), Max Rubner Inst, Inst Food Technol & Bioproc Engn, Karlsruhe, Germany.	kathleen.oehlke@mri.bund.de			Federal Ministry of Food and Agriculture (BMEL)	Federal Ministry of Food and Agriculture (BMEL)	The project was supported by funds of the Federal Ministry of Food and Agriculture (BMEL) based on a decision of the Parliament of the Federal Republic of Germany via the Federal Office for Agriculture and Food (BLE) under the innovation support programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aditya NP, 2014, LWT-FOOD SCI TECHNOL, V59, P115, DOI 10.1016/j.lwt.2014.04.058; Ahlin P, 2000, INT J PHARM, V196, P241, DOI 10.1016/S0378-5173(99)00431-7; Berton-Carabin CC, 2013, COLLOID SURFACE A, V431, P9, DOI 10.1016/j.colsurfa.2013.04.016; Bondi ML, 2009, CURR NANOSCI, V5, P26, DOI 10.2174/157341309787314656; Bose S, 2013, INT J PHARMACEUT, V441, P56, DOI 10.1016/j.ijpharm.2012.12.013; Bunjes H, 2000, LANGMUIR, V16, P5234, DOI 10.1021/la990856l; Bunjes H, 2007, ADV DRUG DELIVER REV, V59, P379, DOI 10.1016/j.addr.2007.04.013; Bunjes H, 2011, CURR OPIN COLLOID IN, V16, P405, DOI 10.1016/j.cocis.2011.06.007; Campos DA, 2014, COLLOID SURFACE B, V115, P109, DOI 10.1016/j.colsurfb.2013.10.035; Carbone C, 2014, EUR J PHARM SCI, V52, P12, DOI 10.1016/j.ejps.2013.10.003; Carvalho S.M., 2013, IND CROP PROD, V49, P278; Dijkstra A. J., 2007, LIPID HDB, P471, DOI DOI 10.1201/9781420009675.CH7; Dingler A, 1999, J MICROENCAPSUL, V16, P751; Elisabettini P, 1996, J AM OIL CHEM SOC, V73, P187, DOI 10.1007/BF02523893; Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5; Gokce EH, 2012, INT J NANOMED, V7, P1841, DOI 10.2147/IJN.S29710; Heins A, 2007, LIPIDS, V42, P573, DOI 10.1007/s11745-007-3052-6; Heins A, 2007, LIPIDS, V42, P561, DOI 10.1007/s11745-007-3053-5; Helgason T, 2008, J AM OIL CHEM SOC, V85, P501, DOI 10.1007/s11746-008-1219-9; Helgason T, 2009, J COLLOID INTERF SCI, V334, P75, DOI 10.1016/j.jcis.2009.03.012; Helgason T, 2009, J AGR FOOD CHEM, V57, P8033, DOI 10.1021/jf901682m; Hentschel A, 2008, J FOOD SCI, V73, pN1, DOI 10.1111/j.1750-3841.2007.00641.x; Jenning V, 2000, J CONTROL RELEASE, V66, P115, DOI 10.1016/S0168-3659(99)00223-0; Jores K, 2005, PHARM RES-DORDR, V22, P1887, DOI 10.1007/s11095-005-7148-5; Jores K, 2003, PHARM RES-DORDR, V20, P1274, DOI 10.1023/A:1025065418309; Korkmaz E, 2013, ACTA PHARMACEUT, V63, P517, DOI 10.2478/acph-2013-0039; Lacatusu I, 2013, SOFT MATER, V11, P75, DOI 10.1080/1539445X.2011.582914; LAVIGNE F, 1993, J PHYS IV, V3, P137, DOI 10.1051/jp4:1993825; Niculae G, 2014, COMPTES RENDUS CHIMI; Nik AM, 2012, J AGR FOOD CHEM, V60, P4126, DOI 10.1021/jf204810m; Noack A, 2012, INT J PHARMACEUT, V423, P440, DOI 10.1016/j.ijpharm.2011.12.011; Oehlke K, 2011, FOOD CHEM, V124, P781, DOI 10.1016/j.foodchem.2010.06.095; Oehlke K, 2010, FOOD CHEM, V118, P48, DOI 10.1016/j.foodchem.2009.04.078; Oh JH, 2005, J AM OIL CHEM SOC, V82, P13, DOI 10.1007/s11746-005-1036-y; Oh JH, 2002, J FOOD SCI, V67, P2911, DOI 10.1111/j.1365-2621.2002.tb08837.x; Rousseau D, 2005, J AM OIL CHEM SOC, V82, P7, DOI 10.1007/s11746-005-1035-z; Sanchez-Paz V, 2008, J COLLOID INTERF SCI, V320, P1, DOI 10.1016/j.jcis.2007.12.018; Seetapan N, 2010, MICRON, V41, P51, DOI 10.1016/j.micron.2009.08.003; Sonnen AFP, 2005, J AM CHEM SOC, V127, P15575, DOI 10.1021/ja054367l; Trombino S, 2013, COLLOID SURFACE B, V109, P273, DOI 10.1016/j.colsurfb.2013.04.005; Trombino S, 2009, COLLOID SURFACE B, V72, P181, DOI 10.1016/j.colsurfb.2009.03.032; Unruh T, 2001, COLLOID POLYM SCI, V279, P398, DOI 10.1007/s003960000436; Weiss J, 2008, FOOD BIOPHYS, V3, P146, DOI 10.1007/s11483-008-9065-8; Westesen K, 1997, J CONTROL RELEASE, V48, P223, DOI 10.1016/S0168-3659(97)00046-1; Yucel U, 2013, J COLLOID INTERF SCI, V394, P20, DOI 10.1016/j.jcis.2012.12.042; Zimmermann E, 2001, EUR J PHARM BIOPHARM, V52, P203, DOI 10.1016/S0939-6411(01)00167-9	46	48	48	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0171662	10.1371/journal.pone.0171662	http://dx.doi.org/10.1371/journal.pone.0171662			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192494	Green Published, Green Submitted, gold			2023-01-03	WOS:000394423800036
J	Shin, SS; Song, JH; Hwang, B; Noh, DH; Park, SL; Kim, WT; Park, SS; Kim, WJ; Moon, SK				Shin, Seung-Shick; Song, Jun-Hui; Hwang, Byungdoo; Noh, Dae-Hwa; Park, Sung Lyea; Kim, Won Tae; Park, Sung-Soo; Kim, Wun-Jae; Moon, Sung-Kwon			HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation	PLOS ONE			English	Article							UP-REGULATION; DIALLYL TRISULFIDE; EXPRESSION; GROWTH; ACTIVATION; APOPTOSIS; INACTIVATION; SUPPRESSES	Although recent studies have demonstrated the anti-tumor effects of garlic extract (GE), the exact molecular mechanism is still unclear. In this study, we investigated the molecular mechanism associated with the inhibitory action of GE against bladder cancer EJ cell responses. Treatment with GE significantly inhibited proliferation of EJ cells dose-dependently through G2/M-phase cell cycle arrest. This G2/M-phase cell cycle arrest by GE was due to the activation of ATM and CHK2, which appears to inhibit phosphorylation of Cdc25C (Ser216) and Cdc2 (Thr14/Tyr15), this in turn was accompanied by down-regulation of cyclin B1 and up-regulation of p21WAF1. Furthermore, GE treatment was also found to induce phosphorylation of MAPK (ERK1/2, p38MAPK, and JNK) and AKT. In addition, GE impeded the migration and invasion of EJ cells via inhibition of MMP-9 expression followed by decreased binding activities of AP-1, Sp-1, and NF-KB motifs. Based on microarray data sets, we selected Heat shock protein A6 (HSPA6) as the most up-regulated gene responsible for the inhibitory effects of GE. Interestingly, overexpression of HSPA6 gene resulted in an augmentation effect with GE inhibiting proliferation, migration, and invasion of EJ cells. The augmentation effect of HSPA6 was verified by enhancing the induction of G2/M-phasemediated ATM-CHK2-Cdc25C-p21WAF1-Cdc2 cascade, phosphorylation of MAPK and AKT signaling, and suppression of transcription factor-associated MMP-9 regulation in response to GE in EJ cells. Overall, our novel results indicate that HSPA6 reinforces the GE-mediated inhibitory effects of proliferation, migration, and invasion of EJ cells and may provide a new approach for therapeutic treatment of malignancies.	[Shin, Seung-Shick; Park, Sung-Soo] Jeju Natl Univ, Dept Food Sci & Nutr, Jeju, South Korea; [Song, Jun-Hui; Hwang, Byungdoo; Noh, Dae-Hwa; Park, Sung Lyea; Moon, Sung-Kwon] Chung Ang Univ, Dept Food & Nutr, Anseong, South Korea; [Kim, Won Tae; Kim, Wun-Jae] Chungbuk Natl Univ, Dept Urol, Cheongju, Chungbuk, South Korea	Jeju National University; Chung Ang University; Chungbuk National University	Moon, SK (corresponding author), Chung Ang Univ, Dept Food & Nutr, Anseong, South Korea.	sumoon66@dreamwiz.com		Shin, Seung-Shick/0000-0002-8536-2056	National Research Foundation of Korea (NRF) - government of Korea (MSIP) [2014007036]	National Research Foundation of Korea (NRF) - government of Korea (MSIP)(National Research Foundation of Korea)	This study was supported by a National Research Foundation of Korea (NRF) grant by the government of Korea (MSIP) (no. 2014007036), http://www.nrf.re.kr/.	Bianco FJ, 1998, CLIN CANCER RES, V4, P3011; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Calvo-Gomez O, 2004, J CHROMATOGR A, V1036, P91, DOI 10.1016/j.chroma.2004.02.072; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Cho TM, 2014, FOOD CHEM TOXICOL, V64, P344, DOI 10.1016/j.fct.2013.12.009; Das A, 2007, CANCER-AM CANCER SOC, V110, P1083, DOI 10.1002/cncr.22888; DAVIES B, 1993, CANCER RES, V53, P5365; Dong MH, 2014, BIOMED REP, V2, P250, DOI 10.3892/br.2014.226; Hosono T, 2005, J BIOL CHEM, V280, P41487, DOI 10.1074/jbc.M507127200; Huang J, 2015, MOL NUTR FOOD RES, V59, P1063, DOI 10.1002/mnfr.201400668; IBERL B, 1990, PLANTA MED, V56, P320, DOI 10.1055/s-2006-961198; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Khalouei S, 2014, CELL STRESS CHAPERON, V19, P321, DOI 10.1007/s12192-013-0459-2; Kim KH, 2013, INT J MOL MED, V32, P67, DOI 10.3892/ijmm.2013.1362; Lai KC, 2013, ENVIRON TOXICOL, V28, P479, DOI 10.1002/tox.20737; Lee SJ, 2013, J BIOL CHEM, V288, P5539, DOI 10.1074/jbc.M112.410233; Lee SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040267; Liu Y, 2015, J SENSORS, V2015, DOI 10.1155/2015/903981; Luke C, 2010, INTERN MED J, V40, P357, DOI 10.1111/j.1445-5994.2009.01980.x; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Noonan EJ, 2007, CELL STRESS CHAPERON, V12, P393, DOI 10.1379/CSC-278e.1; Nutt JE, 2003, BJU INT, V91, P99, DOI 10.1046/j.1464-410X.2003.04020.x; Qiu LH, 2006, ONCOL REP, V16, P907; Ramirez VP, 2015, CELL STRESS CHAPERON, V20, P95, DOI 10.1007/s12192-014-0529-0; Redondo-Gonzalez E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/168682; Reis ST, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-18; SATO H, 1993, ONCOGENE, V8, P395; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; Seiler R, 2011, J CLIN PATHOL, V64, P1078, DOI 10.1136/jclinpath-2011-200153; Suda S, 2014, BIOSCI BIOTECH BIOCH, V78, P1415, DOI 10.1080/09168451.2014.921563; Tang HL, 2013, CANCER LETT, V340, P72, DOI 10.1016/j.canlet.2013.06.027; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang YM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-8	34	35	36	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2017	12	2							e0171860	10.1371/journal.pone.0171860	http://dx.doi.org/10.1371/journal.pone.0171860			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK9KV	28187175	gold, Green Published, Green Submitted			2023-01-03	WOS:000394244300053
J	Callahan, CM; Boustani, MA; Schmid, AA; LaMantia, MA; Austrom, MG; Miller, DK; Gao, SJ; Ferguson, DY; Lane, KA; Hendrie, HC				Callahan, Christopher M.; Boustani, Malaz A.; Schmid, Arlene A.; LaMantia, Michael A.; Austrom, Mary G.; Miller, Douglas K.; Gao, Sujuan; Ferguson, Denisha Y.; Lane, Kathleen A.; Hendrie, Hugh C.			Targeting Functional Decline in Alzheimer Disease A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							LOWER-EXTREMITY FUNCTION; OLDER-ADULTS; NEUROPSYCHIATRIC INVENTORY; OCCUPATIONAL-THERAPY; BEHAVIORAL SYMPTOMS; PHYSICAL-EXERCISE; DEMENTIA CARE; INTERVENTION; PERFORMANCE; MANAGEMENT	Background: Alzheimer disease results in progressive functional decline, leading to loss of independence. Objective: To determine whether collaborative care plus 2 years of home-based occupational therapy delays functional decline. Design: Randomized, controlled clinical trial. (ClinicalTrials. gov: NCT01314950) Setting: Urban public health system. Patients: 180 community-dwelling participants with Alzheimer disease and their informal caregivers. Intervention: All participants received collaborative care for dementia. Patients in the intervention group also received in-home occupational therapy delivered in 24 sessions over 2 years. Measurements: The primary outcome measure was the Alzheimer's Disease Cooperative Study Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Physical Performance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM). Results: At baseline, clinical characteristics did not differ significantly between groups; the mean Mini-Mental State Examination score for both groups was 19 (SD, 7). The intervention group received a median of 18 home visits from the study occupational therapists. In both groups, ADCS ADL scores declined over 24 months. At the primary end point of 24 months, ADCS ADL scores did not differ between groups (mean difference, 2.34 [95% CI, -5.27 to 9.96]). We also could not definitively demonstrate between-group differences in mean SPPB or SPSM values. Limitation: The results of this trial are indeterminate and do not rule out potential clinically important effects of the intervention. Conclusion: The authors could not definitively demonstrate whether the addition of 2 years of in-home occupational therapy to a collaborative care management model slowed the rate of functional decline among persons with Alzheimer disease. This trial underscores the burden undertaken by caregivers as they provide care for family members with Alzheimer disease and the difficulty in slowing functional decline.	Indiana Univ Sch Med, Indiana Univ, Ctr Aging Res, Regenstrief Inst, Indianapolis, IN 46202 USA; Indiana Alzheimer Dis Ctr, Indianapolis, IN USA; Colorado State Univ, Ft Collins, CO 80523 USA; [Callahan, Christopher M.; Miller, Douglas K.; Ferguson, Denisha Y.; Hendrie, Hugh C.] Indiana Univ, Ctr Aging Res, 1101 West 10th St, Indianapolis, IN 46202 USA; [Schmid, Arlene A.] Colorado State Univ, Dept Occupat Therapy, Integrat Rehabil Lab, Hlth & Human Sci, 3185 Rampart Rd,Bldg V1, Ft Collins, CO 80521 USA; [LaMantia, Michael A.] Univ Vermont, Coll Med, 4th Floor, Burlington, VT 05401 USA; [Austrom, Mary G.] Indiana Univ, Dept Psychiat, 355 West 16th St,GH 2800, Indianapolis, IN 46202 USA; [Gao, Sujuan; Lane, Kathleen A.] Indiana Univ, Dept Biostat, 410 West 10th St,HS 3000, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Colorado State University; Indiana University System; Indiana University-Purdue University Indianapolis; Colorado State University; University of Vermont; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Callahan, CM (corresponding author), Indiana Univ, Ctr Aging Res, 1101 West 10th St, Indianapolis, IN 46202 USA.	ccallaha@iu.edu	Boustani, Malaz/Q-3850-2019	Boustani, Malaz/0000-0003-0330-677X; Schmid, Arlene/0000-0002-7755-199X	National Institute on Aging [R01 AG034946]; NATIONAL INSTITUTE ON AGING [R01AG034946] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By National Institute on Aging grant R01 AG034946.	Alderson P, 2004, BMJ-BRIT MED J, V328, P476, DOI 10.1136/bmj.328.7438.476; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Arling G, 2013, MED CARE, V51, P575, DOI 10.1097/MLR.0b013e31828d4d4a; Austrom MG, 2004, GERONTOLOGIST, V44, P548, DOI 10.1093/geront/44.4.548; Barreto PD, 2015, AGEING RES REV, V24, P274, DOI 10.1016/j.arr.2015.09.001; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Bernard BL, 2016, ALZ DIS ASSOC DIS, V30, P169, DOI 10.1097/WAD.0000000000000101; Boustani MA, 2011, AGING MENT HEALTH, V15, P13, DOI 10.1080/13607863.2010.496445; Callahan CM, 2015, J AM GERIATR SOC, V63, P1495, DOI 10.1111/jgs.13540; Callahan CM, 2014, HEALTH AFFAIR, V33, P626, DOI 10.1377/hlthaff.2013.1260; Callahan CM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-92; Callahan CM, 2011, AGING MENT HEALTH, V15, P5, DOI 10.1080/13607861003801052; Callahan CM, 2006, JAMA-J AM MED ASSOC, V295, P2148, DOI 10.1001/jama.295.18.2148; Clarfield AM, 2013, JAMA INTERN MED, V173, P901, DOI 10.1001/jamainternmed.2013.1215; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Daviglus ML, 2010, ANN INTERN MED, V153, P176, DOI 10.7326/0003-4819-153-3-201008030-00260; DeWaal H, 2013, DESIGNING AND DELIVERING DEMENTIA SERVICES, P1, DOI 10.1002/9781118378663; Fitzmaurice GM, 2011, APPL LONGITUDINAL AN, P124; Forbes D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub4; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Gitlin LN, 2008, AM J GERIAT PSYCHIAT, V16, P229, DOI 10.1097/JGP.0b013e318160da72; Gitlin LN, 2012, JAMA-J AM MED ASSOC, V308, P2020, DOI 10.1001/jama.2012.36918; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; Lin SY, 2015, GERONTOLOGIST, V55, P237, DOI 10.1093/geront/gnu122; McDermott MM, 1998, J AM GERIATR SOC, V46, P1355, DOI 10.1111/j.1532-5415.1998.tb06001.x; McLaren AN, 2013, AGING MENT HEALTH, V17, P655, DOI 10.1080/13607863.2013.781121; Miller DK, 2009, J GERONTOL A-BIOL, V64, P388, DOI 10.1093/gerona/gln033; Monahan PO, 2012, CLIN INTERV AGING, V7, P143, DOI 10.2147/CIA.S30663; Ohman H, 2014, DEMENT GERIATR COGN, V38, P347, DOI 10.1159/000365388; Pitkala K, 2013, EXP GERONTOL, V48, P85, DOI 10.1016/j.exger.2012.08.008; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Schmid AA, 2015, OCCUP THER MENT HEAL, V31, P19, DOI 10.1080/0164212X.2014.1002963; Tang LQ, 2005, STAT MED, V24, P2111, DOI 10.1002/sim.2099; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; Toots A, 2016, J AM GERIATR SOC, V64, P55, DOI 10.1111/jgs.13880; Weiner MF, 1996, ALZ DIS ASSOC DIS, V10, P20, DOI 10.1097/00002093-199601010-00005	42	24	24	2	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2017	166	3					164	+		10.7326/M16-0830	http://dx.doi.org/10.7326/M16-0830			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EL7DL	27893087	Green Submitted, Green Accepted			2023-01-03	WOS:000394781200005
J	Ruskin, DN; Murphy, MI; Slade, SL; Masino, SA				Ruskin, David N.; Murphy, Michelle I.; Slade, Sierra L.; Masino, Susan A.			Ketogenic diet improves behaviors in a maternal immune activation model of autism spectrum disorder	PLOS ONE			English	Article							ADENYLOSUCCINATE LYASE DEFICIENCY; FETAL-BRAIN-DEVELOPMENT; OF-THE-LITERATURE; ADULT MICE; METABOLISM; ADENOSINE; INFECTION; EPILEPTOGENESIS; SYMPTOMS; CHILDREN	Prenatal factors influence autism spectrum disorder (ASD) incidence in children and can increase ASD symptoms in offspring of animal models. These may include maternal immune activation (MIA) due to viral or bacterial infection during the first trimesters. Unfortunately, regardless of ASD etiology, existing drugs are poorly effective against core symptoms. For nearly a century a ketogenic diet (KD) has been used to treat seizures, and recent insights into mechanisms of ASD and a growing recognition that immune/inflammatory conditions exacerbate ASD risk has increased interest in KD as a treatment for ASD. Here we studied the effects of KD on core ASD symptoms in offspring exposed to MIA. To produce MIA, pregnant C57BI/6 mice were injected with the viral mimic polyinosinic-polycytidylic acid; after weaning offspring were fed KD or control diet for three weeks. Consistent with an ASD phenotype of a higher incidence in males, control diet-fed MIA male offspring were not social and exhibited high levels of repetitive self-directed behaviors; female offspring were unaffected. However, KD feeding partially or completely reversed all MIA-induced behavioral abnormalities in males; it had no effect on behavior in females. KD-induced metabolic changes of reduced blood glucose and elevated blood ketones were quantified in offspring of both sexes. Prior work from our laboratory and others demonstrate KDs improve relevant behaviors in several ASD models, and here we demonstrate clear benefits of KD in the MIA model of ASD. Together these studies suggest a broad utility for metabolic therapy in improving core ASD symptoms, and support further research to develop and apply ketogenic and/or metabolic strategies in patients with ASD.	[Ruskin, David N.; Murphy, Michelle I.; Slade, Sierra L.; Masino, Susan A.] Trinity Coll, Dept Psychol, Neurosci Program, Hartford, CT 06106 USA	Trinity College	Ruskin, DN (corresponding author), Trinity Coll, Dept Psychol, Neurosci Program, Hartford, CT 06106 USA.	david.ruskin@trincoll.edu			National Institute of Neurological Disease and Stroke [NS066392, NS065957]; National Center for Complementary and Integrative Health [AT008742]; National Center for Complementary & Integrative Health [R15AT008742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065957, R15NS066392] Funding Source: NIH RePORTER	National Institute of Neurological Disease and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Center for Complementary and Integrative Health; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work received support from the following sources: National Institute of Neurological Disease and Stroke, NS066392, NS 065957 (SAM), www.ninds.nih.gov/ and the National Center for Complementary and Integrative Health, AT008742 (DNR), https://nccih.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Ahn Y, 2014, DEV NEUROSCI-BASEL, V36, P371, DOI 10.1159/000362645; Arvio Maria, 2010, Duodecim, V126, P557; Atladottir HO, 2010, J AUTISM DEV DISORD, V40, P1423, DOI 10.1007/s10803-010-1006-y; Atladottir HO, 2012, PEDIATRICS, V130, pE1447, DOI 10.1542/peds.2012-1107; Byers SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035538; Castro K., 2016, NUTR NEUROS IN PRESS; Castro K, 2015, RES AUTISM SPECT DIS, V20, P31, DOI 10.1016/j.rasd.2015.08.005; Chen JY, 2016, J HUNTINGTONS DIS, V5, P65, DOI 10.3233/JHD-150181; Dupuis N, 2015, EPILEPSIA, V56, pe95, DOI 10.1111/epi.13038; Eapen V, 2011, AUTISM NEURODEVELOPM, P103; El-Ansary A, 2010, CLIN BIOCHEM, V43, P63, DOI 10.1016/j.clinbiochem.2009.09.008; Evangeliou A, 2003, J CHILD NEUROL, V18, P113, DOI 10.1177/08830738030180020501; Frye RE, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-37; GALEF BG, 1983, ANIM BEHAV, V31, P748, DOI 10.1016/S0003-3472(83)80232-2; Gano LB, 2014, J LIPID RES, V55, P2211, DOI 10.1194/jlr.R048975; Grindstaff JL, 2012, HORM BEHAV, V62, P337, DOI 10.1016/j.yhbeh.2012.04.005; HAAS RH, 1986, AM J MED GENET, V24, P225; Henley SJ, 2014, MMWR-MORBID MORTAL W, V63, P1; Herbert MR, 2013, J CHILD NEUROL, V28, P975, DOI 10.1177/0883073813488668; Jiang Y, 2012, NEUROSCI LETT, V508, P22, DOI 10.1016/j.neulet.2011.12.002; Jurecka A, 2014, NEUROPEDIATRICS, V45, P50, DOI 10.1055/s-0033-1337335; Kawamura M, 2014, J LIPID RES, V55, P2254, DOI 10.1194/jlr.M046755; Kawamura M, 2010, J NEUROSCI, V30, P3886, DOI 10.1523/JNEUROSCI.0055-10.2010; Lee BK, 2015, BRAIN BEHAV IMMUN, V44, P100, DOI 10.1016/j.bbi.2014.09.001; Liebhaber GM, 2003, J CHILD NEUROL, V18, P74, DOI 10.1177/08830738030180011801; Lusardi TA, 2015, NEUROPHARMACOLOGY, V99, P500, DOI 10.1016/j.neuropharm.2015.08.007; Malkova NV, 2012, BRAIN BEHAV IMMUN, V26, P607, DOI 10.1016/j.bbi.2012.01.011; Marie S, 2002, AM J HUM GENET, V71, P14, DOI 10.1086/341036; Masino SA, 2009, CURR NEUROPHARMACOL, V7, P257, DOI 10.2174/157015909789152164; Masino S.A., 2015, HOMEOSTATIC CONTROL, P586; Masino SA, 2013, NEUROPHARMACOLOGY, V68, P116, DOI 10.1016/j.neuropharm.2012.08.013; Masino SA, 2011, NEUROSCI LETT, V500, P1, DOI 10.1016/j.neulet.2011.06.007; Masino SA, 2011, J CLIN INVEST, V121, P2679, DOI 10.1172/JCI57813; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Mueller BR, 2007, PHYSIOL BEHAV, V91, P55, DOI 10.1016/j.physbeh.2007.01.017; Nandivada P, 2016, LIPIDS, V51, P703, DOI 10.1007/s11745-016-4156-7; Napoli E, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00069; Naviaux JC, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.33; Naviaux RK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057380; Oliveira G, 2005, DEV MED CHILD NEUROL, V47, P185, DOI 10.1017/S0012162205000332; Page T, 2002, PROG NEURO-PSYCHOPH, V26, P397, DOI 10.1016/S0278-5846(01)00249-4; Page T, 2000, BBA-MOL BASIS DIS, V1500, P291, DOI 10.1016/S0925-4439(99)00113-1; Patterson PH, 2011, TRENDS MOL MED, V17, P389, DOI 10.1016/j.molmed.2011.03.001; Patterson PH, 2002, CURR OPIN NEUROBIOL, V12, P115, DOI 10.1016/S0959-4388(02)00299-4; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Ruskin DN, 2017, PHYSIOL BEHAV, V168, P138, DOI 10.1016/j.physbeh.2016.10.023; Ruskin DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065021; Ruskin DN, 2013, J PAIN, V14, P467, DOI 10.1016/j.jpain.2012.12.015; Ruskin DN, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00033; Smith J, 2016, BEHAV BRAIN RES, V304, P67, DOI 10.1016/j.bbr.2016.02.015; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Spilioti M, 2016, EUR J PAEDIATR NEURO, V20, P555, DOI 10.1016/j.ejpn.2016.04.003; Spilioti M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00858; Todorova MT, 2000, EPILEPSIA, V41, P933, DOI 10.1111/j.1528-1157.2000.tb00275.x; Verpeut JL, 2016, PHYSIOL BEHAV, V161, P90, DOI 10.1016/j.physbeh.2016.04.001; Weissman JR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003815; Xuan ICY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104433; Zerbo O, 2015, J AUTISM DEV DISORD, V45, P4015, DOI 10.1007/s10803-013-2016-3; Zilkha N, NEUROSCIENC IN PRESS; [No title captured]	60	58	58	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2017	12	2							e0171643	10.1371/journal.pone.0171643	http://dx.doi.org/10.1371/journal.pone.0171643			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK1QH	28166277	gold, Green Published, Green Submitted			2023-01-03	WOS:000393700100058
J	Lane, R				Lane, Richard			Veronika Wirtz: global leader in improving access to medicines	LANCET			English	Biographical-Item																			0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2017	389	10067					357	357		10.1016/S0140-6736(16)32137-7	http://dx.doi.org/10.1016/S0140-6736(16)32137-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EI9CK	27836190				2023-01-03	WOS:000392804700018
J	Compton, WM; Han, B; Hughes, A; Jones, CM; Blanco, C				Compton, Wilson M.; Han, Beth; Hughes, Arthur; Jones, Christopher M.; Blanco, Carlos			Use of Marijuana for Medical Purposes Among Adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Compton, Wilson M.; Blanco, Carlos] Natl Inst Drug Abuse, 6001 Execut Blvd,MSC 9589, Bethesda, MD 20892 USA; [Han, Beth; Hughes, Arthur] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA; [Jones, Christopher M.] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Compton, WM (corresponding author), Natl Inst Drug Abuse, 6001 Execut Blvd,MSC 9589, Bethesda, MD 20892 USA.	wcompton@nida.nih.gov	Blanco, Carlos/I-4906-2013	Blanco, Carlos/0000-0001-6187-3057	Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse of the National Institutes of Health; Office of the Assistant Secretary for Planning and Evaluation of the US Department of Health and Human Services	Substance Abuse and Mental Health Services Administration(United States Department of Health & Human Services); National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Office of the Assistant Secretary for Planning and Evaluation of the US Department of Health and Human Services	The National Survey on Drug Use and Health was supported by contracts from the Substance Abuse and Mental Health Services Administration. This study was jointly sponsored by the National Institute on Drug Abuse of the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, and the Office of the Assistant Secretary for Planning and Evaluation of the US Department of Health and Human Services.	Chaudhry HJ, 2016, JAMA-J AM MED ASSOC, V316, P577, DOI 10.1001/jama.2016.7741; Lin LA, 2016, ADDICT BEHAV, V61, P99, DOI 10.1016/j.addbeh.2016.05.015; Roy-Byrne P, 2015, AM J ADDICTION, V24, P599, DOI 10.1111/ajad.12270; Schauer GL, 2016, AM J PREV MED, V50, P1, DOI 10.1016/j.amepre.2015.05.027	4	85	85	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2017	317	2					209	211		10.1001/jama.2016.18900	http://dx.doi.org/10.1001/jama.2016.18900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH5PV	27992636	Green Accepted, Bronze			2023-01-03	WOS:000391826200024
J	Bender, E				Bender, Eric			CELLS ON TRIAL	NATURE			English	Editorial Material																			0	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2016	540	7634					S106	S108		10.1038/540S106a	http://dx.doi.org/10.1038/540S106a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EG6XV	28002399	Bronze			2023-01-03	WOS:000391190500006
J	Villanueva, G; Murphy, MS; Vickers, D; Harrop, E; Dworzynski, K				Villanueva, Gemma; Murphy, M. Stephen; Vickers, David; Harrop, Emily; Dworzynski, Katharina			GUIDELINES End of life care for infants, children and young people with life limiting conditions: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Villanueva, Gemma; Murphy, M. Stephen; Dworzynski, Katharina] Royal Coll Gynaecologists & Obstetricians, Natl Guideline Alliance, London NW1 4RG, England; [Vickers, David] Cambridgeshire Community Serv NHS Trust, St Ives PE27 4LG, England; [Vickers, David] East Anglias Childrens Hosp, Milton Keynes CB24 6DF, Bucks, England; [Harrop, Emily] Helen & Douglas House, Oxford OX4 1RW, England		Dworzynski, K (corresponding author), Royal Coll Gynaecologists & Obstetricians, Natl Guideline Alliance, London NW1 4RG, England.	KDworzynskikdworzynski@rcog.org.uk	Villanueva, Gemma/AAB-3822-2019	Harrop, Emily/0000-0002-2480-2062; Villanueva, Gemma/0000-0002-1306-1721				National Institute for Health and Care Excellence, 2016, END LIF CAR INF CHIL; WHO, 1998, CANC PAIN REL PALL C	2	12	12	2	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 8	2016	355								i6385	10.1136/bmj.i6385	http://dx.doi.org/10.1136/bmj.i6385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF0SY	27932317				2023-01-03	WOS:000390037500001
J	Huggett, B				Huggett, Brady			America's drug problem	NATURE BIOTECHNOLOGY			English	Article									[Huggett, Brady] Nat Biotechnol, New York, NY 10004 USA		Huggett, B (corresponding author), Nat Biotechnol, New York, NY 10004 USA.							[Anonymous], 2016, RESTAURANTS VOTED MO; [Anonymous], 2016, CMS PROPOSES TEST B; [Anonymous], 2016, MED USE SPENDING US; Claxton G., 2015, EMPLOYER HLTH BENEFI; Claxton G, 2016, PAYMENTS COST SHARIN; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; IMS Health, 2016, IMS HLTH STUDY US DR; Kapczynski A, 2016, HEALTH AFFAIR, V35, P791, DOI 10.1377/hlthaff.2015.1120; Karlin-Smith S, 2016, POLITICO; Kirzinger A, 2016, KAISER HLTH TRACKING; Parker-Hope T., 2016, NY TIMES; Sullivan T., 2016, VERMONT 1 STATE PASS; Tefferi A, 2015, MAYO CLIN PROC, V90, P996, DOI 10.1016/j.mayocp.2015.06.001; Truven Health Analytics, 2013, TRUVEN HLTH ANALYTIC	14	4	5	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2016	34	12					1231	1241		10.1038/nbt.3734	http://dx.doi.org/10.1038/nbt.3734			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	EF2WC	27842061				2023-01-03	WOS:000390185300010
J	Kavalieratos, D; Corbelli, J; Zhang, D; Dionne-Odom, JN; Ernecoff, NC; Hanmer, J; Hoydich, ZP; Ikejiani, DZ; Klein-Fedyshin, M; Zimmermann, C; Morton, SC; Arnold, RM; Heller, L; Schenker, Y				Kavalieratos, Dio; Corbelli, Jennifer; Zhang, Di; Dionne-Odom, J. Nicholas; Ernecoff, Natalie C.; Hanmer, Janel; Hoydich, Zachariah P.; Ikejiani, Dara Z.; Klein-Fedyshin, Michele; Zimmermann, Camilla; Morton, Sally C.; Arnold, Robert M.; Heller, Lucas; Schenker, Yael			Association Between Palliative Care and Patient and Caregiver Outcomes A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; ADVANCED CANCER; HEART-FAILURE; CLINICAL-TRIAL; LUNG-CANCER; MULTIDISCIPLINARY INTERVENTION; MEDICINE CONSULTATION; FAMILY INTERVENTION; MULTIPLE-SCLEROSIS	IMPORTANCE The use of palliative care programs and the number of trials assessing their effectiveness have increased. OBJECTIVE To determine the association of palliative care with quality of life (QOL), symptom burden, survival, and other outcomes for people with life-limiting illness and for their caregivers. DATA SOURCES MEDLINE, EMBASE, CINAHL, and Cochrane CENTRAL to July 2016. STUDY SELECTION Randomized clinical trials of palliative care interventions in adults with life-limiting illness. DATA EXTRACTION AND SYNTHESIS Two reviewers independently extracted data. Narrative synthesis was conducted for all trials. Quality of life, symptom burden, and survival were analyzed using random-effects meta-analysis, with estimates of QOL translated to units of the Functional Assessment of Chronic Illness Therapy-palliative care scale (FACIT-Pal) instrument (range, 0-184 [worst-best]; minimal clinically important difference [MCID], 9 points); and symptom burden translated to the Edmonton Symptom Assessment Scale (ESAS) (range, 0-90 [best-worst]; MCID, 5.7 points). MAIN OUTCOMES AND MEASURES Quality of life, symptom burden, survival, mood, advance care planning, site of death, health care satisfaction, resource utilization, and health care expenditures. RESULTS Forty-three RCTs provided data on 12 731 patients (mean age, 67 years) and 2479 caregivers. Thirty-five trials used usual care as the control, and 14 took place in the ambulatory setting. In the meta-analysis, palliative care was associated with statistically and clinically significant improvements in patient QOL at the 1- to 3-month follow-up (standardized mean difference, 0.46; 95% CI, 0.08 to 0.83; FACIT-Pal mean difference, 11.36] and symptom burden at the 1- to 3-month follow-up (standardized mean difference, -0.66; 95% CI, -1.25 to -0.07; ESAS mean difference, -10.30). When analyses were limited to trials at low risk of bias (n = 5), the association between palliative care and QOL was attenuated but remained statistically significant (standardized mean difference, 0.20; 95% CI, 0.06 to 0.34; FACIT-Pal mean difference, 4.94), whereas the association with symptom burden was not statistically significant (standardized mean difference, -0.21; 95% CI, -0.42 to 0.00; ESAS mean difference, -3.28). There was no association between palliative care and survival (hazard ratio, 0.90; 95% CI, 0.69 to 1.17). Palliative care was associated consistently with improvements in advance care planning, patient and caregiver satisfaction, and lower health care utilization. Evidence of associations with other outcomes was mixed. CONCLUSIONS AND RELEVANCE In this meta-analysis, palliative care interventions were associated with improvements in patient QOL and symptom burden. Findings for caregiver outcomes were inconsistent. However, many associations were no longer significant when limited to trials at low risk of bias, and there was no significant association between palliative care and survival.	[Kavalieratos, Dio; Arnold, Robert M.; Schenker, Yael] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA USA; [Kavalieratos, Dio; Corbelli, Jennifer; Hanmer, Janel; Hoydich, Zachariah P.; Ikejiani, Dara Z.; Arnold, Robert M.; Schenker, Yael] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA; [Kavalieratos, Dio; Ernecoff, Natalie C.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA; [Zhang, Di] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA; [Dionne-Odom, J. Nicholas] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA; [Klein-Fedyshin, Michele] Univ Pittsburgh, Hlth Sci Lib Syst, Pittsburgh, PA USA; [Zimmermann, Camilla] Univ Hlth Network, Dept Support Care, Toronto, ON, Canada; [Zimmermann, Camilla] Univ Toronto, Dept Med, Toronto, ON, Canada; [Morton, Sally C.] Virginia Tech, Coll Sci, Blacksburg, VA USA; [Heller, Lucas] Univ Pittsburgh, Dept Med, Div Endocrinol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Virginia Polytechnic Institute & State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kavalieratos, D (corresponding author), Univ Pittsburgh, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.	diok@pitt.edu	Kavalieratos, Dio/GLV-4567-2022; Kavalieratos, Dio/GLR-1388-2022; Harding, Richard/G-9729-2012	Kavalieratos, Dio/0000-0001-5283-0792; Klein-Fedyshin, Michele/0000-0003-4519-1472; Dionne-Odom, James/0000-0001-6764-0254; Zimmermann, Camilla/0000-0003-4889-0244	AHRQ HHS [K12 HS022989] Funding Source: Medline; NCATS NIH HHS [L30 TR001226, KL2 TR000146] Funding Source: Medline; NHLBI NIH HHS [K01 HL133466] Funding Source: Medline; NINR NIH HHS [K99 NR015903] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS022989] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL133466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [K99NR015903] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Abernethy AP, 2010, J PALLIAT MED, V13, P1407, DOI 10.1089/jpm.2010.0261; Ahronheim J C, 2000, J Palliat Med, V3, P265, DOI 10.1089/jpm.2000.3.265; Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; [Anonymous], 2014, LANCET, V383, P383; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Bekelman DB, 2015, JAMA INTERN MED, V175, P725, DOI 10.1001/jamainternmed.2015.0315; Brannstrom M, 2014, EUR J HEART FAIL, V16, P1142, DOI 10.1002/ejhf.151; Bruera E, 1991, J Palliat Care, V7, P6; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Chapman DG, 2007, SOC WORK, V52, P321, DOI 10.1093/sw/52.4.321; Cheung W, 2010, CRIT CARE RESUSC, V12, P28; Clark Matthew M, 2006, Am J Hosp Palliat Care, V23, P185, DOI 10.1177/1049909106289074; Clark MM, 2013, CANCER-AM CANCER SOC, V119, P880, DOI 10.1002/cncr.27776; Currow DC, 2012, J PAIN SYMPTOM MANAG, V44, P595, DOI 10.1016/j.jpainsymman.2011.10.028; Dahlin C, 2013, CLIN PRACT GUID QUAL; Dionne-Odom JN, 2015, J CLIN ONCOL, V33, P1446, DOI 10.1200/JCO.2014.58.7824; Dumanovsky T, 2016, J PALLIAT MED, V19, P8, DOI 10.1089/jpm.2015.0351; Dyar S, 2012, J PALLIAT MED, V15, P890, DOI 10.1089/jpm.2012.0014; Edmonds P, 2010, MULT SCLER J, V16, P627, DOI 10.1177/1352458510364632; El-Jawahri Areej, 2011, J Support Oncol, V9, P87; Engelhardt JB, 2006, AM J MANAG CARE, V12, P93; Fang JC, 2015, J CARD FAIL, V21, P519, DOI 10.1016/j.cardfail.2015.04.013; Farquhar MC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1304-6; Farquhar MC, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0194-2; Ferrell B, 2015, J PAIN SYMPTOM MANAG, V50, P758, DOI 10.1016/j.jpainsymman.2015.07.005; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Gaertner J, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0110-y; Given Barbara, 2002, Oncol Nurs Forum, V29, P949, DOI 10.1188/02.ONF.949-956; Grande GE, 2000, PALLIATIVE MED, V14, P375, DOI 10.1191/026921600701536200; Grande GE, 1999, BRIT MED J, V319, P1472, DOI 10.1136/bmj.319.7223.1472; Grudzen CR, 2016, JAMA ONCOL, V2, P591, DOI 10.1001/jamaoncol.2015.5252; Hanks GW, 2002, BRIT J CANCER, V87, P733, DOI 10.1038/sj.bjc.6600522; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, COCHRANE HDB SYSTEMA; Higgins JPT, COCHRANE HDB SYSTEMA, P4; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Higginson IJ, 2011, POSTGRAD MED J, V87, P769, DOI 10.1136/postgradmedj-2011-130290; Hopp FP., 2016, J CARD FAIL; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; Hui D, 2016, J PAIN SYMPTOM MANAG, V51, P262, DOI 10.1016/j.jpainsymman.2015.10.004; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Kamal AH, 2013, J PAIN SYMPTOM MANAG, V46, P254, DOI 10.1016/j.jpainsymman.2012.07.018; KANE RL, 1984, LANCET, V1, P890; Kavalieratos D, 2014, PROSPERO; Kavalieratos D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000544; Kellehear, 2014, INNER LIFE DYING PER; Kelley AS, 2010, NEW ENGL J MED, V363, P781, DOI 10.1056/NEJMe1004139; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lowther K, 2015, LANCET HIV, V2, pE328, DOI 10.1016/S2352-3018(15)00111-3; Lyons KD, 2009, J PAIN SYMPTOM MANAG, V37, P23, DOI 10.1016/j.jpainsymman.2007.12.015; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; McCorkle R, 2015, J PALLIAT MED, V18, P962, DOI 10.1089/jpm.2015.0113; Morrison RS, 2011, HEALTH AFFAIR, V30, P454, DOI 10.1377/hlthaff.2010.0929; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Northouse L, 2005, PSYCHO-ONCOLOGY, V14, P478, DOI 10.1002/pon.871; Northouse LL, 2007, CANCER-AM CANCER SOC, V110, P2809, DOI 10.1002/cncr.23114; Northouse LL, 2013, PSYCHO-ONCOLOGY, V22, P555, DOI 10.1002/pon.3036; O'Hara RE, 2010, PALLIAT SUPPORT CARE, V8, P395, DOI 10.1017/S1478951510000258; Pantilat SZ, 2010, ARCH INTERN MED, V170, P2038, DOI 10.1001/archinternmed.2010.460; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Radwany SM, 2014, POPUL HEALTH MANAG, V17, P106, DOI 10.1089/pop.2013.0017; Ringash J, 2007, CANCER-AM CANCER SOC, V110, P196, DOI 10.1002/cncr.22799; Rummans TA, 2006, J CLIN ONCOL, V24, P635, DOI 10.1200/JCO.2006.06.209; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Sidebottom AC, 2015, J PALLIAT MED, V18, P134, DOI 10.1089/jpm.2014.0192; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Steel JL, 2016, CANCER-AM CANCER SOC, V122, P1270, DOI 10.1002/cncr.29906; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wallen GR, 2012, QUAL LIFE RES, V21, P405, DOI 10.1007/s11136-011-0065-7; Wong FKY, 2016, HEART, V102, P1100, DOI 10.1136/heartjnl-2015-308638; ZIMMER JG, 1984, J AM GERIATR SOC, V32, P288, DOI 10.1111/j.1532-5415.1984.tb02023.x; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134; Zimmermann C, 2008, JAMA-J AM MED ASSOC, V299, P1698, DOI 10.1001/jama.299.14.1698; Zimmermann C, 2016, CAN MED ASSOC J, V188, pE217, DOI 10.1503/cmaj.151171	78	539	546	6	110	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2016	316	20					2104	2114		10.1001/jama.2016.16840	http://dx.doi.org/10.1001/jama.2016.16840			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ED1XD	27893131	Green Accepted			2023-01-03	WOS:000388637300018
J	Bianco, A; Larosa, E; Pileggi, C; Pavia, M				Bianco, Aida; Larosa, Elisabetta; Pileggi, Claudia; Pavia, Maria		Collaborative Working Grp	Appropriateness of Intrapartum Antibiotic Prophylaxis to Prevent Neonatal Group B Streptococcus Disease	PLOS ONE			English	Article							VERTICAL TRANSMISSION; UNITED-STATES; COLONIZATION; EPIDEMIOLOGY; STRATEGIES; AGALACTIAE; EFFICACY	The aims of this study were to describe the adherence to CDC guidelines for intrapartum antibiotic prophylaxis (IAP) and to identify possible factors influencing noncompliance with guidelines. We conducted a retrospective study in Italy. Our cohort included women in whom antenatal Group B Streptococcus (GBS) screening was not performed, was performed, but results were not available at the time of labor or delivery and women who were positive for GBS colonization. The indications for complete execution of IAP according to revised CDC guidelines was evaluated. It was considered adequate when performed with a recommended antibiotic at least four hours prior to delivery. The cohort included 902 women. Among those who had performed rectal and vaginal swabs (or recto-vaginal swabs), results were available in 86.9% of vaginal swabs and in 87.1% of rectal swabs and GBS was detected in 59.8% of vaginal swabs and in 71% of rectal swabs. 49.2% women had indication for GBS prophylaxis. Among these, 91.1% received an antibiotic during labor. Totally appropriate IAP was performed in 36.3% deliveries, an inappropriate antibiotic was administered in 10.4% women, the remaining 45.3% women received partially appropriate IAP; of these, 15.5% had received antibiotics through an inappropriate route of administration, 18.2% an inappropriate dosage regimen. Overall, 27.5% women received intrapartum ampicillin with inappropriate timing. Multivariate analysis showed that totally appropriate prophylaxis was significantly more likely in women who had no previous live birth, who had vaginal delivery, and a positive result at antenatal GBS screening. Despite satisfactory GBS screening implementation, there is still a substantial gap between optimal and actual IAP. We hypothesize that the complexity of the CDC guidelines may partially explain this shortcoming. Future efforts will include initiatives focused at enabling and reinforcing adherence to evidence-based prevention practices.	[Bianco, Aida; Larosa, Elisabetta; Pileggi, Claudia; Pavia, Maria; Collaborative Working Grp] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Catanzaro, Italy	Magna Graecia University of Catanzaro	Pavia, M (corresponding author), Univ Catanzaro Magna Graecia, Dept Hlth Sci, Catanzaro, Italy.	pavia@unicz.it	PILEGGI, Claudia/AGU-6397-2022	PILEGGI, Claudia/0000-0002-6288-5540; BIANCO, Aida/0000-0003-4674-0306; PAVIA, Maria/0000-0003-3879-1322				ALLEN UD, 1993, CAN MED ASSOC J, V149, P1659; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; Berardi A, 2011, J MED SCREEN, V18, P60, DOI 10.1258/jms.2011.011023; Berardi A, 2011, J MATERN-FETAL NEO M, V24, P1221, DOI 10.3109/14767058.2011.552652; Berardi A, 2011, J MATERN-FETAL NEO M, V24, P619, DOI 10.3109/14767058.2010.511347; De Cueto M, 1998, OBSTET GYNECOL, V91, P112, DOI 10.1016/S0029-7844(97)00587-5; De Luca C, 2016, J MATERN-FETAL NEO M, V29, P911, DOI 10.3109/14767058.2015.1023188; Diaz TM, 2008, REV CHIL INFECTOL, V25, P108, DOI /S0716-10182008000300003; Edmond KM, 2012, LANCET, V379, P547, DOI 10.1016/S0140-6736(11)61651-6; Edwards RK, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.03.047; El Aila NA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-285; Goins WP, 2010, OBSTET GYNECOL, V115, P1217, DOI 10.1097/AOG.0b013e3181dd916f; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; Joachim A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-437; Lijoi Davide, 2007, Archives of Gynecology and Obstetrics, V275, P373, DOI 10.1007/s00404-006-0263-7; Madani TA, 1998, INFECTION, V26, P288, DOI 10.1007/BF02962249; MCCRACKEN GH, 1973, J PEDIATR-US, V82, P703, DOI 10.1016/S0022-3476(73)80603-1; National System for Guidelines, 2011, PHYSL PREGN GUID 20; Phares CR, 2008, JAMA-J AM MED ASSOC, V299, P2056, DOI 10.1001/jama.299.17.2056; Puccio G, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-23; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Scasso S, 2015, INT J GYNECOL OBSTET, V129, P9, DOI 10.1016/j.ijgo.2014.10.018; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Schrag SJ, 2002, NEW ENGL J MED, V347, P233, DOI 10.1056/NEJMoa020205; SCHUCHAT A, 1994, EPIDEMIOL REV, V16, P374, DOI 10.1093/oxfordjournals.epirev.a036159; StataCorp, 2015, STAT REL 14 STAT SOF; Stoll BJ, 2011, PEDIATRICS, V127, P817, DOI 10.1542/peds.2010-2217; Turrentine M, 2014, AM J OBSTET GYNECOL, V211, P15, DOI 10.1016/j.ajog.2013.12.010; Turrentine Mark A, 2013, Infect Dis Obstet Gynecol, V2013, P525878, DOI 10.1155/2013/525878; Van Dyke MK, 2009, NEW ENGL J MED, V360, P2626, DOI 10.1056/NEJMoa0806820; Verani JR, 2014, OBSTET GYNECOL, V123, P828, DOI 10.1097/AOG.0000000000000163; Woldu ZL, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-80; Yancey MK, 1996, OBSTET GYNECOL, V88, P811, DOI 10.1016/0029-7844(96)00320-1; YOW MD, 1980, AM J OBSTET GYNECOL, V137, P34, DOI 10.1016/0002-9378(80)90382-8	34	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							e0166179	10.1371/journal.pone.0166179	http://dx.doi.org/10.1371/journal.pone.0166179			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC7WC	27861568	Green Published, gold, Green Submitted			2023-01-03	WOS:000388350300033
J	Zinkstok, SM; Beenen, LF; Luitse, JS; Majoie, CB; Nederkoorn, PJ; Roos, YB				Zinkstok, Sanne M.; Beenen, Ludo F.; Luitse, Jan S.; Majoie, Charles B.; Nederkoorn, Paul J.; Roos, Yvo B.			Thrombolysis in Stroke within 30 Minutes: Results of the Acute Brain Care Intervention Study	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; TO-NEEDLE TIMES; CODE STROKE; INTRAVENOUS THROMBOLYSIS; IMPROVEMENT; TRIALS; PROTOCOL; DELAYS	Background and Purpose Time is brain: benefits of intravenous thrombolysis (IVT) in ischemic stroke last for 4.5 hours but rapidly decrease as time progresses following symptom onset. The goal of the Acute Brain Care (ABC) intervention study was to reduce the door-to-needle time (DNT) to <= 30 minutes by optimizing in-hospital stroke treatment. Methods We performed a single-centre before (pre-intervention period: 2000-2005) versus after (post-intervention period: 2006-2012) comparison in a cohort of consecutive patients treated with IVT. The intervention consisted of the implementation of a multidisciplinary stroke protocol combining simple strategies to reduce the DNT. Primary endpoint was the DNT, presented as proportion <= 30 minutes and median time. Secondary clinical endpoints were symptomatic intracranial hemorrhage (SICH), and favourable outcome defined as a modified Rankin scale (mRs) score of 0-2 at 3 months. Endpoints were additionally adjusted for baseline imbalances between the groups. Results In the pre-intervention period, none (0.0%) of the 100 patients (mean age 63.8 years, median National Institutes of Health Stroke Scale [ NIHSS] score 14) treated with IVT had a DNT <= 30 minutes compared to 234 (62.7%) of the 373 patients (mean age 66.7 years, median NIHSS score 10) in the post-intervention period (p<0.001). The median DNT decreased from 75 (IQR 60-105) to 28 minutes (IQR 20-37, p<0.001). SICH rate remained stable (3.0% versus 4.4%, OR 1.50, 95% CI 0.43-5.25; adjusted OR 5.47, 95% CI 0.69-42.12).The proportion of patients with a favourable outcome increased (38.9% versus 52.3%, OR 1.72, 95% CI 1.09-2.73) but lost statistical significance after adjustment (adjusted OR 1.46, 95% CI 0.82-2.61). Conclusions Important and sustained reduction of the DNT to 30 minutes or less can be safely achieved by optimizing in-hospital stroke treatment. With its simple strategies, the ABC-protocol is a pragmatic framework for increasing the therapeutic yield in time-dependent stroke treatment.	[Zinkstok, Sanne M.; Nederkoorn, Paul J.; Roos, Yvo B.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Beenen, Ludo F.; Majoie, Charles B.] Univ Amsterdam, Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; [Luitse, Jan S.] Univ Amsterdam, Acad Med Ctr, Dept Emergency Med, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Roos, YB (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands.	y.b.roos@amc.uva..nl	Beenen, Ludo F/AAA-3114-2021; Roos, Yvo BWEM/B-9843-2013	Beenen, Ludo F/0000-0001-9204-1026; Majoie, Charles/0000-0002-7600-9568				[Anonymous], 2000, Circulation, V102, pI172; Brandler ES, 2015, J STROKE CEREBROVASC, V24, P2161, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.004; Breuer L, 2010, STROKE, V41, P2867, DOI 10.1161/STROKEAHA.110.578062; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112228; Committee on Trauma American College of Surgeons, 2004, ADV TRAUMA LIFE SUPP; El Husseini N, 2013, J STROKE CEREBROVASC, V22, P345, DOI 10.1016/j.jstrokecerebrovasdis.2011.09.012; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203; Frank B, 2013, STROKE, V44, P727, DOI 10.1161/STROKEAHA.112.674622; Ghrooda E, 2012, CAN J NEUROL SCI, V39, P789, DOI 10.1017/S0317167100015626; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Green TL, 2008, CAN J NEUROL SCI, V35, P348, DOI 10.1017/S0317167100008945; Gumbinger C, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3429; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Harbison J, 1999, LANCET, V353, P1935, DOI 10.1016/S0140-6736(99)00966-6; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kim SK, 2009, EUR J NEUROL, V16, P1331, DOI 10.1111/j.1468-1331.2009.02762.x; Kohrmann M, 2011, INT J STROKE, V6, P493, DOI 10.1111/j.1747-4949.2011.00585.x; Kruyt ND, 2013, STROKE, V44, P3249, DOI 10.1161/STROKEAHA.113.001885; Levine SR, 2013, STROKE, V44, P2500, DOI 10.1161/STROKEAHA.113.000878; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Oostema JA, 2015, STROKE, V46, P1513, DOI 10.1161/STROKEAHA.115.008650; Ruff IM, 2014, STROKE, V45, P504, DOI 10.1161/STROKEAHA.113.004073; Sattin JA, 2006, STROKE, V37, P2935, DOI 10.1161/01.STR.0000249057.44420.4b; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Smith C, 2014, INT J STROKE, V9, P939, DOI 10.1111/j.1747-4949.2012.00924.x; Sohn SW, 2015, J STROKE CEREBROVASC, V24, P465, DOI 10.1016/j.jstrokecerebrovasdis.2014.09.020; Strbian D, 2015, STROKE, V46, P1275, DOI 10.1161/STROKEAHA.114.007170; Studnek JR, 2013, PREHOSP EMERG CARE, V17, P348, DOI 10.3109/10903127.2013.773113; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Van Schaik SM, 2014, J STROKE CEREBROVASC, V23, P2900, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.025; Wardlaw JM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub3; Zinkstok SM, 2013, STROKE, V44, P1080, DOI 10.1161/STROKEAHA.111.000126	35	27	27	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							e0166668	10.1371/journal.pone.0166668	http://dx.doi.org/10.1371/journal.pone.0166668			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC7WC	27861540	Green Published, Green Submitted, gold			2023-01-03	WOS:000388350300085
J	Brison, RJ; Day, AG; Pelland, L; Pickett, W; Johnson, AP; Aiken, A; Pichora, DR; Brouwer, B				Brison, Robert J.; Day, Andrew G.; Pelland, Lucie; Pickett, William; Johnson, Ana P.; Aiken, Alice; Pichora, David R.; Brouwer, Brenda			Effect of early supervised physiotherapy on recovery from acute ankle sprain: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY-DEPARTMENTS; INJURIES; REHABILITATION; EPIDEMIOLOGY; FOOT; SCORE	OBJECTIVE To assess the efficacy of a programme of supervised physiotherapy on the recovery of simple grade 1 and 2 ankle sprains. DESIGN A randomised controlled trial of 503 participants followed for six months. Setting Participants were recruited from two tertiary acute care settings in Kingston, ON, Canada. PARTICIPANTS The broad inclusion criteria were patients aged >= 16 presenting for acute medical assessment and treatment of a simple grade 1 or 2 ankle sprain. Exclusions were patients with multiple injuries, other conditions limiting mobility, and ankle injuries that required immobilisation and those unable to accommodate the time intensive study protocol. INTERVENTION Participants received either usual care, consisting of written instructions regarding protection, rest, cryotherapy, compression, elevation, and graduated weight bearing activities, or usual care enhanced with a supervised programme of physiotherapy. MAIN OUTCOME MEASURES The primary outcome of efficacy was the proportion of participants reporting excellent recovery assessed with the foot and ankle outcome score (FAOS). Excellent recovery was defined as a score >= 450/500 at three months. A difference of at least 15% increase in the absolute proportion of participants with excellent recovery was deemed clinically important. Secondary analyses included the assessment of excellent recovery at one and six months; change from baseline using continuous scores at one, three, and six months; and clinical and biomechanical measures of ankle function, assessed at one, three, and six months. RESULTS The absolute proportion of patients achieving excellent recovery at three months was not significantly different between the physiotherapy (98/229, 43%) and usual care (79/214, 37%) arms (absolute difference 6%, 95% confidence interval -3% to 15%). The observed trend towards benefit with physiotherapy did not increase in the per protocol analysis and was in the opposite direction by six months. These trends remained similar and were never statistically or clinically important when the FAOS was analysed as a continuous change score. CONCLUSIONS In a general population of patients seeking hospital based acute care for simple ankle sprains, there is no evidence to support a clinically important improvement in outcome with the addition of supervised physiotherapy to usual care, as provided in this protocol.	[Brison, Robert J.; Pickett, William] Queens Univ, Dept Emergency Med, Kingston, ON, Canada; [Brison, Robert J.; Day, Andrew G.] Kingston Gen Hosp, Res Inst, Kingston, ON, Canada; [Brison, Robert J.; Day, Andrew G.; Pickett, William; Johnson, Ana P.] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada; [Pelland, Lucie; Aiken, Alice; Brouwer, Brenda] Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada; [Pelland, Lucie; Pichora, David R.; Brouwer, Brenda] Kingston Gen Hosp, Human Mobil Res Ctr, Kingston, ON, Canada; [Pelland, Lucie; Pichora, David R.; Brouwer, Brenda] Queens Univ, Kingston, ON, Canada; [Pichora, David R.] Queens Univ, Div Orthopaed, Kingston, ON, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	Brison, RJ (corresponding author), Queens Univ, Clin Res Ctr, Kingston Gen Hosp, Victory 3,76 Stuart St, Kingston, ON K7L 2V7, Canada.	brisonr@kgh.kari.net		Aiken, Alice/0000-0003-2469-9445	Canadian Institutes of Health Research [MCT-94833]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The study was funded by the Canadian Institutes of Health Research (MCT-94833). The sponsors had no role in the design, conduct, and analysis or involvement in the preparation or submission of the manuscript for publication	Anandacoomarasamy A, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.011676; Ardevol J, 2002, KNEE SURG SPORT TR A, V10, P371, DOI 10.1007/s00167-002-0308-9; Audenaert A, 2010, J EVAL CLIN PRACT, V16, P933, DOI 10.1111/j.1365-2753.2009.01231.x; BACKX FJG, 1989, AM J SPORT MED, V17, P234, DOI 10.1177/036354658901700214; Bennell Kim L, 1998, Aust J Physiother, V44, P175; Birrer RB, 1999, J EMERG MED, V17, P651, DOI 10.1016/S0736-4679(99)00060-8; Bleakley CM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1964; Braun BL, 1999, ARCH FAM MED, V8, P143, DOI 10.1001/archfami.8.2.143; Bridgman SA, 2003, EMERG MED J, V20, P508, DOI 10.1136/emj.20.6.508; Chorley JN, 2005, PEDIATR EMERG CARE, V21, P498, DOI 10.1097/01.pec.0000173346.15154.f3; Cooke MW, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13130; Cooke MW, 2003, EMERG MED J, V20, P505, DOI 10.1136/emj.20.6.505; de Bie RA, CLIN PRACTICE GUIDEL; Gerber JP, 1998, FOOT ANKLE INT, V19, P653, DOI 10.1177/107110079801901002; Greenland S, 2008, MODERN EPIDEMIOLOGY, P216; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Haywood KL, 2004, J EVAL CLIN PRACT, V10, P339, DOI 10.1111/j.1365-2753.2003.00435.x; Hultman K, 2010, EUR J PHYSIOTHER, V12, P65, DOI 10.3109/14038190903174262; Karlsson J, 1996, SCAND J MED SCI SPOR, V6, P341; Karlsson J, 1991, FOOT, V1, P15, DOI DOI 10.1016/0958-2592(91)90006-W; Kerkhoffs G.M., 2002, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD003762, DOI 10.1002/14651858.CD003762]; Kerkhoffs GMMJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000380.pub2; Kerkhoffs GM, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002938; Konradsen L, 2002, SCAND J MED SCI SPOR, V12, P129, DOI 10.1034/j.1600-0838.2002.02104.x; Lambers K, 2012, CLIN ORTHOP RELAT R, V470, P284, DOI 10.1007/s11999-011-1982-z; Leanderson J, 1995, ACTA ORTHOP SCAND, V66, P529, DOI 10.3109/17453679509002308; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Littell R.C., 2006, SAS SYSTEM MIXED MOD, V2nd; Littell RC, 2000, STAT MED, V19, P1793, DOI 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.3.CO;2-H; Liu M, 2006, PHARM STAT, V5, P7, DOI 10.1002/pst.189; Martin RL, 2007, J ORTHOP SPORT PHYS, V37, P72, DOI 10.2519/jospt.2007.2403; Mattacola CG, 2002, J ATHL TRAINING, V37, P413; MILGROM C, 1991, FOOT ANKLE, V12, P26, DOI 10.1177/107110079101200105; Novak AC, 2012, ARCH PHYS MED REHAB, V93, P683, DOI 10.1016/j.apmr.2011.10.009; Peters SAE, 2012, J CLIN EPIDEMIOL, V65, P686, DOI 10.1016/j.jclinepi.2011.11.012; Petersen EJ, 1999, J ORTHOP SPORT PHYS, V29, P609, DOI 10.2519/jospt.1999.29.10.609; Roos EM, 2001, FOOT ANKLE INT, V22, P788, DOI 10.1177/107110070102201004; Roos EM, 2003, USERS GUIDE FOOT ANK; Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P64, DOI 10.1186/1477-7525-1-64; Safran MR, 1999, MED SCI SPORT EXER, V31, pS438, DOI 10.1097/00005768-199907001-00005; SANDERS R, 1993, CLIN ORTHOP RELAT R, P87; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Shultz S, 2013, INT J SPORTS PHYS TH, V8, P838; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; Tadros AMA, 2010, INJURY, V41, P137, DOI 10.1016/j.injury.2009.05.031; Thabane L, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-92; Thomee R, 1997, PHYS THER, V77, P1690, DOI 10.1093/ptj/77.12.1690; van de Mortel TF, 2008, AUST J ADV NURS, V25, P40; van Rijn RM, 2008, AM J MED, V121, P324, DOI 10.1016/j.amjmed.2007.11.018; van Rijn RM, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5688; van Rijn RM, 2009, AUST J PHYSIOTHER, V55, P107, DOI 10.1016/S0004-9514(09)70040-6; Waterman BR, 2010, J BONE JOINT SURG AM, V92A, P2279, DOI 10.2106/JBJS.I.01537; Wees A., 2006, DUTCH J PHYS THER S, V116, P1; WEINSTEIN ML, 1993, MIL MED, V158, P771, DOI 10.1093/milmed/158.12.771; Wolfe MW, 2001, AM FAM PHYSICIAN, V63, P93; Zoch C, 2003, BRIT J SPORT MED, V37, P291, DOI 10.1136/bjsm.37.4.291	56	31	31	3	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2016	355								i5650	10.1136/bmj.i5650	http://dx.doi.org/10.1136/bmj.i5650			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ED5VQ	27852621	Green Published, hybrid			2023-01-03	WOS:000388920900002
J	Groff, AC; Colla, CH; Lee, TH				Groff, Adam C.; Colla, Carrie H.; Lee, Thomas H.			Days Spent at Home - A Patient-Centered Goal and Outcome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Groff, Adam C.; Colla, Carrie H.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA; [Groff, Adam C.] Bayada Home Hlth Care, Moorestown, NJ 08057 USA; [Lee, Thomas H.] Harvard Med Sch, Boston, MA USA; [Lee, Thomas H.] Press Ganey, Wakefield, MA USA	Dartmouth College; Harvard University; Harvard Medical School	Groff, AC (corresponding author), Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA.; Groff, AC (corresponding author), Bayada Home Hlth Care, Moorestown, NJ 08057 USA.				NIA NIH HHS [P01 AG019783] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Sayer C, 2016, NEJM CATALYST   0426; Wennberg JE., DARTMOUTH ATLAS HLTH	3	117	117	2	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2016	375	17					1610	1612		10.1056/NEJMp1607206	http://dx.doi.org/10.1056/NEJMp1607206			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB2DX	27783911	Green Accepted			2023-01-03	WOS:000387168900006
J	George, SK; Abolbashari, M; Jackson, JD; Aboushwareb, T; Atalal, A; Yoo, JJ				George, Sunil K.; Abolbashari, Mehran; Jackson, John D.; Aboushwareb, Tamer; Atalal, Anthony; Yoo, James J.			Potential Use of Autologous Renal Cells from Diseased Kidneys for the Treatment of Renal Failure	PLoS One			English	Article							PROXIMAL TUBULE CELLS; ERYTHROPOIETIN-PRODUCING CELLS; EPITHELIAL-CELLS; OXIDATIVE STRESS; PROGENITOR CELLS; TIGHT JUNCTIONS; STEM-CELLS; IN-VITRO; THERAPY; PROLIFERATION	Chronic kidney disease (CKD) occurs when certain conditions cause the kidneys to gradually lose function. For patients with CKD, renal transplantation is the only treatment option that restores kidney function. In this study, we evaluated primary renal cells obtained from diseased kidneys to determine whether their normal phenotypic and functional characteristics are retained, and could be used for cell therapy. Primary renal cells isolated from both normal kidneys (NK) and diseased kidneys (CKD) showed similar phenotypic characteristics and growth kinetics. The expression levels of renal tubular cell markers, Aquaporin-1 and E-Cadherin, and podocyte-specific markers, WT-1 and Nephrin, were similar in both NK and CKD kidney derived cells. Using fluorescence-activated cell sorting (FACS), specific renal cell populations were identified and included proximal tubular cells (83.1% from NK and 80.3% from CKD kidneys); distal tubular cells (11.03% from NK and 10.9% from CKD kidneys); and podocytes (1.91% from NK and 1.78% from CKD kidneys). Ultra-structural analysis using scanning electron microscopy (SEM) revealed microvilli on the apical surface of cultured cells from NK and CKD samples. Moreover, transmission electron microscopy (TEM) analysis showed a similar organization of tight junctions, desmosomes, and other intracellular structures. The Na+ uptake characteristics of NK and CKD derived renal cells were also similar (24.4 mmol/L and 25 mmol/L, respectively) and no significant differences were observed in the protein uptake and transport characteristics of these two cell isolates. These results show that primary renal cells derived from diseased kidneys such as CKD have similar structural and functional characteristics to their counterparts from a normal healthy kidney (NK) when grown in vitro. This study suggests that cells derived from diseased kidney may be used as an autologous cell source for renal cell therapy, particularly in patients with CKD or end-stage renal disease (ESRD).	[George, Sunil K.; Jackson, John D.; Atalal, Anthony; Yoo, James J.] Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA; [Abolbashari, Mehran] Texas Tech Univ, Paul L Foster Sch Med, El Paso, TX 79905 USA; [Aboushwareb, Tamer] Allergen Med Affairs, RSS Urol Mid Atlantic, POB 19534, Irvine, CA 92623 USA	Wake Forest University; Texas Tech University System; Texas Tech University	Yoo, JJ (corresponding author), Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jyoo@wakehealth.edu	Yoo, James J./L-4850-2017		Tengion Inc.; Wake Forest Institute for Regenerative Medicine	Tengion Inc.; Wake Forest Institute for Regenerative Medicine	This study was supported by Tengion Inc. through a sponsored research agreement, and Wake Forest Institute for Regenerative Medicine. In addition to supporting the study financially, Tengion Inc. was involved in the discussion of the study design and progress. There was no additional external funding received for this study.	Abolbashari M, 2016, ACTA BIOMATER, V29, P52, DOI 10.1016/j.actbio.2015.11.026; Aboushwareb T, 2008, WORLD J UROL, V26, P295, DOI 10.1007/s00345-008-0301-0; Atala A, 2004, AM J TRANSPLANT, V4, P58, DOI 10.1111/j.1600-6135.2004.0346.x; Baer PC, 2006, CELLS TISSUES ORGANS, V184, P16, DOI 10.1159/000096947; Bariety J, 2006, J AM SOC NEPHROL, V17, P2770, DOI 10.1681/ASN.2006040325; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Chung HC, 2015, KOREAN J UROL, V56, P412, DOI 10.4111/kju.2015.56.6.412; Souza Clarissa Vasconcellos de, 2012, Rev. Bras. Hematol. Hemoter., V34, P345, DOI 10.5581/1516-8484.20120090; Denker BM, 2011, J AM SOC NEPHROL, V22, P622, DOI 10.1681/ASN.2010090922; DETRISAC CJ, 1984, KIDNEY INT, V25, P383, DOI 10.1038/ki.1984.28; Duffield JS, 2005, J CLIN INVEST, V115, P1743, DOI 10.1172/JCI22593; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Gekle M, 2005, ANNU REV PHYSIOL, V67, P573, DOI 10.1146/annurev.physiol.67.031103.154845; George SK, 2011, AGING CELL, V10, P584, DOI 10.1111/j.1474-9726.2011.00686.x; Guimaraes-Souza NK, 2012, NEPHROL DIAL TRANSPL, V27, P3082, DOI 10.1093/ndt/gfr785; Hajhosseiny R, 2013, INT J CLIN PRACT, V67, P14, DOI 10.1111/j.1742-1241.2012.02954.x; Hryciw DH, 2012, CELL PHYSIOL BIOCHEM, V30, P1215, DOI 10.1159/000343313; Hugo C, 1998, KIDNEY INT, V54, P1934, DOI 10.1046/j.1523-1755.1998.00195.x; Jamiolkowski Ryan M., 2012, Yale Journal of Biology and Medicine, V85, P37; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Lanza RP, 2002, NAT BIOTECHNOL, V20, P689, DOI 10.1038/nbt703; NKUDIC, 2012, NAT KIDN UR DIS INF; Oakley FD, 2009, ANTIOXID REDOX SIGN, V11, P1313, DOI 10.1089/ARS.2008.2363; Oliver JA, 2004, CURR OPIN NEPHROL HY, V13, P17, DOI 10.1097/00041552-200401000-00003; Pavenstadt H, 2000, AM J PHYSIOL-RENAL, V278, pF173, DOI 10.1152/ajprenal.2000.278.2.F173; Phillips AO, 2002, HISTOL HISTOPATHOL, V17, P247, DOI 10.14670/HH-17.247; Presnell SC, 2011, TISSUE ENG PART C-ME, V17, P261, DOI [10.1089/ten.tec.2010.0399, 10.1089/ten.TEC.2010.0399]; Prevention: CfDCa, 2014, NAT CHRON KIDN DIS F; Reilly RF, 2007, STRUCTURAL FUNCTIONA; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Ronconi E, 2009, J AM SOC NEPHROL, V20, P322, DOI 10.1681/ASN.2008070709; Sabahi R, 2006, DRUGS, V66, P1933, DOI 10.2165/00003495-200666150-00004; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; Sakakima M, 2008, NEPHRON EXP NEPHROL, V109, pE57, DOI 10.1159/000142100; Sasaki S, 2004, HYPERTENSION, V43, P286, DOI 10.1161/01.HYP.0000112421.18551.1e; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shimada IS, 2011, J CELL BIOCHEM, V112, P374, DOI 10.1002/jcb.22963; Smeets B, 2013, J PATHOL, V229, P645, DOI 10.1002/path.4125; Souma T, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00167; Strutz F, 2001, KIDNEY INT, V59, P579, DOI 10.1046/j.1523-1755.2001.059002579.x; Tallheden T, 2005, ARTHRITIS RES THER, V7, pR560, DOI 10.1186/ar1709; Thomas R, 2008, PRIMARY CARE, V35, P329, DOI 10.1016/j.pop.2008.01.008; Vincent AS, 2004, KIDNEY INT, V65, P393, DOI 10.1111/j.1523-1755.2004.00391.x; Westover AJ, 2012, J TISSUE ENG REGEN M, V6, P589, DOI 10.1002/term.471; Yamaleyeva LM, 2012, STEM CELL TRANSL MED, V1, P373, DOI 10.5966/sctm.2011-0048; Yang M, 2011, ADV CHRONIC KIDNEY D, V18, P400, DOI 10.1053/j.ackd.2011.10.001; Zhai XY, 2000, KIDNEY INT, V58, P1523, DOI 10.1046/j.1523-1755.2000.00314.x; Zhao SA, 2009, REPROD SCI, V16, P970, DOI 10.1177/1933719109338630	48	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2016	11	10							e0164997	10.1371/journal.pone.0164997	http://dx.doi.org/10.1371/journal.pone.0164997			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED7AX	27776163	gold, Green Submitted, Green Published			2023-01-03	WOS:000389009200033
J	Keck, CW				Keck, C. William			The United States and Cuba - Turning Enemies into Partners for Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Keck, C. William] Med Educ Cooperat Cuba, Oakland, CA 94612 USA; [Keck, C. William] Northeast Ohio Med Univ, Dept Family & Community Med, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Keck, CW (corresponding author), Med Educ Cooperat Cuba, Oakland, CA 94612 USA.; Keck, CW (corresponding author), Northeast Ohio Med Univ, Dept Family & Community Med, Rootstown, OH 44272 USA.							[Anonymous], 2016, HHS ENG HIST HLTH CO; Berlanga J, 2013, MEDICC REV, V15, P11, DOI 10.37757/MR2013V15.N1.4; Drain PK, 2015, AM J PUBLIC HEALTH, V105, P2210, DOI 10.2105/AJPH.2015.302894; Pelaez O., 2016, HEBERPROT P REGISTRA; Rodriguez PC, 2016, CLIN CANCER RES, V22, P3782, DOI 10.1158/1078-0432.CCR-15-0855	5	12	12	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2016	375	16					1507	1509		10.1056/NEJMp1608859	http://dx.doi.org/10.1056/NEJMp1608859			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EJ3HF	27797312				2023-01-03	WOS:000393102500002
J	Harris, JA; Byhoff, E; Perumalswami, CR; Langa, KM; Wright, AA; Griggs, JJ				Harris, John A.; Byhoff, Elena; Perumalswami, Chithra R.; Langa, Kenneth M.; Wright, Alexi A.; Griggs, Jennifer J.			The Relationship of Obesity to Hospice Use and Expenditures A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							OF-LIFE CARE; PALLIATIVE CARE; MEDICARE BENEFICIARIES; FAMILY PERSPECTIVES; RISK-FACTORS; HEALTH; END; PATIENT; CANCER; COSTS	Background: Obesity complicates medical, nursing, and informal care in severe illness, but its effect on hospice use and Medicare expenditures is unknown. Objective: To describe the associations between body mass index (BMI) and hospice use and Medicare expenditures in the last 6 months of life. Design: Retrospective cohort. Setting: The HRS (Health and Retirement Study). Participants: 5677 community-dwelling Medicare fee-forservice beneficiaries who died between 1998 and 2012. Measurements: Hospice enrollment, days enrolled in hospice, in-home death, and total Medicare expenditures in the 6 months before death. Body mass index was modeled as a continuous variable with a quadratic functional form. Results: For decedents with BMI of 20 kg/m(2), the predicted probability of hospice enrollment was 38.3% (95% CI, 36.5% to 40.2%), hospice duration was 42.8 days (CI, 42.3 to 43.2 days), probability of in-home death was 61.3% (CI, 59.4% to 63.2%), and total Medicare expenditures were $ 42 803 (CI, $ 41 085 to $ 44 521). When BMI increased to 30 kg/m2, the predicted probability of hospice enrollment decreased by 6.7 percentage points (CI, -9.3 to -4.0 percentage points), hospice duration decreased by 3.8 days (CI, -4.4 to -3.1 days), probability of in-home death decreased by 3.2 percentage points (CI, -6.0 to -0.4 percentage points), and total Medicare expenditures increased by $ 3471 (CI, $ 955 to $ 5988). For morbidly obese decedents (BMI = 40 kg/m2), the predicted probability of hospice enrollment decreased by 15.2 percentage points (CI, -19.6 to -10.9 percentage points), hospice duration decreased by 4.3 days (CI, -5.7 to -2.9 days), and in-home death decreased by 6.3 percentage points (CI, -11.2 to -1.5 percentage points) versus decedents with BMI of 20 kg/m(2). Limitation: Baseline data were self-reported, and the interval between reported BMI and time of death varied. Conclusion: Among community-dwelling decedents in the HRS, increasing obesity was associated with reduced hospice use and in-home death and higher Medicare expenditures in the last 6 months of life.	[Byhoff, Elena; Perumalswami, Chithra R.] Univ Michigan, Dept Med, Inst Healthcare Policy & Innovat, 2800 Plymouth Rd,Bldg 10,Room G100, Ann Arbor, MI 48109 USA; [Langa, Kenneth M.] Univ Michigan, Inst Gerontol, Inst Healthcare Policy & Innovat, 2800 Plymouth Rd,Bldg 16,Room 444E, Ann Arbor, MI 48109 USA; [Griggs, Jennifer J.] Univ Michigan, Sch Publ Hlth, Dept Med & Hlth Management & Policy, Div Hematol & Oncol, 2800 Plymouth Rd,Bldg 16,Room 116W, Ann Arbor, MI 48109 USA; [Wright, Alexi A.] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Harris, JA (corresponding author), Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, 300 Halket St,Suite 2328, Pittsburgh, PA 15213 USA.	harrisja@mail.magee.edu	Wright, Alexi/T-5793-2019	Perumalswami, Chithra/0000-0002-6679-1090; , Elena/0000-0003-3438-2695; Harris, John/0000-0002-7907-8139; Langa, Kenneth/0000-0002-2798-1836	National Institute on Aging [U01 AG009740, P30 AG024824]; Robert Wood Johnson Foundation; U.S. Department of Veterans Affairs; National Cancer Institute [K07 CA166210]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD063087] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K07CA166210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG009740] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Health and Retirement Study is funded by the National Institute on Aging (U01 AG009740) and performed at the Institute for Social Research, University of Michigan. Drs. Harris and Byhoff were supported by the Robert Wood Johnson Foundation at the time the manuscript was originally submitted. Dr. Byhoff was supported by the U.S. Department of Veterans Affairs. Dr. Perumalswami is supported by the Robert Wood Johnson Foundation and the U.S. Department of Veterans Affairs. Dr. Langa is supported by the U.S. Department of Veterans Affairs and the National Institute on Aging (P30 AG024824). Dr. Wright is supported by the National Cancer Institute (K07 CA166210).	Alley DE, 2010, AM J EPIDEMIOL, V172, P558, DOI 10.1093/aje/kwq168; Boyd K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4863; Broome CA, 2015, REHABIL NURS, V40, P92, DOI 10.1002/rnj.165; Budd GM, 2011, APPL NURS RES, V24, P127, DOI 10.1016/j.apnr.2009.05.001; Byhoff E, 2016, JAMA INTERN MED, V176, P1020, DOI 10.1001/jamainternmed.2016.2266; Carlson MDA, 2012, HEALTH AFFAIR, V31, P2690, DOI 10.1377/hlthaff.2012.0286; Casarett D, 2006, J AM GERIATR SOC, V54, P472, DOI 10.1111/j.1532-5415.2005.00628.x; Cawley J, 2012, J HEALTH ECON, V31, P219, DOI 10.1016/j.jhealeco.2011.10.003; Chong HS, 2012, CRITICAL CARE MANAGE, P147; Crimmins EM, 2011, J GERONTOL B-PSYCHOL, V66, P162, DOI 10.1093/geronb/gbr048; Dee Anne, 2014, BMC Res Notes, V7, P242, DOI 10.1186/1756-0500-7-242; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Durden ED, 2008, J OCCUP ENVIRON MED, V50, P991, DOI 10.1097/JOM.0b013e318182f730; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Franks PW, 2010, NEW ENGL J MED, V362, P485, DOI 10.1056/NEJMoa0904130; Gallagher S M, 1999, J Wound Ostomy Continence Nurs, V26, P292, DOI 10.1016/S1071-5754(99)90064-5; Gazelle G, 2007, NEW ENGL J MED, V357, P321, DOI 10.1056/NEJMp078067; Goodell T T, 1996, J Trauma Nurs, V3, P36; Griggs JJ, 2005, ARCH INTERN MED, V165, P1267, DOI 10.1001/archinte.165.11.1267; Gupta D, 2009, J PALLIAT MED, V12, P515, DOI 10.1089/jpm.2009.0043; Han B, 2006, MED CARE, V44, P731, DOI 10.1097/01.mlr.0000215858.37118.65; Harris John A, 2016, BMC Obes, V3, P24, DOI 10.1186/s40608-016-0105-5; Hauck K, 2010, MED CARE, V48, P335, DOI 10.1097/MLR.0b013e3181ca3d85; Huizinga MM, 2009, J GEN INTERN MED, V24, P1236, DOI 10.1007/s11606-009-1104-8; Kellehear, 2014, INNER LIFE DYING PER; Kelley AS, 2014, J PALLIAT MED, V17, P506, DOI 10.1089/jpm.2013.0648; King DR, 2010, CRIT CARE MED, V38, pS478, DOI 10.1097/CCM.0b013e3181ec54f6; Maruthur NM, 2009, OBESITY, V17, P375, DOI 10.1038/oby.2008.480; Maruthur NM, 2009, J GEN INTERN MED, V24, P665, DOI 10.1007/s11606-009-0939-3; Miesfeldt S, 2012, J PALLIAT MED, V15, P548, DOI 10.1089/jpm.2011.0310; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Nwosu AC, 2012, J PALLIAT MED, V15, P7, DOI 10.1089/jpm.2011.0333; Obermeyer Z, 2015, HEALTH AFFAIR, V34, P993, DOI 10.1377/hlthaff.2014.1055; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Park NS, 2012, J PALLIAT MED, V15, P149, DOI 10.1089/jpm.2011.0220; Phillips J, 2013, J RADIOL NURS, V32, P21; Prescott HC, 2014, CRIT CARE MED, V42, P1766, DOI 10.1097/CCM.0000000000000336; Puhl R, 2001, OBES RES, V9, P788, DOI 10.1038/oby.2001.108; Puhl RM, 2010, AM J PUBLIC HEALTH, V100, P1019, DOI 10.2105/AJPH.2009.159491; Quesenberry CP, 1998, ARCH INTERN MED, V158, P466, DOI 10.1001/archinte.158.5.466; Sonnega A, 2014, INT J EPIDEMIOL, V43, P576, DOI 10.1093/ije/dyu067; StataCorp, 2015, STAT 14 BAS REF MAN, P1359; Stevenson DG, 2012, NEW ENGL J MED, V367, P1683, DOI 10.1056/NEJMp1208465; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2007, J PAIN SYMPTOM MANAG, V34, P120, DOI 10.1016/j.jpainsymman.2007.04.014; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Varney S., 2015, NY TIMES, pD1; Wong ES, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-175; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	53	12	12	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2017	166	6					381	+		10.7326/M16-0749	http://dx.doi.org/10.7326/M16-0749			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO9RM	28166546	Green Accepted			2023-01-03	WOS:000397025800013
J	Bor, D; Schwartzman, DJ; Barrett, AB; Seth, AK				Bor, Daniel; Schwartzman, David J.; Barrett, Adam B.; Seth, Anil K.			Theta-burst transcranial magnetic stimulation to the prefrontal or parietal cortex does not impair metacognitive visual awareness	PLOS ONE			English	Article							ACTIVITY FLUCTUATIONS; ACCURACY; DECISION; MEMORY; CONSCIOUSNESS; MECHANISMS; STRATEGIES; THRESHOLD; RIVALRY	Neuroimaging studies commonly associate dorsolateral prefrontal cortex (DLPFC) and posterior parietal cortex with conscious perception. However, such studies only investigate correlation, rather than causation. In addition, many studies conflate objective performance with subjective awareness. In an influential recent paper, Rounis and colleagues addressed these issues by showing that continuous theta burst transcranial magnetic stimulation (cTBS) applied to the DLPFC impaired metacognitive (subjective) awareness for a perceptual task, while objective performance was kept constant. We attempted to replicate this finding, with minor modifications, including an active cTBS control site. Using a between-subjects design for both DLPFC and posterior parietal cortices, we found no evidence of a cTBS-induced metacognitive impairment. In a second experiment, we devised a highly rigorous within-subjects cTBS design for DLPFC, but again failed to find any evidence of metacognitive impairment. One crucial difference between our results and the Rounis study is our strict exclusion of data deemed unsuitable for a signal detection theory analysis. Indeed, when we included this unstable data, a significant, though invalid, metacognitive impairment was found. These results cast doubt on previous findings relating metacognitive awareness to DLPFC, and inform the current debate concerning whether or not prefrontal regions are preferentially implicated in conscious perception.	[Bor, Daniel; Schwartzman, David J.; Barrett, Adam B.; Seth, Anil K.] Univ Sussex, Sackler Ctr Consciousness Sci, Brighton, E Sussex, England; [Bor, Daniel; Barrett, Adam B.; Seth, Anil K.] Univ Sussex, Dept Informat, Brighton, E Sussex, England	University of Sussex; University of Sussex	Bor, D (corresponding author), Univ Sussex, Sackler Ctr Consciousness Sci, Brighton, E Sussex, England.; Bor, D (corresponding author), Univ Sussex, Dept Informat, Brighton, E Sussex, England.	danielxbor@gmail.com		Bor, Daniel/0000-0002-0741-8157; Schwartzman, David/0000-0002-3779-396X	Dr Mortimer and Theresa Sackler Foundation; EPSRC [EP/L005131/1]; Engineering and Physical Sciences Research Council [EP/L005131/1] Funding Source: researchfish; EPSRC [EP/G007543/1] Funding Source: UKRI	Dr Mortimer and Theresa Sackler Foundation; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by The Dr Mortimer and Theresa Sackler Foundation. ABB is funded by EPSRC grant EP/L005131/1.; We thank the Alex Henderson and Arin Baboumian for all their work collecting the data, Ryan Scott and Zoltan Dienes for helpful theoretical discussions, and Justyna Hobot on many constructive comments on an earlier draft. This work was supported by The Dr Mortimer and Theresa Sackler Foundation. ABB is funded by EPSRC grant EP/L005131/1.	Barrett AB, 2013, PSYCHOL METHODS, V18, P535, DOI 10.1037/a0033268; Beck DM, 2006, CEREB CORTEX, V16, P712, DOI 10.1093/cercor/bhj017; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bor D, 2003, NEURON, V37, P361, DOI 10.1016/S0896-6273(02)01171-6; Bor D, 2004, EUR J NEUROSCI, V19, P3365, DOI 10.1111/j.1460-9568.2004.03438.x; Bor D, 2007, CEREB CORTEX, V17, P778, DOI 10.1093/cercor/bhk035; Bor D, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00063; Brascamp J, 2015, NAT NEUROSCI, V18, P1672, DOI 10.1038/nn.4130; Civardi C, 2000, CLIN NEUROPHYSIOL, V111, P624, DOI 10.1016/S1388-2457(99)00301-6; Dehaene S, 2001, NAT NEUROSCI, V4, P752, DOI 10.1038/89551; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Del Cul A, 2009, BRAIN, V132, P2531, DOI 10.1093/brain/awp111; Dienes Z, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00781; Duncan J, 2006, Q J EXP PSYCHOL, V59, P2, DOI 10.1080/17470210500260674; Duncan J, 2013, NEURON, V80, P35, DOI 10.1016/j.neuron.2013.09.015; Fleming SM, 2014, BRAIN, V137, P2811, DOI 10.1093/brain/awu221; Fleming SM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00443; Fleming SM, 2012, J NEUROSCI, V32, P6117, DOI 10.1523/JNEUROSCI.6489-11.2012; Fleming SM, 2012, PHILOS T R SOC B, V367, P1338, DOI 10.1098/rstb.2011.0417; Fleming SM, 2010, SCIENCE, V329, P1541, DOI 10.1126/science.1191883; Frasle S, 2014, J NEUROSCI, V34, P1738, DOI 10.1523/JNEUROSCI.4403-13.2014; Herwig U, 2001, BIOL PSYCHIAT, V50, P58, DOI 10.1016/S0006-3223(01)01153-2; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Kaller CP, 2013, HUM BRAIN MAPP, V34, P36, DOI 10.1002/hbm.21423; Kanai R, 2010, CURR BIOL, V20, P1626, DOI 10.1016/j.cub.2010.07.027; Kiani R, 2009, SCIENCE, V324, P759, DOI 10.1126/science.1169405; Ko JH, 2008, EUR J NEUROSCI, V28, P2147, DOI 10.1111/j.1460-9568.2008.06501.x; Koch C, 2016, NAT REV NEUROSCI, V17, P307, DOI 10.1038/nrn.2016.22; Lau HC, 2006, P NATL ACAD SCI USA, V103, P18763, DOI 10.1073/pnas.0607716103; Lumer ED, 1999, P NATL ACAD SCI USA, V96, P1669, DOI 10.1073/pnas.96.4.1669; Lumer ED, 1998, SCIENCE, V280, P1930, DOI 10.1126/science.280.5371.1930; Macmillan N., 2005, DETECTION THEORY, V2; Maniscalco B, 2012, CONSCIOUS COGN, V21, P422, DOI 10.1016/j.concog.2011.09.021; McCurdy LY, 2013, J NEUROSCI, V33, P1897, DOI 10.1523/JNEUROSCI.1890-12.2013; Panagiotaropoulos TI, 2012, NEURON, V74, P924, DOI 10.1016/j.neuron.2012.04.013; Rahnev D, 2016, P NATL ACAD SCI USA, V113, P6059, DOI 10.1073/pnas.1522551113; Rees G, 2007, PHILOS T R SOC B, V362, P877, DOI 10.1098/rstb.2007.2094; Rounis E, 2010, COGN NEUROSCI-UK, V1, P165, DOI 10.1080/17588921003632529; Sadaghiani S, 2009, J NEUROSCI, V29, P13410, DOI 10.1523/JNEUROSCI.2592-09.2009; Schicktanz N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120640; Simons JS, 2010, CEREB CORTEX, V20, P479, DOI 10.1093/cercor/bhp116; Tsuchiya N, 2015, TRENDS COGN SCI, V19, P757, DOI 10.1016/j.tics.2015.10.002; Turatto M, 2004, NEUROREPORT, V15, P2549, DOI 10.1097/00001756-200411150-00024; Voytek B, 2010, NEURON, V68, P401, DOI 10.1016/j.neuron.2010.09.018; Westin GG, 2014, CLIN NEUROPHYSIOL, V125, P142, DOI 10.1016/j.clinph.2013.06.187	45	25	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0171793	10.1371/journal.pone.0171793	http://dx.doi.org/10.1371/journal.pone.0171793			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192502	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000394423800042
J	Gayrard, N; Ficheux, A; Duranton, F; Guzman, C; Szwarc, I; Vetromile, F; Cazevieille, C; Brunet, P; Servel, MF; Argiles, A; Le Quintrec, M				Gayrard, Nathalie; Ficheux, Alain; Duranton, Flore; Guzman, Caroline; Szwarc, Ilan; Vetromile, Fernando; Cazevieille, Chantal; Brunet, Philippe; Servel, Marie-Francoise; Argiles, Angel; Le Quintrec, Moglie			Consequences of increasing convection onto patient care and protein removal in hemodialysis	PLOS ONE			English	Article							ALL-CAUSE MORTALITY; ONLINE HEMODIAFILTRATION; ULTRAFILTRATION COEFFICIENT; SERUM-ALBUMIN; UREMIC TOXINS; DIALYSIS; POSTDILUTION; EFFICIENCY; MODALITY	Introduction Recent randomised controlled trials suggest that on-line hemodiafiltration (OL-HDF) improves survival, provided that it reaches high convective volumes. However, there is scant information on the feasibility and the consequences of modifying convection volumes in clinics. Methods Twelve stable dialysis patients were treated with high-flux 1.8 m(2) polysulphone dialyzers and 4 levels of convection flows (Q(UF)) based on K-G(D-UF) monitoring of the system, for 1 week each. The consequences on dialysis delivery (transmembrane pressure (TMP), number of alarms, % of achieved prescribed convection) and efficacy (mass removal of low and high molecular weight compounds) were analysed. Results TMP increased exponentially with Q(UF) (p < 0.001 for N > 56,000 monitoring values). Beyond 21 L/session, this resulted into frequent TMP alarms requiring nursing staff interventions (mean +/- SEM: 10.3 +/- 2.2 alarms per session, p < 0.001 compared to lower convection volumes). Optimal convection volumes as assessed by K-G(D-UF)-max were 20.6 +/- 0.4 L/session, whilst 4 supplementary litres were obtained in the maximum situation (24.5 +/- 0.6 L/session) but the proportion of sessions achieving the prescribed convection volume decreased from 94% to only 33% (p < 0.001). Convection increased high molecular weight compound removal and shifted the membrane cut-off towards the higher molecular weight range. Conclusions Reaching high convection volumes as recommended by the recent RCTs (> 20L) is feasible by setting an HDF system at its optimal conditions based upon the K-G(D-UF) monitoring. Prescribing higher convection volumes resulted in instability of the system, provoked alarms, was bothersome for the nursing staff and the patients, rarely achieved the prescribed convection volumes and increased removal of high molecular weight compounds, notably albumin.	[Gayrard, Nathalie; Ficheux, Alain; Duranton, Flore; Guzman, Caroline; Argiles, Angel] Univ Montpellier, RD Nephrol, Montpellier, France; [Gayrard, Nathalie; Ficheux, Alain; Duranton, Flore; Guzman, Caroline; Argiles, Angel] Univ Montpellier, EA7288, Montpellier, France; [Szwarc, Ilan; Vetromile, Fernando; Servel, Marie-Francoise; Argiles, Angel] Ctr Dialyse Nephrol Dialyse St Guilhem, Sete, France; [Cazevieille, Chantal] INM Montpellier, CoMET, NRI Facil, Montpellier, France; [Brunet, Philippe] Univ Aix Marseille, Hop La Concept, Serv Nephrol, Marseille, France; [Brunet, Philippe; Argiles, Angel] ERA EDTA EUTox, European Uraem Toxin Working Grp ESAO, Krems, Austria; [Le Quintrec, Moglie] CHU Montpellier, Hop Lapeyronie, Serv Nephrol & Transplantat, Montpellier, France	Universite de Montpellier; Universite de Montpellier; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite de Montpellier; CHU de Montpellier	Argiles, A (corresponding author), Univ Montpellier, RD Nephrol, Montpellier, France.; Argiles, A (corresponding author), Univ Montpellier, EA7288, Montpellier, France.; Argiles, A (corresponding author), Ctr Dialyse Nephrol Dialyse St Guilhem, Sete, France.; Argiles, A (corresponding author), ERA EDTA EUTox, European Uraem Toxin Working Grp ESAO, Krems, Austria.	oargiles@rd-n.org	FICHEUX, Alain/ABD-6370-2021; gayrard, nathalie/AAO-2888-2020; Duranton, Flore/ABB-6225-2021	FICHEUX, Alain/0000-0003-3958-4210; gayrard, nathalie/0000-0001-8283-8429; Duranton, Flore/0000-0003-3202-0551; Le Quintrec, Moglie/0000-0002-5857-1207; Argiles, Angel/0000-0001-7029-4532				Ahrenholz P, 1997, INT J ARTIF ORGANS, V20, P81, DOI 10.1177/039139889702000206; Ahrenholz PG, 2004, CLIN NEPHROL, V62, P21; Argiles A, 1997, KIDNEY INT, V52, P530, DOI 10.1038/ki.1997.364; ARGILES A, 1987, KIDNEY INT, V32, P714, DOI 10.1038/ki.1987.265; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; ERA-EDTA Registry, 2012, ERA EDTA REG ANN REP; Ficheux A, 2000, KIDNEY INT, V57, P1755, DOI 10.1038/sj.ki.4495464; Ficheux A, 2016, NEPHROL DIAL TRANSPL; Ficheux A, 2015, NEPHROL DIAL TRANSPL, V30, P204, DOI 10.1093/ndt/gft493; Ficheux A, 2011, NEPHROL DIAL TRANSPL, V26, P636, DOI 10.1093/ndt/gfq510; Grooteman MPC, 2012, J AM SOC NEPHROL, V23, P1087, DOI 10.1681/ASN.2011121140; HENDERSON LW, 1975, J LAB CLIN MED, V85, P372; Henderson LW, 1967, ASAIO J, V13, P216; Joyeux V, 2008, INT J ARTIF ORGANS, V31, P928, DOI 10.1177/039139880803101102; KERR PB, 1992, KIDNEY INT, V41, P1035, DOI 10.1038/ki.1992.157; Krieter DH, 2005, KIDNEY INT, V67, P349, DOI 10.1111/j.1523-1755.2005.00088.x; Maduell F, 2015, NEFROLOGIA, V35, P50, DOI 10.3265/Nefrologia.pre2014.Sep.12726; Maduell F, 2013, J AM SOC NEPHROL, V24, P487, DOI 10.1681/ASN.2012080875; Mares J, 2009, KIDNEY INT, V76, P404, DOI 10.1038/ki.2009.138; Meert N, 2009, NEPHROL DIAL TRANSPL, V24, P562, DOI 10.1093/ndt/gfn522; NIWA T, 1995, AM J NEPHROL, V15, P463, DOI 10.1159/000168887; Ok E, 2013, NEPHROL DIAL TRANSPL, V28, P192, DOI 10.1093/ndt/gfs407; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Panichi V, 2012, INT J ARTIF ORGANS, V35, P435, DOI 10.5301/ijao.5000106; Polkinghorne K, ANZDATA REGISTRY REP; Sichart JM, 2011, CONTRIB NEPHROL, V175, P163, DOI 10.1159/000333634; Smith JR, 2016, AM J KIDNEY DIS; Takahashi R, 2012, AM J NEPHROL, V36, P136, DOI 10.1159/000339940; Tattersall J, 2007, NEPHROL DIAL TRANSPL, V22, P5, DOI 10.1093/ndt/gfm022; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x	30	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2017	12	2							e0171179	10.1371/journal.pone.0171179	http://dx.doi.org/10.1371/journal.pone.0171179			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK1QH	28166268	Green Submitted, Green Published, gold			2023-01-03	WOS:000393700100028
J	Kim, EJ; Choi, MJ; Lee, JH; Oh, JE; Seo, JW; Lee, YK; Yoon, JW; Kim, HJ; Noh, JW; Koo, JR				Kim, Eun-Jung; Choi, Myung-Jin; Lee, Jeoung-Hwan; Oh, Ji-Eun; Seo, Jang-Won; Lee, Young-Ki; Yoon, Jong-Woo; Kim, Hyung-Jik; Noh, Jung-Woo; Koo, Ja-Ryong			Extracellular Fluid/Intracellular Fluid Volume Ratio as a Novel Risk Indicator for All-Cause Mortality and Cardiovascular Disease in Hemodialysis Patients	PLOS ONE			English	Article							ATHEROSCLEROSIS MIA SYNDROME; CHRONIC KIDNEY-DISEASE; BIOIMPEDANCE SPECTROSCOPY; DIALYSIS PATIENTS; MALNUTRITION; INFLAMMATION; HEART; ASSOCIATION; DEPRESSION; FAILURE	Background In hemodialysis patients, fluid overload and malnutrition are accompanied by extracellular fluid (ECF) expansion and intracellular fluid (ICF) depletion, respectively. We investigated the relationship between ECF/ICF ratio (as an integrated marker reflecting both fluid overload and malnutrition) and survival and cardiovascular disease (CVD) in the context of malnutrition -inflammation-arteriosclerosis (MIA) complex. Methods Seventy-seven patients from a single hemodialysis unit were prospectively enrolled. The ECF/ICF volume was measured by segmental multi-frequency bioimpedance analysis. MIA and volume status were measured by serum albumin, C-reactive protein (CRP), pulse wave velocity (PWV) and plasma B-type natriuretic peptide (BNP), respectively. Results The mean ECF/ICF ratio was 0.56+/-0.06 and the cut-off value for maximum discrimination of survival was 0.57. Compared with the low ECF/ICF group, the high ECF/ICF group (ratio >= 0.57, 42%) had higher all-cause mortality, CVD, CRP, PWV, and BNP, but lower serum albumin. During the 5-year follow-up, 24 all-cause mortality and 38 CVD occurred (18 and 24, respectively, in the high ECF/ICF group versus 6 and 14 respectively in the low ECF/ICF group, P<0.001). In the adjusted Cox analysis, the ECF/ICF ratio nullifies the effects of the MIA and volume status on survival and CVD and was an independent predictor of all-cause mortality and CVD: hazard ratio (95% confidence interval); 1.12 (1.01-1.25) and 1.09 (1.01-1.18) for a 0.01 increase in the ECF/ICF ratio. The degree of malnutrition (albumin), inflammation (CRP), arteriosclerosis (PWV), and fluid overload (BNP) were correlated well with the ECF/ICF ratio. Conclusions Hemodialysis patients with high ECF/ICF ratio are not only fluid overloaded, but malnourished and have stiff artery with more inflammation. The ECF/ICF ratio is highly related to the MIA complex, and is a major risk indicator for all-cause mortality and CVD.	[Kim, Eun-Jung; Choi, Myung-Jin; Lee, Jeoung-Hwan; Oh, Ji-Eun; Seo, Jang-Won; Lee, Young-Ki; Yoon, Jong-Woo; Kim, Hyung-Jik; Noh, Jung-Woo; Koo, Ja-Ryong] Hallym Univ, Coll Med, Hallym Kidney Res Inst, Dept Internal Med, Chunchon, South Korea; [Kim, Eun-Jung; Seo, Jang-Won; Koo, Ja-Ryong] Hallym Univ, Med Ctr, Dongtan Sacred Heart Hosp, Div Nephrol, Hwaseong Si, South Korea	Hallym University; Hallym University	Koo, JR (corresponding author), Hallym Univ, Coll Med, Hallym Kidney Res Inst, Dept Internal Med, Chunchon, South Korea.; Koo, JR (corresponding author), Hallym Univ, Med Ctr, Dongtan Sacred Heart Hosp, Div Nephrol, Hwaseong Si, South Korea.	jrkoo@hallym.ac.kr	Lee, Jeonghwan/C-5214-2011	Lee, Jeonghwan/0000-0003-3199-635X; CHOI, MYUNG JIN/0000-0002-2761-7161				Achinger SG, 2013, NEPHROL DIAL TRANSPL, V28, P770, DOI 10.1093/ndt/gfs480; CHA KC, 1995, J APPL PHYSIOL, V79, P1316, DOI 10.1152/jappl.1995.79.4.1316; Chazot C, 2012, NEPHROL DIAL TRANSPL, V27, P2404, DOI 10.1093/ndt/gfr678; Choi MJ, 2012, NEPHRON CLIN PRACT, V122, P44, DOI 10.1159/000348509; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; De Lorenzo A, 2003, CURR OPIN CLIN NUTR, V6, P551, DOI [10.1097/01.mco.000087970.83880.41, 10.1097/00075197-200309000-00008]; Earthman C, 2007, NUTR CLIN PRACT, V22, P389, DOI 10.1177/0115426507022004389; Fan S, 2012, INT J ARTIF ORGANS, V35, P338, DOI 10.5301/ijao.5000080; Hung SC, 2014, KIDNEY INT, V85, P703, DOI 10.1038/ki.2013.336; Hur E, 2013, AM J KIDNEY DIS, V61, P957, DOI 10.1053/j.ajkd.2012.12.017; Johansen KL, 2014, J AM SOC NEPHROL, V25, P381, DOI 10.1681/ASN.2013040431; Kim YJ, 2015, KIDNEY RES CLIN PRAC, V34, P212, DOI 10.1016/j.krcp.2015.10.006; Koo JR, 2005, AM J MED SCI, V329, P1, DOI 10.1097/00000441-200501000-00001; Martola L, 2005, BLOOD PURIFICAT, V23, P203, DOI 10.1159/000084890; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Mulasi U, 2015, NUTR CLIN PRACT, V30, P180, DOI 10.1177/0884533614568155; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; Onofriescu M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135691; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; Pupim LB, 2004, KIDNEY INT, V66, P2054, DOI 10.1111/j.1523-1755.2004.00978.x; Qureshi AR, 2002, J AM SOC NEPHROL, V13, pS28; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Stenvinkel P, 2000, NEPHROL DIAL TRANSPL, V15, P953, DOI 10.1093/ndt/15.7.953; Tai R, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-189; Vuurmans JLT, 2002, J AM SOC NEPHROL, V13, P177, DOI 10.1681/ASN.V131177; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Yamashina A, 2002, HYPERTENS RES, V25, P359, DOI 10.1291/hypres.25.359; Zhu F, 1998, ASAIO J, V44, pM541, DOI 10.1097/00002480-199809000-00045	28	35	37	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2017	12	1							e0170272	10.1371/journal.pone.0170272	http://dx.doi.org/10.1371/journal.pone.0170272			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3HH	28099511	Green Published, gold, Green Submitted			2023-01-03	WOS:000392380100067
J	Zickler, D; Schindler, R; Willy, K; Martus, P; Pawlak, M; Storr, M; Hulko, M; Boehler, T; Glomb, MA; Liehr, K; Henning, C; Templin, M; Trojanowicz, B; Ulrich, C; Werner, K; Fiedler, R; Girndt, M				Zickler, Daniel; Schindler, Ralf; Willy, Kevin; Martus, Peter; Pawlak, Michael; Storr, Markus; Hulko, Michael; Boehler, Torsten; Glomb, Marcus A.; Liehr, Kristin; Henning, Christian; Templin, Markus; Trojanowicz, Bogusz; Ulrich, Christof; Werner, Kristin; Fiedler, Roman; Girndt, Matthias			Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial	PLOS ONE			English	Article							ALL-CAUSE MORTALITY; ONLINE HEMODIAFILTRATION; REMOVAL; FLUX; MYELOMA; ALPHA	Background To increase the removal of middle-sized uremic toxins a new membrane with enhanced permeability and selectivity, called Medium Cut-Off membrane (MCO-Ci) has been developed that at the same time ensures the retention of albumin. Because many middle-sized substances may contribute to micro-inflammation we hypothesized that the use of MCO-Ci influences the inflammatory state in hemodialysis patients. Methods The randomized crossover trial in 48 patients compared MCO-Ci dialysis to High-flux dialysis of 4 weeks duration each plus 8 weeks extension phase. Primary endpoint was the gene expression of TNF-alpha and IL-6 in peripheral blood mononuclear cells (PBMCs), secondary endpoints were plasma levels of specified inflammatory mediators and cytokines. Results After four weeks of MCO-Ci the expression of TNF-alpha mRNA (Relative quantification (RQ) from 0.92 +/- 0.34 to 0.75 +/- 0.31, -18.5%, p< 0.001)-alpha and IL-6 mRNA (RQ from 0.78 +/- 0.80 to 0.60 +/- 0.43, -23.1%, p< 0.01) was reduced to a significantly greater extent than with Highflux dialyzers (TNF mRNA-RQ: -14.3%; IL-6 mRNA-RQ: -3.5%). After retransformation of logarithmically transformed data, measurements after MCO were reduced to 82% of those after HF (95% CI 74%-91%). 4 weeks use of MCO-Ci resulted in long-lasting change in plasma levels of several cytokines and other substances with a significant decrease for sTNFR1, kappa and lambda free light chains, urea and an increase for Lp-PLA2 (PLA2G7) compared to High-flux. Albumin levels dropped significantly after 4 weeks of MCO dialysis but increased after additional 8 weeks of MCO dialysis. Twelve weeks treatment with MCOCi was well tolerated regarding the number of (S) AEs. In the extension period levels of CRP, TNF-alpha-mRNA and IL-6 mRNA remained stable in High-flux as well as in MCO-Ci. Conclusions MCO-Ci dialyzers modulate inflammation in chronic HD patients to a greater extent compared to High-flux dialyzers. Transcription of pro-inflammatory cytokines in peripheral leukocytes is markedly reduced and removal of soluble mediators is enhanced with MCO dialysis. Serum albumin concentrations stabilize after an initial drop. These results encourage further trials with longer treatment periods and clinical endpoints.	[Zickler, Daniel; Schindler, Ralf; Willy, Kevin] Charite, Dept Nephrol & Intens Care Med, Campus Virchow Clin, Berlin, Germany; [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany; [Pawlak, Michael; Templin, Markus] NMI Technol Transfer GmbH, Reutlingen, Germany; [Storr, Markus; Hulko, Michael; Boehler, Torsten; Werner, Kristin] Gambro Dialysatoren GmbH, Dept Res & Dev, Hechingen, Germany; [Glomb, Marcus A.; Liehr, Kristin; Henning, Christian] Martin Luther Univ Halle Wittenberg, Inst Chem, Food Chem, Halle, Germany; [Trojanowicz, Bogusz; Ulrich, Christof; Fiedler, Roman; Girndt, Matthias] Martin Luther Univ Halle Wittenberg, Dept Internal Med 2, Halle, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Zickler, D (corresponding author), Charite, Dept Nephrol & Intens Care Med, Campus Virchow Clin, Berlin, Germany.	Daniel.zickler@charite.de	Storr, Markus/AAU-9454-2021; Girndt, Matthias/M-1436-2019; Trojanowicz, Bogusz/I-3042-2019	Girndt, Matthias/0000-0003-2823-0847; Trojanowicz, Bogusz/0000-0001-7429-381X	German Ministry for Education and Research [FKZ 13N11796-99]; Gambro Dialysatoren GmbH, Hechingen; Gambro Dialysatoren GmbH; NMI Technology Transfers GmbH	German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); Gambro Dialysatoren GmbH, Hechingen; Gambro Dialysatoren GmbH; NMI Technology Transfers GmbH	Financial support for the study came from the German Ministry for Education and Research (FKZ 13N11796-99, https://www.bmbf.de/ and in part from Gambro Dialysatoren GmbH, Hechingen. (http://www.gambro.de/). Gambro Dialysatoren GmbH provided support in the form of salaries for authors Markus Storr, Michael Hulko, Torsten Boehler and Kristin Werner, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. NMI Technology Transfers GmbH provided support in the form of salaries for authors Markus Pawlak & Markus Templin, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Al-Aly Z, 2008, TRANSL RES, V151, P233, DOI 10.1016/j.trsl.2007.12.005; Boschetti-de-Fierro A, 2015, SCI REP-UK, V5, DOI 10.1038/srep18448; Boschetti-de-Fierro A, 2013, INT J ARTIF ORGANS, V36, P455, DOI 10.5301/ijao.5000220; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Girndt M, 2015, EUR J CLIN INVEST; Grooteman MPC, 2012, J AM SOC NEPHROL, V23, P1087, DOI 10.1681/ASN.2011121140; Haase M, 2007, INT J ARTIF ORGANS, V30, P385, DOI 10.1177/039139880703000505; Hsu HY, 2008, MED ENG PHYS, V30, P976, DOI 10.1016/j.medengphy.2008.01.003; Hutchison CA, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-11; Karabina Sonia, 2015, Enzymes, V38, P145, DOI 10.1016/bs.enz.2015.09.002; Katan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083393; Keir R, 2014, COMPUT METH PROG BIO, V114, pE29, DOI 10.1016/j.cmpb.2013.07.017; Kirsch AH, 2017, NEPHROL DIAL TRANSPL, V32, P165, DOI 10.1093/ndt/gfw310; Kneis C, 2013, BLOOD PURIFICAT, V36, P287, DOI 10.1159/000356224; Krieter DH, 2014, ARTIF ORGANS, V38, P888, DOI 10.1111/aor.12248; Liabeuf S, 2012, KIDNEY INT, V82, P1297, DOI 10.1038/ki.2012.301; Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590; Lu PP, 2015, MOL MED REP, V12, P6145, DOI 10.3892/mmr.2015.4149; Maduell F, 2013, J AM SOC NEPHROL, V24, P487, DOI 10.1681/ASN.2012080875; Meert N, 2009, NEPHROL DIAL TRANSPL, V24, P562, DOI 10.1093/ndt/gfn522; Neirynck N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122073; Ok E, 2013, NEPHROL DIAL TRANSPL, V28, P192, DOI 10.1093/ndt/gfs407; Talmud PJ, 2015, ARTERIOSCL THROM VAS, V35, P2281, DOI 10.1161/ATVBAHA.115.305234; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636; Zickler D, 2016, HIGH CUT OFF DIALYSI	27	78	78	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2017	12	1							e0169024	10.1371/journal.pone.0169024	http://dx.doi.org/10.1371/journal.pone.0169024			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH7SJ	28085888	Green Published, gold, Green Submitted			2023-01-03	WOS:000391972600011
J	Kujawska, M; Hilgert, NI; Keller, HA; Gil, G				Kujawska, Monika; Hilgert, Norma I.; Keller, Hector A.; Gil, Guillermo			Medicinal Plant Diversity and Inter-Cultural Interactions between Indigenous Guarani, Criollos and Polish Migrants in the Subtropics of Argentina	PLOS ONE			English	Article							KNOWLEDGE; ETHNOBOTANY; CONSENSUS	Numerous studies highlight the importance of phytotherapy for indigenous and non-indigenous people in different parts of the world. In this work we analyze the richness (number of species), diversity (plant identity and the number of illnesses for which it is used) and similarity of plant species and illnesses treated with them, in order to contribute new data and insight into the importance of plant medicines to the local medical systems of people living in Misiones province, in the subtropics of Argentina. Three sympatric groups were compared: Guarani Indians, Criollos (mestizos) and Polish migrants. Quantitative scrutiny was focused on both primary and secondary sources. The similarity and diversity of medicinal plants and uses between groups was calculated by applying the Sorensen quantitative coefficient and the Shannon-Wiener index, respectively. In order to identify the characteristic plant species used by each group, the Cultural Importance and Prevalence Value (CIPV) was calculated based on the species Indicator Value (IndVal), which combines a species relative abundance with its relative frequency of occurrence in the various groups, and modified according to the type of the analyzed data. The important finding is a great variation in the number of species used by the study groups. Altogether, 509 botanical species were registered: Guarani (397), Criollos (243) and Polish migrants (137). For all groups, the use of native medicinal plants prevailed. The Guarani appear to be the local experts in use of medicinal plants. There is the significant difference in the number of treated illnesses by each taxon among three groups. Criollos and Polish migrants exhibit the greatest similarity in illnesses treated with medicinal plants. These groups share a corpus of knowledge related to illness nosology, and have a symptomatic approach to illness treatment. The Guarani have an etiological approach to illness diagnosis and healing, which may be viewed as a barrier to the exchange of knowledge about home medicine with other ethnic groups of Misiones.	[Kujawska, Monika] Univ Lodz, Inst Ethnol & Cultural Anthropol, Lodz, Poland; [Hilgert, Norma I.] Univ Nacl Misiones, Ctr Invest Bosque Atlantico, CONICET, Inst Biol Subtrop, Iguazu, Misiones, Argentina; [Hilgert, Norma I.] Univ Nacl Misiones, Fac Ciencias Forest, Eldorado, Misiones, Argentina; [Keller, Hector A.] Consejo Nacl Invest Cient & Tecn, Inst Bot Nordeste, Corrientes, Corrientes, Argentina; [Gil, Guillermo] Adm Parques Nacl, Ctr Invest Ecol Subtrop, Delegac Reg Nordeste, Iguazu, Misiones, Argentina	University of Lodz; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Hilgert, NI (corresponding author), Univ Nacl Misiones, Ctr Invest Bosque Atlantico, CONICET, Inst Biol Subtrop, Iguazu, Misiones, Argentina.; Hilgert, NI (corresponding author), Univ Nacl Misiones, Fac Ciencias Forest, Eldorado, Misiones, Argentina.	normahilgert@yahoo.com.ar	Hilgert, Norma I./I-3866-2015	Hilgert, Norma I./0000-0002-7359-3535; Kujawska, Monika/0000-0002-5643-3417	Ministry of Science and Higher Education; National Science Centre in Poland [NN109 05 11 38, 2013/09/N/HS3/02226]	Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); National Science Centre in Poland(National Science Centre, Poland)	MK received two research grants from Ministry of Science and Higher Education and from National Science Centre in Poland [https://www.ncn.gov.pl/?language=en], grant numbers: NN109 05 11 38; 2013/09/N/HS3/02226. The first grant is already finished. The funding from grants were destined for field research in Argentina and the data analysis. MK and the rest of the authors did not receive special funding for paying this publication. Therefore, after contacting Billing Office, we have decided to pay the publication, if it is accepted, from mixed sources: MK will pay from institutional sources her current employer, Lodz University, agrees to pay a half, and NIH and HK will pay from their current employer, Universidad Nacional de Misiones, the second half.	Amat A. G., 1998, FARMACOBOTANICA FARM, P119; Arasaratnam LA, 2013, INT J INTERCULT REL, V37, P676, DOI 10.1016/j.ijintrel.2013.09.006; ARENAS P, 1987, J ETHNOPHARMACOL, V21, P279, DOI 10.1016/0378-8741(87)90104-8; Balee WL., 1994, FOOTPRINTS FOREST KA; Bartolome L. J., 1982, COLONIAS COLONIZADOR; Begossi A, 1996, ECON BOT, V50, P280, DOI 10.1007/BF02907333; Begossi A, 2002, HUM ECOL, V30, P281, DOI 10.1023/A:1016564217719; Bogado M., 2005, REPRESENTACIONES PRA; Bourdy G, 2004, J ETHNOPHARMACOL, V91, P189, DOI 10.1016/j.jep.2003.09.013; Cadogan L., 1959, AYVU RAPYTA; Collins S, 2006, ECON BOT, V60, P347, DOI 10.1663/0013-0001(2006)60[347:QEOTET]2.0.CO;2; de Boer H, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-25; de Boer HJ, 2012, J ETHNOPHARMACOL, V141, P481, DOI 10.1016/j.jep.2012.03.017; Abreu DBD, 2015, J ETHNOPHARMACOL, V175, P124, DOI 10.1016/j.jep.2015.09.019; Dufrene M, 1997, ECOL MONOGR, V67, P345, DOI 10.1890/0012-9615(1997)067[0345:SAAIST]2.0.CO;2; Ferreira Junior WS., 2015, EVOLUTIONARY ETHNOBI, P105, DOI DOI 10.1007/978-3-319-19917-7; Ferrero B., 2005, ESTUDIO GESTION TERR; FILIPOV A, 1994, J ETHNOPHARMACOL, V44, P181, DOI 10.1016/0378-8741(94)01185-0; FOSTER GM, 1976, AM ANTHROPOL, V78, P773, DOI 10.1525/aa.1976.78.4.02a00030; Furlong SJ, 1962, MISIONES SUS PUEBLOS; Galvez Lucia, 1995, GUARANIES JESUITAS T; Giovannini P, 2011, SOC SCI MED, V72, P928, DOI 10.1016/j.socscimed.2011.01.007; Giraudo AR, 2003, STATE HOTS, P160; Heckler SL, 2007, MED ANTHROPOL Q, V21, P41, DOI 10.1525/maq.2007.21.1.41; Heinrich M, 1998, SOC SCI MED, V47, P1859, DOI 10.1016/S0277-9536(98)00181-6; Hernandez P., 1913, ORG SOCIAL DOCTRINAS; Hilgert NI, 2008, BOL LATINOAM CARIBE, V7, P130; Hilgert NI, 2007, J ETHNOBIOL ETHNOMED, V3, DOI 10.1186/1746-4269-3-19; Holz S, 2003, STATE HOTS, P207; Keller H.A., 2006, BONPLANDIA, V15, P125, DOI [10.30972/bon.153-4103, DOI 10.30972/BON.153-4103]; Keller H.A., 2011, AVA, V18, P25; Keller H. A., 2007, SUPLEMENTO ANTROPOLO, V42, P345; Keller HA, 2008, THESIS; KELLER HA, 2013, BONPLADIA, V22, P171; Kujawska M, 2016, ANTHROPOL MED, V23, P205, DOI 10.1080/13648470.2016.1180580; Kujawska M, 2015, J ETHNOPHARMACOL, V172, P347, DOI 10.1016/j.jep.2015.06.037; Kujawska M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/579350; Kujawska M, 2014, J ETHNOPHARMACOL, V153, P810, DOI 10.1016/j.jep.2014.03.044; Lambert J., 1997, World Bank Technical Paper; Leonti M, 2003, J ETHNOPHARMACOL, V88, P119, DOI 10.1016/S0378-8741(03)00188-0; Leonti M, 2009, J ETHNOPHARMACOL, V121, P55, DOI 10.1016/j.jep.2008.10.027; Moerman DE, 2007, J ETHNOPHARMACOL, V112, P451, DOI 10.1016/j.jep.2007.04.001; Molares S, 2009, J ETHNOPHARMACOL, V122, P251, DOI 10.1016/j.jep.2009.01.003; Moreau D., 2006, MEMOIRE DIPLOME U ET; Moreno C.E, 2001, METODOS MEDIR BIODIV, V1; Morris Brian, 2011, Anthropol Med, V18, P245, DOI 10.1080/13648470.2011.591200; Muniz de Medeiros P., 2015, EVOLUTIONARY ETHNOBI, P163; Nolan JM, 1999, HUM ORGAN, V58, P67, DOI 10.17730/humo.58.1.k1854516076003p6; Pieroni A, 2005, J ETHNOPHARMACOL, V101, P258, DOI 10.1016/j.jep.2005.04.028; PLACCI G, 2006, SITUACION AMBIENTAL, P197; Pouliot M, 2011, SOC SCI MED, V73, P1498, DOI 10.1016/j.socscimed.2011.08.037; Quinlan MB, 2007, MED ANTHROPOL Q, V21, P169, DOI [10.1525/maq.2007.21.2.169, 10.1525/MAQ.2007.21.2.169]; SCHMEDAHIRSCHMANN G, 1993, J ETHNOPHARMACOL, V39, P105, DOI 10.1016/0378-8741(93)90025-Z; Shannon Claude Elwood, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Smith JW, 2012, HUM ECOL, V40, P341, DOI 10.1007/s10745-012-9470-y; Srensen T., 1948, BIOL SKAR, V5, P1; Stampella PC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/868394; Tardio J, 2008, ECON BOT, V62, P24, DOI 10.1007/s12231-007-9004-5; Torres V.E., 2014, FOLIA HIST NORDESTE, V22, P89; Trotter RT., 1986, PLANTS INDIGENOUS ME, P91, DOI [10.4324/9781315060385-6, DOI 10.4324/9781315060385-6]; van Andel T, 2012, J ETHNOPHARMACOL, V143, P840, DOI 10.1016/j.jep.2012.08.008; Vandebroek I, 2010, ECON BOT, V64, P303, DOI 10.1007/s12231-010-9135-y; Zamudio F., 2010, OPEN COMPLEMENTARY M, V2, P58, DOI [10.2174/1876391X01002020058, DOI 10.2174/1876391X01002020058]; Zar J.H., 1996, BIOSTAT ANAL, V3rd	64	19	19	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2017	12	1							e0169373	10.1371/journal.pone.0169373	http://dx.doi.org/10.1371/journal.pone.0169373			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH6BJ	28076407	gold, Green Submitted, Green Published			2023-01-03	WOS:000391857100035
J	Block, GA; Bushinsky, DA; Cunningham, J; Drueke, TB; Ketteler, M; Kewalramani, R; Martin, KJ; Mix, TC; Moe, SM; Patel, UD; Silver, J; Spiegel, DM; Sterling, L; Walsh, L; Chertow, GM				Block, Geoffrey A.; Bushinsky, David A.; Cunningham, John; Drueke, Tilman B.; Ketteler, Markus; Kewalramani, Reshma; Martin, Kevin J.; Mix, T. Christian; Moe, Sharon M.; Patel, Uptal D.; Silver, Justin; Spiegel, David M.; Sterling, Lulu; Walsh, Liron; Chertow, Glenn M.			Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism Two Randomized Clinical Trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIBROBLAST GROWTH FACTOR-23; CALCIUM-SENSING RECEPTOR; CHRONIC KIDNEY-DISEASE; DOSE VITAMIN-D; EVOLVE TRIAL; CARDIOVASCULAR-DISEASE; MAINTENANCE HEMODIALYSIS; MINERAL METABOLISM; CINACALCET HCL; AMG 416	IMPORTANCE Secondary hyperparathyroidism contributes to extraskeletal complications in chronic kidney disease. OBJECTIVE To evaluate the effect of the intravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concentrations in patients receiving hemodialysis. DESIGN, SETTING, AND PARTICIPANTS Two parallel, phase 3, randomized, placebo-controlled treatment trials were conducted in 1023 patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism. Trial A was conducted in 508 patients at 111 sites in the United States, Canada, Europe, Israel, Russia, and Australia from March 12, 2013, to June 12, 2014; trial B was conducted in 515 patients at 97 sites in the same countries from March 12, 2013, to May 12, 2014. INTERVENTIONS Intravenous administration of etelcalcetide (n = 503) or placebo (n = 513) after each hemodialysis session for 26 weeks. MAIN OUTCOMES AND MEASURES The primary efficacy end point was the proportion of patients achieving greater than 30% reduction from baseline in mean PTH during weeks 20-27. A secondary efficacy end point was the proportion of patients achieving mean PTH of 300 pg/mL or lower. RESULTS The mean age of the 1023 patients was 58.2 (SD, 14.4) years and 60.4% were men. Mean PTH concentrations at baseline and during weeks 20-27 were 849 and 384 pg/mL vs 820 and 897 pg/mL in the etelcalcetide and placebo groups, respectively, in trial A; corresponding values were 845 and 363 pg/mL vs 852 and 960 pg/mL in trial B. Patients randomized to etelcalcetide were significantly more likely to achieve the primary efficacy end point: in trial A, 188 of 254 (74.0%) vs 21 of 254 (8.3%; P <.001), for a difference in proportions of 65.7%(95% CI, 59.4%-72.1%) and in trial B, 192 of 255 (75.3%) vs 25 of 260(9.6%; P <.001), for a difference in proportions of 65.7%(95% CI, 59.3%-72.1%). Patients randomized to etelcalcetide were significantly more likely to achieve a PTH level of 300 pg/mL or lower: in trial A, 126 of 254 (49.6%) vs 13 of 254 (5.1%; P <.001), for a difference in proportions of 44.5%(95% CI, 37.8%-51.2%) and in trial B, 136 of 255 (53.3%) vs 12 of 260(4.6%; P <.001), for a difference in proportions of 48.7%(95% CI, 42.1%-55.4%). In trials A and B, respectively, patients receiving etelcalcetide had more muscle spasms (12.0% and 11.1% vs 7.1% and 6.2% with placebo), nausea (12.4% and 9.1% vs 5.1% and 7.3%), and vomiting (10.4% and 7.5% vs 7.1% and 3.1%). CONCLUSIONS AND RELEVANCE Among patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism, use of etelcalcetide compared with placebo resulted in greater reduction in serum PTH over 26 weeks. Further studies are needed to assess clinical outcomes as well as longer-term efficacy and safety. Copyright 2016 American Medical Association. All rights reserved.	[Block, Geoffrey A.] Denver Nephrol, Denver, CO USA; [Bushinsky, David A.] Univ Rochester, Rochester, NY 14627 USA; [Cunningham, John] UCL, London, England; [Drueke, Tilman B.] Univ Picardie, INSERM, Amiens, France; [Ketteler, Markus] Klinikum Coburg GmbH, Coburg, Germany; [Kewalramani, Reshma; Mix, T. Christian; Spiegel, David M.; Sterling, Lulu; Walsh, Liron] Amgen Inc, Thousand Oaks, CA 91320 USA; [Martin, Kevin J.] St Louis Univ, St Louis, MO 63103 USA; [Moe, Sharon M.] Indiana Univ, Indianapolis, IN USA; [Patel, Uptal D.] Duke Univ, Durham, NC 27708 USA; [Silver, Justin] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel; [Chertow, Glenn M.] Stanford Univ, Stanford, CA 94305 USA	University of Rochester; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); Klinikum Coburg; Amgen; Saint Louis University; Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; Hebrew University of Jerusalem; Hadassah University Medical Center; Stanford University	Chertow, GM (corresponding author), Stanford Univ, Sch Med, 1070 Arastradero Rd,Ste 313, Palo Alto, CA 93034 USA.	gchertow@stanford.edu	DRUEKE, Tilman B./B-4958-2010; Block, Geoffrey/AAV-8070-2021	DRUEKE, Tilman B./0000-0002-0700-7681; Block, Geoffrey/0000-0002-4646-7074; Chertow, Glenn/0000-0002-7599-0534	Amgen Inc.	Amgen Inc.(Amgen)	The trials were sponsored by Amgen Inc. An academically led trial steering committee supervised trial design and operation; Amgen employees were nonvoting members of the trial steering committee.	[Anonymous], 2009, KIDNEY INT S113, V76, P1; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Block GA, 2013, AM SOC NEPHR ANN M N; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chen P, 2015, J CLIN PHARMACOL, V55, P620, DOI 10.1002/jcph.460; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523-1755.2005.00596.x; Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Floege J, 2015, CLIN J AM SOC NEPHRO, V10, P800, DOI 10.2215/CJN.10221014; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Hu MC, 2013, ANNU REV PHYSIOL, V75, P503, DOI 10.1146/annurev-physiol-030212-183727; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826; Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47; Ishani A, 2015, CLIN J AM SOC NEPHRO, V10, P90, DOI 10.2215/CJN.03520414; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018; Martin KJ, 2014, NEPHROL DIAL TRANSPL, V29, P385, DOI 10.1093/ndt/gft417; Meir T, 2014, KIDNEY INT, V86, P1106, DOI 10.1038/ki.2014.215; Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876; Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414; Parfrey PS, 2013, J CLIN ENDOCR METAB, V98, P4834, DOI 10.1210/jc.2013-2975; Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725; Rebholz CM, 2015, J AM SOC NEPHROL, V26, P192, DOI 10.1681/ASN.2014020218; Rodriguez-Ortiz ME, 2012, J AM SOC NEPHROL, V23, P1190, DOI 10.1681/ASN.2011101006; Scialla JJ, 2014, J AM SOC NEPHROL, V25, P349, DOI 10.1681/ASN.2013050465; Scialla JJ, 2013, J AM SOC NEPHROL, V24, P125, DOI 10.1681/ASN.2012070713; Streja E, 2013, KIDNEY INT SUPPL, V3, P462, DOI 10.1038/kisup.2013.96; Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213	29	91	100	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2017	317	2					146	155		10.1001/jama.2016.19456	http://dx.doi.org/10.1001/jama.2016.19456			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH5PV	28097355	Green Published			2023-01-03	WOS:000391826200017
J	Webb, M; Fahimi, S; Singh, GM; Khatibzadeh, S; Micha, R; Powles, J; Mozaffarian, D				Webb, Michael; Fahimi, Saman; Singh, Gitanjali M.; Khatibzadeh, Shahab; Micha, Renata; Powles, John; Mozaffarian, Dariush			Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DIETARY SALT; INTERVENTIONS; PREVENTION; MORTALITY; HEALTH; CHOLESTEROL; CONSUMPTION; REDUCTION	OBJECTIVE To quantify the cost effectiveness of a government policy combining targeted industry agreements and public education to reduce sodium intake in 183 countries worldwide. DESIGN Global modeling study. SETTING 183 countries. POPULATION Full adult population in each country. INTERVENTION A "soft regulation" national policy that combines targeted industry agreements, government monitoring, and public education to reduce population sodium intake, modeled on the recent successful UK program. To account for heterogeneity in efficacy across countries, a range of scenarios were evaluated, including 10%, 30%, 0.5 g/day, and 1.5 g/day sodium reductions achieved over 10 years. We characterized global sodium intakes, blood pressure levels, effects of sodium on blood pressure and of blood pressure on cardiovascular disease, and cardiovascular disease rates in 2010, each by age and sex, in 183 countries. Country specific costs of a sodium reduction policy were estimated using the World Health Organization Noncommunicable Disease Costing Tool. Country specific impacts on mortality and disability adjusted life years (DALYs) were modeled using comparative risk assessment. We only evaluated program costs, without incorporating potential healthcare savings from prevented events, to provide conservative estimates of cost effectiveness MAIN OUTCOME MEASURE Cost effectiveness ratio, evaluated as purchasing power parity adjusted international dollars (equivalent to the country specific purchasing power of US$) per DALY saved over 10 years. RESULTS Worldwide, a 10% reduction in sodium consumption over 10 years within each country was projected to avert approximately 5.8 million DALYs/year related to cardiovascular diseases, at a population weighted mean cost of I$1.13 per capita over the 10 year intervention. The population weighted mean cost effectiveness ratio was approximately I$204/DALY. Across nine world regions, estimated cost effectiveness of sodium reduction was best in South Asia (I$116/DALY); across the world's 30 most populous countries, best in Uzbekistan (I$26.08/DALY) and Myanmar (I$33.30/DALY). Cost effectiveness was lowest in Australia/New Zealand (I$880/DALY, or 0.02xgross domestic product (GDP) per capita), although still substantially better than standard thresholds for cost effective (<3.0xGDP per capita) or highly cost effective (<1.0xGDP per capita) interventions. Most (96.0%) of the world's adult population lived in countries in which this intervention had a cost effectiveness ratio <0.1xGDP per capita, and 99.6% in countries with a cost effectiveness ratio <1.0xGDP per capita. CONCLUSION A government "soft regulation" strategy combining targeted industry agreements and public education to reduce dietary sodium is projected to be highly cost effective worldwide, even without accounting for potential healthcare savings.	[Webb, Michael] Stanford Univ, Stanford, CA 94305 USA; [Webb, Michael] Inst Fiscal Studies, London, England; [Fahimi, Saman; Khatibzadeh, Shahab] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Singh, Gitanjali M.; Micha, Renata; Mozaffarian, Dariush] Tufts Friedman Sch Nutr Sci & Policy, 150 Harrison Ave, Boston, MA 02111 USA; [Powles, John] Cambridge Inst Publ Hlth, Cambridge, England	Stanford University; University of London; London School Economics & Political Science; Harvard University; Harvard T.H. Chan School of Public Health; University of Cambridge	Mozaffarian, D (corresponding author), Tufts Friedman Sch Nutr Sci & Policy, 150 Harrison Ave, Boston, MA 02111 USA.	dariush.mozaffarian@tufts.edu	Mozaffarian, Dariush/ABC-2822-2020		National Heart, Lung, and Blood Institute, National Institutes of Health [R01 HL115189]; National Institute of Diabetes and Digestive and Kidney Diseases (T32 training grant in academic nutrition), National Institutes of Health [DK007703]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL115189] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases (T32 training grant in academic nutrition), National Institutes of Health; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported by the National Heart, Lung, and Blood Institute (R01 HL115189; principal investigator DM) and the National Institute of Diabetes and Digestive and Kidney Diseases (T32 training grant in academic nutrition, DK007703; GMS), National Institutes of Health. The sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	Abelson P., 2001, RETURNS INVESTMENT P; Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1326; [Anonymous], NEWS WHO; Asaria P, 2007, LANCET, V370, P2044, DOI 10.1016/S0140-6736(07)61698-5; Barton P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4044; Bertram MY, 2012, SAMJ S AFR MED J, V102, P743, DOI [10.7196/samj.5832, 10.7196/SAMJ.5832]; Bibbins-Domingo K, 2010, NEW ENGL J MED, V362, P590, DOI 10.1056/NEJMoa0907355; Christoforou A, 2016, J EPIDEMIOL COMMUN H, V70, P1140, DOI 10.1136/jech-2015-206997; Cobb LK, 2014, CIRCULATION, V129, P1173, DOI 10.1161/CIR.0000000000000015; Cobiac LJ, 2010, HEART, V96, P1920, DOI 10.1136/hrt.2010.199240; Cook NR, 2014, CIRCULATION, V129, P981, DOI 10.1161/CIRCULATIONAHA.113.006032; Danaei G, 2011, LANCET, V377, P568, DOI 10.1016/S0140-6736(10)62036-3; European Commission, SURV MEMB STAT IMPL; Gaziano T., 2011, 20112 UN DEP EC SOC; Gillespie DOS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127927; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Graudal NA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004022.pub3; Griffith R, 2014, W1415 IFS; Hyseni L, 2016, CIRCULATION S1, V133, P154; Institute of Medicine, 2010, EVALUATION BIOMARKER; Institute of Medicine, 2013, SOD INT POP ASEV; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Joossens JV, 1996, INT J EPIDEMIOL, V25, P494, DOI 10.1093/ije/25.3.494; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LICHTENSTEIN AH, 1994, ARTERIOSCLER THROMB, V14, P168, DOI 10.1161/01.ATV.14.1.168; Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206; MATTES RD, 1991, J AM COLL NUTR, V10, P383; Meltzer D, 2012, ELGAR COMPANION TO HEALTH ECONOMICS, 2ND EDITION, P481; Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; O'Donnell M, 2014, NEW ENGL J MED, V371, P612, DOI 10.1056/NEJMoa1311889; Palar K, 2009, AM J HEALTH PROMOT, V24, P49, DOI 10.4278/ajhp.080826-QUAN-164; Penz ED, 2008, CAN J CARDIOL, V24, P497, DOI 10.1016/S0828-282X(08)70625-1; Powles J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003733; Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427; Sadler K, 2011, NATL DIET NUTR SURVE; Selmer RM, 2000, J EPIDEMIOL COMMUN H, V54, P697, DOI 10.1136/jech.54.9.697; Smith-Spangler CM, 2010, ANN INTERN MED, V152, P481, DOI 10.7326/0003-4819-152-8-201004200-00212; SUMMERS R, 1991, Q J ECON, V106, P327, DOI 10.2307/2937941; Trieu K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130247; UK Food Standards Agency, UK SALT RED IN; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; Williamson JD, 2016, JAMA-J AM MED ASSOC, V315, P2673, DOI 10.1001/jama.2016.7050; Xie XF, 2016, LANCET, V387, P435, DOI 10.1016/S0140-6736(15)00805-3	47	70	75	3	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2017	356								i6699	10.1136/bmj.i6699	http://dx.doi.org/10.1136/bmj.i6699			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9BS	28073749	Green Published, hybrid			2023-01-03	WOS:000392067300002
J	Lipsitz, YY; Bedford, P; Davies, AH; Timmins, NE; Zandstra, PW				Lipsitz, Yonatan Y.; Bedford, Patrick; Davies, Anthony H.; Timmins, Nicholas E.; Zandstra, Peter W.			Achieving Efficient Manufacturing and Quality Assurance through Synthetic Cell Therapy Design	CELL STEM CELL			English	Editorial Material									[Lipsitz, Yonatan Y.; Zandstra, Peter W.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada; [Bedford, Patrick] Hlth Canada, Biol & Genet Therapies Directorate, Ottawa, ON K1A 0K9, Canada; [Davies, Anthony H.] Dark Horse Consulting, Campbell, CA 95008 USA; [Bedford, Patrick; Timmins, Nicholas E.; Zandstra, Peter W.] CCRM, Toronto, ON M5G 1L5, Canada; [Zandstra, Peter W.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada; [Zandstra, Peter W.] Univ Toronto, Med Design Canada Res Excellence Fund Program 1, Toronto, ON M5S 3E1, Canada	University of Toronto; Health Canada; University of Toronto; University of Toronto	Zandstra, PW (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada.; Zandstra, PW (corresponding author), CCRM, Toronto, ON M5G 1L5, Canada.; Zandstra, PW (corresponding author), Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada.; Zandstra, PW (corresponding author), Univ Toronto, Med Design Canada Res Excellence Fund Program 1, Toronto, ON M5S 3E1, Canada.	peter.zandstra@utoronto.ca			NSERC Alexander Graham Bell Canada Graduate Scholarship; Canada Research Chair in Stem Cell Bioengineering; Medicine by Design: A Canada First Research Excellence Fund Program at the University of Toronto	NSERC Alexander Graham Bell Canada Graduate Scholarship; Canada Research Chair in Stem Cell Bioengineering; Medicine by Design: A Canada First Research Excellence Fund Program at the University of Toronto	We thank L. Prochazka for constructive comments and apologize to colleagues whose research we were unable to cite due to space constraints. Y.Y.L. is supported by an NSERC Alexander Graham Bell Canada Graduate Scholarship, and P.W.Z. is supported as the Canada Research Chair in Stem Cell Bioengineering, and by Medicine by Design: A Canada First Research Excellence Fund Program at the University of Toronto.	Birket MJ, 2015, NAT BIOTECHNOL, V33, P970, DOI 10.1038/nbt.3271; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Hackett JA, 2014, CELL STEM CELL, V15, P416, DOI 10.1016/j.stem.2014.09.015; June CH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3643; Kramer NJ, 2016, SCIENCE, V353, P708, DOI 10.1126/science.aaf7791; Lipsitz YY, 2016, NAT BIOTECHNOL, V34, P393, DOI 10.1038/nbt.3525; Miki K, 2015, CELL STEM CELL, V16, P699, DOI 10.1016/j.stem.2015.04.005; Saxena P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11247; Shi JH, 2014, P NATL ACAD SCI USA, V111, P10131, DOI 10.1073/pnas.1409861111; Xie Z, 2011, SCIENCE, V333, P1307, DOI 10.1126/science.1205527	10	23	23	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JAN 5	2017	20	1					13	17		10.1016/j.stem.2016.12.003	http://dx.doi.org/10.1016/j.stem.2016.12.003			5	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	EO0FR	28061350	Bronze			2023-01-03	WOS:000396374200007
J	Lynch, SV; Pedersen, O				Lynch, Susan V.; Pedersen, Oluf			The Human Intestinal Microbiome in Health and Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN GUT MICROBIOME; FECAL MICROBIOTA; METABOLIC-CHANGES; INNATE IMMUNITY; BACTERIA; EXPOSURE; STRAINS; CELLS; SHAPE; OBESE		[Lynch, Susan V.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, 513 Parnassus Ave,S357D, San Francisco, CA 94143 USA; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn, Ctr Basic Metab Res, Copenhagen, Denmark	University of California System; University of California San Francisco; Novo Nordisk Foundation; University of Copenhagen	Lynch, SV (corresponding author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, 513 Parnassus Ave,S357D, San Francisco, CA 94143 USA.; Pedersen, O (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn, Ctr Basic Metab Res,DIKU, Univ Pk 1,1st Floor, DK-2100 Copenhagen, Denmark.	susan.lynch@ucsf.edu; oluf@sund.ku.dk	Pedersen, Oluf/AAG-8015-2020					Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Ahern PP, 2014, IMMUNITY, V40, P815, DOI 10.1016/j.immuni.2014.05.012; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Backhed F, 2015, CELL HOST MICROBE, V17, P852, DOI 10.1016/j.chom.2015.05.012; Beaumont M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1052-7; Braat H, 2006, CLIN GASTROENTEROL H, V4, P754, DOI 10.1016/j.cgh.2006.03.028; Brahe LK, 2015, BRIT J NUTR, V114, P406, DOI 10.1017/S0007114515001786; Breton J, 2016, CELL METAB, V23, P324, DOI 10.1016/j.cmet.2015.10.017; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Canfora EE, 2015, NAT REV ENDOCRINOL, V11, P577, DOI 10.1038/nrendo.2015.128; Cebula A, 2013, NATURE, V497, P258, DOI 10.1038/nature12079; Chen ZY, 2014, J CLIN INVEST, V124, P3391, DOI 10.1172/JCI72517; Cheng J, 2016, ISME J, V10, P1002, DOI 10.1038/ismej.2015.177; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Claesson MJ, 2012, NATURE, V488, P178, DOI 10.1038/nature11319; Colman RJ, 2014, J CROHNS COLITIS, V8, P1569, DOI 10.1016/j.crohns.2014.08.006; Cotillard A, 2013, NATURE, V500, P585, DOI 10.1038/nature12480; Cotter PD, 2005, NAT REV MICROBIOL, V3, P777, DOI 10.1038/nrmicro1273; Dasgupta S, 2014, CELL HOST MICROBE, V15, P413, DOI 10.1016/j.chom.2014.03.006; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Devlin AS, 2015, NAT CHEM BIOL, V11, P685, DOI [10.1038/NCHEMBIO.1864, 10.1038/nchembio.1864]; DiGiulio DB, 2010, AM J REPROD IMMUNOL, V64, P38, DOI 10.1111/j.1600-0897.2010.00830.x; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Duan FP, 2008, APPL ENVIRON MICROB, V74, P7437, DOI 10.1128/AEM.01019-08; Duan FF, 2015, DIABETES, V64, P1794, DOI 10.2337/db14-0635; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Falony G, 2016, SCIENCE, V352, P560, DOI 10.1126/science.aad3503; Feng Q, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7528; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Fulde M, 2014, IMMUNOL REV, V260, P21, DOI 10.1111/imr.12190; Gerritsen J, 2011, GENES NUTR, V6, P209, DOI 10.1007/s12263-011-0229-7; Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053; Gosalbes MJ, 2013, CLIN EXP ALLERGY, V43, P198, DOI 10.1111/cea.12063; Graessler J, 2013, PHARMACOGENOMICS J, V13, P514, DOI 10.1038/tpj.2012.43; Ha CWY, 2014, WORLD J GASTROENTERO, V20, P16498, DOI 10.3748/wjg.v20.i44.16498; Haiser HJ, 2013, SCIENCE, V341, P295, DOI 10.1126/science.1235872; Hansen TH, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0157-z; Hollister EB, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0101-x; Hsiao A, 2014, NATURE, V515, P423, DOI 10.1038/nature13738; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Ijssennagger N, 2015, P NATL ACAD SCI USA, V112, P10038, DOI 10.1073/pnas.1507645112; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Kamada N, 2013, NAT IMMUNOL, V14, P685, DOI 10.1038/ni.2608; Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198; Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Knights D, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0107-1; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Konichi H, 2016, NAT COMMUN; Koren O, 2012, CELL, V150, P470, DOI 10.1016/j.cell.2012.07.008; Lakshminarayanan B, 2013, J APPL MICROBIOL, V114, P886, DOI 10.1111/jam.12085; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Lozupone CA, 2014, GUT MICROBES, V5, P562, DOI 10.4161/gmic.32132; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Macfarlane S, 2013, ALIMENT PHARM THER, V38, P804, DOI 10.1111/apt.12453; Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990; Marinho FAV, 2010, CLIN EXP ALLERGY, V40, P1541, DOI 10.1111/j.1365-2222.2010.03502.x; Martens EC, 2008, CELL HOST MICROBE, V4, P447, DOI 10.1016/j.chom.2008.09.007; Maurice CF, 2013, CELL, V152, P39, DOI 10.1016/j.cell.2012.10.052; Neef A, 2013, CURR OPIN CLIN NUTR, V16, P679, DOI 10.1097/MCO.0b013e328365c258; Neuman H, 2015, FEMS MICROBIOL REV, V39, P509, DOI 10.1093/femsre/fuu010; Nielsen HB, 2014, NAT BIOTECHNOL, V32, P822, DOI 10.1038/nbt.2939; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Pedersen HK, 2016, NATURE, V535, P376, DOI 10.1038/nature18646; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Qin N, 2014, NATURE, V513, P59, DOI 10.1038/nature13568; Reinhardt C, 2012, NATURE, V483, P627, DOI 10.1038/nature10893; Reyes A, 2010, NATURE, V466, P334, DOI 10.1038/nature09199; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Sharon I, 2013, GENOME RES, V23, P111, DOI 10.1101/gr.142315.112; Shoaie S, 2015, CELL METAB, V22, P320, DOI 10.1016/j.cmet.2015.07.001; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; STALEY JT, 1985, ANNU REV MICROBIOL, V39, P321, DOI 10.1146/annurev.mi.39.100185.001541; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Subramanian S, 2014, NATURE, V510, P417, DOI 10.1038/nature13421; Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400; Thaiss CA, 2014, CELL, V159, P514, DOI 10.1016/j.cell.2014.09.048; Tremaroli V, 2015, CELL METAB, V22, P228, DOI 10.1016/j.cmet.2015.07.009; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Tvede M, 2015, CLIN MICROBIOL INFEC, V21, P48, DOI 10.1016/j.cmi.2014.07.003; Uusitalo U, 2016, JAMA PEDIATR, V170, P20, DOI 10.1001/jamapediatrics.2015.2757; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Vujkovic-Cvijin I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006438; Walsh CJ, 2014, FEBS LETT, V588, P4120, DOI 10.1016/j.febslet.2014.03.035; Wang S, 2015, IMMUNITY, V43, P289, DOI 10.1016/j.immuni.2015.06.014; Wang WL, 2015, WORLD J GASTROENTERO, V21, P803, DOI 10.3748/wjg.v21.i3.803; Wang ZN, 2015, CELL, V163, P1585, DOI 10.1016/j.cell.2015.11.055; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Westendorf AM, 2005, FEMS IMMUNOL MED MIC, V43, P373, DOI 10.1016/j.femsim.2004.10.023; Wu H, 2015, TRENDS ENDOCRIN MET, V26, P758, DOI 10.1016/j.tem.2015.09.011; Yallapragada SG, 2015, PEDIATR ANN, V44, pE265, DOI 10.3928/00904481-20151112-09; Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zeller G, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145645; Zhang X, 2015, NAT MED, V21, P895, DOI 10.1038/nm.3914; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369	112	1480	1586	55	760	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2016	375	24					2369	2379		10.1056/NEJMra1600266	http://dx.doi.org/10.1056/NEJMra1600266			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF0SO	27974040				2023-01-03	WOS:000390036500008
J	Torres, PC; Morsello, C; Parry, L; Pardini, R				Torres, Patricia Carignano; Morsello, Carla; Parry, Luke; Pardini, Renata			Who Cares about Forests and Why? Individual Values Attributed to Forests in a Post-Frontier Region in Amazonia	PLOS ONE			English	Article							CULTURAL ECOSYSTEM SERVICES; WILDLIFE CONSUMPTION; RURAL HOUSEHOLDS; CONSERVATION; BUSHMEAT; ATTITUDE; BIODIVERSITY; PERCEPTIONS; MANAGEMENT; INSIGHTS	Understanding the multiple ways people value forests is important, as individual values regarding nature have been shown to partly determine willingness to participate in conservation initiatives. As individual values are influenced by past experiences, the way people value forests may be related to the ecosystem services they use and receive. We here aim to investigate if people value forests because of material and non-material benefits forest provide (material and non-material values), and if these values are defined by previous experiences associated with using forest resources and having frequent contact with forests. By interviewing 363 residents across 20 landscapes varying in forest cover in a post-frontier region in Amazonia, we evaluated: (1) if the use of forest resources-especially bushmeat, important for sustenance and cash income in virtually all tropical forests-is associated with attributing higher material value to forests; (2) whether the contact with forest (estimated by local forest cover and visits to forests) is associated with attributing higher non-material value to forests. As expected, respondents from households where hunting occurs and bushmeat consumption is more frequent attributed higher material value to forests, and those living in more deforested landscapes and that visited forests less often attributed lower non-material value to forests. The importance of bushmeat in shaping the way people value forests suggests that encouraging the sustainable use of this product will encourage forest conservation. Results also point to a potential dangerous reinforcing cycle: low forest cover and the loss of contact with forests may erode forest values and facilitate further deforestation. Engaging rural communities in forest conservation initiatives is challenging yet urgent in degraded landscapes, although harnessing appreciation for bushmeat could offer a starting point.	[Torres, Patricia Carignano] Univ Sao Paulo, Inst Biociencias, Dept Ecol, Cidade Univ, Sao Paulo, SP, Brazil; [Morsello, Carla] Univ Sao Paulo, Escola Artes Ciencias & Humanidades, Sao Paulo, SP, Brazil; [Parry, Luke] Univ Lancaster, Lancaster Environm Ctr, Lancaster, Lancs, England; [Parry, Luke] Fed Univ Para, NAEA, Belem, Para, Brazil; [Pardini, Renata] Univ Sao Paulo, Inst Biociencias, Dept Zool, Cidade Univ, Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Lancaster University; Universidade Federal do Para; Universidade de Sao Paulo	Torres, PC (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Ecol, Cidade Univ, Sao Paulo, SP, Brazil.	patriciactorres@gmail.com	Morsello, Carla/D-7393-2012; Carignano Torres, Patricia/F-2794-2016; Pardini, Renata/C-4095-2012; Parry, Luke/ABD-4194-2021	Morsello, Carla/0000-0001-7548-6541; Carignano Torres, Patricia/0000-0003-0426-8277; Pardini, Renata/0000-0002-3769-8401; Parry, Luke/0000-0003-0330-9516	INCT - Biodiversidade e Uso da Terra na Amazonia [CNPq 574008/2008-0]; Embrapa [SEG: 02.08.06.005.00]; UK government Darwin Initiative [17-023]; Nature Conservancy; Natural Environment Research Council (NERC) [NE/F01614X/1, NE/G000816/1]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/19108-0]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2011/19606-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [308205/2014-6]; NERC [NE/F01614X/1, NE/G000816/1] Funding Source: UKRI; Natural Environment Research Council [NE/G000816/1, NE/F01614X/1, ceh010010] Funding Source: researchfish	INCT - Biodiversidade e Uso da Terra na Amazonia; Embrapa(Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)); UK government Darwin Initiative; Nature Conservancy; Natural Environment Research Council (NERC)(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was supported by INCT - Biodiversidade e Uso da Terra na Amazonia (CNPq 574008/2008-0), Embrapa (SEG: 02.08.06.005.00), the UK government Darwin Initiative (17-023), the Nature Conservancy, the Natural Environment Research Council (NERC) (NE/F01614X/1 and NE/G000816/1) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(2011/19108-0). PCT had doctoral scholarships from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (2011/19606-0). RP had a research fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (308205/2014-6) during the development of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Albrechtsen L, 2005, ENVIRON CONSERV, V32, P340, DOI 10.1017/S0376892906002694; Angelsen A, 2014, WORLD DEV, V64, pS12, DOI 10.1016/j.worlddev.2014.03.006; [Anonymous], 2007, R BOOK; ARCURY TA, 1990, ENVIRON BEHAV, V22, P387, DOI 10.1177/0013916590223004; Arnold TW, 2010, J WILDLIFE MANAGE, V74, P1175, DOI 10.2193/2009-367; Bates D., 2011, R PACKAGE VERSION 1, P1; Bhagwat SA, 2009, ENVIRON VALUE, V18, P417, DOI 10.3197/096327109X12532653285731; Brancalion PHS, 2014, RESTOR ECOL, V22, P65, DOI 10.1111/rec.12025; Brashares JS, 2011, P NATL ACAD SCI USA, V108, P13931, DOI 10.1073/pnas.1011526108; Brown G, 2000, FOREST SCI, V46, P240; Brown G, 2012, APPL SPAT ANAL POLIC, V5, P317, DOI 10.1007/s12061-011-9072-x; Burnhan KP, 2002, MODEL SELECTION MULT; Carifio J., 2007, J SOCIAL SCI, V3, P106, DOI DOI 10.3844/JSSP.2007.106.116; Castro E, 2004, DINAMICA ATORES USO, V179; Chan KMA, 2012, ECOL ECON, V74, P8, DOI 10.1016/j.ecolecon.2011.11.011; Coomes OT, 2004, ECOL ECON, V51, P47, DOI 10.1016/j.ecolecon.2004.04.004; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98; D'Antona AO, 2006, POPUL ENVIRON, V27, P373, DOI 10.1007/s11111-006-0031-4; de Merode E, 2004, BIOL CONSERV, V118, P573, DOI 10.1016/j.biocon.2003.10.005; De Vaus, 2002, SURVEYS SOCIAL RES; Dietz T, 2005, ANNU REV ENV RESOUR, V30, P335, DOI 10.1146/annurev.energy.30.050504.144444; Dunlap RE, 2000, J SOC ISSUES, V56, P425, DOI 10.1111/0022-4537.00176; Fa JE, 2009, ANIM CONSERV, V12, P599, DOI 10.1111/j.1469-1795.2009.00289.x; Fearnside PM, 2005, CONSERV BIOL, V19, P680, DOI 10.1111/j.1523-1739.2005.00697.x; Foerster S, 2012, CONSERV BIOL, V26, P335, DOI 10.1111/j.1523-1739.2011.01802.x; Fonseca WD, SANTAREM MOMENTOS HI; Fulton D.C., 1996, HUM DIMENS WILDL, V1, P24, DOI DOI 10.1080/10871209609359060; Futemma C, 2003, HUM ECOL, V31, P369, DOI 10.1023/A:1025067721480; George D, 2003, SPSS WINDOWS STEP ST; Godoy R, 2010, ANIM CONSERV, V13, P265, DOI 10.1111/j.1469-1795.2009.00330.x; Hicks CC, 2015, CONSERV BIOL, V29, P1471, DOI 10.1111/cobi.12550; IBGE, 2010, CENS DEM 2010; Ives CD, 2014, J ENVIRON MANAGE, V144, P67, DOI 10.1016/j.jenvman.2014.05.013; Jax K, 2013, ECOL ECON, V93, P260, DOI 10.1016/j.ecolecon.2013.06.008; Jenkins CN, 2009, BIOL CONSERV, V142, P2166, DOI 10.1016/j.biocon.2009.04.016; Justus J, 2009, TRENDS ECOL EVOL, V24, P187, DOI 10.1016/j.tree.2008.11.011; Kareiva P, 2003, AM SCI, V91, P344, DOI 10.1511/2003.4.344; Kareiva P, 2007, SCI AM, V297, P50, DOI 10.1038/scientificamerican1007-50; Kijazi MH, 2010, FOREST POLICY ECON, V12, P357, DOI 10.1016/j.forpol.2010.02.007; Likert R, 1932, ARCH PSYCHOL, V22, P3; Lockwood M, 1999, ENVIRON VALUE, V8, P381, DOI 10.3197/096327199129341888; Lockwood M., 2005, Australasian Journal of Environmental Management, V12, P8; Luckert M., 2002, UNCOVERING HIDDEN HA; Maio G.R., 2003, HDB SOCIAL PSYCHOL, P283, DOI DOI 10.1007/0-387-36921-X_12; Marvier M, 2014, CONSERV BIOL, V28, P1, DOI 10.1111/cobi.12206; Mascia MB, 2003, CONSERV BIOL, V17, P649, DOI 10.1046/j.1523-1739.2003.01738.x; Meijaard E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073008; Michalski F, 2007, CONSERV BIOL, V21, P1626, DOI 10.1111/j.1523-1739.2007.00797.x; Millennium Ecosystem Assessment, 2005, SCIENCE; Miller JR, 2005, TRENDS ECOL EVOL, V20, P430, DOI 10.1016/j.tree.2005.05.013; Milner-Gulland EJ, 2003, TRENDS ECOL EVOL, V18, P351, DOI 10.1016/S0169-5347(03)00123-X; Nepstad DC, 2006, CONSERV BIOL, V20, P1595, DOI 10.1111/j.1523-1739.2006.00510.x; Nesheim I, 2006, HUM ECOL, V34, P99, DOI 10.1007/s10745-005-9004-y; Olson JM, 2005, HANDBOOK OF ATTITUDES, P223; Oppenheim A.N, 2000, QUESTIONNAIRE DESIGN; Paletto A, 2013, ENVIRON MANAGE, V51, P414, DOI 10.1007/s00267-012-9974-7; Parry L, 2014, CONSERV LETT, V7, P565, DOI 10.1111/conl.12151; Peres CA, 2007, BIOTROPICA, V39, P304, DOI 10.1111/j.1744-7429.2007.00272.x; Plieninger T, 2013, LAND USE POLICY, V33, P118, DOI 10.1016/j.landusepol.2012.12.013; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; RAMCILOVIC-SUOMINEN S., 2013, VOLUME, V12, P235, DOI DOI 10.1007/S11842-012-9209-Z; Revelle W., 2014, PSYCH PROCEDURES PER; Reyers B, 2012, BIOSCIENCE, V62, P503, DOI 10.1525/bio.2012.62.5.12; Rokeach M., 1973, NATURE HUMAN VALUES; Schultz PW, 1999, J ENVIRON PSYCHOL, V19, P255; Schultz PW, 2001, J ENVIRON PSYCHOL, V21, P327; SCHWARTZ SH, 1994, J SOC ISSUES, V50, P19, DOI 10.1111/j.1540-4560.1994.tb01196.x; Seymour E, 2010, AUSTRALAS J ENV MAN, V17, P142, DOI 10.1080/14486563.2010.9725261; Soares B, 2014, SCIENCE, V344, P363, DOI 10.1126/science.1246663; STERN PC, 1995, J APPL SOC PSYCHOL, V25, P1611, DOI 10.1111/j.1559-1816.1995.tb02636.x; Tabachnick BG, 2001, USING MULTIVARIATE S, V4th; Tarrant MA, 2002, ENVIRON MANAGE, V30, P692, DOI 10.1007/s00267-002-2722-7; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; Tomicevic J, 2010, FOREST POLICY ECON, V12, P157, DOI 10.1016/j.forpol.2009.09.006; Torres PC, 2014, THESIS; Turner WR, 2004, BIOSCIENCE, V54, P585, DOI 10.1641/0006-3568(2004)054[0585:GUATSO]2.0.CO;2; Xu JY, 2006, J ENVIRON MANAGE, V78, P362, DOI 10.1016/j.jenvman.2005.05.003; Zhang WZ, 2014, BIOL CONSERV, V177, P109, DOI 10.1016/j.biocon.2014.06.011; Zuur Alain F., 2009, P1; [No title captured]	81	6	6	4	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0167691	10.1371/journal.pone.0167691	http://dx.doi.org/10.1371/journal.pone.0167691			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI8HA	27942038	Green Published, Green Submitted, gold			2023-01-03	WOS:000392745600025
J	Tuttolomondo, A; Di Raimondo, D; Bellia, C; Clemente, G; Pecoraro, R; Maida, C; Simonetta, I; Vassallo, V; Di Bona, D; Gulotta, E; Ciaccio, M; Pinto, A				Tuttolomondo, Antonino; Di Raimondo, Domenico; Bellia, Chiara; Clemente, Giuseppe; Pecoraro, Rosaria; Maida, Carlo; Simonetta, Irene; Vassallo, Valerio; Di Bona, Danilo; Gulotta, Eliana; Ciaccio, Marcello; Pinto, Antonio			Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites	PLOS ONE			English	Article							BRAIN NATRIURETIC PEPTIDE; CHRONIC LIVER-DISEASE; CHRONIC HEPATITIS-C; NONALCOHOLIC STEATOHEPATITIS; DECOMPENSATED CIRRHOSIS; VIRUS-INFECTION; LEPTIN LEVELS; CYTOKINES; FIBROSIS; RESISTANCE	Introduction Patients with chronic liver diseases are usually thin as a result of hypermetabolism and malnutrition expressed by reduced levels of leptin and impairment of other adyponectins such as visfatin. Aims We evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites. Methods 59 consecutive cirrhotic patients with refractory ascites unresponsive to outpatient treatment. Enrolled subjects were randomized to treatment with intravenous infusion of furosemide (125-250mg/bid) plus small volumes of HSS from the first day after admission until 3 days before discharge (Group A, n: 38), or repeated paracentesis from the first day after admission until 3 days before discharge (Group B, n: 21). Plasma levels of ANP, BNP, Leptin, visfatin, IL-1 beta, TNF-a, IL-6 were measured before and after the two type of treatment. Results Subjects in group A were observed to have a significant reduction of serum levels of TNF-alpha, IL-1 beta, IL-6, ANP, BNP, and visfatin, thus regarding primary efficacy endpoints, in Group A vs. Group B we observed higher Delta-TNF-alpha, Delta-IL-1 beta, Delta-IL-6, Delta-ANP, Delta-BNP, Delta-visfatin, Delta-Leptin at discharge. Discussion Our findings underline the possible inflammatory and metabolic effect of saline overload correction in treatment of cirrhosis complications such as refractory ascites, suggesting a possible role of inflammatory and metabolic-nutritional variables as severity markers in these patients.	[Tuttolomondo, Antonino; Di Raimondo, Domenico; Clemente, Giuseppe; Pecoraro, Rosaria; Maida, Carlo; Simonetta, Irene; Vassallo, Valerio; Pinto, Antonio] Univ Palermo, Dipartimento Biomed Med Interna & Specialist DiBi, UOC Med Interna & Stroke Care, I-90133 Palermo, Italy; [Bellia, Chiara; Ciaccio, Marcello] Univ Palermo, Azienda Osped Univ Policlin, Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biochim Clin,UOC CoreLab, Palermo, Italy; [Bellia, Chiara; Ciaccio, Marcello] Univ Palermo, Azienda Osped Univ Policlin, Dipartimento Biopatol & Biotecnol Med & Forensi, UOC CoreLab,Med Mol Clin, Palermo, Italy; [Di Bona, Danilo] Univ Bari, Dipartimento Emergenze & Trapianti Organo, Sch & Chair Allergol, I-70121 Bari, Italy; [Gulotta, Eliana] Univ Palermo, Policlin Univ Paolo Giaccone, Dipartimento Chirurg Gen & Urgenza, I-90133 Palermo, Italy	University of Palermo; University of Palermo; Policlinico Paolo Giaccone; University of Palermo; Policlinico Paolo Giaccone; Universita degli Studi di Bari Aldo Moro; University of Palermo; Policlinico Paolo Giaccone	Tuttolomondo, A (corresponding author), Univ Palermo, Dipartimento Biomed Med Interna & Specialist DiBi, UOC Med Interna & Stroke Care, I-90133 Palermo, Italy.	bruno.tuttolomondo@unipa.it	Simonetta, Irene/HDM-7402-2022; Di Raimondo, Domenico/AAB-2379-2019; Di+Raimondo, Domenico/AFM-3500-2022; Bellia, Chiara/AAO-3725-2020	Simonetta, Irene/0000-0003-1574-104X; Di Raimondo, Domenico/0000-0002-4529-3703; Di+Raimondo, Domenico/0000-0002-4529-3703; Bellia, Chiara/0000-0003-0611-9363; maida, carlo/0000-0002-4868-9033; Pinto, Antonio/0000-0002-8083-3699				Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122; BAC DJ, 1995, LIVER, V15, P265; beda UA, 2010, HEPATOLOGY, V52, P2086, DOI [10.1002/hep.23961, DOI 10.1002/HEP.23961]; Cacciarelli TV, 1996, HEPATOLOGY, V24, P6, DOI 10.1053/jhep.1996.v24.pm0008707283; Choi S, 2005, CURR OPIN GASTROEN, V21, P702, DOI 10.1097/01.mog.0000182863.96421.47; Coombes JD, 2016, BBA-MOL BASIS DIS, V1862, P135, DOI 10.1016/j.bbadis.2015.10.028; Farrell GC, 2014, LIVER INT, V34, P1084, DOI 10.1111/liv.12335; Figueiredo A, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/539412; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Giannini E, 2004, DIGEST DIS SCI, V49, P275, DOI 10.1023/B:DDAS.0000017451.48031.b6; Guglielmi FW, 2005, DIGEST LIVER DIS, V37, P681, DOI 10.1016/j.dld.2005.03.010; Henriksen JH, 2003, GUT, V52, P1511, DOI 10.1136/gut.52.10.1511; Hsu CS, 2015, HEPATOL INT, V9, P231, DOI 10.1007/s12072-015-9616-2; Jovicic N, 2015, PLOS ONE, V28; Kalafateli M, 2015, WORLD J GASTROENTERO, V21, P3020, DOI 10.3748/wjg.v21.i10.3020; Kitaoka S, 2003, HEPATO-GASTROENTEROL, V50, P1569; Li Z, HEPATOLOGY, V42, P880, DOI DOI 10.1002/HEP; Licata G, 2009, ALIMENT PHARM THER, V30, P227, DOI 10.1111/j.1365-2036.2009.04040.x; Missale G, 1997, HEPATOLOGY, V26, P792, DOI 10.1053/jhep.1997.v26.pm0009303515; Phillip V, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-18; Pimenta J, 2010, LIVER INT, V30, P1059, DOI 10.1111/j.1478-3231.2010.02266.x; Polyzos SA, 2015, METABOLISM, V64, P60, DOI 10.1016/j.metabol.2014.10.012; Prieto-Frias C, 2016, EUR J GASTROEN HEPAT, V28, P139, DOI 10.1097/MEG.0000000000000516; PRUIMBOOM WM, 1995, INT J IMMUNOPHARMACO, V17, P375, DOI 10.1016/0192-0561(95)00015-T; RECTOR WG, 1990, GASTROENTEROLOGY, V99, P766, DOI 10.1016/0016-5085(90)90966-5; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Santetti D, 2015, WORLD J GASTROENTERO, V21, P8927, DOI 10.3748/wjg.v21.i29.8927; Schoeller DA, 1997, J CLIN INVEST, V100, P1882, DOI 10.1172/JCI119717; Simsek H, 1996, J INT MED RES, V24, P239, DOI 10.1177/030006059602400302; Tuttolomondo A, 2011, NUTR METAB CARDIOVAS, V21, P372, DOI 10.1016/j.numecd.2009.10.014; Vanni E, 2009, HEPATOLOGY, V50, P697, DOI 10.1002/hep.23031; Wong F, 2001, CLIN SCI, V101, P621, DOI 10.1042/CS20010183; Zekri ARN, 2005, WORLD J GASTROENTERO, V11, P6624, DOI 10.3748/wjg.v11.i42.6624	34	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0165443	10.1371/journal.pone.0165443	http://dx.doi.org/10.1371/journal.pone.0165443			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27941973	Green Published, gold, Green Submitted			2023-01-03	WOS:000392745600003
J	Su, W; Liu, J; Miles, BA; Genden, EM; Misiukiewicz, KJ; Posner, M; Gupta, V; Bakst, RL				Su, William; Liu, Jerry; Miles, Brett A.; Genden, Eric M.; Misiukiewicz, Krzysztof J.; Posner, Marshall; Gupta, Vishal; Bakst, Richard L.			Adjuvant Radiation Therapy Alone for HPV Related Oropharyngeal Cancers with High Risk Features	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; CHEMORADIOTHERAPY; CHEMORADIATION; SURGERY; CHEMOTHERAPY; RADIOTHERAPY; TOXICITY	Background Current standard of care for oropharyngeal cancers with positive surgical margins and/or extracapsular extension is adjuvant chemoradiotherapy. It is unknown whether HPV+ oropharyngeal cancer benefits from this treatment intensification. Objective To investigate the outcomes of HPV+ patients treated with adjuvant radiotherapy alone when chemoradiotherapy was indicated based on high risk pathological features. They were compared with high risk HPV+ patients treated with adjuvant chemoradiotherapy. Methods All high risk HPV+ oropharyngeal cancer patients (9) who received radiotherapy alone were identified. We also identified 17 patients who received chemoradiotherapy as a comparison group. Median follow up time was 37.3 months. Results No local failures developed in adjuvant radiotherapy group. There was 1 distant recurrence in this cohort and 3 in CRT cohort. Regarding toxicity, 8 (47.1%) chemoradiotherapy patients had >10 lb. weight loss (p = 0.013), despite 75% of them having a percutaneous endoscopic gastrostomy tube placed. No individuals in radiotherapy group experienced a >10 lb. weight loss and none required a gastrostomy tube. Conclusions This series provides preliminary evidence suggesting that the omission of concurrent chemotherapy to adjuvant radiotherapy may offer comparative local control rates with a lower toxicity profile in the setting of HPV+ patients with traditional high risk features.	[Su, William] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Liu, Jerry] Mt Sinai Beth Israel, Dept Radiat Oncol, New York, NY USA; [Miles, Brett A.; Genden, Eric M.] Icahn Sch Med Mt Sinai, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA; [Misiukiewicz, Krzysztof J.; Posner, Marshall] Icahn Sch Med Mt Sinai, Dept Med Oncol, New York, NY 10029 USA; [Gupta, Vishal; Bakst, Richard L.] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bakst, RL (corresponding author), Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA.	Richard.Bakst@mountsinai.org	Liu, Jerry/AAO-1599-2021	Su, William/0000-0002-5198-2054; Liu, Jerry/0000-0002-4743-6675				Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; [Anonymous], 2016, SIN ROB SURG TRIAL H; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Broglie MA, 2015, EUR ARCH OTO-RHINO-L, V272, P1755, DOI 10.1007/s00405-014-3099-y; Carpenter TJ, 2014, ANN OTO RHINOL LARYN, V123, P791, DOI 10.1177/0003489414535560; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Habbous S, 2014, HEAD NECK-J SCI SPEC, V36, P802, DOI 10.1002/hed.23360; Hanasoge S, 2016, HEAD NECK-J SCI SPEC, V38, P846, DOI 10.1002/hed.24073; Henk J M, 1997, Clin Oncol (R Coll Radiol), V9, P308, DOI 10.1016/S0936-6555(05)80064-0; Kaczmar JM, 2016, HEAD NECK-J SCI SPEC, V38, P59, DOI 10.1002/hed.23850; Kann BH, 2014, HEAD NECK-J SCI SPEC, V36, P1689, DOI 10.1002/hed.23512; Lawrence TS, 2003, SEMIN RADIAT ONCOL, V13, P13, DOI 10.1053/srao.2003.50002; Machtay M, 2008, J CLIN ONCOL, V26, P3582, DOI 10.1200/JCO.2007.14.8841; Moore EJ, 2013, INT J RADIAT ONCOL, V85, P1163, DOI 10.1016/j.ijrobp.2012.08.033; O'Sullivan B, 2013, J CLIN ONCOL, V31, P543, DOI 10.1200/JCO.2012.44.0164; Pederson AW, 2010, HEAD NECK-J SCI SPEC, V32, P1519, DOI 10.1002/hed.21360; Sedaghat AR, 2009, LARYNGOSCOPE, V119, P1542, DOI 10.1002/lary.20533; Shaw RJ, 2010, HEAD NECK-J SCI SPEC, V32, P714, DOI 10.1002/hed.21244; Sinha P, 2015, CANCER-AM CANCER SOC, V121, P1747, DOI 10.1002/cncr.29242; Ward MC, 2016, HEAD NECK-J SCI SPEC, V38, pE1054, DOI 10.1002/hed.24157; Ward MJ, 2015, HEAD NECK-J SCI SPEC, V37, P1002, DOI 10.1002/hed.23697; Yokota T, 2014, INT J CLIN ONCOL, V19, P38, DOI 10.1007/s10147-013-0532-y	23	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2016	11	12							e0168061	10.1371/journal.pone.0168061	http://dx.doi.org/10.1371/journal.pone.0168061			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4OA	27930732	Green Published, gold, Green Submitted			2023-01-03	WOS:000389580900076
J	Li, Y; Tian, X; Xiong, ZY; Liao, JL; Hao, L; Liu, GL; Ren, YP; Wang, Q; Duan, LP; Zheng, ZX; Quan, WX; Dong, J				Li, Yi; Tian, Xue; Xiong, Zu-Ying; Liao, Jin-Lan; Hao, Li; Liu, Gui-Ling; Ren, Ye-Ping; Wang, Qin; Duan, Li-Ping; Zheng, Zhao-Xia; Quan, Wen-Xiang; Dong, Jie			Performance of the Modified Mini-Mental State Examination (3MS) in Assessing Specific Cognitive Function in Patients Undergoing Peritoneal Dialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; IMPAIRMENT; DEMENTIA; PREVALENCE; DECLINE	Purpose While Cognitive impairment (CI) has been identified as an independent risk factors for mortality in patients undergoing peritoneal dialysis (PD), it is inadequately assessed. We evaluated the applicability of the Modified Mini-Mental State Examination (3MS) in assessing specific cognitive function and compared it to a detailed neuropsychological test battery as the reference standard. Methods In this multicentric cross-sectional study, we enrolled 445 clinically stable patients from five PD units, who were undergoing PD for at least 3 months. The 3MS was evaluated for general cognitive function. A detailed neuropsychological battery including domains of immediate memory, delayed memory, executive function, language, and visuospatial ability were evaluated as reference standards. Sensitivity and specificity of the 3MS was determined by using receiver operating characteristic (ROC) analysis. Results The CI prevalence evaluated by 3MS was 23.6%. PD patients with CI performed worse in all cognitive domains. The 3MS correlated well with specific cognitive domains. However, 18.5%, 57.4%, 12.6%, 8.8%, and 41.2% of patients whom were idendified as normal by 3MS still showed executive dysfunction, immediate memory impairment, delayed memory impairment, and language-ability and visuospatial-ability impairment, respectively. The 3MS identified patients having specific cognitive dysfunction with varied extent of diagnostic value, with 0.50, 0.42, 0.35, 0.34, and 0.26 of Youden index in executive function, delayed memory, language ability, immediate memory, and visuospatial ability, respectively. Conclusions The 3MS is not a comprehensive instrument for major cognitive domains in PD patients. It could, however, be used for executive dysfunction and delayed memory impairment screening.	[Li, Yi; Tian, Xue; Dong, Jie] Peking Univ, Hosp 1, Dept Med, Div Renal, Beijing, Peoples R China; [Xiong, Zu-Ying; Liao, Jin-Lan] Peking Univ, Shenzhen Hosp, Div Renal, Shenzhen, Peoples R China; [Hao, Li; Liu, Gui-Ling] Anhui Med Univ, Hosp 2, Div Renal, Hefei, Anhui, Peoples R China; [Ren, Ye-Ping; Wang, Qin] Harbin Med Univ, Affiliated Hosp 2, Div Renal, Harbin, Heilongjiang, Peoples R China; [Duan, Li-Ping; Zheng, Zhao-Xia] Handan Cent Hosp, Div Renal, Handan, Hebei, Peoples R China; [Quan, Wen-Xiang] Peking Univ, Hosp 6, Inst Mental Hlth, Key Lab Mental Hlth,Minist Hlth, Beijing, Peoples R China	Peking University; Peking University; Anhui Medical University; Harbin Medical University; Peking University	Dong, J (corresponding author), Peking Univ, Hosp 1, Dept Med, Div Renal, Beijing, Peoples R China.	jie.dong@bjmu.edu.cn	LIAO, JINLAN/M-7953-2019; Dong, Jie/AFM-0048-2022		New Century Excellent Talents from Education Department of China; ISN Research Award from ISN GO RP Committee	New Century Excellent Talents from Education Department of China(Program for New Century Excellent Talents in University (NCET)); ISN Research Award from ISN GO RP Committee	This work was in part supported by the New Century Excellent Talents from Education Department of China, and the ISN Research Award from ISN GO R&P Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to express their appreciation to the patients, doctors, and nursing staff of the Peritoneal Dialysis Centers of Peking University First Hospital, Peking University Shenzhen Hospital, the Second Hospital of Anhui Medical University, the Second Affiliated Hospital of Harbin Medical University, and Handan Central Hospital, who participated in this study. This work was in part supported by the New Century Excellent Talents from Education Department of China, and the ISN Research Award from ISN GO R&P Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1998, C R RBANS MAN REP BA; Asimakopoulou K., 2002, DIABETES SPECTR, V15, P116, DOI [10.2337/diaspect.15.2.116, DOI 10.2337/DIASPECT.15.2.116]; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Cheng Y, 2011, ARCH MED SCI, V7, P850, DOI 10.5114/aoms.2011.25561; Costa AS, 2014, AM J KIDNEY DIS, V64, P434, DOI 10.1053/j.ajkd.2014.02.012; D'Elia L., 1996, COLOR TRAILS TEST PR; Dong J, 2016, AM J KIDNEY DIS, V67, P111, DOI 10.1053/j.ajkd.2015.06.025; Drew DA, 2015, AM J KIDNEY DIS, V65, P303, DOI 10.1053/j.ajkd.2014.07.009; Fadili W, 2014, AGING MENT HEALTH, V18, P207, DOI 10.1080/13607863.2013.823375; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Griva K, 2010, AM J KIDNEY DIS, V56, P693, DOI 10.1053/j.ajkd.2010.07.003; Helmer C, 2011, NEUROLOGY, V77, P2043, DOI 10.1212/WNL.0b013e31823b4765; Kalirao P, 2011, AM J KIDNEY DIS, V57, P612, DOI 10.1053/j.ajkd.2010.11.026; Kurella M, 2005, J AM SOC NEPHROL, V16, P2127, DOI 10.1681/ASN.2005010005; Kurella M, 2004, J AM GERIATR SOC, V52, P1863, DOI 10.1111/j.1532-5415.2004.52508.x; Kurella M, 2006, NEPHROL DIAL TRANSPL, V21, P2543, DOI 10.1093/ndt/gfl275; Lin FR, 2013, JAMA INTERN MED, V173, P293, DOI 10.1001/jamainternmed.2013.1868; Lux S, 2010, KIDNEY INT, V78, P794, DOI 10.1038/ki.2010.253; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Obi Y, 2016, AM J KIDNEY DIS OFFI; Oliver MJ, 2007, KIDNEY INT, V71, P673, DOI 10.1038/sj.ki.5002107; Roy M, 2013, CAN GERIATR J, V16, P120, DOI 10.5770/cgj.16.76; Sarnak MJ, 2013, NEUROLOGY, V80, P471, DOI 10.1212/WNL.0b013e31827f0f7f; Sehgal AR, 1997, AM J KIDNEY DIS, V30, P41, DOI 10.1016/S0272-6386(97)90563-1; Seidel UK, 2014, KIDNEY INT, V85, P693, DOI 10.1038/ki.2013.366; Shavit L, 2014, CLIN NEPHROL, V82, P313, DOI 10.5414/CN108335; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Tamura MK, 2011, CLIN J AM SOC NEPHRO, V6, P248, DOI 10.2215/CJN.02660310; Tamura MK, 2011, KIDNEY INT, V79, P14, DOI 10.1038/ki.2010.336; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Weiner DE, 2011, AM J KIDNEY DIS, V58, P773, DOI 10.1053/j.ajkd.2011.03.034; World Health Organization, 1987, CLIN DESCR DIAGN GUI; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	36	7	7	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2016	11	12							e0166470	10.1371/journal.pone.0166470	http://dx.doi.org/10.1371/journal.pone.0166470			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3TF	27911914	Green Submitted, gold, Green Published			2023-01-03	WOS:000389520600008
J	Song, ZR; Blumenthal, DM				Song, Zirui; Blumenthal, Daniel M.			Expanding Payment Reform in Medicare The Cardiology Episode-Based Payment Model	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERCUTANEOUS CORONARY INTERVENTION		[Song, Zirui; Blumenthal, Daniel M.] Massachusetts Gen Hosp, Dept Med, 55 Fruit St,Bigelow 730, Boston, MA 02114 USA; [Song, Zirui; Blumenthal, Daniel M.] Harvard Med Sch, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Song, ZR (corresponding author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,Bigelow 730, Boston, MA 02114 USA.	zirui_song@post.harvard.edu			NIA NIH HHS [F30 AG039175] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [F30AG039175] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aragam KG, 2015, J AM COLL CARDIOL, V65, P2079, DOI 10.1016/j.jacc.2015.02.063; Centers for Medicare & Medicaid Services, 2016, READM DEATHS NAT; Fanning JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004815.pub4; Jha AK., 2016, JAMA FORUM      0804; Joynt KE, 2012, JAMA-J AM MED ASSOC, V308, P1460, DOI 10.1001/jama.2012.12922; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Newhouse JP, 2013, JAMA-J AM MED ASSOC, V310, P1227, DOI 10.1001/jama.2013.278139	7	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2016	316	19					1973	1974		10.1001/jama.2016.16146	http://dx.doi.org/10.1001/jama.2016.16146			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB8XC	27838725				2023-01-03	WOS:000387673800011
J	Wahlster, L; Daley, GQ				Wahlster, Lara; Daley, George Q.			Progress towards generation of human haematopoietic stem cells	NATURE CELL BIOLOGY			English	Article							RED-BLOOD-CELLS; ADULT HUMAN FIBROBLASTS; LARGE-SCALE PRODUCTION; DE-NOVO GENERATION; EX-VIVO EXPANSION; IN-VITRO; FATE CONVERSION; YOLK-SAC; DIFFERENTIATION; INDUCTION	De novo generation of haematopoietic stem cells from different human pluripotent stem cell sources remains a high priority for haematology and regenerative medicine. At present, efficient derivation of functional haematopoietic stem cells with the capability for definitive in vivo engraftment and multi-lineage potential remains challenging. Here, we discuss recent progress and strategies to overcome obstacles that have thwarted past efforts. In addition, we review promising advances in the generation of mature blood lineages and the potential of induced pluripotent stem cells.	[Wahlster, Lara; Daley, George Q.] Childrens Hosp Boston, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA; [Wahlster, Lara; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Wahlster, Lara; Daley, George Q.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Wahlster, Lara; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA; [Wahlster, Lara] Heidelberg Univ, Dept Gen Pediat, Univ Heidelberg Hosp, D-69120 Heidelberg, Germany	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Ruprecht Karls University Heidelberg	Daley, GQ (corresponding author), Childrens Hosp Boston, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA.; Daley, GQ (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.; Daley, GQ (corresponding author), Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.; Daley, GQ (corresponding author), Harvard Stem Cell Inst, Boston, MA 02115 USA.	George.Daley@childrens.harvard.edu			Young Investigator Award Program at Heidelberg University	Young Investigator Award Program at Heidelberg University	L.W. is supported by the Young Investigator Award Program at Heidelberg University. The authors thank D. Ebrahimi-Fakhari, A. Saffari, M. Cesana, S. Doulatov, R. Sugimura and L. Vo for helpful discussions.	Adamo L, 2009, NATURE, V459, P1131, DOI 10.1038/nature08073; Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792; Alvarez-Dominguez JR, 2014, INT J HEMATOL, V99, P531, DOI 10.1007/s12185-014-1552-8; Amabile G, 2013, BLOOD, V121, P1255, DOI 10.1182/blood-2012-06-434407; Batta K, 2014, CELL REP, V9, P1871, DOI 10.1016/j.celrep.2014.11.002; Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764; Cahan P, 2014, CELL, V158, P903, DOI 10.1016/j.cell.2014.07.020; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Chang CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025761; Choi KD, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2010.184; Choi KD, 2009, J CLIN INVEST, V119, P2818, DOI 10.1172/JCI38591; Clarke RL, 2015, STEM CELL REP, V5, P291, DOI 10.1016/j.stemcr.2015.07.008; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Daniel MG, 2016, TRENDS CELL BIOL, V26, P202, DOI 10.1016/j.tcb.2015.10.002; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dias J, 2011, STEM CELLS DEV, V20, P1639, DOI 10.1089/scd.2011.0078; Diaz MF, 2015, J EXP MED, V212, P665, DOI 10.1084/jem.20142235; Ditadi A, 2015, NAT CELL BIOL, V17, P580, DOI 10.1038/ncb3161; Doulatov S, 2013, CELL STEM CELL, V13, P459, DOI 10.1016/j.stem.2013.09.002; Ebina W, 2015, EMBO J, V34, P694, DOI 10.15252/embj.201490804; Eilken HM, 2009, NATURE, V457, P896, DOI 10.1038/nature07760; Elcheva I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5372; Ema H, 2005, DEV CELL, V8, P907, DOI 10.1016/j.devcel.2005.03.019; Fares I, 2014, SCIENCE, V345, P1509, DOI 10.1126/science.1256337; Gao YD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7328; Giani FC, 2016, CELL STEM CELL, V18, P73, DOI 10.1016/j.stem.2015.09.015; Giarratana MC, 2011, BLOOD, V118, P5071, DOI 10.1182/blood-2011-06-362038; Gori JL, 2015, J CLIN INVEST, V125, P1243, DOI 10.1172/JCI79328; Gragert L, 2014, NEW ENGL J MED, V371, P339, DOI 10.1056/NEJMsa1311707; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302; Jeong M, 2014, NAT GENET, V46, P17, DOI 10.1038/ng.2836; Kardel MD, 2012, EXP HEMATOL, V40, P601, DOI 10.1016/j.exphem.2012.04.001; Kaufman DS, 2009, BLOOD, V114, P3513, DOI 10.1182/blood-2009-03-191304; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kennedy M, 2012, CELL REP, V2, P1722, DOI 10.1016/j.celrep.2012.11.003; Kim PG, 2015, J EXP MED, V212, P633, DOI 10.1084/jem.20141514; Kobari L, 2012, HAEMATOL-HEMATOL J, V97, P1795, DOI 10.3324/haematol.2011.055566; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lachmann N, 2015, STEM CELL REP, V4, P282, DOI 10.1016/j.stemcr.2015.01.005; Ledran MH, 2008, CELL STEM CELL, V3, P85, DOI 10.1016/j.stem.2008.06.001; Lee HY, 2015, NATURE, V522, P474, DOI 10.1038/nature14326; Lee HJ, 2013, DIFFERENTIATION, V86, P92, DOI 10.1016/j.diff.2013.06.004; Liu YF, 2015, STEM CELL TRANSL MED, V4, P309, DOI 10.5966/sctm.2014-0183; Lu SJ, 2011, CELL RES, V21, P530, DOI 10.1038/cr.2011.8; Matsuoka S, 2001, BLOOD, V98, P6, DOI 10.1182/blood.V98.1.6; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Migliaccio AR, 2012, CELL STEM CELL, V10, P115, DOI 10.1016/j.stem.2012.01.001; Mitchell R, 2014, STEM CELLS, V32, P2178, DOI 10.1002/stem.1721; Morris SA, 2014, CELL, V158, P889, DOI 10.1016/j.cell.2014.07.021; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Nakamura S, 2014, CELL STEM CELL, V14, P535, DOI 10.1016/j.stem.2014.01.011; Nimmo R, 2013, DEV CELL, V26, P237, DOI 10.1016/j.devcel.2013.06.023; North TE, 2009, CELL, V137, P736, DOI 10.1016/j.cell.2009.04.023; O'Connell RM, 2015, BLOOD, V125, P2180, DOI 10.1182/blood-2015-02-626424; Olivier EN, 2006, EXP HEMATOL, V34, P1635, DOI 10.1016/j.exphem.2006.07.003; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pereira CF, 2013, CELL STEM CELL, V13, P205, DOI 10.1016/j.stem.2013.05.024; Pick M, 2007, STEM CELLS, V25, P2206, DOI 10.1634/stemcells.2006-0713; Pulecio J, 2014, STEM CELLS, V32, P2923, DOI 10.1002/stem.1800; Qu Q, 2016, CYTOTHERAPY, V18, P452, DOI 10.1016/j.jcyt.2015.12.005; Riddell J, 2014, CELL, V157, P549, DOI 10.1016/j.cell.2014.04.006; Rousseau GF, 2014, BIOTECHNOL J, V9, P28, DOI 10.1002/biot.201200368; Roy L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004959; Sandler VM, 2014, NATURE, V511, P312, DOI 10.1038/nature13547; Sandler VM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018265; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shi JH, 2014, P NATL ACAD SCI USA, V111, P10131, DOI 10.1073/pnas.1409861111; Slukvin II, 2013, BLOOD, V122, P4035, DOI 10.1182/blood-2013-07-474825; Smith MJ, 2015, STEM CELLS, V33, P3174, DOI 10.1002/stem.2115; Souilhol C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10784; Sturgeon CM, 2014, NAT BIOTECHNOL, V32, P554, DOI 10.1038/nbt.2915; Suzuki N, 2013, MOL THER, V21, P1424, DOI 10.1038/mt.2013.71; Szabo E, 2010, NATURE, V468, P521, DOI 10.1038/nature09591; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takayama N, 2008, BLOOD, V111, P5298, DOI 10.1182/blood-2007-10-117622; Themeli M, 2015, CELL STEM CELL, V16, P357, DOI 10.1016/j.stem.2015.03.011; Themeli M, 2013, NAT BIOTECHNOL, V31, P928, DOI 10.1038/nbt.2678; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Timmermans F, 2009, J IMMUNOL, V182, P6879, DOI 10.4049/jimmunol.0803670; Torisawa YS, 2014, NAT METHODS, V11, P663, DOI [10.1038/NMETH.2938, 10.1038/nmeth.2938]; Vo LT, 2015, BLOOD, V125, P2641, DOI 10.1182/blood-2014-10-570234; Walasek MA, 2012, ANN NY ACAD SCI, V1266, P138, DOI 10.1111/j.1749-6632.2012.06549.x; Wang LS, 2005, J EXP MED, V201, P1603, DOI 10.1084/jem.20041888; Zhang NY, 2016, BLOOD, V127, P675, DOI 10.1182/blood-2015-10-675751	87	54	55	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2016	18	11					1111	1117		10.1038/ncb3419	http://dx.doi.org/10.1038/ncb3419			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	EB2CV	27723718				2023-01-03	WOS:000387165600001
J	Bateni, SB; Meyers, FJ; Bold, RJ; Canter, RJ				Bateni, Sarah B.; Meyers, Frederick J.; Bold, Richard J.; Canter, Robert J.			Increased Rates of Prolonged Length of Stay, Readmissions, and Discharge to Care Facilities among Postoperative Patients with Disseminated Malignancy: Implications for Clinical Practice	PLOS ONE			English	Article							COLORECTAL-CANCER-SURGERY; BOWEL OBSTRUCTION; LIVER METASTASES; QUALITY; LIFE; MORTALITY; OUTCOMES; END; RESECTION; CARCINOMATOSIS	Background The impact of surgery on end of life care for patients with disseminated malignancy (DMa) is incompletely characterized. The purpose of this study was to evaluate postoperative outcomes impacting quality of care among DMa patients, specifically prolonged length of hospital stay, readmission, and disposition. Methods The American College of Surgeons National Surgical Quality Improvement Program (ACSNSQIP) database was queried for years 2011-2012. DMa patients were matched to nonDMa patients with comparable clinical characteristics and operation types. Primary hepatic operations were excluded, leaving a final cohort of 17,972 DMa patients. The primary outcomes were analyzed using multivariate Cox regression models. Results DMa patients represented 2.1% of all ACS-NSQIP procedures during the study period. The most frequent operations were bowel resections (25.3%). Compared to non-DMa matched controls, DMa patients had higher rates of postoperative overall morbidity (24.4% vs. 18.7%, p<0.001), serious morbidity (14.9% vs. 12.0%, p<0.001), mortality (7.6% vs. 2.5%, p<0.001), prolonged length of stay (32.2% vs. 19.8%, p<0.001), readmission (15.7% vs. 9.6%, p<0.001), and discharges to facilities (16.2% vs. 12.9%, p<0.001). Subgroup analyses of patients by procedure type showed similar results. Importantly, DMa patients who did not experience any postoperative complication experienced significantly higher rates of prolonged length of stay (23.0% vs. 11.8%, p<0.001), readmissions (10.0% vs. 5.2%, p<0.001), discharges to a facility (13.2% vs. 9.5%, p<0.001), and 30-day mortality (4.7% vs. 0.8%, p<0.001) compared to matched non-DMa patients. Conclusion Surgical interventions among DMa patients are associated with poorer postoperative outcomes including greater postoperative complications, prolonged length of hospital stay, readmissions, disposition to facilities, and death compared to non- DMa patients. These data reinforce the importance of clarifying goals of care for DMa patients, especially when acute changes in health status potentially requiring surgery occur.	[Bateni, Sarah B.; Bold, Richard J.; Canter, Robert J.] Univ Calif Sacramento, Davis Med Ctr, Dept Surg, Div Surg Oncol, Sacramento, CA 95819 USA; [Meyers, Frederick J.] Univ Calif Sacramento, Davis Med Ctr, Dept Internal Med, Hematol Oncol, Sacramento, CA USA	California State University System; California State University Sacramento; California State University System; California State University Sacramento	Bateni, SB; Canter, RJ (corresponding author), Univ Calif Sacramento, Davis Med Ctr, Dept Surg, Div Surg Oncol, Sacramento, CA 95819 USA.	sbbateni@ucdavis.edu; rjcanter@ucdavis.edu						Adam R, 2006, ANN SURG, V244, P524, DOI 10.1097/01.sla.0000239036.46827.5f; Al-Refaie WB, 2011, ANN SURG, V253, P947, DOI 10.1097/SLA.0b013e318216f56e; Al-Refaie WB, 2010, ANN SURG, V251, P311, DOI 10.1097/SLA.0b013e3181b6b04c; Alese OB, 2015, CANCER-AM CANCER SOC, V121, P1772, DOI 10.1002/cncr.29297; Aloia TA, 2006, ARCH SURG-CHICAGO, V141, P460, DOI 10.1001/archsurg.141.5.460; American College of Surgeons, 2013, US GUID 2012 ACS NSQ; Bateni SB, 2015, J SURG RES, V197, P118, DOI 10.1016/j.jss.2015.03.063; Blair SL, 2001, ANN SURG ONCOL, V8, P632, DOI 10.1007/s10434-001-0632-1; Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Feuer DJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002764; Francescutti V, 2013, ANN SURG ONCOL, V20, P707, DOI 10.1245/s10434-012-2662-2; Gregg JR, 2011, J UROLOGY, V185, P90, DOI 10.1016/j.juro.2010.09.021; Henry JC, 2012, SURGERY, V152, P747, DOI 10.1016/j.surg.2012.07.009; Hui D, 2014, CANCER-AM CANCER SOC, V120, P1743, DOI 10.1002/cncr.28628; McCahill LE, 2003, ANN SURG ONCOL, V10, P654, DOI 10.1245/ASO.2003.06.011; Miner TJ, 2004, ANN SURG, V240, P719, DOI 10.1097/01.sla.0000141707.09312.dd; Olson TJP, 2014, JAMA SURG, V149, P383, DOI 10.1001/jamasurg.2013.4059; Reisinger KW, 2015, ANN SURG, V261, P345, DOI 10.1097/SLA.0000000000000628; Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031; Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; Tseng WH, 2011, ANN SURG, V254, P333, DOI 10.1097/SLA.0b013e31822513ed; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863; Zhang BH, 2012, ARCH INTERN MED, V172, P1133, DOI 10.1001/archinternmed.2012.2364	27	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0165315	10.1371/journal.pone.0165315	http://dx.doi.org/10.1371/journal.pone.0165315			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED7LQ	27780274	Green Published, gold, Green Submitted			2023-01-03	WOS:000389046900045
J	Lei, Z; Chen, XD; Mercade-Prieto, R				Lei, Zhao; Chen, Xiao Dong; Mercade-Prieto, Ruben			Effect of N-Ethylmaleimide as a Blocker of Disulfide Crosslinks Formation on the Alkali-Cold Gelation of Whey Proteins	PLOS ONE			English	Article							BETA-LACTOGLOBULIN GELS; GELLING PROPERTIES; PH; DISSOLUTION; AGGREGATION; ENVIRONMENT; CYSTEINE; BONDS; SIZE	N-ethylmaleimide (NEM) was used to verify that no new disulfide crosslinks were formed during the fascinating rheology of the alkali cold-gelation of whey proteins, which show Sol-Gel-Sol transitions with time at pH > 11.5. These dynamic transitions involve the formation and subsequent destruction of non-covalent interactions between soluble whey aggregates. Therefore, incubation of aggregates with NEM was expected not to affect much the rheology. Experiments show that very little additions of NEM, such as 0.5 mol per mol of protein, delayed and significantly strengthened the metastable gels formed. Interactions between whey protein aggregates were surprisingly enhanced during incubation with NEM as inferred from oscillatory rheometry at different protein concentrations, dynamic swelling, Trp fluorescence and SDS-PAGE measurements.	[Lei, Zhao; Chen, Xiao Dong; Mercade-Prieto, Ruben] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Sch Chem & Environm Engn, Suzhou Key Lab Green Chem Engn, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China	Mercade-Prieto, R (corresponding author), Soochow Univ, Coll Chem Chem Engn & Mat Sci, Sch Chem & Environm Engn, Suzhou Key Lab Green Chem Engn, Suzhou 215123, Jiangsu, Peoples R China.	ruben@suda.edu.cn	Chen, Xiao Dong/ADG-8612-2022; chen, xia/GXM-5435-2022; chen, xia/GYR-3948-2022	Chen, Xiao Dong/0000-0002-0150-0491; Mercade Prieto, Ruben/0000-0003-0487-7400	Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions; "Jiangsu Specially-Appointed Professors Program" of China; Youth Fund of Natural Science Foundation of Jiangsu Province of China [BK20140343]	Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions; "Jiangsu Specially-Appointed Professors Program" of China; Youth Fund of Natural Science Foundation of Jiangsu Province of China	This work was supported by the project funding from the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions and the "Jiangsu Specially-Appointed Professors Program" of China, and the Youth Fund of Natural Science Foundation of Jiangsu Province of China (no. BK20140343)	Alting AC, 2000, J AGR FOOD CHEM, V48, P5001, DOI 10.1021/jf000474h; Alting AC, 2003, FOOD HYDROCOLLOID, V17, P469, DOI 10.1016/S0268-005X(03)00023-7; Altlng AC, 2003, J AGR FOOD CHEM, V51, P3150, DOI 10.1021/jf0209342; Betz M, 2012, SOFT MATTER, V8, P2477, DOI 10.1039/c2sm06976h; Boye JI, 2004, J DAIRY RES, V71, P207, DOI 10.1017/S0022029904000184; BREWER CF, 1967, ANAL BIOCHEM, V18, P248, DOI 10.1016/0003-2697(67)90007-3; Carrotta R, 2001, PROTEIN SCI, V10, P1312, DOI 10.1110/ps.42501; Chihi ML, 2016, J AGR FOOD CHEM, V64, P2780, DOI 10.1021/acs.jafc.6b00087; Collini M, 2000, PROTEIN SCI, V9, P1968, DOI 10.1110/ps.9.10.1968; Creamer LK, 2004, J AGR FOOD CHEM, V52, P7660, DOI 10.1021/jf049388y; Delahaije RJBM, 2016, J AGR FOOD CHEM, V64, P4362, DOI 10.1021/acs.jafc.6b00816; Dissanayake M, 2010, J AGR FOOD CHEM, V58, P6825, DOI 10.1021/jf1009796; Foegeding EA, 2002, TRENDS FOOD SCI TECH, V13, P151, DOI 10.1016/S0924-2244(02)00111-5; Gosal WS, 2004, BIOMACROMOLECULES, V5, P2420, DOI 10.1021/bm049660c; Havea P, 2009, J AGR FOOD CHEM, V57, P1506, DOI 10.1021/jf802559z; Hua YF, 2005, FOOD RES INT, V38, P377, DOI 10.1016/j.foodres.2004.10.006; Kaneko R, 1999, J AGR FOOD CHEM, V47, P4950, DOI 10.1021/jf990267l; Kitabatake N, 2001, J AGR FOOD CHEM, V49, P4011, DOI 10.1021/jf001380a; Lei Z, 2016, RHEOL ACTA IN PRESS; Mercade-Prieto R, 2007, FOOD HYDROCOLLOID, V21, P1275, DOI 10.1016/j.foodhyd.2006.09.015; Mercade-Prieto R, 2007, BIOMACROMOLECULES, V8, P1162, DOI 10.1021/bm061100l; Mercade-Prieto R, 2007, BIOMACROMOLECULES, V8, P469, DOI 10.1021/bm060553n; Mercade-Prieto R, 2006, J AGR FOOD CHEM, V54, P5437, DOI 10.1021/jf0605650; Mercade-Prieto R, 2009, LANGMUIR, V25, P5793, DOI 10.1021/la804094n; Mercade-Prieto R, 2009, LANGMUIR, V25, P5785, DOI 10.1021/la804093d; Mercade-Prieto R, 2009, FOOD HYDROCOLLOID, V23, P1587, DOI 10.1016/j.foodhyd.2008.11.007; Nicolai T, 2011, FOOD HYDROCOLLOID, V25, P1945, DOI 10.1016/j.foodhyd.2011.02.006; Purwanti N, 2011, FOOD HYDROCOLLOID, V25, P1482, DOI 10.1016/j.foodhyd.2011.02.027; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Rabiey L, 2009, FOOD HYDROCOLLOID, V23, P973, DOI 10.1016/j.foodhyd.2008.07.009; Renard D, 1998, INT J BIOL MACROMOL, V22, P41, DOI 10.1016/S0141-8130(97)00086-X; Ryan KN, 2013, J FOOD SCI, V78, pR1105, DOI 10.1111/1750-3841.12207; Simons JWFA, 2002, ARCH BIOCHEM BIOPHYS, V406, P143, DOI 10.1016/S0003-9861(02)00429-0; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; Taulier N, 2001, J MOL BIOL, V314, P873, DOI 10.1006/jmbi.2001.5188; Wada R, 2001, J AGR FOOD CHEM, V49, P4971, DOI 10.1021/jf001457v; XIONG YL, 1993, J DAIRY SCI, V76, P70, DOI 10.3168/jds.S0022-0302(93)77324-5; Zhang YH, 2010, FOOD HYDROCOLLOID, V24, P266, DOI 10.1016/j.foodhyd.2009.10.002; Zhu D, 2008, J AGR FOOD CHEM, V56, P7113, DOI 10.1021/jf800909w	39	1	1	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2016	11	10							e0164496	10.1371/journal.pone.0164496	http://dx.doi.org/10.1371/journal.pone.0164496			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CQ	27732644	Green Published, gold, Green Submitted			2023-01-03	WOS:000385505300061
J	de Medeiros, AKA; Speeckaert, R; Desmet, E; Van Gele, M; De Schepper, S; Lambert, J				de Medeiros, Ana Karina Alves; Speeckaert, Reinhart; Desmet, Eline; Van Gele, Mireille; De Schepper, Sofie; Lambert, Jo			JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases	PLOS ONE			English	Article							KINASE INHIBITOR TOFACITINIB; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; ATOPIC-DERMATITIS; LICHEN-PLANUS; PSORIASIS; EXPRESSION; STAT3; KERATINOCYTES; PATHWAY	The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia areata. Patients suffering from other ISDs might also benefit from JAK inhibition. Given the development of specific JAK inhibitors, the expression patterns of JAKs in different ISDs needs to be clarified. We aimed to analyze the expression of JAK/STAT family members in a set of prevalent ISDs: psoriasis, lichen planus (LP), cutaneous lupus erythematosus (CLE), atopic dermatitis (AD), pyoderma gangrenosum (PG) and alopecia areata (AA) versus healthy controls for (p) JAK1, (p) JAK2, (p) JAK3, (p) TYK2, pSTAT1, pSTAT2 and pSTAT3. The epidermis carried in all ISDs, except for CLE, a strong JAK3 signature. The dermal infiltrate showed a more diverse expression pattern. JAK1, JAK2 and JAK3 were significantly overexpressed in PG and AD suggesting the need for pan-JAK inhibitors. In contrast, psoriasis and LP showed only JAK1 and JAK3 upregulation, while AA and CLE were characterized by a single dermal JAK signal (pJAK3 and pJAK1, respectively). This indicates that the latter diseases may benefit from more targeted JAK inhibitors. Our in vitro keratinocyte psoriasis model displayed reversal of the psoriatic JAK profile following tofacitinib treatment. This direct interaction with keratinocytes may decrease the need for deep skin penetration of topical JAK inhibitors in order to exert its effects on dermal immune cells. In conclusion, these results point to the important contribution of the JAK/STAT pathway in several ISDs. Considering the epidermal JAK3 expression levels, great interest should go to the investigation of topical JAK3 inhibitors as therapeutic option of ISDs.	[de Medeiros, Ana Karina Alves; Speeckaert, Reinhart; De Schepper, Sofie; Lambert, Jo] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium; [de Medeiros, Ana Karina Alves; Speeckaert, Reinhart; Desmet, Eline; Van Gele, Mireille; Lambert, Jo] Univ Ghent, Dept Dermatol, Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	de Medeiros, AKA (corresponding author), Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium.; de Medeiros, AKA (corresponding author), Univ Ghent, Dept Dermatol, Ghent, Belgium.	Ana.AlvesdeMedeiros@uzgent.be	Jo, Lambert LW/AAG-4880-2021; Jo, Lambert LW/ABD-3264-2021; Lauschner, Flavia H/P-2457-2018		TGO ("transformationeel geneeskundig onderzoek") (IWT, Belgium) [120829]	TGO ("transformationeel geneeskundig onderzoek") (IWT, Belgium)	This research was funded by a TGO ("transformationeel geneeskundig onderzoek") grant (number 120829, IWT, Belgium).	Andres RM, 2013, EXP DERMATOL, V22, P323, DOI 10.1111/exd.12128; Bachelez H, 2015, LANCET, V386, P552, DOI 10.1016/S0140-6736(14)62113-9; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Bao L, 2012, MOL IMMUNOL, V50, P91, DOI 10.1016/j.molimm.2011.12.008; Bracke S, 2013, ARCH DERMATOL RES, V305, P501, DOI 10.1007/s00403-013-1379-9; Camporeale A, 2012, FRONT BIOSCI-LANDMRK, V17, P2306, DOI 10.2741/4054; Chang BY, 2009, J IMMUNOL, V183, P2183, DOI 10.4049/jimmunol.0804063; Chen L, 2004, CLIN EXP IMMUNOL, V138, P375, DOI 10.1111/j.1365-2249.2004.02649.x; Craiglow BG, 2014, J INVEST DERMATOL, V134, P2988, DOI 10.1038/jid.2014.260; Dawson M a, 2013, EUROPE PMC FUNDERS G, V461, P819; Di TT, 2016, INT IMMUNOPHARMACOL, V32, P32, DOI 10.1016/j.intimp.2015.12.035; Fujii Y, 2013, PHARMACOLOGY, V91, P207, DOI 10.1159/000347184; Gambichler T, 2012, EUR J DERMATOL, V22, P319, DOI 10.1684/ejd.2012.1725; Gamero AM, 2010, CANCER PREV RES, V3, P495, DOI 10.1158/1940-6207.CAPR-09-0105; Ghoreschi K, 2014, EXP DERMATOL, V23, P7, DOI 10.1111/exd.12265; Guttman-Yassky E., 2011, ALLERGY CLIN IMMUNOL, V127, P1420, DOI DOI 10.1016/J.JACI.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Ishizaki M, 2014, INT IMMUNOL, V26, P257, DOI 10.1093/intimm/dxt062; Levy LL, 2015, J AM ACAD DERMATOL, V73, P395, DOI 10.1016/j.jaad.2015.06.045; Li Jie, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P109, DOI 10.3969/j.issn.1672-7347.2011.02.003; Miyoshi K, 2011, J INVEST DERMATOL, V131, P108, DOI 10.1038/jid.2010.255; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Palanivel JA, 2014, CLIN EXP DERMATOL, V39, P513, DOI 10.1111/ced.12273; Payeras MR, 2013, ARCH ORAL BIOL, V58, P1057, DOI 10.1016/j.archoralbio.2013.04.004; Ports WC, 2013, BRIT J DERMATOL, V169, P137, DOI 10.1111/bjd.12266; Punwani N, 2012, J AM ACAD DERMATOL, V67, P658, DOI 10.1016/j.jaad.2011.12.018; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Shaker O, 2012, BRIT J DERMATOL, V166, P1367, DOI 10.1111/j.1365-2133.2011.10793.x; Shi XW, 2011, J INVEST DERMATOL, V131, P2401, DOI 10.1038/jid.2011.222; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Terlou A, 2012, J INVEST DERMATOL, V132, P658, DOI 10.1038/jid.2011.369; van de Kerkhof PCM, 2015, DERMATOL CLIN, V33, P73, DOI 10.1016/j.det.2014.09.006; Villarino AV, 2015, J IMMUNOL, V194, P21, DOI 10.4049/jimmunol.1401867; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Wohlmann A, 2010, BIOL CHEM, V391, P181, DOI [10.1515/BC.2010.029, 10.1515/bc.2010.029]; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Zouein FA, 2011, GROWTH FACTORS, V29, P245, DOI 10.3109/08977194.2011.614949	39	93	100	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2016	11	10							e0164080	10.1371/journal.pone.0164080	http://dx.doi.org/10.1371/journal.pone.0164080			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UR	27711196	Green Published, Green Submitted, gold			2023-01-03	WOS:000385697600074
J	Pool, AC; Kraschnewski, JL; Poger, JM; Smyth, J; Stuckey, HL; Craig, TJ; Lehman, EB; Yang, CW; Sciamanna, CN				Pool, Andrew C.; Kraschnewski, Jennifer L.; Poger, Jennifer M.; Smyth, Joshua; Stuckey, Heather L.; Craig, Timothy J.; Lehman, Erik B.; Yang, Chengwu; Sciamanna, Christopher N.			Impact of online patient reminders to improve asthma care: A randomized controlled trial	PLOS ONE			English	Article							UNITED-STATES; DIABETES-MELLITUS; ADHERENCE; DISEASE; QUALITY; ADULTS; RISK; POPULATION; PREVENTION; MANAGEMENT	Importance Asthma is one of the most burdensome chronic illnesses in the US. Despite widespread dissemination of evidence-based guidelines, more than half of the adults with asthma have uncontrolled symptoms. Objective To examine the efficacy of an online tool designed to improve asthma control. Design 12-month single blind randomized controlled trial of the online tool (Intervention condition, IC) versus an active control tool (CC). Setting Patients enrolled in an insurance plan. Participants Participants were 408 adults (21-60 years of age) with persistent asthma. Intervention At least once each month and before provider visits, participants in the IC answered questions online about their asthma symptoms, asthma medications and asthma care received from providers, such as an asthma management plan. The tool then provided tailored feedback to remind patients 1) to ask health care providers specific questions that may improve asthma control (e.g., additional controller medications) and 2) to consistently perform specific self-care behaviors (e.g., proper inhaler technique). Participants in the CC received similar questions and feedback, yet focused instead on preventive services unrelated to asthma control (e.g., cancer screening). Main outcome measures The main outcome measure was asthma control, as assessed by the 5-question Asthma Control Test (ACT). Secondary outcomes included quality of life, medication use and healthcare utilization (e.g., emergency department visits). Results After 12 months, 323 participants completed follow-up measures (79.2%). Participants in the IC reported a greater mean improvement in the ACT score than participants in the CC (2.3 vs. 1.2; p = 0.02) and 9 of 11 individual asthma control survey items showed non-significant improvements favoring the IC. No differences were observed in medication adherence, number of asthma controller medications or health care utilization. Conclusion and relevance Simple and brief online patient reminders improved asthma control among insured patients. Although future studies are needed to understand the mechanism of the improvement, the magnitude of the effect on asthma control was similar to the addition of an additional controller medication. Given the widespread use of the Internet, simple tools such as this may be useful for improving the control of other chronic diseases as well.	[Pool, Andrew C.] Temple Univ, Coll Hlth Profess & Social Work, Dept Publ Hlth, Philadelphia, PA 19122 USA; [Pool, Andrew C.] Temple Univ, Sch Med, CORE, Philadelphia, PA 19122 USA; [Kraschnewski, Jennifer L.; Poger, Jennifer M.; Stuckey, Heather L.; Craig, Timothy J.; Sciamanna, Christopher N.] Penn State Coll Med, Dept Med, Hershey, PA 17033 USA; [Kraschnewski, Jennifer L.; Craig, Timothy J.] Penn State Coll Med, Dept Pediat, Hershey, PA USA; [Kraschnewski, Jennifer L.; Stuckey, Heather L.; Lehman, Erik B.; Yang, Chengwu; Sciamanna, Christopher N.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA; [Smyth, Joshua] Penn State Univ, Dept Biobehav Hlth, State Coll, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Sciamanna, CN (corresponding author), Penn State Coll Med, Dept Med, Hershey, PA 17033 USA.; Sciamanna, CN (corresponding author), Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA.	csciamanna@hmc.psu.edu	Yang, Chengwu/X-6178-2018	Yang, Chengwu/0000-0003-0561-2340; Poger, Jennifer/0000-0003-3276-805X; Pool, Andrew/0000-0001-7249-6090; Smyth, Joshua/0000-0002-0904-5390	National Heart, Lung, And Blood Institute [R01HL088590]; National Institutes of Health; National Center for Advancing Translational Sciences, NIH [UL1RR033184, KL2RR033180]	National Heart, Lung, And Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences, NIH	The design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication was funded, in part, by grant R01HL088590 from the National Heart, Lung, And Blood Institute (PI, Sciamanna). The preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication was funded, in part, from the National Institutes of Health and by National Center for Advancing Translational Sciences, NIH through Grant UL1RR033184 and KL2RR033180 (PI, Kraschnewski). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Akinbami Lara J, 2012, NCHS Data Brief, P1; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Balkrishnan R, 2003, CLIN THER, V25, P2958, DOI 10.1016/S0149-2918(03)80347-8; Beckman TJ, 2001, DIABETES CARE, V24, P2049, DOI 10.2337/diacare.24.12.2049; Bell RA, 2001, PREV MED, V32, P163, DOI 10.1006/pmed.2000.0785; Broderick JE, 2004, ANN BEHAV MED, V27, P50, DOI 10.1207/s15324796abm2701_7; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; Centers for Disease Control and Prevention, 2012, ASTHM IMP NAT DAT CD; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Elliott WJ, 2007, J AM BOARD FAM MED, V20, P72, DOI 10.3122/jabfm.2007.01.060094; Flay BR, 2004, ARCH PEDIAT ADOL MED, V158, P377, DOI 10.1001/archpedi.158.4.377; Fontana SA, 1997, AM J PUBLIC HEALTH, V87, P1190, DOI 10.2105/AJPH.87.7.1190; Fox S, 2005, DIGITAL DIVISIONS; Fox S, HLTH ONLINE 2013; GIBSON JT, 1988, AM J HOSP PHARM, V45, P337, DOI 10.1093/ajhp/45.2.337; Greenlund KJ, 2005, AM J PREV MED, V29, P81, DOI 10.1016/j.amepre.2005.07.007; Halm EA, 2005, CHEST, V128, P1943, DOI 10.1378/chest.128.4.1943; Halterman JS, 2007, AMBUL PEDIATR, V7, P153, DOI 10.1016/j.ambp.2006.11.007; Hartmann CW, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.1.e3; Hess LM, 2006, ANN PHARMACOTHER, V40, P1280, DOI 10.1345/aph.1H018; Kim C, 2004, AM J PREV MED, V27, P1, DOI 10.1016/j.amepre.2004.03.008; Kravitz RL, 2003, ARCH INTERN MED, V163, P1673, DOI 10.1001/archinte.163.14.1673; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Krishna S, 2003, PEDIATRICS, V111, P503, DOI 10.1542/peds.111.3.503; Lion A, 2003, CHEST, V124, P1781, DOI 10.1378/chest.124.5.1781; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Mularski RA, 2006, CHEST, V130, P1844, DOI 10.1378/chest.130.6.1844; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Heart Lung and Blood Institute National Asthma Educa- tion and Prevention Program, 2007, 3 NAT HEART LUNG BLO; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, J ASTHMA, V44, P341, DOI 10.1080/02770900701344421; Schatz M, 2010, AM J MANAG CARE, V16, pE281; Schonlau M, 2005, ANN FAM MED, V3, P200, DOI 10.1370/afm.269; Sciamanna CN, 2006, HEADACHE, V46, P92, DOI 10.1111/j.1526-4610.2006.00312.x; Sciamanna CN, 2005, AM J MED QUAL, V20, P127, DOI 10.1177/1062860605274518; Slejko JF, 2014, J ALLERGY CLIN IMMUN, V133, P1579, DOI 10.1016/j.jaci.2013.10.028; Smith SK, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5370; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Sullivan PW, 2011, J ALLERGY CLIN IMMUN, V127, P363, DOI 10.1016/j.jaci.2010.10.042; Talreja N, 2011, ANN ALLERG ASTHMA IM, V106, P24, DOI 10.1016/j.anai.2010.10.017; Thiboutot J, 2013, J MED INTERNET RES, V15, P20, DOI 10.2196/jmir.2298; Thiboutot J, 2010, CONTEMP CLIN TRIALS, V31, P634, DOI 10.1016/j.cct.2010.08.012; van der Meer V, 2009, ANN INTERN MED, V151, P110, DOI 10.7326/0003-4819-151-2-200907210-00008; Van Sickle D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055335; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Yasui H, 2012, RESP MED, V106, P508, DOI 10.1016/j.rmed.2011.12.014; Yong PL, 2009, J ALLERGY CLIN IMMUN, V124, P961, DOI 10.1016/j.jaci.2009.07.027; [No title captured], DOI DOI 10.5888/PCD11.130389	52	22	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0170447	10.1371/journal.pone.0170447	http://dx.doi.org/10.1371/journal.pone.0170447			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7DG	28158200	Green Published, Green Submitted, gold			2023-01-03	WOS:000396161700012
J	Barker, I; Steventon, A; Deeny, SR				Barker, Isaac; Steventon, Adam; Deeny, Sarah R.			Association between continuity of care in general practice and hospital admissions for ambulatory care sensitive conditions: cross sectional study of routinely collected, person level data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; INTERPERSONAL CONTINUITY; PATIENT SATISFACTION; QUALITY; IMPACT; VETERANS; OUTCOMES; LENGTH	OBJECTIVE To assess whether continuity of care with a general practitioner is associated with hospital admissions for ambulatory care sensitive conditions for older patients. DESIGN Cross sectional study. SETTING Linked primary and secondary care records from 200 general practices participating in the Clinical Practice Research Datalink in England. PARTICIPANTS 230 472 patients aged between 62 and 82 years and who experienced at least two contacts with a general practitioner between April 2011 and March 2013. MAIN OUTCOME MEASURE Number of hospital admissions for ambulatory care sensitive conditions (those considered manageable in primary care) per patient between April 2011 and March 2013. RESULTS We assessed continuity of care using the usual provider of care index, which we defined as the proportion of contacts occurring between April 2011 and March 2013 that were with the most frequently seen general practitioner. On average, the usual provider of care index score was 0.61. Continuity of care was lower among practices with more doctors (average score 0.59 in large practices versus 0.70 in small practices). Higher continuity of care was associated with fewer admissions for ambulatory care sensitive conditions. When modelled, controlling for demographic and clinical patient characteristics, an increase in the usual provider of care index of 0.2 for all patients would reduce these admissions by 6.22% (95% confidence interval 4.87% to 7.55%). There was greater evidence for an association among patients who were heavy users of primary care. Heavy users also experienced more admissions for ambulatory care sensitive conditions than other patients (0.36 admissions per patient for those with = 18 contacts with a general practitioner, compared with 0.04 admissions per patient for those with 2-4 contacts). CONCLUSIONS Strategies that improve the continuity of care in general practice may reduce secondary care costs, particularly for the heaviest users of healthcare. Promoting continuity might also improve the experience of patients and those working in general practice.	[Barker, Isaac; Steventon, Adam; Deeny, Sarah R.] Hlth Fdn, Data Analyt, London WC2E 9RA, England		Barker, I (corresponding author), Hlth Fdn, Data Analyt, London WC2E 9RA, England.	isaac.barker@health.org.uk						Adler R, 2010, FAM PRACT, V27, P171, DOI 10.1093/fampra/cmp099; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Baird B, 2016, UNDERSTANDING PRESSU; BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Bankart MJG, 2011, EMERG MED J, V28, P558, DOI 10.1136/emj.2010.108548; Bardsley M., 2016, UNDERSTANDING ANAL C; Bardsley M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002007; Barker I, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011422; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; Blecker S, 2014, INT J QUAL HEALTH C, V26, P530, DOI 10.1093/intqhc/mzu065; Campbell JL, 2001, BRIT J GEN PRACT, V51, P644; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Charlton J, 2013, J HEALTH SERV RES PO, V18, P215, DOI 10.1177/1355819613493772; Chen HM, 2017, CLIN NURS RES, V26, P266, DOI 10.1177/1054773815625467; Cheng SH, 2010, ARCH INTERN MED, V170, P1671, DOI 10.1001/archinternmed.2010.340; CLARK WAV, 1976, GEOGR ANAL, V8, P428; Cowling Thomas E, 2013, PLoS One, V8, pe66699, DOI 10.1371/journal.pone.0066699; Department of Health, 2014, TRANSF PRIM CAR; Edes T, 2014, J AM GERIATR SOC, V62, P1954, DOI 10.1111/jgs.13030; Freeman GK, 2003, FAM PRACT, V20, P623, DOI 10.1093/fampra/cmg601; Gunther S, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-11; Guthrie Bruce, 2006, BMC Fam Pract, V7, P11, DOI 10.1186/1471-2296-7-11; HENDERSON C, 2013, BMJ-BRIT MED J, V346, DOI DOI 10.1136/BMJ.F1035; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; Hibbard JH, 2007, HEALTH SERV RES, V42, P1443, DOI 10.1111/j.1475-6773.2006.00669.x; Hilbe J.M, 2011, NEGATIVE BINOMIAL RE, DOI [10.1017/cbo9780511973420, DOI 10.1017/CBO9780511973420, 10.1017/CBO9780511973420]; Huntley A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004746; Institute of Medicine, 2001, CROSSING THE QUALITY; Ionescu-Ittu R, 2007, CAN MED ASSOC J, V177, P1362, DOI 10.1503/cmaj.061615; Ipsos MORI, 2015, GP PAT SURV NAT SUMM; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; KASSLER WJ, 1991, ACAD MED, V66, P41, DOI 10.1097/00001888-199101000-00012; Katz DA, 2015, J AM GERIATR SOC, V63, P2510, DOI 10.1111/jgs.13841; Ladapo JA, 2014, HLTH AFFAIRS BLOG; Lin W, 2010, INT J QUAL HEALTH C, V22, P3, DOI 10.1093/intqhc/mzp059; Lloyd T, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2450; Marshall M, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5698; National Survey of GPs, 2015, NAT SURV GPS FUT GEN; NHS England, 5 YEAR FORW VIEW; Office for National Statistics, 2010, ATL DEPR 2010; Osborn R, 2015, HEALTH AFFAIR, V34, P2104, DOI 10.1377/hlthaff.2015.1018; Poteliakhoff CRLLSE, 2012, CONTINUITY CARE OLDE, P1; Reddy A, 2015, JAMA INTERN MED, V175, P1157, DOI 10.1001/jamainternmed.2015.1853; Ridd MJ, 2015, BRIT J GEN PRACT, V65, pE305, DOI 10.3399/bjgp15X684829; Roland M, 2012, INT J INTEGR CARE, V12; Roland M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6017; Rosenblatt RA, 2000, AM J PUBLIC HEALTH, V90, P97, DOI 10.2105/AJPH.90.1.97; Royal College of General Practitioners, 2012, RCGP CONT CAR TOOLK; Royal College of General Practitioners, 2016, CONT CAR GEN PRACT; Salisbury C, 2009, BRIT J GEN PRACT, V59, P276, DOI 10.3399/bjgp09X420257; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Stroup WW., 2012, GEN LINEAR MIXED MOD; Tian, 2012, DATA BRIEFING EMERGE; Tsai HY, 2015, INT J PUBLIC HEALTH, V60, P505, DOI 10.1007/s00038-015-0671-1; Whittington JW, 2015, MILBANK Q, V93, P263, DOI 10.1111/1468-0009.12122	58	191	195	0	42	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	2017	356								j84	10.1136/bmj.j84	http://dx.doi.org/10.1136/bmj.j84			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EJ8BQ	28148478	hybrid, Green Submitted			2023-01-03	WOS:000393449800014
J	Sharma, J; Leslie, HH; Kundu, F; Kruk, ME				Sharma, Jigyasa; Leslie, Hannah H.; Kundu, Francis; Kruk, Margaret E.			Poor Quality for Poor Women? Inequities in the Quality of Antenatal and Delivery Care in Kenya	PLOS ONE			English	Article							UNIVERSAL HEALTH COVERAGE; OF-CARE; NEWBORN HEALTH; MEDICAL-CARE; INTERVENTIONS; AFRICA; INDIA	Background Quality of healthcare is an important determinant of future progress in global health. However, the distributional aspects of quality of care have received inadequate attention. We assessed whether high quality maternal care is equitably distributed by (1) mapping the quality of maternal care in facilities located in poorer versus wealthier areas of Kenya; and (2) comparing the quality of maternal care available to Kenyans in and not in poverty. Methods We assessed three measures of maternal care quality: facility infrastructure and clinical quality of antenatal care and delivery care, using indicators from the 2010 Kenya Service Provision Assessment (SPA), a standardized facility survey with direct observation of maternal care provision. We calculated poverty of the area served by antenatal or delivery care facilities using the Multidimensional Poverty Index. We used regression analyses and nonparametric tests to assess differences in maternal care quality in facilities located in more and less impoverished areas. We estimated effective coverage with a minimum standard of care for the full population and those in poverty. Results A total of 564 facilities offering at least one maternal care service were included in this analysis. Quality of maternal care was low, particularly clinical quality of antenatal and delivery care, which averaged 0.52 and 0.58 out of 1 respectively, compared to 0.68 for structural inputs to care. Maternal healthcare quality varied by poverty level: at the facility level, all quality metrics were lowest for the most impoverished areas and increased significantly with greater wealth. Population access to a minimum standard (>= 0.75 of 1.00) of quality maternal care was both low and inequitable: only 17% of all women and 8% of impoverished women had access to minimally adequate delivery care. Conclusion The quality of maternal care is low in Kenya, and care available to the impoverished is significantly worse than that for the better off. To achieve the national targets of maternal and neonatal mortality reduction, policy initiatives need to tackle low quality of care, starting with high-poverty areas.	[Sharma, Jigyasa; Leslie, Hannah H.; Kruk, Margaret E.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Kundu, Francis] Natl Council Populat & Dev, Nairobi, Kenya	Harvard University; Harvard T.H. Chan School of Public Health	Sharma, J (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	jigyasa.sharma@mail.harvard.edu	Kruk, Margaret E/E-3058-2010	Kruk, Margaret E/0000-0002-9549-8432; Leslie, Hannah Hogan/0000-0002-7464-3645; Sharma, Jigyasa/0000-0001-8860-0710				[Anonymous], 2014, COUNTIES HIGHEST BUR; Barber SL, 2007, HEALTH AFFAIR, V26, pW352, DOI 10.1377/hlthaff.26.3.w352; Barber SL, 2007, HEALTH AFFAIR, V26, pW310, DOI 10.1377/hlthaff.26.3.w310; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Board on Global Health Institute of Medicine The National Academies of Sciences Engineering and Medicine., 2015, REV EV DIFF QUAL IMP; Das J, 2007, HEALTH AFFAIR, V26, pW338, DOI 10.1377/hlthaff.26.3.w338; Das J, 2014, ANNU REV ECON, V6, P525, DOI 10.1146/annurev-economics-080213-041350; Das J, 2012, HEALTH AFFAIR, V31, P2774, DOI 10.1377/hlthaff.2011.1356; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Hansen PM, 2008, INT J QUAL HEALTH C, V20, P375, DOI 10.1093/intqhc/mzn039; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HerediaPi IB, 2016, B WHO, V94; Institute of Medicine, 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Jha AK, 2013, BMJ QUAL SAF, V22, P809, DOI 10.1136/bmjqs-2012-001748; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Kruk ME, 2016, LANCET GLOB HEALTH, V4, pE594, DOI 10.1016/S2214-109X(16)30131-0; Kruk ME, 2014, B WORLD HEALTH ORGAN, V92, P246, DOI 10.2471/BLT.13.126417; Kruk ME, 2016, LANCET GLOBAL HLTH; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Lee E, 2016, HLTH POLICY PLANNING; Leslie HH, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002151; Leslie HH, 2016, HEALTH AFFAIR, V35, P1716, DOI 10.1377/hlthaff.2016.0261; Maru DSR, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-41; Ministry of Health, 2014, KEN HLTH POL 2014 20; Nesbitt RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081089; Reidpath DD, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000062; Rosen HE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0728-4; SDJS-UN, 2015, 2030 AG SUST DEV; Sobel HL, 2016, HEALTH POLICY PLANN, V31, P547, DOI 10.1093/heapol/czv095; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Stevens FR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0107042; Tangcharoensathien V, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0342-3; Tatem A, 2014, FINAL REPORT DEV HIG; The Partnership for Maternal Newborn and Child Health, 2006, OPP AFR NEWB; Tripathi V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129491; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; Wirth Meg, 2008, East Afr J Public Health, V5, P133; World Bank, 2014, WORLD DEV IND 2014; World Health Organization, 2015, GLOB OBS DAT REP; World Health Organization, 2016, MAT CHILD HLTH; World Health Organization, 2016, NEON CHILD HLTH PROF	42	58	58	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2017	12	1							e0171236	10.1371/journal.pone.0171236	http://dx.doi.org/10.1371/journal.pone.0171236			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN6QW	28141840	Green Submitted, gold, Green Published			2023-01-03	WOS:000396129500051
J	Onarheim, KH; Lander, F; Rasmussen, AR; Adamjee, R; Akyea, RK; Barber, MJ; Browne, J; Cubahiro, N; Jarvis, JD; Li, SWS; Mishra, SR; Nasab, MA; Omobo, O; Ramachandran, R; Sharma, A; Walker, A				Onarheim, Kristine Husoy; Lander, Fiona; Rasmussen, Anna Roe; Adamjee, Rehan; Akyea, Ralph Kwame; Barber, Melissa J.; Browne, Jorge; Cubahiro, Nobel; Jarvis, Jordan D.; Li, Sam Wing Sum; Mishra, Shiva Raj; Nasab, Motahareh Akhoondi; Omobo, Oluwaseun; Ramachandran, Reshma; Sharma, Abhishek; Walker, Alex		Youth Commission Essential Med	Youth demand action on the shared global challenge of access to medicines	LANCET			English	Editorial Material									[Onarheim, Kristine Husoy; Lander, Fiona; Rasmussen, Anna Roe; Adamjee, Rehan; Akyea, Ralph Kwame; Barber, Melissa J.; Browne, Jorge; Cubahiro, Nobel; Jarvis, Jordan D.; Li, Sam Wing Sum; Mishra, Shiva Raj; Nasab, Motahareh Akhoondi; Omobo, Oluwaseun; Ramachandran, Reshma; Sharma, Abhishek; Walker, Alex; Youth Commission Essential Med] Univ Bergen, POB 7800, N-5020 Bergen, Norway	University of Bergen	Onarheim, KH (corresponding author), Univ Bergen, POB 7800, N-5020 Bergen, Norway.	Kristine.Onarheim@uib.no	Akyea, Ralph Kwame/ABP-5358-2022; Akyea, Ralph Kwame/K-4979-2019; Mishra, Shiva Raj/C-4172-2014	Akyea, Ralph Kwame/0000-0003-4529-8237; Akyea, Ralph Kwame/0000-0003-4529-8237; Mishra, Shiva Raj/0000-0002-2993-3504; Li, Wing Sum/0000-0002-3502-6839	Swedish International Development Cooperation Agency; Johns Hopkins University; Robert Wood Johnson Foundation; Norwegian Forum for Global Health Research; Norwegian Agency for Development Cooperation; University of Bergen	Swedish International Development Cooperation Agency; Johns Hopkins University(Johns Hopkins University); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Norwegian Forum for Global Health Research; Norwegian Agency for Development Cooperation; University of Bergen	We declare no competing interests. The Youth Commission on Essential Medicines Policies was initiated by members of the student organisation Universities Allied for Essential Medicines. Of the members of the Youth Commission on Essential Medicines Policies, JDJ is employed at the Young Professionals Chronic Disease Network, a US non-for-profit organisation; OO worked as a consultant for WHO and for the Nigerian National Agency for Food and Drug Administration and Control; and RR received funding from the Swedish International Development Cooperation Agency, Johns Hopkins University, and the Robert Wood Johnson Foundation (pending) through her work at the IDEA initiative. We thank the Norwegian Forum for Global Health Research, the Norwegian Agency for Development Cooperation, and the University of Bergen for funding the Youth Commission on Essential Medicines Policies. The funders had no role in preparation of this Comment. We thank Dilyara Nurkhametova for her contributions to the Youth Commission on Essential Medicines Policies and extend our thanks to our secretariat, Johanne Iversen and Arwin Timmermans.	Consultative Expert Working Group on Research and Development Financing and Coordination, 2012, RES DEV MEET HLTH NE; Gotham D, 2016, LANCET GLOB HEALTH, V4, pE296, DOI 10.1016/S2214-109X(16)00066-8; Iyengar S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002032; Mishra SR, 2016, LANCET DIABETES ENDO, V4, P733, DOI 10.1016/S2213-8587(16)30153-X; UN Secretary-General and Co-Chairs of the High-Level Panel, 2016, UN SECR GEN HIGH LEV; Wirtz VJ, 2016, LANCET; Youth Commission on Essential Medicines Policies, 2016, REAL ACC ESS MED ALL	7	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2017	389	10067					345	347		10.1016/S0140-6736(16)31906-7	http://dx.doi.org/10.1016/S0140-6736(16)31906-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EI9CK	27832873				2023-01-03	WOS:000392804700011
J	Le Roux, E; Gottot, S; Aupiais, C; Girard, T; Teixeira, M; Alberti, C				Le Roux, Enora; Gottot, Serge; Aupiais, Camille; Girard, Thomas; Teixeira, Maria; Alberti, Corinne			Professional's Perspectives on Care Management of Young People with Perinatally Acquired HIV during Transition: A Qualitative Study in Adult Care Setting	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE; ADOLESCENTS; MEDICINE; NETWORK; PREVALENCE; CHALLENGES	Background Increasing numbers of young people with perinatally acquired HIV are surviving to adulthood. When they come of age, they leave pediatric services in which they were followed and have to be transferred to the adult health care system. Difficulties in adaptation to adult care and the numbers of young people lost to follow up after transfer to adult care have been reported. This transition phase and their retention in adult care are crucial in maintaining the clinical status of these young with HIV in adulthood. Our study aimed to explore how HIV professionals working in adult care perceive and adapt their practices to young people in transition. Methods Qualitative interviews were conducted with 18 health and social services professionals in hospitals or patient associations in France. A thematic analysis was conducted. Results Adult care professionals were found to be making a distinction between these young people and their patients who were infected during adulthood. On the basis of the health-care teams' experience, a simplified categorization of these young people into four levels can be used: those "who have everything good"; those who have some deficiencies that must be addressed; those "who have everything bad"; and those lost to follow up. Professionals interviewed highlighted the difficulties they encountered with young people in transition. Three types of problematic situations were identified: problems of acceptance of the disease; communication problems; and problems of disorientation in the new care environment. Conclusions Despite the lack of specific training or national policy recommendations for the integration of young people with perinatally acquired HIV into adult services, all the adult healthcare teams interviewed tried to adapt their practice to this population. The results suggested that professional involvement during transition should depend on the characteristics of the patient, not be limited to a single transition model and that a dedicated structure for transition care is not appropriate for all young people.	[Le Roux, Enora; Gottot, Serge; Aupiais, Camille; Teixeira, Maria; Alberti, Corinne] Univ Paris Diderot, Sorbonne Paris Cite, ECEVE, UMRS 1123, Paris, France; [Le Roux, Enora; Gottot, Serge; Aupiais, Camille; Teixeira, Maria; Alberti, Corinne] INSERM, ECEVE U1123, Paris, France; [Le Roux, Enora; Gottot, Serge; Aupiais, Camille; Teixeira, Maria; Alberti, Corinne] CIC EC, CIC 1426, Paris, France; [Gottot, Serge; Aupiais, Camille; Teixeira, Maria; Alberti, Corinne] Hop Robert Debre, AP HP, Unite Epidemiol Clin, Paris, France; [Girard, Thomas] Hop Hotel Dieu, AP HP, Unite Guy Mocquet, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Le Roux, E (corresponding author), Univ Paris Diderot, Sorbonne Paris Cite, ECEVE, UMRS 1123, Paris, France.; Le Roux, E (corresponding author), INSERM, ECEVE U1123, Paris, France.; Le Roux, E (corresponding author), CIC EC, CIC 1426, Paris, France.	enora.le-roux@inserm.fr	Le Roux, Enora/AAN-8370-2020; aupiais, camille/J-8386-2019	aupiais, camille/0000-0001-7482-0405	Roche Foundation to our institution [2014RDB010]; French Ministry of Health (PREPS); UPMC Universite Paris 6 Sorbonne Paris Cite	Roche Foundation to our institution; French Ministry of Health (PREPS); UPMC Universite Paris 6 Sorbonne Paris Cite	This study was funded by a grant from the Roche Foundation to our institution (contract number 2014RDB010) and by the French Ministry of Health (PREPS2013). The first author was supported by a doctoral contract funded by the UPMC Universite Paris 6 Sorbonne Paris Cite for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agwu AL, 2015, J ADOLESCENT HEALTH, V56, P345, DOI 10.1016/j.jadohealth.2014.11.009; Agwu AL, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18579; [Anonymous], 2011, TRANSITIONING HIV IN; [Anonymous], 2014, HIV SURV REP; Arora S, 2010, MED EDUC, V44, P749, DOI 10.1111/j.1365-2923.2010.03709.x; Bennett DL, 2005, MED J AUSTRALIA, V182, P373, DOI 10.5694/j.1326-5377.2005.tb06751.x; BLUM RW, 1993, J ADOLESCENT HEALTH, V14, P570, DOI 10.1016/1054-139X(93)90143-D; Blum RW, 2002, PEDIATRICS, V110, P1301; Bodenlos JS, 2007, J ASSOC NURSE AIDS C, V18, P65, DOI 10.1016/j.jana.2007.03.002; Cadario F, 2009, CLIN ENDOCRINOL, V71, P346, DOI 10.1111/j.1365-2265.2008.03467.x; Fish R, 2014, HIV MED, V15, P239, DOI 10.1111/hiv.12091; Gilliam PP, 2011, J ASSOC NURSE AIDS C, V22, P283, DOI 10.1016/j.jana.2010.04.003; Glaser B. G., 2009, DISCOVERY GROUNDED T; Hazra R, 2010, ANNU REV MED, V61, P169, DOI 10.1146/annurev.med.050108.151127; Hersh AO, 2009, PEDIATR RHEUMATOL, V7, DOI 10.1186/1546-0096-7-13; Hill Terry E, 2010, Philos Ethics Humanit Med, V5, P11, DOI 10.1186/1747-5341-5-11; Hussen SA, 2014, FUTURE VIROL, V9, P921, DOI 10.2217/FVL.14.73; Ingersoll KS, 2005, AIDS BEHAV, V9, P89, DOI 10.1007/s10461-005-1684-1; KELLY MP, 1982, J ADV NURS, V7, P147, DOI 10.1111/j.1365-2648.1982.tb00222.x; Krebs EE, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-128; MAYER JD, 1997, MAYER SALOVEY CARUSI, V3, P34; Monaghan M, 2013, CURR DIABETES REP, V13, P900, DOI 10.1007/s11892-013-0420-x; Newman C, 2014, AIDS PATIENT CARE ST, V28, P381, DOI 10.1089/apc.2013.0346; Orban LA, 2010, AIDS CARE, V22, P420, DOI 10.1080/09540120903193724; Paille P, 2008, ANAL QUALITATIVE SCI; Sohn AH, 2013, J INT AIDS SOC, V16; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; UNAIDS, 2013, GLOBAL REPORT UNAIDS; Vaudre G, 2012, ARCH PEDIATRIE, V19, P786, DOI 10.1016/j.arcped.2012.05.003; Velter A, 2013, AIDS BEHAV, V17, P1266, DOI 10.1007/s10461-012-0303-1; Wasan AD, 2005, REGION ANESTH PAIN M, V30, P184, DOI 10.1016/j.rapm.2004.11.005; Watson AR, 2005, PEDIATR NEPHROL, V20, P113, DOI 10.1007/s00467-004-1763-y; WHO, 2013, HIV AD GUID HIV TEST; World Health organization, 2014, ADOLESCENT HIV TESTI	34	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2017	12	1							e0169782	10.1371/journal.pone.0169782	http://dx.doi.org/10.1371/journal.pone.0169782			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN6QR	28114376	Green Published, gold, Green Submitted			2023-01-03	WOS:000396129000011
J	Bouman, AIE; Hemmen, B; Evers, SMAA; van de Meent, H; Ambergen, T; Vos, PE; Brink, PRG; Seelen, HAM				Bouman, Ans I. E.; Hemmen, Bea; Evers, Silvia M. A. A.; van de Meent, Henk; Ambergen, Ton; Vos, Pieter E.; Brink, Peter R. G.; Seelen, Henk A. M.			Effects of an Integrated 'Fast Track' Rehabilitation Service for Multi-Trauma Patients: A Non-Randomized Clinical Trial in the Netherlands	PLOS ONE			English	Article							QUALITY-OF-LIFE; SF-36 HEALTH SURVEY; FUNCTIONAL CONSEQUENCES; INJURIES; VALIDATION; DISABILITY; CARE	Objectives The effects on health related outcomes of a newly-developed rehabilitation program, called `supported Fast Track multi-trauma rehabilitation service' (Fast Track), were evaluated in comparison with conventional trauma rehabilitation service (Care as Usual). Methods Prospective, multi-center, non-randomized controlled study. Between 2009 and 2012, 132 adult multi-trauma patients were included: 65 Fast Track and 67 Care as Usual patients with an Injury Severity Score >16, complex multiple injuries in several extremities or complex pelvic and/or acetabulum fractures. The Fast Track program involved: integrated coordination between trauma surgeon and rehabilitation physician, shorter stay in hospital with faster transfer to a specialized trauma rehabilitation unit, earlier start of multidisciplinary treatment and 'non-weight bearing' mobilization. Primary outcomes were functional status (FIM) and quality of life (SF-36) measured through questionnaires at baseline, 3, 6, 9 and 12 months post-trauma. Outcomes were analyzed using a linear mixed-effects regression model. Results The FIM scores significantly increased between 0 and 3 months (p<0.001) for both groups showing that they had improved overall, and continued to improve between 3 and 6 months for Fast Track (p = 0.04) and between 3 and 9 months for Care as Usual (p = 0.03). SF-36 scores significantly improved in both groups between 3 and 6 months (Fast Track, p<0.001; Care as Usual, p = 0.01). At 12 months, SF-36 scores were still below (self-reported) baseline measurements of patient health prior to the accident. However, the FIM and SF-36 scores differed little between the groups at any of the measured time points. Conclusion Both Fast Track and Care as Usual rehabilitation programs were effective in that multi trauma patients improved their functional status and quality of life. A faster (maximum) recovery in functional status was observed for Fast Track at 6 months compared to 9 months for Care as Usual. At twelve months follow-up no differential effects between treatment conditions were found.	[Bouman, Ans I. E.; Evers, Silvia M. A. A.] Maastricht Univ, Caphri, Sch Publ Hlth & Primary Care, Dept Hlth Serv Res,Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Hemmen, Bea; Seelen, Henk A. M.] Adelante Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands; [Hemmen, Bea; Seelen, Henk A. M.] Maastricht Univ, Caphri, Sch Publ Hlth & Primary Care, Dept Rehabil Med,Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Hemmen, Bea] Maastricht Univ, Dept Rehabil Med, Med Ctr, Maastricht, Netherlands; [van de Meent, Henk] Radboud Univ Nijmegen, Dept Rehabil, Med Ctr, Nijmegen, Netherlands; [Ambergen, Ton] Maastricht Univ, Sch Publ Hlth & Primary Care, Caphri, Dept Methodol & Stat,Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Vos, Pieter E.] Slingeland Hosp, Dept Neurol, Doetinchem, Netherlands; [Brink, Peter R. G.] Maastricht Univ, Netwerk Acute Zorg Limburg, Med Ctr, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Radboud University Nijmegen; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University	Bouman, AIE (corresponding author), Maastricht Univ, Caphri, Sch Publ Hlth & Primary Care, Dept Hlth Serv Res,Fac Hlth Med & Life Sci, Maastricht, Netherlands.; Hemmen, B; Seelen, HAM (corresponding author), Adelante Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands.; Hemmen, B; Seelen, HAM (corresponding author), Maastricht Univ, Caphri, Sch Publ Hlth & Primary Care, Dept Rehabil Med,Fac Hlth Med & Life Sci, Maastricht, Netherlands.; Hemmen, B (corresponding author), Maastricht Univ, Dept Rehabil Med, Med Ctr, Maastricht, Netherlands.	a.bouman@maastrichtuniversity.nl; bea.hemmen@mumc.nl; H.Seelen@adelante-zorggroep.nl	Evers, Silvia MAA/K-9720-2015; Evers, Silvia/ABG-2128-2020	Evers, Silvia MAA/0000-0003-1026-570X; Evers, Silvia/0000-0003-1026-570X	ZonMw, the Netherlands Organization for Health Research and Development; Hague, the Netherlands;  [170882704]	ZonMw, the Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and DevelopmentNetherlands Government); Hague, the Netherlands(Netherlands Government); 	This manuscript is part of a study funded by ZonMw, the Netherlands Organization for Health Research and Development, The Hague, the Netherlands (http/www.zonmw.nl/en/). The Grant number was 170882704. The funding was received by BH, PB and HS. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Attenberger C, 2012, INJURY, V43, P1566, DOI 10.1016/j.injury.2011.01.002; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Brown H, 2006, APPL MIXED MODELS ME, P218; Cameron PA, 2008, MED J AUSTRALIA, V189, P546, DOI 10.5694/j.1326-5377.2008.tb02176.x; Czyrny JJ, 1998, AM J PHYS MED REHAB, V77, P407, DOI 10.1097/00002060-199809000-00008; Deeks J J, 2003, Health Technol Assess, V7, piii; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Govan L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub2; Halcomb Elizabeth, 2005, Aust Crit Care, V18, P17, DOI 10.1016/S1036-7314(05)80020-7; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; HETHERINGTON H, 1995, EUR J SURG, V161, P549; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hoffman K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103082; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Khan F, 2011, BRIT J SURG, V99, P88; Khan F, 2008, COCHRANE DATABASE SY, V2; Khan F, 2007, COCHRANE DATABASE SY, V2; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Kosar Sevginur, 2009, J Trauma Manag Outcomes, V3, P1, DOI 10.1186/1752-2897-3-1; Launois R, 2004, STROKE, V35, P770, DOI 10.1161/01.STR.0000117574.19517.80; Minkman M M N, 2005, Int J Integr Care, V5, pe14; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Pape HC, 2006, INJURY, V37, P1197, DOI 10.1016/j.injury.2006.07.032; Pfeifer R, 2011, J TRAUMA; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Prince D., 2015, CURR PHYS MED REHAB, V3, P214; Probst C, 2009, INJURY, V40, P77, DOI 10.1016/j.injury.2008.10.004; Rainer TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103396; Simmel S, 2013, CHIRURG, V84, P771, DOI 10.1007/s00104-013-2479-y; Sittaro N A, 2007, Versicherungsmedizin, V59, P20; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2012, ARCH PHYS MED REHAB, V93, P765, DOI 10.1016/j.apmr.2011.08.050; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Turner-Stokes L., 2011, COCHRANE SYSTEM REV, V5, P1; van Vree F, 2001, BELEIDSVISIE TRAUMAZ; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; Verenso, 2014, VER TRIAG INSTR REH	41	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2017	12	1							e0170047	10.1371/journal.pone.0170047	http://dx.doi.org/10.1371/journal.pone.0170047			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH6BJ	28076441	Green Published, gold, Green Submitted			2023-01-03	WOS:000391857100083
J	Heintz, C; Doktor, TK; Lanjuin, A; Escoubas, CC; Zhang, Y; Weir, HJ; Dutta, S; Silva-Garcia, CG; Bruun, GH; Morantte, I; Hoxhaj, G; Manning, BD; Andresen, BS; Mair, WB				Heintz, Caroline; Doktor, Thomas K.; Lanjuin, Anne; Escoubas, Caroline C.; Zhang, Yue; Weir, Heather J.; Dutta, Sneha; Silva-Garcia, Carlos Giovanni; Bruun, Gitte H.; Morantte, Ianessa; Hoxhaj, Gerta; Manning, Brendan D.; Andresen, Brage S.; Mair, William B.			Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans	NATURE			English	Article							U2AF LARGE SUBUNIT; LIFE-SPAN; FACTOR SF1; PROTEIN; INTERACTS; GENETICS; REVEALS; DISEASE; CRTC-1; GENES	Ageing is driven by a loss of transcriptional and protein homeostasis(1-3) and is the key risk factor for multiple chronic diseases. Interventions that attenuate or reverse systemic dysfunction associated with age therefore have the potential to reduce overall disease risk in the elderly. Precursor mRNA (pre-mRNA) splicing is a fundamental link between gene expression and the proteome, and deregulation of the splicing machinery is linked to several age-related chronic illnesses(4,5). However, the role of splicing homeostasis in healthy ageing remains unclear. Here we demonstrate that pre-mRNA splicing homeostasis is a biomarker and predictor of life expectancy in Caenorhabditis elegans. Using transcriptomics and in-depth splicing analysis in young and old animals fed ad libitum or subjected to dietary restriction, we find defects in global pre-mRNA splicing with age that are reduced by dietary restriction via splicing factor 1 (SFA-1; the C. elegans homologue of SF1, also known as branchpoint binding protein, BBP). We show that SFA-1 is specifically required for lifespan extension by dietary restriction and by modulation of the TORC1 pathway components AMPK, RAGA-1 and RSKS-1/S6 kinase. We also demonstrate that overexpression of SFA-1 is sufficient to extend lifespan. Together, these data demonstrate a role for RNA splicing homeostasis in dietary restriction longevity and suggest that modulation of specific spliceosome components may prolong healthy ageing.	[Heintz, Caroline; Lanjuin, Anne; Escoubas, Caroline C.; Zhang, Yue; Weir, Heather J.; Dutta, Sneha; Silva-Garcia, Carlos Giovanni; Morantte, Ianessa; Hoxhaj, Gerta; Manning, Brendan D.; Mair, William B.] Harvard TH Chan Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Doktor, Thomas K.; Bruun, Gitte H.; Andresen, Brage S.] Univ Southern Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; [Doktor, Thomas K.; Bruun, Gitte H.; Andresen, Brage S.] Univ Southern Denmark, Villum Ctr Bioanalyt Sci, DK-5230 Odense, Denmark; [Escoubas, Caroline C.] Univ Nice Sophia Antipolis, Fac Med, CNRS, IRCAN,INSERM U1081,UMR7284, F-06107 Nice, France; [Morantte, Ianessa] Rockefeller Univ, Lab Neurophysiol & Behav, New York, NY 10065 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Southern Denmark; University of Southern Denmark; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Rockefeller University	Mair, WB (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA.	wmair@hsph.harvard.edu	Doktor, Thomas K/G-9923-2014; Andresen, Brage/D-2515-2012; Heintz, Caroline/R-3272-2017; Manning, Brendan/ABD-6528-2021; Doktor, Thomas/AAB-2216-2020	Doktor, Thomas K/0000-0002-5315-8325; Andresen, Brage/0000-0001-7488-3035; Manning, Brendan/0000-0003-3895-5956; Doktor, Thomas/0000-0002-5315-8325; Mair, William/0000-0002-0661-1342; Hoxhaj, Gerta/0000-0001-6179-3583	Swiss National Science Foundation [P2ZHP3_151609]; Fonds National de la Recherche Luxembourg [AFR7883116]; Lawrence Ellison Medical Foundation [U54CA155626]; Glenn Foundation for Medical Research; National Institutes of Health (NIH) [1R01AG044346]; Ligue Nationale contre le Cancer; Novo Nordisk Foundation [NNF13OC0007939]; NATIONAL CANCER INSTITUTE [U54CA155626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG044346] Funding Source: NIH RePORTER; Novo Nordisk Fonden [NNF13OC0007939] Funding Source: researchfish; Villum Fonden [00007292] Funding Source: researchfish	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Fonds National de la Recherche Luxembourg(Luxembourg National Research Fund); Lawrence Ellison Medical Foundation; Glenn Foundation for Medical Research; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Novo Nordisk Fonden(Novo Nordisk Foundation); Villum Fonden(Villum Fonden)	C.H. is supported by the Swiss National Science Foundation (P2ZHP3_151609) and the Fonds National de la Recherche Luxembourg (AFR7883116). W.B.M. is funded by The Lawrence Ellison Medical Foundation (U54CA155626), The Glenn Foundation for Medical Research and the National Institutes of Health (NIH, 1R01AG044346). C.E. is supported by the Ligue Nationale contre le Cancer. G.H.B and T.K.D. were supported through a grant to B.S.A. from The Novo Nordisk Foundation (NNF13OC0007939). We are grateful to H. Kuroyanagi for providing the splicing reporter strain and corresponding plasmids. We thank K. Blackwell for providing the glp-4 mutant strain and RNAi constructs. We also thank the Caenorhabditis Genetics Center for providing worm strains. We also thank the Mair laboratory members for comments and discussion on the project and manuscript.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Burkewitz K, 2015, CELL, V160, P842, DOI 10.1016/j.cell.2015.02.004; Ching TT, 2011, JOVE-J VIS EXP, DOI 10.3791/2701; Cunningham F, 2015, NUCLEIC ACIDS RES, V43, pD662, DOI 10.1093/nar/gku1010; Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Gao XY, 2014, RNA BIOL, V11, P1148, DOI 10.4161/rna.36100; Hansen KD, 2012, BIOSTATISTICS, V13, P204, DOI 10.1093/biostatistics/kxr054; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; Kuroyanagi H, 2013, NUCLEIC ACIDS RES, V41, P4015, DOI 10.1093/nar/gkt097; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee BP, 2016, AGING CELL, V15, P903, DOI 10.1111/acel.12499; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Ma L, 2011, RNA, V17, P2201, DOI 10.1261/rna.027458.111; Ma L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000708; Mair W, 2011, NATURE, V470, P404, DOI 10.1038/nature09706; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Mazin P, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.67; Ramani AK, 2011, GENOME RES, V21, P342, DOI 10.1101/gr.114645.110; Rodriguez SA, 2016, AGING CELL, V15, P267, DOI 10.1111/acel.12433; Seo M, 2016, CELL CYCLE, V15, P1821, DOI 10.1080/15384101.2016.1183845; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Stamm S, 2008, J BIOL CHEM, V283, P1223, DOI 10.1074/jbc.R700034200; Tanackovic G, 2005, MOL BIOL CELL, V16, P1366, DOI 10.1091/mbc.E04-11-1034; Taylor RC, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004440; Vermulst M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9065; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zahler A., 2012, WORMBOOK; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zhang T, 2012, J BIOL CHEM, V287, P8371, DOI 10.1074/jbc.M111.311977	41	88	91	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 5	2017	541	7635					102	+		10.1038/nature20789	http://dx.doi.org/10.1038/nature20789			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6NA	27919065	Green Accepted, Green Submitted			2023-01-03	WOS:000396119500038
J	Fujimoto, D; Kato, R; Morimoto, T; Shimizu, R; Sato, Y; Kogo, M; Ito, J; Teraoka, S; Nagata, K; Nakagawa, A; Otsuka, K; Tomii, K				Fujimoto, Daichi; Kato, Ryoji; Morimoto, Takeshi; Shimizu, Ryoko; Sato, Yuki; Kogo, Mariko; Ito, Jiro; Teraoka, Shunsuke; Nagata, Kazuma; Nakagawa, Atsushi; Otsuka, Kojiro; Tomii, Keisuke			Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small Cell Lung Cancer	PLOS ONE			English	Article							PULMONARY-FIBROSIS; INTENSIVE-CARE; RADIATION PNEUMONITIS; PERFORMANCE STATUS; JAPANESE PATIENTS; DECISION-MAKING; SINGLE-AGENT; RISK-FACTORS; CHEMOTHERAPY; DISEASE	Background Data on characteristics, outcomes, and prognosis of advanced non-small-cell lung cancer (NSCLC) patients who develop pneumonitis during systemic anti-cancer therapy (pneumonitis) are currently lacking. Methods We conducted a retrospective cohort study of 910 consecutive patients diagnosed with advanced NSCLC between January 2004 and January 2014. Of these, 140 patients were excluded because they did not receive systemic anti-cancer therapy at this hospital. Results A total of 770 patients were included in the study, of whom 44 (6%) were diagnosed with pneumonitis. The mortality rate of pneumonitis was 36%. The incidence of pneumonitis was independently associated with pre-existing ILD (adjusted odds ratio, 2.99, P = 0.008), and survivors were significantly associated with younger age (P = 0.003) and radiographic non-acute interstitial pneumonia pattern (P = 0.004). In all patients, pneumonitis was identified as an independent predictor of overall survival (OS) (adjusted hazard ratio 1.53, 95% Cl, 1.09-2.09, P = 0.015). Performance status was poor in 82% of survivors of pneumonitis; in 62% of survivors, the PS worsened after the pneumonitis improved. Additionally, 54% of survivors received no further systemic anti-cancer therapy after pneumonitis. The median survival time of survivors after pneumonitis was 3.5 months (95% Cl, 2.3-7.2 months). Conclusions Our study indicated that 6% of patients with advanced NSCLC developed pneumonitis during systemic anti-cancer therapy. The early mortality rate of pneumonitis is high, and the survival and PS after pneumonitis is extremely poor. Additionally, pneumonitis has an adverse impact on the survival of patients with advanced NSCLC. These data should be considered for the management of pneumonitis, and we recommend that future work focuses on pneumonitis particularly to improve the survival of patients with advanced NSCLC.	[Fujimoto, Daichi; Kato, Ryoji; Shimizu, Ryoko; Sato, Yuki; Kogo, Mariko; Ito, Jiro; Teraoka, Shunsuke; Nagata, Kazuma; Nakagawa, Atsushi; Otsuka, Kojiro; Tomii, Keisuke] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan; [Morimoto, Takeshi] Kobe City Med Ctr Gen Hosp, Clin Res Ctr, Kobe, Hyogo, Japan; [Morimoto, Takeshi] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan	Kobe City Medical Center General Hospital; Kobe City Medical Center General Hospital; Hyogo College of Medicine	Fujimoto, D (corresponding author), Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan.	daichianzen@yahoo.co.jp	Ito, Jiro/M-1811-2019	Ito, Jiro/0000-0003-4836-9379; Fujimoto, Daichi/0000-0003-0615-3000	Ethics Committee of Kobe City Medical Center General Hospital	Ethics Committee of Kobe City Medical Center General Hospital	This study was supported by internal funding and the Ethics Committee of Kobe City Medical Center General Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, N Engl J Med, V373, P782, DOI 10.1056/NEJMx150012; Aubry MC, 2002, MAYO CLIN PROC, V77, P763, DOI 10.4065/77.8.763; Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Bonomi MR, 2012, LUNG CANCER, V77, P600, DOI 10.1016/j.lungcan.2012.05.103; Camus P, 2001, EUR RESPIR J, V18, p93S; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; Cushley MJ, 1999, THORAX, V54, pS1; Dhokarh R, 2012, CHEST, V142, P845, DOI 10.1378/chest.11-2103; Enomoto Y, 2016, LUNG CANCER, V96, P63, DOI 10.1016/j.lungcan.2016.03.017; Fujimoto D, 2015, EUR RESPIR J, V45, P1098, DOI 10.1183/09031936.00068114; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Isobe K, 2010, RESPIROLOGY, V15, P88, DOI 10.1111/j.1440-1843.2009.01666.x; Kane HL, 2014, CA-CANCER J CLIN, V64, P377, DOI 10.3322/caac.21245; Katz SJ, 2013, JAMA-J AM MED ASSOC, V310, P1559, DOI 10.1001/jama.2013.278944; Kenmotsu H, 2015, CANCER CHEMOTH PHARM, V75, P521, DOI 10.1007/s00280-014-2670-y; Kenmotsu H, 2011, J THORAC ONCOL, V6, P1242, DOI 10.1097/JTO.0b013e318216ee6b; Kim JY, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-59; Kinoshita T, 2012, ONCOL LETT, V4, P477, DOI 10.3892/ol.2012.753; Kubo K, 2013, RESPIR INVESTIG, V51, P260, DOI 10.1016/j.resinv.2013.09.001; Kudoh S, 2008, AM J RESP CRIT CARE, V177, P1348, DOI 10.1164/rccm.200710-1501OC; Lilenbaum RC, 2004, ONCOLOGY-NY, V18, P1321; Minami-Shimmyo Y, 2012, J THORAC ONCOL, V7, P177, DOI 10.1097/JTO.0b013e31823c4c07; Minegishi Y, 2014, LUNG CANCER, V85, P258, DOI 10.1016/j.lungcan.2014.05.016; Morth C, 2014, LUNG CANCER, V84, P209, DOI 10.1016/j.lungcan.2014.03.015; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Nishino M, 2016, CLIN CANC RES OFFICI; Nishino M, 2015, EUR J RADIOL, V84, P1259, DOI 10.1016/j.ejrad.2015.03.017; Niu XM, 2012, J THORAC ONCOL, V7, P1668, DOI 10.1097/JTO.0b013e318267cf5b; Ozawa Y, 2016, CANCER CHEMOTH PHARM, V77, P1031, DOI 10.1007/s00280-016-3025-7; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102; Rodrigues G, 2004, RADIOTHER ONCOL, V71, P127, DOI 10.1016/j.radonc.2004.02.015; Sakurada T, 2015, ANN PHARMACOTHER, V49, P398, DOI 10.1177/1060028014566446; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Slatore CG, 2012, J CLIN ONCOL, V30, P1686, DOI 10.1200/JCO.2011.40.0846; Soares M, 2014, ANN ONCOL, V25, P1829, DOI 10.1093/annonc/mdu234; Soares M, 2007, CHEST, V131, P840, DOI 10.1378/chest.06-2244; Takeda M, 2015, LUNG CANCER, V88, P74, DOI 10.1016/j.lungcan.2015.01.026; Togashi Y, 2012, CLIN LUNG CANCER, V13, P304, DOI 10.1016/j.cllc.2011.11.001; Tomassetti S, 2015, CHEST, V147, P157, DOI 10.1378/chest.14-0359; Usui K, 2011, RESPIROLOGY, V16, P326, DOI 10.1111/j.1440-1843.2010.01907.x; Vahid B, 2008, CHEST, V133, P528, DOI 10.1378/chest.07-0851; Yagihashi K, 2016, EUR RESPIR J, V47, P1189, DOI 10.1183/13993003.01680-2015; Zukin M, 2013, J CLIN ONCOL, V31, P2849, DOI 10.1200/JCO.2012.48.1911	44	33	36	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2016	11	12							e0168465	10.1371/journal.pone.0168465	http://dx.doi.org/10.1371/journal.pone.0168465			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QH	28006019	Green Published, gold, Green Submitted			2023-01-03	WOS:000392843200056
J	Jung, NH; Gleich, B; Gattinger, N; Hoess, C; Haug, C; Siebner, HR; Mall, V				Jung, Nikolai H.; Gleich, Bernhard; Gattinger, Norbert; Hoess, Catrina; Haug, Carolin; Siebner, Hartwig R.; Mall, Volker			Quadri-Pulse Theta Burst Stimulation using Ultra-High Frequency Bursts - A New Protocol to Induce Changes in Cortico-Spinal Excitability in Human Motor Cortex	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; DEPENDENT SYNAPTIC PLASTICITY; HOMEOSTATIC PLASTICITY; TERM DEPRESSION; HALF-SINE; METAPLASTICITY; DIRECTION; NETWORKS; CIRCUITS; MEMORY	Patterned transcranial magnetic stimulation (TMS) such as theta burst stimulation (TBS) or quadri-pulse stimulation (QPS) can induce changes in cortico-spinal excitability, commonly referred to as long-term potentiation (LTP)-like and long-term depression (LTD)-like effects in human motor cortex (M1). Here, we aimed to test the plasticity-inducing capabilities of a novel protocol that merged TBS and QPS. 360 bursts of quadri-pulse TBS (qTBS) were continuously given to M1 at 90% of active motor threshold (1440 full-sine pulses). In a first experiment, stimulation frequency of each burst was set to 666 Hz to mimic the rhythmicity of the descending cortico-spinal volleys that are elicited by TMS (i.e., I-wave periodicity). In a second experiment, burst frequency was set to 200 Hz to maximize postsynaptic Ca2+ influx using a temporal pattern unrelated to I-wave periodicity. The second phase of sinusoidal TMS pulses elicited either a posterior-anterior (PA) or anterior-posterior (AP) directed current in M1. Motor evoked potentials (MEPs) were recorded before and after qTBS to probe changes in cortico-spinal excitability. PA-qTBS at 666 Hz caused a decrease in PAMEP amplitudes, whereas AP-qTBS at 666 Hz induced an increase in mean AP-MEP amplitudes. At a burst frequency of 200 Hz, PA-qTBS and AP-qTBS produced an increase in cortico- spinal excitability outlasting for at least 60 minutes in PA- and AP-MEP amplitudes, respectively. Continuous qTBS at 666 Hz or 200 Hz can induce lasting changes in corticospinal excitability. Induced current direction in the brain appears to be relevant when qTBS targets I-wave periodicity, corroborating that high-fidelity spike timing mechanisms are critical for inducing bi-directional plasticity in human M1.	[Jung, Nikolai H.; Hoess, Catrina; Haug, Carolin; Mall, Volker] Tech Univ Munich, Dept Pediat, Heiglhofstr 63, Munich, Germany; [Gleich, Bernhard; Gattinger, Norbert] Tech Univ Munich IMETUM, Zentralinst Med Tech, Boltzmannstr 11, Garching, Germany; [Siebner, Hartwig R.] Copenhagen Univ Hosp Hvidovre, Danish Res Ctr Magnet Resonance, Kettegaard Alle 30, Hvidovre, Denmark; [Siebner, Hartwig R.] Copenhagen Univ Hosp Bispebjerg, Dept Neurol, Copenhagen, Denmark	Technical University of Munich; Technical University of Munich; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Mall, V (corresponding author), Tech Univ Munich, Dept Pediat, Heiglhofstr 63, Munich, Germany.	volker.mall@tum.de	Gleich, Bernhard/D-4803-2009	Gleich, Bernhard/0000-0002-0574-7678	Lundbeck Foundation [R59-A5399]; Novo Nordisk Foundation Interdisciplinary Synergy Program "Biophysically adjusted state-informed cortex stimulation (BASICS) [NNF14OC0011413]; Novo Nordisk Fonden [NNF14OC0011413] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation Interdisciplinary Synergy Program "Biophysically adjusted state-informed cortex stimulation (BASICS); Novo Nordisk Fonden(Novo Nordisk Foundation)	Hartwig R. Siebner received financial support from the Lundbeck Foundation [Grant of Excellence "Mapping, Modulation and Modeling the Control of Actions"; grant number R59-A5399] and the Novo Nordisk Foundation Interdisciplinary Synergy Program 2014 ["Biophysically adjusted state-informed cortex stimulation (BASICS); grant number NNF14OC0011413]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham WC, 2008, NAT REV NEUROSCI, V9, P387, DOI 10.1038/nrn2356; Awiszus F, 2003, SUPPL CLIN NEUROPHYS, V56, P13; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Buschler A, 2012, HIPPOCAMPUS, V22, P2238, DOI 10.1002/hipo.22041; Caroni P, 2012, NAT REV NEUROSCI, V13, P478, DOI 10.1038/nrn3258; Cash RFH, 2013, J NEUROPHYSIOL, V109, P106, DOI 10.1152/jn.00584.2011; Cash RFH, 2009, EXP BRAIN RES, V193, P1, DOI 10.1007/s00221-008-1590-7; Collingridge GL, 2010, NAT REV NEUROSCI, V11, P459, DOI 10.1038/nrn2867; Delvendahl I, 2014, BRAIN STIMUL, V7, P49, DOI 10.1016/j.brs.2013.08.002; Delvendahl I, 2010, CLIN NEUROPHYSIOL, V121, P594, DOI 10.1016/j.clinph.2009.09.034; Di Lazzaro V, 2008, J PHYSIOL-LONDON, V586, P3871, DOI 10.1113/jphysiol.2008.152736; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Di Lazzaro V, 2012, BRAIN STIMUL, V5, P512, DOI 10.1016/j.brs.2011.07.008; Di Lazzaro V, 2001, J PHYSIOL-LONDON, V537, P1047, DOI 10.1113/jphysiol.2001.012572; Grover LM, 2009, LEARN MEMORY, V16, P69, DOI 10.1101/lm.1179109; Hamada M, 2008, J PHYSIOL-LONDON, V586, P3927, DOI 10.1113/jphysiol.2008.152793; Hamada M, 2014, J NEUROSCI, V34, P12837, DOI 10.1523/JNEUROSCI.1960-14.2014; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Jung NH, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-139; Karabanov A, 2015, BRAIN STIMUL, V8, P442, DOI 10.1016/j.brs.2015.01.404; Kenney J, 2013, NEUROPHARMACOLOGY, V74, P108, DOI 10.1016/j.neuropharm.2013.02.017; Lang N, 2004, BIOL PSYCHIAT, V56, P634, DOI 10.1016/j.biopsych.2004.07.017; Naie K, 2004, CEREB CORTEX, V14, P189, DOI 10.1093/cercor/bhg118; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Simeoni S, 2016, BRAIN STIMUL, V9, P148, DOI 10.1016/j.brs.2015.10.007; Sommer M, 2006, CLIN NEUROPHYSIOL, V117, P838, DOI 10.1016/j.clinph.2005.10.029; Sommer M, 2013, BRAIN STIMUL, V6, P363, DOI 10.1016/j.brs.2012.07.003; Thickbroom GW, 2011, BRAIN STIMUL, V4, P77, DOI 10.1016/j.brs.2010.04.002; Wankerl K, 2010, J NEUROSCI, V30, P6197, DOI 10.1523/JNEUROSCI.4673-09.2010; Ziemann U, 2001, BRAIN, V124, P1171, DOI 10.1093/brain/124.6.1171; Ziemann U, 2008, BRAIN STIMUL, V1, P164, DOI 10.1016/j.brs.2008.06.006	34	14	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							e0168410	10.1371/journal.pone.0168410	http://dx.doi.org/10.1371/journal.pone.0168410			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7HN	27977758	Green Submitted, gold, Green Published			2023-01-03	WOS:000391217400106
J	Ueda, K; Kasao, M; Shimamura, M; Haruta, H; Nitta, S; Kaneko, M; Uemura, Y; Morita, H; Komuro, I; Shirai, T				Ueda, Kazutaka; Kasao, Masashi; Shimamura, Motoaki; Haruta, Hironori; Nitta, Shuya; Kaneko, Mitsunobu; Uemura, Yukari; Morita, Hiroyuki; Komuro, Issei; Shirai, Tetsuro			Impact of Oral Treatment on Physical Function in Older Patients Hospitalized for Heart Failure: A Randomized Clinical Trial	PLOS ONE			English	Article							MORTALITY; SURVIVAL; PREDICTION; VALIDATION; TOLVAPTAN; OUTCOMES; FRAILTY	Background Frailty is a characteristic of older patients with heart failure, who undergo functional decline during hospitalization. At present, continuous intravenous infusion of diuretics is widely used for the treatment of hospitalized patients with heart failure. In this prospective, randomized, open-label controlled trial, we tested whether an early switch from continuous intravenous infusion therapy to oral treatment with diuretics prevents functional decline in patients hospitalized for heart failure. Methods A total of 59 patients hospitalized for heart failure were randomized to either continuous intravenous infusion (n = 30) or oral medication (n = 29) within 48 h of admission. The primary outcome was the Barthel index, a universally utilized scale to assess the functional status of patients in their activities of daily living, assessed at 10 days. Secondary outcomes included the number of daily steps counted using pedometers and average hospital costs. Results Barthel index scores were significantly higher in the oral medication group than in the intravenous group (78.1 +/- 20.8 vs. 59.6 +/- 34.2, P = 0.029). The number of daily steps was significantly higher in the oral treatment group relative to the intravenous group (P < 0.001), and the average hospital costs were similar between the randomized groups. Multivariate analysis revealed that oral medication was a significant independent predictor of Barthel index score at day 10, and the number of daily steps was significantly associated with the patient's functional outcome. Conclusions This trial showed that, in patients hospitalized for heart failure, oral medication increased functional independence during hospitalization compared with sustained continuous intravenous infusion, most likely because the release from the infusion line enabled the patients to be more mobile. Notably, these beneficial effects were achieved without increasing hospital costs.	[Ueda, Kazutaka; Kasao, Masashi; Shimamura, Motoaki; Haruta, Hironori; Nitta, Shuya; Kaneko, Mitsunobu; Shirai, Tetsuro] Tokyo Metropolitan Police Hosp, Dept Cardiol, Tokyo, Japan; [Ueda, Kazutaka; Morita, Hiroyuki; Komuro, Issei] Tokyo Univ Hosp, Dept Cardiovasc Med, Tokyo, Japan; [Uemura, Yukari] Tokyo Univ Hosp, Clin Res Support Ctr, Cent Coordinating Unit, Biostat Div, Tokyo, Japan	University of Tokyo; University of Tokyo	Ueda, K (corresponding author), Tokyo Metropolitan Police Hosp, Dept Cardiol, Tokyo, Japan.	uedak-tky@umin.ac.jp		ueda, kazutaka/0000-0002-0509-1840	Nakatomi Foundation	Nakatomi Foundation	This work was supported by a grant from The Nakatomi Foundation, and the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank all the nurses in the cardiology ward at Tokyo Metropolitan Police Hospital for data collection. This work was supported by a grant from The Nakatomi Foundation. The authors have no conflicts of interest to declare.	Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Afilalo J, 2014, J AM COLL CARDIOL, V63, P747, DOI 10.1016/j.jacc.2013.09.070; Barnes DE, 2013, J GEN INTERN MED, V28, P261, DOI 10.1007/s11606-012-2226-y; Bootsma AM, 2013, J AM MED DIR ASSOC, V14, P147; Chiarantini D, 2010, J CARD FAIL, V16, P390, DOI 10.1016/j.cardfail.2010.01.004; Collard RM, 2012, J AM GERIATR SOC, V60, P1487, DOI 10.1111/j.1532-5415.2012.04054.x; Formiga F, 2007, CARDIOLOGY, V108, P73, DOI 10.1159/000095885; Klein L, 2005, CIRCULATION, V111, P2454, DOI 10.1161/01.CIR.0000165065.82609.3D; Koelling TM, 2004, AM HEART J, V147, P74, DOI 10.1016/j.ahj.2003.07.021; Kortebein P, 2007, JAMA-J AM MED ASSOC, V297, P1772, DOI 10.1001/jama.297.16.1772-b; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; MAHONEY F I, 1965, Md State Med J, V14, P61; Mozaffarian D, 2015, CIRCULATION, V131, P434, DOI 10.1161/CIR.0000000000000157; Peacock WF, 2009, CARDIOLOGY, V113, P12, DOI 10.1159/000164149; Schrier RW, 2006, NEW ENGL J MED, V355, P2099, DOI 10.1056/NEJMoa065181; Suzuki S, 2013, J CLIN PHARMACOL, V53, P1277, DOI 10.1002/jcph.197	18	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2016	11	12							e0167933	10.1371/journal.pone.0167933	http://dx.doi.org/10.1371/journal.pone.0167933			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8JY	27959941	gold, Green Published, Green Submitted			2023-01-03	WOS:000392753900025
J	Maccarone, R; Rapino, C; Zerti, D; di Tommaso, M; Battista, N; Di Marco, S; Bisti, S; Maccarrone, M				Maccarone, Rita; Rapino, Cinzia; Zerti, Darin; di Tommaso, Monia; Battista, Natalia; Di Marco, Stefano; Bisti, Silvia; Maccarrone, Mauro			Modulation of Type-1 and Type-2 Cannabinoid Receptors by Saffron in a Rat Model of Retinal Neurodegeneration	PLOS ONE			English	Article							PHOTORECEPTOR CELL-DEATH; DAMAGING LIGHT; ENDOCANNABINOIDS; DEGENERATION; MECHANISMS; APOPTOSIS; RESPONSES; NEUROPROTECTION; SUPPLEMENTATION; LOCALIZATION	Experimental studies demonstrated that saffron (Crocus sativus) given as a dietary supplement counteracts the effects of bright continuous light (BCL) exposure in the albino rat retina, preserving both morphology and function and probably acting as a regulator of programmed cell death [1]. The purpose of this study was to ascertain whether the neuroprotective effect of saffron on rat retina exposed to BCL is associated with a modulation of the endocannabinoid system (ECS). To this aim, we used eight experimental groups of Sprague-Dawley rats, of which six were exposed to BCL for 24 hours. Following retinal function evaluation, retinas were quickly removed for biochemical and morphological analyses. Rats were either saffron-prefed or intravitreally injected with selective type-1 (CB1) or type-2 (CB2) cannabinoid receptor antagonists before BCL. Prefeeding and intravitreally injections were combined in two experimental groups before BCL. BCL exposure led to enhanced gene and protein expression of retinal CB1 and CB2 without affecting the other ECS elements. This effect of BCL on CB1 and CB2 was reversed by saffron treatment. Selective CB1 and CB2 antagonists reduced photoreceptor death, preserved morphology and visual function of retina, and mitigated the outer nuclear layer (ONL) damage due to BCL. Of interest, CB2-dependent neuroprotection was more pronounced than that conferred by CB1. These data suggest that BCL modulates only distinct ECS elements like CB1 and CB2, and that saffron and cannabinoid receptors could share the same mechanism in order to afford retinal protection.	[Maccarone, Rita; Zerti, Darin; Di Marco, Stefano; Bisti, Silvia] Univ Aquila, Biotechnol & Appl Clin Sci Dept, Laquila, Italy; [Rapino, Cinzia; di Tommaso, Monia] Univ Teramo, Fac Vet Med, Teramo, Italy; [Battista, Natalia] Univ Teramo, Fac Biosci, Teramo, Italy; [Bisti, Silvia] Australian Natl Univ, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia; [Bisti, Silvia] Interuniv Consortium Ist Nazl Biostrutture & Bios, Rome, Italy; [Maccarrone, Mauro] Campus Biomed Univ Rome, Dept Med, Rome, Italy; [Maccarrone, Mauro] IRCCS Santa Lucia Fdn, European Ctr Brain Res, Rome, Italy	University of L'Aquila; University of Teramo; University of Teramo; Australian National University; John Curtin School of Medical Research; University Campus Bio-Medico - Rome Italy; IRCCS Santa Lucia	Bisti, S (corresponding author), Univ Aquila, Biotechnol & Appl Clin Sci Dept, Laquila, Italy.; Bisti, S (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.; Bisti, S (corresponding author), Interuniv Consortium Ist Nazl Biostrutture & Bios, Rome, Italy.; Maccarrone, M (corresponding author), Campus Biomed Univ Rome, Dept Med, Rome, Italy.; Maccarrone, M (corresponding author), IRCCS Santa Lucia Fdn, European Ctr Brain Res, Rome, Italy.	silvia.bisti@univaq.it; m.maccarrone@unicampus.it	Zerti, Darin/AAF-7078-2021; Battista, Natalia/AAC-2529-2019; Maccarrone, Mauro/K-5398-2012; Di Marco, Stefano/AAO-8073-2020	Zerti, Darin/0000-0003-0865-8088; Maccarrone, Mauro/0000-0002-3990-2963; Di Marco, Stefano/0000-0003-4847-6270; MACCARONE, Rita/0000-0003-0648-3771; Battista, Natalia/0000-0002-1936-6710	Ministero dell'Istruzione, dell'Universita e della Ricerca	Ministero dell'Istruzione, dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR))	This investigation was supported by Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN 2010-2011 grant) to MM, to SB and by Mr. Francesco Segafredo, Essse Caffe S.p.A. The company Hortus Novus s.r.l. provided the saffron used in this study. These supporters had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABDULLAEV FI, 1993, BIOFACTORS, V4, P83; Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Ahn K, 2008, CHEM REV, V108, P1687, DOI 10.1021/cr0782067; Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108; Bouchard JF, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9247057; Cairns EA, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9364091; Cecyre B, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00150; Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862; Chiurchiu V, 2015, J NEUROIMMUNE PHARM, V10, P268, DOI 10.1007/s11481-015-9584-2; Corso L, 2016, PURINERG SIGNAL, V12, P161, DOI 10.1007/s11302-015-9490-3; Di Marzo V, 2008, REV PHYSIOL BIOCH P, V160, P1, DOI 10.1007/112_0505; Di Marzo V, 2010, CURR MED CHEM, V17, P1430; El-Remessy AB, 2003, AM J PATHOL, V163, P1997, DOI 10.1016/S0002-9440(10)63558-4; Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995; Fezza F, 2014, MOLECULES, V19, P17078, DOI 10.3390/molecules191117078; Gargini C, 2004, NEUROSCIENCE, V126, P775, DOI 10.1016/j.neuroscience.2004.04.028; Gasperi V, 2007, CELL MOL LIFE SCI, V64, P219, DOI 10.1007/s00018-006-6445-4; Guabiraba R, 2013, INFLAMM RES, V62, P811, DOI 10.1007/s00011-013-0638-8; Karlstetter M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-125; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152; Latini L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.364; Lograno MD, 2004, EUR J PHARMACOL, V494, P55, DOI 10.1016/j.ejphar.2004.04.039; Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438; Maccarrone M, 2014, NAT REV NEUROSCI, V15, P786, DOI 10.1038/nrn3846; Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228; Marigo V, 2007, CELL CYCLE, V6, P652, DOI 10.4161/cc.6.6.4029; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523; Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001; Natoli R, 2010, MOL VIS, V16, P1801; Nucci C, 2007, INVEST OPHTH VIS SCI, V48, P2997, DOI 10.1167/iovs.06-1355; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Pertwee RG, 2010, CURR MED CHEM, V17, P1360, DOI 10.2174/092986710790980050; Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124; Pucci M, 2012, J BIOL CHEM, V287, P15466, DOI 10.1074/jbc.M111.314880; Racz I, 2008, J NEUROSCI, V28, P12125, DOI 10.1523/JNEUROSCI.3400-08.2008; Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925; Ryskamp Daniel A, 2014, Cells, V3, P914, DOI 10.3390/cells3030914; Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9; Soeda S, 2001, LIFE SCI, V69, P2887, DOI 10.1016/S0024-3205(01)01357-1; Starowicz K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060040; Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9; Strettoi E, 2010, P NATL ACAD SCI USA, V107, P18706, DOI 10.1073/pnas.1007644107; Ueda N, 2011, BIOFACTORS, V37, P1, DOI 10.1002/biof.131; Unsicker K, 2013, CELL TISSUE RES, V353, P205, DOI 10.1007/s00441-013-1585-y; Urquhart P, 2015, J LIPID RES, V56, P1419, DOI 10.1194/jlr.M055772; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Wei Y, 2013, MOL VIS, V19, P357; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717; Yazulla S, 1999, J COMP NEUROL, V415, P80, DOI 10.1002/(SICI)1096-9861(19991206)415:1<80::AID-CNE6>3.0.CO;2-H; Yazulla S, 2008, PROG RETIN EYE RES, V27, P501, DOI 10.1016/j.preteyeres.2008.07.002	53	23	23	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							0166827	10.1371/journal.pone.0166827	http://dx.doi.org/10.1371/journal.pone.0166827			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC7WC	27861558	Green Published, Green Submitted, gold			2023-01-03	WOS:000388350300117
J	Horii, N; Sato, K; Mesaki, N; Iemitsu, M				Horii, Naoki; Sato, Koji; Mesaki, Noboru; Iemitsu, Motoyuki			Increased Muscular 5 alpha-Dihydrotestosterone in Response to Resistance Training Relates to Skeletal Muscle Mass and Glucose Metabolism in Type 2 Diabetic Rats	PLOS ONE			English	Article							INSULIN-RESISTANCE; EXERCISE; DHEA; TESTOSTERONE; STRENGTH; DEHYDROEPIANDROSTERONE; TRANSLOCATION; ENZYMES	Regular resistance exercise induces skeletal muscle hypertrophy and improvement of glycemic control in type 2 diabetes patients. Administration of dehydroepiandrosterone (DHEA), a sex steroid hormone precursor, increases 5 alpha-dihydrotestosterone (DHT) synthesis and is associated with improvements in fasting blood glucose level and skeletal muscle hypertrophy. Therefore, the aim of this study was to investigate whether increase in muscle DHT levels, induced by chronic resistance exercise, can contribute to skeletal muscle hypertrophy and concomitant improvement of muscular glucose metabolism in type 2 diabetic rats. Male 20-week-old type 2 diabetic rats (OLETF) were randomly divided into 3 groups: sedentary control, resistance training (3 times a week on alternate days for 8 weeks), or resistance training with continuous infusion of a 5 alpha-reductase inhibitor (n = 8 each group). Age-matched, healthy nondiabetic Long-Evans Tokushima Otsuka (LETO) rats (n = 8) were used as controls. The results indicated that OLETF rats showed significant decrease in muscular DHEA, free testosterone, DHT levels, and protein expression of steroidogenic enzymes, with loss of skeletal muscle mass and hyperglycemia, compared to that of LETO rats. However, 8-week resistance training in OLETF rats significantly increased the levels of muscle sex steroid hormones and protein expression of steroidogenic enzymes with a concomitant increase in skeletal muscle mass, improved fasting glucose level, and insulin sensitivity index. Moreover, resistance training accelerated glucose transporter-4 (GLUT-4) translocation and protein kinase B and C-zeta/lambda(IA phosphorylation. Administering the 5a-reductase inhibitor in resistance-trained OLETF rats resulted in suppression of the exercise induced effects on skeletal muscle mass, fasting glucose level, insulin sensitivity index, and GLUT-4 signaling, with a decline in muscular DHT levels. These findings suggest that resistance training-induced elevation of muscular DHT levels may contribute to improvement of hyperglycemia and skeletal muscle hypertrophy in type 2 diabetic rats.	[Horii, Naoki; Iemitsu, Motoyuki] Ritsumeikan Univ, Fac Sport Hlth Sci, Kusatsu, Shiga, Japan; [Sato, Koji] Kobe Univ, Grad Sch Human Dev & Environm, Kobe, Hyogo, Japan; [Mesaki, Noboru] Univ Tsukuba, Tsukuba, Ibaraki, Japan	Ritsumeikan University; Kobe University; University of Tsukuba	Iemitsu, M (corresponding author), Ritsumeikan Univ, Fac Sport Hlth Sci, Kusatsu, Shiga, Japan.	iemitsu@fc.ritsumei.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [26282199, 15H03091]; Grants-in-Aid for Scientific Research [15H03091] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#26282199, M. lemitsu and #15H03091, N. Mesaki). Please show the URL in this grant as follows: https://www.jsps.go.jp/english/ndex.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Therefore, all authors have no conflict of interest.	Aizawa K, 2007, AM J PHYSIOL-ENDOC M, V292, pE577, DOI 10.1152/ajpendo.00367.2006; Almurdhi MM, 2016, DIABETES CARE, V39, P441, DOI 10.2337/dc15-0995; [Anonymous], 2012, GLOBAL STATUS REPORT; Atlantis E, 2009, METABOLISM, V58, P1013, DOI 10.1016/j.metabol.2009.02.027; Bacchi E, 2012, DIABETES CARE, V35, P676, DOI 10.2337/dc11-1655; Benomar Y, 2006, ENDOCRINOLOGY, V147, P2550, DOI 10.1210/en.2005-1464; Cacho J, 2008, AM J PHYSIOL-ENDOC M, V295, pE1269, DOI 10.1152/ajpendo.90207.2008; Church TS, 2010, JAMA-J AM MED ASSOC, V304, P2253, DOI 10.1001/jama.2010.1710; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Hikim IS, 2002, AM J PHYSIOL-ENDOC M, V283, pE154, DOI 10.1152/ajpendo.00502.2001; Holten MK, 2004, DIABETES, V53, P294, DOI 10.2337/diabetes.53.2.294; Horii N, 2016, HORM METAB RES, V48, P207, DOI 10.1055/s-0035-1564132; Hornberger TA, 2004, CAN J APPL PHYSIOL, V29, P16, DOI 10.1139/h04-002; Kim JY, 2015, DIABETES METAB J, V39, P424, DOI 10.4093/dmj.2015.39.5.424; Kristiansen S, 2001, AM J PHYSIOL-ENDOC M, V281, pE608, DOI 10.1152/ajpendo.2001.281.3.E608; Labrie F, 2005, J ENDOCRINOL, V187, P169, DOI 10.1677/joe.1.06264; Liu N, 2014, P NATL ACAD SCI USA, V111, P4109, DOI 10.1073/pnas.1401732111; Motamed N, 2016, J DIABETES COMPLICAT, V30, P269, DOI 10.1016/j.jdiacomp.2015.11.019; Sato K, 2008, AM J PHYSIOL-ENDOC M, V294, pE961, DOI 10.1152/ajpendo.00678.2007; Sato K, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.1000239; Sato K, 2014, FASEB J, V28, P1891, DOI 10.1096/fj.13-245480; Sato K, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-47; Sato K, 2011, AM J PHYSIOL-ENDOC M, V301, pE274, DOI 10.1152/ajpendo.00564.2010; Searls YM, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-8; Sigal RJ, 2007, ANN INTERN MED, V147, P357, DOI 10.7326/0003-4819-147-6-200709180-00005; Srikanthan P, 2011, J CLIN ENDOCR METAB, V96, P2898, DOI 10.1210/jc.2011-0435; Srikanthan P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010805; Usui T, 2014, FEBS LETT, V588, P1935, DOI 10.1016/j.febslet.2014.03.051; White JR, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-6; World Health Organization, 2014, GLOB HLTH EST DEATHS, DOI 10.1371/journal.pgen.1004412.20; Yamaguchi Y, 1998, CLIN ENDOCRINOL, V49, P377, DOI 10.1046/j.1365-2265.1998.00533.x; Yang ZY, 2014, SPORTS MED, V44, P487, DOI 10.1007/s40279-013-0128-8	32	11	13	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2016	11	11							e0165689	10.1371/journal.pone.0165689	http://dx.doi.org/10.1371/journal.pone.0165689			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9ON	27832095	Green Published, Green Submitted, gold			2023-01-03	WOS:000387725000025
J	Wagland, R; Brindle, L; Ewings, S; James, E; Moore, M; Rivas, C; Esqueda, AI; Corner, J				Wagland, Richard; Brindle, Lucy; Ewings, Sean; James, Elizabeth; Moore, Mike; Rivas, Carol; Esqueda, Ana Ibanez; Corner, Jessica			Promoting Help-Seeking in Response to Symptoms amongst Primary Care Patients at High Risk of Lung Cancer: A Mixed Method Study	PLOS ONE			English	Article							DIAGNOSIS; DELAY; GP; EXPERIENCES; AWARENESS; SURVIVAL; IMPACT; UK	Background Lung cancer symptoms are vague and difficult to detect. Interventions are needed to promote early diagnosis, however health services are already pressurised. This study explored symptomology and help-seeking behaviours of primary care patients at 'high-risk' of lung cancer (>= 50 years old, recent smoking history), to inform targeted interventions. Methods Mixed method study with patients at eight general practitioner (GP) practices across south England. Study incorporated: postal symptom questionnaire; clinical records review of participant consultation behaviour 12 months pre-and post-questionnaire; qualitative participant interviews (n = 38) with a purposive sample. Results A small, clinically relevant group (n = 61/908, 6.7%) of primary care patients was identified who, despite reporting potential symptoms of lung cancer in questionnaires, had not consulted a GP >= 12 months. Of nine symptoms associated with lung cancer, 53.4% (629/1172) of total respondents reported >= 1, and 35% (411/1172) reported >= 2. Most participants (77.3%, n = 686/908) had comorbid conditions; 47.8%, (n = 414/908) associated with chest and respiratory symptoms. Participant consulting behaviour significantly increased in the 3-month period following questionnaire completion compared with the previous 3month period (p = .002), indicating questionnaires impacted upon consulting behaviour. Symptomatic non-consulters were predominantly younger, employed, with higher multiple deprivation scores than their GP practice mean. Of symptomatic non-consulters, 30% (18/61) consulted <= 1 month post-questionnaire, with comorbidities subsequently diagnosed for five participants. Interviews ( n = 39) indicated three overarching differences between the views of consulting and non-consulting participants: concern over wasting their own as well as GP time; high tolerance threshold for symptoms; a greater tendency to self-manage symptoms. Conclusions This first study to examine symptoms and consulting behaviour amongst a primary care population at 'high-risk' of lung cancer, found symptomatic patients who rarely consult GPs, might respond to a targeted symptom elicitation intervention. Such GP-based interventions may promote early diagnosis of lung cancer or other comorbidities, without burdening already pressurised services.	[Wagland, Richard; Brindle, Lucy; James, Elizabeth; Rivas, Carol; Esqueda, Ana Ibanez] Univ Southampton, Fac Hlth Sci, Southampton SO17 1BJ, Hants, England; [Ewings, Sean] Univ Southampton, Southampton Stat Sci Res Inst, Fac Social Human & Math Sci, Southampton, Hants, England; [Moore, Mike] Univ Southampton, Fac Med, Southampton SO17 1BJ, Hants, England; [Corner, Jessica] Univ Nottingham, Execut Off, Univ Pk, Nottingham NG7 2RD, England	University of Southampton; University of Southampton; University of Southampton; University of Nottingham	Wagland, R (corresponding author), Univ Southampton, Fac Hlth Sci, Southampton SO17 1BJ, Hants, England.	R.Wagland@soton.ac.uk	rivas, carol/Q-1196-2015; Moore, Michael/C-3447-2011	rivas, carol/0000-0002-0316-8090; Moore, Michael/0000-0002-5127-4509; Wagland, Richard/0000-0003-1825-7587; Corner, Jessica/0000-0002-2240-8133; Ewings, Sean/0000-0001-7214-4917	National Awareness and Early Diagnosis Initiative (NAEDI) [C3801/A14137]; National Institute for Health Research [14/156/15] Funding Source: researchfish	National Awareness and Early Diagnosis Initiative (NAEDI); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by the National Awareness and Early Diagnosis Initiative (NAEDI), grant number C3801/A14137.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Athey VL, 2012, THORAX, V67, P412, DOI 10.1136/thoraxjnl-2011-200714; Berrino F, 2007, LANCET ONCOL, V8, P773, DOI 10.1016/S1470-2045(07)70245-0; Birt L, 2013, BMJ OPEN RESPIR RES, V1, DOI 10.1136/bmjresp-2014-000067; Biswas M, 2015, BRIT J CANCER, V112, P271, DOI 10.1038/bjc.2014.597; Bowen EF, 2002, LUNG CANCER-J IASLC, V37, P227, DOI 10.1016/S0169-5002(02)00143-5; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brindle LA, 2014, EUR J CANCER CARE, V23, P3; Brindle LA, 2015, BEHALF IPCARD FEASIB; Brindle L, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001977; Cancer Research UK, 2014, BE CLEAR CANC EV SUM; Chambers SK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-184; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; Corner J, 2005, THORAX, V60, P314, DOI 10.1136/thx.2004.029264; Corner J, 2006, THORAX, V60, P1382; Corner J, 2011, J EPIDEMIOL COMMUN H, V65, P477, DOI 10.1136/jech.2008.084285; Cromme SK, 2016, BRIT J GEN PRACT, V66, pE474, DOI 10.3399/bjgp16X685621; Department of Health, 2014, IMPR OUTC STRAT CANC; Hamilton W, 2005, THORAX, V60, P1059, DOI 10.1136/thx.2005.045880; Hamilton W, 2004, FAM PRACT, V21, P605, DOI 10.1093/fampra/cmh605; Hamilton W, 2009, BRIT J CANCER, V101, pS80, DOI 10.1038/sj.bjc.6605396; Hippisley-Cox J, 2013, BR J GEN PRACT; Hippisley-Cox J, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X606627; Ironmonger L, 2015, BRIT J CANCER, V112, P207, DOI 10.1038/bjc.2014.596; Lyratzopoulos G, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7400; Moffat J, 2015, BRIT J CANCER, V112, pS14, DOI 10.1038/bjc.2015.31; Molassiotis A, 2010, EUR J CANCER CARE, V19, P98, DOI 10.1111/j.1365-2354.2008.01020.x; Murray SR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008046; Newcombe RG, 1998, STAT MED, V17, P2635, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C; O'Dowd EL, 2015, THORAX, V70, P161, DOI 10.1136/thoraxjnl-2014-205692; PULSE, 2014, 3 WEEK COUGH LUNG CA; Richards MA, 2009, BRIT J CANCER, V101, pS125, DOI 10.1038/sj.bjc.6605402; Rose PW, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007212; Rubin G, 2006, BRIT J GEN PRACT, V56, P743; Scott SE, 2013, BRIT J HEALTH PSYCH, V18, P45, DOI 10.1111/j.2044-8287.2012.02077.x; Simon AE, 2010, CANCER EPIDEM BIOMAR, V19, P2272, DOI 10.1158/1055-9965.EPI-10-0219; Smith LK, 2005, LANCET, V366, P825, DOI 10.1016/S0140-6736(05)67030-4; Smith SM, 2009, THORAX, V64, P523, DOI 10.1136/thx.2008.096560; Smith S, 2013, BRIT J GEN PRACT, V63, DOI 10.3399/bjgp13X660779; Walter FM, 2015, BRIT J CANCER, V112, pS6, DOI 10.1038/bjc.2015.30; Walton L, 2013, FAM PRACT; Weller D, 2012, BRIT J CANCER, V106, P1262, DOI 10.1038/bjc.2012.68; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208	42	20	20	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2016	11	11							e0165677	10.1371/journal.pone.0165677	http://dx.doi.org/10.1371/journal.pone.0165677			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA8TH	27814375	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000386911100013
J	Zhang, LY; Niu, K; Zhu, K; Xia, C; Yan, J; Zhao, W; Wei, JR; Duan, ML; Zheng, GX				Zhang, Luyao; Niu, Kai; Zhu, Kang; Xia, Cui; Yan, Jing; Zhao, Wei; Wei, Junrong; Duan, Maoli; Zheng, Guoxi			Long-Term Prognostic Analysis after Endoscopic Endonasal Surgery for Olfactory Neuroblastoma: A Retrospective Study of 13 Cases	PLOS ONE			English	Article							ESTHESIONEUROBLASTOMA; EXPERIENCE; MANAGEMENT; RESECTION; CHEMOTHERAPY; METAANALYSIS; OUTCOMES; THERAPY; TUMORS	Objectives To summarize the characteristics and long-term outcomes of olfactory neuroblastoma through the analysis of 13 cases in single institution, with the assessment of treatment modality, prognostic factors. Method A retrospective study of thirteen cases diagnosed as olfactory neuroblastoma and underwent combined treatments during the period 2000-2010. Statistical analysis was performed to search for prognostic factors and compared different treatment modalities. Results 13 patients were enrolled in this study, including 8 male and 5 female, ranging from 15 to 69 (median 43) years old. One patient at stage A was only treated with endoscopic endonasal surgery (EES). Seven patients were treated with preoperative radiotherapy and EES, two with EES and postoperative radiotherapy, and the other three with combined radiotherapy and chemotherapy. The range of follow-up time varied from 23 to 116 months (median 65 months). The 5-year overall survival rate was 46.2% (6/13). To date, these thirteen patients have not suffered local recurrences while two patients had lymph node recurrences and one had distant metastasis in the bone marrow. In 13 patients, 61.5% were diagnosed as late T stage (T3/4), 69.2% late Kadish stage (C/D) and 53.8% were high Hyams grade (I/II), which indicated poor prognosis. Related prognostic factors were the TNM stage (T stage P = 0.028, N stage P = 0.000, M stage P = 0.007), Kadish stage (P = 0.025) and treatment modality (P = 0.015). Conclusion Late stage of TNM and Kadish staging system indicated a poor prognosis. Combined treatment modality, including endoscopic endonasal surgery, achieved a better outcome than non-surgical approach.	[Zhang, Luyao; Zhu, Kang; Xia, Cui; Yan, Jing; Wei, Junrong; Zheng, Guoxi] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Otorhinolaryngol Head & Neck Surg, Xian, Shaanxi, Peoples R China; [Niu, Kai; Duan, Maoli] Karolinska Inst, Karolinska Hosp, Dept Clin Sci Technol & Intervent, Stockholm, Sweden; [Niu, Kai] Jilin Univ, Affiliated Hosp 1, Dept Otorhinolaryngol Head & Neck Surg, Changchun, Jilin, Peoples R China; [Zhao, Wei] Shangluo Cent Hosp, Dept Otorhinolaryngol, Shangluo, Shaanxi, Peoples R China	Xi'an Jiaotong University; Karolinska Institutet; Karolinska University Hospital; Jilin University	Zheng, GX (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Otorhinolaryngol Head & Neck Surg, Xian, Shaanxi, Peoples R China.; Duan, ML (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Clin Sci Technol & Intervent, Stockholm, Sweden.	Maoli.Duan@ki.se; zhengguoxi@21cn.com			National Natural Science Foundation of China [81271057]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study is supported by the National Natural Science Foundation of China (No. 81271057,) (http://www.nsfc.gov.cn/publish/portall/). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bachar G, 2008, HEAD NECK-J SCI SPEC, V30, P1607, DOI 10.1002/hed.20920; Bell D, 2015, HEAD NECK PATHOL, V9, P51, DOI 10.1007/s12105-014-0547-3; Bossi P, 2015, CANCER TREAT REV, V41, P836, DOI 10.1016/j.ctrv.2015.07.004; Bradley Patrick J, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P112, DOI 10.1097/00020840-200304000-00009; Castelnuovo P, 2007, HEAD NECK-J SCI SPEC, V29, P845, DOI 10.1002/hed.20610; Devaiah AK, 2009, LARYNGOSCOPE, V119, P1412, DOI 10.1002/lary.20280; Devaney K, 1996, MODERN PATHOL, V9, P658; Devi Parvathi, 2014, J Oral Maxillofac Pathol, V18, pS135, DOI 10.4103/0973-029X.141367; DULGUEROV P, 1992, LARYNGOSCOPE, V102, P843, DOI 10.1288/00005537-199208000-00001; Dulguerov P, 2001, LANCET ONCOL, V2, P683, DOI 10.1016/S1470-2045(01)00558-7; Ferlito A, 2003, LARYNGOSCOPE, V113, P1935, DOI 10.1097/00005537-200311000-00015; FOOTE RL, 1993, INT J RADIAT ONCOL, V27, P835, DOI 10.1016/0360-3016(93)90457-7; Fu TS, 2016, HEAD NECK-J SCI SPEC, V38, pE2306, DOI 10.1002/hed.24233; Guled M, 2008, MODERN PATHOL, V21, P770, DOI 10.1038/modpathol.2008.57; HIROSE T, 1995, CANCER, V76, P4, DOI 10.1002/1097-0142(19950701)76:1<4::AID-CNCR2820760103>3.0.CO;2-E; Jethanamest D, 2007, ARCH OTOLARYNGOL, V133, P276, DOI 10.1001/archotol.133.3.276; KADISH S, 1976, CANCER, V37, P1571, DOI 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L; Kane AJ, 2010, J NEUROSURG, V113, P340, DOI 10.3171/2010.2.JNS091897; Komotar RJ, 2013, WORLD NEUROSURG, V80, P148, DOI 10.1016/j.wneu.2012.12.003; Lund VJ, 2015, RHINOLOGY, V53, P204, DOI 10.4193/Rhino14.318; Lund VJ, 1998, HEAD NECK-J SCI SPEC, V20, P97, DOI 10.1002/(SICI)1097-0347(199803)20:2<97::AID-HED1>3.0.CO;2-Y; Malouf GG, 2013, EUR J CANCER, V49, P1324, DOI 10.1016/j.ejca.2012.12.008; McElroy EA, 1998, NEUROSURGERY, V42, P1023, DOI 10.1097/00006123-199805000-00040; MORITA A, 1993, NEUROSURGERY, V32, P706, DOI 10.1227/00006123-199305000-00002; Ow TJ, 2014, HEAD NECK-J SCI SPEC, V36, P524, DOI 10.1002/hed.23327; Porter AB, 2008, J NEURO-ONCOL, V90, P201, DOI 10.1007/s11060-008-9645-y; Saade RE, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-014-0423-z; Song CM, 2012, LARYNGOSCOPE, V122, P2389, DOI 10.1002/lary.23641; Tajudeen BA, 2015, J NEUROL SURG PART B, V76, P43, DOI 10.1055/s-0034-1390011; Thompson LDR, 2009, HEAD NECK PATHOL, V3, P252, DOI 10.1007/s12105-009-0125-2; TROJANOWSKI JQ, 1982, NEW ENGL J MED, V307, P159, DOI 10.1056/NEJM198207153070305; Unger F, 2001, MINIM INVAS NEUROSUR, V44, P79, DOI 10.1055/s-2001-16000; Vucinic N, 2015, ACTA NEUROL BELG, V115, P195, DOI 10.1007/s13760-014-0319-6; Zafereo ME, 2008, OTOLARYNG HEAD NECK, V138, P452, DOI 10.1016/j.otohns.2007.12.038	34	10	11	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2016	11	11							e0166046	10.1371/journal.pone.0166046	http://dx.doi.org/10.1371/journal.pone.0166046			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA6DJ	27806104	Green Published, Green Submitted, gold			2023-01-03	WOS:000386715500079
J	Moriyama, M; Moriyama, H; Uda, J; Kubo, H; Nakajima, Y; Goto, A; Akaki, J; Yoshida, I; Matsuoka, N; Hayakawa, T				Moriyama, Mariko; Moriyama, Hiroyuki; Uda, Junki; Kubo, Hirokazu; Nakajima, Yuka; Goto, Arisa; Akaki, Junji; Yoshida, Ikuyo; Matsuoka, Nobuya; Hayakawa, Takao			Beneficial Effects of the Genus Aloe on Wound Healing, Cell Proliferation, and Differentiation of Epidermal Keratinocytes	PLOS ONE			English	Article							E-CADHERIN; VERA; GEL; EXTRACT; GROWTH; CREAM	Aloe has been used as a folk medicine because it has several important therapeutic properties. These include wound and burn healing, and Aloe is now used in a variety of commercially available topical medications for wound healing and skin care. However, its effects on epidermal keratinocytes remain largely unclear. Our data indicated that both Aloe vera gel (AVG) and Cape aloe extract (CAE) significantly improved wound healing in human primary epidermal keratinocytes (HPEKs) and a human skin equivalent model. In addition, flow cytometry analysis revealed that cell surface expressions of beta 1-, alpha 6-, beta 4-integrin, and E-cadherin increased in HPEKs treated with AVG and CAE. These increases may contribute to cell migration and wound healing. Treatment with Aloe also resulted in significant changes in cell-cycle progression and in increases in cell number. Aloe increased gene expression of differentiation markers in HPEKs, suggesting roles for AVG and CAE in the improvement of keratinocyte function. Furthermore, human skin epidermal equivalents developed from HPEKs with medium containing Aloe were thicker than control equivalents, indicating the effectiveness of Aloe on enhancing epidermal development. Based on these results, both AVG and CAE have benefits in wound healing and in treatment of rough skin.	[Moriyama, Mariko; Moriyama, Hiroyuki; Uda, Junki; Kubo, Hirokazu; Nakajima, Yuka; Goto, Arisa; Hayakawa, Takao] Kindai Univ, Pharmaceut Res & Technol Inst, Osaka, Japan; [Akaki, Junji; Yoshida, Ikuyo; Matsuoka, Nobuya] KOBAYASHI Pharmaceut Co Ltd, Cent R&D Lab, Osaka, Japan	Kindai University (Kinki University); Kobayashi Pharmaceutical Co Ltd	Moriyama, M (corresponding author), Kindai Univ, Pharmaceut Res & Technol Inst, Osaka, Japan.	mariko@phar.kindai.ac.jp			Ministry of Education, culture, sports, science, and technology (MEXT) KAKENHI grant [26461672]; Japan Agency for Medical Research and Development (AMED); KOBAYASHI Pharmaceutical Co., Ltd; MEXT KAKENHI [26461672]; Grants-in-Aid for Scientific Research [26501007] Funding Source: KAKEN	Ministry of Education, culture, sports, science, and technology (MEXT) KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); KOBAYASHI Pharmaceutical Co., Ltd; MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the Ministry of Education, culture, sports, science, and technology (MEXT) KAKENHI grant (http://www.mext.go.jp/a_menu/shinkou/hojyo/main5_a5.html) 26461672 to MM. In addition, the study was supported in part by grants from Japan Agency for Medical Research and Development (AMED) (http://www.amed.go.jp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. KOBAYASHI Pharmaceutical Co., Ltd provided support in the form of salaries for authors JA, IY, and NM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; We thank Ryo Morita and Takashi Morita for technical support. This study was financially supported by Kobayashi Pharmaceutical Co., Ltd. It was also supported by MEXT KAKENHI grant 26461672 to MM. In addition, the study was supported in part by grants from Japan Agency for Medical Research and Development (AMED).	BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Chen WY, 2012, PHYTOCHEM LETT, V5, P1, DOI 10.1016/j.phytol.2011.09.001; Choi S, 2003, SEMINARS INTEGRATIVE; Choi SW, 2001, BRIT J DERMATOL, V145, P535, DOI 10.1046/j.1365-2133.2001.04410.x; Dagne E, 2000, CURR ORG CHEM, V4, P1055, DOI 10.2174/1385272003375932; DAVIS RH, 1994, J AM PODIAT MED ASSN, V84, P77, DOI 10.7547/87507315-84-2-77; GRINDLAY D, 1986, J ETHNOPHARMACOL, V16, P117, DOI 10.1016/0378-8741(86)90085-1; Habeeb F, 2007, METHODS, V42, P388, DOI 10.1016/j.ymeth.2007.03.005; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hwang S, 2012, J BIOL CHEM, V287, P22227, DOI 10.1074/jbc.M112.367979; Jia YM, 2008, J ETHNOPHARMACOL, V120, P181, DOI 10.1016/j.jep.2008.08.008; KAWAI K, 1993, PHYTOTHER RES, V7, pS5, DOI 10.1002/ptr.2650070705; MABUSELA WT, 1990, PHYTOCHEMISTRY, V29, P3555, DOI 10.1016/0031-9422(90)85275-K; Manvitha K, 2014, J PHARMACOGNOSY PHYT, P2; Moriyama M, 2006, J CELL BIOL, V173, P333, DOI 10.1083/jcb.200509084; Moriyama N, 2001, J LAB CLIN MED, V138, P236, DOI 10.1067/mlc.2001.118177; O'Brien C, 2011, S AFR J BOT, V77, P988, DOI 10.1016/j.sajb.2011.08.004; Radha Maharjan H, 2015, J Tradit Complement Med, V5, P21, DOI 10.1016/j.jtcme.2014.10.006; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Stuart RW, 1997, INT J IMMUNOPHARMACO, V19, P75, DOI 10.1016/S0192-0561(97)00010-6; Syed TA, 1996, TROP MED INT HEALTH, V1, P505, DOI 10.1046/j.1365-3156.1996.d01-91.x; Takahashi M, 2009, J OLEO SCI, V58, P643, DOI 10.5650/jos.58.643; Tarameshloo M, 2012, ANAT CELL BIOL, V45, P170, DOI 10.5115/acb.2012.45.3.170; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Vogler BK, 1999, BRIT J GEN PRACT, V49, P823; Xing W, 2015, J DERMATOL SCI, V79, P101, DOI 10.1016/j.jdermsci.2015.03.016; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zawahry M E, 1973, Int J Dermatol, V12, P68, DOI 10.1111/j.1365-4362.1973.tb00215.x	29	35	37	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2016	11	10							e0164799	10.1371/journal.pone.0164799	http://dx.doi.org/10.1371/journal.pone.0164799			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CV	27736988	Green Published, gold, Green Submitted			2023-01-03	WOS:000385505800131
J	McCartney, M				McCartney, Margaret			Margaret McCartney: General practice is a long game	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358					0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	2017	356								j736	10.1136/bmj.j736	http://dx.doi.org/10.1136/bmj.j736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL4GI	28193638	Bronze, Green Published			2023-01-03	WOS:000394579300004
J	Lipska, KJ				Lipska, Kasia J.			Metformin Use in Patients With Historical Contraindications	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OUTCOMES		[Lipska, Kasia J.] Yale Sch Med, New Haven, CT USA	Yale University	Lipska, KJ (corresponding author), Yale Sch Med, Endocrinol Sect, Dept Internal Med, POB 208020, New Haven, CT 06520 USA.	kasia.lipska@yale.edu			National Institute on Aging; American Federation of Aging Research through a Paul Beeson Career Development Award [K23AG048359]; Yale Claude D. Pepper Older Americans Independence Center [P30AG021342]; NATIONAL INSTITUTE ON AGING [P30AG021342, K23AG048359] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation of Aging Research through a Paul Beeson Career Development Award; Yale Claude D. Pepper Older Americans Independence Center; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	From the National Institute on Aging and the American Federation of Aging Research through a Paul Beeson Career Development Award (K23AG048359) and the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342).	Bax JJ, 2007, DIABETES CARE, V30, P1295, DOI 10.2337/dc06-2094; Bennett WL, 2011, ANN INTERN MED, V154, P602, DOI 10.7326/0003-4819-154-9-201105030-00336; Crowley MJ, 2017, ANN INTERN MED, V166, P191, DOI 10.7326/M16-1901; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Lipska KJ, 2016, CIRCULATION, V134, P1405, DOI 10.1161/CIRCULATIONAHA.116.023041; Misbin RI, 1998, NEW ENGL J MED, V338, P265, DOI 10.1056/NEJM199801223380415; Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; US Department of Health and Human Services Guidance for Industry, 2008, DIAB MELL EV CARD RI; Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827	10	8	8	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2017	166	3					225	+		10.7326/M16-2712	http://dx.doi.org/10.7326/M16-2712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL7DL	28055052	Green Accepted			2023-01-03	WOS:000394781200013
J	Someya, S; Kujoth, GC; Kim, MJ; Hacker, TA; Vermulst, M; Weindruch, R; Prolla, TA				Someya, Shinichi; Kujoth, Gregory C.; Kim, Mi-Jung; Hacker, Timothy A.; Vermulst, Marc; Weindruch, Richard; Prolla, Tomas A.			Effects of calorie restriction on the lifespan and healthspan of POLG mitochondrial mutator mice	PLOS ONE			English	Article							OXIDATIVE DAMAGE; DNA POLYMERASE; AGED RAT; MUTATIONS; OVEREXPRESSION; MUSCLE; REPLICATION; PHENOTYPES; STRESS; BRAIN	Mitochondrial DNA (mtDNA) mutations are thought to have a causative role in age-related pathologies. We have shown previously that mitochondrial mutator mice (Polg(D257A/D257A)), harboring a proofreading-deficient version of the mtDNA polymerase gamma (POLG), accumulate mtDNA mutations in multiple tissues and display several features of accelerated aging. Calorie restriction (CR) is known to delay the onset of age-related diseases and to extend the lifespan of a variety of species, including rodents. In the current study we investigated the effects of CR on the lifespan and healthspan of mitochondrial mutator mice. Longterm CR did not increase the median or maximum lifespan of Polg(D257A/D257A) mice. Furthermore, CR did not reduce mtDNA deletions in the heart and muscle, accelerated sarcopenia, testicular atrophy, nor improve the alterations in cardiac parameters that are present in aged mitochondrial mutator mice. Therefore, our findings suggest that accumulation of mtDNA mutations may interfere with the beneficial action of CR in aging retardation.	[Someya, Shinichi; Kim, Mi-Jung] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA; [Kujoth, Gregory C.] Univ Wisconsin, Dept Neurol Surg, Madison, WI USA; [Hacker, Timothy A.] Univ Wisconsin, Dept Med, Madison, WI USA; [Vermulst, Marc] Univ Penn, Ctr Mitochondrial & Epigen Med, Philadelphia, PA 19104 USA; [Weindruch, Richard] Univ Wisconsin, Geriatr Res Educ & Clin Ctr, Vet Adm Hosp, Madison, WI USA; [Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; [Prolla, Tomas A.] Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA	State University System of Florida; University of Florida; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Pennsylvania; Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Prolla, TA (corresponding author), Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.; Prolla, TA (corresponding author), Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA.	taprolla@wisc.edu		Someya, Shinichi/0000-0001-9895-6227	NIH [RO1 AG021905, RO1 DC012552, R01 DC014437, R03 DC011840]; American Federation for Aging Research Grant; NIH/NIA Claude D. Pepper Older Americans Independence Center Junior Scholar Award; NATIONAL INSTITUTE ON AGING [R01AG021905, P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC014437, R03DC011840, R01DC012552] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Federation for Aging Research Grant; NIH/NIA Claude D. Pepper Older Americans Independence Center Junior Scholar Award; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This research was supported by NIH grants RO1 AG021905 (T.A.P.), RO1 DC012552 (S.S.), R01 DC014437 (S.S.) and R03 DC011840 (S.S.), American Federation for Aging Research Grant (S.S.), and NIH/NIA Claude D. Pepper Older Americans Independence Center Junior Scholar Award (S.S.).	Ahlqvist KJ, 2012, CELL METAB, V15, P100, DOI 10.1016/j.cmet.2011.11.012; Al-Regaiey KA, 2005, ENDOCRINOLOGY, V146, P851, DOI 10.1210/en.2004-1120; Alderman JM, 2010, GERONTOLOGY, V56, P404, DOI 10.1159/000235720; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045; Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646; Copeland WC, 2010, SUBCELL BIOCHEM, V50, P211, DOI 10.1007/978-90-481-3471-7_11; Dai DF, 2010, AGING CELL, V9, P536, DOI 10.1111/j.1474-9726.2010.00581.x; Dai DF, 2009, CIRCULATION, V119, P2789, DOI 10.1161/CIRCULATIONAHA.108.822403; Dai Y, 2013, MITOCHONDRION, V13, P282, DOI 10.1016/j.mito.2013.03.006; Diderich K, 2011, DNA REPAIR, V10, P772, DOI 10.1016/j.dnarep.2011.04.025; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Fox RG, 2012, AM J PHYSIOL-GASTR L, V302, pG914, DOI 10.1152/ajpgi.00402.2011; Hamilton R, 2016, J NEUROL SCI, V370, P47, DOI 10.1016/j.jns.2016.09.021; Han C, 2013, EXP GERONTOL, V48, P1091, DOI 10.1016/j.exger.2013.02.014; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Kolesar JE, 2014, FREE RADICAL BIO MED, V75, P241, DOI 10.1016/j.freeradbiomed.2014.07.038; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kujoth GC, 2007, PLOS GENET, V3, P161, DOI 10.1371/journal.pgen.0030024; Lezza AMS, 2008, NEUROCHEM RES, V33, P2609, DOI 10.1007/s11064-008-9866-7; Masternak MM, 2009, J GERONTOL A-BIOL, V64, P516, DOI 10.1093/gerona/glp024; McKiernan SH, 2011, EXP GERONTOL, V46, P23, DOI 10.1016/j.exger.2010.09.011; Muller FL, 2007, AM J PHYSL REGUL INT, V293; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Safdar A, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0075-9; Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95; Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407	36	13	14	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171159	10.1371/journal.pone.0171159	http://dx.doi.org/10.1371/journal.pone.0171159			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DG	28158260	Green Published, gold, Green Submitted			2023-01-03	WOS:000396161700034
J	Henley, AB; Yang, L; Chuang, KL; Sahuri-Arisoylu, M; Wu, LH; Bligh, SWA; Bell, JD				Henley, Aine Brigette; Yang, Ling; Chuang, Kun-Lin; Sahuri-Arisoylu, Meliz; Wu, Li-Hong; Bligh, S. W. Annie; Bell, Jimmy David			Withania somnifera Root Extract Enhances Chemotherapy through 'Priming'	PLOS ONE			English	Article							CELL LUNG-CARCINOMA; MITOCHONDRIAL DYSFUNCTION; COLON-CANCER; IN-VITRO; WITHAFERIN; ATP; INHIBITION; METABOLISM; GENERATION; QUERCETIN	Withania somnifera extracts are known for their anti-cancerous, anti-inflammatory and antioxidative properties. One of their mechanisms of actions is to modulate mitochondrial function through increasing oxidative stress. Recently `priming' has been suggested as a potential mechanism for enhancing cancer cell death. In this study we demonstrate that `priming', in HT-29 colon cells, with W. somnifera root extract increased the potency of the chemotherapeutic agent cisplatin. We have also showed the W. somnifera root extract enhanced mitochondrial dysfunction and that the underlying mechanism of `priming' was selectively through increased ROS. Moreover, we showed that this effect was not seen in non-cancerous cells.	[Henley, Aine Brigette; Sahuri-Arisoylu, Meliz; Bligh, S. W. Annie; Bell, Jimmy David] Univ Westminster, Fac Sci & Technol, Dept Life Sci, London, England; [Yang, Ling; Chuang, Kun-Lin] China Med Univ, Coll Pharm, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung, Taiwan; [Wu, Li-Hong] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai, Peoples R China; [Henley, Aine Brigette] Karolinska Inst, Dept Microbiol Tumour & Cell Biol, Stockholm, Sweden	University of Westminster; China Medical University Taiwan; Shanghai University of Traditional Chinese Medicine; Karolinska Institutet	Bligh, SWA (corresponding author), Univ Westminster, Fac Sci & Technol, Dept Life Sci, London, England.	a.bligh@westminster.ac.uk	Bligh, Annie/AAI-9786-2020	Bligh, Annie/0000-0002-4757-2159; Bell, Jimmy/0000-0003-3804-1281	MRC [MC_U120061305] Funding Source: UKRI; Medical Research Council [MC_U120061305] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Arisan ED, 2010, BREAST CANCER RES TR, V119, P271, DOI 10.1007/s10549-009-0343-z; Biswal BM, 2013, INTEGR CANCER THER, V12, P312, DOI 10.1177/1534735412464551; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Caley ACR., 2012, SURGERY, V30, P186, DOI DOI 10.1016/J.MPSUR.2012.01.004; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Ferber EC, 2012, CELL DEATH DIFFER, V19, P968, DOI 10.1038/cdd.2011.179; Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354; Hahm ER, 2011, MOL CARCINOGEN, V50, P614, DOI 10.1002/mc.20760; Halder B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137498; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang HY, 2013, J BIOL CHEM, V288, P19870, DOI 10.1074/jbc.M112.448290; Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007; Jiang K, 2015, ONCOL REP, V33, P2711, DOI 10.3892/or.2015.3915; Kuhar M, 2006, ANTICANCER RES, V26, P1297; Kuhar M., 2007, J CANC MOL, V3, P121, DOI DOI 10.29685/JCM.200708.0004; Kumar A, 2012, MOL CELL BIOCHEM, V371, P43, DOI 10.1007/s11010-012-1421-9; Kumar P, 2009, J MED FOOD, V12, P591, DOI 10.1089/jmf.2008.0028; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Li X, 2015, CANCER LETT, V357, P219, DOI 10.1016/j.canlet.2014.11.026; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Malik F, 2007, APOPTOSIS, V12, P2115, DOI 10.1007/s10495-007-0129-x; Malik F, 2009, EUR J CANCER, V45, P1494, DOI 10.1016/j.ejca.2009.01.034; Mei Y., 2014, BIOCH BIOPHYS ACTA; Muller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3; Muralikrishnan G, 2010, IMMUNOL INVEST, V39, P688, DOI 10.3109/08820139.2010.487083; Oh J, 2008, APOPTOSIS, V13, P1494, DOI 10.1007/s10495-008-0273-y; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Rajeswaran A, 2008, LUNG CANCER, V59, P1, DOI 10.1016/j.lungcan.2007.07.012; Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722; Sarosiek KA, 2013, TRENDS CELL BIOL, V23, P612, DOI 10.1016/j.tcb.2013.08.003; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Sharma H, 2005, CANCER BIOL THER, V4, P949, DOI 10.4161/cbt.4.9.1908; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tiwari BS, 2002, PLANT PHYSIOL, V128, P1271, DOI 10.1104/pp.010999; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Yadav B, 2010, INDIAN J PHARM SCI, V72, P659, DOI 10.4103/0250-474X.78543; Yu YK, 2010, BIOCHEM PHARMACOL, V79, P542, DOI 10.1016/j.bcp.2009.09.017; Zhang X, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3983	47	12	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2017	12	1							e0170917	10.1371/journal.pone.0170917	http://dx.doi.org/10.1371/journal.pone.0170917			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7VX	28129345	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000396211400027
J	Chen, YA; Lien, HM; Kao, MC; Lo, UG; Lin, LC; Lin, CJ; Chang, SJ; Chen, CC; Hsieh, JT; Lin, H; Tang, CH; Lai, CH				Chen, Yu-An; Lien, Hsiu-Man; Kao, Min-Chuan; Lo, U-Ging; Lin, Li-Chiung; Lin, Chun Jung; Chang, Sheau-Jiun; Chen, Chia-Chang; Hsieh, Jer-Tsong; Lin, Ho; Tang, Chih-Hsin; Lai, Chih-Ho			Sensitization of Radioresistant Prostate Cancer Cells by Resveratrol Isolated from Arachis hypogaea Stems	PLOS ONE			English	Article							CYTOLETHAL DISTENDING TOXIN; GENE-EXPRESSION; DOWN-REGULATION; DNA-DAMAGE; DAB2IP; APOPTOSIS; PEANUTS; RADIOTHERAPY; PATHWAYS; INFLAMMATION	Resveratrol (RV, 3,4' ,5-trihydroxystilbene) is naturally produced by a wide variety of plants including grapes and peanuts (Arachis hypogaea). However, the yield of RV from peanut stem and its potential radiosensitizing effects in prostate cancer (PCa) have not been well investigated. In this study, we characterized RV in peanut stem extract (PSE) for the first time and showed that both RV and PSE dose-dependently induced cell death in DOC-2/DAB2 interactive protein (DAB2IP)-deficient PCa cells with the radio-resistant phenotype. Furthermore, the combination of radiation with either RV or PSE induced the death of radioresistant PCa cells through delayed repair of radiation-induced DNA double-strand break (DSB) and prolonged G2/M arrest, which induced apoptosis. The administration of RV and PSE effectively enhanced radiation therapy in the shDAB2IP PCa xenograft mouse model. These results demonstrate the promising synergistic effect of RV and PSE combined with radiation in the treatment of radioresistant PCa.	[Chen, Yu-An; Tang, Chih-Hsin; Lai, Chih-Ho] China Med Univ, Grad Inst Basic Med Sci, Sch Med, Taichung, Taiwan; [Lien, Hsiu-Man] Hungkuang Univ, Biotechnol Res Inst, Taichung, Taiwan; [Kao, Min-Chuan; Lai, Chih-Ho] Chang Gung Univ, Grad Inst Biomed Sci, Dept Microbiol & Immunol, Coll Med, Taoyuan, Taiwan; [Lo, U-Ging; Lin, Li-Chiung; Lin, Chun Jung; Hsieh, Jer-Tsong] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Lin, Li-Chiung; Lin, Ho] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Chang, Sheau-Jiun] Dachien Gen Hosp, Dept Rehabil, Miaoli, Taiwan; [Chen, Chia-Chang] Feng Chia Univ, Sch Management, Taichung, Taiwan; [Lai, Chih-Ho] Asia Univ, Dept Nursing, Taichung, Taiwan; [Lai, Chih-Ho] Chang Gung Mem Hosp, Mol Infect Dis Res Ctr, Taoyuan, Taiwan	China Medical University Taiwan; Hungkuang University; Chang Gung University; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Chung Hsing University; Feng Chia University; Asia University Taiwan; Chang Gung Memorial Hospital	Lai, CH (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA.	jt.hsieh@utsouthwestern.edu; hlin@dragen.nchu.edu.tw; chtang@mail.cmu.edu.tw; chlai@mail.cgu.edu.tw		Lin, Chun-Jung/0000-0002-2955-6913; Lin, Ho/0000-0001-7849-9137	Central Taiwan Science Park [103-RB04]; Ministry of Science and Technology [104-2911-I-005-501, 104-2320-B-182-040, 105-2313-B-182-001]; Chang Gung Memorial Hospital [CMRPD1F0011-3, CMRPD1F0431-3, BMRPE90]; Tomorrow Medical Foundation	Central Taiwan Science Park; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Tomorrow Medical Foundation	This study was supported by grants from Central Taiwan Science Park (103-RB04), Ministry of Science and Technology (104-2911-I-005-501, 104-2320-B-182-040, and 105-2313-B-182-001), Chang Gung Memorial Hospital (CMRPD1F0011-3, CMRPD1F0431-3, and BMRPE90), and the Tomorrow Medical Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Latif GA, 2015, SCI REP-UK, V5, DOI 10.1038/srep12054; Angele S, 2004, AM J CLIN PATHOL, V121, P231, DOI 10.1309/JTKGGGKURFX3XMGT; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Benitez DA, 2009, PROSTATE, V69, P1045, DOI 10.1002/pros.20953; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Chen RS, 2013, N-S ARCH PHARMACOL, V386, P1047, DOI 10.1007/s00210-013-0905-9; Clement MV, 1998, BLOOD, V92, P996; de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405; Dearnaley DP, 1999, LANCET, V353, P267, DOI 10.1016/S0140-6736(98)05180-0; DORNER JW, 1989, MYCOPATHOLOGIA, V105, P117, DOI 10.1007/BF00444034; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Francisco MLDL, 2008, CRIT REV FOOD SCI, V48, P715, DOI 10.1080/10408390701640718; Gao Y, 2015, J ETHNOPHARMACOL, V169, P24, DOI 10.1016/j.jep.2015.03.074; Giovinazzo G, 2012, PLANT FOOD HUM NUTR, V67, P191, DOI 10.1007/s11130-012-0299-8; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jasinski M, 2013, CENT EUR J UROL, V66, P144, DOI 10.5173/ceju.2013.02.art8; Kma L, 2013, ASIAN PAC J CANCER P, V14, P6197, DOI 10.7314/APJCP.2013.14.11.6197; Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919; Lai CK, 2015, FUTURE MICROBIOL, V10, P489, DOI [10.2217/FMB.14.119, 10.2217/fmb.14.119]; Lai CK, 2014, NANOMEDICINE-UK, V9, P803, DOI [10.2217/NNM.13.54, 10.2217/nnm.13.54]; Lai CH, 2014, ONCOTARGET, V5, P5523, DOI 10.18632/oncotarget.2133; Lien HM, 2013, J ETHNOPHARMACOL, V145, P397, DOI 10.1016/j.jep.2012.11.015; Lin CJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146432; Lin HJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00341; Liu HH, 2014, BIOMEDICINE-TAIWAN, V4, P7, DOI 10.7603/s40681-014-0002-5; McMillan TJ, 2001, INT J RADIAT ONCOL, V49, P373, DOI 10.1016/S0360-3016(00)01467-X; Pong RC, 2006, CANCER RES, V66, P8822, DOI 10.1158/0008-5472.CAN-05-4672; Rao YK, 2012, FOOD CHEM, V132, P780, DOI 10.1016/j.foodchem.2011.11.037; Rashid A, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-144; Romero-Perez AI, 1999, J AGR FOOD CHEM, V47, P1533, DOI 10.1021/jf981024g; Sanders TH, 2000, J AGR FOOD CHEM, V48, P1243, DOI 10.1021/jf990737b; Selvaraj S, 2016, MOL CARCINOGEN, V55, P818, DOI 10.1002/mc.22324; Sim HG, 2005, EUR J CANCER, V41, P834, DOI 10.1016/j.ejca.2004.12.033; Smoliga JM, 2011, MOL NUTR FOOD RES, V55, P1129, DOI 10.1002/mnfr.201100143; Sobolev VS, 1999, J AGR FOOD CHEM, V47, P1435, DOI 10.1021/jf9809885; Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tang FY, 2008, MOL NUTR FOOD RES, V52, P683, DOI 10.1002/mnfr.200700325; Tsai YS, 2014, ONCOTARGET, V5, P6425, DOI 10.18632/oncotarget.2228; Tsunoda T, 2014, ANTICANCER RES, V34, P4551; Tyagi A, 2011, CLIN CANCER RES, V17, P5402, DOI 10.1158/1078-0432.CCR-11-1072; Vergara D, 2012, MOL BIOSYST, V8, P1078, DOI 10.1039/c2mb05486h; Wang Y, 2002, J AGR FOOD CHEM, V50, P431, DOI 10.1021/jf010812u; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Yun EJ, 2014, ONCOGENE; Yun EJ, 2016, CLIN CANCER RES, V22, P670, DOI 10.1158/1078-0432.CCR-15-0190; Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200	50	33	35	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2017	12	1							e0169204	10.1371/journal.pone.0169204	http://dx.doi.org/10.1371/journal.pone.0169204			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH7JQ	28081154	gold, Green Published, Green Submitted			2023-01-03	WOS:000391949500031
J	Magalhaes, LP; dos Reis, LM; Graciolli, FG; Pereira, BJ; de Oliveira, RB; de Souza, AAL; Moyses, RM; Elias, RM; Jorgetti, V				Magalhaes, Luciene P.; dos Reis, Luciene M.; Graciolli, Fabiana G.; Pereira, Benedito J.; de Oliveira, Rodrigo B.; de Souza, Altay A. L.; Moyses, Rosa M.; Elias, Rosilene M.; Jorgetti, Vanda			Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis	PLOS ONE			English	Article							GROWTH-FACTOR 23; DISEASE; INFLAMMATION; OUTCOMES	Background Chronic kidney disease (CKD) affects 10-15% of adult population worldwide. Incident patients on hemodialysis, mainly those on urgent-start dialysis at the emergency room, have a high mortality risk, which may reflect the absence of nephrology care. A lack of data exists regarding the influence of baseline factors on the mortality of these patients. The aim of this study was to evaluate the clinical and laboratory characteristics of this population and identify risk factors that contribute to their mortality. Patients and methods We studied 424 patients who were admitted to our service between 01/2006 and 12/2012 and were followed for 1 year. We analyzed vascular access, risk factors linked to cardiovascular disease (CVD) and mineral and bone disease associated with CKD (CKD-MBD), and clinical events that occurred during the follow-up period. Factors that influenced patient survival were evaluated by Cox regression analysis. Results The patient mean age was 50 18 years, and 58.7% of them were male. Hypertension was the main cause of primary CKD (31.8%). Major risk factors were smoking (19.6%), dyslipidemia (48.8%), and CVD (41%). Upon admission, most patients had no vascular access for hemodialysis (89.4%). Biochemical results showed that most patients were anemic with high C-reactive protein levels, hypocalcemia, hyperphosphatemia, elevated parathyroid hormone and decreased 25-hydroxy vitamin D. At the end of one year, 60 patients died (14.1%). These patients were significantly older, had a lower percentage of arteriovenous fistula in one year, and low levels of 25-hydroxy vitamin D. Conclusions The combined evaluation of clinical and biochemical parameters and risk factors revealed that the mortality in urgent-start dialysis is associated with older age and low levels of vitamin D deficiency. A lack of a permanent hemodialysis access after one year was also a risk factor for mortality in this population.	[Magalhaes, Luciene P.; dos Reis, Luciene M.; Graciolli, Fabiana G.; Pereira, Benedito J.; Moyses, Rosa M.; Elias, Rosilene M.; Jorgetti, Vanda] Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil; [Pereira, Benedito J.; Moyses, Rosa M.] Univ Nove Julho UNINOVE, Med Master Degree Program, Sao Paulo, Brazil; [de Oliveira, Rodrigo B.] Univ Estadual Campinas, Sch Med Sci, Div Nephrol, UNICAMP, Campinas, SP, Brazil; [de Souza, Altay A. L.] Fed Univ Sao Paulo UNIFESP, Dept Psychobiol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Nove de Julho; Universidade Estadual de Campinas; Universidade Federal de Sao Paulo (UNIFESP)	Jorgetti, V (corresponding author), Univ Sao Paulo, Sch Med, Div Nephrol, Sao Paulo, Brazil.	vandajor@usp.br	dos Reis, Luciene M/C-7143-2013; de Oliveira, Rodrigo Bueno/I-2186-2015; Elias, Rosilene M/J-1099-2012; JORGETTI, VANDA/C-9470-2012; Moyses, Rosa M A/F-8268-2012	dos Reis, Luciene M/0000-0001-8476-6780; de Oliveira, Rodrigo Bueno/0000-0002-8273-6200; Elias, Rosilene M/0000-0003-2212-041X; JORGETTI, VANDA/0000-0002-4824-8879; Moyses, Rosa M A/0000-0002-7902-2127	Sao Paulo Research Foundation (FAPESP) [2010/03867-7]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Sao Paulo Research Foundation (FAPESP) - Grant number: 2010/03867-7 to VJ.	Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Jimenez ZNC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042290; Carrero JJ, 2010, SEMIN DIALYSIS, V23, P498, DOI 10.1111/j.1525-139X.2010.00784.x; Charytan DM, 2015, AM J KIDNEY DIS, V66, P196, DOI 10.1053/j.ajkd.2014.12.016; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Diegoli Henrique, 2015, Braz. J. Nephrol., V37, P32, DOI 10.5935/0101-2800.20150006; Drueke TB, 2010, NAT REV NEPHROL, V6, P723, DOI 10.1038/nrneph.2010.143; Foley RN, 2014, KIDNEY INT, V86, P392, DOI 10.1038/ki.2014.15; Fouque D, 2011, KIDNEY INT, V80, P348, DOI 10.1038/ki.2011.118; Gutierrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506; Hayashi T, 2000, AM J KIDNEY DIS, V35, P250, DOI 10.1016/S0272-6386(00)70334-9; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Isakova T, 2012, CURR OPIN NEPHROL HY, V21, P334, DOI 10.1097/MNH.0b013e328351a391; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT SUPPL, V3, P1, DOI [DOI 10.1038/KISUP.2012.73, 10.1038/kisup.2012.73]; Kim SM, 2014, J RENAL NUTR, V24, P20, DOI 10.1053/j.jrn.2013.07.003; Kosa SD, 2013, SEMIN DIALYSIS, V26, P482, DOI 10.1111/sdi.12115; LINK CL, 1984, BIOMETRICS, V40, P601, DOI 10.2307/2530904; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Machowska A, 2016, TRANSL RES, V167, P204, DOI 10.1016/j.trsl.2015.06.012; Malas MB, 2015, JAMA SURG, V150, P441, DOI 10.1001/jamasurg.2014.3484; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Pisoni RL, 2009, AM J KIDNEY DIS, V53, P475, DOI 10.1053/j.ajkd.2008.10.043; Rastogi Anjay, 2013, Ther Adv Cardiovasc Dis, V7, P322, DOI 10.1177/1753944713513061; Robinson BM, 2014, KIDNEY INT, V85, P158, DOI 10.1038/ki.2013.252; Scott MC, 2015, EMERG MED CLIN N AM, V33, P553, DOI 10.1016/j.emc.2015.04.006; Smart NA, 2014, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD007333:PUB2; Smart NA, 2011, AM J MED, V124, P1073, DOI 10.1016/j.amjmed.2011.04.026; Stevens PE, 2013, ANN INTERN MED, V158, P825, DOI 10.7326/0003-4819-158-11-201306040-00007; Unger MD, 2010, CLIN NUTR, V29, P784, DOI 10.1016/j.clnu.2010.06.009; United States Renal Data System, 2015, 2015 USRDS ANN DAT R; Wang AYM, 2008, J AM SOC NEPHROL, V19, P1643, DOI 10.1681/ASN.2008010012	31	9	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0167895	10.1371/journal.pone.0167895	http://dx.doi.org/10.1371/journal.pone.0167895			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2QJ	28045952	gold, Green Published, Green Submitted			2023-01-03	WOS:000391612300010
J	Coskun, A; Baykal, AT; Kazan, D; Akgoz, M; Senal, MO; Berber, I; Titiz, I; Bilsel, G; Kilercik, H; Karaosmanoglu, K; Cicek, M; Yurtsever, I; Yazici, C				Coskun, Abdurrahman; Baykal, Ahmet Tarik; Kazan, Dilek; Akgoz, Muslum; Senal, Merve Oztug; Berber, Ibrahim; Titiz, Izzet; Bilsel, Gokhan; Kilercik, Hakan; Karaosmanoglu, Kubra; Cicek, Muslum; Yurtsever, Ilknur; Yazici, Cevat			Proteomic Analysis of Kidney Preservation Solutions Prior to Renal Transplantation	PLOS ONE			English	Article							ISCHEMIA; PROTEINS; EXPRESSION; ACTIN; APOPTOSIS; INJURY; BETA	One of the main issues in kidney transplantation is the optimal functional preservation of the organ until its transplantation into the appropriate recipient. Despite intensive efforts, the functional preservation period remains limited to hours. During this time, as a result of cellular injury, various proteins, peptides, and other molecules are released by the organ into the preservation medium. In this study, we used proteomic techniques to analyze the protein profiles of preservation solutions in which organs had been preserved prior to their transplantation. Samples were obtained from the preservation solutions of 25 deceased donor kidneys scheduled for transplantation. The protein profiles of the solutions were analyzed using 2D gel electrophoresis/MALDI-TOF and LC-MS/MS. We identified and quantified 206 proteins and peptides belonging to 139 different groups. Of these, 111 proteins groups were belonging to kidney tissues. This study used proteomic techniques to analyze the protein profiles of organ preservation solutions. These findings will contribute to the development of improved preservation solutions to effectively protect organs for transplantation.	[Coskun, Abdurrahman; Baykal, Ahmet Tarik] Acibadem Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey; [Kazan, Dilek; Karaosmanoglu, Kubra] Marmara Univ, Fac Engn, Dept Bioengn, Istanbul, Turkey; [Akgoz, Muslum; Senal, Merve Oztug; Bilsel, Gokhan] Natl Metrol Inst, Gebze, Turkey; [Berber, Ibrahim] Acibadem Univ, Sch Med, Dept Gen Surg, Istanbul, Turkey; [Titiz, Izzet] Haydarpasa Numune Res & Training Hosp, Dept Gen Surg, Istanbul, Turkey; [Kilercik, Hakan; Cicek, Muslum] Yeni Yuzyil Univ, Gaziosmanpasa Hosp, Dept Anesthesiol, Istanbul, Turkey; [Yurtsever, Ilknur] Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, Beykoz Istanbul, Turkey; [Yazici, Cevat] Erciyes Univ, Sch Med, Dept Med Biochem, Kayseri, Turkey	Acibadem University; Marmara University; National Metrology Institute of Turkey; Acibadem University; Istanbul Haydarpasa Numune Training & Research Hospital; Gaziosmanpasa University; Yeni Yuzyil University; Istanbul Medipol University; Erciyes University	Coskun, A (corresponding author), Acibadem Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey.	Coskun2002@gmail.com	Oztug, Merve/ABC-4768-2021; cicek, muslum/AGX-0585-2022; Akgoz, Muslum/AAG-4598-2019; cicek, muslum/P-5252-2019; yurtsever, ilknur/G-2560-2019; Oztug, Merve/AAH-6132-2021; Berber, Ibrahim/C-2852-2019; Baykal, Ahmet T/C-3948-2013; Coskun, Abdurrahman/C-3906-2015; YAZICI, Cevat/AAE-2558-2019; Berber, ibrahim/E-2583-2016	cicek, muslum/0000-0001-9187-8342; Akgoz, Muslum/0000-0001-5065-8087; Oztug, Merve/0000-0002-6287-2774; Baykal, Ahmet T/0000-0002-8814-7351; Coskun, Abdurrahman/0000-0002-1273-0604; YAZICI, Cevat/0000-0003-0625-9542; Berber, ibrahim/0000-0002-6618-8347	Scientific and Technological Research Council of Turkey (TUBITAK) [110S103]	Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK))	This study was financed by The Scientific and Technological Research Council of Turkey (TUBITAK), project number 110S103, http://www.tubitak.gov.tr/en. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARON P, 1994, ANN NY ACAD SCI, V723, P401, DOI 10.1111/j.1749-6632.1994.tb36758.x; Baykal AT, 2013, TURK J BIOL, V37, P414, DOI 10.3906/biy-1208-14; Caron A, 2004, ARCH BIOCHEM BIOPHYS, V431, P31, DOI 10.1016/j.abb.2004.07.009; Chatauret N, 2011, CURR OPIN ORGAN TRAN, V16, P180, DOI 10.1097/MOT.0b013e3283446b1d; Desai MM, 2005, BJU INT, V95, P377, DOI 10.1111/j.1464-410X.2005.05304.x; Ebert T, 2014, NUTR METAB CARDIOVAS, V24, P1027, DOI 10.1016/j.numecd.2014.03.006; Fox C, 2016, SCI REP-UK, V6, DOI 10.1038/srep20101; Genesca M, 2006, APOPTOSIS, V11, P563, DOI 10.1007/s10495-006-4937-1; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; Gottmann U, 2007, TRANSPLANTATION, V84, P755, DOI 10.1097/01.tp.0000281410.85659.48; GRONE HJ, 1987, AM J PATHOL, V129, P1; Gunal O, 2010, TURK J MED SCI, V40, P465, DOI 10.3906/sag-0811-26; Hauet T, 2008, KIDNEY INT, V74, P998, DOI 10.1038/ki.2008.336; Joosten SA, 2002, AM J PATHOL, V160, P1301, DOI 10.1016/S0002-9440(10)62557-6; Kaga E, 2013, J PROTEOMICS, V92, P260, DOI 10.1016/j.jprot.2013.06.015; Kelly KJ, 2005, CONTRIB NEPHROL, V148, P86, DOI 10.1159/000086054; Kepka Alina, 2008, Pol Merkur Lekarski, V24, P125; Kruidering M, 1998, CELL DEATH DIFFER, V5, P601, DOI 10.1038/sj.cdd.4400392; Lefaucheur C, 2014, CLIN EXP IMMUNOL, V178, P57, DOI 10.1111/cei.12511; MOLITORIS BA, 1989, J CLIN INVEST, V84, P1334, DOI 10.1172/JCI114302; MOLITORIS BA, 1992, AM J PHYSIOL, V263, pF488, DOI 10.1152/ajprenal.1992.263.3.F488; Nanda N, 2009, BIOMARK INSIGHTS, V4, P111; Noris M, 2012, CLIN KIDNEY J, V5, P94, DOI 10.1093/ckj/sfs032; O'Neill S, 2014, NEPHRON EXP NEPHROL, V126, P167, DOI 10.1159/000363323; PFALLER W, 1994, KIDNEY INT, pS68; Rienstra H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009095; Serhatli M, 2014, J PROTEOME RES, V13, P5071, DOI 10.1021/pr5006586; Smith MPW, 2013, KIDNEY INT, V84, P1214, DOI 10.1038/ki.2013.200; Spiegel HU, 2001, SPR SP SURG SER, P265; Tamura M, 1996, BIOCHEM BIOPH RES CO, V222, P683, DOI 10.1006/bbrc.1996.0804; Tang Z, 2014, J PROTEOME RES, V13, P2433, DOI 10.1021/pr500192g; Thelen S, 2015, AM J PHYSIOL-RENAL, V309, pF501, DOI 10.1152/ajprenal.00220.2014; Tian X, 2014, J CLIN INVEST, V124, P1098, DOI 10.1172/JCI69778; Wang F, 2015, KIDNEY INT, V88, P796, DOI 10.1038/ki.2015.176; Whitaker RM, 2015, TOXICOL SCI, V145, P108, DOI 10.1093/toxsci/kfv038; Yamauchi A, 2002, J PHARM PHARMACOL, V54, P205, DOI 10.1211/0022357021778394; Zager RA, 2012, AM J PHYSIOL-RENAL, V303, pF1460, DOI 10.1152/ajprenal.00426.2012; Zager RA, 2009, AM J PHYSIOL-RENAL, V296, pF1032, DOI 10.1152/ajprenal.00061.2009	38	12	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2016	11	12							e0168755	10.1371/journal.pone.0168755	http://dx.doi.org/10.1371/journal.pone.0168755			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7LN	28036361	Green Published, Green Submitted, gold			2023-01-03	WOS:000391229300025
J	Hoberman, A; Paradise, JL; Rockette, HE; Kearney, DH; Bhatnagar, S; Shope, TR; Martin, JM; Kurs-Lasky, M; Copelli, SJ; Colborn, DK; Block, SL; Labella, JJ; Lynch, TG; Cohen, NL; Haralam, M; Pope, MA; Nagg, JP; Green, MD; Shaikh, N				Hoberman, Alejandro; Paradise, Jack L.; Rockette, Howard E.; Kearney, Diana H.; Bhatnagar, Sonika; Shope, Timothy R.; Martin, Judith M.; Kurs-Lasky, Marcia; Copelli, Susan J.; Colborn, D. Kathleen; Block, Stan L.; Labella, John J.; Lynch, Thomas G.; Cohen, Norman L.; Haralam, MaryAnn; Pope, Marcia A.; Nagg, Jennifer P.; Green, Michael D.; Shaikh, Nader			Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIALS; INFANTS	BACKGROUND Limiting the duration of antimicrobial treatment constitutes a potential strategy to reduce the risk of antimicrobial resistance among children with acute otitis media. METHODS We assigned 520 children, 6 to 23 months of age, with acute otitis media to receive amoxicillin-clavulanate either for a standard duration of 10 days or for a reduced duration of 5 days followed by placebo for 5 days. We measured rates of clinical response (in a systematic fashion, on the basis of signs and symptomatic response), recurrence, and nasopharyngeal colonization, and we analyzed episode outcomes using a noninferiority approach. Symptom scores ranged from 0 to 14, with higher numbers indicating more severe symptoms. RESULTS Children who were treated with amoxicillin-clavulanate for 5 days were more likely than those who were treated for 10 days to have clinical failure (77 of 229 children [34%] vs. 39 of 238 [16%]; difference, 17 percentage points [based on unrounded data]; 95% confidence interval, 9 to 25). The mean symptom scores over the period from day 6 to day 14 were 1.61 in the 5-day group and 1.34 in the 10-day group (P=0.07); the mean scores at the day-12-to-14 assessment were 1.89 versus 1.20 (P=0.001). The percentage of children whose symptom scores decreased more than 50% (indicating less severe symptoms) from baseline to the end of treatment was lower in the 5-day group than in the 10-day group (181 of 227 children [80%] vs. 211 of 233 [91%], P=0.003). We found no significant between-group differences in rates of recurrence, adverse events, or nasopharyngeal colonization with penicillin-nonsusceptible pathogens. Clinical-failure rates were greater among children who had been exposed to three or more children for 10 or more hours per week than among those with less exposure (P=0.02) and were also greater among children with infection in both ears than among those with infection in one ear (P<0.001). CONCLUSIONS Among children 6 to 23 months of age with acute otitis media, reduced-duration antimicrobial treatment resulted in less favorable outcomes than standard-duration treatment; in addition, neither the rate of adverse events nor the rate of emergence of antimicrobial resistance was lower with the shorter regimen. (Funded by the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources; ClinicalTrials.gov number, NCT01511107.)	[Hoberman, Alejandro; Paradise, Jack L.; Kearney, Diana H.; Bhatnagar, Sonika; Shope, Timothy R.; Martin, Judith M.; Kurs-Lasky, Marcia; Copelli, Susan J.; Colborn, D. Kathleen; Haralam, MaryAnn; Pope, Marcia A.; Nagg, Jennifer P.; Green, Michael D.; Shaikh, Nader] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr UPMC, Dept Pediat,Sch Med, Pittsburgh, PA 15213 USA; [Rockette, Howard E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Labella, John J.; Lynch, Thomas G.; Cohen, Norman L.] Childrens Community Pediat, Pittsburgh, PA USA; [Block, Stan L.] Kentucky Pediat & Adult Res, Bardstown, KY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hoberman, A (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Gen Acad Pediat, 3414 5th Ave, Pittsburgh, PA 15213 USA.	hoberman@chp.edu		Shope, Timothy/0000-0002-0974-2639	National Institute of Allergy and Infectious Diseases; National Center for Research Resources; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Funded by the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources	Dagan R, 2002, PEDIATR INFECT DIS J, V21, P894, DOI 10.1097/00006454-200210000-00003; Finkelstein JA, 2000, ARCH PEDIAT ADOL MED, V154, P395, DOI 10.1001/archpedi.154.4.395; Hoberman A, 2011, NEW ENGL J MED, V364, P105, DOI 10.1056/NEJMoa0912254; KALEIDA PH, 1992, AM J DIS CHILD, V146, P433, DOI 10.1001/archpedi.1992.02160160053013; Kaleida PH, 2009, PEDIATRICS, V124, pE714, DOI 10.1542/peds.2008-2838; Kozyrskyj A, 2010, COCHRANE DB SYST REV, V9; Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488; Lipsitch M, 2001, CLIN INFECT DIS, V32, P1044, DOI 10.1086/319604; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; Schappert Susan M, 2011, Vital Health Stat 13, P1; Schumi J, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-106; Shaikh N, 2009, PEDIATR INFECT DIS J, V28, P5, DOI 10.1097/INF.0b013e318185a387; Shaikh N, 2015, PEDIATR INFECT DIS J, V34, pE41, DOI 10.1097/INF.0000000000000557; Tahtinen PA, 2011, NEW ENGL J MED, V364, P116, DOI 10.1056/NEJMoa1007174	14	61	61	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2016	375	25					2446	2456		10.1056/NEJMoa1606043	http://dx.doi.org/10.1056/NEJMoa1606043			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF1NL	28002709	Green Accepted			2023-01-03	WOS:000390091500008
J	Ferrario, C; Strepponi, I; Esfahani, K; Charamis, H; Langleben, A; Scarpi, E; Nanni, O; Miller, WH; Panasci, LC				Ferrario, Cristiano; Strepponi, Ivan; Esfahani, Khashayar; Charamis, Helen; Langleben, Adrian; Scarpi, Emanuela; Nanni, Oriana; Miller, Wilson H., Jr.; Panasci, Lawrence C.			Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer	PLOS ONE			English	Article							DOUBLE-BLIND; III TRIAL; PLACEBO; CAPECITABINE; BEVACIZUMAB; PACLITAXEL; EFFICACY; TARGETS; PATHWAY; SAFETY	Background Preclinical models have reported a synergistic interaction between sorafenib and vinorelbine. We investigated the toxicity, efficacy, and pharmacokinetics interaction of this combination as first-line treatment for patients with metastatic breast cancer. Methods Patients were HER2-negative and treated with vinorelbine 30 mg/m(2) IV days 1,8 every 21 plus daily oral sorafenib. In the phase I portion (3+3 design) patients received sorafenib 200 mg BID (cohort 1) or 400 mg BID (cohort 2). In the phase II expansion, 21 more evaluable patients were planned to receive the maximum tolerated dose (MTD). Pharmacokinetic analysis was performed in 6 patients: blood concentrations were compared for each drug in the presence or absence of the other drug. Results In cohort 1, one patient experienced a dose-limiting toxicity (DLT) (grade 3 pancreatitis), requiring the expansion of this cohort to 6 patients, without further documented DLTs. In cohort 2, one patient of six experienced a grade 4 DLT (asymptomatic rise in amylase not requiring drug discontinuation), establishing this dose level as the MTD (sorafenib 400 mg BID). After expansion at the MTD, a total of 27 patients (median age 57) were treated for a median of 8 cycles. One grade 5 febrile neutropenia occurred. With repeated cycles, 52% of patients required at least 1 dose reduction of either drug. One patient experienced a sustained grade 3 fatigue resulting in treatment discontinuation. The response rate was 30%. Median PFS was 5.7 months (95% CI 4.4-7.6), and clinical benefit (absence of disease progression at 6 months) was 48%. PK analysis showed a significant interaction between the two drugs, resulting in a higher Cmax of vinorelbine in the presence of sorafenib. Conclusion The combination of sorafenib and vinorelbine at full doses is feasible but not devoid of toxicity, likely also due to a significant PK interaction.	[Ferrario, Cristiano; Esfahani, Khashayar; Charamis, Helen; Langleben, Adrian; Miller, Wilson H., Jr.; Panasci, Lawrence C.] McGill Univ, Dept Med Oncol, Montreal, PQ, Canada; [Strepponi, Ivan] Sede Secondaria Cell Therapeut, Dept Cell Therapeut, Bresso, Italy; [Scarpi, Emanuela; Nanni, Oriana] Ist Sci Romagnolo Studio Cura Tumori, Dept Stat, Rome, Italy	McGill University; IRCCS Meldola (IRST)	Ferrario, C; Esfahani, K (corresponding author), McGill Univ, Dept Med Oncol, Montreal, PQ, Canada.	cristianoferrario@gmail.com; Khashayar.esfahani@mail.mcgill.ca	Scarpi, Emanuela/AAD-7036-2019; nanni, oriana/K-3240-2016	Scarpi, Emanuela/0000-0001-7230-9267; nanni, oriana/0000-0001-7338-2896	Bayer Pharmaceutical [12661]	Bayer Pharmaceutical	The study is funded by Bayer Pharmaceutical (Grant number 12661; https://www.bayer.ca.). The funder provided support in the form of research materials for author LP, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.	Baselga J, 2012, J CLIN ONCOL, V30, P1484, DOI 10.1200/JCO.2011.36.7771; Bianchi G, 2009, ANTI-CANCER DRUG, V20, P616, DOI 10.1097/CAD.0b013e32832b2ea0; Brufsky AM, 2011, J CLIN ONCOL, V29, P4286, DOI 10.1200/JCO.2010.34.1255; Carter CA, 2007, CANCER CHEMOTH PHARM, V59, P183, DOI 10.1007/s00280-006-0257-y; Gradishar WJ, 2013, EUR J CANCER, V49, P312, DOI 10.1016/j.ejca.2012.08.005; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Luu T, 2014, CLIN BREAST CANCER, V14, P94, DOI 10.1016/j.clbc.2013.10.013; Mano M, 2006, CANCER TREAT REV, V32, P106, DOI 10.1016/j.ctrv.2005.12.008; Mariani G, 2011, EUR J CANCER, V47, P10, DOI 10.1016/S0959-8049(11)70116-2; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Moreno-Aspitia A, 2009, J CLIN ONCOL, V27, P11, DOI 10.1200/JCO.2007.15.5242; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Rossari JR, 2012, J ONCOL, V2012, DOI 10.1155/2012/417673; Schwartzberg LS, 2013, CLIN CANCER RES, V19, P2745, DOI 10.1158/1078-0432.CCR-12-3177; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443	17	8	8	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2016	11	12							e0167906	10.1371/journal.pone.0167906	http://dx.doi.org/10.1371/journal.pone.0167906			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QC	27992451	Green Published, Green Submitted, gold			2023-01-03	WOS:000392842600024
J	Jia, PL; Zhang, LH; Chen, JJ; Zhao, PJ; Zhang, MM				Jia, Pengli; Zhang, Longhao; Chen, Jingjing; Zhao, Pujing; Zhang, Mingming			The Effects of Clinical Decision Support Systems on Medication Safety: An Overview	PLOS ONE			English	Article							PHYSICIAN ORDER ENTRY; ADVERSE DRUG EVENTS; PATIENT OUTCOMES; PRIMARY-CARE; INTERVENTIONS; MANAGEMENT; IMPACT; ERRORS; PERFORMANCE; REMINDERS	Background The clinical decision support system(CDSS) has potential to improving medication safety. However, the effects of the intervention were conflicting and uncertain. Meanwhile, the reporting and methodological quality of this field were unknown. Objective The aim of this overview is to evaluate the effects of CDSS on medication safety and to examine the methodological and reporting quality. Methods PubMed, Embase and Cochrane Library were searched to August 2015. Systematic reviews (SRs) investigating the effects of CDSS on medication safety were included. Outcomes were determined in advance and assessed separately for process of care and patient outcomes. The methodological quality was assessed by Assessment of Multiple Systematic Reviews (AMSTAR) and the reporting quality was examined by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results Twenty systematic reviews, consisting of 237 unique randomized controlled trials(RCTs) and 176 non-RCTs were included. Evidence that CDSS significantly impacted process of care was found in 108 out of 143 unique studies of the 16 SRs examining this effect (75%). Only 18 out of 90 unique studies of the 13 SRs reported significantly evidence that CDSS positively impacted patient outcomes (20%). Ratings for the overall scores of AMSTAR resulted in a mean score of 8.3 with a range of scores from 7.5 to 10.5. The reporting quality was varied. Some contents were particularly strong. However, some contents were poor. Conclusions CDSS reduces medication error by obviously improving process of care and inconsistently improving patient outcomes. Larger samples and longer-term studies are required to ensure more reliable evidence base on the effects of CDSS on patient outcomes. The methodological and reporting quality were varied and some realms need to be improved.	[Jia, Pengli; Zhang, Longhao; Zhao, Pujing; Zhang, Mingming] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu, Peoples R China; [Chen, Jingjing] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Hangzhou, Zhejiang, Peoples R China	Sichuan University; Zhejiang Chinese Medical University	Zhang, MM (corresponding author), Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu, Peoples R China.	mingming-zhang@163.com			National Natural Science Foundation [70973083]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This project was supported by the National Natural Science Foundation NO. 70973083.	Alldred DP, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009095.pub2; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bayoumi I, 2014, INT J MED INFORM, V83, P406, DOI 10.1016/j.ijmedinf.2014.03.003; Bennett JW, 2003, MED J AUSTRALIA, V178, P217, DOI 10.5694/j.1326-5377.2003.tb05166.x; Berner ES, 2009, CLIN DECISION SUPPOR; Brahma DK, 2013, J PHARMACOL PHARMACO, V4, P91, DOI 10.4103/0976-500X.110872; Chiang SJ, 2010, CLIN DECISION SUPPOR; FERYLEMONNIER E, 1995, INTENS CARE MED, V21, P356, DOI 10.1007/BF01705416; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Ge L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085908; Gillaizeau F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002894.pub3; Haynes RB, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-12; Hemens BJ, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-89; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Jaspers MWM, 2011, J AM MED INFORM ASSN, V18, P327, DOI 10.1136/amiajnl-2011-000094; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Julie B, 2012, COCHRANE DB SYST REV; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Keers RN, 2014, DRUG SAFETY, V37, P317, DOI 10.1007/s40264-014-0152-0; Kuperman GJ, 2007, J AM MED INFORM ASSN, V14, P29, DOI 10.1197/jamia.M2170; Lainer M, 2013, INT J QUAL HEALTH C, V25, P590, DOI 10.1093/intqhc/mzt043; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lees KR, 2003, QJM-INT J MED, V96, P143, DOI 10.1093/qjmed/hcg019; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Loganathan M, 2011, AGE AGEING, V40, P150, DOI 10.1093/ageing/afq161; Manias E, 2012, BRIT J CLIN PHARMACO, V74, P411, DOI 10.1111/j.1365-2125.2012.04220.x; Montesi G, 2009, BRIT J CLIN PHARMACO, V67, P651, DOI 10.1111/j.1365-2125.2009.03422.x; Nieuwlaat R, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-90; Papageorgiou SN, 2014, EUR J ORTHODONT, V36, P74, DOI 10.1093/ejo/cjt008; Pearson Sallie-Anne, 2009, BMC Health Serv Res, V9, P154, DOI 10.1186/1472-6963-9-154; Robertson Jane, 2010, Int J Pharm Pract, V18, P69; Sahota N, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-91; Sandars J, 2003, FAM PRACT, V20, P231, DOI 10.1093/fampra/cmg301; Schedlbauer A, 2009, J AM MED INFORM ASSN, V16, P531, DOI 10.1197/jamia.M2910; Seo HJ, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-129; Sequeira-Byron P, 2011, J APPL ORAL SCI, V19, P440, DOI 10.1590/S1678-77572011000500002; Shamliyan TA, 2008, HEALTH SERV RES, V43, P32, DOI 10.1111/j.1475-6773.2007.00751.x; Shea BJ, 2007, BMC MED RES METHODOL, V15, P7, DOI [10.1186/1471-2288-7-10, DOI 10.1186/1471-2288-7-10]; Shojania Kaveh G, 2009, Cochrane Database Syst Rev, pCD001096, DOI 10.1002/14651858.CD001096.pub2; Tawadrous D, 2011, AM J KIDNEY DIS, V58, P903, DOI 10.1053/j.ajkd.2011.07.022; Teich JM, 2005, J AM MED INFORM ASSN, V12, P365, DOI 10.1197/jamia.M1822; Vervloet M, 2012, J AM MED INFORM ASSN, V19, P696, DOI 10.1136/amiajnl-2011-000748; Walton R, 1999, BRIT MED J, V318, P984, DOI 10.1136/bmj.318.7189.984; Wolfstadt JI, 2008, J GEN INTERN MED, V23, P451, DOI 10.1007/s11606-008-0504-5	46	39	40	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							0167683	10.1371/journal.pone.0167683	http://dx.doi.org/10.1371/journal.pone.0167683			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EG7HN	27977697	Green Published, gold, Green Submitted			2023-01-03	WOS:000391217400028
J	Phillips, AN; Cambiano, V; Nakagawa, F; Bansi-Matharu, L; Sow, PS; Ehrenkranz, P; Ford, D; Mugurungi, O; Apollo, T; Murungu, J; Bangsberg, DR; Revill, P				Phillips, Andrew N.; Cambiano, Valentina; Nakagawa, Fumiyo; Bansi-Matharu, Loveleen; Sow, Papa Salif; Ehrenkranz, Peter; Ford, Deborah; Mugurungi, Owen; Apollo, Tsitsi; Murungu, Joseph; Bangsberg, David R.; Revill, Paul			Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE-INCOME COUNTRIES; DRUG-RESISTANCE; VIROLOGICAL FAILURE; SOUTH-AFRICA; VIRAL LOAD; HIV CARE; COHORT; PATTERNS; PEOPLE	Background Interventions based around objective measurement of adherence to antiretroviral drugs for HIV have potential to improve adherence and to enable differentiation of care such that clinical visits are reduced in those with high adherence. It would be useful to understand the approximate upper limit of cost that could be considered for such interventions of a given effectiveness in order to be cost effective. Such information can guide whether to implement an intervention in the light of a trial showing a certain effectiveness and cost. Methods An individual-based model, calibrated to Zimbabwe, which incorporates effects of adherence and resistance to antiretroviral therapy, was used to model the potential impact of adherence monitoring-based interventions on viral suppression, death rates, disability adjusted life years and costs. Potential component effects of the intervention were: enhanced average adherence when on ART, reduced risk of ART discontinuation, and reduced risk of resistance acquisition. We considered a situation in which viral load monitoring is not available and one in which it is. In the former case, it was assumed that care would be differentiated based on the adherence level, with fewer clinic visits in those demonstrated to have high adherence. In the latter case, care was assumed to be primarily differentiated according to viral load level. The maximum intervention cost required to be cost effective was calculated based on a cost effectiveness threshold of $500 per DALY averted. Findings In the absence of viral load monitoring, an adherence monitoring-based intervention which results in a durable 6% increase in the proportion of ART experienced people with viral load < 1000 cps/mL was cost effective if it cost up to $ 50 per person-year on ART, mainly driven by the cost savings of differentiation of care. In the presence of viral load monitoring availability, an intervention with a similar effect on viral load suppression was cost-effective when costing $23-$32 per year, depending on whether the adherence intervention is used to reduce the level of need for viral load measurement. Conclusion The cost thresholds identified suggest that there is clear scope for adherence monitoring-based interventions to provide net population health gain, with potential cost-effective use in situations where viral load monitoring is or is not available. Our results guide the implementation of future adherence monitoring interventions found in randomized trials to have health benefit.	[Phillips, Andrew N.; Cambiano, Valentina; Nakagawa, Fumiyo; Bansi-Matharu, Loveleen] UCL, Res Dept Infect & Populat Hlth, London, England; [Sow, Papa Salif; Ehrenkranz, Peter] Bill & Melinda Gates Fdn, Seattle, WA USA; [Ford, Deborah] UCL, Inst Clin Trials & Methodol, London, England; [Mugurungi, Owen; Apollo, Tsitsi; Murungu, Joseph] Minist Hlth Child Care, Harare, Zimbabwe; [Bangsberg, David R.] Portland State Univ, Oregon Hlth Sci Univ, Sch Publ Hlth, Portland, OR 97207 USA; [Revill, Paul] Univ York, Ctr Hlth Econ, York, N Yorkshire, England	University of London; University College London; Bill & Melinda Gates Foundation; University of London; University College London; Oregon Health & Science University; Portland State University; University of York - UK	Phillips, AN (corresponding author), UCL, Res Dept Infect & Populat Hlth, London, England.	andrew.phillips@ucl.ac.uk	Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807; Revill, Paul/0000-0001-8632-0600	Bill & Melinda Gates Foundation [42889]; Medical Research Council [MC_UU_12023/23] Funding Source: researchfish	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded by the Bill & Melinda Gates Foundation, Investment ID 42889. PSS and PE from the Foundation determined the overall study question in collaboration with the other authors. PSS and PE from the Foundation encouraged manuscript submission but this was the final decision of AP with all the authors.	Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bangsberg DR, 2004, J ANTIMICROB CHEMOTH, V53, P696, DOI 10.1093/jac/dkh162; Blaschke TF, 2012, ANNU REV PHARMACOL, V52, P275, DOI 10.1146/annurev-pharmtox-011711-113247; Bonner K, 2013, JAIDS-J ACQ IMM DEF, V64, P74, DOI 10.1097/QAI.0b013e31829f05ac; Cambiano V, 2014, AIDS, V28, pS15, DOI 10.1097/QAD.0000000000000082; Cambiano V, 2010, AIDS, V24, P1153, DOI 10.1097/QAD.0b013e32833847af; Campbell JI, 2015, CURR HIV-AIDS REP, V12, P523, DOI 10.1007/s11904-015-0282-8; Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005; Chaiyachati KH, 2014, AIDS, V28, pS187, DOI 10.1097/QAD.0000000000000252; Chi BH, 2009, INT J EPIDEMIOL, V38, P746, DOI 10.1093/ije/dyp004; Claxton K, 2010, 54 U YORK CTR HLTH E, P54; Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M; Demonceau J, 2013, DRUGS, V73, P545, DOI 10.1007/s40265-013-0041-3; Duncombe C, 2015, TROP MED INT HEALTH, V20, P430, DOI 10.1111/tmi.12460; El-Khatib Z, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-88; Fox MP, 2012, JAIDS-J ACQ IMM DEF, V60, P428, DOI 10.1097/QAI.0b013e3182557785; Genberg BL, 2012, AIDS, V26, P1415, DOI 10.1097/QAD.0b013e328354bed6; Glass TR, 2010, JAIDS-J ACQ IMM DEF, V54, P197, DOI 10.1097/QAI.0b013e3181ca48bf; Grund B for the SMART Study Group, 2006, 16 INT AIDS C AUG 13; Haberer JE, 2016, 11 INT C HIV TREAT P; Haberer JE, 2013, AIDS, V27, P2166, DOI 10.1097/QAD.0b013e328363b53f; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Hassan AS, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-9; Hoffmann CJ, 2014, TROP MED INT HEALTH, V19, P236, DOI 10.1111/tmi.12237; Hoffmann CJ, 2009, CLIN INFECT DIS, V49, P1928, DOI 10.1086/648444; Hoffmann CJ, 2013, TROP MED INT HLTH; Hyle EP, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001725; Johannessen A, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-108; Kessler J, 2015, VALUE HEALTH, V18, P946, DOI 10.1016/j.jval.2015.09.2940; Kleeberger CA, 2004, AIDS, V18, P683, DOI 10.1097/00002030-200403050-00013; Kobin AB, 2011, ANN PHARMACOTHER, V45, P372, DOI 10.1345/aph.1P587; Kranzer K, 2011, TROP MED INT HEALTH, V16, P1297, DOI 10.1111/j.1365-3156.2011.02828.x; Kranzer K, 2010, JAIDS-J ACQ IMM DEF, V55, pE17, DOI 10.1097/QAI.0b013e3181f275fd; Lazo M, 2007, CLIN INFECT DIS, V45, P1377, DOI 10.1086/522762; Levine AJ, 2005, AIDS BEHAV, V9, P355, DOI 10.1007/s10461-005-9009-y; Li JZ, 2014, AIDS, V28, P181, DOI 10.1097/QAD.0000000000000123; Mackie NE, 2010, J INFECT DIS, V201, P1303, DOI 10.1086/651618; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Mathes T, 2013, INT J TECHNOL ASSESS, V29, P227, DOI 10.1017/S0266462313000317; Meresse M, 2014, HIVMED; MSF Access Campaign, 2014, UNT WEB ANT PRIC RED; Nakagawa F, 2012, AIDS, V26, P335, DOI 10.1097/QAD.0b013e32834dcec9; Orrell C, 2007, ANTIVIR THER, V12, P83; Orrell C, 2015, JAIDS-J ACQ IMM DEF, V70, P495, DOI 10.1097/QAI.0000000000000770; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Pellowski JA, 2012, CURR HIV-AIDS REP, V9, P326, DOI 10.1007/s11904-012-0133-9; Petersen ML, 2007, CLIN INFECT DIS, V45, P908, DOI 10.1086/521250; Phillips AN, 1997, AIDS, V11, P169, DOI 10.1097/00002030-199702000-00006; Phillips A, 2015, NATURE, V528, pS68, DOI 10.1038/nature16046; Phillips AN, 2011, AIDS, V25, P843, DOI 10.1097/QAD.0b013e328344037a; Roberts T, 2016, CLIN INFECT DIS; Rosenblum M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007196; Rutstein SE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124748; Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8; Siapka M, 2014, B WORLD HEALTH ORGAN, V92, P499, DOI 10.2471/BLT.13.127639; Tagar E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108304; Tassie JM, 2010, JAIDS-J ACQ IMM DEF, V54, P437, DOI 10.1097/QAI.0b013e3181d73e1b; Tran D.-X. T., 2014, BIOMEDICAL RES THERA, V1, P1, DOI DOI 10.1039/C4P00104D; Usitalo A, 2014, AIDS CARE, V26, P107, DOI 10.1080/09540121.2013.802280; von Wyl V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077691; Wandeler G, 2012, JAIDS-J ACQ IMM DEF, V59, pE9, DOI 10.1097/QAI.0b013e31823edb6a; Ware NC, 2016, AIDS, V30, P1287, DOI 10.1097/QAD.0000000000001035; Woods E, COUNTRY LEVEL COST E	64	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							0167654	10.1371/journal.pone.0167654	http://dx.doi.org/10.1371/journal.pone.0167654			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7HN	27977702	Green Published, Green Accepted, gold			2023-01-03	WOS:000391217400025
J	Yan, ZM; Liu, XS; Liu, Y; Han, Y; Lin, M; Wang, WM; Guan, XB; Zhu, SR; Zhang, HD; Wang, QT; Chou, LH; Zhu, XH; Hua, H				Yan, Zhimin; Liu, Xiaosong; Liu, Yang; Han, Ying; Lin, Mei; Wang, Wenmei; Guan, Xiaobing; Zhu, Shengrong; Zhang, Handong; Wang, Qintao; Chou, Lihong; Zhu, Xinghao; Hua, Hong			The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial	PLOS ONE			English	Article							OROPHARYNGEAL CANDIDIASIS; BUCCAL TABLET; PREVENTION; GUIDELINES; RESISTANCE; BLIND; GEL	Background Oral candidiasis (OC) is a common oral fungal infection. Recently, miconazole mucoadhesive tablets have been gaining attention for OC treatment. Despite trials in patients with human immunodeficiency virus and cancer, evidence of its application in the large-scale, general population with OC is lacking. This study aimed to evaluate the efficacy and safety of miconazole nitrate mucoadhesive tablets in comparison with itraconazole capsules for OC treatment. Methods The study was a randomized, open-label, parallel-armed, multicenter clinical trial. Totally, 343 patients diagnosed with OC, who met the inclusion criteria, were randomly assigned to either a treatment group that received miconazole nitrate mucoadhesive tablets (10 mg) once daily or a control group that received itraconazole capsules (100 mg QD) for 2 weeks, and were followed up for 2 weeks. The clinical cure, improvement of clinical symptoms/signs, mycologic cure, and safety were evaluated. Results The mucoadhesive tablets (n = 171) did not show inferiority to itraconazole (n = 172) in the treatment of OC. At the end of the 14-day treatment, the clinical cure rates were 45.29% and 41.76% in the miconazole and itraconazole groups, respectively (P = 0.3472). At the end of the 14-day follow-up, the clinical cure rates were 51.18% and 41.76% in the miconazole and itraconazole groups, respectively (P = 0.0329). Adverse events occurred in 53 subjects (33 in the miconazole group and 20 in the itraconazole group). There was no statistical difference in the safety profile between miconazole and itraconazole (P = 0.0533). Thrombocytopenic purpura, although rare, occurred in one patient in the miconazole group and was considered a drug-related, severe adverse event. Conclusion Miconazole nitrate mucoadhesive tablets may be as effective as systemic itraconazole capsule for OC treatment. Physicians should be cautious about thrombocytopenic purpura occurring as a rare and serious adverse event of miconazole nitrate.	[Yan, Zhimin; Liu, Xiaosong; Liu, Yang; Han, Ying; Hua, Hong] Peking Univ, Sch & Hosp Stomatol, Dept Oral Med, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China; [Lin, Mei] Sichuan Univ, West China Sch Stomatol, Dept Oral Med, Chengdu, Peoples R China; [Wang, Wenmei] Nanjing Univ, Sch Med, Dept Oral Med, Inst & Hosp Dent, Nanjing, Jiangsu, Peoples R China; [Guan, Xiaobing] Capital Med Univ, Beijing Stomatol Hosp, Dept Periodont & Oral Med, Beijing, Peoples R China; [Zhu, Shengrong] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Stomatol, Tongji Med Coll, Wuhan, Peoples R China; [Zhang, Handong] Huazhong Univ Sci & Technol, Union Hosp, Dept Stomatol, Tongji Med Coll, Wuhan, Peoples R China; [Wang, Qintao] Fourth Mil Med Univ, Sch Stomatol, Dept Periodontol, Xian, Peoples R China; [Chou, Lihong] China Med Univ, Hosp Stomatol, Shenyang, Peoples R China; [Zhu, Xinghao] Wenzhou Med Univ, Affiliated Hosp 1, Dept Stomatol, Wenzhou, Peoples R China	Peking University; Sichuan University; Nanjing University; Capital Medical University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Air Force Military Medical University; China Medical University; Wenzhou Medical University	Hua, H (corresponding author), Peking Univ, Sch & Hosp Stomatol, Dept Oral Med, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China.; Lin, M (corresponding author), Sichuan Univ, West China Sch Stomatol, Dept Oral Med, Chengdu, Peoples R China.	linmei2k@163.com; honghua68@hotmail.com						Bensadoun RJ, 2008, CANCER, V112, P204, DOI 10.1002/cncr.23152; BOUCKAERT S, 1992, EUR J CLIN PHARMACOL, V43, P137, DOI 10.1007/BF01740659; Cardot JM, 2004, BRIT J CLIN PHARMACO, V58, P345, DOI 10.1111/j.1365-2125.2004.02154.x; Fothergill Annette W, 2006, Expert Rev Anti Infect Ther, V4, P171, DOI 10.1586/14787210.4.2.171; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Hoepelman IM, 1996, INT J ANTIMICROB AG, V6, P155, DOI 10.1016/0924-8579(95)00050-X; [华红 Hua Hong], 2004, [中国新药与临床杂志, Chinese Journal of New Drugs and Clinical Remedies], V23, P335; KF S DG A D M Group C, 2010, OPEN MED, V8, P18, DOI DOI 10.7326/0003-4819-152-11-201006010-00232; Kulak-Ozkan Y, 2002, J ORAL REHABIL, V29, P300, DOI 10.1046/j.1365-2842.2002.00816.x; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; Pappas PG, 2004, CLIN INFECT DIS, V38, P161, DOI 10.1086/380796; Patton LL, 2001, ORAL SURG ORAL MED O, V92, P170, DOI 10.1067/moe.2001.116600; Prentice AG, 2005, J ANTIMICROB CHEMOTH, V56, P17; Quatresooz P, 2008, EXPERT OPIN PHARMACO, V9, P1927, DOI [10.1517/14656566.9.11.1927, 10.1517/14656566.9.11.1927 ]; Ruhnke M, 2000, J ANTIMICROB CHEMOTH, V46, P291, DOI 10.1093/jac/46.2.291; Samaranayake L P, 1988, Dent Update, V15, P227; Van Roey J, 2004, JAIDS-J ACQ IMM DEF, V35, P144, DOI 10.1097/00126334-200402010-00007; Vazquez JA, 2010, HIV CLIN TRIALS, V11, P186, DOI 10.1310/hct1104-186	19	7	8	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							0167880	10.1371/journal.pone.0167880	http://dx.doi.org/10.1371/journal.pone.0167880			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7HN	27977721	gold, Green Published, Green Submitted			2023-01-03	WOS:000391217400039
J	Limgala, RP; Ioanou, C; Plassmeyer, M; Ryherd, M; Kozhaya, L; Austin, L; Abidoglu, C; Unutmaz, D; Alpan, O; Goker-Alpan, O				Limgala, Renuka Pudi; Ioanou, Chidima; Plassmeyer, Matthew; Ryherd, Mark; Kozhaya, Lina; Austin, Lauren; Abidoglu, Cem; Unutmaz, Derya; Alpan, Oral; Goker-Alpan, Ozlem			Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease	PLoS One			English	Article							HUMAN TH17 CELLS; DENDRITIC CELLS; SCORING SYSTEM; MOUSE MODEL; HIV; INFECTION; DIAGNOSIS; MYELOMA; ADULTS; GOALS	Gaucher disease (GD) patients often present with abnormalities in immune response that may be the result of alterations in cellular and/or humoral immunity. However, how the treatment and clinical features of patients impact the perturbation of their immunological status remains unclear. To address this, we assessed the immune profile of 26 GD patients who were part of an enzyme replacement therapy (ERT) study. Patients were evaluated clinically for onset of GD symptoms, duration of therapy and validated outcome measures for ERT. According to DS3 disease severity scoring system criteria, they were assigned to have mild, moderate or severe GD. Flow cytometry based immunophenotyping was performed to analyze subsets of T, B, NK, NKT and dendritic cells. GD patients showed multiple types of immune abnormalities associated to T and B lymphocytes with respect to their subpopulations as well as memory and activation markers. Skewing of CD4 and CD8 T cell numbers resulting in lower CD4/CD8 ratio and an increase in overall T cell activation were observed. A decrease in the overall B cells and an increase in NK and NKT cells were noted in the GD patients compared to controls. These immune alterations do not correlate with GD clinical type or level of biomarkers. However, subjects with persistent immune alterations, especially in B cells and DCs correlate with longer delay in initiation of ERT (Delta TX). Thus, while ERT may reverse some of these immune abnormalities, the immune cell alterations become persistent if therapy is further delayed. These findings have important implications in understanding the immune disruptions before and after treatment of GD patients.	[Limgala, Renuka Pudi; Ioanou, Chidima; Goker-Alpan, Ozlem] Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA USA; [Limgala, Renuka Pudi; Plassmeyer, Matthew; Ryherd, Mark; Austin, Lauren; Alpan, Oral] O&O Alpan LLC, Amerimmune, Fairfax, VA 22030 USA; [Kozhaya, Lina; Abidoglu, Cem; Unutmaz, Derya] Jackson Lab Genom Med, Farmington, CT USA	Jackson Laboratory	Limgala, RP (corresponding author), Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA USA.; Limgala, RP (corresponding author), O&O Alpan LLC, Amerimmune, Fairfax, VA 22030 USA.	rlimgala@ldrtc.org		Limgala, Renuka/0000-0001-6957-6284	Amerimmune, O O Alpan, LLC	Amerimmune, O O Alpan, LLC	Amerimmune, O & O Alpan, LLC provided support in the form of salaries to authors [RPL, MP, MR, LA and OA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ayto Robert, 2013, Critical Reviews in Oncogenesis, V18, P247; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Bennett LL, 2013, ANN PHARMACOTHER, V47, P1182, DOI 10.1177/1060028013500469; Charrow J, 2015, AM J HEMATOL, V90, pS19, DOI 10.1002/ajh.24056; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Goker-Alpan O, 2010, THER CLIN RISK MANAG, V6, P315; Hemann EA, 2014, IMMUNOL RES, V59, P66, DOI 10.1007/s12026-014-8530-3; Hivroz C, 2012, CRIT REV IMMUNOL, V32, P139, DOI 10.1615/CritRevImmunol.v32.i2.30; Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052; Mistry PK, 2009, BRIT J HAEMATOL, V147, P561, DOI 10.1111/j.1365-2141.2009.07872.x; Mistry PK, 2007, AM J HEMATOL, V82, P697, DOI 10.1002/ajh.20908; Mackern-Oberti JP, 2015, AUTOIMMUN REV, V14, P127, DOI 10.1016/j.autrev.2014.10.010; Pandey MK, 2014, MOL GENET METAB, V111, P163, DOI 10.1016/j.ymgme.2013.09.002; Pandey Manoj Kumar, 2013, Critical Reviews in Oncogenesis, V18, P197; Pandey MK, 2012, MOL GENET METAB, V106, P310, DOI 10.1016/j.ymgme.2012.04.020; Pastores GM, 2004, SEMIN HEMATOL, V41, P4, DOI 10.1053/j.seminhematol.2004.07.009; Pavlova EV, 2013, J PATHOL, V231, P88, DOI 10.1002/path.4227; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Ratnam I, 2006, CLIN INFECT DIS, V42, P418, DOI 10.1086/499356; Rawlings SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126917; Rodic P, 2013, BLOOD CELL MOL DIS, V50, P222, DOI 10.1016/j.bcmd.2012.11.012; Serrano-Villar S, 2015, LANCET HIV, V2, pE76, DOI 10.1016/S2352-3018(15)00018-1; Sonder SU, 2016, BLOOD CELL MOL DIS, V59, P8, DOI 10.1016/j.bcmd.2016.02.003; Thomas AS, 2014, BRIT J HAEMATOL, V165, P427, DOI 10.1111/bjh.12804; Weinreb N, 2008, AM J HEMATOL, V83, P890, DOI 10.1002/ajh.21280; Weinreb NJ, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0280-3; Weinreb NJ, 2010, GENET MED, V12, P44, DOI 10.1097/GIM.0b013e3181c39194; Zimran A, 2014, PEDIATR ENDOCR REV P, V12, P82	28	21	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0168135	10.1371/journal.pone.0168135	http://dx.doi.org/10.1371/journal.pone.0168135			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27942037	Green Submitted, gold, Green Published			2023-01-03	WOS:000392745600053
J	Blanco-Reina, E; Garcia-Merino, MR; Ocana-Riola, R; Aguilar-Cano, L; Valdellos, J; Bellido-Estevez, I; Ariza-Zafra, G				Blanco-Reina, Encarnacion; Garcia-Merino, Maria Rosa; Ocana-Riola, Ricardo; Aguilar-Cano, Lorena; Valdellos, Jennifer; Bellido-Estevez, Inmaculada; Ariza-Zafra, Gabriel			Assessing Potentially Inappropriate Prescribing in Community-Dwelling Older Patients Using the Updated Version of STOPP-START Criteria: A Comparison of Profiles and Prevalences with Respect to the Original Version	PLOS ONE			English	Article							STOPP/START CRITERIA; SCREENING TOOL; PRIMARY-CARE; PRESCRIPTIONS/SCREENING TOOL; HOSPITALIZED-PATIENTS; ALERT DOCTORS; COST OUTCOMES; PEOPLE; POPULATION; ADULTS	Emerging and changing evidence made it necessary to update STOPP-START criteria, and version 2 was published recently. In this study the objectives were to determine the prevalence of potentially inappropriate medication prescribing (PIM) in primary care using STOPP versions 1 (v1) and 2 (v2), as well as 2012 AGS Beers criteria, and analyze the factors associated with inappropriate prescribing according to STOPP/START v2. A cross-sectional study was carried out including community-dwelling older adults over the age of 65. Socio-demographic, clinical, functional and comprehensive drug therapy data were collected. The primary endpoint was the percentage of patients receiving at least one PIM. This variable was measured using three tools: STOPP v1, 2012 AGS Beers criteria and STOPP v2. Similarly, the percentage of patients receiving at least one potential prescribing omission (PPO) was calculated using START versions 1 and 2. A total of 1,615 prescriptions were reviewed. The median number of medications per patient was 7.1 drugs (+/- 3.8). The prevalence of elderly people exposed to polypharmacy (>= 5 medications) was 72.9%, whereas 28.4% of the participants took >= 10 drugs regularly. PIM were present in 18.7%, 37.3% and 40.4% of participants, according to the STOPP v1, 2012 Beers criteria and STOPP v2, respectively. According to STOPP v2, the number of medications taken (OR: 1.14, 1.06-1.25), the presence of a psychological disorder (OR: 2.22, 1.13-4.37) and insomnia (OR: 3.35, 1.80-6.32) were risk factors for taking a PIM. The prevalence of PPOs was 34.7% and 21.8% according to version 1 and 2, respectively. In conclusion, STOPP-START criteria have been remarkably modified, which is evidenced by the different prevalence rates detected using version 2, as compared to version 1. In fact, the level of agreement between version 1 and the updated version is only moderate. Special attention should be paid on benzodiazepines, which keep being the most frequent PIM.	[Blanco-Reina, Encarnacion; Bellido-Estevez, Inmaculada] Univ Malaga, Malaga Biomed Inst IBIMA, Sch Med, Dept Pharmacol & Therapeut, Malaga, Spain; [Garcia-Merino, Maria Rosa] Hlth Dist Cordoba Sur, Cordoba, Spain; [Ocana-Riola, Ricardo] Andalusian Sch Publ Hlth, Dept Stat, Granada, Spain; [Aguilar-Cano, Lorena] Hlth Dist Malaga, Malaga, Spain; [Valdellos, Jennifer] Hlth Area Malaga Norte, Malaga, Spain; [Ariza-Zafra, Gabriel] Univ Hosp Albacete, Dept Geriatr, Albacete, Spain	Universidad de Malaga; Escuela Andaluza de Salud Publica	Blanco-Reina, E (corresponding author), Univ Malaga, Malaga Biomed Inst IBIMA, Sch Med, Dept Pharmacol & Therapeut, Malaga, Spain.	eblanco@uma.es	Estevez, Inmaculada Bellido/AAU-9222-2021; Ocaña-Riola, Ricardo/F-1576-2011	Ocaña-Riola, Ricardo/0000-0002-8965-0418; Bellido, Inmaculada/0000-0002-9362-8635; Valdellos Cabello, Jenifer/0000-0002-1034-5649; Blanco Reina, Encarnacion/0000-0001-5892-5450; Ariza-Zafra, Gabriel/0000-0001-9171-5535	Fundacion Publica Andaluza Progreso y Salud, Consejena de Salud, Junta de Andalucia [PI 0234/14]	Fundacion Publica Andaluza Progreso y Salud, Consejena de Salud, Junta de Andalucia	This research has been supported by public grant funding provided by the Fundacion Publica Andaluza Progreso y Salud, Consejena de Salud, Junta de Andalucia (grant number PI 0234/14). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahat G, 2016, GERIATR GERONTOL INT; Blanco-Reina E, 2015, EUR J CLIN PHARMACOL, V71, P199, DOI 10.1007/s00228-014-1780-0; Blanco-Reina E, 2014, J AM GERIATR SOC, V62, P1217, DOI 10.1111/jgs.12891; Bradley MC, 2012, EUR J CLIN PHARMACOL, V68, P1425, DOI 10.1007/s00228-012-1249-y; Cahir C, 2014, BRIT J CLIN PHARMACO, V77, P201, DOI 10.1111/bcp.12161; Cahir C, 2010, BRIT J CLIN PHARMACO, V69, P543, DOI 10.1111/j.1365-2125.2010.03628.x; Di Giorgio C, 2016, INT J CLIN PHARM-NET, V38, P462, DOI 10.1007/s11096-016-0284-7; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0; Galvin R, 2014, EUR J CLIN PHARMACOL, V70, P599, DOI 10.1007/s00228-014-1651-8; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Hedna K, 2015, EUR J CLIN PHARMACOL, V71, P1525, DOI 10.1007/s00228-015-1950-8; Hill-Taylor B, 2016, J CLIN PHARM THER, V41, P158, DOI 10.1111/jcpt.12372; Hill-Taylor B, 2013, J CLIN PHARM THER, V38, P360, DOI 10.1111/jcpt.12059; Khong TP, 2012, CALCIFIED TISSUE INT, V91, P24, DOI 10.1007/s00223-012-9603-8; Kovacevic SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095536; Lozano-Montoya I, 2015, AGE AGEING, V44, P861, DOI 10.1093/ageing/afv079; Martinez-Almazan E, 2013, J AM GERIATR SOC, V61, P1622, DOI 10.1111/jgs.12432; Moriarty F, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008656; Moriarty F, 2015, EUR J CLIN PHARMACOL, V71, P473, DOI 10.1007/s00228-015-1815-1; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; O'Sullivan DP, 2013, DRUG AGING, V30, P39, DOI 10.1007/s40266-012-0039-7; Lopez NP, 2014, ATEN PRIM, V46, P290, DOI 10.1016/j.aprim.2013.12.007; Projovic I, 2016, EUR J CLIN PHARMACOL, V72, P93, DOI 10.1007/s00228-015-1957-1; Ryan C, 2013, INT J CLIN PHARM-NET, V35, P230, DOI 10.1007/s11096-012-9733-0; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Tommelein E, 2015, EUR J CLIN PHARMACOL, V71, P1415, DOI 10.1007/s00228-015-1954-4; Tosato M, 2014, AGE AGEING, V43, P767, DOI 10.1093/ageing/afu029; Verdoorn S, 2015, EUR J CLIN PHARMACOL, V71, P1255, DOI 10.1007/s00228-015-1908-x	30	28	30	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167586	10.1371/journal.pone.0167586	http://dx.doi.org/10.1371/journal.pone.0167586			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3JC	27907210	gold, Green Submitted, Green Published			2023-01-03	WOS:000389482700204
J	Ahonkhai, V; Martins, SF; Portet, A; Lumpkin, M; Hartman, D				Ahonkhai, Vincent; Martins, Samuel F.; Portet, Alexandre; Lumpkin, Murray; Hartman, Dan			Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization	PLOS ONE			English	Article								Background The United Nations Millennium Development Goals galvanized global efforts to alleviate suffering of the world's poorest people through unprecedented public-private partnerships. Donor aid agencies have demonstrably saved millions of lives that might otherwise have been lost to disease through increased access to quality-assured vaccines and medicines. Yet, the introduction of these health interventions in low- and middle-income countries (LMICs) continues to face a time lag due to factors which remain poorly understood. Methods and Findings A recurring theme from our partnership engagements was that an optimized regulatory process would contribute to improved access to quality health products. Therefore, we investigated the current system for medicine and vaccine registration in LMICs as part of our comprehensive regulatory strategy. Here, we report a fact base of the registration timelines for vaccines and drugs used to treat certain communicable diseases in LMICs. We worked with a broad set of stakeholders, including the World Health Organization's prequalification team, national regulatory authorities, manufacturers, procurers, and other experts, and collected data on the timelines between first submission and last approval of applications for product registration sub-Saharan Africa. We focused on countries with the highest burden of communicable disease and the greatest need for the products studied. The data showed a typical lag of 4 to 7 years between the first regulatory submission which was usually to a regulatory agency in a high-income country, and the final approval in Sub-Saharan Africa. Two of the three typical registration steps which products undergo before delivery in the countries involve lengthy timelines. Failure to leverage or rely on the findings from reviews already performed by competent regulatory authorities, disparate requirements for product approval by the countries, and lengthy timelines by manufacturers to respond to regulatory queries were key underlying factors for the delays. Conclusions We propose a series of measures which we developed in close collaboration with key stakeholders that could be taken to reduce registration time and to make safe, effective medicines more quickly available in countries where they are most needed. Many of these recommendations are being implemented by the responsible stakeholders, including the WHO pre-qualification team and the national regulatory authorities in Sub-Saharan Africa. Those efforts will be the focus of subsequent publications by the pertinent groups.	[Ahonkhai, Vincent; Martins, Samuel F.; Portet, Alexandre; Lumpkin, Murray; Hartman, Dan] Bill & Melinda Gates Fdn, Integrated Dev Global Hlth, Seattle, WA 98109 USA	Bill & Melinda Gates Foundation	Ahonkhai, V (corresponding author), Bill & Melinda Gates Fdn, Integrated Dev Global Hlth, Seattle, WA 98109 USA.	Vincent.ahonkhai@gatesfoundation.org			Bill & Melinda Gates Foundation (BMGF)	Bill & Melinda Gates Foundation (BMGF)(Bill & Melinda Gates Foundation)	Not applicable. See partly related statement above and pasted below: Important background-The Bill & Melinda Gates Foundation (BMGF) is a private non-profit philanthropic organization with a vision for healthy and productive life for the poor through partnerships grant support. This manuscript documents one component of a BMGF partnership work on a strategy to increase access to medical products in low-and middle-income countries. The department responsible for the specific program that we work on is headed by DH. VIA and AP led the project with support from team members. ML contributed to the interpretation of results and SM supported data and issue analyses and both ML and SM contributed to the overall recommendation development for the strategy. Our research was conducted with the services of a management consulting firm. The foundation is currently funding many partnerships in the implementation of a number of the initiatives described in this manuscript.	Bollyky TJ, 2010, CLIN TRIALS, V7, P719, DOI 10.1177/1740774510386390; Daugla DM, 2014, LANCET, V383, P40, DOI 10.1016/S0140-6736(13)61612-8; Doua JY, 2014, TROP MED INT HEALTH, V19, P23, DOI 10.1111/tmi.12201; GAVI Alliance, 2015, GLOB LEV IND; Goosby E, 2012, JAIDS-J ACQ IMM DEF, V60, pS51, DOI 10.1097/QAI.0b013e31825ca721; Lakkis MM, 2010, DRUG INF J, V44, P289, DOI 10.1177/009286151004400311; Lee LA, 2013, VACCINE, V31, pB61, DOI 10.1016/j.vaccine.2012.11.035; McAuslane N, 2009, DRUG INF J, V43, P349, DOI 10.1177/009286150904300314; Moran M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000411; Rago L, 2014, ANTIVIR THER, V19, P69, DOI 10.3851/IMP2902; Stahl M., 2012, J GENER MED, V9, P63, DOI [10.1177/1741134312448062, DOI 10.1177/1741134312448062]; 't Hoen EFM, 2014, J PUBLIC HEALTH POL, V35, P137, DOI 10.1057/jphp.2013.53; The George Institute for International Health, 2010, REG NEW DRUGS AFR CO; WARDELL WM, 1974, CLIN PHARMACOL THER, V15, P73; WHO, 2013, WHO TECH REP SER, V981, P1; WHO, 2010, ASS MED REG SYST SUB; Zelman B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115714	17	33	33	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2016	11	11							e0166515	10.1371/journal.pone.0166515	http://dx.doi.org/10.1371/journal.pone.0166515			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC1ZU	27851831	Green Published, Green Submitted, gold			2023-01-03	WOS:000387909300059
J	Kaale, E; Manyanga, V; Chambuso, M; Liana, J; Rutta, E; Embrey, M; Layloff, T; Johnson, K				Kaale, Eliangiringa; Manyanga, Vicky; Chambuso, Mhina; Liana, Jafary; Rutta, Edmund; Embrey, Martha; Layloff, Thomas; Johnson, Keith			The Quality of Selected Essential Medicines Sold in Accredited Drug Dispensing Outlets and Pharmacies in Tanzania	PLOS ONE			English	Article							TROPICAL CONDITIONS; CHEMICAL-STABILITY; ERGOMETRINE; INSTABILITY; COUNTRIES; INJECTION; TABLETS	Introduction The purpose of this study was to investigate the quality of a select group of medicines sold in accredited drug dispensing outlets (ADDOs) and pharmacies in different regions of Tanzania as part of an in-depth cross-sectional assessment of community access to medicines and community use of medicines. Methods We collected 242 samples of amoxicillin trihydrate, artemether-lumefantrine (ALu), co-trimoxazole, ergometrine maleate, paracetamol, and quinine from selected ADDOs and pharmacies in Mbeya, Morogoro, Singida, and Tanga regions. The analysis included physical examination and testing with validated analytical techniques. Assays for eight of nine products were conducted using high-performance thin-layer chromatography (HPTLC). For ALu tablets, we used a two-tiered approach, where tier 1 was a semi-quantitative Global Pharma Health Fund-Minilab (R) method and tier 2 was high-performance liquid chromatography (HPLC) as described in The International Pharmacopoeia's monograph for artemether-lumefantrine. Results and Discussion The physical examination of samples revealed no defects in the solid and oral liquid dosage forms, but unusual discoloration in an injectable solution, ergometrine maleate. For ALu, the results showed that of 38 samples, 31 (81.6%) passed tier 1 testing and 7 (18.4%) gave inconclusive drug content results. The inconclusive ALu samples were submitted for tier 2 testing and all met the quality standards. The pass rate using the HPTLC and TLC/HPLC assays was 93.8%; the failures were the ergometrine maleate samples purchased from both ADDOs and pharmacies. The disintegration testing of the solid dosage forms was conducted in accordance with US Pharmacopeia monographs. Only two samples of paracetamol, 1.2% of the solid dosage forms, failed to comply to standards. The study revealed a high overall rate of 92.6% of samples that met the quality standards. Although the overall failure rate was 7.4%, it is important to note that this was largely limited to one product and likely due to poor distribution and storage rather than poor manufacturing practices. Conclusions Over 90% of the medicines sold in ADDOs and pharmacies met quality standards. Policy makers need to reconsider ergometrine maleate's place on the list of medicines that ADDOs are allowed to dispense, by either substituting a more temperature-stable therapeutically equivalent product or requiring those sites to have refrigerators, which is not a feasible option for rural Tanzania.	[Kaale, Eliangiringa; Manyanga, Vicky; Chambuso, Mhina] Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dar Es Salaam, Tanzania; [Liana, Jafary] Pharmaceut & Hlth Technol Grp, Management Sci Hlth, Dar Es Salaam, Tanzania; [Rutta, Edmund; Embrey, Martha; Layloff, Thomas; Johnson, Keith] Pharmaceut & Hlth Technol Grp, Management Sci Hlth, Arlington, VA USA	Muhimbili University of Health & Allied Sciences	Kaale, E (corresponding author), Muhimbili Univ Hlth & Allied Sci, Sch Pharm, Dar Es Salaam, Tanzania.	Elia.kaale@muha.ac.tz	Kaale, Eliangiringa/AAC-8561-2019	Kaale, Eliangiringa/0000-0001-6008-3539	Bill & Melinda Gates Foundation [0PP1017439]	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	The study on which this manuscript is based was funded by the Bill & Melinda Gates Foundation through a grant to Management Sciences for Health (MSH) (URL: http://www.msh.org/), #0PP1017439, that, in turn, subcontracted with MUHAS (#SDSI-2012- 17). MSH employees, Dr. Edmund Rutta, Mr. Keith Johnson, Dr. Suleiman Kimatta, and Mr. Jafary Liana were involved as technical advisors in the design of the study and provided logistics support during data collection and advice during data analysis. The Gates Foundation had no input into the study design, data collection, analysis or the preparation of the manuscript. MSH provided MUHAS unrestricted access to the data.	Al-Abdulla I, 2013, TOXICON, V64, P38, DOI 10.1016/j.toxicon.2012.12.022; Almuzaini T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002923; [Anonymous], 2012, INT PHARM; ASKER AF, 1990, DRUG DEV IND PHARM, V16, P165, DOI 10.3109/03639049009115993; Bate R, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-33; Batty KT, 1996, J PHARM PHARMACOL, V48, P22, DOI 10.1111/j.2042-7158.1996.tb05870.x; DEGROOT ANJA, 1995, J CLIN PHARM THER, V20, P115; Eu/ACP/WHO Renewed Paetnership, 2016, WHOEMPPAU201607 EUAC; HOGERZEIL HV, 1994, BRIT MED J, V308, P59; Hogerzeil HV, 1996, EUR J OBSTET GYN R B, V69, P25, DOI 10.1016/0301-2115(95)02530-8; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; HOGERZEIL HV, 1994, TROP DOCT, V24, P112, DOI 10.1177/004947559402400305; Jahnke RWO, 2001, DRUG INF J, V35, P941; Jansen FH, 2007, CURR MED CHEM, V14, P3243, DOI 10.2174/092986707782793844; Herrera ASM, 2009, TOXICON, V53, P609, DOI 10.1016/j.toxicon.2009.01.012; Nayyar GML, 2012, LANCET INFECT DIS, V12, P488, DOI 10.1016/S1473-3099(12)70064-6; Risha PG, 2003, EUR J CLIN PHARMACOL, V59, P135, DOI 10.1007/s00228-003-0587-1; Rutta E, 2014, INT J TUBERC LUNG D, V18, P1108, DOI 10.5588/ijtld.14.0020; Rutta Edmund, 2015, J Pharm Policy Pract, V8, P23, DOI 10.1186/s40545-015-0044-4; Rutta E, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-22; WALKER GJA, 1988, LANCET, V2, P393; Zahn M, 2006, J PHARM SCI-US, V95, P946, DOI 10.1002/jps.20584	22	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2016	11	11							e0165785	10.1371/journal.pone.0165785	http://dx.doi.org/10.1371/journal.pone.0165785			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC0MG	27846216	gold, Green Published, Green Submitted			2023-01-03	WOS:000387794600019
J	Boussiotis, VA				Boussiotis, Vassiliki A.			Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL-ACTIVATION; INHIBITORY RECEPTOR PD-1; TUMOR MICROENVIRONMENT; PROGRAMMED DEATH-1; PROTEIN STABILITY; CHRONIC INFECTION; CTLA-4 BLOCKADE; B7 FAMILY; EXPRESSION; CANCER		[Boussiotis, Vassiliki A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Boussiotis, VA (corresponding author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Dana 513, Boston, MA 02215 USA.	vboussio@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA183605] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA183605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; ALLISON JP, 1995, CURR OPIN IMMUNOL, V7, P682, DOI 10.1016/0952-7915(95)80077-8; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Derks S, 2016, ONCOTARGET, V7, P32925, DOI 10.18632/oncotarget.9076; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fang WF, 2014, ONCOTARGET, V5, P12189, DOI 10.18632/oncotarget.2608; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Honda T, 2014, IMMUNITY, V40, P235, DOI 10.1016/j.immuni.2013.11.017; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jaudszus A, 2013, J LIPID RES, V54, P923, DOI 10.1194/jlr.P031260; Kao C, 2011, NAT IMMUNOL, V12, P663, DOI 10.1038/ni.2046; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Mathieu M, 2013, IMMUNOL CELL BIOL, V91, P82, DOI 10.1038/icb.2012.53; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Oestreich KJ, 2008, J IMMUNOL, V181, P4832, DOI 10.4049/jimmunol.181.7.4832; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Patsoukis N, 2013, MOL CELL BIOL, V33, P3091, DOI 10.1128/MCB.00319-13; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Quigley M, 2010, NAT MED, V16, P1147, DOI 10.1038/nm.2232; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Sheppard KA, 2004, FEBS LETT, V574, P37, DOI 10.1016/j.febslet.2004.07.083; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Staron MM, 2014, IMMUNITY, V41, P802, DOI 10.1016/j.immuni.2014.10.013; Terawaki S, 2011, J IMMUNOL, V186, P2772, DOI 10.4049/jimmunol.1003208; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tkachev V, 2015, J IMMUNOL, V194, P5789, DOI 10.4049/jimmunol.1402180; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wei F, 2013, P NATL ACAD SCI USA, V110, pE2480, DOI 10.1073/pnas.1305394110; Xiao YP, 2014, J EXP MED, V211, P943, DOI 10.1084/jem.20130790; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Yoshida T, 2008, P NATL ACAD SCI USA, V105, P3533, DOI 10.1073/pnas.0710951105; Zinselmeyer BH, 2013, J EXP MED, V210, P757, DOI 10.1084/jem.20121416; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	68	711	774	16	265	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2016	375	18					1767	1778		10.1056/NEJMra1514296	http://dx.doi.org/10.1056/NEJMra1514296			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB0BB	27806234	Green Accepted			2023-01-03	WOS:000387007300010
J	Stefanowicz-Hajduk, J; Sparzak-Stefanowska, B; Krauze-Baranowska, M; Ochocka, JR				Stefanowicz-Hajduk, Justyna; Sparzak-Stefanowska, Barbara; Krauze-Baranowska, Miroslawa; Ochocka, J. Renata			Securinine from Phyllanthus glaucus Induces Cell Cycle Arrest and Apoptosis in Human Cervical Cancer HeLa Cells	PLOS ONE			English	Article							CYTOTOXIC LIGNAN; EXPRESSION; DEATH; VIROSECURININE; ALKALOIDS; GROWTH; BCL-2; BETA	Background The Securinega-type alkaloids occur in plants belonging to Euphorbiaceae family. One of the most widely distributed alkaloid of this group is securinine, which was identified next to allosecurinine in Phyllanthus glaucus (leafflower). Recently, some Securinega-type alkaloids have paid attention to its antiproliferative potency towards different cancer cells. However, the cytotoxic properties of allosecurinine have not yet been evaluated. Methods The cytotoxicity of the extract, alkaloid fraction obtained from P. glaucus, isolated securinine and allosecurinine against HeLa cells was evaluated by real-time xCELLigence system and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was detected by annexin V and 7-amino-actinomycin (7-AAD) staining and confirmed with fluorescent Hoechst 33342 dye. The assessment of mitochondrial membrane potential (MMP), reactive oxygen species (ROS) generation, the level of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), caspase-3/7 activity and cell cycle analysis were measured by flow cytometry. The enzymatic activity of caspase-9 was assessed by a luminometric assay. The expression of apoptosis associated genes was analyzed by realtime PCR. Results The experimental data revealed that securinine and the alkaloid fraction were significantly potent on HeLa cells growth inhibition with IC50 values of 7.02 +/- 0.52 mu g/ml (32.3 mu M) and 25.46 +/- 1.79 mu g/ml, respectively. The activity of allosecurinine and Phyllanthus extract were much lower. Furthermore, our study showed that the most active securinine induced apoptosis in a dose-dependent manner in the tested cells, increased the percentage of ROS positive cells and depolarized cells as well as stimulated the activity of ERK1/2, caspase-9 and -3/7. Securinine also induced cell cycle arrest in S phase. Real-time PCR analysis showed high expression of TNFRSF genes in the cells stimulated with securinine. Conclusions Securinine induces apoptosis and activates cell cycle checkpoints in HeLa cells which is associated with oxidative stress. The results indicate that the mitochondrial pathway is involved in the programmed cell death.	[Stefanowicz-Hajduk, Justyna; Ochocka, J. Renata] Med Univ Gdansk, Dept Biol & Pharmaceut Bot, Gdansk, Poland; [Sparzak-Stefanowska, Barbara; Krauze-Baranowska, Miroslawa] Med Univ Gdansk, Dept Pharmacognosy Med Plant Garden, Gdansk, Poland	Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk	Stefanowicz-Hajduk, J (corresponding author), Med Univ Gdansk, Dept Biol & Pharmaceut Bot, Gdansk, Poland.	justynastef@gumed.edu.pl		Krauze-Baranowska, Miroslawa/0000-0002-0344-7401; Sparzak-Stefanowska, Barbara/0000-0001-9658-0553	(NCN) National Science Centre grant [DEC-2012/05/N/NZ/00957]; Ministry of Science and Higher Education of the Republic of Poland under the Leading National Research Centre (KNOW) program	(NCN) National Science Centre grant; Ministry of Science and Higher Education of the Republic of Poland under the Leading National Research Centre (KNOW) program	The project was financed by a (NCN) National Science Centre grant (DEC-2012/05/N/NZ/00957). This project was supported by the Ministry of Science and Higher Education of the Republic of Poland, from the qualit-promoting subsidy, under the Leading National Research Centre (KNOW) program for the years 2012-2017.	Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BEUTLER JA, 1985, BRAIN RES, V330, P135, DOI 10.1016/0006-8993(85)90014-9; Blaser H, 2016, TRENDS CELL BIOL, V26, P249, DOI 10.1016/j.tcb.2015.12.002; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Calixto JB, 1998, MED RES REV, V18, P225, DOI 10.1002/(SICI)1098-1128(199807)18:4&lt;225::AID-MED2&gt;3.0.CO;2-X; Chen CR, 2012, PHARMAZIE, V67, P351, DOI 10.1691/ph.2012.1634; GUPTA K, 2011, PLOS ONE, V6; Han SW, 2014, ONCOL REP, V31, P2245, DOI 10.3892/or.2014.3101; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Kao SJ, 2017, ENVIRON TOXICOL, V32, P1426, DOI 10.1002/tox.22336; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kustermann S, 2013, TOXICOL IN VITRO, V27, P1589, DOI 10.1016/j.tiv.2012.08.019; Lee S A, 2011, PLOS ONE, V6; Li MD, 2014, PHARMAZIE, V69, P217, DOI 10.1691/ph.2014.3802; Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Ma CG, 2014, TOXICOL REP, V1, P114, DOI 10.1016/j.toxrep.2014.04.008; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Pu H, 2001, Zhong Yao Cai, V24, P278; Rana S, 2010, FASEB J, V24, P2126, DOI 10.1096/fj.09-148999; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Shin D, 2015, CELL PHYSIOL BIOCHEM, V36, P1151, DOI 10.1159/000430286; Singh A. K., 2007, Mycobiology, V35, P62, DOI 10.4489/MYCO.2007.35.2.062; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Sparzak B, 2008, JPC-J PLANAR CHROMAT, V21, P103, DOI 10.1556/JPC.21.2008.2.5; Sparzak B, 2015, MOLECULES, V20, P7915, DOI 10.3390/molecules20057915; Sparzak B, 2015, PHYTOCHEM LETT, V11, P353, DOI 10.1016/j.phytol.2014.10.013; Sparzak B, 2009, J AOAC INT, V92, P1343; Stefanowicz-Hajduk J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135993; Tang YQ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012644, 10.1371/journal.pone.0015631]; Xia YH, 2011, FITOTERAPIA, V82, P1258, DOI 10.1016/j.fitote.2011.08.015; Yu S, 2016, NAT PROD RES, V30, P419, DOI 10.1080/14786419.2015.1023198; Yuan W, 2007, NAT PROD RES, V21, P234, DOI 10.1080/14786410701189781; Zhang G, 2014, MOL MED REP, V10, P2365, DOI 10.3892/mmr.2014.2531; Zhang W., 2011, J CHINESE PHARM SCI, V20, P203; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	39	16	16	4	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2016	11	10							e0165372	10.1371/journal.pone.0165372	http://dx.doi.org/10.1371/journal.pone.0165372			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3YA	27792748	Green Published, gold, Green Submitted			2023-01-03	WOS:000389537000019
J	Busse, JW; Bhandari, M; Einhorn, TA; Schemitsch, E; Heckman, JD; Tornetta, P; Leung, KS; Heels-Ansdell, D; Makosso-Kallyth, S; Della Rocca, GJ; Jones, CB; Guyatt, GH				Busse, Jason W.; Bhandari, Mohit; Einhorn, Thomas A.; Schemitsch, Emil; Heckman, James D.; Tornetta, Paul, III; Leung, Kwok-Sui; Heels-Ansdell, Diane; Makosso-Kallyth, Sun; Della Rocca, Gregory J.; Jones, Clifford B.; Guyatt, Gordon H.			Re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST): randomized clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MULTICENTER; RELIABILITY; PHYSICIANS; THERAPY; COLLEGE; QUALITY	OBJECTIVE To determine whether low intensity pulsed ultrasound (LIPUS), compared with sham treatment, accelerates functional recovery and radiographic healing in patients with operatively managed tibial fractures. DESIGN A concealed, randomized, blinded, sham controlled clinical trial with a parallel group design of 501 patients, enrolled between October 2008 and September 2012, and followed for one year. SETTING 43 North American academic trauma centers. PARTICIPANTS Skeletally mature men or women with an open or closed tibial fracture amenable to intramedullary nail fixation. Exclusions comprised pilon fractures, tibial shaft fractures that extended into the joint and required reduction, pathological fractures, bilateral tibial fractures, segmental fractures, spiral fractures >7.5 cm in length, concomitant injuries that were likely to impair function for at least as long as the patient's tibial fracture, and tibial fractures that showed <25% cortical contact and >1 cm gap after surgical fixation. 3105 consecutive patients who underwent intramedullary nailing for tibial fracture were assessed, 599 were eligible and 501 provided informed consent and were enrolled. INTERVENTIONS Patients were allocated centrally to self administer daily LIPUS (n=250) or use a sham device (n=251) until their tibial fracture showed radiographic healing or until one year after intramedullary fixation. Main outcome measures Primary registry specified outcome was time to radiographic healing within one year of fixation; secondary outcome was rate of non-union. Additional protocol specified outcomes included short form-36 (SF-36) physical component summary (PCS) scores, return to work, return to household activities, return to >= 80% of function before injury, return to leisure activities, time to full weight bearing, scores on the health utilities index (mark 3), and adverse events related to the device. RESULTS SF-36 PCS data were acquired from 481/501 (96%) patients, for whom we had 2303/2886 (80%) observations, and radiographic healing data were acquired from 482/501 (96%) patients, of whom 82 were censored. Results showed no impact on SF-36 PCS scores between LIPUS and control groups (mean difference 0.55, 95% confidence interval -0.75 to 1.84; P=0.41) or for the interaction between time and treatment (P=0.30); minimal important difference is 3-5 points) or in other functional measures. There was also no difference in time to radiographic healing (hazard ratio 1.07, 95% confidence interval 0.86 to 1.34; P=0.55). There were no differences in safety outcomes between treatment groups. Patient compliance was moderate; 73% of patients administered >= 50% of all recommended treatments. CONCLUSIONS Postoperative use of LIPUS after tibial fracture fixation does not accelerate radiographic healing and fails to improve functional recovery.	[Busse, Jason W.; Bhandari, Mohit; Heels-Ansdell, Diane; Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada; [Busse, Jason W.; Makosso-Kallyth, Sun] McMaster Univ, Dept Anesthesia, 1200 Main St West,HSC 2U1, Hamilton, ON L8S 4K1, Canada; [Busse, Jason W.] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON L8S 4K1, Canada; [Bhandari, Mohit] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; [Einhorn, Thomas A.; Tornetta, Paul, III] NYU, Langone Med Ctr, Dept Orthoped Surg, 550 1St Ave, New York, NY 10016 USA; [Schemitsch, Emil] Univ Western Ontario, Dept Surg, London, ON N6A 4V2, Canada; [Heckman, James D.] Dartmouth Hitchcock Med Ctr, Dept Orthoped Surg, Lebanon, NH 03766 USA; [Leung, Kwok-Sui] Chinese Univ Hong Kong, Dept Orthoped & Traumatol, Shatin, Hong Kong, Peoples R China; [Della Rocca, Gregory J.] Univ Missouri, Dept Orthoped Surg, Columbia, MO 65212 USA; [Jones, Clifford B.] Banner Univ, CORE, Ctr Orthoped Res & Educ, Phoenix, AZ 85023 USA; [Guyatt, Gordon H.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; McMaster University; McMaster University; New York University; NYU Langone Medical Center; Western University (University of Western Ontario); Dartmouth College; Chinese University of Hong Kong; University of Missouri System; University of Missouri Columbia; McMaster University	Busse, JW (corresponding author), McMaster Univ, Dept Anesthesia, 1200 Main St West,HSC 2U1, Hamilton, ON L8S 4K1, Canada.	bussejw@mcmaster.ca	Della Rocca, Gregory/AAM-5281-2021; Madden, Kim/N-5761-2015; Bhandari, Mohit/AAQ-1675-2021; Schemitsch, Emil/G-5706-2017; Busse, Jason/CAH-3696-2022	Madden, Kim/0000-0002-2861-9636; Schemitsch, Emil/0000-0002-6435-9069; Busse, Jason/0000-0002-0178-8712; Einhorn, Thomas/0000-0002-5075-4885; Tornetta, Paul/0000-0002-6448-8864	Canadian Institutes of Health Research (CIHR) [MCT 67815]; Smith Nephew	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Smith Nephew	This study was an investigator-initiated trial, supported by grants from the Canadian Institutes of Health Research (CIHR) (MCT 67815, Co-PIs: GH Guyatt, M Bhandari), and an industry grant from Smith & Nephew. The CIHR had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Smith & Nephew personnel reviewed initial drafts of the trial protocol and raised many issues about alternative approaches to study design. Issues regarding the protocol were resolved through negotiation between Smith & Nephew and the trial steering committee. Final decisions regarding the protocol and issues that arose during the conduct of the trial were the purview of the trial steering committee. The investigators had full access to all trial data. Smith & Nephew had no role the initial preparation of the current study manuscript but had the right to review the manuscript and make non-binding comments and suggestions.	[Anonymous], 2005, THE ORTHO PEOPLE OCT; Bhandari M, 2004, J ORTHOP TRAUMA, V18, P338, DOI 10.1097/00005131-200407000-00002; Busse JW, 2008, ACTA ORTHOP, V79, P689, DOI 10.1080/17453670810016722; Busse JW, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-206; Busse JW, 2009, J CLIN EPIDEMIOL, V62, P1210, DOI 10.1016/j.jclinepi.2009.01.014; Busse JW, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b351; Carpenter JA, 2013, STUD WORLD CHR SER, P1; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Falck-Ytter Y, 2012, CHEST, V141, pE278S, DOI 10.1378/chest.11-2404; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Griffin XL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008579.pub3; Heckman J D, 1997, Bull Hosp Jt Dis, V56, P63; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623-199401000-00004; Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54; Kooistra BW, 2010, J ORTHOP TRAUMA, V24, pS81, DOI 10.1097/BOT.0b013e3181ca3fd1; Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623-199707000-00002; Lenzer J, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6230; Marcus HJ, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2587; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Moynihan R, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1271; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623-200102000-00015; Rue JPH, 2004, ORTHOPEDICS, V27, P1192, DOI 10.3928/0147-7447-20041101-18; SARMIENTO A, 1995, CLIN ORTHOP RELAT R, P8; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Thompson M, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2973; Tsumaki N, 2004, J BONE JOINT SURG AM, V86A, P2399, DOI 10.2106/00004623-200411000-00006; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Wachovia Capital Markets, 2007, EQ RES BON GROWTH ST; Ware J. E., 1997, SF 36 PHYS MENTAL HL; Wilmshurst P, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2822	32	54	56	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	2016	355								i5351	10.1136/bmj.i5351	http://dx.doi.org/10.1136/bmj.i5351			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA5LA	27797787	Green Published, hybrid			2023-01-03	WOS:000386660700001
J	Chatterjee, S; Sarkar, A; Rao, KD				Chatterjee, Susmita; Sarkar, Anupam; Rao, Krishna D.			Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage - Do Costs Matter?	PLOS ONE			English	Article							MANAGEMENT	Background Postpartum heammorrhage (PPH), defined as blood loss greater than or equal to 500 ml within 24 hours after birth, is the leading cause of maternal deaths globally and in India. Misoprostol is an important option for PPH management in setting where oxytocin (the gold standard for PPH prevention and treatment) in not available or not feasible to use. For the substantial number of deliveries which take place at home or at lower level heatlh facilities in India, misoprostol pills can be adminstered to prevent PPH. The standard approach using misoprostol is to administer it prophylactically as primary prevention (600 mcg). An alternative strategy could be to administer misoprostol only to those who are at high risk of having PPH i.e. as secondary prevention. Methods This study reports on the relative cost per person of a strategy involving primary versus secondary prevention of PPH using misoprostol. It is based on a randomized cluster trial that was conducted in Bijapur district in Karnataka, India between December 2011 and March 2014 among pregnant women to compare two community-level strategies for the prevention of PPH: primary and secondary. The analysis was conducted from the government perspective using an ingredient approach. Results The cluster trial showed that there were no significant differences in clinical outcomes between the two study arms. However, the results of the cost analysis show that there is a difference of INR 6 (US$ 0.1) per birth for implementing the strategies primary versus secondary prevention. In India where 14.9 million births take place at sub-centres and at home, this additional cost of INR 6 per birth translates to an additional cost of INR 94 (US$ 1.6) million to the government to implement the primary prevention compared to the secondary prevention strategy. Conclusion As clinical outcomes did not differ significantly between the two arms in the trial, taking into account the difference in costs and potential issues with sustainability, secondary prevention might be a more strategic option.	[Chatterjee, Susmita; Sarkar, Anupam] Publ Hlth Fdn India, New Delhi, India; [Rao, Krishna D.] Johns Hopkins Univ, Baltimore, MD USA	Public Health Foundation of India; Johns Hopkins University	Chatterjee, S (corresponding author), Publ Hlth Fdn India, New Delhi, India.	susmita.c@phfi.org		Sarkar, Anupam/0000-0001-7445-2155	Gynuity Health Projects, USA; Gynuity Health projects	Gynuity Health Projects, USA; Gynuity Health projects	This work was supported by Gynuity Health Projects, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We sincerely thank Gynuity Health projects for providing funding support of this study. We are thankful to the partner institutes: University of Chicago, Illinois and University of California, San Francisco. We are grateful to KLE University, BLDE University and the ANMs of the sub-centres for their support and co-operation during field data collection.	Bellad MB, 2012, COMPREHENSIVE TXB PO, P275; Bradley SEK, 2007, INT J GYNECOL OBSTET, V97, P52, DOI 10.1016/j.ijgo.2006.12.005; Dabash R, 2012, COMPREHENSIVE TXB PO, P296; Derman RJ, 2006, LANCET, V368, P1248, DOI 10.1016/S0140-6736(06)69522-6; Drummond M.F., 2005, METHODS EC EVALUATIO, V3d, P55; International Institute for Population Sciences (IIPS), 2010, DISTR LEV HOUS FAC S; Mobeen N, 2011, BJOG-INT J OBSTET GY, V118, P353, DOI 10.1111/j.1471-0528.2010.02807.x; Montgomery AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083331; Prata N, 2006, INT J GYNECOL OBSTET, V94, P149, DOI 10.1016/j.ijgo.2006.05.027; Raghavan S, 2016, BJOG-INT J OBSTET GY, V123, P120, DOI 10.1111/1471-0528.13540; Walker D, 2002, HEALTH POLICY PLANN, V17, P112, DOI 10.1093/heapol/17.1.112; Walraven G, 2005, BJOG-INT J OBSTET GY, V112, P1277, DOI 10.1111/j.1471-0528.2005.00711.x; World Health Organisation (WHO), 2009, WHO GUID MAN POSTP H, V1; World Health Organization, 2012, WHO REC PREV TREATM	14	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2016	11	10							e0164718	10.1371/journal.pone.0164718	http://dx.doi.org/10.1371/journal.pone.0164718			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NV	27755601	Green Submitted, Green Published, gold			2023-01-03	WOS:000386203800029
J	Barnighausen, T; Bloom, DE; Humair, S				Barnighausen, Till; Bloom, David E.; Humair, Salal			Human Resources for Treating HIV/AIDS: Are the Preventive Effects of Antiretroviral Treatment a Game Changer?	PLOS ONE			English	Article							SOUTH-AFRICA; INTERNATIONAL RECRUITMENT; HIV TRANSMISSION; HEALTH PERSONNEL; GLOBAL CODE; SCALE-UP; THERAPY; ACCESS; CARE; ACQUISITION	Shortages of human resources for treating HIV/AIDS (HRHA) are a fundamental barrier to reaching universal antiretroviral treatment (ART) coverage in developing countries. Previous studies suggest that recruiting HRHA to attain universal ART coverage poses an insurmountable challenge as ART significantly increases survival among HIV-infected individuals. While new evidence about ART's prevention benefits suggests fewer infections may mitigate the challenge, new policies such as treatment-as-prevention (TasP) will exacerbate it. We develop a mathematical model to analytically study the net effects of these countervailing factors. Using South Africa as a case study, we find that contrary to previous results, universal ART coverage is achievable even with current HRHA numbers. However, larger health gains are possible through a surge-capacity policy that aggressively recruits HRHA to reach universal ART coverage quickly. Without such a policy, TasP roll-out can increase health losses by crowding out sicker patients from treatment, unless a surge capacity exclusively for TasP is also created.	[Barnighausen, Till; Bloom, David E.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA; [Barnighausen, Till] AHRI, Mtubatuba, Kwazulu Natal, South Africa; [Barnighausen, Till] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany; [Humair, Salal] Amazon Com Inc, Seattle, WA 98109 USA	Harvard University; Harvard T.H. Chan School of Public Health; Africa Health Research Institute; Ruprecht Karls University Heidelberg; Amazon.com	Humair, S (corresponding author), Amazon Com Inc, Seattle, WA 98109 USA.	salal@alum.mit.edu	Bärnighausen, Till/Y-2388-2019	Humair, Salal/0000-0002-9354-5389				Alistar SS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000423; [Anonymous], 2014, GLOB UPD HLTH SECT R; Atun RA, 2008, DO VERTICAL STAND AL; Atun R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009656; Baernighausen T, 2011, NEW ENGL J MED, V364, P2181, DOI 10.1056/NEJMp1014255; Barnighausen T, 2010, B WORLD HEALTH ORGAN, V88, P951, DOI 10.2471/BLT.09.073890; Barnighausen T, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-86; Barnighausen T, 2009, SOC SCI MED, V68, P544, DOI 10.1016/j.socscimed.2008.11.009; Bajunirwe F, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002875; Barnighausen T, 2011, OXFORD HDB HLTH EC; Barnighausen T, 2009, 15517 NBER; Barnighausen T, 2007, AIDS PATIENT CARE ST, V21, P799, DOI 10.1089/apc.2007.0193; Bongaarts J, 2010, SCIENCE, V328, P1359, DOI 10.1126/science.1191804; Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413; Bossert T, 2007, ASSESSING FINANCING; Bowser D, 2013, HLTH POLICY PLANNING; Brown T, 2010, SEX TRANSM INFECT, V86, pI3, DOI 10.1136/sti.2010.044784; Brundage SC., 2011, TERRA NOVA ACHIEVE S; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Colvin CJ, 2010, SAMJ S AFR MED J, V100, P210, DOI 10.7196/SAMJ.4124; Cometto G, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001514; de Vries E, 2010, SAMJ S AFR MED J, V100, P227, DOI 10.7196/SAMJ.3856; DFID, 2007, TAK ACT HIV STIGM DI; Di Giorgio L, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0653-z; Dovlo Delanyo, 2004, Hum Resour Health, V2, P7, DOI 10.1186/1478-4491-2-7; Eaton JW, 2014, LANCET GLOB HEALTH, V2, pE23, DOI 10.1016/S2214-109X(13)70172-4; Eaton JW, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001245; ECONEX, 2010, HLTH REFORM NOTE; Edge JS, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-60; Fairall L, 2012, LANCET, V380, P889, DOI 10.1016/S0140-6736(12)60730-2; Filler SJ, 2011, JAIDS-J ACQ IMM DEF, V57, pE1, DOI 10.1097/QAI.0b013e3182158980; Geldsetzer P, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0675-6; George G, 2009, HUMAN RESOURCES HLTH; George G, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-15; GH Tech, 2011, 1101530 USAID GH TEC; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hagopian A, 2008, HUM RESOUR HEALTH, V6, DOI 10.1186/1478-4491-6-3; Hirschhorn Lisa R, 2006, Hum Resour Health, V4, P1, DOI 10.1186/1478-4491-4-1; Hontelez JAC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158015; Hontelez JAC, 2012, HUM RESOUR HEALTH, V10, DOI 10.1186/1478-4491-10-39; Houlihan CF, 2011, INT J EPIDEMIOL, V40, P318, DOI 10.1093/ije/dyp402; HPCSA, 2012, HPCSA 2012 DATA SPRE; HSRC, 2008, MULT SOURC ID VER SC; IOM (Institute of Medicine), 2013, EV PEPFAR; Jack A., 2010, FINANCIAL TIMES; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Johnson C, 2014, AIDS BEHAV, V18, pS391, DOI 10.1007/s10461-014-0832-x; Johnson L., 2011, S AFR J HIV MED, V13, P22; Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418; Kalichman SC, 2010, AIDS PATIENT CARE ST, V24, P271, DOI 10.1089/apc.2009.0309; Kasper J, 2012, ARCH DIS CHILD, V97, P973, DOI 10.1136/archdischild-2012-301900; Katz IT, 2013, NEW ENGL J MED, V369, P1385, DOI 10.1056/NEJMp1310982; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Leahy B, MOVING FORWARD TREAT; Levine R, 2009, JAIDS-J ACQ IMM DEF, V52, pS3, DOI 10.1097/QAI.0b013e3181bbc807; Lima VD, 2008, J INFECT DIS, V198, P59, DOI 10.1086/588673; Malaza A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070126; McNairy ML, 2014, CLIN INFECT DIS, V58, P1003, DOI 10.1093/cid/ciu018; Mills EJ, 2011, AIDS, V25, P851, DOI 10.1097/QAD.0b013e32834564e9; Mullan F, 2007, JAMA-J AM MED ASSOC, V297, P744, DOI 10.1001/jama.297.7.744; Mutevedzi PC, 2010, B WORLD HEALTH ORGAN, V88, P593, DOI 10.2471/BLT.09.069419; Ooms G, 2007, PLOS MED, V4, P605, DOI 10.1371/journal.pmed.0040128; Over M., 2008, PREVENTION FAILURE B; PEPFAR, 2011, PARTN FRAM SUPP S AF; Pfeiffer J, 2010, ANNU REV ANTHROPOL, V39, P149, DOI 10.1146/annurev.anthro.012809.105101; Rosen S, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002015, 10.1371/journal.pmed.1002106]; Rosenberg NE, 2014, JAIDS-J ACQ IMM DEF, V65, pE162, DOI 10.1097/QAI.0000000000000066; Schoffelen AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058526; Senthilingam M, 2015, NATURE NEWS, V10, DOI [10.1038/nature.2015.18017., DOI 10.1038/NATURE.2015.18017]; Sheikh A, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-43; Sidibe M, 2011, 4 DECADE AIDS WHAT I, VXLVIII; Slomski A, 2013, JAMA-J AM MED ASSOC, V309, P1672, DOI 10.1001/jama.2013.3394; South Africa. Department of Health, 2014, NAT CONS GUID PREV M; South Africa Department of Health, 2013, FOR WORKF MAN S AFR; South Africa Department of Labor, 2009, SKILLS SHORT S AFRIC; South Africa Department of Labor, 2008, SHORT DOCT S AFR SCA; Stilwell Barbara, 2003, Hum Resour Health, V1, P8, DOI 10.1186/1478-4491-1-8; Stover J, 2010, SEX TRANSM INFECT, V86, pII16, DOI 10.1136/sti.2010.044222; Stover J, 2007, HEALTH AFFAIR, V26, P1147, DOI 10.1377/hlthaff.26.4.1147; Stover J, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/738271; Suthar AB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001496; Tankwanchi ABS, 2014, LANCET GLOB HEALTH, V2, pE390, DOI 10.1016/S2214-109X(14)70240-2; Tankwanchi ABS, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001513; Tanser F, 2013, SCIENCE, V339, P966, DOI 10.1126/science.1228160; Uebel KE, 2013, JAIDS-J ACQ IMM DEF, V63, pE94, DOI 10.1097/QAI.0b013e318291cd08; UNAIDS, 2015, TREATMENT 2015, DOI [10.1097/QAI.0000000000000066, DOI 10.1097/QAI.0000000000000066]; UNAIDS, 2014, AMB TREATM TARG WRIT; Van Damme W, 2008, SOC SCI MED, V66, P2108, DOI 10.1016/j.socscimed.2008.01.043; Vandormael A, 2014, LANCET GLOB HEALTH, V2, pE209, DOI 10.1016/S2214-109X(14)70018-X; Vermund SH, 2012, AIDS, V26, P1303, DOI 10.1097/QAD.0b013e3283552185; Wadee H, 2007, S AFRICAN HLTH REV 2; Waning B, 2010, J GENERIC MED BUSINE, V7, P159, DOI [DOI 10.1057/JGM.2010.6, 10.1057/jgm.2010.6]; Waning B, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-9; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; WHO, 2012, WHO HIV DRUG RESISTA; WHO, 2008, FIN EC ASP HLTH WORK; WHO, 2010, INCR ACC HLTH REM RU; WHO UNAIDS UNICEF, 2013, GLOB UPD HIV TREAT 2; WHO UNAIDS UNICEF, 2011, 2011 WHO UNAIDS UNIC; World Health Organisation, 2012, ANT TREATM PREV TASP; World Health Organization, 2008, TASK SHIFT RAT RED T; Yu DB, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-8	102	12	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2016	11	10							e0163960	10.1371/journal.pone.0163960	http://dx.doi.org/10.1371/journal.pone.0163960			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DZ2UW	27716813	Green Published, gold, Green Submitted			2023-01-03	WOS:000385698100014
J	Toft-Petersen, AP; Torp-Pedersen, C; Weinreich, UM; Rasmussen, BS				Toft-Petersen, Anne Pernille; Torp-Pedersen, Christian; Weinreich, Ulla Moller; Rasmussen, Bodil Steen			Trends in assisted ventilation and outcome for obstructive pulmonary disease exacerbations. A nationwide study	PLOS ONE			English	Article							ACUTE RESPIRATORY-FAILURE; INTENSIVE-CARE-UNIT; NONINVASIVE VENTILATION; MECHANICAL VENTILATION; COPD EXACERBATIONS; MORTALITY; HOSPITALIZATION; EPIDEMIOLOGY; METAANALYSIS; PREVALENCE	Background Non-invasive ventilation (NIV) has been used for decades in treatment of exacerbations of chronic obstructive pulmonary disease (COPD). The impact of the changing use of assisted ventilation in acute exacerbations on outcomes has not been fully elucidated and we aimed to describe these changes in the Danish population and describe their consequences for mortality. Methods A register-based study was conducted of a cohort of 12,847 patients admitted for acute exacerbation of COPD (AECOPD) from 2004 through 2011, treated with invasive mechanical ventilation (IMV) or NIV for the first time. Age, sex, in-hospital mortality rates, time to death or readmission for AECOPD were established and changes over time tracked. Results The number of admissions for AECOPD where assisted ventilation was used was 1,130 in 2004 and had increased by 145% in 2011. First time ventilations increased by 88%. This was mainly due to an increase in use of NIV accounting for 36% of the total number of assisted ventilations in 2004 and 67% in 2011. The number of IMV with or without NIV treatments remained constant. The mean age of NIV patients increased from 71.5 to 73.6 years, but remained constant at 70.0 years in IMV patients. Mortality rates both in hospital and after discharge for patients receiving NIV remained constant throughout the period. In-hospital mortality following IMV increased from 30% to 38%, but mortality after discharge remained stable. Conclusion Assisted ventilation has been increasingly used in a broader spectrum of AECOPD patients since the introduction of NIV. The changes in treatment strategies have been followed by shifts in in-hospital mortality rates following IMV.	[Toft-Petersen, Anne Pernille; Torp-Pedersen, Christian; Weinreich, Ulla Moller; Rasmussen, Bodil Steen] Aalborg Univ, Dept Clin Med, Aalborg, Denmark; [Torp-Pedersen, Christian] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark; [Weinreich, Ulla Moller] Aalborg Univ Hosp, Dept Resp Dis, Aalborg, Denmark; [Rasmussen, Bodil Steen] Aalborg Univ Hosp, Dept Anaesthesia & Intens Care, Aalborg, Denmark	Aalborg University; Aalborg University; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital	Toft-Petersen, AP (corresponding author), Aalborg Univ, Dept Clin Med, Aalborg, Denmark.	aptp@rn.dk; ctp@heart.dk	Weinreich, Ulla M/L-9069-2013	Weinreich, Ulla M/0000-0003-1975-3654; Rasmussen, Bodil Steen/0000-0003-2190-145X; Toft-Petersen, Anne Pernille/0000-0001-6029-255X				Blichert-Hansen Linea, 2013, Clin Epidemiol, V5, P9, DOI 10.2147/CLEP.S37763; Carpe-Carpe B, 2013, ARCH BRONCONEUMOL, V49, P330, DOI 10.1016/j.arbres.2013.04.006; Chandra D, 2012, AM J RESP CRIT CARE, V185, P152, DOI 10.1164/rccm.201106-1094OC; Conti G, 2002, INTENS CARE MED, V28, P1701, DOI 10.1007/s00134-002-1478-0; de Miguel-Diez J, 2013, RESP MED, V107, P717, DOI 10.1016/j.rmed.2013.01.007; Dres M, 2013, CRIT CARE MED, V41, P1884, DOI 10.1097/CCM.0b013e31828a2bd8; Fiorino S, 2015, INTERN MED J; Funk GC, 2013, EUR RESPIR J, V41, P792, DOI 10.1183/09031936.00226411; Gacouin A, 2015, RESP CARE, V60, P210, DOI 10.4187/respcare.03467; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2015, GLOBAL STRATEGY DIAG; Husted MG, 2014, BMJ SUPPORT PALLIAT, V4, P146, DOI 10.1136/bmjspcare-2013-000601; Johannesdottir Sigrun A, 2013, J Med Econ, V16, P897, DOI 10.3111/13696998.2013.800525; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; Jurjevic M, 2009, COLLEGIUM ANTROPOL, V33, P791; Kaul S, 2009, COPD, V6, P171, DOI 10.1080/15412550902902646; Larsen OB, 2005, SUNDHEDSSTYRELSEN KL; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; Lindenauer PK, 2014, JAMA INT MED, V1-12; Lykkegaard J, 2012, RESP MED, V106, P1396, DOI 10.1016/j.rmed.2012.06.004; Lykkegaard J, 2012, RESP MED, V106, P549, DOI 10.1016/j.rmed.2011.11.001; Mery E, 2013, CRIT CARE, V17, DOI 10.1186/cc12688; Ongel EA, 2014, INT J CHRONIC OBSTR, V9, P1187, DOI 10.2147/COPD.S70257; Pierson DJ, 2009, RESP CARE, V54, P40; Quintana JM, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-66; Radovanovic D, 2014, HEART, V100, P288, DOI 10.1136/heartjnl-2013-304588; Roberts CM, 2011, THORAX, V66, P43, DOI 10.1136/thx.2010.153114; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Singanayagam Aran, 2013, Ann Am Thorac Soc, V10, P81, DOI 10.1513/AnnalsATS.201208-043OC; Stefan MS, 2014, CHEST J; Stefan MS, 2015, CRIT CARE MED, V1; Stelfox HT, 2012, ARCH INTERN MED, V172, P467, DOI 10.1001/archinternmed.2011.2315; Thomsen RW, 2011, RESP MED, V105, P1063, DOI 10.1016/j.rmed.2011.01.012; Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-83; Titlestad IL, 2013, INT J CHRONIC OBSTR, V8, P215, DOI 10.2147/COPD.S42632; Titlestad Ingrid Louise, 2008, Ugeskr Laeger, V170, P240; Tottenborg SS, 2013, DAN MED J, V60; Walkey Allan J, 2013, Ann Am Thorac Soc, V10, P10, DOI 10.1513/AnnalsATS.201206-034OC	37	9	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171713	10.1371/journal.pone.0171713	http://dx.doi.org/10.1371/journal.pone.0171713			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DG	28158267	Green Published, Green Submitted, gold			2023-01-03	WOS:000396161700119
J	Giezendanner, S; Jung, C; Banderet, HR; Otte, IC; Gudat, H; Haller, DM; Elger, BS; Zemp, E; Bally, K				Giezendanner, Stephanie; Jung, Corinna; Banderet, Hans-Ruedi; Otte, Ina Carola; Gudat, Heike; Haller, Dagmar M.; Elger, Bernice S.; Zemp, Elisabeth; Bally, Klaus			General Practitioners' Attitudes towards Essential Competencies in End-of-Life Care: A Cross-Sectional Survey	PLOS ONE			English	Article							PALLIATIVE CARE; QUALITY INDICATORS; BARRIERS; SPIRITUALITY; EUTHANASIA; COMMUNICATION; PROFESSIONALS; FACILITATORS; CONFIDENCE; FRAMEWORK	Background Identifying essential competencies in end-of-life care, as well as general practitioners' (GPs) confidence in these competencies, is essential to guide training and quality improvement efforts in this domain. Aim To determine which competencies in end-of-life care are considered important by GPs, to assess GPs' confidence in these competencies in a European context and their reasons to refer terminally ill patients to a specialist. Design and Setting Cross-sectional postal survey involving a stratified random sample of 2000 GPs in Switzerland in 2014. Method Survey development was informed by a previous qualitative exploration of relevant end-of-life GP competencies. Main outcome measures were GPs' assessment of the importance of and confidence in 18 attributes of end-of-life care competencies, and reasons for transferring care of terminally-ill patients to a specialist. GP characteristics associated with main outcome measures were tested using multivariate regression models. Results The response rate was 31%. Ninety-nine percent of GPs considered the recognition and treatment of pain as important, 86% felt confident about it. Few GPs felt confident in cultural (16%), spiritual (38%) and legal end-of-life competencies such as responding to patients seeking assisted suicide (35%) although more than half of the respondents regarded these competencies as important. Most frequent reasons to refer terminally ill patients to a specialist were lack of time (30%), better training of specialists (23%) and end-of-life care being incompatible with other duties (19%). In multiple regression analyses, confidence in end-of-life care was positively associated with GPs' age, practice size, home visits and palliative training. Conclusions GPs considered non-somatic competencies (such as spiritual, cultural, ethical and legal aspects) nearly as important as pain and symptom control. Yet, few GPs felt confident in these non-somatic competencies. These findings should inform training and quality improvement efforts in this domain, in particular for younger, less experienced GPs.	[Giezendanner, Stephanie; Jung, Corinna; Banderet, Hans-Ruedi; Bally, Klaus] Univ Basel, Ctr Primary Hlth Care, Basel, Switzerland; [Otte, Ina Carola; Elger, Bernice S.] Univ Basel, Inst Biomed Eth, Basel, Switzerland; [Gudat, Heike] Hosp Palliat Care, Hospiz Pk, Arlesheim, Basel District, Switzerland; [Haller, Dagmar M.] Univ Geneva, Primary Care Unit, Geneva, Switzerland; [Haller, Dagmar M.] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia; [Elger, Bernice S.] Univ Geneva, Ctr Legal Med, Geneva, Switzerland; [Zemp, Elisabeth] Univ Basel, Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Zemp, Elisabeth] Univ Basel, Basel, Switzerland	University of Basel; University of Basel; University of Geneva; University of Melbourne; University of Geneva; University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Giezendanner, S (corresponding author), Univ Basel, Ctr Primary Hlth Care, Basel, Switzerland.	stephanie.giezendanner@unibas.ch	Elger, Bernice Simone/V-7265-2017; Haller, Dagmar M./AAA-5078-2021	Elger, Bernice Simone/0000-0002-4249-7399; Otte, Ina/0000-0003-0280-0899; Haller, Dagmar/0000-0003-1781-3318; Giezendanner, Stephanie/0000-0001-5660-9446	Swiss National Science Foundation [SNSF: 406740_139341]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This work was supported by The Swiss National Science Foundation (http://www.snf.ch/D/Seiten/default.aspx) (SNSF: 406740_139341). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, SCHWEIZ ARZTEZTG, V90; Becker G, 2007, WIEN KLIN WOCHENSCHR, V119, P112, DOI 10.1007/s00508-006-0724-9; Blank RH, 2011, J LAW MED ETHICS, V39, P201, DOI 10.1111/j.1748-720X.2011.00589.x; Boerma W., 2003, PROFILES GEN PRACTIC; Borgsteede SD, 2006, BRIT J GEN PRACT, V56, P20; Brauer S, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14142; Claessen SJJ, 2011, J PAIN SYMPTOM MANAG, V42, P169, DOI 10.1016/j.jpainsymman.2010.10.267; Dale J, 2009, QUAL SAF HEALTH CARE, V18, P174, DOI 10.1136/qshc.2007.024836; De Roo ML, 2013, J PAIN SYMPTOM MANAG, V46, P556, DOI 10.1016/j.jpainsymman.2012.09.013; De Vleminck A, 2013, SCAND J PRIM HEALTH, V31, P215, DOI 10.3109/02813432.2013.854590; Dunn TJ, 2014, BRIT J PSYCHOL, V105, P399, DOI 10.1111/bjop.12046; EAPC Task Force on Medical Education, 2007, CURRICULUM IN PALLIA; Economist Intelligence Unit, 2010, RANK END OF LIF CAR, DOI [10.1111/1.1748-720X.2011.00589.x, DOI 10.1111/J.1748-720X.2011.00589.X]; Eychmuller S, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0485-0; Fletcher T. D., 2010, PSYCHOMETRIC APPL PS; Gamondi C., 2013, EUROPEAN J PALLIATIV, V20, P86; Garcia C, 2007, ARCH DERMATOL, V143, P120, DOI 10.1001/archderm.143.1.120-b; Georges JJ, 2008, J MED ETHICS, V34, P150, DOI 10.1136/jme.2007.020909; Gorlen T, 2012, DAN MED J, V59; Groot MM, 2005, PALLIATIVE MED, V19, P111, DOI 10.1191/0269216305pm937oa; Gysels M, 2012, J PAIN SYMPTOM MANAG, V44, P285, DOI 10.1016/j.jpainsymman.2011.09.013; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; Hansford P, 2007, END LIFE CARE, V1, P56; Helena K, 2015, BMC MED ED, V15; Hirooka K, 2014, JPN J CLIN ONCOL, V44, P249, DOI 10.1093/jjco/hyt204; Hostettler S., 2015, SCHWEIZERISCHE ARZTE, V96, P462; Iversen T, 2011, INT J HEALTH CARE FI, V11, P245, DOI 10.1007/s10754-011-9101-y; Kelley K, 2012, METHODOLOGY; Kelley K, 2012, PSYCHOL METHODS, V17, P137, DOI 10.1037/a0028086; Koller M, 2011, COMPUT STAT DATA AN, V55, P2504, DOI 10.1016/j.csda.2011.02.014; Liddy C, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-22; Lynch T, 2013, J PAIN SYMPTOM MANAG, V45, P1094, DOI 10.1016/j.jpainsymman.2012.05.011; Marr L, 2007, J PALLIAT MED, V10, P169, DOI 10.1089/jpm.2006.0076.R1; McDonald R.P., 1999, TEST THEORY UNIFIED; McGlade KJ, 2000, BRIT J GEN PRACT, V50, P794; Mitchell GK, 2011, AUST FAM PHYSICIAN, V40, P517; Mitchell GK, 2004, MED J AUSTRALIA, V180, P207, DOI 10.5694/j.1326-5377.2004.tb05885.x; O'Brien AP, 2012, ASIA-PAC J CLIN ONCO, V8, P3, DOI 10.1111/j.1743-7563.2011.01510.x; Pasman HRW, 2009, J PAIN SYMPTOM MANAG, V38, P145, DOI 10.1016/j.jpainsymman.2008.07.008; Pereira J, 2008, PALLIATIVE MED, V22, P730, DOI 10.1177/0269216308094560; Puchalski CM, 2004, CLIN GERIATR MED, V20, P689, DOI 10.1016/j.cger.2004.07.004; Revelle W., 2014, PSYCH PROCEDURES PER, V1; Rhee JJO, 2008, J PALLIAT MED, V11, P980, DOI 10.1089/jpm.2007.0251; Ruijs CDM, 2011, FAM PRACT, V28, P689, DOI 10.1093/fampra/cmr035; Schnakenberg R, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1257-1; Schweizer Arzteschaft (FMH), 2014, FMH ARZT; Selman L, 2016, BMJ SUPPORT PALLIAT, V6, P231, DOI 10.1136/bmjspcare-2015-000879; Shipman C, 2001, PALLIATIVE MED, V15, P191, DOI 10.1191/026921601678576176; Slort W, 2011, PALLIATIVE MED, V25, P613, DOI 10.1177/0269216310395987; Steinhauser K. E., 2000, JAMA, V284; Team R.C., 2021, R FOUN DATION STAT C; Theile G, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-24; Todorov V, 2009, J STAT SOFTW, V32, P1; Trizano-Hermosilla I, 2016, BEST ALTERNATIVES CR; van den Berg Michael J, 2006, BMC Fam Pract, V7, P58, DOI 10.1186/1471-2296-7-58; van den Brink-Muinen A, 2003, FAM PRACT, V20, P478, DOI 10.1093/fampra/cmg426; Vermandere M, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X606663; Wasner M, 2005, PALLIATIVE MED, V19, P99, DOI 10.1191/0269216305pm995oa; YOHAI VJ, 1987, ANN STAT, V15, P642, DOI 10.1214/aos/1176350366	59	23	23	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2017	12	2							e0170168	10.1371/journal.pone.0170168	http://dx.doi.org/10.1371/journal.pone.0170168			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN6RS	28146566	Green Published, gold, Green Submitted			2023-01-03	WOS:000396131700015
J	Yan, YY; Yang, YH; Wang, WW; Pan, YT; Zhan, SY; Sun, MY; Zhang, H; Zhai, SD				Yan, Ying-Ying; Yang, Yi-Heng; Wang, Wei-Wei; Pan, Yu-Ting; Zhan, Si-Yan; Sun, Ming-Yang; Zhang, Hong; Zhai, Suo-Di			Post-Marketing Safety Surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: A Real World Study	PLOS ONE			English	Article							MAGNESIUM LITHOSPERMATE-B; ADVERSE DRUG-REACTIONS; HOSPITAL PHARMACISTS; CHINA; PHARMACOKINETICS; INJECTION; DISEASE; DANSHEN; ACID	Background Salvia Miltiorrhiza Depside Salt for Infusion (SMDS) is made of a group of highly purified listed drugs. However, its safety data is still reported limitedly. Compared with the clinical trials, its safety in the real world setting is barely assessed. Objective To investigate the safety issues, including adverse events (AEs), adverse events related to SMDS (ADEs), and adverse drug reactions (ADRs) of the SMDS in the real world clinical practice. Methods This is a prospective, multicenter, pharmacist-led, cohort study in the real world setting. Consecutive patients prescribed with SMDS were all included in 36 sites. Pharmacists were well trained to standardized collect the patients information, including demographics, medical history, prescribing patterns of SMDS, combined medications, adverse events, laboratory investigations, outcomes of the treatment when discharge, and interventions by pharmacists. Adverse events and adverse drug reactions were collected in details. Multivariate possion regression analysis was applied to identify risk factors associated with ADEs using the significance level (a) 0.05. ClinicalTrials. gov Identifier: NCT01872520. Results Thirty six hospitals were participated in the study and 30180 consecutive inpatients were included. The median age was 62 (interquartile range [IQR], 50-73) years, and male was 17384 (57.60%) among the 30180 patients. The incidences of the AEs, ADEs and ADRs were 6.40%, 1.57% and 0.79%, respectively. There were 9 kinds of new ADEs which werenot on the approved label found in the present study. According to the multivariate analysis, male ( RR = 1.381, P = 0.009, 95% CI [ 1.085 similar to 1.759]), more concomitant medications ( RR = 1.049, P< 0.001, 95% CI [ 1.041 similar to 1.057]), longer duration of SMDS therapy ( RR = 1.027, P< 0.001, 95% CI [ 1.013 similar to 1.041]), higher drug concentration ( RR = 1.003, P = 0.014, 95% CI [ 1.001 similar to 1.006]), and resolvent unapproved ( RR = 1.900, P = 0.002, 95% CI [ 1.260 similar to 2.866]) were the independent risk factors of the ADEs. Moreover, following the approved indication ( RR = 0.655, P< 0.001, 95% CI [ 0.532 similar to 0.807]) was associated with lower incidence of ADEs. Conclusions SMDS was well tolerated in the general population. The incidences of the AEs, ADEs and ADRs were 6.40%, 1.57% and 0.79%, respectively. Several risk factors of its ADEs have been identified. It is recommended to follow the instructions when prescribing and administrating SMDS in the real world clinical practice.	[Yan, Ying-Ying; Yang, Yi-Heng; Sun, Ming-Yang; Zhai, Suo-Di] Peking Univ, Hosp 3, Dept Pharm, 49 North Garden Rd, Beijing, Peoples R China; [Wang, Wei-Wei; Pan, Yu-Ting; Zhan, Si-Yan] Peking Univ, Ctr Hlth, Sch Publ Hlth, 38 Xueyuan Rd, Beijing, Peoples R China; [Sun, Ming-Yang] Peking Univ, Ctr Hlth, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, 38 Xueyuan Rd, Beijing, Peoples R China; [Zhang, Hong] State Adm Tradit Chinese Med Peoples Republ China, 55 Xingfu Yicun, Beijing, Peoples R China	Peking University; Peking University; Peking University	Zhai, SD (corresponding author), Peking Univ, Hosp 3, Dept Pharm, 49 North Garden Rd, Beijing, Peoples R China.	zhaisuodi@163.com	Wang, Weiwei/N-7890-2017		State Administration of Traditional Chinese Medicine of the People's Republic of China [2013ZX03]; Shanghai Green Valley Pharmaceutical Co, Ltd.	State Administration of Traditional Chinese Medicine of the People's Republic of China; Shanghai Green Valley Pharmaceutical Co, Ltd.	This study was supported by State Administration of Traditional Chinese Medicine of the People's Republic of China (2013ZX03) and the Shanghai Green Valley Pharmaceutical Co, Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BORDEN EK, 1982, J CHRON DIS, V35, P803, DOI 10.1016/0021-9681(82)90092-3; Chen CG, 2006, ACTA PHARMACOL SIN, V27, P217, DOI 10.1111/j.1745-7254.2006.00225.x; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Fang C, 2014, CLIN EXP PHARMACOL P, V41, P558, DOI 10.1111/1440-1681.12257; HARTWIG SC, 1992, AM J HOSP PHARM, V49, P2229, DOI 10.1093/ajhp/49.9.2229; Jegou D, 2015, EUR J CANCER, V51, P1099, DOI 10.1016/j.ejca.2014.02.025; Ji KM, 2009, ALLERGY, V64, P816, DOI 10.1111/j.1398-9995.2009.01942.x; Ji KM, 2009, REGUL TOXICOL PHARM, V55, P134, DOI 10.1016/j.yrtph.2009.06.008; Jia JY, 2010, CURR THER RES CLIN E, V71, P260, DOI 10.1016/j.curtheres.2010.08.004; Lee GT, 2003, J AM SOC NEPHROL, V14, P709, DOI 10.1097/01.ASN.0000051660.82593.19; Li XC, 2004, RAPID COMMUN MASS SP, V18, P2878, DOI 10.1002/rcm.1703; Li XL, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/610846; Liu J, 2015, INT J CLIN PHARM-NET, V37, P457, DOI 10.1007/s11096-015-0065-8; Liu YR, 2007, J ETHNOPHARMACOL, V111, P573, DOI 10.1016/j.jep.2007.01.005; [苗阳 MIAO Yang], 2006, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V17, P140; Qin CZ, 2015, INT J CLIN EXP MED, V8, P15549; Saturni S, 2014, PULM PHARMACOL THER, V27, P129, DOI 10.1016/j.pupt.2014.01.005; Shan Y, 2013, CHIN J GERIATR HEART, V02, P135; Shrank WH, 2011, J GEN INTERN MED, V26, P546, DOI 10.1007/s11606-010-1609-1; Su CH, 2010, PHARMACOEPIDEM DR S, V19, P217, DOI 10.1002/pds.1792; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wang DY, 2014, CHIN J PHARMACOVIGIL, V11, P732; Wang J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/247948; WHO Collaborating Centre for International Drug Monitoring Uppsala, US WHO UMC SYST STAN; Zhang DF, 2015, EUR J PHARMACOL, V761, P174, DOI 10.1016/j.ejphar.2015.05.003; Zhang L, 2014, DRUG SAFETY, V37, P765, DOI 10.1007/s40264-014-0222-3; Zhang XF, 2015, J INEQUAL APPL, DOI 10.1186/1029-242X-2015-1; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630; Zhou XL, 2015, J PHARM PHARMACOL, V67, P980, DOI 10.1111/jphp.12381	29	13	15	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2017	12	1							e170182	10.1371/journal.pone.0170182	http://dx.doi.org/10.1371/journal.pone.0170182			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7IT	28125608	Green Submitted, Green Published, gold			2023-01-03	WOS:000396176100126
J	Zhang, YJ; Huang, LL; Su, YX; Zhan, ZX; Li, YA; Lai, XQ				Zhang, Yingjie; Huang, Lulu; Su, Youxin; Zhan, Zhengxuan; Li, Yanan; Lai, Xingquan			The Effects of Traditional Chinese Exercise in Treating Knee Osteoarthritis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TAI CHI PROGRAM; OLDER-ADULTS; COGNITIVE IMPAIRMENT; PHYSICAL FUNCTION; MUSCLE STRENGTH; JI QUAN; HEALTH; MANAGEMENT; PAIN	Background and Aims Traditional Chinese exercise (TCE) includes a variety of exercise, which is being accepted by more and more people in the treatment of knee osteoarthritis (OA) from different countries. With the attendant, many clinical reports focus on it. Our meta-analysis aimed to systematically assess the effects of traditional Chinese exercise on pain, stiffness, physical function, quality of life, mental health and adverse events in people with knee osteoarthritis. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), the Web of Science, and Chinese Biomedical Literature Database (CBM) were searched from the time of their inception through April 2016 and risk of bias was independently assessed by two authors. Outcome measures included pain, physical functional, joint stiffness, quality of life, mental health and safety. For pooled outcomes, standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated. Results Eight randomized controlled trials with a sample size of 375 cases met the criteria to be included in the study indicating that high quality literature is lacking in this field. Results of the meta-analysis showed that short-term TCE could relieve pain (SMD: -0.77; 95% CI: -1.13 to -0.41; P<0.0001), improve physical function (SMD -0.75; 95% CI: -0.98 to -0.52; P<0.00001), and alleviate stiffness (SMD: -0.56; 95%: CI -0.96 to -0.16; P<0.006), but had no significant effect on quality of life (SMD: 0.57; 95% CI: 0.17 to 0.97; P = 0.005), and mental health (SMD 4.12; 95% CI: -0.50 to 8.73; P = 0.08). Moreover, TCE was not associated with serious adverse events. Conclusions Our systematic review revealed that short-term TCE was potentially beneficial in terms of reducing pain, improving physical function and alleviating stiffness. These results may suggest that TCE could prove useful as an adjuvant treatment for patients with knee OA. Further studies are urgently needed to confirm these results.	[Zhang, Yingjie; Huang, Lulu; Zhan, Zhengxuan; Li, Yanan; Lai, Xingquan] Fujian Univ Tradit Chinese Med, Dept Rehabil, Coll Med, 1 Qiuyang Rd, Fuzhou, Fujian, Peoples R China; [Su, Youxin] Fujian Univ Tradit Chinese Med, Dept Traumatol, 1 Qiuyang Rd, Fuzhou, Fujian, Peoples R China; [Su, Youxin] Fujian Univ Tradit Chinese Med, Orthoped Coll, 1 Qiuyang Rd, Fuzhou, Fujian, Peoples R China	Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine	Su, YX (corresponding author), Fujian Univ Tradit Chinese Med, Dept Traumatol, 1 Qiuyang Rd, Fuzhou, Fujian, Peoples R China.; Su, YX (corresponding author), Fujian Univ Tradit Chinese Med, Orthoped Coll, 1 Qiuyang Rd, Fuzhou, Fujian, Peoples R China.	suyouxin777@hotmail.com	zhang, ying/HJB-1230-2022		State Administration of Traditional Chinese Medicine [201307004]	State Administration of Traditional Chinese Medicine	This work was supported by grants from the State Administration of Traditional Chinese Medicine (grant number 201307004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; An BC, 2013, CHIN J INTEGR MED, V19, P143, DOI 10.1007/s11655-012-1211-y; An BC, 2008, J ALTERN COMPLEM MED, V14, P167, DOI 10.1089/acm.2007.0600; Baker KR, 2001, J RHEUMATOL, V28, P1655; Belo JN, 2009, OSTEOARTHR CARTILAGE, V17, P1288, DOI 10.1016/j.joca.2009.04.002; Brismee JM, 2007, CLIN REHABIL, V21, P99, DOI 10.1177/0269215506070505; Buckwalter JA, 2001, CLIN ORTHOP RELAT R, P36; Burks Kathryn, 2005, J Gerontol Nurs, V31, P11; BUTT JH, 1988, ALIMENT PHARM THERAP, V2, P121; Cadore EL, 2014, AGING DIS, V5, P183, DOI 10.14336/AD.2014.0500183; Chan JSM, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/106048; Chen KW, 2008, CLIN RHEUMATOL, V27, P1497, DOI 10.1007/s10067-008-0955-4; Cheng FK, 2015, J BODYW MOV THER, V19, P138, DOI 10.1016/j.jbmt.2014.11.001; Cohen J., STAT POWER ANAL BEHA, V2nd; Cramer H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/863905; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Fan Yuan-zhi, 2012, J ACUPUNCTURE TUINA, V10, P321; Field T, 2016, COMPLEMENT THER CLIN, V22, P87, DOI 10.1016/j.ctcp.2016.01.001; Fortun PJ, 2007, CURR OPIN GASTROEN, V23, P134; Fransen M, 2007, ARTHRIT RHEUM-ARTHR, V57, P407, DOI 10.1002/art.22621; Frost H, 2002, CLIN REHABIL, V16, P200, DOI 10.1191/0269215502cr483oa; FZ L., 2014, J SPORT HEALTH SCI, V3, P9, DOI [10.1016/j.jshs.2013.11.002, DOI 10.1016/J.JSHS.2013.11.002]; Gok H, 2002, ACTA ORTHOP SCAND, V73, P647, DOI 10.1080/000164702321039606; Guo YC, 2014, J SPORT HEALTH SCI, V3, P3, DOI 10.1016/j.jshs.2013.10.004; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Jahnke Roger, 2010, Am J Health Promot, V24, pe1, DOI 10.4278/ajhp.081013-LIT-248; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kang JW, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000035; Klein PJ, 2004, AM J PHYS MED REHAB, V83, P735, DOI 10.1097/01.PHM.0000137317.98890.74; Lane N., NOVEL TARGETED THERA; Lauche R, 2013, COMPLEMENT THER MED, V21, P396, DOI 10.1016/j.ctim.2013.06.001; Lee HJ, 2009, CLIN REHABIL, V23, P504, DOI 10.1177/0269215508101746; Li YN, 2016, CLIN REHABIL, V30, P947, DOI 10.1177/0269215515610039; Mahajan A, 2005, J Assoc Physicians India, V53, P200; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Mili F, 2003, J RHEUMATOL, V30, P160; Misso ML, 2008, MED J AUSTRALIA, V189, P394, DOI 10.5694/j.1326-5377.2008.tb02086.x; Morgan NL, 2013, OSTEOARTHR CARTILAGE, V21, pS139, DOI 10.1016/j.joca.2013.02.296; Ni GX, 2010, JCR-J CLIN RHEUMATOL, V16, P64, DOI 10.1097/RHU.0b013e3181cf344f; Oiestad BE, 2016, ARTHRIT CARE RES, V68, P325, DOI 10.1002/acr.22674; Paradowski PT, 2016, OSTEOARTHR CARTILAGE, V24, P794, DOI 10.1016/j.joca.2015.12.002; Raskin JB, 1999, AM J MED, V106, P3; Rhon D, 2008, OSTEOARTHR CARTILAGE, V16, P1585, DOI 10.1016/j.joca.2008.04.019; Sanders JO, 2014, J BONE JOINT SURG AM, V96A, P1220, DOI 10.2106/JBJS.N.00225; Savovic J, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-37; Shen CL, 2008, AM J CHINESE MED, V36, P219, DOI 10.1142/S0192415X08005734; Song R, 2003, J RHEUMATOL, V30, P2039; Song R, 2010, J ALTERN COMPLEM MED, V16, P227, DOI 10.1089/acm.2009.0165; Stevens JA, 2014, J SPORT HEALTH SCI, V3, P21, DOI 10.1016/j.jshs.2013.10.002; Symonds T, 2015, ARTHRIT CARE RES, V67, P1553, DOI 10.1002/acr.22631; Takeshima N, 2007, MED SCI SPORT EXER, V39, P2036, DOI 10.1249/mss.0b013e31814844b7; Tsai PF, 2013, J PAIN SYMPTOM MANAG, V45, P660, DOI 10.1016/j.jpainsymman.2012.04.009; Tsai PF, 2009, RES GERONTOL NURS, V2, P228, DOI 10.3928/19404921-20090731-03; Tsang HWH, 2002, INT J GERIATR PSYCH, V17, P1146, DOI 10.1002/gps.739; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wang CC, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-333; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Wang CC, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-108; Wang XQ, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002562; Wang XQ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-375; Wortley M, 2013, J SPORT HEALTH SCI, V2, P209, DOI 10.1016/j.jshs.2013.01.001; Wyatt FB, 2001, J STRENGTH COND RES, V15, P337; Yang J, 2012, WORLD J GASTROENTERO, V18, P7378, DOI 10.3748/wjg.v18.i48.7378; Ye JJ, 2014, J PHYS THER SCI, V26, P1133, DOI 10.1589/jpts.26.1133; 2000, ARTHRITIS RHEUM, V43, P1905, DOI DOI 10.1002/1529-0131(200009)43:	65	17	18	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2017	12	1							e0170237	10.1371/journal.pone.0170237	http://dx.doi.org/10.1371/journal.pone.0170237			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7FK	28121996	gold, Green Submitted, Green Published			2023-01-03	WOS:000396167300050
J	Fernandes, JM; Felix-Silva, J; da Cunha, LM; Gomes, JAD; Siqueira, EMD; Gimenes, LP; Lopes, NP; Soares, LAL; Fernandes-Pedrosa, MD; Zucolotte, SM				Fernandes, Julia Morais; Felix-Silva, Juliana; da Cunha, Lorena Medeiros; dos Santos Gomes, Jacyra Antunes; da Silva Siqueira, Emerson Michell; Gimenes, Luisa Possamai; Lopes, Norberto Peporine; Lira Soares, Luiz Alberto; Fernandes-Pedrosa, Matheus de Freitas; Zucolotte, Silvana Maria			Inhibitory Effects of Hydroethanolic Leaf Extracts of Kalanchoe brasiliensis and Kalanchoe pinnata (Crassulaceae) against Local Effects Induced by Bothrops jararaca Snake Venom	PLOS ONE			English	Article							PHOSPHOLIPASES A(2); MASS-SPECTROMETRY; NATURAL-PRODUCTS; ASPER VENOM; FRAGMENTATION; ENVENOMINGS; NEWBORN; PROTEIN; BITE; NEED	The species Kalanchoe brasiliensis and Kalanchoe pinnata, both known popularly as "Saiao," are used interchangeably in traditional medicine for their antiophidic properties. Studies evaluating the anti-venom activity of these species are scarce. This study aims to characterize the chemical constituents and evaluate the inhibitory effects of hydroethanolic leaf extracts of K. brasiliensis and K. pinnata against local effects induced by Bothrops jararaca snake venom. Thin Layer Chromatography (TLC) and High Performance Liquid Chromatography coupled with Diode Array Detection and Electrospray Mass Spectrometry (HPLC-DAD-MS/MS) were performed for characterization of chemical markers of the extracts from these species. For antiophidic activity evaluation, B. jararaca venom-induced paw edema and skin hemorrhage in mice were evaluated. In both models, hydroethanolic extracts (125-500 mg/kg) were administered intraperitoneally in different protocols. Inhibition of phospholipase enzymatic activity of B. jararaca was evaluated. The HPLC-DAD-MS/MS chromatographic profile of extracts showed some particularities in the chemical profile of the two species. K. brasileinsis exhibited major peaks that have UV spectra similar to flavonoid glycosides derived from patuletin and eupafolin, while K. pinnata showed UV spectra similar to flavonoids glycosides derived from quercetin and kaempferol. Both extracts significantly reduced the hemorrhagic activity of B. jararaca venom in pre-treatment protocol, reaching about 40% of inhibition, while only K. pinnata was active in post-treatment protocol (about 30% of inhibition). In the antiedematogenic activity, only K. pinnata was active, inhibiting about 66% and 30% in pre and post-treatment protocols, respectively. Both extracts inhibited phospholipase activity; however, K. pinnata was more active. In conclusion, the results indicate the potential antiophidic activity of Kalanchoe species against local effects induced by B. jararaca snake venom, suggesting their potential use as a new source of bioactive molecules against bothropic venom.	[Fernandes, Julia Morais; da Cunha, Lorena Medeiros; da Silva Siqueira, Emerson Michell; Zucolotte, Silvana Maria] Univ Fed Rio Grande Norte UFRN, Dept Farm, Lab Farmacognosia, Grp Pesquisa Prod Nat Bioat PNBio, Natal, RN, Brazil; [Felix-Silva, Juliana; dos Santos Gomes, Jacyra Antunes; Fernandes-Pedrosa, Matheus de Freitas] Univ Fed Rio Grande Norte UFRN, PPgCF, Lab Tecnol & Biotecnol Farmaceut TecBioFar, Natal, RN, Brazil; [Gimenes, Luisa Possamai; Lopes, Norberto Peporine] Fac Ciencias Farmaceut, Dept Quim & Fis, NPPNS, Ribeirao Preto, SP, Brazil; [Lira Soares, Luiz Alberto] Univ Fed Pernambuco UFPE, Lab Farmacognosia, Recife, PE, Brazil; [Zucolotte, Silvana Maria] Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Dept Farm, Lab Farmacognosia, Natal, RN, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal de Pernambuco; Universidade Federal do Rio Grande do Norte	Zucolotte, SM (corresponding author), Univ Fed Rio Grande Norte UFRN, Dept Farm, Lab Farmacognosia, Grp Pesquisa Prod Nat Bioat PNBio, Natal, RN, Brazil.; Zucolotte, SM (corresponding author), Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Dept Farm, Lab Farmacognosia, Natal, RN, Brazil.	szucolotto@hotmail.com	Soares, Luiz Alberto/AAS-3050-2020; Fapesp, Biota/F-8655-2017; Félix-Silva, Juliana/K-7066-2012; Fernandes-Pedrosa, Matheus/C-6398-2014; Soares, Luiz/R-3373-2016; Zucolotto, Silvana Maria/A-8557-2014; Félix-Silva, Juliana/AAA-1737-2019; Lopes, Norberto P/C-7148-2012; Fernandes, Júlia Morais/AAM-2962-2020	Fapesp, Biota/0000-0002-9887-8449; Félix-Silva, Juliana/0000-0003-3131-9025; Fernandes-Pedrosa, Matheus/0000-0003-4221-9580; Zucolotto, Silvana Maria/0000-0002-2768-0793; Félix-Silva, Juliana/0000-0003-3131-9025; Lopes, Norberto P/0000-0002-8159-3658; Fernandes, Júlia Morais/0000-0001-9769-5352; Soares, Luiz/0000-0002-3142-6173	CNPq [447857/2014-2]; Master Degree Scholarship from Capes of Julia Morais Fernandes	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Master Degree Scholarship from Capes of Julia Morais Fernandes	This work was supported by CNPq (447857/2014-2) and Master Degree Scholarship from Capes of Julia Morais Fernandes.	Afzal M, 2012, FITOTERAPIA, V83, P853, DOI 10.1016/j.fitote.2012.03.013; AKIHISA T, 1991, LIPIDS, V26, P660, DOI 10.1007/BF02536432; Amaral A.C.F., 2005, COLETANEA CIENTIFICA; Pereanez JA, 2014, CHEM-BIOL INTERACT, V220, P94, DOI 10.1016/j.cbi.2014.06.015; Antunes TC, 2010, TOXICON, V56, P1443, DOI 10.1016/j.toxicon.2010.08.011; Arni RK, 1996, TOXICON, V34, P827, DOI 10.1016/0041-0101(96)00036-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Patino AC, 2015, TOXINS, V7, P1532, DOI 10.3390/toxins7051532; Cardozo KHM, 2008, INT J MASS SPECTROM, V273, P11, DOI 10.1016/j.ijms.2008.02.014; Carvalho BMA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/153045; Chibli LA, 2014, J ETHNOPHARMACOL, V154, P330, DOI 10.1016/j.jep.2014.03.035; Costa ACO, 2013, J LIQ CHROMATOGR R T, V38, P795; COSTA SS, 1994, J NAT PRODUCTS, V57, P1503, DOI 10.1021/np50113a005; Cotrim CA, 2011, CHEM-BIOL INTERACT, V189, P9, DOI 10.1016/j.cbi.2010.10.016; Cruz EA, 2012, PHYTOMEDICINE, V19, P115, DOI 10.1016/j.phymed.2011.06.030; de Moura VM, 2015, J ETHNOPHARMACOL, V161, P224, DOI 10.1016/j.jep.2014.12.020; de Paula RC, 2009, PROTEIN PEPTIDE LETT, V16, P899, DOI 10.2174/092986609788923365; de Roodt AR, 2000, TOXICON, V38, P865, DOI 10.1016/S0041-0101(99)00205-6; Demarque DP, 2016, NAT PROD REP, V33, P432, DOI 10.1039/c5np00073d; Felix-Silva J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104952; Fonseca F. V., 2004, Rev. bras. farmacogn., V14, P26; Garcia-Mediavilla V, 2007, EUR J PHARMACOL, V557, P221, DOI 10.1016/j.ejphar.2006.11.014; Gehrig H, 2001, PLANT SCI, V160, P827, DOI 10.1016/S0168-9452(00)00447-7; Gomes A, 2010, INDIAN J EXP BIOL, V48, P865; GUTIERREZ J M, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P211; Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9; Gutierrez JM, 2006, PLOS MED, V3, P727, DOI 10.1371/journal.pmed.0030150; Gutierrez JM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002162; HOUGHTON PJ, 1993, J ETHNOPHARMACOL, V39, P1, DOI 10.1016/0378-8741(93)90047-9; Ibrahim T, 2002, INT IMMUNOPHARMACOL, V2, P875, DOI 10.1016/S1567-5769(02)00020-6; Kang TS, 2011, FEBS J, V278, P4544, DOI 10.1111/j.1742-4658.2011.08115.x; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Kothari N, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.09.001; Lomonte B, 2011, ACTA CHIM SLOV, V58, P647; Lomonte B, 2009, TOXICON, V54, P1012, DOI 10.1016/j.toxicon.2009.03.015; Lorenzi H., 2000, PLANTAS MED BRASIL N; LOURENCO WR, 1996, BIOGEOGRAPHIE MADAGA; Gutierrez JM, 2007, CURR PHARM DESIGN, V13, P2935, DOI 10.2174/138161207782023784; Gutierrez JM, 2013, TOXICON, V62, P27, DOI 10.1016/j.toxicon.2012.09.006; Gutierrez JM, 2011, BIOLOGICALS, V39, P129, DOI 10.1016/j.biologicals.2011.02.005; Markham KR, FLAVONOIDS, DOI 10.1016/0022-2860(71)87109-0; Mendes MM, 2013, PHYTOCHEMISTRY, V86, P72, DOI 10.1016/j.phytochem.2012.10.007; Ministerio da Saude, 2009, GUIA VIGILANCIA EPID, V7; Mors WB, 2000, PHYTOCHEMISTRY, V55, P627, DOI 10.1016/S0031-9422(00)00229-6; Mourao RHV, 1999, PHYTOTHER RES, V13, P352, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;352::AID-PTR452&gt;3.0.CO;2-T; Muzitano MF, 2006, PLANTA MED, V72, P81, DOI 10.1055/s-2005-873183; Muzitano MF, 2006, PHYTOCHEMISTRY, V67, P2071, DOI 10.1016/j.phytochem.2006.06.027; Nagpure, 2012, MINTAGE J PHARM MED, V1, P1; Paiva LS, 2008, J LEUKOCYTE BIOL, V83, P1; Patrao-Neto FC, 2013, TOXICON, V69, P55, DOI 10.1016/j.toxicon.2013.01.023; Pinho F M, 2001, Rev Assoc Med Bras (1992), V47, P24, DOI 10.1590/S0104-42302001000100026; Santhosh MS, 2013, MINI-REV MED CHEM, V13, P106; Sarkhel Sumana, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P416, DOI 10.12980/APJTB.4.2014C1120; Domingos TFS, 2015, MOLECULES, V20, P3515, DOI 10.3390/molecules20033515; Srinivasa V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106364; Strauch MA, 2013, J ETHNOPHARMACOL, V145, P50, DOI 10.1016/j.jep.2012.10.033; Supratman U, 2000, BIOSCI BIOTECH BIOCH, V64, P1310, DOI 10.1271/bbb.64.1310; Supratman U, 2001, BIOSCI BIOTECH BIOCH, V65, P947, DOI 10.1271/bbb.65.947; Vasquez J, 2013, J ETHNOPHARMACOL, V146, P449, DOI 10.1016/j.jep.2012.12.043; Vessecchi R, 2011, RAPID COMMUN MASS SP, V25, P2020, DOI 10.1002/rcm.5075; Wagner H., 2001, PLANT DRUGS ANAL THI; Zelanis A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001554	63	20	22	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2016	11	12							e0168658	10.1371/journal.pone.0168658	http://dx.doi.org/10.1371/journal.pone.0168658			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7KQ	28033347	Green Published, gold, Green Submitted			2023-01-03	WOS:000391226900034
J	Lee, JS; Giesler, DL; Fine, MJ				Lee, Jonathan S.; Giesler, Daniel L.; Fine, Michael J.			Duration of Antibiotic Therapy for Community-Acquired Pneumonia in the Era of Personalized Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GUIDELINES	IMPORTANCE The optimal duration of antibiotic treatment for community acquired pneumonia (CAP) has not been well established. OBJECTIVE To validate Infectious Diseases Society of America/American Thoracic Society guidelines for duration of antibiotic treatment in hospitalized patients with CAP. DESIGN, SETTING, AND PARTICIPANTS This study was a multicenter, noninferiority randomized clinical trial performed at 4 teaching hospitals in Spain from January 1, 2012, through August 31, 2013. A total of 312 hospitalized patients diagnosed as having CAP were studied. Data analysis was performed from January 1, 2014, through February 28, 2015. INTERVENTIONS Patients were randomized at day 5 to an intervention or control group. Those in the intervention group were treated with antibiotics for a minimum of 5 days, and the antibiotic treatment was stopped at this point if their body temperature was 37.8 degrees C or less for 48 hours and they had no more than 1 CAP-associated sign of clinical instability. Duration of antibiotic treatment in the control group was determined by physicians. MAIN OUTCOMES AND MEASURES Clinical success rate at days 10 and 30 since admission and CAP-related symptoms at days 5 and 10 measured with the 18-item CAP symptom questionnaire score range, 0-90; higher scores indicate more severe symptoms. RESULTS Of the 312 patients included, 150 and 162 were randomized to the control and intervention groups, respectively. The mean (SD) age of the patientswas 66.2 (17.9) years and 64.7 (18.7) years in the control and intervention groups, respectively. Therewere 95 men (63.3%) and 55women (36.7%) in the control group and 101 men (62.3%) and 61 women (37.7%) in the intervention group. In the intent-to-treat analysis, clinical success was 48.6%(71 of 150) in the control group and 56.3% (90 of 162) in the intervention group at day 10 (P =.18) and 88.6%(132 of 150) in the control group and 91.9%(147 of 162) in the intervention group at day 30 (P =.33). The mean (SD) CAP symptom questionnaire scoreswere 24.7 (11.4) vs 27.2 (12.5) at day 5 (P =.10) and 18.6 (9.0) vs 17.9 (7.6) at day 10 (P =.69). In the per-protocol analysis, clinical successwas 50.4%(67 of 137) in the control group and 59.7%(86 of 146) in the intervention group at day 10 (P =.12) and 92.7%(126 of 137) in the control group and 94.4%(136 of 146) in the intervention group at day 30 (P = .54). The mean (SD) CAP symptom questionnaire scores were 24.3 (11.4) vs 26.6 (12.1) at day 5 (P = .16) and 18.1 (8.5) vs 17.6 (7.4) at day 10 (P = .81). CONCLUSIONS AND RELEVANCE The Infectious Diseases Society of America/American Thoracic Society recommendations for duration of antibiotic treatment based on clinical stability criteria can be safely implemented in hospitalized patients with CAP.	[Lee, Jonathan S.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA; [Giesler, Daniel L.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA; [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr,Bldg 30, Pittsburgh, PA 15240 USA	University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Fine, MJ (corresponding author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr,Bldg 30, Pittsburgh, PA 15240 USA.	michael.fine@va.gov						Gadsby NJ, 2016, CLIN INFECT DIS, V62, P817, DOI 10.1093/cid/civ1214; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; Li JZ, 2007, AM J MED, V120, P783, DOI 10.1016/j.amjmed.2007.04.023; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Schuetz P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub2; Uranga A, 2016, JAMA INTERN MED, V176, P1257, DOI 10.1001/jamainternmed.2016.3633	6	2	2	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2016	316	23					2544	+		10.1001/jama.2016.17589	http://dx.doi.org/10.1001/jama.2016.17589			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG3QH	27997641				2023-01-03	WOS:000390959300022
J	Sun, XY; Yu, ZW; Cai, ZY; Yu, LY; Lv, YY				Sun, Xiaoyi; Yu, Zhenwei; Cai, Zhengyuan; Yu, Lingyan; Lv, Yuanyuan			Voriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-beta-Cyclodextrin Nanofibers for Ophthalmic Delivery	PLOS ONE			English	Article							IN-VIVO EVALUATION; OCULAR INSERTS; DRUG-RELEASE; SUSTAINED-RELEASE; ANTIFUNGAL DRUGS; CYCLOSPORINE-A; VITRO; STABILITY; FORMULATION; SOLUBILITY	Voriconazole (VRC) incorporated in composited polyvinyl alcohol (PVA)/hydroxypropyl-beta cyclodextrin (HP beta CD) blended nanofibers were produced via electrospinning for efficient ophthalmic delivery. The VRC loading capacity increased with increasing HP beta CD content. The optimal solution for electrospinning consisted of 8% (w/v) PVA, 4% (w/v) HP beta CD and 0.5% (w/v) VRC. The nanofibers exhibited bead- free average fiber diameters of 307 +/- 31 nm and VRC was released in vitro in a sustained manner. The VRC nanofibers were characterized by infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM). The proton nuclear magnetic resonance (H-1-NMR) was used to analyze the molar ratio of HP beta CD/VRC in the nanofibers. Compared with a VRC solution, the nanofibers significantly prolonged the half life, and increased the bioavailability of VRC in rabbit tears. No obvious signs of irritation were observed after application in the conjunctival sac. VRC nanofibers are promising for ophthalmic drug delivery and further pharmacodynamics studies are needed.	[Sun, Xiaoyi; Cai, Zhengyuan; Lv, Yuanyuan] Zhejiang Univ City Coll, Dept Pharm, Huzhou St, Hangzhou, Zhejiang, Peoples R China; [Yu, Zhenwei] Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Hangzhou, Zhejiang, Peoples R China; [Yu, Lingyan] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China	Zhejiang University City College; Zhejiang University; Zhejiang University	Lv, YY (corresponding author), Zhejiang Univ City Coll, Dept Pharm, Huzhou St, Hangzhou, Zhejiang, Peoples R China.; Yu, ZW (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Hangzhou, Zhejiang, Peoples R China.	zhenweiyu84@126.com; lvyy@zucc.edu.cn		YU, Zhenwei/0000-0002-3776-2290	Public Welfare Technology Research and Social Development Project of Zhejiang [2013C33234]; National Nature Science Foundation of China [81402872, 51303155]; Natural Science Foundation of Zhejiang Province of China [LQ16H120004, LY17H160002]; Health and Family Planning Commission of Zhejiang, China [2014RCA012]	Public Welfare Technology Research and Social Development Project of Zhejiang; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province of China(Natural Science Foundation of Zhejiang Province); Health and Family Planning Commission of Zhejiang, China	This work was supported by Public Welfare Technology Research and Social Development Project of Zhejiang (2013C33234: http://www.zjkjt.gov.cn/ to ZWY),the National Nature Science Foundation of China (81402872 to XYS, 51303155 to YYL:http://www.nsfc.gov.cn/), Natural Science Foundation of Zhejiang Province of China (LQ16H120004 to LYY and LY17H160002 to XYS:http://www.zjnsf.gov.cn/), and Health and Family Planning Commission of Zhejiang, China (2014RCA012 to ZWY:http://www.zjwst.gov.cn/).	Amoros-Reboredo P, 2015, AM J HEALTH-SYST PH, V72, P479, DOI 10.2146/ajhp140127; Del Valle EMM, 2004, PROCESS BIOCHEM, V39, P1033, DOI 10.1016/S0032-9592(03)00258-9; DiDomenico B, 1999, CURR OPIN MICROBIOL, V2, P509, DOI 10.1016/S1369-5274(99)00009-0; DILUCCIO RC, 1994, J PHARM SCI, V83, P104, DOI 10.1002/jps.2600830124; Dupuis A, 2009, ANTIMICROB AGENTS CH, V53, P798, DOI 10.1128/AAC.01126-08; Duxfield L, 2015, DRUG DEV IND PHARM; Gower EW, 2010, OPHTHALMOLOGY, V117, P2263, DOI 10.1016/j.ophtha.2010.03.048; Goyal R., 2015, J CONTROL RELEASE; Hermans K, 2014, INT J PHARMACEUT, V472, P10, DOI 10.1016/j.ijpharm.2014.06.017; Higuchi T., 1965, ADV ANAL CHEM INSTRU, V4, P117; Iyer Sandhya A, 2006, Eye Contact Lens, V32, P267, DOI 10.1097/01.icl.0000249595.27520.2e; Jain D, 2011, DRUG DEV IND PHARM, V37, P167, DOI 10.3109/03639045.2010.502533; Jayaraman P, 2015, ADV DRUG DELIVER REV, V94, P77, DOI 10.1016/j.addr.2015.09.007; Jeong S, 2009, ANTIMICROB AGENTS CH, V53, P541, DOI 10.1128/AAC.01123-08; Karn PR, 2014, INT J NANOMED, V9, P3791, DOI 10.2147/IJN.S65601; Kumar R, 2014, COLLOID SURFACE B, V117, P82, DOI 10.1016/j.colsurfb.2014.02.007; Lat Asma, 2011, Infect Drug Resist, V4, P43, DOI 10.2147/IDR.S12714; Li GX, 2015, INT J CLIN EXP MED, V8, P12949; Loftssona T, 1996, ADV DRUG DELIV REV, V36, P59; Luke DR, 2010, J PHARM SCI-US, V99, P3291, DOI 10.1002/jps.22109; Miletic T, 2013, CARBOHYD POLYM, V98, P122, DOI 10.1016/j.carbpol.2013.05.084; Morrison PWJ, 2013, MOL PHARMACEUT, V10, P756, DOI 10.1021/mp3005963; Nafee NA, 2003, INT J PHARMACEUT, V264, P1, DOI 10.1016/S0378-5173(03)00371-5; Negishi J, 2010, EUR J PHARM SCI, V41, P617, DOI 10.1016/j.ejps.2010.09.001; Nivoix Y, 2008, CLIN PHARMACOKINET, V47, P779, DOI 10.2165/0003088-200847120-00003; Pahuja P, 2014, CURR DRUG DELIV, V11, P223, DOI 10.2174/1567201810666131224105205; Pawar P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/341218; Peeters J, 2002, J PHARM SCI, V91, P1414, DOI 10.1002/jps.10126; de Sa FAP, 2015, COLLOID SURFACE B, V133, P331, DOI 10.1016/j.colsurfb.2015.06.036; Reynolds TD, 2002, DRUG DEV IND PHARM, V28, P457, DOI 10.1081/DDC-120003007; SAETTONE MF, 1995, ADV DRUG DELIVER REV, V16, P95, DOI 10.1016/0169-409X(95)00014-X; Schulze J, 2016, ACTA BIOMATER; Sebe I, 2015, INT J PHARMACEUT, V494, P516, DOI 10.1016/j.ijpharm.2015.08.054; Shivaprakash MR, 2011, MYCOSES, V54, pE583, DOI 10.1111/j.1439-0507.2010.01996.x; Shukr M, 2014, ARCH PHARM RES, V37, P882, DOI 10.1007/s12272-013-0317-x; Shukr MH, 2016, J MICROENCAPSUL, V33, P71, DOI 10.3109/02652048.2015.1128489; Siafaka PI, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030282; Sun XZ, 2013, CARBOHYD POLYM, V94, P147, DOI 10.1016/j.carbpol.2012.12.064; Szente L, 1999, ADV DRUG DELIVER REV, V36, P17, DOI 10.1016/S0169-409X(98)00092-1; Taepaiboon P, 2006, NANOTECHNOLOGY, V17, P2317, DOI 10.1088/0957-4484/17/9/041; Tonglairoum P, 2016, AAPS PHARM SCI TECH; Tonglairoum P, 2014, PHARM RES-DORDR, V31, P1893, DOI 10.1007/s11095-013-1291-1; Xu JK, 2010, J BIOMAT SCI-POLYM E, V21, P1023, DOI 10.1163/156856209X463690; Yang W, 2010, EUR J PHARM SCI, V39, P336, DOI 10.1016/j.ejps.2010.01.001	44	42	42	3	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2016	11	12							e0167961	10.1371/journal.pone.0167961	http://dx.doi.org/10.1371/journal.pone.0167961			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER6ZW	27974859	Green Published, Green Submitted, gold			2023-01-03	WOS:000398960300001
J	Gershengorn, HB; Xu, YC; Chan, CW; Armony, M; Gong, MN				Gershengorn, Hayley B.; Xu, Yunchao; Chan, Carri W.; Armony, Mor; Gong, Michelle N.			The Impact of Adding a Physician Assistant to a Critical Care Outreach Team	PLOS ONE			English	Article							RAPID RESPONSE TEAMS; NURSE-PRACTITIONERS; INPATIENT; SYSTEMS; TIME	Rationale Hospitals are increasingly using critical care outreach teams (CCOTs) to respond to patients deteriorating outside intensive care units (ICUs). CCOT staffing is variable across hospitals and optimal team composition is unknown. Objectives To assess whether adding a critical care medicine trained physician assistant (CCM-PA) to a critical care outreach team (CCOT) impacts clinical and process outcomes. Methods We performed a retrospective study of two cohorts-one with a CCM-PA added to the CCOT (intervention hospital) and one with no staffing change (control hospital)-at two facilities in the same system. All adults in the emergency department and hospital for whom CCOT consultation was requested from October 1, 2012-March 16, 2013 (pre-intervention) and January 5-March 31, 2014 (post-intervention) were included. We performed difference-in-differences analyses comparing pre- to post-intervention periods in the intervention versus control hospitals to assess the impact of adding the CCM-PA to the CCOT. Measurements and Main Results Our cohort consisted of 3,099 patients (control hospital: 792 pre- and 595 post-intervention; intervention hospital: 1114 pre- and 839 post-intervention). Intervention hospital patients tended to be younger, with fewer comorbidities, but with similar severity of acute illness. Across both periods, hospital mortality (p = 0.26) and hospital length of stay (p = 0.64) for the intervention vs control hospitals were similar, but time-to-transfer to the ICU was longer for the intervention hospital (13.3-17.0 vs 11.5-11.6 hours, p = 0.006). Using the difference-in-differences approach, we found a 19.2% reduction (95 confidence interval: 6.7%-31.6%, p = 0.002) in the time-to-transfer to the ICU associated with adding the CCM-PA to the CCOT; we found no difference in hospital mortality (p = 0.20) or length of stay (p = 0.52). Conclusions Adding a CCM-PA to the CCOT was associated with a notable reduction in time-to-transfer to the ICU; hospital mortality and length of stay were not impacted.	[Gershengorn, Hayley B.; Gong, Michelle N.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Crit Care Med, Bronx, NY 10467 USA; [Gershengorn, Hayley B.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; [Xu, Yunchao; Armony, Mor] NYU, Stern Sch Business, Dept Informat Operat & Management Sci, New York, NY USA; [Chan, Carri W.] Columbia Business Sch, Div Decis Risk & Operat, New York, NY USA; [Gong, Michelle N.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; New York University; Columbia University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Gershengorn, HB (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Div Crit Care Med, Bronx, NY 10467 USA.; Gershengorn, HB (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA.	hgershen@montefiore.org	Chan, Carri W/J-3237-2016	Gershengorn, Hayley/0000-0002-7360-2489	National Science Foundation [CMII 1233547]; National Heart Lung Blood Institute [U01 HL122998, U01 HL123009, UH2 HL125119]	National Science Foundation(National Science Foundation (NSF)); National Heart Lung Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Science Foundation (CMII 1233547) for CWC; National Heart Lung Blood Institute (U01 HL122998, U01 HL123009, UH2 HL125119) for MNG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abadie A, 2005, REV ECON STUD, V72, P1, DOI 10.1111/0034-6527.00321; Alvarez AA, 2013, MED INTENSIVA, V37, P12, DOI 10.1016/j.medin.2012.08.006; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2014, 2013 AAPA ANN SURVEY; [Anonymous], 2011, AG HEALTHC RES QUAL; ASHENFELTER O, 1985, REV ECON STAT, V67, P648, DOI 10.2307/1924810; Bing-Hua YU, 2014, AM J SURG, V208, P268, DOI 10.1016/j.amjsurg.2013.08.044; Cardoso LTQ, 2011, CRIT CARE, V15, DOI 10.1186/cc9975; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Chan PS, 2010, ARCH INTERN MED, V170, P18, DOI 10.1001/archinternmed.2009.424; Cretikos M A, 2005, Minerva Anestesiol, V71, P259; Dimick JB, 2014, JAMA-J AM MED ASSOC, V312, P2401, DOI 10.1001/jama.2014.16153; DUBAYBO BA, 1991, CHEST, V99, P89, DOI 10.1378/chest.99.1.89; Edelson DP, 2011, J HOSP MED, V6, P475, DOI 10.1002/jhm.886; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Escobar GJ, 2008, MED CARE, V46, P232, DOI 10.1097/MLR.0b013e3181589bb6; Garland A, 2013, CHEST, V143, P214, DOI 10.1378/chest.12-1531; Gershengorn HB, 2012, AM J RESP CRIT CARE, V185, P600, DOI 10.1164/rccm.201107-1261CP; Gershengorn HB, 2011, CHEST; Harris Steve, 2015, Lancet, V385 Suppl 1, pS40, DOI 10.1016/S0140-6736(15)60355-5; Health Care Protocol: Rapid Response Team, 2011, HLTH CARE PROTOCOL R; Jones D, 2009, CRIT CARE, V13, DOI 10.1186/cc7996; Kapu AN, 2014, CRIT CARE NURSE, V34, P51, DOI 10.4037/ccn2014847; Kawar Eyad, 2011, JAAPA, V24, P36; Kleinpell RM, 2008, CRIT CARE MED, V36, P2888, DOI 10.1097/CCM.0b013e318186ba8c; Laurens NH, 2010, INT J NURS PRACT, V16, P533, DOI 10.1111/j.1440-172X.2010.01879.x; McGaughey J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005529; McNeill G, 2013, RESUSCITATION, V84, P1652, DOI 10.1016/j.resuscitation.2013.08.006; Morris DS, 2012, RESUSCITATION; Niven DJ, CRIT CARE MED, V201; Puymirat E, 2015, EUR HEART J ACUTE CA; Repasky TM, 2005, J EMERG NURS, V31, P376, DOI 10.1016/j.jen.2005.06.025; Rothberg MB, 2012, J HOSP MED, V7, P98, DOI 10.1002/jhm.953; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Society of Critical Care Medicine, 2014, COMP CRIT CAR PROF; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Winters BD, 2013, ANN INTERN MED, V158, P417, DOI 10.7326/0003-4819-158-5-201303051-00009	37	9	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0167959	10.1371/journal.pone.0167959	http://dx.doi.org/10.1371/journal.pone.0167959			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27942002	gold, Green Published, Green Submitted			2023-01-03	WOS:000392745600040
J	Wajima, T; Anzai, Y; Yamada, T; Ikoshi, H; Noguchi, N				Wajima, Takeaki; Anzai, Yui; Yamada, Tetsuya; Ikoshi, Hideaki; Noguchi, Norihisa			Oldenlandia diffusa Extract Inhibits Biofilm Formation by Haemophilus influenzae Clinical Isolates	PLOS ONE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; OTITIS-MEDIA; BETA; LUXS; CLARITHROMYCIN; AUTOINDUCER-2; RESISTANCE; CHILDREN; SYNTHASE; SURFACE	Oldenlandia diffusa has been empirically used as a therapeutic adjunct for the treatment of respiratory infections. To establish the basic evidence of its clinical usefulness, antimicrobial and biofilm inhibitory activities of an O. diffusa extract were examined against clinical isolates of Haemophilus influenzae, a major causative pathogen of respiratory and sensory organ infections. No significant growth inhibitory activity was observed during incubation for more than 6 h after the extract addition into a culture of H. influenzae. On the other hand, biofilm formation by H. influenzae, evaluated by a crystal violet method, was significantly and dose-dependently inhibited by the O. diffusa extract. Furthermore, the mRNA level of the biofilm-associated gene luxS of H. influenzae significantly decreased soon after the extract addition, and the suppressive effect continued for at least 2 h. At 2 h after the addition of the O. diffusa extract, the autoinducer in the culture supernatant was also significantly reduced by the O. diffusa extract in a dose-dependent manner. These results revealed that O. diffusa extract shows inhibitory activity against luxS-dependent biofilm formation but has no antimicrobial activity against planktonic cells of H. influenzae. Thus, O. diffusa extract might be useful as an adjunctive therapy for the treatment of respiratory infections caused by H. influenzae.	[Wajima, Takeaki; Anzai, Yui; Noguchi, Norihisa] Tokyo Univ Pharm & Life Sci, Dept Microbiol, Sch Pharm, Tokyo, Japan; [Yamada, Tetsuya; Ikoshi, Hideaki] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Tradit Chinese Med, Tokyo, Japan	Tokyo University of Pharmacy & Life Sciences; Tokyo University of Pharmacy & Life Sciences	Noguchi, N (corresponding author), Tokyo Univ Pharm & Life Sci, Dept Microbiol, Sch Pharm, Tokyo, Japan.	noguchin@toyaku.ac.jp	Wajma, Takeaki/AAF-4743-2020	Wajma, Takeaki/0000-0001-9506-707X; Noguchi, Norihisa/0000-0003-4710-7297				Armbruster CE, 2009, INFECT IMMUN, V77, P4081, DOI 10.1128/IAI.00320-09; Benninger MS, 2008, OTOLARYNG HEAD NECK, V138, P274, DOI 10.1016/j.otohns.2007.11.011; Chung HS, 2002, BIOL PHARM BULL, V25, P1142, DOI 10.1248/bpb.25.1142; Erwin AL, 2007, TRENDS MICROBIOL, V15, P355, DOI 10.1016/j.tim.2007.06.004; Goossens H, 2009, CLIN MICROBIOL INFEC, V15, P12, DOI 10.1111/j.1469-0691.2009.02725.x; Gupta Salin, 2004, J Herb Pharmacother, V4, P21, DOI 10.1080/J157v04n01_03; Hardie KR, 2008, NAT REV MICROBIOL, V6, P635, DOI 10.1038/nrmicro1916; Iino Y, 2015, ACTA OTO-LARYNGOL, V135, P217, DOI 10.3109/00016489.2014.975893; Kalia M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135495; Morozumi M, 2013, J INFECT CHEMOTHER, V19, P432, DOI 10.1007/s10156-012-0500-x; MURPHY TF, 1987, REV INFECT DIS, V9, P1; Novotny LA, 2015, MOL MICROBIOL, V96, P276, DOI 10.1111/mmi.12934; Puig C, 2014, INFECT IMMUN, V82, P1591, DOI 10.1128/IAI.01445-13; Sakaue Y, 2016, MICROBIOL IMMUNOL, V60, P10, DOI 10.1111/1348-0421.12343; Seyama S, 2016, ANTIMICROB AGENTS CH, V60, P3207, DOI 10.1128/AAC.00163-16; Song YH, 2012, BIOL PHARM BULL, V35, P1022, DOI 10.1248/bpb.b110660; Teng J, 2007, CHINESE MAT MED; Unal CM, 2012, INT J MED MICROBIOL, V302, P261, DOI 10.1016/j.ijmm.2012.07.013; Vilchez R, 2007, ANAL BIOANAL CHEM, V387, P489, DOI 10.1007/s00216-006-0824-4; Wajima T, 2016, J GLOB ANTIMICROB RE, V6, P22, DOI 10.1016/j.jgar.2016.01.014; Wiertsema SP, 2011, VACCINE, V29, P5163, DOI 10.1016/j.vaccine.2011.05.035	21	10	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2016	11	11							e0167335	10.1371/journal.pone.0167335	http://dx.doi.org/10.1371/journal.pone.0167335			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FV	27902758	Green Published, Green Submitted, gold			2023-01-03	WOS:000389474100074
J	Kaplan, RS; Haas, DA; Warsh, J				Kaplan, Robert S.; Haas, Derek A.; Warsh, Jonathan			Adding Value by Talking More	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EXPECTATIONS		[Kaplan, Robert S.; Haas, Derek A.; Warsh, Jonathan] Harvard Sch Business, Boston, MA 02163 USA	Harvard University	Kaplan, RS (corresponding author), Harvard Sch Business, Boston, MA 02163 USA.		Kaplan, Robert/AAB-9571-2021					Haas DA, 2014, HARVARD BUSINESS REV; Henn RF, 2007, J BONE JOINT SURG AM, V89A, P1913, DOI 10.2106/JBJS.F.00358; James J., 2013, HLTH AFFAIRS; Myers SS, 2008, J GEN INTERN MED, V23, P148, DOI 10.1007/s11606-007-0460-5; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	5	24	25	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2016	375	20					1918	1920		10.1056/NEJMp1607079	http://dx.doi.org/10.1056/NEJMp1607079			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EC1HS	27959597				2023-01-03	WOS:000387856100003
J	Langsrud, S; Steinhauer, K; Luthje, S; Weber, K; Goroncy-Bermes, P; Holck, AL				Langsrud, Solveig; Steinhauer, Katrin; Luthje, Sonja; Weber, Klaus; Goroncy-Bermes, Peter; Holck, Askild L.			Ethylhexylglycerin Impairs Membrane Integrity and Enhances the Lethal Effect of Phenoxyethanol	PLOS ONE			English	Article							COLI NCTC 5933; DEHYDROGENASE ENZYME-SYSTEMS; ESCHERICHIA-COLI; COSMETIC PRESERVATIVES; BURKHOLDERIA-CEPACIA; 2-PHENOXYETHANOL; RESPIRATION; INHIBITION; OUTBREAK	Preservatives are added to cosmetics to protect the consumers from infections and prevent product spoilage. The concentration of preservatives should be kept as low as possible and this can be achieved by adding potentiating agents. The aim of the study was to investigate the mechanisms behind potentiation of the bactericidal effect of a commonly used preservative, 2-phenoxyethanol (PE), by the potentiating agent ethylhexylglycerin (EHG). Sub-lethal concentrations of EHG (0.075%) and PE (0.675%) in combination led to rapid killing of E. coli (> 5 log reduction of cfu after 30 min), leakage of cellular constituents, disruption of the energy metabolism, morphological deformities of cells and condensation of DNA. Used alone, EHG disrupted the membrane integrity even at low concentrations. In conclusion, sub-lethal concentrations of EHG potentiate the effect of PE through damage of the cell membrane integrity. Thus, adding EHG to PE in a 1: 9 ratio has a similar effect on membrane damage and bacterial viability as doubling the concentration of PE. This study provides insight about the mechanism of action of a strong potentiating agent, EHG, which is commonly used in cosmetics together with PE.	[Langsrud, Solveig; Holck, Askild L.] Nofima Norwegian Inst Food Fisheries & Aquacultur, Osloveien 1, N-1430 As, Norway; [Steinhauer, Katrin; Luthje, Sonja; Weber, Klaus; Goroncy-Bermes, Peter] Schulke & Mayr GmbH, Res & Dev, Robert Koch Str 2, D-22851 Norderstedt, Germany	Nofima	Langsrud, S (corresponding author), Nofima Norwegian Inst Food Fisheries & Aquacultur, Osloveien 1, N-1430 As, Norway.	solveig.langsrud@nofima.no	Langsrud, Solveig/I-1241-2012	Langsrud, Solveig/0000-0001-6415-017X; Steinhauer, Katrin/0000-0002-4218-6152	Schulke & Mayr GmbH, Norderstedt, Germany; Foundation for Research Levy on Agricultural Products (FRLAP) [224921/F40]	Schulke & Mayr GmbH, Norderstedt, Germany; Foundation for Research Levy on Agricultural Products (FRLAP)	This study was funded by Schulke & Mayr GmbH, Norderstedt, Germany and Foundation for Research Levy on Agricultural Products (FRLAP, Grant no. 224921/F40). FRLAP had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Schulke & Mayr, through the co-authors participated in planning, interpretation of results and the decision to publish.	Alvarez-Lerma F, 2008, CRIT CARE, V12, DOI 10.1186/cc6778; Beilfuss W, 2005, SOFW-J, V11, P2; Denyer SP, 1995, INT BIODETER BIODEGR, V36, P227, DOI 10.1016/0964-8305(96)00015-7; FITZGERALD KA, 1992, MICROBIOS, V70, P215; GILBERT P, 1976, J PHARM PHARMACOL, V28, pP51; GILBERT P, 1977, MICROBIOS, V19, P17; GILBERT P, 1977, MICROBIOS, V20, P29; GILBERT P, 1977, MICROBIOS, V19, P125; GILBERT P, 1980, MICROBIOS, V28, P7; Harries C, 2016, CONTACT DERMATITIS, V74, P181, DOI 10.1111/cod.12471; Hiom SJ, 2004, DISINFECTION PRESERV; HUGO WB, 1956, J GEN MICROBIOL, V15, P315, DOI 10.1099/00221287-15-2-315; HUGO WB, 1952, J GEN MICROBIOL, V6, P90, DOI 10.1099/00221287-6-1-2-90; Kalchayanand N, 2004, INT J FOOD MICROBIOL, V91, P91, DOI 10.1016/S0168-1605(03)00324-6; Krowka J., 2014, COSM TOIL, V129, P24; Lee E, 2007, CONTACT DERMATITIS, V56, P131, DOI 10.1111/j.1600-0536.2007.01001.x; Lundov MD, 2011, INT J COSMETIC SCI, V33, P190, DOI 10.1111/j.1468-2494.2010.00619.x; Lundov MD, 2013, CONTACT DERMATITIS, V69, P271, DOI 10.1111/cod.12149; Maillard JY, 2002, J APPL MICROBIOL, V92, p16S, DOI 10.1046/j.1365-2672.92.5s1.3.x; Martin M, 2012, ANAESTHESIST, V61, P25, DOI 10.1007/s00101-011-1954-4; ROBINOW C, 1994, MICROBIOL REV, V58, P211, DOI 10.1128/MMBR.58.2.211-232.1994; Scognamiglio J, 2012, FOOD CHEM TOXICOL, V50, pS244, DOI 10.1016/j.fct.2011.10.030; Steinberg D.C., 2010, COSMET TOILETRIES, V125, P46; STEINBERG DC, 2008, COSMET TOILETRIES, V123, P47; Yazar K, 2011, CONTACT DERMATITIS, V64, P265, DOI 10.1111/j.1600-0536.2010.01828.x; ZUSMAN DR, 1973, J BACTERIOL, V115, P1167, DOI 10.1128/JB.115.3.1167-1178.1973	26	13	13	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2016	11	10							e0165228	10.1371/journal.pone.0165228	http://dx.doi.org/10.1371/journal.pone.0165228			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4VE	27783695	Green Published, Green Submitted, gold			2023-01-03	WOS:000389602800064
J	Mendelson, A; Kondo, K; Damberg, C; Low, A; Motuapuaka, M; Freeman, M; O'Neil, M; Relevo, R; Kansagara, D				Mendelson, Aaron; Kondo, Karli; Damberg, Cheryl; Low, Allison; Motuapuaka, Makalapua; Freeman, Michele; O'Neil, Maya; Relevo, Rose; Kansagara, Devan			The Effects of Pay-for-Performance Programs on Health, Health Care Use, and Processes of Care	ANNALS OF INTERNAL MEDICINE			English	Review							FINANCIAL INCENTIVES; OUTCOMES FRAMEWORK; DIABETES CARE; QUALITY INCENTIVES; HOSPITAL PAY; RISK-FACTORS; LONG-TERM; IMPACT; PHYSICIANS; ENGLAND	Background: The benefits of pay-for-performance (P4P) programs are uncertain. Purpose: To update and expand a prior review examining the effects of P4P programs targeted at the physician, group, managerial, or institutional level on process-of-care and patient outcomes in ambulatory and inpatient settings. Data Sources: PubMed from June 2007 to October 2016; MEDLINE, PsycINFO, CINAHL, Business Economics and Theory, Business Source Elite, Scopus, Faculty of 1000, and Gartner Research from June 2007 to February 2016. Study Selection: Trials and observational studies in ambulatory and inpatient settings reporting process-of-care, health, or utilization outcomes. Data Extraction: Two investigators extracted data, assessed study quality, and graded the strength of the evidence. Data Synthesis: Among 69 studies, 58 were in ambulatory settings, 52 reported process-of-care outcomes, and 38 reported patient outcomes. Low-strength evidence suggested that P4P programs in ambulatory settings may improve process-of-care outcomes over the short term (2 to 3 years), whereas data on longer-term effects were limited. Many of the positive studies were conducted in the United Kingdom, where incentives were larger than in the United States. The largest improvements were seen in areas where baseline performance was poor. There was no consistent effect of P4P on intermediate health outcomes (low-strength evidence) and insufficient evidence to characterize any effect on patient health outcomes. In the hospital setting, there was low-strength evidence that P4P had little or no effect on patient health outcomes and a positive effect on reducing hospital readmissions. Limitation: Few methodologically rigorous studies; heterogeneous population and program characteristics and incentive targets. Conclusion: Pay-for-performance programs may be associated with improved processes of care in ambulatory settings, but consistently positive associations with improved health outcomes have not been demonstrated in any setting.	[Kondo, Karli; Low, Allison; Motuapuaka, Makalapua; Freeman, Michele; O'Neil, Maya; Relevo, Rose; Kansagara, Devan] VA Portland Hlth Care Syst, Mail Code R&D 71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Mendelson, Aaron] Oregon Hlth & Sci Univ, Mail Code MDYCHSE,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA; RAND Corp, Santa Monica, CA USA; [Damberg, Cheryl] RAND Hlth, 1776 Main St, Santa Monica, CA 90407 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University; RAND Corporation; RAND Corporation	Kansagara, D (corresponding author), VA Portland Hlth Care Syst, Mail Code R&D 71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	kansagar@ohsu.edu	Callahan, Charles D/L-1641-2013; Kondo, Karli/R-3994-2019	Kondo, Karli/0000-0002-4635-5056	U.S. Department of Veterans Affairs; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS022981] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs(US Department of Veterans Affairs); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	U.S. Department of Veterans Affairs.	Alshamsan R, 2012, ANN FAM MED, V10, P228, DOI 10.1370/afm.1335; Andriole KP, 2010, J AM COLL RADIOL, V7, P198, DOI 10.1016/j.jacr.2009.11.011; Arrowsmith ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092205; Asch DA, 2015, JAMA-J AM MED ASSOC, V314, P1926, DOI 10.1001/jama.2015.14850; Benzer JK, 2014, J GEN INTERN MED, V29, P127, DOI 10.1007/s11606-013-2572-4; Berkman N, 2011, AHRQ PUBLICATION, V11-E006; Calvert M, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1870; Casalino LP, 2016, HEALTH AFFAIR, V35, P401, DOI 10.1377/hlthaff.2015.1258; Chang RE, 2012, HEALTH AFFAIR, V31, P93, DOI 10.1377/hlthaff.2010.0402; Chen CC, 2016, HEALTH POLICY PLANN, V31, P83, DOI 10.1093/heapol/czv024; Chen HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161002; Chen YC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004197; Cheng SH, 2012, MED CARE, V50, P109, DOI 10.1097/MLR.0b013e31822d5d36; Colais P, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-393; Damberg CL, 2014, MEASURING SUCCESS HL; Doran T, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3590; Eijkenaar F, 2013, HEALTH POLICY, V110, P115, DOI 10.1016/j.healthpol.2013.01.008; Emanuel EJ, 2016, ANN INTERN MED, V164, P114, DOI 10.7326/M15-1330; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; Esse T, 2013, J MANAGE CARE PHARM, V19, P317, DOI 10.18553/jmcp.2013.19.4.317; Evidence-based Synthesis Program Coordinating Center, 2014, ESP REP PROGR; Figueroa JF, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2214; Findlay S, 2016, HLTH AFFAIRS; Friedberg MW, 2014, JAMA-J AM MED ASSOC, V311, P815, DOI 10.1001/jama.2014.353; Gallagher N, 2015, DIABETIC MED, V32, P62, DOI 10.1111/dme.12575; Gillam S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f659; Gillam SJ, 2012, ANN FAM MED, V10, P461, DOI 10.1370/afm.1377; Greene J, 2013, HEALTH SERV RES, V48, P1415, DOI 10.1111/1475-6773.12033; Hamilton FL, 2016, NICOTINE TOB RES, V18, P341, DOI 10.1093/ntr/ntv107; Harrison MJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6423; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Houle SKD, 2012, ANN INTERN MED, V157, P889, DOI 10.7326/0003-4819-157-12-201212180-00009; Hsieh HM, 2016, PREV MED, V85, P53, DOI 10.1016/j.ypmed.2015.12.013; Hsieh HM, 2015, MED CARE, V53, P106, DOI 10.1097/MLR.0000000000000264; Institute of Medicine, 2001, REP BRIEF CROSS QUAL; Kalwij S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-802; Kansagara D, 2014, J GEN INTERN MED, V29, P607, DOI 10.1007/s11606-013-2764-y; Karunaratne K, 2013, NEPHROL DIAL TRANSPL, V28, P2107, DOI 10.1093/ndt/gft093; Kendrick T, 2015, J AFFECT DISORDERS, V186, P171, DOI 10.1016/j.jad.2015.06.052; Kiran T, 2014, ANN FAM MED, V12, P317, DOI 10.1370/afm.1664; Kirschner K, 2013, FAM PRACT, V30, P161, DOI 10.1093/fampra/cms055; Kizer KW, 2012, J GEN INTERN MED, V27, P395, DOI 10.1007/s11606-011-1981-5; Kondo K, 2015, UNDERSTANDING INTERV; Kondo KK, 2016, J GEN INTERN MED, V31, P61, DOI 10.1007/s11606-015-3567-0; Kontopantelis E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h904; Kontopantelis E, 2013, BMJ QUAL SAF, V22, P53, DOI 10.1136/bmjqs-2012-001033; Kristensen SR, 2014, NEW ENGL J MED, V371, P540, DOI 10.1056/NEJMoa1400962; Kruse GR, 2013, AM J MANAG CARE, V19, P554; Kuo RNC, 2011, J ONCOL PRACT, V7, pE8S, DOI 10.1200/JOP.2011.000314; Lee CY, 2015, AM J MANAG CARE, V21, pE35; Lee TT, 2010, AM J MANAG CARE, V16, P65; Lemak CH, 2015, HEALTH AFFAIR, V34, P645, DOI 10.1377/hlthaff.2014.0426; Li JH, 2014, HEALTH ECON, V23, P962, DOI 10.1002/hec.2971; Li YH, 2010, HEALTH POLICY PLANN, V25, P334, DOI 10.1093/heapol/czq006; Liao PJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003282; MacBride-Stewart SP, 2008, FAM PRACT, V25, P27, DOI 10.1093/fampra/cmm074; Martens JD, 2007, J EVAL CLIN PRACT, V13, P369, DOI 10.1111/j.1365-2753.2006.00707.x; Mason T, 2015, ADDICTION, V110, P1120, DOI 10.1111/add.12920; McLintock K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005178; Michel-Lepage A, 2016, EUR J HEALTH ECON, V17, P723, DOI 10.1007/s10198-015-0717-6; Millett C, 2009, J ROY SOC MED, V102, P369, DOI 10.1258/jrsm.2009.090171; Murray J, 2010, FAM PRACT, V27, P430, DOI 10.1093/fampra/cmq030; Norbury M, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X583146; Parast L, 2015, J GEN INTERN MED, V30, P359, DOI 10.1007/s11606-014-3150-0; Pechlivanoglou P, 2015, HEALTH ECON, V24, P439, DOI 10.1002/hec.3030; Petersen LA, 2017, HEALTH SERV RES, V52, P1138, DOI 10.1111/1475-6773.12517; Petersen LA, 2013, JAMA-J AM MED ASSOC, V310, P1042, DOI 10.1001/jama.2013.276303; Powell AA, 2012, J GEN INTERN MED, V27, P405, DOI 10.1007/s11606-011-1906-3; Rat C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-301; Roland M, 2014, NEW ENGL J MED, V370, P1944, DOI 10.1056/NEJMhpr1316051; Rosenthal MB, 2016, HEALTH SERV RES, V51, P1444, DOI 10.1111/1475-6773.12426; Rosenthal MB, 2016, J GEN INTERN MED, V31, P289, DOI 10.1007/s11606-015-3521-1; Ryan A, 2014, HEALTH SERV RES, V49, P568, DOI 10.1111/1475-6773.12097; Ryan AM, 2015, HEALTH SERV RES, V50, P81, DOI 10.1111/1475-6773.12206; Scott A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008451.pub2; Share DA, 2012, HEALTH AFFAIR, V31, P1993, DOI 10.1377/hlthaff.2012.0328; Sicsic J, 2016, EUR J HLTH EC; Simpson CR, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X583407; Smith CJP, 2008, QJM-INT J MED, V101, P145, DOI 10.1093/qjmed/hcm155; Sutton M, 2010, HEALTH ECON, V19, P1, DOI 10.1002/hec.1440; Szatkowski L, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-291; Taggar JS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-329; Tahrani AA, 2007, BRIT J GEN PRACT, V57, P483; Tan ECH, 2014, QUAL LIFE RES, V23, P689, DOI 10.1007/s11136-013-0502-x; Torchiana DF, 2013, HEALTH AFFAIR, V32, P1748, DOI 10.1377/hlthaff.2013.0377; Treadwell JR, 2011, FRAMEWORK BEST EVIDE; Tricco AC, 2012, LANCET, V379, P2252, DOI 10.1016/S0140-6736(12)60480-2; Vaghela P, 2009, DIABETES CARE, V32, P427, DOI 10.2337/dc08-1999; Vamos EP, 2011, CAN MED ASSOC J, V183, pE809, DOI 10.1503/cmaj.101187; Vermeulen MJ, 2016, ANN EMERG MED, V67, P496, DOI 10.1016/j.annemergmed.2015.06.028; Wells G, 2014, NEWCASTLE OTTAWA SCA; Yang JH, 2016, INT J QUAL HEALTH C, V28, P580, DOI 10.1093/intqhc/mzw081; Young GJ, 2012, J ORGAN BEHAV, V33, P964, DOI 10.1002/job.1770; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	94	183	184	3	61	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					341	+		10.7326/M16-1881	http://dx.doi.org/10.7326/M16-1881			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EO1BO	28114600				2023-01-03	WOS:000396432800007
J	Yaya, S; Bishwajit, G; Ekholuenetale, M				Yaya, Sanni; Bishwajit, Ghose; Ekholuenetale, Michael			Factors associated with the utilization of institutional delivery services in Bangladesh	PLOS ONE			English	Article							REDUCING MATERNAL MORTALITY; CARE SERVICES; HEALTH; WOMEN	Introduction Bangladesh has made remarkable progress towards reducing its maternal mortality rate (MMR) over the last two decades and is one of the few countries on track to achieving the MMR-related Millennium Development Goals (MDG-5A). However, the provision of universal access to reproductive healthcare (MDG-5B) and the utilization of maternal healthcare services (MHS) such as institutional delivery, which are crucial to the reduction of maternal mortality, are far behind the internationally agreed-upon target. Effective policymaking to promote the utilization of MHS can be greatly facilitated by the identification of the factors that hinder service uptake. In this study, we therefore aim to measure the prevalence of institutional delivery services and explore the factors associated with their utilization in Bangladesh. Methods Data for this study were extracted from the 2011 Bangladesh Demographic and Health Survey (BDHS, 2011); participants were 7,313 women between the ages of 15 and 49 years, selected from both urban and rural households. Data were analyzed using Chi-square analysis, and conditional logistic regression. Results According to the findings, fewer than one in three women reported delivering at a health facility. The multivariable regression analysis showed that participants from rural areas were 46.9% less likely to have institutional deliveries compared to urban dwellers (OR = 0.531; p<0.001; 95% CI: 0.467-0.604), and participants aged between 30 and 49 years had a 23.6% higher prevalence of institutional delivery service utilization compared to those aged 15 to 29 years (OR = 1.236; p = 0.006; 95% CI: 1.062-1.437). Moreover, participants with higher educational attainment were about twice as likely to deliver at a standard health facility when compared to those without formal education (OR = 2.081; p<0.001; 95% CI: 1.650-2.624), and similarly, husbands with higher educational attainment exhibited an approximately 71% higher service utilization of institutional delivery facilities compared to those without formal education (OR = 1.709; p<0.001; 95% CI: 1.412-2.069). Wealth status was also a significant predictor of institutional delivery service use, with participants belonging to the highest economic stratum being more likely to receive skilled care compared to the lowest economic stratum (OR = 2.507; p<0.001; 95% CI: 2.118-2.968). In addition, results indicated that households of average economic class had a 27% higher level of institutional delivery service utilization compared to those of lower economic status (OR = 1.272; p = 0.011; 95% CI: 1.057-1.531). Furthermore, institutional health service use was 18% higher among participants who were aware of community clinical services compared to those who were hardly aware of these services (OR = 0.816; p = 0.012; 95% CI: 0.696-0.957). Lastly, the odds of utilizing delivery services was 1.553 times more likely for participants who use family planning compared to those who do not (p<0.001; 95% CI: 1.374-1.754), and 3.639 times more likely for those who receive antenatal care compared to those who do not (p<0.001; 95% CI: 3.074-4.308). These were found to be significant predictors of the choice of delivery services. Discussion Our results suggest that efforts towards reducing national maternal mortality in Bangladesh could be aided by investments into education, poverty reduction and the strengthening of reproductive healthcare services through community clinics, with particular focus on rural areas.	[Yaya, Sanni] Univ Ottawa, Sch Int Dev & Global Studies, Fac Social Sci, Ottawa, ON, Canada; [Bishwajit, Ghose] Huazhong Univ Sci & Technol, Sch Med & Hlth Management, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Ekholuenetale, Michael] Womens Hlth & Act Res Ctr, Benin, Nigeria	University of Ottawa; Huazhong University of Science & Technology	Yaya, S (corresponding author), Univ Ottawa, Sch Int Dev & Global Studies, Fac Social Sci, Ottawa, ON, Canada.	sanni.yaya@uOttawa.ca	Yaya, Sanni/C-1079-2019; Ekholuenetale, Michael/AAL-3655-2021	Yaya, Sanni/0000-0002-4876-6043; Ekholuenetale, Michael/0000-0002-2372-3020				Adegoke AA, 2009, BJOG-INT J OBSTET GY, V116, P33, DOI 10.1111/j.1471-0528.2009.02336.x; Ahmed SM, 2011, HUM RESOUR HEALTH, V9, DOI 10.1186/1478-4491-9-3; ALAUDDIN M, 1986, STUD FAMILY PLANN, V17, P13, DOI 10.2307/1966951; Anwar I, 2009, J HEALTH POPUL NUTR, V27, P139, DOI 10.3329/jhpn.v27i2.3327; Bishwajit G, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3915-y; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chola L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130077; Chowdhury ME, 2007, LANCET, V370, P1320, DOI 10.1016/S0140-6736(07)61573-6; Chowdhury ME, 2009, J HEALTH POPUL NUTR, V27, P108; Dutamo Z, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1047-1; El Arifeen S, 2014, LANCET, V384, P1366, DOI 10.1016/S0140-6736(14)60955-7; El Mhamdi S, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0198-x; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Igberase GO, 2009, ANN AFR MED, V8, P261, DOI 10.4103/1596-3519.59582; Kamal SMM, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1372, DOI 10.1177/1010539513486178; Karkee R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004372; Khan N, 2013, J HEALTH POPUL NUTR, V31, P262; Koblinsky M, 2008, J HEALTH POPUL NUTR, V26, P280; Koblinsky M, 2006, LANCET, V368, P1377, DOI 10.1016/S0140-6736(06)69382-3; NIPORT, 2013, NAT I POP RES TRAIN; Nour Nawal M, 2008, Rev Obstet Gynecol, V1, P77; Prakash R, 2013, J BIOSOC SCI, V45, P433, DOI 10.1017/S0021932012000831; Prata N, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-78; Ruiz JI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140796; Sen A, 2013, LANCET, V382, P1966, DOI 10.1016/S0140-6736(13)62162-5; Sibley LM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005460; Steinberg L, 2008, DEV REV, V28, P78, DOI 10.1016/j.dr.2007.08.002; United Nations General Assembly, 2000, UN MILL DECL; WHO, 2014, TRENDS MAT MORT 1990; Woldemicael G, 2010, MATERN CHILD HLTH J, V14, P988, DOI 10.1007/s10995-009-0535-5; Yaya S, 2016, BMJ GLOBAL HLTH; Zahodne LB, 2015, J INT NEUROPSYCH SOC, V21, P297, DOI 10.1017/S1355617715000193; Zanconato G, 2006, SEMIN FETAL NEONAT M, V11, P15, DOI 10.1016/j.siny.2005.10.002	34	52	52	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0171573	10.1371/journal.pone.0171573	http://dx.doi.org/10.1371/journal.pone.0171573			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192478	Green Published, gold, Green Submitted			2023-01-03	WOS:000394423800030
J	Berry, M; Brink, E; Harris, J; Sleeman, KE				Berry, M.; Brink, E.; Harris, J.; Sleeman, K. E.			Supporting relatives and carers at the end of a patient's life	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Berry, M.] Imperial Sch Anaesthesia, Anaesthesia & Intens Care, London, England; [Brink, E.] Cambridge Cty Council, Adults Phys Disabil Team, Cambridge, England; [Harris, J.] Beyond Goodbye Project, Bereaved Mother & Daughter, Stroud, England; [Sleeman, K. E.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, Palliat Med, London, England	Imperial College London; University of London; King's College London	Sleeman, KE (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, Palliat Med, London, England.	katherine.sleeman@kcl.ac.uk		Sleeman, Katherine/0000-0002-9777-4373	Academy of Medical Sciences (AMS) [AMS-SGCL10-Sleeman] Funding Source: researchfish; National Institute for Health Research [CL-2010-17-009, CS-2015-15-005] Funding Source: researchfish	Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); National Institute for Health Research(National Institute for Health Research (NIHR))		Abernethy AP, 2008, SUPPORT CARE CANCER, V16, P585, DOI 10.1007/s00520-007-0342-8; [Anonymous], 2014, LEADERSHIP ALLIANCE; Azoulay E, 2002, AM J RESP CRIT CARE, V165, P438, DOI 10.1164/ajrccm.165.4.200108-006oc; COLLIS E, 2013, BMJ-BRIT MED J, V347, P23993, DOI DOI 10.1136/BMJ.F4085; General Medical Council, 2008, CONS PAT DOCT MAK DE; General Medical Council, 2009, CONF; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lebus C, 2014, J PALLIAT MED, V17, P712, DOI 10.1089/jpm.2013.0483; Mayor S, 2007, BRIT MED J, V334, P278, DOI 10.1136/bmj.39118.686100.DB; Neimeyer RA, 2012, COUNSELING CLIENTS N; Neimeyer RA, 2011, GRIEF BEREAVEMENT CO; SLEEMAN KE, 2013, BMJ-BRIT MED J, V346, DOI DOI 10.1136/BMJ.F2174; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; The Greater Manchester Mental Health NHS Foundation Trust, THE HANDBOOK OF FAIT	14	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	2017	356								j367	10.1136/bmj.j367	http://dx.doi.org/10.1136/bmj.j367			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ8BT	28154119	Green Published			2023-01-03	WOS:000393450100004
J	Montigny, C; Dieudonne, T; Orlowski, S; Vazquez-Ibar, JL; Gauron, C; Georgin, D; Lund, S; le Maire, M; Moller, JV; Champeil, P; Lenoir, G				Montigny, Cedric; Dieudonne, Thibaud; Orlowski, Stephane; Vazquez-Ibar, Jose Luis; Gauron, Carole; Georgin, Dominique; Lund, Sten; le Maire, Marc; Moller, Jesper V.; Champeil, Philippe; Lenoir, Guillaume			Slow Phospholipid Exchange between a Detergent-Solubilized Membrane Protein and Lipid-Detergent Mixed Micelles: Brominated Phospholipids as Tools to Follow Its Kinetics	PLOS ONE			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; MECHANOSENSITIVE CHANNEL; ADENOSINE-TRIPHOSPHATASE; FLUORESCENCE; BINDING; CRYSTALLIZATION; STABILIZATION; CA-2+-ATPASE; INHIBITION; MECHANISM	Membrane proteins are largely dependent for their function on the phospholipids present in their immediate environment, and when they are solubilized by detergent for further study, residual phospholipids are critical, too. Here, brominated phosphatidylcholine, a phospholipid which behaves as an unsaturated phosphatidylcholine, was used to reveal the kinetics of phospholipid exchange or transfer from detergent mixed micelles to the environment of a detergent-solubilized membrane protein, the paradigmatic P-type ATPase SERCA1a, in which Trp residues can experience fluorescence quenching by bromine atoms present on phospholipid alkyl chains in their immediate environment. Using dodecylmaltoside as the detergent, exchange of (brominated) phospholipid was found to be much slower than exchange of detergent under the same conditions, and also much slower than membrane solubilization, the latter being evidenced by light scattering changes. The kinetics of this exchange was strongly dependent on temperature. It was also dependent on the total concentration of the mixed micelles, revealing the major role for such exchange of the collision of detergent micelles with the detergent-solubilized protein. Back-transfer of the brominated phospholipid from the solubilized protein to the detergent micelle was much faster if lipid-free DDM micelles instead of mixed micelles were added for triggering dissociation of brominated phosphatidylcholine from the solubilized protein, or in the additional presence of C12E8 detergent during exchange, also emphasizing the role of the chemical nature of the micelle/protein interface. This protocol using brominated lipids appears to be valuable for revealing the possibly slow kinetics of phospholipid transfer to or from detergent-solubilized membrane proteins. Independently, continuous recording of the activity of the protein can also be used in some cases to correlate changes in activity with the exchange of a specific phospholipid, as shown here by using the Drs2p/Cdc50p complex, a lipid flippase with specific binding sites for lipids.	[Montigny, Cedric; Dieudonne, Thibaud; Orlowski, Stephane; Vazquez-Ibar, Jose Luis; Gauron, Carole; le Maire, Marc; Champeil, Philippe; Lenoir, Guillaume] Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Integrat Biol Cell I2BC,CEA, Gif Sur Yvette, France; [Georgin, Dominique] CEA, iBiTec S, Serv Chim Bioorgan & Marquage, Gif Sur Yvette, France; [Lund, Sten] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Med Res Lab, Aarhus, Denmark; [Moller, Jesper V.] Aarhus Univ, Danish Natl Res Fdn, PUMPKIN, Ctr Membrane Pumps Cells & Dis, Aarhus, Denmark; [Moller, Jesper V.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Gauron, Carole] CIRB, CNRS UMR 7241, INSERM, U1050,Coll France, Paris, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University; Aarhus University; Danmarks Grundforskningsfond; Aarhus University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Montigny, C; Lenoir, G (corresponding author), Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Integrat Biol Cell I2BC,CEA, Gif Sur Yvette, France.	cedric.montigny@i2bc.paris-saclay.fr; guillaume.lenoir@i2bc.paris-saclay.fr	Lenoir, Guillaume/I-4002-2019; MONTIGNY, Cédric/AAH-4216-2021; Vazquez-Ibar, Jose-Luis/AAD-8827-2021	Lenoir, Guillaume/0000-0002-8759-5179; Vazquez-Ibar, Jose-Luis/0000-0002-8314-3378; Dieudonne, Thibaud/0000-0001-6988-4121; Lund, Sten/0000-0002-3805-6267	Agence Nationale de la Recherche (ANR) [ANR-14-CE09-0022]; French Infrastructure for Integrated Structural Biology (FRISBI) [ANR-10-INSB-05-01]; Centre National de la Recherche Scientifique (CNRS)	Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); French Infrastructure for Integrated Structural Biology (FRISBI); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	This work was funded by a grant from the Agence Nationale de la Recherche (ANR, htttp://www.agence-nationale-recherche.fr) to GL ('AsymLip', ANR-14-CE09-0022) and by the French Infrastructure for Integrated Structural Biology (FRISBI, http://frisbi.eu, ANR-10-INSB-05-01). This work was also supported by the Centre National de la Recherche Scientifique (CNRS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Autzen HE, 2015, MOL MEMBR BIOL, V32, P75, DOI 10.3109/09687688.2015.1073382; Azouaoui H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112176; BAYERL TM, 1988, BIOCHEMISTRY-US, V27, P6078, DOI 10.1021/bi00416a037; Bechara C, 2015, NAT CHEM, V7, P255, DOI [10.1038/NCHEM.2172, 10.1038/nchem.2172]; BENZONAN.G, 1969, BIOCHIM BIOPHYS ACTA, V176, P836, DOI 10.1016/0005-2760(69)90265-3; Betaneli V, 2012, BIOPHYS J, V102, P523, DOI 10.1016/j.bpj.2011.12.049; Bogdanov M, 2010, P NATL ACAD SCI USA, V107, P15057, DOI 10.1073/pnas.1006286107; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; Carney J, 2006, JOHN; Chae PS, 2010, NAT METHODS, V7, P1003, DOI 10.1038/NMETH.1526; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; Dalton KA, 1998, BIOCHEM J, V329, P637; de Foresta B, 1999, BIOPHYS J, V77, P3071, DOI 10.1016/S0006-3495(99)77138-9; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; deForesta B, 1996, EUR J BIOCHEM, V241, P343; Drachmann ND, 2014, FEBS J, V281, P4249, DOI 10.1111/febs.12957; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; FULLINGTON DA, 1990, BIOCHEMISTRY-US, V29, P879, DOI 10.1021/bi00456a005; Georgin D, 2001, J LABELLED COMPD RAD, V44, P575, DOI 10.1002/jlcr.485; Haviv H, 2013, J BIOL CHEM, V288, P10073, DOI 10.1074/jbc.M112.446997; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; Laganowsky A, 2014, NATURE, V510, P172, DOI 10.1038/nature13419; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lemieux MJ, 2002, J STRUCT BIOL, V137, P322; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1932, DOI 10.1021/bi00510a032; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; LUND S, 1989, J BIOL CHEM, V264, P4907; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Needham D, 1997, BIOPHYS J, V73, P2615, DOI 10.1016/S0006-3495(97)78291-2; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P3925, DOI 10.1021/bi00411a006; null Aoudia, 1998, J COLLOID INTERF SCI, V206, P158, DOI [10.1006/jcis.1998.5627, DOI 10.1006/JCIS.1998.5627]; Picard M, 2006, J BIOL CHEM, V281, P3360, DOI 10.1074/jbc.M511385200; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5873, DOI 10.1021/bi047439e; Powl AM, 2003, BIOCHEMISTRY-US, V42, P14306, DOI 10.1021/bi034995k; POWNALL HJ, 1991, BIOCHEMISTRY-US, V30, P5696, DOI 10.1021/bi00237a009; ROUX M, 1984, FEBS LETT, V171, P169, DOI 10.1016/0014-5793(84)80481-0; SHOEMAKER DG, 1992, BIOCHEMISTRY-US, V31, P3414, DOI 10.1021/bi00128a016; VARSANYI M, 1983, EMBO J, V2, P1543, DOI 10.1002/j.1460-2075.1983.tb01621.x; WARREN GB, 1974, BIOCHEMISTRY-US, V13, P5501, DOI 10.1021/bi00724a008; Zana R, 2006, ADV COLLOID INTERFAC, V123, P345, DOI 10.1016/j.cis.2006.05.011; Zhou XM, 2013, J BIOL CHEM, V288, P31807, DOI 10.1074/jbc.M113.481986; Zoonens M, 2007, BIOCHEMISTRY-US, V46, P10392, DOI 10.1021/bi7007596	45	5	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2017	12	1							e0170481	10.1371/journal.pone.0170481	http://dx.doi.org/10.1371/journal.pone.0170481			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7CU	28118404	gold, Green Published, Green Submitted			2023-01-03	WOS:000396160500031
J	Finetti, F; Terzuoli, E; Donnini, S; Uva, M; Ziche, M; Morbidelli, L				Finetti, Federica; Terzuoli, Erika; Donnini, Sandra; Uva, Marianna; Ziche, Marina; Morbidelli, Lucia			Monitoring Endothelial and Tissue Responses to Cobalt Ferrite Nanoparticles and Hybrid Hydrogels	PLOS ONE			English	Article							IRON-OXIDE NANOPARTICLES; POLYSACCHARIDE-BASED HYDROGELS; MAGNETIC NANOPARTICLES; SYSTEM	Iron oxide nanoparticles (NPs) have been proposed for many biomedical applications as in vivo imaging and drug delivery in cancer treatment, but their toxicity is an ongoing concern. When NPs are intravenously administered, the endothelium represents the first barrier to tissue diffusion/penetration. However, there is little information about the biological effects of NPs on endothelial cells. In this work we showed that cobalt-ferrite (CoFe2O4) NPs affect endothelial cell integrity by increasing permeability, oxidative stress, inflammatory profile and by inducing cytoskeletal modifications. To overcome these problems, NPs have be loaded into biocompatible gels to form nanocomposite hybrid material (polysaccharide hydrogels containing magnetic NPs) that can be further conjugated with anticancer drugs to allow their release close to the target. The organic part of hybrid biomaterials is a carboxymethylcellulose (CMC) polymer, while the inorganic part consists of CoFe2O4 NPs coated with (3-aminopropyl) trimethoxysilane. The biological activity of these hybrid hydrogels was evaluated in vitro and in vivo. Our findings showed that hybrid hydrogels, instead of NPs alone, were not toxic on endothelial, stromal and epithelial cells, safe and biodegradable in vivo. In conclusion, biohydrogels with paramagnetic NPs as cross-linkers can be further exploited for antitumor drug loading and delivery systems.	[Finetti, Federica; Terzuoli, Erika; Donnini, Sandra; Ziche, Marina; Morbidelli, Lucia] Univ Siena, Dept Life Sci, Siena, Italy; [Uva, Marianna] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy	University of Siena; University of Siena	Finetti, F (corresponding author), Univ Siena, Dept Life Sci, Siena, Italy.	finetti2@unisi.it	Finetti, Federica/J-9089-2016; Donnini, Sandra/K-9252-2019; Morbidelli, Lucia/AAC-7858-2020; Terzuoli, Erika/M-7346-2016	Donnini, Sandra/0000-0001-6617-1644; Ziche, Marina/0000-0002-9564-214X; Terzuoli, Erika/0000-0001-9248-4505; Finetti, Federica/0000-0003-1144-3360	M.I.U.R. (Ministero Istruzione, Universita e Ricerca)	M.I.U.R. (Ministero Istruzione, Universita e Ricerca)(Ministry of Education, Universities and Research (MIUR))	The authors thank the M.I.U.R. (Ministero Istruzione, Universita e Ricerca) for financial support for the project "Strategies for engineering ferromagnetic nanoparticles as cross-linkers of polymer chains: application as a targeted drug delivery system in primary and secondary bone tumors", (F.I.R.B. project RBAP11ZJFA, 2010) and Istituto Toscano Tumori (ITT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amiri S, 2013, Mater Sci Eng C Mater Biol Appl, V33, P1, DOI 10.1016/j.msec.2012.09.003; Astanina K, 2014, ACTA BIOMATER, V10, P4896, DOI 10.1016/j.actbio.2014.07.027; Baldi G, 2007, J MAGN MAGN MATER, V311, P10, DOI 10.1016/j.jmmm.2006.11.157; Barbucci R, 2012, ACTA BIOMATER, V8, P4244, DOI 10.1016/j.actbio.2012.09.006; Barbucci R, 2011, SOFT MATTER, V7, P5558, DOI 10.1039/c1sm05174a; Barrefelt A, 2013, INT J NANOMED, V8, P3241, DOI 10.2147/IJN.S49948; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Donnini S, 2007, FASEB J, V21, P2418, DOI 10.1096/fj.06-7581com; Giani G, 2012, POLYMERS-BASEL, V4, P1157, DOI 10.3390/polym4021157; Gobbo OL, 2015, THERANOSTICS, V5, P1249, DOI 10.7150/thno.11544; Grabbe S, 2016, NANOMEDICINE-UK, V11, P2621, DOI 10.2217/nnm-2016-0281; Hong SC, 2011, INT J NANOMED, V6, P3219, DOI 10.2147/IJN.S26355; Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e; Liang YY, 2007, CHEMPHYSCHEM, V8, P2367, DOI 10.1002/cphc.200700359; Liu HX, 2009, INT J PHARMACEUT, V376, P92, DOI 10.1016/j.ijpharm.2009.04.031; Mahmoudi M, 2009, J PHYS CHEM C, V113, P8124, DOI 10.1021/jp900798r; Monti M, 2014, J PHARMACOL EXP THER, V351, P500, DOI 10.1124/jpet.114.218404; Monti M, 2010, J MOL CELL CARDIOL, V48, P746, DOI 10.1016/j.yjmcc.2009.11.002; Morbidelli Lucia, 2016, Cardiooncology, V2, P3, DOI 10.1186/s40959-016-0010-6; Pasqui D, 2012, POLYMERS-BASEL, V4, P1517, DOI 10.3390/polym4031517; Pasqui D, 2011, MATER LETT, V65, P392, DOI 10.1016/j.matlet.2010.10.053; Schexnailder P, 2009, COLLOID POLYM SCI, V287, P1, DOI 10.1007/s00396-008-1949-0; Sivakumar B, 2013, LANGMUIR, V29, P3453, DOI 10.1021/la305048m; Uva M., 2014, J BIOMATER NANOBIOTE, V05, P116, DOI [10.4236/jbnb.2014.52014, DOI 10.4236/JBNB.2014.52014]; Uva M, 2015, GELS-BASEL, V1, P24, DOI 10.3390/gels1010024; Weng LH, 2013, ACTA BIOMATER, V9, P6823, DOI 10.1016/j.actbio.2013.02.017; Wu XY, 2010, INT J NANOMED, V5, P385	28	20	21	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2016	11	12							e0168727	10.1371/journal.pone.0168727	http://dx.doi.org/10.1371/journal.pone.0168727			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7LN	28036325	gold, Green Published, Green Submitted			2023-01-03	WOS:000391229300023
J	da Costa, BR; Hari, R; Juni, P				da Costa, Bruno R.; Hari, Roman; Juni, Peter			Intra-articular Corticosteroids for Osteoarthritis of the Knee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[da Costa, Bruno R.; Hari, Roman] Univ Bern, Inst Primary Hlth Care, Bern, Switzerland; [Juni, Peter] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada	University of Bern; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Juni, P (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	peter.juni@utoronto.ca	Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Hari, Roman/0000-0002-3972-9056; R. da Costa, Bruno/0000-0002-1786-6332				DIEPPE PA, 1980, RHEUMATOL REHABIL, V19, P212, DOI 10.1093/rheumatology/19.4.212; Henriksen M, 2015, JAMA INTERN MED, V175, P923, DOI 10.1001/jamainternmed.2015.0461; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Jevsevar DS, 2013, J AM ACAD ORTHOP SUR, V21, P571, DOI 10.5435/JAAOS-21-09-571; Juni P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005328.pub3; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003	6	34	34	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2016	316	24					2671	2672		10.1001/jama.2016.17565	http://dx.doi.org/10.1001/jama.2016.17565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG5UN	28027351	Green Published			2023-01-03	WOS:000391110200021
J	Catalogna, M; Doenyas-Barak, K; Sagi, R; Abu-Hamad, R; Nevo, U; Ben-Jacob, E; Efrati, S				Catalogna, Merav; Doenyas-Barak, Keren; Sagi, Roi; Abu-Hamad, Ramzia; Nevo, Uri; Ben-Jacob, Eshel; Efrati, Shai			Effect of Peripheral Electrical Stimulation (PES) on Nocturnal Blood Glucose in Type 2 Diabetes: A Randomized Crossover Pilot Study	PLOS ONE			English	Article							LOW-FREQUENCY ELECTROACUPUNCTURE; GLYCEMIC VARIABILITY; HORMONAL-REGULATION; SAMPLE-SIZE; INSULIN; HYPERGLYCEMIA; EXERCISE; GLUCONEOGENESIS	Background Regulation of hepatic glucose production has been a target for antidiabetic drug development, due to its major contribution to glucose homeostasis. Previous pre-clinical study demonstrated that peripheral electrical stimulation (PES) may stimulate glucose utilization and improve hepatic insulin sensitivity. The aim of the present study was to evaluate safety, tolerability, and the glucose-lowering effect of this approach in patients with type 2 diabetes (T2DM). Methods Twelve patients with T2DM were recruited for an open label, interventional, randomized trial. Eleven patients underwent, in a crossover design, an active, and a no-intervention control periods, separated with a two-week washout phase. During the active period, the patients received a daily lower extremity PES treatment (1.33Hz/16Hz burst mode), for 14 days. Study endpoints included changes in glucose levels, number of hypoglycemic episodes, and other potential side effects. Endpoints were analyzed based on continuous glucose meter readings, and laboratory evaluation. Results We found that during the active period, the most significant effect was on nocturnal glucose control (P < 0.0004), as well as on pre-meal mean glucose levels (P < 0.02). The mean daily glucose levels were also decreased although it did not reach clinical significance (P = 0.07). A reduction in serum cortisol (P < 0.01) but not in insulin was also detected after 2 weeks of treatment. No adverse events were recorded. Conclusions These results indicate that repeated PES treatment, even for a very short duration, can improve blood glucose control, possibly by suppressing hepatic glucose production. This effect may be mediated via hypothalamic-pituitary-adrenal axis modulation.	[Catalogna, Merav; Nevo, Uri] Tel Aviv Univ, Dept Biomed Engn, Fac Engn, Tel Aviv, Israel; [Doenyas-Barak, Keren; Sagi, Roi; Abu-Hamad, Ramzia; Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, Zerifin, Israel; [Doenyas-Barak, Keren; Sagi, Roi; Abu-Hamad, Ramzia; Efrati, Shai] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Ben-Jacob, Eshel] Tel Aviv Univ, Sch Phys & Astron, Raymond & Beverly Sackler Fac Exact Sci, Tel Aviv, Israel; [Ben-Jacob, Eshel] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA	Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Rice University	Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Res & Dev Unit, Zerifin, Israel.; Efrati, S (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	efratishai@013.net			research fund of Assaf-Harofeh medical center; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University; Tauber Family Foundation; Direct For Mathematical & Physical Scien [1427654] Funding Source: National Science Foundation	research fund of Assaf-Harofeh medical center; Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University; Tauber Family Foundation; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	The study was supported by the research fund of Assaf-Harofeh medical center, by the Tauber Family Foundation and the Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University.	Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS81, DOI 10.2337/dc14-S081; Belivani M, 2014, ACUPUNCTURE MED; Cabioglu MT, 2006, AM J CHINESE MED, V34, P367, DOI 10.1142/S0192415X06003904; Catalogna M, 2016, METABOLISM, V65, P863, DOI 10.1016/j.metabol.2016.03.004; Cersosimo E, 2000, ENDOTEXT; Chiodini I, 2007, DIABETES CARE, V30, P83, DOI 10.2337/dc06-1267; Clarke W, 2009, DIABETES TECHNOL THE, V11, pS45, DOI 10.1089/dia.2008.0138; Di Dalmazi G, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/525093; Dowswell T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007214.pub2; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Hamada T, 2004, J APPL PHYSIOL, V96, P911, DOI 10.1152/japplphysiol.00664.2003; Hamada T, 2003, J APPL PHYSIOL, V94, P2107, DOI 10.1152/japplphysiol.00486.2002; Harno E, 2010, TRENDS ENDOCRIN MET, V21, P619, DOI 10.1016/j.tem.2010.06.004; Hausdorff JM, 2008, AM J PHYS MED REHAB, V87, P4, DOI 10.1097/PHM.0b013e31815e6680; Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247; Higashimura Y, 2009, AUTON NEUROSCI-BASIC, V150, P100, DOI 10.1016/j.autneu.2009.06.003; Ishizaki N, 2009, METABOLISM, V58, P1372, DOI 10.1016/j.metabol.2009.05.001; JENG CY, 1994, DIABETES, V43, P1440, DOI 10.2337/diabetes.43.12.1440; Jitrapakdee S, 2012, INT J BIOCHEM CELL B, V44, P33, DOI 10.1016/j.biocel.2011.10.001; Johansson J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054357; Johansson J, 2010, AM J PHYSIOL-ENDOC M, V299, pE551, DOI 10.1152/ajpendo.00323.2010; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kovatchev B, 2008, DIABETES CARE, V31, P1160, DOI 10.2337/dc07-2401; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; Kuo T, 2013, MOL CELL ENDOCRINOL, V380, P79, DOI 10.1016/j.mce.2013.03.003; Liang F, 2011, EVIDENCE BASED COMPL, V2011; Lin RT, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-26; Lin RT, 2013, EVID-BASED COMPL ALT, V2013, P9; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Man KM, 2011, EUR J ANAESTH, V28, P420, DOI 10.1097/EJA.0b013e32833fad52; Miyamoto T, 2012, DIABETES RES CLIN PR, V96, P306, DOI 10.1016/j.diabres.2012.01.006; Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881; Monnier L, 2013, DIABETES CARE, V36, P4057, DOI 10.2337/dc12-2127; Monnier L, 2009, DIABETES CARE, V32, pS199, DOI 10.2337/dc09-S310; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Osundiji MA, 2013, ENDOCRIN METAB CLIN, V42, P1, DOI 10.1016/j.ecl.2012.11.006; Pai HC, 2009, J ACUPUNCT MERIDIAN, V2, P147, DOI 10.1016/S2005-2901(09)60047-9; Peplow PV, 2014, J ACUPUNCT MERIDIAN, V7, P1, DOI 10.1016/j.jams.2013.04.014; Rodbard D, 2011, DIABETES TECHNOL THE, V13, P1077, DOI 10.1089/dia.2011.0104; Rodbard D, 2009, DIABETES TECHNOL THE, V11, pS55, DOI 10.1089/dia.2008.0132; Rose AJ, 2005, PHYSIOLOGY, V20, P260, DOI 10.1152/physiol.00012.2005; SHIMAZU T, 1965, SCIENCE, V150, P1607, DOI 10.1126/science.150.3703.1607; SHIMAZU T, 1975, AM J PHYSIOL, V228, P1787, DOI 10.1152/ajplegacy.1975.228.6.1787; Siegelaar SE, 2010, ENDOCR REV, V31, P171, DOI 10.1210/er.2009-0021; Stener-Victorin E, 2016, OBESITY SCI PRACTICE; Stener-Victorin E, 2009, AM J PHYSIOL-REG I, V297, pR387, DOI 10.1152/ajpregu.00197.2009; Tominaga A, 2011, ACUPUNCT MED, V29, P276, DOI 10.1136/acupmed-2011-010006; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Walsh DM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006142.pub2	51	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2016	11	12							e0168805	10.1371/journal.pone.0168805	http://dx.doi.org/10.1371/journal.pone.0168805			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QF	27997608	gold, Green Published, Green Submitted			2023-01-03	WOS:000392842900077
J	Chakraborty, S; Bharucha, AE				Chakraborty, Subhankar; Bharucha, Adil E.			In chronic severe functional constipation, electroacupuncture increased complete spontaneous bowel movements	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Chakraborty, Subhankar; Bharucha, Adil E.] Mayo Clin, Rochester, MN 55902 USA	Mayo Clinic	Chakraborty, S (corresponding author), Mayo Clin, Rochester, MN 55902 USA.							American Gastroenterological Association, 2013, Gastroenterology, V144, P211, DOI 10.1053/j.gastro.2012.10.029; Bharucha AE, 2013, GASTROENTEROLOGY, V144, P218, DOI 10.1053/j.gastro.2012.10.028; Jin Xun, 2010, Zhongguo Zhen Jiu, V30, P97; Wang Li-juan, 2011, Zhongguo Zhen Jiu, V31, P320	4	2	2	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 20	2016	165	12					JC69	JC69		10.7326/ACPJC-2016-165-12-069	http://dx.doi.org/10.7326/ACPJC-2016-165-12-069			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG7OJ	27992925				2023-01-03	WOS:000391236900008
J	He, S; Zhao, TC; Guo, H; Meng, YZ; Qin, GJ; Goukassian, DA; Han, JH; Gao, XM; Zhu, Y				He, Shuang; Zhao, Tiechan; Guo, Hao; Meng, Yanzhi; Qin, Gangjian; Goukassian, David A.; Han, Jihong; Gao, Xuimei; Zhu, Yan			Coordinated Activation of VEGF/VEGFR-2 and PPARd Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice	PLOS ONE			English	Article							ISCHEMIA-INDUCED NEOVASCULARIZATION; DANHONG INJECTION; HYDROXYSAFFLOR YELLOW; SALVIA-MILTIORRHIZA; RECEPTOR-DELTA; RAT MODEL; IN-VIVO; ANGIOGENESIS; DANSHENSU; PROMOTES	Diabetic mellitus (DM) patients are at an increased risk of developing peripheral arterial disease (PAD). Danhong injection (DHI) is a Chinese patent medicine widely used for several cardiovascular indications but the mechanism of action is not well-understood. We investigated the therapeutic potential of DHI on experimental PAD in mice with chemically induced as well as genetic (KKAy) type 2 DM and the overlapping signaling pathways regulating both therapeutic angiogenesis and glucose homeostasis. Compared with normal genetic background wild type (WT) mice, both DM mice showed impaired perfusion recovery in hind-limb ischemia (HLI) model. DHI treatment significantly accelerated perfusion recovery, lowered blood glucose and improved glucose tolerance in both DM models. Bioluminescent imaging demonstrated a continuous ischemia-induced vascular endothelial growth factor receptor 2 (VEGFR-2) gene expressions with a peak time coincident with the maximal DHI stimulation. Flow cytometry analysis showed a DHI-mediated increase in endothelial progenitor cell (EPC) mobilization from bone marrow to circulating peripheral blood. DHI administration upregulated the expression of vascular endothelial growth factor A (VEGF-A) and VEGF receptor-2 (VEGFR-2) in ischemic muscle. A cross talk between ischemia-induced angiogenesis and glucose tolerance pathways was analyzed by Ingenuity Pathway Analysis (IPA) which suggested an interaction of VEGF-A/VEGFR-2 and peroxisome proliferator-activated receptor delta (PPAR delta)/peroxisome proliferator-activated receptor gamma (PPAR gamma) genes. We confirmed that upregulation of VEGF-A/VEGFR-2 by DHI promoted PPAR delta gene expression in both type 2 diabetic mice. Our findings demonstrated that a multi-component Chinese medicine DHI effectively increased blood flow recovery after tissue ischemia in diabetic mice by promoting angiogenesis and improving glucose tolerance through a concomitant activation of VEGF-A/VEGFR-2 and PPAR delta signaling pathways.	[He, Shuang; Zhao, Tiechan; Guo, Hao; Meng, Yanzhi; Qin, Gangjian; Gao, Xuimei; Zhu, Yan] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China; [He, Shuang; Zhao, Tiechan; Guo, Hao; Meng, Yanzhi; Zhu, Yan] Tianjin Int Joint Acad Biotechnol & Med, Res & Dev Ctr TCM, Tianjin, Peoples R China; [Zhu, Yan] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA USA; [Zhu, Yan] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Qin, Gangjian] Northwestern Univ, Feinberg Sch Med, Dept Med Cardiol, Chicago, IL 60611 USA; [Qin, Gangjian] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; [Goukassian, David A.] Tufts Univ, Sch Med, Ctr Biomed Res, Boston, MA 02111 USA; [Han, Jihong] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Han, Jihong] Nankai Univ, Collaborat Innovat Ctr Biotherapy, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin International Joint Academy of Biomedicine; Tufts Medical Center; Tufts University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Tufts University; Nankai University; Nankai University	Zhu, Y (corresponding author), Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China.; Zhu, Y (corresponding author), Tianjin Int Joint Acad Biotechnol & Med, Res & Dev Ctr TCM, Tianjin, Peoples R China.; Zhu, Y (corresponding author), Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA USA.; Zhu, Y (corresponding author), Tufts Univ, Sch Med, Boston, MA 02111 USA.	yanzhu.harvard@iCloud.com	Zhu, Yan/A-1548-2017	Zhu, Yan/0000-0002-3197-7936; Goukassian, David/0000-0001-5270-5270	National Key Basic Research Program of China [2012CB723504]; National Major New Drug Discovery Grant [2013ZX09201020]; National Science Foundation of China [NSFC 81274128]; Program for Tianjin Innovative Research Team in University [TD12-5031]	National Key Basic Research Program of China(National Basic Research Program of China); National Major New Drug Discovery Grant; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Tianjin Innovative Research Team in University	This study was supported by grants from the National Key Basic Research Program of China (2012CB723504), the National Major New Drug Discovery Grant (2013ZX09201020), the National Science Foundation of China (NSFC 81274128); and the Program for Tianjin Innovative Research Team in University (TD12-5031). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bishop-Bailey D, 2011, BIOCHEM SOC T, V39, P1601, DOI 10.1042/BST20110643; Bojic LA, 2014, J LIPID RES, V55, P1254, DOI 10.1194/jlr.M046037; Boucher JM, 2014, NAT MED, V20, P1383, DOI 10.1038/nm.3767; Chen HX, 2014, SCI REP-UK, V4, DOI 10.1038/srep06222; Clark N, 2003, DIABETES CARE, V26, P3333; Dokun AO, 2014, CARDIOVASC RES, V101, P364, DOI 10.1093/cvr/cvt342; Ehrenborg E, 2013, ATHEROSCLEROSIS, V231, P95, DOI 10.1016/j.atherosclerosis.2013.08.027; Freudenberg U, 2015, J CONTROL RELEASE, V220, P79, DOI 10.1016/j.jconrel.2015.10.028; Guo H, 2014, NEUROCHEM RES, V39, P1817, DOI 10.1007/s11064-014-1384-1; He HB, 2008, J PHARM PHARMACOL, V60, P115, DOI 10.1211/jpp.60.1.0015; He Y, 2012, J ETHNOPHARMACOL, V144, P387, DOI 10.1016/j.jep.2012.09.025; Herkenne S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2403; Huang PH, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-99; Huang PH, 2012, ANGIOGENESIS, V15, P377, DOI 10.1007/s10456-012-9267-z; Huang PH, 2010, ATHEROSCLEROSIS, V212, P426, DOI 10.1016/j.atherosclerosis.2010.06.034; Huang PH, 2009, ARTERIOSCL THROM VAS, V29, P1179, DOI 10.1161/ATVBAHA.109.189175; Ishikawa Y, 2012, EXP DIABETES RES, DOI 10.1155/2012/702948; Jiang MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105412; Jiang XQ, 2015, J ETHNOPHARMACOL, V174, P270, DOI 10.1016/j.jep.2015.08.026; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Li YG, 2015, CHEM-BIOL INTERACT, V225, P70, DOI 10.1016/j.cbi.2014.11.003; Li YJ, 2014, J ETHNOPHARMACOL, V151, P218, DOI 10.1016/j.jep.2013.10.019; Liao P, 2015, EVID-BASED COMPL ALT, V2015, DOI [10.1155/2015/646530, DOI 10.1155/2015646530]; Liu HT, 2013, BIOMED CHROMATOGR, V27, P655, DOI 10.1002/bmc.2842; Liu MY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11219; Lu HY, 2014, BIOL PHARM BULL, V37, P961, DOI 10.1248/bpb.b13-00921; Mao HP, 2016, J ETHNOPHARMACOL, V186, P20, DOI 10.1016/j.jep.2016.03.015; Nie PH, 2012, J ETHNOPHARMACOL, V139, P746, DOI 10.1016/j.jep.2011.11.054; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Petznick Allison M, 2010, Osteopath Med Prim Care, V4, P5, DOI 10.1186/1750-4732-4-5; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Rao XQ, 2011, CIRCULATION, V123, P2964, DOI 10.1161/CIRCULATIONAHA.110.966408; Selvin E, 2006, DIABETES CARE, V29, P877, DOI 10.2337/diacare.29.04.06.dc05-2018; Sun K, 2014, PAK J PHARM SCI, V27, P1699; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vazquez-Carrera M, 2016, TRENDS ENDOCRIN MET, V27, P319, DOI 10.1016/j.tem.2016.02.008; Wang DD, 2013, J CARDIOVASC PHARM, V62, P457, DOI 10.1097/FJC.0b013e3182a29657; Yang MZ, 2016, BRAIN RES, V1642, P516, DOI 10.1016/j.brainres.2016.04.046; Yang RX, 2010, ACTA PHARMACOL SIN, V31, P1395, DOI 10.1038/aps.2010.167; Yoon JW, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0131785, DOI 10.1371/JOURNALPONE0131785]; Youngblood RC, 2014, INT J MED SCI, V11, P545, DOI 10.7150/ijms.6994; Yu JW, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0408-3; Yu JM, 2015, MOL MED REP, V12, P6718, DOI 10.3892/mmr.2015.4307; Zhang Hao, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P44, DOI 10.3969/j.issn.1672-7347.2011.01.007; Zhang QQ, 2016, CHIN J NAT MEDICINES, V14, P147, DOI 10.1016/S1875-5364(16)60008-0; Zhao BL, 1996, BIOCHEM MOL BIOL INT, V38, P1171; Zhao DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071472; Zhao GR, 2008, FOOD CHEM TOXICOL, V46, P73, DOI 10.1016/j.fct.2007.06.034; Zhou XL, 2012, PHYTOMEDICINE, V19, P1263, DOI 10.1016/j.phymed.2012.08.011	51	25	27	4	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2016	11	12							e0167305	10.1371/journal.pone.0167305	http://dx.doi.org/10.1371/journal.pone.0167305			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4OA	27930695	Green Submitted, Green Published, gold			2023-01-03	WOS:000389580900024
J	Caskey, M; Klein, F; Nussenzweig, MC				Caskey, Marina; Klein, Florian; Nussenzweig, Michel C.			FOCUS ON RESEARCH Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							3BNC117; HUMANS		[Caskey, Marina; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; [Klein, Florian] Univ Cologne, Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Internal Med 1,Lab Expt Immunol,CMMC, Cologne, Germany; [Klein, Florian] German Ctr Infect Res, Partner Site Bonn Cologne, Cologne, Germany	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; University of Cologne; German Center for Infection Research; University of Cologne	Caskey, M (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.		Nussenzweig, Michel/AAE-7292-2019					Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Gautam R, 2016, NATURE, V533, P105, DOI 10.1038/nature17677; Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Scheid JF, 2009, J IMMUNOL METHODS, V343, P65, DOI 10.1016/j.jim.2008.11.012	5	49	50	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2016	375	21					2019	2021		10.1056/NEJMp1613362	http://dx.doi.org/10.1056/NEJMp1613362			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EC9KU	27959740				2023-01-03	WOS:000388464300004
J	Kabwijamu, L; Waiswa, P; Kawooya, V; Nalwadda, CK; Okuga, M; Nabiwemba, EL				Kabwijamu, Lydia; Waiswa, Peter; Kawooya, Vincent; Nalwadda, Christine K.; Okuga, Monica; Nabiwemba, Elizabeth L.			Newborn Care Practices among Adolescent Mothers in Hoima District, Western Uganda	PLOS ONE			English	Article							CHILD HEALTH-CARE; EASTERN UGANDA; RURAL UGANDA; BANGLADESH; OUTCOMES; BABIES	Introduction Adolescent childbearing remains a major challenge to improving neonatal mortality especially in Sub Saharan countries which are still struggling with high neonatal mortality rates. We explored essential newborn care practices and associated factors among adolescent mothers in Western Uganda. Methods Data were collected among 410 adolescent mothers with children aged one to six months in Hoima district. Three composite variables (appropriate neonatal breastfeeding, cord care and thermal protection) were derived by combining related practices from a list of recommended newborn care practices. Logistic regression analysis was conducted to identify factors independently associated with practice of essential newborn care. Results Appropriate newborn feeding, optimal thermal protection and dry cord care were practiced by 60.5%, 67.2% and 31% of adolescent mothers respectively. Independent predictors' of cord care were: knowledge of cord care (AOR 5.34, 95% CI (1.51-18.84) and having delivered twins (AOR 0.04, 95% CI (0.01-0.22). The only predictor of thermal care was knowledge (AOR 25.15, 95% CI (7.01-90.20). Staying in a hospital for more than one day postpartum (AOR 2.45, 95%Cl (1.23-4.86), knowledge of the correct time of breastfeeding initiation (AOR 14.71, 95% CI (5.20-41.58), predicted appropriate neonatal feeding, whereas; adolescent mothers who had had a caesarean delivery (AOR 0.19, 95% CI (I 0.04-0.96) and a male caretaker in the postnatal period (AOR 0.18, 95% CI (0.07-0.49) were less likely to practice the recommended newborn feeding. Conclusion Sub optimal essential newborn care practice was noted especially suboptimal cord care. Adolescent mothers should be a focus of strategies to improve maternal and neonatal health.	[Kabwijamu, Lydia; Waiswa, Peter; Kawooya, Vincent; Nalwadda, Christine K.; Okuga, Monica; Nabiwemba, Elizabeth L.] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Kampala, Uganda; [Waiswa, Peter; Okuga, Monica] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Ctr Excellence Maternal & Newborn Hlth, Kampala, Uganda; [Waiswa, Peter] Karolinska Inst, Dept Publ Hlth Sci, Global Hlth, Stockholm, Sweden	Makerere University; Makerere University; Karolinska Institutet	Kabwijamu, L (corresponding author), Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Kampala, Uganda.	lkabwijamu@gmail.com			Saving Newborn Lives through the Makerere University Centre of Excellence for Maternal and Newborn Health Research; Saving Newborn Lives/ Centre for Maternal and Newborn Health Research at Makerere University School of Public Health; Hoima District Health Office	Saving Newborn Lives through the Makerere University Centre of Excellence for Maternal and Newborn Health Research; Saving Newborn Lives/ Centre for Maternal and Newborn Health Research at Makerere University School of Public Health; Hoima District Health Office	The study was funded by Saving Newborn Lives through the Makerere University Centre of Excellence for Maternal and Newborn Health Research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the adolescent mothers, research assistants and the staff of Hoima District Local Government especially the health department for participating in this study. We also acknowledge the Saving Newborn Lives/ Centre for Maternal and Newborn Health Research at Makerere University School of Public Health that financed this study. The field work was supported by the Hoima District Health Office.	Atuyambe Lynn, 2008, Reprod Health, V5, P13, DOI 10.1186/1742-4755-5-13; Ayiasi MR, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-176; Ayiasi RM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-114; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; Byaruhanga R, 2005, J TROP PEDIATRICS, V51, P212, DOI 10.1093/tropej/fmh098; Byaruhanga RN, 2011, MIDWIFERY, V27, P775, DOI 10.1016/j.midw.2010.02.005; Ganchimeg T, 2014, BJOG-INT J OBSTET GY, V121, P40, DOI 10.1111/1471-0528.12630; Hidalgo Luis A., 2005, Archives of Gynecology and Obstetrics, V271, P207, DOI 10.1007/s00404-004-0600-7; Jutte DP, 2010, ACAD PEDIATR, V10, P293, DOI 10.1016/j.acap.2010.06.008; Karas DJ, 2012, J TROP PEDIATRICS, V58, P200, DOI 10.1093/tropej/fmr057; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Kongnyuy EJ, 2008, MATERN CHILD HLTH J, V12, P149, DOI 10.1007/s10995-007-0235-y; Kurth F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014367; Mbonye AK, 2012, HEALTH POLICY PLANN, V27, P104, DOI 10.1093/heapol/czs045; MoH, 2011, NAT POL GUID SERV ST; MOH, 2013, REPR MAT NEWB CHILDH; Nankabirwa V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019674; Nasreen HE, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-18; Okigbo CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129286; Rahman M, 2011, JOGNN-J OBST GYN NEO, V40, P262, DOI 10.1111/j.1552-6909.2011.01240.x; Rahman M, 2011, HEALTH SOC CARE COMM, V19, P138, DOI 10.1111/j.1365-2524.2010.00953.x; Shamba D, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-267; Sines E., 2007, POSTNATAL CARE CRITI; Singh L, 2012, J BIOSOC SCI, V44, P1, DOI 10.1017/S0021932011000472; Sreeramareddy Chandrashekhar T, 2006, BMC Pregnancy Childbirth, V6, P27, DOI 10.1186/1471-2393-6-27; Tweheyo R, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-53; UBOS I, 2012, UG DEM HLTH SURV 201; Uzun AK, 2013, J MATERN-FETAL NEO M, V26, P454, DOI 10.3109/14767058.2012.733748; Vogel JP, 2015, ARCH DIS CHILD, V100, pS43, DOI 10.1136/archdischild-2013-305514; Waiswa P, 2010, TROP MED INT HEALTH, V15, P964, DOI 10.1111/j.1365-3156.2010.02557.x; Waiswa P, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-9; Waiswa Peter, 2008, BMC Pregnancy Childbirth, V8, P21, DOI 10.1186/1471-2393-8-21; WHO, 2014, EV NEWB ACT PLAN END; World Health Organization, 2011, WHO GUID PREV EARL P; World Health Organization, 2012, EARL MARR AD YOUNG P; World Health Organization, 1996, ESS NEWB CAR; World Health Organization Department of Maternal N, 2013, WHO REC POSTN CAR MO	37	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2016	11	11							e0166405	10.1371/journal.pone.0166405	http://dx.doi.org/10.1371/journal.pone.0166405			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC2AC	27855186	Green Submitted, Green Published, gold			2023-01-03	WOS:000387910200030
J	Alexander, J; Cifu, AS				Alexander, Jason; Cifu, Adam S.			Transfusion of Red Blood Cells	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESTRICTIVE TRANSFUSION		[Alexander, Jason; Cifu, Adam S.] Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA	University of Chicago	Cifu, AS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu	Alexander, Jason Mark/GZH-2353-2022					Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; National Clinical Guideline Centre (UK), 2015, BLOOD TRANSFUSION, V24; National Institute for Health and Clinical Excellence, 2012, GUID MAN; Whitaker B, 2016, TRANSFUSION, V56, P2173, DOI 10.1111/trf.13676; Whitaker BI, 2011 NATL BLOOD COLL	9	15	15	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2016	316	19					2038	2039		10.1001/jama.2016.12870	http://dx.doi.org/10.1001/jama.2016.12870			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB8XC	27732722				2023-01-03	WOS:000387673800022
J	Kim, DW; Kim, EJ; Kim, EN; Sung, MW; Kwon, TK; Cho, YW; Kwon, SK				Kim, Dong Wook; Kim, Eun Ji; Kim, Eun Na; Sung, Myung Whun; Kwon, Tack-Kyun; Cho, Yong Woo; Kwon, Seong Keun			Human Adipose Tissue Derived Extracellular Matrix and Methylcellulose Hydrogels Augments and Regenerates the Paralyzed Vocal Fold	PLOS ONE			English	Article							FAT INJECTION LARYNGOPLASTY; TERM FOLLOW-UP; XENOGRAFT MODEL; CORD PARALYSIS; SCAFFOLD; TRANSPLANTATION; STRATEGIES; DELIVERY; SURGERY	Vocal fold paralysis results from various etiologies and can induce voice changes, swallowing complications, and issues with aspiration. Vocal fold paralysis is typically managed using injection laryngoplasty with fat or synthetic polymers. Injection with autologous fat has shown excellent biocompatibility. However, it has several disadvantages such as unpredictable resorption rate, morbidities associated with liposuction procedure which has to be done in operating room under general anesthesia. Human adipose-derived extracellular matrix (ECM) grafts have been reported to form new adipose tissue and have greater biostability than autologous fat graft. Here, we present an injectable hydrogel that is constructed from adipose tissue derived soluble extracellular matrix (sECM) and methylcellulose (MC) for use in vocal fold augmentation. Human sECM derived from adipose tissue was extracted using two major steps-ECM was isolated from human adipose tissue and was subsequently solubilized. Injectable sECM/MC hydrogels were prepared by blending of sECM and MC. Sustained vocal fold augmentation and symmetric vocal fold vibration were accomplished by the sECM/MC hydrogel in paralyzed vocal fold which were confirmed by laryngoscope, histology and a high-speed imaging system. There were increased number of collagen fibers and fatty granules at the injection site without significant inflammation or fibrosis. Overall, these results indicate that the sECM/MC hydrogel can enhance vocal function in paralyzed vocal folds without early resorption and has potential as a promising material for injection laryngoplasty for stable vocal fold augmentation which can overcome the shortcomings of autologous fat such as unpredictable duration and morbidity associated with the fat harvest.	[Kim, Dong Wook; Sung, Myung Whun; Kwon, Tack-Kyun; Kwon, Seong Keun] Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul Natl Univ Hosp, Seoul, South Korea; [Kim, Eun Ji; Cho, Yong Woo] Hanyang Univ, Dept Chem Engn, Ansan 426791, Gyeonggi Do, South Korea; [Kim, Eun Na] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Hanyang University; University of Ulsan; Asan Medical Center	Kwon, SK (corresponding author), Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul Natl Univ Hosp, Seoul, South Korea.; Cho, YW (corresponding author), Hanyang Univ, Dept Chem Engn, Ansan 426791, Gyeonggi Do, South Korea.	ywcho77@gmail.com; otolarynx@snuh.org	Kim, Eun Na/GVU-5478-2022		National Research Foundation of Korea [NRF-2014R1A2A2A04003979]; Korea Health Industry Development Institute [HI14C1541, HI15C3049]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Health Industry Development Institute(Korea Health Industry Development Institute (KHIDI))	This research was supported by National Research Foundation of Korea (https://www.nrf.re.kr) Grant # NRF-2014R1A2A2A04003979 to SKK, Korea Health Industry Development Institute (https://www.khidi.or.kr) Grant # HI14C1541 to SKK and the Korea Health Industry Development Institute HI15C3049 to SKK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad J, 2011, AESTHET SURG J, V31, P214, DOI 10.1177/1090820X10395508; Badylak SF, 2009, ACTA BIOMATER, V5, P1, DOI 10.1016/j.actbio.2008.09.013; CHAJCHIR A, 1989, PLAST RECONSTR SURG, V84, P921, DOI 10.1097/00006534-198912000-00009; Chen CZC, 2009, FIBROGENESIS TISSUE, V2, DOI 10.1186/1755-1536-2-7; Cho SW, 2005, BIOMATERIALS, V26, P3577, DOI 10.1016/j.biomaterials.2004.09.013; Choi JS, 2010, TISSUE ENG PART C-ME, V16, P387, DOI [10.1089/ten.tec.2009.0276, 10.1089/ten.TEC.2009.0276]; Choi JS, 2011, J BIOMED MATER RES A, V97A, P292, DOI 10.1002/jbm.a.33056; Choi JS, 2009, J CONTROL RELEASE, V139, P2, DOI 10.1016/j.jconrel.2009.05.034; Craft RO, 2009, J PLAST RECONSTR AES, V62, P235, DOI 10.1016/j.bjps.2007.11.017; DeFatta RA, 2012, J VOICE, V26, P614, DOI 10.1016/j.jvoice.2011.08.005; Fang TJ, 2010, ARCH OTOLARYNGOL, V136, P457, DOI 10.1001/archoto.2010.42; Fonseca-Alaniz MH, 2007, J PEDIAT-BRAZIL, V83, pS192, DOI [10.1590/S0021-75572007000700011, 10.2223/JPED.1709]; Friedl P, 1998, MICROSC RES TECHNIQ, V43, P369, DOI 10.1002/(SICI)1097-0029(19981201)43:5<369::AID-JEMT3>3.0.CO;2-6; Han KD, 2012, AESTHET SURG J, V32, P745, DOI 10.1177/1090820X12452422; Havas TE, 2003, ANZ J SURG, V73, P938, DOI 10.1046/j.1445-2197.2003.02824.x; Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421; Kim DY, 2003, ACTA OTO-LARYNGOL, V123, P1102, DOI 10.1080/00016480310001880; Kwon SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085512; Kwon SK, 2013, LARYNGOSCOPE, V123, P1694, DOI 10.1002/lary.23879; Kwon Tack-Kyun, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P538, DOI 10.1097/01.moo.0000144393.40874.98; Ma PX, 2001, TISSUE ENG, V7, P23, DOI 10.1089/107632701300003269; McCulloch TM, 2002, LARYNGOSCOPE, V112, P1235, DOI 10.1097/00005537-200207000-00017; MIKUS JL, 1995, LARYNGOSCOPE, V105, P17, DOI 10.1288/00005537-199501000-00007; Mizuta M, 2013, LARYNGOSCOPE; NIECHAJEV I, 1994, PLAST RECONSTR SURG, V94, P496, DOI 10.1097/00006534-199409000-00012; O'Leary MA, 2006, OTOLARYNG CLIN N AM, V39, P43, DOI 10.1016/j.otc.2005.10.008; Patrick CW, 2001, ANAT RECORD, V263, P361, DOI 10.1002/ar.1113; Philips BJ, 2013, PLAST RECONSTR SURG, V132, P845, DOI 10.1097/PRS.0b013e31829fe5b1; PINSKI KS, 1992, J DERMATOL SURG ONC, V18, P179, DOI 10.1111/j.1524-4725.1992.tb02795.x; Fraga MFP, 2008, J PLAST RECONSTR AES, V61, P1044, DOI 10.1016/j.bjps.2007.06.034; Umeno H, 2009, J LARYNGOL OTOL, V123, P35, DOI 10.1017/S0022215109005064; Umeno H, 2012, ANN OTO RHINOL LARYN, V121, P185, DOI 10.1177/000348941212100308; Veidal SS, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-5	33	8	9	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2016	11	10							e0165265	10.1371/journal.pone.0165265	http://dx.doi.org/10.1371/journal.pone.0165265			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9OE	27768757	gold, Green Submitted, Green Published			2023-01-03	WOS:000386205400074
J	Lescano, CH; de Oliveira, IP; Zaminelli, T; Baldivia, DD; da Silva, LR; Napolitano, M; Silverio, CBM; Lincopan, N; Sanjinez-Argandona, EJ				Lescano, Caroline Honaiser; de Oliveira, Ivan Pires; Zaminelli, Tiago; Baldivia, Debora da Silva; da Silva, Luan Ramos; Napolitano, Mauro; Mendes Silverio, Camila Bitencourt; Lincopan, Nilton; Sanjinez-Argandona, Eliana Janet			Campomanesia adamantium Peel Extract in Antidiarrheal Activity: The Ability of Inhibition of Heat-Stable Enterotoxin by Polyphenols	PLOS ONE			English	Article							ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; CYCLIC-NUCLEOTIDE; ANTIMICROBIAL ACTIVITY; ESSENTIAL OIL; IN-VITRO; O. BERG; ANTIOXIDANT; PLANTS; CELLS	Campomanesia adamantium (Myrtaceae) is a medicinal plant distributed in Brazilian Cerrado. Different parts of this plant are used in popular medicine for treatment of several diseases like fever, diarrhea, hypercholesterolemia and rheumatism. The aim of this work was to evaluate the inhibition of heat-stable enterotoxin type A (STa) by gallic acid present in the peel of C. adamantium fruit and assays to assess the antidiarrheal activity, anti-inflammatory and cytotoxic properties of peel extract using the T84 cell line model. The possible inhibition exerted by the gallic acid of the peel extract on the STa peptide was inferred by molecular dynamics simulations. The antidiarrheal effects were investigated measuring cGMP accumulation in cells after stimulation by STa toxin and antibacterial activity was assessed. The anti-inflammatory activity was assessed by inhibition of COX-1 and COX-2. MTT and LDH assays were used to evaluate any possible cytotoxic action while the CyQUANT test was used to investigate the effect on cell proliferation. A representation showing how the possible interactions between STa and the gallic acid of the extract might reduce the action of the enterotoxin is presented. C. adamantium peel extract significantly decreased the levels of cGMP in T84 cells. However, no effect on the species of microorganisms was observed. The extract also inhibited COX-1 (IC50 255.70 +/- 0.04 ng/mL) and COX-2 (IC50 569.50 +/- 0.11 ng/mL) enzymes. Cytotoxicity assay have shown significant changes in cells treated with the extract, which inhibited the cell proliferation until 72 hours of treatment. Direct interactions of phenolic compounds present in the extract with the STa toxin may limit its activity. Curative effect in the diarrhea treatment and its anti-inflammatory action is based on the pharmacological properties, mechanism of action of the C. adamantium peel extract, and no toxic effects of the peel extract presented on this work.	[Lescano, Caroline Honaiser; Zaminelli, Tiago; Mendes Silverio, Camila Bitencourt] Univ Estadual Campinas, Dept Pharmacol, Sao Paulo, Brazil; [de Oliveira, Ivan Pires] Univ Estadual Campinas, Inst Chem, Sao Paulo, Brazil; [Baldivia, Debora da Silva] Fed Univ Grande Dourados, Fac Biol & Environm Sci, Dourados, MS, Brazil; [da Silva, Luan Ramos; Sanjinez-Argandona, Eliana Janet] Fed Univ Grande Dourados, Fac Engn, Dourados, MS, Brazil; [Napolitano, Mauro; Lincopan, Nilton] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas; Universidade Federal da Grande Dourados; Universidade Federal da Grande Dourados; Universidade de Sao Paulo	Lescano, CH (corresponding author), Univ Estadual Campinas, Dept Pharmacol, Sao Paulo, Brazil.	carolinehonaiser@gmail.com	ZAMINELLI, TIAGO/S-8882-2017; Lincopan, Nilton/C-3818-2012; Ramos da Silva, Luan/R-2552-2018; Napolitano, Mauro/I-5263-2016; da Silva, Luan Ramos/P-1034-2019; Pires de Oliveira, Ivan/S-6023-2016; Argandoña, Eliana Janet EJSA Sanjinez/J-6524-2012; Lescano, Caroline C.H.L Honaiser/I-2108-2017; da Silva Baldivia, Débora/AAM-8601-2020; Silva Baldivia, Debora/P-9574-2017	ZAMINELLI, TIAGO/0000-0002-6122-891X; Lincopan, Nilton/0000-0003-0161-5800; Ramos da Silva, Luan/0000-0003-1150-6966; Napolitano, Mauro/0000-0001-7399-7276; da Silva, Luan Ramos/0000-0003-1150-6966; Pires de Oliveira, Ivan/0000-0003-1020-4376; Argandoña, Eliana Janet EJSA Sanjinez/0000-0001-9377-8839; Lescano, Caroline C.H.L Honaiser/0000-0003-4193-7361; Silva Baldivia, Debora/0000-0002-1122-8479	Sao Paulo Research Foundation FAPESP [2010/16947-9, 2013/05475-7, 2013/08293-7]; CNPq [470374/2013-6]	Sao Paulo Research Foundation FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The work was supported by Sao Paulo Research Foundation FAPESP (Nos. 2010/16947-9, 2013/05475-7 and 2013/08293-7) and CNPq (N.470374/2013-6).	Alves Andréa Regiani, 2003, Rev. esc. enferm. USP, V37, P85; Biavatti MW, 2004, J ETHNOPHARMACOL, V93, P385, DOI 10.1016/j.jep.2004.04.015; Bonilla A, 2005, PHYTOCHEMISTRY, V66, P1736, DOI 10.1016/j.phytochem.2005.05.025; Breda CA, 2012, FOOD CHEM, V135, P2960, DOI 10.1016/j.foodchem.2012.07.029; Chang CC, 2002, J FOOD DRUG ANAL, V10, P178; Chang R, 2011, LAT AM J PHARM, V30, P1843; Chen JC, 2006, J ETHNOPHARMACOL, V103, P385, DOI 10.1016/j.jep.2005.08.036; Bieski IGC, 2015, J ETHNOPHARMACOL, V173, P383, DOI 10.1016/j.jep.2015.07.025; Coutinho I. D., 2008, Ecletica Quimica, V33, P53, DOI 10.1590/S0100-46702008000400007; Coutinho ID, 2009, BRAZ J PHARM SCI, V45, P767, DOI 10.1590/S1984-82502009000400022; Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S; Croxen MA, 2010, NAT REV MICROBIOL, V8, P26, DOI 10.1038/nrmicro2265; de Souza JC, 2014, NUTR NEUROSCI; Faried A, 2007, INT J ONCOL, V30, P605; Ferreira LC, 2013, J ETHNOPHARMACOL, V145, P100, DOI 10.1016/j.jep.2012.10.037; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; Guerrant RL, 2002, ARCH MED RES, V33, P351, DOI 10.1016/S0188-4409(02)00379-X; Huang YY, 2013, J CHEM INF MODEL, V53, P3044, DOI 10.1021/ci400458z; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Jung YD, 2001, BRIT J CANCER, V84, P844, DOI 10.1054/bjoc.2000.1691; Klafke JZ, 2012, ANTIPLATELET ANTITHR; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Liang CZ, 2012, CANCER BIOTHER RADIO, V27, P701, DOI 10.1089/cbr.2012.1245; Cardoso CAL, 2010, J MED FOOD, V13, P1273, DOI 10.1089/jmf.2009.0047; Lin CS, 2002, INT J IMPOT RES, V14, P15, DOI 10.1038/sj.ijir.3900802; Lin CS, 2001, BIOCHEM BIOPH RES CO, V280, P693, DOI 10.1006/bbrc.2000.4221; Liu FF, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3453713; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224; Maurice DH, 2003, MOL PHARMACOL, V64, P533, DOI 10.1124/mol.64.3.533; Mazzolin LP, 2013, J ETHNOPHARMACOL, V150, P1016, DOI 10.1016/j.jep.2013.10.006; Michel MCP, 2013, REV BRAS FARMACOGN, V23, P927, DOI 10.1590/S0102-695X2013000600010; Morris SS, 2003, INT J EPIDEMIOL, V32, P1041, DOI 10.1093/ije/dyg241; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Moura-Costa GF, 2012, J ETHNOPHARMACOL, V143, P631, DOI 10.1016/j.jep.2012.07.016; Oliveira IP, 2016, PHYS CHEM CHEM PHYS, V18, P21797, DOI 10.1039/c6cp01789d; Pavan FRr, 2009, QUIM NOVA, V32; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Polson JB, 1996, ANNU REV PHARMACOL, V36, P403, DOI 10.1146/annurev.pa.36.040196.002155; Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005; Rao CV, 2008, J NAT MED-TOKYO, V62, P396, DOI 10.1007/s11418-008-0258-8; Read LT, 2014, INFECT IMMUN, V82, P5308, DOI 10.1128/IAI.02496-14; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Roessner A, 2008, PATHOL RES PRACT, V204, P511, DOI 10.1016/j.prp.2008.04.011; Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Souza-Moreira TM, 2011, J MED FOOD, V14, P528, DOI 10.1089/jmf.2009.0278; Tanifum EA, 2009, BIOORG MED CHEM LETT, V19, P3067, DOI 10.1016/j.bmcl.2009.04.024; Vaandrager AB, 2002, MOL CELL BIOCHEM, V230, P73, DOI 10.1023/A:1014231722696; Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367; Wardlaw T, 2010, LANCET, V375, P870, DOI 10.1016/S0140-6736(09)61798-0	53	19	20	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0165208	10.1371/journal.pone.0165208	http://dx.doi.org/10.1371/journal.pone.0165208			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NZ	27764241	gold, Green Published, Green Submitted			2023-01-03	WOS:000386204500134
J	Zhang, HZ; Liu, DH; Zhang, DK; Wang, YH; Li, G; Yan, GL; Cao, LJ; Xiao, XH; Huang, LQ; Wang, JB				Zhang, Hai-zhu; Liu, Da-hui; Zhang, Ding-kun; Wang, Yan-hui; Li, Gang; Yan, Gui-lin; Cao, Li-juan; Xiao, Xiao-he; Huang, Lu-qi; Wang, Jia-bo			Quality Assessment of Panax notoginseng from Different Regions through the Analysis of Marker Chemicals, Biological Potency and Ecological Factors	PLOS ONE			English	Article							PROTOPANAXATRIOL-TYPE SAPONINS; SMOOTH-MUSCLE-CELLS; ROOTS; RATS; CHROMATOGRAPHY; RAW	Panax notoginseng (Burk.) F.H. Chen, called Sanqi in China, is a perennial herb that has been used as a medicinal herb in traditional Chinese medicine for more than 400 years. Because notoginseng is included in many proprietary Chinese medicines, the quality of notoginseng directly affects its efficacy and safety. However, considering the complex and special growth environment requirements of notoginseng, it is insufficient to evaluate its quality based solely on the analysis of marker chemicals. Thus, in this study, we tried to evaluate the quality of notoginseng with integrated indicators: (1) the concentration of five marker chemicals, notoginsenoside R1, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1 and ginsenoside Rd; (2) the anticoagulant activity (ACA); and (3) twenty-one ecological factors (e.g., longitude, latitude, elevation and soil data). Using these 27 parameters, notoginseng from different regions could be distinguished effectively, indicating a remarkable divergence of quality. A correlation analysis showed that variations of the ecological factors were closely associated with the saponins content and biopotency. For instance, the total nitrogen (TN), alkali hydrolysis nitrogen (AHN) and rapidly available potassium (RAPT) were significantly correlated with ACA, and RAPT was significantly correlated with the content of ginsenoside Rd and notoginsenoside R1. The results demonstrated that the high-quality notoginseng was produced from the emerging regions such as Kunming, Qujing and Honghe, which had higher ACA and saponin content than the notoginseng produced in traditional regions such as Wenshan and Baise.	[Zhang, Hai-zhu; Zhang, Ding-kun; Xiao, Xiao-he; Wang, Jia-bo] Chengdu Univ Tradit Chinese Med, Chengdu 611137, Peoples R China; [Zhang, Hai-zhu; Zhang, Ding-kun; Wang, Yan-hui; Xiao, Xiao-he; Wang, Jia-bo] 302 Mil Hosp, China Mil Inst Chinese Med, Beijing 100039, Peoples R China; [Zhang, Hai-zhu] Dali Univ, Dali 671003, Peoples R China; [Liu, Da-hui] Kunming Univ Sci & Technol, Yunnan Genuine Med Mat Res & Dev Ctr, Kunming 650500, Peoples R China; [Li, Gang; Yan, Gui-lin; Cao, Li-juan] China Med Corp, Int Bldg 811,Guang Qu Men St 80, Beijing 100062, Peoples R China; [Huang, Lu-qi] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Mat Med, Beijing 100700, Peoples R China	Chengdu University of Traditional Chinese Medicine; Fifth Medical Center of Chinese PLA General Hospital; Dali University; Kunming University of Science & Technology; China Academy of Chinese Medical Sciences; National Resource Center for Chinese Materia Medica, CACMS	Xiao, XH; Wang, JB (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu 611137, Peoples R China.; Xiao, XH; Wang, JB (corresponding author), 302 Mil Hosp, China Mil Inst Chinese Med, Beijing 100039, Peoples R China.	Pharmacy302xxh@126.com; wjb0128@126.com	xiao, xiang/GWU-6035-2022; Zhang, Ding-kun/AAF-1142-2020		National Natural Science Foundation of China [81274026, 81403126]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research is supported by the National Natural Science Foundation of China (No. 81274026, 81403126).; This research is supported by the National Natural Science Foundation of China (No. 81274026, 81403126).	[安娜 AN Na], 2006, [中草药, Chinese Traditional and Herbal Drugs], V37, P1086; Chan ECY, 2007, RAPID COMMUN MASS SP, V21, P519, DOI 10.1002/rcm.2864; Chan P, 2002, ACTA PHARMACOL SIN, V23, P1157; Chan RYK, 2002, J CLIN ENDOCR METAB, V87, P3691, DOI 10.1210/jc.87.8.3691; Chen SW, 2004, ACTA PHARMACOL SIN, V25, P1151; Cicero AFG, 2003, PHYTOTHER RES, V17, P174, DOI 10.1002/ptr.1262; Cui Xiu-Ming, 2014, Zhongguo Zhong Yao Za Zhi, V39, P553; Dong TTX, 2003, J AGR FOOD CHEM, V51, P4617, DOI 10.1021/jf034229k; Du QZ, 2003, J CHROMATOGR A, V1008, P173, DOI 10.1016/S0021-9673(03)00988-9; Guan YY, 2006, EUR J PHARMACOL, V548, P129, DOI 10.1016/j.ejphar.2006.08.001; Guo XC, 2007, ECOL ECON, V1, P114; Han J, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P227; Huang Chun-mei, 2015, Zhongguo Zhong Yao Za Zhi, V40, P2930; Ji W, 2007, J ETHNOPHARMACOL, V113, P318, DOI 10.1016/j.jep.2007.06.022; Jia Y., 2008, J MED COLL PLA, V23, P38; Lau AJ, 2003, J CHROMATOGR A, V1011, P77, DOI 10.1016/S0021-9673(03)01135-X; LI XH, 1999, CHIN TRADIT HERBAL D, V30, P514; Ling SH, 2008, INT J CARDIOL, V128, P350, DOI 10.1016/j.ijcard.2007.05.111; Liu Da-Hui, 2014, Zhongguo Zhong Yao Za Zhi, V39, P572; [刘莉 Liu Li], 2013, [西南农业学报, Southwest China Journal of Agricultural Sciences], V26, P1946; Liu Y, 2003, SPECTROCHIM ACTA A, V59, P2747, DOI 10.1016/S1386-1425(03)00055-6; Low M, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0525-7; MA LY, 1998, CHIN PHARM J, V33, P467; MA LY, 1998, CHIN PHARM J, V33, P143; Ma WG, 1999, PHYTOCHEMISTRY, V52, P1133, DOI 10.1016/S0031-9422(99)00364-7; Marschner P, 2004, PLANT SOIL, V261, P199, DOI 10.1023/B:PLSO.0000035569.80747.c5; Sun HX, 2006, INT IMMUNOPHARMACOL, V6, P14, DOI 10.1016/j.intimp.2005.07.003; Wan JB, 2007, J SEP SCI, V30, P825, DOI 10.1002/jssc.200600359; Wang D, 2013, PHYTOCHEMISTRY, V93, P88, DOI 10.1016/j.phytochem.2013.03.007; Wei J.X., 1996, MODERN SCI RES APPL, P426; Xu L, 2011, J ETHNOPHARMACOL, V137, P226, DOI 10.1016/j.jep.2011.05.020; Xu QF, 2003, J ETHNOPHARMACOL, V84, P187, DOI 10.1016/S0378-8741(02)00317-3; ZHANG GQ, 1998, CHIN J NEPHROL, V14, P93; Zhang Y, 2013, MOLECULES, V18, P10352, DOI 10.3390/molecules180910352; Zheng Dong-Mei, 2014, Zhongguo Zhong Yao Za Zhi, V39, P558; Zheng GZ, 1994, BIOL PANAX NOTOGINSE; Zhu XX, 1998, CHIN J BIOCH PHARM, V19, P28	37	15	19	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2016	11	10							e0164384	10.1371/journal.pone.0164384	http://dx.doi.org/10.1371/journal.pone.0164384			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CF	27723805	gold, Green Submitted, Green Published			2023-01-03	WOS:000385504100052
J	Schliemann, C; Gerss, J; Wiebe, S; Mikesch, JH; Knoblauch, N; Sauer, T; Angenendt, L; Kewitz, T; Urban, M; Butterfass-Bahloul, T; Edemir, S; Vehring, K; Muller-Tidow, C; Berdel, WE; Krug, U				Schliemann, Christoph; Gerss, Joachim; Wiebe, Stefanie; Mikesch, Jan-Henrik; Knoblauch, Nicola; Sauer, Tim; Angenendt, Linus; Kewitz, Tobias; Urban, Marc; Butterfass-Bahloul, Trude; Edemir, Sabine; Vehring, Kerstin; Mueller-Tidow, Carsten; Berdel, Wolfgang E.; Krug, Utz			A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; OLDER PATIENTS; BONE-MARROW; MYELODYSPLASTIC SYNDROME; AUTOCRINE STIMULATION; OPEN-LABEL; TRIAL; INDUCTION; SURVIVAL; CELLS	Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-alpha/-beta, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dose cytarabine (LDAC) in elderly patients with untreated or relapsed/refractory acute myeloid leukemia (AML) ineligible for intensive chemotherapy in a 3+ 3 design. Nintedanib (dose levels 100, 150, and 200 mg orally twice daily) and LDAC (20 mg subcutaneous injection twice daily for 10 days) were administered in 28-day cycles. Dose-limiting toxicity (DLT) was defined as non-hematological severe adverse reaction CTC grade >= 4 with possible or definite relationship to nintedanib. Between April 2012 and October 2013, 13 patients (median age 73 [range: 62-86] years) were enrolled. One patient did not receive study medication and was replaced. Nine (69%) patients had relapsed or refractory disease and 6 (46%) patients had unfavorable cytogenetics. The most frequently reported treatment-related adverse events (AE) were gastrointestinal events. Twelve SAEs irrespective of relatedness were reported. Two SUSARs were observed, one fatal hypercalcemia and one fatal gastrointestinal infection. Two patients (17%) with relapsed AML achieved a complete remission (one CR, one CRi) and bone marrow blast reductions without fulfilling PR criteria were observed in 3 patients (25%). One-year overall survival was 33%. Nintedanib combined with LDAC shows an adequate safety profile and survival data are promising in a difficult-to-treat patient population. Continuation of this trial with a phase II recommended dose of 2 x 200 mg nintedanib in a randomized, placebo-controlled phase II study is planned. The trial is registered to EudraCT as 2011-001086-41.	[Schliemann, Christoph; Wiebe, Stefanie; Mikesch, Jan-Henrik; Knoblauch, Nicola; Sauer, Tim; Angenendt, Linus; Edemir, Sabine; Vehring, Kerstin; Mueller-Tidow, Carsten; Berdel, Wolfgang E.; Krug, Utz] Univ Hosp Muenster, Dept Med A, Munster, Germany; [Gerss, Joachim] Univ Hosp Muenster, Inst Biostat & Clin Res, Munster, Germany; [Kewitz, Tobias; Urban, Marc; Butterfass-Bahloul, Trude] Univ Hosp Muenster, Ctr Clin Trials, Munster, Germany; [Mueller-Tidow, Carsten] Univ Hosp Halle, Dept Med 4, Halle, Saale, Germany; [Krug, Utz] Klinikum Leverkusen, Dept Med 3, Leverkusen, Germany	University of Munster; University of Munster; University of Munster; Martin Luther University Halle Wittenberg	Krug, U (corresponding author), Univ Hosp Muenster, Dept Med A, Munster, Germany.; Krug, U (corresponding author), Klinikum Leverkusen, Dept Med 3, Leverkusen, Germany.	utz.krug@klinikum-lev.de	Müller-Tidow, Carsten/O-7207-2018; Gerß, Joachim WO/B-5702-2013; A, L/K-2711-2017	Müller-Tidow, Carsten/0000-0002-7166-5232; A, L/0000-0003-2502-9910	Boehringer Ingelheim Pharma GmbH Co. KG; German Federal Ministry of Education and Research (BMBF) [01KN1105]	Boehringer Ingelheim Pharma GmbH Co. KG(Boehringer Ingelheim); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This study was funded by Boehringer Ingelheim Pharma GmbH & Co. KG. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Center for Clinical Trials Muenster was supported by the German Federal Ministry of Education and Research (BMBF, 01KN1105).	Aguayo A, 1999, BLOOD, V94, P3717, DOI 10.1182/blood.V94.11.3717.423k09_3717_3721; Bieker R, 2003, CANCER RES, V63, P7241; Buchner T, 2006, J CLIN ONCOL, V24, P2480, DOI 10.1200/JCO.2005.04.5013; Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245; Burnett AK, 2007, CANCER, V109, P1114, DOI 10.1002/cncr.22496; Burnett AK, 2013, BLOOD, V122, P1384, DOI 10.1182/blood-2013-04-496596; Dennis M, 2015, BLOOD, V125, P2923, DOI 10.1182/blood-2014-10-608117; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Fenaux P, 2008, ECANCERMEDICALSCIENC, V2, DOI 10.3332/ecancer.2008.121; Fiedler W, 1997, BLOOD, V89, P1870, DOI 10.1182/blood.V89.6.1870; Fiedler W, 2010, LEUKEMIA RES, V34, P196, DOI 10.1016/j.leukres.2009.07.020; Foss B, 2001, EUR J HAEMATOL, V67, P267, DOI 10.1034/j.1600-0609.2001.0430a.x; Giles FJ, 2006, LEUKEMIA RES, V30, P801, DOI 10.1016/j.leukres.2005.10.024; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Juliusson G, 2009, BLOOD, V113, P4179, DOI 10.1182/blood-2008-07-172007; Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429; Karajannis MA, 2006, LEUKEMIA, V20, P979, DOI 10.1038/sj.leu.2404203; Kulimova E, 2006, MOL CANCER THER, V5, P3105, DOI 10.1158/1535-7163.MCT-06-0323; Okamoto I, 2010, MOL CANCER THER, V9, P2825, DOI 10.1158/1535-7163.MCT-10-0379; Ossenkoppele GJ, 2012, BLOOD, V120, P4706, DOI 10.1182/blood-2012-04-420596; Padro T, 2002, LEUKEMIA, V16, P1302, DOI 10.1038/sj.leu.2402534; Padro T, 2000, BLOOD, V95, P2637, DOI 10.1182/blood.V95.8.2637.008k07_2637_2644; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Shah CA, 2013, J BIOL CHEM, V288, P32490, DOI 10.1074/jbc.M113.496109; Veiga JP, 2006, EXP HEMATOL, V34, P610, DOI 10.1016/j.exphem.2006.01.013; Wierzbowska A, 2003, EUR CYTOKINE NETW, V14, P149; Zahiragic L, 2007, LEUKEMIA, V21, P1310, DOI 10.1038/sj.leu.2404632	33	9	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2016	11	10							e0164499	10.1371/journal.pone.0164499	http://dx.doi.org/10.1371/journal.pone.0164499			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UW	27716819	Green Published, gold, Green Submitted			2023-01-03	WOS:000385698100059
J	Ghinea, N; Lipworth, W; Day, R; Hill, A; Dore, GJ; Danta, M				Ghinea, Narcyz; Lipworth, Wendy; Day, Richard; Hill, Andrew; Dore, Gregory J.; Danta, Mark			Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries	LANCET			English	Editorial Material							GENOTYPE 1 INFECTION; VIRUS-INFECTION; INJECT DRUGS; CHRONIC HCV; SOFOSBUVIR; RIBAVIRIN; ABT-450/R-OMBITASVIR; LEDIPASVIR; DASABUVIR; DACLATASVIR		[Ghinea, Narcyz; Lipworth, Wendy] Univ Sydney, Ctr Values Eth & Law Med, Med Fdn Bldg K25, Sydney, NSW 2006, Australia; [Day, Richard] St Vincents Hosp, Sch Clin, Clin Pharmacol & Toxicol Therapeut Ctr, Darlinghurst, NSW, Australia; [Danta, Mark] St Vincents Hosp, Sch Clin, Fac Med, Darlinghurst, NSW, Australia; [Hill, Andrew] St Stephens AIDS Trust, Chelsea & Westminster Hosp, London, England; [Dore, Gregory J.] UNSW Australia, Viral Hepatitis Clin Res Program, Kirby Inst, Sydney, NSW, Australia	University of Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; Imperial College London; University of New South Wales Sydney; Kirby Institute	Ghinea, N (corresponding author), Univ Sydney, Ctr Values Eth & Law Med, Med Fdn Bldg K25, Sydney, NSW 2006, Australia.	narcyz.ghinea@sydney.edu.au	Dore, Gregory John/ABD-5665-2021; Day, Richard/D-8699-2011	Dore, Gregory John/0000-0002-4741-2622; Day, Richard/0000-0002-6045-6937; Ghinea, Narcyz/0000-0002-1457-7252; Lipworth, Wendy/0000-0002-0234-657X	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by funding through a grant from the National Health and Medical Research Council. The funding body had no role in the writing or decision to submit for publication.	Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454; Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366; [Anonymous], 2015, REUTERS; Asselah T, 2011, LIVER INT; Australian Society of HIV and Hepatitis, 2015, IMP GEN HCV DRUGS; Barua S, 2015, ANN INTERN MED, V163, P215, DOI 10.7326/M15-0406; Dickson N, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2043; Dore GJ, 2014, J VIRAL HEPATITIS, V21, P1, DOI 10.1111/jvh.12253; El-Serag HB, 2016, HEPATOLOGY, V64, P130, DOI 10.1002/hep.28535; Farwell J., 2015, BANGOR DAILY NE 0224; Feld JJ, 2014, NEW ENGL J MED, V370, P1594, DOI 10.1056/NEJMoa1315722; Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338; Fick M, 2014, REUTERS; FixHepC, 2015, CUR HEP C SOF LED DA; Freeman J, 2016, INT LIV C BARC; Gilead sciences, 2015, GIL SCI ANN 4 QUART; Gilead sciences, 2016, GIL SCI ANN 4 QUART; Gotham D, 2016, INT AIDS C DURB; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; Grebely J, 2014, ANTIVIR RES, V104, P62, DOI 10.1016/j.antiviral.2014.01.002; Hill A, 2016, J VIRUS ERAD, V2, P28; Hoen E., 2014, ACCESS CANC TREATMEN; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Kowdley KV, 2014, NEW ENGL J MED, V370, P1879, DOI 10.1056/NEJMoa1402355; Leroy V, 2016, HEPATOLOGY, V63, P1430, DOI 10.1002/hep.28473; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Martin NK, 2013, HEPATOLOGY, V58, P1598, DOI 10.1002/hep.26431; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Medicines Patet Pool, 2015, MPP LIC DACL DCV; Minister for Health, 2015, TURNB GOV INV 1 BILL; NHS England, 2015, 1000 MOR PAT BE CUR; Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Rockstroh JK, 2015, LANCET HIV, V2, pE319, DOI 10.1016/S2352-3018(15)00114-9; 't Hoen EFM, 2016, LANCET, V387, P2272, DOI 10.1016/S0140-6736(16)30656-0; The Kirby Institute, 2016, HEP B C AUSTR ANN SU; Therapeutic Goods Administration, 2016, WARN LETT PROM PRESC; United States Senate Committee on Finance, 2015, WYD GRASSL SOV INV F; US Food and Drug Administration, 2015, IMP OF DRUGS; Weisman R., 2016, BOSTON GLOBE; WHO, 2015, WHO MOV IMPR ACC LIF; World Health Organization, 2015, 19 WHO MOD LIST ESS; Wyles DL, 2015, NEW ENGL J MED, V373, P714, DOI 10.1056/NEJMoa1503153; Zeuzem S, 2015, ANN INTERN MED, V163, P1, DOI 10.7326/M15-0785	44	28	29	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2017	389	10075					1268	1272		10.1016/S0140-6736(16)32051-7	http://dx.doi.org/10.1016/S0140-6736(16)32051-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EP1KL	27832868				2023-01-03	WOS:000397143700038
J	Chew, F; Wu, XW				Chew, Fiona; Wu, Xianwei			Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage	PLOS ONE			English	Article							HEALTH INITIATIVE TRIAL; CORONARY-HEART-DISEASE; OBSTETRICIAN-GYNECOLOGISTS; POSTMENOPAUSAL WOMEN; NEWSPAPER COVERAGE; PRIMARY PREVENTION; TIMING HYPOTHESIS; PRACTICE PATTERNS; PARADIGM SHIFT; ATTITUDES	Objective Medical reviews and research comprise a key information source for news media stories on medical therapies and innovations as well as for physicians in updating their practice. The present study examined medical review journal articles, physician surveys and news media coverage of hormone replacement therapy (HT) to assess the relationship between the three information sources and whether/if they contributed to a state-of-the-science gap (a condition when the evaluation of a medical condition or therapy ascertained by the highest standards of investigation is incongruent with the science-in-practice such as physician recommendations and patient actions). Methods We content-analyzed 177 randomly sampled HT medical reviews between 2002 and 2014, and HT news valence in three major TV networks, newspapers and magazines/internet sites in 2002-2003, 2008-2009 and 2012-14. The focus in both analyses was whether HT benefits outweighed risks, risks outweighed benefits or both risks and benefits were presented. We also qualitatively content-analyzed all 19 surveys of US physicians' HT recommendations from 2002 to 2009, and 2012 to 2014. Results Medical reviews yielded a mixed picture about HT (40.1% benefits, 26.0% risks, and 33.9% both benefits and risks). While a majority of physician surveys were pro-HT 10/19), eight showed varied attitudes and one was negative. Newspaper and television coverage reflected a pro and con balance while magazine stories were more positive in the later reporting period. Conclusion Medical journal review articles, physicians, and media reports all provide varying view points towards hormone therapy use thus leading to limited knowledge about the actual risks and benefits of HT among peri-and menopausal women and a state-of-the-science gap.	[Chew, Fiona] Syracuse Univ, SI Newhouse Sch Publ Commun, Syracuse, NY USA; [Wu, Xianwei] Univ Iowa, Sch Journalism & Mass Commun, Iowa City, IA USA	Syracuse University; University of Iowa	Chew, F (corresponding author), Syracuse Univ, SI Newhouse Sch Publ Commun, Syracuse, NY USA.	cmrfchew@syr.edu						[Anonymous], 2012, MONDAYMORNING   0625; [Anonymous], 2010, NAT AMB MED CAR SURV; Audit Bureau of Circulation, 2010, AV CIRC US NEWSP; Birkhauser MH, 2008, CLIMACTERIC, V11, P192, DOI 10.1080/13697130802060455; Breslau Erica S, 2003, J Am Med Womens Assoc (1972), V58, P33; Brett AS, 2005, J GEN INTERN MED, V20, P416, DOI 10.1111/j.1525-1497.2005.0089.x; Chew F, 2004, FAM MED, V36, P645; Chew F, 1995, PUBLIC UNDERST SCI, V4, P17; Chew F, 2006, SCI COMMUN, V27, P1; Christian AH, 2007, J WOMENS HEALTH, V16, P68, DOI 10.1089/jwh.2006.M072; Coomarasamy A, 2001, Health Info Libr J, V18, P183, DOI 10.1046/j.1365-2532.2001.00349.x; Devi Gayatri, 2013, Menopause Int, V19, P121, DOI 10.1177/1754045313478941; Dutta-Bergman MJ, 2004, HEALTH COMMUN, V16, P273, DOI 10.1207/S15327027HC1603_1; Ettinger B, 2003, OBSTET GYNECOL, V102, P1225, DOI 10.1016/j.obstetgynecol.2003.08.007; Food and Drug Administration, 2009, QUEST ANSW ESTR ESTR; Fugh-Berman A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000425; Fugh-Berman AJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000335; Gallup, 2002, AM RAT CONF DOCT; Gurney EP, 2014, J STEROID BIOCHEM, V142, P4, DOI 10.1016/j.jsbmb.2013.10.009; Haas JS, 2007, J GEN INTERN MED, V22, P68, DOI 10.1007/s11606-007-0122-7; Haas JS, 2006, J GEN INTERN MED, V21, P304, DOI 10.1111/j.1525-1497.2006.00342.x; Henwood F, 2003, SOCIOL HEALTH ILL, V25, P589, DOI 10.1111/1467-9566.00360; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hesse BW, 2005, ARCH INTERN MED, V165, P2618, DOI 10.1001/archinte.165.22.2618; Hing E, 2006, OBSTET GYNECOL, V108, P33, DOI 10.1097/01.AOG.0000220502.77153.5a; Hodis HN, 2014, J STEROID BIOCHEM, V142, P68, DOI 10.1016/j.jsbmb.2013.06.011; Hodis HN, 2013, J AM GERIATR SOC, V61, P1011, DOI 10.1111/jgs.12281; Hodis HN, 2013, J AM GERIATR SOC, V61, P1005, DOI 10.1111/jgs.12140; Hou NQ, 2013, JNCI-J NATL CANCER I, V105, P1365, DOI 10.1093/jnci/djt207; Huston SA, 2009, WOMEN HEALTH ISS, V19, P144, DOI 10.1016/j.whi.2009.01.004; Jones Teresa H, 2007, BMC Pediatr, V7, P1, DOI 10.1186/1471-2431-7-1; Kahn C, 2001, Mark Health Serv, V21, P12; Kelly JP, 2005, PHARMACOEPIDEM DR S, V14, P837, DOI 10.1002/pds.1103; Kiatpongsan S, 2014, MENOPAUSE, V21, P33, DOI [10.1097/GME.0000000000000129, 10.1097/gme.0000000000000129]; Kim N, 2005, J GEN INTERN MED, V20, P1026, DOI 10.1111/j.1525-1497.2005.0221.x; Kosteniuk JG, 2013, J MED LIBR ASSOC, V101, P32, DOI 10.3163/1536-5050.101.1.006; Langer RD, 2012, CLIMACTERIC, V15, P206, DOI 10.3109/13697137.2012.666916; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; McIntosh J, 2005, AM J HEALTH-SYST PH, V62, P1031, DOI [10.1111/j.1525-1497.2005.0221.x, DOI 10.1111/J.1525-1497.2005.0221.X]; Morgan MA, 2010, OBSTET GYNECOL, V116, P715, DOI 10.1097/AOG.0b013e3181eeb630; MRI+, 2009, AUD SURV REP; Neuendorf K., 2002, CONTENT ANAL GUIDEBO; Newton KM, 2010, MENOPAUSE, V17, P734, DOI 10.1097/gme.0b013e3181d2ce57; North American Menopause Society, 2012, OV MEN; Power ML, 2008, MED DECIS MAKING, V28, P411, DOI 10.1177/0272989X07312722; Power ML, 2007, MENOPAUSE, V14, P20, DOI 10.1097/01.gme.0000229571.44505.cb; Power ML, 2006, J REPROD MED, V51, P525; Power ML, 2009, MENOPAUSE, V16, P500, DOI 10.1097/gme.0b013e31818fc36e; Power ML, 2006, MENOPAUSE, V13, P434, DOI 10.1097/01.gme.0000185753.77704.65; Rigby AJ, 2007, MENOPAUSE, V14, P853, DOI 10.1097/gme.0b013e3180333a33; Rolnick SJ, 2005, MENOPAUSE, V12, P399, DOI 10.1097/01.GME.0000148644.55486.36; Rossouw JE, 2013, OBSTET GYNECOL, V121, P172, DOI [10.1097/AOG.0b013e31827a08c8, http://10.1097/AOG.0b013e31827a08c8]; Rossouw JE, 2002, J HYPERTENS, V20, pS62; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schwitzer G, 2005, PLOS MED, V2, P576, DOI 10.1371/journal.pmed.0020215; Seagram B., 2003, GREATEST EXPT EVER P; Singer N., 2009, NY TIMES; Stevenson JC, 2013, MATURITAS, V76, P10, DOI 10.1016/j.maturitas.2013.05.018; Tsai SA, 2011, MENOPAUSE, V18, P385, DOI 10.1097/gme.0b013e3181f43404; TVbythenumbers.com, 2011, WORLD NEWS DIAN SAW; USPSTF, 2012, FIN REC STAT MEN HOR; Verschoor CC, 2012, STRATEGIC FINANC AUG, P11; Viera AJ, 2005, FAM MED, V37, P360; Wathen CN, 2006, J HEALTH COMMUN, V11, P477, DOI 10.1080/10810730600751979; Wilson RA, 1966, FEMININE FOREVER	65	3	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171189	10.1371/journal.pone.0171189	http://dx.doi.org/10.1371/journal.pone.0171189			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7DG	28158240	Green Published, gold, Green Submitted			2023-01-03	WOS:000396161700039
J	Zanus, C; Battistutta, S; Aliverti, R; Montico, M; Cremaschi, S; Ronfani, L; Monasta, L; Carrozzi, M				Zanus, Caterina; Battistutta, Sara; Aliverti, Renata; Montico, Marcella; Cremaschi, Silvana; Ronfani, Luca; Monasta, Lorenzo; Carrozzi, Marco			Adolescent Admissions to Emergency Departments for Self-Injurious Thoughts and Behaviors	PLOS ONE			English	Article							ATTEMPTED-SUICIDE; YOUNG-PEOPLE; INFLICTED INJURY; COMMUNITY SAMPLE; HARM; CARE; CHILDREN; VISITS; EPIDEMIOLOGY; MULTICENTER	The objective of the present study was to describe the incidence and the characteristics of Self-Injurious Thoughts and Behaviors (SITBs), among adolescents aged 11-18 admitted, over a two year period, to all the Emergency Departments of a Region of North-eastern Italy through a comprehensive analysis of medical records. A two-step search was performed in the regional ED electronic database. First, we identified the cases that had been clearly diagnosed as SITBs by an Emergency Department physician. Secondly, suspect cases were detected through a keyword search of the database, and the medical records of these cases were hand screened to identify SITBs. The mean annual incidence rate of SITBs was 90 per 100,000 adolescents aged 11-18 years. Events were more frequent in females. Drug poisoning was the most frequently adopted method (54%). In 42% of cases a diagnosis of SITB was not explicitly reported by the physician. In 65% of cases adolescents were discharged within hours of admission. Only 9% of patients started a psychiatric assessment and treatment program during hospital stay. This research confirms the high incidence of SITBs among adolescents and highlights the difficulty in their proper diagnosis and management. Such difficulty is confirmed by the fact that only a few patients, even among those with a clear diagnosis, were sent for psychiatric assessment. Correct identification and management of SITB patients needs to be improved, since SITBs are an important public health problem in adolescence and one of the main risk factors for suicide.	[Zanus, Caterina; Battistutta, Sara; Aliverti, Renata; Montico, Marcella; Ronfani, Luca; Monasta, Lorenzo; Carrozzi, Marco] Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Trieste, Italy; [Cremaschi, Silvana] ASS4 Medio Friuli, Child & Adolescent Neuropsychiat Serv, Udine, Italy	IRCCS Burlo Garofolo	Monasta, L (corresponding author), Inst Maternal & Child Hlth IRCCS Burlo Garofolo, Trieste, Italy.	lorenzo.monasta@burlo.trieste.it	Ronfani, Luca/B-6668-2013; Monasta, Lorenzo/B-1388-2012; Montico, Marcella/B-5290-2013	Ronfani, Luca/0000-0001-5710-3914; Monasta, Lorenzo/0000-0001-7774-548X; Montico, Marcella/0000-0003-0377-8232; Carrozzi, Marco/0000-0001-6282-4417				Aydin A, 2013, INT J PSYCHIAT CLIN, V17, P110, DOI 10.3109/13651501.2012.697565; Babeva K, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0738-6; Ballard ED, 2016, PREV SCI; Bennewith O, 2005, J AFFECT DISORDERS, V89, P91, DOI 10.1016/j.jad.2005.08.011; Bethell Jennifer, 2009, Health Rep, V20, P35; Betz ME, 2013, DEPRESS ANXIETY, V30, P1005, DOI 10.1002/da.22071; Bossuyt N, 2007, INT J PUBLIC HEALTH, V52, P153, DOI 10.1007/s00038-007-5060-y; Bridge JA, 2012, J AM ACAD CHILD PSY, V51, P213, DOI 10.1016/j.jaac.2011.11.002; Brunner R, 2014, J CHILD PSYCHOL PSYC, V55, P337, DOI 10.1111/jcpp.12166; Chun TH, 2016, PEDIATRICS, V138; Chun TH, 2015, CHILD ADOL PSYCH CL, V24, P21, DOI 10.1016/j.chc.2014.09.003; Clerici CA, 2016, J FORENSIC LEG MED, V37, P15, DOI 10.1016/j.jflm.2015.09.016; Colman Ian, 2004, CJEM, V6, P313; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Cotter P, 2015, SOC PSYCH PSYCH EPID, V50, P973, DOI 10.1007/s00127-015-1016-3; Cutler GJ, 2015, PEDIATRICS, V136, P28, DOI 10.1542/peds.2014-3573; Di Napoli Wilma Angela, 2015, Psychiatr Danub, V27 Suppl 1, pS279; Dieppe C, 2009, EMERG MED J, V26, P418, DOI 10.1136/emj.2008.062463; Doshi A, 2005, ANN EMERG MED, V46, P369, DOI 10.1016/j.annemergmed.2005.04.018; Ferrara P, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0069-3; Fox KR, 2016, PSYCHIAT RES, V244, P235, DOI 10.1016/j.psychres.2016.07.052; Glenn CR, 2015, J CLIN CHILD ADOLESC, V44, P1, DOI 10.1080/15374416.2014.945211; Hawton K, 2000, J ADOLESCENCE, V23, P47, DOI 10.1006/jado.1999.0290; Hawton K., 2008, RUTTERS CHILD ADOLES, V5th ed, P648; Hawton K, 2007, J CLIN PSYCHIAT, V68, P1574, DOI 10.4088/JCP.v68n1017; Hawton K, 2012, LANCET, V379, P2373, DOI 10.1016/S0140-6736(12)60322-5; Hooley JM, 2008, APPL PREV PSYCHOL, V12, P155, DOI 10.1016/j.appsy.2008.08.001; Horowitz LM, 2012, ARCH PEDIAT ADOL MED, V166, P1170, DOI 10.1001/archpediatrics.2012.1276; Horowitz LM, 2009, CURR OPIN PEDIATR, V21, P620, DOI 10.1097/MOP.0b013e3283307a89; Janssens A, 2013, PEDIATR EMERG CARE, V29, P1041, DOI 10.1097/PEC.0b013e3182a393e7; Jessen G, 1999, ARCH SUICIDE RES, V5, P57, DOI 10.1080/13811119908258315; Klonsky ED, 2016, ANNU REV CLIN PSYCHO, V12, P307, DOI 10.1146/annurev-clinpsy-021815-093204; Kolves K, 2011, SOC PSYCH PSYCH EPID, V46, P805, DOI 10.1007/s00127-010-0251-x; Larkin GL, 2010, CRISIS, V31, P1, DOI 10.1027/0227-5910/a000001; Levine LJ, 2005, ARCH PEDIAT ADOL MED, V159, P860, DOI 10.1001/archpedi.159.9.860; Madge N, 2008, J CHILD PSYCHOL PSYC, V49, P667, DOI 10.1111/j.1469-7610.2008.01879.x; Mergl R, 2010, EUR ARCH PSY CLIN N, V260, P393, DOI 10.1007/s00406-009-0086-1; Mitchell AJ, 2006, EMERG MED J, V23, P251, DOI 10.1136/emj.2005.027250; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Nock MK, 2010, ANNU REV CLIN PSYCHO, V6, P339, DOI 10.1146/annurev.clinpsy.121208.131258; Olfson M, 2005, ARCH GEN PSYCHIAT, V62, P1122, DOI 10.1001/archpsyc.62.10.1122; Olfson M, 2014, JAMA-J AM MED ASSOC, V311, P1107, DOI 10.1001/jama.2014.501; Perry IJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031663; Petrik ML, 2015, GEN HOSP PSYCHIAT, V37, P581, DOI 10.1016/j.genhosppsych.2015.06.018; Polewka Andrzej, 2004, Przegl Lek, V61, P269; Pompili M, 2009, EUR CHILD ADOLES PSY, V18, P525, DOI 10.1007/s00787-009-0007-x; Preti A, 2001, J AFFECT DISORDERS, V65, P253, DOI 10.1016/S0165-0327(00)00232-9; Ribeiro JD, 2016, PSYCHOL MED, V46, P225, DOI 10.1017/S0033291715001804; Rodham K, 2004, J AM ACAD CHILD PSY, V43, P80, DOI 10.1097/00004583-200401000-00017; Rosychuk RJ, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0941-3; Swanepoel A, 2016, ARCH DIS CHILDHOOD-E, V101, P287, DOI 10.1136/archdischild-2016-310782; Ting SA, 2012, GEN HOSP PSYCHIAT, V34, P557, DOI 10.1016/j.genhosppsych.2012.03.020; Ting SA, 2012, ACAD EMERG MED, V19, P239, DOI 10.1111/j.1553-2712.2011.01272.x; Victor SE, 2014, CLIN PSYCHOL REV, V34, P282, DOI 10.1016/j.cpr.2014.03.005; World Health Organization, 2015, MANT HLTH SUIC DAT	55	16	16	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2017	12	1							e0170979	10.1371/journal.pone.0170979	http://dx.doi.org/10.1371/journal.pone.0170979			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7IT	28125701	Green Published, Green Submitted, gold			2023-01-03	WOS:000396176100012
J	Leroi, C; Balestre, E; Messou, E; Minga, A; Sawadogo, A; Drabo, J; Maiga, M; Zannou, M; Seydi, M; Dabis, F; Jaquet, A				Leroi, Charline; Balestre, Eric; Messou, Eugene; Minga, Albert; Sawadogo, Adrien; Drabo, Joseph; Maiga, Moussa; Zannou, Marcel; Seydi, Moussa; Dabis, Francois; Jaquet, Antoine		IeDEA West Africa Collaboration	Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COTE-DIVOIRE; ABIDJAN; ADULTS; COTRIMOXAZOLE; ZIDOVUDINE; BACTEREMIA; COHORT; TRIAL; AIDS	Background In sub-Saharan Africa, antiretroviral therapy (ART) including drugs with potential toxicity such as Zidovudine (ZDV) are routinely prescribed. This study aimed at estimating the incidence of severe neutropenia and associated factors after ART initiation in five West African countries. Methods A retrospective cohort analysis was conducted within the international epidemiologic database to evaluate AIDS (IeDEA) collaboration in West Africa. All HIV-infected adults, initiating ART between 2002 and 2014, with a baseline and at least one follow-up absolute neutrophil count (ANC) measurement were eligible. Incidence of severe neutropenia (ANC <750 cells/mm(3)) was estimated with 95% confidence interval (CI) according to age, gender, HIV clinic, hemoglobin, CD4 count, clinical stage, and ART duration. A Cox proportional hazard model was used to identify factors associated with severe neutropenia, expressed with their adjusted hazard ratios (aHR). Results Between 2002 and 2014, 9,426 HIV-infected adults were enrolled. The crude incidence rate of a first severe neutropenia was 9.1 per 100 person-years (95% CI: 8.6-9.8). Factors associated with severe neutropenia were exposure to ZDV <6 months (aHR = 2.2; 95% CI: 1.8-2.6), >= 6-12 months (aHR = 2.1; 95% CI: 1.6-2.8) and >= 12 months (aHR = 1.6; 95% CI: 1.2-2.2) [Ref. no ZDV exposure], CD4 count <350 cells/mm(3) (aHR = 1.3; 95% CI: 1.1-1.5) and advanced clinical stage at ART initiation ( aHR = 1.2; 95% CI: 1.0-1.4). Conclusion The incidence of severe neutropenia after ART initiation in West Africa is high and associated with ZDV exposure and advanced HIV disease. In this context, efforts are needed to scale-up access to less toxic first-line ART drugs and to promote early ART initiation.	[Leroi, Charline; Balestre, Eric; Dabis, Francois; Jaquet, Antoine] Bordeaux Univ, Sch Publ Hlth ISPED, Ctr INSERM Epidemiol Biostat U1219, Bordeaux, France; [Leroi, Charline; Balestre, Eric; Dabis, Francois; Jaquet, Antoine] INSERM, ISPED, Ctr INSERM Epidemiol Biostat Bordeaux U1219, Bordeaux, France; [Messou, Eugene] CHU Treichville, Programme PAC CI, Abidjan, Cote Ivoire; [Messou, Eugene] Hop Yopougon Attie, Ctr Prise Charge Rech & Format, Abidjan, Cote Ivoire; [Minga, Albert] Ctr Med Suivi Donneurs Sang CNTS PRIMO CI, Abidjan, Cote Ivoire; [Sawadogo, Adrien] CHU Souro Sanou, Dept Malad Infect, Bobo Dioulasso, Burkina Faso; [Drabo, Joseph] CHU Yalgado Ouedraogo, Serv Med Interne, Ouagadougou, Burkina Faso; [Maiga, Moussa] Hop Gabriel Toure, Serv Hepatogastroenterol, Bamako, Mali; [Zannou, Marcel] CNHU, Ctr Prise Charge Personnes Vivant Avec VIH, Cotonou, Benin; [Seydi, Moussa] CHU Fann, CRCF, Serv Malad Infect & Trop, Dakar, Senegal	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Leroi, C (corresponding author), Bordeaux Univ, Sch Publ Hlth ISPED, Ctr INSERM Epidemiol Biostat U1219, Bordeaux, France.; Leroi, C (corresponding author), INSERM, ISPED, Ctr INSERM Epidemiol Biostat Bordeaux U1219, Bordeaux, France.	charlineleroi.bx@gmail.com	DABIS, FRANCOIS/S-9298-2019; Jaquet, Antoine/T-2794-2019	DABIS, FRANCOIS/0000-0002-1614-8857; Jaquet, Antoine/0000-0002-3426-9492	National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID) [5U01AI069919]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069919] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was partly funded by the following institutes: the National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), the National Institute of Allergy and Infectious Diseases (NIAID) (grant no 5U01AI069919). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Braitstein P, 2010, JAIDS-J ACQ IMM DEF, V53, P254, DOI 10.1097/QAI.0b013e3181b8f26e; Caperna J, 1998, EPIDEMIOL INFECT, V120, P71, DOI 10.1017/S095026889700842X; Division of AIDS, 2004, DIV AIDS TABL GRAD S; Egger M, 2012, INT J EPIDEMIOL, V41, P1256, DOI 10.1093/ije/dyr080; Firnhaber C, 2010, INT J INFECT DIS, V14, pE1088, DOI 10.1016/j.ijid.2010.08.002; Hermans P, 1999, J Hematother Stem Cell Res, V8 Suppl 1, pS23; Hoffmann CJ, 2008, AIDS, V22, P67, DOI 10.1097/QAD.0b013e3282f2306e; Jaquet A, 2011, PHARMACOEPIDEM DR S, V20, P1303, DOI 10.1002/pds.2182; Keiser P, 1996, AM J MED SCI, V312, P118, DOI 10.1097/00000441-199609000-00004; Levine AM, 2006, ARCH INTERN MED, V166, P405, DOI 10.1001/.405; Moh R, 2005, ANTIVIR THER, V10, P615; Moore DAJ, 2001, CLIN INFECT DIS, V32, P469, DOI 10.1086/318495; MOORE RD, 1995, ARCH INTERN MED, V155, P1965, DOI 10.1001/archinte.155.18.1965; Nacoulma E W C, 2007, Bull Soc Pathol Exot, V100, P271; Ortega M, 2008, EUR J CLIN MICROBIOL, V27, P969, DOI 10.1007/s10096-008-0531-5; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; Toure S, 2006, T ROY SOC TROP MED H, V100, P785, DOI 10.1016/j.trstmh.2005.11.008; UNAIDS, 2020, UNAIDS 2020 GLOB REP; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2013, CPMS GUID US ANT DRU	21	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2017	12	1							e0170753	10.1371/journal.pone.0170753	http://dx.doi.org/10.1371/journal.pone.0170753			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7FK	28122041	gold, Green Submitted, Green Published			2023-01-03	WOS:000396167300022
J	Ryu, JA; Park, TK; Chung, CR; Cho, YH; Sung, K; Suh, GY; Lee, TR; Sim, MS; Yang, JH				Ryu, Jeong-Am; Park, Taek Kyu; Chung, Chi Ryang; Cho, Yang Hyun; Sung, Kiick; Suh, Gee Young; Lee, Tae Rim; Sim, Min Seob; Yang, Jeong Hoon			Association between Body Temperature Patterns and Neurological Outcomes after Extracorporeal Cardiopulmonary Resuscitation	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; AMERICAN-HEART-ASSOCIATION; LIFE-SUPPORT; BRAIN TEMPERATURE; THERAPEUTIC HYPOTHERMIA; HYPERTHERMIA; GUIDELINES; MANAGEMENT; SURVIVAL; ADULTS	We evaluated the association of body temperature patterns with neurological outcomes after extracorporeal cardiopulmonary resuscitation (ECPR). Between December 2013 and December 2015, we enrolled 48 patients with cardiac arrest who survived for at least 24 hours after ECPR. Based on their body temperature patterns and the intention to control fever, we divided the patients into those in whom fever was actively controlled (N = 25), those with normothermia (N = 17), and those with unintended hypothermia (N = 6). The primary outcome was the Cerebral Performance Categories (CPC) scale at discharge. Of the 48 ECPR patients, 23 patients (47.9%) had good neurological outcomes (CPC 1 and 2) and 27 patients (56.3%) survived to discharge. The normothermia group showed a pattern of higher temperatures compared with the other groups during 48 hours after ECPR. Not only poor neurological outcomes but also intensive care unit (ICU) mortality occurred more often in the unintended hypothermia group than in the other two groups, regardless of the fever control strategy (p = 0.023 and p = 0.002, respectively). There were no differences in neurological outcomes and ICU mortality between the actively controlled fever group and the normothermia group (p = 0.845 and p = 0.616, respectively). Unintentionally sustained hypothermia may be associated with poor neurological outcomes after ECPR. These findings suggest that patients who are unable to generate a fever following ECPR may incur severe hypoxic brain injury.	[Ryu, Jeong-Am; Chung, Chi Ryang; Suh, Gee Young; Yang, Jeong Hoon] Sungkyunkwan Univ, Dept Crit Care Med, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Park, Taek Kyu; Yang, Jeong Hoon] Sungkyunkwan Univ, Div Cardiol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea; [Cho, Yang Hyun; Sung, Kiick] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac & Cardiovasc Surg, Seoul, South Korea; [Suh, Gee Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med,Sch Med, Seoul, South Korea; [Lee, Tae Rim; Sim, Min Seob] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Emergency Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Yang, JH (corresponding author), Sungkyunkwan Univ, Dept Crit Care Med, Samsung Med Ctr, Sch Med, Seoul, South Korea.; Yang, JH (corresponding author), Sungkyunkwan Univ, Div Cardiol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea.	jhysmc@gmail.com	Suh, Gee Young/O-3676-2019	Suh, Gee Young/0000-0001-5473-1712				Adrie Christophe, 2004, Curr Opin Crit Care, V10, P208, DOI 10.1097/01.ccx.0000126090.06275.fe; [Anonymous], AM HEART ASS CIRC, DOI DOI 10.1161/01.CIR.95.8.2213; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bro-Jeppesen J, 2013, RESUSCITATION, V84, P1734, DOI 10.1016/j.resuscitation.2013.07.023; Cabanac M, 2006, J APPL PHYSIOL, V100, P1338, DOI 10.1152/japplphysiol.01021.2005; Chen YS, 2008, LANCET, V372, P554, DOI 10.1016/S0140-6736(08)60958-7; Childs C, 2008, BRIT J NEUROSURG, V22, P486, DOI 10.1080/02688690802245541; Choi DH, 2016, CLIN EXP EMERG MED, V3, P132, DOI 10.15441/ceem.16.145; Cronberg T, 2015, JAMA NEUROL, V72, P634, DOI 10.1001/jamaneurol.2015.0169; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Fountas KN, 2003, J NEUROSURG ANESTH, V15, P87, DOI 10.1097/00008506-200304000-00004; Gebhardt K, 2013, RESUSCITATION, V84, P1062, DOI 10.1016/j.resuscitation.2013.03.038; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Ha T.S., 2016, EMERG MED J; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Holzer M, 2002, NEW ENGL J MED, V346, P549; Howes D, 2016, RESUSCITATION, V98, P48, DOI 10.1016/j.resuscitation.2015.07.052; Kang MJ, 2014, J KOREAN MED SCI, V29, P1301, DOI 10.3346/jkms.2014.29.9.1301; Kim F, 2014, JAMA-J AM MED ASSOC, V311, P45, DOI 10.1001/jama.2013.282173; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4; Le Guen M, 2011, CRIT CARE, V15, DOI 10.1186/cc9976; Leary M, 2013, RESUSCITATION, V84, P1056, DOI 10.1016/j.resuscitation.2012.11.003; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Massetti M, 2005, ANN THORAC SURG, V79, P178, DOI 10.1016/j.athoracsur.2004.06.095; Megarbane B, 2007, INTENS CARE MED, V33, P758, DOI 10.1007/s00134-007-0568-4; Megarbane B, 2011, RESUSCITATION, V82, P1154, DOI 10.1016/j.resuscitation.2011.05.007; Morimura N, 2011, RESUSCITATION, V82, P10, DOI 10.1016/j.resuscitation.2010.08.032; Morrison SF, 2011, FRONT BIOSCI-LANDMRK, V16, P74, DOI 10.2741/3677; Mrozek S, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/989487; Nagao K, 2010, CIRC J, V74, P77, DOI 10.1253/circj.CJ-09-0502; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Park SB, 2014, INT J CARDIOL, V177, P1031, DOI 10.1016/j.ijcard.2014.09.124; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Romanovsky AA, 2007, AM J PHYSIOL-REG I, V292, pR37, DOI 10.1152/ajpregu.00668.2006; Ryu JA, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0002-3; Sakamoto T, 2014, RESUSCITATION, V85, P762, DOI 10.1016/j.resuscitation.2014.01.031; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Takasu A, 2001, RESUSCITATION, V49, P273, DOI 10.1016/S0300-9572(00)00360-9; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	41	8	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2017	12	1							e0170711	10.1371/journal.pone.0170711	http://dx.doi.org/10.1371/journal.pone.0170711			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6QR	28114337	Green Published, gold, Green Submitted			2023-01-03	WOS:000396129000086
J	Timm, FP; Houle, TT; Grabitz, SD; Lihn, AL; Stokholm, JB; Eikermann-Haerter, K; Nozari, A; Kurth, T; Eikermann, M				Timm, Fanny P.; Houle, Timothy T.; Grabitz, Stephanie D.; Lihn, Anne-Louise; Stokholm, Janne B.; Eikermann-Haerter, Katharina; Nozari, Ala; Kurth, Tobias; Eikermann, Matthias			Migraine and risk of perioperative ischemic stroke and hospital readmission: hospital based registry study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATENT FORAMEN OVALE; WHITE-MATTER HYPERINTENSITIES; SILENT BRAIN INFARCTS; CARDIOVASCULAR-DISEASE; CARDIAC-SURGERY; COMPLICATIONS; HEADACHE; NOREPINEPHRINE; AURA; DEPOLARIZATION	Objective To evaluate whether patients with migraine are at increased risk of perioperative ischemic stroke and whether this may lead to an increased hospital readmission rate. Design Prospective hospital registry study. Setting Massachusetts General Hospital and two satellite campuses between January 2007 and August 2014. Participants 124 558 surgical patients (mean age 52.6 years; 54.5% women). Main outcome measures The primary outcome was perioperative ischemic stroke occurring within 30 days after surgery in patients with and without migraine and migraine aura. The secondary outcome was hospital readmission within 30 days of surgery. Exploratory outcomes included post-discharge stroke and strata of neuroanatomical stroke location. Results 10 179 (8.2%) patients had any migraine diagnosis, of whom 1278 (12.6%) had migraine with aura and 8901 (87.4%) had migraine without aura. 771 (0.6%) perioperative ischemic strokes occurred within 30 days of surgery. Patients with migraine were at increased risk of perioperative ischemic stroke (adjusted odds ratio 1.75, 95% confidence interval 1.39 to 2.21) compared with patients without migraine. The risk was higher in patients with migraine with aura (adjusted odds ratio 2.61, 1.59 to 4.29) than in those with migraine without aura (1.62, 1.26 to 2.09). The predicted absolute risk is 2.4 (2.1 to 2.8) perioperative ischemic strokes for every 1000 surgical patients. This increases to 4.3 (3.2 to 5.3) for every 1000 patients with any migraine diagnosis, 3.9 (2.9 to 5.0) for migraine without aura, and 6.3 (3.2 to 9.5) for migraine with aura. Patients with migraine had a higher rate of readmission to hospital within 30 days of discharge (adjusted odds ratio 1.31, 1.22 to 1.41). Conclusions Surgical patients with a history of migraine are at increased risk of perioperative ischemic stroke and have an increased 30 day hospital readmission rate. Migraine should be considered in the risk assessment for perioperative ischemic stroke.	[Timm, Fanny P.; Houle, Timothy T.; Grabitz, Stephanie D.; Lihn, Anne-Louise; Stokholm, Janne B.; Nozari, Ala; Eikermann, Matthias] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA; [Timm, Fanny P.; Houle, Timothy T.; Grabitz, Stephanie D.; Lihn, Anne-Louise; Stokholm, Janne B.; Nozari, Ala; Eikermann, Matthias] Harvard Med Sch, 55 Fruit St, Boston, MA 02114 USA; [Lihn, Anne-Louise; Stokholm, Janne B.] Univ Copenhagen, Herlev Hosp, Dept Anesthesiol, Copenhagen, Denmark; [Eikermann-Haerter, Katharina] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Eikermann-Haerter, Katharina] Harvard Med Sch, Boston, MA USA; [Kurth, Tobias] Charite Univ Med Berlin, Inst Publ Hlth, Berlin, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Copenhagen; Herlev & Gentofte Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eikermann, M (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.; Eikermann, M (corresponding author), Harvard Med Sch, 55 Fruit St, Boston, MA 02114 USA.	meikermann@partners.org	Houle, Timothy T/CAF-5465-2022; Nozari, Ala/AAH-6070-2021; Houle, Timothy T/I-7649-2019; Kurth, Tobias/A-9243-2012	Kurth, Tobias/0000-0001-7169-2620; Grabitz, Stephanie D./0000-0002-3071-873X; Lihn, Anne-Louise/0000-0002-2772-1321; Houle, Timothy/0000-0001-9584-5580	Jeff and Judy Buzen	Jeff and Judy Buzen	This study was funded by Jeff and Judy Buzen in an unrestricted grant to ME.	Alsheikh-Ali AA, 2009, STROKE, V40, P2349, DOI 10.1161/STROKEAHA.109.547828; Anzola GP, 1999, NEUROLOGY, V52, P1622, DOI 10.1212/WNL.52.8.1622; Assmann SF, 1996, EPIDEMIOLOGY, V7, P286, DOI 10.1097/00001648-199605000-00012; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bateman BT, 2009, ANESTHESIOLOGY, V110, P231, DOI 10.1097/ALN.0b013e318194b5ff; Bigal ME, 2010, NEUROLOGY, V74, P628, DOI 10.1212/WNL.0b013e3181d0cc8b; Bijker JB, 2012, ANESTHESIOLOGY, V116, P658, DOI 10.1097/ALN.0b013e3182472320; Brassard P, 2009, BRIT J ANAESTH, V102, P800, DOI 10.1093/bja/aep065; Bucerius J, 2003, ANN THORAC SURG, V75, P472, DOI 10.1016/S0003-4975(02)04370-9; Calvillo-King L, 2010, STROKE, V41, P2786, DOI 10.1161/STROKEAHA.110.599019; Camara-Lemarroy CR, 2016, WORLD J GASTROENTERO, V22, P8149, DOI 10.3748/wjg.v22.i36.8149; Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; Crassard I, 2001, CEPHALALGIA, V21, P630, DOI 10.1046/j.1468-2982.2001.00205.x; Cullen KA, 2006, AMBULATORY SURG US; Davenport DL, 2005, ANN SURG, V242, P463, DOI 10.1097/01.sla.0000183348.15117.ab; de Jong MAC, 2016, ANN SURG, V264, P362, DOI 10.1097/SLA.0000000000001499; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; Di Tullio MR, 2007, J AM COLL CARDIOL, V49, P797, DOI 10.1016/j.jacc.2006.08.063; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Eikermann-Haerter K, 2014, HEADACHE, V54, P1146, DOI 10.1111/head.12386; Eikermann-Haerter K, 2012, CIRCULATION, V125, P335, DOI 10.1161/CIRCULATIONAHA.111.045096; Elkind MSV, 2010, STROKE, V41, pS3, DOI 10.1161/STROKEAHA.110.594945; Gaist D, 2016, BRAIN, V139, P2015, DOI 10.1093/brain/aww099; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Grabitz Stephanie D, 2017, Crit Care Med, V45, pe30; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; Hines AL, 2006, CONDITIONS LARGEST N; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kurth T, 2005, NEUROLOGY, V64, P1020, DOI 10.1212/01.WNL.0000154528.21485.3A; Kurth T, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a636; Kurth T, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2610; Kurth T, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7357; Kurth T, 2006, JAMA-J AM MED ASSOC, V296, P283, DOI 10.1001/jama.296.3.283; Ladha K, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3646; Likosky DS, 2003, STROKE, V34, P2830, DOI 10.1161/01.STR.0000098650.12386.B3; Maas JJ, 2013, CRIT CARE MED, V41, P143, DOI 10.1097/CCM.0b013e318265ea64; MacClellan LR, 2007, STROKE, V38, P2438, DOI 10.1161/STROKEAHA.107.488395; Macellari F, 2012, CEREBROVASC DIS, V34, P175, DOI 10.1159/000339982; Malik R, 2015, NEUROLOGY, V84, P2132, DOI 10.1212/WNL.0000000000001606; Mashour GA, 2013, ANESTHESIOLOGY, V119, P1340, DOI 10.1097/ALN.0b013e318295a25f; Mashour GA, 2011, ANESTHESIOLOGY, V114, P1289, DOI 10.1097/ALN.0b013e318216e7f4; Meissner I, 2006, J AM COLL CARDIOL, V47, P440, DOI 10.1016/j.jacc.2005.10.044; Monteith T, 2014, STROKE, V45, P1830, DOI 10.1161/STROKEAHA.114.005447; Moran AE, 2014, GLOB HEART, V9, P3, DOI 10.1016/j.gheart.2014.03.1220; Nozari A, 2010, ANN NEUROL, V67, P221, DOI 10.1002/ana.21871; Palm-Meinders IH, 2012, JAMA-J AM MED ASSOC, V308, P1889, DOI 10.1001/jama.2012.14276; PARIKH S, 1993, NEW YORK STATE J MED, V93, P162; Peng KP, 2016, CEPHALALGIA; Petty GW, 2006, MAYO CLIN PROC, V81, P602, DOI 10.4065/81.5.602; Putaala J, 2009, NEUROLOGY, V72, P1823, DOI 10.1212/WNL.0b013e3181a711df; Rizzoli P, 2016, HEADACHE, V56, P1132, DOI 10.1111/head.12850; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Scher AI, 2005, NEUROLOGY, V64, P614, DOI 10.1212/01.WNL.0000151857.43225.49; Scher AI, 2009, JAMA-J AM MED ASSOC, V301, P2563, DOI 10.1001/jama.2009.932; Schurks Markus, 2009, BMJ, V339, pb3914, DOI 10.1136/bmj.b3914; Schwedt TJ, 2008, CEPHALALGIA, V28, P531, DOI 10.1111/j.1468-2982.2008.01554.x; Selim M, 2007, NEW ENGL J MED, V356, P706, DOI 10.1056/NEJMra062668; Sharifpour M, 2013, ANESTH ANALG, V116, P424, DOI 10.1213/ANE.0b013e31826a1a32; Smitherman TA, 2013, HEADACHE, V53, P427, DOI 10.1111/head.12074; Spector JT, 2010, AM J MED, V123, P612, DOI 10.1016/j.amjmed.2009.12.021; Stavrinou P, 2016, J NEUROSURG SCI, V60, P11; Su AW, 2016, SPINE, V41, P1523, DOI 10.1097/BRS.0000000000001558; Tietjen GE, 2009, CEPHALALGIA, V29, P989, DOI 10.1111/j.1468-2982.2009.01937.x; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Vasivej T, 2016, J STROKE CEREBROVASC, V25, P1172, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.051; Wong GY, 2000, ANESTHESIOLOGY, V92, P425, DOI 10.1097/00000542-200002000-00024	67	35	35	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2017	356								i6635	10.1136/bmj.i6635	http://dx.doi.org/10.1136/bmj.i6635			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9BS	28073753	hybrid, Green Published			2023-01-03	WOS:000392067300001
J	Seebacher, V; Reinthaller, A; Koelbl, H; Concin, N; Nehoda, R; Polterauer, S				Seebacher, Veronika; Reinthaller, Alexander; Koelbl, Heinz; Concin, Nicole; Nehoda, Regina; Polterauer, Stephan			The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study	PLOS ONE			English	Article							RELATIVE DOSE INTENSITY; CLINICAL-PRACTICE; OPEN-LABEL; CARBOPLATIN; PACLITAXEL; MULTICENTER; TRIALS; WOMEN; DENSE	Objective The aim of the present study was to investigate the prognostic role of the duration of adjuvant chemotherapy in patients with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Materials and Methods Within the present study we retrospectively evaluated the data of 165 consecutive patients with EOC treated with primary surgery followed by six completed cycles of platinum-taxan based intravenous adjuvant chemotherapy. Medians of total duration of chemotherapy were compared with clinical-pathological parameters. Patients were stratified into four risk groups according to the delay in days of total duration of chemotherapy, and univariate and multi-variable survival analyses were performed. Results The median duration of six completed cycles of chemotherapy comprised 113 days (IQR 107-124 days). Uni- and multi-variable survival analyses revealed a delay of total duration of chemotherapy of at least 9 days to be associated with progression-free (PFS), cancer-specific (CSS) and overall survival (OS). Hazard ratios (HR), confidence intervals (95% CI) and p-values for PFS, CSS and OS due to delay of chemo-duration were 2.9 (1.6-5.4; p = 0.001), 2.9 (1.3-6.2; p = 0.008) and 2.6 (1.3-5.4; p = 0.008), respectively. Prolonged total chemo-duration was associated with the amount of postoperative residual disease (p = 0.001) and the patients' age (p = 0.03). Conclusion The present study suggests a prolonged duration of adjuvant chemotherapy after primary surgery to adversely affect PFS, CSS and OS in patients with EOC. Yet larger studies are required to validate our results.	[Seebacher, Veronika; Reinthaller, Alexander; Koelbl, Heinz; Polterauer, Stephan] Med Univ Vienna, Ctr Comprehens Canc, Dept Gynecol & Gynecol Oncol, Gynecol Canc Unit, Vienna, Austria; [Reinthaller, Alexander; Polterauer, Stephan] Karl Landsteiner Inst Gen Gynecol & Expt Gynecol, Vienna, Austria; [Concin, Nicole; Nehoda, Regina] Med Univ Innsbruck, Dept Gynecol & Obstet, Innsbruck, Austria	Medical University of Vienna; Medical University of Innsbruck	Seebacher, V (corresponding author), Med Univ Vienna, Ctr Comprehens Canc, Dept Gynecol & Gynecol Oncol, Gynecol Canc Unit, Vienna, Austria.	veronika.seebacher@meduniwien.ac.at	Polterauer, Stephan/AAG-1331-2021	Polterauer, Stephan/0000-0002-9649-4505; Concin, Nicole/0000-0002-9795-2643				Anuradha S, 2016, ACTA ONCOL, V55, P226, DOI 10.3109/0284186X.2015.1054950; Ben-Josef E, 2010, J CLIN ONCOL, V28, P5061, DOI 10.1200/JCO.2010.29.1351; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; Chang J, 2000, EUR J CANCER, V36, pS11; Chen SW, 2003, RADIOTHER ONCOL, V67, P69, DOI 10.1016/S0167-8140(02)00439-5; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; du Bois A, 2009, CANCER-AM CANCER SOC, V115, P1234, DOI 10.1002/cncr.24149; Fauci JM, 2011, GYNECOL ONCOL, V122, P532, DOI 10.1016/j.ygyno.2011.05.023; Ferlay J, 2013, GLOBOCAN2012 V1 0 CA; Gibson SJ, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00063; Hanna RK, 2013, GYNECOL ONCOL, V129, P74, DOI 10.1016/j.ygyno.2012.12.017; Katsumata N, 2013, LANCET ONCOL, V14, P1020, DOI 10.1016/S1470-2045(13)70363-2; Ma BBY, 2010, LANCET ONCOL, V11, P75, DOI 10.1016/S1470-2045(09)70160-3; McGuire WP, 2003, BRIT J CANCER, V89, pS3, DOI 10.1038/sj.bjc.6601494; Nagel CI, 2012, GYNECOL ONCOL, V124, P221, DOI 10.1016/j.ygyno.2011.10.003; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Pecorelli S, 2009, J CLIN ONCOL, V27, P4642, DOI 10.1200/JCO.2009.21.9691; Pignata S, 2014, LANCET ONCOL, V15, P396, DOI 10.1016/S1470-2045(14)70049-X; REPETTO L, 1993, EUR J CANCER, V29A, P181, DOI 10.1016/0959-8049(93)90169-G; Smith TJ, 2015, J CLIN ONCOL, V33, P3199, DOI 10.1200/JCO.2015.62.3488	21	4	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2017	12	1							e0169272	10.1371/journal.pone.0169272	http://dx.doi.org/10.1371/journal.pone.0169272			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH3AX	28060918	Green Submitted, gold, Green Published			2023-01-03	WOS:000391641500073
J	Klausenitz, C; Hacker, H; Hesse, T; Kohlmann, T; Endlich, K; Hahnenkamp, K; Usichenko, T				Klausenitz, Catharina; Hacker, Henriette; Hesse, Thomas; Kohlmann, Thomas; Endlich, Karlhans; Hahnenkamp, Klaus; Usichenko, Taras			Auricular Acupuncture for Exam Anxiety in Medical Students-A Randomized Crossover Investigation	PLOS ONE			English	Article							UNIVERSITY-STUDENTS; INTERVENTIONS; PERFORMANCE	Auricular acupuncture (AA) is effective in the treatment of preoperative anxiety. The aim was to investigate whether AA can reduce exam anxiety as compared to placebo and no intervention. Forty-four medical students were randomized to receive AA, placebo, or no intervention in a crossover manner and subsequently completed three comparable oral anatomy exams with an interval of 1 month between the exams/interventions. AA was applied using indwelling fixed needles bilaterally at points MA-IC1, MA-TF1, MA -SC, MA-AT1 and MA-TG one day prior to each exam. Placebo needles were used as control. Levels of anxiety were measured using a visual analogue scale before and after each intervention as well as before each exam. Additional measures included the State-Trait-Anxiety Inventory, duration of sleep at night, blood pressure, heart rate and the extent of participant blinding. All included participants finished the study. Anxiety levels were reduced after AA and placebo intervention compared to baseline and the no intervention condition (p < 0.003). AA was better at reducing anxiety than placebo in the evening before the exam (p = 0.018). Participants were able to distinguish between AA and placebo intervention. Both AA and placebo interventions reduced exam anxiety in medical students. The superiority of AA over placebo may be due to insufficient blinding of participants.	[Klausenitz, Catharina; Hacker, Henriette; Hesse, Thomas; Hahnenkamp, Klaus; Usichenko, Taras] Univ Med Greifswald, Dept Anesthesiol, Greifswald, Germany; [Klausenitz, Catharina] Univ Med Greifswald, Inst Diagnost Radiol & Neuroradiol, Greifswald, Germany; [Kohlmann, Thomas] Univ Med Greifswald, Inst Community Med, Greifswald, Germany; [Endlich, Karlhans] Univ Med Greifswald, Inst Anat, Greifswald, Germany; [Usichenko, Taras] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada	Greifswald Medical School; Greifswald Medical School; Greifswald Medical School; Greifswald Medical School; McMaster University	Usichenko, T (corresponding author), Univ Med Greifswald, Dept Anesthesiol, Greifswald, Germany.; Usichenko, T (corresponding author), McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.	usichent@mcmaster.ca		Endlich, Karlhans/0000-0001-6052-6061				Blanch DC, 2008, PATIENT EDUC COUNS, V72, P374, DOI 10.1016/j.pec.2008.05.021; Brockmeyer H, 2005, PRUFUNGSANGST EXPT S, P79; DEFFENBACHER JL, 1988, COUNS PSYCHOL, V16, P9, DOI 10.1177/0011000088161002; DENDATO KM, 1986, J COUNS PSYCHOL, V33, P131; Eisenberg D, 2013, J NERV MENT DIS, V201, P60, DOI 10.1097/NMD.0b013e31827ab077; Hesse T, 2016, ACUPUNCT MED, V34, P14, DOI 10.1136/acupmed-2015-010852; Karst M, 2007, ANESTH ANALG, V104, P295, DOI 10.1213/01.ane.0000242531.12722.fd; Klausenitz C, 2016, ACUPUNCT MED, V34, P90, DOI 10.1136/acupmed-2015-010887; Latas Milan, 2010, Med Pregl, V63, P863; Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049; MacPherson H, 2001, COMPLEMENT THER MED, V9, P246, DOI 10.1054/ctim.2001.0488; Maurice-Szamburski A, 2015, JAMA-J AM MED ASSOC, V313, P916, DOI 10.1001/jama.2015.1108; Michalek-Sauberer A, 2012, CLIN ORAL INVEST, V16, P1517, DOI 10.1007/s00784-011-0662-4; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Neuderth S, 2009, J NEURAL TRANSM, V116, P785, DOI 10.1007/s00702-008-0123-7; Ogal H., 2004, DTSCH Z AKUPUNKTUR, V47, P6, DOI DOI 10.1078/0415-6412-00048; Ramirez G, 2011, SCIENCE, V331, P211, DOI 10.1126/science.1199427; REED M, 1980, J CLIN PSYCHOL, V36, P683, DOI 10.1002/1097-4679(198007)36:3<683::AID-JCLP2270360313>3.0.CO;2-P; Regehr C, 2013, J AFFECT DISORDERS, V148, P1, DOI 10.1016/j.jad.2012.11.026; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Usichenko TI, 2010, ACUPUNCT MED, V28, P165, DOI 10.1136/aim.2010.003244; Wang SM, 2001, ANESTH ANALG, V93, P1178, DOI 10.1097/00000539-200111000-00024; Zhang ZH, 2011, CLIN EXP HYPERTENS, V33, P281, DOI 10.3109/10641963.2010.531850	23	19	22	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2016	11	12							e0168338	10.1371/journal.pone.0168338	http://dx.doi.org/10.1371/journal.pone.0168338			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EG7KQ	28033320	gold, Green Published, Green Submitted			2023-01-03	WOS:000391226900021
J	Sharfo, AWM; Breedveld, S; Voet, PWJ; Heijkoop, ST; Mens, JWM; Hoogeman, MS; Heijmen, BJM				Sharfo, Abdul Wahab M.; Breedveld, Sebastiaan; Voet, Peter W. J.; Heijkoop, Sabrina T.; Mens, Jan-Willem M.; Hoogeman, Mischa S.; Heijmen, Ben J. M.			Validation of Fully Automated VMAT Plan Generation for Library-Based Plan-of-the-Day Cervical Cancer Radiotherapy	PLOS ONE			English	Article							MODULATED ARC THERAPY; PELVIC RADIOTHERAPY; RADIATION-THERAPY; LUNG-CANCER; IMRT; OPTIMIZATION; QUALITY; WOMEN; HEAD	Purpose To develop and validate fully automated generation of VMAT plan-libraries for plan-of-the day adaptive radiotherapy in locally-advanced cervical cancer. Material and Methods Our framework for fully automated treatment plan generation (Erasmus-iCycle) was adapted to create dual-arc VMAT treatment plan libraries for cervical cancer patients. For each of 34 patients, automatically generated VMAT plans (autoVMAT) were compared to manually generated, clinically delivered 9-beam IMRT plans (CLINICAL), and to dual-arc VMAT plans generated manually by an expert planner (manVMAT). Furthermore, all plans were benchmarked against 20-beam equi-angular IMRT plans (autolMRT). For all plans, a PTV coverage of 99.5% by at least 95% of the prescribed dose (46 Gy) had the highest planning priority, followed by minimization of V-45Gy for small bowel (SB). Other OARs considered were bladder, rectum, and sigmoid. Results All plans had a highly similar PTV coverage, within the clinical constraints (above). After plan normalizations for exactly equal median PTV doses in corresponding plans, all evaluated OAR parameters in autoVMAT plans were on average lower than in the CLINICAL plans with an average reduction in SB V-45Gy of 34.6% (p<0.001). For 41/44 autoVMAT plans, SB V45Gy was lower than for manVMAT (p<0.001, average reduction 30.3%), while SB V-15Gy increased by 2.3% (p = 0.011). AutoIMRT reduced SB V-45Gy by another 2.7% compared to autoVMAT, while also resulting in a 9.0% reduction in SB V15Gy (p<0.001), but with a prolonged delivery time. Differences between manVMAT and autoVMAT in bladder, rectal and sigmoid doses were <= 1%. Improvements in SB dose delivery with autoVMAT instead of manVMAT were higher for empty bladder PTVs compared to full bladder PTVs, due to differences in concavity of the PTVs. Conclusions Quality of automatically generated VMAT plans was superior to manually generated plans. Automatic VMAT plan generation for cervical cancer has been implemented in our clinical routine. Due to the achieved workload reduction, extension of plan libraries has become feasible.	[Sharfo, Abdul Wahab M.; Breedveld, Sebastiaan; Voet, Peter W. J.; Heijkoop, Sabrina T.; Mens, Jan-Willem M.; Hoogeman, Mischa S.; Heijmen, Ben J. M.] Erasmus MC Canc Inst, Dept Radiat Oncol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Sharfo, AWM (corresponding author), Erasmus MC Canc Inst, Dept Radiat Oncol, Rotterdam, Netherlands.	a.sharto@erasmusmc.nl			Elekta AB, Stockholm, Sweden; Dutch Cancer Society [EMCR 2012-5396]; Elekta AB; Dutch Cancer Society	Elekta AB, Stockholm, Sweden; Dutch Cancer Society(KWF Kankerbestrijding); Elekta AB; Dutch Cancer Society(KWF Kankerbestrijding)	This work was in part funded by a research grant of Elekta AB, Stockholm, Sweden (https://www.elekta.com/) and by a grant of the Dutch Cancer Society (Grant EMCR 2012-5396) (https://www.kwf.nl/). Elekta AB provided financial support to Erasmus MC Cancer Institute for hiring AWMS for the work. The Dutch Cancer Society sponsored the appointment of STH for this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad R, 2011, RADIOTHER ONCOL, V98, P340, DOI 10.1016/j.radonc.2010.11.010; Bedford JL, 2013, J APPL CLIN MED PHYS, V14, P172, DOI 10.1120/jacmp.v14i2.4136; Bondar ML, 2012, INT J RADIAT ONCOL, V83, P1617, DOI 10.1016/j.ijrobp.2011.10.011; Breedveld S, 2007, PHYS MED BIOL, V52, P6339, DOI 10.1088/0031-9155/52/20/016; Breedveld S, 2012, MED PHYS, V39, P951, DOI 10.1118/1.3676689; Breedveld S, 2009, PHYS MED BIOL, V54, P7199, DOI 10.1088/0031-9155/54/23/011; Chen MF, 2007, INT J RADIAT ONCOL, V67, P1438, DOI 10.1016/j.ijrobp.2006.11.005; Cosgrove VP, 2009, INT J RADIAT ONCOL, V75, pS722, DOI 10.1016/j.ijrobp.2009.07.1646; Fernandez-Ots A, 2013, REP PRACT ONCOL RADI, V18, P363, DOI 10.1016/j.rpor.2013.08.001; Feuvret L, 2006, INT J RADIAT ONCOL, V64, P333, DOI 10.1016/j.ijrobp.2005.09.028; Heijkoop ST, 2014, INT J RADIAT ONCOL, V90, P673, DOI 10.1016/j.ijrobp.2014.06.046; Hoogeman MS, 2008, INT J RADIAT ONCOL, V70, P609, DOI 10.1016/j.ijrobp.2007.08.066; Kavanagh BD, 2010, INT J RADIAT ONCOL, V76, pS101, DOI 10.1016/j.ijrobp.2009.05.071; Mundt AJ, 2002, INT J RADIAT ONCOL, V52, P1330, DOI 10.1016/S0360-3016(01)02785-7; Quan EM, 2012, INT J RADIAT ONCOL, V84, pE69, DOI 10.1016/j.ijrobp.2012.02.017; Quan EZM, 2012, INT J RADIAT ONCOL, V83, P1169, DOI 10.1016/j.ijrobp.2011.09.015; Roeske JC, 2003, RADIOTHER ONCOL, V69, P201, DOI 10.1016/j.radonc.2003.05.001; Sharfo AWM, 2015, RADIOTHER ONCOL, pS0167; Shiraishi S, 2015, MED PHYS, V42, P908, DOI 10.1118/1.4906183; Tol JP, 2015, INT J RADIAT ONCOL, V91, P612, DOI 10.1016/j.ijrobp.2014.11.014; van de Bunt L, 2006, INT J RADIAT ONCOL, V64, P189, DOI 10.1016/j.ijrobp.2005.04.025; Voet PWJ, 2014, INT J RADIAT ONCOL, V88, P1175, DOI 10.1016/j.ijrobp.2013.12.046; Voet PWJ, 2013, INT J RADIAT ONCOL, V85, P866, DOI 10.1016/j.ijrobp.2012.04.015; Wu BB, 2013, MED PHYS, V40, DOI 10.1118/1.4788671; Zhang XD, 2011, PHYS MED BIOL, V56, P3873, DOI 10.1088/0031-9155/56/13/009	25	49	49	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2016	11	12							e0169202	10.1371/journal.pone.0169202	http://dx.doi.org/10.1371/journal.pone.0169202			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7KQ	28033342	Green Published, gold, Green Submitted			2023-01-03	WOS:000391226900086
J	Yasuda, T; Ura, T; Taniguchi, M; Yoshida, H				Yasuda, Takuwa; Ura, Takehiro; Taniguchi, Masaru; Yoshida, Hisahiro			Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy	PLOS ONE			English	Article							TRANSDERMAL DRUG-DELIVERY; DERMAL DENDRITIC CELLS; INFLUENZA VACCINE; EPICUTANEOUS IMMUNOTHERAPY; MICRONEEDLE ARRAYS; ATOPIC-DERMATITIS; IMMUNE-RESPONSES; BARRIER FUNCTION; STRATUM-CORNEUM; LYMPH-NODE	Skin is protected by a tough but flexible multilayered barrier and is a front line for immune responses against invading particles. For many years now, skin has been a tissue where certain vaccines are injected for the prevention of infectious disease, however, the detailed mechanisms of the skin immune response are not yet well understood. Using thin and small injection needles, we carefully injected OVA into a restricted region of mouse skin, i.e., intradermal (ID), and examined the antibody response in comparison with subcutaneous (SC) injection or epicutaneous patch administration of OVA. Epicutaneous patches induced a high IgE response against OVA, but IgG production was low. High IgG production was induced by both ID and SC injection, moreover, ID injection induced higher IgG production without any adjutants. Furthermore, OVA-specific IgE production was diminished by ID injection. We found that ID injection could efficiently stimulate skin resident DCs, drive Th1-biased conditions and diminish IgE production. The ID injection response was regulated by Langerin(+) dermal DCs, because OVA was taken up mainly by these cells and, after transiently deleting them, the IgE response was no longer diminished and IgG1 production was enhanced. We also tested whether ID injection might be an effective allergy treatment by attempting to inhibit ongoing IgE production in mice with experimentally induced high serum IgE levels. Multiple ID injections of OVA were shown to prevent elevation of serum OVA-specific IgE after repeated allergen challenge. In contrast, SC OVA injection could only transiently inhibit the OVA-specific IgE production. These findings indicated that ID injection results in higher induction of antigen-specific IgG, and thus may be useful for vaccine delivery with little or no adjuvant components. Moreover, the observed diminishment of IgE and induction of Th1-biased immune responses suggest that ID may be a useful injection route for allergy immunotherapy.	[Yasuda, Takuwa; Yoshida, Hisahiro] RIKEN Res Ctr Integrat Med Sci IMS, Immunogenet Lab, Yokohama, Kanagawa, Japan; [Ura, Takehiro] Terumo Co Ltd, Hosp Co R&D Dept, Nakai, Kanagawa, Japan; [Taniguchi, Masaru] RIKEN Res Ctr Integrat Med Sci IMS, Lab Immune Regulat, Yokohama, Kanagawa, Japan	RIKEN; Terumo Corporation; RIKEN	Yasuda, T (corresponding author), RIKEN Res Ctr Integrat Med Sci IMS, Immunogenet Lab, Yokohama, Kanagawa, Japan.	takuwa@riken.jp			Terumo Corporation	Terumo Corporation	One of the authors (TU) is employee of Terumo Corporation. About the Funding Statement, Terumo Corporation provided support in the form of salary for author [TU] and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the author are articulated in the 'author contributions' section.	Alvarez-Roman R, 2004, J CONTROL RELEASE, V99, P53, DOI 10.1016/j.jconrel.2004.06.015; Anaya JM, 2015, CLIN EXP RHEUMATOL, V33, P545; Ansaldi F, 2011, EXPERT OPIN BIOL TH, V11, P415, DOI 10.1517/14712598.2011.557658; Arakane R, 2015, VACCINE, V33, P6650, DOI 10.1016/j.vaccine.2015.10.088; Arakane R, 2015, VACCINE, V33, P6340, DOI 10.1016/j.vaccine.2015.09.010; Batard T, 2015, ALLERGY; Beyer K, 2012, J ALLERGY CLIN IMMUN, V129, P1179, DOI 10.1016/j.jaci.2012.03.037; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Ferrari L, 2011, RES VET SCI, V90, P64, DOI 10.1016/j.rvsc.2010.04.026; Flacher V, 2012, J IMMUNOL, V188, P2146, DOI 10.4049/jimmunol.1004120; Gorse GJ, 2013, VACCINE, V31, P2358, DOI 10.1016/j.vaccine.2013.03.008; Grunewald SM, 2001, INT ARCH ALLERGY IMM, V125, P322, DOI 10.1159/000053833; Guimaraes LE, 2015, PHARMACOL RES, V100, P190, DOI 10.1016/j.phrs.2015.08.003; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Jakasa I, 2011, J INVEST DERMATOL, V131, P540, DOI 10.1038/jid.2010.307; Jin GH, 2012, J DERMATOL SCI, V67, P181, DOI 10.1016/j.jdermsci.2012.06.005; Kabashima K, 2007, AM J PATHOL, V171, P1249, DOI 10.2353/ajpath.2007.070225; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kumamoto Y, 2013, IMMUNITY, V39, P733, DOI 10.1016/j.immuni.2013.08.029; Matsui T, 2015, INT IMMUNOL, V27, P269, DOI 10.1093/intimm/dxv013; Matsushima H, 2003, J DERMATOL SCI, V32, P223, DOI 10.1016/S0923-1811(03)00106-3; Murakami R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073270; Naito S, 2012, VACCINE, V30, P1191, DOI 10.1016/j.vaccine.2011.11.111; Nishifuji K, 2013, VET DERMATOL, V24, P60, DOI 10.1111/j.1365-3164.2012.01090.x; Okubo Kimihiro, 2010, Journal of Nippon Medical School, V77, P285, DOI 10.1272/jnms.77.285; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Ptak W, 2002, INT ARCH ALLERGY IMM, V128, P8, DOI 10.1159/000057998; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Rotiroti G, 2012, J ALLERGY CLIN IMMUN, V130, P918, DOI 10.1016/j.jaci.2012.06.052; Rutkowski K, 2012, POSTGRAD MED J, V88, P458, DOI 10.1136/postgradmedj-2011-130634; Saad Abdel Hakim, 2006, Journal of the Egyptian Society of Parasitology, V36, P867; Schafer B, 2013, J ALLERGY CLIN IMMUN, V131, P541, DOI 10.1016/j.jaci.2012.05.009; Simon L, 2009, J PHARM SCI-US, V98, P187, DOI 10.1002/jps.21408; Sixt M, 2005, IMMUNITY, V22, P19, DOI 10.1016/j.immuni.2004.11.013; Skobe M, 2000, J INVEST DERM SYMP P, V5, P14, DOI 10.1046/j.1087-0024.2000.00001.x; Suzuki Yusuke, 2011, Allergology International, V60, P11, DOI 10.2332/allergolint.10-RAI-0281; Tanizaki H, 2015, J DERMATOL SCI, V79, P310, DOI 10.1016/j.jdermsci.2015.06.010; Tarnow K, 2004, APPL NURS RES, V17, P275, DOI 10.1016/S0897-1897(04)00079-5; Tozuka M, 2016, J DERMATOL SCI, V82, P38, DOI 10.1016/j.jdermsci.2015.11.008; Tsang P, 2014, VACCINE, V32, P2507, DOI 10.1016/j.vaccine.2013.09.074; Tuan-Mahmood TM, 2013, EUR J PHARM SCI, V50, P623, DOI 10.1016/j.ejps.2013.05.005; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wang G, 2007, CLIN EXP ALLERGY, V37, P151, DOI 10.1111/j.1365-2222.2006.02621.x; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Yan GA, 2010, INT J PHARMACEUT, V391, P7, DOI 10.1016/j.ijpharm.2010.02.007; Zaric M, 2013, ACS NANO, V7, P2042, DOI 10.1021/nn304235j	47	14	14	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2016	11	12							e0167952	10.1371/journal.pone.0167952	http://dx.doi.org/10.1371/journal.pone.0167952			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8KC	27973543	Green Published, gold, Green Submitted			2023-01-03	WOS:000392754300050
J	Huang, XL; Knoble, JL; Zeng, M; Aguila, FN; Patel, T; Chambers, LW; Hu, HL; Liu, H				Huang, Xiaolun; Knoble, Jeanna L.; Zeng, Ming; Aguila, Fernando N.; Patel, Tara; Chambers, Lowell W.; Hu, Honglin; Liu, Hao			Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients	PLOS ONE			English	Article							RADIATION-THERAPY; INDUCTION CHEMOTHERAPY; CHEMORADIATION; RADIOTHERAPY; LUNG; OXALIPLATIN; CARCINOMA; OUTCOMES; PHASE-2; TRIAL	Background To study the feasibility of down stage the borderline resectable pancreatic cancer (BRPC) to resectable disease, we reported our institutional results using an intensity-modulated radiation therapy (IMRT) simultaneous integrated boost (SIB) dose escalation approach to improve R0 resectability. Methods We reviewed our past 7 years of experience of using neoadjuvant induction chemotherapy with Gemcitabine followed by concurrent chemoradiaiton for BRPC. During the concurrent, chemo was 5-FU and radiation were IMRT with SIB technique to target the key areas with dose escalation to 5600 in 28 fractions. The key areas were defined by PET positive area. This was followed by restaging imaging to rule out distant metastases before resection. Results 25 finished dose escalation protocol. 2 of the 25 cases developed distant metastases, 23 (92%) patients without distant metastases underwent pancreatectomy. Among the those received pancreatectomy, 22 (95%) achieved negative margin (R0). The gastrointestinal toxicity > grade 2 was 8% and there was no grade 4 toxicity. Conclusion Neoadjuvant Gemcitabine-based induction chemotherapy followed by 5-FU-based IMRT-SIB is a feasible option in improving the likelihood of R0 resection rate in BRPC without compromising the organs at risk for toxicity.	[Huang, Xiaolun] Univ Elect Sci & Technol, Dept Hepatobiliary Pancreat Surg, Chengdu, Sichuan, Peoples R China; [Huang, Xiaolun] Univ Elect Sci & Technol, Affiliated Hosp, Cell Transplant Ctr, Chengdu, Sichuan, Peoples R China; [Knoble, Jeanna L.; Patel, Tara] Mt Carmel Hlth Syst, Dept Hematol & Oncol, Zangmeister Canc Ctr, Columbus, OH USA; [Zeng, Ming] Mt Carmel Hlth Syst, Dept Radiat Oncol, Columbus, OH 43215 USA; [Aguila, Fernando N.; Chambers, Lowell W.] Cent Ohio Surg Associates Inc, Columbus, OH USA; [Hu, Honglin; Liu, Hao] Univ Elect Sci & Technol, Ctr Canc, Affiliated Hosp, Chengdu, Sichuan, Peoples R China	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Zeng, M (corresponding author), Mt Carmel Hlth Syst, Dept Radiat Oncol, Columbus, OH 43215 USA.	miller2002@yahoo.com		zeng, ming/0000-0002-4294-2077				Assifi MM, 2011, SURGERY, V150, P466, DOI 10.1016/j.surg.2011.07.006; Ben-Josef E, 2012, INT J RADIAT ONCOL, V84, P1166, DOI 10.1016/j.ijrobp.2012.02.051; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Compton CC, 2012, AJCC CANC STAGING MA, DOI [DOI 10.1007/978-1-4614-2080-4, 10.1007/978-1-4614-2080-4]; COX JD, 1993, INT J RADIAT ONCOL, V27, P493, DOI 10.1016/0360-3016(93)90371-2; Dirkx MLP, 2004, LUNG CANCER-J IASLC, V45, P57, DOI 10.1016/j.lungcan.2004.01.003; Esnaola NF, 2014, INT J RADIAT ONCOL, V88, P837, DOI 10.1016/j.ijrobp.2013.12.030; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Jabbour SK, 2014, PRACT RADIAT ONCOL, V4, P82, DOI 10.1016/j.prro.2013.06.004; Katz MHG, 2012, CANCER-AM CANCER SOC, V118, P5749, DOI 10.1002/cncr.27636; Katz MHG, 2011, ANN SURG ONCOL, V18, P608, DOI 10.1245/s10434-010-1460-y; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim EJ, 2013, CANCER-AM CANCER SOC, V119, P2692, DOI 10.1002/cncr.28117; Krishnan S, 2007, CANCER-AM CANCER SOC, V110, P47, DOI 10.1002/cncr.22735; Machtay M, 2005, INT J RADIAT ONCOL, V63, P667, DOI 10.1016/j.ijrobp.2005.03.037; Mellon EA, 2015, ACTA ONCOL, V54, P979, DOI 10.3109/0284186X.2015.1004367; Murphy JD, 2007, INT J RADIAT ONCOL, V68, P801, DOI 10.1016/j.ijrobp.2006.12.053; Patel M, 2011, J SURG ONCOL, V104, P155, DOI 10.1002/jso.21954; Takahashi H, 2013, ANN SURG, V258, P1040, DOI 10.1097/SLA.0b013e31829b3ce4; Yates F, 1934, J R STAT SOC, V1, P217, DOI 10.2307/2983604	20	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0166606	10.1371/journal.pone.0166606	http://dx.doi.org/10.1371/journal.pone.0166606			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4PU	27935952	Green Published, gold, Green Submitted			2023-01-03	WOS:000389587100036
J	Bierman, AS; Tinetti, ME				Bierman, Arlene S.; Tinetti, Mary E.			Precision medicine to precision care: managing multimorbidity	LANCET			English	Editorial Material							CLINICAL-PRACTICE GUIDELINES; DISEASE		[Bierman, Arlene S.] Agcy Healthcare Res & Qual, Ctr Evidence & Practice Improvement, Rockville, MD 20857 USA; [Tinetti, Mary E.] Yale Sch Med, Dept Med, New Haven, CT USA; [Tinetti, Mary E.] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA	Agency for Healthcare Research & Quality; Yale University; Yale University	Bierman, AS (corresponding author), Agcy Healthcare Res & Qual, Ctr Evidence & Practice Improvement, Rockville, MD 20857 USA.	arlene.bierman@ahrq.hhs.gov						Arnett DK, 2014, J AM COLL CARDIOL, V64, P1851, DOI 10.1016/j.jacc.2014.07.012; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Ickowicz E, 2012, J AM GERIATR SOC, V60, pE1, DOI 10.1111/j.1532-5415.2012.04188.x; Korsen NBA, 2016, INTEGRATION PLAYBOOK; Moreno G, 2013, J AM GERIATR SOC, V61, P2027, DOI 10.1111/jgs.12513; Muth C, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0223-1; National Guideline Clearinghouse, 2016, MULT CHRON COND MCC; National Institute for Health and Care Excellence, 2016, MULTIMORBIDITY CLIN; Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7; Tinetti ME, 2016, CLIN GERIATR MED, V32, P261, DOI 10.1016/j.cger.2016.01.012; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Ward BW, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120203; Wyatt KD, 2014, MED CARE, V52, pS92, DOI 10.1097/MLR.0b013e3182a51b3d	13	47	48	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	2016	388	10061					2721	2723		10.1016/S0140-6736(16)32232-2	http://dx.doi.org/10.1016/S0140-6736(16)32232-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EE5FB	27924764				2023-01-03	WOS:000389629800008
J	Zhu, DQ; Wang, SS; Lawless, J; He, JC; Zheng, ZG				Zhu, Dongqing; Wang, Shanshan; Lawless, John; He, Jianchen; Zheng, Zhengui			Dose Dependent Dual Effect of Baicalin and Herb Huang Qin Extract on Angiogenesis	PLOS ONE			English	Article							SCUTELLARIA-BAICALENSIS; TUMOR ANGIOGENESIS; IN-VITRO; THERAPEUTIC ANGIOGENESIS; ANTICANCER ACTIVITY; RADIX-SCUTELLARIAE; OVARIAN-CANCER; GROWTH; EXPRESSION; WOGONIN	Huang Qin (root of Scutellaria baicalensis) is a widely used herb in different countries for adjuvant therapy of inflammation, diabetes, hypertension, different kinds of cancer and virus related diseases. Baicalin is the main flavonoid in this herb and has been extensively studied for 30 years. The angiogenic effect of herb Huang Qin extract and baicalin was found 13 years ago, however, the results were controversial with pro-angiogenic effect in some studies and anti-angiogenic effect in others. In this paper, the angiogenic effect of baicalin, its aglycone form baicalein and aqueous extract of Huang Qin was studied in chick embryo chorioallantoic membrane (CAM) model. Dose dependent dual effect was found in both aqueous extract and baicalin, but not in baicalein, in which only inhibitory effect was observed. In order to reveal the cellular and molecular mechanism of how baicalin and baicalein affect angiogenesis, cell proliferation and programmed cell death assays were performed in treated CAM. In addition, quantitative PCR array including 84 angiogenesis related genes was used to detect high and low dosage of baicalin and baicalein responsive genes. Low dose baicalin increased cell proliferation in developing blood vessels through upregulation of multiple angiogenic genes expression, but high dose baicalin induced cell death, performing inhibitory effect on angiogenesis. Both high and low dose of baicalein down regulated the expression of multiple angiogenic genes, decreased cell proliferation, and leads to inhibitory effects on angiogenesis.	[Zhu, Dongqing; Wang, Shanshan; Lawless, John; Zheng, Zhengui] Southern Illinois Univ Carbondale, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; [Zhu, Dongqing] Jiangsu Food & Pharmaceut Sci Coll, Dept Pharm, Huaian, Jiangsu, Peoples R China; [He, Jianchen] Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Shanghai, Peoples R China	Southern Illinois University System; Southern Illinois University; Jiangsu Food & Pharmaceutical Science College; Shanghai University of Traditional Chinese Medicine	Zheng, ZG (corresponding author), Southern Illinois Univ Carbondale, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.; He, JC (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Shanghai, Peoples R China.	hejc@shutcm.edu.cn; zzheng@siu.edu		Zheng, Zhengui/0000-0003-0997-2976	School of Medicine at Southern Illinois University	School of Medicine at Southern Illinois University	ZZ was supported by the School of Medicine at Southern Illinois University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahnfelt-Ronne J, 2007, J HISTOCHEM CYTOCHEM, V55, P925, DOI 10.1369/jhc.7A7226.2007; Alanentalo T, 2007, NAT METHODS, V4, P31, DOI 10.1038/NMETH985; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Bai Y, 2014, CELL TISSUE RES, V356, P109, DOI 10.1007/s00441-013-1781-9; Bassino E, 2016, NAT PROD RES, V2, P1; Bisht M, 2010, INDIAN J PHARMACOL, V42, P2, DOI 10.4103/0253-7613.62395; Bochorakova H, 2003, PHYTOTHER RES, V17, P640, DOI 10.1002/ptr.1216; Bokhari AA, 2015, J CELL BIOCHEM, V116, P1797, DOI 10.1002/jcb.25138; Bonham M, 2005, CLIN CANCER RES, V11, P3905, DOI 10.1158/1078-0432.CCR-04-1974; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chan FL, 2000, CANCER LETT, V160, P219, DOI 10.1016/S0304-3835(00)00591-7; Chen JC, 2013, INT J MOL SCI, V14, P6012, DOI 10.3390/ijms14036012; Chen SS, 2012, DISCOV MED, V13, P7; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; Chong HC, 2014, MOL THER, V22, P1593, DOI 10.1038/mt.2014.102; Chung H, 2015, BIOCHEM BIOPH RES CO, V458, P707, DOI 10.1016/j.bbrc.2015.02.032; Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356; Cook KM, 2010, CA-CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075; Deveza L, 2012, THERANOSTICS, V2, P801, DOI 10.7150/thno.4419; El Sayed KA, 2005, MINI-REV MED CHEM, V5, P971, DOI 10.2174/138955705774575291; El-Kenawi AE, 2013, BRIT J PHARMACOL, V170, P712, DOI 10.1111/bph.12344; Fantin A, 2014, DEVELOPMENT, V141, P556, DOI 10.1242/dev.103028; Fogel JL, 2012, JOVE-J VIS EXP, DOI 10.3791/4254; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gao J, 2008, J PHARM PHARM SCI, V11, P77; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Gu YX, 2016, INSTRUM SCI TECHNOL, V44, P593, DOI 10.1080/10739149.2016.1177541; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hehlgans T, 2002, CANCER RES, V62, P4034; Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698; Huang Y, 2015, MOL CARCINOG; ISHIMARU K, 1995, PHYTOCHEMISTRY, V40, P279, DOI 10.1016/0031-9422(95)00200-Q; Jo H, 2015, BMB REP, V48, P271, DOI 10.5483/BMBRep.2015.48.5.131; Kee HJ, 2004, FEBS LETT, V569, P307, DOI 10.1016/j.febslet.2004.06.011; Kim EH, 2009, J ETHNOPHARMACOL, V126, P320, DOI 10.1016/j.jep.2009.08.027; Kren V, 2001, CURR MED CHEM, V8, P1303, DOI 10.2174/0929867013372193; Li GH, 2016, NEURAL REGEN RES, V11, P1015, DOI 10.4103/1673-5374.184506; Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005; Liu JJ, 2003, INT J CANCER, V106, P559, DOI 10.1002/ijc.11267; Liu W, 2015, BIOMED RES-INDIA, V26, P13; Logsdon EA, 2014, J CELL MOL MED, V18, P1491, DOI 10.1111/jcmm.12164; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Lu N, 2008, LIFE SCI, V82, P956, DOI 10.1016/j.lfs.2008.02.013; Miocinovic R, 2005, INT J ONCOL, V26, P241; Padwal M., 2016, NEPHROL DIAL TRANSPL; Reizis A, 2005, J EXP BIOL, V208, P2483, DOI 10.1242/jeb.01662; Ribatti D, 2008, ONCOL REP, V19, P1109; Rosing H, 2000, J LIQ CHROMATOGR R T, V23, P329, DOI 10.1081/JLC-100101455; Sagar S M, 2006, Curr Oncol, V13, P99; Sagar S M, 2006, Curr Oncol, V13, P14; Sato D, 2013, MOL CLIN ONCOL, V1, P105, DOI 10.3892/mco.2012.14; Scheck Adrienne C, 2006, BMC Complement Altern Med, V6, P27, DOI 10.1186/1472-6882-6-27; Seifert AW, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1020; Shang DD, 2015, ONCOL REP, V33, P2077, DOI 10.3892/or.2015.3786; Shang XF, 2010, J ETHNOPHARMACOL, V128, P279, DOI 10.1016/j.jep.2010.01.006; Shao ZH, 1999, J MOL CELL CARDIOL, V31, P1885, DOI 10.1006/jmcc.1999.1021; Silvestre JS, 2002, ARCH MAL COEUR VAISS, V95, P189; Soikkeli J, 2010, AM J PATHOL, V177, P387, DOI 10.2353/ajpath.2010.090748; Song XM, 2013, TOXICOL APPL PHARM, V271, P144, DOI 10.1016/j.taap.2013.04.031; Tang W, 2004, PHYTOMEDICINE, V11, P277, DOI 10.1078/0944711041495173; TPCoPR C, 2005, PHARMACOPOEIA PEOPLE; Tufan AC, 2005, CURR CANCER DRUG TAR, V5, P249, DOI 10.2174/1568009054064624; Vale PR, 2001, REV ESP CARDIOL, V54, P1210, DOI 10.1016/S0300-8932(01)76480-9; Waisundara VY, 2008, AM J CHINESE MED, V36, P517, DOI 10.1142/S0192415X08005953; Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200; Wang SS, 2004, LIFE SCI, V74, P2467, DOI 10.1016/j.lfs.2003.03.005; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yance DR, 2006, INTEGR CANCER THER, V5, P9, DOI 10.1177/1534735405285562; Yang Li-xin, 2002, Zhongguo Zhongyao Zazhi, V27, P166; Ye F, 2002, J ALTERN COMPLEM MED, V8, P567, DOI 10.1089/107555302320825075; Yin Hui-Fu, 2014, Zhongguo Zhong Yao Za Zhi, V39, P3757; Zhang KQ, 2011, CARDIOVASC RES, V89, P426, DOI 10.1093/cvr/cvq296; Zhang X, 2016, J ETHNOPHARMACOL, V186, P91, DOI 10.1016/j.jep.2016.03.057; Zheng ZG, 2015, P NATL ACAD SCI USA, V112, pE7194, DOI 10.1073/pnas.1515981112; Zhou M, 2014, VASC PHARMACOL, V60, P110, DOI 10.1016/j.vph.2014.01.010	76	23	27	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2016	11	11							e0167125	10.1371/journal.pone.0167125	http://dx.doi.org/10.1371/journal.pone.0167125			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FV	27902752	Green Submitted, Green Published, gold			2023-01-03	WOS:000389474100053
J	Weeks, A; Temmerman, M				Weeks, Andrew; Temmerman, Marleen			New WHO antenatal care model-quality worth paying for?	LANCET			English	Editorial Material									[Weeks, Andrew] Univ Liverpool, Dept Womens & Childrens Hlth, Sanyu Res Unit, Liverpool L69 3BX, Merseyside, England; [Weeks, Andrew] Liverpool Womens Hosp, Matern Div, Liverpool, Merseyside, England; [Temmerman, Marleen] Aga Khan Univ, Dept Obstet & Gynaecol, Nairobi, Kenya; [Temmerman, Marleen] Univ Ghent, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	University of Liverpool; University of Liverpool; Aga Khan University; Ghent University	Temmerman, M (corresponding author), Aga Khan Univ, Dept Obstet & Gynaecol, Nairobi, Kenya.; Temmerman, M (corresponding author), Univ Ghent, Fac Med & Hlth Sci, B-9000 Ghent, Belgium.	marleen.temmerman@aku.edu		Weeks, Andrew/0000-0002-1909-337X	MRC [G1100686, MR/M017990/1] Funding Source: UKRI; Medical Research Council [G1100686, MR/K007408/1, MR/M017990/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Dowswell T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub2; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; National Institute for Health and Clinical Excellence (NICE), 2008, ANT CAR UNC PREGN; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; WHO, 2022, WHO RECOMMENDATIONS; World Health Organization, 2001, WHO ANT CAR RAND TRI	6	7	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	2016	388	10060					2574	2575		10.1016/S0140-6736(16)32233-4	http://dx.doi.org/10.1016/S0140-6736(16)32233-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ED0EW	27894650				2023-01-03	WOS:000388516800009
J	Cui, MX; Wu, XY; Mao, JF; Wang, X; Nie, M				Cui, Mingxuan; Wu, Xueyan; Mao, Jiangfeng; Wang, Xi; Nie, Min			T2DM Self-Management via Smartphone Applications: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							MOBILE PHONE; HEALTH; CARE; INTERVENTIONS; ADULTS; USABILITY; EFFICACY; PROGRAM; INSULIN	Background Mobile health interventions (mHealth) based on smartphone applications (apps) are promising tools to help improve diabetes care and self-management; however, more evidence on the efficacy of mHealth in diabetes care is needed. The objective of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effect of mHealth apps on changes in hemoglobin A1c (HbA1c), blood glucose, blood pressure, serum lipids, and body weight in type 2 diabetes mellitus (T2DM) patients. Methods Two independent reviewers searched three online databases (PubMed, the Cochrane Library, and EMBASE) to identify relevant studies published between January 2005 and June 2016. Of the 2,596 articles retrieved, 13 RCTs were included. We used random effects model to estimate the pooled results. Results Thirteen studies were selected for the systematic review, six of which with data available containing 1,022 patients were included for the meta-analysis. There was a moderate effect on glycemic control after the mHealth app-based interventions. The overall effect on HbA1c shown as mean difference (MD) was -0.40% (-4.37 mmol/mol) (95% confidence interval [CI] -0.69 to -0.11% [-7.54 to -1.20 mmol/mol]; p = 0.007) and standardized mean differences (SMD) was -0.40% (-4.37 mmol/mol) (95% confidence interval [CI] -0.69 to -0.10% [-7.54 to -1.09 mmol/mol]; p = 0.008). A subgroup analysis showed a similar effect with -0.33% (-3.61 mmol/mol) (95% CI-0.59 to -0.06% [-6.45 to -0.66 mmol/mol]; p = 0.02) in MD and -0.38% (-4.15 mmol/mol) (95% CI -0.71 to -0.05% [-7.76 to -0.55 mmol/mol]; p = 0.02) in SMD in studies where patients' baseline HbA1c levels were less than 8.0%. No effects of mHealth app interventions were found on blood pressure, serum lipids, or weight. Assessment of overall study quality and publication bias demonstrated a low risk of bias among the six studies. Conclusions Smartphone apps offered moderate benefits for T2DM self-management. However, more research with valid study designs and longer follow-up is needed to evaluate the impact of mHealth apps for diabetes care and self-management.	[Nie, Min] Chinese Acad Med Sci, Dept Endocrinol, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing, Peoples R China; Natl Hlth & Family Planning Commiss, Key Lab Endocrine, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Nie, M (corresponding author), Chinese Acad Med Sci, Dept Endocrinol, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing, Peoples R China.	nm_pumch@aliyun.com			Project of National Natural Science Foundation of China [81070630, 81270879]; National Key Program of Clinical Science [WBYZ2011-873]	Project of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Program of Clinical Science	This study was supported by the research grants (to MN) from the Project of National Natural Science Foundation of China (No 81070630, 81270879) (www.nsfc.gov.cn) and National Key Program of Clinical Science (WBYZ2011-873). The funders had played a role in data collection and analysis and decision to publish.	Arnhold M, 2014, J MED INTERNET RES, V16, P34, DOI 10.2196/jmir.2968; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Costa BM, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-72; Devi BR, 2015, COMPUT METH PROG BIO, V122, P257, DOI 10.1016/j.cmpb.2015.08.003; E S RS I JA C A L A S, 2009, C P ANN INT C IEEE E; El-Gayar Omar, 2013, J Diabetes Sci Technol, V7, P247; Eng DS, 2013, PEDIATR DIABETES, V14, P231, DOI 10.1111/pedi.12034; Fery F, 2005, Rev Med Liege, V60, P361; Mateo GF, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4836; Geiss Linda S., 2012, Morbidity and Mortality Weekly Report, V61, P918; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Hirsch IB, 2008, DIABETES TECHNOL THE, V10, P419, DOI 10.1089/dia.2008.0104; Holmen H, 2014, DIABETES TECHNOLOGY, V18, pS58; Hsu WC, 2016, DIABETES TECHNOL THE, V18, P59, DOI 10.1089/dia.2015.0160; Humble James R T EAR, 2015, J TELEMED TELECARE O; I RS Z K H D M N S A T B, 2009, J TELEMED TELECARE; Karhula T, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4059; Liang X, 2011, DIABETIC MED, V28, P455, DOI 10.1111/j.1464-5491.2010.03180.x; Lyles CR, 2011, DIABETES TECHNOL THE, V13, P563, DOI 10.1089/dia.2010.0200; Marcolino MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079246; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moncrieft AE, 2016, PSYCHOSOM MED; Mulvaney SA, 2011, CURR DIABETES REP, V11, P486, DOI 10.1007/s11892-011-0230-y; Nour M, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5082; Orsama AL, 2013, DIABETES TECHNOL THE, V15, P662, DOI 10.1089/dia.2013.0056; Pal K, 2014, DIABETES CARE, V37, P1759, DOI 10.2337/dc13-1386; Pludwinski S, 2015, J TELEMED TELECARE; Polidori D, 2016, DIABETES OBES METAB, V18, P348, DOI 10.1111/dom.12615; Q CC C SS M JM L D O MC G A, 2008, DIABETES TECHNOL THE; Q CC S MD T ML B EA B SH G AL, 2011, DIABETES TECHNOL S1; Q CC S PL S ML T ML B EA G AL, 2014, J DIABETES SCI TECHN; Rodri Guez-Idi Goras Mari A I SJ, 2009, TELEMEDICINE INFLUEN, DOI [10.1089/dia.2008.0114, DOI 10.1089/DIA.2008.0114]; Shea S, 2006, J AM MED INFORM ASSN, V13, P40, DOI 10.1197/jamia.M1917; van der Weegen S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4579; Welch G, 2015, TELEMED E-HEALTH, V21, P395, DOI 10.1089/tmj.2014.0069; Wesley KM, 2015, ADOLESC HEALTH MED T, V6, P141, DOI 10.2147/AHMT.S69209; Whitehead LC, 2016, J EVAL CLIN PRACT; Wiley F, 2016, DIABETES SELF MANAG, V33, P42; Wiley F, 2016, DIABETES SELF MANAG, V33, P37; Wiley F, 2016, DIABETES SELF MANAG, V33, P39; Wiley Frieda, 2016, Diabetes Self Manag, V33, P42; Y HJ P MS K TN Y SJ C GJ H TG, 2009, DIABETIC MED J BRIT	42	111	117	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							e0166718	10.1371/journal.pone.0166718	http://dx.doi.org/10.1371/journal.pone.0166718			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EC7WC	27861583	gold, Green Published, Green Submitted			2023-01-03	WOS:000388350300095
J	Kruger, J; Meffert, PJ; Vogt, LJ; Gartner, S; Steveling, A; Kraft, M; Mayerle, J; Lerch, MM; Aghdassi, AA				Kruger, Janine; Meffert, Peter J.; Vogt, Lena J.; Gartner, Simone; Steveling, Antje; Kraft, Matthias; Mayerle, Julia; Lerch, Markus M.; Aghdassi, Ali A.			Early Parenteral Nutrition in Patients with Biliopancreatic Mass Lesions, a Prospective, Randomized Intervention Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; BIOELECTRICAL-IMPEDANCE ANALYSIS; ADVANCED PANCREATIC-CANCER; CACHEXIA; SUPPLEMENTATION; CHEMOTHERAPY; OUTCOMES; SUPPORT	Purpose Patients with biliopancreatic tumors frequently suffer from weight loss and cachexia. The in-hospital work-up to differentiate between benign and malignant biliopancreatic lesions requires repeated pre-interventional fasting periods that can aggravate this problem. We conducted a randomized intervention study to test whether routine in-hospital peripheral intravenous nutrition on fasting days (1000 ml/24 h, 700 kcal) has a beneficial effect on body weight and body composition. Material and Methods 168 patients were screened and 100 enrolled in the trial, all undergoing in-hospital work-up for biliopancreatic mass lesions and randomized to either intravenous nutrition or control. Primary endpoint was weight loss at time of hospital discharge; secondary endpoints were parameters determined by bioelectric impedance analysis and quality of life recorded by the EORTC questionnaire. Results Within three months prior to hospital admission patients had a median self-reported loss of 4.0 kg (25*th: -10.0 kg and 75*th* percentile: 0.0kg) of body weight. On a multivariate analysis nutritional intervention increased body weight by 1.7 kg (95% CI: 0.204; 3.210, p = 0.027), particularly in patients with malignant lesions (2.7 kg (95% CI: 0.71; 4.76, p < 0.01). Conclusions In a hospital setting, patients with suspected biliopancreatic mass lesions stabilized their body weight when receiving parenteral nutrition in fasting periods even when no total parenteral nutrition was required. Analysis showed that this effect was greatest in patients with malignant tumors. Further studies will be necessary to see whether patient outcome is affected as well.	[Kruger, Janine; Vogt, Lena J.; Gartner, Simone; Steveling, Antje; Mayerle, Julia; Lerch, Markus M.; Aghdassi, Ali A.] Univ Med Greifswald, Dept Med A, Greifswald, Germany; [Meffert, Peter J.] Univ Med Greifswald, Inst Community Med, Greifswald, Germany; [Kraft, Matthias] Cts Vinzentius Krankenhaus, Landau, Germany	Greifswald Medical School; Greifswald Medical School	Lerch, MM (corresponding author), Univ Med Greifswald, Dept Med A, Greifswald, Germany.	lerch@uni-greitswald.de	Mayerle, Julia/W-7907-2019; Lerch, Markus M./E-2206-2016; Aghdassi, Ali/X-5836-2019	Lerch, Markus M./0000-0002-9643-8263; Aghdassi, Ali/0000-0002-0569-7316; Mayerle, Julia/0000-0002-3666-6459	Baxter Deutschland GmbH (Unterschleissheim, Germany); Medinal GmbH (Greven, Germany); Nutricia GmbH (Erlangen, Germany)	Baxter Deutschland GmbH (Unterschleissheim, Germany); Medinal GmbH (Greven, Germany); Nutricia GmbH (Erlangen, Germany)	JK and LJV received a Gerhard Domagk scholarship from University Medicine Greifswald made possible through an unrestricted educational grant from Baxter Deutschland GmbH (Unterschleissheim, Germany), Medinal GmbH (Greven, Germany) and Nutricia GmbH (Erlangen, Germany).	Andersson R, 2000, NUTR ASPECTS MANAGEM, V13, P221; [Anonymous], 2001, EORTC QLQ C30 SCOR M, P30; Bachmann J, 2008, J GASTROINTEST SURG, V12, P1193, DOI 10.1007/s11605-008-0505-z; Bachmann Jeannine, 2009, BMC Cancer, V9, P255, DOI 10.1186/1471-2407-9-255; Bauer JD, 2005, SUPPORT CARE CANCER, V13, P270, DOI 10.1007/s00520-004-0746-7; Bozzetti F, 2009, CLIN NUTR, V28, P445, DOI 10.1016/j.clnu.2009.04.011; Braga M A, 2009, CLIN NUTR, V28, P461; Chari ST, 2015, PANCREAS, V44, P693, DOI 10.1097/MPA.0000000000000368; Davidson W, 2004, CLIN NUTR, V23, P239, DOI 10.1016/j.clnu.2003.07.001; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; Di Sebastiano KM, 2013, ACCELERATED MUSCLE A, P302; Fazal S, 2007, J PANCREAS, V8, P240; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Fearon KCH, 2010, HPB, V12, P323, DOI 10.1111/j.1477-2574.2010.00178.x; Ferreira IM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000998.pub3; Ferrucci LM, 2011, SUPPORT CARE CANCER, V19, P1729, DOI 10.1007/s00520-010-1011-x; Girke J, 2016, NUTR CLIN PRACT; GRESS TM, 1994, Z GASTROENTEROL, V32, P221; Hasenberg T, 2010, COLORECTAL DIS, V12, pE190, DOI 10.1111/j.1463-1318.2009.02111.x; Keim V, 2001, AM J MED, V111, P622, DOI 10.1016/S0002-9343(01)00958-5; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; Kraft M, 2012, DEV TELEMEDICAL MONI, V72, P126; Kraft M, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-52; Kristina Norman, 2012, CLIN NUTR, V31, P854, DOI [10.1016/j.clnu.2012.05.008, DOI 10.1016/J.CLNU.2012.05.008]; Kyle UG, 2005, CLIN NUTR, V24, P133, DOI 10.1016/j.clnu.2004.08.012; Kyle UG, 2004, CLIN NUTR, V23, P1430, DOI 10.1016/j.clnu.2004.09.012; Kyle UG, 2004, CLIN NUTR, V23, P1226, DOI 10.1016/j.clnu.2004.06.004; Mueller TC, 2014, WORLD J GASTROENTERO, V20, P9361, DOI 10.3748/wjg.v20.i28.9361; Pelzer U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-86; Poulsen GM, 2014, CLIN NUTR, V33, P749, DOI 10.1016/j.clnu.2013.10.019; Reissfelder C, 2007, CHIRURG, V78, P1059, DOI 10.1007/s00104-007-1412-7; Richter E, 2012, ANTICANCER RES, V32, P2111; Royston P, 2008, MULTIVARIABLE MODEL, P172; Rutenacht U, 2010, NUTR COUNSELING IMPR; Seufferlein T, 2013, Z GASTROENTEROL, V51, P1395, DOI 10.1055/s-0033-1356220; Shang E, 2006, JPEN-PARENTER ENTER, V30, P222, DOI 10.1177/0148607106030003222; Sharma C, 2011, WORLD J GASTROENTERO, V17, P867, DOI 10.3748/wjg.v17.i7.867; Tan CR, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00088; Teich N, 2010, PANCREAS, V39, P1088, DOI 10.1097/MPA.0b013e3181d3ce05; Uomo G, 2006, J PANCREAS, V7, P157; Uster A, 2013, NUTRITION, V29, P1342, DOI 10.1016/j.nut.2013.05.004; Vashi PG, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-593; Wallengren O, 2015, SUPPORT CARE CANCER, V23, P79, DOI 10.1007/s00520-014-2332-y; Wigmore SJ, 2000, BRIT J SURG, V87, P53, DOI 10.1046/j.1365-2168.2000.01317.x	44	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							e0166513	10.1371/journal.pone.0166513	http://dx.doi.org/10.1371/journal.pone.0166513			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC7WC	27861546	Green Published, Green Submitted, gold			2023-01-03	WOS:000388350300066
J	Miller, G				Miller, Greg			POT AND PAIN	SCIENCE			English	Editorial Material																			0	7	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2016	354	6312					566	568		10.1126/science.354.6312.566	http://dx.doi.org/10.1126/science.354.6312.566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EA8FD	27811265				2023-01-03	WOS:000386869800034
J	Ritch, CR; Cookson, MS				Ritch, Chad R.; Cookson, Michael S.			Advances in the management of castration resistant prostate cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANDROGEN-DEPRIVATION THERAPY; PLACEBO PLUS PREDNISONE; QUALITY-OF-LIFE; DOUBLE-BLIND; ABIRATERONE ACETATE; ANTIANDROGEN WITHDRAWAL; OPEN-LABEL; INCREASED SURVIVAL; CONTROLLED-TRIAL; ANTIGEN DECLINE	Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel-T), bone seeking radionuclides (radium-223), and second line chemotherapy (cabazitaxel). In addition, new agents have been developed to reduce skeletal related events (denosumab). Given that docetaxel was the standard first line treatment for metastatic CRPC, the newer oral agents that affect the androgen axis were initially approved in the post-docetaxel setting. However, subsequent randomized trials have led to their approval in the pre-chemotherapy setting as well. Patients with CRPC are clinically heterogeneous, ranging from patients who are asymptomatic and do not have metastases to those with substantial symptoms and both bony and visceral metastases. CRPC is a clinically challenging disease entity, therefore, with a wide array of treatment options and multiple possible sequencing combinations depending on the individual patient. This review will summarize the findings of the randomized trials that led to the approval of the therapies for CRPC. It will also discuss recent guidelines and provide suggestions for sequencing of drugs based on the best available evidence. Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel-T), bone seeking radionuclides (radium-223), and second line chemotherapy (cabazitaxel). In addition, new agents have been developed to reduce skeletal related events (denosumab). Given that docetaxel was the standard first line treatment for metastatic CRPC, the newer oral agents that affect the androgen axis were initially approved in the post-docetaxel setting. However, subsequent randomized trials have led to their approval in the pre-chemotherapy setting as well. Patients with CRPC are clinically heterogeneous, ranging from patients who are asymptomatic and do not have metastases to those with substantial symptoms and both bony and visceral metastases. CRPC is a clinically challenging disease entity, therefore, with a wide array of treatment options and multiple possible sequencing combinations depending on the individual patient. This review will summarize the findings of the randomized trials that led to the approval of the therapies for CRPC. It will also discuss recent guidelines and provide suggestions for sequencing of drugs based on the best available evidence.	[Ritch, Chad R.] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA; [Cookson, Michael S.] Univ Oklahoma, Coll Med, Dept Urol, Oklahoma City, OK 73190 USA; [Cookson, Michael S.] Stephenson Canc Ctr, Oklahoma City, OK 73104 USA	University of Miami; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Cookson, MS (corresponding author), Univ Oklahoma, Coll Med, Dept Urol, Oklahoma City, OK 73190 USA.; Cookson, MS (corresponding author), Stephenson Canc Ctr, Oklahoma City, OK 73104 USA.	michael-cookson@ouhsc.edu						Alemayehu B, 2010, J Med Econ, V13, P351, DOI 10.3111/13696998.2010.491435; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Azad AA, 2015, EUR UROL, V67, P441, DOI 10.1016/j.eururo.2014.01.030; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Cella D, 2015, ANN ONCOL, V26, P179, DOI 10.1093/annonc/mdu510; Chu FM, 2015, EUR J CANCER, V51, P1555, DOI 10.1016/j.ejca.2015.04.028; Cookson MS, 2015, J UROLOGY, V193, P491, DOI 10.1016/j.juro.2014.10.104; Cookson MS, 2013, J UROLOGY, V190, P429, DOI 10.1016/j.juro.2013.05.005; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Di Lorenzo G, 2011, BJU INT, V107, P234, DOI 10.1111/j.1464-410X.2010.09498.x; Fay AP, 2015, EXPERT REV ANTICANC, V15, P151, DOI 10.1586/14737140.2015.1003047; Fizazi K, 2015, J CLIN ONCOL, V33, P723, DOI 10.1200/JCO.2014.56.5119; Fizazi K, 2014, LANCET ONCOL, V15, P1147, DOI 10.1016/S1470-2045(14)70303-1; Fizazi K, 2014, LANCET ONCOL, V15, P975, DOI 10.1016/S1470-2045(14)70240-2; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Garcia JA, 2012, CANCER-AM CANCER SOC, V118, P2583, DOI 10.1002/cncr.26582; Gartrell BA, 2014, EUR UROL, V65, P278, DOI 10.1016/j.eururo.2013.05.015; Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257; Gomella LG, 1997, J UROLOGY, V157, P1366, DOI 10.1016/S0022-5347(01)64984-X; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hirst CJ, 2012, CANCER EPIDEMIOL, V36, pE349, DOI 10.1016/j.canep.2012.07.012; Hoskin P, 2014, LANCET ONCOL, V15, P1397, DOI 10.1016/S1470-2045(14)70474-7; Hoy SM, 2013, DRUGS, V73, P2077, DOI 10.1007/s40265-013-0150-z; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; Joyce R, 1998, J UROLOGY, V159, P149, DOI 10.1016/S0022-5347(01)64039-4; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kassouf W, 2003, J UROLOGY, V169, P1742, DOI 10.1097/01.ju.0000057795.97626.66; Keizman D, 2012, PROSTATE, V72, P461, DOI 10.1002/pros.21447; KELLY WK, 1993, J UROLOGY, V149, P607; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Klotz L, 2014, PROSTATE CANCER P D, V17, P320, DOI 10.1038/pcan.2014.24; Kojima S, 2004, J UROLOGY, V171, P679, DOI 10.1097/01.ju.0000106190.32540.6c; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470-2045(12)70473-4; Lorente D, 2015, LANCET ONCOL, V16, pE279, DOI 10.1016/S1470-2045(15)70033-1; Marques RB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013500; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mohler JL, 2016, J NATL COMPR CANC NE, V14, P19, DOI 10.6004/jnccn.2016.0004; Noonan KL, 2013, ANN ONCOL, V24, P1802, DOI 10.1093/annonc/mdt138; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Omlin A, 2013, EUR UROL, V64, P300, DOI 10.1016/j.eururo.2012.12.029; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Patrikidou A, 2014, PROSTATE CANCER P D, V17, P348, DOI 10.1038/pcan.2014.35; Penson DF, 2016, J CLIN ONCOL, V34, P2098, DOI 10.1200/JCO.2015.64.9285; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pia A, 2013, CANCER TREAT REV, V39, P966, DOI 10.1016/j.ctrv.2013.03.003; Podrazil M, 2015, ONCOTARGET, V6, P18192, DOI 10.18632/oncotarget.4145; Romanel A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9511; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Sartor AO, 2008, CANCER-AM CANCER SOC, V112, P2393, DOI 10.1002/cncr.23473; Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034; Sartor Oliver, 2004, Rev Urol, V6 Suppl 10, pS3; Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994; Schellhammer PF, 2013, UROLOGY, V81, P1297, DOI 10.1016/j.urology.2013.01.061; Scher HI, 1997, J CLIN ONCOL, V15, P2928, DOI 10.1200/JCO.1997.15.8.2928; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Scher HI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139440; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Scholz M, 2005, J UROLOGY, V173, P1947, DOI 10.1097/01.ju.0000158449.83022.40; Shore ND, 2016, LANCET ONCOL, V17, P153, DOI 10.1016/S1470-2045(15)00518-5; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SMALL EJ, 1994, UROLOGY, V43, P408, DOI 10.1016/0090-4295(94)90092-2; Smith MR, 2014, J CLIN ONCOL, V32, P3391, DOI 10.1200/JCO.2013.54.5954; Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003; Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529; Smith MR, 2016, EUR UROL; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taplin ME, 2009, CLIN CANCER RES, V15, P7099, DOI 10.1158/1078-0432.CCR-09-1722; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Yoshimura K, 2016, EUR UROL, V70, P35, DOI 10.1016/j.eururo.2015.12.050; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	80	56	57	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	2016	355								i4405	10.1136/bmj.i4405	http://dx.doi.org/10.1136/bmj.i4405			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ8KK	27754846				2023-01-03	WOS:000386119100001
J	Moler, FW; Silverstein, FS; Holubkov, R; Slomine, BS; Christensen, JR; Nadkarni, VM; Meert, KL; Browning, B; Pemberton, VL; Page, K; Gildea, MR; Scholefield, BR; Shankaran, S; Hutchison, JS; Berger, JT; Ofori-Amanfo, G; Newth, CJL; Topjian, A; Bennett, KS; Koch, JD; Pham, N; Chanani, NK; Pineda, JA; Harrison, R; Dalton, HJ; Alten, J; Schleien, CL; Goodman, DM; Zimmerman, JJ; Bhalala, US; Schwarz, AJ; Porter, MB; Shah, S; Fink, EL; McQuillen, P; Wu, T; Skellett, S; Thomas, NJ; Nowak, JE; Baines, PB; Pappachan, J; Mathur, M; Lloyd, E; van der Jagt, EW; Dobyns, EL; Meyer, MT; Sanders, RC; Clark, AE; Dean, JM				Moler, F. W.; Silverstein, F. S.; Holubkov, R.; Slomine, B. S.; Christensen, J. R.; Nadkarni, V. M.; Meert, K. L.; Browning, B.; Pemberton, V. L.; Page, K.; Gildea, M. R.; Scholefield, B. R.; Shankaran, S.; Hutchison, J. S.; Berger, J. T.; Ofori-Amanfo, G.; Newth, C. J. L.; Topjian, A.; Bennett, K. S.; Koch, J. D.; Pham, N.; Chanani, N. K.; Pineda, J. A.; Harrison, R.; Dalton, H. J.; Alten, J.; Schleien, C. L.; Goodman, D. M.; Zimmerman, J. J.; Bhalala, U. S.; Schwarz, A. J.; Porter, M. B.; Shah, S.; Fink, E. L.; McQuillen, P.; Wu, T.; Skellett, S.; Thomas, N. J.; Nowak, J. E.; Baines, P. B.; Pappachan, J.; Mathur, M.; Lloyd, E.; van der Jagt, E. W.; Dobyns, E. L.; Meyer, M. T.; Sanders, R. C., Jr.; Clark, A. E.; Dean, J. M.		THAPCA Trial Investigators	Therapeutic Hypothermia after In-Hospital Cardiac Arrest in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; GUIDELINES UPDATE; CARE; EXPERIENCE; HYPERTHERMIA; SURVIVAL	BACKGROUND Targeted temperature management is recommended for comatose adults and children after out-of-hospital cardiac arrest; however, data on temperature management after in-hospital cardiac arrest are limited. METHODS In a trial conducted at 37 children's hospitals, we compared two temperature interventions in children who had had in-hospital cardiac arrest. Within 6 hours after the return of circulation, comatose children older than 48 hours and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degrees C) or therapeutic normothermia (target temperature, 36.8 degrees C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a score of 70 or higher on the Vineland Adaptive Behavior Scales, second edition (VABS-II, on which scores range from 20 to 160, with higher scores indicating better function), was evaluated among patients who had had a VABS-II score of at least 70 before the cardiac arrest. RESULTS The trial was terminated because of futility after 329 patients had undergone randomization. Among the 257 patients who had a VABS-II score of at least 70 before cardiac arrest and who could be evaluated, the rate of the primary efficacy outcome did not differ significantly between the hypothermia group and the normothermia group (36% [48 of 133 patients] and 39% [48 of 124 patients], respectively; relative risk, 0.92; 95% confidence interval [CI], 0.67 to 1.27; P=0.63). Among 317 patients who could be evaluated for change in neurobehavioral function, the change in VABS-II score from baseline to 12 months did not differ significantly between the groups (P = 0.70). Among 327 patients who could be evaluated for 1-year survival, the rate of 1-year survival did not differ significantly between the hypothermia group and the normothermia group (49% [81 of 166 patients] and 46% [74 of 161 patients], respectively; relative risk, 1.07; 95% CI, 0.85 to 1.34; P = 0.56). The incidences of blood-product use, infection, and serious adverse events, as well as 28-day mortality, did not differ significantly between groups. CONCLUSIONS Among comatose children who survived in-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in survival with a favorable functional outcome at 1 year. (Funded by the National Heart, Lung, and Blood Institute; THAPCA-IH ClinicalTrials.gov number, NCT00880087.)	[Moler, F. W.; Silverstein, F. S.] Univ Michigan, Ann Arbor, MI 48109 USA; [Meert, K. L.; Shankaran, S.] Wayne State Univ, Detroit, MI USA; [Holubkov, R.; Browning, B.; Page, K.; Gildea, M. R.; Bennett, K. S.; Clark, A. E.; Dean, J. M.] Univ Utah, Salt Lake City, UT USA; [Slomine, B. S.; Christensen, J. R.] Kennedy Krieger Inst, Baltimore, MD USA; [Slomine, B. S.; Christensen, J. R.] Johns Hopkins Univ, Baltimore, MD USA; [Bhalala, U. S.] Johns Hopkins Childrens Ctr, Baltimore, MD USA; [Pemberton, V. L.] NHLBI, Bldg 10, Bethesda, MD 20892 USA; [Nadkarni, V. M.; Topjian, A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Fink, E. L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Thomas, N. J.] Penn State Childrens Hosp, Hershey, PA USA; [Scholefield, B. R.] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Skellett, S.] Great Ormond St Hosp Sick Children, London, England; [Baines, P. B.] Alder Hey Childrens Hosp, Liverpool, Merseyside, England; [Pappachan, J.] Southampton Univ Hosp, Southampton, Hants, England; [Hutchison, J. S.] Hosp Sick Children, Toronto, ON, Canada; [Berger, J. T.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Ofori-Amanfo, G.] Duke Childrens Hosp, Durham, NC USA; [Newth, C. J. L.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Harrison, R.] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA; [Schwarz, A. J.] Childrens Hosp Orange Cty, Orange, CA 92668 USA; [McQuillen, P.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Mathur, M.] Loma Linda Univ, Childrens Hosp, Loma Linda, CA 92350 USA; [Koch, J. D.] Univ Texas Southwestern Med Sch, Childrens Med Ctr Dallas, Dallas, TX USA; [Wu, T.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Pham, N.; Chanani, N. K.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Pineda, J. A.] Washington Univ, St Louis, MO USA; [Dalton, H. J.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Alten, J.] Childrens Hosp Alabama, Birmingham, AL USA; [Schleien, C. L.] Columbia Univ, Childrens Hosp New York, Med Ctr, New York, NY USA; [van der Jagt, E. W.] Univ Rochester, Med Ctr, Golisano Childrens Hosp, Rochester, NY 14642 USA; [Goodman, D. M.] Robert Lurie Childrens Hosp Chicago, Chicago, IL USA; [Zimmerman, J. J.] Seattle Childrens Hosp, Seattle, WA USA; [Porter, M. B.] Univ Louisville, Kosair Childrens Hosp, Louisville, KY 40292 USA; [Shah, S.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Nowak, J. E.] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Lloyd, E.] Nationwide Childrens Hosp, Columbus, OH USA; [Dobyns, E. L.] Childrens Hosp Colorado, Aurora, CO USA; [Meyer, M. T.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Sanders, R. C., Jr.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA	University of Michigan System; University of Michigan; Wayne State University; Utah System of Higher Education; University of Utah; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Birmingham; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Southampton; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's National Health System; Duke University; Children's Hospital Los Angeles; University of California System; University of California Los Angeles; Childrens Hospital of Orange County; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Loma Linda University; University of Texas System; University of Texas Health San Antonio; Children's Healthcare of Atlanta (CHOA); Washington University (WUSTL); Phoenix Children's Hospital; Columbia University; University of Rochester; Ann & Robert H. Lurie Children's Hospital of Chicago; Seattle Children's Hospital; University of Louisville; University of Tennessee System; University of Tennessee Health Science Center; Children's Hospitals & Clinics of Minnesota; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Children's Hospital Colorado; Medical College of Wisconsin; Arkansas Children's Hospital	Moler, FW (corresponding author), Univ Michigan Hlth Syst, F-6900 UH S,SPF 5243,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	fmoler@umich.edu	Pineda, Jose/W-2806-2019; Curley, Martha A/F-3579-2016; Gazit, Avihu Z./J-4439-2019; McQuillen, Patrick/AAF-7119-2020; Skellett, Sophie/AAF-5538-2020; Fink, Ericka/AAU-9792-2021; Scholefield, Barney/ABG-7312-2021	Curley, Martha A/0000-0001-5228-6694; McQuillen, Patrick/0000-0002-8837-364X; Goodman, Denise/0000-0001-9766-9453; Shankaran, Seetha/0000-0001-5512-9571; Scholefield, Barney/0000-0002-6198-4985; Pappachan, John/0000-0002-3559-0595; Gazit, Avihu/0000-0002-6211-2636	National Heart, Lung, and Blood Institute [HL094345, HL094339]; THAPCA trials [HD044955, HD050531]; Pediatric Emergency Care Applied Research Network [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]; Collaborative Pediatric Critical Care Research Network [U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, U01HD049934]; National Emergency Medical Services for Children Data Analysis Resource Center Demonstration grant [U07MC09174];  [UL1RR024986];  [UL1TR000433];  [U54HD087011];  [UL1TR000003];  [P30HD040677]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD049934, U54HD079123, U10HD050096, U10HD049981, U10HD050012, UG1HD050096, P30HD040677, U54HD087011, U10HD049983] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD049945, R21HD044955, R34HD050531, U10HD050009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003, UL1TR000433, UL1TR001878, UL1TR001422] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024986] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL094345, U10HL109741, U01HL094339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS075363] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); THAPCA trials; Pediatric Emergency Care Applied Research Network; Collaborative Pediatric Critical Care Research Network; National Emergency Medical Services for Children Data Analysis Resource Center Demonstration grant; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from the National Heart, Lung, and Blood Institute (HL094345, to Dr. Moler; and HL094339, to Dr. Dean), federal planning grants for the planning of the THAPCA trials (HD044955 and HD050531, both to Dr. Moler), cooperative agreements from the Pediatric Emergency Care Applied Research Network (U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008) and the Collaborative Pediatric Critical Care Research Network (U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012 and U01HD049934), and a National Emergency Medical Services for Children Data Analysis Resource Center Demonstration grant (U07MC09174). Several centers were supported by supplemental grants or cooperative agreements (UL1RR024986, UL1TR000433, U54HD087011, UL1TR000003, and P30HD040677).	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; *AM GUID SERV, 1995, MULL SCAL EARL LEARN; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Chan PS, 2016, JAMA-J AM MED ASSOC, V316, P1375, DOI 10.1001/jama.2016.14380; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; de Caen AR, 2015, CIRCULATION, V132, pS526, DOI 10.1161/CIR.0000000000000266; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Field D, 2013, PEDIATRICS, V132, pE1247, DOI 10.1542/peds.2013-1754; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Girotra S, 2013, CIRC-CARDIOVASC QUAL, V6, P42, DOI 10.1161/CIRCOUTCOMES.112.967968; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holubkov R, 2015, PEDIATR CRIT CARE ME, V16, P1, DOI 10.1097/PCC.0000000000000272; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Laptook AR, 2013, ANN NEUROL, V73, P520, DOI 10.1002/ana.23843; Marshall LF, 2001, J NEUROSURG, V95, P733, DOI 10.3171/jns.2001.95.5.0733; Meert KL, 2009, PEDIATR CRIT CARE ME, V10, P544, DOI 10.1097/PCC.0b013e3181a7045c; Moler FW, 2015, NEW ENGL J MED, V372, P1898, DOI 10.1056/NEJMoa1411480; Moler FW, 2013, PEDIATR CRIT CARE ME, V14, pE304, DOI 10.1097/PCC.0b013e31828a863a; Moler FW, 2011, CRIT CARE MED, V39, P141, DOI 10.1097/CCM.0b013e3181fa3c17; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Pemberton VL, 2013, PEDIATR CRIT CARE ME, V14, P19, DOI 10.1097/PCC.0b013e31825b860b; Psychological Corporation, 1999, WECHSLER ABBREVIATED; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Sparrow S. S., 2005, VINELAND ADAPTIVE BE, DOI [10.1037/t15164-000, DOI 10.1037/T15164-000]; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	40	162	169	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2017	376	4					318	329		10.1056/NEJMoa1610493	http://dx.doi.org/10.1056/NEJMoa1610493			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ3KR	28118559	Green Accepted, Green Published			2023-01-03	WOS:000393111600007
J	Cortegiani, A; Russotto, V; Montalto, F; Lozzo, P; Meschis, R; Pugliesi, M; Mariano, D; Benenati, V; Raineri, SM; Gregoretti, C; Giarratano, A				Cortegiani, Andrea; Russotto, Vincenzo; Montalto, Francesca; Lozzo, Pasquale; Meschis, Roberta; Pugliesi, Marinella; Mariano, Dario; Benenati, Vincenzo; Raineri, Santi Maurizio; Gregoretti, Cesare; Giarratano, Antonino			Use of a Real-Time Training Software (Laerdal QCPR (R)) Compared to Instructor-Based Feedback for High-Quality Chest Compressions Acquisition in Secondary School Students: A Randomized Trial	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION QUALITY; HOSPITAL CARDIAC-ARREST; BASIC LIFE-SUPPORT; AUDIOVISUAL FEEDBACK; EUROPEAN RESUSCITATION; COUNCIL GUIDELINES; CPR; IMPROVEMENT; SURVIVAL; DEVICE	High-quality chest compressions are pivotal to improve survival from cardiac arrest. Basic life support training of school students is an international priority. The aim of this trial was to assess the effectiveness of a real-time training software (Laerdal QCPR (R)) compared to a standard instructor-based feedback for chest compressions acquisition in secondary school students. After an interactive frontal lesson about basic life support and high quality chest compressions, 144 students were randomized to two types of chest compressions training: 1) using Laerdal QCPR (R) (QCPR group- 72 students) for real-time feedback during chest compressions with the guide of an instructor who considered software data for students' correction 2) based on standard instructor-based feedback (SF group- 72 students). Both groups had a minimum of a 2-minute chest compressions training session. Students were required to reach a minimum technical skill level before the evaluation. We evaluated all students at 7 days from the training with a 2-minute chest compressions session. The primary outcome was the compression score, which is an overall measure of chest compressions quality calculated by the software expressed as percentage. 125 students were present at the evaluation session (60 from QCPR group and 65 from SF group). Students in QCPR group had a significantly higher compression score (median 90%, IQR 81.9-96.0) compared to SF group (median 67%, IQR 27.7-87.5), p = 0.0003. Students in QCPR group performed significantly higher percentage of fully released chest compressions (71% [IQR 24.5-99.0] vs 24% [IQR 2.5-88.2]; p = 0.005) and better chest compression rate (117.5/min [IQR 106-123.5] vs 125/min [115-135.2]; p = 0.001). In secondary school students, a training for chest compressions based on a real-time feedback software (Laerdal QCPR (R)) guided by an instructor is superior to instructor-based feedback training in terms of chest compression technical skill acquisition.	[Cortegiani, Andrea; Russotto, Vincenzo; Montalto, Francesca; Lozzo, Pasquale; Meschis, Roberta; Pugliesi, Marinella; Mariano, Dario; Benenati, Vincenzo; Raineri, Santi Maurizio; Gregoretti, Cesare; Giarratano, Antonino] Univ Palermo, Policlin P Giaccone, Dept Biopathol & Med Biotechnol,DIBIMED, Sect Anesthesia Analgesia Intens Care & Emergency, Palermo, Italy	University of Palermo	Cortegiani, A (corresponding author), Univ Palermo, Policlin P Giaccone, Dept Biopathol & Med Biotechnol,DIBIMED, Sect Anesthesia Analgesia Intens Care & Emergency, Palermo, Italy.	cortegiania@gmail.com	Russotto, Vincenzo/AAC-2388-2022; Cortegiani, Andrea/H-4902-2016; Russotto, Vincenzo/AAM-3265-2020	Cortegiani, Andrea/0000-0003-1416-9993; Russotto, Vincenzo/0000-0003-1411-9099				Abella BS, 2007, RESUSCITATION, V73, P54, DOI 10.1016/j.resuscitation.2006.10.027; Abella BS, 2016, CURR OPIN CRIT CARE, V22, P218, DOI 10.1097/MCC.0000000000000296; Abella BS, 2013, CURR OPIN CRIT CARE, V19, P175, DOI 10.1097/MCC.0b013e328360ac76; [Anonymous], 2015, RESUSCITATION, V94, pA5, DOI 10.1016/j.resuscitation.2015.07.005; Bobrow BJ, 2013, ANN EMERG MED, V62, P47, DOI 10.1016/j.annemergmed.2012.12.020; Bohn A, 2012, RESUSCITATION, V83, P619, DOI 10.1016/j.resuscitation.2012.01.020; Colquhoun M, 2012, RESUSCITATION, V83, P543, DOI 10.1016/j.resuscitation.2012.03.004; Cortegiani A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125685; Couper K, 2015, CRIT CARE MED, V43, P2321, DOI 10.1097/CCM.0000000000001202; Edelson DP, 2006, RESUSCITATION, V71, P137, DOI 10.1016/j.resuscitation.2006.04.008; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Gonzalez-Salvado V, 2016, AM J EMERG MED, V34, P993, DOI 10.1016/j.ajem.2016.02.047; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; Hostler David, 2011, BMJ, V342, pd512, DOI 10.1136/bmj.d512; Idris AH, 2012, CIRCULATION, V125, P3004, DOI 10.1161/CIRCULATIONAHA.111.059535; Kirkbright S, 2014, RESUSCITATION, V85, P460, DOI 10.1016/j.resuscitation.2013.12.012; Levine AI, 2013, COMPREHENSIVE TXB HE; Lin S, 2016, CRITICAL CARE, V20, P1; Miro O, 2006, RESUSCITATION, V70, P107, DOI 10.1016/j.resuscitation.2005.11.015; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Nolan JP, 2014, CURR OPIN CRIT CARE, V20, P227, DOI 10.1097/MCC.0000000000000083; Reder S, 2006, RESUSCITATION, V69, P443, DOI 10.1016/j.resuscitation.2005.08.020; Stiell IG, 2012, CRIT CARE MED, V40, P1192, DOI 10.1097/CCM.0b013e31823bc8bb; Vahedian-Azimi A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1296-3; Wallace SK, 2013, CIRC-CARDIOVASC QUAL, V6, P148, DOI 10.1161/CIRCOUTCOMES.111.000041; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012	28	38	38	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2017	12	1							e0169591	10.1371/journal.pone.0169591	http://dx.doi.org/10.1371/journal.pone.0169591			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH3AE	28056076	Green Published, gold, Green Submitted			2023-01-03	WOS:000391639100058
J	Hong, TS; Gray, PJ; Allen, JN; Shellito, PC; Lowry, KP; Zukerberg, LR				Hong, Theodore S.; Gray, Phillip J.; Allen, Jill N.; Shellito, Paul C.; Lowry, Kathryn P.; Zukerberg, Lawrence R.			Case 39-2016: A 74-Year-Old Man with Rectal Bleeding and a History of Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-PAPILLOMAVIRUS; RANDOMIZED-TRIAL; CARCINOMA; RADIOTHERAPY; CHEMOTHERAPY; RADIATION; RISK; CHEMORADIATION; BRACHYTHERAPY; MITOMYCIN		[Hong, Theodore S.; Gray, Phillip J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Allen, Jill N.] Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA; [Shellito, Paul C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Lowry, Kathryn P.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Zukerberg, Lawrence R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Hong, Theodore S.; Gray, Phillip J.] Harvard Med Sch, Dept Radiat Oncol, Boston, MA 02115 USA; [Allen, Jill N.] Harvard Med Sch, Dept Hematol, Boston, MA 02115 USA; [Shellito, Paul C.] Harvard Med Sch, Dept Surg, Boston, MA 02115 USA; [Lowry, Kathryn P.] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA; [Zukerberg, Lawrence R.] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hong, TS (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.; Hong, TS (corresponding author), Harvard Med Sch, Dept Radiat Oncol, Boston, MA 02115 USA.							Ajani JA, 2008, JAMA-J AM MED ASSOC, V299, P1914, DOI 10.1001/jama.299.16.1914; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Arnott SJ, 1996, LANCET, V348, P1049; Bartelink H, 1997, J CLIN ONCOL, V15, P2040, DOI 10.1200/JCO.1997.15.5.2040; Bonin SR, 1999, CANCER-AM CANCER SOC, V85, P1226, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1226::AID-CNCR3>3.0.CO;2-B; Gunderson LL, 2012, J CLIN ONCOL, V30, P4344, DOI 10.1200/JCO.2012.43.8085; Hamilton SN, 2014, INT J RADIAT ONCOL, V90, P934, DOI 10.1016/j.ijrobp.2014.07.032; Hinnen KA, 2011, J CLIN ONCOL, V29, P4510, DOI 10.1200/JCO.2011.35.0991; James ND, 2012, NEW ENGL J MED, V366, P1477, DOI 10.1056/NEJMoa1106106; Kachnic LA, 2013, INT J RADIAT ONCOL, V86, P27, DOI 10.1016/j.ijrobp.2012.09.023; Kerr DA, 2015, AM J SURG PATHOL, V39, P1643, DOI 10.1097/PAS.0000000000000516; Nazarian RM, 2014, AM J SURG PATHOL, V38, P78, DOI 10.1097/PAS.0000000000000111; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; Norval M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1495, DOI 10.1562/2006-07-28-IR-987; Surveillance Epidemiology and End Results Program, 2014, SEER CANC STAT REV A; Takam R, 2009, PHYS MED BIOL, V54, P611, DOI 10.1088/0031-9155/54/3/009	16	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2016	375	25					2481	2488		10.1056/NEJMcpc1613458	http://dx.doi.org/10.1056/NEJMcpc1613458			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EF1NL	28002705				2023-01-03	WOS:000390091500012
J	Newton, PN; Timmermann, B				Newton, Paul N.; Timmermann, Brigitte			Fake penicillin, The Third Man, and Operation Claptrap	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Newton, Paul N.] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Viangchan, Laos; [Newton, Paul N.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [Newton, Paul N.] Univ Oxford, WorldWide Antimalarial Resistance Network & Inf, Oxford, England	University of Oxford; University of Oxford; Worldwide Antimalarial Resistance Network (WWARN)	Newton, PN (corresponding author), Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Viangchan, Laos.; Newton, PN (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England.; Newton, PN (corresponding author), Univ Oxford, WorldWide Antimalarial Resistance Network & Inf, Oxford, England.	paul@tropmedres.ac		Newton, Paul/0000-0002-4608-6431				[Anonymous], 2006, DAILY MOTION    1024; [Anonymous], 2013, LE PARISIEN     0325; [Anonymous], 1946, NEW YORK TIMES  0421, P29; [Anonymous], 1946, TIMES; [Anonymous], 2013, TELEGRAPH; [Anonymous], 1946, WASH POST, P3; British Film Institute, 1999, VIENN PROJ; Bud Robert, 2007, PENICILLIN TRIUMPH T; Drazin C., 2000, SEARCH 3 MAN; Fake penicillin, 1946, MERC HOB TASM, P7; Greene G., 1971, 3 MAN FALLEN IDOL; Mehaffey PC, 1995, DIAGN MICR INFEC DIS, V23, P11, DOI 10.1016/0732-8893(95)00148-4; Milano JU, 2000, SOLDIERS SPIES RAT L; Monge ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095353; National Agency for Food and Drug Administration and Control-Government of Nigeria, 2015, CIRC FALS AM AMP; Newton PN, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001139; Sherry N., 2004, LIFE G GREENE, V2, P1939; Timmermann B., 2006, 3 MANS VIENNA	18	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 13	2016	355								i6494	10.1136/bmj.i6494	http://dx.doi.org/10.1136/bmj.i6494			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF2JN	27965195	hybrid, Green Published			2023-01-03	WOS:000390150800006
J	Anderson, T				Anderson, Tatum			Doctors lobby for better chronic pain management	LANCET			English	Editorial Material																			0	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 10	2016	388	10062					2856	2858		10.1016/S0140-6736(16)32514-4	http://dx.doi.org/10.1016/S0140-6736(16)32514-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EE5FU	27979397				2023-01-03	WOS:000389631700017
J	Li, N; Yan, LJL; Niu, WY; Yao, C; Feng, XX; Zhang, JX; Shi, JP; Zhang, YH; Zhang, RJ; Hao, ZX; Chu, HL; Zhang, J; Li, X; Pan, JH; Li, ZF; Sun, JX; Zhou, B; Zhao, Y; Yu, Y; Engelgau, M; Labarthe, D; Ma, JX; MacMahon, S; Elliott, P; Wu, YF; Neal, B				Li, Nicole; Yan, Lijing L.; Niu, Wenyi; Yao, Chen; Feng, Xiangxian; Zhang, Jianxin; Shi, Jingpu; Zhang, Yuhong; Zhang, Ruijuan; Hao, Zhixin; Chu, Hongling; Zhang, Jing; Li, Xian; Pan, Jianhong; Li, Zhifang; Sun, Jixin; Zhou, Bo; Zhao, Yi; Yu, Yan; Engelgau, Michael; Labarthe, Darwin; Ma, Jixiang; MacMahon, Stephen; Elliott, Paul; Wu, Yangfeng; Neal, Bruce			The Effects of a Community-Based Sodium Reduction Program in Rural China - A Cluster-Randomized Trial	PLOS ONE			English	Article							BLOOD-PRESSURE; SALT SUBSTITUTE; UNITED-KINGDOM; ENRICHED SALT; MINERAL SALT; POTASSIUM; MAGNESIUM; POPULATION; DISEASE; STATES	Background Average sodium intake and stroke mortality in northern China are both among the highest in the world. An effective, low-cost strategy to reduce sodium intake in this population is urgently needed. Objective We sought to determine the effects of a community-based sodium reduction program on salt consumption in rural northern China. Design This study was a cluster-randomized trial done over 18 months in 120 townships (one village from each township) from five provinces. Sixty control villages were compared to 60 intervention villages that were given access to a reduced-sodium, added-potassium salt substitute in conjunction with a community-based health education program focusing on sodium reduction. The primary outcome was the difference in 24-hour urinary sodium excretion between randomized groups. Results Among 1,903 people with valid 24-hour urine collections, mean urinary sodium excretion in intervention compared with control villages was reduced by 5.5% (-14mmol/day, 95% confidence interval -26 to -1; p = 0.03), potassium excretion was increased by 16% (+7mmol/day, +4 to +10; p<0.001), and sodium to potassium ratio declined by 15% (-0.9, -1.2 to -0.5; p<0.001). Mean blood pressure differences were -1.1 mm Hg systolic (-3.3 to +1.1; p = 0.33) and -0.7 mm Hg diastolic (-2.2 to +0.8, p = 0.35) and the difference in the proportion with hypertension was -1.3% (-5.1 to 2.5, p = 0.56). Conclusion There were clear differences in population sodium and potassium intake between villages that were most likely a consequence of increased use of salt substitute. The absence of effects on blood pressure reflects the moderate changes in sodium and potassium intake achieved.	[Li, Nicole; Yan, Lijing L.; Hao, Zhixin; Chu, Hongling; Zhang, Jing; Li, Xian; Wu, Yangfeng] Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Beijing, Peoples R China; [Li, Nicole; MacMahon, Stephen; Neal, Bruce] George Inst Global Hlth, Sydney, NSW, Australia; [Li, Nicole; MacMahon, Stephen; Neal, Bruce] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Yan, Lijing L.; Labarthe, Darwin] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Niu, Wenyi; Chu, Hongling; Wu, Yangfeng] Peking Univ, Sch Publ Hlth, Hlth Sci Ctr, Beijing, Peoples R China; [Yao, Chen; Pan, Jianhong; Wu, Yangfeng] Peking Univ, Clin Res Inst, Beijing, Peoples R China; [Feng, Xiangxian; Li, Zhifang] Changzhi Med Coll, Changzhi, Shanxi, Peoples R China; [Zhang, Jianxin; Sun, Jixin] Hebei Prov Ctr Dis Prevent & Control, Shijiazhuang, Hebei, Peoples R China; [Shi, Jingpu; Zhou, Bo] China Med Univ, Hosp 1, Shenyang, Liaoning, Peoples R China; [Zhang, Yuhong; Zhao, Yi] Ningxia Med Univ, Ningxia, Peoples R China; [Zhang, Ruijuan; Yu, Yan] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China; [Engelgau, Michael] US Ctr Dis Control & Prevent, Beijing, Peoples R China; [Ma, Jixiang] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China; [Elliott, Paul; Neal, Bruce] Imperial Coll London, London, England; [Neal, Bruce] Royal Prince Alfred Hosp, Sydney, NSW, Australia	Peking University; George Institute for Global Health; University of Sydney; University of Sydney; Northwestern University; Feinberg School of Medicine; Peking University; Peking University; Changzhi Medical College; China Medical University; Ningxia Medical University; Xi'an Jiaotong University; Chinese Center for Disease Control & Prevention; Imperial College London; University of Sydney	Yan, LJL; Wu, YF (corresponding author), Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Beijing, Peoples R China.; Yan, LJL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.; Wu, YF (corresponding author), Peking Univ, Sch Publ Hlth, Hlth Sci Ctr, Beijing, Peoples R China.; Wu, YF (corresponding author), Peking Univ, Clin Res Inst, Beijing, Peoples R China.	lyan@georgeinstitute.org.cn; ywu@georgeinstitute.org.cn	Zhang, Yuhong/I-5056-2012	Elliott, Paul/0000-0002-7511-5684; Zhang, Yuhong/0000-0002-7110-8401; MacMahon, Stephen/0000-0003-2064-7699; Li, Xian/0000-0001-5445-4022; Neal, Bruce/0000-0002-0490-7465	National Center for Chronic Disease Prevention and Health Promotion (CDC) [HHSN268200900027C]; National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services; United Health Group Chronic Disease Initiative; Australian Research Council Future Fellowship; National Health and Medical Research Council Senior Research Fellowship; Australian National Health and Medical Research Council Overseas Fellowship; MRC-PHE Centre for Environment and Health; Imperial College London; National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare NHS Trust; Medical Research Council [MR/L01341X/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10136] Funding Source: researchfish; MRC [MR/L01341X/1] Funding Source: UKRI	National Center for Chronic Disease Prevention and Health Promotion (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); United Health Group Chronic Disease Initiative; Australian Research Council Future Fellowship(Australian Research Council); National Health and Medical Research Council Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian National Health and Medical Research Council Overseas Fellowship(National Health and Medical Research Council (NHMRC) of Australia); MRC-PHE Centre for Environment and Health(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Imperial College London(General Electric); National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare NHS Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This project has been funded in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, and National Center for Chronic Disease Prevention and Health Promotion (CDC), under Contract No. HHSN268200900027C. Additional support has been received from the United Health Group Chronic Disease Initiative. Bruce Neal is supported by an Australian Research Council Future Fellowship and National Health and Medical Research Council Senior Research Fellowship and Nicole Li by an Australian National Health and Medical Research Council Overseas Fellowship. Paul Elliott is supported through the MRC-PHE Centre for Environment and Health, Imperial College London, and by the National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare NHS Trust and Imperial College London; he is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of any sponsors.	Anderson CAM, 2010, J AM DIET ASSOC, V110, P736, DOI 10.1016/j.jada.2010.02.007; Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Chang HY, 2006, AM J CLIN NUTR, V83, P1289, DOI 10.1093/ajcn/83.6.1289; Charlton KE, 2008, PUBLIC HEALTH NUTR, V11, P1397, DOI 10.1017/S136898000800342X; China Ministry of Health, 2013, CHIN ANN HLTH STAT Y; ELLIOTT P, 1988, BRIT MED J, V297, P319; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; Gilleran G, 1996, J HUM HYPERTENS, V10, P517; He F. J., 2013, BMJ, V346; KARPPANEN H, 1984, J CARDIOVASC PHARM, V6, pS236, DOI 10.1097/00005344-198400061-00037; Kawasaki T, 1998, HYPERTENS RES-CLIN E, V21, P235, DOI 10.1291/hypres.21.235; Li N, 2007, J HYPERTENS, V25, P2011, DOI 10.1097/HJH.0b013e3282b9714b; Li N, 2013, AM HEART J, V166, P815, DOI 10.1016/j.ahj.2013.07.009; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MERVAALA EMA, 1994, BRIT J PHARMACOL, V111, P1189, DOI 10.1111/j.1476-5381.1994.tb14871.x; Mu J, 2009, AM J HYPERTENS, V22, P943, DOI 10.1038/ajh.2009.136; Neutel J, 1996, AM J HYPERTENS, V9, p94A; ROSE G, 1986, J HYPERTENS, V4, P781; Sarkkinen ES, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-88; Stolarz-Skrzypek K, 2011, JAMA-J AM MED ASSOC, V305, P1777, DOI 10.1001/jama.2011.574; Turnbull F, 2003, LANCET, V362, P1527; Vandevijvere S, 2010, EUR J CLIN NUTR, V64, P1260, DOI 10.1038/ejcn.2010.148; Venezia A, 2010, EUR J CLIN NUTR, V64, P518, DOI 10.1038/ejcn.2010.22; Zhou BF, 2003, J HUM HYPERTENS, V17, P623, DOI 10.1038/sj.jhh.1001605; Zhou X, 2009, AM J HYPERTENS, V22, P934, DOI 10.1038/ajh.2009.135	26	43	43	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0166620	10.1371/journal.pone.0166620	http://dx.doi.org/10.1371/journal.pone.0166620			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4PU	27935977	Green Submitted, Green Published, gold			2023-01-03	WOS:000389587100037
J	Wang, LS; Lee, CT; Su, WL; Huang, SC; Wang, SC				Wang, Lung-Shuo; Lee, Chun-Ting; Su, Wei-Lieh; Huang, Shih-Che; Wang, Shu-Chi			Delonix regia Leaf Extract (DRLE): A Potential Therapeutic Agent for Cardioprotection	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; DOWN-REGULATES ENOS; ANTIINFLAMMATORY ACTIVITY; PHENOLIC-COMPOUNDS; HEART-FAILURE; FLAVONOIDS; HYPERTROPHY; RAT; ANTIOXIDANTS	Delonix regia (Boj. Ex. Hook) is a flowering plant in the pea family found in tropical areas and its leaves are used informally to treat diseases in folk medicine. However, the cardioprotective effects in this plant are still unclear. In this study, we found that the Delonix regia leaf extract (DRLE) (400 mg/kg/d) can reduce the mortality rate in an isoproterenol (ISO)-induced heart injury and hypertrophy mouse model. Decreased serum levels of creatine phosphokinase, LDH, GOT, TNF-alpha and increased nitric oxide levels were found in DRLE-treated ISO-injured mice. In the in vitro study, the porcine coronary artery exhibited vasodilation effect induced by DRLE in a dose-dependent manner. In the DRLE toxic test, overdose of DRLE showed the high safety in normal mice and may have the ability to remove the metabolic wastes in blood. In conclusion, we demonstrated for the first time that DRLE has the cardioprotective effects by activating the vasodilation through NO pathway and preventing the myocyte injury via inhibition of TNF-alpha pathway. We suggest that DRLE may act as a promising novel herbal medicine for cardioprotection.	[Wang, Lung-Shuo] Tainan Sin Lau Hosp, Dept Chinese Med, Tainan, Taiwan; [Lee, Chun-Ting] Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, Kaohsiung, Taiwan; [Su, Wei-Lieh] Kaohsiung Med Univ, Dept Occupat Therapy, Kaohsiung, Taiwan; [Huang, Shih-Che; Wang, Shu-Chi] I Shou Univ, Sch Med Int Students, Kaohsiung, Taiwan; [Huang, Shih-Che] E DA Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Wang, Shu-Chi] I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Kaohsiung Medical University; I Shou University; E-Da Hospital; I Shou University	Wang, SC (corresponding author), I Shou Univ, Sch Med Int Students, Kaohsiung, Taiwan.; Wang, SC (corresponding author), I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan.	wansuchi@isu.edu.tw			Intramural Industry-University Collaboration Projects in I-Shou university; E-Da hospital, Kaohsiung, Taiwan [ISU-103-INT-05E]	Intramural Industry-University Collaboration Projects in I-Shou university; E-Da hospital, Kaohsiung, Taiwan	This study was sponsored by the Intramural Industry-University Collaboration Projects in I-Shou university and E-Da hospital, Kaohsiung, Taiwan (ISU-103-INT-05E). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Ahmed J, 2011, PHYTOPHARMACOL, V5, P118; Alves MJ, 2013, J APPL MICROBIOL, V115, P346, DOI 10.1111/jam.12196; Anderson HDI, 2004, J BIOL CHEM, V279, P963, DOI 10.1074/jbc.M309552200; Arul V., 1999, Journal of Pharmacy and Pharmacology, V51, P252; Azab SS, 2013, MED CHEM RES, V22, P4269, DOI 10.1007/s00044-012-0420-4; Barros L, 2009, FOOD CHEM TOXICOL, V47, P1076, DOI 10.1016/j.fct.2009.01.039; Bi FangJie, 2012, African Journal of Biotechnology, V11, P9270; BOLUYT MO, 1995, AM J PHYSIOL-HEART C, V269, pH638; Bouic P J, 1999, Altern Med Rev, V4, P170; Bouic PJD, 2002, DRUG DISCOV TODAY, V7, P775, DOI 10.1016/S1359-6446(02)02343-7; Carocho M, 2013, ANTI-CANCER AGENT ME, V13, P1236, DOI 10.2174/18715206113139990301; Condorelli G, 2002, FASEB J, V16, P1732, DOI 10.1096/fj.02-0419com; Fatmawaty, 2013, Journal of Natural Products (India), V6, P61; Fuhrman B, 2001, CURR OPIN LIPIDOL, V12, P41, DOI 10.1097/00041433-200102000-00008; Ganapathy P, 2014, J ACAD IND RES, V3, P209; Geetha T, 2001, J ETHNOPHARMACOL, V76, P77, DOI 10.1016/S0378-8741(01)00175-1; Gomes A, 2012, BIOFACTORS, V38, P378, DOI 10.1002/biof.1033; Grassi D, 2010, NUTRIENTS, V2, P889, DOI 10.3390/nu2080889; Heleno SA, 2015, FOOD CHEM, V173, P501, DOI 10.1016/j.foodchem.2014.10.057; Huang CC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/364741; Huang SC, 2010, NEUROGASTROENT MOTIL, V22, P1009, DOI 10.1111/j.1365-2982.2010.01513.x; Huang SC, 2011, REGUL PEPTIDES, V167, P246, DOI 10.1016/j.regpep.2011.02.007; Husain A, 2012, AM J PHARMTECH RES, V2, P380; Izzi V, 2012, FRONT BIOSCI-LANDMRK, V17, P2396, DOI 10.2741/4061; Jahan I, 2010, ACTA PHARMACEUT, V60, P207, DOI 10.2478/v10007-010-0018-7; Kleinbongard P, 2002, METHOD ENZYMOL, V359, P158; Krenek P, 2009, EUR J HEART FAIL, V11, P140, DOI 10.1093/eurjhf/hfn026; LAKSHMI V, 1987, NATL ACAD SCI LETT, V10, P197; Lee MC, 2013, SCAND J GASTROENTERO, V48, P205, DOI 10.3109/00365521.2012.741615; Leifert WR, 2008, NUTR RES, V28, P729, DOI [10.1016/j.nutres.2008.08.007, 10.1016/j.nutres.2008.09.001]; Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048872; Li XB, 2012, J PHARM PHARMACOL, V64, P1107, DOI 10.1111/j.2042-7158.2012.01502.x; Loizou S, 2010, MOL NUTR FOOD RES, V54, P551, DOI 10.1002/mnfr.200900012; Lotito SB, 2006, FREE RADICAL BIO MED, V41, P1727, DOI 10.1016/j.freeradbiomed.2006.04.033; Maity P, 2009, INDIAN J EXP BIOL, V47, P849; Mehta JL, 1999, CARDIOVASC RES, V43, P291, DOI 10.1016/S0008-6363(99)00132-7; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Modi A, 2016, CHIN J NAT MEDICINES, V14, P31, DOI 10.3724/SP.J.1009.2016.00031; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Ozaki M, 2002, CIRC J, V66, P851, DOI 10.1253/circj.66.851; Ragasa CY, 2011, MANILA J SCI, V7, P7; Rahman M, 2011, AFR J TRADIT COMPLEM, V8, P34; Rani P. M. J., 2011, African Journal of Biochemistry Research, V5, P341; Romagnolo Donato F., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P206, DOI 10.1080/21551197.2012.702534; Rosenthal K, 2003, RODENT REFERENCE RAN; Sack MN, 2000, CARDIOVASC RES, V45, P688, DOI 10.1016/S0008-6363(99)00228-X; Sama K, 2011, INT J PHARM LIFE SCI, V2, P42; Shabir G, 2011, MOLECULES, V16, P7302, DOI 10.3390/molecules16097302; Shanmukha I, 2011, INT J CHEMTECH RES, V3, P280; Shewale VD, 2012, ADV PHARM SCI, V2012, P1; Shiramane RS, 2011, INT J RES PHARM CHEM, V1, P2231; Shiramane RS, 2011, INT J RES PHARM CHEM, V2, P234; Siasos G, 2013, CURR MED CHEM, V20, P2641, DOI 10.2174/0929867311320210003; Song F, 2013, J ETHNOPHARMACOL, V150, P125, DOI 10.1016/j.jep.2013.08.019; Sun M, 2007, CIRCULATION, V115, P1398, DOI 10.1161/CIRCULATIONAHA.106.643585; Takaki Miyako, 2012, Pathophysiology, V19, P163, DOI 10.1016/j.pathophys.2012.04.004; Valerio A, 2006, J CLIN INVEST, V116, P2791, DOI [10.1172/JCI28570, 10.1172/JCI28570.]; Verma SK, 2012, CIRCULATION, V126, P418, DOI 10.1161/CIRCULATIONAHA.112.112185; WEXLER BC, 1978, AM HEART J, V96, P70, DOI 10.1016/0002-8703(78)90128-X; White RE, 2005, AM J PHYSIOL-HEART C, V289, pH1468, DOI 10.1152/ajpheart.01173.2004; Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001; Xie J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2240; Yang AL, 2011, CHINESE J PHYSIOL, V54, P87, DOI 10.4077/CJP.2011.AMM011	64	4	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0167768	10.1371/journal.pone.0167768	http://dx.doi.org/10.1371/journal.pone.0167768			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4PU	27936072	gold, Green Published, Green Submitted			2023-01-03	WOS:000389587100181
J	Menon, N; Rogers, CJ; Lukaszewicz, AI; Axtelle, J; Yadav, M; Song, FF; Chakravarti, A; Jacob, NK				Menon, Naresh; Rogers, Claude J.; Lukaszewicz, Agnes I.; Axtelle, James; Yadav, Marshleen; Song, Feifei; Chakravarti, Arnab; Jacob, Naduparambil K.			Detection of Acute Radiation Sickness: A Feasibility Study in Non-Human Primates Circulating miRNAs for Triage in Radiological Events	PLOS ONE			English	Article							BODY IRRADIATION MODEL; IONIZING-RADIATION; IN-VIVO; MICRORNA EXPRESSION; PERIPHERAL-BLOOD; CELLS; INJURY; RNA; MANAGEMENT; EXPOSURE	Development of biomarkers capable of estimating absorbed dose is critical for effective triage of affected individuals after radiological events. Levels of cell-free circulating miRNAs in plasma were compared for dose-response analysis in non-human primates (NHP) exposed to lethal (6.5 Gy) and sub-lethal (1 and 3 Gy) doses over a 7 day period. The doses and test time points were selected to mimic triage needs in the event of a mass casualty radiological event. Changes in miRNA abundance in irradiated animals were compared to a non-irradiated cohort and a cohort experiencing acute inflammation response from exposure to lipopolysaccharide (LPS). An amplification-free, hybridization-based direct digital counting method was used for evaluation of changes in microRNAs in plasma from all animals. Consistent with previous murine studies, circulating levels of miR-150-5p exhibited a dose-and time-dependent decrease in plasma. Furthermore, plasma miR-150-5p levels were found to correlate well with lymphocyte and neutrophil depletion kinetics. Additionally, plasma levels of several other evolutionarily and functionally conserved miRNAs were found altered as a function of dose and time. Interestingly, miR-574-5p exhibited a distinct, dose-dependent increase 24 h post irradiation in NHPs with lethal versus sub-lethal exposure before returning to the baseline level by day 3. This particular miRNA response was not detected in previous murine studies but was observed in animals exposed to LPS, indicating distinct molecular and inflammatory responses. Furthermore, an increase in low-abundant miR-126, miR-144, and miR-21 as well as high-abundant miR-1-3p and miR-206 was observed in irradiated animals on day 3 and/or day 7. The data from this study could be used to develop a multi-marker panel with known tissue-specific origin that could be used for developing rapid assays for dose assessment and evaluation of radiation injury on multiple organs. Furthermore this approach may be utilized to screen for tissue toxicity in patients who receive myeloablative and therapeutic radiation.	[Menon, Naresh; Rogers, Claude J.; Lukaszewicz, Agnes I.; Axtelle, James] ChromoLogic LLC, Monrovia, CA 91016 USA; [Yadav, Marshleen; Song, Feifei; Chakravarti, Arnab; Jacob, Naduparambil K.] Ohio State Univ, Comprehens Canc Ctr Columbus, Dept Radiat Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Menon, N (corresponding author), ChromoLogic LLC, Monrovia, CA 91016 USA.; Jacob, NK (corresponding author), Ohio State Univ, Comprehens Canc Ctr Columbus, Dept Radiat Oncol, Columbus, OH 43210 USA.	nmenon@chromologic.com; naduparambil.jacob@osumc.edu	Yadav, Marshleen/J-8795-2019	Yadav, Marshleen/0000-0002-4778-8347; /0000-0002-4700-8064	Biomedical Advanced Research and Development Agency, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services [HHS0100201000005C]; National Institute of Allergies and Infectious Disease (NIAID) [1R43AI108019-01 A1]; Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program [W81XWH-15-2-0054]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI108019] Funding Source: NIH RePORTER	Biomedical Advanced Research and Development Agency, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services; National Institute of Allergies and Infectious Disease (NIAID); Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	All NHP studies were performed at CiTox Laboratories (Laval, Canada). This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Agency, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services (Contract No. HHS0100201000005C); the National Institute of Allergies and Infectious Disease (NIAID; Grant 1R43AI108019-01 A1); the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program (Award No. W81XWH-15-2-0054). The Grants 1R43AI108019-01 A1 provided support in the form of salaries for authors [NJ, CR, AL, NM, JA], purchasing reagents and services, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Contract W81XWH-15-2-0054 provided support in the form of salaries for authors [MY, FS, NJ], and purchasing reagents and services, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Contract HHS0100201000005C provided support in the form of salaries for authors [NM, JA], and purchasing reagents and services, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; All NHP studies were performed at CiTox Laboratories (Laval, Canada). This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Agency, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services (Contract No. HHS0100201000005C); the National Institute of Allergies and Infectious Disease (NIAID; Grant 1R43AI108019-01 A1); the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program (Award No. W81XWH-15-2-0054).; The Grants 1R43AI108019-01 A1 provided support in the form of salaries for authors [NJ, CR, AIL, NM, JA], purchasing reagents and services, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Contract W81XWH-15-2-0054 provided support in the form of salaries for authors [MY, FS, NJ], and purchasing reagents and services, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Contract HHS0100201000005C provided support in the form of salaries for authors [NM, JA], and purchasing reagents and services, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Only authors [CR, AIL, JA, NM] are full time employees of ChromoLogic LLC while authors [NJ, MY, AC] have no financial interest in ChromoLogic LLC. Grant 1R43AI108019-01 A1 and Contract HHS0100201000005C were awarded to ChromoLogic LLC. All ChromoLogic LLC staff adhere strictly to Ethical Scientific Conduct guidelines documented by the company in their Employee Agreement and, independently, those established by the National Institutes of Health. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Abend M, 2016, RADIAT RES, V185, P109, DOI 10.1667/RR14221.1; ACHARYA SS, 2015, SCI TRANSL MED, V7; Adams BD, 2012, CELL REP, V2, P1048, DOI 10.1016/j.celrep.2012.09.014; Al-Mayah AHJ, 2012, RADIAT RES, V177, P539, DOI 10.1667/RR2868.1; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042; Blakely WF, 2014, RADIAT PROT DOSIM, V159, P46, DOI 10.1093/rpd/ncu127; Bolduc DL, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/685286; Buddemeir B. R., 2011, KEY RESPONSE PLANNIN; Carver JR, 2007, J CLIN ONCOL, V25, P3991, DOI 10.1200/JCO.2007.10.9777; Cheng HS, 2013, EMBO MOL MED, V5, P1017, DOI 10.1002/emmm.201202318; Christensen DM, 2014, J AM OSTEOPATH ASSOC, V114, P189, DOI 10.7556/jaoa.2014.037; Dainiak N, 2007, EXP HEMATOL, V35, P17, DOI 10.1016/j.exphem.2007.01.007; Dicarlo AL, 2011, DISASTER MED PUBLIC, P5; Dickey JS, 2011, RADIAT ENVIRON BIOPH, V50, P491, DOI 10.1007/s00411-011-0386-5; Fliedner TM, 2005, BR J RADIOL S27, P1, DOI DOI 10.1259/BJR/77700378; Flynn DF, 2006, SURG CLIN N AM, V86, P601, DOI 10.1016/j.suc.2006.03.005; Forsbach A, 2008, J IMMUNOL, V180, P3729, DOI 10.4049/jimmunol.180.6.3729; Ghosh SP, 2009, INT J RADIAT BIOL, V85, P598, DOI 10.1080/09553000902985128; Girardi C, 2012, PLOS ONE, P7; GOANS RE, 1997, HLTH PHYS, V72; Graessle DH, 2015, HEALTH PHYS, V109, P493, DOI 10.1097/HP.0000000000000355; He Y, 2014, INFLAMMATION, V37, P71, DOI 10.1007/s10753-013-9713-0; Horai R, 2011, J INTERF CYTOK RES, V31, P733, DOI 10.1089/jir.2011.0042; Jacob NK, 2013, PLOS ONE, P8; Jusufovic E, 2012, PLOS ONE, P7; Knebel AR, 2011, DISASTER MED PUBLIC, V5, pS20, DOI 10.1001/dmp.2011.25; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Li Q., 2012, IACR CRYPTOL EPRINT, V2012, P7, DOI DOI 10.1371/J0URNAL.P0NE.0048278; Ludwig N, 2016, NUCLEIC ACIDS RES, P1; Ludwig N., 2016, NUCL ACIDS RES; LUSHBAUGH CC, 1987, BRIT J RADIOL, V60, P1159, DOI 10.1259/0007-1285-60-720-1159; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Ossetrova NI, 2014, RADIAT PROT DOSIM, V159, P61, DOI 10.1093/rpd/ncu165; Ossetrova NI, 2010, HEALTH PHYS, V98, P204, DOI 10.1097/HP.0b013e3181abaabf; Ossetrova NI, 2009, INT J RADIAT BIOL, V85, P837, DOI 10.3109/09553000903154799; Prasanna Pataje G S, 2010, Radiat Res, V173, P245, DOI 10.1667/RR1993.1; Quesenberry PJ, 2014, STEM CELLS DEV, V23, P1429, DOI 10.1089/scd.2013.0594; Ranganathan P, 2015, AM J PHYSIOL-RENAL, V309, pF551, DOI 10.1152/ajprenal.00076.2015; Rothkamm K, 2013, RADIAT RES, V180, P111, DOI 10.1667/RR3231.1; Shin S, 2009, INT J ONCOL, V35, P81, DOI 10.3892/ijo_00000315; Simone N.L., 2009, PLOS ONE, P4; Sine R C, 2001, Mil Med, V166, P85; Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4; Tano N, 2011, PLOS ONE, P6; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Templin T, 2011, INT J RADIAT ONCOL, V80, P549, DOI 10.1016/j.ijrobp.2010.12.061; Templin T, 2011, INT J RADIAT BIOL, V87, P653, DOI 10.3109/09553002.2010.549537; Van der Meeren A, 2005, RADIAT RES, V163, P144, DOI 10.1667/RR3293; Vincenti S, 2011, RADIAT RES, V175, P535, DOI 10.1667/RR2200.1; Wagner-Ecker M, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-25; Weber JM, 2010, BONE, P281; Williams JP, 2010, RADIAT RES, V173, P557, DOI 10.1667/RR1880.1; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Yu ZY, 2013, MOL MED REP, V8, P287, DOI 10.3892/mmr.2013.1493; Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104	57	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167333	10.1371/journal.pone.0167333	http://dx.doi.org/10.1371/journal.pone.0167333			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27907140	Green Submitted, Green Published, gold			2023-01-03	WOS:000389482700121
J	Santos, UP; Campos, JF; Torquato, HFV; Paredes-Gamero, EJ; Carollo, CA; Estevinho, LM; Souza, KD; dos Santos, EL				Santos, Uilson P.; Campos, Jaqueline F.; Torquato, Heron Fernandes V.; Paredes-Gamero, Edgar Julian; Carollo, Carlos Alexandre; Estevinho, Leticia M.; Souza, Kely de Picoli; dos Santos, Edson Lucas			Antioxidant, Antimicrobial and Cytotoxic Properties as Well as the Phenolic Content of the Extract from Hancornia speciosa Gomes	PLOS ONE			English	Article							MEDICINAL-PLANTS; CELL-DEATH; OXIDATIVE DAMAGE; NATURAL-PRODUCTS; BLOOD-CELLS; APOPTOSIS; INHIBITION; RUTIN; ANTIBACTERIAL; PROPOLIS	Hancornia speciosa Gomes (Apocynaceae) is a fruit tree, popularly known as mangabeira, and it is widely distributed throughout Brazil. Several parts of the plant are used in folk medicine, and the leaf and bark extracts have anti-inflammatory, antihypertensive, antidiabetic, and antimicrobial properties. In this study, we investigated the chemical composition of the ethanolic extract of Hancornia speciosa leaves (EEHS) and its antioxidant, antimicrobial, and cytotoxic activities as well as the mechanisms involved in cell death. The chemical compounds were identified by liquid chromatography coupled to mass spectrometry (LC-MS/MS). The antioxidant activity of the EEHS was investigated using the method that involves the scavenging of 2,2-dipheny1-1-picrylhydrazyl free radicals as well as the inhibition of oxidative hemolysis and lipid peroxidation induced by 2,2'-azobis (2-amidinopropane) in human erythrocytes. The antimicrobial activity was determined by calculating the minimum inhibitory concentration, minimum bactericidal concentration, minimum fungicidal concentration, and zone of inhibition. Kasumi-1 leukemic cells were used to assess the cytotoxic activity and mechanisms involved in cell death promoted by the EEHS. The chemical compounds identified were quinic acid, chlorogenic acid, catechin, rutin, isoquercitrin, kaempferol-rutinoside, and catechin-pentoside. The EEHS demonstrated antioxidant activity via the sequestration of free radicals, inhibition of hemolysis, and inhibition of lipid peroxidation in human erythrocytes incubated with an oxidizing agent. The antimicrobial activity was observed against American Type Culture Collection (ATCC) and hospital strains of bacteria and fungi, filamentous fungi and dermatophytes. The cytotoxic activity of the EEHS was induced by apoptosis, reduction of the mitochondrial membrane potential, and activation of cathepsins. Together, these results indicate the presence of phenolic compounds and flavonoids in the EEHS and that their antioxidant, antimicrobial, and cytotoxic activities in acute myeloid leukemia cells are mediated by apoptosis.	[Santos, Uilson P.; Campos, Jaqueline F.; Souza, Kely de Picoli; dos Santos, Edson Lucas] Fed Univ Grande Dourados, Sch Environm & Biol Sci, Rodovia Dourados Ithaum, Dourados, MS, Brazil; [Torquato, Heron Fernandes V.; Paredes-Gamero, Edgar Julian] Univ Fed Sao Paulo, Dept Biochem, Sao Paulo, SP, Brazil; [Paredes-Gamero, Edgar Julian] Univ Mogi Das Cruzes, Ctr Interdisciplinary Res Biochem, Av Dr Candido Xavier de Almeida Souza, Mogi Das Cruzes, SP, Brazil; [Carollo, Carlos Alexandre] Univ Fed Mato Grosso do Sul, Ctr Biol & Hlth Sci, Lab Nat Prod & Mass Spectrometry, Campo Grande, MS, Brazil; [Estevinho, Leticia M.] Polytech Inst Braganca, Agr Coll Braganca, Campus Santa Apolonia, Braganca, Portugal; [Estevinho, Leticia M.] Univ Minho, Ctr Mol & Environm Biol, Campus Gualtar, Braga, Portugal	Universidade Federal da Grande Dourados; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Mogi das Cruzes; Universidade Federal de Mato Grosso do Sul; Instituto Politecnico de Braganca; Universidade do Minho	dos Santos, EL (corresponding author), Fed Univ Grande Dourados, Sch Environm & Biol Sci, Rodovia Dourados Ithaum, Dourados, MS, Brazil.	edson.lucas@pq.cnpq.br	dos Santos, Edson Lucas/AAU-5857-2020; de Picoli Souza, Kely/AAU-5978-2020; Santos, Edson/C-6820-2014; Estevinho, Leticia M./L-2656-2017; de Picoli Souza, Kely/I-1248-2015; Torquato, Heron/AAQ-2462-2020; Paredes-Gamero, Edgar J/C-4791-2012	dos Santos, Edson Lucas/0000-0002-6557-7914; de Picoli Souza, Kely/0000-0001-5764-2125; Santos, Edson/0000-0002-6557-7914; Estevinho, Leticia M./0000-0002-9249-1948; de Picoli Souza, Kely/0000-0001-5764-2125; Paredes-Gamero, Edgar J/0000-0003-3686-8402	Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT, Brazil); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil); PRODER [24.073]; CNPq, Brazil	Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT, Brazil)(Fundacao de Apoio ao Desenvolvimento do Ensino Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT MS)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PRODER; CNPq, Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by grants from Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT, Brazil), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil) and PRODER, (24.073 - A, Portugal). E.L.S.; E.J.P.G e C.A.L.C., were recipient of felowship from CNPq, Brazil. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants from Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT, Brazil), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil) and PRODER, (24.073 - A Portugal). E.L.S.; E.J.P.G e C.A.L.C., were recipient of felowship from CNPq, Brazil.	Akintobi OA, 2013, REPORT OPINION, V5, P41; Al-Fatimi M, 2007, J ETHNOPHARMACOL, V111, P657, DOI 10.1016/j.jep.2007.01.018; Amin MU, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0580-0; Bardaweel SK, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/790838; Joray MB, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/912484; Almeida MMB, 2011, FOOD RES INT, V44, P2155, DOI 10.1016/j.foodres.2011.03.051; Brown DG, 2014, BIOORG MED CHEM LETT, V24, P413, DOI 10.1016/j.bmcl.2013.12.059; Campos JF, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/296186; Campos JF, 2014, FOOD CHEM TOXICOL, V65, P374, DOI 10.1016/j.fct.2014.01.008; Casagrande JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112748; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; da Silva AO, 2014, J ETHNOPHARMACOL, V154, P319, DOI 10.1016/j.jep.2014.03.017; Marcondes DBD, 2014, J ETHNOPHARMACOL, V157, P243, DOI 10.1016/j.jep.2014.09.018; Pereira ABD, 2012, J CHROMATOGR B, V887, P133, DOI 10.1016/j.jchromb.2012.01.009; Djeridane A, 2006, FOOD CHEM, V97, P654, DOI 10.1016/j.foodchem.2005.04.028; Endringer DC, 2007, ACTA CRYSTALLOGR E, V63, pO1067, DOI 10.1107/S1600536806037019; Endringer DC, 2010, PHYTOTHER RES, V24, P928, DOI 10.1002/ptr.3050; Endringer DC, 2009, PHYTOMEDICINE, V16, P1064, DOI 10.1016/j.phymed.2009.03.022; Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102; Favela-Hernandez JMJ, 2015, MOLECULES, V20, P12450, DOI 10.3390/molecules200712450; Feas X, 2013, MOLECULES, V18, P4573, DOI 10.3390/molecules18044573; Ferreira HC, 2007, PHYTOMEDICINE, V14, P473, DOI 10.1016/j.phymed.2006.11.008; Ferreira HC, 2007, J ETHNOPHARMACOL, V109, P161, DOI 10.1016/j.jep.2006.06.009; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Franci G, 2015, MOLECULES, V20, P8856, DOI 10.3390/molecules20058856; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Geller FC, 2015, PHYTOTHER RES, V29, P1887, DOI 10.1002/ptr.5438; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Grandi TSM, 1989, ACTA BOT BRAS, V3, P185, DOI [10.1590/S0102-33061989000300018, DOI 10.1590/S0102-33061989000300018]; Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520; Gudlaugsson O, 2003, CLIN INFECT DIS, V37, P1172, DOI 10.1086/378745; Gupta D, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-13; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Havlickova B, 2008, MYCOSES, V51, P2, DOI 10.1111/j.1439-0507.2008.01606.x; Henneberg Railson, 2013, Rev. Bras. Hematol. Hemoter., V35, P52, DOI 10.5581/1516-8484.20130015; HIRSCHMANN GS, 1990, J ETHNOPHARMACOL, V29, P159, DOI 10.1016/0378-8741(90)90052-U; Kaznelson DW, 2004, VIROLOGY, V320, P301, DOI 10.1016/j.virol.2003.12.018; Kesharwani Rajesh Kumar, 2012, Org Med Chem Lett, V2, P12, DOI 10.1186/2191-2858-2-12; Khan R, 2009, MOLECULES, V14, P586, DOI 10.3390/molecules14020586; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Li TY, 2016, FOOD FUNCT, V7, P1147, DOI 10.1039/c5fo01036e; Liberio SA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-108; Marinho DG, 2011, J ETHNOPHARMACOL, V135, P530, DOI 10.1016/j.jep.2011.03.059; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Meda A, 2005, FOOD CHEM, V91, P571, DOI 10.1016/j.foodchem.2004.10.006; Moraes TDM, 2008, J ETHNOPHARMACOL, V120, P161, DOI 10.1016/j.jep.2008.08.001; Moraes VWR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.190; Morais M, 2011, FOOD CHEM TOXICOL, V49, P1096, DOI 10.1016/j.fct.2011.01.020; Moreira L, 2008, FOOD CHEM TOXICOL, V46, P3482, DOI 10.1016/j.fct.2008.08.025; Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055; Oliveira P. S., 2002, THE CERRADOS OF BRAZ; Owen S.O., 2006, HANDBOOK OF PHARMACE; Paredes-Gamero EJ, 2012, BBA-GEN SUBJECTS, V1820, P1062, DOI 10.1016/j.bbagen.2012.02.015; Pereira AC, 2015, J ETHNOPHARMACOL, V161, P30, DOI 10.1016/j.jep.2014.11.050; Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025; Plaper A, 2003, BIOCHEM BIOPH RES CO, V306, P530, DOI 10.1016/S0006-291X(03)01006-4; Ribeiro AB, 2015, PHARM BIOL, V53, P1691, DOI 10.3109/13880209.2014.1001407; Rizzo JA, 1990, C NAC BOT AN, V2, P691; Rodrigues V. E. G., 2001, Ciencia e Agrotecnologia, V25, P102; Roy S, 2014, ENVIRON TOXICOL PHAR, V37, P234, DOI 10.1016/j.etap.2013.11.008; Sahreen S, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-372; Sharma S, 2013, EXPERT OPIN INV DRUG, V22, P1063, DOI 10.1517/13543784.2013.805744; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Silva GC, 2011, J ETHNOPHARMACOL, V137, P709, DOI 10.1016/j.jep.2011.06.031; Sofi FR, 2016, J FOOD SCI TECH MYS, V53, P104, DOI 10.1007/s13197-015-1983-0; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; The Japanese Mycology Study Group, 2007, GUIDELINES FOR MANAG; Umarani V, 2015, TOXICOL MECH METHOD, V25, P143, DOI 10.3109/15376516.2014.1003359; Valente MJ, 2011, FOOD CHEM TOXICOL, V49, P86, DOI 10.1016/j.fct.2010.10.001; Wannes WA, 2010, FOOD CHEM TOXICOL, V48, P1362, DOI 10.1016/j.fct.2010.03.002; Williams GM, 1999, FOOD CHEM TOXICOL, V37, P1027, DOI 10.1016/S0278-6915(99)00085-X; Wintola OA, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0835-9; Yu XL, 2015, FOOD FUNCT, V6, P3296, DOI 10.1039/c5fo00500k; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x; Zou CG, 2001, LIFE SCI, V69, P75, DOI 10.1016/S0024-3205(01)01112-2	77	28	28	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167531	10.1371/journal.pone.0167531	http://dx.doi.org/10.1371/journal.pone.0167531			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27907185	gold, Green Submitted, Green Published			2023-01-03	WOS:000389482700185
J	Giles, C				Giles, Ceinwen			Coping with self management	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												ceinwen.giles@gmail.com							0	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2016	355								i6442	10.1136/bmj.i6442	http://dx.doi.org/10.1136/bmj.i6442			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EE0ZD	27903523				2023-01-03	WOS:000389308600011
J	de Miguel-Diez, J; Lopez-de-Andres, A; Jimenez-Garcia, R; Puente-Maestu, L; Jimenez-Trujillo, I; Hernandez-Barrera, V; Resino, S; Alvaro-Meca, A				de Miguel-Diez, Javier; Lopez-de-Andres, Ana; Jimenez-Garcia, Rodrigo; Puente-Maestu, Luis; Jimenez-Trujillo, Isabel; Hernandez-Barrera, Valentin; Resino, Salvador; Alvaro-Meca, Alejandro			Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012)	PLOS ONE			English	Article							HEPATITIS-C VIRUS; OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION; RISK-FACTORS; PREVALENCE; MORTALITY; ABNORMALITIES; COMORBIDITY	Purpose The aim of this study was to estimate trends of incidence of hospital admissions and in-hospital mortality (IHM) in HIV-infected patients with COPD in the combination antiretroviral therapy (cART) era in Spain (1997-2012). Methods A retrospective study with data from nationwide population-based COPD diagnoses in the Spanish Minimum Basic Data Set (MBDS) was performed. We established groups according to their HIV and HCV infections: 1) HIV-uninfected patients; 2) HIV-infected patients (with or without HCV coinfection). Results 1,580,207 patients discharge with a COPD diagnosis were included in the study, 8902 of them were HIV-infected patients (5000 HIV-monoinfected patients and 3902 HIV/HCVcoinfected patients). The HIV-infected patients had higher incidence rates of hospital admissions for COPD than the HIV-uninfected patients during the study period. The HIV-monoinfected patients had higher rates of hospitalizations for COPD than the HIV/HCV-coinfected patients in the early-period cART (1997-1999), but these rates decreased in the first group and increased in the second, being even similar in both groups in the late-period cART (2004-2011). On the other hand, the HIV-infected patients with COPD had higher IHM than the HIV-uninfected patients with COPD. The mortality rates were higher in the HIV-monoinfected patients with COPD than in the HIV/HCV-coinfected patients with COPD in the earlyperiod cART; however, in the late-period cART, the mortality rates trends seems higher in the HIV/HCV group. The likelihood of death in HIV/HCV-coinfected patients with COPD was similar to than in HIV-monoinfected patients with COPD. Conclusions Incidence of hospital admissions for COPD and IHM have decreased among HIV-monoinfected individuals but have increased steadily among HIV/HCV-coinfected individuals in the cART era.	[de Miguel-Diez, Javier; Puente-Maestu, Luis] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Fac Med, Inst Invest Sanitaria Gregorio Maranon IiSGM,Pneu, Madrid, Spain; [Lopez-de-Andres, Ana; Jimenez-Garcia, Rodrigo; Jimenez-Trujillo, Isabel; Hernandez-Barrera, Valentin; Alvaro-Meca, Alejandro] Univ Rey Juan Carlos, Dept Hlth Sci, Prevent Med & Publ Hlth Teaching & Res Unit, Madrid, Spain; [Resino, Salvador] Inst Salud Carlos III, Natl Ctr Microbiol, Madrid, Spain	Complutense University of Madrid; General University Gregorio Maranon Hospital; Universidad Rey Juan Carlos; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	de Miguel-Diez, J (corresponding author), Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Fac Med, Inst Invest Sanitaria Gregorio Maranon IiSGM,Pneu, Madrid, Spain.	javier.miguel@saluci.madrid.org	Jimenez-Trujillo, Isabel/AAP-7746-2021; Resino, Salvador/B-2430-2008; Lopez-de-Andres, Ana/D-4498-2019; Jimenez-Garcia, Rodrigo/D-4953-2019; Lopez-de-Andres, Ana/AAD-8703-2019	Jimenez-Trujillo, Isabel/0000-0002-9394-6799; Resino, Salvador/0000-0001-8783-0450; Lopez-de-Andres, Ana/0000-0001-5551-5181; Jimenez-Garcia, Rodrigo/0000-0001-5906-9393; Lopez-de-Andres, Ana/0000-0001-5551-5181; Alvaro-Meca, Alejandro/0000-0003-1315-4386; de Miguel-Diez, Javier/0000-0003-4543-573X; Hernandez-Barrera, Valentin/0000-0001-5790-1959; Puente-Maestu, Luis/0000-0001-8501-0117	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Institute de Salud Carlos III) [PI11/00245, PI12/00019, PI12/02734]; European Union through the Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa"); Grupo de Excelencia Investigadora URJC-Banco: Investigacion traslacional en el proceso de salud-enfermedad (ITPSE) [30VCPIGI03]	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Institute de Salud Carlos III); European Union through the Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa"); Grupo de Excelencia Investigadora URJC-Banco: Investigacion traslacional en el proceso de salud-enfermedad (ITPSE)	This study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Institute de Salud Carlos III grants no. PI11/00245 to SR, PI12/00019 to MM and PI12/02734 to LPM) co-financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa") and by the Grupo de Excelencia Investigadora URJC-Banco Santander No 30VCPIGI03: Investigacion traslacional en el proceso de salud-enfermedad (ITPSE) to RJG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias- Health Research Fund, Instituto de Salud Carlos III grants no. PI11/00245 to SR, PI12/00019 to AAM and PI12/02734 to LPM) co-financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa") and by the Grupo de Excelencia Investigadora URIC-Banco Santander No 30VCPIGI03: Investigacion traslacional en el proceso de salud-enfermedad (ITPSE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akanbi MO, 2015, J AIDS CLIN RES, V6; Akgun KM, 2013, JAIDS-J ACQ IMM DEF, V62, P52, DOI 10.1097/QAI.0b013e318278f3fa; Alkaline Software Inc, WEBS FREE 2014 MED C; Alvaro-Meca A, 2014, J INFECTION, V68, P355, DOI 10.1016/j.jinf.2013.12.003; [Anonymous], 2001, SUBD GEN DES; Bednasz CJ, 2015, FUTURE VIROL, V10, P981, DOI 10.2217/FVL.15.64; Brown T, 2010, SEX TRANSM INFECT, V86, pI3, DOI 10.1136/sti.2010.044784; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Crothers K, 2006, CHEST, V130, P1326, DOI 10.1378/chest.130.5.1326; Crothers K, 2011, AM J RESP CRIT CARE, V183, P388, DOI 10.1164/rccm.201006-0836OC; Diez M, 2014, EURO SURVEILL, V19; Drummond MB, 2012, THORAX, V67, P309, DOI 10.1136/thoraxjnl-2011-200702; Erol S, 2009, HEPAT MON, V9, P39; Estebanez-Munoz M, 2012, ARCH BRONCONEUMOL, V48, P126, DOI 10.1016/j.arbres.2011.12.001; Fischer WA, 2014, COPD, V11, P10, DOI 10.3109/15412555.2013.800854; George MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006328; Gingo MR, 2010, AM J RESP CRIT CARE, V182, P790, DOI 10.1164/rccm.200912-1858OC; Gonzalez-Garcia J, 2012, 19 C RETR OPP INF CR; Kanazawa H, 2003, CHEST, V123, P596, DOI 10.1378/chest.123.2.596; Kristoffersen US, 2012, CLIN PHYSIOL FUNCT I, V32, P288, DOI 10.1111/j.1475-097X.2012.01124.x; Madeddu G, 2013, INFECTION, V41, P347, DOI 10.1007/s15010-012-0330-x; Magalhaes MG, 2007, J AM DENT ASSOC, V138, P1468, DOI 10.14219/jada.archive.2007.0083; Makinson A, 2015, EUR RESPIR J, V45, P828, DOI 10.1183/09031936.00154914; Moorman J, 2005, CHEST, V128, P2882, DOI 10.1378/chest.128.4.2882; Morris Alison, 2011, Proc Am Thorac Soc, V8, P320, DOI 10.1513/pats.201006-045WR; Norris KA, 2011, IMMUNOL RES, V50, P175, DOI 10.1007/s12026-011-8218-x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Petrache I, 2008, THORAX, V63, P463, DOI 10.1136/thx.2007.079111; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Rahmanian Shiva, 2011, Proc Am Thorac Soc, V8, P313, DOI 10.1513/pats.201009-058WR; Raynaud C, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-117; Roca B, 2003, J INFECTION, V47, P117, DOI 10.1016/S0163-4453(03)00067-7; Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355; Samperiz G, 2014, HIV MED, V15, P321, DOI 10.1111/hiv.12117; Schwarcz SK, 2014, AIDS PATIENT CARE ST, V28, P517, DOI 10.1089/apc.2014.0079; Silva DR, 2010, EPIDEMIOL INFECT, V138, P167, DOI 10.1017/S0950268809990276; Simmons RD, 2013, HIV MED, V14, P596, DOI 10.1111/hiv.12045; Simonetti JA, 2014, J AIDS CLIN RES, V5; Soriano V, 2015, CURR OPIN HIV AIDS, V10, P309, DOI 10.1097/COH.0000000000000175; Stover J, 2004, SEX TRANSM INFECT, V80, DOI 10.1136/sti.2004.010157; UN Joint Programme on HIV/AIDS, 2010, GLOB REP UN REP GLOB; Vallecillo G, 2010, CURR HIV RES, V8, P641, DOI 10.2174/157016210794088272; Yearsley MM, 2005, DIAGN MOL PATHOL, V14, P48, DOI 10.1097/01.pas.0000142168.72253.11	43	7	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2016	11	11							e0166421	10.1371/journal.pone.0166421	http://dx.doi.org/10.1371/journal.pone.0166421			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC0MG	27846297	Green Submitted, Green Published, gold			2023-01-03	WOS:000387794600062
J	Gaudry, S; Hajage, D; Dreyfuss, D				Gaudry, Stephane; Hajage, David; Dreyfuss, Didier			Initiation of Renal-Replacement Therapy in the Intensive Care Unit REPLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Gaudry, Stephane; Hajage, David; Dreyfuss, Didier] Assistance Publ Hop Paris, Paris, France	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Dreyfuss, D (corresponding author), Assistance Publ Hop Paris, Paris, France.	didier.dreyfuss@aphp.fr	Hajage, David/D-5226-2014	Hajage, David/0000-0002-8475-4090				Pocock SJ, 2016, NEW ENGL J MED, V375, P971, DOI 10.1056/NEJMra1601511; Ridgeon EE, 2016, CRIT CARE MED, V44, P1278, DOI 10.1097/CCM.0000000000001670; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	4	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2016	375	19					1901	1902						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB6ZK	27959653				2023-01-03	WOS:000387534200021
J	Scheicher, B; Lorenzer, C; Gegenbauer, K; Partlic, J; Andreae, F; Kirsch, AH; Rosenkranz, AR; Werzer, O; Zimmer, A				Scheicher, Bernhard; Lorenzer, Cornelia; Gegenbauer, Katrin; Partlic, Julia; Andreae, Fritz; Kirsch, Alexander H.; Rosenkranz, Alexander R.; Werzer, Oliver; Zimmer, Andreas			Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration	PLOS ONE			English	Article							IN-VITRO; OLIGONUCLEOTIDE-NANOPARTICLES; PHYSICOCHEMICAL CHARACTERIZATION; ALBUMIN NANOPARTICLES; GOLD NANOPARTICLES; ENDOTHELIAL-CELLS; SECRETOGRANIN-II; BASIC FGF; ANGIOGENESIS; NEUROPEPTIDE	Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances clinical implementation. Over the last years, the focus of our group was laid on protamine-oligonucleotide-nanoparticles (so called proticles), however, the possibility to modify the size, zeta potential or loading efficiencies was limited. Therefore, at the present study we integrated a stepwise addition of protamine (titration) into the formation process of proticles loaded with the angiogenic neuropeptide secretoneurin (SN). A particle size around 130 nm was determined when proticles were assembled by the commonly used protamine addition at once. Through application of the protamine titration process it was possible to modify and adjust the particle size between approx. 120 and 1200 nm (dependent on mass ratio) without influencing the SN loading capacity. Dynamic light scattering pointed out that the difference in particle size was most probably the result of a secondary aggregation. Initially-formed particles of early stages in the titration process aggregated towards bigger assemblies. Atomic-force-microscopy images also revealed differences in morphology along with different particle size. In contrast, the SN loading was only influenced by the applied mass ratio, where a slight saturation effect was observable. Up to 65% of deployed SN could be imbedded into the proticle matrix. An in-vivo biodistribution study (i.m.) showed a retarded distribution of SN from the site of injection after the application of a SN-proticle formulation. Further, it was demonstrated that SN loaded proticles can be successfully freeze-dried and resuspended afterwards. To conclude, the integration of the protamine titration process offers new possibilities for the formulation of proticles in order to address key parameters of drug delivery systems as size, API loading or modified drug release.	[Scheicher, Bernhard; Lorenzer, Cornelia; Gegenbauer, Katrin; Partlic, Julia; Werzer, Oliver; Zimmer, Andreas] Graz Univ, Inst Pharmaceut Sci, Dept Pharmaceut Technol, Graz, Austria; [Andreae, Fritz] PiCHEM, Kahngasse 20, Graz, Austria; [Kirsch, Alexander H.; Rosenkranz, Alexander R.] Med Univ Graz, Dept Internal Med, Clin Div Nephrol, Auenbruggerpl 27, Graz, Austria	University of Graz; Medical University of Graz	Zimmer, A (corresponding author), Graz Univ, Inst Pharmaceut Sci, Dept Pharmaceut Technol, Graz, Austria.	andreas.zimmer@uni-graz.at	; Zimmer, Andreas/C-7290-2012; Werzer, Oliver/A-2752-2014	Kirsch, Alexander/0000-0001-6711-7834; Zimmer, Andreas/0000-0003-3127-287X; Werzer, Oliver/0000-0003-0732-4422	CEO of piCHEM	CEO of piCHEM	Dr. Fritz Andreae is the owner and CEO of piCHEM, who provided financial support in the form of salary for Dr. Andreae. piCHEM was the manufacturer of the peptides in this study. piCHEM did not have any additional role in the study design, data collection and analysis as well as the decision to publish our data.	Albrecht-Schgoer K, 2014, ANGIOGENESIS, V17, P27, DOI 10.1007/s10456-013-9375-4; Albrecht-Schgoer K, 2012, CIRCULATION, V126, P2491, DOI 10.1161/CIRCULATIONAHA.111.076950; Almer G, 2014, INT J NANOMED, V9, P4211, DOI 10.2147/IJN.S66830; Bartczak D, 2013, ACS NANO, V7, P5628, DOI 10.1021/nn402111z; Bartczak D, 2012, SMALL, V8, P122, DOI 10.1002/smll.201101422; Bastiat G, 2013, J CONTROL RELEASE, V170, P334, DOI 10.1016/j.jconrel.2013.06.014; Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014; Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3; Budhian A, 2008, INT J PHARMACEUT, V346, P151, DOI 10.1016/j.ijpharm.2007.06.011; Dinauer N, 2004, J CONTROL RELEASE, V96, P497, DOI 10.1016/j.jconrel.2004.02.020; Egger M, 2007, FASEB J, V21, P2906, DOI 10.1096/fj.06-7440com; El-Shabouri MH, 2002, INT J PHARM, V249, P101, DOI 10.1016/S0378-5173(02)00461-1; Essa S, 2011, INT J PHARMACEUT, V411, P178, DOI 10.1016/j.ijpharm.2011.02.039; FINSY R, 1991, PART PART SYST CHAR, V8, P187, DOI 10.1002/ppsc.19910080135; Fischer-Colbrie R, 2005, CURR PROTEIN PEPT SC, V6, P373, DOI 10.2174/1389203054546334; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065; Henk M., 2009, PARTICLE SIZE MEASUR; Hiemenz P.C., 1986, PRINCIPLES COLLOID S, VSecond; Hoffmann J A, 1990, Protein Expr Purif, V1, P127, DOI 10.1016/1046-5928(90)90005-J; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; Junghans M, 2001, BBA-PROTEIN STRUCT M, V1544, P177, DOI 10.1016/S0167-4838(00)00219-3; Junghans M, 2000, Nucleic Acids Res, V28, pE45, DOI 10.1093/nar/28.10.e45; Kerkmann M, 2006, OLIGONUCLEOTIDES, V16, P313, DOI 10.1089/oli.2006.16.313; Kirchmair R, 2004, CIRCULATION, V110, P1121, DOI 10.1161/01.CIR.0000139884.81390.56; Kirchmair R, 2004, CIRCULATION, V109, P777, DOI 10.1161/01.CIR.0000112574.07422.C1; KIRCHMAIR R, 1993, NEUROSCIENCE, V53, P359, DOI 10.1016/0306-4522(93)90200-Y; Lochmann D, 2005, EUR J PHARM BIOPHARM, V59, P419, DOI 10.1016/j.ejpb.2004.04.001; Lochmann D, 2004, J MICROENCAPSUL, V21, P625, DOI 10.1080/02652040400000504; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Mayer G, 2005, J CONTROL RELEASE, V106, P181, DOI 10.1016/j.jconrel.2005.04.019; Mori Y, 2010, INT J NANOMED, V5, P147; Pali-Scholl I, 2013, EUR J PHARM BIOPHARM, V85, P656, DOI 10.1016/j.ejpb.2013.03.003; Sadeghi R, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2565-1; Schatz C, 2004, BIOMACROMOLECULES, V5, P1882, DOI 10.1021/bm049786+; Scheicher B, 2015, EUR J PHARM SCI, V75, P54, DOI 10.1016/j.ejps.2015.04.009; Schgoer W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074029; Schgoer W, 2009, CIRC RES, V105, P994, DOI 10.1161/CIRCRESAHA.109.199513; Takikawa M, 2015, J SURG RES, V196, P247, DOI 10.1016/j.jss.2015.03.022; Tilley AJ, 2013, J COLLOID INTERF SCI, V392, P288, DOI 10.1016/j.jcis.2012.09.051; Vogel V, 2005, J CONTROL RELEASE, V103, P99, DOI 10.1016/j.jconrel.2004.11.029; Wernig K, 2008, J CONTROL RELEASE, V130, P192, DOI 10.1016/j.jconrel.2008.06.005	42	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2016	11	11							e0164149	10.1371/journal.pone.0164149	http://dx.doi.org/10.1371/journal.pone.0164149			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9OG	27828968	Green Submitted, Green Published, gold			2023-01-03	WOS:000387724300014
J	De Backer, D; Dorman, T				De Backer, Daniel; Dorman, Todd			Surviving Sepsis Guidelines A Continuous Move Toward Better Care of Patients With Sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTENSIVE-CARE		[De Backer, Daniel] Univ Libre Bruxelles, CHIREC Hosp, Dept Intens Care, Brussels, Belgium; [Dorman, Todd] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Universite Libre de Bruxelles; Johns Hopkins University	Dorman, T (corresponding author), Johns Hopkins Univ Hosp, Dept Anesthesiol, Crit Care Med, Turner 17,720 Rutland Ave, Baltimore, MD 21205 USA.	tdorman@jhmi.edu	De Backer, Daniel/AAF-4177-2020	De Backer, Daniel/0000-0001-9841-5762; dorman, todd/0000-0002-8616-8677				Angus DC, 2015, INTENS CARE MED, V41, P1549, DOI 10.1007/s00134-015-3822-1; Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x; Howell MD, 2017, JAMA-J AM MED ASSOC, V317, P847, DOI 10.1001/jama.2017.0131; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Levy MM, 2015, CRIT CARE MED, V43, P3, DOI [10.1097/CCM.0000000000000723, 10.1007/s00134-014-3496-0]; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rhodes A, 2015, INTENS CARE MED, V41, P1620, DOI 10.1007/s00134-015-3906-y; Roberts JA, 2014, CLIN INFECT DIS, V58, P1072, DOI 10.1093/cid/ciu027	9	55	56	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	2017	317	8					807	808		10.1001/jama.2017.0059	http://dx.doi.org/10.1001/jama.2017.0059			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM7PW	28114630				2023-01-03	WOS:000395505600015
J	Kamei, J; Hayashi, S; Sakai, A; Nakanishi, Y; Kai, M; Ikegami, M; Ikeda, H				Kamei, Junzo; Hayashi, Shunsuke; Sakai, Akane; Nakanishi, Yuki; Kai, Misa; Ikegami, Megumi; Ikeda, Hiroko			Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NF kappa B) phosphorylation in spinal cord of mice	PLOS ONE			English	Article							CHRONIC CONSTRICTION INJURY; METASTATIC BREAST-CANCER; ACETYL-L-CARNITINE; LEUKEMIA GROUP-B; MECHANICAL ALLODYNIA; CYTOKINE EXPRESSION; INFLAMMATORY PAIN; INDUCED APOPTOSIS; DOSE PACLITAXEL; RATS	Peripheral neuropathy is the major side effect caused by paclitaxel, a microtubule-binding antineoplastic drug. Paclitaxel-induced peripheral neuropathy causes a long-term negative impact on the patient's quality of life. However, the mechanism underlying paclitaxel-induced peripheral neuropathy is still unknown, and there is no established treatment. Ghrelin is known to attenuate thermal hyperalgesia and mechanical allodynia in chronic constriction injury of the sciatic nerve, and inhibit the activation of nuclear factor kappa B (NF kappa B) in the spinal dorsal horn. Rikkunshito (RKT), a kampo medicine, increases the secretion of ghrelin in rodents and humans. Thus, RKT may attenuate paclitaxel-induced peripheral neuropathy by inhibiting phosphorylated NF kappa B (pNF kappa B) in the spinal cord. We found that paclitaxel dose-dependently induced mechanical hyperalgesia in mice. Paclitaxel increased the protein levels of spinal pNF kappa B, but not those of spinal NF kappa B. NF kappa B inhibitor attenuated paclitaxel-induced mechanical hyperalgesia suggesting that the activation of NF kappa B mediates paclitaxel-induced hyperalgesia. RKT dose-dependently attenuated paclitaxel-induced mechanical hyperalgesia. Ghrelin receptor antagonist reversed the RKT-induced attenuation of paclitaxel-induced mechanical hyperalgesia. RKT inhibited the paclitaxel-induced increase in the protein levels of spinal pNF kappa B. Taken together, the present study indicates that RKT exerts an antihyperalgesic effect in paclitaxel-induced neuropathic pain by suppressing the activation of spinal NF kappa B.	[Kamei, Junzo; Hayashi, Shunsuke; Sakai, Akane; Nakanishi, Yuki; Kai, Misa; Ikegami, Megumi; Ikeda, Hiroko] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol & Therapeut, Shinagawa Ku, Tokyo, Japan	Hoshi University	Kamei, J (corresponding author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol & Therapeut, Shinagawa Ku, Tokyo, Japan.	kamei@hoshi.ac.jp						Akerley W, 2003, CANCER, V97, P2480, DOI 10.1002/cncr.11375; Argyriou AA, 2008, CRIT REV ONCOL HEMAT, V66, P218, DOI 10.1016/j.critrevonc.2008.01.008; Bames P.J., 1997, NEW ENGL J MED, V336, P1066; Bava SV, 2005, J BIOL CHEM, V280, P6301, DOI 10.1074/jbc.M410647200; Boyette-Davis J, 2011, PAIN, V152, P308, DOI 10.1016/j.pain.2010.10.030; Cata JP, 2008, BRAIN RES, V1229, P100, DOI 10.1016/j.brainres.2008.07.001; Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021; Esin E, 2014, ONCOTARGETS THER, V7, P599, DOI 10.2147/OTT.S60995; Ferrini F, 2009, CURR NEUROPHARMACOL, V7, P37, DOI 10.2174/157015909787602779; Flatters SJL, 2006, PAIN, V122, P245, DOI 10.1016/j.pain.2006.01.037; Flatters SJL, 2006, NEUROSCI LETT, V397, P219, DOI 10.1016/j.neulet.2005.12.013; Forsyth PA, 1997, J NEURO-ONCOL, V35, P47, DOI 10.1023/A:1005805907311; Gahete MD, 2011, PEPTIDES, V32, P2225, DOI 10.1016/j.peptides.2011.09.019; Garcia JM, 2008, ENDOCRINOLOGY, V149, P455, DOI 10.1210/en.2007-0828; Gogas H, 1996, GYNECOL ONCOL, V61, P22, DOI 10.1006/gyno.1996.0090; Guneli E, 2010, NEUROSCI LETT, V479, P226, DOI 10.1016/j.neulet.2010.05.066; Guo CJ, 2004, GLIA, V48, P259, DOI 10.1002/glia.20079; Hatton T., 2010, INT J PEPT; Hiyama T, 2008, WORLD J GASTROENTERO, V14, P3123, DOI 10.3748/wjg.14.3123; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Ito S, 2012, J PHARMACOL EXP THER, V342, P53, DOI 10.1124/jpet.111.187401; Jin HW, 2008, EXP NEUROL, V210, P229, DOI 10.1016/j.expneurol.2007.11.001; Kawahara H, 2007, PEDIATR SURG INT, V23, P1001, DOI 10.1007/s00383-007-1986-7; Kim HK, 2010, ANESTHESIOLOGY, V112, P432, DOI 10.1097/ALN.0b013e3181ca31bd; Ledeboer A, 2007, BRAIN BEHAV IMMUN, V21, P686, DOI 10.1016/j.bbi.2006.10.012; Lee HL, 2004, NEUROREPORT, V15, P2807; Lee JJ, 2006, J CLIN ONCOL, V24, P1633, DOI 10.1200/JCO.2005.04.0543; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; LIPTON RB, 1989, NEUROLOGY, V39, P368, DOI 10.1212/WNL.39.3.368; Ma VY, 1998, BRAIN RES, V797, P243, DOI 10.1016/S0006-8993(98)00380-1; Matsumoto M, 2006, J PHARMACOL EXP THER, V318, P735, DOI 10.1124/jpet.106.103614; Matsumura T, 2010, J GASTROENTEROL, V45, P300, DOI 10.1007/s00535-009-0166-z; Nabholtz JM, 1996, J CLIN ONCOL, V14, P1858, DOI 10.1200/JCO.1996.14.6.1858; Pan YD, 2010, REGION ANESTH PAIN M, V35, P231, DOI 10.1097/AAP.0b013e3181df245b; Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3; Rowinsky E K, 1993, J Natl Cancer Inst Monogr, P107; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; Sakaue G, 2001, NEUROREPORT, V12, P2079, DOI 10.1097/00001756-200107200-00008; Scripture CD, 2006, CURR NEUROPHARMACOL, V4, P165, DOI 10.2174/157015906776359568; Sibilia V, 2006, NEUROPHARMACOLOGY, V51, P497, DOI 10.1016/j.neuropharm.2006.04.009; Sibilia V, 2012, AMINO ACIDS, V43, P1751, DOI 10.1007/s00726-012-1260-8; Sun T, 2012, EUR J PHARMACOL, V682, P79, DOI 10.1016/j.ejphar.2012.02.017; Takeda H, 2008, GASTROENTEROLOGY, V134, P2004, DOI 10.1053/j.gastro.2008.02.078; Tanabe Y, 2013, INT J CLIN ONCOL, V18, P132, DOI 10.1007/s10147-011-0352-x; TATSUTA M, 1993, ALIMENT PHARM THERAP, V7, P459; Tegeder I, 2004, J NEUROSCI, V24, P1637, DOI 10.1523/JNEUROSCI.3118-03.2004; Tominaga K, 2013, J GASTROENTEROL, V48, P452, DOI 10.1007/s00535-013-0788-z; Tominaga K, 2012, J GASTROENTEROL, V47, P284, DOI 10.1007/s00535-011-0488-5; Vergnano AM, 2008, ENDOCRINOLOGY, V149, P2306, DOI 10.1210/en.2007-1164; Wang W, 2009, AM J PHYSIOL-RENAL, V297, pF1032, DOI 10.1152/ajprenal.00044.2009; WIERNIK PH, 1987, CANCER RES, V47, P2486; Winer EP, 2004, J CLIN ONCOL, V22, P2061, DOI 10.1200/JCO.2004.08.048; Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018; Xiao W, 2007, NEUROSCIENCE, V144, P714, DOI 10.1016/j.neuroscience.2006.09.044; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yanai M, 2013, J GASTROENTEROL, V48, P611, DOI 10.1007/s00535-012-0687-8; Zhou CH, 2014, REGION ANESTH PAIN M, V39, P137, DOI 10.1097/AAP.0000000000000050	57	6	7	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2017	12	2							e0171819	10.1371/journal.pone.0171819	http://dx.doi.org/10.1371/journal.pone.0171819			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK9GJ	28182729	Green Submitted, Green Published, gold			2023-01-03	WOS:000394231800120
J	Gucluler, G; Adiguzel, E; Gungor, B; Kahraman, T; Gursel, M; Yilmaz, B; Gursel, I				Gucluler, Gozde; Adiguzel, Emre; Gungor, Bilgi; Kahraman, Tamer; Gursel, Mayda; Yilmaz, Bilge; Gursel, Ihsan			Impaired toll like receptor-7 and 9 induced immune activation in chronic spinal cord injured patients contributes to immune dysfunction	PLOS ONE			English	Article							C-REACTIVE PROTEIN; OXIDATIVE STRESS; CHRONIC INFLAMMATION; PATTERN-RECOGNITION; INNATE IMMUNITY; SYSTEM FUNCTION; MORTALITY; SCI	Reduced immune activation or immunosuppression is seen in patients withneurological diseases. Urinary and respiratory infections mainly manifested as septicemia and pneumonia are the most frequent complications following spinal cord injuries and they account for the majority of deaths. The underlying reason of these losses is believed to arise due to impaired immune responses to pathogens. Here, we hypothesized that susceptibility to infections of chronic spinal cord injured (SCI) patients might be due to impairment in recognition of pathogen associated molecular patterns and subsequently declining innate and adaptive immune responses that lead to immune dysfunction. We tested our hypothesis on healthy and chronic SCI patients with a level of injury above T-6. Donor PBMCs were isolated and stimulated with different toll like receptor ligands and T-cell inducers aiming to investigate whether chronic SCI patients display differential immune activation to multiple innate and adaptive immune cell stimulants. We demonstrate that SCI patients' B-cell and plasmacytoid dendritic cells retain their functionality in response to TLR7 and TLR9 ligand stimulation as they secreted similar levels of IL6 and IFN alpha. The immune dysfunction is not probably due to impaired T-cell function, since neither CD4(+) T-cell dependent IFN. producing cell number nor IL10 producing regulatory T-cells resulted different outcomes in response to PMA-Ionomycin and PHA-LPS stimulation, respectively. We showed that TLR7 dependent IFN gamma and IP10 levels and TLR9 mediated APC function reduced substantially in SCI patients compared to healthy subjects. More importantly, IP10 producing monocytes were significantly fewer compared to healthy subjects in response to TLR7 and TLR9 stimulation of SCI PBMCs. When taken together this work implicated that these defects could contribute to persistent complications due to increased susceptibility to infections of chronic SCI patients.	[Gucluler, Gozde; Kahraman, Tamer; Gursel, Ihsan] Bilkent Univ, Dept Mol Biol & Genet, THORLAB, Ankara, Turkey; [Adiguzel, Emre; Yilmaz, Bilge] Gaziler Phys Med & Rehabil Educ & Res Hosp, Ankara, Turkey; [Gungor, Bilgi; Gursel, Mayda] Middle East Tech Univ, Dept Mol Biol & Genet, Ankara, Turkey; [Yilmaz, Bilge] Univ Hlth Sci, Gaziler Phys Med & Rehabil Educ & Res Hosp, Dept Phys Med & Rehabil, Gulhane Med Sch, Ankara, Turkey	Ihsan Dogramaci Bilkent University; Gaziler Physical Therapy & Research Hospital; Middle East Technical University; Gaziler Physical Therapy & Research Hospital; University of Health Sciences Turkey	Gursel, I (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, THORLAB, Ankara, Turkey.; Yilmaz, B (corresponding author), Gaziler Phys Med & Rehabil Educ & Res Hosp, Ankara, Turkey.; Yilmaz, B (corresponding author), Univ Hlth Sci, Gaziler Phys Med & Rehabil Educ & Res Hosp, Dept Phys Med & Rehabil, Gulhane Med Sch, Ankara, Turkey.	biyilmaz@gata.edu.tr; ihsangursel@bilkent.edu.tr	YILMAZ, Bilge/A-7428-2013; Gursel, Ihsan/AAT-7168-2021; YILMAZ, Bilge/W-6481-2019; Gursel, M/H-1812-2012; Adiguzel, Emre/G-9138-2015	YILMAZ, Bilge/0000-0003-1173-9399; YILMAZ, Bilge/0000-0003-1173-9399; Gursel, M/0000-0003-0044-9054; Kahraman, Tamer/0000-0002-5527-7336; Gursel, Ihsan/0000-0003-3761-1166; Adiguzel, Emre/0000-0002-2447-5065	Bilkent University	Bilkent University(Ihsan Dogramaci Bilkent University)	This study is partly supported by Bilkent University account to IG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison DJ, 2015, SPINAL CORD, V53, P14, DOI 10.1038/sc.2014.184; Campagnolo DI, 2008, SPINAL CORD, V46, P477, DOI 10.1038/sc.2008.4; Campagnolo D I, 2000, J Spinal Cord Med, V23, P121; CAMPAGNOLO DI, 1994, AM J PHYS MED REHAB, V73, P387, DOI 10.1097/00002060-199411000-00003; CRUSE JM, 1992, IMMUNOL RES, V11, P104, DOI 10.1007/BF02918615; Davies AL, 2007, ARCH PHYS MED REHAB, V88, P1384, DOI 10.1016/j.apmr.2007.08.004; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Fallarino F, 2016, METHODS MOL BIOL, V1390, P383, DOI 10.1007/978-1-4939-3335-8_23; Gibson AE, 2008, SPINAL CORD, V46, P616, DOI 10.1038/sc.2008.32; Held KS, 2010, EXP NEUROL, V226, P242, DOI 10.1016/j.expneurol.2010.08.036; Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043; Leszek J, 2016, CNS NEUROL DISORD-DR, V15, P329, DOI 10.2174/1871527315666160202125914; Liang HF, 2008, ARCH PHYS MED REHAB, V89, P36, DOI 10.1016/j.apmr.2007.08.121; Lidal IB, 2007, J REHABIL MED, V39, P145, DOI 10.2340/16501977-0017; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987; Mills KHG, 2011, NAT REV IMMUNOL, V11, P807, DOI 10.1038/nri3095; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Riegger T, 2009, NEUROSCIENCE, V158, P1194, DOI 10.1016/j.neuroscience.2008.08.021; Riegger T, 2007, EUR J NEUROSCI, V25, P1743, DOI 10.1111/j.1460-9568.2007.05447.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421	24	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2017	12	2							e0171003	10.1371/journal.pone.0171003	http://dx.doi.org/10.1371/journal.pone.0171003			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK1SG	28170444	Green Published, Green Submitted, gold			2023-01-03	WOS:000393705500018
J	Kim, HJ; Lee, J; Park, M; Kim, Y; Lee, H; Kim, DK; Joo, KW; Kim, YS; Cho, EJ; Ahn, C; Oh, KH				Kim, Hyo Jin; Lee, Joongyub; Park, Miseon; Kim, Yuri; Lee, Hajeong; Kim, Dong Ki; Joo, Kwon Wook; Kim, Yon Su; Cho, Eun Jin; Ahn, Curie; Oh, Kook-Hwan			Lower Education Level Is a Risk Factor for Peritonitis and Technique Failure but Not a Risk for Overall Mortality in Peritoneal Dialysis under Comprehensive Training System	PLOS ONE			English	Article							CORD INJURY PATIENTS; RETROSPECTIVE COHORT; SKIN FLORA; PREDICTORS; SURVIVAL; CARE; COLONIZATION; DETERMINANTS; COMORBIDITY; CREATININE	Background Lower education level could be a risk factor for higher peritoneal dialysis (PD)-associated peritonitis, potentially resulting in technique failure. This study evaluated the influence of lower education level on the development of peritonitis, technique failure, and overall mortality. Methods Patients over 18 years of age who started PD at Seoul National University Hospital between 2000 and 2012 with information on the academic background were enrolled. Patients were divided into three groups: middle school or lower (academic year <= 9, n = 102), high school (9<academic year <= 12, n = 229), and higher than high school (academic year>12, n = 324). Outcomes were analyzed using Cox proportional hazards models and competing risk regression. Results A total of 655 incident PD patients (60.9% male, age 48.4+/-14.1 years) were analyzed. During follow-up for 41 (interquartile range, 20-65) months, 255 patients (38.9%) experienced more than one episode of peritonitis, 138 patients (21.1%) underwent technique failure, and 78 patients (11.9%) died. After adjustment, middle school or lower education group was an independent risk factor for peritonitis (adjusted hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.10-2.36; P=0.015) and technique failure (adjusted HR, 1.87; 95% CI, 1.103.18; P= 0.038), compared with higher than high school education group. However, lower education was not associated with increased mortality either by as-treated (adjusted HR, 1.11; 95% CI, 0.53-2.33; P= 0.788) or intent-to-treat analysis (P=0.726). Conclusions Although lower education was a significant risk factor for peritonitis and technique failure, it was not associated with increased mortality in PD patients. Comprehensive training and multidisciplinary education may overcome the lower education level in PD.	[Kim, Hyo Jin] Dongguk Univ, Gyeongju Hosp, Dept Internal Med, Gyeongju Si, Gyeongsangbuk D, South Korea; [Lee, Joongyub] Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea; [Park, Miseon; Kim, Yuri; Lee, Hajeong; Kim, Dong Ki; Joo, Kwon Wook; Kim, Yon Su; Ahn, Curie; Oh, Kook-Hwan] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Cho, Eun Jin] Hongseong Med Ctr, Dept Internal Med, Hongseong, South Korea	Dongguk University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital	Oh, KH (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.	khoh@snu.ac.kr	Kim, Dong Ki/J-5389-2012	Kim, Dong Ki/0000-0002-5195-7852				Brown MC, 2011, PERITON DIALYSIS INT, V31, P639, DOI 10.3747/pdi.2010.00185; Chern YB, 2013, PERITON DIALYSIS INT, V33, P552, DOI 10.3747/pdi.2012.00065; Chidambaram M, 2011, PERITON DIALYSIS INT, V31, P565, DOI 10.3747/pdi.2010.00096; CHIN P, 1976, J HYG-CAMBRIDGE, V77, P93, DOI 10.1017/S0022172400055558; Cho EJ, 2012, NEPHROLOGY, V17, P472, DOI 10.1111/j.1440-1797.2012.01598.x; Davenport A, 2009, PERITON DIALYSIS INT, V29, P297; DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272-6386(95)90657-6; Davies SJ, 2002, NEPHROL DIAL TRANSPL, V17, P1085, DOI 10.1093/ndt/17.6.1085; de Moraes TP, 2014, PERITON DIALYSIS INT, V34, P714, DOI 10.3747/pdi.2013.00282; Fan XG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107485; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gould D, 1994, J Clin Nurs, V3, P339, DOI 10.1111/j.1365-2702.1994.tb00410.x; Kumar VA, 2014, PERITON DIALYSIS INT, V34, P171, DOI 10.3747/pdi.2012.00165; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Martin LC, 2011, CLIN J AM SOC NEPHRO, V6, P1944, DOI 10.2215/CJN.11431210; MONTGOMERIE JZ, 1980, AM J EPIDEMIOL, V112, P508, DOI 10.1093/oxfordjournals.aje.a113020; MONTGOMERIE JZ, 1989, J CLIN MICROBIOL, V27, P1613, DOI 10.1128/JCM.27.7.1613-1616.1989; NOBLE WC, 1974, BRIT J DERMATOL, V91, P201, DOI 10.1111/j.1365-2133.1974.tb15866.x; O'Shea S, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-19; Oliver MJ, 2007, KIDNEY INT, V71, P673, DOI 10.1038/sj.ki.5002107; Oliver MJ, 2010, NEPHROL DIAL TRANSPL, V25, P2737, DOI 10.1093/ndt/gfq085; Shen JI, 2013, PERITON DIALYSIS INT, V33, P155, DOI 10.3747/pdi.2011.00233; SIEKMANN L, 1985, J CLIN CHEM CLIN BIO, V23, P137; Stack AG, 2002, J AM SOC NEPHROL, V13, P1279, DOI 10.1681/ASN.V1351279; Xu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050766; Yang ZK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095894	27	13	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2017	12	1							e0169063	10.1371/journal.pone.0169063	http://dx.doi.org/10.1371/journal.pone.0169063			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH3AE	28056058	Green Published, Green Submitted, gold			2023-01-03	WOS:000391639100018
J	Park, HY; Park, JW; Song, HJ; Sohn, HS; Kwon, JW				Park, Hae-Young; Park, Ji-Won; Song, Hong Ji; Sohn, Hyun Soon; Kwon, Jin-Won			The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea	PLOS ONE			English	Article							POTENTIALLY INAPPROPRIATE MEDICATIONS; DWELLING OLDER-ADULTS; BODY-MASS INDEX; ELDERLY-PATIENTS; PEOPLE; RISK; OUTCOMES; MULTIMORBIDITY; PREVALENCE; FAILURE	Dementia is a major concern among growing chronic diseases in the aging society and its association with polypharmacy has not been adequately assessed. The objective of this study was to determine the association between polypharmacy and dementia through multiple statistical approaches. We conducted a nested case-control study for newly diagnosed dementia cases using the South Korean National Health Insurance Service sample cohort database (2002-2013, n = 1,025,340). Interactions between polypharmacy (an average use of >= 5 prescription drugs daily) and comorbidities or potentially inappropriate medications (PIMs) were tested. The odds ratios (ORs) for dementia were analyzed according to the presence of comorbidities, PIM uses, the average number of prescribed daily drugs, and significant interactions with polypharmacy using univariate and multiple logistic regression analyses. A higher prevalence of comorbidities, history of PIM use, higher PIM exposure, and higher proportion of polypharmacy were noted among cases than in controls. In the univariate analysis, the OR for dementia increased significantly with the increase in the number of prescribed drugs [1-<5 drugs: 1.72, 95% confidence interval (CI): 1.56-1.88; 5-<10 drugs: 2.64, 95% CI: 2.32-3.05; >= 10 drugs: 3.35, 95% CI: 2.38-4.71; <1 drug used as reference]. Polypharmacy was correlated with comorbidities and PIM use, and significant interactions were observed between polypharmacy and anticholinergics; H2-receptor antagonists; and comorbidities such as hypertension, peripheral or cerebrovascular disease, congestive heart failure, hemiplegia, diabetes, depression, all other mental disorders, chronic obstructive pulmonary disease, peptic ulcer disease, and chronic liver disease (p<0.001). In the multiple regression analysis, most cases exhibited increasing ORs for dementia with increasing polypharmacy levels. Moreover, the increase in OR was more evident in the absence of drugs or comorbidities that showed significant interactions with poly pharmacy than in their presence. Polypharmacy increases the risk of PIM administration, and as some PIMs may have cognition-impairing effects, prolonged polypharmacy may result in dementia. Therefore, efforts are needed to limit or decrease the prescription of medications that have been associated with risk of dementia in the elderly.	[Park, Hae-Young; Kwon, Jin-Won] Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea; [Park, Hae-Young; Kwon, Jin-Won] Kyungpook Natl Univ, Pharmaceut Sci Res Inst, Daegu, South Korea; [Park, Ji-Won] Kyungpook Natl Univ, Coll Nat Sci, Daegu, South Korea; [Song, Hong Ji] Hallym Univ, Sacred Heart Hosp, Dept Family Med, Gyeonggi Do, South Korea; [Sohn, Hyun Soon] CHA Univ, Grad Sch Clin Pharm, Gyeonggi Do, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Hallym University; Pochon Cha University	Kwon, JW (corresponding author), Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea.; Kwon, JW (corresponding author), Kyungpook Natl Univ, Pharmaceut Sci Res Inst, Daegu, South Korea.	jwkwon@knu.ac.kr		Park, Hae-Young/0000-0001-8348-0887	National Research Foundation of Korea (NRF) grant - Korean government (MSIP) [2015R1C1A2A01052768]	National Research Foundation of Korea (NRF) grant - Korean government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (no. 2015R1C1A2A01052768). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhmoud E, 2015, INT J CLIN PHARM-NET, V37, P815, DOI 10.1007/s11096-015-0125-0; Andersen F, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-58; [Anonymous], 2011, WORKSH HLTH PROM PRO; Boustani M, 2007, J AM GERIATR SOC, V55, P1248, DOI 10.1111/j.1532-5415.2007.01270.x; Brown J, 2015, J NEUROL NEUROSUR PS, V86, P680, DOI 10.1136/jnnp-2014-309086; Dohoo IR, 1997, PREV VET MED, V29, P221, DOI 10.1016/S0167-5877(96)01074-4; Draper B, 2011, INT PSYCHOGERIATR, V23, P1649, DOI 10.1017/S1041610211001694; Dublin S, 2015, J AM GERIATR SOC, V63, P1519, DOI 10.1111/jgs.13562; Evans MD, 2011, SEIZURE-EUR J EPILEP, V20, P509, DOI 10.1016/j.seizure.2011.02.009; Fields J, 2015, CURR THER RES CLIN E, V77, P79, DOI 10.1016/j.curtheres.2015.08.002; Franchi C, 2016, PHARMACOEPIDEM DR S, V25, P204, DOI 10.1002/pds.3938; Frazier Susan C, 2005, J Gerontol Nurs, V31, P4; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Fried TR, 2011, ARCH INTERN MED, V171, P1854, DOI 10.1001/archinternmed.2011.424; Gallacher KI, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0151-0; Garcia-Ptacek S, 2014, EUR J CLIN NUTR, V68, P1204, DOI 10.1038/ejcn.2014.199; Garfinkel D, 2015, THER ADV DRUG SAF, V6, P212, DOI 10.1177/2042098615613984; Gillette C, 2015, RES SOC ADMIN PHARM, V11, P468, DOI 10.1016/j.sapharm.2014.08.010; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Grandner MA, 2015, OBESITY, V23, P2491, DOI 10.1002/oby.21247; Gray SL, 2015, JAMA INTERN MED, V175, P401, DOI 10.1001/jamainternmed.2014.7663; Gupta M, 2013, BMJ CASE REPORTS, P2013; Haenisch B, 2015, EUR ARCH PSY CLIN N, V265, P419, DOI 10.1007/s00406-014-0554-0; Hajjar Emily R, 2003, Am J Geriatr Pharmacother, V1, P82; Hwang Hee-Jin, 2015, Drugs Real World Outcomes, V2, P355, DOI 10.1007/s40801-015-0046-1; Jung YH, 2013, 20133119 KOR I HLTH; Jyrkka J, 2011, PHARMACOEPIDEM DR S, V20, P514, DOI 10.1002/pds.2116; Kim KW, 2011, J ALZHEIMERS DIS, V23, P279, DOI 10.3233/JAD-2010-101221; Kim KW, 2011, STUDY DEMENTED ELDER; Kim Kyoungnam, 2015, [Asia-pacific Journal of Multimedia Services Convergent with Art, Humanities, and Sociology, 예술인문사회 융합 멀티미디어 논문지], V5, P197, DOI 10.14257/AJMAHS.2015.06.22; Korean Statisticcal Information Service, EST FUT POP; Lai SW, 2012, GERIATR GERONTOL INT, V12, P491, DOI 10.1111/j.1447-0594.2011.00800.x; Lau DT, 2011, AM J ALZHEIMERS DIS, V26, P606, DOI 10.1177/1533317511432734; Lau DT, 2010, ALZ DIS ASSOC DIS, V24, P56, DOI 10.1097/WAD.0b013e31819d6ec9; Lebedev AV, 2014, AM J GERIATRIC PSYCH, V22; Lee Juneyoung, 2016, INT J EPIDEMIOLOGY; LoGiudice D, 2014, INTERN MED J, V44, P1066, DOI 10.1111/imj.12572; Marengoni A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1059; Martin Prince EA, 2014, WORLD ALZHEIMER REPO; Montastruc F, 2013, EUR J CLIN PHARMACOL, V69, P1589, DOI 10.1007/s00228-013-1506-8; National Institute on Aging National Institutes of Health, 2011, NIH PUBLICATION, V11-7737; Onder G, 2013, J AM MED DIR ASSOC, V14, DOI 10.1016/j.jamda.2013.03.014; Park HY, 2016, INT J CLIN PHARM TH, V54, P369, DOI 10.5414/CP202484; Patterson SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub2; Pedditizi E, 2016, AGE AGEING, V45, P14, DOI 10.1093/ageing/afv151; Peng D., 2011, GLOBAL BURDEN DEMENT; PERROTTA M, 2016, INT J MOL SCI, V17; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Sakakibara M, 2015, J PHARM PHARM SCI, V18, P705, DOI 10.18433/J37P5X; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Turner JP, 2015, SUPPORTIVE CARE CANC; Viswanathan H, 2005, CLIN THER, V27, P88, DOI 10.1016/j.clinthera.2005.01.009; Wang R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142123; Wolkowitz OM, 2004, ANN NY ACAD SCI, V1032, P191, DOI 10.1196/annals.1314.018; Wolkowitz OM, 2007, NEUROCASE, V13, P189, DOI 10.1080/13554790701475468; World Health Organization, AG HLTH TECHN REP GL, V5; Zhong GC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127836	58	48	50	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2017	12	1							e0169463	10.1371/journal.pone.0169463	http://dx.doi.org/10.1371/journal.pone.0169463			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH3AE	28056068	gold, Green Published, Green Submitted			2023-01-03	WOS:000391639100044
J	Desai, NR; Ross, JS; Kwon, JY; Herrin, J; Dharmarajan, K; Bernheim, SM; Krumholz, HM; Horwitz, LI				Desai, Nihar R.; Ross, Joseph S.; Kwon, Ji Young; Herrin, Jeph; Dharmarajan, Kumar; Bernheim, Susannah M.; Krumholz, Harlan M.; Horwitz, Leora I.			Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADMINISTRATIVE CLAIMS MEASURE; INTERRUPTED TIME-SERIES; PERFORMANCE	IMPORTANCE Readmission rates declined after announcement of the Hospital Readmission Reduction Program (HRRP), which penalizes hospitals for excess readmissions for acute myocardial infarction (AMI), heart failure (HF), and pneumonia. OBJECTIVE To compare trends in readmission rates for target and nontarget conditions, stratified by hospital penalty status. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of Medicare fee-for-service beneficiaries older than 64 years discharged between January 1, 2008, and June 30, 2015, from 2214 penalty hospitals and 1283 nonpenalty hospitals. Difference-interrupted time-series models were used to compare trends in readmission rates by condition and penalty status. EXPOSURE Hospital penalty status or target condition under the HRRP. MAIN OUTCOMES AND MEASURES Thirty-day risk adjusted, all-cause unplanned readmission rates for target and nontarget conditions. RESULTS The study included 48 137 102 hospitalizations of 20 351 161 Medicare beneficiaries. In January 2008, the mean readmission rates for AMI, HF, pneumonia, and nontarget conditions were 21.9%, 27.5%, 20.1%, and 18.4%, respectively, at hospitals later subject to financial penalties and 18.7%, 24.2%, 17.4%, and 15.7% at hospitals not subject to penalties. Between January 2008 and March 2010, prior to HRRP announcement, readmission rates were stable across hospitals (except AMI at nonpenalty hospitals). Following announcement of HRRP (March 2010), readmission rates for both target and nontarget conditions declined significantly faster for patients at hospitals later subject to financial penalties compared with those at nonpenalized hospitals (for AMI, additional decrease of -1.24 [95% CI, -1.84 to -0.65] percentage points per year relative to nonpenalty discharges; for HF, -.25 [95% CI, -1.64 to -0.86]; for pneumonia, -1.37 [95% CI, -1.80 to -0.95]; and for nontarget conditions, -0.27 [95% CI, -0.38 to -0.17]; P < .001 for all). For penalty hospitals, readmission rates for target conditions declined significantly faster compared with nontarget conditions (for AMI, additional decline of -0.49 [95% CI, -0.81 to -0.16] percentage points per year relative to nontarget conditions [P = .004]; for HF, -0.90 [95% CI, -1.18 to -0.62; P < .001]; and for pneumonia, -0.57 [95% CI, -0.92 to -0.23; P < .001]). In contrast, among nonpenalty hospitals, readmissions for target conditions declined similarly or more slowly compared with nontarget conditions (for AMI, additional increase of 0.48 [95% CI, 0.01-0.95] percentage points per year [P = .05]; for HF, 0.08 [95% CI, -0.30 to 0.46; P = .67]; for pneumonia, 0.53 [95% CI, 0.13-0.93; P = .01]). After HRRP implementation in October 2012, the rate of change for readmission rates plateaued (P < .05 for all except pneumonia at nonpenalty hospitals), with the greatest relative change observed among hospitals subject to financial penalty. CONCLUSIONS AND RELEVANCE Medicare fee-for-service patients at hospitals subject to penalties under the HRRP had greater reductions in readmission rates compared with those at nonpenalized hospitals. Changes were greater for target vs nontarget conditions for patients at the penalized hospitals but not at the other hospitals.	[Desai, Nihar R.; Herrin, Jeph; Dharmarajan, Kumar; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA; [Desai, Nihar R.; Ross, Joseph S.; Kwon, Ji Young; Dharmarajan, Kumar; Bernheim, Susannah M.; Krumholz, Harlan M.] Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Sect Gen Med, New Haven, CT 06510 USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Fdn,Clin Scholars Program, New Haven, CT 06510 USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Herrin, Jeph] Hlth Res & Educ Trust, Chicago, IL USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY USA; [Horwitz, Leora I.] NYU, Langone Med Ctr, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Med, New York, NY USA	Yale University; Yale University; Robert Wood Johnson Foundation (RWJF); Yale University; Yale University; New York University; New York University; NYU Langone Medical Center; New York University	Horwitz, LI (corresponding author), NYU, Sch Med, 550 First Ave,TRB 607, New York, NY 10016 USA.	leora.horwitz@nyumc.org	Horwitz, Leora/ABD-1292-2020; Kwon, Ji Young/HJG-4704-2022; , Harlan/AAI-2875-2020	Ross, Joseph/0000-0002-9218-3320	Agency for Healthcare Research and Quality [R01HS022882, K12 HS023000-01]; National Institute on Aging [K23AG048331]; American Federation for Aging Research through Paul B. Beeson Career Development Award Program; Yale Claude D. Pepper Older Americans Independence Center [P30AG021342]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS022882, K12HS023000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG048331, P30AG021342] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research through Paul B. Beeson Career Development Award Program; Yale Claude D. Pepper Older Americans Independence Center; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by the Agency for Healthcare Research and Quality (grant R01HS022882). Dr Desai is supported by grant K12 HS023000-01 from the Agency for Healthcare Research and Quality. Dr Dharmarajan is supported by grant K23AG048331 from the National Institute on Aging and the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. He is also supported by grant P30AG021342 via the Yale Claude D. Pepper Older Americans Independence Center.	Boccuti C., 2017, AIMING FEWER HOSP U; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Centers for Medicare & Medicaid Services, 2011, HOSP ENG NETW CONN H; Conover M., 2012, HOSP WIDE ALL CAUSE; DeVore AD, 2016, J AM COLL CARDIOL, V67, P963, DOI 10.1016/j.jacc.2015.12.037; Horwitz LI, 2015, J HOSP MED, V10, P670, DOI 10.1002/jhm.2416; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Horwitz LI, 2013, CTR MED MED SERVICES; Joynt KE, 2016, AM J MANAG CARE, V22, pE287; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Penfold RB, 2013, ACAD PEDIATR, V13, pS38, DOI 10.1016/j.acap.2013.08.002; Rau J., 2015, KAISER HLTH NEWS; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	16	189	190	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2016	316	24					2647	2656		10.1001/jama.2016.18533	http://dx.doi.org/10.1001/jama.2016.18533			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG5UN	28027367	Green Accepted, Bronze			2023-01-03	WOS:000391110200018
J	Tran, BX; Hwang, JN; Nguyen, LH; Nguyen, AT; Latkin, NRK; Tran, NK; Thuc, VTM; Nguyen, HLT; Phan, HTT; Le, HT; Tran, TD; Latkin, CA				Bach Xuan Tran; Hwang, Jongnam; Long Hoang Nguyen; Anh Tuan Nguyen; Latkin, Noah Reed Knowlton; Ngoc Kim Tran; Vu Thi Minh Thuc; Huong Lan Thi Nguyen; Huong Thu Thi Phan; Huong Thi Le; Tho Dinh Tran; Latkin, Carl A.			Impact of Socioeconomic Inequality on Access, Adherence, and Outcomes of Antiretroviral Treatment Services for People Living with HIV/AIDS in Vietnam	PLOS ONE			English	Article							HEALTH-CARE; HIV; THERAPY; MORTALITY; DETERMINANTS; POPULATION; INITIATION; ADULTS; VIRUS	Background Ensuring an equal benefit across different patient groups is necessary while scaling up free-of-charge antiretroviral treatment (ART) services. This study aimed to measure the disparity in access, adherence, and outcomes of ART in Vietnam and the effects of socioeconomic status (SES) characteristics on the levels of inequality. Methods A cross-sectional study was conducted in 1133 PLWH in Vietnam. ART access, adherence, and treatment outcomes were self-reported using a structured questionnaire. Wealth-related inequality was calculated using a concentration index, and a decomposition analysis was used to determine the contribution of each SES variable to inequality in access, adherence, and outcomes of ART. Results Based on SES, minor inequality was found in ART access and adherence while there was considerable inequality in ART outcomes. Poor people were more likely to start treatment early, while rich people had better adherence and overall treatment outcomes. Decomposition revealed that occupation and education played important roles in inequality in ART access, adherence, and treatment outcomes Conclusion The findings suggested that health services should be integrated into the ART regimen. Furthermore, occupational orientation and training courses should be provided to reduce inequality in ART access, adherence, and treatment outcomes.	[Bach Xuan Tran; Huong Thi Le] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam; [Bach Xuan Tran; Latkin, Noah Reed Knowlton; Latkin, Carl A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Hwang, Jongnam] Daegu Univ, Dept Hlth Promot, Gyongsan, South Korea; [Long Hoang Nguyen] Vietnam Natl Univ, Sch Med & Pharm, Hanoi, Vietnam; [Anh Tuan Nguyen; Huong Lan Thi Nguyen] Duy Tan Univ, Inst Global Hlth Innovat, Da Nang, Vietnam; [Ngoc Kim Tran] Woolcock Med Res Inst, Hanoi, Vietnam; [Vu Thi Minh Thuc] Natl Otolaryngol Hosp, Dept Immunol & Allergy, Hanoi, Vietnam; [Huong Thu Thi Phan] Minist Hlth, Author HIV AIDS Control, Hanoi, Vietnam; [Tho Dinh Tran] Vietnam Germany Hosp, Dept Hepatobiliary Surg, Hanoi, Vietnam	Hanoi Medical University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Daegu University; Vietnam National University Hanoi; Duy Tan University	Tran, BX (corresponding author), Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam.; Tran, BX (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	bach@hmu.edu.vn	Nguyen, Huy/GWQ-6433-2022; Nguyen, Huy/AAF-9560-2019; Hwang, Jongnam/GLQ-6437-2022	Nguyen, Huy/0000-0002-5896-9661; Hwang, Jongnam/0000-0001-7078-9244; Tran Kim, Ngoc/0000-0001-7521-5813				Alaba O, 2014, INT J ENV RES PUB HE, V11, P3387, DOI 10.3390/ijerph110303387; Duong AT, 2014, JAIDS-J ACQ IMM DEF, V65, pE1, DOI 10.1097/QAI.0b013e3182a17d15; Tran BX, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0640-z; Tran BX, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.20690; Tran BX, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI [10.3402/gha.v6i0.18619, 10.3402/gha.v6i0.19570]; Tran BX, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-132; Tran BX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041062; Tran BX, 2011, AIDS CARE, V23, P1236, DOI 10.1080/09540121.2011.555749; Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Braveman PA, 2010, AM J PUBLIC HEALTH, V100, pS186, DOI 10.2105/AJPH.2009.166082; Castelnuovo B, 2009, CLIN INFECT DIS, V49, P965, DOI 10.1086/605500; Control VAoHA, 2016, ANN REV HIV AIDS CON; Tran DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051289; Dray-Spira R, 2003, AIDS, V17, P283, DOI 10.1097/00002030-200302140-00001; Duc Duong Bui, 2011, ADAPTING TREATMENT 2; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Entezarmahdi R, 2014, INT J PREVENTIVE MED, V5, P414; equity PfH, 2011, HLTH EQ VIETN TARG E; Giordano TP, 2004, HIV CLIN TRIALS, V5, P74, DOI 10.1310/JFXH-G3X2-EYM6-D6UG; Girardi E, 2004, JAIDS-J ACQ IMM DEF, V36, P951, DOI 10.1097/00126334-200408010-00009; Go Vietnam, 2012, VIETN AIDS RESP PROG; Group E, 2011, EQ 5D 5L USER GUIDE; Health VMo Group HP, 2013, JOINT ANN HLTH REV 2; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Jain MK, 2009, CLIN INFECT DIS, V48, P1772, DOI 10.1086/599111; Joint United Nations Programme on HIV/ AIDS (UNAIDS), 2016, GLOB AIDS UPD 2016; Kobin AB, 2011, ANN PHARMACOTHER, V45, P372, DOI 10.1345/aph.1P587; Lim T, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18637; Lim TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090723; Lodi S, 2014, AIDS, V28, P2297, DOI 10.1097/QAD.0000000000000410; May M, 2011, IMPACT LATE DIAGNOSI; Mitchell CG, 2004, SOC WORK, V49, P469, DOI 10.1093/sw/49.3.469; Montarroyos UR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084276; National Committee for AIDS DaPPaC, 2012, NAT STRAT HIV AIDS P; Olaleye A, 2013, AJAR-AFR J AIDS RES, V12, P85, DOI 10.2989/16085906.2013.851718; Posse M, 2008, TROP MED INT HEALTH, V13, P904, DOI 10.1111/j.1365-3156.2008.02091.x; Rougemont Mathieu, 2009, AIDS Res Ther, V6, P21, DOI 10.1186/1742-6405-6-21; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Schmitt JK, 2004, SOUTH MED J, V97, P329, DOI 10.1097/01.SMJ.0000118132.01508.F0; Scott VE, 2005, SAMJ S AFR MED J, V95, P109; Sobrino-Vegas P, 2012, ANTIVIR THER, V17, P1, DOI 10.3851/IMP1939; Sozmen K, 2014, IRAN J PUBLIC HEALTH, V43, P736; Suthar AB, 2014, AIDS, V28, pS175, DOI 10.1097/QAD.0000000000000259; Tran BX, 2013, TROP MED INT HEALTH, V18, P212, DOI 10.1111/tmi.12032; Turner BJ, 2002, J INFECT DIS, V185, pS143, DOI 10.1086/340197; VAAC VAoHAC, 2014, REP CURR SIT HIV INF; Vu VT, 2011, AIDS CARE, V23, P139, DOI 10.1080/09540121.2010.507741; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2011, TREATM 2 0 CAT NEXT; Zwahlen M, 2009, INT J EPIDEMIOL, V38, P1624, DOI 10.1093/ije/dyp306	51	22	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2016	11	12							e0168687	10.1371/journal.pone.0168687	http://dx.doi.org/10.1371/journal.pone.0168687			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI9QH	28005937	Green Submitted, gold, Green Published			2023-01-03	WOS:000392843200081
J	Legramante, JM; Morciano, L; Lucaroni, F; Gilardi, F; Caredda, E; Pesaresi, A; Coscia, M; Orlando, S; Brandi, A; Giovagnoli, G; Di Lecce, VN; Visconti, G; Palombi, L				Legramante, Jacopo M.; Morciano, Laura; Lucaroni, Francesca; Gilardi, Francesco; Caredda, Emanuele; Pesaresi, Alessia; Coscia, Massimo; Orlando, Stefano; Brandi, Antonella; Giovagnoli, Germano; Di Lecce, Vito N.; Visconti, Giuseppe; Palombi, Leonardo			Frequent Use of Emergency Departments by the Elderly Population When Continuing Care Is Not Well Established	PLOS ONE			English	Article							OLDER-ADULTS; HOSPITAL ADMISSIONS; RISK; ACCESS; MODEL	Introduction The elderly, who suffer from multiple chronic diseases, represent a substantial proportion of Emergency Department (ED) frequent users, thus contributing to ED overcrowding, although they could benefit from other health care facilities, if those were available. The aim of this study was to evaluate and characterize hospital visits of older patients (age 65 or greater) to the ED of a university teaching hospital in Rome from the 1st of January to the 31st of December 2014, in order to identify clinical and social characteristics potentially associated with "elderly frequent users". Material and Methods A retrospective study was performed during the calendar year 2014 (1st January 2014-31st December 2014) analyzing all ED admissions to the University Hospital of Rome Tor Vergata. Variables collected included age, triage code, arrival data, discharge diagnosis, and visit outcome. We performed a risk analysis using univariate binary logistic regression models. Results A total number of 38,016 patients accessed the ED, generating 46,820 accesses during the study period, with an average of 1.23 accesses for patient. The elderly population represented a quarter of the total ED population and had an increased risk of frequent use (OR 1.5: CI 1.4-1.7) and hospitalization (OR 3.8: CI 3.7-4). Moreover, they showed a greater diagnostic complexity, as demonstrated by the higher incidence of yellow and red priority codes compared to other ED populations (OR 3.1: CI 2.9-3.2). Discussion Older patients presented clinical and social characteristics related to the definition of "elderly frail frequent users". The fact that a larger number of hospitalizations occurred in such patients is indirect evidence of frailty in this specific population, suggesting that hospital admissions may be an inappropriate response to frailty, especially when continued care is not established. Conclusion Enhancement of continuity of care, establishment of a tracking system for those who are at greater risk of visiting the ED and evaluating fragile individuals should be the highest priority in addressing ED frequent usage by the elderly.	[Legramante, Jacopo M.] Univ Roma Tor Vergata, Fdn Policlin Tor Vergata, Dept Med Syst, Rome, Italy; [Morciano, Laura; Lucaroni, Francesca; Gilardi, Francesco; Caredda, Emanuele; Pesaresi, Alessia; Coscia, Massimo; Orlando, Stefano; Palombi, Leonardo] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Visconti, Giuseppe] Fdn Policlin Tor Vergata, Sanit Director, Rome, Italy; [Brandi, Antonella; Giovagnoli, Germano; Di Lecce, Vito N.] Fdn Policlin Tor Vergata, Emergengy Dept, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata	Palombi, L (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.	Leonardo.palombi@gmail.com	Gilardi, Francesco/AAA-1999-2020; Orlando, Stefano/AAU-2937-2021; Caredda, Emanuele/AAB-5230-2020	Orlando, Stefano/0000-0001-9706-4075; Caredda, Emanuele/0000-0002-2828-6202; Gilardi, Francesco/0000-0002-4038-6003				Affleck A, 2013, CAN J EMERG MED, V15, P359; Aminzadeh F, 2002, ANN EMERG MED, V39, P238, DOI 10.1067/mem.2002.121523; Asplin BR, 2003, ANN EMERG MED, V42, P173, DOI 10.1067/mem.2003.302; Ciccone MM, 2013, CLIN AUDIT, V2013, P49; de Stampa M, 2014, ARCH GERONTOL GERIAT, V58, P350, DOI 10.1016/j.archger.2014.01.005; Deschodt M, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0055-7; Di Bari M, 2012, J GERONTOL A-BIOL, V67, P544, DOI 10.1093/gerona/glr209; Di Somma S, 2015, INTERN EMERG MED, V10, P171, DOI 10.1007/s11739-014-1154-8; Ellis G, 2014, CLIN INTERV AGING, V9, P2033, DOI 10.2147/CIA.S29662; Ercoli L, 2015, MINERVA PEDIATR, V67, P11; Franchi C, 2017, AGING CLIN EXP RES, V29, P319, DOI 10.1007/s40520-016-0550-5; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Fuda KK, 2006, ANN EMERG MED, V48, P9, DOI 10.1016/j.annemergmed.2006.03.001; Hastings SN, 2014, J AM GERIATR SOC, V62, P711, DOI 10.1111/jgs.12746; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Hunt KA, 2006, ANN EMERG MED, V48, P1, DOI 10.1016/j.annemergmed.2005.12.030; LaCalle E, 2010, ANN EMERG MED, V56, P42, DOI 10.1016/j.annemergmed.2010.01.032; LaCalle EJ, 2013, J EMERG MED, V44, P1167, DOI 10.1016/j.jemermed.2012.11.042; Latham LP, 2014, CAN GERIATR J, V17, P118, DOI 10.5770/cgj.17.108; Lowthian JA, 2012, MED J AUSTRALIA, V196, P128, DOI 10.5694/mja11.10955; Ondler C, 2014, AM J EMERG MED, V32, P1215, DOI 10.1016/j.ajem.2014.07.013; Oredsson S, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-43; Palmer E, 2014, CAN FAM PHYSICIAN, V60, pE223; Palombi Leonardo, 2013, Ig Sanita Pubbl, V69, P105; Pines JM, 2011, ACAD EMERG MED, V18, P1358, DOI 10.1111/j.1553-2712.2011.01235.x; Raven MC, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-270; Salvi F, 2011, G GERONTOL, V59, P179; Samaras N, 2010, ANN EMERG MED, V56, P261, DOI 10.1016/j.annemergmed.2010.04.015; Sona A, 2012, EUR J PUBLIC HEALTH, V22, P76, DOI 10.1093/eurpub/ckr008; Tricco AC, 2014, CAN MED ASSOC J, V186, pE568, DOI 10.1503/cmaj.140289; van der Linden MC, 2014, INT J EMERG MED, V7, DOI 10.1186/1865-1380-7-9; Vinton DT, 2014, EMERG MED J, V31, P526, DOI 10.1136/emermed-2013-202407; Wajnberg A, 2012, J EMERG MED, V43, P376, DOI 10.1016/j.jemermed.2011.06.056; Waldner A, 2014, REDEFINING FREQUENT; Yim VWT, 2009, INT J EMERG MED, V2, P19, DOI 10.1007/s12245-009-0087-x	35	50	51	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2016	11	12							e0165939	10.1371/journal.pone.0165939	http://dx.doi.org/10.1371/journal.pone.0165939			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI8KC	27973563	Green Submitted, gold, Green Published			2023-01-03	WOS:000392754300006
J	Yamazaki, R; Nishiyama, O; Sano, H; Iwanaga, T; Higashimoto, Y; Kume, H; Tohda, Y				Yamazaki, Ryo; Nishiyama, Osamu; Sano, Hiroyuki; Iwanaga, Takashi; Higashimoto, Yuji; Kume, Hiroaki; Tohda, Yuji			Clinical Features and Outcomes of IPF Patients Hospitalized for Pulmonary Infection: A Japanese Cohort Study	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; REQUIRING HOSPITALIZATION; ACUTE EXACERBATION; FIBROSIS; DIAGNOSIS; RISK; STANDARDIZATION; GUIDELINES; MANAGEMENT; CULTURE	Many patients with idiopathic pulmonary fibrosis (IPF) undergo hospitalizations due to pulmonary infections. We retrospectively investigated the characteristics of hospitalizations due to pulmonary infection in patients with IPF to elucidate causative pathogens and mortality. We reviewed patients with IPF who were admitted between January 2008 and December 2014 for pulmonary infections including pneumonia and bronchitis. The causative pathogen, the relationship between the site of pneumonia and existing IPF radiological patterns on high-resolution chest CT, and predictors of mortality were evaluated. Forty-eight IPF patients were hospitalized a totally of 81 times due to pulmonary infection during the study period. In the 48 first-time admissions after IPF diagnosis, causative pathogens were detected in 20 patients (41.6%). The most common pathogen was Haemophilus influenzae (14.5%) followed by Pseudomonas aeruginosa (4.1%), Staphylococcus aureus (4.1%), Branhamella catarrhalis (4.1%), and Klebsiella pneumoniae (4.1%). Among all 81 admissions, the most common pathogen was P. aeruginosa (12.3%), followed by H. influenzae (8.6%), S. aureus (6.1%) and Escherichia coli (4.9%). No relationship was observed between the detected pathogen and the site of pneumonia. The 30-day and hospital mortality rates were 14.5% and 18.7%, respectively. Pneumonia severity index on admission was significantly associated with both 30-day and hospital mortality. In conclusion, IPF patients hospitalized for pulmonary infections had high 30-day and hospital mortality. In contrast to community-acquired pneumonia, the causative pathogens mainly consisted of gram-negative bacteria. The PSI score may be a significant predictor of mortality. These results provide information for empiric antibiotic selection when treating IPF patients with pulmonary infections.	[Yamazaki, Ryo; Nishiyama, Osamu; Sano, Hiroyuki; Iwanaga, Takashi; Higashimoto, Yuji; Kume, Hiroaki; Tohda, Yuji] Kindai Univ, Fac Med, Dept Resp Med & Allergol, Osakasayama, Osaka, Japan		Nishiyama, O (corresponding author), Kindai Univ, Fac Med, Dept Resp Med & Allergol, Osakasayama, Osaka, Japan.	nishiyama_o@yahoo.co.jp	Higashimoto, Yuji/AAW-2703-2021	Nishiyama, Osamu/0000-0002-9163-9605				Andruska A, 2015, CHEST, V148, P103, DOI 10.1378/chest.14-2129; Arancibia F, 2002, ARCH INTERN MED, V162, P1849, DOI 10.1001/archinte.162.16.1849; Brown AW, 2015, CHEST, V147, P173, DOI 10.1378/chest.13-2424; Cilloniz C, 2011, THORAX, V66, P340, DOI 10.1136/thx.2010.143982; Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI; Durheim MT, 2015, LANCET RESP MED, V3, P388, DOI 10.1016/S2213-2600(15)00093-4; Fine MJ, 1999, ARCH INTERN MED, V159, P970, DOI 10.1001/archinte.159.9.970; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Garcia-Vazquez E, 2004, ARCH INTERN MED, V164, P1807, DOI 10.1001/archinte.164.16.1807; Han MK, 2014, LANCET RESP MED, V2, P548, DOI 10.1016/S2213-2600(14)70069-4; Hanamoto S, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P2051; Hirama T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024474; Ishida T, 1998, CHEST, V114, P1588, DOI 10.1378/chest.114.6.1588; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI [10.1056/NEJMoa1500245, 10.1056/NEJMc1511751]; Kubota M, 2014, RESPIR INVESTIG, V52, P242, DOI 10.1016/j.resinv.2014.03.003; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Martinez FJ, 2005, ANN INTERN MED, V142, P963, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00005; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miyashita N, 2008, MED SCI MONITOR, V14, pCR171; Molyneaux PL, 2014, AM J RESP CRIT CARE, V190, P906, DOI 10.1164/rccm.201403-0541OC; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709; Zalacain R, 2003, EUR RESPIR J, V21, P294, DOI 10.1183/09031936.03.00064102	24	12	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2016	11	12							e0168164	10.1371/journal.pone.0168164	http://dx.doi.org/10.1371/journal.pone.0168164			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8JY	27959904	Green Published, Green Submitted, gold			2023-01-03	WOS:000392753900044
J	Papapetrou, EP				Papapetrou, Eirini P.			Patient-derived induced pluripotent stem cells in cancer research and precision oncology	NATURE MEDICINE			English	Article							COPY NUMBER; HEMATOPOIETIC PROGENITORS; GENOMIC INSTABILITY; ORGANOID CULTURES; GENE-EXPRESSION; SOMATIC-CELLS; DISEASE; MODEL; GENERATION; DIFFERENTIATION	Together with recent advances in the processing and culture of human tissue, bioengineering, xenotransplantation and genome editing, Induced pluripotent stem cells (iPSCs) present a range of new opportunities for the study of human cancer. Here we discuss the main advantages and limitations of iPSC modeling, and how the method intersects with other patient-derived models of cancer, such as organoids, organson- chips and patient-derived xenografts (PDXs). We highlight the opportunities that iPSC models can provide beyond those offered by existing systems and animal models and present current challenges and crucial areas for future improvements toward wider adoption of this technology.	[Papapetrou, Eirini P.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Papapetrou, Eirini P.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Papapetrou, Eirini P.] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, New York, NY 10029 USA; [Papapetrou, Eirini P.] Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Papapetrou, EP (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.; Papapetrou, EP (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Papapetrou, EP (corresponding author), Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, New York, NY 10029 USA.; Papapetrou, EP (corresponding author), Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA.	eirini.papapetrou@mssm.edu		Papapetrou, Eirini/0000-0001-7002-417X	US National Institutes of Health (NIH) [R00 DK087923, R01 HL121570]; Lawrence Ellison Foundation; Damon Runyon Cancer Research Foundation; Edward Evans Foundation; Taub Foundation for MDS research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL121570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R00DK087923] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lawrence Ellison Foundation(Lawrence Ellison Foundation); Damon Runyon Cancer Research Foundation; Edward Evans Foundation; Taub Foundation for MDS research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	E.P.P. is supported by US National Institutes of Health (NIH) grants R00 DK087923 and R01 HL121570; by the Lawrence Ellison Foundation; by the Damon Runyon Cancer Research Foundation; by the Edward Evans Foundation; and by the Taub Foundation for MDS research.	Abyzov A, 2012, NATURE, V492, P438, DOI 10.1038/nature11629; Antony-Debre I, 2015, BLOOD, V125, P930, DOI 10.1182/blood-2014-06-585513; Apostolou E, 2013, NATURE, V502, P462, DOI 10.1038/nature12749; Blelloch RH, 2004, P NATL ACAD SCI USA, V101, P13985, DOI 10.1073/pnas.0405015101; Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Burridge PW, 2016, NAT MED, V22, P547, DOI 10.1038/nm.4087; Burrows CK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005793; Cao LS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7653; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chen KG, 2014, CELL STEM CELL, V14, P13, DOI 10.1016/j.stem.2013.12.005; Chen YJ, 2015, CELL STEM CELL, V17, P233, DOI 10.1016/j.stem.2015.06.001; Cheng LZ, 2012, CELL STEM CELL, V10, P337, DOI 10.1016/j.stem.2012.01.005; Chin MH, 2010, CELL STEM CELL, V7, P263, DOI 10.1016/j.stem.2010.06.019; Choi J, 2015, NAT BIOTECHNOL, V33, P1173, DOI 10.1038/nbt.3388; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Corominas-Faja B, 2013, CELL CYCLE, V12, P3109, DOI 10.4161/cc.26173; Cox DBT, 2015, NAT MED, V21, P121, DOI 10.1038/nm.3793; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Day CP, 2015, CELL, V163, P39, DOI 10.1016/j.cell.2015.08.068; De Los Angeles A, 2015, NATURE, V525, P469, DOI 10.1038/nature15515; Dye BR, 2015, ELIFE, V4, DOI 10.7554/eLife.05098; Eggert US, 2013, NAT CHEM BIOL, V9, P206, DOI 10.1038/nchembio.1206; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engle SJ, 2014, J BIOL CHEM, V289, P4562, DOI 10.1074/jbc.R113.529156; Engle SJ, 2013, CELL STEM CELL, V12, P669, DOI 10.1016/j.stem.2013.05.011; Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312; Feraud O, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149291; Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015; Gandre-Babbe S, 2013, BLOOD, V121, P4925, DOI 10.1182/blood-2013-01-478412; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Garbes L, 2013, HUM MOL GENET, V22, P398, DOI 10.1093/hmg/dds437; Ghosh Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008975; Giobbe GG, 2015, NAT METHODS, V12, P637, DOI [10.1038/NMETH.3411, 10.1038/nmeth.3411]; Gould SE, 2015, NAT MED, V21, P431, DOI 10.1038/nm.3853; Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577; Guenther MG, 2010, CELL STEM CELL, V7, P249, DOI 10.1016/j.stem.2010.06.015; Guo SQ, 2014, CELL, V156, P649, DOI 10.1016/j.cell.2014.01.020; Guye P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10243; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; HENDERSON E, 1977, VIROLOGY, V76, P152, DOI 10.1016/0042-6822(77)90292-6; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Hockemeyer D, 2016, CELL STEM CELL, V18, P573, DOI 10.1016/j.stem.2016.04.013; Hosoi M, 2014, EXP HEMATOL, V42, P816, DOI 10.1016/j.exphem.2014.03.010; Hrvatin S, 2014, P NATL ACAD SCI USA, V111, P3038, DOI 10.1073/pnas.1400709111; Hu KJ, 2011, BLOOD, V117, pE109, DOI 10.1182/blood-2010-07-298331; Huang L, 2015, NAT MED, V21, P1364, DOI 10.1038/nm.3973; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Ingber DE, 2016, CELL, V164, P1105, DOI 10.1016/j.cell.2016.02.049; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Ji JF, 2012, STEM CELLS, V30, P435, DOI 10.1002/stem.1011; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Kim J, 2015, EMBO J, V34, P739, DOI 10.15252/embj.201490736; Kim J, 2013, CELL REP, V3, P2088, DOI 10.1016/j.celrep.2013.05.036; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Kotini AG, 2015, NAT BIOTECHNOL, V33, P646, DOI 10.1038/nbt.3178; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Krijger PHL, 2016, CELL STEM CELL, V18, P597, DOI 10.1016/j.stem.2016.01.007; Kumano K, 2012, BLOOD, V119, P6234, DOI 10.1182/blood-2011-07-367441; Kyttala A, 2016, STEM CELL REP, V6, P200, DOI 10.1016/j.stemcr.2015.12.009; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Laurent LC, 2011, CELL STEM CELL, V8, P106, DOI 10.1016/j.stem.2010.12.003; Lee DF, 2015, CELL, V161, P240, DOI 10.1016/j.cell.2015.02.045; Lee G, 2012, NAT BIOTECHNOL, V30, P1244, DOI 10.1038/nbt.2435; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Liang GY, 2013, CELL STEM CELL, V13, P149, DOI 10.1016/j.stem.2013.07.001; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Maddalo D, 2014, NATURE, V516, P423, DOI 10.1038/nature13902; Maherali N, 2008, CELL STEM CELL, V3, P595, DOI 10.1016/j.stem.2008.11.008; Majumder B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7169; Mandegar MA, 2016, CELL STEM CELL, V18, P541, DOI 10.1016/j.stem.2016.01.022; Maqsood MI, 2013, CELL BIOL INT, V37, P1038, DOI 10.1002/cbin.10137; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Mayshar Y, 2010, CELL STEM CELL, V7, P521, DOI 10.1016/j.stem.2010.07.017; McCracken KW, 2014, NATURE, V516, P400, DOI 10.1038/nature13863; Mertens J, 2015, NATURE, V527, P95, DOI 10.1038/nature15526; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Morizane R, 2015, NAT BIOTECHNOL, V33, P1193, DOI 10.1038/nbt.3392; Muller LUW, 2012, BLOOD, V119, P5449, DOI 10.1182/blood-2012-02-408674; Mulero-Navarro S, 2015, CELL REP, V13, P504, DOI 10.1016/j.celrep.2015.09.019; Naryshkin NA, 2014, SCIENCE, V345, P688, DOI 10.1126/science.1250127; Ogawa M, 2015, NAT BIOTECHNOL, V33, P853, DOI 10.1038/nbt.3294; Onder TT, 2012, CURR OPIN GENET DEV, V22, P500, DOI 10.1016/j.gde.2012.05.005; Papapetrou EP, 2016, SCIENCE, V353, P991, DOI 10.1126/science.aai7626; Papapetrou EP, 2011, NAT PROTOC, V6, P1251, DOI 10.1038/nprot.2011.374; Papapetrou EP, 2009, P NATL ACAD SCI USA, V106, P12759, DOI 10.1073/pnas.0904825106; Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043; Passier R, 2016, CELL STEM CELL, V18, P309, DOI [10.1016/j.stem.2016.02.011, 10.1016/j.stem.2016.02.013]; Peterson SE, 2014, J BIOL CHEM, V289, P4578, DOI 10.1074/jbc.R113.516419; Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039; Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667; Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Rouhani F, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004432; Rowe RG, 2016, CELL STEM CELL, V18, P707, DOI 10.1016/j.stem.2016.05.016; Ruiz S, 2011, CURR BIOL, V21, P45, DOI 10.1016/j.cub.2010.11.049; Sachs N, 2014, CURR OPIN GENET DEV, V24, P68, DOI 10.1016/j.gde.2013.11.012; Sampaziotis F, 2015, NAT BIOTECHNOL, V33, P845, DOI 10.1038/nbt.3275; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schwartz MP, 2015, P NATL ACAD SCI USA, V112, P12516, DOI 10.1073/pnas.1516645112; Soldner F, 2016, NATURE, V533, P95, DOI 10.1038/nature17939; Soyombo AA, 2013, STEM CELL REP, V1, P336, DOI 10.1016/j.stemcr.2013.08.004; Sterneckert JL, 2014, NAT REV GENET, V15, P625, DOI 10.1038/nrg3764; Stricker SH, 2013, GENE DEV, V27, P654, DOI 10.1101/gad.212662.112; Suprynowicz FA, 2012, P NATL ACAD SCI USA, V109, P20035, DOI 10.1073/pnas.1213241109; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Takasato M, 2015, NATURE, V526, P564, DOI 10.1038/nature15695; Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271; Tapia N, 2016, CELL STEM CELL, V19, P298, DOI 10.1016/j.stem.2016.06.017; Terrenoire C, 2013, J GEN PHYSIOL, V141, P61, DOI 10.1085/jgp.201210899; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Vaira V, 2010, P NATL ACAD SCI USA, V107, P8352, DOI 10.1073/pnas.0907676107; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; van den Berg CW, 2015, DEVELOPMENT, V142, P3231, DOI 10.1242/dev.123810; Varela C, 2012, J CLIN INVEST, V122, P569, DOI 10.1172/JCI46268; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wainger BJ, 2014, CELL REP, V7, P1, DOI 10.1016/j.celrep.2014.03.019; Watson CL, 2014, NAT MED, V20, P1310, DOI 10.1038/nm.3737; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wu J, 2016, CELL, V165, P1572, DOI 10.1016/j.cell.2016.05.043; Ye ZH, 2014, STEM CELLS, V32, P269, DOI 10.1002/stem.1545; Ye ZH, 2009, BLOOD, V114, P5473, DOI 10.1182/blood-2009-04-217406; Young MA, 2012, CELL STEM CELL, V10, P570, DOI 10.1016/j.stem.2012.03.002; Zeltner N, 2015, CURR OPIN CELL BIOL, V37, P102, DOI 10.1016/j.ceb.2015.10.008; Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237	128	88	92	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2016	22	12					1392	1401		10.1038/nm.4238	http://dx.doi.org/10.1038/nm.4238			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EE4CI	27923030	Green Accepted			2023-01-03	WOS:000389549000016
J	Maeda, K; Yasui, H; Yamamori, T; Matsuura, T; Takao, S; Suzuki, M; Matsuda, A; Inanami, O; Shirato, H				Maeda, Kenichiro; Yasui, Hironobu; Yamamori, Tohru; Matsuura, Taeko; Takao, Seishin; Suzuki, Motofumi; Matsuda, Akira; Inanami, Osamu; Shirato, Hiroki			A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-beta-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam	PLOS ONE			English	Article							RELATIVE BIOLOGICAL EFFECTIVENESS; CURRENT SITUATION; ION-BEAMS; RADIATION; TAS106; CONSEQUENCES; INACTIVATION; PERSPECTIVES; SENSITIVITY; THERAPY	The effect of 1-(3-C-ethyny1-beta-D-ribo-pentofuranosyl)cytosine (ECyd) on proton-induced cell death was evaluated in human lung carcinoma cell line A549 and Chinese hamster fibroblast cell line V79 to enhance relative biological effectiveness (RBE) within the spread-out Bragg peak (SOBP) of proton beams. Treatment with ECyd significantly enhanced the proton -induced loss of clonogenicity and increased senescence at the center, but not at the distal edge of SOBP. The p53-binding protein 1 foci formation assay showed that ECyd decelerated the rate of DNA double-strand break (DSB) repair at the center, but not the distal region of SOBP, suggesting that the ECyd-induced enhancement of proton-induced cell death is partially associated with the inhibition of DSB repair. This study demonstrated that ECyd enhances proton-induced cell killing at all positions of SOBP, except for the distal region and minimizes the site-dependent differences in RBE within SOBP. Thus, ECyd is a unique radiosensitizer for proton therapy that may be useful because it levels the biological dose within SOBP, which improves tumor control and reduces the risk of adverse effects at the distal edge of SOBP.	[Maeda, Kenichiro; Shirato, Hiroki] Hokkaido Univ, Grad Sch Med, Dept Radiat Med, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan; [Yasui, Hironobu; Yamamori, Tohru; Inanami, Osamu] Hokkaido Univ, Grad Sch Vet Med, Dept Environm Vet Sci, Radiat Biol Lab,Kita Ku, Kita 18 Nishi 9, Sapporo, Hokkaido 0600818, Japan; [Matsuura, Taeko] Hokkaido Univ, Fac Engn, Div Quantum Sci & Engn, Kita Ku, Kita 13 Nishi 8, Sapporo, Hokkaido 0608628, Japan; [Takao, Seishin] Hokkaido Univ Hosp, Proton Beam Therapy Ctr, Kita Ku, Kita 14 Nishi 5, Sapporo, Hokkaido 0608648, Japan; [Matsuda, Akira] Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita-12 Nishi-6, Sapporo, Hokkaido 0600812, Japan; [Shirato, Hiroki] Hokkaido Univ, Global Inst Collaborat Res & Educ, Kita 14 Nishi 5, Sapporo, Hokkaido 0608648, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Shirato, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Radiat Med, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.; Inanami, O (corresponding author), Hokkaido Univ, Grad Sch Vet Med, Dept Environm Vet Sci, Radiat Biol Lab,Kita Ku, Kita 18 Nishi 9, Sapporo, Hokkaido 0600818, Japan.; Shirato, H (corresponding author), Hokkaido Univ, Global Inst Collaborat Res & Educ, Kita 14 Nishi 5, Sapporo, Hokkaido 0608648, Japan.	inanami@vetmed.hokudai.ac.jp; shirato@med.hokudai.ac.jp	Inanami, Osamu/A-5197-2012; Suzuki, Motofumi/GXN-2635-2022; Yasui, Hironobu/E-3794-2010	Inanami, Osamu/0000-0001-7895-3918; Yasui, Hironobu/0000-0002-6757-1110	Japan Society for the Promotion of Science KAKENHI [15H04768, 24659551, 26461875, 15K09983, 15K09984]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Numbers: 15H04768 (HS) (https://kaken.nii. ac.jp/ja/grant/KAKENHI-PROJECT-15H04768/) (Data collection and analysis and decision to publish); 24659551(OI) (https://kaken.nii.ac.jp/ja/ grant/KAKENHI-PROJECT-24659551/), 26461875 (TY) (https://kaken.niiac..jp/ja/grant/KAKENHI-PROJECT 26461875/), and 15K09983 (HY) (https://kaken.nii.ac.jp/ja/grant/KAKENH-IPROJECT-15K09983i) (Study design); and 15K09984 (TM) (https://kaken.nill.ac.jp/en/grant/ KAKENHI-PROJECT-15K09984/) (Preparation of the manuscript).	Ando K, 2001, J RADIAT RES, V42, P79, DOI 10.1269/jrr.42.79; Ballarini F, 2015, RADIAT PROT DOSIM, V166, P75, DOI 10.1093/rpd/ncv135; Belli M, 1998, INT J RADIAT BIOL, V74, P501, DOI 10.1080/095530098141375; Belli M, 2008, J RADIAT RES, V49, P597, DOI 10.1269/jrr.08052; Chaudhary P, 2014, INT J RADIAT ONCOL, V90, P27, DOI 10.1016/j.ijrobp.2014.05.010; Doyen J, 2015, CANCER RADIOTHER, V19, P231, DOI 10.1016/j.canrad.2015.03.002; Doyen J, 2015, CANCER RADIOTHER, V19, P211, DOI 10.1016/j.canrad.2014.12.010; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Hattori H, 1996, J MED CHEM, V39, P5005, DOI 10.1021/jm960537g; Kagawa K, 2002, INT J RADIAT ONCOL, V54, P928, DOI 10.1016/S0360-3016(02)02949-8; Kantemiris I, 2011, MED PHYS, V38, P6585, DOI 10.1118/1.3662911; Liu CJ, 2010, PHYS MED BIOL, V55, P931, DOI 10.1088/0031-9155/55/4/002; Lui VWY, 2010, BIOCHEM PHARMACOL, V79, P1772, DOI 10.1016/j.bcp.2010.02.012; Maeda K, 2016, J RAD RES; Matsuda A, 2004, CANCER SCI, V95, P105, DOI 10.1111/j.1349-7006.2004.tb03189.x; Matsumoto Y, 2014, J RADIAT RES, V55, P816, DOI 10.1093/jrr/rrt230; Meike S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-92; Oshiro Y, 2014, J RADIAT RES, V55, P959, DOI 10.1093/jrr/rru034; Polf JC, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3589914; SCHOLZ M, 1996, ADV SPACE RES-SERIES, V18, P5, DOI 10.1016/0273-1177(95)00784-C; Shikazono N, 2006, NUCLEIC ACIDS RES, V34, P3722, DOI 10.1093/nar/gkl503; Shimamoto Y, 2002, JPN J CANCER RES, V93, P825, DOI 10.1111/j.1349-7006.2002.tb01325.x; Takayama K, 2016, J CANCER RES CLIN, V142, P659, DOI 10.1007/s00432-015-2069-0; Tilly N, 2005, PHYS MED BIOL, V50, P2765, DOI 10.1088/0031-9155/50/12/003; van de Water TA, 2011, ONCOLOGIST, V16, P366, DOI 10.1634/theoncologist.2010-0171; WARD JF, 1981, RADIAT RES, V86, P185, DOI 10.2307/3575500; Wilkens JJ, 2004, PHYS MED BIOL, V49, P2811, DOI 10.1088/0031-9155/49/13/004; Wilkens JJ, 2003, MED PHYS, V30, P806, DOI 10.1118/1.1567852; Yasui H, 2008, BRIT J CANCER, V99, P1442, DOI 10.1038/sj.bjc.6604720; Yasui H, 2007, INT J RADIAT ONCOL, V68, P218, DOI 10.1016/j.ijrobp.2006.12.061	30	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2016	11	11							e0166848	10.1371/journal.pone.0166848	http://dx.doi.org/10.1371/journal.pone.0166848			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED5IV	27875573	gold, Green Submitted, Green Published			2023-01-03	WOS:000388886000030
J	Forsmark, CE; Vege, SS; Wilcox, CM				Forsmark, Chris E.; Vege, Santhi Swaroop; Wilcox, C. Mel			Acute Pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ALCOHOL-ASSOCIATED PANCREATITIS; MILD ACUTE-PANCREATITIS; POST-ERCP PANCREATITIS; NECROTIZING PANCREATITIS; RISK-FACTORS; FLUID RESUSCITATION; ANTIBIOTIC-TREATMENT; RANDOMIZED-TRIAL; PRIMARY-CARE; DOUBLE-BLIND		[Forsmark, Chris E.] Univ Florida, Div Gastroenterol Hepatol & Nutr, 1329 SW 16th St,Suite 5251,POB 100214, Gainesville, FL 32610 USA; [Vege, Santhi Swaroop] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Wilcox, C. Mel] Univ Alabama Birmingham, Div Gastroenterol & Hepatol, Birmingham, AL USA	State University System of Florida; University of Florida; Mayo Clinic; University of Alabama System; University of Alabama Birmingham	Forsmark, CE (corresponding author), Univ Florida, Div Gastroenterol Hepatol & Nutr, 1329 SW 16th St,Suite 5251,POB 100214, Gainesville, FL 32610 USA.	chris.forsmark@medicine.ufl.edu			Calci-Medica; Takeda; Bharat Serums and Vaccines; Teva; BCH Mumbai; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK108320] Funding Source: NIH RePORTER	Calci-Medica; Takeda(Takeda Pharmaceutical Company Ltd); Bharat Serums and Vaccines; Teva(Teva Pharmaceutical Industries); BCH Mumbai; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr. Swaroop Vege reports receiving consulting fees from Calci-Medica, Takeda, Bharat Serums and Vaccines, and Teva and fees for educational activities for residents and fellows from BCH Mumbai. No other potential conflict of interest relevant to this article was reported.	Al-Omran M, 2010, COCHRANE DB SYST REV, V1; Andersen DK, 2013, PANCREAS, V42, P1227, DOI 10.1097/MPA.0b013e3182a9ad9d; Apte MV, 2010, J GASTROEN HEPATOL, V25, P1816, DOI 10.1111/j.1440-1746.2010.06445.x; Bakker OJ, 2014, NEW ENGL J MED, V371, P1983, DOI 10.1056/NEJMoa1404393; Bakker OJ, 2013, GUT, V62, P1475, DOI 10.1136/gutjnl-2012-302870; Bakker OJ, 2012, JAMA-J AM MED ASSOC, V307, P1053, DOI 10.1001/jama.2012.276; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Bertilsson S, 2015, PANCREAS, V44, P1096, DOI 10.1097/MPA.0000000000000406; Bertin C, 2012, AM J GASTROENTEROL, V107, P311, DOI 10.1038/ajg.2011.424; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; Chang YS, 2013, CRIT CARE, V17, DOI 10.1186/cc12790; Cote GA, 2012, GASTROENTEROLOGY, V143, P1502, DOI 10.1053/j.gastro.2012.09.006; Cote GA, 2011, CLIN GASTROENTEROL H, V9, P266, DOI 10.1016/j.cgh.2010.10.015; Cotton PB, 2014, JAMA-J AM MED ASSOC, V311, P2101, DOI 10.1001/jama.2014.5220; da Costa DW, 2015, LANCET, V386, P1261, DOI 10.1016/S0140-6736(15)00274-3; Dellinger EP, 2007, ANN SURG, V245, P674, DOI 10.1097/01.sla.0000250414.09255.84; Dellinger EP, 2012, ANN SURG, V256, P875, DOI 10.1097/SLA.0b013e318256f778; DiMagno MJ, 2012, AM J GASTROENTEROL, V107, P318, DOI 10.1038/ajg.2011.430; Ding X, 2015, SURG-J R COLL SURG E, V13, P218, DOI 10.1016/j.surge.2014.11.005; Eckerwall GE, 2007, CLIN NUTR, V26, P758, DOI 10.1016/j.clnu.2007.04.007; Elmunzer BJ, 2012, NEW ENGL J MED, V366, P1414, DOI 10.1056/NEJMoa1111103; En-Qiang M, 2009, CHINESE MED J-PEKING, V122, P169, DOI 10.3760/cma.j.issn.0366-6999.2009.02.011; Forsmark CE, 2016, PANCREATOLOGY, V16, P10, DOI 10.1016/j.pan.2015.11.009; Freeman ML, 2012, PANCREAS, V41, P1176, DOI 10.1097/MPA.0b013e318269c660; Gardner TB, 2008, CLIN GASTROENTEROL H, V6, P1070, DOI 10.1016/j.cgh.2008.05.005; Gardner TB, 2009, PANCREATOLOGY, V9, P770, DOI 10.1159/000210022; Gurusamy KS, 2013, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD010326.PUB2; Haydock MD, 2013, ANN SURG, V257, P182, DOI 10.1097/SLA.0b013e31827773ff; Hazra N, 2014, BRIT J GEN PRACT, V64, pE295, DOI 10.3399/bjgp14X679732; Isenmann R, 2004, GASTROENTEROLOGY, V126, P997, DOI 10.1053/j.gastro.2003.12.050; Jacobson BC, 2007, CLIN GASTROENTEROL H, V5, P946, DOI 10.1016/j.cgh.2007.04.012; Krishna SG, 2015, AM J GASTROENTEROL, V110, P1607, DOI 10.1038/ajg.2015.343; Law R, 2015, EXPERT REV GASTROENT, V9, P167, DOI 10.1586/17474124.2014.943186; Lim CLL, 2015, J GASTROINTEST SURG, V19, P480, DOI 10.1007/s11605-014-2662-6; Lindkvist B, 2004, CLIN GASTROENTEROL H, V2, P831, DOI 10.1016/S1542-3565(04)00355-6; Mazaki T, 2014, J GASTROENTEROL, V49, P343, DOI 10.1007/s00535-013-0806-1; McAlister VC, 2007, COCHRANE DB SYST REV, V4; Mole DJ, 2011, HPB, V13, P51, DOI 10.1111/j.1477-2574.2010.00241.x; Mouli VP, 2013, GASTROENTEROLOGY, V144, P333, DOI 10.1053/j.gastro.2012.10.004; Mounzer R, 2012, GASTROENTEROLOGY, V142, P1476, DOI 10.1053/j.gastro.2012.03.005; Nitsche Claudia, 2012, Curr Gastroenterol Rep, V14, P131, DOI 10.1007/s11894-012-0245-9; Nordback I, 2009, GASTROENTEROLOGY, V136, P848, DOI 10.1053/j.gastro.2008.11.044; Pant C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095552; Peery AF, 2015, GASTROENTEROLOGY, V149, P1731, DOI 10.1053/j.gastro.2015.08.045; Pelli H, 2008, SCAND J GASTROENTERO, V43, P614, DOI 10.1080/00365520701843027; Phillip V, 2011, CLIN GASTROENTEROL H, V9, P995, DOI 10.1016/j.cgh.2011.06.016; Sadr-Azodi O, 2013, AM J GASTROENTEROL, V108, P133, DOI 10.1038/ajg.2012.381; Sand J, 2007, PANCREATOLOGY, V7, P147, DOI 10.1159/000104251; Sankaran SJ, 2015, GASTROENTEROLOGY, V149, P1490, DOI 10.1053/j.gastro.2015.07.066; Shen H, 2011, EUR J GASTROEN HEPAT, V23, P1136, DOI 10.1097/MEG.0b013e32834b0e0e; Spanier BWM, 2013, WORLD J GASTROENTERO, V19, P3018, DOI 10.3748/wjg.v19.i20.3018; Sun E, 2013, J PANCREAS, V14, P221, DOI 10.6092/1590-8577/871; Teich N, 2010, PANCREAS, V39, P1088, DOI 10.1097/MPA.0b013e3181d3ce05; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Tse F, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009779.pub2; Valdivielso P, 2014, EUR J INTERN MED, V25, P689, DOI 10.1016/j.ejim.2014.08.008; van Baal MC, 2012, ANN SURG, V255, P860, DOI 10.1097/SLA.0b013e3182507646; van Santvoort HC, 2011, GASTROENTEROLOGY, V141, P1254, DOI 10.1053/j.gastro.2011.06.073; Varadarajulu S, 2013, GASTROENTEROLOGY, V145, P583, DOI 10.1053/j.gastro.2013.05.046; Villatoro E, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002941.pub3; Vlada AC, 2013, HPB, V15, P822, DOI 10.1111/hpb.12140; Whitcomb DC, 2013, GASTROENTEROLOGY, V144, P1292, DOI 10.1053/j.gastro.2013.01.069; Whitcomb DC, 2012, NAT GENET, V44, P1349, DOI 10.1038/ng.2466; Wu BU, 2008, GASTROENTEROLOGY, V135, P816, DOI 10.1053/j.gastro.2008.05.053; Wu BU, 2011, CLIN GASTROENTEROL H, V9, P710, DOI 10.1016/j.cgh.2011.04.026; Yadav D, 2003, J CLIN GASTROENTEROL, V36, P54, DOI 10.1097/00004836-200301000-00016; Yadav D, 2006, PANCREAS, V33, P323, DOI 10.1097/01.mpa.0000236733.31617.52; Yadav D, 2014, PANCREAS, V43, P630, DOI 10.1097/MPA.0000000000000078; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yang CJ, 2014, DIGEST LIVER DIS, V46, P446, DOI 10.1016/j.dld.2014.01.158; Yi FM, 2012, INTERNAL MED, V51, P523, DOI 10.2169/internalmedicine.51.6685	71	366	438	12	161	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2016	375	20					1972	1981		10.1056/NEJMra1505202	http://dx.doi.org/10.1056/NEJMra1505202			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EC1HS	27959604				2023-01-03	WOS:000387856100009
J	Guldner, D; Hwang, JK; Cardieri, MCD; Eren, M; Ziaei, P; Norton, MG; Souza, CD				Guldner, Delphine; Hwang, Julianne K.; Cardieri, Maria Clara D.; Eren, Meaghan; Ziaei, Parissa; Norton, M. Grant; Souza, Cleverson D.			In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A	PLOS ONE			English	Article							DENDRITIC CELLS; VACCINE DELIVERY; T-CELLS; NANOTECHNOLOGY; TECHNOLOGY; ENHANCE	Poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) have been considerably studied as a promising biodegradable delivery system to induce effective immune responses and to improve stability, safety, and cost effectiveness of vaccines. The study aimed at evaluating early inflammatory effects and cellular safety of PLGA NPs, co-encapsulating ovalbumin (PLGA/OVA NPs), as a model antigen and the adjuvant monophosphoryl lipid A (PLGA/MPLA NPs) as an adjuvant, on primary canine macrophages. The PLGA NPs constructs were prepared following the emulsion-solvent evaporation technique and further physicchemically characterized. Peripheral blood mononuclear cells were isolated from canine whole blood by magnetic sorting and further cultured to generate macrophages. The uptake of PLGA NP constructs by macrophages was demonstrated by flow cytometry, transmission electron microscopy and confocal microscopy. Macrophage viability and morphology were evaluated by trypan blue exclusion and light microscopy. Macrophages were immunophenotyped for the expression of MHC-I and MHC-II and gene expression of Interleukin-10 (IL-10), Interleukin-12 (IL-12p40), and tumor necrosis factor alpha (TNF-alpha) were measured. The results showed that incubation of PLGA NP constructs with macrophages revealed effective early uptake of the PLGA NPs without altering the viability of macrophages. PLGA/OVA/MPLA NPs strongly induced TNF-alpha and IL-12p40 expression by macrophages as well as increase relative expression of MHC-I but not MHC-II molecules. Taken together, these results indicated that PLGA NPs with addition of MPLA represent a good model, when used as antigen carrier, for further, in vivo, work aiming to evaluate their potential to induce strong, specific, immune responses in dogs.	[Guldner, Delphine; Hwang, Julianne K.; Cardieri, Maria Clara D.; Eren, Meaghan; Souza, Cleverson D.] Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Pullman, WA 99164 USA; [Ziaei, Parissa; Norton, M. Grant] Washington State Univ, Sch Mech & Mat Engn, Pullman, WA 99164 USA	Washington State University; Washington State University	Souza, CD (corresponding author), Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Pullman, WA 99164 USA.	souza@vetmed.wsu.edu		Hwang, Julianne/0000-0002-9222-1729	WSU - College of Veterinary Medicine	WSU - College of Veterinary Medicine	Most of this work was supported by WSU - College of Veterinary Medicine, intramural grants.; The authors would like to thank Elizabeth Laws for technical help. This work was supported by WSU-College of Veterinary Medicine, intramural grants.	Balogh L, 2007, NANOMED-NANOTECHNOL, V3, P281, DOI 10.1016/j.nano.2007.09.001; Bergman PJ, 2007, VET CLIN N AM-SMALL, V37, P1111, DOI 10.1016/j.cvsm.2007.06.005; Brewer JM, 2006, IMMUNOL LETT, V102, P10, DOI 10.1016/j.imlet.2005.08.002; Cooper DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113558; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Elamanchili P, 2007, J IMMUNOTHER, V30, P378, DOI 10.1097/CJI.0b013e31802cf3e3; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Joshi VB, 2013, HUM VACC IMMUNOTHER, V9, P2584, DOI 10.4161/hv.26136; Keijzer C, 2013, J CONTROL RELEASE, V168, P35, DOI 10.1016/j.jconrel.2013.02.027; Keijzer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026684; Kim H, 2016, CLIN EXP VACCINE RES, V5, P12, DOI 10.7774/cevr.2016.5.1.12; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Ma WX, 2012, INT J NANOMED, V7, P1475, DOI 10.2147/IJN.S29506; McVey S, 2010, VET CLIN N AM-SMALL, V40, P381, DOI 10.1016/j.cvsm.2010.02.001; Minigo G, 2007, VACCINE, V25, P1316, DOI 10.1016/j.vaccine.2006.09.086; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; Petrizzo A, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0231-9; Poteet E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136862; Proudfoot AG, 2014, IMMUNOL CELL BIOL, V92, P739, DOI 10.1038/icb.2014.73; Romagnani S, 1995, RES IMMUNOL, V146, P457, DOI 10.1016/0923-2494(96)83015-X; Sarti F, 2011, BIOMATERIALS, V32, P4052, DOI 10.1016/j.biomaterials.2011.02.011; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; Silva AL, 2015, VACCINE, V33, P847, DOI 10.1016/j.vaccine.2014.12.059; Valle I., 2015, J PREVENTIVE MED HYG, V56, P21; Wagner JL, 2002, TISSUE ANTIGENS, V59, P205, DOI 10.1034/j.1399-0039.2002.590304.x; Wang KS, 2000, BLOOD, V95, P3183, DOI 10.1182/blood.V95.10.3183.010k36_3183_3190; Weiss DJ, 2005, AM J VET RES, V66, P721, DOI 10.2460/ajvr.2005.66.721; Wijewardana V, 2006, VET IMMUNOL IMMUNOP, V114, P37, DOI 10.1016/j.vetimm.2006.07.002; Wu F, 2009, MOL PHARMACEUT, V6, P1506, DOI 10.1021/mp900081y; Zhang N, 2008, BIOCONJUGATE CHEM, V19, P145, DOI 10.1021/bc700227z	34	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2016	11	11							e0165477	10.1371/journal.pone.0165477	http://dx.doi.org/10.1371/journal.pone.0165477			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC0HG	27835636	Green Published, gold, Green Submitted			2023-01-03	WOS:000387779200006
J	Legato, MJ; Johnson, PA; Manson, JE				Legato, Marianne J.; Johnson, Paula A.; Manson, JoAnn E.			Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK-FACTOR; GENDER; PERSPECTIVES; TRIAL		[Legato, Marianne J.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Johnson, Paula A.] Wellesley Coll, Wellesley, MA 02181 USA; [Manson, JoAnn E.] Harvard Med Sch, Brigham & Womens Hosp, Connors Ctr Womens Hlth & Gender Biol, Boston, MA USA; [Manson, JoAnn E.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Columbia University; Wellesley College; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Manson, JE (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, 900 Commonwealth Ave,Third Floor, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu						Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Garcia M, 2016, CIRC RES, V118, P1273, DOI 10.1161/CIRCRESAHA.116.307547; Ghali JK, 2002, CIRCULATION, V105, P1585, DOI 10.1161/01.CIR.0000012546.20194.33; Lundberg V, 1997, J INTERN MED, V241, P485; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; Niewada M, 2005, NEUROEPIDEMIOLOGY, V24, P123, DOI 10.1159/000082999; OS I, 1992, LANCET, V339, P372, DOI 10.1016/0140-6736(92)91694-4; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Wolbrette DL, 2003, AM J CARDIOL, V91, p39D, DOI 10.1016/S0002-9149(02)03378-7	9	91	91	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2016	316	18					1865	1866		10.1001/jama.2016.13995	http://dx.doi.org/10.1001/jama.2016.13995			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB1MN	27802499				2023-01-03	WOS:000387116500009
J	Rigo-Adrover, MD; Franch, A; Castell, M; Perez-Cano, FJ				del Mar Rigo-Adrover, Maria; Franch, Angels; Castell, Margarida; Jose Perez-Cano, Francisco			Preclinical Immunomodulation by the Probiotic Bifidobacterium breve M-16V in Early Life	PLOS ONE			English	Article							IMMUNE-SYSTEM; ALLERGIC SYMPTOMS; SMALL-INTESTINE; T-LYMPHOCYTES; SYNBIOTICS; ADHESION; MODEL; OLIGOSACCHARIDES; INTERVENTION; MODULATION	This study aimed to investigate the effect of supplementation with the probiotic Bifidobacterium breve M-16V on the maturation of the intestinal and circulating immune system during suckling. In order to achieve this purpose, neonatal Lewis rats were supplemented with the probiotic strain from the 6th to the 18th day of life. The animals were weighed during the study, and faecal samples were obtained and evaluated daily. On day 19, rats were euthanized and intestinal wash samples, mesenteric lymph node (MLN) cells, splenocytes and intraepithelial lymphocytes (IEL) were obtained. The probiotic supplementation in early life did not modify the growth curve and did not enhance the systemic immune maturation. However, it increased the proportion of cells bearing TLR4 in the MLN and IEL, and enhanced the percentage of the integrin alpha E beta 7+ and CD62L+ cells in the MLN and that of the integrin alpha E beta 7+ cells in the IEL, suggesting an enhancement of the homing process of naive T lymphocytes to the MLN, and the retention of activated lymphocytes in the intraepithelial compartment. Interestingly, B. breve M-16V enhanced the intestinal IgA synthesis. In conclusion, supplementation with the probiotic strain B. breve M-16V during suckling improves the development of mucosal immunity in early life.	[del Mar Rigo-Adrover, Maria; Franch, Angels; Castell, Margarida; Jose Perez-Cano, Francisco] Univ Barcelona, Dept Bioquim & Fisiol, Fac Farm & Ciencies Alimentacio, Barcelona, Spain; [del Mar Rigo-Adrover, Maria; Franch, Angels; Castell, Margarida; Jose Perez-Cano, Francisco] Inst Recerca Nutr & Seguretat Alimentaria INSA, Barcelona, Spain	University of Barcelona; University of Barcelona	Perez-Cano, FJ (corresponding author), Univ Barcelona, Dept Bioquim & Fisiol, Fac Farm & Ciencies Alimentacio, Barcelona, Spain.; Perez-Cano, FJ (corresponding author), Inst Recerca Nutr & Seguretat Alimentaria INSA, Barcelona, Spain.	franoiscoperez@ub.edu	Franch, Àngels/G-5669-2019; Castell, Margarida/G-9078-2015; Perez-Cano, Francisco J/G-6516-2019	Franch, Àngels/0000-0002-2362-1374; Castell, Margarida/0000-0001-5408-0593; Perez-Cano, Francisco J/0000-0001-6243-9164				Agace W, 2010, IMMUNOL LETT, V128, P21, DOI 10.1016/j.imlet.2009.09.012; Agace WW, 2008, TRENDS IMMUNOL, V29, P514, DOI 10.1016/j.it.2008.08.003; Amit-Romach E, 2010, MOL NUTR FOOD RES, V54, P277, DOI 10.1002/mnfr.200800591; Aureli P, 2011, PHARMACOL RES, V63, P366, DOI 10.1016/j.phrs.2011.02.006; Bermudez-Brito M, 2012, ANN NUTR METAB, V61, P160, DOI 10.1159/000342079; Bernardo D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036262; Bertelsen RJ, 2016, BEST PRACT RES CL GA, V30, P39, DOI 10.1016/j.bpg.2016.01.001; Bodera P, 2009, RECENT PATENTS INFLA, V3, P58, DOI 10.2174/187221309787158461; Borruel N, 2002, GUT, V51, P659, DOI 10.1136/gut.51.5.659; Carasi P, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/361604; Carol M, 2006, J LEUKOCYTE BIOL, V79, P917, DOI 10.1189/jlb.0405188; Castillo NA, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-177; Cauley LS, 2013, MUCOSAL IMMUNOL, V6, P14, DOI 10.1038/mi.2012.96; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chu ZX, 2010, DIGEST DIS SCI, V55, P2505, DOI 10.1007/s10620-009-1063-2; de Kivit S, 2012, ALLERGY, V67, P343, DOI 10.1111/j.1398-9995.2011.02771.x; de Vrese M, 2008, ADV BIOCHEM ENG BIOT, V111, P1, DOI 10.1007/10_2008_097; Delcenserie V, 2008, CURR ISSUES MOL BIOL, V10, P37; Escribano E, 2014, ARCH DIS CHILD; FAO/WHO, 2006, PROB FOOD HLTH NUTR; Frei R, 2015, CURR OPIN GASTROEN, V31, P153, DOI 10.1097/MOG.0000000000000151; Fukushima Y, 1998, INT J FOOD MICROBIOL, V42, P39, DOI 10.1016/S0168-1605(98)00056-7; Galdeano CM, 2007, CLIN VACCINE IMMUNOL, V14, P485, DOI 10.1128/CVI.00406-06; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Guarner F, 2012, J CLIN GASTROENTEROL, V46, P468, DOI 10.1097/MCG.0b013e3182549092; Gueimonde M, 2006, J PEDIATR GASTR NUTR, V42, P604, DOI 10.1097/01.mpg.0000221897.45910.d3; Hashemi A, 2016, FOOD FUNCT, V7, P1752, DOI [10.1039/C5FO01148E, 10.1039/c5fo01148e]; Hong M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117451; Hougee S, 2010, INT ARCH ALLERGY IMM, V151, P107, DOI 10.1159/000236000; Hu GZ, 2016, EXP THER MED, V11, P33, DOI 10.3892/etm.2015.2854; Ivetic A, 2013, INT J BIOCHEM CELL B, V45, P550, DOI 10.1016/j.biocel.2012.12.023; Kaplan JL, 2011, PEDIATR RES, V69, P465, DOI 10.1203/PDR.0b013e318217638a; Kick AR, 2012, J ANIM SCI, V90, P649, DOI 10.2527/jas.2010-3470; Kilshaw PJ, 1999, J CLIN PATHOL-MOL PA, V52, P203, DOI 10.1136/mp.52.4.203; Knight SC, 2016, DIGEST DIS, V34, P51, DOI 10.1159/000442926; Kotzamanidis C, 2010, INT J FOOD MICROBIOL, V140, P154, DOI 10.1016/j.ijfoodmicro.2010.04.004; Liu YY, 2012, AM J PHYSIOL-GASTR L, V302, pG608, DOI 10.1152/ajpgi.00266.2011; Macfarlane GT, 2011, J CLIN GASTROENTEROL, V45, pS120, DOI 10.1097/MCG.0b013e31822fecfe; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Mann ER, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/573576; Marin-Gallen S, 2008, DEV COMP IMMUNOL, V32, P1405, DOI 10.1016/j.dci.2008.06.011; Martin R, 2010, BENEF MICROBES, V1, P367, DOI 10.3920/BM2010.0027; Park JH, 2002, CELL IMMUNOL, V219, P22, DOI 10.1016/S0008-8749(02)00579-8; Partty A, 2015, PEDIATR RES, V77, P823, DOI 10.1038/pr.2015.51; Perez-Cano FJ, 2005, PEDIATR RES, V58, P885, DOI 10.1203/01.pdr.0000182187.88505.49; Perez-Cano FJ, 2005, PEDIATR RES, V58, P164, DOI 10.1203/01.PDR.0000156367.60769.36; Perez-Cano FJ, 2007, DEV COMP IMMUNOL, V31, P1264, DOI 10.1016/j.dci.2007.03.004; Perez-Cano FJ, 2007, BRIT J NUTR, V98, pS80, DOI 10.1017/S0007114507838074; Perez-Cano FJ, 2007, PEDIATR RES, V62, P658, DOI 10.1203/PDR.0b013e318159a273; Perez-Cano FJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/537310; Perez-Cano FJ, 2010, IMMUNOBIOLOGY, V215, P996, DOI 10.1016/j.imbio.2010.01.004; Ramos-Romero S, 2012, BRIT J NUTR, V107, P378, DOI 10.1017/S0007114511003035; Rigo-Adrover M, 2017, EUR J NUTR, V56, P1657, DOI 10.1007/s00394-016-1213-1; Salvatore S, 2010, BIOACTIVE FOODS IN PROMOTING HEALTH: PROBIOTICS AND PREBIOTICS, P181, DOI 10.1016/B978-0-12-374938-3.00013-X; Serazin Andrew C, 2010, Nat Immunol, V11, P769, DOI 10.1038/ni0910-769; Smelt MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068952; van de Pol MA, 2011, ALLERGY, V66, P39, DOI 10.1111/j.1398-9995.2010.02454.x; Veereman-Wauters G, 2011, J PEDIATR GASTR NUTR, V52, P763, DOI 10.1097/MPG.0b013e3182139f39; Verheijden KAT, 2016, EUR J NUTR, V55, P1141, DOI 10.1007/s00394-015-0928-8; Westerbeek EAM, 2011, ACTA PAEDIATR, V100, P1426, DOI 10.1111/j.1651-2227.2011.02295.x; Yan F, 2011, CURR OPIN GASTROEN, V27, P496, DOI 10.1097/MOG.0b013e32834baa4d; Yang X, 2013, J HUAZHONG U SCI-MED, V33, P661, DOI 10.1007/s11596-013-1177-9	63	16	18	4	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2016	11	11							e0166082	10.1371/journal.pone.0166082	http://dx.doi.org/10.1371/journal.pone.0166082			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB8BB	27820846	Green Published, gold, Green Submitted			2023-01-03	WOS:000387614800031
J	Lin, KH; Liu, CL; Kuo, WW; Paul, CR; Chen, WK; Wen, SY; Day, CH; Wu, HC; Viswanadha, VP; Huang, CY				Lin, Kuan-Ho; Liu, Chien-Liang; Kuo, Wei-Wen; Paul, Catherine Reena; Chen, Wei-Kung; Wen, Su-Ying; Day, Cecilia Hsuan; Wu, Hsi-Chin; Viswanadha, Vijaya Padma; Huang, Chih-Yang			Early Fluid Resuscitation by Lactated Ringer's Solution Alleviate the Cardiac Apoptosis in Rats with Trauma-Hemorrhagic Shock	PLOS ONE			English	Article							TNF-ALPHA; POLYTRAUMA; PATHWAY; SALINE	Cardiac trauma has been recognized as a complication associated with blunt chest trauma involving coronary artery injury, myocardium contusion and myocardial rupture. Secondary cardiac injuries after trauma supposed to be a critical factor in trauma patients, but the mechanism is not fully explored. Overproduction of TNF-alpha had been reported in multiple trauma animals, this induces oxidative stress resulting in cardiac apoptosis. Apoptosis gradually increases after trauma and reaches to a maximum level in 12 h time. TNF-alpha increases the expression of NF kappa B, and induces the expression of caspase-3 and resulted in cell apoptosis. The effect can be attenuated by non-selective caspase inhibitor and IL10. Fas induced cardiac apoptosis and hypertrophy in ischemic heart disease. In this study, we demonstrated a trauma-hemorrhagic shock (THS) model in rats and resuscitated rats by lactated Ringer's (L/R) solution after shock in different hours (0 hour, 4 hours, 8 hours). NF kappa B gradually increased after the first 8 hours of shock, and can be reduced by fluid resuscitation. NF kappa B is known as a downstream pathway of Fas related apoptosis, we found Fas ligand, caspase-8 levels elevate after shock, and can be reduced by resuscitation. In addition, resuscitation can activate insulin-like growth factor (IGF-1)/Akt pathway, at the same time. It can block mitochondrial damage by decrease the effect of tBid. In conclusion, THS can induce secondary cardiac injury. Fas showed to be an important element in caspase cascade induced myocardium apoptosis. By L/R fluid resuscitation, the suppression of caspase cascade and activation of IGF-I/Akt pathway showed antiapoptotic effects in traumatic heart of rats.	[Lin, Kuan-Ho; Wu, Hsi-Chin] China Med Univ, Coll Med, Taichung 40402, Taiwan; [Lin, Kuan-Ho; Chen, Wei-Kung] China Med Univ Hosp, Dept Emergency Med, Taichung, Taiwan; [Liu, Chien-Liang] China Med Univ & Hosp, Sch Chinese Med, Coll Chinese Med, Taichung, Taiwan; [Kuo, Wei-Wen; Huang, Chih-Yang] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Paul, Catherine Reena] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Wen, Su-Ying] Taipei City Hosp, Renai Branch, Dept Dermatol, Taipei, Taiwan; [Wen, Su-Ying] Mackay Jr Coll Med Nursing & Management, Ctr Gen Educ, Taipei, Taiwan; [Day, Cecilia Hsuan] MeiHo Univ, Dept Nursing, Pingtung, Taiwan; [Viswanadha, Vijaya Padma] Bharathiar Univ, Dept Biotechnol, Coimbatore 641046, Tamil Nadu, India; [Huang, Chih-Yang] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan; [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; Taipei City Hospital; Mackay Junior College of Medicine, Nursing & Management; Bharathiar University; China Medical University Taiwan; Asia University Taiwan	Huang, CY (corresponding author), China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan.; Huang, CY (corresponding author), China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.; Huang, CY (corresponding author), Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.	cyhuarig@rnail.cmu.edu.tw	Viswanadha, Vijaya Padma/ABG-4936-2020	Viswanadha, Vijaya Padma/0000-0001-9154-027X	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW105-TDU-B-212-133019]	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cheng SM, 2013, INT J CARDIOL, V167, P478, DOI 10.1016/j.ijcard.2012.01.031; Chou TC, 2014, BIOMEDICINE-TAIWAN, V4, P17, DOI 10.7603/s40681-014-0024-z; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Didwania A, 1997, CRIT CARE MED, V25, P1851, DOI 10.1097/00003246-199711000-00024; El Sayad M, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/638956; Euler G, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00066; Gebhard F, 2008, LANGENBECK ARCH SURG, V393, P825, DOI 10.1007/s00423-008-0334-2; Guan J, 2002, J TRAUMA, V52, P104, DOI 10.1097/00005373-200201000-00018; Hsieh SR, 2014, BIOMEDICINE-TAIWAN, V4, P7, DOI 10.7603/s40681-014-0023-0; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Lu YQ, 2007, J TRAUMA, V63, P798, DOI 10.1097/TA.0b013e31815202c9; McCunn M, 2000, Curr Opin Anaesthesiol, V13, P147, DOI 10.1097/00001503-200004000-00011; Meldrum DR, 1997, J MOL CELL CARDIOL, V29, P2849, DOI 10.1006/jmcc.1997.0506; Rahbar E, 2015, SHOCK, V44, P417, DOI 10.1097/SHK.0000000000000449; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Shahani R, 2000, AM J PHYSIOL-HEART C, V278, pH942, DOI 10.1152/ajpheart.2000.278.3.H942; Todd SR, 2007, J TRAUMA, V62, P636, DOI 10.1097/TA.0b013e31802ee521; Wilson MH, 2015, LANCET, V386, P2526, DOI 10.1016/S0140-6736(15)00985-X; Wu BU, 2011, CLIN GASTROENTEROL H, V9, P710, DOI 10.1016/j.cgh.2011.04.026; Xu YJ, 2015, INT J CLIN EXP PATHO, V8, P6245	20	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0165406	10.1371/journal.pone.0165406	http://dx.doi.org/10.1371/journal.pone.0165406			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED7LQ	27780234	Green Published, Green Submitted, gold			2023-01-03	WOS:000389046900052
J	de Carvalho, PR; Ropero, DR; Pinheiro, MM; Fernandes, PD; Boylan, F				de Carvalho, Patricia Ribeiro; Ropero, Denise Ricoy; Pinheiro, Mariana Martins; Fernandes, Patricia Dias; Boylan, Fabio			Quinoline Alkaloids Isolated from Choisya Aztec-Pearl and Their Contribution to the Overall Antinociceptive Activity of This Plant	PLOS ONE			English	Article							ZANTHOXYLUM-RHOIFOLIUM; ORBIGNYA-SPECIOSA; NICOTINIC RECEPTORS; ETHANOL EXTRACT; TERNATA KUNTH; IN-VITRO; PAIN; CLONIDINE; MECHANISM; LEAVES	Choisya 'Aztec-Pearl', a hybrid of Choisya ternata and Choisya dumosa var. arizonica, had the antinociceptive activity in the ethanol extract (EECA) of its leaves evaluated. Two quinoline alkaloids, anhydroevoxine (A) and choisyine (C), isolated from these leaves were also tested. The results obtained pointed out to a very high antinociceptive activity measured by the hot plate model for EECA (at doses of 10, 30 and 100 mg/kg) as well as for A and C (at doses of 1, 3 and 10 mg/kg). The magnitude of the activity was two-fold higher than the one observed for the morphine treated animals for the higher doses of extracts/compounds (30, 100 mg/kg and 3, 10 mg/kg respectively). The mechanism of action for this activity was also investigated and it seems that for EECA as well as A and C, the opiate system plays an important role. Results have also shown that the nitric oxide (NO) system also play a pivotal role in the case of EECA and A while for C it seems that the cholinergic system have some involvement. The acute toxicity was evaluated for EECA with results showing no important toxic effect.	[de Carvalho, Patricia Ribeiro; Pinheiro, Mariana Martins; Fernandes, Patricia Dias] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Farmacol Dor & Inflamacao, Rio De Janeiro, Brazil; [Ropero, Denise Ricoy; Boylan, Fabio] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Pharm & Pharmaceut Sci, Dublin, Ireland	Universidade Federal do Rio de Janeiro; Trinity College Dublin	Boylan, F (corresponding author), Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Pharm & Pharmaceut Sci, Dublin, Ireland.	Fabio.boylan@tcd.ie	Fernandes, Patricia Dias/W-1565-2019; Boylan, Fabio/K-9707-2015	Fernandes, Patricia Dias/0000-0001-6870-6745; Boylan, Fabio/0000-0001-5531-1787	SFI (Science Foundation Ireland); CAPES (Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior); FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico); High Education Authority's Programme for Research in Third- Level Institutions Cycle 5; SFI programme ISCA-Brazil [SFI/13/ISCA/2843]; CAPES [BEX 5962 13-7]; FAPERJ [E26/203.018/2015]; CNPq [401683/2013-3]	SFI (Science Foundation Ireland)(Science Foundation Ireland); CAPES (Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); High Education Authority's Programme for Research in Third- Level Institutions Cycle 5; SFI programme ISCA-Brazil; CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was financed by the following granting agencies: SFI (Science Foundation Ireland), CAPES (Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior), FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), the High Education Authority's Programme for Research in Third- Level Institutions Cycle 5's funding support for TBSI. SFI programme ISCA-Brazil Grant no. SFI/13/ISCA/2843, CAPES Grant no BEX 5962 13-7, FAPERJ Grant no E26/203.018/2015, CNPq Grant no 401683/2013-3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors from Brazil thank Mr. Alan Minho for technical assistance and the Instituto Vital Brazil for donations of animals used. They also want to acknowledge the grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro (FAPERJ). The authors from Ireland wish to acknowledge the High Education Authority's Programme for Research in Third- Level Institutions Cycle 5's funding support for TBSI and to reinforce the importance of SFI programme ISCA-Brazil (Grant no. SFI/13/ISCA/2843) that contributed to the collaborative work between Brazil and Ireland.	Abdul-Wahab I.R., 2012, PLANTA MED, V78, P1597, DOI [10.1055/s-0032-1315044, DOI 10.1055/S-0032-1315044]; Abdul-Wahab IR, 2012, J ETHNOPHARMACOL, V144, P741, DOI 10.1016/j.jep.2012.10.029; Aceto MD, 1997, EUR J PHARMACOL, V338, P215, DOI 10.1016/S0014-2999(97)81924-3; [Anonymous], 1994, IASP TASK FORCE TAXO; Benson L, 1943, AM J BOT, V30, P630, DOI 10.2307/2437477; Bessonova I.A., 1982, KHIM PRIR SOEDIN, V4, P530; Boyd DR, 2007, ORG BIOMOL CHEM, V5, P2983, DOI 10.1039/b707576f; Boyd DR, 2002, CHEM COMMUN, P3070, DOI 10.1039/b208978e; Bruehl S, 2009, NEUROSCI BIOBEHAV R, V33, P475, DOI 10.1016/j.neubiorev.2008.12.003; Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893; Cruz G.L., 1995, DICIONARIO PLANTAS U, V5, P436; Dayton W.A., 1931, IMPORTANT W BROWSE P, P1931; de Moura NF, 1997, PHYTOCHEMISTRY, V46, P1443, DOI 10.1016/S0031-9422(97)00498-6; Duflo F, 2003, ANESTHESIOLOGY, V98, P1237, DOI 10.1097/00000542-200305000-00028; Dussor GO, 2004, PAIN, V107, P22, DOI 10.1016/j.pain.2003.09.022; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; FROLOVA VI, 1963, ZH OBSHCH KHIM+, V33, P121; Ghelardini C, 2004, PHARMACOL RES, V50, P351, DOI 10.1016/j.phrs.2004.02.005; Pinheiro MMG, 2014, EUR J PHARMACOL, V727, P106, DOI 10.1016/j.ejphar.2013.12.042; Pinheiro MMG, 2012, LIFE SCI, V91, P293, DOI 10.1016/j.lfs.2012.06.013; Gonzaga WD, 2003, PLANTA MED, V69, P773, DOI 10.1055/s-2003-42783; GRUNDON MF, 1974, J CHEM SOC CHEM COMM, P51, DOI 10.1039/c39740000051; HOOD DD, 1995, ANESTHESIOLOGY, V82, P331, DOI 10.1097/00000542-199502000-00003; Ji RR, 2004, SCI STKE, V2004; JOHNS SR, 1967, AUST J CHEM, V20, P1975, DOI 10.1071/CH9671975; Jullian V, 2006, J ETHNOPHARMACOL, V106, P348, DOI 10.1016/j.jep.2006.01.011; Lancaster R, 1991, SHRUBS SEASONS; LORKE D, 1983, ARCH TOXICOL, V54, P275, DOI 10.1007/BF01234480; Martins FO, 2009, NAT PROD COMMUN, V4, P1693; Matheus ME, 2005, J ETHNOPHARMACOL, V102, P377, DOI 10.1016/j.jep.2005.06.033; Moreira Déborah Luíza, 2009, Polibotánica, P159; MULLER CORNELIUS H., 1940, AMER MIDLAND NAT, V24, P729, DOI 10.2307/2420869; Niv D, 2001, Pain Pract, V1, P150, DOI 10.1046/j.1533-2500.2001.01016.x; Otuki MF, 2005, J PHARMACOL EXP THER, V313, P310, DOI 10.1124/jpet.104.071779; Pan HL, 1999, ANESTHESIOLOGY, V90, P509, DOI 10.1097/00000542-199902000-00027; Pinheiro MMG, 2013, J ETHNOPHARMACOL, V146, P324, DOI 10.1016/j.jep.2012.12.053; Pinheiro MMG, 2010, J ETHNOPHARMACOL, V127, P407, DOI 10.1016/j.jep.2009.10.025; Radulovic N, 2012, FOOD CHEM TOXICOL, V50, P274, DOI 10.1016/j.fct.2011.10.060; Radulovic NS, 2013, PHYTOTHER RES, V27, P1334, DOI 10.1002/ptr.4877; Radulovic NS, 2011, J ETHNOPHARMACOL, V135, P610, DOI 10.1016/j.jep.2011.03.035; de Souza PAVR, 2011, J ETHNOPHARMACOL, V135, P135, DOI 10.1016/j.jep.2011.03.003; Renno MN, 2008, AN ACAD BRAS CIENC, V80, P467, DOI 10.1590/S0001-37652008000300008; SAHLEY TL, 1979, PSYCHOPHARMACOLOGY, V65, P279, DOI 10.1007/BF00492216; Tabarelli Z, 2004, BRAZ J MED BIOL RES, V37, P1531, DOI 10.1590/S0100-879X2004001000013; TJOLSEN A, 1991, J PHARMACOL METHOD, V25, P241, DOI 10.1016/0160-5402(91)90014-V; Woodcock J, 2007, NAT REV DRUG DISCOV, V6, P703, DOI 10.1038/nrd2335; Xie YF, 2009, ACTA PHARMACOL SIN, V30, P31, DOI 10.1038/aps.2008.14; Xu ZM, 2000, BRAIN RES, V861, P390, DOI 10.1016/S0006-8993(00)02051-5; ZIMET PO, 1986, DRUG DEVELOP RES, V7, P277, DOI 10.1002/ddr.430070309	49	5	5	4	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2016	11	10							e0164998	10.1371/journal.pone.0164998	http://dx.doi.org/10.1371/journal.pone.0164998			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9OE	27768733	Green Published, gold			2023-01-03	WOS:000386205400042
J	Chessman, AW				Chessman, Alexander W.			Review: Acupuncture reduces migraine frequency more than usual care, sham acupuncture, or prophylactic drugs	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Chessman, Alexander W.] Med Univ South Carolina, Charleston, SC 29425 USA	Medical University of South Carolina	Chessman, AW (corresponding author), Med Univ South Carolina, Charleston, SC 29425 USA.							Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75	2	4	6	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2016	165	8					JC44	JC44		10.7326/ACPJC-2016-165-8-044	http://dx.doi.org/10.7326/ACPJC-2016-165-8-044			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ6BM	27750304				2023-01-03	WOS:000385946600009
J	Laxy, M; Knoll, G; Schunk, M; Meisinger, C; Huth, C; Holle, R				Laxy, Michael; Knoll, Gabriella; Schunk, Michaela; Meisinger, Christa; Huth, Cornelia; Holle, Rolf			Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies	PLOS ONE			English	Article							DISEASE MANAGEMENT PROGRAMS; COST-EFFECTIVENESS; MULTIFACTORIAL INTERVENTION; GLUCOSE CONTROL; FOLLOW-UP; TYPE-2; INDIVIDUALS; MORTALITY; OUTCOMES; LIFE	Objective Little is known about the development of the quality of diabetes care in Germany. The aim of this study is to analyze time trends in patient self-management, physician-delivered care, medication, risk factor control, complications and quality of life from 2000 to 2014. Methods Analyses are based on data from individuals with type 2 diabetes of the population-based KORA S4 (1999-2001, n = 150), F4 (2006-2008, n = 203), FF4 (2013/14, n = 212) cohort study. Information on patient self-management, physician-delivered care, medication, risk factor control and quality of life were assessed in standardized questionnaires and examinations. The 10-year coronary heart disease (CHD) risk was calculated using the UKPDS risk engine. Time trends were analyzed using multivariable linear and logistic regression models adjusted for age, sex, education, diabetes duration, and history of cardiovascular disease. Results From 2000 to 2014 the proportion of participants with type 2 diabetes receiving oral antidiabetic/cardio-protective medication and of those reaching treatment goals for glycemic control (HbA1c<7%, 60% to 71%, p = 0.09), blood pressure (<140/80 mmHg, 25% to 69%, p<0.001) and LDL cholesterol (<2.6 mmol/l, 13% to 27%, p<0.001) increased significantly. However, improvements were generally smaller from 2007 to 2014 than from 2000 to 2007. Modeled 10-year CHD risk decreased from 30% in 2000 to 24% in 2007 to 19% in 2014 (p<0.01). From 2007 to 2014, the prevalence of microvascular complications decreased and quality of life increased, but no improvements were observed for the majority of indicators of self-management. Conclusion Despite improvements, medication and risk factor control has remained suboptimal. The flattening of improvements and deteriorations in quality of (self-) care since 2007 indicate that more effort is needed to improve quality of care and patient self-management. Due to selection or lead time bias an overestimation of quality of care improvements cannot be ruled out.	[Laxy, Michael; Knoll, Gabriella; Schunk, Michaela; Holle, Rolf] Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, Neuherberg, Germany; [Laxy, Michael; Meisinger, Christa; Huth, Cornelia; Holle, Rolf] German Ctr Diabet Res DZD, Munich, Germany; [Knoll, Gabriella] Univ Munich, Inst Med Informat Biometr & Epidemiol, Munich, Germany; [Meisinger, Christa; Huth, Cornelia] Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Laxy, M (corresponding author), Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, Neuherberg, Germany.; Laxy, M (corresponding author), German Ctr Diabet Res DZD, Munich, Germany.	michael.laxy@helmholtz-muenchen.de	Holle, Rolf/D-9333-2013; Huth, Cornelia/B-5350-2014; Meisinger, Christine/B-5358-2014	Holle, Rolf/0000-0001-5395-2695; Huth, Cornelia/0000-0003-2421-433X; Laxy, Michael/0000-0001-8775-7417; Schunk, Michaela/0000-0002-1200-1903	Helmholtz Zentrum Munchen - German Research Center for Environmental Health; German Federal Ministry of Education and Research; State of Bavaria; Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universitat, LMU innovative	Helmholtz Zentrum Munchen - German Research Center for Environmental Health(Helmholtz Association); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); State of Bavaria; Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universitat, LMU innovative	The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum Munchen - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universitat, as part of the LMU innovative.	Ab E, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-24; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Busse R, 2004, HEALTH AFFAIR, V23, P56, DOI 10.1377/hlthaff.23.3.56; Costa J, 2006, BMJ-BRIT MED J, V332, P1115, DOI 10.1136/bmj.38793.468449.AE; Drabik A, 2012, DIABETES RES CLIN PR, V95, P194, DOI 10.1016/j.diabres.2011.09.015; Du Y, 2015, BMJ OPEN DIAB RES CA, V3, DOI 10.1136/bmjdrc-2015-000135; Fuchs S, 2014, DTSCH ARZTEBL INT, V111, P453, DOI 10.3238/arztebl.2014.0453; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Gray A, 2000, BMJ-BRIT MED J, V320, P1373, DOI 10.1136/bmj.320.7246.1373; Gregg EW, 2014, NEW ENGL J MED, V370, P1514, DOI 10.1056/NEJMoa1310799; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Holman RR, 2008, NEW ENGL J MED, V359, P1565, DOI 10.1056/NEJMoa0806359; Hunger M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-1; Hunger M, 2012, J DIABETES COMPLICAT, V26, P413, DOI 10.1016/j.jdiacomp.2012.05.008; Hunger M, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-53; Ikonen TS, 2010, DIABETES CARE, V33, P2598, DOI 10.2337/dc10-0462; Knight K, 2005, AM J MANAG CARE, V11, P242; Koster I, 2014, EXP CLIN ENDOCR DIAB, V122, P510, DOI 10.1055/s-0034-1375675; Laxy M, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0065-9; Laxy M, 2014, DIABETES CARE, V37, P1604, DOI 10.2337/dc13-2533; Lazar LD, 2011, CIRCULATION, V124, P146, DOI 10.1161/CIRCULATIONAHA.110.986349; Li R, 2010, DIABETES CARE, V33, P1193, DOI 10.2337/dc09-1888; Meisinger C, 2010, DIABETIC MED, V27, P360, DOI 10.1111/j.1464-5491.2009.02905.x; Norris SL, 2002, AM J PREV MED, V22, P15, DOI 10.1016/S0749-3797(02)00423-3; Rathmann W, 2003, DIABETOLOGIA, V46, P182, DOI 10.1007/s00125-002-1025-0; Rueckert IM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133493; Schunk M, 2012, DIABETIC MED, V29, P646, DOI 10.1111/j.1464-5491.2011.03465.x; Schunk M, 2011, BUNDESGESUNDHEITSBLA, V54, P1187, DOI 10.1007/s00103-011-1364-4; Schunk M, 2009, EXP CLIN ENDOCR DIAB, V117, P88, DOI 10.1055/s-2008-1078734; Schwarz PEH, 2008, EXP CLIN ENDOCR DIAB, V116, P167, DOI 10.1055/s-2007-992115; Stark RG, 2011, DIABETES-METAB RES, V27, P383, DOI 10.1002/dmrr.1186; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Tamayo T, 2016, DTSCH ARZTEBL INT, V113, P177, DOI 10.3238/arztebl.2016.0177; Tamayo T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099773; Tao LB, 2013, VALUE HEALTH, V16, P1074, DOI 10.1016/j.jval.2013.06.001; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; Vamos EP, 2010, DIABETES CARE, V33, P2592, DOI 10.2337/dc10-0989; van Hateren KJJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001387	41	32	32	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2016	11	10							e0164704	10.1371/journal.pone.0164704	http://dx.doi.org/10.1371/journal.pone.0164704			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NL	27749939	Green Submitted, gold, Green Published			2023-01-03	WOS:000386202300022
J	Rutherford, GW; Horvath, H				Rutherford, George W.; Horvath, Hacsi			Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review	PLOS ONE			English	Review							ONCE-DAILY DOLUTEGRAVIR; NAIVE ADULTS; DOUBLE-BLIND; INFECTION; SAFETY; RALTEGRAVIR; RESISTANCE; EFFICACY	Background Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor that along with two nucleoside reverse transcriptase inhibitors is one of several regimens recommended by the United States, United Kingdom and European Union for first-line antiretroviral treatment of people with HIV infection. Our objective was to review the evidence for the efficacy and safety of DTG-based first-line regimens compared to efavirenz (EFV)based regimens. Methods We conducted a systematic review. We comprehensively searched a range of databases as well as conference abstracts and a trials registry. We used Cochrane methods in screening and data collection and assessed each study's risk of bias with the Cochrane tool. We meta-analyzed data using a fixed-effects model. We used GRADE to assess evidence quality. Results From 492 search results, we identified two randomized controlled trials, reported in five peer-reviewed articles and one conference abstract. One trial tested two DTG-based regimens (DTG+ abacavir (ABC)+ lamivudine (3TC) or DTG + tenofovir + emtricitabine) against an EFV-based regimen (EFV+ABC+3TC). The other trial tested DTG+ABC+3TC against EFV+ABC+3TC. In meta-analysis, DTG-containing regimens were superior to EFV-containing regimens at 48 weeks and at 96 weeks (RR = 1.10, 95% CI 1.04-1.16; and RR = 1.12, 95% CI 1.04-1.21, respectively). In one trial, the DTG-containing regimen was superior at 144 weeks (RR = 1.13, 95% CI 1.02-1.24). DTG-containing regimens were superior in reducing treatment discontinuation compared to those containing EFV at 96 weeks and at 144 weeks (RR = 0.27, 95% CI 0.15-0.50; and RR = 0.28, 95% CI 0.16-0.48, respectively). Risk of serious adverse events was similar in each regimen at 96 weeks (RR = 1.15, 95% CI 0.80-1.63) and 144 weeks (RR = 0.93, 95% CI 0.68-1.29). Risk of bias was moderate overall, as was GRADE evidence quality. Conclusions DTG-based regimens should be considered in future World Health Organization guidelines for initial HIV treatment.	[Rutherford, George W.; Horvath, Hacsi] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rutherford, GW (corresponding author), Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94143 USA.	george.rutherford@ucsf.edu		Horvath, Hacsi/0000-0001-7569-3524	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		British HIV Association (BHIVA), 2015, BHIVA GUID TREATM HI; Cahn P, 2013, LANCET, V382, P700, DOI 10.1016/S0140-6736(13)61221-0; Clotet B, 2014, LANCET, V383, P2222, DOI 10.1016/S0140-6736(14)60084-2; Curtis L, 2014, HIV CLIN TRIALS, V15, P199, DOI 10.1310/hct1505-199; European AIDS Clinical Society, 2015, GUID 8 0; Ford N, 2015, JAIDS-J ACQ IMM DEF, V69, P422, DOI 10.1097/QAI.0000000000000606; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Kandel CE, 2015, DRUG DES DEV THER, V9, P3547, DOI 10.2147/DDDT.S84850; Llibre JM, 2015, AIDS REV, V17, P56; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Panel of Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR; Raffi F, 2015, AIDS, V29, P167, DOI 10.1097/QAD.0000000000000519; Raffi F, 2013, LANCET, V381, P735, DOI 10.1016/S0140-6736(12)61853-4; Shubber Z, 2013, AIDS, V27, P1403, DOI 10.1097/QAD.0b013e32835f1db0; Sinclair D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063715; Stellbrink HJ, 2013, AIDS, V27, P1771, DOI 10.1097/QAD.0b013e3283612419; Taha H, 2015, INFECT DRUG RESIST, V8, P339, DOI 10.2147/IDR.S68396; van Lunzen J, 2012, LANCET INFECT DIS, V12, P111, DOI 10.1016/S1473-3099(11)70290-0; Walmsley S, 2014, 21 C RETR OPP INF BO; Walmsley S, 2015, JAIDS-J ACQ IMM DEF, V70, P515, DOI 10.1097/QAI.0000000000000790; Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541; Weinberg MA, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00090; World Health Organization, 2016, CONSOLIDATED GUIDELI, V2nd ed; World Health Organization, 2014, WHO HDB GUID DEV, Vsecond	25	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2016	11	10							e0162775	10.1371/journal.pone.0162775	http://dx.doi.org/10.1371/journal.pone.0162775			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CV	27736859	Green Published, Green Submitted, gold			2023-01-03	WOS:000385505800005
J	Torjesen, I				Torjesen, Ingrid			Doctors who prescribe antibiotics online face GMC investigation	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2016	355								i5423	10.1136/bmj.i5423	http://dx.doi.org/10.1136/bmj.i5423			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ4UM	27758784				2023-01-03	WOS:000385856000010
J	Korthuis, PT; McCarty, D; Weimer, M; Bougatsos, C; Blazina, I; Zakher, B; Grusing, S; Devine, B; Chou, R				Korthuis, P. Todd; McCarty, Dennis; Weimer, Melissa; Bougatsos, Christina; Blazina, Ian; Zakher, Bernadette; Grusing, Sara; Devine, Beth; Chou, Roger			Primary Care-Based Models for the Treatment of Opioid Use Disorder A Scoping Review	ANNALS OF INTERNAL MEDICINE			English	Review							PATIENTS RECEIVING BUPRENORPHINE/NALOXONE; HIV CLINICAL CARE; NEONATAL ABSTINENCE SYNDROME; DEPENDENT PATIENTS; INTEGRATED BUPRENORPHINE/NALOXONE; RELEASE NALTREXONE; COLLABORATIVE CARE; TREATMENT OUTCOMES; INFECTED PATIENTS; RANDOMIZED-TRIAL	Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for OUD, based on a literature review and interviews with key informants in the field. The report describes 12 representative models of care for integrating MAT into primary care settings that could be considered for adaptation across diverse health care settings. Common components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provider and community education, coordination and integration of OUD treatment with other medical and psychological needs, and psychosocial services and interventions. Models vary in how each component is implemented. Decisions about adopting MAT models of care should be individualized to address the unique milieu of each implementation setting.	[Korthuis, P. Todd; Weimer, Melissa] Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA; [Devine, Beth] Univ Washington, Box 357630, Seattle, WA 98195 USA; [McCarty, Dennis] OHSU PSU Sch Publ Hlth, CB669,3186 SW Sam Jackson Pk Rd, Portland, OR 97239 USA; [Bougatsos, Christina; Blazina, Ian; Zakher, Bernadette; Grusing, Sara; Chou, Roger] Oregon Hlth & Sci Univ, Mail Code BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle; Oregon Health & Science University	Korthuis, PT (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA.	korthuis@ohsu.edu	Weimer, Melissa/M-5599-2019	Weimer, Melissa/0000-0002-5624-2434; Chou, Roger/0000-0001-9889-8610; Korthuis, Philip/0000-0001-5556-3597; Blazina, Ian/0000-0003-0164-6674	AHRQ, U.S. Department of Health and Human Services [HHSA290201500009I]; NATIONAL INSTITUTE ON DRUG ABUSE [UG1DA015815, P50DA010233, R01DA037441] Funding Source: NIH RePORTER	AHRQ, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This project was funded under contract HHSA290201500009I, Task Order 4, from the AHRQ, U.S. Department of Health and Human Services.	Alford DP, 2007, J GEN INTERN MED, V22, P171, DOI 10.1007/s11606-006-0023-1; Alford DP, 2011, ARCH INTERN MED, V171, P425, DOI 10.1001/archinternmed.2010.541; Alliance of Community Health Plans, 2013, VERM HLTH HOM OP ADD; Altice FL, 2011, JAIDS-J ACQ IMM DEF, V56, pS22, DOI 10.1097/QAI.0b013e318209751e; [Anonymous], 2011, J ACQUIR IMMUNE D S1, V56, pS46, DOI [10.1097/QAI.0b013e3182097561, DOI 10.1097/QAI.0B013E3182097561]; Carrieri MP, 2003, DRUG ALCOHOL DEPEN, V72, P13, DOI 10.1016/S0376-8716(03)00189-3; Center for Behavioral Health Statistics and Quality, 2015, HHS PUBL; Center for Substance Abuse Treatment. Substance Abuse Treatment: Group Therapy, 2005, SUBSTANCE ABUSE TREA, V41; Chaudhry AA, 2011, JAIDS-J ACQ IMM DEF, V56, pS14, DOI 10.1097/QAI.0b013e318209d3b9; Cheever LW, 2011, JAIDS-J ACQ IMM DEF, V56, pS3, DOI 10.1097/QAI.0b013e318209740f; Chen H., 2014, REPORT VERMONT LEGIS; Chou R, 2016, 290201500009I AG HEA; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Comer SD, 2006, ARCH GEN PSYCHIAT, V63, P210, DOI 10.1001/archpsyc.63.2.210; Commonwealth of Massachusetts Executive Office of Health and Human Services, 2015, GET HELP TYP TREATM; Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Fiellin DA, 2002, AM J DRUG ALCOHOL AB, V28, P231, DOI 10.1081/ADA-120002972; Fiellin DA, 2008, AM J ADDICTION, V17, P116, DOI 10.1080/10550490701860971; Fiellin DA, 2006, NEW ENGL J MED, V355, P365, DOI 10.1056/NEJMoa055255; Fiellin DA, 2011, JAIDS-J ACQ IMM DEF, V56, pS33, DOI 10.1097/QAI.0b013e3182097537; Finkelstein R, 2011, JAIDS-J ACQ IMM DEF, V56, pS98, DOI 10.1097/QAI.0b013e31820a9a97; Friedland G, 2011, JAIDS-J ACQ IMM DEF, V56, pS1, DOI 10.1097/QAI.0b013e31820bc9ba; Health Resources and Services Administration, 2016, RYAN WHIT HIV AIDS P; HIV/AIDS Bureau, 2011, INT BUPR THER HIV PR; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Jones HE, 2005, DRUG ALCOHOL DEPEN, V79, P1, DOI 10.1016/j.drugalcdep.2004.11.013; Jones HE, 2010, NEW ENGL J MED, V363, P2320, DOI 10.1056/NEJMoa1005359; Komaromy M, 2016, SUBST ABUS, V37, P20, DOI 10.1080/08897077.2015.1129388; Korthuis PT, 2011, JAIDS-J ACQ IMM DEF, V56, pS39, DOI 10.1097/QAI.0b013e318209754c; Korthuis PT, 2011, JAIDS-J ACQ IMM DEF, V56, pS83, DOI 10.1097/QAI.0b013e31820bc9a5; Korthuis PT, 2010, J ADDICT MED, V4, P204, DOI 10.1097/ADM.0b013e3181cc9610; Krupitsky E, 2011, LANCET, V377, P1506, DOI 10.1016/S0140-6736(11)60358-9; LaBelle CT, 2016, J SUBST ABUSE TREAT, V60, P6, DOI 10.1016/j.jsat.2015.06.010; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; LifeSpring Health Systems, 2016, US LOC; Lucas GM, 2010, ANN INTERN MED, V152, P704, DOI 10.7326/0003-4819-152-11-201006010-00003; Lum PJ, 2011, JAIDS-J ACQ IMM DEF, V56, pS91, DOI 10.1097/QAI.0b013e31820a9a82; Macrae J, 2015, HHS BLOG        0727; Mann C, 2014, MEDICATION ASSISTED; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McConnell KJ, 2016, JAMA-J AM MED ASSOC, V315, P869, DOI 10.1001/jama.2016.0206; Moses K., 2015, DESIGNING MEDICAID H; National Institute on Drug Abuse, 2015, OV DEATH RAT; National Institute on Drug Abuse, 2012, TOP BRIEF MED ASS TR; Oregon Pain Guidance, 2016, PAIN MAN GUID TOOLS; Patient-Centered Primary Care Collaborative, 2015, VERM HUB SPOK HLTH H; Pecoraro A, 2012, SUBST USE MISUSE, V47, P1026, DOI 10.3109/10826084.2012.663292; Project ECHO, 2014, ECHO ACC OP US DIS T; Pupillo J., 2014, PROJECT ECHO TRAINS; Raymond SC, 2012, INTEGRATING BUPRENOR; Schackman BR, 2011, JAIDS-J ACQ IMM DEF, V56, pS76, DOI 10.1097/QAI.0b013e31820a9a66; Shanahan CW, 2010, J GEN INTERN MED, V25, P803, DOI 10.1007/s11606-010-1311-3; Stoller K., 2015, INNOVATIVE PRACTICES; Stoller K.B., 2015, ADDICT SCI CLIN PRAC, V10, pA63, DOI [10.1186/1940-0640-10-S1-A63, DOI 10.1186/1940-0640-10-S1-A63, 10.1186/1940-0640-10-s1-a63.]; Sullivan LE, 2006, CLIN INFECT DIS, V43, pS184, DOI 10.1086/508182; Sullivan LE, 2011, JAIDS-J ACQ IMM DEF, V56, pS54, DOI 10.1097/QAI.0b013e3182097576; TARGET Center, 2009, BEEHIVE BUPR PROGR T; The White House, 2015, PRES MEM ADDR PRESCR; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419; Vergara-Rodriguez P, 2011, JAIDS-J ACQ IMM DEF, V56, pS62, DOI 10.1097/QAI.0b013e31820a820f; Vermont Agency of Human Services, 2012, INT TREATM CONT SUBS; Weiss L, 2011, JAIDS-J ACQ IMM DEF, V56, pS7, DOI 10.1097/QAI.0b013e3182097426; Weiss L, 2011, JAIDS-J ACQ IMM DEF, V56, pS68, DOI 10.1097/QAI.0b013e31820a8226	66	167	168	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2017	166	4					268	+		10.7326/M16-2149	http://dx.doi.org/10.7326/M16-2149			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EL7FO	27919103	Green Accepted			2023-01-03	WOS:000394786700016
J	Muller, F; Hagedoorn, M; Tuinman, MA				Mueller, Fabiola; Hagedoorn, Mariet; Tuinman, Marrit A.			Chronic multimorbidity impairs role functioning in middle-aged and older individuals mostly when non-partnered or living alone	PLOS ONE			English	Article							QUALITY-OF-LIFE; MENTAL-HEALTH; CHRONIC DISEASES; COMORBIDITY; DISTRESS; PEOPLE; ARRANGEMENTS; DECLINE; ADULTS	Background Due to the aging of the population, society includes a growing proportion of older individuals prone to chronic morbidity. This study aimed to investigate the adverse effects of single and multiple chronic morbidity on psychosocial health and whether these effects are more pronounced in individuals who are non-partnered or living alone. Materials and methods Baseline data from the 'Lifelines Cohort Study' collected between 2006 and 2013 in the Netherlands were used. Individuals aged 50+ (n = 25,214) were categorized according to their health status (healthy, single chronic morbidity, multiple chronic morbidity), relationship status (partnered, non-partnered), and living arrangement (living with someone, living alone). Analyses of covariance (ANCOVA) were performed to study the main- and the interaction-effects on mental health and role functioning as assessed with the RAND-36. Results Irrespective of having chronic morbidity, having a partner was associated with better mental health when partners shared a home. Individuals with single and especially multiple chronic morbidity had impaired role functioning. Having a partner mitigated the adverse effects of multimorbidity on role functioning, but only in individuals who shared a home with their partner. Non-partnered individuals with multimorbidity and those not sharing a home with their partner demonstrated impaired role functioning. Conclusions The results demonstrate that multimorbidity negatively affects role functioning, but not the mental health, of middle-aged and older individuals. Sharing a home with a partner can mitigate these adverse effects, while other combinations of relationship status and living arrangement do not. Offering intervention to those individuals most vulnerable to impaired functioning may relieve some of the increasing pressure on the health care system. An individual's relationship status along with one's living arrangement could foster the identification of a target group for such interventions attempting to sustain physical functioning or to adapt daily goals.	[Mueller, Fabiola; Hagedoorn, Mariet; Tuinman, Marrit A.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Psychol, Antonius Deusinglaan 1, Groningen, Netherlands	University of Groningen	Muller, F (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Psychol, Antonius Deusinglaan 1, Groningen, Netherlands.	f.muller@umcg.nl	Müller, Fabiola/AFM-7755-2022; Hagedoorn, Mariet/B-5056-2010	Müller, Fabiola/0000-0002-0412-7469; Hagedoorn, Mariet/0000-0003-3444-3662	Dutch Cancer Society [RUG 2009-4442]	Dutch Cancer Society(KWF Kankerbestrijding)	This work was supported by the Dutch Cancer Society (URL: https://www.kwf.nl/english/). The grant number is RUG 2009-4442 (Fellowship Marrit Tuinman). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarts S, 2012, J PSYCHOSOM RES, V73, P211, DOI 10.1016/j.jpsychores.2012.05.014; Alonso J, 2004, QUAL LIFE RES, V13, P283, DOI 10.1023/B:QURE.0000018472.46236.05; [Anonymous], 2012, METEN ALGEMENE GEZON; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; BRETTSCHNEIDER C, 2013, PLOS ONE, V0008; Brown CJ, 2013, JAMA-J AM MED ASSOC, V310, P1168, DOI 10.1001/jama.2013.276566; Diener E, 2000, J CROSS CULT PSYCHOL, V31, P419, DOI 10.1177/0022022100031004001; Hagedoorn M, 2006, PSYCHOL AGING, V21, P611, DOI 10.1037/0882-7974.21.3.611; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; Henning-Smith C, 2016, J APPL GERONTOL, V35, P39, DOI 10.1177/0733464814530805; Holden L, 2015, QUAL LIFE RES, V24, P2075, DOI 10.1007/s11136-015-0946-2; Hopman P, 2016, QUAL LIFE RES, V25, P651, DOI 10.1007/s11136-015-1102-8; Hughes ME, 2002, J HEALTH SOC BEHAV, V43, P1, DOI 10.2307/3090242; Ip EH, 2013, J GERONTOL A-BIOL, V68, P426, DOI 10.1093/gerona/gls186; Jayasinghe UW, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-50; Jones SMW, 2016, AGING MENT HEALTH, V20, P309, DOI 10.1080/13607863.2015.1008988; Joutsenniemi K, 2006, J EPIDEMIOL COMMUN H, V60, P468, DOI 10.1136/jech.2005.040741; Kamiya Y, 2013, AGING MENT HEALTH, V17, P349, DOI 10.1080/13607863.2012.747078; Klijs B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137203; Kriegsman DMW, 2004, J CLIN EPIDEMIOL, V57, P55, DOI 10.1016/S0895-4356(03)00258-0; Lewin AC., 2016, J FAM ISSUES, P1; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Matcham F, 2014, SEMIN ARTHRITIS RHEU, V44, P123, DOI 10.1016/j.semarthrit.2014.05.001; Norris SL, 2011, J CLIN EPIDEMIOL, V64, P358, DOI 10.1016/j.jclinepi.2010.04.016; Rijken M, 2005, QUAL LIFE RES, V14, P45, DOI 10.1007/s11136-004-0616-2; Scholtens S, 2015, INT J EPIDEMIOL, V44, P1172, DOI 10.1093/ije/dyu229; Sharpe L, 2006, SOC SCI MED, V62, P1153, DOI 10.1016/j.socscimed.2005.07.010; Singer MA, 1999, QUAL LIFE RES, V8, P687, DOI 10.1023/A:1008917016998; Soulsby L.K., 2015, PSYCHOLOGY, V6, P1349, DOI [DOI 10.4236/PSYCH.2015.611132, 10.4236/psych.2015.611132]; Sprangers MAG, 2000, J CLIN EPIDEMIOL, V53, P895, DOI 10.1016/S0895-4356(00)00204-3; Strohm CQ, 2009, DEMOGR RES, V21, P177, DOI 10.4054/DemRes.2009.21.7; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Trevisol DJ, 2011, J HYPERTENS, V29, P179, DOI 10.1097/HJH.0b013e328340d76f; Tuinman MA, 2015, PSYCHO-ONCOLOGY, V24, P699, DOI 10.1002/pon.3712; Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; van Oostrom SH, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-715; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wikman A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018952	38	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2017	12	2							e0170525	10.1371/journal.pone.0170525	http://dx.doi.org/10.1371/journal.pone.0170525			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7DB	28151967	Green Published, gold, Green Submitted			2023-01-03	WOS:000396161200024
J	Loturco, I; Pereira, LA; Moraes, JE; Kitamura, K; Abad, CCC; Kobal, R; Nakamura, FY				Loturco, Irineu; Pereira, Lucas A.; Moraes, Jose E.; Kitamura, Katia; Cal Abad, Cesar C.; Kobal, Ronaldo; Nakamura, Fabio Y.			Jump-Squat and Half-Squat Exercises: Selective Influences on Speed-Power Performance of Elite Rugby Sevens Players	PLOS ONE			English	Article							SPRINT PERFORMANCE; DIRECTION PERFORMANCE; STRENGTH; TESTS; AGILITY	The aim of this study was to evaluate the relation between the maximum mean propulsive power (MPP) obtained in the loaded jump squat (JS) and half squat (HS) exercises and functional performances in vertical jumps, 40m linear speed (VEL) and change-of-direction (COD) tests, using the median split technique. Twenty-two male rugby sevens players from the Brazilian National Olympic Team (Rio-2016) performed vertical jumping tests (squat and countermovement jumps [SJ and CMJ]), JS and HS exercises, COD speed test and sprinting velocity in 40 m, in this order. Based on the results of the MPP in the JS and HS exercises the participants were divided, using the median split, into four groups as follows: higher JS, lower JS, higher HS, and lower HS. Between-group differences in the functional tasks were detected via magnitude-based inferences. The athletes with higher MPP in the JS were capable of jumping higher and sprinting faster (including the COD speed test) than their weaker counterparts. This pattern was not observed in the HS exercise. To conclude, JS was shown to be more connected to sprinting, COD speed and jumping abilities than HS in elite rugby sevens players and should be preferred for assessing and possibly training elite athletes needing to improve speed-power related abilities.	[Loturco, Irineu; Pereira, Lucas A.; Kitamura, Katia; Cal Abad, Cesar C.; Kobal, Ronaldo; Nakamura, Fabio Y.] NAR Nucleus High Performance Sport, Sao Paulo, SP, Brazil; [Moraes, Jose E.] CBRu Brazilian Rugby Confederat, Sao Paulo, SP, Brazil; [Nakamura, Fabio Y.] Univ Estadual Londrina, Londrina, PR, Brazil	Universidade Estadual de Londrina	Loturco, I (corresponding author), NAR Nucleus High Performance Sport, Sao Paulo, SP, Brazil.	irineu.loturco@terra.com.br	PEREIRA, LUCAS/HHZ-5877-2022; Loturco, Irineu/AAH-4916-2019; Nakamura, Fábio Yuzo/AAC-3069-2020; Pereira, Lucas/S-3110-2019; Kobal, Ronaldo/AAU-8415-2021	Loturco, Irineu/0000-0003-1309-2568; Nakamura, Fábio Yuzo/0000-0002-5336-3652; Pereira, Lucas/0000-0003-1079-2446; Kobal, Ronaldo/0000-0003-0243-2133				Aagaard P, 2003, EXERC SPORT SCI REV, V31, P61, DOI 10.1097/00003677-200304000-00002; Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; Argus CK, 2012, INT J SPORT PHYSIOL, V7, P68, DOI 10.1123/ijspp.7.1.68; Baker D, 1999, J STRENGTH COND RES, V13, P224, DOI 10.1519/00124278-199908000-00008; Barnes C, 2014, INT J SPORTS MED, V35, P1095, DOI 10.1055/s-0034-1375695; Batterham AM, 2006, INT J SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Bloomfield J, 2007, J SPORT SCI MED, V6, P63; Chelly MS, 2009, J STRENGTH COND RES, V23, P2241, DOI 10.1519/JSC.0b013e3181b86c40; Cohen J., 2013, STAT POWER ANAL BEHA; Cormie P, 2007, MED SCI SPORT EXER, V39, P340, DOI 10.1249/01.mss.0000246993.71599.bf; Cormie P, 2011, SPORTS MED, V41, P125, DOI 10.2165/11538500-000000000-00000; COSTILL DL, 1968, RES QUART, V39, P785, DOI 10.1080/10671188.1968.10616615; Cronin JB, 2005, J STRENGTH COND RES, V19, P349; Faude O, 2012, J SPORT SCI, V30, P625, DOI 10.1080/02640414.2012.665940; Hewit JK, 2012, INT J SPORTS SCI COA, V7, P503, DOI 10.1260/1747-9541.7.3.503; Hori N, 2008, J STRENGTH COND RES, V22, P54, DOI 10.1519/JSC.0b013e31815ef052; Iacobucci D, 2015, J CONSUM PSYCHOL, V25, P690, DOI 10.1016/j.jcps.2015.06.014; Kraemer, 1994, STRENGTH COND, V16, P20, DOI DOI 10.1519/1073-6840(1994)016<0020:DEMPIF>2.3.CO;2; Kumagai K, 2000, J APPL PHYSIOL, V88, P811, DOI 10.1152/jappl.2000.88.3.811; Little T, 2005, J STRENGTH COND RES, V19, P76; Loturco I, 2016, INT J SPORTS MED, V37, P211, DOI 10.1055/s-0035-1559694; Loturco I, 2015, INT J SPORT IN PRESS; Loturco I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153958; Loturco I, 2016, J STRENGTH COND RES, V30, P109, DOI 10.1519/JSC.0000000000001075; Loturco I, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00323; Loturco I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140102; Loturco I, 2015, J STRENGTH COND RES, V29, P2771, DOI 10.1519/JSC.0000000000000951; Loturco I, 2015, J STRENGTH COND RES, V29, P1966, DOI 10.1519/JSC.0000000000000849; Loturco I, 2015, J SPORT SCI, V33, P1283, DOI 10.1080/02640414.2015.1022574; Loturco I, 2015, J STRENGTH COND RES, V29, P758, DOI 10.1519/JSC.0000000000000660; Loturco I, 2013, J SPORT SCI MED, V12, P109; Loturco I, 2013, J STRENGTH COND RES, V27, P188, DOI 10.1519/JSC.0b013e3182503807; McBride JM, 2005, J STRENGTH COND RES, V19, P893, DOI 10.1519/00124278-200511000-00029; McBride JM, 2002, J STRENGTH COND RES, V16, P75, DOI 10.1519/00124278-200202000-00011; Newton RU, 1996, J APPL BIOMECH, V12, P31, DOI 10.1123/jab.12.1.31; Nibali ML, 2013, J STRENGTH COND RES, V27, P388, DOI 10.1519/JSC.0b013e3182576feb; Nimphius S, 2012, J STRENGTH COND RES, V26, P2655, DOI 10.1519/JSC.0b013e318269f81e; Nimphius S, 2010, J STRENGTH COND RES, V24, P885, DOI 10.1519/JSC.0b013e3181d4d41d; Rampinini E, 2007, INT J SPORTS MED, V28, P228, DOI 10.1055/s-2006-924340; Rhea MR, 2004, J STRENGTH COND RES, V18, P918, DOI 10.1519/00124278-200411000-00040; Sanchez-Medina L, 2010, INT J SPORTS MED, V31, P123, DOI 10.1055/s-0029-1242815; Sheppard JM, 2006, J SPORT SCI, V24, P919, DOI 10.1080/02640410500457109; Stone MH, 2006, STRENGTH COND J, V28, P44, DOI 10.1519/00126548-200606000-00008; VIITASALO JT, 1978, EUR J APPL PHYSIOL O, V40, P7, DOI 10.1007/BF00420984; Wisloff U, 2004, BRIT J SPORT MED, V38, P285, DOI 10.1136/bjsm.2002.002071; Young W, 2006, STRENGTH COND J, V28, P24, DOI 10.1519/1533-4295(2006)28[24:AROAPA]2.0.CO;2	46	28	28	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2017	12	1							e0170627	10.1371/journal.pone.0170627	http://dx.doi.org/10.1371/journal.pone.0170627			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6QR	28114431	Green Published, gold, Green Submitted			2023-01-03	WOS:000396129000078
J	Eastwood, J; Ogbo, FA; Hendry, A; Noble, J; Page, A				Eastwood, John; Ogbo, Felix A.; Hendry, Alexandra; Noble, Justine; Page, Andrew		EYRG	The Impact of Antenatal Depression on Perinatal Outcomes in Australian Women	PLOS ONE			English	Article							POSTNATAL DEPRESSION; MATERNAL DEPRESSION; POSTPARTUM DEPRESSION; MENTAL-HEALTH; RISK-FACTORS; PRENATAL DEPRESSION; MULTIPLE IMPUTATION; CHRONIC ILLNESS; BIRTH OUTCOMES; PREVALENCE	Background In Australia, there is limited evidence on the impact of antenatal depression on perinatal outcomes. This study investigates the association between maternal depressive symptoms during pregnancy and key perinatal outcomes, including birth weight, gestational age at birth, breastfeeding indicators and postnatal depressive symptoms. Method A retrospective cohort of mothers (N = 17,564) of all infants born in public health facilities within South Western Sydney Local Health District and Sydney Local Health District in 2014, in the state of New South Wales (NSW), Australia, was enumerated from routinely collected antenatal data to investigate the risk of adverse perinatal outcomes associated with maternal depressive symptoms during pregnancy. Antenatal depressive symptoms were measured using the Edinburgh Postnatal Depression Scale (EPDS). Logistic regression models that adjusted for confounders were conducted to determine associations between antenatal depressive symptoms and low birth weight, early gestational age at birth (<37 weeks), breast feeding indicators and postnatal depressive symptoms. Results The prevalence of maternal depressive symptoms during pregnancy was 7.0% in the cohort, and was significantly associated with postnatal depressive symptoms [Adjusted Odd Ratios (AOR) = 6.4, 95% CI: 4.8-8.7, P<0.001]. Antenatal depressive symptoms was associated with a higher odds of low birth weight [AOR = 1.7, 95% CI: 1.2-2.3, P = 0.003] and a gestational age at birth of <37 weeks [AOR = 1.3, 95% CI: 1.1-1.7, P = 0.018] compared to women who reported lower EPDS scores in antenatal period. Antenatal depressive symptoms were not strongly associated with non-exclusive breast feeding in the early postnatal period. Conclusion Maternal depressive symptoms in the antenatal period are strongly associated with postnatal depressive symptoms and adverse perinatal outcomes in Australian infants. Early identification of antenatal and postnatal depressive symptoms, and referral for appropriate management could benefit not only the mother's mental health, but also the infant's health and development.	[Eastwood, John] Univ New South Wales, Sch Womens & Childrens Hlth, Kensington, NSW, Australia; [Eastwood, John] Univ Sydney, Sch Publ Hlth, Menzies Ctr Hlth Policy, Charles Perkins Ctr, Sydney, NSW, Australia; [Eastwood, John] Griffith Univ, Sch Publ Hlth, Gold Coast, Qld, Australia; [Eastwood, John; Noble, Justine] Croydon Community Hlth Ctr, Sydney Local Hlth Dist, Dept Community Paediat, Croydon, NSW, Australia; [Eastwood, John; Ogbo, Felix A.; Hendry, Alexandra; Noble, Justine; Page, Andrew] Ingham Inst Appl Med Res, Liverpool, NSW, Australia; [Ogbo, Felix A.] Univ Western Sydney, Sch Med, Ctr Hlth Res, Campbelltown Campus,Locked Bag 1797, Penrith, NSW, Australia; [Hendry, Alexandra; Page, Andrew] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Coverage & Surveillance, Locked Bag 4001, Westmead, NSW, Australia	University of New South Wales Sydney; University of Sydney; Griffith University; Ingham Institute for Applied Medical Research; Western Sydney University; University of Sydney	Ogbo, FA (corresponding author), Ingham Inst Appl Med Res, Liverpool, NSW, Australia.; Ogbo, FA (corresponding author), Univ Western Sydney, Sch Med, Ctr Hlth Res, Campbelltown Campus,Locked Bag 1797, Penrith, NSW, Australia.	felgbo@yahoo.co.uk						Accortt EE, 2015, MATERN CHILD HLTH J, V19, P1306, DOI 10.1007/s10995-014-1637-2; Adewuya AO, 2008, J AFFECT DISORDERS, V108, P191, DOI 10.1016/j.jad.2007.09.013; Alder J, 2007, J MATERN-FETAL NEO M, V20, P189, DOI 10.1080/14767050701209560; Andersson L, 2003, AM J OBSTET GYNECOL, V189, P148, DOI 10.1067/mob.2003.336; [Anonymous], 2005, PERINATAL DEPRESSION; Australian Bureau of Statistics, 2013, TECHN PAP SOC IND AR; Banti S, 2011, COMPR PSYCHIAT, V52, P343, DOI 10.1016/j.comppsych.2010.08.003; Bennett HA, 2004, CLIN DRUG INVEST, V24, P157, DOI 10.2165/00044011-200424030-00004; beyondblue National Postnatal Depression Program, 2005, BEYONDBLUE NATL POST; Bond L, 1998, AUST NZ J PUBL HEAL, V22, P441, DOI 10.1111/j.1467-842X.1998.tb01411.x; BOYCE P, 1993, AUST NZ J PSYCHIAT, V27, P472, DOI 10.3109/00048679309075805; Brown S, 2000, BRIT J OBSTET GYNAEC, V107, P1194, DOI 10.1111/j.1471-0528.2000.tb11607.x; Brown S, 1997, J REPROD INFANT PSYC, V15, P185; CADMAN D, 1987, PEDIATRICS, V79, P805; Centre for Epidemiology and Evidence, 2016, NEW S WAL MOTH BAB 2; Centre for Epidemiology and Evidence, 2014, MOTH BAB 2012; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; David Dunt, 2009, BEYONDBLUE NATL DEPR; De Luca CR, 2013, PEDIATRICS; Dias CC, 2015, J AFFECT DISORDERS, V171, P142, DOI 10.1016/j.jad.2014.09.022; Dwyer JM, 2004, AUSTR NZ HLTH POLICY, V1, P1, DOI DOI 10.1186/1743-8462-1-1; Eberhard-Gran M, 2001, ACTA PSYCHIAT SCAND, V104, P243, DOI 10.1034/j.1600-0447.2001.00187.x; Faisal-Cury A, 2012, REV BRAS PSIQUIATR, V34, P446, DOI 10.1016/j.rbp.2012.01.003; FIELD T, 1992, DEV PSYCHOPATHOL, V4, P49, DOI 10.1017/S0954579400005551; Field T, 2010, INFANT BEHAV DEV, V33, P409, DOI 10.1016/j.infbeh.2010.04.005; Fuggle P, 2002, J REPROD INFANT PSYC, V20, P71, DOI 10.1080/02646830220134603; Gaffney KF, 2014, J PEDIATR HEALTH CAR, V28, P43, DOI 10.1016/j.pedhc.2012.10.005; Gausia K, 2007, J REPROD INFANT PSYC, V25, P308, DOI 10.1080/02646830701644896; Gentile S, 2015, NEUROSCIENCE; Gotlib I. H, 2008, HDB DEPRESSION; GOTLIB IH, 1989, J CONSULT CLIN PSYCH, V57, P269, DOI 10.1037/0022-006X.57.2.269; Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4; Grigoriadis S, 2013, J CLIN PSYCHIAT, V74, pE321, DOI 10.4088/JCP.12r07968; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Haeri S, 2013, J OBSTET GYNAECOL RE, V39, P948, DOI 10.1111/jog.12017; Hauck YL, 2011, MATERN CHILD HLTH J, V15, P260, DOI 10.1007/s10995-009-0554-2; Henderson JJ, 2003, BIRTH-ISS PERINAT C, V30, P175, DOI 10.1046/j.1523-536X.2003.00242.x; Hiscock H, 2001, PEDIATRICS, V107, P1317, DOI 10.1542/peds.107.6.1317; Huizink AC, 2004, PSYCHOL BULL, V130, P115, DOI 10.1037/0033-2909.130.1.115; Institute for Health Metrics and Evaluation (IHME), 2016, GBD 2015 U WASH IHME; KITAMURA T, 1993, PSYCHOL MED, V23, P967, DOI 10.1017/S003329170002643X; Kohlhoff J, 2015, AUSTR NZ J OBSTET GY; Kramer RA, 1998, J AM ACAD CHILD PSY, V37, P602, DOI 10.1097/00004583-199806000-00010; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; Lee AM, 2007, OBSTET GYNECOL, V110, P1102, DOI 10.1097/01.AOG.0000287065.59491.70; Leigh B, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-24; Leverton T, 2000, IS EPDS MAGIC WAND 1; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P287; Marcus SM, 2008, CAN J CLIN PHARM, V16, pe15; Matthey S, 2006, ARCH WOMEN MENT HLTH, V9, P309, DOI 10.1007/s00737-006-0152-x; Mazhari S, 2007, ARCH WOMEN MENT HLTH, V10, P293, DOI 10.1007/s00737-007-0204-x; Milgrom J, 2008, J AFFECT DISORDERS, V108, P147, DOI 10.1016/j.jad.2007.10.014; Minkovitz CS, 2005, PEDIATRICS, V115, P306, DOI 10.1542/peds.2004-0341; Montazeri A, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-11; Murray D., 1990, J REPROD INFANT PSYC, V8, P99, DOI [DOI 10.1080/02646839008403615, 10.1080/02646839008403615]; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Odalovic M, 2015, WOMEN BIRTH, V28, pE31, DOI 10.1016/j.wombi.2015.01.014; Olfson M, 2003, MED CARE, V41, P716, DOI 10.1097/00005650-200306000-00004; Pariante CM, 2008, TRENDS NEUROSCI, V31, P464, DOI 10.1016/j.tins.2008.06.006; Parslow RA, 2000, AUST NZ J PSYCHIAT, V34, P997, DOI 10.1080/000486700276; Rahman A, 2004, ARCH GEN PSYCHIAT, V61, P946, DOI 10.1001/archpsyc.61.9.946; Rahman A, 2002, CHILD CARE HLTH DEV, V28, P51, DOI 10.1046/j.1365-2214.2002.00239.x; Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006; Ross LE, 2013, JAMA PSYCHIAT, V70, P436, DOI 10.1001/jamapsychiatry.2013.684; Segre LS, 2007, SOC PSYCH PSYCH EPID, V42, P316, DOI 10.1007/s00127-007-0168-1; Shakespeare J, 2004, MIDWIFERY, V20, P251, DOI 10.1016/j.midw.2003.12.011; Smith MV, 2011, MATERN CHILD HLTH J, V15, P401, DOI 10.1007/s10995-010-0595-6; South Western Sydney Local Health District, 2014, HLTH PROF LOC COMM S; South Western Sydney Local Health District, 2012, RES STRAT S W SYDN L; Spratt M, 2010, AM J EPIDEMIOL, V172, P478, DOI 10.1093/aje/kwq137; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Stewart RC, 2007, MATERN CHILD NUTR, V3, P94, DOI 10.1111/j.1740-8709.2007.00088.x; Sydney Local Health District, 2012, COMM HLTH STRAT PLAN; Szegda K, 2013, J MATERNAL FETAL NEO; Talge NM, 2007, J CHILD PSYCHOL PSYC, V48, P245, DOI 10.1111/j.1469-7610.2006.01714.x; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Vivilaki V. G., 2009, BMC Public Health, V9; Wang YQ, 2009, INT J NURS STUD, V46, P813, DOI 10.1016/j.ijnurstu.2009.01.010; Weinstock M, 2005, BRAIN BEHAV IMMUN, V19, P296, DOI 10.1016/j.bbi.2004.09.006; World Health Organization (Department of Child and Adolescent Health and Development), 2008, CONCL CONS M HELD 6; Yonkers KA, 2001, AM J PSYCHIAT; Zubaran C, 2013, SEX REPROD HEALTHC, V4, P9, DOI 10.1016/j.srhc.2012.12.001; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1	84	90	95	3	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2017	12	1							e0169907	10.1371/journal.pone.0169907	http://dx.doi.org/10.1371/journal.pone.0169907			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI3EK	28095461	Green Published, Green Submitted, gold			2023-01-03	WOS:000392372300042
J	Gleed, G				Gleed, Gemma			Commentary: We're under financial strain without prescriptions for gluten-free food	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												media@coeliac.org.uk							0	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	2017	356								j119	10.1136/bmj.j119	http://dx.doi.org/10.1136/bmj.j119			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9BZ	28077350				2023-01-03	WOS:000392068000003
J	Handelzalts, JE; Peyser, AW; Krissi, H; Levy, S; Wiznitzer, A; Peled, Y				Handelzalts, Jonathan E.; Peyser, Avigail Waldman; Krissi, Haim; Levy, Sigal; Wiznitzer, Arnon; Peled, Yoav			Indications for Emergency Intervention, Mode of Delivery, and the Childbirth Experience	PLOS ONE			English	Article							STRESS FOLLOWING CHILDBIRTH; WOMENS SATISFACTION; BIRTH EXPERIENCE; RISK-FACTORS; PREVALENCE; EVENTS; TRAUMA; IMPACT	Background Although the impact of emergency procedures on the childbirth experience has been studied extensively, a possible association of childbirth experience with indications for emergency interventions has not been reported. Objectives To compare the impacts on childbirth experience of 'planned' delivery (elective cesarean section and vaginal delivery) versus 'unplanned' delivery (vacuum extraction or emergency cesarean section); the intervention itself (vacuum extraction versus emergency cesarean section); and indications for intervention (arrest of labor versus risk to the mother or fetus). Study design A total of 469 women, up to 72 hours post-partum, in the maternity ward of one tertiary health care institute completed the Subjective Childbirth Experience Questionnaire (score: 0-4, a higher score indicated a more negative experience) and a Personal Information Questionnaire. Intra-partum information was retrieved from the medical records. One-way analysis of variance and two-way analysis of variance, followed by analysis of covariance, to test the unique contribution of variables, were used to examine differences between groups in outcome. Tukey's Post-Hoc analysis was used when appropriate. Results Planned delivery, either vaginal or elective cesarean section, was associated with a more positive experience than unplanned delivery, either vacuum or emergency cesarean section (mean respective Subjective Childbirth Experience scores: 1.58 and 1.49 vs. 2.02 and 2.07, P <0.01). The difference in mean Subjective Childbirth Experience scores following elective cesarean section and vaginal delivery was not significant; nor was the difference following vacuum extraction and emergency cesarean section. Interventions due to immediate risk to mother or fetus resulted in a more positive birth experience than interventions due to arrest of labor (Subjective Childbirth Experience: 1.9 vs. 2.2, P <0.01). Conclusions Compared to planned interventions, unplanned interventions were shown to be associated with a more negative maternal childbirth experience. However, the indication for unplanned intervention appears to have a greater effect than the nature of the intervention on the birth experience. Women who underwent emergency interventions due to delay of birth (arrest of labor) perceived their birth experience more negatively than those who underwent interventions due to risk for the mother or fetus, regardless of the nature of the intervention (vacuum or emergency cesarean section). The results indicate the importance of follow-up after unexpected emergency interventions, especially following arrest of labor, as negative birth experience may have repercussions in a woman's psychosocial life and well-being.	[Handelzalts, Jonathan E.; Peyser, Avigail Waldman; Levy, Sigal] Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel; [Krissi, Haim; Wiznitzer, Arnon; Peled, Yoav] Helen Schneider Hosp Women, Rabin Med Ctr, Petah Tiqwa, Israel; [Krissi, Haim; Wiznitzer, Arnon; Peled, Yoav] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Handelzalts, JE (corresponding author), Acad Coll Tel Aviv Yaffo, Sch Behav Sci, Tel Aviv, Israel.	jonathanh@013.net; dr.peled@gmail.com		Handelzalts, Jonathan/0000-0002-9045-6057				Ayers S, 2016, PSYCHOL MED, V46, P1121, DOI 10.1017/S0033291715002706; Bar-On S, 2014, J PERINAT MED, V42, P435, DOI 10.1515/jpm-2013-0236; Blomquist JL, 2011, AM J PERINAT, V28, P383, DOI 10.1055/s-0031-1274508; Callister LC, 2004, JOGNN-J OBST GYN NEO, V33, P508, DOI 10.1177/0884217504266898; Creedy DK, 2000, BIRTH-ISS PERINAT C, V27, P104, DOI 10.1046/j.1523-536x.2000.00104.x; Fenwick Jennifer, 2003, Int J Nurs Pract, V9, P10, DOI 10.1046/j.1440-172X.2003.00397.x; Figley C. R., 1986, TRAUMA ITS WAKE, P39; Ford E, 2009, J ANXIETY DISORD, V23, P260, DOI 10.1016/j.janxdis.2008.07.009; Goodman P, 2004, J ADV NURS, V46, P212, DOI 10.1111/j.1365-2648.2003.02981.x; Gottvall K, 2002, BJOG-INT J OBSTET GY, V109, P254, DOI 10.1016/S1470-0328(02)01200-4; Handelzalts JE, 2015, ARCH GYNECOL OBSTET, V291, P1055, DOI 10.1007/s00404-014-3532-x; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Lev-Wiesel R, 2009, J WOMENS HEALTH, V18, P119, DOI 10.1089/jwh.2008.0774; Olde E, 2006, CLIN PSYCHOL REV, V26, P1, DOI 10.1016/j.cpr.2005.07.002; Pang MW, 2008, BIRTH-ISS PERINAT C, V35, P121, DOI 10.1111/j.1523-536X.2008.00225.x; Righetti-Veltema M, 1998, J AFFECT DISORDERS, V49, P167, DOI 10.1016/S0165-0327(97)00110-9; Ryding EL, 1998, BIRTH-ISS PERINAT C, V2, P246; SALMON P, 1992, J PSYCHOSOM RES, V36, P317, DOI 10.1016/0022-3999(92)90068-D; Schindl M, 2003, ACTA OBSTET GYN SCAN, V82, P834, DOI 10.1034/j.1600-0412.2003.00194.x; Shorten A, 2012, J MIDWIFERY WOM HEAL, V57, P126, DOI 10.1111/j.1542-2011.2011.00106.x; Soet JE, 2003, BIRTH-ISS PERINAT C, V30, P36, DOI 10.1046/j.1523-536X.2003.00215.x; Spaich S, 2013, EUR J OBSTET GYN R B, V170, P401, DOI 10.1016/j.ejogrb.2013.07.040; Waldenstrom U, 2004, BIRTH-ISS PERINAT C, V31, P17, DOI 10.1111/j.0730-7659.2004.0270.x; Waldenstrom U, 1996, BIRTH-ISS PERINAT C, V23, P144, DOI 10.1111/j.1523-536X.1996.tb00475.x	24	33	34	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0169132	10.1371/journal.pone.0169132	http://dx.doi.org/10.1371/journal.pone.0169132			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH2QJ	28046019	gold, Green Published, Green Submitted			2023-01-03	WOS:000391612300124
J	Yu, N; Fang, X; Zhao, DD; Mu, QQ; Zuo, JC; Ma, Y; Zhang, Y; Mo, FF; Zhang, DW; Jiang, GJ; Wu, R; Gao, SH				Yu, Na; Fang, Xin; Zhao, Dandan; Mu, Qianqian; Zuo, Jiacheng; Ma, Yue; Zhang, Yi; Mo, Fangfang; Zhang, Dongwei; Jiang, Guangjian; Wu, Rui; Gao, Sihua			Anti-Diabetic Effects of Jiang Tang Xiao Ke Granule via PI3K/Akt Signalling Pathway in Type 2 Diabetes KKAy Mice	PLOS ONE			English	Article							MUSCLE INSULIN-RESISTANCE; TRADITIONAL CHINESE MEDICINE; BETA-CELL DYSFUNCTION; GLUCOSE-UPTAKE; 3T3-L1 ADIPOCYTES; FATTY-ACIDS; PPAR-GAMMA; TRANSLOCATION; OBESITY; EXPRESSION	Jiang Tang Xiao Ke (JTXK) granule, a Chinese herbal formula, has been used clinically to treat type 2 diabetes (T2DM) for decades. Our previous studies showed that JTXK granule exhibited anti-diabetic and anti-oxidative functions in experimental diabetic rats induced by a high fat diet and streptozotocin. However, the underlying mechanisms remain poorly understood. Herein, we aimed to investigate the therapeutic effect of JTXK granule on T2DM KKAy mice and the possible associations with skeletal muscle in the current study. Our results showed that JTXK granule significantly reduced food intake and body weight in T2DM KKAy mice. JTXK granule treatment also decreased the blood glucose and HbA1c levels and increased the insulin sensitivity in a time-dependent manner. Additionally, it ameliorated hyperlipidaemia and induced a lower free fatty acid level, displaying an effect on disorders of lipid metabolism. JTXK granule significantly increased the expression of insulin receptor substrate-1 (IRS-1), phosphoinositide 3-kinase (PI3K), protein kinase B (PKB/Akt) and glucose transporter 4 (Glut4) and decreased the expression of glycogen synthase kinase 3 beta (GSK3 beta). We concluded that JTXK granule is an effective drug for T2DM through regulating the PI3K/Akt signalling pathway in skeletal muscle.	[Yu, Na; Mu, Qianqian; Zuo, Jiacheng; Ma, Yue; Zhang, Yi] Beijing Univ Chinese Med, Preclin Med Sch, Beijing, Peoples R China; [Fang, Xin] Beijing Univ Chinese Med, Dept Endocrinol, Affiliated Hosp 3, Beijing, Peoples R China; [Zhao, Dandan; Mo, Fangfang; Zhang, Dongwei; Jiang, Guangjian; Gao, Sihua] Beijing Univ Chinese Med, Diabet Res Ctr, Beijing, Peoples R China; [Wu, Rui] China Acad Chinese Med Sci, South Area Guanganmen Hosp, Dept Endocrinol, Beijing, Peoples R China	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences	Gao, SH (corresponding author), Beijing Univ Chinese Med, Diabet Res Ctr, Beijing, Peoples R China.	gaosihua1216@163.com	Zhang, Dongwei/AAS-8384-2020	Zhang, Dongwei/0000-0002-7793-1482	key drug development Programme of MOST [20122X09103201- 005]; National Natural Science Foundation of China [NSFC81274041, NSFC81503540]; International Cooperation Projects of MOE [2011DFA30920]	key drug development Programme of MOST; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Cooperation Projects of MOE	This work is supported by grants from the key drug development Programme of MOST (20122X09103201- 005), the National Natural Science Foundation of China (NSFC81274041 and NSFC81503540) and the International Cooperation Projects of MOE (2011DFA30920).	Altaf QA, 2015, DIABETES OBES METAB, V17, P319, DOI 10.1111/dom.12400; Arner P, 2015, OBESITY FACTS, V8, P147, DOI 10.1159/000381224; Bhupathiraju SN, 2016, CIRC RES, V118, P1723, DOI 10.1161/CIRCRESAHA.115.306825; Boden G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4765; Chan Chung-Hung, 2012, Pharmacogn Rev, V6, P22, DOI 10.4103/0973-7847.95854; Chen KK, 2014, APOPTOSIS, V19, P946, DOI 10.1007/s10495-014-0977-0; DeFronzo RA, 2009, DIABETES CARE, V32, pS157, DOI 10.2337/dc09-S302; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Fang X, 2015, CHINESE J INTEGRATIV; Favaretto F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109540; Federation ID, 2014, IDF DIABETES ATLAS; Gandhi GR, 2013, BBA-GEN SUBJECTS, V1830, P2243, DOI 10.1016/j.bbagen.2012.10.016; Gao J, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-198; Gu JY, 2011, COMPUT BIOL CHEM, V35, P293, DOI 10.1016/j.compbiolchem.2011.07.003; Guo YB, 2016, LIFE SCI, V148, P24, DOI 10.1016/j.lfs.2016.02.056; Gustafson B, 2015, TRENDS ENDOCRIN MET, V26, P193, DOI 10.1016/j.tem.2015.01.006; Higaki Y, 2008, AM J PHYSIOL-ENDOC M, V294, pE889, DOI 10.1152/ajpendo.00150.2007; Kahn S E, 2000, Postgrad Med, V107, P11, DOI 10.3810/pgm.5.15.2000.suppl4.22; Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Lee OH, 2011, PHYTOTHER RES, V25, P768, DOI 10.1002/ptr.3322; Li XH, 2015, 2ND INTERNATIONAL CONFERENCE ON ADVANCED EDUCATION TECHNOLOGY AND MANAGEMENT SCIENCE (AETMS 2014), P31; Lian FM, 2014, J CLIN ENDOCR METAB, V99, P648, DOI 10.1210/jc.2013-3276; Magnoni LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031219; Mu QQ, 2015, BIOCHEM BIOPH RES CO, V466, P530, DOI 10.1016/j.bbrc.2015.09.064; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Peng J, 2014, PPAR RES, V2014, DOI 10.1155/2014/538183; [秦培洁 Qin Peijie], 2014, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V37, P236; Rachek LI, 2014, PROG MOL BIOL TRANSL, V121, P267, DOI 10.1016/B978-0-12-800101-1.00008-9; Raymond KL, 2016, J DIABETES COMPLICAT, V30, P651, DOI 10.1016/j.jdiacomp.2016.01.020; Raymond KL, 2015, APPETITE, V95, P383, DOI 10.1016/j.appet.2015.07.030; Sharma BR, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0412-5; Stein SA, 2013, EXPERT OPIN DRUG SAF, V12, P153, DOI 10.1517/14740338.2013.752813; Steinberg GR, 2009, DIABETES, V58, P829, DOI 10.2337/db08-0659; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Yan XF, 2014, CHIN J INTEGR MED, V20, P633, DOI 10.1007/s11655-013-1462-2; Zhang JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100918; Zhang XX, 2015, J DIABETES INVEST, V6, P708, DOI 10.1111/jdi.12352; Zhao DD, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/475192; [赵丹丹 Zhao Dandan], 2014, [中医杂志, Journal of Traditional Chinese Medicine], V55, P205; Zhao XY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002522; 2006, NATURE, V444, P840, DOI DOI 10.1038/NATURE05482	44	25	28	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0168980	10.1371/journal.pone.0168980	http://dx.doi.org/10.1371/journal.pone.0168980			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2QJ	28045971	Green Submitted, Green Published, gold			2023-01-03	WOS:000391612300082
J	Nath, M; Chandra, P; Halder, N; Singh, B; Deorari, AK; Kumar, A; Azad, R; Velpandian, T				Nath, Madhu; Chandra, Parijat; Halder, Nabanita; Singh, Baskar; Deorari, Ashok Kumar; Kumar, Atul; Azad, Rajvardhan; Velpandian, Thirumurthy			Involvement of Renin-Angiotensin System in Retinopathy of Prematurity - A Possible Target for Therapeutic Intervention	PLOS ONE			English	Article							OXYGEN-INDUCED RETINOPATHY; RAT MODEL; TYPE-1 RECEPTOR; INHIBITION; RETINA	Objective Examining the Retinal Renin Angiotensin System (RRAS) in the ROP neonates and analyzing the possibility of modulating the RRAS to prevent the progression in Oxygen Induced Retinopathy (OIR) model. Method Vitreous of ROP patients (n = 44, median age 5.5 months) was quantified for RRAS components, VEGF, HIF-1 alpha and compared with age matched control. The involvement of RRAS in ROP was tested in the rat model of OIR and compared with normoxia. Expressions of RAS components, VEGF and HIF-1 alpha in retina were analyzed using qPCR and retinal structure and function was also analyzed. Effect of Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) was evaluated and compared with Bevacizumab which served as a positive control. Drug penetration into retina was confirmed by liquid chromatography coupled ESI-tandem mass spectroscopy (LC-MS/MS). Results Multifold increase in the expression of RAS components in human vitreous and rat retina showed their involvement in ROP. ERG & fundus studies in OIR revealed the altered function of retina and were successfully prevented by ARB (telmisartan), ACEI (lisinopril) and bevacizumab. Retinal analysis revealed the presence of ACEI and ARB in their therapeutic levels. Conclusion This study for the first time demonstrates the upregulated level of RAS components in human ROP vitreous and further that the pharmacological intervention in RRAS can functionally and structurally preserve retina against the progression of ROP in the OIR model.	[Nath, Madhu; Chandra, Parijat; Kumar, Atul; Azad, Rajvardhan] All India Inst Med Sci, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India; [Halder, Nabanita; Velpandian, Thirumurthy] All India Inst Med Sci, Dept Ocular Pharmacol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India; [Singh, Baskar] All India Inst Med Sci, Dept Biophys, New Delhi, India; [Deorari, Ashok Kumar] All India Inst Med Sci, Dept NICU, Pediat, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra Prasad Centre for Ophthalmic Sciences; All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra Prasad Centre for Ophthalmic Sciences; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Velpandian, T (corresponding author), All India Inst Med Sci, Dept Ocular Pharmacol, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India.	tvelpandian@hotmail.com	Velpandian, Thirumurthy/ABE-7016-2021; Chandra, Parijat/I-2929-2013	Chandra, Parijat/0000-0002-7516-1410	Department of Science and Technology (DST/SSTP/New Delhi)	Department of Science and Technology (DST/SSTP/New Delhi)(Department of Science & Technology (India))	Department of Science and Technology for the funding to carry out this research work (DST/SSTP/New Delhi/2012-13/12th Plan/149(c).	Autrata R, 2012, Cesk Slov Oftalmol, V68, P29; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008; Downie LE, 2010, J COMP NEUROL, V518, P41, DOI 10.1002/cne.22205; Favazza TL, 2013, DOC OPHTHALMOL, V127, P3, DOI 10.1007/s10633-013-9392-z; Gilbert RE, 2000, DIABETOLOGIA, V43, P1360, DOI 10.1007/s001250051539; Hancock HA, 2004, INVEST OPHTH VIS SCI, V45, P1002, DOI 10.1167/iovs.03-1080; Hernandez C, 2012, ENDOCRINE, V41, P220, DOI 10.1007/s12020-011-9579-6; Liu K, 2005, INVEST OPHTH VIS SCI, V47, P5447; Liu K, 2006, INVEST OPHTH VIS SCI, V47, P2639, DOI 10.1167/iovs.06-0016; Lonchampt M, 2002, INVEST OPHTH VIS SCI, V42, P429; McColm JR, 2004, PEDIATR RES, V55, P107, DOI 10.1203/01.PDR.0000099772.66376.02; Michael W. Pfaffl, 2002, NUCL ACIDS RES, V30; Moravski CJ, 2003, AM J PATHOL, V162, P151, DOI 10.1016/S0002-9440(10)63806-0; Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099; Nakamura H, 2009, OPHTHALMIC RES, V41, P210, DOI 10.1159/000217725; Patten DA, 2010, MOL BIOL CELL, V21, P3247, DOI 10.1091/mbc.E10-01-0025; Ramirez M, 1996, J OCUL PHARMACOL TH, V12, P299, DOI 10.1089/jop.1996.12.299; RE RN, 1984, ARCH INTERN MED, V144, P2037, DOI 10.1001/archinte.144.10.2037; RICCI B, 1995, GRAEF ARCH CLIN EXP, V233, P226, DOI 10.1007/BF00183596; Roberto KA, 1996, CURR EYE RES, V15, P932, DOI 10.3109/02713689609017637; Sarlos S, 2005, INVEST OPHTH VIS SCI, V46, P1069, DOI 10.1167/iovs.04-0885; Senanayake PD, 2007, INVEST OPHTH VIS SCI, V48, P3301, DOI 10.1167/iovs.06-1024; Shapiro MJ, 2001, MALHOTRA ENTERPRISES, P23; Sramek SJ, 2002, INVEST OPHTH VIS SCI, V29, P1749; Sramek SJ, 2002, INVEST OPHTH VIS SCI, V29, P1198; Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159; Wu LH, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2005	28	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2016	11	12							e0168809	10.1371/journal.pone.0168809	http://dx.doi.org/10.1371/journal.pone.0168809			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7KQ	28033392	Green Published, gold, Green Submitted			2023-01-03	WOS:000391226900050
J	Shin, B; Koh, WJ; Shin, SW; Jeong, BH; Park, HY; Suh, GY; Jeon, K				Shin, Beomsu; Koh, Won-Jung; Shin, Sung Wook; Jeong, Byeong-Ho; Park, Hye Yun; Suh, Gee Young; Jeon, Kyeongman			Outcomes of Bronchial Artery Embolization for Life-Threatening Hemoptysis in Patients with Chronic Pulmonary Aspergillosis	PLoS One			English	Article							INFECTIOUS-DISEASES SOCIETY; CLINICAL CHARACTERISTICS; PRACTICE GUIDELINES; CHRONIC CAVITARY; MANAGEMENT; DIAGNOSIS; TUBERCULOSIS; VORICONAZOLE; PROGNOSIS; SPECTRUM	Background Bronchial artery embolization (BAE) is an important treatment option for short-term control of hemoptysis in patients with simple aspergilloma (SA). However, there are no data on the outcomes of BAE in patients with chronic pulmonary aspergillosis (CPA). In this study, the clinical characteristics and outcomes of BAE were investigated and compared in patients with CPA and SA. Methods We retrospectively analyzed the clinical data of 64 patients (55 [86%] with CPA and 9 [14%] with SA) who underwent BAE for life-threatening hemoptysis. The clinical characteristics and outcomes of BAE in CPA patients were compared to those of patients with SA. Results The most common angiographic abnormality was hypervascularity (n = 60, 94%), followed by contrast extravasation (n = 50, 78%) and systemic-pulmonary shunt (n = 48, 75%), with similar incidence rates in both groups. Immediate success was achieved in 41 (64%) BAE procedures, but it was incomplete in 23 (36%) cases due to difficulty with the approach and/or overuse of contrast medium. Clinical failure of BAE was observed in only one (2%) patient. Complications following BAE were observed in four (6%) patients. Recurrence of hemoptysis was seen in a total of 33 patients (52%) within a median of 2.0 (0.3-10.0) months, and repeat BAE was performed in 25 (76%) of these cases. In comparing the outcomes of patients with CPA and SA, there were no differences in the rates of success of initial BAE, incomplete embolization, or clinical failure in the two groups. However, recurrence of hemoptysis tended to be higher in patients with CPA (55%) than in those with SA (33%). In addition, antifungal medications following BAE were more commonly prescribed in the CPA group (56%) compared to the SA group (0%). Conclusions BAE was a safe and effective procedure for the management of life-threatening hemoptysis in patients with CPA. However, recurrence of hemoptysis was common, especially in patients with CPA. Therefore, definitive treatment for CPA following successful BAE should be considered to ensure the long-term success of the embolization in these patients.	[Shin, Beomsu; Koh, Won-Jung; Jeong, Byeong-Ho; Park, Hye Yun; Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea; [Shin, Sung Wook] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, Seoul, South Korea; [Suh, Gee Young; Jeon, Kyeongman] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Jeon, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea.; Jeon, K (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea.	kjeon@skku.edu	shin, sw/O-6248-2014; Koh, Won-Jung/D-9586-2018; Jeon, Kyeongman/F-5963-2019; park, hy/O-5934-2014; Koh, Won Jung/C-9595-2011; Suh, Gee Young/O-3676-2019; Shin, Beomsu/AAP-3328-2020	Koh, Won-Jung/0000-0002-4756-3527; Jeon, Kyeongman/0000-0002-4822-1772; Suh, Gee Young/0000-0001-5473-1712; Jeong, Byeong-Ho/0000-0002-3124-1718				Abdulmalak C, 2015, EUR RESPIR J, V46, P503, DOI 10.1183/09031936.00218214; Agarwal R, 2013, MYCOSES, V56, P559, DOI 10.1111/myc.12075; Brinson GM, 1998, AM J RESP CRIT CARE, V157, P1951, DOI 10.1164/ajrccm.157.6.9708067; Cadranel J, 2012, EUR J CLIN MICROBIOL, V31, P3231, DOI 10.1007/s10096-012-1690-y; Camuset J, 2007, CHEST, V131, P1435, DOI 10.1378/chest.06-2441; Chan VL, 2009, INT J TUBERC LUNG D, V13, P1167; Chun JY, 2010, CARDIOVASC INTER RAD, V33, P240, DOI 10.1007/s00270-009-9788-z; Chun JY, 2010, EUR RADIOL, V20, P558, DOI 10.1007/s00330-009-1591-3; Corr P, 2006, CARDIOVASC INTER RAD, V29, P807, DOI 10.1007/s00270-005-0329-0; Denning DW, 2016, EUR RESPIR J, V47, P45, DOI 10.1183/13993003.00583-2015; Denning DW, 2003, CLIN INFECT DIS, V37, pS265, DOI 10.1086/376526; Izumikawa K, 2016, RESPIR INVESTIG, V54, P85, DOI 10.1016/j.resinv.2015.10.003; Jhun BW, 2013, MED MYCOL, V51, P811, DOI 10.3109/13693786.2013.806826; Kim SW, 2015, LUNG, V193, P575, DOI 10.1007/s00408-015-9728-4; Kosmidis C, 2015, THORAX, V70, P270, DOI 10.1136/thoraxjnl-2014-206291; Lee JH, 2007, INT J TUBERC LUNG D, V11, P781; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Nam HS, 2010, INT J INFECT DIS, V14, pE479, DOI 10.1016/j.ijid.2009.07.011; Ohba H, 2012, RESP MED, V106, P724, DOI 10.1016/j.rmed.2012.01.014; Otani Y, 1997, SURG TODAY, V27, P812, DOI 10.1007/BF02385271; Patterson KC, 2014, CHEST, V146, P1358, DOI 10.1378/chest.14-0917; Patterson TF, 2016, CLIN INFECT DIS, V63, pE1, DOI 10.1093/cid/ciw326; Pei RG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115956; Shin BS, 2011, INT J TUBERC LUNG D, V15, P1093, DOI 10.5588/ijtld.10.0659; Shin B, 2014, J INFECTION, V68, P494, DOI 10.1016/j.jinf.2014.01.005; Sopko David R, 2011, Semin Intervent Radiol, V28, P48, DOI 10.1055/s-0031-1273940; Soubani AO, 2002, CHEST, V121, P1988, DOI 10.1378/chest.121.6.1988; UFLACKER R, 1985, RADIOLOGY, V157, P637, DOI 10.1148/radiology.157.3.4059552; van den Heuvel MM, 2007, INT J TUBERC LUNG D, V11, P909; Walsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258	30	20	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2016	11	12							e0168373	10.1371/journal.pone.0168373	http://dx.doi.org/10.1371/journal.pone.0168373			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QH	28006828	Green Published, Green Submitted, gold			2023-01-03	WOS:000392843200047
J	Ribeiro, RS; Terry, SA; Sacramento, JP; Silveira, SRE; Bento, CBP; da Silva, EF; Mantovani, HC; da Gama, MAS; Pereira, LGR; Tomich, TR; Mauricio, RM; Chaves, AV				Ribeiro, Rafael Sandin; Terry, Stephanie Amelia; Sacramento, Joao Paulo; Rocha e Silveira, Sylvia; Pereira Bento, Claudia Braga; da Silva, Elsa Fernandes; Mantovani, Hilario Cuquetto; Sundfeld da Gama, Marco Antonio; Ribeiro Pereira, Luiz Gustavo; Tomich, Thierry Ribeiro; Mauricio, Rogerio Martins; Chaves, Alexandre Vieira			Tithonia diversifolia as a Supplementary Feed for Dairy Cows	PLOS ONE			English	Article							CONJUGATED LINOLEIC-ACID; NEUTRAL DETERGENT FIBER; METHANE PRODUCTION; TRACER TECHNIQUE; FATTY-ACIDS; IN-VITRO; MILK-FAT; CORN; DIET; BIOHYDROGENATION	The objective of this study was to examine the effects of Tithonia diversifolia as a supplementary forage on dairy cow performance and methane production. Nine lactating Holstein x Zebu dairy cows (519 +/- 53.3 kg of body weight and 66 +/- 13.3 d in milk) were paired by milk yield (21.3 +/- 2.34 kg/d) and body weight and randomly assigned to three dietary treatments in a Latin square design with 21-d experimental periods (14 d for diet adaptation and 7 d for measurements and sample collection). The dietary treatments included the control diet consisting of fresh sugar cane plus concentrate (44:56, % of diet DM), and two treatment diets containing different levels of fresh T. diversifolia (6.5 and 15.4%, DM basis) which partially replaced both sugarcane and concentrates. Methane production was measured using the sulphur hexafluoride (SF6) technique from d 16 to d 21 of each experimental period. Analysis of the gas samples was performed by gas chromatography. The inclusion of T. diversifolia at 15.4% DM had no effects on DM intake, milk production, nitrogen balance or methane production. There was no effect on the concentrations of total saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), and polyunsaturated fatty acids (PUFA) in milk fat (P >= 0.28), though individual milk fatty acids were affected. Serum concentrations of glucose, urea nitrogen (BUN), triglycerides, P-hydroxybutyrate (BHBA), and cholesterol were unaffected by the dietary treatments (P >= 0.13). There was a time (2 and 6 h post-feeding) and dietary treatment effect (P < 0.01) on the acetate to propionate ratio in the rumen. A denaturing gradient gel electrophoresis analysis of the archaeal community showed distinct clustering of the archaea populations for control and treatment diets. Taken together, our results indicate the potential of T. diversifolia as a supplementary forage for dairy cattle in the tropics.	[Ribeiro, Rafael Sandin; Sacramento, Joao Paulo; Rocha e Silveira, Sylvia; Mauricio, Rogerio Martins] Univ Fed Sao Joao Del Rei, Bioengn Dept, Sao Joao Del Rei, MG, Brazil; [Terry, Stephanie Amelia; Chaves, Alexandre Vieira] Univ Sydney, Sch Life & Environm Sci, Fac Vet Sci, Sydney, NSW, Australia; [Pereira Bento, Claudia Braga; da Silva, Elsa Fernandes; Mantovani, Hilario Cuquetto] Univ Fed Vicosa, Dept Microbiol, Vicosa, MG, Brazil; [Sundfeld da Gama, Marco Antonio; Ribeiro Pereira, Luiz Gustavo; Tomich, Thierry Ribeiro] Embrapa Gado Leite, Juiz De Fora, MG, Brazil	Universidade Federal de Sao Joao del-Rei; University of Sydney; Universidade Federal de Vicosa; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	Chaves, AV (corresponding author), Univ Sydney, Sch Life & Environm Sci, Fac Vet Sci, Sydney, NSW, Australia.	alex.chaves@sydney.edu.au	Mantovani, Hilario C/J-5287-2012; Bento, Cláudia Braga Pereira/AAW-4415-2021; Mauricio, Rogerio M/G-3728-2013; Chaves, Alexandre Vieira/B-8843-2012	Mantovani, Hilario C/0000-0002-3481-5318; Chaves, Alexandre Vieira/0000-0001-5065-7367; Terry, Stephanie Amelia/0000-0003-2567-6368	CAPES	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	All the funding of support received during this specific study came from CAPES, http://www.capes.gov.br/, proposal n#129089 (Funding from Feb 2014 to Feb 2016), title: "Adaptacao de bovinos leiteiros as mudancas climaticas e avancos tecnologicos para mensuracao de metano enterico". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Alexandre V. Chaves received R$14,000/month during his stay in Brazil during this proposal. Dr Chaves spent 7 months in total during this 3 year period project (2014-2016) funded by CAPES.	Barros-Rodriguez MA, 2015, TROP ANIM HEALTH PRO, V47, P757, DOI 10.1007/s11250-015-0790-y; AOAC, 2002, OFFICIAL METHODS ANA; Association of Official Analytical Chemistry, 1990, OFFICIAL METHODS ANA; Baldin M, 2013, J ANIM SCI, V91, P3305, DOI 10.2527/jas.2012-5766; Berends H, 2014, J THEOR BIOL, V353, P1, DOI 10.1016/j.jtbi.2014.02.040; Berndt A., 2014, GUIDELINES USE SULPH; Broderick GA, 2004, J DAIRY SCI, V87, P2997, DOI 10.3168/jds.S0022-0302(04)73431-1; Broucek J., 2014, Journal of Environmental Protection, V5, P1482, DOI 10.4236/jep.2014.515141; Delgado DC, 2012, TROP ANIM HEALTH PRO, V44, P1097, DOI 10.1007/s11250-011-0045-5; CHANEY AL, 1962, CLIN CHEM, V8, P130; Chilliard Y, 2007, EUR J LIPID SCI TECH, V109, P828, DOI 10.1002/ejlt.200700080; Cruz-Hernandez C, 2007, J DAIRY SCI, V90, P3786, DOI 10.3168/jds.2006-698; Deighton MH, 2014, ANIM FEED SCI TECH, V197, P47, DOI 10.1016/j.anifeedsci.2014.08.003; Henderson G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14567; Holtshausen L, 2009, J DAIRY SCI, V92, P2809, DOI 10.3168/jds.2008-1843; Jayanegara A, 2011, ANIM PROD SCI, V51, P1127, DOI 10.1071/AN11059; JOHNSON KA, 1995, J ANIM SCI, V73, P2483; Kay JK, 2004, J DAIRY SCI, V87, P369, DOI 10.3168/jds.S0022-0302(04)73176-8; Kratz M, 2013, EUR J NUTR, V52, P1, DOI 10.1007/s00394-012-0418-1; Lana RP, 1998, J ANIM SCI, V76, P2190; Lee C, 2013, J DAIRY SCI, V96, P5295, DOI 10.3168/jds.2012-6442; Mahecha L, 2007, LIVEST RES RURAL DEV, P19; Martin C, 2008, J ANIM SCI, V86, P2642, DOI 10.2527/jas.2007-0774; McCann JC, 2014, BIOINFORM BIOL INSIG, V8, P109, DOI 10.4137/BBI.S15389; Moate PJ, 2016, ANIM PROD SCI, V56, P1017, DOI 10.1071/AN15222; Motta EF, 2014, 19 NAT M METH EMBR L; Muhling M, 2008, ISME J, V2, P379, DOI 10.1038/ismej.2007.97; Olabode O. S., 2007, World Journal of Agricultural Sciences, V3, P503; Palmquist DL, 2005, BIOSYNTHESIS CONJUGA, P179; Petri RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083424; Ramirez-Rivera U, 2010, AGROFOREST SYST, V80, P295, DOI 10.1007/s10457-010-9320-0; Ruiz T. E., 2014, Cuban Journal of Agricultural Science, V48, P79; Sao VN, 2010, LIVEST RES RURAL DEV, P22; Shingfield KJ, 2008, ADV EXP MED BIOL, V606, P3, DOI 10.1007/978-0-387-74087-4_1; SIEGFRIED R, 1984, LANDWIRT FORSCH, V37, P298; Stevenson DM, 2007, APPL MICROBIOL BIOT, V75, P165, DOI 10.1007/s00253-006-0802-y; SUKHIJA PS, 1988, J AGR FOOD CHEM, V36, P1202, DOI 10.1021/jf00084a019; Tendonkeng F, 2014, TROP ANIM HEALTH PRO, V46, P981, DOI 10.1007/s11250-014-0597-2; Terry SA, 2016, ANIM PROD SCI, V56, P437, DOI 10.1071/AN15560; Valadares RFD, 1999, J DAIRY SCI, V82, P2686, DOI 10.3168/jds.S0022-0302(99)75525-6; VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583, DOI 10.3168/jds.S0022-0302(91)78551-2; Waghorn G, 2008, ANIM FEED SCI TECH, V147, P116, DOI 10.1016/j.anifeedsci.2007.09.013; Wambui C. C., 2006, Livestock Research for Rural Development, V18, P64; Ward AT, 2003, J DAIRY SCI, V86, P1742, DOI 10.3168/jds.S0022-0302(03)73760-6; Wolff RL, 1995, J AM OIL CHEM SOC, V72, P1471, DOI 10.1007/BF02577840	45	11	13	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0165751	10.1371/journal.pone.0165751	http://dx.doi.org/10.1371/journal.pone.0165751			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27906983	Green Published, gold, Green Submitted			2023-01-03	WOS:000389482700011
J	Prema, A; Thenmozhi, AJ; Manivasagam, T; Essa, MM; Akbar, MD; Akbar, M				Prema, Asokan; Thenmozhi, Arokiasamy Justin; Manivasagam, Thamilarasan; Essa, Musthafa Mohamed; Akbar, Mohammed D.; Akbar, Mohammed			Fenugreek Seed Powder Nullified Aluminium Chloride Induced Memory Loss, Biochemical Changes, A beta Burden and Apoptosis via Regulating Akt/GSK3 beta Signaling Pathway	PLOS ONE			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE; NEURONAL SURVIVAL; PROTEIN-KINASE; RAT-BRAIN; ACETYLCHOLINESTERASE; NEUROTOXICITY; EXTRACT; DEATH; PHOSPHORYLATION	Alzheimer's disease (AD) is the most common form of dementia that mainly affects the cognitive functions of the aged populations. Trigonella foenum-graecum (L.) (fenugreek), a traditionally well utilized medicinal plant ubiquitously used as one of the main food additive worldwide, is known to have numerous beneficial health effects. Fenugreek seed extract could be able to inhibit the activity of acetylcholinesterase (AChE), a key enzyme involved in the pathogenesis of AD, and further shown to have anti-parkinsonic effect. The present study was aimed to explore the neuroprotective effect of fenugreek seed powder (FSP) against aluminium chloride (AlCl3) induced experimental AD model. Administration of germinated FSP (2.5, 5 and 10% mixed with ground standard rat feed) protected AlCl3 induced memory and learning impairments, Al overload, AChE hyperactivity, amyloid beta (A beta) burden and apoptosis via activating Akt/GSK3 beta pathway. Our present data could confirm the neuroprotective effect of fenugreek seeds. Further these results could lead a possible therapeutics for the management of neurodegenerative diseases including AD in future.	[Prema, Asokan; Thenmozhi, Arokiasamy Justin; Manivasagam, Thamilarasan] Annamalai Univ, Dept Biochem & Biotechnol, Fac Sci, Annamalainagar 608002, Tamil Nadu, India; [Essa, Musthafa Mohamed] Sultan Qaboos Univ, CAMS, Dept Food Sci & Nutr, Muscat, Oman; [Essa, Musthafa Mohamed] Sultan Qaboos Univ, Ageing & Dementia Res Grp, Muscat, Oman; [Essa, Musthafa Mohamed] Food & Brain Res Fdn, Madras 600094, Tamil Nadu, India; [Akbar, Mohammed D.; Akbar, Mohammed] NIAAA, SMPT, NIH, Rockville, MD 20852 USA	Annamalai University; Sultan Qaboos University; Sultan Qaboos University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Thenmozhi, AJ (corresponding author), Annamalai Univ, Dept Biochem & Biotechnol, Fac Sci, Annamalainagar 608002, Tamil Nadu, India.	justinthenmozhi@rediffmail.com	Thenmozhi, Arokiasamy Justin/U-7619-2019; Manivasagam, Thamilarasan/U-3209-2019; Essa, Mohamed/AAX-2596-2020; A, Justinthenmozhi/W-4465-2019	Manivasagam, Thamilarasan/0000-0003-4440-7323; Musthafa Mohamed, Essa/0000-0001-7505-9785; Justin Thenmozhi, Arokiasamy/0000-0001-8822-4751; Manivasagam, Thamilarasan/0000-0002-3948-8328	University Grants Commission-Basic Science Research Fellowship, New Delhi, India; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000036] Funding Source: NIH RePORTER	University Grants Commission-Basic Science Research Fellowship, New Delhi, India; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We gratefully acknowledge the University Grants Commission-Basic Science Research Fellowship, New Delhi, India for financial assistance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Hashem F., 2009, American Journal of Biochemistry and Biotechnology, V5, P98; [Anonymous], ASIA PAC J CLIN NUTR; Bai B, 2013, P NATL ACAD SCI USA, V110, P16562, DOI 10.1073/pnas.1310249110; Basch Ethan, 2003, Altern Med Rev, V8, P20; Baydar T, 2003, BIOL TRACE ELEM RES, V92, P231, DOI 10.1385/BTER:92:3:231; Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Braidy N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/685909; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Bukhari SB, 2008, PAK J ANAL ENV CHEM, V9; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carreiras MC, 2013, CURR TOP MED CHEM, V13, P1745, DOI 10.2174/15680266113139990135; Chaudhary M, 2014, ANN NEUROSCI, V21, P5, DOI 10.5214/ans.0972.7531.210103; CLAUBERG M, 1993, P NATL ACAD SCI USA, V90, P1009, DOI 10.1073/pnas.90.3.1009; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dhanalakshmi C, 2016, NEUROCHEM R IN PRESS; Flaten TP, 1996, J TOXICOL ENV HEALTH, V48, P527, DOI 10.1080/009841096161050; Fuller S, 2015, ADV NUTR, V6, P189, DOI 10.3945/an.114.007807; Garrido JL, 2002, FASEB J, V16, P1982, DOI 10.1096/fj.02-0327fje; Giacobini E, 2002, J NEURAL TRANSM, V109, P1053, DOI 10.1007/s007020200089; Hamza N, 2012, J ETHNOPHARMACOL, V142, P516, DOI 10.1016/j.jep.2012.05.028; HEISE GA, 1984, MED RES REV, V4, P535, DOI 10.1002/med.2610040405; Hu YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064460; Humpel C, 2011, EXP GERONTOL, V46, P225, DOI 10.1016/j.exger.2010.11.032; Janakiraman U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146671; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; Jelenkovic A, 2014, PHYTOTHER RES, V28, P82, DOI 10.1002/ptr.4962; Ji LN, 2009, J ALZHEIMERS DIS, V18, P105, DOI 10.3233/JAD-2009-1127; Justin Thenmozhi A, 2015, NUTR NEUROS IN PRESS; Justin Thenmozhi A, 2016, NUTR NEUROS IN PRESS; Kaizer RR, 2004, NEUROCHEM RES, V29, P2251, DOI 10.1007/s11064-004-7033-3; Kandhare AD, 2015, CHEM-BIOL INTERACT, V237, P151, DOI 10.1016/j.cbi.2015.06.019; Khursheed R, 2014, PAK J PHARM SCI, V27, P1419; Kumar A, 2009, N-S ARCH PHARMACOL, V380, P431, DOI 10.1007/s00210-009-0442-8; Kumar A, 2009, BEHAV BRAIN RES, V205, P384, DOI 10.1016/j.bbr.2009.07.012; Liang JG, 2012, FREE RADICAL BIO MED, V53, P1459, DOI 10.1016/j.freeradbiomed.2012.08.003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mani V., 2009, PHARMACOLOGY, V2, P827; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; Mathiyazahan DB, 2015, J FUNCT FOODS, V16, P423, DOI 10.1016/j.jff.2015.05.001; Meghwal M, 2012, SCI REP, V1, P1, DOI DOI 10.4172/SCIENTIFICREPORTS.129; Mesulam MM, 2002, NEUROSCIENCE, V110, P627, DOI 10.1016/S0306-4522(01)00613-3; Modi PK, 2012, MOL BIOL CELL, V23, P3722, DOI 10.1091/mbc.E12-02-0125; Muirhead KEA, 2010, BIOCHEM J, V426, P255, DOI 10.1042/BJ20091941; Namikawa K, 2000, J NEUROSCI, V20, P2875; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Prakash A, 2013, NEUROL SCI, V34, P1403, DOI 10.1007/s10072-012-1252-1; Rao PU, 1996, NUTR RES, V16, P1495, DOI 10.1016/0271-5317(96)00163-7; Roberson ED, 2006, SCIENCE, V314, P781, DOI 10.1126/science.1132813; Saini D., 2011, AJPCR, V4, P76; SatheeshKumar N, 2010, PHYTOMEDICINE, V17, P292, DOI 10.1016/j.phymed.2009.06.006; Sharma P, 2006, REPROD TOXICOL, V21, P313, DOI 10.1016/j.reprotox.2005.06.004; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takashima A, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P309; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Thenmozhi AJ, 2015, NEUROCHEM RES, V40, P767, DOI 10.1007/s11064-015-1525-1; Walton J R, 2012, Int J Alzheimers Dis, V2012, P914947, DOI 10.1155/2012/914947; Wang LP, 2014, NEUROCHEM RES, V39, P1338, DOI 10.1007/s11064-014-1317-z; WANG QM, 1994, J BIOL CHEM, V269, P14566; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Yellamma K, 2010, Toxicol Int, V17, P106, DOI 10.4103/0971-6580.72682; Yokel RA, 2002, ENVIRON HEALTH PERSP, V110, P699, DOI 10.1289/ehp.02110s5699; Yokel RA, 2002, COORDIN CHEM REV, V228, P97, DOI 10.1016/S0010-8545(02)00078-4; ZATTA P, 1994, NEUROREPORT, V5, P1777, DOI 10.1097/00001756-199409080-00023; Zhang H, 2016, NEUROTOX RE IN PRESS; Zhang HF, 2016, NEUROTOX RES, V29, P484, DOI 10.1007/s12640-016-9597-5; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249	71	32	32	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2016	11	11							e0165955	10.1371/journal.pone.0165955	http://dx.doi.org/10.1371/journal.pone.0165955			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FE	27893738	gold, Green Published, Green Submitted			2023-01-03	WOS:000389472400013
J	Gupta, I; Chowdhury, S; Prinja, S; Trivedi, M				Gupta, Indrani; Chowdhury, Samik; Prinja, Shankar; Trivedi, Mayur			Out-of-Pocket Spending on Out-Patient Care in India: Assessment and Options Based on Results from a District Level Survey	PLOS ONE			English	Article							HEALTH-CARE; PAYMENTS; POOR	Out-of-pocket spending at out-patient departments (OPD) by households is relatively less analyzed compared to hospitalization expenses in India. This paper provides new evidence on the levels and drivers of expenditure on out-patient care, as well as choice of providers, using household survey data from 8 districts in 3 states of India. Results indicate that the economically vulnerable spend more on OPD as a proportion of per capita consumption expenditure, out-patient care remains overwhelmingly private and switches of providers-while not very prevalent-is mostly towards private providers. A key result is that choice of public providers tend to lower OPD spending significantly. It indicates that an improvement in the overall quality and accessibility of government facilities still remain an important tool that should be considered in the context of financial protection.	[Gupta, Indrani; Chowdhury, Samik] Inst Econ Growth, Delhi, India; [Prinja, Shankar] Post Grad Inst Med Educ & Res, Chandigarh, India; [Trivedi, Mayur] Indian Inst Publ Hlth, Gandhinagar, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Gupta, I (corresponding author), Inst Econ Growth, Delhi, India.	indrani@iegindia.org	Trivedi, Mayur/AFU-4877-2022; Chowdhury, Samik/AAM-9819-2020; Trivedi, Mayur/AHA-6256-2022	Trivedi, Mayur/0000-0002-4532-2340	Indian Council of Social Science Research (ICSSR)	Indian Council of Social Science Research (ICSSR)	This research was supported by a grant from the Indian Council of Social Science Research (ICSSR) (www.icssr.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by a grant from the Indian Council of Social Science Research (ICSSR).	Berman P., 2010, Economic and Political Weekly, V45, P65; CRAGG JG, 1971, ECONOMETRICA, V39, P829, DOI 10.2307/1909582; Deenadayalan Vaishnavi Salem, 2009, J INT DEV, V21, P169; Dror DM, 2008, INDIAN J MED RES, V127, P347; Gupta I, 2015, 346 IEG; Gupta Monica Das, 2010, ECON POLIT WEEKLY, V45, P46; Habibov Nazim, 2009, J Health Organ Manag, V23, P170; Hajizadeh M, 2011, INT J HEALTH CARE FI, V11, P267, DOI 10.1007/s10754-011-9099-1; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; Joan Fontab Costa, 2007, APPL ECON, V39, P541; Joe W, 2015, HEALTH POLICY PLANN, V30, P728, DOI 10.1093/heapol/czu050; Kapur A, 2007, INDIAN J MED RES, V125, P473; Onwujekwe OE, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-67; Patankar AM, 2011, PUBLIC HEALTH, V125, P157, DOI 10.1016/j.puhe.2010.11.009; Planning Commission, 2011, HIGH LEV EXP GROUP R; Ramani K V, 2006, J Health Organ Manag, V20, P560, DOI 10.1108/14777260610702307; Raza Wameq A., 2016, BMC HEALTH SERV RES, P1, DOI [10.1186/s12913-015-1254-9, DOI 10.1186/S12913-015-1254-9]; Shahrawat R, 2012, HEALTH POLICY PLANN, V27, P213, DOI 10.1093/heapol/czr029; Thomas D, 2015, SOC SCI MED, V145, P154, DOI 10.1016/j.socscimed.2015.06.010; You X, 2011, APPL HEALTH ECON HEA, V9, P39, DOI 10.2165/11530730-000000000-00000	20	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							e0166775	10.1371/journal.pone.0166775	http://dx.doi.org/10.1371/journal.pone.0166775			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EC7WC	27861559	Green Published, Green Submitted, gold			2023-01-03	WOS:000388350300105
J	Sugiura, Y; Tanimoto, Y; Imbe, A; Inaba, Y; Sakai, S; Shishikura, K; Tanimoto, K; Hanafusa, T				Sugiura, Yumiko; Tanimoto, Yoshimi; Imbe, Ayumi; Inaba, Yuiko; Sakai, Satoshi; Shishikura, Kanako; Tanimoto, Keiji; Hanafusa, Toshiaki			Association between Functional Capacity Decline and Nutritional Status Based on the Nutrition Screening Initiative Checklist: A 2-Year Cohort Study of Japanese Community-Dwelling Elderly	PLOS ONE			English	Article							OLDER-ADULTS; HEALTH; INDEX; NSI	Aim To assess whether nutritional status based on the Nutrition Screening Initiative Checklist is useful for predicting functional capacity decline in community-dwelling Japanese elderly. Methods This two-year observational cohort study included 536 community-dwelling Japanese (65 years and older at baseline) who were independent in both activities and instrumental activities of daily living. Demographic attributes, chronic illness, lifestyle-related habits, nutritional status, functional capacity, and anthropometric measurements were assessed, with decline in functional capacity used as the outcome measure. Results Subjects were classified into three groups as follows based on the Nutrition Screening Initiative Checklist: low (59.5%), moderate (23.7%), and high (16.8%) nutritional risk. Significant differences were found between nutritional status and the following four baseline variables: age, hypertension, cerebrovascular diseases, and current smoking. However, no significant differences were evident between nutritional status and sex, body mass index, diabetes, drinking habit, or exercise habit. Logistic regression analysis adjusted for age, sex, body mass index, hypertension, cerebrovascular diseases and smoking habit showed that the high nutritional risk group was significantly associated with a decline in both activities of daily living (odds ratio: 4.96; 95% confidence interval (CI): 1.59-15.50) and instrumental activities of daily living (OR: 2.58; 95% CI: 1.31-5.06) compared with the low nutritional risk group. Conclusions Poor nutritional status based on the Nutrition Screening Initiative Checklist was associated with a decline in functional capacity over a 2-year period in community-dwelling Japanese elderly. These results suggest that the Nutrition Screening Initiative Checklist is a suitable tool for predicting functional capacity decline in community-dwelling elderly.	[Sugiura, Yumiko] Med Corp Hatsunekai, Sugiura Clin, Kariya, Aichi, Japan; [Tanimoto, Yoshimi; Imbe, Ayumi; Inaba, Yuiko; Sakai, Satoshi; Shishikura, Kanako; Tanimoto, Keiji; Hanafusa, Toshiaki] Osaka Med Coll, Dept Internal Med 1, Takatsuki, Osaka, Japan	Osaka Medical College	Tanimoto, Y (corresponding author), Osaka Med Coll, Dept Internal Med 1, Takatsuki, Osaka, Japan.	hyg022@osaka-med.ac.jp			Japan Society for the Promotion of Science KAKENHI Grant [24590823]	Japan Society for the Promotion of Science KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Number 24590823.	Aida J, 2012, J AM GERIATR SOC, V60, P338, DOI 10.1111/j.1532-5415.2011.03791.x; BARROCAS A, 1995, J AM DIET ASSOC, V95, P647, DOI 10.1016/S0002-8223(95)00177-8; Bartlett S, 1997, GERIATRIC NUTR HDB, P27; Cabinet Office Government of Japan, 2013, WHIT PAP AG SOC VERS; Chen CCH, 2007, J CLIN NURS, V16, P2015, DOI 10.1111/j.1365-2702.2006.01867.x; de Groot LCPGM, 1998, EUR J CLIN NUTR, V52, P877, DOI 10.1038/sj.ejcn.1600658; Fujiwara Y, 2008, GERONTOLOGY, V54, P373, DOI 10.1159/000151221; Ishizaki T, 2002, ARCH GERONTOL GERIAT, V35, P107, DOI 10.1016/S0167-4943(02)00002-X; Kamo T, 2014, GERIATR GERONTOL INT, V14, P799, DOI 10.1111/ggi.12169; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Keller HH, 2004, J GERONTOL A-BIOL, V59, P68; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Kumagai Shu, 2003, Nihon Koshu Eisei Zasshi, V50, P1117; Kusabiraki Toshiyuki, 2014, Bulletin of the Osaka Medical College, V60, P27; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Alvarenga MRM, 2010, REV ESC ENFERM USP, V44, P1041; Nutrition Screening Initiative, 1991, REP NUTR SCREEN 1 CO; Okamura T, 2008, J AM GERIATR SOC, V56, P529, DOI 10.1111/j.1532-5415.2007.01549.x; Phillips MB, 2010, ASIA PAC J CLIN NUTR, V19, P440; POSNER BM, 1993, AM J PUBLIC HEALTH, V83, P972, DOI 10.2105/AJPH.83.7.972; REUBEN DB, 1995, J AM GERIATR SOC, V43, P415, DOI 10.1111/j.1532-5415.1995.tb05818.x; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Sherina M S Jr, 2004, Malays J Nutr, V10, P149; Simsek H, 2014, GERIATR GERONTOL INT, V14, P960, DOI 10.1111/ggi.12166; Takahashi Ryutaro, 2006, Nihon Ronen Igakkai Zasshi, V43, P375; WHITE JV, 1991, J AM DIET ASSOC, V91, P783; Yap K. B., 2007, SMJ Singapore Medical Journal, V48, P911	27	13	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2016	11	11							e0166037	10.1371/journal.pone.0166037	http://dx.doi.org/10.1371/journal.pone.0166037			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EB8BE	27824916	Green Published, gold, Green Submitted			2023-01-03	WOS:000387615200056
J	de Moraes, AV; Carvalho, CDS; Carneiro, CC; do Vale, CR; Lima, DCD; Carvalho, WF; Vieira, TB; Silva, DDE; Cunha, KS; Chen-Chen, L				de Moraes Filho, Aroldo Vieira; Silva Carvalho, Claudia de Jesus; Carneiro, Cristiene Costa; do Vale, Camila Regina; da Silva Lima, Debora Cristina; Carvalho, Wanessa Fernandes; Vieira, Thiago Bernardi; de Melo e Silva, Daniela; Cunha, Kenya Silva; Chen-Chen, Lee			Genotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone Marrow	PLOS ONE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; TENOFOVIR DISOPROXIL FUMARATE; HPRT LYMPHOCYTE MUTANTS; COMET ASSAY; MICRONUCLEUS ASSAY; LYMPHOBLASTOID-CELLS; GENETIC-DAMAGE; DNA-DAMAGE; ZIDOVUDINE; LAMIVUDINE	Commonly used guidelines for the management of human immunodeficiency virus (HIV) infection (highly active antiretroviral therapy, HAART) include drug combinations such as tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) and combivir [zidovudine (AZT) + 3TC] + efavirenz (EFV). These combinations may enhance the genotoxic effects induced by such drugs individually, since the therapy requires lifelong adherence and the drugs have unknown effects during treatment. Thus, the evaluation of the benefits and risks of HAART is of great importance. In order to assess the cytotoxic and genotoxic potential of three concentrations of each of the antiretroviral combinations TDF + 3TC (800 + 400, 1600 + 800, and 3200 + 1600 mg/kg body weight, BW) and combivir + EFV (200 + 100 + 400, 400 + 200 + 800, and 800 + 400 + 1600 mg/kg BW) after two exposure periods (24 h and 48 h), in the present study the in vivo comet assay (single-cell gel electrophoresis) and the mouse bone marrow micronucleus test were used. Neither TDF + 3TC nor combivir + EFV induced DNA damage at any concentrations tested after 24 h or 48 h using the comet assay. After 24 h, both combinations increased the micronucleus frequency at all concentrations tested. After 48 h, combivir + EFV increased the micronucleated polychromatic erythrocyte (MNPCE) frequency at the two highest concentrations tested. Polychromatic erythrocytes (PCE)/normochromatic erythrocytes (NCE) ratio was high for both combinations, suggesting that they can be mitogenic. Since genotoxicity may be related to carcinogenesis, it is necessary to conduct further studies to verify the long-term mutagenic effects of these drugs.	[de Moraes Filho, Aroldo Vieira; Silva Carvalho, Claudia de Jesus; Carneiro, Cristiene Costa; do Vale, Camila Regina; da Silva Lima, Debora Cristina; Carvalho, Wanessa Fernandes; de Melo e Silva, Daniela; Cunha, Kenya Silva; Chen-Chen, Lee] Univ Fed Goias, ICB, Dept Genet, Lab Radiobiol & Mutagenese, Campus Samambaia,Caixa Postal 131, BR-74001970 Goiania, Go, Brazil; [Vieira, Thiago Bernardi] Univ Estado Mato Grosso, Programa Posgrad Ecol & Conservacao, Campus Univ Nova Xavantina,BR 158,Caixa Postal 8, BR-78690000 Nova Xavantina, MT, Brazil	Universidade Federal de Goias; Universidade do Estado de Mato Grosso	de Moraes, AV (corresponding author), Univ Fed Goias, ICB, Dept Genet, Lab Radiobiol & Mutagenese, Campus Samambaia,Caixa Postal 131, BR-74001970 Goiania, Go, Brazil.	aroldodemoraes@gmail.com	Chen, Lee Chen/B-1668-2013; Vieira, Thiago Bernardi/H-4520-2017; Vieira, Thiago Bernardi/P-5233-2015; Filho, Aroldo Moraes/AAQ-5257-2021; Chen-Chen, Lee/Q-9797-2019	Chen, Lee Chen/0000-0002-0386-247X; Vieira, Thiago Bernardi/0000-0003-1762-8294; Vieira, Thiago Bernardi/0000-0003-1762-8294; Chen-Chen, Lee/0000-0002-0386-247X; Carvalho, Wanessa Fernandes/0000-0003-4297-5191	CAPES Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior	CAPES Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was funded by CAPES Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior.	Anderson PL, 2003, AIDS, V17, P2159, DOI 10.1097/00002030-200310170-00003; Attia SM, 2014, MUTAGENESIS, V29, P55, DOI 10.1093/mutage/get063; Barditch-Crovo P, 2001, ANTIMICROB AGENTS CH, V45, P2733, DOI 10.1128/AAC.45.10.2733-2739.2001; Bayram S, 2008, ENVIRON MOL MUTAGEN, V49, P328, DOI 10.1002/em.20393; Bialkowska A, 2000, CARCINOGENESIS, V21, P1059, DOI 10.1093/carcin/21.5.1059; Bishop JB, 2004, ENVIRON MOL MUTAGEN, V43, P3, DOI 10.1002/em.10210; Bisset LR, 2002, ANTIVIR RES, V53, P35, DOI 10.1016/S0166-3542(01)00190-5; Bonassi S, 2007, CARCINOGENESIS, V28, P625, DOI 10.1093/carcin/bgl177; Brambilla G, 2011, MUTAGENESIS, P1, DOI [10.1093/mutage/ger052, DOI 10.1093/MUTAGE/GER052]; Brambilla G, 2012, MUTAT RES-REV MUTAT, V750, P1, DOI 10.1016/j.mrrev.2011.09.002; Carter MM, 2007, ENVIRON MOL MUTAGEN, V48, P239, DOI 10.1002/em.20282; Cihlar T, 2002, ANTIVIR RES, V54, P37, DOI 10.1016/S0166-3542(01)00210-8; COLEGIO BRASILEIRO DE EXPERIMENTACAO ANIMAL-COBEA, 1991, PRINC ET EXP AN; Collins A, 2014, MUTAT RES-REV MUTAT, V759, P27, DOI 10.1016/j.mrrev.2013.10.001; Collins AR, 2014, BBA-GEN SUBJECTS, V1840, P794, DOI 10.1016/j.bbagen.2013.04.022; de Baar MP, 2007, ANTIVIR RES, V76, P68, DOI 10.1016/j.antiviral.2007.05.004; de Oliveira HM, 2014, ENVIRON TOXICOL PHAR, V37, P390, DOI 10.1016/j.etap.2013.12.011; Decordier I, 2002, MUTAGENESIS, V17, P337, DOI 10.1093/mutage/17.4.337; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Diaz-Delfin J, 2011, ANTIVIR RES, V91, P112, DOI 10.1016/j.antiviral.2011.04.018; Duan CY, 2001, J INFECT DIS, V184, P1336, DOI 10.1086/323995; Ehteshami M, 2008, J BIOL CHEM, V283, P29904, DOI 10.1074/jbc.M804882200; Escobar PA, 2007, ENVIRON MOL MUTAGEN, V48, P330, DOI 10.1002/em.20285; Friedrich A, 2011, REGUL TOXICOL PHARM, V60, P225, DOI 10.1016/j.yrtph.2011.04.001; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Godschalk RWL, 2013, MUTAT RES-GEN TOX EN, V757, P60, DOI 10.1016/j.mrgentox.2013.06.020; Guimaraes NN, 2013, FOOD CHEM TOXICOL, V53, P299, DOI 10.1016/j.fct.2012.12.005; Hartmann A, 2004, MUTAGENESIS, V19, P51, DOI 10.1093/mutage/geg038; HAYASHI M, 1994, MUTAT RES, V312, P293, DOI 10.1016/0165-1161(94)90039-6; Hecht M, 2013, AIDS, V27, P2031, DOI 10.1097/QAD.0b013e3283625444; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; Herd O., 2014, Journal of AIDS and Clinical Research, V5, P397; Krishna G, 2000, MUTAT RES-FUND MOL M, V455, P155, DOI 10.1016/S0027-5107(00)00117-2; Lei FX, 2011, CHIN J ANTIBIOT; Lourenco ED, 2010, GENET MOL BIOL, V33, P756, DOI 10.1590/S1415-47572010005000084; MACGREGOR JT, 1987, MUTAT RES, V189, P103, DOI 10.1016/0165-1218(87)90016-4; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2016, GUIDELINES USE ANTIR; Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Ribaudo HJ, 2006, CLIN INFECT DIS, V42, P401, DOI 10.1086/499364; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; SCHILLING BE, 1995, CURR THER RES CLIN E, V56, P201, DOI 10.1016/0011-393X(95)85025-2; SCHLEGEL R, 1984, MUTAT RES, V127, P169, DOI 10.1016/0027-5107(84)90018-6; SHAFIK HM, 1991, ANTIVIR RES, V16, P205, DOI 10.1016/0166-3542(91)90026-N; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Tripathi DN, 2008, MUTAT RES-GEN TOX EN, V653, P134, DOI 10.1016/j.mrgentox.2008.03.004; Von Tungeln LS, 2007, ENVIRON MOL MUTAGEN, V48, P258, DOI 10.1002/em.20237; Von Tungeln LS, 2002, CARCINOGENESIS, V23, P1427, DOI 10.1093/carcin/23.9.1427; Walker DM, 2009, ENVIRON MOL MUTAGEN, V50, P460, DOI 10.1002/em.20482; Wu KM, 2012, INT J TOXICOL, V31, P211, DOI 10.1177/1091581812439585; Xiang GG, 2013, FOOD CHEM TOXICOL, V53, P352, DOI 10.1016/j.fct.2012.12.020	51	10	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2016	11	11							e0165706	10.1371/journal.pone.0165706	http://dx.doi.org/10.1371/journal.pone.0165706			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA6DJ	27806085	Green Submitted, Green Published, gold			2023-01-03	WOS:000386715500051
J	Chen, LH; Chen, JQ; Peng, QY; Chen, JJ; Zou, YC; Liu, G				Chen, Lianghua; Chen, Junqi; Peng, Qiyuan; Chen, Jingjie; Zou, Yucong; Liu, Gang			Effect of Sling Exercise Training on Balance in Patients with Stroke: A Meta-Analysis	PLOS ONE			English	Article							TRUNK STABILIZATION EXERCISES; LOW-BACK-PAIN; VALIDATION; GAIT; THERAPY; SCALE	Objective This study aims to evaluate the effect of sling exercise training (SET) on balance in patients with stroke. Methods PubMed, Cochrane Library, Ovid LWW, CBM, CNKI, WanFang, and VIP databases were searched for randomized controlled trials of the effect of SET on balance in patients with stroke. The study design and participants were subjected to metrological analysis. Berg balance Scale (BBS), Barthel index score (BI), and Fugl-Meyer Assessment (FMA) were used as independent parameters for evaluating balance function, activities of daily living (ADL) and motor function after stroke respectively, and were subjected to meta-analysis by RevMan5.3 software. Results Nine studies with 460 participants were analyzed. Results of meta-analysis showed that the SET treatment combined with conventional rehabilitation was superior to conventional rehabilitation treatments, with increased degrees of BBS (WMD = 3.81, 95% CI [0.15, 7.48], P = 0.04), BI (WMD = 12.98, 95% CI [8.39, 17.56], P < 0.00001), and FMA (SMD = 0.76, 95% CI [0.41, 1.11], P < 0.0001). Conclusion Based on limited evidence from 9 trials, the SET treatment combined with conventional rehabilitation was superior to conventional rehabilitation treatments, with increased degrees of BBS, BI and FMA, So the SET treatment can improvement of balance function after stroke, but the interpretation of our findings is required to be made with caution due to limitations in included trials such as small sample sizes and the risk of bias. Therefore, more multi-center and large-sampled randomized controlled trials are needed to confirm its clinical applications.	[Chen, Lianghua; Chen, Junqi; Peng, Qiyuan; Chen, Jingjie; Zou, Yucong; Liu, Gang] Southern Med Univ, Affiliated Hosp 3, Dept Rehabil Med, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Liu, G (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Rehabil Med, Guangzhou, Guangdong, Peoples R China.	13580350999@126.com		chen, jun-qi/0000-0001-6847-0891	Tianhe District Science and Technology Projects of Guangdong, China [201404KW021]	Tianhe District Science and Technology Projects of Guangdong, China	This work was supported by Tianhe District Science and Technology Projects of Guangdong, China (No. 201404KW021). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson K, 2005, CAN J APPL PHYSIOL, V30, P33, DOI 10.1139/h05-103; Anderson KG, 2004, J STRENGTH COND RES, V18, P637; Bae SH, 2013, J PHYS THER SCI, V25, P741, DOI 10.1589/jpts.25.741; Benaim C, 1999, STROKE, V30, P1862, DOI 10.1161/01.STR.30.9.1862; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Cabanas-Valdes R, 2013, NEUROREHABILITATION, V33, P575, DOI 10.3233/NRE-130996; Chen C, 2012, AM J CLIN ONCOL-CANC, V27, P27, DOI DOI 10.5301/JBM.2011.8736; Chinese society for neuroscience and Chinese society of department of neurosurgery, 1996, CHINESE J NEUROLOGY, V29, P379; [崔贵祥 CUI Guixiang], 2009, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V24, P530; Duffy L, 2013, STROKE, V44, P462, DOI 10.1161/STROKEAHA.112.678615; French B, 2010, J REHABIL MED, V42, P9, DOI 10.2340/16501977-0473; Gu Shaohua, 2012, CHINESE J REHABILITA, V28, P452; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hu Chuan, 2015, CHINESE J REHABILITA, V30, P114; Kirkesola G, 2009, J FYSIOTERAPEUTEN, V76, P16; Krutulyte Grazina, 2003, Medicina (Kaunas), V39, P889; Lee JS, 2014, J PHYS THER SCI, V26, P655, DOI 10.1589/jpts.26.655; Lee JS, 2014, J PHYS THER SCI, V26, P1301, DOI 10.1589/jpts.26.1301; Li Ziqiang, 2013, CHINESE J COAL IND M, V16, P1835; Liu Gang, 2014, BASIC CLIN SLING EXE; Liu KP, 2004, ARCH PHYS MED REHAB, V85, P1403, DOI 10.1016/j.apmr.2003.12.035; Mao HF, 2002, STROKE, V33, P1022, DOI 10.1161/01.STR.0000012516.63191.C5; [缪亚萍 Miao Yaping], 2011, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V33, P285; Miller CE, 2009, STROKE, V40, P1973, DOI 10.1161/STROKEAHA.108.539528; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; O'Sullivan PB, 1997, SPINE, V22, P2959, DOI 10.1097/00007632-199712150-00020; Park JH, 2014, J PHYS THER SCI, V26, P219, DOI 10.1589/jpts.26.219; Qian JG, 2015, J PHYS THER SCI, V27, P3541, DOI 10.1589/jpts.27.3541; Rathore SS, 2002, STROKE, V33, P2718, DOI 10.1161/01.STR.0000035286.87503.31; ROSSITERFORNOFF JE, 1995, J GERONTOL A-BIOL, V50, pM291, DOI 10.1093/gerona/50A.6.M291; Sawacha Z, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-95; Sorinola IO, 2014, NEUROREHABILITATION, V35, P205, DOI 10.3233/NRE-141123; Spaich EG, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-81; Sun ZX., 2012, EFFECT SLING EXERCIS; Verheyden G, 2004, CLIN REHABIL, V18, P326, DOI 10.1191/0269215504cr733oa; [杨国梁 Yang Guoliang], 2011, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V33, P281; Yavuzer G, 2006, CLIN REHABIL, V20, P960, DOI 10.1177/0269215506070315; You YL, 2015, J PHYS THER SCI, V27, P2591, DOI 10.1589/jpts.27.2591; Yue YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099307; 傅建明, 2012, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V34, P926	41	11	18	6	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2016	11	10							e0163351	10.1371/journal.pone.0163351	http://dx.doi.org/10.1371/journal.pone.0163351			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CI	27727288	Green Published, gold, Green Submitted			2023-01-03	WOS:000385504400007
J	Rugo, HS; Klein, P; Melin, SA; Hurvitz, SA; Melisko, ME; Moore, A; Park, G; Mitchel, J; Bageman, E; D'Agostino, RB; Ver Hoeve, ES; Esserman, L; Cigler, T				Rugo, Hope S.; Klein, Paula; Melin, Susan Anitra; Hurvitz, Sara A.; Melisko, Michelle E.; Moore, Anne; Park, Glen; Mitchel, Jules; Bageman, Erika; D'Agostino, Ralph B., Jr.; Ver Hoeve, Elizabeth S.; Esserman, Laura; Cigler, Tessa			Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED HAIR LOSS; QUALITY-OF-LIFE; ADJUVANT CHEMOTHERAPY; PREVENTION; EFFICACY; DOCETAXEL; IMPACT; HYPOTHERMIA; SYSTEM; WOMEN	Importance Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited. Objectives To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. Design, Setting, and Participants A prospective cohort study conducted at 5 US medical centers of women with stage I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 in the control group; 14 matched by both age and chemotherapy regimen). The study was conducted between August 2013 and October 2014 with ongoing annual follow-up for 5 years. Exposures Use of a scalp cooling system. Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3 degrees C (37 degrees F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Main Outcomes and Measures Self-estimated hair loss using the Dean scale was assessed 4 weeks after the last dose of chemotherapy by unblinded patient review of 5 photographs. A Dean scale score of 0 to 2 (<= 50% hair loss) was defined as treatment success. A positive association between scalp cooling and reduced risk of hair loss would be demonstrated if 50% or more of patients in the scalp cooling group achieved treatment success, with the lower bound of the 95% CI greater than 40% of the success proportion. Quality of life was assessed at baseline, at the start of the last chemotherapy cycle, and 1 month later. Median follow-up was 29.5 months. Results Among the 122 patients in the study, the mean age was 53 years (range, 28-77 years); 77.0% were white, 9.0% were black, and 10.7% were Asian; and the mean duration of chemotherapy was 2.3 months (median, 2.1 months). No participants in the scalp cooling group received anthracyclines. Hair loss of 50% or less (Dean score of 0-2) was seen in 67 of 101 patients (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0%) in the control group (P < .001). Three of 5 quality-of-life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27.3% (95% CI, 18.0%-36.6%) reported feeling less physically attractive compared with 56.3% (95% CI, 31.9%-80.6%) of patients in the control group (P = .02). Of the 106 patients in the scalp cooling group, 4 (3.8%) experienced the adverse event of mild headache and 3 (2.8%) discontinued scalp cooling due to feeling cold. Conclusions and Relevance Among women undergoing nonanthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs no scalp cooling was associated with less hair loss at 4 weeks after the last dose of chemotherapy. Further research is needed to assess outcomes after patients receive anthracycline regimens, longer-term measures of alopecia, and adverse effects.	[Rugo, Hope S.; Melisko, Michelle E.; Esserman, Laura] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Klein, Paula] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Melin, Susan Anitra] Wake Forest Sch Med, Wake Forest Baptist Hlth Med Ctr, Winston Salem, NC USA; [Hurvitz, Sara A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Moore, Anne; Cigler, Tessa] Weill Cornell Med Coll, New York, NY USA; [Park, Glen; Mitchel, Jules] Target Hlth Inc, New York, NY USA; [Bageman, Erika] Dignitana AB, Lund, Sweden; [D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Winston Salem, NC USA; [Ver Hoeve, Elizabeth S.] Columbia Univ, New York, NY USA; [Ver Hoeve, Elizabeth S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Icahn School of Medicine at Mount Sinai; Wake Forest University; Wake Forest Baptist Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Cornell University; Wake Forest University; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Rugo, HS (corresponding author), Helen Diller Family Comprehens Canc Ctr, 1600 Divisidero St,POB 1710, San Francisco, CA 94115 USA.	hope.rugo@ucsf.edu			Dignitana AB; Lazlo Tauber Family Foundation; Anne Moore Breast Cancer Research Fund; Friedman Family Foundation; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER	Dignitana AB; Lazlo Tauber Family Foundation; Anne Moore Breast Cancer Research Fund; Friedman Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study was funded partially by Dignitana AB, the Lazlo Tauber Family Foundation (awarded to the University of California, San Francisco), the Anne Moore Breast Cancer Research Fund (awarded to the Weil Cornell Medical College), and the Friedman Family Foundation (awarded to Mount Sinai Beth Israel).	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Batchelor D, 2001, EUR J CANCER CARE, V10, P147, DOI 10.1046/j.1365-2354.2001.00272.x; Betticher DC, 2013, SUPPORT CARE CANCER, V21, P2565, DOI 10.1007/s00520-013-1804-9; Breed W.P.M., 2011, EXPERT REV DERMATOLO, V6, P109, DOI DOI 10.1586/EDM.10.76; BULOW J, 1985, SCAND J CLIN LAB INV, V45, P505, DOI 10.3109/00365518509155250; Cigler T, 2015, CLIN BREAST CANCER, V15, P332, DOI 10.1016/j.clbc.2015.01.003; DEAN JC, 1979, NEW ENGL J MED, V301, P1427, DOI 10.1056/NEJM197912273012605; Ekwall EM, 2013, MOL CLIN ONCOL, V1, P1065, DOI 10.3892/mco.2013.178; Friedrichs K, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-500; Giordano SH, 2012, J CLIN ONCOL, V30, P2232, DOI 10.1200/JCO.2011.40.1273; Grevelman EG, 2005, ANN ONCOL, V16, P352, DOI 10.1093/annonc/mdi088; Hesketh PJ, 2004, SUPPORT CARE CANCER, V12, P543, DOI 10.1007/s00520-003-0562-5; Janssen FPEM, 2007, PHYSIOL MEAS, V28, P829, DOI 10.1088/0967-3334/28/8/006; Kargar M, 2011, J ADV NURS, V67, P2473, DOI 10.1111/j.1365-2648.2011.05668.x; Komen MMC, 2013, ONCOLOGIST, V18, P885, DOI 10.1634/theoncologist.2012-0332; Lemieux J, 2015, BREAST CANCER RES TR, V149, P263, DOI 10.1007/s10549-014-3231-0; Lemieux J, 2008, PSYCHO-ONCOLOGY, V17, P317, DOI 10.1002/pon.1245; Lemieux J, 2009, BREAST CANCER RES TR, V118, P547, DOI 10.1007/s10549-009-0342-0; McAndrews PJ, DEGREE OF HAIR LOSS; Nangia J, 2017, JAMA-J AM MED ASSOC, V317, P596, DOI 10.1001/jama.2016.20939; Protiere C, 2002, SUPPORT CARE CANCER, V10, P529, DOI 10.1007/s00520-002-0375-y; Ridderheim M, 2003, SUPPORT CARE CANCER, V11, P371, DOI 10.1007/s00520-003-0451-y; Roe Helen, 2011, Br J Nurs, V20, pS4; Rugo H.S., 2013, ST GALL 13 INT BREAS; Rugo HS, 2012, CANC RES S, V72, pA2; Shin H, 2015, INT J CANCER, V136, pE442, DOI 10.1002/ijc.29115; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Trueb RM, 2009, SEMIN CUTAN MED SURG, V28, P11, DOI 10.1016/j.sder.2008.12.001; van den Hurk CJG, 2015, SUPPORT CARE CANCER, V23, P1197, DOI 10.1007/s00520-015-2647-3; van den Hurk CJG, 2013, BREAST, V22, P1001, DOI 10.1016/j.breast.2013.07.039; van den Hurk CJG, 2013, EUR J ONCOL NURS, V17, P536, DOI 10.1016/j.ejon.2013.02.004; van den Hurk CJG, 2012, SUPPORT CARE CANCER, V20, P3255, DOI 10.1007/s00520-012-1465-0; van den Hurk CJ, 2012, ACTA ONCOL, V51, P497, DOI 10.3109/0284186X.2012.658966; van den Hurk CJG, 2010, PSYCHO-ONCOLOGY, V19, P701, DOI 10.1002/pon.1615	34	85	89	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2017	317	6					606	614		10.1001/jama.2016.21038	http://dx.doi.org/10.1001/jama.2016.21038			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL8LI	28196257	Green Accepted			2023-01-03	WOS:000394870900015
J	Amjad, MS; Qaeem, MF; Ahmad, I; Khan, SU; Chaudhari, SK; Malik, NZ; Shaheen, H; Khan, AM				Amjad, Muhammad Shoaib; Qaeem, Mirza Faisal; Ahmad, Israr; Khan, Sami Ullah; Chaudhari, Sunbal Khalil; Malik, Nafeesa Zahid; Shaheen, Humaira; Khan, Arshad Mehmood			Descriptive study of plant resources in the context of the ethnomedicinal relevance of indigenous flora: A case study from Toli Peer National Park, Azad Jammu and Kashmir, Pakistan	PLOS ONE			English	Article							MEDICINAL-PLANTS; ETHNOBOTANICAL SURVEY; TRADITIONAL MEDICINE; HEALERS CONSENSUS; KNOWLEDGE; DISTRICT; PEOPLE; VALLEY; HILLS; COMMUNITIES	Background This paper presents the first quantitative ethnobotanical study of the flora in Toli Peer National Park of Azad Jammu and Kashmir, Pakistan. Being a remote area, there is a strong dependence by local people on ethnobotanical practices. Thus, we attempted to record the folk uses of the native plants of the area with a view to acknowledging and documenting the ethnobotanical knowledge. The aims of the study were to compile an inventory of the medicinal plants in the study area and to record the methods by which herbal drugs were prepared and administered. Materials and methods Information on the therapeutic properties of medicinal plants was collected from 64 local inhabitants and herbalists using open ended and semi-structured questionnaires over the period Aug 2013-Jul 2014. The data were recorded into a synoptic table comprising an ethnobotanical inventory of plants, the parts used, therapeutic indications and modes of application or administration. Different ethnobotanical indices i.e. relative frequencies of citation (RFC), relative importance (RI), use value (UV) and informant consensus factor (Fic), were calculated for each of the recorded medicinal plants. In addition, a correlation analysis was performed using SPSS ver. 16 to check the level of association between use value and relative frequency of citation. Results A total of 121 species of medicinal plants belonging to 57 families and 98 genera were recorded. The study area was dominated by herbaceous species (48%) with leaves (41%) as the most exploited plant part. The Lamiaceae and Rosaceae (9% each) were the dominant families in the study area. Among different methods of preparation, the most frequently used method was decoction (26 species) of different plant parts followed by use as juice and powder (24 species each), paste (22 species), chewing (16 species), extract (11 species), infusion (10 species) and poultice (8 species). The maximum Informant consensus factor (Fic) value was for gastro-intestinal, parasitic and hepatobiliary complaints (0.90). Berberis lycium Ajuga bracteosa, Prunella vulgaris, Adiantum capillus-veneris, Desmodium polycarpum, Pinus roxburgii, Albizia lebbeck, Cedrella serrata, Rosa brunonii, Punica granatum, Jasminum mesnyi and Zanthoxylum armatum were the most valuable plants with the highest UV, RFC and relative importance values. The Pearson correlation coefficient between UV and RFC (0.881) reflects a significant positive correlation between the use value and relative frequency of citation. The coefficient of determination indicated that 77% of the variability in UV could be explained in terms of RFC. Conclusion Systematic documentation of the medicinal plants in the Toli Peer National Park shows that the area is rich in plants with ethnomedicinal value and that the inhabitants of the area have significant knowledge about the use of such plants with herbal drugs commonly used to cure infirmities. The results of this study indicate that carrying out subsequent pharmacological and phytochemical investigations in this part of Pakistan could lead to new drug discoveries.	[Amjad, Muhammad Shoaib; Ahmad, Israr; Khan, Sami Ullah] Women Univ Azad Jammu & Kashmir, Dept Bot, Bagh, Pakistan; [Amjad, Muhammad Shoaib; Qaeem, Mirza Faisal; Chaudhari, Sunbal Khalil; Khan, Arshad Mehmood] Univ Arid Agr, PMAS, Dept Bot, Rawalpindi, Pakistan; [Malik, Nafeesa Zahid] Mirpur Univ Sci & Technol, Dept Bot, Mirpur, Pakistan; [Shaheen, Humaira] Comsat Gen Corp, Inst Informat Technol, Dept Biosci, Islamabad, Pakistan	Arid Agriculture University; COMSATS University Islamabad (CUI)	Amjad, MS (corresponding author), Women Univ Azad Jammu & Kashmir, Dept Bot, Bagh, Pakistan.; Amjad, MS (corresponding author), Univ Arid Agr, PMAS, Dept Bot, Rawalpindi, Pakistan.	malikshoaib1165@yahoo.com	Amjad, Muhammad Shoaib/GQQ-1505-2022; Khan, Arshad Mahmood/V-7426-2019	Khan, Arshad Mahmood/0000-0003-0683-1553; Chaudhari, Sunbal Khalil/0000-0002-9590-3514	IDEA WILD USA; IDEA WILD of the U.S. Department of Agriculture; Women University of Azad Jammu Kashmir; PMAS-University of Arid Agriculture Rawalpindi, Pakistan	IDEA WILD USA; IDEA WILD of the U.S. Department of Agriculture; Women University of Azad Jammu Kashmir; PMAS-University of Arid Agriculture Rawalpindi, Pakistan	This work was supported by the The IDEA WILD USA (http://www.ideawild.org/). The IDEA WILD of the U.S. Department of Agriculture (http://www.sare.org/) provided research instrument and funding to carry out field survey. None of the current authors were Pls on the initial grants and the authors do not have a record of the grant numbers. Funding to support student research collaborators was received from Women University of Azad Jammu & Kashmir and PMAS-University of Arid Agriculture Rawalpindi, Pakistan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbasi AM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-84; Abbasi AM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-66; Adzu B, 2003, ACTA TROP, V87, P245, DOI 10.1016/S0001-706X(03)00114-1; Ahmad M, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-36; Ahmed E, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-13; Alam N, 2011, PAK J BOT, V43, P773; Albuquerque U. P., 2006, Ethnobotany Research and Applications, V4, P51; Ali H, 2009, PAK J BOT, V41, P2009; Ali S. I., 1993, FLORA PAKISTAN NOS 1; Amjad Muhammad Shoaib, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P292; Amjad Muhammad Shoaib, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P234, DOI 10.1016/S2221-1691(15)30011-3; Amjad Muhammad Shoaib, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P952; Ankli A, 1999, ECON BOT, V53, P144, DOI 10.1007/BF02866493; Arshad M, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-13; Bahar G., 2013, J ETHNOPHARMACOL, V146, P113, DOI DOI 10.1016/J.JEP.2012.12.012; Balick MJ, 1996, ANN MO BOT GARD, V83, P58, DOI 10.2307/2399968; Bano A, 2014, J ETHNOPHARMACOL, V155, P1046, DOI 10.1016/j.jep.2014.05.045; Bano A, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-43; BASUALDO I, 1995, ECON BOT, V49, P387, DOI 10.1007/BF02863089; Baydoun S, 2015, J ETHNOPHARMACOL, V173, P139, DOI 10.1016/j.jep.2015.06.052; Bennett BC, 2000, ECON BOT, V54, P90, DOI 10.1007/BF02866603; Bibi T, 2014, J ETHNOPHARMACOL, V157, P79, DOI 10.1016/j.jep.2014.08.042; Bruni A, 1997, J ETHNOPHARMACOL, V57, P97, DOI 10.1016/S0378-8741(97)00055-X; Camou-Guerrero A, 2008, HUM ECOL, V36, P259, DOI 10.1007/s10745-007-9152-3; Chen GT, 2008, BIOMED CHROMATOGR, V22, P779, DOI 10.1002/bmc.1001; Edwards S, 2005, J ETHNOPHARMACOL, V100, P30, DOI 10.1016/j.jep.2005.05.026; El Amri J., 2015, J RES BIOL, V4, P1568; FAIZ AUH, 2014, BIOLOGIA-LAHORE, V60, P43; Farooq S., 2012, PAKISTAN J WEED SCI, V18, P277; Ghorbani A, 2005, J ETHNOPHARMACOL, V102, P58, DOI 10.1016/j.jep.2005.05.035; Ghorbani A, 2011, J ETHNOPHARMACOL, V134, P651, DOI 10.1016/j.jep.2011.01.011; Gonza T. M. R., 2008, J ETHNOPHARMACOL, V116, P341, DOI DOI 10.1016/J.JEP.2007.11.045; Hamayun M., 2005, ETHNOBOTANICAL PROFI; Han J, 2007, J PHARMACEUT BIOMED, V44, P430, DOI 10.1016/j.jpba.2007.02.023; Heinrich M, 1998, SOC SCI MED, V47, P1859, DOI 10.1016/S0277-9536(98)00181-6; Heinrich M, 2009, J ETHNOPHARMACOL, V124, P1, DOI 10.1016/j.jep.2009.03.043; Husain SZ, 2008, PAK J BOT, V40, P1897; Ijaz F, 2016, J ETHNOPHARMACOL, V179, P208, DOI 10.1016/j.jep.2015.12.050; Islam MK, 2014, J ETHNOPHARMACOL, V151, P921, DOI 10.1016/j.jep.2013.11.056; JAIN S K, 1977, P157; Jamila F, 2014, J ETHNOPHARMACOL, V154, P76, DOI 10.1016/j.jep.2014.03.016; Jeruto P, 2008, J ETHNOPHARMACOL, V116, P370, DOI 10.1016/j.jep.2007.11.041; Kargioglu M, 2008, HUM ECOL, V36, P763, DOI 10.1007/s10745-008-9198-x; Kayani S, 2015, J ETHNOPHARMACOL, V164, P186, DOI 10.1016/j.jep.2015.02.004; Kayani S, 2014, J ETHNOPHARMACOL, V156, P47, DOI 10.1016/j.jep.2014.08.005; Khan M. A., 2012, Pakistan Journal of Weed Science Research, V18, P495; Khan M. A., 2010, Ethnobotany Research and Applications, V8, P107; Khan M. B., 2008, THESIS; Khan MPZ, 2015, J ETHNOPHARMACOL, V173, P191, DOI 10.1016/j.jep.2015.07.029; Khan SM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-4; Khatoon S., 2004, INT J BIOTECHNOLOGY, V1, P584; Kichu M, 2015, J ETHNOPHARMACOL, V166, P5, DOI 10.1016/j.jep.2015.02.053; Ladio A, 2007, J ARID ENVIRON, V69, P695, DOI 10.1016/j.jaridenv.2006.11.008; Leonti M, 2003, J ETHNOPHARMACOL, V88, P119, DOI 10.1016/S0378-8741(03)00188-0; Leonti M, 2011, J ETHNOPHARMACOL, V134, P542, DOI 10.1016/j.jep.2011.01.017; Lin J, 2002, J ETHNOPHARMACOL, V79, P53, DOI 10.1016/S0378-8741(01)00353-1; Madikizela B, 2012, J ETHNOPHARMACOL, V141, P61, DOI 10.1016/j.jep.2012.01.053; Mahmood A, 2011, J MED PLANTS RES, V5, P4493; Mahmood A, 2011, PAK J BOT, V43, P105; Mahmood AS, 2011, J APPL PHARM, V3, P212, DOI DOI 10.21065/19204159.3.212; Malla B, 2015, J ETHNOPHARMACOL, V165, P103, DOI 10.1016/j.jep.2014.12.057; Miraldi E, 2001, J ETHNOPHARMACOL, V75, P77, DOI 10.1016/S0378-8741(00)00381-0; Moerman DE., 1998, NATIVE AM ETHNOBOTAN; MOORE PD, 1994, NATURE, V372, P410, DOI 10.1038/372410a0; Mosaddegh M, 2012, J ETHNOPHARMACOL, V141, P80, DOI 10.1016/j.jep.2012.02.004; Muhammad Ishtiaq, 2012, African Journal of Biotechnology, V11, P3087; Mukheriee PK, 2006, J ETHNOPHARMACOL, V103, P25, DOI 10.1016/j.jep.2005.09.024; Mukherjee PK, 2012, J ETHNOPHARMACOL, V143, P424, DOI 10.1016/j.jep.2012.07.036; Murad W, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-77; Nasab FK, 2014, J ETHNOPHARMACOL, V154, P190, DOI 10.1016/j.jep.2014.04.003; Nasir E., 1970, FLORA PAKISTAN ISLAM; Nondo R. S. O., 2015, Journal of Medicinal Plants Research, V9, P179; Qureshi R, 2001, PAKISTAN J BOT, V33, P109; Qureshi R., 2002, HAMDARD MED, V45, P86; Qureshi R, 2008, FITOTERAPIA, V79, P468, DOI 10.1016/j.fitote.2008.03.010; ROBINSON T, 1974, SCIENCE, V184, P430, DOI 10.1126/science.184.4135.430; Sadeghi Z, 2014, J ETHNOPHARMACOL, V153, P111, DOI 10.1016/j.jep.2014.01.007; Safa O, 2012, AVICENNA J PHYTOMEDI, V3, P64; Savikin K, 2013, J ETHNOPHARMACOL, V146, P803, DOI 10.1016/j.jep.2013.02.006; Schlage C, 2000, PLANT BIOLOGY, V2, P83, DOI 10.1055/s-2000-296; Schoene RB, 1999, LUNG DIS HIGH ALTITU, P47; Shaheen H, 2012, PAK J BOT, V44, P739; Shinwari ZK, 2010, J MED PLANTS RES, V4, P161; Siew YY, 2014, J ETHNOPHARMACOL, V155, P1450, DOI 10.1016/j.jep.2014.07.024; Singh H, 2014, J ETHNOPHARMACOL, V154, P98, DOI 10.1016/j.jep.2014.03.026; Srithi K, 2009, J ETHNOPHARMACOL, V123, P335, DOI 10.1016/j.jep.2009.02.035; Tangjitman K, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/s13002-015-0011-9; Thirumalai T., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS910; Trotter I. I. R. T., 1986, PLANTS INDIGENOUS ME; Ullah R, 2010, J MED PLANTS RES, V4, P1815; Vijayakumar S, 2015, J ETHNOPHARMACOL, V161, P238, DOI 10.1016/j.jep.2014.12.006; Vitalini S, 2013, J ETHNOPHARMACOL, V145, P517, DOI 10.1016/j.jep.2012.11.024; Zhang JL, 2005, J PHARMACEUT BIOMED, V36, P1029, DOI 10.1016/j.jpba.2004.09.009	93	56	56	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0171896	10.1371/journal.pone.0171896	http://dx.doi.org/10.1371/journal.pone.0171896			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EL2AZ	28192466	gold, Green Published, Green Submitted			2023-01-03	WOS:000394423800048
J	Prajapati, HJ; Kim, HS				Prajapati, Hasmukh J.; Kim, Hyun S.			Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization	PLOS ONE			English	Article							DRUG-ELUTING BEADS; CONCURRENT TRANSARTERIAL CHEMOEMBOLIZATION; PROGNOSTIC-FACTORS; PREDICT SURVIVAL; LIVER-CANCER; PHASE-II; SORAFENIB; EFFICACY; SAFETY; COHORT	Purpose To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). Methods Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE. Kaplan Meier and Cox Proportional Hazard model were used for survival analysis. The SS was constructed from MVA and named BCLC C HCC Prognostic (BCHP) staging system (SS). Results Overall median survival (OS) was 16.2 months. In HCC patients with venous thrombosis (VT) of large vein [main portal vein (PV), right or left PV, hepatic vein, inferior vena cava] (22.7%) versus small vein (segmental/subsegmental PV) (9.7%) versus no VT had OSs of 6.4 months versus 20 months versus 22.8 months respectively (p<0.001). On MVA, the significant independent prognostic factors (PFs) of survival were CP class, eastern cooperative oncology group (ECOG) performance status (PS), single HCC<5 cm, site of VT, metastases, serum creatinine and serum alpha-feto protein. Based on these PFs, the BCHP staging system was constructed. The OSs of stages I, II and III were 28.4 months, 11.8 months and 2.4 months accordingly (p<0.001). The treatment plan was proposed according to the different stages. Conclusion On MVA of patients with advanced HCC treated with TACE, significant independent prognostic factors (PFs) of survival were CP class, ECOG PS, single HCC<5 cm or others, site of VT, metastases, serum creatinine and serum alpha-feto protein. New BCHP SS was proposed based on MVA data to identify the suitable advanced HCC patients for TACE treatments.	[Prajapati, Hasmukh J.] Univ Tennessee, Hlth Sci Ctr, Div Pediat Intervent Radiol, Dept Radiol, Memphis, TN USA; [Kim, Hyun S.] Yale Univ, Dept Radiol & Biomed Imaging, Div Intervent Radiol, New Haven, CT 06520 USA; [Kim, Hyun S.] Yale Univ, Yale Canc Ctr, New Haven, CT 06520 USA	University of Tennessee System; University of Tennessee Health Science Center; Yale University; Yale University	Kim, HS (corresponding author), Yale Univ, Dept Radiol & Biomed Imaging, Div Intervent Radiol, New Haven, CT 06520 USA.; Kim, HS (corresponding author), Yale Univ, Yale Canc Ctr, New Haven, CT 06520 USA.	kevin.kim@yale.edu		Kim, Hyun/0000-0002-3077-9989				Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Brown DB, 2004, J VASC INTERV RADIOL, V15, P1209, DOI 10.1097/01.RVI.0000128123.04554.C1; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Chung YE, 2009, AM J ROENTGENOL, V193, pW7, DOI 10.2214/AJR.07.3947; Dhanasekaran R, 2010, HPB, V12, P174, DOI 10.1111/j.1477-2574.2009.00138.x; Hiraoka A, 2009, HEPATO-GASTROENTEROL, V56, P213; Hu HT, 2011, J VASC INTERV RADIOL, V22, P917, DOI 10.1016/j.jvir.2011.03.005; Hung H, 2005, CURR CANCER DRUG TAR, V5, P131, DOI 10.2174/1568009053202063; Huo TI, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-146; Jin B, 2011, AM J ROENTGENOL, V196, P919, DOI 10.2214/AJR.10.4770; Kalva SP, 2013, J VASC INTERV RADIOL, V24, P257, DOI 10.1016/j.jvir.2012.10.021; Kalva SP, 2013, CARDIOVASCULAR INTER, P1; Lance C, 2011, J VASC INTERV RADIOL, V22, P1697, DOI 10.1016/j.jvir.2011.08.013; Lewandowski RJ, 2010, RADIOLOGY, V255, P955, DOI 10.1148/radiol.10091473; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Malagari K, 2012, CARDIOVASC INTER RAD, V35, P1119, DOI 10.1007/s00270-012-0394-0; Olivo M, 2010, DIGEST LIVER DIS, V42, P515, DOI 10.1016/j.dld.2009.09.012; Park JW, 2012, J HEPATOL, V56, P1336, DOI 10.1016/j.jhep.2012.01.006; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pawlik TM, 2011, J CLIN ONCOL, V29, P3960, DOI 10.1200/JCO.2011.37.1021; Pinter M, 2012, RADIOLOGY, V263, P590, DOI 10.1148/radiol.12111550; Prajapati HJ, 2013, ANN ONCOL, V24, P965, DOI 10.1093/annonc/mds605; Prajapati HJ, 2013, J VASC INTERV RADIOL, V24, P307, DOI 10.1016/j.jvir.2012.11.026; Sellers MT, 2013, J VASC INTERV RADIOL, V24, P647, DOI 10.1016/j.jvir.2012.12.003; Shin BS, 2011, ACTA RADIOL, V52, P331, DOI 10.1258/ar.2010.100369; Uraki J, 2004, EUR J RADIOL, V51, P12, DOI 10.1016/S0720-048X(03)00219-5; Yau T, 2014, GASTROENTEROLOGY, V146, P1691, DOI 10.1053/j.gastro.2014.02.032	28	7	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2017	12	2							e0170750	10.1371/journal.pone.0170750	http://dx.doi.org/10.1371/journal.pone.0170750			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK1SG	28170405	Green Published, Green Submitted, gold			2023-01-03	WOS:000393705500010
J	Jans, J; Wicht, O; Widjaja, I; Ahout, IML; de Groot, R; Guichelaar, T; Luytjes, W; de Jonge, MI; de Haan, CAM; Ferwerda, G				Jans, Jop; Wicht, Oliver; Widjaja, Ivy; Ahout, Inge M. L.; de Groot, Ronald; Guichelaar, Teun; Luytjes, Willem; de Jonge, Marien I.; de Haan, Cornelis A. M.; Ferwerda, Gerben			Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age	PLOS ONE			English	Article							SYNCYTIAL VIRUS-INFECTION; NEUTRALIZING ANTIBODIES; FUSION GLYCOPROTEIN; BIRTH-COHORT; INFANTS; RESPONSES; PROTECTION; CHILDREN; IMMUNIZATION; GENERATION	Respiratory syncytial virus (RSV) is the leading cause for respiratory illness that requires hospitalization in infancy. High levels of maternal antibodies can protect against RSV infection. However, RSV-infected infants can suffer from severe disease symptoms even in the presence of high levels of RSV-specific antibodies. This study analyzes several serological characteristics to explore potential deficiencies or surpluses of antibodies that could relate to severe disease symptoms. We compare serum antibodies from hospitalized patients who suffered severe symptoms as well as uninfected infants. Disease severity markers were oxygen therapy, tachypnea, oxygen saturation, admission to the intensive care unit and duration of hospitalization. Antibodies against RSV G protein and a prefusion F epitope correlated with in vitro neutralization. Avidity of RSV-specific IgG antibodies was lower in RSVinfected infants compared to uninfected controls. Severe disease symptoms were unrelated to RSV-specific IgG antibody titers, avidity of RSV-IgG, virus neutralization capacity or titers against pre-and postfusion F or G protein ectodomains and the prefusion F antigenic site O. In conclusion, the detailed serological characterization did not indicate dysfunctional or epitope- skewed composition of serum antibodies in hospitalized RSV-infected infants suffering from severe disease symptoms. It remains unclear, whether specific antibody fractions could diminish disease symptoms.	[Jans, Jop; Wicht, Oliver; Ahout, Inge M. L.; de Groot, Ronald; de Jonge, Marien I.; Ferwerda, Gerben] Radboud Univ Nijmegen, Med Ctr, Lab Pediat Infect Dis, Dept Pediat,Radboud Inst Mol Life Sci, Nijmegen, Netherlands; [Wicht, Oliver; Guichelaar, Teun; Luytjes, Willem] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [Widjaja, Ivy; de Haan, Cornelis A. M.] Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, Utrecht, Netherlands	Radboud University Nijmegen; Netherlands National Institute for Public Health & the Environment; Utrecht University	Ferwerda, G (corresponding author), Radboud Univ Nijmegen, Med Ctr, Lab Pediat Infect Dis, Dept Pediat,Radboud Inst Mol Life Sci, Nijmegen, Netherlands.	Gerben.Ferwerda@radboudumc.nl	Guichelaar, Teun/AEQ-7065-2022; Ferwerda, J.G./L-4305-2015; de Groot, R./H-8039-2014; Ahout, Inge ML/P-8666-2015; de Jonge, Marien I./P-5869-2015; Wicht, Oliver/L-8714-2013	Guichelaar, Teun/0000-0002-5112-8923; de Jonge, Marien I./0000-0003-2812-5895; Wicht, Oliver/0000-0003-3266-8075; de Haan, Cornelis/0000-0002-4459-9874	Virgo consortium - Dutch government [FES0908]; Netherlands Genomics Initiative (NGI) [050-060-452]; Dutch Ministry of Health, Welfare and Sport [S112008]	Virgo consortium - Dutch government; Netherlands Genomics Initiative (NGI); Dutch Ministry of Health, Welfare and Sport	GF is supported by the Virgo consortium, funded by the Dutch government project number FES0908, and by the Netherlands Genomics Initiative (NGI) project number 050-060-452. OW and WL are supported by the Strategic Program RIVM (SPR) S112008, Dutch Ministry of Health, Welfare and Sport. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225; Atwell JE, 2016, J INFECT DIS, V213, P423, DOI 10.1093/infdis/jiv401; Bont L, 2016, INFECT DIS THER, V5, P271, DOI 10.1007/s40121-016-0123-0; Chu HY, 2014, J INFECT DIS, V210, P1582, DOI 10.1093/infdis/jiu316; Cullen LM, 2015, J VIROL, V89, P6835, DOI 10.1128/JVI.00384-15; Eick A, 2008, PEDIATR INFECT DIS J, V27, P207, DOI 10.1097/INF.0b013e31815ac585; Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894; Freitas GRO, 2011, J MED VIROL, V83, P1826, DOI 10.1002/jmv.22134; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; Gomez RS, 2016, IMMUNOLOGY, V147, P55, DOI 10.1111/imm.12541; Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC; Hancock GE, 1996, J VIROL, V70, P7783, DOI 10.1128/JVI.70.11.7783-7791.1996; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; Krarup A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9143; Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071; McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11; MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Ngwuta JO, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4241; Nyiro JU, 2015, VACCINE, V33, P1797, DOI 10.1016/j.vaccine.2015.02.039; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; Rigter A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071072; Shinoff JJ, 2008, J INFECT DIS, V198, P1007, DOI 10.1086/591460; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P398, DOI 10.1016/j.jaci.2008.10.043; van der Zalm MM, 2009, PEDIATR INFECT DIS J, V28, P472, DOI 10.1097/INF.0b013e318195e26e; van Remmerden Y, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-253; Vermont CL, 2002, INFECT IMMUN, V70, P584, DOI 10.1128/IAI.70.2.584-590.2002; Vissers M, 2014, INFECT IMMUN, V82, P4952, DOI 10.1128/IAI.02150-14; Widjaja I, 2016, J VIROL, V90, P5965, DOI 10.1128/JVI.00235-16; Widjaja I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130829; Widjojoatmodjo MN, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-114; Wright PF, 2002, J INFECT DIS, V185, P1011, DOI 10.1086/339822; Zorc JJ, 2010, PEDIATRICS, V125, P342, DOI 10.1542/peds.2009-2092	33	21	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2017	12	1							e0170877	10.1371/journal.pone.0170877	http://dx.doi.org/10.1371/journal.pone.0170877			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6PA	28135305	Green Published, Green Submitted, gold			2023-01-03	WOS:000396124700026
J	Kekic, M; McClelland, J; Bartholdy, S; Boysen, E; Musiat, P; Dalton, B; Tiza, M; David, AS; Campbell, IC; Schmidt, U				Kekic, Maria; McClelland, Jessica; Bartholdy, Savani; Boysen, Elena; Musiat, Peter; Dalton, Bethan; Tiza, Meyzi; David, Anthony S.; Campbell, Iain C.; Schmidt, Ulrike			Single-Session Transcranial Direct Current Stimulation Temporarily Improves Symptoms, Mood, and Self-Regulatory Control in Bulimia Nervosa: A Randomised Controlled Trial	PLOS ONE			English	Article							ANORECTIC COGNITIONS QUESTIONNAIRE; EATING-DISORDERS; ANOREXIA-NERVOSA; MAGNETIC STIMULATION; NEGATIVE AFFECT; BEHAVIORAL THERAPY; COMMUNITY SAMPLE; DECISION-MAKING; MORTALITY-RATES; FOOD CRAVINGS	Background Evidence suggests that pathological eating behaviours in bulimia nervosa (BN) are underpinned by alterations in reward processing and self-regulatory control, and by functional changes in neurocircuitry encompassing the dorsolateral prefrontal cortex (DLPFC). Manipulation of this region with transcranial direct current stimulation (tDCS) may therefore alleviate symptoms of the disorder. Objective This double-blind sham-controlled proof-of-principle trial investigated the effects of bilateral tDCS over the DLPFC in adults with BN. Methods Thirty-nine participants (two males) received three sessions of tDCS in a randomised and counterbalanced order: anode right/cathode left (AR/CL), anode left/cathode right (AL/CR), and sham. A battery of psychological/neurocognitive measures was completed before and after each session and the frequency of bulimic behaviours during the following 24-hours was recorded. Results AR/CL tDCS reduced eating disorder cognitions (indexed by the Mizes Eating Disorder Cognitions Questionnaire-Revised) when compared to AL/CR and sham tDCS. Both active conditions suppressed the self-reported urge to binge-eat and increased self-regulatory control during a temporal discounting task. Compared to sham stimulation, mood (assessed with the Profile of Mood States) improved after AR/CL but not AL/CR tDCS. Lastly, the three tDCS sessions had comparable effects on the wanting/liking of food and on bulimic behaviours during the 24 hours post-stimulation. Conclusions These data suggest that single-session tDCS transiently improves symptoms of BN. They also help to elucidate possible mechanisms of action and highlight the importance of selecting the optimal electrode montage. Multi-session trials are needed to determine whether tDCS has potential for development as a treatment for adult BN.	[Kekic, Maria; McClelland, Jessica; Bartholdy, Savani; Boysen, Elena; Musiat, Peter; Dalton, Bethan; Tiza, Meyzi; Campbell, Iain C.; Schmidt, Ulrike] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, Sect Eating Disorders, London, England; [David, Anthony S.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, London, England; [Boysen, Elena] Med Univ Hosp Tubingen, Dept Psychosomat Med & Psychotherapy, Osianderstr 5, D-72076 Tubingen, Germany	University of London; King's College London; University of London; King's College London; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Kekic, M (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, Sect Eating Disorders, London, England.	maria.kekic@kcl.ac.uk	David, Anthony/O-1750-2019; Dalton, Bethan/AAQ-6779-2020; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Schwarz, Elena/0000-0002-1010-9734; Dalton, Bethan/0000-0003-0898-1926	Medical Research Council/Institute of Psychiatry, Psychology & Neuroscience Excellence studentship; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London	Medical Research Council/Institute of Psychiatry, Psychology & Neuroscience Excellence studentship; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London	This research was funded by a Medical Research Council/Institute of Psychiatry, Psychology & Neuroscience Excellence studentship, awarded to Maria Kekic in 2012. Ulrike Schmidt, Iain Campbell, and Anthony David receive salary support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Open access for this article was funded by King's College London. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso-Alonso M, 2007, JAMA-J AM MED ASSOC, V297, P1819, DOI 10.1001/jama.297.16.1819; Alonzo A, 2012, BRAIN STIMUL, V5, P208, DOI 10.1016/j.brs.2011.04.006; Arcelus J, 2011, ARCH GEN PSYCHIAT, V68, P724, DOI 10.1001/archgenpsychiatry.2011.74; Bartholdy S, 2016, NEUROSCI BIOBEHAV R, V64, P35, DOI 10.1016/j.neubiorev.2016.02.010; Beam W, 2009, BRAIN STIMUL, V2, P50, DOI 10.1016/j.brs.2008.09.006; Berg KC, 2013, J ABNORM PSYCHOL, V122, P111, DOI 10.1037/a0029703; Berner LA, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00395; Bohon C, 2012, APPETITE, V58, P964, DOI 10.1016/j.appet.2012.02.051; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Burgess E. E., 2016, INT J EAT DISORD; Cowdrey FA, 2013, AM J CLIN NUTR, V97, P463, DOI 10.3945/ajcn.112.046011; Diana Marco, 2011, Front Psychiatry, V2, P64, DOI 10.3389/fpsyt.2011.00064; Fairburn C.G., 2008, COGNITIVE BEHAV THER, P265, DOI DOI 10.1037/T03975-000; Farmer RF, 2001, J BEHAV THER EXP PSY, V32, P211, DOI 10.1016/S0005-7916(01)00036-2; Fregni F, 2008, APPETITE, V51, P34, DOI 10.1016/j.appet.2007.09.016; Friederich HC, 2013, INT J EAT DISORDER, V46, P425, DOI 10.1002/eat.22099; Garcia-Garcia I, 2013, EUR EAT DISORD REV, V21, P89, DOI 10.1002/erv.2216; Gluck ME, 2015, OBESITY, V23, P2149, DOI 10.1002/oby.21313; Goldman RL, 2011, APPETITE, V56, P741, DOI 10.1016/j.appet.2011.02.013; Gray JC, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01104; Hare TA, 2009, SCIENCE, V324, P646, DOI 10.1126/science.1168450; Hausmann A, 2004, INT J NEUROPSYCHOPH, V7, P371, DOI 10.1017/S1461145704004420; Heatherton TF, 2011, TRENDS COGN SCI, V15, P132, DOI 10.1016/j.tics.2010.12.005; Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040; Kekic M, 2016, INT J EAT D IN PRESS; Kekic M, 2016, J PSYCHIATR RES, V74, P70, DOI 10.1016/j.jpsychires.2015.12.018; Kekic M, 2014, APPETITE, V78, P55, DOI 10.1016/j.appet.2014.03.010; Khedr EM, 2014, RESTOR NEUROL NEUROS, V32, P789, DOI 10.3233/RNN-140392; Koffarnus MN, 2013, J EXP ANAL BEHAV, V99, P32, DOI 10.1002/jeab.2; Lovibond S.H., 1995, MANUAL DEPRESSION AN, V2; Loxton NJ, 2001, INT J EAT DISORDER, V29, P455, DOI 10.1002/eat.1042; Macedo IC, 2016, APPETITE, V103, P29, DOI 10.1016/j.appet.2016.03.014; Marsh R, 2011, AM J PSYCHIAT, V168, P1210, DOI 10.1176/appi.ajp.2011.11010094; Marsh R, 2009, ARCH GEN PSYCHIAT, V66, P51, DOI 10.1001/archgenpsychiatry.2008.504; Marsh-Richard DM, 2009, BEHAV RES METHODS, V41, P99, DOI 10.3758/BRM.41.1.99; Mauler BI, 2006, J ABNORM PSYCHOL, V115, P567, DOI 10.1037/0021-843X.115.3.567; McClelland J, 2016, NEUROSCI BIOBEHAV R, V71, P506, DOI 10.1016/j.neubiorev.2016.09.024; McClelland J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148606; McClelland J, 2016, EUR EAT DISORD REV, V24, P157, DOI 10.1002/erv.2414; McClelland J, 2013, EUR EAT DISORD REV, V21, P436, DOI 10.1002/erv.2256; McNair D.M., 1971, MANUAL PROFILES MOOD; Meron D, 2015, NEUROSCI BIOBEHAV R, V57, P46, DOI 10.1016/j.neubiorev.2015.07.012; Mizes JS, 2000, INT J EAT DISORDER, V28, P415, DOI 10.1002/1098-108X(200012)28:4<415::AID-EAT9>3.3.CO;2-Q; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; National Institute for Health and Care Excellence, 2004, EATING DISORDERS COR; O'Brien KM, 2003, CLIN PSYCHOL REV, V23, P57, DOI 10.1016/S0272-7358(02)00201-5; Ochner CN, 2009, APPETITE, V53, P44, DOI 10.1016/j.appet.2009.04.220; Peak NJ, 2012, EAT BEHAV, V13, P94, DOI 10.1016/j.eatbeh.2011.12.004; Penas-Lledo E, 2013, PSYCHOTHER PSYCHOSOM, V82, P125, DOI 10.1159/000339620; Poulsen S, 2014, AM J PSYCHIAT, V171, P109, DOI 10.1176/appi.ajp.2013.12121511; Read D, 2001, J RISK UNCERTAINTY, V23, P5, DOI 10.1023/A:1011198414683; Ro O, 2012, EAT BEHAV, V13, P158, DOI 10.1016/j.eatbeh.2011.12.001; Sauvaget A, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00349; Smink FRE, 2012, CURR PSYCHIAT REP, V14, P406, DOI 10.1007/s11920-012-0282-y; Steinglass JE, 2012, J INT NEUROPSYCH SOC, V18, P773, DOI 10.1017/S1355617712000446; Stice E, 2000, PSYCHOL ASSESSMENT, V12, P123, DOI 10.1037//1040-3590.12.2.123; Stice E, 2013, J ABNORM PSYCHOL, V122, P445, DOI 10.1037/a0030679; Uher R, 2005, BIOL PSYCHIAT, V58, P840, DOI 10.1016/j.biopsych.2005.05.043; Van den Eynde F, 2012, EUR PSYCHIAT, V27, P290, DOI 10.1016/j.eurpsy.2010.08.015; Van den Eynde F., 2011, EUROPEAN PSYCHIAT, V28, P98; Van den Eynde F, 2010, BIOL PSYCHIAT, V67, P793, DOI 10.1016/j.biopsych.2009.11.023; Wagner DD, 2012, J COGNITIVE NEUROSCI, V24, P1625, DOI 10.1162/jocn_a_00238; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weber EU, 2007, PSYCHOL SCI, V18, P516, DOI 10.1111/j.1467-9280.2007.01932.x; WEINGARTEN HP, 1990, APPETITE, V15, P231, DOI 10.1016/0195-6663(90)90023-2; Wierenga CE, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00410; Wu MD, 2016, NEUROSCI BIOBEHAV R, V61, P177, DOI 10.1016/j.neubiorev.2015.11.017	67	46	49	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2017	12	1							e0167606	10.1371/journal.pone.0167606	http://dx.doi.org/10.1371/journal.pone.0167606			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7FK	28121991	Green Submitted, gold, Green Published			2023-01-03	WOS:000396167300081
J	Chen, YX; Liu, B; Glass, K; Du, W; Banks, E; Kirk, M				Chen, Yingxi; Liu, Bette; Glass, Kathryn; Du, Wei; Banks, Emily; Kirk, Martyn			Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis	PLOS ONE			English	Article							ACID-SUPPRESSING DRUGS; THERAPY; COHORT	Introduction To quantify the association between PPI use, type and dose and infectious gastroenteritis hospitalization in a population-based cohort of middle-aged and older adults. Methods Prospective study of 38,019 concession card holders followed up over 6 years in the Sax Institute's 45 and Up Study. Data from the baseline questionnaire were linked to prescription medication, hospitalization, notifiable disease, cancer registry and death datasets from 2006-2012. Associations between PPI use and gastroenteritis hospitalization were examined using Cox regressions with age as the underlying time variable. Results Among 38,019 participants, the median age was 69.7 years, and 57.3% were women. Compared to non-users, current PPI users were more likely to be older, and have a higher BMI. During follow-up there were 1,982 incident gastroenteritis hospitalizations (crude rate: 12.9 per 1000 person-years, 95% CI: 12.3-13.5). PPI use was significantly associated with infectious gastroenteritis hospitalization (aHR 1.4, 95% CI: 1.2-1.5). Among current users, a dose-response relationship was observed between the average daily dose (DDD) dispensed per day and infectious gastroenteritis hospitalization (P trend<0.001). We also observed higher rates of infectious gastroenteritis hospitalization and greater PPI use among participants with a history of chronic bowel problems (aHR 2.2, 95% CI: 1.9-2.5). There was no difference in risk by type of PPI. Recent use of H2 receptors was not associated with gastroenteritis hospitalization. Conclusion PPI use is associated with an increased risk of infectious gastroenteritis hospitalization. Clinicians should be aware of this risk when considering PPI therapy.	[Chen, Yingxi; Glass, Kathryn; Du, Wei; Banks, Emily; Kirk, Martyn] Australian Natl Univ, Canberra, ACT, Australia; [Liu, Bette] Univ New South Wales, Sydney, NSW, Australia; [Banks, Emily] Sax Inst, Sydney, NSW, Australia	Australian National University; University of New South Wales Sydney; University of Sydney	Kirk, M (corresponding author), Australian Natl Univ, Canberra, ACT, Australia.	martyn.kirk@anu.edu.au	Du, Wei/H-5376-2012; Chen, Yingxi/ABF-2593-2020	Du, Wei/0000-0003-3622-2265; Chen, Yingxi/0000-0002-3565-1052; Banks, Emily/0000-0002-4617-1302; Kirk, Martyn/0000-0001-5432-5984; Glass, Kathryn/0000-0001-5905-1310	Australian Government Department of Education and Training [3929_2014]; Australian National Health & Medical Research Council Career Development Fellowship	Australian Government Department of Education and Training(Australian GovernmentDepartment of Industry, Innovation and Science); Australian National Health & Medical Research Council Career Development Fellowship	YC received the 2014 Prime Minister's Australia Asia Postgraduate Scholarship from the Australian Government Department of Education and Training (3929_2014). BL is funded by an Australian National Health & Medical Research Council Career Development Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, ATC DDD IND; [Anonymous], 2015, PROTON PUMP INHIBITO; Atkinson JAM, 2015, PUBLIC HEALTH RES PR, V25, DOI 10.17061/phrp2531531; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; Chen Y, FOODBORNE P IN PRESS; Compare D, 2011, EUR J CLIN INVEST, V41, P380, DOI 10.1111/j.1365-2362.2010.02419.x; Cunningham R, 2003, J HOSP INFECT, V54, P243, DOI 10.1016/S0195-6701(03)00088-4; Dial MS, 2009, AM J GASTROENTEROL, V104, pS10, DOI 10.1038/ajg.2009.46; Duckett SJ, 2004, HEALTH CARE FINANC R, V25, P55; Filion KB, 2014, GUT, V63, P552, DOI 10.1136/gutjnl-2013-304738; Forgacs I, 2008, BMJ-BRIT MED J, V336, P2, DOI 10.1136/bmj.39406.449456.BE; Rodriguez LAG, 2007, CLIN GASTROENTEROL H, V5, P1418, DOI 10.1016/j.cgh.2007.09.010; Garnett WR, 1998, AM J HEALTH-SYST PH, V55, P2268, DOI 10.1093/ajhp/55.21.2268; Hassing RJ, 2016, EUR J EPIDEMIOL, V31, P1057, DOI 10.1007/s10654-016-0136-8; Hollingworth S, 2010, PHARMACOEPIDEM DR S, V19, P1019, DOI 10.1002/pds.1969; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; Howell MD, 2010, ARCH INTERN MED, V170, P784, DOI 10.1001/archinternmed.2010.89; Hungin APS, 2012, CLIN GASTROENTEROL H, V10, P109, DOI 10.1016/j.cgh.2011.07.008; Jackson MA, GUT; Jacobson BC, 2003, AM J GASTROENTEROL, V98, P51, DOI 10.1111/j.1572-0241.2003.07186.x; Kwok CS, 2012, AM J GASTROENTEROL, V107, P1011, DOI 10.1038/ajg.2012.108; Lazarus B, 2016, JAMA INTERN MED, V176, P238, DOI 10.1001/jamainternmed.2015.7193; Lombardo L, 2010, CLIN GASTROENTEROL H, V8, P504, DOI 10.1016/j.cgh.2009.12.022; Martinsen TC, 2005, BASIC CLIN PHARMACOL, V96, P94, DOI 10.1111/j.1742-7843.2005.pto960202.x; Mealing NM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-26; National Centre for Classification in Health, 2006, INT STAT CLASS DIS H; [Organization WH. World Health Organization Collaborating Centre for Drug Statistics Methodology], 2005, ATC IND DDDS; Renom-Guiteras A, 2015, EUR J CLIN PHARMACOL, P1; RYDER SD, 1994, BRIT MED J, V308, P827, DOI 10.1136/bmj.308.6932.827; Schoenfeld AJ, 2016, JAMA INTERN MED, V176, P172, DOI 10.1001/jamainternmed.2015.7927; SHARMA BK, 1984, GUT, V25, P957, DOI 10.1136/gut.25.9.957; Shin JM, 2013, J NEUROGASTROENTEROL, V19, P25, DOI 10.5056/jnm.2013.19.1.25; Simren M, 2013, GUT, V62, P159, DOI 10.1136/gutjnl-2012-302167; Vesper BJ, 2009, CURR DRUG METAB, V10, P84, DOI 10.2174/138920009787048392; Williams C, 2006, ALIMENT PHARM THER, V23, P3, DOI 10.1111/j.1365-2036.2006.02707.x; Wolfe MM, 2000, GASTROENTEROLOGY, V118, pS9, DOI 10.1016/S0016-5085(00)70004-7; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947	37	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2016	11	12							e0168618	10.1371/journal.pone.0168618	http://dx.doi.org/10.1371/journal.pone.0168618			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QF	27997598	Green Submitted, Green Published, gold			2023-01-03	WOS:000392842900064
J	Baljin, B; Baldan, G; Chimeddorj, B; Tulgaa, K; Gunchin, B; Sandag, T; Pfeffer, K; MacKenzie, CR; Wendel, AF				Baljin, Bayaraa; Baldan, Ganbaatar; Chimeddorj, Battogtokh; Tulgaa, Khosbayar; Gunchin, Batbaatar; Sandag, Tsogtsaikhan; Pfeffer, Klaus; MacKenzie, Colin R.; Wendel, Andreas F.			Faecal Carriage of Gram-Negative Multidrug-Resistant Bacteria among Patients Hospitalized in Two Centres in Ulaanbaatar, Mongolia	PLOS ONE			English	Article							SPECTRUM BETA-LACTAMASES; SEQUENCE TYPING SCHEME; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; HIGH PREVALENCE; MULTIPLEX PCR; RISK-FACTORS; CTX-M; GENES; COMMUNITY	Gram-negative multidrug-resistant organisms (GN-MDRO) producing beta-lactamases (ESBL, plasmid-mediated AmpC beta-lactamases and carbapenemases) are increasingly reported throughout Asia. The aim of this surveillance study was to determine the rate of bacterial colonization in patients from two hospitals in the Mongolian capital Ulaanbaatar. Rectal swabs were obtained from patients referred to the National Traumatology and Orthopaedics Research Centre (NTORC) or the Burn Treatment Centre (BTC) between July and September 2014, on admission and again after 14 days. Bacteria growing on selective chromogenic media (CHROMagar ESBL/KPC) were identified by MALDI-ToF MS. We performed susceptibility testing by disk diffusion and PCR (bla(IMP-1), bla(VIM), bla(GES), bla(NDM), bla(KPC), bla(OXA-48), bla(GIM-1), bla(OXA-23), bla(OXA-24/40), bla(OXA-51), bla(OXA-58), bla(OXA-143), bla(OXA-235), bla(CTX-M), bla(SHV) bla(TEM) and plasmid-mediated bla(AmpC)). Carbapenemase-producing isolates were additionally genotyped by PFGE and MLST. During the study period 985 patients in the NTORC and 65 patients in the BTC were screened on admission. The prevalence of GN-MDRO-carriage was 42.4% and 69.2% respectively (p< 0.001). Due to the different medical specialities the two study populations differed significantly in age (p< 0.029) and gender (p< 0.001) with younger and more female patients in the burn centre (BTC). We did not observe a significant difference in colonization rate in the respective age groups in the total study population. In both centres most carriers were colonized with CTX-M-producing E. coli, followed by CTX-M-producing K. pneumoniae and CTX-M-producing E. cloacae. 158 patients from the NTORC were re-screened after 14 days of whom 99 had acquired a new GN-MDRO (p< 0.001). Carbapenemases were detected in both centres in four OXA-58-producing A. baumannii isolates (ST642) and six VIM-2-producing P. aeruginosa isolates (ST235). This study shows a high overall prevalence of GN-MDRO in the study population and highlights the importance of routine surveillance, appropriate infection control practice and antibiotic prescribing policies to prevent further spread especially of carbapenemases.	[Baljin, Bayaraa; Baldan, Ganbaatar; Chimeddorj, Battogtokh; Gunchin, Batbaatar; Sandag, Tsogtsaikhan] Mongolian Natl Univ Med Sci, Sch Biomed, Dept Microbiol & Immunol, Ulaanbaatar, Mongolia; [Tulgaa, Khosbayar] Mongolian Natl Univ Med Sci, Sch Biomed, Dept Mol Biol & Genet, Ulaanbaatar, Mongolia; [Pfeffer, Klaus; MacKenzie, Colin R.; Wendel, Andreas F.] Heinrich Heine Univ, Univ Hosp, Inst Med Microbiol & Hosp Hyg, Dusseldorf, Germany	Mongolian National University of Medical Sciences; Mongolian National University of Medical Sciences; Heinrich Heine University Dusseldorf	Wendel, AF (corresponding author), Heinrich Heine Univ, Univ Hosp, Inst Med Microbiol & Hosp Hyg, Dusseldorf, Germany.	Andreas.Wendel@med.uni-duesseldorf.de	MacKenzie, Colin R/E-9368-2011; San, Tsogt/AAX-6434-2020	MacKenzie, Colin R/0000-0001-7732-2698; San, Tsogt/0000-0003-4916-5108; Tulgaa, Khosbayar/0000-0001-6288-9624; Batbaatar, Gunchin/0000-0002-6678-7569; Baljin, Bayaraa/0000-0002-2750-0588	Medical Faculty of the Heinrich-Heine-University, Dusseldorf, Germany; ESCMID Study Group on Genomic and Molecular Diagnostics (ESGMD), Basel, Switzerland; DAAD-PAGEL program [54448058]	Medical Faculty of the Heinrich-Heine-University, Dusseldorf, Germany; ESCMID Study Group on Genomic and Molecular Diagnostics (ESGMD), Basel, Switzerland; DAAD-PAGEL program	This work was supported by the Medical Faculty of the Heinrich-Heine-University, Dusseldorf, Germany, in collaboration with the ESCMID Study Group on Genomic and Molecular Diagnostics (ESGMD), Basel, Switzerland. and by the DAAD-PAGEL program (54448058).	Azzopardi EA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095042; Bartual SG, 2005, J CLIN MICROBIOL, V43, P4382, DOI 10.1128/JCM.43.9.4382-4390.2005; Bataar O, 2010, B WORLD HEALTH ORGAN, V88, P839, DOI 10.2471/BLT.10.077073; Castanheira M, 2004, ANTIMICROB AGENTS CH, V48, P4654, DOI 10.1128/AAC.48.12.4654-4661.2004; Curran B, 2004, J CLIN MICROBIOL, V42, P5644, DOI 10.1128/JCM.42.12.5644-5649.2004; Dallenne C, 2010, J ANTIMICROB CHEMOTH, V65, P490, DOI 10.1093/jac/dkp498; Edelstein MV, 2013, LANCET INFECT DIS, V13, P867, DOI 10.1016/S1473-3099(13)70168-3; EUCAST, EUCAST GUID DET RES; Evans BA, 2008, CLIN MICROBIOL INFEC, V14, P268, DOI 10.1111/j.1469-0691.2007.01919.x; Higgins PG, 2013, ANTIMICROB AGENTS CH, V57, P2121, DOI 10.1128/AAC.02413-12; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Ider BE, 2010, J HOSP INFECT, V75, P209, DOI 10.1016/j.jhin.2010.02.022; Kao CY, 2016, J MICROBIOL IMMUNOL, V49, P692, DOI 10.1016/j.jmii.2015.05.009; Kao CY, 2014, INFECT GENET EVOL, V28, P313, DOI 10.1016/j.meegid.2014.10.024; Kao CY, 2014, INFECT GENET EVOL, V25, P66, DOI 10.1016/j.meegid.2014.04.012; Khandarmaa TO, 2012, BURNS, V38, P751, DOI 10.1016/j.burns.2011.11.006; Khorsandi M, 2015, ANN ROY COLL SURG, V97, P298, DOI 10.1308/003588415X14181254789169; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; Molton JS, 2013, CLIN INFECT DIS, V56, P1310, DOI 10.1093/cid/cit020; Nakajima Rie, 2010, South Med Rev, V3, P19; Partridge SR, 2011, FEMS MICROBIOL REV, V35, P820, DOI 10.1111/j.1574-6976.2011.00277.x; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perez-Perez FJ, 2002, J CLIN MICROBIOL, V40, P2153, DOI 10.1128/JCM.40.6.2153-2162.2002; Schlesinger J, 2005, ANTIMICROB AGENTS CH, V49, P1150, DOI 10.1128/AAC.49.3.1150-1156.2005; Sun Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113121; Swayne RL, 2011, INT J ANTIMICROB AG, V38, P35, DOI 10.1016/j.ijantimicag.2011.03.010; Takehara K, 2016, MATERN CHILD HLTH J, V20, P1072, DOI 10.1007/s10995-015-1893-9; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Togoobaatar G, 2010, B WORLD HEALTH ORGAN, V88, P930, DOI 10.2471/BLT.10.079004; Valenza G, 2014, ANTIMICROB AGENTS CH, V58, P1228, DOI 10.1128/AAC.01993-13; Wendel AF, 2013, ANTIMICROB AGENTS CH, V57, P5162, DOI 10.1128/AAC.00118-13; Woerther PL, 2013, CLIN MICROBIOL REV, V26, P744, DOI 10.1128/CMR.00023-13; Woodford N, 2006, INT J ANTIMICROB AG, V27, P351, DOI 10.1016/j.ijantimicag.2006.01.004; World Health Organization, 2014, ANTIMICROBIAL RESIST; Zhang HN, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00239; Zhang J, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0659-0	36	8	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0168146	10.1371/journal.pone.0168146	http://dx.doi.org/10.1371/journal.pone.0168146			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27942042	Green Published, gold, Green Submitted			2023-01-03	WOS:000392745600056
J	Ho, GJ; Liew, SM; Ng, CJ; Shunmugam, RH; Glasziou, P				Ho, Gah Juan; Liew, Su May; Ng, Chirk Jenn; Shunmugam, Ranita Hisham; Glasziou, Paul			Development of a Search Strategy for an Evidence Based Retrieval Service	PLOS ONE			English	Article							BIBLIOGRAPHIC DATABASES; INFORMATION; QUALITY	Background Physicians are often encouraged to locate answers for their clinical queries via an evidence-based literature search approach. The methods used are often not clearly specified. Inappropriate search strategies, time constraint and contradictory information complicate evidence retrieval. Aims Our study aimed to develop a search strategy to answer clinical queries among physicians in a primary care setting Methods Six clinical questions of different medical conditions seen in primary care were formulated. A series of experimental searches to answer each question was conducted on 3 commonly advocated medical databases. We compared search results from a PICO (patients, intervention, comparison, outcome) framework for questions using different combinations of PICO elements. We also compared outcomes from doing searches using text words, Medical Subject Headings (MeSH), or a combination of both. All searches were documented using screenshots and saved search strategies. Results Answers to all 6 questions using the PICO framework were found. A higher number of systematic reviews were obtained using a 2 PICO element search compared to a 4 element search. A more optimal choice of search is a combination of both text words and MeSH terms. Despite searching using the Systematic Review filter, many non-systematic reviews or narrative reviews were found in PubMed. There was poor overlap between outcomes of searches using different databases. The duration of search and screening for the 6 questions ranged from 1 to 4 hours. Conclusion This strategy has been shown to be feasible and can provide evidence to doctors' clinical questions. It has the potential to be incorporated into an interventional study to determine the impact of an online evidence retrieval system.	[Ho, Gah Juan; Liew, Su May; Ng, Chirk Jenn; Shunmugam, Ranita Hisham] Univ Malaya, Dept Primary Care Med, Fac Med, Kuala Lumpur, Malaysia; [Glasziou, Paul] Bond Univ, Fac Hlth Sci & Med, Southport, Qld 4229, Australia	Universiti Malaya; Bond University	Liew, SM (corresponding author), Univ Malaya, Dept Primary Care Med, Fac Med, Kuala Lumpur, Malaysia.	su_mayliew@um.edu.my	Glasziou, Paul/A-7832-2008; Hisham Shunmugam, Ranita/F-5073-2011; LIEW, Su May/B-8852-2010; NG, CHIRK JENN/C-1344-2010	Glasziou, Paul/0000-0001-7564-073X; Hisham Shunmugam, Ranita/0000-0002-3356-2291; LIEW, Su May/0000-0003-2865-7955; Ng, Chirk Jenn/0000-0002-8320-1603	University of Malaya Research Grant (UMRG) [RP037A-15HTM]	University of Malaya Research Grant (UMRG)	This work was supported by the University of Malaya Research Grant (UMRG) under the Grant Number RP037A-15HTM, which was received by SML. The funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agoritsas T, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0125-9; Agoritsas T, 2012, J MED INTERNET RES, V14, P389, DOI 10.2196/jmir.2021; Alper BS, 2001, J FAM PRACTICE, V50, P960; Bastian H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000326; Booth A, 2006, HEALTH INFO LIBR J, V23, P229, DOI 10.1111/j.1471-1842.2006.00663.x; Brettle AJ, 2001, B MED LIBR ASSOC, V89, P353; Cheng GYT, 2004, J MED LIBR ASSOC, V92, P445; Clark E, 2006, INT J QUAL HEALTH C, V18, P165, DOI 10.1093/intqhc/mzl007; Del Mar CB, 2001, MED J AUSTRALIA, V175, P134, DOI 10.5694/j.1326-5377.2001.tb143060.x; Gehanno JF, 1998, OCCUP ENVIRON MED, V55, P562, DOI 10.1136/oem.55.8.562; Glasziou P, 2008, EVIDENCE BASED PRACT, P24; Grandage KK, 2002, J MED LIBR ASSOC, V90, P298; Greenhalgh T, 2002, BRIT MED J, V324, P524, DOI 10.1136/bmj.324.7336.524; Huang Xiaoli, 2006, AMIA Annu Symp Proc, P359; Jankowski TA, 2008, MED LIB ASS ESSENTIA, P131; Lefebvre C, 2011, COCHRANE COLLABORATI; McGowan J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003785; Montori VM, 2002, EVID BASED MED, V7, P104; Perrier L, 2014, J AM MED INFORM ASSN, V21, P1118, DOI 10.1136/amiajnl-2014-002825; Prorok JC, 2012, J CLIN EPIDEMIOL, V65, P1289, DOI 10.1016/j.jclinepi.2012.05.003; Royle PL, 2005, DIABETIC MED, V22, P1386, DOI 10.1111/j.1464-5491.2005.01645.x; Sampson M, 2009, J CLIN EPIDEMIOL, V62, P944, DOI 10.1016/j.jclinepi.2008.10.012; Sanders S, 2005, BRIT MED J, V330, P1162, DOI 10.1136/bmj.330.7501.1162; Savoie I, 2003, INT J TECHNOL ASSESS, V19, P168, DOI 10.1017/S0266462303000163; Schwartz K, 2003, FAM MED, V35, P251; Slawson DC, 1997, BRIT MED J, V314, P947, DOI 10.1136/bmj.314.7085.947; Straus S., 2005, EVIDENCE BASED MED P; Straus S.E., 2004, BMJ-BRIT MED J, V329, P1029, DOI DOI 10.1136/BMJ.329.7473; Tsafnat G, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-74; Walton J, PRIORY MED J; Wilczynski NL, 2013, J AM MED INFORM ASSN, V20, P363, DOI 10.1136/amiajnl-2012-001075	31	18	19	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0167170	10.1371/journal.pone.0167170	http://dx.doi.org/10.1371/journal.pone.0167170			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE4PU	27935993	Green Published, gold, Green Submitted			2023-01-03	WOS:000389587100069
J	Tokuno, M; Taguchi, K; Yamasaki, K; Sakai, H; Otagiri, M				Tokuno, Masahiro; Taguchi, Kazuaki; Yamasaki, Keishi; Sakai, Hiromi; Otagiri, Masaki			Long-Term Stored Hemoglobin-Vesicles, a Cellular Type of Hemoglobin-Based Oxygen Carrier, Has Resuscitative Effects Comparable to That for Fresh Red Blood Cells in a Rat Model with Massive Hemorrhage without Post-Transfusion Lung Injury	PLOS ONE			English	Article							ANESTHETIZED RATS; TRAUMA-HEMORRHAGE; HEAT-TREATMENT; TRANSFUSION; SHOCK; PRESERVATION; INFUSION; STORAGE; FLUID; MICE	Hemoglobin-vesicles (HbV), encapsulating highly concentrated human hemoglobin in liposomes, were developed as a substitute for red blood cells (RBC) and their safety and efficacy in transfusion therapy has been confirmed in previous studies. Although HbV suspensions are structurally and physicochemically stabile for least 1-year at room temperature, based on in vitro experiments, the issue of whether the use of long-term stored HbV after a massive hemorrhage can be effective in resuscitations without adverse, post-transfusion effects remains to be clarified. We report herein on a comparison of the systemic response and the induction of organ injuries in hemorrhagic shock model rats resuscitated using 1-year-stored HbV, freshly packed RBC (PRBC-0) and by 28-day-stored packed RBC (PRBC-28). The six-hour mortality after resuscitation was not significantly different among the groups. Arterial blood pressure and blood gas parameters revealed that, using HbV, recovery from the shock state was comparable to that when PRBC-0 was used. Although no significant change was observed in serum parameters reflecting liver and kidney injuries at 6 hours after resuscitation among the three resuscitation groups, results based on Evans Blue and protein leakage in bronchoalveolar lavage fluid, the lung wet/dry weight ratio and histopathological findings indicated that HbV as well as PRBC-0 was less predisposed to result in a post-transfusion lung injury than PRBC-28, as evidenced by low levels of myeloperoxidase accumulation and subsequent oxidative damage in the lung. The findings reported herein indicate that 1-year-stored HbV can effectively function as a resuscitative fluid without the induction of post-transfused lung injury and that it is comparable to fresh PRBC, suggesting that HbV is a promising RBC substitute with a long shelf-life.	[Tokuno, Masahiro; Taguchi, Kazuaki; Yamasaki, Keishi; Otagiri, Masaki] Sojo Univ, Fac Pharmaceut Sci, Kumamoto, Japan; [Yamasaki, Keishi; Otagiri, Masaki] Sojo Univ, DDS Res Inst, Kumamoto, Japan; [Sakai, Hiromi] Nara Med Univ, Dept Chem, Nara, Japan	Sojo University; Sojo University; Nara Medical University	Otagiri, M (corresponding author), Sojo Univ, Fac Pharmaceut Sci, Kumamoto, Japan.; Otagiri, M (corresponding author), Sojo Univ, DDS Res Inst, Kumamoto, Japan.	otagirim@ph.sojo-u.ac.jp	Sakai, Hiromi/J-2529-2019	Sakai, Hiromi/0000-0002-0681-3032; Yamasaki, Keishi/0000-0003-0537-2367	Ministry of Health, Labor and Welfare of Japan [H24-SOUYAKUSOUGOU-IPPAN-009]; Japan Society for the Promotion of Science (JSPS) (KAKENHI) [26860121]; Grants-in-Aid for Scientific Research [26860121] Funding Source: KAKEN	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Society for the Promotion of Science (JSPS) (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported, in part, by Health Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan (H24-SOUYAKUSOUGOU-IPPAN-009 to HS and MO) and by a Grant-in-Aid for Young Scientist (B) from the Japan Society for the Promotion of Science (JSPS) (KAKENHI 26860121 to KT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe H, 2001, ARTIF CELL BLOOD SUB, V29, P381, DOI 10.1081/BIO-100106921; Allan PF, 2011, MIL MED, V176, P332, DOI 10.7205/MILMED-D-10-00272; Araki J, 2015, TRANSPLANTATION, V99, P687, DOI 10.1097/TP.0000000000000528; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Flegel WA, 2014, BRIT J HAEMATOL, V165, P3, DOI 10.1111/bjh.12747; Fujihara M, 2014, ARTIF ORGANS, V38, P234, DOI 10.1111/aor.12148; Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857; Li H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15271; Maeshima K, 2005, BIOCHEM PHARMACOL, V69, P1667, DOI 10.1016/j.bcp.2005.03.007; Ministry of Health LaW Japan, P BLOOD DON PROM COM; Murakami K, 2002, SHOCK, V18, P236, DOI 10.1097/00024382-200209000-00006; Nagao S, 2016, J CONTROL RELEASE, V234, P49, DOI 10.1016/j.jconrel.2016.05.016; Nagao S, 2014, BIOMATERIALS, V35, P6553, DOI 10.1016/j.biomaterials.2014.04.049; Nicholson SE, 2011, J TRAUMA, V70, P466, DOI 10.1097/TA.0b013e3182032584; Obrador R, 2015, J VET EMERG CRIT CAR, V25, P187, DOI 10.1111/vec.12252; Ogaki S, 2014, J PHARM SCI-US, V103, P2199, DOI 10.1002/jps.24029; SAKAI H, 1993, PROTEIN EXPRES PURIF, V4, P563, DOI 10.1006/prep.1993.1074; Sakai H, 1997, BIOCONJUGATE CHEM, V8, P23, DOI 10.1021/bc960069p; Sakai H, 2000, BIOCONJUGATE CHEM, V11, P425, DOI 10.1021/bc990173h; Sakai H, 2004, BIOMATERIALS, V25, P4317, DOI 10.1016/j.biomaterials.2003.11.005; Sakai H, 2004, CRIT CARE MED, V32, P539, DOI 10.1097/01.CCM.0000109774.99665.22; Sakai H, 2001, AM J PATHOL, V159, P1079, DOI 10.1016/S0002-9440(10)61783-X; Sakai H, 2007, ARTIF CELL BLOOD SUB, V35, P81, DOI 10.1080/10731190600974582; Sakai H, 2009, SHOCK, V31, P192, DOI 10.1097/SHK.0b013e31817d4066; Sakai H, 2009, ARTIF ORGANS, V33, P139, DOI 10.1111/j.1525-1594.2008.00698.x; Seishi Y, 2012, SHOCK, V38, P153, DOI 10.1097/SHK.0b013e31825ad7cf; Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135; Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x; Silliman CC, 2009, BLOOD REV, V23, P245, DOI 10.1016/j.blre.2009.07.005; Sparrow RL, 2015, TRANSFUS MED REV, V29, P120, DOI 10.1016/j.tmrv.2014.09.007; Stapley R, 2015, FREE RADICAL BIO MED, V85, P207, DOI 10.1016/j.freeradbiomed.2015.04.025; Taguchi K, 2015, BIOL PHARM BULL, V38, P1606, DOI 10.1248/bpb.b15-00420; Taguchi K, 2010, TOXICOL APPL PHARM, V248, P234, DOI 10.1016/j.taap.2010.08.006; Taguchi K, 2009, DRUG METAB DISPOS, V37, P1456, DOI 10.1124/dmd.109.027094	34	21	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2016	11	10							e0165557	10.1371/journal.pone.0165557	http://dx.doi.org/10.1371/journal.pone.0165557			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA6BX	27798697	Green Published, gold, Green Submitted			2023-01-03	WOS:000386711100044
J	van der Vorst, A; Zijlstra, GAR; De Witte, N; Duppen, D; Stuck, AE; Kempen, GIJM; Schols, JMGA				van der Vorst, Anne; Zijlstra, G. A. Rixt; De Witte, Nico; Duppen, Daan; Stuck, Andreas E.; Kempen, Gertrudis I. J. M.; Schols, Jos M. G. A.		D-SCOPE Consortium	Limitations in Activities of Daily Living in Community-Dwelling People Aged 75 and Over: A Systematic Literature Review of Risk and Protective Factors	PLOS ONE			English	Review							FUNCTIONAL DECLINE; PHYSICAL-ACTIVITY; ELDERLY-PEOPLE; ADL DISABILITY; OLDER-ADULTS; HEALTH; ONSET; PERFORMANCE; PREDICTORS; PROGNOSIS	Background Most older people wish to age in place, for which functional status or being able to perform activities of daily living (ADLs) is an important precondition. However, along with the substantial growth of the (oldest) old, the number of people who develop limitations in ADLs or have functional decline dramatically increases in this part of the population. Therefore, it is important to gain insight into factors that can contribute to developing intervention strategies at older ages. As a first step, this systematic review was conducted to identify risk and protective factors as predictors for developing limitations in ADLs in community-dwelling people aged 75 and over. Methods Four electronic databases (CINAHL (EBSCO), EMBASE, PsycINFO and PubMed) were searched systematically for potentially relevant studies published between January 1998 and March 2016. Results After a careful selection process, 6,910 studies were identified and 25 were included. By far most factors were examined in one study only, and most were considered risk factors. Several factors do not seem to be able to predict the development of limitations in ADLs in people aged 75 years and over, and for some factors ambiguous associations were found. The following risk factors were found in at least two studies: higher age, female gender, diabetes, hypertension, and stroke. A high level of physical activity and being married were protective in multiple studies. Notwithstanding the fact that research in people aged 65 years and over is more extensive, risk and protective factors seem to differ between the 'younger' and 'older' olds. Conclusion Only a few risk and protective factors in community-dwelling people aged 75 years and over have been analysed in multiple studies. However, the identified factors could serve both detection and prevention purposes, and implications for future research are given as well.	[van der Vorst, Anne; Zijlstra, G. A. Rixt; Kempen, Gertrudis I. J. M.; Schols, Jos M. G. A.] Maastricht Univ, Dept Hlth Serv Res, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [De Witte, Nico; Duppen, Daan] Vrije Univ Brussel, Fac Psychol & Educ Sci, Brussels, Belgium; [De Witte, Nico] Univ Coll Ghent, Fac Educ Hlth & Social Work, Ghent, Belgium; [Stuck, Andreas E.] Univ Bern, Univ Hosp, Dept Geriatr, Bern, Switzerland; [Schols, Jos M. G. A.] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Family Med, Maastricht, Netherlands	Maastricht University; Vrije Universiteit Brussel; HOGENT University College of Applied Sciences & Arts; University of Bern; University Hospital of Bern; Maastricht University	van der Vorst, A (corresponding author), Maastricht Univ, Dept Hlth Serv Res, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands.	a.vandervorst@maastrichtuniversity.nl	Duppen, Daan/GVT-9546-2022; Kempen, Gertrudis I/H-5978-2016; Kempen, Gertrudis/Y-8796-2019; Schoenmakers, Birgitte/AAL-2426-2021	Kempen, Gertrudis I/0000-0002-7053-2198; Kempen, Gertrudis/0000-0002-7053-2198; Schoenmakers, Birgitte/0000-0003-1909-9613; Duppen, Daan/0000-0002-5481-0231; De Witte, Nico/0000-0001-8957-6425; Zijlstra, Rixt/0000-0001-7377-5745; van der Vorst, Anne/0000-0002-8235-6662	Flemish government Agency for Innovation by Science and Technology [IWT-140027-SBO]	Flemish government Agency for Innovation by Science and Technology	This work is part of the D-SCOPE project, which is supported by the Flemish government Agency for Innovation by Science and Technology, and is embedded in the Strategic Basic Research (IWT-140027-SBO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Diaz-Ramos JA, 2012, J AM GERIATR SOC, V60, P384, DOI 10.1111/j.1532-5415.2011.03805.x; Avlund K, 2004, J GERONTOL B-PSYCHOL, V59, pS44, DOI 10.1093/geronb/59.1.S44; Avlund K, 2002, J CLIN EPIDEMIOL, V55, P965, DOI 10.1016/S0895-4356(02)00463-8; Beswick AD, 2008, LANCET, V371, P725, DOI 10.1016/S0140-6736(08)60342-6; Black SA, 2002, J AM GERIATR SOC, V50, P1978, DOI 10.1046/j.1532-5415.2002.50609.x; Centers for Disease Control and Prevention, 2014, EARL REL SEL EST BAS; Corona LP, 2013, J AGING HEALTH, V25, P119, DOI 10.1177/0898264312466261; De Witte N, 2012, TOGETHER SIDEWALKS S; Donald IP, 1999, AGE AGEING, V28, P121, DOI 10.1093/ageing/28.2.121; Due P., 1993, LIFE SITUATION OLD W; European Comission, 2014, 2015 AG REP; European Council, 2010, 30 19 EMPL SOC POL H; Freedman VA, 2008, SOC SCI MED, V66, P1588, DOI 10.1016/j.socscimed.2007.11.037; Fukutomi E, 2013, GERIATR GERONTOL INT, V13, P654, DOI 10.1111/j.1447-0594.2012.00959.x; GAGNON M, 1994, NEUROEPIDEMIOLOGY, V13, P145, DOI 10.1159/000110373; Gu D., 2004, DEMOGR RES, V11, P1, DOI [10.4054/DemRes.2004.11.1, DOI 10.4054/DEMRES.2004.11.1]; Guilley E, 2008, RES AGING, V30, P299, DOI 10.1177/0164027507312115; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Houston DK, 2011, J AM GERIATR SOC, V59, P1793, DOI 10.1111/j.1532-5415.2011.03601.x; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Idland G, 2013, ARCH GERONTOL GERIAT, V56, P501, DOI 10.1016/j.archger.2012.12.005; Jiang Jingmei, 2002, J Epidemiol, V12, P280; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kempen G. I. J. M., 2006, J GERONTOL B-PSYCHOL, V61, P95, DOI [DOI 10.1093/geronb/61.2.P95, DOI 10.1093/GERONB/61.2.P95]; Kuijpers T, 2004, PAIN, V109, P420, DOI 10.1016/j.pain.2004.02.017; Landi F, 2007, J CLIN EPIDEMIOL, V60, P518, DOI 10.1016/j.jclinepi.2006.09.010; Landi F, 2010, J AM MED DIR ASSOC, V11, P268, DOI 10.1016/j.jamda.2009.12.088; Li LW, 2009, SOC SCI MED, V68, P220, DOI 10.1016/j.socscimed.2008.10.013; Luoh MC, 2002, J HEALTH SOC BEHAV, V43, P490, DOI 10.2307/3090239; MACKENBACH JP, 1994, INT J EPIDEMIOL, V23, P1273, DOI 10.1093/ije/23.6.1273; McLaughlin D, 2012, AGE AGEING, V41, P674, DOI 10.1093/ageing/afs036; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moody-Ayers SY, 2005, J GERONTOL A-BIOL, V60, P933, DOI 10.1093/gerona/60.7.933; National Public Health Partnership, 2006, LANG PREV; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Okumiya K, 1999, J AM GERIATR SOC, V47, P497, DOI 10.1111/j.1532-5415.1999.tb07252.x; Ostchega Y, 2000, J AM GERIATR SOC, V48, P1132, DOI 10.1111/j.1532-5415.2000.tb04791.x; Rantanen Taina, 2002, Aging Clin Exp Res, V14, P10; Sabayan B, 2012, J AM GERIATR SOC, V60, P2014, DOI 10.1111/j.1532-5415.2012.04203.x; Scharlach A, 2012, AGEING INT, V37, P25, DOI 10.1007/s12126-011-9140-1; Shah RC, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-63; Simard M, 1998, CANADIAN ALZHEIMERS, P10; Stessman J, 2014, J GERONTOL A-BIOL, V69, P744, DOI 10.1093/gerona/glt147; Stessman J, 2009, ARCH INTERN MED, V169, P1476, DOI 10.1001/archinternmed.2009.248; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Sun F, 2009, INT J AGING HUM DEV, V69, P181, DOI 10.2190/AG.69.3.b; Tak E, 2013, AGEING RES REV, V12, P329, DOI 10.1016/j.arr.2012.10.001; Vass M, 2002, AGING CLIN EXP RES, V14, P509, DOI 10.1007/BF03327352; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Walker A, 2012, INT J SOC WELF, V21, pS117, DOI 10.1111/j.1468-2397.2012.00871.x; WHO, 2001, ACT AG POL FRAM; WHO, 2016, COMM BEC MOR AG FRIE; World Health Organization, 2001, ICF INT CLASFUNCT	53	61	61	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2016	11	10							e0165127	10.1371/journal.pone.0165127	http://dx.doi.org/10.1371/journal.pone.0165127			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DZ9NW	27760234	Green Published, gold			2023-01-03	WOS:000386204000086
J	Denkert, C; Liedtke, C; Tutt, A; von Minckwitz, G				Denkert, Carsten; Liedtke, Cornelia; Tutt, Andrew; von Minckwitz, Gunter			Molecular alterations in triple-negative breast cancer-the road to new treatment strategies	LANCET			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; ADENOID CYSTIC CARCINOMAS; DOSE-DENSE DOXORUBICIN; NEOADJUVANT CHEMOTHERAPY; BASAL-LIKE; PHASE-II; GENE-EXPRESSION; OPEN-LABEL; ADJUVANT BEVACIZUMAB; SYNTHETIC LETHALITY	Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-negative breast cancer have been identified on the basis of protein expression, mRNA signatures, and genomic alterations. Important elements of triple-negative breast cancer biology include high proliferative activity, an increased immunological infiltrate, a basal-like and a mesenchymal phenotype, and deficiency in homologous recombination, which is in part associated with loss of BRCA1 or BRCA2 function. A minority of triple-negative tumours express luminal markers, such as androgen receptors, and have a lower proliferative activity. These biological subgroups are overlapping and currently cannot be combined into a unified model of triple-negative breast cancer biology. Nevertheless, the molecular analysis of this disease has identified potential options for targeted therapeutic intervention. This has led to promising clinical strategies, including modified chemotherapy approaches targeting the DNA damage response, angiogenesis inhibitors, immune checkpoint inhibitors, or even anti-androgens, all of which are being evaluated in phase 1-3 clinical studies. This Series paper focuses on the most relevant clinical questions, summarises the results of recent clinical trials, and gives an overview of ongoing studies and trial concepts that will lead to a more refined therapy for this tumour type.	[Denkert, Carsten] Charite, Inst Pathol, D-10117 Berlin, Germany; [Denkert, Carsten] German Canc Consortium DKTK, Partner Site Berlin, Berlin, Germany; [Liedtke, Cornelia] Univ Hosp Schleswig Holstein, Campus Lubeck, Lubeck, Germany; [Tutt, Andrew] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England; [Tutt, Andrew] Kings Coll London, Breast Canc Now Res Unit, London, England; [von Minckwitz, Gunter] German Breast Grp, Neu Isenburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); University of Kiel; Schleswig Holstein University Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; German Breast Group	Denkert, C (corresponding author), Charite, Inst Pathol, D-10117 Berlin, Germany.	carsten.denkert@charite.de	Denkert, Carsten/AHE-2675-2022	Tutt, Andrew/0000-0001-8715-2901; Denkert, Carsten/0000-0002-2249-0982	TRANSCAN-I grant [BMBF-01KT1314 (TRANSCAN-I UGI1)]; German Cancer Consortium (DKTK); Sividon Diagnostics; AstraZeneca; Tesaro; Myrad Genetics; Nanostring	TRANSCAN-I grant; German Cancer Consortium (DKTK); Sividon Diagnostics; AstraZeneca(AstraZeneca); Tesaro; Myrad Genetics; Nanostring	CD had full access to all data in the study and had final responsibility for the decision to submit for publication. The study is funded partially by TRANSCAN-I, grant BMBF-01KT1314 (TRANSCAN-I UGI1) and a grant from the German Cancer Consortium (DKTK), with a focus on triple-negative breast cancer, both to CD. CD reports other funding from Sividon Diagnostics, personal fees from Celgene, AstraZeneca, Teva, Myriad, and Roche, outside of the submitted work. AT reports other fees from AstraZeneca, Tesaro, Myrad Genetics, and Nanostring during the study; and other fees from Vertex and Celgene outside of the submitted work. In addition, AT has a patent with the Institute of Cancer Research (with paid royalties), and a patent pending with King's College London. GvM reports grants and personal fees from Pfizer, GSK, Sanofi-Aventis, Amgen, Roche, Novartis, Celgene, Teva, AstraZeneca, and Myriad, outside the submitted work. CL declares no competing interests.	Adams S, 2016, 2016 ASCO ANN M CHIC; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Alba E, BREAST CANC RES TREA, V136, P487; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Andre F, 2015, LANCET ONCOL, V16, P600, DOI 10.1016/S1470-2045(15)70201-9; Andre F, 2015, BREAST CANCER RES TR, V150, P1, DOI 10.1007/s10549-015-3301-y; Anestis A, 2015, CANCER TREAT REV, V41, P547, DOI 10.1016/j.ctrv.2015.04.009; [Anonymous], 2015, WHO IARC CLASSIFICAT; Bear HD, 2015, LANCET ONCOL, V16, P1037, DOI 10.1016/S1470-2045(15)00041-8; Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Bonilla L, 2010, JNCI-J NATL CANCER I, V102, P1845, DOI 10.1093/jnci/djq409; Bonnefoi H, 2016, ANN ONCOL, V27, P812, DOI 10.1093/annonc/mdw067; Budczies J, 2015, J PATHOL CLIN RES, V1, P225, DOI 10.1002/cjp2.25; Bulut N, 2008, CANCER CHEMOTH PHARM, V63, P189, DOI 10.1007/s00280-008-0717-7; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Byrski T, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3231; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Colleoni M, 2016, J CLIN ONCOL, V34, P3400, DOI 10.1200/JCO.2015.65.6595; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Curigliano G, 2015, 2015 ASCO ANN M CHIC; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Earl HM, 2015, LANCET ONCOL, V16, P656, DOI 10.1016/S1470-2045(15)70137-3; Emens LA, 2015, 2015 AACR ANN M PHIL; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492; Gucalp A, 2011, 2011 ASCO ANN M CHIC; Gucalp A, 2016, 2016 ASCO ANN M CHIC; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Harrison H, 2010, CANCER RES, V70, P8973, DOI 10.1158/0008-5472.CAN-10-1559; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Hu XC, 2015, LANCET ONCOL, V16, P436, DOI 10.1016/S1470-2045(15)70064-1; Huober J, 2012, ANN ONCOL, V23, P2843, DOI 10.1093/annonc/mds105; Isakoff SJ, 2015, J CLIN ONCOL, V33, P1902, DOI 10.1200/JCO.2014.57.6660; Iwamoto T, 2012, J CLIN ONCOL, V30, P729, DOI 10.1200/JCO.2011.36.2574; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0406-x; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li DL, 2012, MODERN PATHOL, V25, P567, DOI 10.1038/modpathol.2011.190; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Lord CJ, 2015, ANNU REV MED, V66, P455, DOI 10.1146/annurev-med-050913-022545; Marchio C, 2010, J CLIN PATHOL, V63, P220, DOI 10.1136/jcp.2009.073908; Marquard AM, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0033-4; Marra P, 2014, CANCER RES, V74, P4908, DOI 10.1158/0008-5472.CAN-14-0637; Martelotto LG, 2015, J PATHOL, V237, P179, DOI 10.1002/path.4573; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Moebus V, 2010, J CLIN ONCOL, V28, P2874, DOI 10.1200/JCO.2009.24.7643; Montagna E, 2013, CLIN BREAST CANCER, V13, P31, DOI 10.1016/j.clbc.2012.09.002; Nahleh ZA, 2016, BREAST CANCER RES TR, V158, P485, DOI 10.1007/s10549-016-3889-6; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Parker JS, 2015, 2015 ASCO ANN M CHIC; Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246; PEDERSEN L, 1989, BREAST CANCER RES TR, V14, P91, DOI 10.1007/BF01805979; Podetta M, 2009, TUMORI, V95, P264; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Rakha EA, 2009, EUR J CANCER, V45, P1780, DOI 10.1016/j.ejca.2009.02.014; Ring BZ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2198-0; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sharpe R, 2011, CLIN CANCER RES, V17, P5275, DOI 10.1158/1078-0432.CCR-10-2727; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Sikov WM, 2015, 2015 SAN ANT BREAST; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stanton SE, 2016, JAMA ONCOL, V2, P1354, DOI 10.1001/jamaoncol.2016.1061; Stoeck A, 2014, CANCER DISCOV, V4, P1154, DOI 10.1158/2159-8290.CD-13-0830; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Telli ML, 2015, J CLIN ONCOL, V33, P1895, DOI 10.1200/JCO.2014.57.0085; Timms KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0475-x; Toi M, 2015, 2015 SAN ANT BREAST; Traina TA, 2015, 2015 ASCO ANN M CHIC; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Tutt A, 2014, SAN ANTONIO BREAST C, V2014, pS3; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Tutt ANJ, 2015, 2015 ASCO ANN M CHIC; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P248; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; von Minckwitz G, 2014, ANN ONCOL, V25, P2363, DOI 10.1093/annonc/mdu455; von Minckwitz G, 2014, 2014 ASCO ANN M CHIC; Von Minckwitz G, 2015, 2015 SAN ANT BREAST; von Minckwitz G, 2015, 2015 ASCO ANN M CHIC; von Minckwitz G, 2014, LANCET ONCOL, V15, P747, DOI 10.1016/S1470-2045(14)70160-3; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065; Wang CJ, 2016, ONCOTARGET, V7, P46482, DOI 10.18632/oncotarget.10208; Wang K, 2015, CLIN CANCER RES, V21, P1487, DOI 10.1158/1078-0432.CCR-14-1348; Wetterskog D, 2012, J PATHOL, V226, P84, DOI 10.1002/path.2974; Zardavas D, 2014, BRIT J CANCER, V111, P1881, DOI 10.1038/bjc.2014.341	108	432	451	17	177	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2017	389	10087					2430	2442		10.1016/S0140-6736(16)32454-0	http://dx.doi.org/10.1016/S0140-6736(16)32454-0			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX6ED	27939063	Green Submitted			2023-01-03	WOS:000403334400028
J	Wang, XF; Hui, Y; Zhao, L; Hao, YL; Guo, HY; Ren, FZ				Wang, Xifan; Hui, Yan; Zhao, Liang; Hao, Yanling; Guo, Huiyuan; Ren, Fazheng			Oral administration of Lactobacillus paracasei L9 attenuates PM2.5-induced enhancement of airway hyperresponsiveness and allergic airway response in murine model of asthma	PLOS ONE			English	Article							IL-17 FAMILY CYTOKINES; REGULATORY T-CELLS; MOUSE MODEL; TH17 CELLS; POLLUTION; MICE; INFLAMMATION; PROBIOTICS; PARTICLES; METAL	This study investigated allergy immunotherapy potential of Lactobacillus paracasei L9 to prevent or mitigate the particulate matter 2.5 (PM2.5) enhanced pre-existing asthma in mice. Firstly, we used a mouse model of asthma (a 21-day ovalbumin (OVA) sensitization and challenge model) followed by PM2.5 exposure twice on the same day of the last challenge. PM2.5 was collected from the urban area of Beijing and underwent analysis for metals and polycyclic aromatic hydrocarbon contents. The results showed that PM2.5 exposure enhanced airway hyper-responsiveness (AHR) and lead to a mixed Th2/IL-17 response in asthmatic mice. Secondly, the PM2.5 exposed asthmatic mice were orally administered with L9 (4x10(7), 4x10(9) CFU/mouse, day) from the day of first sensitization to the endpoint, for 20 days, to investigate the potential mitigative effect of L9 on asthma. The results showed that L9 ameliorated PM2.5 exposure enhanced AHR with an approximate 50% decrease in total airway resistance response to methacholine (48 mg/ml). L9 also prevented the exacerbated eosinophil and neutrophil infiltration in bronchoalveolar lavage fluid (BALF), and decreased the serum level of total IgE and OVA-specific IgG1 by 0.44-fold and 0.3-fold, respectively. Additionally, cytokine production showed that L9 significantly decreased T-helper cell type 2 (Th2)- related cytokines (IL-4, -5, -13) and elevated levels of Th1 related IFN-gamma in BALF. L9 also reduced the level of IL-17A and increased the level of TGF-beta. Taken together, these results indicate that L9 may exert the anti-allergic benefit, possibly through rebalancing Th1/Th2 immune response and modulating IL-17 pro-inflammatory immune response. Thus, L9 is a promising candidate for preventing PM exposure enhanced pre-existing asthma.	[Wang, Xifan; Hui, Yan; Zhao, Liang; Hao, Yanling; Guo, Huiyuan; Ren, Fazheng] China Agr Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing, Peoples R China; [Wang, Xifan; Hui, Yan; Guo, Huiyuan; Ren, Fazheng] China Agr Univ, Key Lab Funct Dairy, Minist Educ & Beijing Govt, Coll Food Sci & Nutr Engn, Beijing, Peoples R China; [Zhao, Liang; Ren, Fazheng] China Agr Univ, Beijing Higher Inst Engn Res Ctr Anim Prod, Coll Food Sci & Nutr Engn, Beijing, Peoples R China	China Agricultural University; China Agricultural University; China Agricultural University	Ren, FZ (corresponding author), China Agr Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing, Peoples R China.; Ren, FZ (corresponding author), China Agr Univ, Key Lab Funct Dairy, Minist Educ & Beijing Govt, Coll Food Sci & Nutr Engn, Beijing, Peoples R China.; Ren, FZ (corresponding author), China Agr Univ, Beijing Higher Inst Engn Res Ctr Anim Prod, Coll Food Sci & Nutr Engn, Beijing, Peoples R China.	renfazheng@cau.edu.cn	Hui, Yan/X-4011-2019; Hui, Yan/J-8811-2017	Hui, Yan/0000-0002-2388-131X; Hui, Yan/0000-0002-2388-131X; Zhao, Liang/0000-0001-9244-3121	National Natural Science Foundation of China [31401668]; Beijing Municipal Commission of Education Co-constructed program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Commission of Education Co-constructed program	This study was supported by National Natural Science Foundation of China (31401668), and the Beijing Municipal Commission of Education Co-constructed program.	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Aldinucci C, 2002, EUR J CLIN NUTR, V56, P1155, DOI 10.1038/sj.ejcn.1601465; Belkaid Y, 2003, EXPERT OPIN BIOL TH, V3, P875, DOI 10.1517/14712598.3.6.875; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Chen RJ, 2013, AM J RESP CRIT CARE, V188, P1170, DOI 10.1164/rccm.201304-0678LE; Feleszko W, 2007, CLIN EXP ALLERGY, V37, P498, DOI 10.1111/j.1365-2222.2006.02629.x; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Forsythe P, 2011, CHEST, V139, P901, DOI 10.1378/chest.10-1861; Fujiwara D, 2004, INT ARCH ALLERGY IMM, V135, P205, DOI 10.1159/000081305; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P1471, DOI 10.1289/ehp.6300; Gavett SH, 1997, ENVIRON RES, V72, P162, DOI 10.1006/enrs.1997.3732; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Hong HJ, 2010, J CLIN IMMUNOL, V30, P449, DOI 10.1007/s10875-010-9375-8; Hougee S, 2010, INT ARCH ALLERGY IMM, V151, P107, DOI 10.1159/000236000; Huang RJ, 2014, NATURE, V514, P218, DOI 10.1038/nature13774; Jan RL, 2012, BRIT J NUTR, V108, P130, DOI 10.1017/S0007114511005265; Jang SO, 2012, ALLERGY ASTHMA IMMUN, V4, P150, DOI 10.4168/aair.2012.4.3.150; Julia V, 2015, NAT REV IMMUNOL, V15, P308, DOI 10.1038/nri3830; Kim H, 2005, FEMS IMMUNOL MED MIC, V45, P259, DOI 10.1016/j.femsim.2005.05.005; Kim HJ, 2014, CLIN IMMUNOL, V153, P178, DOI 10.1016/j.clim.2014.04.008; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Laake KO, 2005, SCAND J GASTROENTERO, V40, P43, DOI 10.1080/00365520410009339; Laan M, 1999, J IMMUNOL, V162, P2347; Lambert AL, 1999, AM J RESP CRIT CARE, V159, pA26; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Lim LH, 2009, INT ARCH ALLERGY IMM, V148, P297, DOI 10.1159/000170383; Liu YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085323; Luo X, 2015, J MICROBIOL BIOTECHN, V25, P1687, DOI [10.4014/imb.1503.03022, DOI 10.4014/JMB.1503.03022]; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Mazzoli-Rocha F, 2008, ENVIRON RES, V108, P35, DOI 10.1016/j.envres.2008.05.004; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895; Nikasinovic L, 2006, J ALLERGY CLIN IMMUN, V117, P1382, DOI 10.1016/j.jaci.2006.03.023; Ogino K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092710; Olin JT, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5517; Ouyang YD, 2013, LANCET RESP MED, V1, P12, DOI 10.1016/S2213-2600(12)70065-6; Pappu R, 2012, TRENDS IMMUNOL, V33, P343, DOI 10.1016/j.it.2012.02.008; Penton PC, 2013, J ALLERGY CLIN IMMUN, V131, P512, DOI 10.1016/j.jaci.2012.07.039; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Saunders V, 2010, ENVIRON HEALTH PERSP, V118, P640, DOI 10.1289/ehp.0901461; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Shibamori M, 2006, LIFE SCI, V78, P987, DOI 10.1016/j.lfs.2005.06.020; Triggianese P, 2016, CLIN EXP RHEUMATOL, V34, P1085; van Voorhis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082545; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Wagner JG, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-45; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Yao XJ, 2014, CLIN EXP ALLERGY, V44, P765, DOI 10.1111/cea.12298; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	60	42	46	1	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2017	12	2							e0171721	10.1371/journal.pone.0171721	http://dx.doi.org/10.1371/journal.pone.0171721			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BF	28199353	Green Published, Green Submitted, gold			2023-01-03	WOS:000394424400046
J	Nangia, J; Wang, T; Osborne, C; Niravath, P; Otte, K; Papish, S; Holmes, F; Abraham, J; Lacouture, M; Courtright, J; Paxman, R; Rude, M; Hilsenbeck, S; Osborne, CK; Rimawi, M				Nangia, Julie; Wang, Tao; Osborne, Cynthia; Niravath, Polly; Otte, Kristen; Papish, Steven; Holmes, Frankie; Abraham, Jame; Lacouture, Mario; Courtright, Jay; Paxman, Richard; Rude, Mari; Hilsenbeck, Susan; Osborne, C. Kent; Rimawi, Mothaffar			Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer The SCALP Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED HAIR LOSS; BODY-IMAGE; PREVENTION; HYPOTHERMIA	Importance Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized clinical trial. Objectives To assess whether a scalp cooling device is effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects. Design, Setting, and Participants Multicenter randomized clinical trial of women with breast cancer undergoing chemotherapy. Patients were enrolled from December 9, 2013, to September 30, 2016. One interim analysis was planned to allow the study to stop early for efficacy. Data reported are from the interim analysis. This study was conducted at 7 sites in the United States, and 182 women with breast cancer requiring chemotherapy were enrolled and randomized. Interventions Participants were randomized to scalp cooling (n = 119) or control (n = 63). Scalp cooling was done using a scalp cooling device. Main Outcomes and Measures The primary efficacy end points were successful hair preservation assessed using the Common Terminology Criteria for Adverse Events version 4.0 scale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wig] were considered to have hair preservation) at the end of 4 cycles of chemotherapy by a clinician unaware of treatment assignment, and device safety. Secondary end points included wig use and scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, Hospital Anxiety and Depression Scale, and a summary scale of the Body Image Scale. Results At the time of the interim analysis, 142 participants were evaluable. The mean (SD) age of the patients was 52.6 (10.1) years; 36% (n = 51) received anthracycline-based chemotherapy and 64% (n = 91) received taxane-based chemotherapy. Successful hair preservation was found in 48 of 95 women with cooling (50.5%; 95% CI, 40.7%-60.4%) compared with 0 of 47 women in the control group (0%; 95% CI, 0%-7.6%) (success rate difference, 50.5%; 95% CI, 40.5%-60.6%). Because the 1-tailed P value from the Fisher exact test was <.001, which crossed the superiority boundary (P = .0061), the data and safety monitoring board recommended study termination on September 26, 2016. There were no statistically significant differences in changes in any of the scales of quality of life from baseline to chemotherapy cycle 4 among the scalp cooling and control groups. Only adverse events related to device use were collected; 54 adverse events were reported in the cooling group, all grades 1 and 2. There were no serious adverse device events. Conclusions and Relevance Among women with stage I to II breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scalp cooling were significantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared with those who received no scalp cooling. Further research is needed to assess longer-term efficacy and adverse effects.	[Nangia, Julie; Wang, Tao; Niravath, Polly; Otte, Kristen; Rude, Mari; Hilsenbeck, Susan; Osborne, C. Kent; Rimawi, Mothaffar] Baylor Coll Med, One Baylor Plaza,BCM 660, Houston, TX 77030 USA; [Osborne, Cynthia; Holmes, Frankie; Courtright, Jay] US Oncol, Texas Oncol, Dallas, TX USA; [Niravath, Polly] Methodist Hosp, 6535 Fannin, Houston, TX 77030 USA; [Papish, Steven] Univ Texas MD Anderson Canc Ctr, Summit Med Grp, Morristown, NJ USA; [Abraham, Jame] Cleveland Clin, Cleveland, OH 44106 USA; [Lacouture, Mario] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Paxman, Richard] Paxman Coolers Ltd, Huddersfield, W Yorkshire, England	Baylor College of Medicine; Texas Oncology; US Oncology Network; The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; UTMD Anderson Cancer Center; Cleveland Clinic Foundation; Memorial Sloan Kettering Cancer Center	Nangia, J (corresponding author), Baylor Coll Med, One Baylor Plaza,BCM 660, Houston, TX 77030 USA.	nangia@bcm.edu	Rimawi, Mothaffar/AAI-3520-2020	Rimawi, Mothaffar/0000-0002-4284-5656; Lacouture, Mario/0000-0002-4818-3710	Paxman Coolers Ltd; Baylor College of Medicine; National Cancer Institute [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Paxman Coolers Ltd; Baylor College of Medicine; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Paxman Coolers Ltd, which contracted with Baylor College of Medicine to conduct the study. Dr Lacouture is supported in part by grant P30 CA008748 from the National Cancer Institute.	Breed W.P.M., 2011, EXPERT REV DERMATOLO, V6, P109, DOI DOI 10.1586/EDM.10.76; Christodoulou C, 2006, Ann Oncol, V17, P350, DOI 10.1093/annonc/mdj008; EDELSTYN GA, 1977, LANCET, V2, P253; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; GIACCONE G, 1988, CANCER NURS, V11, P170; Hopwood P, 2001, EUR J CANCER, V37, P189, DOI 10.1016/S0959-8049(00)00353-1; Kennedy M, 1983, Oncol Nurs Forum, V10, P19; Komen MMC, 2013, ONCOLOGIST, V18, P885, DOI 10.1634/theoncologist.2012-0332; Kornblith A., 1998, PSYCHO-ONCOLOGY, V1, P223; Lemieux J, 2008, PSYCHO-ONCOLOGY, V17, P317, DOI 10.1002/pon.1245; Lemieux J, 2011, BREAST CANCER RES TR, V128, P563, DOI 10.1007/s10549-011-1453-y; Lemieux J, 2009, BREAST CANCER RES TR, V118, P547, DOI 10.1007/s10549-009-0342-0; Macduff C, 2003, EUR J CANCER CARE, V12, P154, DOI 10.1046/j.1365-2354.2003.00382.x; Massey Carolyn S, 2004, Eur J Oncol Nurs, V8, P121, DOI 10.1016/j.ejon.2003.10.006; Mols F, 2009, SUPPORT CARE CANCER, V17, P181, DOI 10.1007/s00520-008-0475-4; Munstedt K, 1997, SUPPORT CARE CANCER, V5, P139, DOI 10.1007/s005200050056; Parker R, 1987, Oncol Nurs Forum, V14, P49; Peerbooms M, 2011, 34 ANN CTRC AACR SAN; Pozo-Kaderman C, 1999, NURS PRACT FORUM, V10, P165; Ron IG, 1997, SUPPORT CARE CANCER, V5, P136, DOI 10.1007/s005200050055; Rugo HS, 2015, 2015 ASCO ANN M MAY; SATTERWHITE B, 1984, CANCER, V54, P34, DOI 10.1002/1097-0142(19840701)54:1<34::AID-CNCR2820540109>3.0.CO;2-W; Shin H, 2015, INT J CANCER, V136, pE442, DOI 10.1002/ijc.29115; SNEEUW KCA, 1992, RADIOTHER ONCOL, V25, P160, DOI 10.1016/0167-8140(92)90262-S; Spaeth D, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.9564; Trusson D, 2017, CANCER NURS, V40, pE9, DOI 10.1097/NCC.0000000000000373; van de Sande Mariska A E, 2010, Ned Tijdschr Geneeskd, V154, pA2134; van den Hurk CJG, 2013, BREAST, V22, P1001, DOI 10.1016/j.breast.2013.07.039; van den Hurk CJ, 2013, SAFETY EFFECTIVENESS; van den Hurk CJ, 2012, ACTA ONCOL, V51, P497, DOI 10.3109/0284186X.2012.658966; van den Hurk CJG, 2010, PSYCHO-ONCOLOGY, V19, P701, DOI 10.1002/pon.1615; Zdenkowski N, 2016, MED J AUSTRALIA, V205, P471, DOI 10.5694/mja16.00947	32	114	115	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2017	317	6					596	605		10.1001/jama.2016.20939	http://dx.doi.org/10.1001/jama.2016.20939			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL8LI	28196254				2023-01-03	WOS:000394870900014
J	Ewen, M; Zweekhorst, M; Regeer, B; Laing, R				Ewen, Margaret; Zweekhorst, Marjolein; Regeer, Barbara; Laing, Richard			Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases	PLOS ONE			English	Article							ACCESS	Background WHO has set a voluntary target of 80% availability of affordable essential medicines, including generics, to treat major non-communicable diseases (NCDs), in the public and private sectors of countries by 2025. We undertook a secondary analysis of data from 30 surveys in low-and middle-income countries, conducted from 2008-2015 using the World Health Organization (WHO)/Health Action International (HAI) medicine availability and price survey methodology, to establish a baseline for this target. Methods Data for 49 medicines (lowest priced generics and originator brands) to treat cardiovascular diseases (CVD), diabetes, chronic obstructive pulmonary diseases (COPD) and central nervous system (CNS) conditions were analysed to determine their availability in healthcare facilities and pharmacies, their affordability for those on low incomes (based on median patient prices of each medicine), and the percentage of medicines that were both available and affordable. Affordability was expressed as the number of days' wages of the lowest-paid unskilled government worker needed to purchase 30 days' supply using standard treatment regimens. Paying more than 1 days' wages was considered unaffordable. Findings In low-income countries, 15.2% and 18.9% of lowest-priced generics met WHO's target in the public and private sectors, respectively, and 2.6% and 5.2% of originator brands. In lower-middle income countries, 23.8% and 23.2% of lowest priced generics, and 0.8% and 1.4% of originator brands, met the target in the public and private sectors, respectively. In upper-middle income countries, the situation was better for generics but still suboptimal as 36.0% and 39.4% met the target in public and private sectors, respectively. For originator brands in upper-middle income countries, none reached the target in the public sector and 13.7% in the private sector. Across the therapeutic groups for lowest priced generics, CVD medicines in low-income countries (11.9%), and CNS medicines in lower-middle (10.2%) and upper-middle income countries (33.3%), were least available and affordable in the public sector. In the private sector for lowest priced generics, CNS medicines were least available and affordable in all three country income groups (11.4%, 5.8% and 29.3% in low-, lower-middle and upper-middle income countries respectively). Interpretation This data, which can act as a baseline for the WHO target, shows low availability and/or poor affordability is resulting in few essential NCD medicines meeting the target in low-and middle-income countries. In the era of Sustainable Development Goals, and as countries work to achieve Universal Health Coverage, increased commitments are needed by governments to improve the situation through the development of evidence-informed, nationally-contextualised interventions, with regular monitoring of NCD medicine availability, patient prices and affordability.	[Ewen, Margaret] Hlth Act Int, Amsterdam, Netherlands; [Zweekhorst, Marjolein; Regeer, Barbara] Vrije Univ Amsterdam, Athena Inst, Amsterdam, Netherlands; [Laing, Richard] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Laing, Richard] Univ Western Cape, Cape Town, South Africa	Vrije Universiteit Amsterdam; Boston University; University of the Western Cape	Ewen, M (corresponding author), Hlth Act Int, Amsterdam, Netherlands.	marg@haiweb.org	Regeer, Barbara J/M-1207-2018	Regeer, Barbara J/0000-0002-9044-9367				[Anonymous], 2013, PRIC AV AFF PRIC COM; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P279; Cameron A, 2012, EPILEPSIA, V53, P962, DOI 10.1111/j.1528-1167.2012.03446.x; Gelders S., 2006, PRICE AVAILABILITY A; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; International Diabetes Federation, 2013, INT DIAB FED DIAB AT; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Niens LM, 2012, B WORLD HEALTH ORGAN, V90, P219, DOI 10.2471/BLT.10.084087; UN General Assembly, 2012, 662 UN GEN ASS; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; Volman B, 2008, DIRECT COSTS AVAILAB; Wagner AK, 2011, HEALTH POLICY, V100, P151, DOI 10.1016/j.healthpol.2010.08.004; WHO, 2015, Q AS ON HYP; World Bank/WHO EMRO/HAI, 2013, PRIC AFF MED TREAT N; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization/Health Action International, 2008, MEAS MED PRIC AV AFF	17	73	75	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2017	12	2							e0171284	10.1371/journal.pone.0171284	http://dx.doi.org/10.1371/journal.pone.0171284			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK1SG	28170413	Green Published, gold, Green Submitted			2023-01-03	WOS:000393705500028
J	Xie, LL; Zhang, K; Rasmussen, D; Wang, JP; Wu, DY; Roemmich, JN; Bundy, A; Johnson, WT; Claycombe, K				Xie, Linglin; Zhang, Ke; Rasmussen, Dane; Wang, Junpeng; Wu, Dayong; Roemmich, James N.; Bundy, Amy; Johnson, W. Thomas; Claycombe, Kate			Effects of prenatal low protein and postnatal high fat diets on visceral adipose tissue macrophage phenotypes and IL-6 expression in Sprague Dawley rat offspring	PLOS ONE			English	Article							PREGNANCY INDUCES HYPERTENSION; LOW-BIRTH-WEIGHT; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; GENE-EXPRESSION; CARDIOVASCULAR-DISEASE; MATERNAL NUTRITION; ISLET FUNCTION; IN-UTERO; OBESITY	Adipose tissue macrophages (ATM) are implicated in adipose tissue inflammation and obesity-related insulin resistance. Maternal low protein models result in fetal programming of obesity. The study aims to answer whether maternal undernutrition by protein restriction affects the ATM M1 or M2 phenotype under postnatal high fat diet in F1 offspring. Using a rat model of prenatal low protein (LP, 8% protein) diet followed by a postnatal high fat energy diet (HE, 45% fat) or low fat normal energy diet (NE, 10% fat) for 12 weeks, we investigated the effects of these diets on adiposity, programming of the offspring ATM phenotype, and the associated inflammatory response in adipose tissue. Fat mass in newborn and 12-week old LP fed offspring was lower than that of normal protein (20%; NP) fed offspring; however, the adipose tissue growth rate was higher compared to the NP fed offspring. While LP did not affect the number of CD68(+) or CD206(+) cells in adipose tissue of NE offspring, it attenuated the number of these cells in offspring fed HE. In offspring fed HE, LP offspring had a lower percentage of CD11c(+) CD206(+) ATMs, whose abundancy was correlated with the size of the adipocytes. Noteworthy, similar to HE treatment, LP increased gene expression of IL-6 within ATMs. Two-way ANOVA showed an interaction of prenatal LP and postnatal HE on IL-6 and IL-1 beta transcription. Overall, both LP and HE diets impact ATM phenotype by affecting the ratio of CD11c(+) CD206(+) ATMs and the expression of IL-6.	[Xie, Linglin] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA; [Xie, Linglin; Rasmussen, Dane] Univ North Dakota, Sch Med & Hlth Sci, Dept Basic Sci, Grand Forks, ND USA; [Zhang, Ke] Univ North Dakota, Sch Med & Hlth Sci, Dept Pathol, Grand Forks, ND USA; [Zhang, Ke] Univ North Dakota, ND INBRE Bioinformat Core, Grand Forks, ND USA; [Wang, Junpeng; Wu, Dayong] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr, Boston, MA 02111 USA; [Roemmich, James N.; Bundy, Amy; Johnson, W. Thomas; Claycombe, Kate] USDA ARS, Grand Forks Human Nutr Res Ctr, Grand Forks, ND 58202 USA	Texas A&M University System; Texas A&M University College Station; University of North Dakota Grand Forks; University of North Dakota Grand Forks; University of North Dakota Grand Forks; Tufts University; United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Xie, LL (corresponding author), Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA.; Xie, LL (corresponding author), Univ North Dakota, Sch Med & Hlth Sci, Dept Basic Sci, Grand Forks, ND USA.; Claycombe, K (corresponding author), USDA ARS, Grand Forks Human Nutr Res Ctr, Grand Forks, ND 58202 USA.	linglin.xie@tamu.edu; kate.claycombe@ars.usda.gov	Wang, Junpeng/K-9909-2018	Wang, Junpeng/0000-0002-5464-7884; Roemmich, James/0000-0002-6270-9678	National Institutes of Health [NIH-1R15HL117238]; National Center for Research Resources [5P20RR016471-12/8 P20 GM103442-12]; American Heart Association [13SDG14650009]; USDA Agricultural Research Service Project [3062-51000-052-00D]; USDA National Institute of Food and Agriculture, [Hatch] project [1010406]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103442] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); American Heart Association(American Heart Association); USDA Agricultural Research Service Project; USDA National Institute of Food and Agriculture, [Hatch] project; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported by grants from the National Institutes of Health (NIH-1R15HL117238 to author LX, National Center for Research Resources, 5P20RR016471-12/8 P20 GM103442-12 to authors LX and KZ) and the American Heart Association (13SDG14650009 to author LX). This work was also supported by USDA Agricultural Research Service Project #3062-51000-052-00D to author KJC and by the USDA National Institute of Food and Agriculture, [Hatch] project [1010406] to author LX.	Andersen LG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014126; Anderson SE, 2012, PEDIATRICS, V129, P132, DOI 10.1542/peds.2011-0972; Berends LM, 2013, INT J OBESITY, V37, P1051, DOI 10.1038/ijo.2012.196; Claycombe KJ, 2013, J NUTR; Cox AR, 2010, PEDIATR RES, V68, P16, DOI [10.1203/PDR.0b013e3181e17c90, 10.1203/00006450-201011001-00026]; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; Ferrante AW, 2007, J INTERN MED, V262, P408, DOI 10.1111/j.1365-2796.2007.01852.x; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Gaillard R, 2016, OBESITY, V24, P1320, DOI 10.1002/oby.21484; Gangula PRR, 2005, AM J OBSTET GYNECOL, V192, P952, DOI 10.1016/j.ajog.2004.09.008; Gosby AK, 2010, OBESITY, V18, P1593, DOI 10.1038/oby.2009.449; Guan HY, 2005, AM J PHYSIOL-ENDOC M, V288, pE663, DOI 10.1152/ajpendo.00461.2004; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KUSIN JA, 1992, LANCET, V340, P623, DOI 10.1016/0140-6736(92)92168-F; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Lindsay RS, 2000, DIABETES, V49, P445, DOI 10.2337/diabetes.49.3.445; Lukaszewski MA, 2011, AM J PHYSIOL-ENDOC M, V301, pE548, DOI 10.1152/ajpendo.00011.2011; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2007, AM J PHYSIOL-ENDOC M, V292, pE166, DOI 10.1152/ajpendo.00284.2006; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; Meier JJ, 2009, DIABETES, V58, P1255, DOI 10.2337/db09-0225; Morris DL, 2011, CURR OPIN CLIN NUTR, V14, P341, DOI 10.1097/MCO.0b013e328347970b; Odegaard JI, 2008, CELL METAB, V7, P496, DOI 10.1016/j.cmet.2008.04.003; Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138; Ong KK, 2002, BEST PRACT RES CL EN, V16, P191, DOI 10.1053/beem.2002.0195; Ortega MT, 2011, CELL IMMUNOL, V271, P124, DOI 10.1016/j.cellimm.2011.06.012; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V271, pE1128, DOI 10.1152/ajpendo.1996.271.6.E1128; Poore KR, 2004, DIABETOLOGIA, V47, P340, DOI 10.1007/s00125-003-1305-3; Poore KR, 2002, DIABETOLOGIA, V45, P1247, DOI 10.1007/s00125-002-0849-y; Ramachandran P, 2002, NUTR REV, V60, pS26, DOI 10.1301/00296640260130704; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Remacle C, 2004, INT J OBESITY, V28, pS46, DOI 10.1038/sj.ijo.0802800; Reynolds CM, 2013, ENDOCRINOLOGY, V154, P2676, DOI 10.1210/en.2013-1146; Sathishkumar K, 2012, BRIT J NUTR, V107, P665, DOI 10.1017/S0007114511003448; Sathishkumar K, 2009, J VASC RES, V46, P229, DOI 10.1159/000166390; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; Tarry-Adkins JL, 2010, FASEB J, V24, P2762, DOI 10.1096/fj.10-156075; Tuchscherer M, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-232; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wilson MR, 1997, J ENDOCRINOL, V154, P177, DOI 10.1677/joe.0.1540177; Woods LL, 2005, AM J PHYSIOL-REG I, V289, pR1131, DOI 10.1152/ajpregu.00037.2003; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	47	20	21	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2017	12	1							e0169581	10.1371/journal.pone.0169581	http://dx.doi.org/10.1371/journal.pone.0169581			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6QW	28141871	Green Published, gold, Green Submitted			2023-01-03	WOS:000396129500004
J	Wirtz, VJ; Hogerzeil, HV; Gray, AL; Bigdeli, M; de Joncheere, CP; Ewen, MA; Gyansa-Lutterodt, M; Jing, S; Luiza, VL; Mbindyo, RM; Moller, H; Moucheraud, C; Pecoul, B; Rago, L; Rashidian, A; Ross-Degnan, D; Stephens, PN; Teerawattananon, Y; 't Hoen, EFM; Wagner, AK; Yadav, P; Reich, MR				Wirtz, Veronika J.; Hogerzeil, Hans V.; Gray, Andrew L.; Bigdeli, Maryam; de Joncheere, Cornelis P.; Ewen, Margaret A.; Gyansa-Lutterodt, Martha; Jing, Sun; Luiza, Vera L.; Mbindyo, Regina M.; Moller, Helene; Moucheraud, Corrina; Pecoul, Bernard; Rago, Lembit; Rashidian, Arash; Ross-Degnan, Dennis; Stephens, Peter N.; Teerawattananon, Yot; 't Hoen, Ellen F. M.; Wagner, Anita K.; Yadav, Prashant; Reich, Michael R.			Essential medicines for universal health coverage	LANCET			English	Review							MIDDLE-INCOME COUNTRIES; BUDGET IMPACT ANALYSIS; ANTIRETROVIRAL MEDICINES; SUBSTANDARD MEDICINES; IMPROVE ACCESS; COUNTERFEIT ARTESUNATE; PRESCRIBING INDICATORS; REGULATORY AUTHORITY; NEGLECTED DISEASES; COST-EFFECTIVENESS		[Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Dept Global Hlth, Boston, MA 02118 USA; [Hogerzeil, Hans V.; 't Hoen, Ellen F. M.] Univ Groningen, Univ Med Ctr Groningen, Global Hlth Unit, Groningen, Netherlands; [Gray, Andrew L.] Univ KwaZulu Natal, Div Pharmacol, Discipline Pharmaceut Sci, Durban, South Africa; [de Joncheere, Cornelis P.] WHO, Dept Essential Med & Hlth Prod, Geneva, Switzerland; [Rago, Lembit] WHO, Regulat Med & Other Hlth Technol, Geneva, Switzerland; [Bigdeli, Maryam] WHO, Geneva, Switzerland; [Ewen, Margaret A.] Hlth Act Int, Amsterdam, Netherlands; [Gyansa-Lutterodt, Martha] Minist Hlth, Accra, Ghana; [Jing, Sun] Peking Union Med Coll, Sch Publ Hlth, Beijing, Peoples R China; [Luiza, Vera L.] Fundacao Oswaldo Cruz, Natl Sch Publ Hlth Sergio Arouca, Rio De Janeiro, Brazil; [Mbindyo, Regina M.] WHO, Country Off, Nairobi, Kenya; [Moller, Helene] United Nations Childrens Fund, Supply Div, Copenhagen, Denmark; [Moucheraud, Corrina] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA; [Pecoul, Bernard] Drugs Neglected Dis Initiat, Geneva, Switzerland; [Rashidian, Arash] WHO, Eastern Mediterranean Reg, Dept Informat Evidence & Res, Cairo, Egypt; [Rashidian, Arash] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran; [Ross-Degnan, Dennis; Wagner, Anita K.] WHO, Eastern Mediterranean Reg, Res, Cairo, Egypt; [Ross-Degnan, Dennis; Wagner, Anita K.] Harvard Med Sch, Boston, MA USA; [Ross-Degnan, Dennis] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Stephens, Peter N.] IMS Hlth, London, England; [Teerawattananon, Yot] Thai Minist Publ Hlth, HITAP, Nonthaburi, Thailand; [Yadav, Prashant] Univ Michigan, William Davidson Inst, Ann Arbor, MI 48109 USA; [Reich, Michael R.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Boston University; University of Groningen; University of Kwazulu Natal; World Health Organization; World Health Organization; World Health Organization; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Fundacao Oswaldo Cruz; World Health Organization; University of California System; University of California Los Angeles; Egyptian Knowledge Bank (EKB); World Health Organization Egypt; World Health Organization; Tehran University of Medical Sciences; Egyptian Knowledge Bank (EKB); World Health Organization Egypt; World Health Organization; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Ministry of Public Health - Thailand; University of Michigan System; University of Michigan; Harvard University; Harvard T.H. Chan School of Public Health	Wirtz, VJ (corresponding author), Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Dept Global Hlth, Boston, MA 02118 USA.	vwirtz@bu.edu	Luiza, Vera Lucia/F-6070-2012; Rago, Lembit/AAF-4732-2019; Wirtz, Veornika/AAG-9712-2019; Gray, Andrew/F-2104-2013	Luiza, Vera Lucia/0000-0001-6245-7522; Yadav, Prashant/0000-0001-7836-6641; Teerawattananon, Yot/0000-0003-2217-2930; Gray, Andrew/0000-0001-7815-8180; Mbindyo, Regina/0000-0001-8011-7580; Wirtz, Veronika J./0000-0002-0863-8768; Rashidian, Arash/0000-0002-4005-5183	Bill & Melinda Gates Foundation; World Health Organization; University Medical Centre Groningen; Boston University	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); World Health Organization(World Health Organization); University Medical Centre Groningen; Boston University	We are very grateful to the many experts who contributed to the production of this report. We thank The Lancet, in particular Pam Das, Senior Executive Editor, for her guidance in the process. We are also extremely grateful to Anya Levy Guyer for her editorial assistance throughout the process. Many researchers have generously contributed their time, eff orts, and unpublished data to the work of the Commission. We thank Amey N Shroff (University of Michigan), Nattha Tritasavit (Health Intervention and Technology Assessment Program, Thai Ministry of Public Health), Tessa Hermens (NPS MedicineWise), Michael Deats (World Health Organization), Peter Hall (Concept Foundation), Nikita V de Jong (University Medical Centre Groningen), Thomas Layloff (Management Sciences for Health), Patrick H Lukulay (United States Pharmacopeial Convention), Zafar Mirza (World Health Organization), Paul Newton (Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit), Sten Olsson (Uppsala Monitoring Centre), Michaella Latkovic (Boston University School of Public Health), Steven Crimaldi (Boston University School of Public Health), Jaime Espin (Escuela Andaluza de Salud Publica), Jean-Pierre Sallet (Axios International), Vusi C Dlamini (KwaZulu-Natal Department of Health) is thanked for providing medicines consumption data, and all external reviewers for their constructive comments. Finally, we thank the University Medical Centre Groningen of the University of Groningen, Netherlands, and the Health Foundation, UK, for providing the Lancet Commission with meeting venues. The work of the Commission was funded by the Bill & Melinda Gates Foundation, World Health Organization, the University Medical Centre Groningen, Boston University, and by all the academic institutions and other organisations that have generously allowed their staff to devote time to the work of the Commission.	Access Campaign MSF, 2016, UNT WEB ANT PRIC RED; Access to Medicine Foundation, ACC MED IND 2014; Access to Medicines Foundation, 2014, ACC MED IND 2014; Access to Medicines Foundation, 2015 METH 2016 ACC M; Achariam T, 2015, THE SUN DAILY   1020; Adamson PC, 2014, NAT REV CLIN ONCOL, V11, P732, DOI 10.1038/nrclinonc.2014.149; Agitha T. G., 2013, J INTELL PROP RTS, V18, P491; Agrawal S, 2013, NEW ENGL J MED, V368, P2054, DOI 10.1056/NEJMp1303523; Ainger J., BLOOMBERG; Alghannam AFA, 2014, INTEGR PHARM RES PRA, V3, P71, DOI 10.2147/IPRP.S63690; Alliance GAVI, 2014, GAVI ALL 2013 ANN PR; Almuzaini T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002923; Alpern JD, 2016, NEW ENGL J MED, V374, P1904, DOI 10.1056/NEJMp1601559; Anderson BO, 2008, CANCER-AM CANCER SOC, V113, P2221, DOI 10.1002/cncr.23844; [Anonymous], 1978, LANCET, V1, P423; [Anonymous], 2015, HLTH GLANC 2015; [Anonymous], 2014, ECONOMIST; [Anonymous], 2015, REV PRESCRIRE, V35, P132; Ardal C, 2016, LANCET, V387, P296, DOI 10.1016/S0140-6736(15)00470-5; Association of Southeastern Nations, 2014, ASEAN DEV MUT REC AR; Australian Government Department of Health, QUAL US MED; Awad A. I., 2007, Eastern Mediterranean Health Journal, V13, P1202; Bach P, 2012, NY TIMES; Bach PB, 2015, JAMA-J AM MED ASSOC, V314, P2503, DOI 10.1001/jama.2015.16843; Balarajan Y, 2011, LANCET, V377, P505, DOI 10.1016/S0140-6736(10)61894-6; Balasegaram M, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001831; Bannenberg W, 2011, PHARM REFORM GUIDE I; Baruwa E, 2008, LIT REV COSTING SUPP; Bauschke R, 2012, HEALTH POLICY, V104, P12, DOI 10.1016/j.healthpol.2011.10.009; Belfrage B, 2015, EUR J CLIN PHARMACOL, V71, P363, DOI 10.1007/s00228-014-1792-9; Beran D, LANCET DIABET ENDOCR, V4, P275; Berman P, 2011, HLTH SYSTEM STRENGTH; Bigdeli M, 2014, MED HLTH SYSTEMS ADV; Bigdeli M, 2013, HEALTH POLICY PLANN, V28, P692, DOI 10.1093/heapol/czs108; Bigdeli Maryam, 2015, J Pharm Policy Pract, V8, P8, DOI 10.1186/s40545-015-0028-4; Bill & Melinda Gates Foundation, 2013, PARTN RED COST BAYER; Bogdanich WFDA, 2007, NY TIMES; Bollyky TJ, 2014, REPORT SAFETY SURVEI; Boulet P, PROCUREMENT PATENTED; Bovens M., EUROPEAN GOVERNANCE; Bredenkamp C, 2015, SOC SCI MED, V145, P243, DOI 10.1016/j.socscimed.2015.07.025; Brennan Z., 2016, COUNTERFEIT VERSIONS; Bryce J, 2005, HEALTH POLICY PLANN, V20, pI5, DOI 10.1093/heapol/czi055; Bryce J, 2004, AM J PUBLIC HEALTH, V94, P406, DOI 10.2105/AJPH.94.3.406; Bulfone L, 2009, VALUE HEALTH, V12, pS28, DOI 10.1111/j.1524-4733.2009.00556.x; Burns W, 2006, B WORLD HEALTH ORGAN, V84, P689; Burrone E, 2015, LANCET HIV, V2, pE362, DOI 10.1016/S2352-3018(15)00157-5; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A, COST SAVINGS SWITCHI; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; Chalkidou K, 2016, B WORLD HEALTH ORGAN, V94, P462, DOI 10.2471/BLT.15.155721; Chhatwal J, 2015, ANN INTERN MED, V162, P397, DOI 10.7326/M14-1336; Chootipongchaivat S, 2015, FACTORS CONDUCIVE DE; Clinton Health Access Initiative (CHAI), 2015, STAT ANT DRUG MARK L; Commission on Intellectual Property Rights Innovation and Public Health (CIPIH), 2006, PUBL HLTH INN INT PR; CORNIPS C, 2010, INT J RISK SAF MED, V22, P77, DOI DOI 10.3233/JRS-2010-0496; Crow D, 2016, FINANCIAL TIMES; da Silva RM, 2015, CIENC SAUDE COLETIVA, V20, P2943, DOI 10.1590/1413-812320152010.17352014; DAP, 2020, SCREEN SHOTS HOSP WE; Dellepiane N, 2015, VACCINE, V33, P52, DOI 10.1016/j.vaccine.2013.11.066; Dentico N, 2005, PLOS MED, V2, P96, DOI 10.1371/journal.pmed.0020014; Department of Health & Human Services, WARN LETT; DeVries TPGM., 1994, GUIDE GOOD PRESCRIBI; Dickens T., 2011, WORLD MED SITUATION; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; Doctors without Borders, CAMP ACC MED; Dong LF, 2008, J ANTIMICROB CHEMOTH, V62, P410, DOI 10.1093/jac/dkn153; Doshi P, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4665; Drugs for Neglected Diseases initiative, BUS PLAN 2015 2023; Drugs for Neglected Diseases initiative, 2013, INN APPR R D NEGL PA; Drummond M, 2013, VALUE HEALTH, V16, pS7, DOI 10.1016/j.jval.2012.10.007; Drummond M, 2012, INT J TECHNOL ASSESS, V28, P159, DOI 10.1017/S0266462312000098; Durairaj V, 2010, 41 WHO; Effective Practice and Organisation of Care (EPOC), 2015, SUGG RISK BIAS CRIT; Effective Practice and Organisation of Care (EPOC), 2013, WHAT STUD DES SHOULD; Elizabeth Glaser Pediatric AIDS Foundation, AB PED AIDS; Espin J., HTA EMERGING COUNTRI; EUnetHTA, 2012, JOINT ACT WP4 POL HT; European Medicines Agency, ART 58 APPL REG PROC; European Medicines Agency, PAED REG EU; European Medicines Agency, FALS MED; Evans DB, 2012, LANCET, V380, P864, DOI 10.1016/S0140-6736(12)61483-4; Experts in Chronic Myeloid Leukemia, 2013, Blood, V121, P4439, DOI 10.1182/blood-2013-03-490003; Ferrario Alessandra, 2014, J Pharm Policy Pract, V7, P4, DOI 10.1186/2052-3211-7-4; Finney E, 2011, CHILDRENS MED SITUAT; Fletcher N., 2015, THE GUARDIAN    0919; Food and Drug Administration, FDAS ROL PREC MED; Ford N, 2007, AIDS, V21, pS21, DOI 10.1097/01.aids.0000279703.78685.a6; Fox M, 2014, NBC NEWS; Frieden T R, 2007, WORLD HOSP HLTH SERV, V43, P30; Fromm MF, 2013, EUR J CLIN PHARMACOL, V69, P975, DOI 10.1007/s00228-012-1425-0; Frost LJ, 2008, ACCESS DO GOOD HLTH; Gaffney A, 2015, REGULATORY EXPLAINER; Gagnon Marc-Andre, 2015, Prescrire Int, V24, P192; Garabedian LF, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001686; Gilead, 2015, CHRON HEP C TREATM E; Gilson L, 2012, HEALTH POLICY PLANN, V27, pi64, DOI 10.1093/heapol/czs007; Global Alliance for TB Drug Development, 2001, EX SUMM EC TB DRUG D; Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, 2011, CANC MED PRIC LOW MI; Gomez-Dantes O, 2012, B WORLD HEALTH ORGAN, V90, P788, DOI 10.2471/BLT.12.106633; Gosden T, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002215; Gostin L O, 2013, COUNTERING PROBLEM F; Government of India, 1970, PAT ACT SECT 3 WH D; Government of the Netherlands Ministry of Health Welfare and Sport, BEN RESP US MED; Grant R, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5950; Gray A, 2015, WHOHISHGFCASESTUDY15; Gray AL, 2015, INT J CLIN PHARM-NET, V37, P717, DOI 10.1007/s11096-015-0156-6; Gray AL, 2015, LANCET, V386, P1601, DOI 10.1016/S0140-6736(15)00514-0; Greene JA, 2011, BIOSOCIETIES, V6, P10, DOI 10.1057/biosoc.2010.39; Gustafsson LL, 2011, BASIC CLIN PHARMACOL, V108, P224, DOI 10.1111/j.1742-7843.2011.00682.x; Hajjou M, 2015, AM J TROP MED HYG, V92, P68, DOI 10.4269/ajtmh.14-0535; Hajjou M, 2013, J PHARMACEUT BIOMED, V74, P47, DOI 10.1016/j.jpba.2012.09.016; Hall C, 2012, PATHOG GLOB HEALTH, V106, P73, DOI 10.1179/204777312X13419245939485; Hall PE, 2016, WHO DRUG INFORM, V30, P35; Hamilton WL, 2016, HEALTH POLICY PLANN, V31, P1448, DOI 10.1093/heapol/czw062; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Hardon A, 1992, DRUGS POLICY DEV COU; Harvard Medical School and Harvard Pilgrim Healthcare/WHO, 2006, WHOTCM20062 HARV MED; Health Action International, 2016, FACT FICT WHAT HEALT; Health Action International, 2016, INS PRIC PROF; Health IMS, 2015, GLOB US MED 2020; Heller PS, 2006, HEALTH POLICY PLANN, V21, P75, DOI 10.1093/heapol/czj013; Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5; Heymann DL, 2013, LANCET, V381, P779, DOI 10.1016/S0140-6736(13)60185-3; Hill A, 2016, CONTRIBUTION UN SECR; Hillen JB, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0984-9; Hirschler B., 2015, REUTERS         1001; Hirschler B., GLAXOSMITHKLINE BOSS; Ho NT, 2015, AM J TROP MED HYG, V92, P24, DOI 10.4269/ajtmh.14-0392; Hogerzeil HV, 2006, B WORLD HEALTH ORGAN, V84, P371, DOI 10.2471/BLT.06.031153; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; Hollande F, 2016, LANCET, V387, P2173, DOI 10.1016/S0140-6736(16)30393-2; Holloway KA, 2013, TROP MED INT HEALTH, V18, P656, DOI 10.1111/tmi.12123; Holloway KA, 2015, PAEDIATR INT CHILD H, V35, P5, DOI 10.1179/2046905514Y.0000000115; Hoppu Kalle, 2011, Handb Exp Pharmacol, V205, P353, DOI 10.1007/978-3-642-20195-0_18; Hotez P, 2013, DIS NEXT DOOR WORLDS; Huang Y., 2004, SARS EPIDEMIC ITS AF; Hubbard T, 2004, PLOS BIOL, V2, P147, DOI 10.1371/journal.pbio.0020052; Hunt P, 2006, A61338, P19; IAEA, 2014, RES, DOI DOI 10.1002/2014JD022002; IDRI, 2015, IDRI SAN PAST TEAM P; IMS Health Institute for Healthcare Informatics, 2015, GLOB MED US 2020 OUT; IMS Institute for Healthcare Informatics, 2015, GLOB US MED OUTL 201; INRUD, INT C IMPR US MED 19; Institute for Safe Medication Practices, ISMP HIGH AL MED; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH GUID; International Federation of Pharmaceutical Manufacturers and Associations, DEV WORLD HLTH PARTN; International Network of Agencies for Health Technology Assessment (INAHTA), INAHTA MEMB LIST; Iyengar S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002032; Jahnke RWO, 2001, DRUG INF J, V35, P941; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Jennings G, 2011, GLOBAL VILLAGE  1005; Johnson & Johnson, OUR CRED VAL; Johnston A, 2014, BRIT J CLIN PHARMACO, V78, P218, DOI 10.1111/bcp.12298; Joint United Nations Programme on HIV/AIDS, 2015, AIDS CHANG EV MDG 6; Jones S., 2015, BR J HEALTHC MANAG, V21, P21, DOI DOI 10.12968/BJHC.2015.21.1.21; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Juhlin K, 2015, DRUG SAFETY, V38, P373, DOI 10.1007/s40264-015-0271-2; Kaale E, 2014, TROP MED INT HEALTH, V19, P747, DOI 10.1111/tmi.12303; Kamal-Yanni MM, 2012, LANCET, V379, P309, DOI 10.1016/S0140-6736(12)60040-3; Kanji N, 1992, DRUGS POLICY DEV COU; Kaplan W., 2013, PRIORITY MED EUROPE; Kaplan W, 2004, WHOEDMPAR20047, VWHO/EDM/PAR//2004.7; Kaplan WA, 2005, LOCAL PRODUCTION PHA; Kaplan WA, 2011, LOCAL PRODUCTION ACC; Kaplan WA, 2012, HEALTH POLICY, V106, P211, DOI 10.1016/j.healthpol.2012.04.015; Katrein F, 2015, CAD SAUDE PUBLICA, V31, P1416, DOI 10.1590/0102-311X00083614; Kelly JC, 2016, MEDSCAPE MED NEWS; Kenber J, 2016, TIMES; Kessides I, 2009, WPS4915 WORLD BANK D; Khatib R, 2016, LANCET, V387, P61, DOI 10.1016/S0140-6736(15)00469-9; Kiddell-Monroe R, 2015, REROUTE MAP ALTERNAT; King M, 1966, MED CARE DEV COUNTRI; Kingkaew P, 2012, VALUE HEALTH, V15, pS20, DOI 10.1016/j.jval.2011.11.015; Kohler JC, 2016, CORRUPTION PHARM SEC; Kosack S, 2014, ANNU REV POLIT SCI, V17, P65, DOI 10.1146/annurev-polisci-032210-144356; Kovacs S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090601; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Langerlov P, 2001, FAM PRACT, V18, P528, DOI 10.1093/fampra/18.5.528; Leach B, 2005, PRESCRIPTION HLTH DE; Levy AR, 2010, PHARMACOECONOMICS, V28, P813, DOI 10.2165/11536150-000000000-00000; Lexchin J, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-24; Li R, 2016, HEALTH SYST REFORM, V2, P71, DOI 10.1080/23288604.2015.1123338; Light DW, 2011, BIOSOCIETIES, V6, P34, DOI 10.1057/biosoc.2010.40; Lipska KJ, 2014, JAMA-J AM MED ASSOC, V311, P2331, DOI 10.1001/jama.2014.6316; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Loftus P., 2015, WALL STREET J; Love J., 2014, KEI COMMENT NEW TUFT; Love J, 2005, HLTH EC DRUGS TCM SE, V18; Lu Y, 2011, WORLD MED SITUATION; Lund BC, 2015, J AM GERIATR SOC, V63, P1601, DOI 10.1111/jgs.13560; Lyons J., 2012, MIRROR          0803; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; MacKenzie R, 2008, J ROY SOC MED, V101, P305, DOI 10.1258/jrsm.2008.070289; Malebona PM, 2014, 134 SESS WHO EX BOAR; Malpani R., 2009, J GENERIC MED, V6, P206, DOI DOI 10.1057/JGM.2009.13; Management Sciences for Health, 2013, SYST IMPR ACC PHARM; Management Sciences for Health, 2012, MAN ACC MED HLTH TEC; Maqbool S, 2015, NEWS; Mayor S, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1208; McCabe C, 2005, BRIT MED J, V331, P1016, DOI 10.1136/bmj.331.7523.1016; McDonald SA, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0564-6; McEwen J, 2012, DRUG SAFETY, V35, P667, DOI 10.2165/11599860-000000000-00000; McKee S., 2012, PHARMATIMES     0807; McNeil DG, 2015, NEW YORK TIMES  1215; MDG Gap Task Force, 2015, REP 2015 MILL DEV GO; Medecins Sans Frontieres, UNT WEB ANT PRIC RED; Medecins Sans Frontieres, 2015, HLTH GROUPS ASK SEN; Medecins Sans Frontieres (MSF), 2016, DR TB DRUGS MICR SOU; Medicine Transparency Alliance, PHARM SECT SCAN; Medicines Patent Pool, PROGR ACH MED PAT PO; Medicines Patent Pool, 2015, MED PAT POOL EXP MAN; Medicines Transparency Alliance, REV PIL; Meikle J, 2005, GUARDIAN; Mendelson M, 2016, LANCET, V387, P188, DOI 10.1016/S0140-6736(15)00547-4; Mestre-Ferrandiz J, 2012, R D COST NEW MED; Mills A, 2016, HEALTH SYST REFORM, V2, P20, DOI 10.1080/23288604.2016.1124173; Ministerio de Salud, 1972, VAD OFF MED BAS SECT; Mission for Essential Drugs and Supplies, QUAL ASS OV; Moberly T., 2011, EXCLUSIVE PCTS BLACK; Mohara A, 2012, VALUE HEALTH, V15, pS95, DOI 10.1016/j.jval.2011.11.016; Moon S, 2012, SCIENTIST; Moon S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001218; Moon S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-39; Mukhopadhyay R, 2007, ANAL CHEM, V79, P5522, DOI 10.1021/ac071943i; National Health and Family Planning Commission China, HLTH FAM PLANN DEV S; Neumann PJ, 2015, NEW ENGL J MED, V373, P2595, DOI 10.1056/NEJMp1512009; Newton PN, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000052; Nguyen HT, 2012, TROP MED INT HEALTH, V17, P1552, DOI 10.1111/j.1365-3156.2012.03081.x; Niens LM, 2012, B WORLD HEALTH ORGAN, V90, P219, DOI 10.2471/BLT.10.084087; Niessen LW, 2016, LANCET, V387, P9, DOI 10.1016/S0140-6736(15)00552-8; Nikogosian H, 2010, B WORLD HEALTH ORGAN, V88, P83, DOI 10.2471/BLT.10.075895; Norris P, 2005, DRUG PROMOTION WHAT; Novartis Silverman E., 2016, STATNEWS        0614; NPS, NPS MEDICINEWISE ANN; NPS Medicine Wise, 2014, NPS MEDICINEWISE 201; O'Sullivan A, 2009, ISPOR CONNECT, V15, P6; Obama B, 2016, JAMA-J AM MED ASSOC, V316, P525, DOI 10.1001/jama.2016.9797; OECD, 2012, PROGR MAD IMPL OECD; OECD, 2013, DELSAHEAWDHWP20134 O; Oh J, 2015, HEALTH SYST REFORM, V1, P62, DOI 10.4161/23288604.2014.991218; OHCHR, 2011, GUIDING PRINCIPLES B; Olivier J, 2015, LANCET, V386, P1765, DOI 10.1016/S0140-6736(15)60251-3; Olski TM, 2011, EUR J CLIN PHARMACOL, V67, P245, DOI 10.1007/s00228-011-0997-4; Onukwugha A, 2015, NAFDACS WAR FAKE DRU; Organisation for Economic Co-operation and Development, INF EXCH COMP COMP L; Organization for Economic Corporation and Development, 2015, HLTH GLANC 2015; Outterson K, 2014, NEW BUSINESS MODELS; Oyugui E, STRUCTURAL ADJUSTMEN; Paediatric ARV Procurement Working Group, 2015, WHO AMDS M PHARM CO; Pal SN, 2013, DRUG SAFETY, V36, P75, DOI 10.1007/s40264-012-0014-6; Papathanasiou P, 2016, DRUG DISCOV TODAY, V21, P1806, DOI 10.1016/j.drudis.2016.06.025; Paris V, 2013, DELSAHEAWDHWP20134 O; Patel A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-297; Patel A, 2010, HEALTH POLICY PLANN, V25, P61, DOI 10.1093/heapol/czp039; PBS Information Management Section Pharmaceutical Policy Branch, EXP PRESCR 12 MONTHS; Pecoul B, FDA VOUCHER LEISHMAN; Pedrique B, 2013, LANCET GLOB HEALTH, V1, pE371, DOI 10.1016/S2214-109X(13)70078-0; Perehudoff SK, B WHO IN PRESS; Peters DH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6753; Pharmaceutical Commerce, 2014, IMS I PROJ GLOB PHAR; Pharmaceutical Services Ministry of Health, 2015, NEW HOL MED; PhRMA, 2015, BIOPH RES IND 2015 P; Pinheiro ED, 2014, ANTIVIR THER, V19, P49, DOI 10.3851/IMP2900; Piot P, 2015, LANCET, V386, P171, DOI 10.1016/S0140-6736(15)60658-4; Prescrire, 2012, WHO BEN EUR PAED REG; Purmonen TT, 2010, INT J TECHNOL ASSESS, V26, P163, DOI 10.1017/S0266462310000103; Rago L, 2008, DRUG BENEFITS AND RISKS: INTERNATIONAL TEXTBOOK OF CLINICAL PHARMACOLOGY, P65; Ranieri N, 2014, AM J TROP MED HYG, V91, P920, DOI 10.4269/ajtmh.13-0644; Ratanawijitrasin S, 2002, EFFECTIVE DRUG REGUL; Rawlins M., 2012, HLTH SERV J, V122, P18; Reich MR, 2016, LANCET, V387, P811, DOI 10.1016/S0140-6736(15)60002-2; REICH MR, 1987, HEALTH POLICY, V8, P39, DOI 10.1016/0168-8510(87)90129-1; Renschler JP, 2015, AM J TROP MED HYG, V92, P119, DOI 10.4269/ajtmh.14-0725; Rentz ED, 2008, B WORLD HEALTH ORGAN, V86, P749; Reproductive Health Supplies Coalition, 2012, COAL SUPP IN TRIGG M; Reproductive Health Supplies Coalition, 2013, SINGL ROD IMPL NOW M; Reproductive Health Supplies Coalition, 2016, DMPA IM DEM FOR METH; Ricci C, 2008, ANAL CHIM ACTA, V623, P178, DOI 10.1016/j.aca.2008.06.007; Risha P, 2006, J AOAC INT, V89, P1300; Roberts MJ., 2004, GETTING HLTH REFORM; Roberts MJ, 2011, PHARM REFORM GUIDE I; ROSSDEGNAN D, 1992, SOC SCI MED, V35, P1329, DOI 10.1016/0277-9536(92)90037-Q; Rossow I, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1615-7; Rowe A, 2015, HLTH CARE PROVIDER P; Ruppenthal LR, 2010, LAT AM J PHARM, V29, P22; Russo G, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/s12992-014-0070-z; Sachs J, 2015, HUFFINGTON POST; Saint Raymond Agnes, 2010, Expert Rev Clin Pharmacol, V3, P593, DOI 10.1586/ecp.10.38; Sam T, R D PHARM IND PERSPE; Pinto CDS, 2010, REV SAUDE PUBL, V44, P611, DOI 10.1590/S0034-89102010005000021; Sarley D, 2009, ESTIMATING GLOBAL IN; Saxenian H, 2015, HEALTH POLICY PLANN, V30, P197, DOI 10.1093/heapol/czu003; Schnipper LE, 2015, J CLIN ONCOL, V33, P2563, DOI 10.1200/JCO.2015.61.6706; Schwarzkopf L, 2015, LUNG CANCER, V90, P274, DOI 10.1016/j.lungcan.2015.09.005; Secretariat NAFTA, 2014, N AM FREE TRAD AGR N; Shakarishvili G., 2010, GLOBAL HLTH GOVERNAN, V3, P1; Shin JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119931; Shretta R, 2015, MALARIA J, V14, DOI 10.1186/s12936-014-0530-1; Smith J, 2016, GLOBALIZATION HEALTH, V12, DOI 10.1186/s12992-016-0178-4; Smits KPJ, 2016, NEPHROL DIAL TRANSPL; So AD, 2008, PLOS BIOL, V6, P2078, DOI 10.1371/journal.pbio.0060262; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Stedman-Bryce G, 2015, MED TRANSPARENCY ALL; Stephens P, 2011, WORLD MED SITUATION; Stocks SJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5501; Stop TB, ROADMAP MDR TB SCALE; Stover J, 2015, CONSOLIDATED FORECAS; Suhrcke M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020724; Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291; Sulston J, 2004, NEGL DIS GROUP M PEN; Sun J, 2016, J MED ECON, V19, P881, DOI 10.1080/13696998.2016.1181641; Sun J, 2016, TROP MED INT HEALTH, V21, P263, DOI 10.1111/tmi.12636; Sun J, 2015, J GLOB ANTIMICROB RE, V3, P95, DOI 10.1016/j.jgar.2015.03.001; Swinburn B, 2015, LANCET, V385, P2534, DOI 10.1016/S0140-6736(14)61747-5; 't Hoen E, 2013, J PUBLIC HEALTH POL, V34, P370, DOI 10.1057/jphp.2013.21; 't Hoen EFM, 2016, LANCET, V387, P2272, DOI 10.1016/S0140-6736(16)30656-0; 't Hoen EFM, 2014, J PUBLIC HEALTH POL, V35, P137, DOI 10.1057/jphp.2013.53; Taylor R, 2009, NPR091114; Teerawattananon Y, 2015, VACCINE, V33, pA11, DOI 10.1016/j.vaccine.2014.12.050; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; The Global Fund and PEPFAR, 2014, GLOB FUND PEPFAR ARV; The Global Fund to Fight AIDS. Tuberculosis and Malaria, 2012, TUB MAL GUID GLOB FU; 'tHoen E, PRIVATE PATENTS PUBL; Thomas SK, 2013, BRIT J CLIN PHARMACO, V76, P797, DOI 10.1111/bcp.12087; Tominaga T, 2012, CLIN PHARMACOL THER, V92, P349, DOI 10.1038/clpt.2012.90; Torjesen I, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3012; Trouiller P, 2001, TROP MED INT HEALTH, V6, P945, DOI 10.1046/j.1365-3156.2001.00803.x; UN, 2000, EC1220004 UN EC SOC; UN, 2015, MILL DEV GOAL 8 TAK; UN, 2014, MILL DEV GOAL REP 20; UN, 2001, SGSM7779REV1 UN; UN, 2011, 2011 HIGH LEV M PREV; UN, GOAL 3 ENS HLTH LIV; UN, 2008, A63263 UN GEN ASS, P6; UN, 2016, UN SECR GEN HIGH LEV; UN, 2015, WE CAN END POV MILL; UN Commission on Life-Saving Commodities for Women and Children, 2012, COMM REP; UNITAID, 2014, TUB MED TECHN MARK L; UNITAID, 2014, TRANSP PARTN AGR IMP; UNITAID, 2016, GLOB MAL DIAGN ART T; United Nations, 2011, GUID PRINC BUS HUM R; United Nations, 1980, UNCTADTT33; United Nations Economic and Social Council, 2000, GEN COMM NO 14 RIGHT; United Nations General Assembly, 2006, A61338 UN GEN ASS; United States Government Publishing Office, 112 C US 2 SESS; Uppsala Monitoring Centre, 2015, NAT PHARM GUID; US Government Accountability Office, 2012, GAO12371R; US Senate Committee on Finance, WYD GRASSL SOV INV F; Van Amelsvoort V, 1970, STANDARD NOTES TANZA; van Onselen L., TPP IP CHAPTER DISAS; Velasquez G, 2011, RETHINKING GLOBAL HL; Vian T, 2008, HEALTH POLICY PLANN, V23, P83, DOI 10.1093/heapol/czm048; Viergever RF, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008932; Vogler S, 2010, RATIONAL USE MED EUR; Vogler S, 2010, PHARM HLTH INFORM RE; Volmink Jimmy, 2007, COCHRANE DB SYST REV, V4, DOI [DOI 10.1002/14651858.CD003343.PUB4, 10.1002/14651858.CD003343.pub4]; Wagner AK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-357; Wagner AK, 2011, HEALTH POLICY, V100, P151, DOI 10.1016/j.healthpol.2010.08.004; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; Waning B, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-9; Waning B, 2009, B WORLD HEALTH ORGAN, V87, P520, DOI 10.2471/BLT.08.058925; Ward JW, 2015, NEW ENGL J MED, V373, P2678, DOI 10.1056/NEJMe1513245; Weekes LM, 2005, BRIT J CLIN PHARMACO, V59, P112, DOI 10.1111/j.1365-2125.2005.02231.x; WHO, 2015, WHO TECH REP SER, V994, P1; WHO, 2012, PROMOTING ACCESS TO MEDICAL TECHNOLOGIES AND INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE, P1; WHO, 2010, WOR HEALT REP, P1; WHO, 2011, GLOB STRAT PLAN ACT; WHO, 2003, WHO POL PERSP MED NO; WHO, ACC AFF ESS MED; WHO, 2010, PHARM EXP 2010; WHO, GLOB PRIC REP MECH; WHO, WHAT IS UN HLTH COV; WHO, 2014, WHO DRUG INFORM, V28, P303; WHO, 1988, DEV IMPL NAT DRUG PO; WHO, 2015, QAS13526REV6 WHO; WHO, ESS MED HLTH PROD; WHO, CALL PART GLOB ANT R; WHO, 2012, PHARM SECT COUNTR PR; WHO, 1988, GUID DEV IMPL NAT DR; WHO, 2007, TECHNICAL REPORT SER, V950; WHO, 2015, 1 WHO WORLD BANK; WHO, 2011, WORLD MED SIT REP; WHO, 2008, MAN HOUS SURV MEAS A; WHO, PURS HIGH QUAL DOTS; Who, 2002, IMP PHARM SAF MON ME; WHO, 2015, INT PHARM; WHO, WHO LIST PREQ MED PR; WHO, 2012, AL NO 125 CONT IS IS; WHO, 2007, MOD QUAL ASS SYST PR; WHO, 1988, ETH CRIT MED DRUG PR; WHO, 1985, C EXP NAIR 25 29 NOV; WHO, 2010, ASS MED REG SYST SUB; Who, 2015, GUID START ANT THER; WHO, TARG 9 PROV ESS MED; WHO, 2002, ESS MED WHO MOD LIST; WHO, EV GOOD GOV MED PROG; WHO, 2011, SURV QUAL SEL ANT ME; WHO, ESS MED; WHO, 2002, TECHNICAL REPORT SER, V914; WHO, 2007, WHA60 WHO; WHO, 2015, GLOB REF LIST 100 CO; WHO, 2012, RES DEV MEET HLTH NE; WHO, 2010, 14 INT C DRUG REG AU; WHO, 2015, WHO LIST PREQ QUAL C; WHO, 2015, UN HLTH COV; WHO, 1977, TECHNICAL REPORT SER; WHO, WHOS GLOB NCD ACT PL; WHO, PUBL HLTH INN INT PR; WHO, 2016, DEF SSFFC MED PROD; WHO, INT C DRUG REG AUTH; WHO, 2009, CONSTR SCAL HLTH REL; WHO, TRIL STUD PROM ACC M; WHO, 1993, WHO EDM RES SER; WHO, 2012, WHOIVB1204; WHO, 2001, MACR HLTH INV HLTH E; WHO, EXP REV PAN; WHO, 2015, PAT SIT KEY PROD TRE; WHO, GLOB HLTH EXP DAT; WHO, 2016, RHTSAVALERT32016 WHO; WHO Consultative Expert Working Group on Research and Development (CEWG), 2012, FIN COORD RES DEV ME; WHO/Ecumenical Pharmaceutical Network, 2006, WHOPSMPAR20062 EC PH; WHO/Health Action International, 2011, REV SER PHARM PRIC P; WHO/Health Action International, 2008, WHOPSMPAR20083 HLTH; WHO/Health Action International, 2016, 7 WHO BOST U SCH PUB; Whyte P., 2013, WHO HAI PROJECT MEDI; William Davidson Institute, 2015, ACT FOR MAL CAS MAN; Wilson KR, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-20; Wirtz V, 2016, GLOBAL MARKET SITUAT; World Bank, GDP PER CAP CURR US; World Health Assembly, 2014, WHA67; World Health Organization, 2015, SUSTAINABLE DEV GOAL; World Health Organization, 2015, PUBLIC HLTH IMPLICAT; World Health Organization, 2011, SCAL ACT NONC DIS MU; World Health Organization, 2016, GLOB HLTH SECT STRAT; World Health Organization, 2007, EVERYBODYS BUSINESS; World Health Organization, 2015, WHO GUID COUNTR PHAR; World Health Organization, 2001, INT CLASS FUNCT DIS; World Health Organization and Health Action International, 2009, UND RESP PHARM PROM; World Health Organization/Health Action International, 2011, REV SER PHARM PRIC P; Xiao YH, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001556; Yadzeck AS, 2016, HLTH SYSTEMS REFORM, V2, P102; Yu H, 2016, J PHARMACEUT BIOMED, V125, P85, DOI 10.1016/j.jpba.2016.03.018; Zopf S, 2016, WORLD J HEPATOL, V8, P139, DOI 10.4254/wjh.v8.i3.139	448	255	261	6	78	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2017	389	10067					403	476		10.1016/S0140-6736(16)31599-9	http://dx.doi.org/10.1016/S0140-6736(16)31599-9			74	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EI9CK	27832874	Green Published, Bronze			2023-01-03	WOS:000392804700037
J	Aaron, SD; Vandemheen, KL; FitzGerald, JM; Ainslie, M; Gupta, S; Lemiere, C; Field, SK; McIvor, RA; Hernandez, P; Mayers, I; Mulpuru, S; Alvarez, GG; Pakhale, S; Mallick, R; Boulet, LP				Aaron, Shawn D.; Vandemheen, Katherine L.; FitzGerald, J. Mark; Ainslie, Martha; Gupta, Samir; Lemiere, Catherine; Field, Stephen K.; McIvor, R. Andrew; Hernandez, Paul; Mayers, Irvin; Mulpuru, Sunita; Alvarez, Gonzalo G.; Pakhale, Smita; Mallick, Ranjeeta; Boulet, Louis-Philippe		Canadian Resp Res Network	Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; OVERDIAGNOSIS; PREVALENCE; MANAGEMENT; CHILDREN; ILLNESS; COST	IMPORTANCE Although asthma is a chronic disease, the expected rate of spontaneous remissions of adult asthma and the stability of diagnosis are unknown. OBJECTIVE To determine whether a diagnosis of current asthma could be ruled out and asthma medications safely stopped in randomly selected adults with physician-diagnosed asthma. DESIGN, SETTING, AND PARTICIPANTS A prospective, multicenter cohort study was conducted in 10 Canadian cities from January 2012 to February 2016. Random digit dialing was used to recruit adult participants who reported a history of physician-diagnosed asthma established within the past 5 years. Participants using long-term oral steroids and participants unable to be tested using spirometry were excluded. Information from the diagnosing physician was obtained to determine how the diagnosis of asthma was originally made in the community. Of 1026 potential participants who fulfilled eligibility criteria during telephone screening, 701 (68.3%) agreed to enter into the study. All participants were assessed with home peak flow and symptom monitoring, spirometry, and serial bronchial challenge tests, and those participants using daily asthma medications had their medications gradually tapered off over 4 study visits. Participants in whom a diagnosis of current asthma was ultimately ruled out were followed up clinically with repeated bronchial challenge tests over 1 year. EXPOSURE Physician-diagnosed asthma established within the past 5 years. MAIN OUTCOMES AND MEASURES The primary outcomewas the proportion of participants in whom a diagnosis of current asthma was ruled out, defined as participants who exhibited no evidence of acute worsening of asthma symptoms, reversible airflow obstruction, or bronchial hyperresponsiveness after having all asthma medications tapered off and after a study pulmonologist established an alternative diagnosis. Secondary outcomes included the proportion with asthma ruled out after 12 months and the proportion who underwent an appropriate initial diagnostic workup for asthma in the community. RESULTS Of 701 participants (mean [SD] age, 51 [16] years; 467 women [67%]), 613 completed the study and could be conclusively evaluated for a diagnosis of current asthma. Current asthma was ruled out in 203 of 613 study participants (33.1%; 95% CI, 29.4%-36.8%). Twelve participants (2.0%) were found to have serious cardiorespiratory conditions that had been previously misdiagnosed as asthma in the community. After an additional 12 months of follow-up, 181 participants (29.5%; 95% CI, 25.9%-33.1%) continued to exhibit no clinical or laboratory evidence of asthma. Participants in whom current asthma was ruled out, compared with those in whom it was confirmed, were less likely to have undergone testing for airflow limitation in the community at the time of initial diagnosis (43.8% vs 55.6%, respectively; absolute difference, 11.8%; 95% CI, 2.1%-21.5%). CONCLUSIONS AND RELEVANCE Among adults with physician-diagnosed asthma, a current diagnosis of asthma could not be established in 33.1% who were not using daily asthma medications or had medications weaned. In patients such as these, reassessing the asthma diagnosis may be warranted.	[Aaron, Shawn D.; Vandemheen, Katherine L.; Mulpuru, Sunita; Alvarez, Gonzalo G.; Pakhale, Smita; Mallick, Ranjeeta] Univ Ottawa, Ottawa Hosp, Res Inst, 501 Smyth Rd,Gen Campus, Ottawa, ON K1H 8L6, Canada; [FitzGerald, J. Mark] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Ainslie, Martha] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Gupta, Samir] Univ Toronto, Dept Med, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Lemiere, Catherine] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Field, Stephen K.] Univ Calgary, Dept Med, Calgary, AB, Canada; [McIvor, R. Andrew] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Hernandez, Paul] Dalhousie Univ, Dept Med, Halifax, NS, Canada; [Mayers, Irvin] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Boulet, Louis-Philippe] Univ Laval, Hop Laval, Ctr Rech, Quebec City, PQ, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of British Columbia; University of Manitoba; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; Universite de Montreal; University of Calgary; McMaster University; Dalhousie University; University of Alberta; Laval University	Aaron, SD (corresponding author), Univ Ottawa, Ottawa Hosp, Res Inst, 501 Smyth Rd,Gen Campus, Ottawa, ON K1H 8L6, Canada.	saaron@ohri.ca		Pakhale, Smita/0000-0002-4051-962X; Alvarez, Gonzalo G/0000-0003-1562-5305	Canadian Institutes of Health Research [MOP-115073]; Methapharm Inc; Trudell Medical International Inc	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Methapharm Inc; Trudell Medical International Inc	Funding/Support: This work was supported by grant MOP-115073 from the Canadian Institutes of Health Research. Methapharm Inc supplied provocholine; Trudell Medical International Inc supplied peak flow meters; and ASDE Survey Sampler Inc organized the random digit dialing.	Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Burney P, 1996, EUR RESPIR J, V9, P687; Bush A, 2016, ARCH DIS CHILD, V101, P688, DOI 10.1136/archdischild-2015-309053; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Drazen JM, 2009, NEW ENGL J MED, V360, P1671, DOI 10.1056/NEJMe0902057; Gershon AS, 2012, CHEST, V141, P1190, DOI 10.1378/chest.11-0831; Global Initiative for Asthma, 2016, GLOB STRAT ASTHM MAN; Heffler E, 2015, J ASTHMA, V52, P931, DOI 10.3109/02770903.2015.1026442; Horne R, 2002, PSYCHOL HEALTH, V17, P17, DOI 10.1080/08870440290001502; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Looijmans-van den Akker I, 2016, BRIT J GEN PRACT, V66, pE152, DOI 10.3399/bjgp16X683965; Lougheed MD, 2012, CAN RESPIR J, V19, P127, DOI 10.1155/2012/635624; Lucas AEM, 2008, FAM PRACT, V25, P86, DOI 10.1093/fampra/cmn006; Luks VP, 2010, EUR RESPIR J, V36, P255, DOI 10.1183/09031936.00165109; Lynch BA, 2010, ALLERGY ASTHMA PROC, V31, pE48, DOI 10.2500/aap.2010.31.3358; McGlynn EA, 2015, JAMA-J AM MED ASSOC, V314, P2501, DOI 10.1001/jama.2015.13453; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Heart Lung and Blood Institute (US), 2007, EXP PAN REP EXP PAN; Pakhale S, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-27; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Schneider Antonius, 2009, BMC Pulm Med, V9, P31, DOI 10.1186/1471-2466-9-31; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Yurdakul AS, 2005, J ASTHMA, V42, P843, DOI 10.1080/02770900500370981	24	248	254	1	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2017	317	3					269	279		10.1001/jama.2016.19627	http://dx.doi.org/10.1001/jama.2016.19627			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9KC	28114551	Bronze			2023-01-03	WOS:000392089200014
J	Ehdaie, B; Rento, CT; Son, V; Turner, SS; Samie, A; Dillingham, RA; Smith, JA				Ehdaie, Beeta; Rento, Chloe T.; Son, Veronica; Turner, Sydney S.; Samie, Amidou; Dillingham, Rebecca A.; Smith, James A.			Evaluation of a Silver-Embedded Ceramic Tablet as a Primary and Secondary Point-of-Use Water Purification Technology in Limpopo Province, S. Africa	PLOS ONE			English	Article							ARTIBONITE VALLEY; CONTROLLED-TRIAL; FILTERS; SUSTAINABILITY; PERFORMANCE	The World Health Organization (WHO) recognizes point-of-use water treatment (PoUWT) technologies as effective means to improve water quality. This paper investigates long-term performance and social acceptance of a novel PoUWT technology, a silver-infused ceramic tablet, in Limpopo Province, South Africa. When placed in a water storage container, the silver-embedded ceramic tablet releases silver ions into water, thereby disinfecting microbial pathogens and leaving the water safe for human consumption. As a result of its simplicity and efficiency, the silver-embedded ceramic tablet can serve as a stand-alone PoUWT method and as a secondary PoUWT to improve exisitng PoUWT methods, such as ceramic water filters. In this paper, three PoUWT interventions were conducted to evaluate the silver-embedded ceramic tablet: (1) the silver-embedded ceramic tablet as a stand-alone PoUWT method, (2) ceramic water filters stand-alone, and (3) a filter-tablet combination. The filter-tablet combination evaluates the silver-embedded ceramic tablet as a secondary PoUWT method when placed in the lower reservoir of the ceramic water filter system to provide residual disinfection post-filtration. Samples were collected from 79 households over one year and analyzed for turbidity, total silver levels and coliform bacteria. Results show that the silver-embedded ceramic tablet effectively reduced total coliform bacteria (TC) and E. coli when used as a stand-alone PoUWT method and when used in combination with ceramic water filters. The silver-embedded ceramic tablet's performance as a stand-alone PoUWT method was comparable to current inexpensive, single-use PoUWT methods, demonstrating 100% and 75% median reduction in E. coli and TC, respectively, after two months of use. Overall, the the filter-tablet combination performed the best of the three interventions, providing a 100% average percent reduction in E. coli over one year. User surveys were also conducted and indicated that the silver-embedded ceramic tablet was simple to use and culturally appropriate. Also, silver levels in all treated water samples remained below 20 mu g/L, significantly lower than the drinking water standard of 100 mu g/L, making it safe for consumption. Long-term data demonstrates that the silver-embedded ceramic tablet has beneficial effects even after one year of use. This study demonstrates that the silver-embedded ceramic tablet can effectively improve water quality when used alone, or with ceramic water filters, to reduce rates of recontamination. Therefore, the tablet has the potential to provide a low-cost means to purify water in resource-limited settings.	[Ehdaie, Beeta; Rento, Chloe T.; Son, Veronica; Turner, Sydney S.; Smith, James A.] Unviers Virginia, Dept Civil & Environm Engn, Charlottesville, VA 22903 USA; [Samie, Amidou] Univ Venda, Dept Chem, Dept Microbiol, Thohoyandou, Limpopo Provinc, South Africa; [Dillingham, Rebecca A.] Univ Virginia, Dept Med, Charlottesville, VA USA	University of Venda; University of Virginia	Smith, JA (corresponding author), Unviers Virginia, Dept Civil & Environm Engn, Charlottesville, VA 22903 USA.	jsmith@virginia.edu	Samie, Amidou/AAG-1647-2021	Samie, Amidou/0000-0002-7410-5695	National Science Foundation [CBET-1438619, EEC 1156999]; University of Virginia's Jefferson Public Citizen's program; University of Virginia Center for Global Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046] Funding Source: NIH RePORTER; Div Of Chem, Bioeng, Env, & Transp Sys [1438619] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); University of Virginia's Jefferson Public Citizen's program; University of Virginia Center for Global Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This research was supported by the U.S. National Science Foundation (Awards CBET-1438619 and EEC 1156999) (URL: nsf.gov), recipient JAS; University of Virginias Jefferson Public Citizens program (URL: http://www.virginia.edu/jpc/), recipients: VS CTR SST; and University of Virginia Center for Global Health (URL: https://globalhealth.virginia.edu), recipients: VS CTR SST.	Abebe LS, 2014, J WATER HEALTH, V12, P288, DOI 10.2166/wh.2013.185; Albert J, 2010, ENVIRON SCI TECHNOL, V44, P4426, DOI 10.1021/es1000566; Boisson S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001497; Clasen T, 2006, WATER PRACT TECHNOL, V1, DOI 10.2166/WPT.2006031; Clasen T, 2004, WATER SCI TECHNOL, V50, P111, DOI 10.2166/wst.2004.0033; Clasen TF, 2004, AM J TROP MED HYG, V70, P651, DOI 10.4269/ajtmh.2004.70.651; Dillingham R, 2004, LANCET, V363, P94, DOI 10.1016/S0140-6736(03)15307-X; Dreibelbis R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1015; Ehdaie B, 2014, ENVIRON SCI TECHNOL, V48, P13901, DOI 10.1021/es503534c; Jain S, 2010, AM J TROP MED HYG, V82, P16, DOI 10.4269/ajtmh.2010.08-0584; Kallman EN, 2011, J ENVIRON ENG-ASCE, V137, P407, DOI 10.1061/(ASCE)EE.1943-7870.0000330; KIRCHHOFF LV, 1985, J HYG-CAMBRIDGE, V94, P173, DOI 10.1017/S0022172400061374; Lantagne D. S., 2006, NAVIGATION-US, V99, P17; Lantagne D, 2010, INT J ENVIRON HEAL R, V20, P171, DOI 10.1080/09603120903440665; Lantagne DS, 2012, ENVIRON SCI TECHNOL, V46, P11352, DOI 10.1021/es301842u; Lantagne DS, 2009, AM J PUBLIC HEALTH, V99, P1975, DOI 10.2105/AJPH.2009.160077; Liang K., 2010, IMPROVING HOUSEHOLD; Limpopo Provincial Government, 2009, LIMP EMPL GROWTH DEV; Liu JY, 2010, ENVIRON SCI TECHNOL, V44, P2169, DOI 10.1021/es9035557; Mausezahl D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000125; Mellor JE, 2014, J ENV ENG; Mellor J, 2014, WATER RES, V49, P286, DOI 10.1016/j.watres.2013.11.035; Oyanedel-Craver VA, 2008, ENVIRON SCI TECHNOL, V42, P927, DOI 10.1021/es071268u; Sisson AJ, 2013, AM J TROP MED HYG, V88, P862, DOI 10.4269/ajtmh.12-0345; Sisson AJ, 2013, J WATER SANIT HYG DE, V3, P51, DOI 10.2166/washdev.2013.092; UNICEF, 2008, PROM HOUS WAT TREAT; Wedgwood A, 2003, WILLINGNESS PAY SURV; WHO, 2014, UN WAT GLOB AN ASS; Xiu ZM, 2012, NANO LETT, V12, P4271, DOI 10.1021/nl301934w	29	14	14	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2017	12	1							e0169502	10.1371/journal.pone.0169502	http://dx.doi.org/10.1371/journal.pone.0169502			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3EK	28095435	Green Submitted, gold, Green Published			2023-01-03	WOS:000392372300020
J	Choquette, A; Troncy, E; Guillot, M; Varin, F; del Castillo, JRE				Choquette, Amelie; Troncy, Eric; Guillot, Martin; Varin, France; del Castillo, Jerome R. E.			Pharmacokinetics of Lidocaine Hydrochloride Administered with or without Adrenaline for the Paravertebral Brachial Plexus Block in Dogs	PLOS ONE			English	Article							NERVE BLOCK; INTRAMUSCULAR INJECTION; SYSTEMIC ABSORPTION; PART II; ROPIVACAINE; BUPIVACAINE; EPINEPHRINE; PROFILES; PLASMA; LEVOBUPIVACAINE	Adrenaline is known to prolong the duration of local anesthesia but its effects on the pharmacokinetic processes of local anesthetic drugs are not fully understood. Our objective was to develop a compartmental model for quantification of adrenaline's impact on the pharmacokinetics of perineurally-injected lidocaine in the dog. Dogs were subjected to paravertebral brachial plexus block using lidocaine alone or adrenalinated lidocaine. Data was collected through a prospective, randomised, blinded crossover protocol performed over three periods. Blood samples were collected during 180 minutes following block execution. Compartmental pharmacokinetic models were developed and their goodness-of-fit were compared. The lowering effects of adrenaline on the absorption of lidocaine were statistically determined with one-sided tests. A one-compartment disposition model with two successive zero-order absorption processes best fitted our experimental data. Adrenaline decreased the peak plasma lidocaine concentration by approximately 60% (P <0.001), decreased this local anesthetic's fast and slow zero-order absorption rates respectively by 50% and 90% (P= 0.046, and P <0.001), which respective durations were prolonged by 90% and 1300% (P <0.020 and P <0.001). Lidocaine demonstrated a previously unreported atypical absorption profile following its paravertebral injection in dogs. Adrenaline decreased the absorption rate of lidocaine and prolonged the duration of its absorption.	[Choquette, Amelie; Troncy, Eric; Guillot, Martin; del Castillo, Jerome R. E.] Univ Montreal, Dept Vet Biomed Sci, Quebecs Anim Pharmacol Res Grp GREPAQ, St Hyacinthe, PQ, Canada; [Varin, France] Univ Montreal, Fac Pharm, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal	del Castillo, JRE (corresponding author), Univ Montreal, Dept Vet Biomed Sci, Quebecs Anim Pharmacol Res Grp GREPAQ, St Hyacinthe, PQ, Canada.	jerome.del.castillo@umontreal.ca	del Castillo, Jérôme RE/J-6976-2013; Troncy, Eric/J-6650-2013; del Castillo, Jerome/AAM-9409-2020	del Castillo, Jérôme RE/0000-0001-5046-7926; Troncy, Eric/0000-0003-0209-5261; del Castillo, Jerome/0000-0001-5046-7926	Bourse de recherche clinique of the Association des medecins veterinaires du Quebec (AMVQ); Fonds de recherche clinique Zoetis of Fonds en Sante des Animaux de Compagnie (FSAC), Faculte de Medecine Veterinaire of Universite de Montreal; Natural Sciences and Engineering Research Council of Canada [327158-2008, 441651-2013]; Canada Foundation for Innovation [9483, 24601]; Natural Sciences and Engineering Research Council of Canada (NSERC)	Bourse de recherche clinique of the Association des medecins veterinaires du Quebec (AMVQ); Fonds de recherche clinique Zoetis of Fonds en Sante des Animaux de Compagnie (FSAC), Faculte de Medecine Veterinaire of Universite de Montreal; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	Financial support was provided by the Bourse de recherche clinique of the Association des medecins veterinaires du Quebec (AMVQ), and the Fonds de recherche clinique Zoetis of Fonds en Sante des Animaux de Compagnie (FSAC), Faculte de Medecine Veterinaire of Universite de Montreal. This study was funded (Pr. Eric Troncy) in part by a Discovery grant (#327158-2008, #441651-2013, supporting salaries) from the Natural Sciences and Engineering Research Council of Canada, as well as by an ongoing New Opportunities Fund grant (#9483) and a Leader Opportunity Fund grant (#24601), supporting pain/function equipment, from the Canada Foundation for Innovation. M. Guillot was the recipient of a Scholarship for postdoctoral research from Natural Sciences and Engineering Research Council of Canada (NSERC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbara C, 2010, BRIT J PHARMACOL, V161, P1857, DOI 10.1111/j.1476-5381.2010.01007.x; Bagshaw HS, 2009, VET RADIOL ULTRASOUN, V50, P649, DOI 10.1111/j.1740-8261.2009.01599.x; BAILEY CS, 1987, J VET INTERN MED, V1, P128, DOI 10.1111/j.1939-1676.1987.tb02000.x; BALLARD BE, 1975, J PHARM SCI, V64, P781, DOI 10.1002/jps.2600640510; BENNETT PN, 1982, J PHARMACOKINET BIOP, V10, P265, DOI 10.1007/BF01059261; BURM AGL, 1986, ANESTH ANALG, V65, P1281; BURM AGL, 1987, CLIN PHARMACOKINET, V13, P191, DOI 10.2165/00003088-198713030-00004; Chalkiadis GA, 2013, PEDIATR ANESTH, V23, P58, DOI 10.1111/pan.12074; Choquette A, 2016, VET ANESTH ANA UNPUB; Cox S, 2012, J VET PHARMACOL THER, V35, P305, DOI 10.1111/j.1365-2885.2011.01328.x; D'Argenio DZ, 2009, ADAPT 5 USERS GUIDE; Duke T, 2000, CAN VET J, V41, P949; Feary DJ, 2005, AM J VET RES, V66, P574, DOI 10.2460/ajvr.2005.66.574; Gaudreault F, 2012, J PHARMACOKINET PHAR, V39, P635, DOI 10.1007/s10928-012-9275-z; Gaudreault F, 2009, THER DRUG MONIT, V31, P753, DOI 10.1097/FTD.0b013e3181bc8014; Gerner P, 2010, ANESTH ANALG, V111, P221, DOI 10.1213/ANE.0b013e3181dd2690; Karmakar MK, 2005, ANESTHESIOLOGY, V103, P704, DOI 10.1097/00000542-200510000-00008; le Cotonnec JY, 1998, FERTIL STERIL, V69, P195, DOI 10.1016/S0015-0282(97)00502-5; Lemay E, 2003, CAN J ANAESTH, V50, P562, DOI 10.1007/BF03018641; Lemke KA, 2008, VET CLIN N AM-SMALL, V38, P1231, DOI 10.1016/j.cvsm.2008.06.003; Mahmood AH, 2015, INT J PHARMACEUT, V481, P71, DOI 10.1016/j.ijpharm.2015.01.046; McLennan Danielle N, 2005, Drug Discov Today Technol, V2, P89, DOI 10.1016/j.ddtec.2005.05.006; Mosing M, 2010, VET ANAESTH ANALG, V37, P154, DOI 10.1111/j.1467-2995.2009.00509.x; Ngo LY, 1997, J PHARM SCI-US, V86, P944, DOI 10.1021/js960399i; O'Donnell BD, 2009, ANESTHESIOLOGY, V111, P25, DOI 10.1097/ALN.0b013e3181a915c7; Simon MJG, 2004, BRIT J ANAESTH, V93, P512, DOI 10.1093/bja/aeh241; Sinnott CJ, 2003, ANESTHESIOLOGY, V98, P181, DOI 10.1097/00000542-200301000-00028; Skarda TR, 2007, LUMB JONES VET ANEST, P395; Skarda TR, 2007, LUMB JONES VET ANEST, P561; Thomasy SM, 2005, AM J VET RES, V66, P1162, DOI 10.2460/ajvr.2005.66.1162; Trumpatori BJ, 2010, VET SURG, V39, P785, DOI 10.1111/j.1532-950X.2010.00712.x; TUCKER GT, 1979, CLIN PHARMACOKINET, V4, P241, DOI 10.2165/00003088-197904040-00001; WILCKE JR, 1983, J VET PHARMACOL THER, V6, P49, DOI 10.1111/j.1365-2885.1983.tb00454.x; Wilson DV, 2004, J VET PHARMACOL THER, V27, P105, DOI 10.1111/j.1365-2885.2004.00552.x; Wu ZM, 2013, J PHARM PHARMACOL, V65, P1429, DOI 10.1111/jphp.12114; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; Zhou HH, 2003, J CLIN PHARMACOL, V43, P211, DOI 10.1177/0091270002250613	37	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2017	12	1							e0169745	10.1371/journal.pone.0169745	http://dx.doi.org/10.1371/journal.pone.0169745			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH5WO	28068408	Green Published, Green Submitted, gold			2023-01-03	WOS:000391843900062
J	Volchenboum, SL; Mayampurath, A; Goksu-Gursoy, G; Edelson, DP; Howell, MD; Churpek, MM				Volchenboum, Samuel L.; Mayampurath, Anoop; Goksu-Gursoy, Gozde; Edelson, Dana P.; Howell, Michael D.; Churpek, Matthew M.			Association Between In-Hospital Critical Illness Events and Outcomes in Patients on the Same Ward	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Volchenboum, Samuel L.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Mayampurath, Anoop] Univ Chicago, Computat Inst, Chicago, IL 60637 USA; [Goksu-Gursoy, Gozde] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA; [Edelson, Dana P.; Churpek, Matthew M.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Howell, Michael D.] Univ Chicago, Ctr Healthcare Delivery Sci & Innovat, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Churpek, MM (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	matthew.churpek@uchospitals.edu		Churpek, Matthew/0000-0002-4030-5250	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL121080] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL121080] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berlot G, 2004, EUR J EMERG MED, V11, P24, DOI 10.1097/00063110-200402000-00005; Churpek MM, 2014, AM J RESP CRIT CARE, V190, P649, DOI 10.1164/rccm.201406-1022OC; Churpek MM, 2014, CRIT CARE MED, V42, P841, DOI 10.1097/CCM.0000000000000038; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Stelfox HT, 2012, ARCH INTERN MED, V172, P467, DOI 10.1001/archinternmed.2011.2315	5	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2016	316	24					2674	2675		10.1001/jama.2016.15505	http://dx.doi.org/10.1001/jama.2016.15505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG5UN	28027358	Green Accepted			2023-01-03	WOS:000391110200022
J	Svagan, AJ; Kusic, A; De Gobba, C; Larsen, FH; Sassene, P; Zhou, Q; van de Weert, M; Mullertz, A; Jorgensen, B; Ulvskov, P				Svagan, Anna J.; Kusic, Anja; De Gobba, Cristian; Larsen, Flemming H.; Sassene, Philip; Zhou, Qi; van de Weert, Marco; Mullertz, Anette; Jorgensen, Bodil; Ulvskov, Peter			Rhamnogalacturonan-I Based Microcapsules for Targeted Drug Release	PLOS ONE			English	Article							POLYSACCHARIDES; POLYURETHANE; DELIVERY; SOLUBILIZATION; DIISOCYANATE; SPECTROSCOPY; ABSORPTION; EXPRESSION; DIGESTION; CAPSULES	Drug targeting to the colon via the oral administration route for local treatment of e.g. inflammatory bowel disease and colonic cancer has several advantages such as needle-free administration and low infection risk. A new source for delivery is plant-polysaccharide based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal tract the RG-I is only degraded by the action of the colonic microflora. For assessment of potential drug delivery properties, RG-I based microcapsules (similar to 1 mu m in diameter) were prepared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a fluorescent dye (model drug). The capsules showed negligible and very little in vitro release when subjected to media simulating gastric and intestinal fluids, respectively. However, upon exposure to a cocktail of commercial RG-I cleaving enzymes, similar to 9 times higher release was observed, demonstrating that the capsules can be opened by enzymatic degradation. The combined results suggest a potential platform for targeted drug delivery in the terminal gastro-intestinal tract.	[Svagan, Anna J.; Kusic, Anja; Sassene, Philip; van de Weert, Marco; Mullertz, Anette] Univ Copenhagen, Dept Pharm, Copenhagen, Denmark; [De Gobba, Cristian; Larsen, Flemming H.] Univ Copenhagen, Dept Food Sci, Copenhagen, Denmark; [Zhou, Qi] Royal Inst Technol KTH, Sch Biotechnol, Stockholm, Sweden; [Jorgensen, Bodil; Ulvskov, Peter] Univ Copenhagen, Dept Plant & Environm Sci, Copenhagen, Denmark; [Svagan, Anna J.] Royal Inst Technol KTH, Dept Fibre & Polymertechnol, Stockholm, Sweden	University of Copenhagen; University of Copenhagen; Royal Institute of Technology; University of Copenhagen; Royal Institute of Technology	Svagan, AJ (corresponding author), Univ Copenhagen, Dept Pharm, Copenhagen, Denmark.; Svagan, AJ (corresponding author), Royal Inst Technol KTH, Dept Fibre & Polymertechnol, Stockholm, Sweden.	svagan@kth.se	Zhou, Qi/B-9095-2013; Larsen, Flemming/A-5255-2015; De Gobba, Cristian/M-5178-2014; van de Weert, Marco/AGR-7726-2022; Ulvskov, Peter/I-1228-2014; Müllertz, Anette/ABF-6935-2021; Jorgensen, Bodil/F-6551-2014	Zhou, Qi/0000-0001-9832-027X; Larsen, Flemming/0000-0001-5180-6870; De Gobba, Cristian/0000-0002-2774-5876; Ulvskov, Peter/0000-0003-3776-818X; Müllertz, Anette/0000-0003-3020-8892; Jorgensen, Bodil/0000-0002-0453-1277; Svagan (Hanner), Anna J./0000-0002-4583-723X	Danish Council for Independent Research	Danish Council for Independent Research(Det Frie Forskningsrad (DFF))	This work was supported by the Danish Council for Independent Research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Lorenzo C, 2013, ADV DRUG DELIVER REV, V65, P1148, DOI 10.1016/j.addr.2013.04.016; Armand M, 1996, AM J PHYSIOL-GASTR L, V271, pG172, DOI 10.1152/ajpgi.1996.271.1.G172; Assifaoui A, 2013, ACTA BIOMATER, V9, P6218, DOI 10.1016/j.actbio.2012.11.031; Assifaoui A, 2011, CARBOHYD POLYM, V85, P388, DOI 10.1016/j.carbpol.2011.02.037; Baier G, 2010, BIOMACROMOLECULES, V11, P960, DOI 10.1021/bm901414k; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Bergstrom CAS, 2014, EUR J PHARM SCI, V57, P173, DOI 10.1016/j.ejps.2013.10.015; Berthelsen R, 2015, MOL PHARMACEUT, V12, P1062, DOI 10.1021/mp500545k; Boulet JC, 2007, CARBOHYD POLYM, V69, P79, DOI 10.1016/j.carbpol.2006.09.003; Buchanan BB, 2007, BIOCH MOL BIOL PLANT; Byg I, 2012, FOOD CHEM, V131, P1207, DOI 10.1016/j.foodchem.2011.09.106; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; Desilets S, 1997, J POLYM SCI POL CHEM, V35, P2991, DOI 10.1002/(SICI)1099-0518(199710)35:14<2991::AID-POLA20>3.0.CO;2-D; Ei-Gibaly I, 2002, INT J PHARM, V232, P199, DOI 10.1016/S0378-5173(01)00903-6; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Humblet-Hua NPK, 2012, J AGR FOOD CHEM, V60, P9502, DOI 10.1021/jf3024529; Kwon OJ, 2007, J APPL POLYM SCI, V103, P1544, DOI 10.1002/app.25363; Li SS, 2015, CHINESE J POLYM SCI, V33, P1196, DOI 10.1007/s10118-015-1670-7; Manderson K, 2005, APPL ENVIRON MICROB, V71, P8383, DOI 10.1128/AEM.71.12.8383-8389.2005; Marquis M, 2015, CARBOHYD POLYM, V116, P189, DOI 10.1016/j.carbpol.2014.01.083; Maxwell EG, 2015, CARBOHYD POLYM, V132, P546, DOI 10.1016/j.carbpol.2015.06.082; METZ G, 1994, J MAGN RESON SER A, V110, P219, DOI 10.1006/jmra.1994.1208; Molgaard SL, 2014, CARBOHYD POLYM, V114, P179, DOI 10.1016/j.carbpol.2014.08.011; Munjeri O, 1997, J CONTROL RELEASE, V46, P273, DOI 10.1016/S0168-3659(96)01607-0; Natrajan VK, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/1/015401; Orfila C, 2012, PLANTA, V236, P185, DOI 10.1007/s00425-012-1596-z; Rueda L, 2011, COMPOS SCI TECHNOL, V71, P1953, DOI 10.1016/j.compscitech.2011.09.014; Sassene P, 2014, AAPS J, V16, P1344, DOI 10.1208/s12248-014-9672-x; SCHOLS HA, 1994, CARBOHYD RES, V256, P97, DOI 10.1016/0008-6215(94)84230-2; Svagan AJ, 2016, CARBOHYD POLYM, V136, P292, DOI 10.1016/j.carbpol.2015.09.040; Thomassen LV, 2011, ENZYME MICROB TECH, V49, P289, DOI 10.1016/j.enzmictec.2011.06.006; Vertzoni M, 2005, EUR J PHARM BIOPHARM, V60, P413, DOI 10.1016/j.ejpb.2005.03.002; Yiamsawas D, 2014, RSC ADV, V4, P11661, DOI 10.1039/c3ra47971d; Zangenberg NH, 2001, EUR J PHARM SCI, V14, P115, DOI 10.1016/S0928-0987(01)00169-5; Zhang ML, 2014, P NATL ACAD SCI USA, V111, pE3708, DOI 10.1073/pnas.1406156111	35	9	10	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2016	11	12							e0168050	10.1371/journal.pone.0168050	http://dx.doi.org/10.1371/journal.pone.0168050			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QC	27992455	Green Published, gold, Green Submitted			2023-01-03	WOS:000392842600030
J	Lee, P				Lee, Paul			Wasting Energy to Treat Obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lee, Paul] St Vincents Hosp, Diabet & Metab Div, Garvan Inst Med Res, Sydney, NSW, Australia; [Lee, Paul] St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; St Vincents Hospital Sydney	Lee, P (corresponding author), St Vincents Hosp, Diabet & Metab Div, Garvan Inst Med Res, Sydney, NSW, Australia.; Lee, P (corresponding author), St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia.							[Anonymous], 1879, DTSCH ARCH KLIN MED, V24, P539; DEDUVE C, 1964, FED PROC, V23, P1045; Kajimura S, 2015, CELL METAB, V22, P546, DOI 10.1016/j.cmet.2015.09.007; Long JZ, 2016, CELL, V166, P424, DOI 10.1016/j.cell.2016.05.071; Tainter ML, 1935, J AMER MED ASSOC, V105, P0332, DOI 10.1001/jama.1935.02760310006002	5	7	7	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 8	2016	375	23					2298	2300		10.1056/NEJMcibr1610015	http://dx.doi.org/10.1056/NEJMcibr1610015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EE0ZQ	27959675				2023-01-03	WOS:000389310000017
J	Sauve, S; Aubin, Y				Sauve, Simon; Aubin, Yves			Dodecylphosphocholine Micelles Induce Amyloid Formation of the PrP(110-136) Peptide via an alpha-Helical Metastable Conformation	PLOS ONE			English	Article							THIOFLAVIN-T-BINDING; PRION PROTEIN; MULTIDIMENSIONAL NMR; SYNUCLEIN; SCRAPIE; VISUALIZATION; RESOLUTION; MECHANISM; FIBRILS; SYSTEM	A peptide encompassing the conserved hydrophobic region and the first beta-strand of the prion protein (PrP(110-136)) shown to interact with the surface of dodecylphosphocholine micelles adopts an alpha-helical conformation that is localized below the head-group layer. This surface-bound peptide has a half-life of one day, and readily initiates the formation of amyloid fibrils. The presence of the latter was confirmed using birefringence microscopy upon Congo red binding and thioflavin T-binding induced fluorescence. The observation of this metastable alpha-helical conformer provides a unique snapshot of the early steps of the interconversion pathway. These findings together with the body of evidence from the prion literature allowed us to propose a mechanism for the conversion of PrPC to amyloid material.	[Sauve, Simon; Aubin, Yves] Hlth Canada, Biol & Genet Therapies Directorate, Ctr Biol Evaluat, Ottawa, ON, Canada; [Aubin, Yves] Carleton Univ, Dept Chem, Ottawa, ON, Canada	Health Canada; Carleton University	Aubin, Y (corresponding author), Hlth Canada, Biol & Genet Therapies Directorate, Ctr Biol Evaluat, Ottawa, ON, Canada.; Aubin, Y (corresponding author), Carleton Univ, Dept Chem, Ottawa, ON, Canada.	yves.aubin@hc-sc.gc.ca		Aubin, Yves/0000-0002-8554-0297	Government of Canada	Government of Canada(CGIAR)	The Government of Canada.	Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Coleman BM, 2014, J VIROL, V88, P2690, DOI 10.1128/JVI.02720-13; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Hawe A, 2008, PHARM RES-DORDR, V25, P1487, DOI 10.1007/s11095-007-9516-9; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 1998, J VIROL, V72, P1153; Hornemann S, 2009, J BIOL CHEM, V284, P22713, DOI 10.1074/jbc.M109.000430; Hyberts SG, 2012, TOP CURR CHEM, V316, P125, DOI 10.1007/128_2011_187; Jaravine V, 2006, NAT METHODS, V3, P605, DOI 10.1038/NMETH900; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Khurana R, 2005, J STRUCT BIOL, V151, P229, DOI 10.1016/j.jsb.2005.06.006; Klauda JB, 2010, J PHYS CHEM B, V114, P7830, DOI 10.1021/jp101759q; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Luhrs TT, 2006, J MOL BIOL, V357, P833, DOI 10.1016/j.jmb.2006.01.016; Norstrom EM, 2005, J BIOL CHEM, V280, P27236, DOI 10.1074/jbc.M413441200; Orekhov VY, 2003, J BIOMOL NMR, V27, P165, DOI 10.1023/A:1024944720653; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Sauve S, 2012, J BIOL CHEM, V287, P1915, DOI 10.1074/jbc.M111.279364; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; Supattapone S, 2014, J BIOL CHEM, V289, P19850, DOI 10.1074/jbc.R113.511329; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; VASSAR PS, 1959, ARCH PATHOL, V68, P487; Vilches S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070881	30	1	1	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2016	11	12							e0168021	10.1371/journal.pone.0168021	http://dx.doi.org/10.1371/journal.pone.0168021			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4OA	27930722	Green Published, gold			2023-01-03	WOS:000389580900071
J	Bachelot, A; Nicolas, C; Gricourt, S; Dulon, J; Leban, M; Golmard, JL; Touraine, P				Bachelot, Anne; Nicolas, Carole; Gricourt, Solenne; Dulon, Jerome; Leban, Monique; Golmard, Jean Louis; Touraine, Philippe			Poor Compliance to Hormone Therapy and Decreased Bone Mineral Density in Women with Premature Ovarian Insufficiency	PLOS ONE			English	Article							EARLY BILATERAL OOPHORECTOMY; YOUNG-WOMEN; TURNER-SYNDROME; EARLY MENOPAUSE; FAILURE; MORTALITY; REPLACEMENT; COHORT	Premature ovarian insufficiency leads to through infertility and estrogen deficiency. Optimal management encompasses estrogen replacement therapy. Long-term outcome of women with POI is not known. We design a study to evaluate the medical care, hormone replacement therapy compliance and bone mineral density (BMD) in POI women with at least a five-year follow-up after the first evaluation. One hundred and sixty-two patients (37.3 +/- 8.0 years) were evaluated (follow-up 7.9 +/- 2.8 years). Sixty-nine patients (42.6%) had stopped their hormone replacement therapy (HRT) for at least one year during the follow up period. BMD determination at initial evaluation and at follow-up visit was completed in 92 patients. At first evaluation, 28 patients (30%) had osteopenia and 7 (8%) had osteoporosis. At follow up, 31 women (34%) had BMD impairment with osteopenia in 61% and osteoporosis in 5%. In univariate analysis and multivariate analysis, there was a significant loss of femoral BMD in women who had stopped their HRT for over a year. In conclusion, this first study concerning long-term follow-up of POI patients shows the poor compliance to their HRT, despite its importance in the prevention of bone demineralization. This study reinforces the need for follow up and specific care for POI women.	[Bachelot, Anne; Nicolas, Carole; Gricourt, Solenne; Dulon, Jerome; Touraine, Philippe] Hop La Pitie Salpetriere, AP HP, IE3M,Dept Endocrinol & Reprod Med,Ctr Reference P, Ctr Reference Malad Endocriniennes Rares Croissan, Paris, France; [Bachelot, Anne; Nicolas, Carole; Golmard, Jean Louis; Touraine, Philippe] Univ Paris, Univ Pierre & Marie Curie, Paris, France; [Leban, Monique] Hop La Pitie Salpetriere, AP HP, Dept Hormonal Biochem, Paris, France; [Golmard, Jean Louis] Hop La Pitie Salpetriere, AP HP, Clin Res Unit, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Touraine, P (corresponding author), Hop La Pitie Salpetriere, AP HP, IE3M,Dept Endocrinol & Reprod Med,Ctr Reference P, Ctr Reference Malad Endocriniennes Rares Croissan, Paris, France.; Touraine, P (corresponding author), Univ Paris, Univ Pierre & Marie Curie, Paris, France.	philippe.touraine@aphp.fr	Bachelot, Anne/GQZ-0551-2022					Amarante F, 2011, BRAZ J MED BIOL RES, V44, P78, DOI [10.1590/S0100-879X2010007500122, 10.1590/S0100-879X2011000100012]; Anasti JN, 1998, OBSTET GYNECOL, V91, P12, DOI 10.1016/S0029-7844(97)00583-8; Arlot ME, 1997, J BONE MINER RES, V12, P683, DOI 10.1359/jbmr.1997.12.4.683; Atsma F, 2006, MENOPAUSE, V13, P265, DOI 10.1097/01.gme.0000218683.97338.ea; Bachelot A, 2016, CLIN ENDOCRINOL OXF; Bachelot A, 2009, EUR J ENDOCRINOL, V161, P179, DOI 10.1530/EJE-09-0231; Bakalov VK, 2003, J CLIN ENDOCR METAB, V88, P5717, DOI 10.1210/jc.2003-030913; Bidet M, 2011, J CLIN ENDOCR METAB, V96, P3864, DOI 10.1210/jc.2011-1038; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; DAVIES MC, 1990, BRIT MED J, V301, P790, DOI 10.1136/bmj.301.6755.790; Francucci C M, 2010, J Endocrinol Invest, V33, P39; Gallagher JC, 2007, MENOPAUSE, V14, P567, DOI 10.1097/gme.0b013e31804c793d; Hanton L, 2003, J WOMENS HEALTH, V12, P971, DOI 10.1089/154099903322643893; Jacobsen BK, 2003, AM J EPIDEMIOL, V157, P923, DOI 10.1093/aje/kwg066; Khadr SN, 2010, CLIN ENDOCRINOL, V73, P637, DOI 10.1111/j.1365-2265.2010.03857.x; Langrish JP, 2009, HYPERTENSION, V53, P805, DOI 10.1161/HYPERTENSIONAHA.108.126516; Management of women with premature ovarian insufficiency, MANAGEMENT WOMEN PRE; Nelson LM, 2009, NEW ENGL J MED, V360, P606, DOI 10.1056/NEJMcp0808697; Popat VB, 2014, J CLIN ENDOCR METAB, V99, P3418, DOI 10.1210/jc.2013-4145; Popat VB, 2009, J CLIN ENDOCR METAB, V94, P2277, DOI 10.1210/jc.2008-1878; Rivera CM, 2009, MENOPAUSE, V16, P15, DOI 10.1097/gme.0b013e31818888f7; Rivera CM, 2009, NEUROEPIDEMIOLOGY, V33, P32, DOI 10.1159/000211951; Schoemaker MJ, 2008, J CLIN ENDOCR METAB, V93, P4735, DOI 10.1210/jc.2008-1049; Shuster LT, 2010, MATURITAS, V65, P161, DOI 10.1016/j.maturitas.2009.08.003; Soares PM, 2010, SAO PAULO MED J, V128, P211, DOI 10.1590/S1516-31802010000400007; van Lennep JER, 2016, EUR J PREV CARDIOL, V23, P178, DOI 10.1177/2047487314556004; Vearncombe KJ, 2009, MENOPAUSE, V16, P188, DOI 10.1097/gme.0b013e3181775eb4	27	15	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0164638	10.1371/journal.pone.0164638	http://dx.doi.org/10.1371/journal.pone.0164638			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27906970	Green Published, Green Submitted, gold			2023-01-03	WOS:000389482700005
J	Fjellman-Wiklundl, A; Nordin, E; Skelton, DA; Lundin-Olsson, L				Fjellman-Wiklundl, Anncristine; Nordin, Ellinor; Skelton, Dawn A.; Lundin-Olsson, Lillemor			Reach the Person behind the Dementia Physical Therapists' Reflections and Strategies when Composing Physical Training	PLOS ONE			English	Article							OLDER-PEOPLE; FOCUS GROUPS; CARE; COMORBIDITY; RESIDENTS; PROGRAM; DISEASE	Dementia is a disease characterized by cognitive impairment and physical decline that worsens over time. Exercise is one lifestyle factor that has been identified as a potential means of reducing or delaying progression of the symptoms of dementia, maximizing function and independence. The purpose of this study was to explore physical therapists' (PTs) experiences and reflections on facilitating high-intensity functional exercise with older people living with dementia, in residential care home settings. The study used a qualitative design based on interviews, individually or in small groups, with seven PTs engaged as leaders in the training of older people with dementia. The interviews were analyzed with a modified Grounded Theory method with focus on constant comparisons. To increase trustworthiness the study used triangulation within investigators and member checking. The core category "Discover and act in the moment-learn over time" reflects how the PTs continuously developed their own learning in an iterative process. They built on previous knowledge to communicate with residents and staff and to tailor the high intensity training in relation to each individual at that time point. The category "Be on your toes" highlights how the PTs searched for sufficient information about each individual, before and during training, by eliciting the person's current status from staff and by interpreting the person's body language. The category "Build a bond with a palette of strategies" describes the importance of confirmation to build up trust and the use of group members and the room to create an interplay between exercise and social interaction. These findings highlight the continuous iterative process of building on existing knowledge, sharing and reflecting, being alert to any alterations needed for individuals that day, communication skills (both with residents and staff) and building a relationship and trust with residents in the effective delivery of high intensity functional exercise to older people living with dementia in care settings.	[Fjellman-Wiklundl, Anncristine; Nordin, Ellinor; Skelton, Dawn A.; Lundin-Olsson, Lillemor] Umea Univ, Physiotherapy, Dept Community Hlth & Rehabil, Umea, Sweden; [Skelton, Dawn A.] Glasgow Caledonian Univ, Inst Appl Hlth Res, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland	Umea University; Glasgow Caledonian University	Fjellman-Wiklundl, A (corresponding author), Umea Univ, Physiotherapy, Dept Community Hlth & Rehabil, Umea, Sweden.	anncristinefielirron-wiklund@umu.se	Skelton, Dawn A/B-7552-2013	Skelton, Dawn A/0000-0001-6223-9840	Dementia Association - The National Association for the Rights of the Demented, in Sweden; Umea University	Dementia Association - The National Association for the Rights of the Demented, in Sweden; Umea University	This work received support from The Dementia Association - The National Association for the Rights of the Demented, in Sweden, http://www.demensforbundet.se/, to LLO and Umea University, http://www.umu.se/, to LLO.	Chartered Society of Physiotherapy United Kingdom, 2011, DEM CAR PHYS DEL PAR; Collin C, 1988, Int Disabil Stud, V10, P61; Corbin J., 1998, BASICS QUALITATIVE R; Dahlgren L, QUALITATIVE METHODOL; Doraiswamy PM, 2002, J GERONTOL A-BIOL, V57, pM173, DOI 10.1093/gerona/57.3.M173; Eggenberger E, 2013, INT PSYCHOGERIATR, V25, P345, DOI 10.1017/S1041610212001664; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes D, 2013, COCHRANE DATABASE SY, V12; Fox C, 2014, AGE AGEING, V43, P741, DOI 10.1093/ageing/afu101; Galik EM, 2009, INT J NURS PRACT, V15, P48, DOI 10.1111/j.1440-172X.2008.01721.x; Guzman-Velez E, 2014, COGN BEHAV NEUROL, V27, P117, DOI 10.1097/WNN.0000000000000020; Johannessen A, 2014, SCAND J CARING SCI, V28, P749, DOI 10.1111/scs.12107; Kitwood T, 1997, AGING MENT HEALTH, V1, P13, DOI 10.1080/13607869757344; KITZINGER J, 1994, SOCIOL HEALTH ILL, V16, P103, DOI 10.1111/1467-9566.ep11347023; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Kovach CR, 2010, AM J ALZHEIMERS DIS, V25, P317, DOI 10.1177/1533317510363471; Laventure B, 2010, J ACTIVE AGING   SEP, P63; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Littbrand H, 2006, PHYS THER, V86, P489, DOI 10.1093/ptj/86.4.489; Martin-Garcia S, 2013, INT PSYCHOGERIATR, V25, P1077, DOI 10.1017/S1041610213000458; Morgan D.L., 1998, PLANNING FOCUS GROUP; NICE, 2011, SUPP PEOPL DEM THEIR; Prince M., 2013, WORLD ALZHEIMER REPO; Rockwood K, 2007, ALZHEIMERS DEMENT, V3, pS38, DOI 10.1016/j.jalz.2007.01.003; Schon D. A, 1986, REFLECTIVE PRACTITIO; Schon D. A, 2016, REFLECTIVE PRACTITIO; Scottish Intercollegiate Guideline Network (SIGN), 2006, MAN PAT DEM NAT CLIN; Shumway-Cook A., 2011, MOTOR CONTROL TRANSL, V4th; Teri L, 2015, HDB PSYCHOL AGING; Toots A, 2015, J AM GER SO IN PRESS; Willemse BM, 2015, AGING MENT HEALTH, V19, P444, DOI 10.1080/13607863.2014.944088	31	19	19	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0166686	10.1371/journal.pone.0166686	http://dx.doi.org/10.1371/journal.pone.0166686			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3JC	27906996	Green Submitted, Green Published, gold			2023-01-03	WOS:000389482700035
J	Palucka, K; Banchereau, J				Palucka, Karolina; Banchereau, Jacques			Diversity and collaboration for effective immunotherapy	NATURE MEDICINE			English	Editorial Material							DENDRITIC CELLS; THERAPY		[Palucka, Karolina; Banchereau, Jacques] Jackson Lab Genom Med, Farmington, CT 06032 USA	Jackson Laboratory	Palucka, K (corresponding author), Jackson Lab Genom Med, Farmington, CT 06032 USA.	Karolina.palucka@jax.org						Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Moynihan KD, 2016, NAT MED, V22, P1402, DOI 10.1038/nm.4200; Palucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049; Palucka K, 2014, CELL, V157, P516, DOI 10.1016/j.cell.2014.03.044; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Stromnes IM, 2015, CANCER CELL, V28, P638, DOI 10.1016/j.ccell.2015.09.022; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]	10	9	9	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2016	22	12					1390	1391		10.1038/nm.4249	http://dx.doi.org/10.1038/nm.4249			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EE4CI	27923023				2023-01-03	WOS:000389549000015
J	Samsiah, A; Othman, N; Jamshed, S; Hassali, MA				Samsiah, A.; Othman, Noordin; Jamshed, Shazia; Hassali, Mohamed Azmi			Perceptions and Attitudes towards Medication Error Reporting in Primary Care Clinics: A Qualitative Study in Malaysia	PLOS ONE			English	Article							ADMINISTRATION ERRORS; NURSING ERRORS; PATIENT SAFETY; BARRIERS; NURSES; SYSTEM; INFORMATION; MANAGEMENT; PHYSICIANS; INCIDENTS	Objective To explore and understand participants' perceptions and attitudes towards the reporting of medication errors (MEs). Methods A qualitative study using in-depth interviews of 31 healthcare practitioners from nine publicly funded, primary care clinics in three states in peninsular Malaysia was conducted for this study. The participants included family medicine specialists, doctors, pharmacists, pharmacist assistants, nurses and assistant medical officers. The interviews were audiotaped and transcribed verbatim. Analysis of the data was guided by the framework approach. Results Six themes and 28 codes were identified. Despite the availability of a reporting system, most of the participants agreed that MEs were underreported. The nature of the error plays an important role in determining the reporting. The reporting system, organisational factors, provider factors, reporter's burden and benefit of reporting also were identified. Conclusions Healthcare practitioners in primary care clinics understood the importance of reporting MEs to improve patient safety. Their perceptions and attitudes towards reporting of MEs were influenced by many factors which affect the decision-making process of whether or not to report. Although the process is complex, it primarily is determined by the severity of the outcome of the errors. The participants voluntarily report the errors if they are familiar with the reporting system, what error to report, when to report and what form to use.	[Samsiah, A.; Jamshed, Shazia] Int Islamic Univ Malaysia, Kulliyyah Pharm, Kuantan, Pahang, Malaysia; [Samsiah, A.] Minist Hlth, Inst Hlth Syst Res, Shah Alam, Selangor, Malaysia; [Othman, Noordin] Taibah Univ, Coll Pharm, Dept Clin & Hosp Pharm, Almadinah Almunawwarah, Saudi Arabia; [Hassali, Mohamed Azmi] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia	International Islamic University Malaysia; Kementerian Kesihatan Malaysia; Taibah University; Universiti Sains Malaysia	Othman, N (corresponding author), Taibah Univ, Coll Pharm, Dept Clin & Hosp Pharm, Almadinah Almunawwarah, Saudi Arabia.	noordin_uia@yahoo.com	Jamshed, Shazia/AAF-6525-2020; Hassali, Mohamed Azmi/A-6895-2011	Jamshed, Shazia/0000-0003-0773-0463; Hassali, Mohamed Azmi/0000-0001-9575-403X; Othman, Noordin/0000-0001-7672-9226				ABOSHAIQAH AE, 2013, MIDDLE EAST J SCI RE, V17, P130, DOI DOI 10.5829/idosi.mejsr.2013.17.02.76110; Ashcroft DM, 2006, QUAL SAF HEALTH CARE, V15, P48, DOI 10.1136/qshc.2005.014639; Bayazidi Snor, 2012, J Caring Sci, V1, P231, DOI 10.5681/jcs.2012.032; Beasley John W, 2004, WMJ, V103, P56; Benn J, 2009, QUAL SAF HEALTH CARE, V18, P11, DOI 10.1136/qshc.2007.024166; Boyle TA, 2011, RES SOC ADMIN PHARM, V7, P93, DOI 10.1016/j.sapharm.2009.12.001; Cheng Lan, 2011, J Evid Based Med, V4, P32, DOI 10.1111/j.1756-5391.2011.01119.x; Cheung KC, 2011, J AM MED INFORM ASSN, V18, P799, DOI 10.1136/amiajnl-2011-000191; Chiang HY, 2010, NURS OUTLOOK, V58, P17, DOI 10.1016/j.outlook.2009.06.001; Covell CL, 2009, J NURS CARE QUAL, V24, P287, DOI 10.1097/NCQ.0b013e3181a4d506; Elder NC, 2007, J AM BOARD FAM MED, V20, P115, DOI 10.3122/jabfm.2007.02.060081; Evans SM, 2006, QUAL SAF HEALTH CARE, V15, P39, DOI 10.1136/qshc.2004.012559; Furukawa H, 2003, ANN PHARMACOTHER, V37, P1716, DOI 10.1345/aph.1C330; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; GLADSTONE J, 1995, J ADV NURS, V22, P628, DOI 10.1046/j.1365-2648.1995.22040628.x; Handler SM, 2007, J AM MED DIR ASSOC, V8, P568, DOI 10.1016/j.jamda.2007.06.009; Hartnell N, 2012, BMJ QUAL SAF, V21, P361, DOI 10.1136/bmjqs-2011-000299; Hashemi F, 2012, BMC NURS, V11, DOI 10.1186/1472-6955-11-20; Hickner J, 2010, ANN FAM MED, V8, P517, DOI 10.1370/afm.1169; Holmstrom AR, 2012, J PATIENT SAF, V8, P165, DOI 10.1097/PTS.0b013e3182676cf3; Jeffe Donna B, 2004, Jt Comm J Qual Saf, V30, P471; Kaldjian LC, 2008, ARCH INTERN MED, V168, P40, DOI 10.1001/archinternmed.2007.12; Kennedy Amanda G, 2004, J Am Pharm Assoc (2003), V44, P434, DOI 10.1331/1544345041475724; Khoo EM, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-127; Kreckler S, 2009, QUAL SAF HEALTH CARE, V18, P116, DOI 10.1136/qshc.2008.026534; Larizgoitia I, 2013, J PUBLIC HEALTH RES, V2, P168, DOI 10.4081/jphr.2013.e29; Lin YH, 2009, WORLDV EVID-BASED NU, V6, P237, DOI 10.1111/j.1741-6787.2009.00169.x; MOH, 2009, GUID MED ERR REP; Mrayyan Majd T, 2007, J Nurs Manag, V15, P659, DOI 10.1111/j.1365-2834.2007.00724.x; Patel I, 2010, INDIAN J PHARM SCI, V72, P539, DOI 10.4103/0250-474X.78518; Patrician PA, 2009, J NURS CARE QUAL, V24, P277, DOI 10.1097/NCQ.0b013e3181afa4cb; Petrova E, 2010, Nurs Stand, V24, P41; Pham Julius Cuong, 2013, J Public Health Res, V2, pe27, DOI 10.4081/jphr.2013.e27; Phillips MAS, 2002, AM J HEALTH-SYST PH, V59, P2326, DOI 10.1093/ajhp/59.23.2326; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Psuedonym Olgen R., 2008, SAGE ENCY QUALITATIV, P195; Rea D, 2016, HEALTH SOC CARE COMM, V24, P411, DOI 10.1111/hsc.12221; Roughead L., 2013, LIT REV MEDICATION S; Roulston KJ, 2008, SAGE ENCY QUALITATIV, P681; Runciman WB, 2006, QUAL SAF HEALTH CARE, V15, pI82, DOI 10.1136/qshc.2005.017467; Samsiah A, 2016, EUR J CLIN PHARM; Sanghera IS, 2007, ANAESTHESIA, V62, P53, DOI 10.1111/j.1365-2044.2006.04858.x; Sarvadikar A, 2010, EUR J CLIN PHARMACOL, V66, P843, DOI 10.1007/s00228-010-0838-x; Saumure K., 2008, SAGE ENCY QUALITATIV, P195; Schectman JM, 2006, JT COMM J QUAL PATIE, V32, P337, DOI 10.1016/S1553-7250(06)32043-0; Teoh BC, 2015, PHARMACOEPIDEMIOL AD, V4; Throckmorton Terry, 2007, J Perianesth Nurs, V22, P400, DOI 10.1016/j.jopan.2007.09.006; Toruner EK, 2012, AUST J ADV NURS, V29, P28; Ulanimo VM, 2007, J NURS CARE QUAL, V22, P28, DOI 10.1097/00001786-200701000-00007; Uribe CL, 2002, J HEALTHC MANAG, V47, P263, DOI 10.1097/00115514-200207000-00009; Wagner LM, 2013, J PATIENT SAF, V9, P1, DOI 10.1097/PTS.0b013e3182699919; Walker S B, 1998, Int J Nurs Pract, V4, P97, DOI 10.1046/j.1440-172X.1998.00058.x; Williams SD, 2013, RES SOC ADMIN PHARM, V9, P80, DOI 10.1016/j.sapharm.2012.02.002; World Health Organization, 2005, WHO DRAFT GUID ADV E; World Health Organization (WHO), 2014, REP LEARN SYST MED E	55	14	14	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0166114	10.1371/journal.pone.0166114	http://dx.doi.org/10.1371/journal.pone.0166114			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3JC	27906960	gold, Green Submitted, Green Published			2023-01-03	WOS:000389482700015
J	Chang, PY; Lo, PC; Chang, HC; Hsueh, KC; Tsai, YW				Chang, Po-Yin; Lo, Po-Ching; Chang, Hui-Chin; Hsueh, Kuang-Chieh; Tsai, Yi-Wen			Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan	PLOS ONE			English	Article							NICOTINE REPLACEMENT THERAPY; RECEPTOR PARTIAL AGONIST; SUSTAINED-RELEASE BUPROPION; GENDER-DIFFERENCES; SEX-DIFFERENCES; VARENICLINE; POPULATION; SMOKERS; PLACEBO; PATCH	Background and objective Relative effectiveness of smoking cessation medications-varenicline, bupropion and nicotine replacement therapy (NRT)-remains unclear among smokers in real-world settings. Evidence in females and smokers with light/moderate nicotine dependence is particularly insufficient. This study compared the effectiveness of varenicline, bupropion or NRT gum relative to NRT patch, in achieving abstinence among recent quitters. Methods In a national smoking cessation program in Taiwan (2012-2015), a cohort of 11,968 participants received varenicline (n = 5,052), bupropion (n = 823), NRT gum (n = 1944) or NRT patch (n = 4,149). The 7-day, 1-month or 6-month point-prevalence was calculated based on self-reported last smoking event via telephone interview after 6 months. Logistic regression modellings estimated odds ratios (OR) and 95% confidence intervals (CI) for achieving abstinence using different modalities (NRT patch as referent). Models included age, sex, education, marital status, geographic region, smoke-years, nicotine-dependence level, medical institution, number of clinic visits and medication use duration. Analyses were further stratified by sex and dependence severity. Results Participants were predominantly male (83%) with a mean age of 43.7 +/- 12.6 years. Varenicline users were more likely than NRT patch users to achieve abstinence, based on 7-day point-prevalence (OR = 1.30, CI: 1.19-1.44), 1-month point-prevalence (OR = 1.36, CI: 1.24-1.50) or 6-month point-prevalence (OR = 1.30, CI: 1.14-1.47). Compared with NRT patch, varenicline was associated with greater odds of being abstinent in women (OR = 1.29, CI: 1.01-1.65), men (OR = 1.31, CI: 1.18-1.46), those with light/moderate dependence (OR = 1.42, CI: 1.24-1.63) or smokers with severe dependence (OR = 1.19, CI: 1.04-1.37), based on 7-day point-prevalence. Differences in effectiveness were not observed between users of bupropion, NRT gum and NRT patch. Conclusions In smoking cessation clinics in Taiwan, varenicline users reported higher abstinence rates than NRT patch users after 6 months. Women and smokers with light/moderate nicotine dependence may also benefit from varenicline in actual clinical practice.	[Chang, Po-Yin] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Lo, Po-Ching; Chang, Hui-Chin; Tsai, Yi-Wen] Natl Yang Ming Univ, Inst Hlth & Welf Policy, Taipei, Taiwan; [Hsueh, Kuang-Chieh] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan	Stanford University; National Yang Ming Chiao Tung University; Kaohsiung Veterans General Hospital	Tsai, YW (corresponding author), Natl Yang Ming Univ, Inst Hlth & Welf Policy, Taipei, Taiwan.	ywtsai@ym.edu.tw			Health Promotion Administration, Ministry of Health and Welfare, Taiwan; Health Promotion Administration, Ministry of Health and Welfare, Taiwan [G1031227-105]	Health Promotion Administration, Ministry of Health and Welfare, Taiwan; Health Promotion Administration, Ministry of Health and Welfare, Taiwan	National Yang-Ming University received research funding from the revenues of tobacco health and welfare surcharges by the Health Promotion Administration, Ministry of Health and Welfare, Taiwan, for project, titled "International Collaborative Project for the Evaluation of Medical Services for Smoking Cessation." Yi-Wen Tsai (PI), Kuang-Chieh Hsueh (Co-PI), Po-Yin Chang, Po-Ching Lo and Hui-Chin Chang received grants (G1031227-105) from the Health Promotion Administration, Ministry of Health and Welfare, Taiwan (http://www.hpa.gov.tw/BHPNet/English/Index.aspx). Health Promotion Administration, Taiwan provided data for the current study; it had no role in study design, analysis, data interpretation, or manuscript writing.	Agaku IT, 2014, MMWR-MORBID MORTAL W, P63; Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Baha MY, 2010, EUR ADDICT RES, V16, P162, DOI 10.1159/000314360; Baker TB, 2016, JAMA-J AM MED ASSOC, V315, P371, DOI 10.1001/jama.2015.19284; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Cahill K, 2014, JAMA-J AM MED ASSOC, V311, P193, DOI 10.1001/jama.2013.283787; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Hsueh SC, 2015, EVAL HEALTH PROF, V38, P115, DOI 10.1177/0163278712466868; Huang Y, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1024; Jarvis MJ, 2013, TOB CONTROL, V22, P356, DOI 10.1136/tobaccocontrol-2011-050279; Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Kotz D, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1163; Kotz D, 2014, PSYCHOPHARMACOLOGY, V231, P37, DOI 10.1007/s00213-013-3202-x; McKee SA, 2015, OFFICIAL J SOC RES N; Mills EJ, 2012, ANN MED, V44, P588, DOI 10.3109/07853890.2012.705016; Munafo M, 2004, NICOTINE TOB RES, V6, P769, DOI 10.1080/14622200410001696556; National Center for Chronic Disease P, 2014, HLTH CONSMOK 50 YE; Nides M, 2006, ARCH INTERN MED, V166, P1561, DOI 10.1001/archinte.166.15.1561; Patnode CD, 2015, ANN INTERN MED, V163, P608, DOI 10.7326/M15-0171; Perkins KA, 2008, NICOTINE TOB RES, V10, P1245, DOI 10.1080/14622200802097506; Scharf D, 2004, ADDICTION, V99, P1462, DOI 10.1111/j.1360-0443.2004.00845.x; Schauer GL, 2014, NICOTINE TOB RES, V16, P58, DOI 10.1093/ntr/ntt113; Smith PH, 2015, NICOTINE TOB RES, V17, P463, DOI 10.1093/ntr/ntu212; Wu PC, 2016, EVAL HEALTH PROF, V39, P317, DOI 10.1177/0163278715616439	26	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2016	11	11							e0166992	10.1371/journal.pone.0166992	http://dx.doi.org/10.1371/journal.pone.0166992			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3FE	27893843	Green Published, Green Submitted, gold			2023-01-03	WOS:000389472400066
J	Dai, L; Sun, CX; Wang, D; Gao, YX				Dai, Lei; Sun, Cuixia; Wang, Di; Gao, Yanxiang			The Interaction between Zein and Lecithin in Ethanol-Water Solution and Characterization of Zein-Lecithin Composite Colloidal Nanoparticles	PLOS ONE			English	Article							MORPHOLOGICAL-CHARACTERISTICS; ANTISOLVENT PRECIPITATION; PICKERING EMULSION; PROTEIN; FLUORESCENCE; STABILITY; COMPLEX; PH; PHOSPHOLIPIDS; LACTOGLOBULIN	Lecithin, a naturally small molecular surfactant, which is widely used in the food industry, can delay aging, enhance memory, prevent and treat diabetes. The interaction between zein and soy lecithin with different mass ratios (20:1, 10:1, 5:1, 3:1, 2:1, 1:1 and 1:2) in ethanol- water solution and characterisation of zein and lecithin composite colloidal nanoparticles prepared by antisolvent co-precipitation method were investigated. The mean size of zein-lecithin composite colloidal nanoparticles was firstly increased with the rise of lecithin concentration and then siginificantly decreased. The nanoparticles at the zein to lecithin mass ratio of 5: 1 had the largest particle size (263 nm), indicating that zein and lecithin formed composite colloidal nanoparticles, which might aggregate due to the enhanced interaction at a higher proportion of lecithin. Continuing to increase lecithin concentration, the zein-lecithin nanoparticles possibly formed a reverse micelle-like or a vesicle-like structure with zein in the core, which prevented the formation of nanoparticle aggregates and decreased the size of composite nanoparticles. The presence of lecithin significantly reduced the.-potential of zein-lecithin composite colloidal nanoparticles. The interaction between zein and lecithin enhanced the intensity of the fluorescence emission of zein in ethanol-water solution. The secondary structure of zein was also changed by the addition of lecithin. Differential scanning calorimetry thermograms revealed that the thermal stability of zein-lecithin nanoparticles was enhanced with the rise of lecithin level. The composite nanoparticles were relatively stable to elevated ionic strengths. Possible interaction mechanism between zein and lecithin was proposed. These findings would help further understand the theory of the interaction between the alcohol soluble protein and the natural small molecular surfactant. The composite colloidal nanoparticles formed in this study can broaden the application of zein and be suitable for incorporating water-insoluble bioactive components in functional food and beverage products.	[Dai, Lei; Sun, Cuixia; Wang, Di; Gao, Yanxiang] China Agr Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing Key Lab Funct Food Plant Resources, Coll Food Sci & Nutr Engn,Beijing Lab Food Qual &, Beijing, Peoples R China	China Agricultural University	Gao, YX (corresponding author), China Agr Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing Key Lab Funct Food Plant Resources, Coll Food Sci & Nutr Engn,Beijing Lab Food Qual &, Beijing, Peoples R China.	gyxcau@126.com	Dai, Lei/HCH-4898-2022; Gao, Y./GWZ-3665-2022; gao, yi/HCI-8298-2022; Gao, Yu/HGE-1937-2022	Dai, Lei/0000-0002-9491-6567; 	National Natural Science Foundation of China [31371835]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The research was funded by the National Natural Science Foundation of China (No.31371835).	Alcantara ACS, 2010, J MAT CHEM, V20; Chen JJ, 2014, FOOD CHEM, V158, P466, DOI 10.1016/j.foodchem.2014.03.003; Comas DI, 2006, FOOD HYDROCOLLOID, V20, P990, DOI 10.1016/j.foodhyd.2005.11.006; Gao ZM, 2014, J AGR FOOD CHEM, V62, P2672, DOI 10.1021/jf500005y; Hu DD, 2012, J FOOD ENG, V109, P545, DOI 10.1016/j.jfoodeng.2011.10.025; Hu K, 2015, FOOD HYDROCOLLOID, V44, P101, DOI 10.1016/j.foodhyd.2014.09.015; Hu K, 2014, FOOD RES INT, V64, P329, DOI 10.1016/j.foodres.2014.07.004; Joye IJ, 2015, FOOD CHEM, V185, P261, DOI 10.1016/j.foodchem.2015.03.128; Kongsawat P., 2011, Proceedings of the 49th Kasetsart University Annual Conference, Kasetsart University, Thailand, 1-4 February, 2011. Volume 7. Subject: Agro-Industry, P406; Li JF, 2014, FOOD SCI BIOTECHNOL, V23, P1785, DOI 10.1007/s10068-014-0244-8; Luo YC, 2011, COLLOID SURFACE B, V85, P145, DOI 10.1016/j.colsurfb.2011.02.020; Maikokera R, 2007, COLLOID SURFACE B, V55, P173, DOI 10.1016/j.colsurfb.2006.11.029; Mantovani RA, 2016, FOOD HYDROCOLLOID, V60, P288, DOI 10.1016/j.foodhyd.2016.03.039; Mc Clements D.J., 2005, FOOD EMULSIONS PRINC, P269; Parris N, 2005, J AGR FOOD CHEM, V53, P4788, DOI 10.1021/jf040492p; Patel A, 2010, SOFT MATTER, V6, P6192, DOI 10.1039/c0sm00800a; Patel AR, 2012, FOOD CHEM, V133, P423, DOI 10.1016/j.foodchem.2012.01.054; Patel AR, 2010, J AGR FOOD CHEM, V58, P12497, DOI 10.1021/jf102959b; Podaralla S, 2012, AAPS PHARMSCITECH, V13, P919, DOI 10.1208/s12249-012-9816-1; Shukla R, 2001, IND CROP PROD, V13, P171, DOI 10.1016/S0926-6690(00)00064-9; Sun CX, 2016, INNOV FOOD SCI EMERG, V34, P161, DOI 10.1016/j.ifset.2016.01.016; Sun CX, 2016, FOOD HYDROCOLLOID, V58, P11, DOI 10.1016/j.foodhyd.2016.02.014; Sun CX, 2015, IND CROP PROD, V77, P476, DOI 10.1016/j.indcrop.2015.09.028; Surh J, 2008, J FOOD ENG, V89, P164, DOI 10.1016/j.jfoodeng.2008.04.023; van Nieuwenhuyzen W, 1998, FETT-LIPID, V100, P282; Wang Q., 2014, J APPL POLYM SCI, V131, P12; Wang XG, 2014, CARBOHYD POLYM, V101, P1027, DOI 10.1016/j.carbpol.2013.10.042; Wang YH, 2016, FOOD HYDROCOLLOID, V54, P40, DOI 10.1016/j.foodhyd.2015.09.020; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Xue J, 2014, J AGR FOOD CHEM, V62, P2956, DOI 10.1021/jf405828s; Yin HY, 2015, INT J BIOL MACROMOL, V72, P480, DOI 10.1016/j.ijbiomac.2014.08.025; Yong YH, 2004, J AGR FOOD CHEM, V52, P7094, DOI 10.1021/jf040133u; Zhang Y, 2003, COLLOID SURFACE A, V223, P11, DOI 10.1016/S0927-7757(03)00099-2; Zhou CP, 2012, J PEPT SCI, V18, P541, DOI 10.1002/psc.2423; Zou LQ, 2016, FOOD RES INT, V81, P74, DOI 10.1016/j.foodres.2015.12.035; Zou Y, 2015, J AGR FOOD CHEM, V63, P7405, DOI 10.1021/acs.jafc.5b03113	36	63	69	14	103	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2016	11	11							e0167172	10.1371/journal.pone.0167172	http://dx.doi.org/10.1371/journal.pone.0167172			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FE	27893802	Green Submitted, Green Published, gold			2023-01-03	WOS:000389472400094
J	Janiszewska, J; Posadas, I; Jativa, P; Bugaj-Zarebska, M; Urbanczyk-Lipkowska, Z; Cena, V				Janiszewska, Jolanta; Posadas, Inmaculada; Jativa, Pablo; Bugaj-Zarebska, Marta; Urbanczyk-Lipkowska, Zofia; Cena, Valentin			Second Generation Amphiphilic Poly-Lysine Dendrons Inhibit Glioblastoma Cell Proliferation without Toxicity for Neurons or Astrocytes	PLOS ONE			English	Article							MEDIATED GENE DELIVERY; SIRNA DELIVERY; DENDRIMERS; PEPTIDE; ACTIVATION; MEMBRANE; POLY(L-LYSINE); TRANSFECTION; HIF-1-ALPHA; APOPTOSIS	Glioblastomas are the most common malignant primary brain tumours in adults and one of the most aggressive and difficult-to-treat cancers. No effective treatment exits actually for this tumour and new therapeutic approaches are needed for this disease. One possible innovative approach involves the nanoparticle-mediated specific delivery of drugs and/or genetic material to glioblastoma cells where they can provide therapeutic benefits. In the present work, we have synthesised and characterised several second generation amphiphilic polylysine dendrons to be used as siRNA carriers. We have found that, in addition to their siRNA binding properties, these new compounds inhibit the proliferation of two glioblastoma cell lines while being nontoxic for non-tumoural central nervous system cells like neurons and glia, cell types that share the anatomical space with glioblastoma cells during the course of the disease. The selective toxicity of these nanoparticles to glioblastoma cells, as compared to neurons and glial cells, involves mitochondrial depolarisation and reactive oxygen species production. This selective toxicity, together with the ability to complex and release siRNA, suggests that these new polylysine dendrons might offer a scaffold in the development of future nanoparticles designed to restrict the proliferation of glioblastoma cells.	[Janiszewska, Jolanta] Inst Ind Res, Warsaw, Poland; [Posadas, Inmaculada; Jativa, Pablo; Cena, Valentin] Inst Salud Carlos III, CIBERNED, Madrid, Spain; [Bugaj-Zarebska, Marta; Urbanczyk-Lipkowska, Zofia] PAS, Inst Organ Chem, Warsaw, Poland; [Posadas, Inmaculada; Jativa, Pablo; Cena, Valentin] Univ Castilla La Mancha, Unidad Asociada Neurodeath, Fac Med, Albacete, Spain	CIBERNED; Instituto de Salud Carlos III; Polish Academy of Sciences; Institute of Organic Chemistry of the Polish Academy of Sciences; Universidad de Castilla-La Mancha	Cena, V (corresponding author), Inst Salud Carlos III, CIBERNED, Madrid, Spain.; Cena, V (corresponding author), Univ Castilla La Mancha, Unidad Asociada Neurodeath, Fac Med, Albacete, Spain.	valentin.cena@gmail.com	Janiszewska, Jolanta/W-4148-2018; Cena, Valentin/L-1751-2017; Posadas, Inmaculada/M-1124-2014	Janiszewska, Jolanta/0000-0003-0958-8018; Cena, Valentin/0000-0001-8928-3681; Posadas, Inmaculada/0000-0003-1854-3372; Jativa Carbajal, Pablo/0000-0003-0288-9416; Urbanczyk-Lipkowska, Zofia/0000-0003-2043-487X; Bugaj-Zarebska, Marta/0000-0002-8308-0450	MINECO [BFU2014-59009-P]; CYTED [214RT0482]; NCN [UMO-2012/07/B/ST5/01941]	MINECO(Spanish Government); CYTED; NCN	Support was provided by: MINECO Grant no. BFU2014-59009-P to VC; CYTED grant no. 214RT0482 to VC; and NCN grant no UMO-2012/07/B/ST5/01941 to ZU-L.	Agrawal A, 2009, ACS NANO, V3, P2495, DOI 10.1021/nn900201e; Al-Jamal KT, 2010, P NATL ACAD SCI USA, V107, P3966, DOI 10.1073/pnas.0908401107; [Anonymous], 2016, NANOMEDICINE-UK, V11, P833; [Anonymous], 2010, NANOMEDICINE-UK, V5, P1219; Battigelli A, 2013, SMALL, V9, P3610, DOI 10.1002/smll.201300264; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Celardo I, 2014, BRIT J PHARMACOL, V171, P1943, DOI 10.1111/bph.12433; Cho KC, 2005, MACROMOL BIOSCI, V5, P512, DOI 10.1002/mabi.200500018; Coantic S, 2008, INT J PEPT RES THER, V14, P143, DOI 10.1007/s10989-008-9123-6; Cookson MR, 1998, J NEUROCHEM, V70, P501; Curtis Carol D., 2009, V505, P187, DOI 10.1007/978-1-60327-575-0_11; Fruchon S, 2009, J LEUKOCYTE BIOL, V85, P553, DOI 10.1189/jlb.0608371; Ghosh PS, 2008, ACS NANO, V2, P2213, DOI 10.1021/nn800507t; Guerra J, 2012, CARBON, V50, P2832, DOI 10.1016/j.carbon.2012.02.050; Inoue Y, 2008, J CONTROL RELEASE, V126, P59, DOI 10.1016/j.jconrel.2007.10.022; Janiszewska J, 2012, BIOORG MED CHEM LETT, V22, P1388, DOI 10.1016/j.bmcl.2011.12.051; Jobin ML, 2013, BBA-BIOMEMBRANES, V1828, P1457, DOI 10.1016/j.bbamem.2013.02.008; Jordan J, 2004, J NEUROCHEM, V89, P124, DOI 10.1046/j.1471-4159.2003.02299.x; Kaneshiro TL, 2007, MOL PHARMACEUT, V4, P759, DOI 10.1021/mp070036z; Kim WJ, 2009, PHARM RES-DORDR, V26, P657, DOI 10.1007/s11095-008-9774-1; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kwok A, 2013, ACS NANO, V7, P4668, DOI 10.1021/nn400343z; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Liu XX, 2015, NANOSCALE, V7, P3867, DOI 10.1039/c4nr04759a; Lopez-Hernandez B, 2012, EXP NEUROL, V233, P543, DOI 10.1016/j.expneurol.2011.11.040; Ma D, 2013, J COLLOID INTERF SCI, V405, P305, DOI 10.1016/j.jcis.2013.05.017; Mader JS, 2007, EXP CELL RES, V313, P2634, DOI 10.1016/j.yexcr.2007.05.015; Malhotra S, 2012, BIOMACROMOLECULES, V13, P3087, DOI 10.1021/bm300892v; Malkoch M, 2002, MACROMOLECULES, V35, P8307, DOI 10.1021/ma0205360; Monteagudo S, 2012, NANOMEDICINE-UK, V7, P493, DOI [10.2217/nnm.11.61, 10.2217/NNM.11.61]; Olson JJ, 2014, J NEURO-ONCOL, V118, P427, DOI 10.1007/s11060-014-1431-4; Papadopoulos A, 2012, MOL PHARMACEUT, V9, P394, DOI 10.1021/mp200490b; Parat A, 2015, NANOMEDICINE-UK, V10, P977, DOI [10.2217/NNM.14.196, 10.2217/nnm.14.196]; Perez-Carrion MD, 2013, PHARM RES-DORDR, V30, P2584, DOI 10.1007/s11095-013-1049-9; Perez-Carrion MD, 2012, J NEUROCHEM, V120, P259, DOI 10.1111/j.1471-4159.2011.07556.x; Perez-Martinez FC, 2011, PHARM RES-DORDR, V28, P1843, DOI 10.1007/s11095-010-0364-7; Polcyn P, 2013, MOLECULES, V18, P7120, DOI 10.3390/molecules18067120; Posadas I, 2012, J NEUROCHEM, V120, P515, DOI 10.1111/j.1471-4159.2011.07599.x; Posadas I, 2009, PHARM RES-DORDR, V26, P1181, DOI 10.1007/s11095-009-9839-9; Rekdal O, 2012, J BIOL CHEM, V287, P233, DOI 10.1074/jbc.M111.279281; Rodrigo AC, 2011, BIOMACROMOLECULES, V12, P1205, DOI 10.1021/bm1014987; Sadler Kristen, 2002, J Biotechnol, V90, P195; Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shcharbin D, 2014, J CONTROL RELEASE, V181, P40, DOI 10.1016/j.jconrel.2014.02.021; Venur VA, 2015, CANCER TREAT RES, V163, P103, DOI 10.1007/978-3-319-12048-5_7; Weller M, 2014, INT J CANCER, V134, P2437, DOI 10.1002/ijc.28576; Woehrer A, 2014, CURR OPIN NEUROL, V27, P666, DOI 10.1097/WCO.0000000000000144; Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020; Zhao J, 2014, ARCH PHARM, V347, P469, DOI 10.1002/ardp.201300415	50	25	26	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2016	11	11							e0165704	10.1371/journal.pone.0165704	http://dx.doi.org/10.1371/journal.pone.0165704			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9ON	27832093	gold, Green Submitted, Green Published			2023-01-03	WOS:000387725000028
J	Kim, D; Jeon, H; Ryu, S; Koo, S; Ha, KT; Kim, S				Kim, Dongsoo; Jeon, Hyongjun; Ryu, Sun; Koo, Sungtae; Ha, Ki-Tae; Kim, Seungtae			Proteomic Analysis of the Effect of Korean Red Ginseng in the Striatum of a Parkinson's Disease Mouse Model	PLOS ONE			English	Article							NEUROPROTECTIVE ACTIVITY; CELLS	Recent studies have shown that Korean Red Ginseng (KRG) suppresses dopaminergic neuronal death in the brain of a Parkinson's disease (PD) mouse model, but the mechanism is still elusive. Using a 2-dimensional electrophoresis technique, we investigated whether KRG can restore the changes in protein expressions in the striatum (ST) of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-injected mice. Male C57BL/6 mice (9 weeks old) were injected with 20 mg/kg MPTP intraperitoneally four times at 2-h intervals. KRG (100 mg/kg) was orally administered once a day for 3 days from one hour after the first MPTP injection. Two hours after the third KRG administration a pole test was performed to evaluate motor function, after which the brains were immediately harvested. Survival of dopaminergic neurons in the nigrostriatal pathway and protein expression in the ST were measured by immunohistochemistry and 2-dimensional electrophoresis. KRG suppressed MPTP-induced behavioral dysfunction and neuronal death in the nigrostriatal pathway. Moreover, 30 proteins changed by MPTP and KRG in the ST were identified and shown to be related to glycolysis/gluconeogenesis and neurodegenerative diseases including Alzheimer's disease and PD. KRG has neuroprotective effects against MPTP toxicity and alleviates protein expression profiles related to enhancing energy metabolism in the ST of MPTP-treated mice.	[Kim, Dongsoo; Jeon, Hyongjun; Ryu, Sun; Koo, Sungtae; Ha, Ki-Tae; Kim, Seungtae] Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea	Pusan National University	Kim, S (corresponding author), Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea.	kimst@pusan.ac.kr	Koo, Sungtae/J-6455-2014	Koo, Sungtae/0000-0001-7773-3905	National Research Foundation of Korea (NRF) - Korea government (MSIP) [NRF-2014R1A5A2009936]	National Research Foundation of Korea (NRF) - Korea government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. NRF-2014R1A5A2009936). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander Garrett E, 2004, Dialogues Clin Neurosci, V6, P259; Bae CH, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/436315, DOI 10.1155/2013/436315]; Cape JL, 2006, TRENDS PLANT SCI, V11, P46, DOI 10.1016/j.tplants.2005.11.007; Chung IM, 2016, J GINSENG RES, V40, P68, DOI 10.1016/j.jgr.2015.05.006; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Gonzalez-Burgos E, 2015, J NEUROIMMUNE PHARM, V10, P14, DOI 10.1007/s11481-014-9569-6; Grunewald A, 2016, ANN NEUROL, V79, P366, DOI 10.1002/ana.24571; Hanganu A, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00138; Jun YL, 2015, J GINSENG RES, V39, P148, DOI 10.1016/j.jgr.2014.10.003; Kim ST, 2010, J PHYSIOL SCI, V60, P27, DOI 10.1007/s12576-009-0061-7; Kim YO, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/817096; L'Episcopo F, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-83; Le WD, 2014, NEUROTHERAPEUTICS, V11, P92, DOI 10.1007/s13311-013-0234-1; Li X, 2015, SHOCK VIB, V2015, DOI 10.1155/2015/431476; Lin WM, 2007, J NEURAL TRANSM-SUPP, P105; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Slemmer JE, 2007, EUR J NEUROSCI, V26, P649, DOI 10.1111/j.1460-9568.2007.05708.x; Thangarajan S, 2014, INT J NEUROSCI, V124, P673, DOI 10.3109/00207454.2013.872642; Wang HK, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-14; Yan MH, 2013, FREE RADICAL BIO MED, V62, P90, DOI 10.1016/j.freeradbiomed.2012.11.014; Yeo HB, 2012, J GINSENG RES, V36, P190, DOI 10.5142/jgr.2012.36.2.190	21	16	16	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2016	11	10							e0164906	10.1371/journal.pone.0164906	http://dx.doi.org/10.1371/journal.pone.0164906			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4VY	27788166	Green Published, gold, Green Submitted			2023-01-03	WOS:000389604900034
J	Cho, H; Ryu, S; Noh, J; Lee, J				Cho, Hyunju; Ryu, Seokjin; Noh, Jeeae; Lee, Jongsun			The Effectiveness of Daily Mindful Breathing Practices on Test Anxiety of Students	PLOS ONE			English	Article							STRESS REDUCTION; SOCIAL ANXIETY; REAPPRAISAL; VALIDATION; PROGRAM; HEALTH	The present study examined the effectiveness of daily mindful breathing practices on test anxiety of university students. A total of 36 participants were randomly assigned to one of three conditions: a training mindful breathing condition (n = 12), a training cognitive reappraisal condition (contrast group, n = 12), and a non-training condition (control group, n = 12). Each of the participants trained by themselves for 6 days after they had taken one session of education for mindful or cognitive reappraisal practices. They wrote their experiences on daily worksheets and sent it by mobile with taking pictures that were confirmed by the researcher. Before and after training, each of the participants completed a questionnaire to assess: test anxiety, positive thought, and positive affect. The results of the study showed that both mindful breathing practice and cognitive reappraisal practice yielded large effect sizes in reducing test anxiety. In addition, the mindful breathing condition scored significantly higher on positive thoughts than the cognitive reappraisal and control conditions. The findings of this study suggest that both daily mindful breathing and cognitive reappraisal practices were effective in reducing test anxiety; however, mindful breathing increased positive automatic thoughts to a greater extent than cognitive reappraisal.	[Cho, Hyunju; Ryu, Seokjin; Noh, Jeeae] Yeungnam Univ, Dept Psychol, Gyongsan, South Korea; [Lee, Jongsun] Kangwon Natl Univ, Dept Psychol, Chuncheon Si, South Korea	Yeungnam University; Kangwon National University	Cho, H (corresponding author), Yeungnam Univ, Dept Psychol, Gyongsan, South Korea.	itslife@ynu.ac.kr		Noh, Seunghye/0000-0002-8899-151X; Cho, Hyunju/0000-0001-8316-9626	Yeungnam University Research Grant	Yeungnam University Research Grant	This study was supported by the Yeungnam University Research Grant (http://www.yu.ac.kr/english/main/index.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerman PL, 1997, PSYCHOL BULL, V121, P219, DOI 10.1037/0033-2909.121.2.219; [Anonymous], 2005, PSYCHOL TESTING PRAC; Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015; Benson J, 1994, STRUCT EQU MODELING, V1, P203, DOI 10.1080/10705519409539975; Burg JM, 2012, SWISS J PSYCHOL; Call D, 2014, MINDFULNESS, V5, P658, DOI 10.1007/s12671-013-0218-6; Carmody J, 2009, J CLIN PSYCHOL, V65, P613, DOI 10.1002/jclp.20579; Cassady J. C., 2010, ANXIETY SCH CAUSES C, V2; Cramer D., 2004, SAGE DISCTIONARY STA, DOI [10.4135/, DOI 10.4135/9780857020123, 10.4135/9780857020123]; Cramer D., 1998, FUNDAMENTAL STAT SOC; Doane DP, 2011, J STAT EDUC, V19, DOI 10.1080/10691898.2011.11889611; Ejei J, 2011, PROCD SOC BEHV, V30, DOI 10.1016/j.sbspro.2011.10.420; EYSENCK MW, 1992, COGNITION EMOTION, V6, P409, DOI 10.1080/02699939208409696; Garland E, 2009, EXPLORE-NY, V5, P37, DOI 10.1016/j.explore.2008.10.001; Greenberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036206; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Hayes SC, 2011, ANNU REV CLIN PSYCHO, V7, P141, DOI 10.1146/annurev-clinpsy-032210-104449; Hayes-Skelton S, 2013, BEHAV COGN PSYCHOTH, V41, P317, DOI 10.1017/S1352465812000902; Huberty T. J., 2009, PRINCIPAL LEADERSHIP, V10, P12; INGRAM RE, 1988, J CONSULT CLIN PSYCH, V56, P898, DOI 10.1037/0022-006X.56.6.898; Jha AP, 2007, COGN AFFECT BEHAV NE, V7, P109, DOI 10.3758/CABN.7.2.109; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; LIEBERT RM, 1967, PSYCHOL REP, V20, P975, DOI 10.2466/pr0.1967.20.3.975; Linda Graham M, 2013, BOUNCING BACK REWIRI; Linehan M. M., 1993, COGNITIVE BEHAV TREA; Martin W.E., 2012, QUANTITATIVE STAT RE; Nadinloyi KB, 2013, PROCD SOC BEHV, V84, P303, DOI 10.1016/j.sbspro.2013.06.556; Rana R.A., 2010, B ED RES, V32, P63; Safran J. D., 1990, INTERPERSONAL PROCES; Shapiro SL, 2007, TRAIN EDUC PROF PSYC, V1, P105, DOI 10.1037/1931-3918.1.2.105; Shi Z, 2014, LEARN INDIVID DIFFER, V32, P178, DOI 10.1016/j.lindif.2014.03.011; Shikatani B, 2014, J ANXIETY DISORD, V28, P570, DOI 10.1016/j.janxdis.2014.05.012; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zeidner, 2007, EMOTION ED, P165, DOI [10.1016/B978-012372545-5/50011-3, DOI 10.1016/B978-012372545-5/50011-3]	35	25	26	5	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0164822	10.1371/journal.pone.0164822	http://dx.doi.org/10.1371/journal.pone.0164822			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DZ9NZ	27764151	Green Submitted, gold, Green Published			2023-01-03	WOS:000386204500068
J	Chung, JK; Brown, E; Crooker, B; Palmieri, KJ; McCauley, TG				Chung, Jou-Ku; Brown, Eilish; Crooker, Bob; Palmieri, Kathleen J.; McCauley, Thomas G.			Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration	PLOS ONE			English	Article							ENZYME REPLACEMENT THERAPY; HUNTER-SYNDROME; BRAIN; DIAGNOSIS; TRANSPORT; PROTEIN	Enzyme replacement therapy with intravenous idursulfase (recombinant iduronate-2-sulfatase) is approved for the treatment of Hunter syndrome. Intravenous administration does not, however, treat the neurological manifestations, due to its low central nervous system bioavailability. Using intrathecal-lumbar administration, iduronate-2-sulfatase is delivered directly to the central nervous system. This study investigates the central nervous system biodistribution of intrathecal-lumbar administered iduronate-2-sulfatase in cynomolgus monkeys. Twelve monkeys were administered iduronate-2-sulfatase in one 30 mg intrathecal-lumbar injection. Brain, spinal cord, liver, and kidneys were collected for iduronate-2-sulfatase concentration (measured by an enzyme linked immunosorbent assay) and enzyme activity measurement (via a method utilizing 4-methylumbelliferyl-alpha-iduronate-2sulfate) at 1, 2, 5, 12, 24, and 48 hours following administration. The tissue enzyme linked immunosorbent assay confirmed iduronate-2-sulfatase uptake to the brain, spinal cord, kidneys, and liver in a time-dependent manner. In spinal cord and brain, iduronate-2-sulfatase appeared as early as 1 hour following administration, and peak concentrations were observed at similar to 2 and similar to 5 hours. Iduronate-2-sulfatase appeared in liver and kidneys 1 hour post intrathecal-lumbar dose with peak concentrations between 5 and 24 hours. Liver iduronate-2-sulfatase concentration was approximately 10-fold higher than kidney. The iduronate-2-sulfatase localization and enzyme activity in the central nervous system, following intrathecal administration, demonstrates that intrathecal-lumbar treatment with iduronate-2-sulfatase may be considered for further investigation as a treatment for Hunter syndrome patients with neurocognitive impairment.	[Chung, Jou-Ku; Brown, Eilish; Crooker, Bob; Palmieri, Kathleen J.; McCauley, Thomas G.] Shire, Lexington, MA 02421 USA	Shire Pharmaceuticals Limited	Chung, JK (corresponding author), Shire, Lexington, MA 02421 USA.	jchung@shire.com			Shire	Shire	This study was funded and conducted by Shire (https://www.shire.com/). Editorial assistance was provided by Robin Smith, PhD, of The Curry Rockefeller Group, LLC, Tarrytown, New York and this assistance was funded by Shire. The funders had a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.	BACH G, 1973, P NATL ACAD SCI USA, V70, P2134, DOI 10.1073/pnas.70.7.2134; Begley DJ, 2008, CURR PHARM DESIGN, V14, P1566, DOI 10.2174/138161208784705504; Calias P, 2014, PHARMACOL THERAPEUT, V144, P114, DOI 10.1016/j.pharmthera.2014.05.009; Calias P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030341; Chen FT, 2006, MOL GENET METAB, V87, P349, DOI 10.1016/j.ymgme.2005.11.017; Felice BR, 2011, TOXICOL PATHOL, V39, P879, DOI 10.1177/0192623311409595; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Martin R, 2008, PEDIATRICS, V121, pE377, DOI 10.1542/peds.2007-1350; Muenzer J, 2006, GENET MED, V8, P465, DOI 10.1097/01.gim.0000232477.37660.fb; Muenzer J, 2016, GENET MED, V18, P73, DOI 10.1038/gim.2015.36; Muenzer J, 2012, EUR J PEDIATR, V171, P181, DOI 10.1007/s00431-011-1606-3; Muenzer J, 2011, GENET MED, V13, P95, DOI 10.1097/GIM.0b013e3181fea459; Muenzer J, 2009, PEDIATRICS, V124, pE1228, DOI 10.1542/peds.2008-0999; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Nielsen H. M., 2009, DELIVERY TECHNOLOGIE, P1; Passini MA, 2002, J NEUROSCI, V22, P6437; Tan ML, 2010, PEPTIDES, V31, P184, DOI 10.1016/j.peptides.2009.10.002; Voznyi YV, 2001, J INHERIT METAB DIS, V24, P675, DOI 10.1023/A:1012763026526; Xie HS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122453; YOUNG ID, 1982, J MED GENET, V19, P408, DOI 10.1136/jmg.19.6.408	20	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0164765	10.1371/journal.pone.0164765	http://dx.doi.org/10.1371/journal.pone.0164765			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NZ	27764180	Green Submitted, Green Published, gold			2023-01-03	WOS:000386204500059
J	Burton, LJ; Rivera, M; Hawsawi, O; Zou, J; Hudson, T; Wang, GD; Zhang, Q; Cubano, L; Boukli, N; Odero-Marah, V				Burton, Liza J.; Rivera, Mariela; Hawsawi, Ohuod; Zou, Jin; Hudson, Tamaro; Wang, Guangdi; Zhang, Qiang; Cubano, Luis; Boukli, Nawal; Odero-Marah, Valerie			Muscadine Grape Skin Extract Induces an Unfolded Protein Response-Mediated Autophagy in Prostate Cancer Cells: A TMT-Based Quantitative Proteomic Analysis	PLOS ONE			English	Article							ASTROCYTE-ELEVATED GENE-1; ANNEXIN-IV; OVARIAN CANCERS; ER STRESS; EXPRESSION; APOPTOSIS; DEATH; RESISTANCE; THERAPY; ADENOCARCINOMA	Muscadine grape skin extract (MSKE) is derived from muscadine grape (Vitis rotundifolia), a common red grape used to produce red wine. Endoplasmic reticulum (ER) stress activates the unfolded protein response (UPR) that serves as a survival mechanism to relieve ER stress and restore ER homeostasis. However, when persistent, ER stress can alter the cytoprotective functions of the UPR to promote autophagy and cell death. Although MSKE has been documented to induce apoptosis, it has not been linked to ER stress/ UPR/autophagy. We hypothesized that MSKE may induce a severe ER stress response-mediated autophagy leading to apoptosis. As a model, we treated C4-2 prostate cancer cells with MSKE and performed a quantitative Tandem Mass Tag Isobaric Labeling proteomic analysis. ER stress response, autophagy and apoptosis were analyzed by western blot, acridine orange and TUNEL/Annexin V staining, respectively. Quantitative proteomics analysis indicated that ER stress response proteins, such as GRP78 were greatly elevated following treatment with MSKE. The up-regulation of pro-apoptotic markers PARP, caspase-12, cleaved caspase-3, -7, BAX and down-regulation of anti-apoptotic marker BCL2 was confirmed by Western blot analysis and apoptosis was visualized by increased TUNEL/Annexin V staining upon MSKE treatment. Moreover, increased acridine orange, and LC3B staining was detected in MSKE-treated cells, suggesting an ER stress/autophagy response. Finally, MSKE-mediated autophagy and apoptosis was antagonized by co-treatment with chloroquine, an autophagy inhibitor. Our results indicate that MSKE can elicit an UPR that can eventually lead to apoptosis in prostate cancer cells.	[Burton, Liza J.; Hawsawi, Ohuod; Zou, Jin; Odero-Marah, Valerie] Clark Atlanta Univ, Dept Biol Sci, Ctr Canc Res & Therapeut Dev, Atlanta, GA 30314 USA; [Rivera, Mariela; Cubano, Luis; Boukli, Nawal] Univ Cent Caribe, Sch Med, Dept Microbiol & Immunol, Bayamon, PR 00956 USA; [Hudson, Tamaro] Howard Univ, Dept Med, Washington, DC 20060 USA; [Wang, Guangdi; Zhang, Qiang] Xavier Univ, Dept Chem, New Orleans, LA 70125 USA	Clark Atlanta University; Howard University; Xavier University of Louisiana	Odero-Marah, V (corresponding author), Clark Atlanta Univ, Dept Biol Sci, Ctr Canc Res & Therapeut Dev, Atlanta, GA 30314 USA.	vodero_marah@cau.edu		Rivera, Mariela/0000-0003-3085-5619	NIH [8G12MD007590, 5 G12RR003062, P20MD002285-01, G12MD007595]; NIH Research Centers in Minority Institutions (RCMI) Program and Biomedical Proteomics Facility [G12MD007583]; U.S. Department of Education [P031S130068]; National Institute on Minority Health and Health Disparities [G12MD007583, G12MD007595, G12MD007590] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Research Centers in Minority Institutions (RCMI) Program and Biomedical Proteomics Facility; U.S. Department of Education(US Department of Education); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	NIH grants 8G12MD007590 (formerly NIH/NCRR Grant Number 5 G12RR003062) (VOM), P20MD002285-01 (VOM), G12MD007595 (GW). This project was also supported by the NIH Research Centers in Minority Institutions (RCMI) Program and Biomedical Proteomics Facility Grant G12MD007583 (NMB) and Title V grant number P031S130068 from the U.S. Department of Education (LAC).	Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; Allahverdiyev A. M., 2012, BIOCH GENETICS MOL B; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Bair WB, 2010, MELANOMA RES, V20, P85, DOI 10.1097/CMR.0b013e3283364903; Bergmann A, 2007, CELL, V131, P1032, DOI 10.1016/j.cell.2007.11.027; Bhutia SK, 2010, P NATL ACAD SCI USA, V107, P22243, DOI 10.1073/pnas.1009479107; Boukli Nawal M, 2012, Clin Proteomics, V9, P11, DOI 10.1186/1559-0275-9-11; Boukli NM, 2010, ALCOHOL CLIN EXP RES, V34, P2081, DOI 10.1111/j.1530-0277.2010.01304.x; Burton LJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-97; Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013; Dean M, 2001, J LIPID RES, V42, P1007; Divisi Duilio, 2006, Acta Biomed, V77, P118; Dong YS, 2015, CELL DEATH DIFFER; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gomes IM, 2012, MOL CANCER RES, V10, P573, DOI 10.1158/1541-7786.MCR-11-0281; Gottlieb RA, 2015, CIRC RES, V116, P504, DOI 10.1161/CIRCRESAHA.116.303787; Han EKH, 2000, BRIT J CANCER, V83, P83; Heinonen IM, 1998, J AGR FOOD CHEM, V46, P25, DOI 10.1021/jf970489o; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Hudson TS, 2007, CANCER RES, V67, P8396, DOI 10.1158/0008-5472.CAN-06-4069; Jeon YJ, 2010, CELL MOL LIFE SCI, V67, P2271, DOI 10.1007/s00018-010-0331-9; Joselin AP, 2006, J BIOL CHEM, V281, P12475, DOI 10.1074/jbc.M509859200; Ke ZF, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0383-9; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kim A, 2010, EXPERT OPIN THER TAR, V14, P963, DOI 10.1517/14728222.2010.511180; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li J, 2009, ONCOGENE, V28, P3188, DOI 10.1038/onc.2009.171; Lin LL, 2008, PROTEOM CLIN APPL, V2, P619, DOI 10.1002/prca.200780088; Masuishi Y, 2011, FEBS J, V278, P1470, DOI 10.1111/j.1742-4658.2011.08059.x; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; Meiyanto E, 2012, ASIAN PAC J CANCER P, V13, P427, DOI 10.7314/APJCP.2012.13.2.427; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moreb JS, 2012, CHEM-BIOL INTERACT, V195, P52, DOI 10.1016/j.cbi.2011.10.007; Paglin S, 2001, CANCER RES, V61, P439; Paller CJ, 2015, PROSTATE, V75, P1518, DOI 10.1002/pros.23024; Rohozinski J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005064; Salazar M, 2011, METHOD ENZYMOL, V489, P297, DOI 10.1016/B978-0-12-385116-1.00017-0; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; Shi X, 2015, INT J CLIN EXP MED, V8, P4795; Shin DY, 2009, ANN NY ACAD SCI, V1171, P137, DOI 10.1111/j.1749-6632.2009.04689.x; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Thirkettle HJ, 2009, ONCOGENE, V28, P3663, DOI 10.1038/onc.2009.223; Toyama A, 2012, CANCER SCI, V103, P747, DOI 10.1111/j.1349-7006.2012.02224.x; Verfaillie T, 2010, INT J CELL BIOL, V2010; Wang K, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.371591; Wang LS, 2008, CANCER LETT, V269, P281, DOI 10.1016/j.canlet.2008.05.020; Zhou CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3144; Zimmermann U, 2004, CANCER LETT, V209, P111, DOI 10.1016/j.canlet.2003.12.002	55	27	27	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2016	11	10							e0164115	10.1371/journal.pone.0164115	http://dx.doi.org/10.1371/journal.pone.0164115			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NV	27755556	Green Published, Green Submitted, gold			2023-01-03	WOS:000386203800011
J	Fukuta, T; Asai, T; Yanagida, Y; Namba, M; Koide, H; Shimizu, K; Oku, N				Fukuta, Tatsuya; Asai, Tomohiro; Yanagida, Yosuke; Namba, Mio; Koide, Hiroyuki; Shimizu, Kosuke; Oku, Naoto			Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke	FASEB JOURNAL			English	Article						blood-brain barrier; drug delivery system; fasudil; photochemically induced thrombosis; liposome	MIDDLE CEREBRAL-ARTERY; RHO-KINASE; HEMORRHAGIC TRANSFORMATION; TIME WINDOW; MATRIX METALLOPROTEINASES; PEGYLATED LIPOSOMES; REPERFUSION THERAPY; THROMBOSIS MODEL; BRAIN; INJURY	For ischemic stroke treatment, extension of the therapeutic time window(TTW) of thrombolytic therapy with tissue plasminogen activator (tPA) and amelioration of secondary ischemia/reperfusion (I/R) injury are most desirable. Our previous studies have indicated that liposomal delivery of neuroprotectants into an ischemic region is effective for stroke treatment. In the present study, for solving the above problems in the clinical setting, the usefulness of combination therapy with tPA and liposomal fasudil (fasudil-Lip) was investigated in ischemic stroke model rats with photochemically induced thrombosis, with clots that were dissolved by tPA. Treatment with tPA3 h after occlusion markedly increased blood-brain barrier permeability and activated matrix metalloproteinase (MMP)-2 and -9, which are involved in cerebralhemorrhage. However, an intravenous administration of fasudil-Lip before tPA markedly suppressed the increase in permeability and the MMP activation stemming from tPA. The combination treatment showed significantly larger neuroprotective effects, even in the case of delayed tPA administration compared with each treatment alone or the tPA/fasudil-treated group. These findings suggest that treatment with fasudil-Lip before tPA could decrease the risk of tPA-derived cerebral hemorrhage and extend the TTW of tPA and that the combination therapy could be a useful therapeutic option for ischemic stroke.-Fukuta, T., Asai, T., Yanagida, Y., Namba, M., Koide, H., Shimizu, K., Oku, N. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.	[Fukuta, Tatsuya; Asai, Tomohiro; Yanagida, Yosuke; Namba, Mio; Koide, Hiroyuki; Shimizu, Kosuke; Oku, Naoto] Univ Shizuoka, Sch Pharmaceut Sci, Dept Med Biochem, Shizuoka, Japan; [Fukuta, Tatsuya] Japan Soc Promot Sci, Tokyo, Japan	University of Shizuoka; Japan Society for the Promotion of Science	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Med Biochem, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp		Fukuta, Tatsuya/0000-0001-8878-8602; Shimizu, Kosuke/0000-0003-3789-2447	Japan Society for the Promotion of Science [14J10730, 16H05081]; Research Grants in the Natural Sciences of the Mitsubishi Foundation; Grants-in-Aid for Scientific Research [15H02569] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Research Grants in the Natural Sciences of the Mitsubishi Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Asahi Kasei Pharma Corp. (Tokyo, Japan) for the gift of fasudil; Norihiro Harada and Dai Fukumoto (Hamamatsu Photonics PET Center, Minamisoma, Japan) for their technical guidance in preparing MCAO rats by the PIT method. This research was supported by Grants-in-Aid for Scientific Research 14J10730 and 16H05081 from the Japan Society for the Promotion of Science, and by the Research Grants in the Natural Sciences of the Mitsubishi Foundation.	Chamorro A, 2016, LANCET NEUROL, V15, P869, DOI 10.1016/S1474-4422(16)00114-9; Cuadrado E, 2008, J LEUKOCYTE BIOL, V84, P207, DOI 10.1189/jlb.0907606; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; del Zoppo GJ, 2009, CEREBROVASC DIS, V27, P65, DOI 10.1159/000200442; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fagan SC, 2004, STROKE, V35, P2220, DOI 10.1161/01.STR.0000138023.60272.9e; Fukuta T, 2016, INT J PHARMACEUT, V506, P129, DOI 10.1016/j.ijpharm.2016.04.046; Fukuta T, 2015, EUR J PHARM BIOPHARM, V97, P1, DOI 10.1016/j.ejpb.2015.09.020; Fukuta T, 2014, ARTIF ORGANS, V38, P662, DOI 10.1111/aor.12350; Gibson CL, 2014, J NEUROCHEM, V129, P816, DOI 10.1111/jnc.12681; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ishiguro M, 2012, NEUROSCIENCE, V220, P302, DOI 10.1016/j.neuroscience.2012.06.015; Ishii T, 2013, FASEB J, V27, P1362, DOI 10.1096/fj.12-221325; Ishii T, 2012, J CONTROL RELEASE, V160, P81, DOI 10.1016/j.jconrel.2012.02.004; Jickling GC, 2015, J CEREBR BLOOD F MET, V35, P888, DOI 10.1038/jcbfm.2015.45; Jickling GC, 2014, J CEREBR BLOOD F MET, V34, P185, DOI 10.1038/jcbfm.2013.203; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Lakhan SE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00032; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Maeda M, 2002, J CEREBR BLOOD F MET, V22, P1205, DOI 10.1097/01.wcb.0000037993.34930.72; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Murata Y, 2008, STROKE, V39, P3372, DOI 10.1161/STROKEAHA.108.514026; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; Niego B, 2012, BLOOD, V119, P4752, DOI 10.1182/blood-2011-07-369512; O'Collins VE, 2012, J CEREBR BLOOD F MET, V32, P585, DOI 10.1038/jcbfm.2011.203; Rogalewski A, 2006, STROKE, V37, P1129, DOI 10.1161/01.STR.0000209330.73175.34; Satoh SI, 2008, BRAIN RES, V1193, P102, DOI 10.1016/j.brainres.2007.11.050; Shibuya M, 2005, J NEUROL SCI, V238, P31, DOI 10.1016/j.jns.2005.06.003; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x; Tsukada H, 2014, J NUCL MED, V55, P473, DOI 10.2967/jnumed.113.125328; UMEMURA K, 1993, STROKE, V24, P1077, DOI 10.1161/01.STR.24.7.1077; Umemura K, 2007, PATHOPHYSIOL HAEMO T, V36, P245, DOI 10.1159/000252820; Vivien D, 2011, J CEREBR BLOOD F MET, V31, P2119, DOI 10.1038/jcbfm.2011.127; Wang W, 2015, MOL NEUROBIOL, V52, P1572, DOI 10.1007/s12035-014-8952-x; Wang XY, 2004, STROKE, V35, P2726, DOI 10.1161/01.STR.0000143219.16695.af; Yagita Y, 2007, J NEUROSCI RES, V85, P2460, DOI 10.1002/jnr.21375; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022	44	57	57	2	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2017	31	5					1879	1890		10.1096/fj.201601209R	http://dx.doi.org/10.1096/fj.201601209R			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ES0DE	28082354				2023-01-03	WOS:000399195500011
J	Li, JJ; Condello, S; Thomes-Pepin, J; Ma, XX; Xia, Y; Hurley, TD; Matei, D; Cheng, JX				Li, Junjie; Condello, Salvatore; Thomes-Pepin, Jessica; Ma, Xiaoxiao; Xia, Yu; Hurley, Thomas D.; Matei, Daniela; Cheng, Ji-Xin			Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells	CELL STEM CELL			English	Article							NF-KAPPA-B; MULLERIAN-INHIBITING SUBSTANCE; UNSATURATED FATTY-ACIDS; RAMAN SCATTERING MCARS; FREE FLOW-CYTOMETRY; VIVO TUMOR-GROWTH; BREAST-CANCER; ALDEHYDE DEHYDROGENASE; SIDE POPULATION; BETA-CATENIN	Lack of sensitive single-cell analysis tools has limited the characterization of metabolic activity in cancer stem cells. By hyperspectral-stimulated Raman scattering imaging of single living cells and mass spectrometry analysis of extracted lipids, we report here significantly increased levels of unsaturated lipids in ovarian cancer stem cells (CSCs) as compared to non-CSCs. Higher lipid unsaturation levels were also detected in CSC-enriched spheroids compared to monolayer cultures of ovarian cancer cell lines or primary cells. Inhibition of lipid desaturases effectively eliminated CSCs, suppressed sphere formation in vitro, and blocked tumor initiation capacity in vivo. Mechanistically, we demonstrate that nuclear factor kB (NF-kB) directly regulates the expression levels of lipid desaturases, and inhibition of desaturases blocks NF-kB signaling. Collectively, our findings reveal that increased lipid unsaturation is a metabolic marker for ovarian CSCs and a target for CSC-specific therapy.	[Li, Junjie; Cheng, Ji-Xin] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Condello, Salvatore; Matei, Daniela] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Thomes-Pepin, Jessica] Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Ma, Xiaoxiao; Xia, Yu; Cheng, Ji-Xin] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; [Hurley, Thomas D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Hurley, Thomas D.] Indiana Univ Sch Med, Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46202 USA; [Matei, Daniela] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Matei, Daniela] Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Cheng, Ji-Xin] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cheng, JX (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.; Matei, D (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA.; Cheng, JX (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.; Matei, D (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.; Matei, D (corresponding author), Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Cheng, JX (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.	daniela.matei@northwestern.edu; jcheng@purdue.edu	Condello, Salvatore/ABB-6743-2021; Li, Junjie/B-1424-2017; Xia, Yu/V-8299-2019	Li, Junjie/0000-0003-4542-300X; Ma, Xiaoxiao/0000-0003-1205-6485; Matei, Daniela/0000-0003-2169-5035; Condello, Salvatore/0000-0003-4979-3681; HURLEY, THOMAS/0000-0002-5942-1163	VA Merit Award [BX000792-05A1]; NCI [CA198409, CA182608]; Walther Cancer Foundation; NIH [P30CA023168]; NATIONAL CANCER INSTITUTE [R21CA198409, R21CA182608, P30CA023168] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000792] Funding Source: NIH RePORTER	VA Merit Award(US Department of Veterans Affairs); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Walther Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Leelyn Chong and Drs. Bin Liu, Chi Zhang, and Bakhtiyor Yakubov for technical support. The authors acknowledge the use of the metabolite profiling facility of the Bindley Bioscience Center at Purdue University. This work was supported by a VA Merit Award (BX000792-05A1), the NCI (CA198409 to D.M. and CA182608 to J.-X.C.), the Walther Cancer Foundation (to J.-X.C.), and the NIH (P30CA023168). J.L. and J.-X.C. are co-founders of Resarci Therapeutics LLC.	Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; Camp CH, 2011, OPT LETT, V36, P2309, DOI 10.1364/OL.36.002309; Camp CH, 2009, OPT EXPRESS, V17, P22879, DOI 10.1364/OE.17.022879; Cheng JX, 2015, SCIENCE, V350, DOI 10.1126/science.aaa8870; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Flesken-Nikitin A, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963435; Foster R, 2013, CANCER LETT, V338, P147, DOI 10.1016/j.canlet.2012.10.023; Fu D, 2013, J PHYS CHEM B, V117, P4634, DOI 10.1021/jp308938t; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Jia D, 2015, CELL DEATH DIFFER, V22, P298, DOI 10.1038/cdd.2014.145; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Lewis DA, 2011, AGING-US, V3, P407, DOI 10.18632/aging.100318; Li S, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-73; Liu B, 2015, APPL PHYS LETT, V106, DOI 10.1063/1.4919104; Liu G, 2007, J MED CHEM, V50, P3086, DOI 10.1021/jm070219p; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Ma XX, 2014, ANGEW CHEM INT EDIT, V53, P2592, DOI 10.1002/anie.201310699; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Meirelles K, 2012, P NATL ACAD SCI USA, V109, P2358, DOI 10.1073/pnas.1120733109; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Movasaghi Z, 2007, APPL SPECTROSC REV, V42, P493, DOI 10.1080/05704920701551530; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Obukowicz MG, 1998, J PHARMACOL EXP THER, V287, P157; Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Poletto AC, 2015, MOL CELL ENDOCRINOL, V401, P65, DOI 10.1016/j.mce.2014.12.001; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Shanmugam R, 2011, INT J CANCER, V128, P2481, DOI 10.1002/ijc.25587; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Slipchenko MN, 2009, J PHYS CHEM B, V113, P7681, DOI 10.1021/jp902231y; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837; Tumanov S, 2015, METHOD ENZYMOL, V561, P197, DOI 10.1016/bs.mie.2015.05.017; van der Zee M, 2015, CANCER RES, V75, P3608, DOI 10.1158/0008-5472.CAN-14-2498; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang HW, 2008, OPT EXPRESS, V16, P5782, DOI 10.1364/OE.16.005782; Wang X, 2013, ONCOGENE, V32, P5512, DOI 10.1038/onc.2013.217; Yang WC, 2007, ANAL CHEM, V79, P5150, DOI 10.1021/ac070311t; Zhang C, 2015, ANNU REV BIOMED ENG, V17, P415, DOI 10.1146/annurev-bioeng-071114-040554; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zhou JB, 2008, CELL CYCLE, V7, P1360, DOI 10.4161/cc.7.10.5953	53	296	302	11	166	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	MAR 2	2017	20	3					303	+		10.1016/j.stem.2016.11.004	http://dx.doi.org/10.1016/j.stem.2016.11.004			17	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	EO0GC	28041894	Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000396375300007
J	Fischer, MA; Avorn, J				Fischer, Michael A.; Avorn, Jerry			Step Therapy-Clinical Algorithms, Legislation, and Optimal Prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAID PRIOR-AUTHORIZATION		[Fischer, Michael A.; Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA; [Fischer, Michael A.; Avorn, Jerry] Harvard Med Sch, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Fischer, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	mfischer@partners.org						Avorn J, 2017, JAMA-J AM MED ASSOC, V317, P361, DOI 10.1001/jama.2016.16036; Desai NR, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.07.033; Fischer MA, 2004, NEW ENGL J MED, V351, P2187, DOI 10.1056/NEJMsa042770; Fischer MA, 2007, HEALTH AFFAIR, V26, P800, DOI 10.1377/hlthaff.26.3.800; Kesselheim AS, 2013, JAMA INTERN MED, V173, P202, DOI 10.1001/2013.jamainternmed.997; Lee JL-Y, 2012, AM J MANAG CARE, V18, pe429; Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783; Thomas Katie, 2016, NY TIMES	8	11	11	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	2017	317	8					801	802		10.1001/jama.2016.20619	http://dx.doi.org/10.1001/jama.2016.20619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM7PW	28166322				2023-01-03	WOS:000395505600012
J	Kim, IY; Kim, JH; Lee, DW; Lee, SB; Rhee, H; Seong, EY; Kwak, IS; Song, SH				Kim, Il Young; Kim, Joo Hui; Lee, Dong Won; Lee, Soo Bong; Rhee, Harin; Seong, Eun Young; Kwak, Ihm Soo; Song, Sang Heon			Fluid overload and survival in critically ill patients with acute kidney injury receiving continuous renal replacement therapy	PLOS ONE			English	Article							CONTINUOUS VENOVENOUS HEMOFILTRATION; SEPTIC SHOCK; RIFLE CRITERIA; FAILURE; BALANCE; MULTICENTER; MORTALITY; RECOVERY; MANAGEMENT; DIALYSIS	Background Fluid overload is known to be associated with increased mortality in patients with acute kidney injury (AKI) who are critically ill. In this study, we intended to uncover whether the adverse effect of fluid overload on survival could be applied to all of the patients with AKI who received continuous renal replacement therapy (CRRT). Methods We analyzed 341 patients with AKI who received CRRT in our intensive care units. The presence of fluid overload was defined as a minimum 10% increase in body weight from the baseline. Demographics, comorbid diseases, clinical data, severity of illness [the sequential organ failure assessment (SOFA) score, number of vasopressors, diagnosis of sepsis, use of ventilator] upon ICU admission, fluid overload status, and time elapsed from AKI diagnosis until CRRT initiation were reviewed from the medical charts. Results Patients with total fluid overload from 3 days before CRRT initiation to ICU discharge had a significantly lower survival rate after ICU admission, as compared to patients with no fluid overload (P < 0.001). Among patients with sepsis (P < 0.001) or with high SOFA scores (P < 0.001), there was a significant difference in survival of the patients with and without fluid overload. In patients without sepsis or with low SOFA score, there was no significant difference in survival of patients irrespective of fluid overload. Conclusion Our study demonstrates that the adverse effect of fluid overload on survival is more evident in patients with sepsis or with more severe illness, and that it might not apply to patients without sepsis or with less severe illness.	[Kim, Il Young; Kim, Joo Hui; Lee, Dong Won; Lee, Soo Bong; Rhee, Harin; Seong, Eun Young; Kwak, Ihm Soo; Song, Sang Heon] Pusan Natl Univ, Dept Internal Med, Sch Med, Yangsan, South Korea; [Kim, Il Young; Kim, Joo Hui; Lee, Dong Won; Lee, Soo Bong] Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan, South Korea; [Rhee, Harin; Seong, Eun Young; Kwak, Ihm Soo; Song, Sang Heon] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea	Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital	Song, SH (corresponding author), Pusan Natl Univ, Dept Internal Med, Sch Med, Yangsan, South Korea.; Song, SH (corresponding author), Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea.	shsong0209@gmail.com	Kim, Il Young/ABG-2153-2021; Kim, Il Young/ABG-2156-2021	Kim, Il Young/0000-0002-1731-6357; song, sangheon/0000-0002-8218-6974				Alsous F, 2000, CHEST, V117, P1749, DOI 10.1378/chest.117.6.1749; Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744; Bagshaw SM, 2008, CRIT CARE, V12, DOI 10.1186/cc6948; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Cantarovich F, 2004, AM J KIDNEY DIS, V44, P402, DOI 10.1053/j.ajkd.2004.05.021; Foland JA, 2004, CRIT CARE MED, V32, P1771, DOI 10.1097/01.CCM.0000132897.52737.49; Gillespie RS, 2004, PEDIATR NEPHROL, V19, P1394, DOI 10.1007/s00467-004-1655-1; Goldstein SL, 2001, PEDIATRICS, V107, P1309, DOI 10.1542/peds.107.6.1309; Grams ME, 2011, CLIN J AM SOC NEPHRO, V6, P966, DOI 10.2215/CJN.08781010; Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915; Jacobs R, 2011, BLOOD PURIFICAT, V32, P262, DOI 10.1159/000330244; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012, KIDNEY INT S, V2, P19, DOI DOI 10.1038/KISUP.2011.32; Kielstein JT, 2004, AM J KIDNEY DIS, V43, P342, DOI 10.1053/j.ajkd.2003.10.021; Langenberg C, 2007, INTENS CARE MED, V33, P1614, DOI 10.1007/s00134-007-0734-8; Licari E, 2007, CONTRIB NEPHROL, V156, P167; Liu KD, 2006, CLIN J AM SOC NEPHRO, V1, P915, DOI 10.2215/CJN.01430406; Mehta RL, 2009, NAT CLIN PRACT NEPHR, V5, P10, DOI 10.1038/ncpneph0988; Mehta RL, 2002, JAMA-J AM MED ASSOC, V288, P2547, DOI 10.1001/jama.288.20.2547; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Piccinni P, 2006, INTENS CARE MED, V32, P80, DOI 10.1007/s00134-005-2815-x; Prowle JR, 2010, NAT REV NEPHROL, V6, P107, DOI 10.1038/nrneph.2009.213; Ricci Z, 2006, NEPHROL DIAL TRANSPL, V21, P690, DOI 10.1093/ndt/gfi296; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Schrier RW, 2010, CLIN J AM SOC NEPHRO, V5, P733, DOI 10.2215/CJN.00060110; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; Wan L, 2008, CRIT CARE MED, V36, pS198, DOI 10.1097/CCM.0b013e318168ccd5; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	31	39	44	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2017	12	2							e0172137	10.1371/journal.pone.0172137	http://dx.doi.org/10.1371/journal.pone.0172137			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BA	28196107	Green Published, gold, Green Submitted			2023-01-03	WOS:000394423900053
J	Gao, YJ; Katz, DF				Gao, Yajing; Katz, David F.			Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema	PLOS ONE			English	Article							MICROBICIDE GEL FORMULATION; INTRAVAGINAL RING; DRUG-DELIVERY; HIV-INFECTION; PREVENTION; SAFETY; SURROGATES; TRANSPORT; COLON	Rectal enemas that contain prophylactic levels of anti-HIV microbicides such as tenofovir have emerged as a promising dosage form to prevent sexually transmitted HIV infections. The enema vehicle is promising due to its likely ability to deliver a large amount of drug along the length of the rectal canal. Computational models of microbicide drug delivery by enemas can help their design process by determining key factors governing drug transport and, more specifically, the time history and degree of protection. They can also inform interpretations of experimental pharmacokinetic measures such as drug concentrations in biopsies. The present work begins rectal microbicide PK modeling, for enema vehicles. Results here show that a paramount factor in drug transport is the time of enema retention; direct connectivity between enema fluid and the fluid within rectal crypts is also important. Computations of the percentage of stromal volume protected by a single enema dose indicate that even with only a minute of enema retention, protection of 100% can be achieved after around 14 minutes post dose. Concentrations in biopsies are dependent on biopsy thickness; and control and/or knowledge of thickness could improve accuracy and decrease variability in biopsy measurements. Results here provide evidence that enemas are a promising dosage form for rectal microbicide delivery, and offer insights into their rational design.	[Gao, Yajing; Katz, David F.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Katz, David F.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA	Duke University; Duke University	Katz, DF (corresponding author), Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.	dkatz@duke.edu			National Institute of Health [R01 HD 072702, U19 Al 077289]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077289, U19AI113127] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study is funded by National Institute of Health grants R01 HD 072702 and U19 Al 077289. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ballard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037410; BILLICH CO, 1969, J CLIN INVEST, V48, P1336, DOI 10.1172/JCI106100; Cao YJ, 2012, BRIT J CLIN PHARMACO, V74, P1013, DOI 10.1111/j.1365-2125.2012.04267.x; Chuchuen O., 2015, DEV APPL RAMAN SPECT; Chuchuen O, 2014, AIDS RES HUM RETROV, V30, pA59, DOI 10.1089/aid.2014.5106.abstract; Clark Meredith R, 2014, Pharmaceutics, V6, P616; das Neves J., 2014, DRUG DELIVERY DEV AN; Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173; Gao Y, 2015, DRUG DELIV TRANSL RE, P1; Gao YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074404; Geonnotti AR, 2010, J PHARM SCI-US, V99, P3514, DOI 10.1002/jps.22120; Ham AS, 2015, ANTIVIR RES, V120, P153, DOI 10.1016/j.antiviral.2015.06.010; Ham AS, 2012, J PHARM SCI-US, V101, P1423, DOI 10.1002/jps.23026; Hawkins T, 2005, JAIDS-J ACQ IMM DEF, V39, P406, DOI 10.1097/01.qai.0000167155.44980.e8; Hendrix C, 2008, CLIN PHARMACOL THER, V83, P97, DOI 10.1038/sj.clpt.6100236; Hendrix CW, 2009, ANNU REV PHARMACOL, V49, P349, DOI 10.1146/annurev.pharmtox.48.113006.094906; Howett MK, 2005, CURR PHARM DESIGN, V11, P3731, DOI 10.2174/138161205774580633; Jarrett AM, 2016, J PHARM SCI-US, V105, P1772, DOI 10.1016/j.xphs.2016.02.015; Katz DF, 2015, ADV DRUG DELIVERY RE; Kearney BP, 2004, CLIN PHARMACOKINET, V43, P595, DOI 10.2165/00003088-200443090-00003; Kiser PF, 2012, AIDS REV, V14, P62; Klijn AJ, 2004, J UROLOGY, V172, P1986, DOI 10.1097/01.ju.0000142686.09532.46; LERICHE M, 1978, DIS COLON RECTUM, V21, P227, DOI 10.1007/BF02586697; Leyva FJ, 2013, AIDS RES HUM RETROV, V29, P1487, DOI [10.1089/aid.2013.0189, 10.1089/AID.2013.0189]; Mahalingam A, 2010, PHARM RES-DORDR, V27, P2478, DOI 10.1007/s11095-010-0244-1; Maisel K, 2015, J CONTROL RELEASE, V209, P280, DOI 10.1016/j.jconrel.2015.04.040; Mathworks, 2010, MATLAB 7 11 0; Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536; NIVATVONGS S, 1981, DIS COLON RECTUM, V24, P600, DOI 10.1007/BF02605754; Ovalle W. K., 2013, NETTERS ESSENTIAL HI; Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310; Schwartz JL, 2009, INT J STD AIDS, V20, P384, DOI 10.1258/ijsa.2008.008309; Slomianka L, 2009, BLUE HIST; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; Tanaka E, 2012, MED MOL MORPHOL, V45, P72, DOI 10.1007/s00795-011-0541-8; Yang KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106196	36	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2017	12	1							e0167696	10.1371/journal.pone.0167696	http://dx.doi.org/10.1371/journal.pone.0167696			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6QR	28114388	Green Submitted, Green Published, gold			2023-01-03	WOS:000396129000001
J	Ziv, E; Tice, JA; Sprague, B; Vachon, CM; Cummings, SR; Kerlikowske, K				Ziv, Elad; Tice, Jeffrey A.; Sprague, Brian; Vachon, Celine M.; Cummings, Steven R.; Kerlikowske, Karla			Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; POSTMENOPAUSAL WOMEN; COMMON VARIANT; PREDICTION; TAMOXIFEN; PREVENTION; RALOXIFENE; DENSITY; REDUCTION	Background Breast cancer can be prevented with selective estrogen receptor modifiers (SERMs) and aromatase inhibitors (AIs). The US Preventive Services Task Force recommends that women with a 5-year breast cancer risk >= 3% consider chemoprevention for breast cancer. More than 70 single nucleotide polymorphisms (SNPs) have been associated with breast cancer. We sought to determine how to best integrate risk information from SNPs with other risk factors to risk stratify women for chemoprevention. Methods We used the risk distribution among women ages 35 -69 estimated by the Breast Cancer Surveillance Consortium (BCSC) risk model. We modeled the effect of adding 70 SNPs to the BCSC model and examined how this would affect how many women are reclassified above and below the threshold for chemoprevention. Results We found that most of the benefit of SNP testing a population is achieved by testing a modest fraction of the population. For example, if women with a 5-year BCSC risk of >2.0% are tested (similar to 21% of all women), similar to 75% of the benefit of testing all women (shifting women above or below 3% 5-year risk) would be derived. If women with a 5-year risk of > 1.5% are tested (similar to 36% of all women), similar to 90% of the benefit of testing all women would be derived. Conclusion SNP testing is effective for reclassification of women for chemoprevention, but is unlikely to reclassify women with <1.5% 5-year risk. These results can be used to implement an efficient two-step testing approach to identify high risk women who may benefit from chemoprevention.	[Ziv, Elad; Tice, Jeffrey A.; Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Ziv, Elad] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Ziv, Elad] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA; [Tice, Jeffrey A.; Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Sprague, Brian] Univ Vermont, Dept Surg, Burlington, VT 05405 USA; [Sprague, Brian] Univ Vermont, Ctr Canc, Burlington, VT USA; [Vachon, Celine M.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN USA; [Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA; [Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Vermont; University of Vermont; Mayo Clinic; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco	Ziv, E (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Ziv, E (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.; Ziv, E (corresponding author), Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.	elad.ziv@ucsf.edu		Tice, Jeffrey/0000-0002-9857-2028	National Cancer Institute [P01 CA154292, HHSN261201100031C, U54 CA163303, K24CA169004]; NATIONAL CANCER INSTITUTE [K24CA169004, P01CA154292, U54CA163303] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute-funded Breast Cancer Surveillance Consortium (P01 CA154292 and HHSN261201100031C) and additional grants from the National Cancer Institute U54 CA163303 and K24CA169004. The National Cancer Institute URL is www.cancer.gov. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Antoniou AC, 2010, NAT GENET, V42, P885, DOI 10.1038/ng.669; Bambhroliya A, 2015, J NATL COMPR CANC NE, V13, P927, DOI 10.6004/jnccn.2015.0107; Bojesen SE, 2013, NAT GENET, V45, P371, DOI 10.1038/ng.2566; Brentnall AR, 2014, BRIT J CANCER, V110, P827, DOI 10.1038/bjc.2013.747; Cai QY, 2014, NAT GENET, V46, P886, DOI 10.1038/ng.3041; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 2009, JNCI-J NATL CANCER I, V101, P384, DOI 10.1093/jnci/djp018; Darabi H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3110; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Fejerman L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6260; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Gail MH, 2009, J NATL CANCER I, V101, P959, DOI 10.1093/jnci/djp130; Garcia-Closas M, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju305; Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561; Ghoussaini M, 2012, NAT GENET, V44, P312, DOI 10.1038/ng.1049; Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507; Haiman CA, 2011, NAT GENET, V43, P1210, DOI 10.1038/ng.985; Kaplan CP, 2012, BREAST CANCER RES TR, V133, P357, DOI 10.1007/s10549-012-1960-5; Lindstrom S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6303; Long JR, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002532; Lu Q, 2008, AM J HUM GENET, V82, P641, DOI 10.1016/j.ajhg.2007.12.025; Lu Q, 2010, BIOMETRICS, V66, P586, DOI 10.1111/j.1541-0420.2009.01278.x; Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402; Mavaddat N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv036; Michailidou K, 2015, NAT GENET, V47, P373, DOI 10.1038/ng.3242; Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563; Milne RL, 2014, HUM MOL GENET, V23, P1934, DOI 10.1093/hmg/ddt581; Moyer VA, 2013, ANN INTERN MED, V159, P698, DOI [10.7326/0003-4819-159-10-201311190-00717, 10.7326/0003-4819-159-10-201311190-00718]; Orr N, 2012, NAT GENET, V44, P1182, DOI 10.1038/ng.2417; Padhukasahasram B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014338; Shieh Y, 2016, BREAST CANCER RES TR, V159, P513, DOI 10.1007/s10549-016-3953-2; Siddiq A, 2012, HUM MOL GENET, V21, P5373, DOI 10.1093/hmg/dds381; So HC, 2011, AM J HUM GENET, V88, P548, DOI 10.1016/j.ajhg.2011.04.001; Tice JA, 2008, ANN INTERN MED, V148, P337, DOI 10.7326/0003-4819-148-5-200803040-00004; Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; Vachon CM, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju397; Vachon CM, 2015, BREAST CANCER RES TR, V149, P517, DOI 10.1007/s10549-014-3175-4; Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727; Waters EA, 2012, BREAST CANCER RES TR, V134, P875, DOI 10.1007/s10549-012-2089-2; Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318	43	12	12	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2017	12	1							e0168601	10.1371/journal.pone.0168601	http://dx.doi.org/10.1371/journal.pone.0168601			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3QC	28107349	Green Published, gold, Green Submitted			2023-01-03	WOS:000392405300014
J	Thirukkumaran, C; Shi, ZQ; Thirukkumaran, P; Luider, J; Kopciuk, K; Spurrell, J; Elzinga, K; Morris, D				Thirukkumaran, Chandini; Shi, Zhong-Qiao; Thirukkumaran, Ponnampalam; Luider, Joanne; Kopciuk, Karen; Spurrell, Jason; Elzinga, Kate; Morris, Don			PUMA and NF-kappa B Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; EXPRESSION; ACTIVATION; PARTICLE; THERAPY; PATHWAY; POTENT; DEATH	Background and purpose Reovirus is a ubiquitous RNA virus that exploits aberrant signaling pathways for its replication. The oncolytic potential of reovirus against numerous cancers under pre-clinical/clinical conditions has been documented by us and others. Despite its proven clinical activity, the underlying mechanisms of reovirus oncolysis is still not well elucidated. If reovirus therapy is to be optimized for cancer, including breast cancer patients, it is imperative to understand the mechanisms of reovirus oncolysis, especially in treatment of resistant tumour. Experimental approach and results In the present study global gene expression profiling was utilized as a preliminary roadmap to tease-out pivotal molecules involved in reovirus induced apoptosis in breast cancer. Reovirus treated HTB133 and MCF7 breast cancer cells revealed transcriptional alteration of a defined subset of apoptotic genes and members of the nuclear factor-kappa B (NF-kappa B) family and p53 upregulated modulator of apoptosis (PUMA) were prominent. Since NF-kappa B can paradoxically suppress or promote apoptosis in cancer, the significance of NF-kappa B in reovirus oncolysis of breast cancer was investigated. Real time PCR analysis indicated a 2.9-4.3 fold increase in NF-kappa B p65 message levels following reovirus infection of MCF7 and HTB133, respectively. Nuclear translocation of NF-kappa B p65 protein was also dramatically augmented post reovirus treatment and correlated with enhanced DNA binding. Pharmacologic inhibition of NF-kappa B lead to oncolytic protection and significant down regulation of PUMA message levels. PUMA down regulation using siRNA suppressed reovirus oncolysis via significantly repressed apoptosis in p53 mutant HTB133 cells. Conclusions This study demonstrates for the first time that a prominent pathway of reovirus oncolysis of breast cancer is mediated through NF-kappa B and that PUMA upregulation is dependent on NF-kappa B activation. These findings represent potential therapeutic indicators of reovirus treatment in future clinical trials.	[Thirukkumaran, Chandini; Shi, Zhong-Qiao; Spurrell, Jason; Elzinga, Kate; Morris, Don] Tom Baker Canc Clin, Translat Res Labs, Calgary, AB, Canada; [Thirukkumaran, Ponnampalam] Hosp Dr NW, Alberta Prov Labs, Calgary, AB, Canada; [Luider, Joanne] Foothills Med Ctr, Calgary Lab Serv, Calgary, AB, Canada; [Kopciuk, Karen] Holy Cross Ctr SW, AHS, Canc Control Alberta, Dept Canc Epidemiol & Prevent Res, Calgary, AB, Canada; [Morris, Don] Univ Calgary, Tom Baker Canc Ctr, Dept Med & Oncol, Calgary, AB, Canada	Tom Baker Cancer Clinic; University of Calgary; University of Calgary; Tom Baker Cancer Clinic; University of Calgary	Morris, D (corresponding author), Tom Baker Canc Clin, Translat Res Labs, Calgary, AB, Canada.; Morris, D (corresponding author), Univ Calgary, Tom Baker Canc Ctr, Dept Med & Oncol, Calgary, AB, Canada.	Don.Morris@albertahealthservices.ca			Canadian Breast Cancer Foundation [10000599]	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS))	This work was supported by grants awarded to DM and CT through the Canadian Breast Cancer Foundation (Project number 10000599). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alain T, 2007, MOL THER, V15, P1512, DOI 10.1038/sj.mt.6300207; [Anonymous], 2012, R STATS PROGR R LANG; Cao Z, 1999, COLD SPRING HARB SYM, V64, P473, DOI 10.1101/sqb.1999.64.473; Cejkova S, 2009, EUR J HAEMATOL, V82, P133, DOI 10.1111/j.1600-0609.2008.01177.x; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Clarke P, 2003, J BIOL CHEM, V278, P18092, DOI 10.1074/jbc.M300265200; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; DeBiasi RL, 2003, J VIROL, V77, P8934, DOI 10.1128/JVI.77.16.8934-8947.2003; Donepudi MS, 2014, J CANCER RES THER, V10, P506, DOI 10.4103/0973-1482.137927; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2; Groll M, 2004, BBA-MOL CELL RES, V1695, P33, DOI 10.1016/j.bbamcr.2004.09.025; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hirasawa K, 2002, CANCER RES, V62, P1696; Katayama Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/468457; Kelly KR, 2015, ONCOTARGET, V6, P41275, DOI 10.18632/oncotarget.5753; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Middelburg R, 2005, CLIN CANCER RES, V11, P1863, DOI 10.1158/1078-0432.CCR-04-1372; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Pan D, 2011, BRIT J CANCER, V105, P1012, DOI 10.1038/bjc.2011.325; Peters C.A., 2001, ENV ENG PROCESSES LA, P1; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Smakman N, 2006, CANCER RES, V66, P5403, DOI 10.1158/0008-5472.CAN-05-4108; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Smith RA, 2012, ONCOLOGY-NY, V26, P471; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Thirukkumaran C, 2005, P 96 ANN M AM ASS CA, P46; Thirukkumaran C, 2007, P 98 ANN M AM ASS CA, P48; Thirukkumaran C, 2011, P 102 ANN M AM ASS C; Thirukkumaran CM, 2012, CLIN CANCER RES, V18, P4962, DOI 10.1158/1078-0432.CCR-11-3085; Thirukkumaran CM, 2010, CANCER RES, V70, P2435, DOI 10.1158/0008-5472.CAN-09-2408; Thirukkumaran CM, 2003, BLOOD, V102, P377, DOI 10.1182/blood-2002-08-2508; Toss A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0560-9; TYLER KL, 1996, FIELDS VIROLOGY, P1597; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wilcox ME, 2001, J NATL CANCER I, V93, P903, DOI 10.1093/jnci/93.12.903; Xu Bo, 2006, Zhongguo Dang Dai Er Ke Za Zhi, V8, P151; Yang WQ, 2004, GENE THER, V11, P1579, DOI 10.1038/sj.gt.3302319; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45	47	21	22	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2017	12	1							e0168233	10.1371/journal.pone.0168233	http://dx.doi.org/10.1371/journal.pone.0168233			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3HH	28099441	gold, Green Published, Green Submitted			2023-01-03	WOS:000392380100008
J	Tang, WT; Pu, CF; Li, M				Tang, Wenting; Pu, Chuanfen; Li, Man			Interaction between Antibacterial Peptide Apep10 and Escherichia coli Membrane Lipids Evaluated Using Liposome as Pseudo-Stationary Phase	PLOS ONE			English	Article							ANTIMICROBIAL PEPTIDE; CAPILLARY-ELECTROPHORESIS; ELECTROKINETIC CHROMATOGRAPHY; STAPHYLOCOCCUS-AUREUS; BINDING; THERMODYNAMICS; PHOSPHOLIPIDS; PERFORMANCE; PROTEINS; BILAYERS	Liposomes constructed from Escherichia coli membrane lipids were used as a pseudo-stationary phase in capillary electrophoresis and immobilised liposome chromatography to evaluate the interaction between antibacterial peptide (ABP) Apep10 and bacterial membrane lipids. The peptide mobility decreased as the concentration of liposomes increased, providing evidence for the existence of this interaction. The binding constant between Apep10 and the Escherichia coli membranes lipid liposome was higher than that of Apep10 with a mixed phospholipids liposome at the same temperature. The capillary electrophoresis results indicate that the binding ability of Apep10 with a liposome was dependent on the liposome's lipid compositions. Thermodynamic analysis by immobilised liposome chromatography indicated that hydrophobic and electrostatic effects contributed to the partitioning of Apep10 in the membrane lipids. The liposomes constructed from bacterial membrane lipid were more suitable as the model membranes used to study dynamic ABP/membrane interactions than those constructed from specific ratios of particular phospholipids, with its more biomimetic phospholipid composition and contents. This study provides an appropriate model for the evaluation of ABP-membrane interactions.	[Tang, Wenting; Pu, Chuanfen; Li, Man] Qingdao Agr Univ, Sch Food Sci & Engn, Qingdao 266109, Peoples R China	Qingdao Agricultural University	Tang, WT (corresponding author), Qingdao Agr Univ, Sch Food Sci & Engn, Qingdao 266109, Peoples R China.	twtfly@126.com			University Science and Technology Project of Shandong Province of China [J16LE22]; Doctoral Science Foundation of Shandong Province of China [BS2015SW019]; Advanced Talents Foundation of Qingdao Agricultural University [6631115030]	University Science and Technology Project of Shandong Province of China; Doctoral Science Foundation of Shandong Province of China; Advanced Talents Foundation of Qingdao Agricultural University	This study was supported by University Science and Technology Project of Shandong Province of China (no. J16LE22, http://www.sdedu.gov.cn/, WT), Doctoral Science Foundation of Shandong Province of China (no. BS2015SW019, http://www.sdstc.gov.cn/, WT), and Advanced Talents Foundation of Qingdao Agricultural University (no. 6631115030, www.qau.edu.cn, WT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aisenbrey C, 2008, J MOL BIOL, V375, P376, DOI 10.1016/j.jmb.2007.10.053; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bilek G, 2006, J CHROMATOGR B, V841, P38, DOI 10.1016/j.jchromb.2006.03.031; Boija E, 2006, BBA-BIOMEMBRANES, V1758, P620, DOI 10.1016/j.bbamem.2006.04.007; Bonev BB, 2000, BIOCHEMISTRY-US, V39, P11425, DOI 10.1021/bi0001170; Choi MJ, 2004, PEPTIDES, V25, P675, DOI 10.1016/j.peptides.2004.01.004; Corradini D, 2004, J CHROMATOGR A, V1051, P103, DOI 10.1016/j.chroma.2004.06.116; Dennison SR, 2006, BIOCHEM BIOPH RES CO, V347, P1006, DOI 10.1016/j.bbrc.2006.06.181; El-Hady D, 2010, J PHARMACEUT BIOMED, V52, P232, DOI 10.1016/j.jpba.2009.12.022; Faccone D, 2014, EUR J MED CHEM, V71, P31, DOI 10.1016/j.ejmech.2013.10.065; Franzen U, 2011, ELECTROPHORESIS, V32, P738, DOI 10.1002/elps.201000552; Fu HQ, 2011, ELECTROPHORESIS, V32, P749, DOI 10.1002/elps.201000618; Gallagher ES, 2015, J CHROMATOGR A, V1385, P28, DOI 10.1016/j.chroma.2015.01.052; Liang C, 2015, TRAC-TREND ANAL CHEM, V68, P28, DOI 10.1016/j.trac.2015.02.009; Liu XY, 2001, J CHROMATOGR B, V750, P51, DOI 10.1016/S0378-4347(00)00427-8; Mady MM, 2012, CELL BIOCHEM BIOPHYS, V62, P481, DOI 10.1007/s12013-011-9334-x; Mady MM, 2011, MOL PHYS, V109, P1593, DOI 10.1080/00268976.2011.575408; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Ngo KX, 2009, COLLOID SURFACE B, V73, P399, DOI 10.1016/j.colsurfb.2009.06.015; Penn SG, 2002, J PHYS CHEM, V99, P3875; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SCHMALZING D, 1993, J CHROMATOGR A, V652, P149, DOI 10.1016/0021-9673(93)80655-R; Sevcsik E, 2007, BBA-BIOMEMBRANES, V1768, P2586, DOI 10.1016/j.bbamem.2007.06.015; Tanaka Y, 2002, J CHROMATOGR B, V768, P81, DOI 10.1016/S0378-4347(01)00488-1; Tang WT, 2014, J AGR FOOD CHEM, V62, P1564, DOI 10.1021/jf4052286; van Kan EJM, 2003, BBA-BIOMEMBRANES, V1615, P84, DOI 10.1016/S0005-2736(03)00233-5; Verma DD, 2003, INT J PHARM, V258, P141, DOI 10.1016/S0378-5173(03)00183-2; Wang TH, 2010, J MOL STRUCT, V970, P128, DOI 10.1016/j.molstruc.2010.02.061; Wiedmer SK, 2004, TRAC-TREND ANAL CHEM, V23, P562, DOI 10.1016/j.trac.2004.03.001; Xiao JH, 2012, J AGR FOOD CHEM, V60, P4535, DOI 10.1021/jf2052509; Yoshimoto N, 2006, BIOCHEM ENG J, V29, P174, DOI 10.1016/j.bej.2005.08.030; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang HJ, 2014, ANAL METHODS-UK, V6, P725, DOI 10.1039/c3ay41541d; ZHANG YX, 1995, ANAL BIOCHEM, V229, P291, DOI 10.1006/abio.1995.1415	34	2	2	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2017	12	1							e0164594	10.1371/journal.pone.0164594	http://dx.doi.org/10.1371/journal.pone.0164594			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2TP	28052090	Green Published, Green Submitted, gold			2023-01-03	WOS:000391621500003
J	Brooks, HL; Pontefract, SK; Vallance, HK; Hirsch, CA; Hughes, E; Ferner, RE; Marriott, JF; Coleman, JJ				Brooks, Hannah L.; Pontefract, Sarah K.; Vallance, Hannah K.; Hirsch, Christine A.; Hughes, Elizabeth; Ferner, Robin E.; Marriott, John F.; Coleman, Jamie J.			Perceptions and Impact of Mandatory eLearning for Foundation Trainee Doctors: A Qualitative Evaluation	PLOS ONE			English	Article							TECHNOLOGY ACCEPTANCE MODEL; VIEWS	Background Junior doctors in the UK must complete various educational components during their two year Foundation training programme. It is important that mandatory learning is informative and engaging. The aim of this study was to evaluate trainee doctors' perceptions of a Technology Enhanced Learning (TEL) programme developed to improve prescribing competency. Method Focus groups and interviews were conducted at three hospital sites in the West Midlands. Codes, sub-themes and themes were determined using deductive and inductive thematic analysis. Results Data were collected from 38 Foundation trainee doctors. Results revealed major themes relating to prescribing education, the user experience and user engagement. Key findings included the positive impact of preparedness following undergraduate education on the user experience of the TEL programme at the postgraduate level; the impact of content, structure, and individual learning needs and styles on the user experience; and the impact of motivation and time on engagement. Most trainees engaged with the programme owing to its mandatory nature; however, some trainees also used the programme voluntarily, for example, to acquire knowledge prior to starting a new placement. Conclusions It is important to ensure that learners are willing to engage with mandatory TEL, and that they have the time and motivation to do so. It is also important to ensure that learners have a positive user experience and that in designing TEL individual differences in learning styles and needs are taken into account. These findings have implications for educators and system developers in the construction and design of mandatory eLearning programmes.	[Brooks, Hannah L.; Pontefract, Sarah K.; Vallance, Hannah K.; Hirsch, Christine A.; Ferner, Robin E.; Marriott, John F.; Coleman, Jamie J.] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Pontefract, Sarah K.; Coleman, Jamie J.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Hughes, Elizabeth] Hlth Educ England, Birmingham, W Midlands, England; [Ferner, Robin E.] Sandwell & West Birmingham NHS Trust, West Midlands Ctr Adverse Drug React, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Pontefract, SK (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England.; Pontefract, SK (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.	s.k.pontefract@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346; Pontefract, Sarah Katie/0000-0002-0344-4075; Coleman, Jamie/0000-0002-7512-5153	Health Education England's West Midland Team	Health Education England's West Midland Team	This study was funded by Health Education England's West Midland Team. This article presents independent research. The views expressed are those of the author(s) and not necessarily those of Health Education England or NHS England. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonnes S, 2016, ACAD MED; Brooks HL, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0651-z; Davis F.D., 1986, TECHNOLOGY ACCEPTANC; Goldacre MJ, 2014, POSTGRAD MED J, V90, P63, DOI 10.1136/postgradmedj-2012-131321; Han WH, 2006, SCOT MED J, V51, P27; Hortsch M, 2015, MED TEACH, V37, P507, DOI 10.3109/0142159X.2014.1001341; Jenner LE, 2014, MED TEACH, P1; KEOGH MJ, 2010, BJMP, V3, P306; Kirkpatrick DL, 2009, EVALUATING TRAINING; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Patton MQ, 2005, QUALITATIVE RES EVAL; Rothwell C, 2012, BRIT J CLIN PHARMACO, V73, P194, DOI 10.1111/j.1365-2125.2011.04061.x; Ruiz JG, 2006, ACAD MED, V81, P207, DOI 10.1097/00001888-200603000-00002; T Dornan, 2009, DEPTH INVESTIGATION; Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926; Venkatesh V, 2008, DECISION SCI, V39, P273, DOI 10.1111/j.1540-5915.2008.00192.x; Walsh K, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.333.5555; Watmough S, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-64; Zehry K, 2011, PROCD SOC BEHV, V15, P3163, DOI 10.1016/j.sbspro.2011.04.265; Zhang MWB, 2014, TECHNOL HEALTH CARE, V22, P847, DOI 10.3233/THC-140861	20	9	9	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2016	11	12							e0168558	10.1371/journal.pone.0168558	http://dx.doi.org/10.1371/journal.pone.0168558			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QH	28005938	gold, Green Published, Green Submitted			2023-01-03	WOS:000392843200064
J	Legriel, S; Lemiale, V; Schenck, M; Chelly, J; Laurent, V; Daviaud, F; Srairi, M; Hamdi, A; Geri, G; Rossignol, T; Hilly-Ginoux, J; Boisrame-Helms, J; Louart, B; Malissin, I; Mongardon, N; Planquette, B; Thirion, M; Merceron, S; Canet, E; Pico, F; Tran-Dinh, YR; Bedos, JP; Azoulay, E; Resche-Rigon, M; Cariou, A				Legriel, Stephane; Lemiale, Virginie; Schenck, Maleka; Chelly, Jonathan; Laurent, Virginie; Daviaud, Fabrice; Srairi, Mohamed; Hamdi, Aicha; Geri, Guillaume; Rossignol, Thomas; Hilly-Ginoux, Julia; Boisrame-Helms, Julie; Louart, Benjamin; Malissin, Isabelle; Mongardon, Nicolas; Planquette, Benjamin; Thirion, Marina; Merceron, Sybille; Canet, Emmanuel; Pico, Fernando; Tran-Dinh, Yves-Roger; Bedos, Jean-Pierre; Azoulay, Elie; Resche-Rigon, Matthieu; Cariou, Alain		HYBERNATUS Study Grp	Hypothermia for Neuroprotection in Convulsive Status Epilepticus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REFRACTORY STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; THERAPEUTIC HYPOTHERMIA; CARDIAC-ARREST; MANAGEMENT; TRIAL; ANTICONVULSANT; TEMPERATURE; PROTOCOL; INJURY	BACKGROUND Convulsive status epilepticus often results in permanent neurologic impairment. We evaluated the effect of induced hypothermia on neurologic outcomes in patients with convulsive status epilepticus. METHODS In a multicenter trial, we randomly assigned 270 critically ill patients with convulsive status epilepticus who were receiving mechanical ventilation to hypothermia (32 to 34 degrees C for 24 hours) in addition to standard care or to standard care alone; 268 patients were included in the analysis. The primary outcome was a good functional outcome at 90 days, defined as a Glasgow Outcome Scale (GOS) score of 5 (range, 1 to 5, with 1 representing death and 5 representing no or minimal neurologic deficit). The main secondary outcomes were mortality at 90 days, progression to electroencephalographically (EEG) confirmed status epilepticus, refractory status epilepticus on day 1, "super-refractory" status epilepticus (resistant to general anesthesia), and functional sequelae on day 90. RESULTS A GOS score of 5 occurred in 67 of 138 patients (49%) in the hypothermia group and in 56 of 130 (43%) in the control group (adjusted common odds ratio, 1.22; 95% confidence interval [CI], 0.75 to 1.99; P=0.43). The rate of progression to EEG-confirmed status epilepticus on the first day was lower in the hypothermia group than in the control group (11% vs. 22%; odds ratio, 0.40; 95% CI, 0.20 to 0.79; P=0.009), but there were no significant differences between groups in the other secondary outcomes. Adverse events were more frequent in the hypothermia group than in the control group. CONCLUSIONS In this trial, induced hypothermia added to standard care was not associated with significantly better 90-day outcomes than standard care alone in patients with convulsive status epilepticus. (Funded by the French Ministry of Health; HYBERNATUS ClinicalTrials.gov number, NCT01359332.)	[Legriel, Stephane; Lemiale, Virginie; Hilly-Ginoux, Julia; Planquette, Benjamin; Merceron, Sybille; Bedos, Jean-Pierre] Ctr Hosp Versailles, Med Surg Intens Care Unit, Site Andre Mignot, Versailles, France; [Pico, Fernando] Ctr Hosp Versailles, Neurol & Stroke Dept, Site Andre Mignot, Versailles, France; [Legriel, Stephane; Cariou, Alain] INSERM, Unite 970, Team 4, Paris Cardiovasc Res Ctr, F-75654 Paris 13, France; [Lemiale, Virginie; Canet, Emmanuel; Azoulay, Elie] St Louis Univ Hosp, AP HP, Med Intens Care Unit, Paris, France; [Resche-Rigon, Matthieu] St Louis Univ Hosp, AP HP, Dept Biostat & Med Informat, Paris, France; [Daviaud, Fabrice; Geri, Guillaume; Mongardon, Nicolas; Cariou, Alain] Cochin Univ Hosp, Hop Univ Paris Ctr, AP HP, Med Intens Care Unit, Paris, France; [Malissin, Isabelle] Lariboisiere Univ Hosp, AP HP, Med Intens Care Unit, Paris, France; [Tran-Dinh, Yves-Roger] Lariboisiere Univ Hosp, AP HP, Dept Neurophysiol, Paris, France; [Resche-Rigon, Matthieu] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, ECSTRA Team,Unite 1153, Paris, France; [Cariou, Alain] Paris Descartes Univ, Sorbonne Paris Cite, Sch Med, Paris, France; [Schenck, Maleka] Hop Univ Strasbourg, Hop Hautepierre, Med Intens Care Unit, Strasbourg, France; [Boisrame-Helms, Julie] Hop Univ Strasbourg, Nouvel Hop Civil, Med Intens Care Unit, Strasbourg, France; [Boisrame-Helms, Julie] Univ Strasbourg, Fac Med, Federat Med Translat Strasbourg, Strasbourg, France; [Chelly, Jonathan] Ctr Hosp Melun, Med Surg Intens Care Unit, Melun, France; [Srairi, Mohamed] Univ Toulouse 3 Paul Sabatier, Toulouse Univ Hosp, Anesthesiol & Crit Care Dept, Toulouse, France; [Hamdi, Aicha] Ctr Hosp Montreuil, Med Surg Intens Care Unit, Montreuil, France; [Rossignol, Thomas] Ctr Hosp Mans, Med Surg Intens Care Unit, Le Mans, France; [Louart, Benjamin] Univ Hosp Nimes, Div Anesthesia Intens Care Pain & Emergency Med, Intens Care Units, Nimes, France; [Thirion, Marina] Ctr Hosp Victor Dupouy, Med Surg Intens Care Unit, Argenteuil, France	Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay; Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre Hospitalier Le Mans; Universite de Montpellier; CHU de Nimes	Legriel, S (corresponding author), Ctr Hosp Versailles, Med Surg Intens Care Unit, Site Andre Mignot,177 Rue Versailles, F-78150 Le Chesnay, France.	slegriel@ch-versailles.fr	PLANQUETTE, Benjamin/AAL-7166-2021; Legriel, Stephane/J-1307-2017; Resche-Rigon, Matthieu/ABA-5374-2021	Legriel, Stephane/0000-0003-4782-6734; herbrecht, jean-etienne/0000-0002-6415-5330; Srairi, Mohamed/0000-0001-7219-501X; Mongardon, Nicolas/0000-0003-2756-4052; Helms, Julie/0000-0003-0895-6800; resche-rigon, matthieu/0000-0003-2220-5085; Chelly, Jonathan/0000-0002-8198-1239; Troche, Gilles/0000-0002-8150-6630; JACQ, Gwenaelle/0000-0003-2927-9570	French Ministry of Health	French Ministry of Health	Funded by the French Ministry of Health	Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Blanco M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030700; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Claassen J, 2002, NEUROLOGY, V58, P139, DOI 10.1212/WNL.58.1.139; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Flynn LMC, 2015, THER HYPOTHERMIA TEM, V5, P143, DOI 10.1089/ther.2015.0002; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Gao Q, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1221-9; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Kollmar R, 2012, INT J STROKE, V7, P168, DOI 10.1111/j.1747-4949.2011.00707.x; Kollmar R, 2010, STROKE, V41, P1684, DOI 10.1161/STROKEAHA.110.587758; Legriel S, 2008, INTENS CARE MED, V34, P476, DOI 10.1007/s00134-007-0915-5; Legriel S, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0159-z; Legriel S, 2016, J CLIN MED, V5, P53, DOI 10.3390/jcm5050053; Legriel S, 2015, CLIN NEUROL NEUROSUR, V131, P87, DOI 10.1016/j.clineuro.2015.01.013; Legriel S, 2010, CRIT CARE MED, V38, P2295, DOI 10.1097/CCM.0b013e3181f859a6; LIU Z, 1993, BRAIN RES, V631, P51, DOI 10.1016/0006-8993(93)91185-U; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; LUNDGREN J, 1994, EXP BRAIN RES, V99, P43; Maeda T, 1999, BRAIN RES, V818, P228, DOI 10.1016/S0006-8993(98)01269-4; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Outin H, 2009, REV NEUROL-FRANCE, V165, P297, DOI 10.1016/j.neurol.2009.01.048; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Rincon F, 2013, NEUROCRIT CARE, V18, P45, DOI 10.1007/s12028-012-9779-9; Rossetti AO, 2014, INTENS CARE MED, V40, P1359, DOI 10.1007/s00134-014-3363-z; Rossetti AO, 2011, LANCET NEUROL, V10, P922, DOI 10.1016/S1474-4422(11)70187-9; Rossetti AO, 2011, NEUROCRIT CARE, V14, P4, DOI 10.1007/s12028-010-9445-z; Sandestig A, 2014, THER HYPOTHERMIA TEM, V4, P10, DOI 10.1089/ther.2013.0024; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Shorvon S, 2011, BRAIN, V134, P2802, DOI 10.1093/brain/awr215; Silvapulle MJ, 2001, BIOMETRICS, V57, P1157, DOI 10.1111/j.0006-341X.2001.01157.x; Steiner T, 2010, STROKE, V41, P402, DOI 10.1161/STROKEAHA.109.552919; Sutter R, 2013, CRIT CARE MED, V41, pE475, DOI 10.1097/CCM.0b013e31829eca06; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Zeiler FA, 2015, CAN J NEUROL SCI, V42, P221, DOI 10.1017/cjn.2015.31	40	96	100	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2016	375	25					2457	2467		10.1056/NEJMoa1608193	http://dx.doi.org/10.1056/NEJMoa1608193			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF1NL	28002714	Bronze			2023-01-03	WOS:000390091500009
J	Seo, KH; Bartley, GE; Tam, C; Kim, HS; Kim, DH; Chon, JW; Kim, H; Yokoyama, W				Seo, Kun-Ho; Bartley, Glenn E.; Tam, Christina; Kim, Hong-Seok; Kim, Dong-Hyeon; Chon, Jung-Whan; Kim, Hyunsook; Yokoyama, Wallace			Chardonnay Grape Seed Flour Ameliorates Hepatic Steatosis and Insulin Resistance via Altered Hepatic Gene Expression for Oxidative Stress, Inflammation, and Lipid and Ceramide Synthesis in Diet-Induced Obese Mice	PLOS ONE			English	Article							FATTY LIVER-DISEASE; ADIPOSE-TISSUE; HYDROXYPROPYL METHYLCELLULOSE; NONALCOHOLIC STEATOHEPATITIS; PLASMA-CHOLESTEROL; METABOLIC SYNDROME; DEFICIENT MICE; WEIGHT-LOSS; GREEN TEA; EXTRACT	To identify differentially expressed hepatic genes contributing to the improvement of high-fat (HF) diet-induced hepatic steatosis and insulin resistance following supplementation of partially defatted flavonoid-rich Chardonnay grape seed flour (ChrSd), diet-induced obese (DIO) mice were fed HF diets containing either ChrSd or microcrystalline cellulose (MCC, control) for 5 weeks. The 2-h insulin area under the curve was significantly lowered by ChrSd, indicating that ChrSd improved insulin sensitivity. ChrSd intake also significantly reduced body weight gain, liver and adipose tissue weight, hepatic lipid content, and plasma low-density lipoprotein (LDL)-cholesterol, despite a significant increase in food intake. Exon microarray analysis of hepatic gene expression revealed down-regulation of genes related to triglyceride and ceramide synthesis, immune response, oxidative stress, and inflammation and upregulation of genes related to fatty acid oxidation, cholesterol, and bile acid synthesis. In conclusion, the effects of ChrSd supplementation in a HF diet on weight gain, insulin resistance, and progression of hepatic steatosis in DIO mice were associated with modulation of hepatic genes related to oxidative stress, inflammation, ceramide synthesis, and lipid and cholesterol metabolism.	[Seo, Kun-Ho; Kim, Hong-Seok; Kim, Dong-Hyeon; Chon, Jung-Whan] Konkuk Univ, Coll Vet Med, Seoul, South Korea; [Bartley, Glenn E.; Tam, Christina; Yokoyama, Wallace] ARS, USDA, Albany, CA USA; [Kim, Hyunsook] Hanyang Univ, Dept Food & Nutr, Seoul, South Korea	Konkuk University; United States Department of Agriculture (USDA); Hanyang University	Kim, H (corresponding author), Hanyang Univ, Dept Food & Nutr, Seoul, South Korea.	hyunsk15@hanyang.ac.kr	Seo, Kun-Ho/AAQ-2666-2020	Kim, Hyunsook/0000-0001-7345-4167; Kim, Dong-Hyeon/0000-0003-0585-2432	National Research Foundation of Korea (NRF) - Korea government (MSIP) [2015R1A2A2A01005017]; National Institute of Food and Agriculture (NIFA) Small Business Innovation Research Program Phase I grant (NIFA/SBIR) [2013-00549]	National Research Foundation of Korea (NRF) - Korea government (MSIP); National Institute of Food and Agriculture (NIFA) Small Business Innovation Research Program Phase I grant (NIFA/SBIR)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No.2015R1A2A2A01005017) and partly by a National Institute of Food and Agriculture (NIFA) Small Business Innovation Research Program Phase I grant (NIFA/SBIR 2013-00549).	Babenko NA, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-1; Bartley GE, 2010, J NUTR, V140, P1255, DOI 10.3945/jn.109.118349; Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677; Brabant G, 2005, FASEB J, V19, P1048, DOI 10.1096/fj.04-2846fje; Chagnon YC, 1997, MOL MED, V3, P663, DOI 10.1007/BF03401705; Charradi K, 2014, DIGEST DIS SCI, V59, P1768, DOI 10.1007/s10620-014-3128-0; Chavez JA, 2012, CELL METAB, V15, P585, DOI 10.1016/j.cmet.2012.04.002; Choquet H, 2010, GENOME MED, V2, DOI 10.1186/gm157; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; De Ceuninck F, 2013, BRIT J PHARMACOL, V168, P339, DOI 10.1111/j.1476-5381.2012.02184.x; De Groote D, 2012, ANN NUTR METAB, V61, P15, DOI 10.1159/000338634; Decorde K, 2009, MOL NUTR FOOD RES, V53, P659, DOI 10.1002/mnfr.200800165; Fernandez-Iglesias A, 2014, MOL NUTR FOOD RES, V58, P727, DOI 10.1002/mnfr.201300455; Ferre T, 2003, DIABETOLOGIA, V46, P1662, DOI 10.1007/s00125-003-1244-z; German JB, 1996, NUTR RES, V16, P1239, DOI 10.1016/0271-5317(96)00127-3; Gonzalez-Gallego J, 2010, BRIT J NUTR, V104, pS15, DOI 10.1017/S0007114510003910; Herman MA, 2012, NATURE, V484, P333, DOI 10.1038/nature10986; Hogan S, 2010, J AGR FOOD CHEM, V58, P11250, DOI 10.1021/jf102759e; Hokayem M, 2013, DIABETES CARE, V36, P1454, DOI 10.2337/dc12-1652; Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2; HORTON JD, 1994, J CLIN INVEST, V93, P2084, DOI 10.1172/JCI117203; Ji C, 2011, HEPATOLOGY, V54, P229, DOI 10.1002/hep.24368; Joven J, 2012, BBA-GEN SUBJECTS, V1820, P894, DOI 10.1016/j.bbagen.2012.03.020; Kadowaki T, 2014, BIOCHEM BIOPH RES CO, V446, P212, DOI 10.1016/j.bbrc.2014.02.089; Kamba A, 2013, CURR MOL MED, V13, P1110; Kar P, 2009, DIABETIC MED, V26, P526, DOI 10.1111/j.1464-5491.2009.02727.x; Kempf T, 2012, EUR J ENDOCRINOL, V167, P671, DOI 10.1530/EJE-12-0466; Khoshbaten Manouchehr, 2010, Saudi J Gastroenterol, V16, P194, DOI 10.4103/1319-3767.65197; Kim H, 2015, J AGR FOOD CHEM, V63, P1460, DOI 10.1021/jf5026373; Kim H, 2014, J AGR FOOD CHEM, V62, P1919, DOI 10.1021/jf404832s; Kim H, 2013, J AGR FOOD CHEM, V61, P6404, DOI 10.1021/jf400545w; Kim SJ, 2012, J NUTR BIOCHEM, V23, P113, DOI 10.1016/j.jnutbio.2010.10.012; LAMUELARAVENTOS RM, 1994, AM J ENOL VITICULT, V45, P1; Lee YS, 2010, J BIOL CHEM, V285, P22174, DOI 10.1074/jbc.M109.085464; Liu ZH, 2013, PROTEOME SCI, V11, DOI 10.1186/1477-5956-11-32; Marcolin E, 2012, J NUTR, V142, P1821, DOI 10.3945/jn.112.165274; Masterjohn C, 2012, NUTR REV, V70, P41, DOI 10.1111/j.1753-4887.2011.00440.x; McArdle Maeve A, 2013, Front Endocrinol (Lausanne), V4, P52, DOI 10.3389/fendo.2013.00052; Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Ohyama K, 2011, ANN NUTR METAB, V58, P250, DOI 10.1159/000330444; Park Su-Hui, 2008, Nutr Res Pract, V2, P227, DOI 10.4162/nrp.2008.2.4.227; Peter A, 2011, J CLIN ENDOCR METAB, V96, pE1126, DOI 10.1210/jc.2010-2017; Procaccini C, 2010, CURR PHARM DESIGN, V16, P1902, DOI 10.2174/138161210791208884; Radonjic M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006646; Rahimi RS, 2013, NUTR CLIN PRACT, V28, P40, DOI 10.1177/0884533612470464; Ress C, 2010, EUR CYTOKINE NETW, V21, P65, DOI 10.1684/ecn.2009.0177; Rinella Mary E, 2014, Gastroenterol Hepatol (N Y), V10, P219; Savini I, 2013, INT J MOL SCI, V14, P10497, DOI 10.3390/ijms140510497; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Soobrattee MA, 2005, MUTAT RES-FUND MOL M, V579, P200, DOI 10.1016/j.mrfmmm.2005.03.023; Takaishi K, 2004, P NATL ACAD SCI USA, V101, P7106, DOI 10.1073/pnas.0401715101; Tomaru U, 2012, AM J PATHOL, V180, P963, DOI 10.1016/j.ajpath.2011.11.012; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Valenti L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/145421; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Waller-Evans H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082825; Warne JP, 2011, CELL METAB, V14, P791, DOI 10.1016/j.cmet.2011.11.001; Xia EQ, 2010, INT J MOL SCI, V11, P622, DOI 10.3390/ijms11020622; Yamamoto M, 2010, GASTROENT RES PRACT, V2010, DOI 10.1155/2010/240365; Yilmaz Y, 2004, J AGR FOOD CHEM, V52, P255, DOI 10.1021/jf030117h; Yogalakshmi B, 2013, J LIPIDS, V2013, DOI 10.1155/2013/153897; Yunoki K, 2008, J AGR FOOD CHEM, V56, P12052, DOI 10.1021/jf8026217	65	21	21	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							0167680	10.1371/journal.pone.0167680	http://dx.doi.org/10.1371/journal.pone.0167680			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7HN	27977712	Green Published, Green Submitted, gold			2023-01-03	WOS:000391217400027
J	Muanda, M; Ndongo, PG; Taub, LD; Bertrand, JT				Muanda, Mbadu; Ndongo, Parfait Gahungu; Taub, Leah D.; Bertrand, Jane T.			Barriers to Modern Contraceptive Use in Kinshasa, DRC	PLOS ONE			English	Article								Recent research from Kinshasa, DRC, has shown that only one in five married women uses modern contraception; over one quarter have an unmet need for family planning; and almost 400 health facilities across Kinshasa report that they provide modern contraception. This study addresses the question: with reasonable physical access and relatively high unmet need, why is modern contraceptive prevalence so low? To this end, the research team conducted 6 focus groups of women (non-users of any method, users of traditional methods, and users of modern methods) and 4 of husbands (of users of traditional methods and in non-user unions) in health zones with relatively strong physical access to FP services. Five key barriers emerged from the focus group discussions: fear of side effects (especially sterility), costs of the method, sociocultural norms (especially the dominant position of the male in family decision-making), pressure from family members to avoid modern contraception, and lack of information/misinformation. These findings are very similar to those from 12 other studies of sociocultural barriers to family planning in sub-Saharan Africa. Moreover, they have strong programmatic implications for the training of FP workers to counsel future clients and for the content of behavior change communication interventions.	[Muanda, Mbadu] Minist Hlth, Programme Natl Sante Adolescent, Natl Program Adolescent Hlth, Kinshasa, DEM REP CONGO; [Ndongo, Parfait Gahungu] Inst Super Dev Rural, Matadi, Kongo Cent, DEM REP CONGO; [Taub, Leah D.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, New Orleans, LA USA; [Bertrand, Jane T.] Tulane Univ, Dept Global Hlth Management & Policy, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA	Tulane University; Tulane University	Bertrand, JT (corresponding author), Tulane Univ, Dept Global Hlth Management & Policy, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.	bertrand@tulanae.edu			Bill and Melinda Gates Foundation [OPP1117997]; Bill & Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	The study was funded by the Bill and Melinda Gates Foundation (grant #OPP1117997; URL: http://www.gatesfoundation.org/). JTB and MM received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This article was developed under grant #OPP1117997 awarded to the Tulane University School of Public Health and Tropical Medicine by the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The authors wish to thank Ms. Perri Sutton for her diligent oversight of the work under this grant.	Adongo PB, 2014, FRONT PUBLIC HEALTH, V2, P1; Adongo PB, 2014, BMC INT HEALTH HUM R, V14, DOI 10.1186/1472-698X-14-16; [Anonymous], 2014, ENQ DEM SANT REP DEM; Aransiola JO, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-869; Barnes J., 2012, TOTAL MARKET INITIAT; Becker G., 1960, EC ANAL FERTILITY DE, P209; Bertrand J. T., 2016, ANAL SUPPLY DEMAND F; Chapman S, 2012, SEX HEALTH, V9, P44, DOI 10.1071/SH10165; Diamond-Smith N, 2012, CULT HEALTH SEX, V14, P421, DOI 10.1080/13691058.2012.664659; Farmer DB, 2015, GLOB HEALTH, V3, P242, DOI 10.9745/GHSP-D-14-00198; Gebremariam Alem, 2014, Int J Family Med, V2014, P878639, DOI 10.1155/2014/878639; Hennink M, 2005, AFRICAN POPULATION S, V20, P101; John NA, 2015, INT PERSPECT SEX R H, V41, P99, DOI 10.1363/4109915; Kabagenyi A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-21; Kayembe P, 2015, GLOB HEALTH-SCI PRAC, V3, P630, DOI 10.9745/GHSP-D-15-00298; Kenya National Bureau of Statistics (KNBS) and ICF Macro, 2015, KENY DEM HLTH SURV K; Mack N., 2005, QUALITATIVE RES METH; Morgan D. L., 1997, FOCUS GROUPS QUALITA, V16; Okwor EU, 2010, INT Q COMMUNITY HEAL, V30, P223, DOI 10.2190/IQ.30.3.d; Patton M.Q., 2014, UTILIZATION FOCUSED, V4th; Pitorak H, 2014, HEALTH CARE WOMEN IN, V35, P234, DOI 10.1080/07399332.2012.736575; PMA, 2015, PMA2015 KINSH ROUND; Rossier C, 2014, POP ASS AM ANN M BOS; Uganda Bureau of Statistics, 2012, UG DEM HLTH SURV 201; United Nations Department of Economic and Social Affairs Population Division, 2016, WORLD POP PROSP 2015; Zambia Statistics Agency Ministry of Health Zambia ICF., 2019, ZAMB DEM HLTH SURV 2; Zimbabwe National Statistics Agency (ZIMSTAT) and ICF International, 2012, ZIMB DEM HLTH SURV 2	27	29	29	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167560	10.1371/journal.pone.0167560	http://dx.doi.org/10.1371/journal.pone.0167560			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27907138	Green Submitted, Green Published, gold			2023-01-03	WOS:000389482700195
J	Chiang, MH; Chen, PH; Chen, YK; Chen, CH; Ho, ML; Wang, YH				Chiang, Min-Hsuan; Chen, Ping-Ho; Chen, Yuk-Kwan; Chen, Chia-Hsin; Ho, Mei-Ling; Wang, Yan-Hsiung			Characterization of a Novel Dermal Fibrosis Model Induced by Areca Nut Extract that Mimics Oral Submucous Fibrosis	PLOS ONE			English	Article							SMOOTH MUSCLE ACTIN; COLLAGEN-SYNTHESIS; IN-VITRO; FIBROBLASTS; STIMULATION; BLEOMYCIN; MECHANISM; CYTOTOXICITY; INHIBITION; ACTIVATION	Oral submucous fibrosis (OSF) is an oral potentially malignant disorder and areca quid chewing is the main etiological factor. However, the molecular mechanism underlying OSF remains unclear, partly due to the lack of an appropriate animal model. The present study aimed to establish and characterize an animal model of areca nut extract (ANE)-induced skin fibrosis that mimics OSF. Mice were divided into 4 groups: the control group; the bleomycin group; and the ANE10 and ANE20 groups, which received 10mg/ml and 20mg/ml subcutaneous (SC) injection of ANE, respectively. Skin fibrosis was evaluated by histological analyses. Additionally, the expression levels of the fibrotic marker genes were determined by immunohistochemical staining and immunoblotting. ANE administration significantly increased dermal thickness and collagen deposition compared with the control group. Moreover, ANE induced the expression of the fibrotic marker genes alpha smooth muscle actin (alpha-SMA) and connective tissue growth factor (CTGF) in the skin lesions. The SC injection of ANE successfully induced skin fibrosis, exhibiting characteristics similar to those of OSF. This model may facilitate future studies of the mechanism underlying OSF.	[Chiang, Min-Hsuan; Chen, Ping-Ho; Chen, Yuk-Kwan; Wang, Yan-Hsiung] Kaohsiung Med Univ, Coll Dent Med, Sch Dent, Kaohsiung, Taiwan; [Chiang, Min-Hsuan; Chen, Chia-Hsin; Ho, Mei-Ling; Wang, Yan-Hsiung] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan; [Chen, Ping-Ho] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Chen, Ping-Ho] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Chen, Ping-Ho] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res CICAR, Kaohsiung, Taiwan; [Chen, Yuk-Kwan] Kaohsiung Med Univ, Oral & Maxillofacial Imaging Ctr, Kaohsiung, Taiwan; [Chen, Yuk-Kwan] Kaohsiung Med Univ Hosp, Dept Dent, Div Oral Pathol & Maxillofacial Radiol, Kaohsiung, Taiwan; [Chen, Chia-Hsin] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Chen, Chia-Hsin] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan; [Ho, Mei-Ling] Kaohsiung Med Univ, Coll Med, Dept Physiol, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University	Wang, YH (corresponding author), Kaohsiung Med Univ, Coll Dent Med, Sch Dent, Kaohsiung, Taiwan.; Wang, YH (corresponding author), Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan.	yhwang@kmu.edu.tw	Chen, Yuk-Kwan/C-8773-2009; Wang, Yan-Hsiung/ABD-4004-2020	Wang, Yan-Hsiung/0000-0001-8161-7472; Chen, Chia-Hsin/0000-0002-6557-9848; Ho, Mei-Ling/0000-0001-8064-8488	Ministry of Science and Technology [MOST-104-2314-B-037-059-]; Kaohsiung Medical University Aim for the Top Universities Grants [KMU-TP103B08, KM U-TP104B11]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University Aim for the Top Universities Grants	The authors gratefully acknowledge the support of research grant from the Ministry of Science and Technology (MOST-104-2314-B-037-059-) and Kaohsiung Medical University Aim for the Top Universities Grants (KMU-TP103B08 and KM U-TP104B11).	ADAMSON IYR, 1984, ENVIRON HEALTH PERSP, V55, P25, DOI 10.1289/ehp.845525; Angadi PV, 2011, ORAL MAXILLOFAC SURG, V15, P1, DOI 10.1007/s10006-010-0219-8; ASO Y, 1976, LAB INVEST, V35, P558; CANNIFF JP, 1981, INT J ORAL MAXILLOF, V10, P163; CHANDLER DB, 1990, CLIN CHEST MED, V11, P21; Chang MC, 2004, J BIOL CHEM, V279, P50676, DOI 10.1074/jbc.M404465200; Chang YC, 2014, J CELL MOL MED, V18, P698, DOI 10.1111/jcmm.12219; Dai JP, 2015, MOLECULES, V20, P6794, DOI 10.3390/molecules20046794; Dai JP, 2014, J ORAL PATHOL MED, V43, P464, DOI 10.1111/jop.12158; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Ham SA, 2015, J DERMATOL SCI, V80, P186, DOI 10.1016/j.jdermsci.2015.10.005; Jeng JH, 1999, J ORAL PATHOL MED, V28, P64; Khan I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051806; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; MA RH, 1995, J ORAL PATHOL MED, V24, P407, DOI 10.1111/j.1600-0714.1995.tb01210.x; MAHER R, 1994, J ORAL PATHOL MED, V23, P65, DOI 10.1111/j.1600-0714.1994.tb00258.x; MEGHJI S, 1987, ARCH ORAL BIOL, V32, P213, DOI 10.1016/0003-9969(87)90138-5; Meier JKH, 2011, INFLAMM BOWEL DIS, V17, P202, DOI 10.1002/ibd.21344; Mukherjee S, 2012, ORAL ONCOL, V48, pE27, DOI 10.1016/j.oraloncology.2012.05.018; Mukherjee S, 2012, J ORAL PATHOL MED, V41, P292, DOI 10.1111/j.1600-0714.2011.01097.x; MURTI PR, 1985, COMMUNITY DENT ORAL, V13, P340, DOI 10.1111/j.1600-0528.1985.tb00468.x; Perera MWS, 2007, J ORAL PATHOL MED, V36, P273, DOI 10.1111/j.1600-0714.2007.00523.x; PINDBORG JJ, 1984, SCAND J DENT RES, V92, P224; Samuel CS, 2007, ADV EXP MED BIOL, V612, P88; Satish L, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-113; SCUTT A, 1987, EXPERIENTIA, V43, P391, DOI 10.1007/BF01940422; Shi-Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002; Swaney JS, 2005, P NATL ACAD SCI USA, V102, P437, DOI 10.1073/pnas.0408704102; Tilakaratne WM, 2006, ORAL ONCOL, V42, P561, DOI 10.1016/j.oraloncology.2005.08.005; Tsai CC, 1999, J ORAL PATHOL MED, V28, P59; Warnakulasuriya S, 2007, J ORAL PATHOL MED, V36, P575, DOI 10.1111/j.1600-0714.2007.00582.x; Yamamoto T, 1999, J INVEST DERMATOL, V112, P456, DOI 10.1046/j.1523-1747.1999.00528.x; Yang SC, 2003, J ORAL PATHOL MED, V32, P600, DOI 10.1034/j.1600-0714.2003.00199.x	33	11	12	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2016	11	11							e0166454	10.1371/journal.pone.0166454	http://dx.doi.org/10.1371/journal.pone.0166454			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC1ZU	27851781	gold, Green Submitted, Green Published			2023-01-03	WOS:000387909300051
J	Bonfrer, I; Breebaart, L; Van de Poel, E				Bonfrer, Igna; Breebaart, Lyn; Van de Poel, Ellen			The Effects of Ghana's National Health Insurance Scheme on Maternal and Infant Health Care Utilization	PLOS ONE			English	Article							PROPENSITY SCORE; IMPLEMENTATION; PERCEPTIONS	Increasing equitable access to health care is a main challenge African policy makers are facing. The Ghanaian government implemented the National Health Insurance Scheme in 2004 and the aim of this study is to evaluate its early effects on maternal and infant healthcare use. We exploit data on births before and after the intervention and apply propensity score matching to limit the bias arising from self-selection into the health insurance. About forty percent of children had a mother who is enrolled in this insurance. The scheme significantly increased the proportion of pregnancies with at least four antenatal care visits with 7 percentage points and had a significant effect on attended deliveries (10 percentage points). Caesarean sections increased (6 percentage points) and the number of children born from an unwanted pregnancy decreased (7 percentage points). Insurance enrollment had almost no effect on child vaccinations. Among the poorest forty percent of the sample, the effects of the scheme on antenatal care and attended deliveries were similar. However, the effects of the scheme on caesarean sections were about half the size (3 percentage points) and the reduction in unwanted pregnancies was larger (10 percentage points) compared to the effects in the full sample. We conclude that in the first years of operation, the National Health Insurance Scheme had a modest impact on the use of antenatal and delivery care. This is important for other African countries currently introducing or considering a national health insurance as a means towards universal health coverage.	[Bonfrer, Igna; Breebaart, Lyn; Van de Poel, Ellen] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, South Holland, Netherlands; [Bonfrer, Igna] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA	Erasmus University Rotterdam; Harvard University; Harvard T.H. Chan School of Public Health	Bonfrer, I (corresponding author), Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, South Holland, Netherlands.; Bonfrer, I (corresponding author), Harvard Univ, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA.	bonfrer@bmg.eur.nl		Bonfrer, Igna/0000-0002-8570-0393	Netherland Organization for Scientific Research, Rubicon fellowship; Beleid en Management van de Gezondheidszorg Innovationfund; Netherlands Organization for Scientific Research [451-11-031]	Netherland Organization for Scientific Research, Rubicon fellowship; Beleid en Management van de Gezondheidszorg Innovationfund; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	Support was provided by: Netherland Organization for Scientific Research, Rubicon fellowship (to IB); Beleid en Management van de Gezondheidszorg Innovationfund, [www.bmg.eurnl] (to IB); and Netherlands Organization for Scientific Research, Veni project 451-11-031 [http://www.nwo.nl/actueel/nieuws//2011/Toekenningen+Verrieuwingsimpuls+Veri+bij+MaGW.html] (to EVdP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agyepong IA, 2008, HEALTH POLICY PLANN, V23, P150, DOI 10.1093/heapol/czn002; Amporfu E, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-4; Arhin A. A., 2013, Developing Country Studies, V3, P151; Arthur E., 2012, HLTH EC REV, V2, P214; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Becker SO, 2002, STATA J, V2, P358, DOI 10.1177/1536867X0200200403; Blanchet N J, 2012, Ghana Med J, V46, P76; Dalinjong PA, 2012, HEALTH ECON REV, V2, DOI 10.1186/2191-1991-2-13; De Allegri M, 2009, TROP MED INT HEALTH, V14, P586, DOI 10.1111/j.1365-3156.2009.02262.x; Dionne K. Y., 2013, GLOB HLTH, V4, P1; Dixon J., 2011, AFRICANPORTAL BACKGR, V8, P1; Dixon J, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-35; Escobar ML, 2010, IMPACT OF HEALTH INSURANCE IN LOW- AND MIDDLE-INCOME COUNTRIES, P1; Fenenga C., 2015, A MATTER OF TRUST; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Gajate-Garrido G, 2013, EFFECT PARENTS INSUR; Gajate-Garrido G, 2013, NATL HLTH INSURANCE, P1; Ghana Statistical Service, 2009, DEM HLTH SURV 2008 R; Giedion U, 2010, IMPACT OF HEALTH INSURANCE IN LOW- AND MIDDLE-INCOME COUNTRIES, P13; Global Alliance for Vaccines and Immunization, 2005, PROGR REP GAVI VACC; Gobah FF., 2011, GLOBAL J HLTH SCI, V3, P90, DOI [10.5539/gjhs.v3n2p90, DOI 10.5539/GJHS.V3N2P90]; Jehu-Appiah C, 2011, SOC SCI MED, V72, P157, DOI 10.1016/j.socscimed.2010.10.025; Khandker S.R., 2010, HDB IMPACT EVALUATIO; Koch S, 2010, SOC SCI MED, V70, P175, DOI 10.1016/j.socscimed.2009.10.015; Leuven E, 2014, PSMATCH2 STATA MODUL; Mensah J, 2010, HEALTH ECON, V19, P95, DOI 10.1002/hec.1633; Ministry of Health Ghana, 2009, IND REV HLTH SECT PR; National Health Insurance Authority, 2009, NAT HLTH INS AUTH 20; National Health Insurance Authority, 2013, NAT HLTH INS AUTH 20; National Health Insurance Authority, 2008, PROV FREE MAT NEON H; National Health Insurance Scheme, 2014, PREM REG FEE; Ofori-Adjei David, 2007, Ghana Med J, V41, P94; Oxfam, 2014, ACH SHAR GOAL FREE U; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Saleh K., 2012, HLTH SECTOR TRANSITI; Van Doorslaer E, 2007, HEALTH ECON, V16, P1159, DOI 10.1002/hec.1209; Wagstaff A, 2003, HEALTH ECON, V12, P921, DOI 10.1002/hec.776; WHO, 2010, GLOB NUMB COSTS ADD; Witter S, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-16; Witter S, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-20	40	31	31	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2016	11	11							e0165623	10.1371/journal.pone.0165623	http://dx.doi.org/10.1371/journal.pone.0165623			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EC0HG	27835639	Green Published, gold, Green Submitted			2023-01-03	WOS:000387779200009
J	Hussain, A; Yadav, MK; Bose, S; Wang, JH; Lim, D; Song, YK; Ko, SG; Kim, H				Hussain, Ahtesham; Yadav, Mukesh Kumar; Bose, Shambhunath; Wang, Jing-Hua; Lim, Dongwoo; Song, Yun-Kyung; Ko, Seong-Gyu; Kim, Hojun			Daesiho-Tang Is an Effective Herbal Formulation in Attenuation of Obesity in Mice through Alteration of Gene Expression and Modulation of Intestinal Microbiota	PLOS ONE			English	Article							DIET-INDUCED OBESITY; GUT-MICROBIOTA; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FAT; POLYSACCHARIDES; CONTRIBUTES; NPC1L1	Background Obesity has become a major global health challenge due to its increasing prevalence, and the associated health risk. It is the main cause of various metabolic diseases including diabetes, hypertension, cardiovascular disease, stroke and certain forms of cancer. Methods and Results In the present study we evaluated the anti-obesity property of Daesiho-tang (DSHT), an herbal medicine, using high fat diet (HFD)-induced obese mice as a model. Our results showed that DSHT ameliorated body weight gain, decreased total body fat, regulated expression of leptin and adiponectin genes of adipose tissue and exerted an anti-diabetic effect by attenuating fasting glucose level and serum insulin level in HFD-fed animals. In addition, DSHT-treatment significantly reduced total cholesterol (TC), triglycerides (TG) and increased high density lipoprotein-cholesterol (HDL), glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) levels in serum and reduced deposition of fat droplets in liver. DSHT treatment resulted in significantly increased relative abundance of bacteria including Bacteroidetes, Bacteroidetes/ Firmicutes ratio, Akkermansia Bifidobacterium., Lactobacillus, and decreased the level of Firmicutes. Using RT2 profiler PCR array, 39 (46%) genes were found to be differentially expressed in HFD-fed mice compared to normal control. However, normal gene expressions were restored in 36 (92%) genes of HFD-fed mice, when co-exposed to DSHT. Conclusion/Major Findings The results of this study demonstrated that DSHT is an effective herbal formulation in attenuation of obesity in HFD-fed mice through alteration of gene expressions and modulation of intestinal microbiota.	[Hussain, Ahtesham; Wang, Jing-Hua; Kim, Hojun] Dongguk Univ, Dept Rehabil Med Korean Med, Goyang, South Korea; [Yadav, Mukesh Kumar] Korea Univ, Dept Otorhinolaryngol Head & Neck Surg, Coll Med, Seoul, South Korea; [Yadav, Mukesh Kumar] Korea Univ, Inst Med Device Clin Trials, Coll Med, Seoul, South Korea; [Bose, Shambhunath] Appl Surface Technol Inc, Adv Inst Convergence Technol, 11th Floor,Bldg A, Suwon 16229, Gyeonggi Do, South Korea; [Wang, Jing-Hua] Anhui Univ Tradit Chinese Med, Key Lab Xinan Med, Minist Educ, Meishan Rd 103, Hefei, Anhui, Peoples R China; [Lim, Dongwoo] Dongguk Univ, Dept Pathol, Coll Korean Med, Goyang, South Korea; [Song, Yun-Kyung] Gachon Univ, Dept Korean Rehabil Med, Coll Korean Med, Inchon, South Korea; [Ko, Seong-Gyu] Kyung Hee Univ, Dept Prevent Med, Coll Korean Med, Seoul, South Korea	Dongguk University; Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine); Anhui University of Chinese Medicine; Dongguk University; Gachon University; Kyung Hee University	Kim, H (corresponding author), Dongguk Univ, Dept Rehabil Med Korean Med, Goyang, South Korea.	kimklar@dongguk.ac.kr	Yadav, Mukesh Kumar/M-9154-2015; Wang, Jing-hua/AAO-2350-2020; Lim, Dongwoo/GLU-0640-2022; Kim, Hojun/AAB-8405-2020	Yadav, Mukesh Kumar/0000-0002-4703-8554; Wang, Jing-hua/0000-0002-2034-7429; Bose, Shambunath/0000-0003-0737-5713; Lim, Dongwoo/0000-0002-3179-9439; Kim, Hojun/0000-0003-1038-0142	Traditional Korean Medicine R&D Project, Ministry for Health & Welfare & Family Affairs, Republic of Korea [HI13C0530]	Traditional Korean Medicine R&D Project, Ministry for Health & Welfare & Family Affairs, Republic of Korea	This study was supported by a grant from the Traditional Korean Medicine R&D Project, Ministry for Health & Welfare & Family Affairs, Republic of Korea (HI13C0530). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abella V, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/343746; Aguirre M, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0472-4; [Anonymous], 1996, GUIDE CARE USE LAB A; Bajzer M, 2006, NATURE, V444, P1009, DOI 10.1038/4441009a; Betters JL, 2010, FEBS LETT, V584, P2740, DOI 10.1016/j.febslet.2010.03.030; Boulange CL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0303-2; Bray GA, 2000, NUTRITION, V16, P953, DOI 10.1016/S0899-9007(00)00424-X; Bullo M, 2005, OBES SURG, V15, P382, DOI 10.1381/0960892053576776; Butsch WS, 2015, CURR OPIN ENDOCRINOL, V22, P360, DOI 10.1097/MED.0000000000000192; Cani PD, 2013, BRIEF FUNCT GENOMICS, V12, P381, DOI 10.1093/bfgp/elt014; Cani PD, 2009, CURR OPIN PHARMACOL, V9, P737, DOI 10.1016/j.coph.2009.06.016; Cox AJ, 2015, LANCET DIABETES ENDO, V3, P207, DOI 10.1016/S2213-8587(14)70134-2; Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Deng YF, 2010, ANN NY ACAD SCI, V1212, pE1, DOI 10.1111/j.1749-6632.2010.05875.x; Diamant M, 2011, OBES REV, V12, P272, DOI 10.1111/j.1467-789X.2010.00797.x; DiBaise JK, 2012, AM J GASTROENTEROL S, V1, P22, DOI [10.1038/ajgsup.2012.5, DOI 10.1038/AJGSUP.2012.5]; Dwivedi S, 2014, ELECTRON J BIOTECHN, V17, P238, DOI 10.1016/j.ejbt.2014.07.004; El Kaoutari A, 2013, NAT REV MICROBIOL, V11, P497, DOI 10.1038/nrmicro3050; Everard A, 2013, BEST PRACT RES CL GA, V27, P73, DOI 10.1016/j.bpg.2013.03.007; Fu JY, 2015, CIRC RES, V117, P817, DOI 10.1161/CIRCRESAHA.115.306807; Fuentes-Zaragoza E, 2011, STARCH-STARKE, V63, P406, DOI 10.1002/star.201000099; Ganesh BP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074963; Cano PG, 2013, OBESITY, V21, P2310, DOI 10.1002/oby.20330; Gerard P, 2016, CELL MOL LIFE SCI, V73, P147, DOI 10.1007/s00018-015-2061-5; Guerciolini R, 1997, INT J OBESITY, V21, pS12; Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Han K, 2015, FOOD FUNCT, V6, P2684, DOI 10.1039/c5fo00232j; Jeffery E, 2015, NAT CELL BIOL, V17, P376, DOI 10.1038/ncb3122; Jeong EJ, 2016, BIOL PHARM BULL, V39, P409, DOI 10.1248/bpb.b15-00849; 여운홍, 2005, [Journal of Physiology & Pathology in Korean Medicine, 동의생리병리학회지], V19, P1573; Jo J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000324; Karimi G, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.29273; Kim C.H., 2004, KOREAN J ORIENT MED, V12, P139; Kim JH, 2001, J KOREAN ORI MED, V22, P63; Koropatkin NM, 2012, NAT REV MICROBIOL, V10, P323, DOI 10.1038/nrmicro2746; Kzhyshkowska J, 2006, J CELL MOL MED, V10, P635, DOI 10.1111/j.1582-4934.2006.tb00425.x; Lecomte V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126931; Lee SJ, 2014, CLIN NUTR, V33, P973, DOI 10.1016/j.clnu.2013.12.006; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mahowald MA, 2009, P NATL ACAD SCI USA, V106, P5859, DOI 10.1073/pnas.0901529106; Martens EC, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001221; Martin ASG, 2006, AM J CLIN NUTR, V83, p461S, DOI 10.1093/ajcn/83.2.461s; Miserez AR, 2002, ATHEROSCLEROSIS, V164, P15, DOI 10.1016/S0021-9150(01)00762-6; Moon YA, 2012, CELL METAB, V15, P240, DOI 10.1016/j.cmet.2011.12.017; Moreno-Indias I, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00190; Musso G, 2010, DIABETES CARE, V33, P2277, DOI 10.2337/dc10-0556; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Park S.D., 2001, KOREAN J ORIENT MED, V9, P289; Patterson E, 2016, POSTGRAD MED J, V92, P286, DOI 10.1136/postgradmedj-2015-133285; Pichiah PBT, 2012, NUTR RES, V32, P856, DOI 10.1016/j.nutres.2012.09.015; Rha YG, 1991, J ORINT MED PATHOL, V6, P1; Sahin M, 2007, CLIN ENDOCRINOL, V67, P346, DOI 10.1111/j.1365-2265.2007.02888.x; Sanz Y, 2013, PHARMACOL RES, V69, P144, DOI 10.1016/j.phrs.2012.10.021; Shen J, 2013, MOL ASPECTS MED, V34, P39, DOI 10.1016/j.mam.2012.11.001; Su ML, 2016, MOLECULES, V21, DOI 10.3390/molecules21080976; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tilg H, 2011, J CLIN INVEST, V121, P2126, DOI 10.1172/JCI58109; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Tsai Franklin, 2009, Curr Gastroenterol Rep, V11, P307, DOI 10.1007/s11894-009-0045-z; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Van den Ende W, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00247; Wang J, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087451, 10.1371/journal.pone.0107012]; Wang JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep08391; WHO, 2021, OB OV; Yang L, 2015, JAMA INTERN MED, V175, P1412, DOI 10.1001/jamainternmed.2015.2405; Yoo HD, 2012, BIOMOL THER, V20, P371, DOI 10.4062/biomolther.2012.20.4.371; Yun JW, 2010, PHYTOCHEMISTRY, V71, P1625, DOI 10.1016/j.phytochem.2010.07.011; Zhang ZJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-62; Zhou SS, 2016, SCI REP-UK, V6, DOI 10.1038/srep22474	75	41	45	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2016	11	11							e0165483	10.1371/journal.pone.0165483	http://dx.doi.org/10.1371/journal.pone.0165483			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA8SX	27812119	Green Published, Green Submitted, gold			2023-01-03	WOS:000386910000032
J	Bynum, B; Bynum, H				Bynum, Bill; Bynum, Helen			Object lessons Silver eye bath	LANCET			English	Editorial Material												w.bynum@ucl.ac.uk							0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 29	2016	388	10056					2107	2107		10.1016/S0140-6736(16)31926-2	http://dx.doi.org/10.1016/S0140-6736(16)31926-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA1DJ	27968740				2023-01-03	WOS:000386332400021
J	Yao, JJ; Zhou, GQ; Zhang, F; Zhang, WJ; Lin, L; Tang, LL; Mao, YP; Ma, J; Sun, Y				Yao, Jin-Jin; Zhou, Guan-Qun; Zhang, Fan; Zhang, Wang-Jian; Lin, Li; Tang, Ling-Long; Mao, Yan-Ping; Ma, Jun; Sun, Ying			Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy	PLOS ONE			English	Article							INDUCTION CHEMOTHERAPY; CISPLATIN-RADIOTHERAPY; RADIATION-THERAPY; PHASE-III; CHEMORADIOTHERAPY; METAANALYSIS; SURVIVAL; TRIAL; EXPERIENCE; MANAGEMENT	Purpose To compare the outcomes of patients with ascending type (T4&N0-1) and descending type (T1-2&N3) of nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT), neoadjuvant chemotherapy (NACT) + intensity-modulated radiotherapy (RT) or NACT + CCRT. Methods Retrospective analysis of 839 patients with ascending or descending types of NPC treated at a single institution between October 2009 to February 2012. CCRT was delivered to 236 patients, NACT + RT to 302 patients, and NACT + CCRT to 301 patients. Results The 4-year overall survival rate, distant metastasis-free survival rate, local relapse-free survival rate, nodal relapse-free survival rate, loco-regional relapse-free survival rate, and progression free survival rate were 75.2% and 73.4% (P = 0.114), 85.7% and 74.1% (P = 0.008), 88.8% and 97.1% (P = 0.013), 96.9% and 94.1% (P = 0.122), 86.9% and 91.2% (P = 0.384), 73.7% and 66.2% (P = 0.063) in ascending type and descending type. Subgroup analyses indicated that NACT + RT significantly improved distant metastasis-free survival rate and progression-free survival rate when compared with CCRT in the ascending type, and there were no significant differences between the survival curves of NACT + RT and NACT + CCRT. For descending type, there were no significant differences among the survival curves of NACT + RT, CCRT, and NACT + CCRT groups, and the survival benefit mainly came from CCRT. Conclusions Compared with NACT + CCRT or CCRT, NACT + RT may be a reasonable approach for ascending type. Although concurrent chemotherapy was effective in descending type, NACT + CCRT may be a more appropriate strategy for descending type.	[Yao, Jin-Jin; Zhou, Guan-Qun; Lin, Li; Tang, Ling-Long; Mao, Yan-Ping; Ma, Jun; Sun, Ying] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Yao, Jin-Jin; Zhang, Fan] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhuhai 519001, Guangdong, Peoples R China; [Zhang, Wang-Jian] Sun Yat Sen Univ, Sch Publ Hlth, Hlth Informat Res Ctr, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Wang-Jian] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Wang-Jian] Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Key Lab Med, Guangzhou 510080, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Sun, Y (corresponding author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.	sunying@sysucc.org.cn	Zhang, Wang-Jian/K-2242-2019; Zhang, Wangjian/AAU-6705-2021	Zhang, Wangjian/0000-0001-9655-6385	Science and Technology Project of Guangzhou City, China [14570006]; National Natural Science Foundation of China [81372409, 81402532]; Sun Yatsen University Clinical Research 5010 Program [2012011]	Science and Technology Project of Guangzhou City, China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sun Yatsen University Clinical Research 5010 Program	This work was funded by the Science and Technology Project of Guangzhou City, China (No. 14570006), the National Natural Science Foundation of China (No.81372409), the Sun Yatsen University Clinical Research 5010 Program (No.2012011), and the National Natural Science Foundation of China (No.81402532)	Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Chan ATC, 2005, J NATL CANCER I, V97, P536, DOI 10.1093/jnci/dji084; Chen C, 2013, CANCER CHEMOTH PHARM, V71, P371, DOI 10.1007/s00280-012-2020-x; Chen JLY, 2013, STRAHLENTHER ONKOL, V189, P1001, DOI 10.1007/s00066-013-0429-8; Chen YP, 2015, J CANCER, V6, P883, DOI 10.7150/jca.11814; Chua DTT, 2005, J CLIN ONCOL, V23, P1118, DOI 10.1200/JCO.2005.12.081; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; El-Sherbieny E, 2011, ASIAN PAC J CANCER P, V12, P1739; Fan TY, 2013, ONCOL LETT, V5, P889, DOI 10.3892/ol.2013.1137; Hareyama M, 2002, CANCER, V94, P2217, DOI 10.1002/cncr.10473; Hsiung CY, 2002, INT J RADIAT ONCOL, V53, P638, DOI 10.1016/S0360-3016(02)02760-8; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2012, SEMIN RADIAT ONCOL, V22, P233, DOI 10.1016/j.semradonc.2012.03.008; Lin JC, 2004, INT J RADIAT ONCOL, V60, P156, DOI 10.1016/j.ijrobp.2004.03.002; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Lin SJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-39; Lu TX, 2004, INT J RADIAT ONCOL, V58, P682, DOI 10.1016/S0360-3016(03)01508-6; Ma J, 2001, J CLIN ONCOL, V19, P1350, DOI 10.1200/JCO.2001.19.5.1350; National Comprehensive Cancer Network, 2008, HEAD NECK CANC VERS; Sun P, 2014, J BUON, V19, P474; Sun XM, 2014, RADIOTHER ONCOL, V110, P398, DOI 10.1016/j.radonc.2013.10.020; Sun XM, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-265; Teo PML, 1999, INT J RADIAT ONCOL, V43, P261, DOI 10.1016/S0360-3016(98)00383-6; Wei WI, 2000, CRIT REV ONCOL HEMAT, V33, P91, DOI 10.1016/S1040-8428(99)00069-4; Wong FCS, 2010, INT J RADIAT ONCOL, V76, P138, DOI 10.1016/j.ijrobp.2009.01.084; Xiao C, 2013, MOL CLIN ONCOL, V1, P507, DOI 10.3892/mco.2013.75; Yin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137383; Zhang BL, 2015, ORAL ONCOL, V51, P1041, DOI 10.1016/j.oraloncology.2015.08.005; Zhang L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-558; Zhao C, 2015, RADIAT ONCOL, V10, P17, DOI [10.1186/s13014-014-0326-z, DOI 10.1186/S13014-014-0326-Z.]	33	6	7	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2016	11	10							e0161878	10.1371/journal.pone.0161878	http://dx.doi.org/10.1371/journal.pone.0161878			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4VE	27783618	Green Submitted, Green Published, gold			2023-01-03	WOS:000389602800010
J	Ahlen, KM; Ortqvist, AK; Gong, T; Wallas, A; Ye, WM; Lundholm, C; Almqvist, C				Ahlen, Katia M.; Ortqvist, Anne K.; Gong, Tong; Wallas, Alva; Ye, Weimin; Lundholm, Cecilia; Almqvist, Catarina			Antibiotic Treatment and Length of Hospital Stay in Relation to Delivery Mode and Prematurity	PLOS ONE			English	Article							EARLY-LIFE EXPOSURE; SECONDARY ANALYSIS; PRETERM BIRTH; CHILDHOOD; BACTERIAL; INFANT; HEALTH; ASTHMA; EPIDEMIOLOGY; REGISTER	Aim To investigate how 1) maternal delivery mode and 2) prematurity in infants are associated to antibiotic treatment and length of hospital stay. Methods Women having given birth and infants 0-12 months discharged from hospital between July 2005 and November 2011 were identified from the Swedish National Patient Register. Medical records were reviewed for 203 women and 527 infants. The risk ratio (RR) between antibiotic treatment and 1) delivery mode in women; 2) prematurity in infants was calculated. Length of stay and days of antibiotic therapy were compared by Wilcoxon rank-sum test. Results Women: There was an association between emergency caesarean section (CS) and antibiotic treatment (RR 5.0 95% confidence interval (CI) 2.2-11.5), but not for elective CS. Length of stay was longer for CS (emergency and elective) compared to vaginal delivery (p< 0.01). Infants: RR for antibiotic treatment in preterm compared to term infants was 1.4 (95% CI 1.0-1.9). Length of stay (p< 0.01), but not days of therapy (p = 0.17), was higher in preterm compared to term infants. Conclusion We found that emergency CS increased the probability of maternal antibiotic treatment during hospitalisation, but no difference was found between term and preterm infants. The results are well aligned with current guidelines and may be considered in future studies on the effects of antibiotics.	[Ahlen, Katia M.; Ortqvist, Anne K.; Gong, Tong; Ye, Weimin; Lundholm, Cecilia; Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Wallas, Alva] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Almqvist, Catarina] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Lung & Allergy Unit, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Ahlen, KM (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.	katia.ahlen@gmail.com	Gong, Tong/HDM-8653-2022; Örtqvist, Anne Kristina/P-6618-2019	Lundholm, Cecilia/0000-0002-6546-3650; ye, weimin/0000-0002-6859-4648	Swedish Research Council (Vetenskapsradet) [2011-3060]; Swedish Initiative for Research on Microdata in the Social And Medical Sciences [80748301, 340-2013-5867]; Stockholm County Council (Stockholms Lans Landsting) ALF-projects [502262, 520344, 530422]; Strategic Research Program in Epidemiology at Karolinska Institutet; Swedish Heart-Lung Foundation	Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Swedish Initiative for Research on Microdata in the Social And Medical Sciences; Stockholm County Council (Stockholms Lans Landsting) ALF-projects; Strategic Research Program in Epidemiology at Karolinska Institutet; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation)	This work was supported by the grants from a) the Swedish Research Council (Vetenskapsradet) Grant number 2011-3060 (http://www.vr.se/) to CA; b) the Swedish Initiative for Research on Microdata in the Social And Medical Sciences Grants no 80748301 and 340-2013-5867) (http://simsam.nu/) to CA and WY; c) Stockholm County Council (Stockholms Lans Landsting) ALF-projects award numbers 502262, 520344 and 530422 (http://www.sll.se/) to CA; d) the Strategic Research Program in Epidemiology at Karolinska Institutet (www.ki.se) to CA; e) the Swedish Heart-Lung Foundation (https://www.hjart-lungfonden.se/) to CA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almqvist C, 2015, ACTA PAEDIATR, V104, P392, DOI 10.1111/apa.12916; Almqvist C, 2012, CLIN EXP ALLERGY, V42, P104, DOI 10.1111/j.1365-2222.2011.03850.x; [Anonymous], 2010, ANT VID KIR INGR SYS; [Anonymous], 2013, GRAV FORL NYF BARN M; [Anonymous], 1956, P 3 BERK S, V4, P135; [Anonymous], 2010, ACTA PAEDIATR, V99, P978, DOI DOI 10.1111/J.1651-2227.2010.01846.X; Azad MB, 2014, INT J OBESITY, V38, P1290, DOI 10.1038/ijo.2014.119; Bergstrom M, ANTIBIOTIKAANVANDNIN; Byington CL, 2004, PEDIATRICS, V113, P1662, DOI 10.1542/peds.113.6.1662; Cantey JB, 2014, PEDIATR INFECT DIS J, DOI [10.1097/int.0000000000000542, DOI 10.1097/INT.0000000000000542]; Cuzick J, WILCOXON TYPE TEST T; Erntell M, 2004, POINT PREVALENCE STU; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Hakansson S, 2013, NEONATAL SEPSIS EPID; Hellman J, 2012, SWEDRES SVARM 2012; Kimland E, 2012, ACTA PAEDIATR, V101, P772, DOI 10.1111/j.1651-2227.2012.02656.x; Kummeling I, 2007, PEDIATRICS, V119, pE225, DOI 10.1542/peds.2006-0896; Liabsuetrakul T, 2014, INT J GYNECOL OBSTET, V124, P240, DOI 10.1016/j.ijgo.2013.07.039; Morisaki N, 2014, BJOG-INT J OBSTET GY, V121, P66, DOI 10.1111/1471-0528.12632; Ortqvist AK, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6979; Ringborg A, 2006, ACTA PAEDIATR, V95, P1550, DOI 10.1080/08035250600778636; Russell ARB, 2006, BJOG-INT J OBSTET GY, V113, P758, DOI 10.1111/j.1471-0528.2006.00952.x; Shane AL, 2013, AM J PERINAT, V30, P131, DOI 10.1055/s-0032-1333413; Sharma AA, 2012, CLIN IMMUNOL, V145, P61, DOI 10.1016/j.clim.2012.08.006; Stensballe LG, 2013, J PEDIATR-US, V162, P832, DOI 10.1016/j.jpeds.2012.09.049; Stokholm J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082932; Sudo N, 1997, J IMMUNOL, V159, P1739; Trasande L, 2013, INT J OBESITY, V37, P16, DOI 10.1038/ijo.2012.132; Tsakok T, 2013, BRIT J DERMATOL, V169, P983, DOI 10.1111/bjd.12476; van Schalkwyk J, 2010, J OBSTET GYNAECOL CA, V32, P878, DOI 10.1016/S1701-2163(16)34662-X; Wee MYK, 2005, INT J OBSTET ANESTH, V14, P147, DOI 10.1016/j.ijoa.2004.09.008; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; Zingg W, 2011, PEDIATR INFECT DIS J, V30, P365, DOI 10.1097/INF.0b013e31820243d3	33	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2016	11	10							e0164126	10.1371/journal.pone.0164126	http://dx.doi.org/10.1371/journal.pone.0164126			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UW	27716779	Green Submitted, Green Published, gold			2023-01-03	WOS:000385698100024
J	Elliott, LS; Henderson, JC; Neradilek, MB; Moyer, NA; Ashcraft, KC; Thirumaran, RK				Elliott, Lindsay S.; Henderson, John C.; Neradilek, Moni B.; Moyer, Nicolas A.; Ashcraft, Kristine C.; Thirumaran, Ranjit K.			Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; EMERGENCY-DEPARTMENT VISITS; HOSPITALIZED-PATIENTS; CYP2D6; CARE; GUIDELINES; GENOTYPES; CYP2C19; EVENTS; ADULTS	Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients. Methods and findings This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript (R) CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32-1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27-0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31-1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34-0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice. Conclusions Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare.	[Elliott, Lindsay S.] Harding Univ, Coll Pharm, Dept Pharm Practice, Unity Hlth White Cty Med Ctr, Searcy, AR 72149 USA; [Henderson, John C.] Unity Hlth White Cty Med Ctr, Searcy, AR USA; [Neradilek, Moni B.] Mt Whisper Light Stat, Seattle, WA USA; [Moyer, Nicolas A.; Ashcraft, Kristine C.; Thirumaran, Ranjit K.] Genelex Corp, Clin Pharmacogen Div, Seattle, WA 98121 USA		Elliott, LS (corresponding author), Harding Univ, Coll Pharm, Dept Pharm Practice, Unity Hlth White Cty Med Ctr, Searcy, AR 72149 USA.; Thirumaran, RK (corresponding author), Genelex Corp, Clin Pharmacogen Div, Seattle, WA 98121 USA.	lselliott@harding.edu; ranjit@genelex.com			Genelex Corporation; Mountain-Whisper-Light Statistics	Genelex Corporation; Mountain-Whisper-Light Statistics	The study was supported by a small non conditional research grant from Genelex Corporation (http://genelex.com/) in the form of compensation for time to author LSE. Genelex Corporation provided in-kind services consisting of buccal swab collection materials, shipping, genotyping all patient DNA and providing the YouScript (R) report. The Genelex Corporation and Mountain-Whisper-Light Statistics provided support in the form of salaries for authors [NAM, KCA, RKT and MBN] and played a role in the design and conduct of the study; management and analysis of data; and the preparation and review of the manuscript. The specific roles of these authors are articulated in the author contributions section.	Alagoz O, 2016, PHARMACOGENOMICS J, V16, P129, DOI 10.1038/tpj.2015.39; [Anonymous], 2010, SEARC ARK POP CENS 2; [Anonymous], 2015, TABLE PHARMACOGENOMI; [Anonymous], 2015, HOM HLTH CAR SERV AS, P213; [Anonymous], 2010, FDA GUID IND PHARM P; Azhar Gohar WJ, 2016, J RES DEV, V4; Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Birdwell KA, 2015, CLIN PHARMACOL THER, V98, P19, DOI 10.1002/cpt.113; Brixner D, 2016, J MED ECON, V19, P213, DOI 10.3111/13696998.2015.1110160; Budnitz DS, 2006, JAMA-J AM MED ASSOC, V296, P1858, DOI 10.1001/jama.296.15.1858; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Cardelli M, 2012, DRUG SAFETY, V35, P3, DOI 10.1007/BF03319099; Caudle KE, 2016, STANDARDIZING TERMS; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fagerness J, 2014, AM J MANAG CARE, V20, pE146; Gaedigk A, 2016, GENET MED; Hajjar Emily R, 2003, Am J Geriatr Pharmacother, V1, P82; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Hampton LM, 2014, JAMA PSYCHIAT, V71, P1006, DOI 10.1001/jamapsychiatry.2014.436; HEPLER CD, 1990, AM J HOSP PHARM, V47, P533, DOI 10.1093/ajhp/47.3.533; Hicks JK, 2015, CLIN PHARMACOL THER, V98, P127, DOI 10.1002/cpt.147; Hocum BT, 2016, AM J HEALTH-SYST PH, V73, P61, DOI 10.2146/ajhp150273; Johnson JA, 2011, CLIN PHARMACOL THER, V90, P625, DOI 10.1038/clpt.2011.185; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-139; Kahan BC, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-99; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lisbeth P, 2016, EUR J CLIN PHARMACOL, V72, P175, DOI 10.1007/s00228-015-1965-1; MLaC K, 2014, TRENDS HLTH CAR EXP; Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892; Rizzo E, 2013, BECKERS HOSP REV; SAFRAN DG, 2005, HLTH AFF MILLWOOD S; Sikdar KC, 2012, ANN PHARMACOTHER, V46, P960, DOI 10.1345/aph.1Q529; U.S. FDA, DRUG DEV DRUG INT TA; Verbeurgt P, 2014, PHARMACOGENOMICS, V15, P655, DOI 10.2217/pgs.14.6; Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007	36	85	88	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2017	12	2							e0170905	10.1371/journal.pone.0170905	http://dx.doi.org/10.1371/journal.pone.0170905			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DB	28151991	Green Published, Green Submitted, gold			2023-01-03	WOS:000396161200058
J	Wang, YY; Ryu, AR; Jin, S; Jeon, YM; Lee, MY				Wang, Yoon-Young; Ryu, A-Reum; Jin, Solee; Jeon, Yu-Mi; Lee, Mi-Young			Chlorin e6-Mediated Photodynamic Therapy Suppresses P. acnes-Induced Inflammatory Response via NF kappa B and MAPKs Signaling Pathway	PLOS ONE			English	Article							PROPIONIBACTERIUM-ACNES; TRANSCRIPTION FACTORS; IN-VITRO; ACTIVATION; EXPRESSION; INNATE; CANCER; FAMILY; CELLS; LIGHT	Photodynamic therapy (PDT), consisting of photosensitizer, light, and oxygen has been used for the treatment of various diseases including cancers, microbial infections and skin disorders. In this study, we examined the anti-inflammatory effect of chlorin e6-mediated PDT in P. acnes-infected HaCaT cells using photosensitizer chlorin e6 (Ce6) and halogen light. The live and heat-killed P. acnes triggered an upregulation of inflammatory molecules such as iNOS, NO, and inflammatory cytokine in HaCaT cells and mouse model. Ce6-mediated PDT notably downregulated the expression of these inflammatory molecules in vitro and in vivo. Similarly, chlorin e6-mediated PDT was capable of regulating inflammatory response in both live and heat killed S. epidermidis exposed HaCaT cells. Moreover, phosphorylation of p38, JNK, and ERK were reduced by Ce6-mediated PDT. Ce6-mediated PDT also reduced the phosphorylation of IKK alpha/beta, IB alpha and NF kappa B p65 in P. acnes-stimulated HaCaT cells. In addition, the dramatic increase in the nuclear translocation of NF kappa B p65 observed upon stimulation with P. acnes was markedly impaired by Ce6-based PDT. This is the first suggestion that Ce6-mediated PDT suppresses P. acnes-induced inflammation through modulating NF kappa B and MAPKs signaling pathways.	[Wang, Yoon-Young; Ryu, A-Reum; Jin, Solee; Jeon, Yu-Mi; Lee, Mi-Young] Soonchunhyang Univ, Dept Med Sci, Coll Med Sci, Asan, Chungnam, South Korea; [Jeon, Yu-Mi] Korea Brain Res Inst, Div Res, Daegu, South Korea; [Lee, Mi-Young] Soonchunhyang Univ, Dept Med Biotechnol, Coll Med Sci, Asan, Chungnam, South Korea	Soonchunhyang University; Korea Brain Research Institute (KBRI); Soonchunhyang University	Lee, MY (corresponding author), Soonchunhyang Univ, Dept Med Sci, Coll Med Sci, Asan, Chungnam, South Korea.; Lee, MY (corresponding author), Soonchunhyang Univ, Dept Med Biotechnol, Coll Med Sci, Asan, Chungnam, South Korea.	miyoung@sch.ac.kr		Ryu, A-Reum/0000-0002-0330-8620	Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HN12C0059]; Soonchunhyang University	Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; Soonchunhyang University	This study was supported by a grant received from Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (Grant No.: HN12C0059). This study was also supported in part by Soonchunhyang University.	Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Chin WWL, 2006, J PHOTOCH PHOTOBIO B, V84, P103, DOI 10.1016/j.jphotobiol.2006.02.002; Eady EA, 2003, DERMATOLOGY, V206, P54, DOI 10.1159/000067822; Grange PA, 2009, J DERMATOL SCI, V56, P106, DOI 10.1016/j.jdermsci.2009.08.001; Guo QZ, 2016, MOL MED REP, V14, P544, DOI 10.3892/mmr.2016.5248; Hay RJ, 2014, J INVEST DERMATOL, V134, P1527, DOI 10.1038/jid.2013.446; Hayashi N, 2015, MOL CANCER THER, V14, P452, DOI 10.1158/1535-7163.MCT-14-0348; Hongcharu W, 2000, J INVEST DERMATOL, V115, P183, DOI 10.1046/j.1523-1747.2000.00046.x; Jeon YM, 2015, LIFE SCI, V124, P56, DOI 10.1016/j.lfs.2014.12.029; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kang S, 2005, AM J PATHOL, V166, P1691, DOI 10.1016/S0002-9440(10)62479-0; Kim J, 2005, DERMATOLOGY, V211, P193, DOI 10.1159/000087011; Kim JH, 2006, BIOCHEM PHARMACOL, V71, P1198, DOI 10.1016/j.bcp.2005.12.031; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Ko JW, 2016, MOL CELL TOXICOL, V12, P185, DOI 10.1007/s13273-016-0023-0; Lee WR, 2014, J INVEST DERMATOL, V134, P1922, DOI 10.1038/jid.2014.75; Lee YJ, 2015, MOL CELL TOXICOL, V11, P295, DOI 10.1007/s13273-015-0029-z; Lehmann P, 2007, BRIT J DERMATOL, V156, P793, DOI 10.1111/j.1365-2133.2007.07833.x; Lin CW, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080883, 10.1371/journal.pone.0056499, 10.1371/journal.pone.0065734, 10.1371/journal.pone.0070187]; Malina L, 2016, TOXICOL IN VITRO, V34, P246, DOI 10.1016/j.tiv.2016.04.010; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Nakatsuji T, 2009, J INVEST DERMATOL, V129, P2480, DOI 10.1038/jid.2009.93; Nishijima S, 2000, J Dermatol, V27, P318; Ozog DM, 2016, DERMATOL SURG, V42, P804, DOI 10.1097/DSS.0000000000000800; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Ryu AR, 2014, MOL CELL TOXICOL, V10, P423, DOI 10.1007/s13273-014-0047-2; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011; Shibata M, 2009, J INVEST DERMATOL, V129, P375, DOI 10.1038/jid.2008.237; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Tanghetti Emil A, 2013, J Clin Aesthet Dermatol, V6, P27; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wang C, 2011, BIOMATERIALS, V32, P6145, DOI 10.1016/j.biomaterials.2011.05.007; Yao R, 2015, MOL CELL TOXICOL, V11, P247, DOI 10.1007/s13273-015-0024-4; Zaenglein AL, 2016, J AM ACAD DERMATOL, V74, P945, DOI 10.1016/j.jaad.2015.12.037	39	34	35	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2017	12	1							e0170599	10.1371/journal.pone.0170599	http://dx.doi.org/10.1371/journal.pone.0170599			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7CU	28118375	Green Published, Green Submitted, gold			2023-01-03	WOS:000396160500025
J	Park, CH; Kim, JH; Lee, EB; Hur, W; Kwon, OJ; Park, HJ; Yoon, SK				Park, Chung-Hwa; Kim, Jung-Hee; Lee, Eun Byul; Hur, Wonhee; Kwon, Oh-Joo; Park, Hyoung-Jin; Yoon, Seung Kew			Aronia melanocarpa Extract Ameliorates Hepatic Lipid Metabolism through PPAR gamma 2 Downregulation	PLOS ONE			English	Article							FATTY LIVER-DISEASE; PPAR-GAMMA; NONALCOHOLIC STEATOHEPATITIS; DIABETES-MELLITUS; OXIDATIVE STRESS; OBESE MICE; LEPTIN; JUICE; ACCUMULATION; LIPOGENESIS	Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. Studies have demonstrated that anthocyanin-rich foods may improve hyperlipidemia and ameliorate hepatic steatosis. Here, effects of Aronia melanocarpa (AM), known to be rich of anthocyanins, on hepatic lipid metabolism and adipogenic genes were determined. AM was treated to C57BL/6N mice fed with high fat diet (HFD) or to FL83B cells treated with free fatty acid (FFA). Changes in levels of lipids, enzymes and hormones were observed, and expressions of adipogenic genes involved in hepatic lipid metabolism were detected by PCR, Western blotting and luciferase assay. In mice, AM significantly reduced the body and liver weight, lipid accumulation in the liver, and levels of biochemical markers such as fatty acid synthase, hepatic triglyceride and leptin. Serum transaminases, indicators for hepatocyte injury, were also suppressed, while superoxide dismutase activity and liver antioxidant capacity were significantly increased. In FL83B cells, AM significantly reduced FFA-induced lipid droplet accumulation. Protein synthesis of an adipogenic transcription factor, peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) was inhibited in vivo. Furthermore, transcriptional activity of PPAR gamma 2 was down-regulated in vitro, and mRNA expression of PPAR gamma 2 and its downstream target genes, adipocyte protein 2 and lipoprotein lipase were down-regulated by AM both in vitro and in vivo. These results show beneficial effects of AM against hepatic lipid accumulation through the inhibition of PPAR gamma 2 expression along with improvements in body weight, liver functions, lipid profiles and antioxidant capacity suggesting the potential therapeutic efficacy of AM on NAFLD.	[Park, Chung-Hwa; Yoon, Seung Kew] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul, South Korea; [Park, Chung-Hwa; Kim, Jung-Hee; Lee, Eun Byul; Hur, Wonhee; Yoon, Seung Kew] Catholic Univ Korea, CULRC, Seoul, South Korea; [Kim, Jung-Hee; Lee, Eun Byul; Hur, Wonhee; Yoon, Seung Kew] Catholic Univ Korea, WHO Collaborating Ctr Viral Hepatitis, Seoul, South Korea; [Kwon, Oh-Joo] Catholic Univ Korea, Coll Med, Dept Med Biochem, Seoul, South Korea; [Park, Hyoung-Jin] MushMed Co LTD, Chuncheon Si, Gangwon Do, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Yoon, SK (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul, South Korea.	yoonsk@catholic.ac.kr		Park, Chung-Hwa/0000-0001-5992-6156	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2015R1A2A1A15052783]; MushMed Co., LTD	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology; MushMed Co., LTD	This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2015R1A2A1A15052783). There was no additional external funding received for this study. MushMed Co., LTD. provided support in the form of salaries for HJP, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section, and this does not alter our adherence to PLOS ONE policies on sharing data and materials.	Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159; Almonacid-Urrego CC, 2012, CURR MED CHEM, V19, P1389, DOI 10.2174/092986712799462586; Badescu M, 2015, PHARM BIOL, V53, P533, DOI 10.3109/13880209.2014.931441; Berlanga A, 2014, CLIN EXP GASTROENTER, V7, P221, DOI 10.2147/CEG.S62831; Broncel M, 2010, MED SCI MONITOR, V16, pCR28; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Chang JJ, 2013, J AGR FOOD CHEM, V61, P6069, DOI 10.1021/jf401171k; Chrubasik C, 2010, PHYTOTHER RES, V24, P1107, DOI 10.1002/ptr.3226; den Besten G, 2015, DIABETES, V64, P2398, DOI 10.2337/db14-1213; Fuchs M, 2012, J HEPATOL, V56, P291, DOI 10.1016/j.jhep.2011.05.019; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Geliebter Allan, 2014, J Diabetes Obes, V1, P1; Greenberg AS, 2011, J CLIN INVEST, V121, P2102, DOI 10.1172/JCI46069; Guo HH, 2011, J LIPID RES, V52, P908, DOI 10.1194/jlr.M013375; Hsu YW, 2010, FOOD CHEM TOXICOL, V48, P1644, DOI 10.1016/j.fct.2010.03.039; Hur W, 2012, NUTR RES, V32, P778, DOI 10.1016/j.nutres.2012.06.017; Hwang YP, 2011, NUTR RES, V31, P896, DOI 10.1016/j.nutres.2011.09.026; Ikejima K, 2005, HEPATOL RES, V33, P151, DOI 10.1016/j.hepres.2005.09.024; Kardum N, 2014, EFFECTS GLUCOMANNAN, V2014, DOI [10.1155/2014/869250, DOI 10.1155/2014/869250]; Kim B, 2013, NUTR RES, V33, P406, DOI 10.1016/j.nutres.2013.03.001; Kohjima M, 2007, INT J MOL MED, V20, P351; Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001; Lomonaco R, 2013, DRUGS, V73, P1, DOI 10.1007/s40265-012-0004-0; Madhujith T, 2006, J AGR FOOD CHEM, V54, P3283, DOI 10.1021/jf0527504; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Mantzaris MD, 2011, FEBS J, V278, P519, DOI 10.1111/j.1742-4658.2010.07972.x; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Matsusue K, 2014, FEBS LETT, V588, P2277, DOI 10.1016/j.febslet.2014.05.012; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Mulero J, 2012, CLIN NUTR, V31, P372, DOI 10.1016/j.clnu.2011.11.014; Neuman MG, 2014, CAN J GASTROENTEROL, V28, P607, DOI 10.1155/2014/757929; Nikolopoulou E, 2014, J LIPID RES, V55, P2479, DOI 10.1194/jlr.M049551; Park S, 2011, J HEPATOL, V54, P984, DOI 10.1016/j.jhep.2010.08.019; Pettinelli P, 2011, J CLIN ENDOCR METAB, V96, P1424, DOI 10.1210/jc.2010-2129; Polyzos SA, 2015, METABOLISM, V64, P60, DOI 10.1016/j.metabol.2014.10.012; Qin BL, 2012, BRIT J NUTR, V108, P581, DOI 10.1017/S000711451100599X; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; Rolo AP, 2012, FREE RADICAL BIO MED, V52, P59, DOI 10.1016/j.freeradbiomed.2011.10.003; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Salamone F, 2012, WORLD J GASTROENTERO, V18, P3862, DOI 10.3748/wjg.v18.i29.3862; Serviddio G, 2013, FREE RADICAL BIO MED, V65, P952, DOI 10.1016/j.freeradbiomed.2013.08.174; Skarpanska-Stejnborn A, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/s12970-014-0048-5; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Sunny NE, 2011, CELL METAB, V14, P804, DOI 10.1016/j.cmet.2011.11.004; Tessari P, 2009, NUTR METAB CARDIOVAS, V19, P291, DOI 10.1016/j.numecd.2008.12.015; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tsuda T, 2003, J NUTR, V133, P2125, DOI 10.1093/jn/133.7.2125; Upadhyay G, 2007, EUR J PHARMACOL, V565, P190, DOI 10.1016/j.ejphar.2007.03.004; Valcheva-Kuzmanova S, 2004, EXP TOXICOL PATHOL, V56, P195, DOI 10.1016/j.etp.2004.04.012; Valcheva-Kuzmanova SV, 2014, FOLIA MED, V56, P199; Valenti L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/145421; Yamazaki T, 2011, J NUTR BIOCHEM, V22, P543, DOI 10.1016/j.jnutbio.2010.04.009; Zhai XG, 2013, BRIT J PHARMACOL, V169, P197, DOI 10.1111/bph.12114	53	27	29	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2017	12	1							e0169685	10.1371/journal.pone.0169685	http://dx.doi.org/10.1371/journal.pone.0169685			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH7JQ	28081181	Green Published, Green Submitted, gold			2023-01-03	WOS:000391949500064
J	Tao, FF; Ruan, SM; Liu, WH; Wang, LB; Xiong, Y; Shen, MH				Tao, Fangfang; Ruan, Shanming; Liu, Wenhong; Wang, Libin; Xiong, Yang; Shen, Minhe			Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGF beta-Induced EMT in Ovarian Cancer	PLOS ONE			English	Article							SALMONELLA-TYPHIMURIUM A1-R; NUDE-MOUSE MODEL; ORTHOTOPIC IMPLANTATION; TUMOR-GROWTH; PATIENT; METASTASIS; CARCINOMA; EFFICACY; TRANSPLANTATION; ANGIOGENESIS	The compound fuling granule (CFG) is a traditional Chinese drug which has been used to treat ovarian cancer in China for over twenty years. Nevertheless, the underlying molecular mechanism of its anti-cancer effect remains unclear. In this study, microarray data analysis was performed to search differentially expressed genes in CFG-treated ovarian cancer cells. Several cell cycle and epithelial-mesenchymal transition (EMT) related genes were identified. The microarray analyses also revealed that CFG potentially regulates EMT in ovarian cancer. We also found that, functionally, CFG significantly suppresses ovarian cancer cell proliferation by cell cycle arrest, apoptosis and senescence and the AKT/GSK-3 beta pathway is possibly involved. Additionally, the invasion and migration ability of ovarian cancer induced by TGF beta is significantly suppressed by CFG. In conclusion, our results demonstrated that CFG suppresses ovarian cancer cell proliferation as well as TGF beta 1-induced EMT in vitro. Finally, we discovered that CFG suppresses tumor growth and distant metastasis in vivo. Overall, these findings provide helpful clues to design novel clinical treatments against cancer.	[Tao, Fangfang; Liu, Wenhong] Zhejiang Chinese Med Univ, Basic Med Coll, Dept Immunol & Microbiol, Hangzhou, Zhejiang, Peoples R China; [Ruan, Shanming; Shen, Minhe] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Wang, Libin] Ningxia Med Univ, Gen Hosp, Inst Stem Cell Res, Ningxia, Peoples R China; [Xiong, Yang] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Ningxia Medical University; Zhejiang Chinese Medical University	Tao, FF (corresponding author), Zhejiang Chinese Med Univ, Basic Med Coll, Dept Immunol & Microbiol, Hangzhou, Zhejiang, Peoples R China.; Shen, MH (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.	taoff@zcmu.edu.cn; shenminhe@aliyun.com	Ruan, Shanming/S-3999-2018	Ruan, Shanming/0000-0003-1061-5255; tao, fang fang/0000-0002-2090-2701	National Natural Science Foundation of China [81302896, 81473434, 81202926]; Zhejiang Provincial Public Welfare Projects [2016C37056]; China Scholarship Council; Youth Talents Foundation of Zhejiang TCM Administration [2013ZQ008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Public Welfare Projects; China Scholarship Council(China Scholarship Council); Youth Talents Foundation of Zhejiang TCM Administration	This work is supported by National Natural Science Foundation of China (FT, No.81302896, http://isisn.nsfc.gov.cn/; YX, No.81473434, http://isisn.nsfc.gov.cn/; YX, No.81202926, http://isisn.nsfc.gov.cn/); Zhejiang Provincial Public Welfare Projects (FT, 2016C37056, http://xm.zjkjt.gov.cn/); China Scholarship Council and Youth Talents Foundation of Zhejiang TCM Administration (FT, 2013ZQ008, http://zgj.zjtcm.net/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASTOUL P, 1993, ANTICANCER RES, V13, P1999; Chen NN, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-2; FU XY, 1993, ANTICANCER RES, V13, P283; Fu Y, 2014, INT J GYNECOL CANCER, V21, P439; Gao F, 2015, ONCOTARGET, V6, P5947, DOI 10.18632/oncotarget.3335; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Hahn HS, 2014, J GYNECOL ONCOL, V25, P130, DOI 10.3802/jgo.2014.25.2.130; Hiroshima Y, 2014, ONCOTARGET, V5, P12346, DOI 10.18632/oncotarget.2641; Hu C, 2014, CLIMACTERIC, V17, P410, DOI 10.3109/13697137.2013.876618; Kiguchi K, 1998, CLIN EXP METASTAS, V16, P751, DOI 10.1023/A:1006537013317; Kong Sai, 2014, Evid Based Complement Alternat Med, V2014, P146383, DOI 10.1155/2014/146383; Lee SE, 2014, PHARM DEV TECHNOL, V19, P438, DOI 10.3109/10837450.2013.789911; Li SH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0083037, 10.1371/journal.pone.0067928, 10.1371/journal.pone.0057604]; Liu HO, 2012, CANCER SCI, V103, P2072, DOI 10.1111/cas.12017; Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Makris N, 2013, INT J ONCOL, V42, P2019, DOI 10.3892/ijo.2013.1888; Matsumoto Y, 2015, ONCOTARGET, V6, P11369, DOI 10.18632/oncotarget.3607; Matsumoto Y, 2014, J CELL BIOCHEM, V115, P1996, DOI 10.1002/jcb.24871; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Murakami T, 2015, ONCOTARGET, V6, P31368, DOI 10.18632/oncotarget.5187; Park B, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/316872; Park JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109055; Patil MA, 2009, CANCER RES, V69, P253, DOI 10.1158/0008-5472.CAN-08-2514; Saiprasad G, 2014, EUR J CANCER, V50, P2489, DOI 10.1016/j.ejca.2014.06.013; Shirakawa H, 2008, TRANSPL P, V40, P1741, DOI 10.1016/j.transproceed.2008.02.089; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sun BG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/752850; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; [陶方方 Tao Fangfang], 2015, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V30, P235; Tao FF, 2013, CHINESE ARCH TRADITI, V31, P559; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Vergara D, 2012, MOL BIOSYST, V8, P1078, DOI 10.1039/c2mb05486h; Wang SS, 2013, IEEE J-STSP, V7, P1101, DOI 10.1109/JSTSP.2013.2272240; Wang Z, 2016, CANC GENE THER; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Wu CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113887; Yi XF, 2005, INT J GYNECOL CANCER, V15, P850, DOI 10.1111/j.1525-1438.2005.00147.x; Yin G, 2015, ANTICANCER RES, V35, P3193; Yu PN, 2014, INT J CANCER, V134, P542, DOI 10.1002/ijc.28399; Zhang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109814; Zhang LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep08693; Zhao BY, 2014, P NATL ACAD SCI USA, V111, P10773, DOI 10.1073/pnas.1323934111; Zhao L, 2015, MOL CARCINOG; Zhou W, 2012, CANCER LETT, V316, P178, DOI 10.1016/j.canlet.2011.10.033	46	16	17	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2016	11	12							e0168892	10.1371/journal.pone.0168892	http://dx.doi.org/10.1371/journal.pone.0168892			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7LN	28036353	gold, Green Submitted, Green Published			2023-01-03	WOS:000391229300037
J	Stoll, M; Stoiber, EM; Grimm, S; Debus, J; Bendl, R; Giske, K				Stoll, Markus; Stoiber, Eva Maria; Grimm, Sarah; Debus, Juergen; Bendl, Rolf; Giske, Kristina			Comparison of Safety Margin Generation Concepts in Image Guided Radiotherapy to Account for Daily Head and Neck Pose Variations	PLOS ONE			English	Article							SETUP UNCERTAINTIES; CANCER-PATIENTS; IGRT; REGISTRATION; ERRORS; IMRT	Purpose Intensity modulated radiation therapy (IMRT) of head and neck tumors allows a precise conformation of the high-dose region to clinical target volumes (CTVs) while respecting dose limits to organs a risk (OARs). Accurate patient setup reduces translational and rotational deviations between therapy planning and therapy delivery days. However, uncertainties in the shape of the CTV and OARs due to e.g. small pose variations in the highly deformable anatomy of the head and neck region can still compromise the dose conformation. Routinely applied safety margins around the CTV cause higher dose deposition in adjacent healthy tissue and should be kept as small as possible. Materials and Methods In this work we evaluate and compare three approaches for margin generation 1) a clinically used approach with a constant isotropic 3 mm margin, 2) a previously proposed approach adopting a spatial model of the patient and 3) a newly developed approach adopting a bio-mechanical model of the patient. All approaches are retrospectively evaluated using a large patient cohort of over 500 fraction control CT images with heterogeneous pose changes. Automatic methods for finding landmark positions in the control CT images are combined with a patient specific biomechanical finite element model to evaluate the CTV deformation. Results The applied methods for deformation modeling show that the pose changes cause deformations in the target region with a mean motion magnitude of 1.80 mm. We found that the CTV size can be reduced by both variable margin approaches by 15.6% and 13.3% respectively, while maintaining the CTV coverage. With approach 3 an increase of target coverage was obtained. Conclusion Variable margins increase target coverage, reduce risk to OARs and improve healthy tissue sparing at the same time.	[Stoll, Markus; Stoiber, Eva Maria; Grimm, Sarah; Debus, Juergen; Bendl, Rolf; Giske, Kristina] German Canc Res Ctr, Dept Med Phys Radiat Oncol, Heidelberg, Germany; [Stoll, Markus; Grimm, Sarah; Debus, Juergen; Bendl, Rolf; Giske, Kristina] Natl Ctr Radiat Res Oncol, Heidelberg Inst Radiat Oncol, Heidelberg, Germany; [Grimm, Sarah; Bendl, Rolf] Heilbronn Univ, Fac Comp Sci, Heilbronn, Germany; [Debus, Juergen] Univ Hosp, Dept Radiat Oncol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Stoll, M (corresponding author), German Canc Res Ctr, Dept Med Phys Radiat Oncol, Heidelberg, Germany.; Stoll, M (corresponding author), Natl Ctr Radiat Res Oncol, Heidelberg Inst Radiat Oncol, Heidelberg, Germany.	m.stoll@dkfz.de	Giske, Kristina/L-3009-2016	Giske, Kristina/0000-0001-7287-3271	German Research Foundation (DFG) [SEIB/I-RR 125]; University Hospital Heidelberg; DFG [GI977/1-2]	German Research Foundation (DFG)(German Research Foundation (DFG)); University Hospital Heidelberg; DFG(German Research Foundation (DFG))	This work was carried out with the support of the German Research Foundation (DFG) within the project CO2 of the Collaborative Research Center SEIB/I-RR 125 "Cognition-Guided Surgery" for MS and SG. EMS was supported by the postdoc fellowship program of the University Hospital Heidelberg. KG and EMS have received support from the DFG under grant GI977/1-2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahunbay EE, 2009, MED PHYS, V36, P4776, DOI 10.1118/1.3215532; Allard J, 2007, STUD HEALTH TECHNOL, V125, P13; Bendl R, 1994, P 11 INT C US COMP R, P226; Bishop C, 2006, PATTERN RECOGN, P140; Chen AM, 2011, INT J RADIAT ONCOL, V81, P943, DOI 10.1016/j.ijrobp.2010.07.017; Clark K, 2013, J DIGIT IMAGING, V26, P1045, DOI 10.1007/s10278-013-9622-7; Donner R, 2010, P MICCAI WORKSH MED, P86; Faure F, 2012, SOFT ISSUE BIOMECHAN; Giske K, 2011, INT J RADIAT ONCOL, V80, P582, DOI 10.1016/j.ijrobp.2010.07.1980; Gonzalez RC, 2013, DIGITAL IMAGE PROCES; Gunn GB, 2015, HEAD NECK CANC; International Commission on Radiation Units and Measurements, 2010, J ICRU, V10; Jackson J.E., 2005, USERS GUIDE PRINCIPA, V587; Jamin C, 2015, ACM T MATH SOFTWARE, V41, DOI 10.1145/2699463; Kendall D. G., 1989, STAT SCI, V4, P87, DOI DOI 10.1002/aqc.3042; Malsch U, 2006, PHYS MED BIOL, V51, P4789, DOI 10.1088/0031-9155/51/19/005; McKee CT, 2011, TISSUE ENG PART B-RE, V17, P155, DOI [10.1089/ten.TEB.2010.0520, 10.1089/ten.teb.2010.0520]; McKenzie A, 2002, RADIOTHER ONCOL, V62, P299, DOI 10.1016/S0167-8140(02)00015-4; McKenzie A, 2000, BR J RADIOL; Nesme M, 2005, EUROGRAPHICS SHORT P, P77; Neubauer E, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-19; Paulson ES, 2011, MED PHYS, V38, DOI [10.1118/1.3560418, 10.1118/1.3613192]; Polat B, 2007, STRAHLENTHER ONKOL, V183, P506, DOI 10.1007/s00066-007-1747-5; Rasch C, 2005, SEMIN RADIAT ONCOL, V15, P136, DOI 10.1016/j.semradonc.2005.01.005; Saunders A, 2014, HEAD NECK CANC TREAT; SCHLEGEL W, 1992, INT J RADIAT ONCOL, V24, P781, DOI 10.1016/0360-3016(92)90729-2; Schlegel W, 2007, 3D CONFORMAL RAD THE; Schwarz M, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-133; Smith K, 2015, DATA QIN HEADNECK; Sohn M, 2012, PHYS MED BIOL, V57, P3693, DOI 10.1088/0031-9155/57/12/3693; Stoiber EM, 2014, ACTA ONCOL, V53, P33, DOI 10.3109/0284186X.2013.790559; Stoll M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-175; Suwelack Stefan, 2014, Stud Health Technol Inform, V196, P394; van Beek S, 2010, RADIOTHER ONCOL, V94, P213, DOI 10.1016/j.radonc.2009.12.017; Van Dye J, 2013, MODERN TECHNOLOGY RA, V3, P361; van Herk M, 2000, INT J RADIAT ONCOL, V47, P1121, DOI 10.1016/S0360-3016(00)00518-6; van Kranen S, 2009, INT J RADIAT ONCOL, V73, P1566, DOI 10.1016/j.ijrobp.2008.11.035; Vergeer MR, 2009, INT J RADIAT ONCOL, V74, P1, DOI 10.1016/j.ijrobp.2008.07.059; Wang Fang, 2010, Proceedings 2010 International Conference on Optoelectronics and Image Processing (ICOIP 2010), P104, DOI 10.1109/ICOIP.2010.322; Werner R, 2009, MED PHYS, V36, P1500, DOI 10.1118/1.3101820; WITHERS HR, 1985, CANCER, V55, P2086, DOI 10.1002/1097-0142(19850501)55:9+<2086::AID-CNCR2820551409>3.0.CO;2-1; Yang JZ, 2012, MED PHYS, V39, P5136, DOI 10.1118/1.4737891; Yock AD, 2013, INT J RADIAT ONCOL, V87, P596, DOI 10.1016/j.ijrobp.2013.06.2036; Yu Y, 2014, HEAD NECK-J SCI SPEC, V36, P992, DOI 10.1002/hed.23401; Zhang LF, 2006, INT J RADIAT ONCOL, V64, P1559, DOI 10.1016/j.ijrobp.2005.12.023	46	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2016	11	12							e0168916	10.1371/journal.pone.0168916	http://dx.doi.org/10.1371/journal.pone.0168916			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7KQ	28033416	gold, Green Submitted, Green Published			2023-01-03	WOS:000391226900059
J	Galante, R; Rediguieri, CF; Kikuchi, IS; Vasquez, PAS; Colaco, R; Serro, AP; Pinto, TJA				Galante, Raquel; Rediguieri, Carolina F.; Kikuchi, Irene Satiko; Vasquez, Pablo A. S.; Colaco, Rogerio; Serro, Ana Paula; Pinto, Terezinha J. A.			About the Sterilization of Chitosan Hydrogel Nanoparticles	PLOS ONE			English	Article							TRIPOLYPHOSPHATE CS/TPP NANOPARTICLES; DRUG-DELIVERY; BIOMEDICAL APPLICATIONS; GLUCOSE COMPLEX; OZONE; CHALLENGES; EFFICIENCY; NANOGELS	In the last years, nanostructured biomaterials have raised a great interest as platforms for delivery of drugs, genes, imaging agents and for tissue engineering applications. In particular, hydrogel nanoparticles (HNP) associate the distinctive features of hydrogels (high water uptake capacity, biocompatibility) with the advantages of being possible to tailor its physicochemical properties at nano-scale to increase solubility, immunocompatibility and cellular uptake. In order to be safe, HNP for biomedical applications, such as injectable or ophthalmic formulations, must be sterile. Literature is very scarce with respect to sterilization effects on nanostructured systems, and even more in what concerns HNP. This work aims to evaluate the effect and effectiveness of different sterilization methods on chitosan (CS) hydrogel nanoparticles. In addition to conventional methods (steam autoclave and gamma irradiation), a recent ozone-based method of sterilization was also tested. A model chitosan-tripolyphosphate (TPP) hydrogel nanoparticles (CS-HNP), with a broad spectrum of possible applications was produced and sterilized in the absence and in the presence of protective sugars (glucose and mannitol). Properties like size, zeta potential, absorbance, morphology, chemical structure and cytotoxicity were evaluated. It was found that the CS-HNP degrade by autoclaving and that sugars have no protective effect. Concerning gamma irradiation, the formation of agglomerates was observed, compromising the suspension stability. However, the nanoparticles resistance increases considerably in the presence of the sugars. Ozone sterilization did not lead to significant physical adverse effects, however, slight toxicity signs were observed, contrarily to gamma irradiation where no detectable changes on cells were found. Ozonation in the presence of sugars avoided cytotoxicity. Nevertheless, some chemical alterations were observed in the nanoparticles.	[Galante, Raquel; Rediguieri, Carolina F.; Kikuchi, Irene Satiko; Pinto, Terezinha J. A.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Farm, Butanta, SP, Brazil; [Galante, Raquel; Colaco, Rogerio; Serro, Ana Paula] Univ Lisbon, Inst Super Tecn, Ctr Quim Estrutural, Lisbon, Portugal; [Rediguieri, Carolina F.] Agencia Nacl Vigilaancia Sanit, Brasilia, DF, Brazil; [Vasquez, Pablo A. S.] Ctr Tecnol Radiacoes, Inst Pesquisas Energet & Nucl, Butanta, SP, Brazil; [Colaco, Rogerio] Univ Lisbon, Inst Super Tecn, Dept Engn Mecan, Lisbon, Portugal; [Colaco, Rogerio] Univ Lisbon, Inst Super Tecn, IDMEC, Lisbon, Portugal; [Serro, Ana Paula] Ctr Invest Interdisciplinar Egas Moniz, Inst Super Ciencias Saude Egas Moniz, Monte De Caparica, Caparica, Portugal	Universidade de Sao Paulo; Universidade de Lisboa; Instituto Superior Tecnico; Comissao Nacional de Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN); Universidade de Lisboa; Instituto Superior Tecnico; Universidade de Lisboa; Instituto Superior Tecnico; Instituto Superior de Ciencias da Saude Egas Moniz	Serro, AP (corresponding author), Univ Lisbon, Inst Super Tecn, Ctr Quim Estrutural, Lisbon, Portugal.; Serro, AP (corresponding author), Ctr Invest Interdisciplinar Egas Moniz, Inst Super Ciencias Saude Egas Moniz, Monte De Caparica, Caparica, Portugal.	anapaula.serro@tecnico.ulisboa.pt	Kikuchi, Irene S./A-4863-2013; de Jesus Andreoli Pinto, Terezinha/AAR-2389-2020; GALANTE, RAQUEL S.C./K-2512-2014; Vasquez, Pablo/C-3862-2016; Pinto, Terezinha JA/C-4777-2012; Serro, Ana/H-7797-2012; Colaco, Rogerio/B-5432-2013	Kikuchi, Irene S./0000-0002-5223-1308; de Jesus Andreoli Pinto, Terezinha/0000-0002-0238-8227; GALANTE, RAQUEL S.C./0000-0001-8616-4775; Vasquez, Pablo/0000-0003-4168-1626; Colaco, Rogerio/0000-0002-5529-1621; Serro, Ana/0000-0002-6179-9296; Colaco, Rogerio/0000-0001-7374-6741	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [140863/2014, 400455/2014-5]; projects M-ERA; Fundacao para a Ciencia e Tecnologia [NET/0005/2012, PTDC/CTM-BIO/3640/2014]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); projects M-ERA; Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission)	This study was supported by PhD grant 140863/2014 and project 400455/2014-5, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (http://cnpq.br/) and projects M-ERA. NET/0005/2012 and PTDC/CTM-BIO/3640/2014, Fundacao para a Ciencia e Tecnologia (http://www.fct.pt/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Hafez SM, 2014, INT J BIOL MACROMOL, V64, P334, DOI 10.1016/j.ijbiomac.2013.11.041; Audenaert WTM, 2010, CHEM ENG J, V157, P551, DOI 10.1016/j.cej.2009.12.051; Azadi A, 2015, INT J BIOL MACROMOL, V79, P326, DOI 10.1016/j.ijbiomac.2015.05.001; Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4; Cataldo F, 2007, INT J BIOL MACROMOL, V41, P210, DOI 10.1016/j.ijbiomac.2007.02.008; De Campos AM, 2001, INT J PHARMACEUT, V224, P54, DOI 10.1016/j.msec.2012.12.066; Dick HB, 2000, ASEPTIC PRODUCTION V, P97; Dufresne S., 2004, AM J INFECT CONTROL, V32, pE26, DOI [10.1016/j.ajic.2004.04.038, DOI 10.1016/J.AJIC.2004.04.038]; Dufresne S, 2008, AM J INFECT CONTROL, V36, P291, DOI 10.1016/j.ajic.2007.06.006; Franca A, 2010, SMALL, V6, P89, DOI 10.1002/smll.200901006; Gao PS, 2013, CARBOHYD POLYM, V95, P371, DOI 10.1016/j.carbpol.2013.03.029; Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002; Hassani S, 2015, COLLOID SURFACE A, V482, P34, DOI 10.1016/j.colsurfa.2015.04.006; HEUSINGER H, 1987, Z LEBENSM UNTERS FOR, V185, P106, DOI 10.1007/BF01850087; HOIGNE J, 1985, WATER RES, V19, P993, DOI 10.1016/0043-1354(85)90368-9; Honary S, 2013, TROP J PHARM RES, V12, P265, DOI 10.4314/tjpr.v12i2.20; Jarry C, 2002, CHEM PHARM B TOKYO, V50; Jayakumar R, 2010, CARBOHYD POLYM, V82, P227, DOI 10.1016/j.carbpol.2010.04.074; Jiang YJ, 2014, BIOMATERIALS, V35, P4969, DOI 10.1016/j.biomaterials.2014.03.001; Jing ZW, 2016, BIOMATERIALS, V84, P276, DOI 10.1016/j.biomaterials.2016.01.045; Kanatt SR, 2008, FOOD CHEM, V106, P521, DOI 10.1016/j.foodchem.2007.06.036; Karajanagi SS, 2011, BIOTECHNOL BIOENG, V108, P1716, DOI 10.1002/bit.23105; Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004; Killeen S., 2012, SURGERY OXFORD, V30, P687; Kitazaki S, 2014, VACUUM, V110, P217, DOI 10.1016/j.vacuum.2014.06.014; Langlais B., 1991, OZONE WATER TREATMEN; Laverty G, 2012, CHARACTERISTICS TREA, V51, P79; Lerouge S, 2012, WOODH PUBL SER BIOM, V46, P1; Li J, 2012, CARBOHYD POLYM, V87, P1670, DOI 10.1016/j.carbpol.2011.09.074; Loncar B, 2009, ARCH MED RES, V40, P136, DOI 10.1016/j.arcmed.2008.11.002; Mata-Alvarez J, 2003, BIOMETHANIZATION ORG, P1, DOI DOI 10.2166/9781780402994; Morris GA, 2011, CARBOHYD POLYM, V84, P1430, DOI 10.1016/j.carbpol.2011.01.044; O'Donnell C, 2012, STATUS TRENDS OZONE, P1; Pharmacopeia US, 2016, USP39NF34, P167; Pharmacopeia US, 2016, USP39NF34, P136; Pharmacopeia US, 2016, USP 39 NF 34, P589; PHILLIPS GO, 1963, J CHEM SOC, P297, DOI 10.1039/jr9630000297; Rediguieri C., 2016, TISSUE ENG C; Rogers WJ, 2012, WOODH PUBL SER BIOM, V46, P151; Rogers W.J., 2012, STERILISATION BIOMAT, P352; Rutala WA, 2008, GUIDELINE DISINFECTI, P69; Sarkar SD, 2013, MAT SCI ENG C-MATER, V33, P1446, DOI 10.1016/j.msec.2012.12.066; Serro AP, 2003, BIOMATERIALS, V24, P4749, DOI 10.1016/S0142-9612(03)00372-7; Silva CLM, ETHYLENE OXIDE EO ST; Sipoli CC, 2015, BIOCHEM ENG J, V94, P65, DOI 10.1016/j.bej.2014.11.008; Talbot P, 2012, WATER RES, V46, P5893, DOI 10.1016/j.watres.2012.07.052; U. S. Environmental Protection Agency (US EPA), 1999, GUID MAN ALT DIS OX, P1; Uzun H, 2012, FOOD CHEM, V134, P647, DOI 10.1016/j.foodchem.2012.02.146; Vetten MA, 2014, NANOMED-NANOTECHNOL, V10, P1391, DOI 10.1016/j.nano.2014.03.017; Vimal S, 2014, AQUACULTURE, V420, P240, DOI 10.1016/j.aquaculture.2013.11.017; Vimal S, 2013, ACTA TROP, V128, P486, DOI 10.1016/j.actatropica.2013.07.013; Xu YM, 2003, INT J PHARMACEUT, V250, P215, DOI 10.1016/S0378-5173(02)00548-3	52	25	26	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2016	11	12							e0168862	10.1371/journal.pone.0168862	http://dx.doi.org/10.1371/journal.pone.0168862			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9TW	28002493	Green Published, Green Submitted, gold			2023-01-03	WOS:000392853100072
J	Ferner, RE; Aronson, JK				Ferner, Robin E.; Aronson, Jeffrey K.			Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)-variants in the spellings of drug names in PubMed: a database review	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONFUSION	OBJECTIVE To examine how misspellings of drug names could impede searches for published literature. DESIGN Database review. DATA SOURCE PubMed. REVIEW METHODS The study included 30 drug names that are commonly misspelt on prescription charts in hospitals in Birmingham, UK (test set), and 30 control names randomly chosen from a hospital formulary (control set). The following definitions were used: standard names-the international non-proprietary names, variant names-deviations in spelling from standard names that are not themselves standard names in English language nomenclature, and hidden reference variants-variant spellings that identified publications in textword (tw) searches of PubMed or other databases, and which were not identified by textword searches for the standard names. Variant names were generated from standard names by applying letter substitutions, omissions, additions, transpositions, duplications, deduplications, and combinations of these. Searches were carried out in PubMed (30 June 2016) for "standard name[tw]" and "variant name[tw] NOT standard name[tw]." RESULTS The 30 standard names of drugs in the test set gave 325 979 hits in total, and 160 hidden reference variants gave 3872 hits (1.17%). The standard names of the control set gave 470 064 hits, and 79 hidden reference variants gave 766 hits (0.16%). Letter substitutions (particularly i to y and vice versa) and omissions together accounted for 2924 (74%) of the variants. Amitriptyline (8530 hits) yielded 18 hidden reference variants (179 (2.1%) hits). Names ending in "in," "ine," or "micin" were commonly misspelt. Failing to search for hidden reference variants of " gentamicin," "amitriptyline," "mirtazapine," and "trazodone" would miss at least 19 systematic reviews. A hidden reference variant related to Christmas, "No-el", was rare; variants of "X-miss" were rarer. CONCLUSION When performing searches, researchers should include misspellings of drug names among their search terms.	[Ferner, Robin E.] City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England; [Ferner, Robin E.] Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England; [Aronson, Jeffrey K.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford, England	University of Birmingham; University of Birmingham; University of Oxford	Ferner, RE (corresponding author), City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.; Ferner, RE (corresponding author), Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				ARONSON JK, 1995, DRUG SAFETY, V12, P155, DOI 10.2165/00002018-199512030-00001; Bryan R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145431; Clarke M, 2008, BAHRAIN MED J, V30, P85; Lambert BL, 1999, MED CARE, V37, P1214, DOI 10.1097/00005650-199912000-00005; Li YJ, 2007, IEEE T PATTERN ANAL, V29, P1091, DOI 10.1109/TPAMI.2007.1070; Ray JG, 1996, BRIT MED J, V313, P1658, DOI 10.1136/bmj.313.7072.1658; Sampson M, 2009, J CLIN EPIDEMIOL, V62, P944, DOI 10.1016/j.jclinepi.2008.10.012	7	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	2016	355								i4854	10.1136/bmj.i4854	http://dx.doi.org/10.1136/bmj.i4854			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF2JS	27974346	hybrid, Green Published			2023-01-03	WOS:000390151300001
J	Kotter, T; Ritter, J; Katalinic, A; Voltmer, E				Koetter, Thomas; Ritter, Johanna; Katalinic, Alexander; Voltmer, Edgar			Predictors of Participation of Sophomore Medical Students in a Health-Promoting Intervention: An Observational Study	PLOS ONE			English	Article							PSYCHOLOGICAL DISTRESS; STRESS REDUCTION; DEPRESSION SCALE; HOSPITAL ANXIETY; CONTROLLED-TRIAL; BEHAVIOR; EXPERIENCES; RELAXATION; PATTERNS	Medical students and doctors have to be particularly stress-resilient, as both medical education and practice are considered very stressful. Specific stressors can lead to increased risks of developing, for example, depression, anxiety and burnout. Relaxation techniques have proven to be effective for the prevention of these outcomes in student populations. However, only a very few medical students practice relaxation techniques regularly early on in their studies. Furthermore, it is unclear which students make use of stress-management offers and hence whether vulnerable students are generally reachable. Therefore, the aim of our study was to explore predictors of participating in a voluntary stress management course for sophomore medical students. One cohort of freshmen at a German medical school was surveyed at the end of the freshman year [t1] and at the end of the sophomore year [t2]. In addition to sociodemographic information, we captured perceived study stress, self-rated general health and mental health and dimensions of study-related behaviour and experience as potential predictors of participation at t1. During the sophomore year, we offered the participants a progressive muscle relaxation (PMR) beginners' course. At t2, we registered participation status. We used binary logistic regression analyses in order to assess correlations between potential predictors and participation. About one third of the whole class took part in the course. The main reason for non-participation was "no time". Being female and higher levels of anxiety were the strongest predictors of course participation. Career ambition (the higher, the less likely to participate) and emotional distancing (the higher, the more likely to participate) were further significant predictors. Future interventions should be attractive to both male and female medical students. Ideally, for every hour of stress management teaching, the curriculum should be cut by at least the same amount of time.	[Koetter, Thomas; Ritter, Johanna; Katalinic, Alexander] Univ Lubeck, Inst Social Med & Epidemiol, Lubeck, Germany; [Voltmer, Edgar] Friedensau Adventist Univ, Dept Hlth Sci, Mockern, Germany	University of Lubeck	Kotter, T (corresponding author), Univ Lubeck, Inst Social Med & Epidemiol, Lubeck, Germany.	thomas.koetter@uksh.de	Katalinic, Alexander/D-2512-2010	Katalinic, Alexander/0000-0003-0490-1554	Lubeck Medical School [E18-2011]	Lubeck Medical School	This research was supported by a grant from Lubeck Medical School (bit.ly/1pcsaZk) received by TK (E18-2011).	Aster-Schenck I, 2010, GMS Z MED AUSBILD, V27, DOI DOI 10.3205/ZMA000698; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; CARLSON CR, 1993, J CONSULT CLIN PSYCH, V61, P1059, DOI 10.1037/0022-006X.61.6.1059; Chew-Graham CA, 2003, MED EDUC, V37, P873, DOI 10.1046/j.1365-2923.2003.01627.x; Dahlin Marie E, 2007, BMC Med Educ, V7, P6, DOI 10.1186/1472-6920-7-6; de Vibe M, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-107; Dehghan-nayeri N, 2011, COMPLEMENT THER MED, V19, P194, DOI 10.1016/j.ctim.2011.06.002; DeSalvo KB, 2006, J GEN INTERN MED, V21, P267, DOI 10.1111/j.1525-1497.2005.00291.x; DeSalvo KB, 2006, QUAL LIFE RES, V15, P191, DOI 10.1007/s11136-005-0887-2; Dunn LB, 2008, ACAD PSYCHIATR, V32, P44, DOI 10.1176/appi.ap.32.1.44; Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; General Medical Council, 2014, STAT MED ED PRACT UK; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Herrmann-Lingen C., 2011, HOSP ANXIETY DEPRESS; Ishak W, 2013, CLIN TEACH, V10, P242, DOI 10.1111/tct.12014; Jordan S, 2013, BUNDESGESUNDHEITSBLA, V56, P878, DOI 10.1007/s00103-013-1664-y; Kjeldstadli Kari, 2006, BMC Med Educ, V6, P48, DOI 10.1186/1472-6920-6-48; Kotter T, 2015, PERSPECT MED EDUC, V4, P128, DOI 10.1007/s40037-015-0189-5; Kotter T, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-134; Kotter Thomas, 2013, GMS Z Med Ausbild, V30, pDoc22, DOI 10.3205/zma000865; Mata DA, 2015, JAMA-J AM MED ASSOC, V314, P2373, DOI 10.1001/jama.2015.15845; McGrady A, 2012, APPL PSYCHOPHYS BIOF, V37, P253, DOI 10.1007/s10484-012-9198-x; Moffat KJ, 2004, MED EDUC, V38, P482, DOI 10.1046/j.1365-2929.2004.01814.x; NOTMAN MT, 1984, COMPR PSYCHIAT, V25, P355, DOI 10.1016/0010-440X(84)90068-3; Quince TA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001519; Rosenzweig S, 2003, TEACH LEARN MED, V15, P88, DOI 10.1207/S15328015TLM1502_03; Schaarschmidt U., 2008, ARBEITSBEZOGENES VER; Shapiro SL, 1998, J BEHAV MED, V21, P581, DOI 10.1023/A:1018700829825; Vaidya V, 2012, J WOMENS HEALTH, V21, P140, DOI 10.1089/jwh.2011.2876; van Dijk I, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0302-9; VITALIANO PP, 1984, J NERV MENT DIS, V172, P730, DOI 10.1097/00005053-198412000-00006; Voltmer E, 2012, MED TEACH, V34, P840, DOI 10.3109/0142159X.2012.706339; Voltmer E, 2010, MED TEACH, V32, pE422, DOI 10.3109/0142159X.2010.496008; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Warnecke E, 2011, MED EDUC, V45, P381, DOI 10.1111/j.1365-2923.2010.03877.x; Wild K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114967; Woolf Katherine, 2007, BMC Med Educ, V7, P50, DOI 10.1186/1472-6920-7-50; World Health Organization, HLTH INT SURV INT HA; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	40	5	5	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0168104	10.1371/journal.pone.0168104	http://dx.doi.org/10.1371/journal.pone.0168104			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI8HA	27942029	Green Submitted, Green Published, gold			2023-01-03	WOS:000392745600051
J	Gupta, R; Shah, ND; Ross, JS				Gupta, Ravi; Shah, Nilay D.; Ross, Joseph S.			The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gupta, Ravi; Ross, Joseph S.] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Ross, Joseph S.] Yale Univ, Dept Hlth Policy & Management, Sch Publ Hlth, New Haven, CT 06520 USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Shah, Nilay D.] Mayo Clin, Div Hlth Care Policy & Res, Rochester, MN USA; [Shah, Nilay D.] Mayo Clin, Kern Ctr Sci Hlth Care Delivery, Rochester, MN USA	Yale University; Yale University; Mayo Clinic; Mayo Clinic	Gupta, R (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.			Ross, Joseph/0000-0002-9218-3320				[Anonymous], 2015, EXPL NAL UPT US PUBL; Beletsky L, 2012, JAMA-J AM MED ASSOC, V308, P1863, DOI 10.1001/jama.2012.14205; Kapczynski A, 2016, HEALTH AFFAIR, V35, P791, DOI 10.1377/hlthaff.2015.1120; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631	5	84	84	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 8	2016	375	23					2213	2215		10.1056/NEJMp1609578	http://dx.doi.org/10.1056/NEJMp1609578			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EE0ZQ	27959694	Bronze			2023-01-03	WOS:000389310000001
J	Machado, DE; Rodrigues-Baptista, KC; Alessandra-Perini, J; de Moura, RS; dos Santos, TA; Pereira, KG; da Silva, YM; Souza, PJC; Nasciutti, LE; Perini, JA				Machado, Daniel Escorsim; Rodrigues-Baptista, Karina Cristina; Alessandra-Perini, Jessica; de Moura, Roberto Soares; dos Santos, Thiago Alves; Pereira, Kariny Gomes; da Silva, Yasmin Marinho; Cunha Souza, Pergentino Jose; Nasciutti, Luiz Eurico; Perini, Jamila Alessandra			Euterpe oleracea Extract (Acai) Is a Promising Novel Pharmacological Therapeutic Treatment for Experimental Endometriosis	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; AMAZONIAN PALM BERRY; MART. ACAI; PHYTOCHEMICAL COMPOSITION; ECTOPIC ENDOMETRIUM; DOWN-REGULATION; IN-VITRO; ANGIOGENESIS; EXPRESSION; CYCLOOXYGENASE-2	This study investigated the therapeutic potential of Euterpe oleracea extract (acai) on the growth and survival of endometriotic lesions using an experimental model. Twenty female Sprague-Dawley rats were randomized into two groups after the implantation and establishment of autologous endometrium onto the peritoneum abdominal wall and treated with 200 mg/kg hydroalcoholic solution extract from acai stone or vehicle via gastric tube for 30 consecutive days. Body weight, lesion surface areas, histological and immunohistochemistry analyses of vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2) and F4-80 were performed. Levels of VEGF, VEGFR-2, MMP-9 and COX-2 mRNA were measured. Flow cytometry of F4-80 was performed, and ELISA immunoassays measured prostaglandin E2 (PGE2), VEGF and nitric oxide (NO) and concentrations. Macrophage cell line J774. G8 was treated with 10, 20, and 40 mu g/mL of acai for 24, 48 and 72 h, and cell viability was measured using 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Acai treatment significantly decreased the implant size, and histological examination indicated atrophy and regression. A reduction in immunostaining and mRNA expression of VEGF, MMP-9 and COX-2 was observed, and F4-80 was lower in the treated group than the control group. The treated group also exhibited lower concentrations of PGE2, VEGF and NO compared to the control group. Macrophages cells treated with 20 and 40 mu g/ml of Acai reduced cell viability in about 50% after 24, 48 and 72 h. Our results suggest that Acai effectively suppressed the establishment and growth of endometriotic lesions, and this agent is a promising novel pharmacological therapeutic treatment for endometriosis.	[Machado, Daniel Escorsim; Rodrigues-Baptista, Karina Cristina; Alessandra-Perini, Jessica; dos Santos, Thiago Alves; Pereira, Kariny Gomes; da Silva, Yasmin Marinho; Perini, Jamila Alessandra] Ctr Univ Estadual Zona Oeste, Unidade Farm, Rio De Janeiro, RJ, Brazil; [Rodrigues-Baptista, Karina Cristina; Alessandra-Perini, Jessica; Perini, Jamila Alessandra] Fundacao Osvaldo Cruz, Escola Nacl Saude Publ, Programa Posgrad Saude Publ & Meio Ambiente, Rio De Janeiro, RJ, Brazil; [de Moura, Roberto Soares] Univ Estado Rio De Janeiro, Dept Farmacol & Psicobiol, Rio De Janeiro, RJ, Brazil; [dos Santos, Thiago Alves] Univ Estadual Norte Fluminense, Programa Posgrad Biociencias & Biotecnol, Campos Dos Goytacazes, RJ, Brazil; [Cunha Souza, Pergentino Jose] Fed Univ Para, Dept Farm, Belem, PA, Brazil; [Nasciutti, Luiz Eurico] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, RJ, Brazil	Centro Universitario Estadual da Zona Oeste; Fundacao Oswaldo Cruz; Universidade do Estado do Rio de Janeiro; Universidade Estadual do Norte Fluminense; Universidade Federal do Para; Universidade Federal do Rio de Janeiro	Perini, JA (corresponding author), Ctr Univ Estadual Zona Oeste, Unidade Farm, Rio De Janeiro, RJ, Brazil.; Perini, JA (corresponding author), Fundacao Osvaldo Cruz, Escola Nacl Saude Publ, Programa Posgrad Saude Publ & Meio Ambiente, Rio De Janeiro, RJ, Brazil.	jamilaperini@yahoo.com.br		Machado, Daniel/0000-0002-2640-8579	Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Riode Janeiro - FAPERJ, Brazil [E-26/010.002619/2014, E-26/010.002644/2014]; Brazilian agency Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ, Brazil [E-26/010.002619/2014, E-26/010.002644/2014]	Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Riode Janeiro - FAPERJ, Brazil(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Brazilian agency Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ, Brazil	This work was funded by Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Riode Janeiro - FAPERJ, Brazil (E-26/010.002619/2014 and E-26/010.002644/2014).; This study was supported by the Brazilian agency Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ, Brazil (E-26/010.002619/2014 and E-26/010.002644/2014).	Becker CM, 2007, MICROVASC RES, V74, P121, DOI 10.1016/j.mvr.2007.04.008; Becker CM, 2011, AM J PATHOL, V178, P1782, DOI 10.1016/j.ajpath.2010.12.037; Castro MM, 2009, FREE RADICAL BIO MED, V46, P1298, DOI 10.1016/j.freeradbiomed.2009.02.011; Chishima F, 2002, AM J REPROD IMMUNOL, V48, P50, DOI 10.1034/j.1600-0897.2002.01101.x; da Costa CA, 2012, N-S ARCH PHARMACOL, V385, P1199, DOI 10.1007/s00210-012-0798-z; de Moura RS, 2012, PHYTOMEDICINE, V19, P262, DOI 10.1016/j.phymed.2011.11.004; de Moura RS, 2011, FOOD CHEM TOXICOL, V49, P855, DOI 10.1016/j.fct.2010.12.007; de Souza MO, 2012, NUTR RES, V32, P976, DOI 10.1016/j.nutres.2012.10.001; Del Pozo-Insfran D, 2006, J AGR FOOD CHEM, V54, P1222, DOI 10.1021/jf052132n; Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n; Di Carlo C, 2009, FERTIL STERIL, V91, P2315, DOI 10.1016/j.fertnstert.2008.03.079; Ergenoglu AM, 2013, REPROD SCI, V20, P1230, DOI 10.1177/1933719113483014; Fang XX, 2015, EUR J CANCER, V51, P2820, DOI 10.1016/j.ejca.2015.09.010; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Fragoso MF, 2013, FOOD CHEM TOXICOL, V58, P68, DOI 10.1016/j.fct.2013.04.011; GALLE PC, 1989, OBSTET GYN CLIN N AM, V16, P29; Ghosh D, 2009, MOL NUTR FOOD RES, V53, P322, DOI 10.1002/mnfr.200800182; Gilabert-Estelles J, 2007, HUM REPROD, V22, P2120, DOI 10.1093/humrep/dem149; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Guo SW, 2007, GYNECOL OBSTET INVES, V64, P24, DOI 10.1159/000098413; Heinrich M, 2011, PHYTOCHEM LETT, V4, P10, DOI 10.1016/j.phytol.2010.11.005; Jackson LW, 2005, HUM REPROD, V20, P2014, DOI 10.1093/humrep/dei001; Jana S, 2012, BIOCHEM PHARMACOL, V83, P797, DOI 10.1016/j.bcp.2011.12.030; Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517; Kang J, 2010, FOOD CHEM, V122, P610, DOI 10.1016/j.foodchem.2010.03.020; Kong Sai, 2014, Evid Based Complement Alternat Med, V2014, P146383, DOI 10.1155/2014/146383; Kumar S, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.017; Laschke MW, 2008, HUM REPROD, V23, P2308, DOI 10.1093/humrep/den245; Laschke MW, 2007, FERTIL STERIL, V87, P163, DOI 10.1016/j.fertnstert.2006.05.068; Laschke MW, 2007, HUM REPROD UPDATE, V13, P331, DOI 10.1093/humupd/dmm006; Lichtenthaler R, 2005, INT J FOOD SCI NUTR, V56, P53, DOI 10.1080/09637480500082082; Lin YJ, 2006, ENDOCRINOLOGY, V147, P1278, DOI 10.1210/en.2005-0790; Machado DE, 2008, FERTIL STERIL, V90, P148, DOI 10.1016/j.fertnstert.2007.05.076; Machado DE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/751460; Machado DE, 2014, HISTOL HISTOPATHOL, V29, P903, DOI 10.14670/HH-29.903; Machado DE, 2010, FERTIL STERIL, V93, P2674, DOI 10.1016/j.fertnstert.2009.11.037; Marques ES, 2016, FOOD CHEM TOXICOL, V93, P13, DOI 10.1016/j.fct.2016.04.018; Matsuzaki S, 2004, FERTIL STERIL, V82, P1309, DOI 10.1016/j.fertnstert.2004.03.059; McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45; Melin A, 2006, HUM REPROD, V21, P1237, DOI 10.1093/humrep/dei462; Nap AW, 2004, J CLIN ENDOCR METAB, V89, P1089, DOI 10.1210/jc.2003-031406; Olivares C, 2008, HUM REPROD, V23, P2701, DOI 10.1093/humrep/den315; Ota H, 2001, HUM REPROD, V16, P561, DOI 10.1093/humrep/16.3.561; Pacheco-Palencia LA, 2009, FOOD CHEM, V115, P1199, DOI 10.1016/j.foodchem.2009.01.034; Perini JA, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0745-x; Perini JA, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-117; Podgaec S, 2007, HUM REPROD, V22, P1373, DOI 10.1093/humrep/del516; Poulose SM, 2012, J AGR FOOD CHEM, V60, P1084, DOI 10.1021/jf203989k; Ribeiro JC, 2010, MUTAT RES-GEN TOX EN, V695, P22, DOI 10.1016/j.mrgentox.2009.10.009; Rocha APM, 2007, VASC PHARMACOL, V46, P97, DOI 10.1016/j.vph.2006.08.411; Rodrigues RB, 2006, J AGR FOOD CHEM, V54, P4162, DOI 10.1021/jf058169p; Ruhland B, 2011, Minerva Ginecol, V63, P247; Schauss AG, 2006, J AGR FOOD CHEM, V54, P8604, DOI 10.1021/jf0609779; Schauss AG, 2006, J AGR FOOD CHEM, V54, P8598, DOI 10.1021/jf060976g; Silva DF, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-175; Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073; Stoner GD, 2009, CANCER PREV RES, V2, P187, DOI 10.1158/1940-6207.CAPR-08-0226; Sudo RT, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0724-2; Swarnakar S, 2009, INDIAN J BIOCHEM BIO, V46, P59; Taylor RN, 2004, GYNECOL OBSTET INVES, V57, P54; Tekin YB, 2015, EUR J OBSTET GYN R B, V184, P1, DOI 10.1016/j.ejogrb.2014.10.041; Tosti C, 2015, REPROD SCI, V22, P1053, DOI 10.1177/1933719115592713; VERNON MW, 1985, FERTIL STERIL, V44, P684; Wang CC, 2013, ANGIOGENESIS, V16, P59, DOI 10.1007/s10456-012-9299-4; Wu Meng-Hsing, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S146239940700021X; Xu H, 2009, HUM REPROD, V24, P608, DOI 10.1093/humrep/den417; Xu H, 2011, FERTIL STERIL, V96, P1021, DOI 10.1016/j.fertnstert.2011.07.008; Zanini S, 2015, CRIT REV FOOD SCI, V55, P1870, DOI 10.1080/10408398.2012.732126; Zhang Y, 2011, INT J MOL MED, V27, P87, DOI 10.3892/ijmm.2010.552	70	29	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2016	11	11							e0166059	10.1371/journal.pone.0166059	http://dx.doi.org/10.1371/journal.pone.0166059			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC1ZU	27851787	gold, Green Published, Green Submitted			2023-01-03	WOS:000387909300033
J	Chenausky, K; Norton, A; Tager-Flusberg, H; Schlaug, G				Chenausky, Karen; Norton, Andrea; Tager-Flusberg, Helen; Schlaug, Gottfried			Auditory-Motor Mapping Training: Comparing the Effects of a Novel Speech Treatment to a Control Treatment for Minimally Verbal Children with Autism	PLOS ONE			English	Article							LANGUAGE-ASSOCIATION CORTEX; MELODIC INTONATION THERAPY; PHONOLOGICAL DISORDERS; NONVERBAL CHILDREN; ARCUATE FASCICULUS; ORAL-MOTOR; SPECTRUM; ASYMMETRY; REPRESENTATION; SKILLS	This study compared Auditory-Motor Mapping Training (AMMT), an intonation-based treatment for facilitating spoken language in minimally verbal children with autism spectrum disorder (ASD), to a matched control treatment, Speech Repetition Therapy (SRT). 23 minimally verbal children with ASD (20 male, mean age 6; 5) received at least 25 sessions of AMMT. Seven (all male) were matched on age and verbal ability to seven participants (five male) who received SRT. Outcome measures were Percent Syllables Approximated, Percent Consonants Correct (of 86), and Percent Vowels Correct (of 61) produced on two sets of 15 bisyllabic stimuli. All subjects were assessed on these measures several times at baseline and after 10, 15, 20, and 25 sessions. The post-25 session assessment timepoint, common to all participants, was compared to Best Baseline performance. Overall, after 25 sessions, AMMT participants increased by 19.4% Syllables Approximated, 13.8% Consonants Correct, and19.1% Vowels Correct, compared to Best Baseline. In the matched AMMT-SRT group, after 25 sessions, AMMT participants produced 29.0% more Syllables Approximated (SRT 3.6%); 17.9% more Consonants Correct (SRT 0.5); and 17.6% more Vowels Correct (SRT 0.8%). Chi-square tests showed that significantly more AMMT than SRT participants in both the overall and matched groups improved significantly in number of Syllables Approximated per stimulus and number of Consonants Correct per stimulus. Pretreatment ability to imitate phonemes, but not chronological age or baseline performance on outcome measures, was significantly correlated with amount of improvement after 25 sessions. Intonation-based therapy may offer a promising new interventional approach for teaching spoken language to minimally verbal children with ASD.	[Chenausky, Karen; Norton, Andrea; Schlaug, Gottfried] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Mus & Neuroimaging Lab, Boston, MA USA; [Chenausky, Karen; Tager-Flusberg, Helen] Boston Univ, Ctr Autism Res Excellence, Dept Psychol & Brain Sci, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Schlaug, G (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Mus & Neuroimaging Lab, Boston, MA USA.	gschlaug@bidmc.harvard.edu			Nancy Lurie Marks Family Foundation; Autism Speaks; NIH [P50 DC 13027]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010290, P50DC013027] Funding Source: NIH RePORTER	Nancy Lurie Marks Family Foundation; Autism Speaks; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Funding for this study was provided by the Nancy Lurie Marks Family Foundation, Autism Speaks, and NIH P50 DC 13027. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Binkofski F, 2004, BRAIN LANG, V89, P362, DOI 10.1016/S0093-934X(03)00358-4; Caruso A, 1999, CLIN MANAGEMENT MOTO, P1; Catani M, 2016, BRAIN, V139, P616, DOI 10.1093/brain/awv351; DAVIS BL, 1995, J SPEECH HEAR RES, V38, P1199, DOI 10.1044/jshr.3806.1199; De Fosse L, 2004, ANN NEUROL, V56, P757, DOI 10.1002/ana.20275; Dominick KC, 2007, RES DEV DISABIL, V28, P145, DOI 10.1016/j.ridd.2006.02.003; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; Fenson L., 2007, MACARTHUR BATES COMM; Fletcher PT, 2010, NEUROIMAGE, V51, P1117, DOI 10.1016/j.neuroimage.2010.01.083; Floris DL, 2016, HUM BRAIN MAPP, V37, P230, DOI 10.1002/hbm.23023; Fritz J, 2013, STRUNGMANN FORUM REP, P417; Gentilucci M, 2000, EXP BRAIN RES, V133, P468, DOI 10.1007/s002210000431; Gernsbacher MA, 2008, J CHILD PSYCHOL PSYC, V49, P43, DOI 10.1111/j.1469-7610.2007.01820.x; HAIRSTON MJP, 1990, J MUSIC THER, V27, P137; Heaton P, 2008, BRIT J DEV PSYCHOL, V26, P171, DOI 10.1348/026151007X206776; Heaton P, 2007, J AUTISM DEV DISORD, V37, P1355, DOI 10.1007/s10803-006-0283-y; Herbert MR, 2002, ANN NEUROL, V52, P588, DOI 10.1002/ana.10349; Hoelzley P., 1993, CANADIAN J MUSIC THE, V1, P54; Howlin P, 2000, J CHILD PSYCHOL PSYC, V41, P561, DOI 10.1017/S0021963099005806; Iverson JM, 2007, J AUTISM DEV DISORD, V37, P158, DOI 10.1007/s10803-006-0339-z; Iverson JM, 2004, CHILD DEV, V75, P1053, DOI 10.1111/j.1467-8624.2004.00725.x; Kasari C, 2013, AUTISM RES, V6, P479, DOI 10.1002/aur.1334; Kaufman N., 1995, KAUFMAN SPEECH PRAXI; Kleinhans NM, 2008, BRAIN RES, V1221, P115, DOI 10.1016/j.brainres.2008.04.080; Knaus TA, 2010, BRAIN LANG, V112, P113, DOI 10.1016/j.bandl.2009.11.005; KOEGEL RL, 1987, J AUTISM DEV DISORD, V17, P187, DOI 10.1007/BF01495055; Koegel RL, 1999, SCHOOL PSYCHOL REV, V28, P576; Lahav A, 2007, J NEUROSCI, V27, P308, DOI 10.1523/JNEUROSCI.4822-06.2007; Leonard HC, 2015, RES AUTISM SPECT DIS, V13-14, P15, DOI 10.1016/j.rasd.2014.12.012; Lo YC, 2011, PSYCHIAT RES-NEUROIM, V192, P60, DOI 10.1016/j.pscychresns.2010.09.008; Lord C., 1999, AUTISM DIAGNOSTIC OB, DOI [10.1037/t17256-000, DOI 10.1037/T17256-000]; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; Marchina S, 2011, STROKE, V42, P2251, DOI 10.1161/STROKEAHA.110.606103; Matson JL, 2009, J DEV PHYS DISABIL, V21, P253, DOI 10.1007/s10882-009-9140-1; Meister IG, 2003, NEUROPSYCHOLOGIA, V41, P401, DOI 10.1016/S0028-3932(02)00179-3; MILLER SB, 1979, J CLIN PSYCHIAT, V40, P201; Mullen Mullen E., 1995, MULLEN SCALES EARLY; Newmeyer AJ, 2007, CLIN PEDIATR, V46, P604, DOI 10.1177/0009922807299545; Norton A, 2009, ANN NY ACAD SCI, V1169, P431, DOI 10.1111/j.1749-6632.2009.04859.x; Ozdemir E, 2006, NEUROIMAGE, V33, P628, DOI 10.1016/j.neuroimage.2006.07.013; Paldino MJ, 2016, AM J NEURORADIOL, V37, P169, DOI 10.3174/ajnr.A4461; Paul R, 2008, CHILD ADOL PSYCH CL, V17, P835, DOI 10.1016/j.chc.2008.06.011; Paul R, 2013, J AUTISM DEV DISORD, V43, P418, DOI 10.1007/s10803-012-1583-z; Prizant BM, 2000, COMM LANG INTERVEN, V9, P193; Rauschecker JP, 2009, NAT NEUROSCI, V12, P718, DOI 10.1038/nn.2331; Rauschecker JP, 2000, P NATL ACAD SCI USA, V97, P11800, DOI 10.1073/pnas.97.22.11800; Rogers SJ, 2006, J AUTISM DEV DISORD, V36, P1007, DOI 10.1007/s10803-006-0142-x; Ross DE, 2003, RES DEV DISABIL, V24, P58, DOI 10.1016/S0891-4222(02)00167-1; Rvachew S., 2012, DEV PHONOLOGICAL DIS; Sahin NT, 2009, SCIENCE, V326, P445, DOI 10.1126/science.1174481; Saporta ASD, 2011, PEDIATR NEUROL, V44, P270, DOI 10.1016/j.pediatrneurol.2010.11.006; Schopler E., 1988, CHILDHOOD AUTISM RAT; SHRIBERG LD, 1982, J SPEECH HEAR DISORD, V47, P256, DOI 10.1044/jshd.4703.256; SHRIBERG LD, 1993, J SPEECH HEAR RES, V36, P105, DOI 10.1044/jshr.3601.105; SHRIBERG LD, 1994, J SPEECH HEAR RES, V37, P1127, DOI 10.1044/jshr.3705.1127; Square P, 1999, CLIN MANAGEMENT MOTO, P149; Tager-Flusberg H., 2005, HDB AUTISM PERVASIVE, P335, DOI 10.1002/9780470939345.CH12; Tager-Flusberg H, 2013, AUTISM RES, V6, P468, DOI 10.1002/aur.1329; Tager-Flusberg H, 2011, NEUROPSYCHOLOGIST HB, P127; Tokimura H, 1996, ANN NEUROL, V40, P628, DOI 10.1002/ana.410400413; Trevarthen C, 1996, CHILDREN WITH AUTISM; Uozumi T, 2004, NEUROLOGY, V62, P757, DOI 10.1212/01.WNL.0000113731.75479.25; VENTER A, 1992, J CHILD PSYCHOL PSYC, V33, P489, DOI 10.1111/j.1469-7610.1992.tb00887.x; Wan CY, 2012, ANN NY ACAD SCI, V1252, P332, DOI 10.1111/j.1749-6632.2012.06446.x; Wan CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025505; Wan CY, 2010, FUTUR NEUROL, V5, P797, DOI 10.2217/FNL.10.55; Wetherby A. M., 2002, COMMUNICATION SYMBOL; Wing L., 1985, AUTISTIC CHILDREN; WOLF M, 1964, BEHAV RES THER, V1, P305; Yeatman J, 2012, J OF COGNITIVE, V23, P3304; Yoder P, 2006, J CONSULT CLIN PSYCH, V74, P426, DOI 10.1037/0022-006X.74.3.426	72	29	29	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2016	11	11							e0164930	10.1371/journal.pone.0164930	http://dx.doi.org/10.1371/journal.pone.0164930			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EB9OG	27829034	Green Published, gold, Green Submitted			2023-01-03	WOS:000387724300022
J	Embrey, M; Vialle-Valentin, C; Dillip, A; Kihiyo, B; Mbwasi, R; Semali, IA; Chalker, JC; Liana, J; Lieber, R; Johnson, K; Rutta, E; Kimatta, S; Shekalaghe, E; Valimba, R; Ross-Degnan, D				Embrey, Martha; Vialle-Valentin, Catherine; Dillip, Angel; Kihiyo, Bernard; Mbwasi, Romuald; Semali, Innocent A.; Chalker, John C.; Liana, Jafary; Lieber, Rachel; Johnson, Keith; Rutta, Edmund; Kimatta, Suleiman; Shekalaghe, Elizabeth; Valimba, Richard; Ross-Degnan, Dennis			Understanding the Role of Accredited Drug Dispensing Outlets in Tanzania's Health System	PLOS ONE			English	Article							MALARIA TREATMENT; COMMUNITY; KNOWLEDGE; ACCESS; FEVER; CARE	Introduction People in many low-income countries access medicines from retail drug shops. In Tanzania, a public-private partnership launched in 2003 used an accreditation approach to improve access to quality medicines and pharmaceutical services in underserved areas. The government scaled up the accredited drug dispensing outlet (ADDO) program nationally, with over 9,000 shops now accredited. This study assessed the relationships between community members and their sources of health care and medicines, particularly antimicrobials, with a specific focus on the role ADDOs play in the health care system. Methods Using mixed methods, we collected data in four regions. We surveyed 1,185 households and audited 96 ADDOs and 84 public/nongovernmental health facilities using a list of 17 tracer drugs. To determine practices in health facilities, we interviewed 1,365 exiting patients. To assess dispensing practices, mystery shoppers visited 306 ADDOs presenting one of three scenarios (102 each) about a child's respiratory symptoms. Results and Discussion Of 614 household members with a recent acute illness, 73% sought outside care-30% at a public facility and 31% at an ADDO. However, people bought medicines more often at ADDOs no matter who recommended the treatment; of the 581 medicines that people had received, 49% came from an ADDO. Although health facilities and ADDOs had similar availability of antimicrobials, ADDOs had more pediatric formulations available (p<0.001). The common perception was that drugs from ADDOs are more expensive, but the difference in the median cost to treat pneumonia was relatively minimal (US$0.26 in a public facility and US$0.30 in an ADDO). Over 20% of households said they had someone with a chronic condition, with 93% taking medication, but ADDOs are allowed to sell very few chronic care-related medicines. ADDO dispensers are trained to refer complicated cases to a health facility, and notably, 99% of mystery shoppers presenting a pneumonia scenario received an antimicrobial (54%), a referral (90%), or both (45%), which are recommended practices for managing pediatric pneumonia. However, one-third of the dispensers needlessly sold antibiotics for cold symptoms, and 85% sold an antibiotic on request. In addition, the pneumonia scenario elicited more advice on handling the illness than the cold symptoms scenario (61% vs. 15%; p<0.0001), but overall, only 44% of the dispensers asked any of the shoppers about danger signs potentially associated with pneumonia in a child. Conclusion ADDOs are the principal source of medicines in Tanzania and an important part of a multifaceted health care system. Poor prescribing in health facilities, poor dispensing at ADDOs, and inappropriate patient demand continue to contribute to inappropriate medicines use. Therefore, while accreditation has attempted to address the quality of pharmaceutical services in private sector drug outlets, efforts to improve access to and use of medicines in Tanzania need to target ADDOs, public/nongovernmental health facilities, and the public to be effective.	[Embrey, Martha; Chalker, John C.; Lieber, Rachel; Johnson, Keith; Rutta, Edmund] Management Sci Hlth, Pharmaceut & Hlth Technol Grp, Arlington, VA 22203 USA; [Vialle-Valentin, Catherine; Ross-Degnan, Dennis] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Drug Policy Res Grp, Boston, MA USA; [Dillip, Angel] Ifakara Hlth Inst, Dar Es Salaam, Tanzania; [Kihiyo, Bernard] Tanzania Consumer Advocacy Soc, Dar Es Salaam, Tanzania; [Mbwasi, Romuald] St Johns Univ Dodoma, Apotheker Consultancy Ltd T, Dodoma, Tanzania; [Semali, Innocent A.] Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth, Dar Es Salaam, Tanzania; [Liana, Jafary; Kimatta, Suleiman; Valimba, Richard] Management Sci Hlth, Pharmaceut & Hlth Technol Grp, Dar Es Salaam, Tanzania; [Shekalaghe, Elizabeth] Pharm Council Tanzania, Dar Es Salaam, Tanzania	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Ifakara Health Institute; Muhimbili University of Health & Allied Sciences	Embrey, M (corresponding author), Management Sci Hlth, Pharmaceut & Hlth Technol Grp, Arlington, VA 22203 USA.	membrey@msh.org		Embrey, Martha/0000-0002-2556-6487	Bill & Melinda Gates Foundation [OPP1017439]	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This study was supported by the Bill & Melinda Gates Foundation, www.gatesfoundation.org/, under grant OPP1017439 to KJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Romuald Mbwasi is employed by Apotheker Consultancy (T) Limited. Apotheker Consultancy (T) Limited provided support in the form of salary for author RM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Alba S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-163; [Anonymous], 2013, 6610 WHA; Awor P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115440; Battersby A, 2003, IMPROVING SUPPLY DIS; Beyeler N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117165; Bigdeli M, 2014, MED HLTH SYSTEMS ADV, P74; Center for Pharmaceutical Management, 2001, ACC ESS MED TANZ 200; Chalker JC, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0075-2; Chipwaza B, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-252; Chipwaza B, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002896; D'Acremont V, 2014, NEW ENGL J MED, V370, P809, DOI 10.1056/NEJMoa1214482; Dillip A, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0073-4; East Africa Drug Seller Initiative, 2011, EV REP; Geldsetzer P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093427; Goodman C, 2007, AM J TROP MED HYG, V77, P203, DOI 10.4269/ajtmh.2007.77.203; Goodman C, 2007, HEALTH POLICY PLANN, V22, P393, DOI 10.1093/heapol/czm033; Hertz JT, 2013, TROP MED INT HEALTH, V18, P1406, DOI 10.1111/tmi.12191; Lagomarsino H, 2009, PUBLIC STEWARDSHIP P; Madden JM, 1997, SOC SCI MED, V45, P1465, DOI 10.1016/S0277-9536(97)00076-2; Management Sciences for Health, 2008, ACCR DRUG DISP OUTL; Metta E, 2014, GLOBAL HEALTH ACTION, V7, P148, DOI 10.3402/gha.v7.23439; Mikkelsen-Lopez I, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-444; Ministry of Health and Social Welfare, 2013, STANDARD TREATMENT G; Ministry of Health and Social Welfare Reproductive and Child Health Section, 2010, NAT FAM PLANN COST I; National Malaria Control Program and Clinton Health Access Initiative. mRDTs, 2014, ADDO PROGR STAK M AR; Rutta D, 2009, PROG COMM HLTH PARTN, p[3, 145], DOI [10.1353/cpr.0.0063PMID: 20208262, DOI 10.1353/CPR.0.0063]; Rutta E, 2014, INT J TUBERC LUNG D, V18, P1108, DOI 10.5588/ijtld.14.0020; Rutta E, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-22; Shah NM, 2011, HEALTH POLICY PLANN, V26, P275, DOI 10.1093/heapol/czq074; The United Republic of Tanzania, 2008, HLTH SECT STRAT PLAN; Tumwikirize W A, 2004, East Afr Med J, VSuppl, pS33; WHO, 2013, WORLD MALARIA REPORT 2013, P1; World Health Organization, GLOB HLTH OBS DAT RE; World Health Organization, 2014, NONC DIS COUNTR PROF; World Health Organization Department of Child Adolescent Health World Health Organization and UNICEF, 2005, HDB IMCI INT MAN CHI	35	24	25	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2016	11	11							e0164332	10.1371/journal.pone.0164332	http://dx.doi.org/10.1371/journal.pone.0164332			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB8BE	27824876	Green Published, Green Submitted, gold			2023-01-03	WOS:000387615200005
J	van Lieshout, R; Pisters, MF; Vanwanseele, B; de Bie, RA; Wouters, EJ; Stukstette, MJ				van Lieshout, Remko; Pisters, Martijn F.; Vanwanseele, Benedicte; de Bie, Rob A.; Wouters, Eveline J.; Stukstette, Mirelle J.			Biofeedback in Partial Weight Bearing: Usability of Two Different Devices from a Patient's and Physical Therapist's Perspective	PLOS ONE			English	Article							LOWER-EXTREMITY; TECHNOLOGY; VALIDITY; FEEDBACK; USERS	Background Partial weight bearing is frequently instructed by physical therapists in patients after lower-limb trauma or surgery. The use of biofeedback devices seems promising to improve the patient's compliance with weight-bearing instructions. SmartStep and OpenGo-Science are biofeedback devices that provide real-time feedback. For a successful implementation, usability of the devices is a critical aspect and should be tested from a user's perspective. Aim To describe the usability from the physical therapists' and a patients' perspective of Smart-step and OpenGo-Science to provide feedback on partial weight bearing during supervised rehabilitation of patients after lower-limb trauma or surgery. Methods In a convergent mixed-methods design, qualitative and quantitative data were collected. Usability was subdivided into user performance, satisfaction and acceptability. Patients prescribed with partial weight bearing and their physical therapists were asked to use SmartStep and OpenGo-Science during supervised rehabilitation. Usability was qualitatively tested by a think-aloud method and a semi-structured interview and quantitatively tested by the System-Usability-Scale (SUS) and closed questions. For the qualitative data thematic content analyses were used. Results Nine pairs of physical therapists and their patients participated. The mean SUS scores for patients and physical therapists were for SmartStep 70 and 53, and for OpenGo-Science 79 and 81, respectively. Scores were interpreted with the Curved Grading Scale. The qualitative data showed that there were mixed views and perceptions from patients and physical therapists on satisfaction and acceptability. Conclusion This study gives insight in the usability of two biofeedback devices from the patient's and physical therapist's perspective. The overall usability from both perspectives seemed to be acceptable for OpenGo-Science. For SmartStep, overall usability seemed only acceptable from the patient's perspective.	[van Lieshout, Remko; Pisters, Martijn F.; Stukstette, Mirelle J.] Julius Hlth Care Ctr, Ctr Phys Therapy Res & Innovat Primary Care, Utrecht, Netherlands; [van Lieshout, Remko; Pisters, Martijn F.; Stukstette, Mirelle J.] Univ Med Ctr Utrecht, Phys Therapy Res, Clin Hlth Sci, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [van Lieshout, Remko; Pisters, Martijn F.; Stukstette, Mirelle J.] Univ Med Ctr Utrecht, Dept Rehabil Nursing Sci & Sport, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [de Bie, Rob A.; Stukstette, Mirelle J.] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands; [Pisters, Martijn F.; Vanwanseele, Benedicte; Wouters, Eveline J.] Fontys Univ Appl Sci, Dept Hlth Innovat & Technol, Eindhoven, Netherlands; [Vanwanseele, Benedicte] Katholieke Univ Leuven, Dept Kinesiol, Human Movement Biomech Res Grp, Leuven, Belgium	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Maastricht University; KU Leuven	Stukstette, MJ (corresponding author), Julius Hlth Care Ctr, Ctr Phys Therapy Res & Innovat Primary Care, Utrecht, Netherlands.; Stukstette, MJ (corresponding author), Univ Med Ctr Utrecht, Phys Therapy Res, Clin Hlth Sci, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.; Stukstette, MJ (corresponding author), Univ Med Ctr Utrecht, Dept Rehabil Nursing Sci & Sport, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.; Stukstette, MJ (corresponding author), Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands.	m.j.p.m.stukstette@umcutrecht.nl	Vanwanseele, Benedicte/AAQ-1706-2021	Vanwanseele, Benedicte/0000-0002-6158-9483; Pisters, Martijn F./0000-0002-2875-1709	Scientific College Physical Therapy (WCF) of the Royal Dutch Society for Physical Therapy (KNGF)	Scientific College Physical Therapy (WCF) of the Royal Dutch Society for Physical Therapy (KNGF)	The Scientific College Physical Therapy (WCF) of the Royal Dutch Society for Physical Therapy (KNGF) funded the study (https://www.fysionet-evidencebased.nl/index.php/wcf-projecten). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Maskari A, 2010, J AM SOC INF SCI TEC, V61, P859, DOI 10.1002/asi.21300; [Anonymous], 1998, 924111 ISO; Arthanat S, 2007, DISABIL REHABIL-ASSI, V2, P235, DOI 10.1080/17483100701343665; Bangor A, 2008, INT J HUM-COMPUT INT, V24, P574, DOI 10.1080/10447310802205776; Boland MR, 2014, J BIOMED INFORM, V52, P141, DOI 10.1016/j.jbi.2013.12.004; Borsci S, 2015, INT J HUM-COMPUT INT, V31, P484, DOI 10.1080/10447318.2015.1064648; Borsci S, 2014, EXPERT REV MED DEVIC, V11, P513, DOI 10.1586/17434440.2014.940312; Borsci S, 2013, ACM T COMPUT-HUM INT, V20, DOI 10.1145/2506210; Borsci S, 2009, COGN PROCESS, V10, P193, DOI 10.1007/s10339-009-0268-9; Brooke J., 1996, USABILITY EVALUATION, P189, DOI 10.1201/9781498710411; Dabke HV, 2004, CLIN ORTHOP RELAT R, P282, DOI 10.1097/01.blo.0000127116.13377.65; Daniels Jeremy, 2007, J Clin Monit Comput, V21, P323, DOI 10.1007/s10877-007-9091-y; De Bleser L, 2011, CIN-COMPUT INFORM NU, V29, P489, DOI 10.1097/NCN.0b013e31821a1555; De Bleser L, 2010, SENSORS-BASEL, V10, P1535, DOI 10.3390/s100301535; Denhaerynck K, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-5; Distasio Anthony J. Ii, 1994, Contemporary Orthopaedics, V29, P273; Fetters MD, 2013, HEALTH SERV RES, V48, P2134, DOI 10.1111/1475-6773.12117; Fu MC, 2014, ORTHOPEDICS, V37, pE993, DOI 10.3928/01477447-20141023-56; Gray F B, 1998, Am J Orthop (Belle Mead NJ), V27, P558; Hensel BK, 2006, J AM MED INFORM ASSN, V13, P428, DOI 10.1197/jamia.M2026; Hermsen S, 2016, COMPUT HUM BEHAV, V57, P61, DOI 10.1016/j.chb.2015.12.023; Hurkmans HL, 2007, ARCH PHYS MED REHAB, V88, P200, DOI 10.1016/j.apmr.2006.11.005; Hurkmans HL, 2012, ARCH PHYS MED REHAB, V93, P565, DOI 10.1016/j.apmr.2011.11.019; Hurkmans HLP, 2003, CLIN BIOMECH, V18, P576, DOI 10.1016/S0268-0033(03)00116-5; Hustedt Joshua W., 2012, Yale Journal of Biology and Medicine, V85, P119; Hustedt JW, 2012, ORTHOPEDICS, V35, pE31, DOI 10.3928/01477447-20111122-14; Isakov E, 2007, Eura Medicophys, V43, P21; Lewis JR, 2014, INT J HUM-COMPUT INT, V30, P663, DOI 10.1080/10447318.2014.930311; Lewis JR, 2009, LECT NOTES COMPUT SC, V5619, P94, DOI 10.1007/978-3-642-02806-9_12; LEWIS JR, 1994, HUM FACTORS, V36, P368, DOI 10.1177/001872089403600215; Lyles CR, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0534-9; Mavcic B, 2012, INT ORTHOP, V36, P689, DOI 10.1007/s00264-012-1487-8; MEADOWS TH, 1990, J BONE JOINT SURG AM, V72A, P1074, DOI 10.2106/00004623-199072070-00018; NIELSEN J, 1993, HUMAN FACTORS IN COMPUTING SYSTEMS, P206; Peek STM, 2014, INT J MED INFORM, V83, P235, DOI 10.1016/j.ijmedinf.2014.01.004; Rubin Guy, 2010, Orthopedics, V33, P729, DOI 10.3928/01477447-20100826-02; Ruiz FK, 2014, ORTHOPEDICS, V37, pE552, DOI 10.3928/01477447-20140528-55; Sauro J, 2012, QUANTIFYING THE USER EXPERIENCE: PRACTICAL STATISTICS FOR USER RESEARCH, P1, DOI 10.1016/B978-0-12-384968-7.00001-1; Shah SGS, 2009, INT J TECHNOL ASSESS, V25, P514, DOI 10.1017/S0266462309990328; Sigrist R, 2013, PSYCHON B REV, V20, P21, DOI 10.3758/s13423-012-0333-8; Tullis T, 2013, MEASURING USER EXPER, V2nd; Turner CW., 2006, INT ENCY ERGONOMICS, V3, P3084, DOI DOI 10.1201/9780849375477.CH597; van Hoof J, 2011, INT J AMBIENT COMPUT, V3, P25, DOI 10.4018/jaci.2011100103; Van Hoof J, 2012, GERONTECHNOLOGY, V11, P134; Van Lieshout R, 2016, J ORTHOP SPORT PHYS, V46, P993, DOI 10.2519/jospt.2016.6625; Vasarhelyi A, 2006, GAIT POSTURE, V23, P99, DOI 10.1016/j.gaitpost.2004.12.005; VIRZI RA, 1992, HUM FACTORS, V34, P457, DOI 10.1177/001872089203400407; Vredenburg K., 2002, Conference Proceedings. Conference on Human Factors in Computing Systems. CHI 2002, P471, DOI 10.1145/503376.503460; Wessels RD, 2003, DISABIL REHABIL, V25, P267, DOI 10.1080/0963828021000031197; Winstein CJ, 1996, PHYS THER, V76, P985, DOI 10.1093/ptj/76.9.985; Yu S, 2014, ORTHOPEDICS, V37, pE10, DOI 10.3928/01477447-20131219-10	51	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2016	11	10							e0165199	10.1371/journal.pone.0165199	http://dx.doi.org/10.1371/journal.pone.0165199			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA6BX	27798674	Green Published, Green Submitted, gold			2023-01-03	WOS:000386711100022
J	Urano, H; Iwatsuki, K; Yamamoto, M; Ohnisi, T; Kurimoto, S; Endo, N; Hirata, H				Urano, Hideki; Iwatsuki, Katsuyuki; Yamamoto, Michiro; Ohnisi, Tetsuro; Kurimoto, Shigeru; Endo, Nobuyuki; Hirata, Hitoshi			Novel Anti-Adhesive CMC-PE Hydrogel Significantly Enhanced Morphological and Physiological Recovery after Surgical Decompression in an Animal Model of Entrapment Neuropathy	PLOS ONE			English	Article							CHRONIC NERVE COMPRESSION; CARPAL-TUNNEL-SYNDROME; SCIATIC-NERVE; RAT MODEL; NEUROLYSIS; ADHESION; SCAR	We developed a novel hydrogel derived from sodium carboxymethylcellulose (CMC) in which phosphatidylethanolamine (PE) was introduced into the carboxyl groups of CMC to prevent perineural adhesions. This hydrogel has previously shown excellent anti-adhesive effects even after aggressive internal neurolysis in a rat model. Here, we confirmed the effects of the hydrogel on morphological and physiological recovery after nerve decompression. We prepared a rat model of chronic sciatic nerve compression using silicone tubing. Morphological and physiological recovery was confirmed at one, two, and three months after nerve decompression by assessing motor conduction velocity (MCV), the wet weight of the tibialis anterior muscle and morphometric evaluations of nerves. Electrophysiology showed significantly quicker recovery in the CMC-PE group than in the control group (24.0 +/- 3.1 vs. 21.0 +/- 2.1 m/s (p < 0.05) at one months and MCV continued to be significantly faster thereafter. Wet muscle weight at one month significantly differed between the CMC-PE (BW) and control groups (0.148 +/- 0.020 vs. 0.108 +/- 0.019% BW). The mean wet muscle weight was constantly higher in the CMC-PE group than in the control group throughout the experimental period. The axon area at one month was twice as large in the CMC-PE group compared with the control group (24.1 +/- 17.3 vs. 12.3 +/- 9 mu m(2)) due to the higher ratio of axons with a larger diameter. Although the trend continued throughout the experimental period, the difference decreased after two months and was not statistically significant at three months. Although anti-adhesives can reduce adhesion after nerve injury, their effects on morphological and physiological recovery after surgical decompression of chronic entrapment neuropathy have not been investigated in detail. The present study showed that the new anti-adhesive CMC-PE gel can accelerate morphological and physiological recovery of nerves after decompression surgery.	[Urano, Hideki] Yokkaichi Municipal Hosp, Dept Orthopaed Surg, 2-2-37 Shibata Cho, Yokaichi, Mie 5108567, Japan; [Urano, Hideki; Iwatsuki, Katsuyuki; Yamamoto, Michiro; Ohnisi, Tetsuro; Kurimoto, Shigeru; Hirata, Hitoshi] Nagoya Univ, Grad Sch Med, Dept Hand Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan; [Endo, Nobuyuki] Teijin Ltd, Healthcare Business Dev, 4-3-2 Asahigaoka Hino, Tokyo 1918512, Japan	Nagoya University; Teijin Limited	Urano, H (corresponding author), Yokkaichi Municipal Hosp, Dept Orthopaed Surg, 2-2-37 Shibata Cho, Yokaichi, Mie 5108567, Japan.; Urano, H (corresponding author), Nagoya Univ, Grad Sch Med, Dept Hand Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	jingarimituki@yahoo.co.jp			Teijin Limited; JSPS KAKENHI Grant [25861309]	Teijin Limited; JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We received financial and/or technical supported from Teijin Limited and a grant in aid for Japan society for the promotion of science KAKENHI Grant Number 25861309. The funder provided support in the form of salaries for authors [N.E.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; This work was supported by JSPS KAKENHI Grant Number 25861309.	ABITBOL JJ, 1994, SPINE, V19, P1809, DOI 10.1097/00007632-199408150-00004; AGUAYO A, 1971, ARCH NEUROL-CHICAGO, V24, P358, DOI 10.1001/archneur.1971.00480340090010; Dam-Hieu Phong, 2005, Neurosurgery, V56, P425, DOI 10.1227/01.NEU.0000156845.41626.E9; Dumanian GA, 1999, J HAND SURG-AM, V24A, P30; Gupta R, 2004, EXP NEUROL, V187, P500, DOI 10.1016/j.expneurol.2004.02.009; Gupta R, 2012, MUSCLE NERVE, V45, P231, DOI 10.1002/mus.22276; Ikeda K, 2010, BR J PLAST SURG, V56, P342; Ikeda Kazuo, 2002, Hand Surg, V7, P11, DOI 10.1142/S0218810402000911; Isla A, 2003, J Neurosurg Sci, V47, P195; Iwatsuki K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057721; Mackinnon SE, 2002, HAND CLIN, V18, P231, DOI 10.1016/S0749-0712(01)00012-9; MACKINNON SE, 1986, HAND CLIN, V2, P639; Mazal PR, 2005, ACT NEUR S, V92, P3; McCall TD, 2001, NEUROSURG CLIN N AM, V12, P329, DOI 10.1016/S1042-3680(18)30058-5; Miillesi H, 1990, ANN HNAD SURG, V9, P87; MILLESI H, 1993, MICROSURG, V14, P430, DOI 10.1002/micr.1920140703; Nishimura T, 2008, HISTOL HISTOPATHOL, V23, P157, DOI 10.14670/HH-23.157; OBRIEN JP, 1987, ANN PLAS SURG, V19, P430, DOI 10.1097/00000637-198711000-00008; Ohsumi H, 2005, PLAST RECONSTR SURG, V116, P823, DOI 10.1097/01.prs.0000176893.44656.8e; Okui N, 2012, MICROSURG, V32, P466, DOI 10.1002/micr.21998; Okui N, 2010, MUSCLE NERVE, V42, P570, DOI 10.1002/mus.21727; Petersen J, 1996, NEUROSURGERY, V38, P976, DOI 10.1097/00006123-199605000-00025; Pham K, 2009, NEUROSCI LETT, V465, P194, DOI 10.1016/j.neulet.2009.09.014; SUNDERLAND S, 1976, J NEUROL NEUROSUR PS, V39, P615, DOI 10.1136/jnnp.39.7.615; Watanabe M, 2001, J HAND SURG-AM, V26A, P663, DOI 10.1053/jhsu.2001.24142; Xu JM, 2000, J HAND SURG-AM, V25A, P93; Yamamoto M, 2010, J ORTHOP RES, V28, P284, DOI 10.1002/jor.21004; Yamamoto T, 2014, MICROSURG, V34, P145, DOI 10.1002/micr.22135; [No title captured]	29	6	7	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2016	11	10							e0164572	10.1371/journal.pone.0164572	http://dx.doi.org/10.1371/journal.pone.0164572			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0DG	27741280	Green Published, Green Submitted, gold			2023-01-03	WOS:000385507000044
J	Lorenz, K; Wasielica-Poslednik, J; Bell, K; Renieri, G; Keicher, A; Ruckes, C; Pfeiffer, N; Thieme, H				Lorenz, Katrin; Wasielica-Poslednik, Joanna; Bell, Katharina; Renieri, Giulia; Keicher, Alexander; Ruckes, Christian; Pfeiffer, Norbert; Thieme, Hagen			Efficacy and safety of preoperative lop reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma	PLOS ONE			English	Article							TOPICAL ANTIGLAUCOMA MEDICATION; SURGERY; DRUGS; CONJUNCTIVA; SUCCESS	Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Delta = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (10P) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this mono centric prospective randomized controlled study. 10P change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative 10P change, hypertension rate and change of conjunctival redness 3 and 6 months post-op. Safety was assessed based on the documentation of adverse events. Results Preoperative treatment with topical dorzolamide/timolol was non-inferior to oral acetazolamide and topical dexamethasone in terms of 10P reduction 3 months after trabeculectomy (adjusted means -8.12 mmHg versus-8.30 mmHg; Difference: 0.18; 95% CI-1.91 to 2.26, p = 0.8662). Similar results were found 6 months after trabeculectomy (-9.13 mmHg versus -9.06 mmHg; p = 0.9401). Comparable results were also shown for both groups concerning the classification of the filtering bleb, corneal staining, and numbers of treatments with 5-FU, needlings and suture lyses. More patients reported AEs in the acetazolamide/dexamethasone group than in the dorzolamide/timolol group. Discussion Preoperative, preservative-free, fixed-dose dorzolamide/timolol seems to be equally effective as preoperative acetazolamide and dexamethasone and has a favourable safety profile.	[Lorenz, Katrin; Wasielica-Poslednik, Joanna; Bell, Katharina; Renieri, Giulia; Keicher, Alexander; Pfeiffer, Norbert; Thieme, Hagen] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Mainz, Germany; [Renieri, Giulia; Thieme, Hagen] Otto von Guericke Univ, Univ Eye Clin, Magdeburg, Germany; [Keicher, Alexander] Augenarzte Basteictr, Ulm, Germany; [Ruckes, Christian] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Interdisciplinary Ctr Clin Trials Mainz, Mainz, Germany	Johannes Gutenberg University of Mainz; Otto von Guericke University; Johannes Gutenberg University of Mainz	Lorenz, K (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Mainz, Germany.	katrin.lorenz@unimedizin-mainz.de	Bell, Katharina/T-5802-2019; Pfeiffer, Norbert/AAO-7586-2020		MSD SHARP & DOHME GmbH, Germany; Santen Pharmaceutical Co., Ltd., Japan; Augenarzte im Basteicenter	MSD SHARP & DOHME GmbH, Germany; Santen Pharmaceutical Co., Ltd., Japan; Augenarzte im Basteicenter	The authors received a research grant by MSD SHARP & DOHME GmbH, Germany and Santen Pharmaceutical Co., Ltd., Japan. This funder reviewed the study protocol, but played no role in data collection, analysis, or decision to publish the data. Augenarzte im Basteicenter also provided support in the form of salaries for author AK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaei M, 2015, DRUG RES, V65, P164, DOI 10.1055/s-0034-1376964; Baudouin C, 1999, OPHTHALMOLOGY, V106, P556, DOI 10.1016/S0161-6420(99)90116-1; Breusegem C, 2010, OPHTHALMOLOGY, V117, P1324, DOI 10.1016/j.ophtha.2009.11.038; BROADWAY DC, 1994, ARCH OPHTHALMOL-CHIC, V112, P1446, DOI 10.1001/archopht.1994.01090230060021; BROADWAY DC, 1994, ARCH OPHTHALMOL-CHIC, V112, P1437, DOI 10.1001/archopht.1994.01090230051020; Broadway DC, 1996, ARCH OPHTHALMOL-CHIC, V114, P262, DOI 10.1001/archopht.1996.01100130258004; FAIRBAIRN WD, 1971, ARCH OPHTHALMOL-CHIC, V86, P138, DOI 10.1001/archopht.1971.01000010140004; Flach Allan Joseph, 2004, Trans Am Ophthalmol Soc, V102, P219; Her Y, 2011, J DERMATOL, V38, P272, DOI 10.1111/j.1346-8138.2010.00921.x; Kelly TE, 2010, HIGH ALT MED BIOL, V11, P319, DOI 10.1089/ham.2010.1051; Klink T, 2013, OPHTHALMOLOGE, V110, P299, DOI 10.1007/s00347-012-2710-0; LAVIN MJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P1543, DOI 10.1001/archopht.1990.01070130045027; Leibowitz HM, 1996, ARCH OPHTHALMOL-CHIC, V114, P933, DOI 10.1001/archopht.1996.01100140141005; LONGSTAFF S, 1990, OPHTHALMIC SURG LAS, V21, P786; Ozturker ZK, 2014, J OCUL PHARMACOL TH, V30, P554, DOI 10.1089/jop.2014.0008; Pfeiffer N, 2006, INFLUENCE LOCAL GLAU; SHERWOOD MB, 1989, OPHTHALMOLOGY, V96, P327, DOI 10.1016/S0161-6420(89)32888-0; SKUTA GL, 1987, SURV OPHTHALMOL, V32, P149, DOI 10.1016/0039-6257(87)90091-9; ZEIMER RC, 1991, OPHTHALMOLOGY, V98, P64; Zimmermann S, 2014, HEART LUNG, V43, P124, DOI 10.1016/j.hrtlng.2013.11.008; ZINK HA, 1975, AM J OPHTHALMOL, V80, P478, DOI 10.1016/0002-9394(75)90537-1	21	9	9	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2017	12	2							e0171636	10.1371/journal.pone.0171636	http://dx.doi.org/10.1371/journal.pone.0171636			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BF	28199397	Green Published, gold, Green Submitted			2023-01-03	WOS:000394424400037
J	Kwiatkowska, A; Granicka, LH; Grzeczkowicz, A; Stachowiak, R; Kaminski, M; Grubek, Z; Bielecki, J; Strawski, M; Szklarczyk, M				Kwiatkowska, Angelika; Granicka, Ludomira H.; Grzeczkowicz, Anna; Stachowiak, Radoslaw; Kaminski, Michal; Grubek, Zuzanna; Bielecki, Jacek; Strawski, Marcin; Szklarczyk, Marek			Stabilized nanosystem of nanocarriers with an immobilized biological factor for anti-tumor therapy	PLOS ONE			English	Article								Objective The inadequate efficiency of existing therapeutic anti-cancer regiments and the increase in the multidrug resistance of cancer cells underscore the need to investigate novel anticancer strategies. The induction of apoptosis in tumors by cytotoxic agents produced by pathogenic microorganisms is an example of such an approach. Nevertheless, even the most effective drug should be delivered directly to targeted sites to reduce any negative impact on other cells. Accordingly, the stabilized nanosystem (SNS) for active agent delivery to cancer cells was designed for further application in local anti-tumor therapy. A product of genetically modified Escherichia coli, listeriolysin O (LLO), was immobilized within the polyelectrolyte membrane (poly(ethylenimine)lhyaluronic acid) shells of 'LLO nanocarriers' coupled with the stabilizing element of natural origin. Methods and results The impact of LLO was evaluated in human leukemia cell lines in vitro. Correspondingly, the influence of the SNS and its elements was assessed in vitro. The viability of targeted cells was evaluated by flow cytometry. Visualization of the system structure was performed using confocal microscopy. The membrane shell applied to the nanocarriers was analyzed using atomic force microscopy and Fourier transform infrared spectroscopy techniques. Furthermore, the presence of a polyelectrolyte layer on the nanocarrier surface and/or in the cell was confirmed by flow cytometry. Finally, the structural integrity of the SNS and the corresponding release of the fluorescent solute listeriolysin were investigated. Conclusion The construction of a stabilized system offers LLO release with a lethal impact on model eukaryotic cells. The applied platform design may be recommended for local anti-tumor treatment purposes.	[Kwiatkowska, Angelika; Granicka, Ludomira H.; Grzeczkowicz, Anna] Polish Acad Sci, Nalecz Inst Biocybernet & Biomed Engn, Warsaw, Poland; [Stachowiak, Radoslaw; Kaminski, Michal; Grubek, Zuzanna; Bielecki, Jacek] Univ Warsaw, Dept Appl Microbiol, Fac Biol, Warsaw, Poland; [Strawski, Marcin; Szklarczyk, Marek] Univ Warsaw, Fac Chem, Lab Electrochem, Warsaw, Poland	Polish Academy of Sciences; Nalecz Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Sciences; University of Warsaw; University of Warsaw	Granicka, LH (corresponding author), Polish Acad Sci, Nalecz Inst Biocybernet & Biomed Engn, Warsaw, Poland.	l.granicka@ibib.waw.pl	Strawski, Marcin/ABD-2231-2020; Grzeczkowicz, Anna/G-3911-2016	Strawski, Marcin/0000-0002-8253-0878; Grzeczkowicz, Anna/0000-0002-8970-4578; Bielecki, Jacek/0000-0001-6533-2282; Stachowiak, Radoslaw/0000-0002-7207-9753	National Science Centre [DEC-2012/07/D/ST5/02257]	National Science Centre(National Science Centre, Poland)	This part of work was financed by The National Science Centre (the number of decisions: DEC-2012/07/D/ST5/02257).	Bienkowski K, 2011, J ELECTROANAL CHEM, V662, P196, DOI 10.1016/j.jelechem.2011.06.014; Carlini L, 2013, REV NANOSCI NANOTECH, V2; Center M., 2011, GLOBAL CANC FACTS FI; Chari RV, ACC CHEM RES, V41, P1; Craft N, J IMMUNOL, V175; Dejugnat C, 2004, LANGMUIR, V20, P7265, DOI 10.1021/la049706n; EKBLOM P, 1983, INT J CANC, V31; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Granicka L, 2014, MEMBRANES MEMBRANES, P355; Granicka L H, ARTIF CELL BLOOD SUB, V39, P5; Granicka L H, J BIOMED MAT RES A, V102; Granicka LH, 1996, ASAIO J, V42, pM863, DOI 10.1097/00002480-199609000-00114; Han F, 2013, J NANOSCI NANOTECHNO, V13, P6996, DOI 10.1166/jnn.2013.7759; Huang SK, 2013, BIOCHEM ENG J, V74, P20, DOI 10.1016/j.bej.2013.02.015; Itoh Y, 2004, CHEM LETT, V33; Jemal A, CA CANC J CLIN, V61; Jensen E R, J VIROL, V71; Kanavos P, 2006, ANN ONCOLOGY S8; Kurapati R, 2013, J MATER CHEM B, V1, P3175, DOI 10.1039/c3tb20192a; Lokeshwar VB, 2014, ADV CANCER RES, V123, P35, DOI 10.1016/B978-0-12-800092-2.00002-2; Lue SJ, 2013, J NANOSCI NANOTECHNO, V13, P5305, DOI 10.1166/jnn.2013.7532; Mainardes RM, 2012, J NANOSCI NANOTECHNO, V12, P8513, DOI 10.1166/jnn.2012.6638; Minotti G, 2004, PHARM REV, V2; Neu B, 2001, J MICROENCAPSUL, V18, P385; Pandey S, 2013, NANOSCI NANOTECHNOL, V5; Pollakis G, 1983, FEBS LETT, V2; SadAbadi H, 2013, J NANOSCI NANOTECHNO, V13; Safra T, 2000, ANN ONCOL, V11, P1029, DOI 10.1023/A:1008365716693; Schuerch D W, 2005, P NAT ACAD SCI US, V102; Shen X, PROT ENG DES SEL, V22, P12; Song J, 2013, J NANOSCI NANOTECHNO, V13; Soto ER, 2008, BIOCONJUGATE CHEM, V19, P840, DOI 10.1021/bc700329p; Stachowiak R, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/954375; Stachowiak R, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/1472-6750-14-77; Stewart W., 2014, WORLD CANC REPORT 20; Sun R, HUM VACC IMMUNOTHER, V9, P5; Theerasilp M, 2013, J MICROENCAPSUL, V30, P390, DOI 10.3109/02652048.2012.746746; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; Wadajkar A S, 2012, REV NANOSCI NANOTECH, V1; Wang N, BR J PHARM, V164, p2b; Wang X., 2013, MATH PROBL ENG, V2013, P13, DOI DOI 10.1109/ICCIS.2013.384; Yoshimura K, CANC RES, V66; Zaboronok A, 2013, NANOSCI NANOTECHNOL, V5; Zhao F, 2013, J NANOSCI NANOTECHNO, V13; Zhao L, 2013, J NANOSCI NANOTECHNO, V13	45	1	1	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2017	12	2							e0170925	10.1371/journal.pone.0170925	http://dx.doi.org/10.1371/journal.pone.0170925			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK1QH	28166290	Green Submitted, Green Published, gold			2023-01-03	WOS:000393700100016
J	Steineck, G; Skokic, V; Sjoberg, F; Bull, C; Alevronta, E; Dunberger, G; Bergmark, K; Wilderang, U; Oh, JH; Deasy, JO; Jornsten, R				Steineck, Gunnar; Skokic, Viktor; Sjoberg, Fei; Bull, Cecilia; Alevronta, Eleftheria; Dunberger, Gail; Bergmark, Karin; Wilderang, Ulrica; Oh, Jung Hun; Deasy, Joseph O.; Jornsten, Rebecka			Identifying radiation-induced survivorship syndromes affecting bowel health in a cohort of gynecological cancer survivors	PLOS ONE			English	Article							QUALITY-OF-LIFE; FECAL INCONTINENCE; BOOTSTRAP; DISEASE	Background During radiotherapy unwanted radiation to normal tissue surrounding the tumor triggers survivorship diseases; we lack a nosology for radiation-induced survivorship diseases that decrease bowel health and we do not know which symptoms are related to which diseases. Methods Gynecological-cancer survivors were followed-up two to 15 years after having undergone radiotherapy; they reported in a postal questionnaire the frequency of 28 different symptoms related to bowel health. Population-based controls gave the same information. With a modified factor analysis, we determined the optimal number of factors, factor loadings for each symptom, factor-specific factor-loading cutoffs and factor scores. Results Altogether data from 623 survivors and 344 population-based controls were analyzed. Six factors best explain the correlation structure of the symptoms; for five of these a statistically significant difference (P< 0.001, Mann-Whitney U test) was found between survivors and controls concerning factor score quantiles. Taken together these five factors explain 42 percent of the variance of the symptoms. We interpreted these five factors as radiation-induced syndromes that may reflect distinct survivorship diseases. We obtained the following frequencies, defined as survivors having a factor loading above the 95 percent percentile of the controls, urgency syndrome (190 of 623, 30 percent), leakage syndrome (164 of 623, 26 percent), excessive gas discharge (93 of 623, 15 percent), excessive mucus discharge (102 of 623, 16 percent) and blood discharge (63 of 623, 10 percent). Conclusion Late effects of radiotherapy include five syndromes affecting bowel health; studying them and identifying the underlying survivorship diseases, instead of the approximately 30 long- term symptoms they produce, will simplify the search for prevention, alleviation and elimination.	[Steineck, Gunnar; Skokic, Viktor; Sjoberg, Fei; Bull, Cecilia; Alevronta, Eleftheria; Bergmark, Karin; Wilderang, Ulrica] Univ Gothenburg, Inst Clin Sci, Div Clin Canc Epidemiol, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden; [Steineck, Gunnar] Karolinska Inst, Div Clin Canc Epidemiol, Dept Pathol & Oncol, Stockholm, Sweden; [Dunberger, Gail] Ersta Skondal Univ Coll, Inst Caring Sci, Stockholm, Sweden; [Oh, Jung Hun; Deasy, Joseph O.] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; [Jornsten, Rebecka] Chalmers, Gothenburg, Sweden	University of Gothenburg; Karolinska Institutet; Memorial Sloan Kettering Cancer Center; Chalmers University of Technology	Steineck, G (corresponding author), Univ Gothenburg, Inst Clin Sci, Div Clin Canc Epidemiol, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.; Steineck, G (corresponding author), Karolinska Inst, Div Clin Canc Epidemiol, Dept Pathol & Oncol, Stockholm, Sweden.	Gunnar.Steineck@gu.se	Steineck, Gunnar/W-1515-2019	Steineck, Gunnar/0000-0002-0787-3969; Oh, Jung Hun/0000-0001-8791-2755; Deasy, Joseph/0000-0002-9437-266X; Sjoberg, Fei/0000-0002-8305-7648	Swedish Cancer Society; King Gustav V Jubilee Clinic Cancer Foundation in Goteborg, Sweden; Swedish state under the ALF agreement in Gbteborg and Stockholm; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Swedish Cancer Society(Swedish Cancer Society); King Gustav V Jubilee Clinic Cancer Foundation in Goteborg, Sweden; Swedish state under the ALF agreement in Gbteborg and Stockholm; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Swedish Cancer Society, the King Gustav V Jubilee Clinic Cancer Foundation in Goteborg, Sweden, the Swedish state under the ALF agreement in Gbteborg and Stockholm.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreyev HJN, 2015, COLORECTAL DIS, V17, P2, DOI 10.1111/codi.12812; Andreyev HJN, 2015, FRONTLINE GASTROENTE, V6, P53, DOI 10.1136/flgastro-2014-100468; Bergmark K, 1999, NEW ENGL J MED, V340, P1383, DOI 10.1056/NEJM199905063401802; BUJA A, 1992, MULTIVAR BEHAV RES, V27, P509, DOI 10.1207/s15327906mbr2704_2; Choi J, 2010, STAT INTERFACE, V3, P429; Dunberger G, 2011, ACTA ONCOL, V50, P233, DOI 10.3109/0284186X.2010.535013; Dunberger G, 2010, INT J GYNECOL CANCER, V20, P449, DOI 10.1111/IGC.0b013e3181d373bf; Dunberger G, 2010, EUR J CANCER, V46, P606, DOI 10.1016/j.ejca.2009.10.023; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; GILMAN A, 1963, AM J SURG, V105, P574, DOI 10.1016/0002-9610(63)90232-0; GOODMAN LS, 1946, JAMA-J AM MED ASSOC, V132, P126, DOI 10.1001/jama.1946.02870380008004; Jackson A, 2010, INT J RADIAT ONCOL, V76, pS155, DOI 10.1016/j.ijrobp.2009.08.074; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; Kreicbergs U, 2004, NEW ENGL J MED, V351, P1175, DOI 10.1056/NEJMoa040366; Mansson A, 2004, EUR UROL, V46, P195, DOI 10.1016/j.eururo.2004.04.010; Michalski JM, 2010, INT J RADIAT ONCOL, V76, pS123, DOI 10.1016/j.ijrobp.2009.03.078; Oh JH, 2016, METHODS INF MED, V55; Spearman C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107; Steineck G, 2002, ACTA ONCOL, V41, P244, DOI 10.1080/02841860260088782; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; Steineck G, 2016, SEMIN RADIAT ONCOL, V26, P236, DOI 10.1016/j.semradonc.2016.03.002; Teo MTW, 2015, CLIN ONCOL-UK, V27, P656, DOI 10.1016/j.clon.2015.06.010; Yamauchi FI, 2015, MAGN RESON IMAGING, V33, P525, DOI 10.1016/j.mri.2015.02.006; Zientek LR, 2007, BEHAV RES METHODS, V39, P318, DOI 10.3758/BF03193163	24	24	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171461	10.1371/journal.pone.0171461	http://dx.doi.org/10.1371/journal.pone.0171461			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7DG	28158314	Green Published, gold, Green Submitted			2023-01-03	WOS:000396161700081
J	Banerjee, J; Sorrell, ME; Celnik, PA; Pelled, G				Banerjee, Jineta; Sorrell, Mary E.; Celnik, Pablo A.; Pelled, Galit			Immediate Effects of Repetitive Magnetic Stimulation on Single Cortical Pyramidal Neurons	PLOS ONE			English	Article							PREFRONTAL CORTEX; CALCIUM-CHANNELS; RAT-BRAIN; NEUROTROPHIC FACTOR; DOPAMINE RELEASE; CONTROLLED TRIAL; CEREBRAL-CORTEX; VISUAL-CORTEX; C-FOS; TMS	Repetitive Transcranial Magnetic Stimulation (rTMS) has been successfully used as a noninvasive therapeutic intervention for several neurological disorders in the clinic as well as an investigative tool for basic neuroscience. rTMS has been shown to induce long-term changes in neuronal circuits in vivo. Such long-term effects of rTMS have been investigated using behavioral, imaging, electrophysiological, and molecular approaches, but there is limited understanding of the immediate effects of TMS on neurons. We investigated the immediate effects of high frequency (20 Hz) rTMS on the activity of cortical neurons in an effort to understand the underlying cellular mechanisms activated by rTMS. We used whole-cell patch clamp recordings in acute rat brain slices and calcium imaging of cultured primary neurons to examine changes in neuronal activity and intracellular calcium respectively. Our results indicate that each TMS pulse caused an immediate and transient activation of voltage gated sodium channels (9.6 +/- 1.8 nA at-45 mV, p value < 0.01) in neurons. Short 500 ms 20 Hz rTMS stimulation induced action potentials in a subpopulation of neurons, and significantly increased the steady state current of the neurons at near threshold voltages (at-45 mV: before TMS: I = 130 +/- 17 pA, during TMS: I = 215 +/- 23 pA, p value = 0.001). rTMS stimulation also led to a delayed increase in intracellular calcium (153.88 +/- 61.94% increase from baseline). These results show that rTMS has an immediate and cumulative effect on neuronal activity and intracellular calcium levels, and suggest that rTMS may enhance neuronal responses when combined with an additional motor, sensory or cognitive stimulus. Thus, these results could be translated to optimize rTMS protocols for clinical as well as basic science applications.	[Banerjee, Jineta; Sorrell, Mary E.; Pelled, Galit] Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD 21205 USA; [Banerjee, Jineta; Sorrell, Mary E.; Pelled, Galit] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA; [Celnik, Pablo A.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University	Pelled, G (corresponding author), Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD 21205 USA.; Pelled, G (corresponding author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA.	Pelled@kennedykrieger.org	Banerjee, Jineta/AAD-3671-2022	Banerjee, Jineta/0000-0002-1775-3645	National Institutes of Health, NINDS [R01NS072171]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS072171] Funding Source: NIH RePORTER	National Institutes of Health, NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Institutes of Health, NINDS, R01NS072171. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMASSIAN VE, 1992, ELECTROEN CLIN NEURO, V85, P291, DOI 10.1016/0168-5597(92)90105-K; Aydin-Abidin S, 2008, EXP BRAIN RES, V188, P249, DOI 10.1007/s00221-008-1356-2; Bauer EP, 2002, J NEUROSCI, V22, P5239, DOI 10.1523/JNEUROSCI.22-12-05239.2002; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BOHNING DE, 2000, TRANSCRANIAL MAGNETI, P13; Cantarero G, J NEUROSCI, V33, P4634, DOI [10.1016/j.neuron.2007.06.026, DOI 10.1016/J.NEURON.2007.06.026]; Cantarero G, 2013, J NEUROSCI, V33, P12862, DOI 10.1523/JNEUROSCI.1399-13.2013; Cantello R, 2007, EPILEPSIA, V48, P366, DOI 10.1111/j.1528-1167.2006.00938.x; Cho SS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006725; Cho SI, 2012, BIOELECTROMAGNETICS, V33, P568, DOI 10.1002/bem.21715; Fournier M, SPIE MED IMAGING; Fujiki M, 2003, J NEUROSURG, V99, P1063, DOI 10.3171/jns.2003.99.6.1063; George MS, 2000, BIOL PSYCHIAT, V48, P962, DOI 10.1016/S0006-3223(00)01048-9; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; Giesel FL, 2012, EUR J RADIOL, V81, P1273, DOI 10.1016/j.ejrad.2011.03.002; Gothe J, 2002, BRAIN, V125, P479, DOI 10.1093/brain/awf045; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Helton TD, 2005, J NEUROSCI, V25, P10247, DOI 10.1523/JNEUROSCI.1089-05.2005; Herbsman T, 2009, HUM BRAIN MAPP, V30, P2044, DOI 10.1002/hbm.20649; Hoogendam JM, 2010, BRAIN STIMUL, V3, P95, DOI 10.1016/j.brs.2009.10.005; Hoyer EH, 2011, RESTOR NEUROL NEUROS, V29, P395, DOI 10.3233/RNN-2011-0611; Huang YZ, 2007, CLIN NEUROPHYSIOL, V118, P1028, DOI 10.1016/j.clinph.2007.01.021; JALINOUS R, 1991, J CLIN NEUROPHYSIOL, V8, P10, DOI 10.1097/00004691-199101000-00004; Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635; Kanno M, 2004, J NEUROL SCI, V217, P73, DOI 10.1016/j.jns.2003.08.013; Kapur A, 1998, J NEUROPHYSIOL, V79, P2181, DOI 10.1152/jn.1998.79.4.2181; KOLBINGER HM, 1995, HUM PSYCHOPHARM CLIN, V10, P305, DOI 10.1002/hup.470100408; Kozyrev V, P NATL ACAD SCI, V111, P13553; Lee SH, 2005, NEUROSCI LETT, V376, P177, DOI 10.1016/j.neulet.2004.11.048; Lee SW, 2014 36 ANN INT C IE; Lee SW, 2015 7 INT IEEE EMBS; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Lenz M, 2015, BRAIN STRUCT FUNCT, V220, P3323, DOI 10.1007/s00429-014-0859-9; Li W, 2007, BRAIN RES BULL, V71, P493, DOI 10.1016/j.brainresbull.2006.11.002; Lipton RB, 2010, LANCET NEUROL, V9, P373, DOI 10.1016/S1474-4422(10)70054-5; Lisanby SH, 2000, DEPRESS ANXIETY, V12, P178, DOI 10.1002/1520-6394(2000)12:3<178::AID-DA10>3.0.CO;2-N; Lu H, SCI REPORTS, V5; Lynnerup N, 2005, HEAD FACE MED, V1, P1, DOI DOI 10.1186/1746-160X-1-13; MACCABEE PJ, 1993, J PHYSIOL-LONDON, V460, P201, DOI 10.1113/jphysiol.1993.sp019467; Mally J, 1999, J NEUROSCI RES, V57, P935, DOI 10.1002/(SICI)1097-4547(19990915)57:6<935::AID-JNR19>3.0.CO;2-8; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; Muller-Dahlhaus F, FRONTIERS MOL NEUROS, V6; Murphy SC, ELIFE, V5, DOI [10.7554/eLife.13598, DOI 10.7554/ELIFE.13598PMID]; Nahas Z, 2001, J NEUROPSYCH CLIN N, V13, P459, DOI 10.1176/appi.neuropsych.13.4.459; Okatan M, 2000, NEURAL NETWORKS, V13, P699, DOI 10.1016/S0893-6080(00)00036-8; Pashut T, FRONTIERS CELLULAR N, V8; Pasley BN, 2009, NEURON, V62, P291, DOI 10.1016/j.neuron.2009.03.012; Pitcher D, 2008, J NEUROSCI, V28, P8929, DOI 10.1523/JNEUROSCI.1450-08.2008; Sachdev PS, 2002, BIOL PSYCHIAT, V51, P474, DOI 10.1016/S0006-3223(01)01298-7; Speer AM, 2009, J AFFECT DISORDERS, V115, P386, DOI 10.1016/j.jad.2008.10.006; Speer AM, 2000, BIOL PSYCHIAT, V48, P1133, DOI 10.1016/S0006-3223(00)01065-9; Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001; Sun P, 2011, J NEUROSCI, V31, P16464, DOI 10.1523/JNEUROSCI.1542-11.2011; Tang A, NEUROSCIENTIST; Theodore WH, 2002, NEUROLOGY, V59, P560, DOI 10.1212/WNL.59.4.560; Valiullina F, 2016, FRONT NEURAL CIRCUIT, V10, DOI [10.3389/fncir.2016.00001, 10.3389/Thcir2016.00001]; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002; Wu D, 2001, J VIS, V1, P198; Zangen A, 2002, NEUROREPORT, V13, P2401, DOI 10.1097/00001756-200212200-00005; Zhang XQ, 2007, J HUAZHONG U SCI-MED, V27, P415, DOI 10.1007/s11596-007-0416-3	62	37	39	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2017	12	1							e0170528	10.1371/journal.pone.0170528	http://dx.doi.org/10.1371/journal.pone.0170528			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN6QR	28114421	Green Published, Green Submitted, gold			2023-01-03	WOS:000396129000064
J	Mori, H; Kubo, M; Nishimura, R; Osako, T; Arima, N; Okumura, Y; Okido, M; Yamada, M; Kai, M; Kishimoto, J; Miyazaki, T; Oda, Y; Otsuka, T; Nakamura, M				Mori, Hitomi; Kubo, Makoto; Nishimura, Reiki; Osako, Tomofumi; Arima, Nobuyuki; Okumura, Yasuhiro; Okido, Masayuki; Yamada, Mai; Kai, Masaya; Kishimoto, Junji; Miyazaki, Tetsuyuki; Oda, Yoshinao; Otsuka, Takao; Nakamura, Masafumi			BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer	PLOS ONE			English	Article							INTERNATIONAL EXPERT CONSENSUS; DEPENDENT PROBE AMPLIFICATION; PRIMARY THERAPY; NEOADJUVANT CHEMOTHERAPY; CLINICAL-FEATURES; AMERICAN-SOCIETY; BASAL-LIKE; PHASE-II; HIGHLIGHTS; SUBTYPES	Background Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases. Methods The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the isolation of DNA from tumor tissue. Classification of BRCAness was performed using multiple ligation-dependent probe amplification (MLPA). The tumor subtypes were determined immunohistochemically using resected specimens. Results Of the 262 TNBCs, the results of the MLPA assays showed that 174 (66.4%) tumors had BRCAness. Patients with BRCAness tumors were younger than patients with non-BRCAness tumors (P = 0.003). There was no significant difference between the two groups regarding their pathological stages. The BRCAness group had a significantly shorter recurrence- free survival (RFS) compared with the non-BRCAness group (P = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance. Adjuvant treatments with anthracycline-based regimens provided significantly greater benefits to the BRCAness group (P = 0.003 for RFS, and P = 0.03 for OS). Multivariate Cox proportional hazard model analysis showed that BRCAness was an independent negative prognostic factor, and the anthracycline-based adjuvant chemotherapy was an independent positive prognostic factor for both RFS and OS in TNBC. Conclusions The 66.4% patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracycline-based adjuvant chemotherapy for patients with TNBCs.	[Mori, Hitomi; Kubo, Makoto; Yamada, Mai; Kai, Masaya; Otsuka, Takao; Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan; [Nishimura, Reiki; Osako, Tomofumi] Kumamoto Shinto Gen Hosp, Breast Ctr, Kumamoto, Japan; [Arima, Nobuyuki] Kumamoto Shinto Gen Hosp, Dept Pathol, Kumamoto, Japan; [Okumura, Yasuhiro] Kumamoto City Hosp, Dept Breast & Endocrine Surg, Kumamoto, Japan; [Okido, Masayuki] Hamanomachi Hosp, Dept Surg, Fukuoka, Japan; [Kishimoto, Junji] Kyushu Univ, Dept Res & Dev Next Generat Med, Fac Med Sci, Fukuoka, Japan; [Miyazaki, Tetsuyuki; Oda, Yoshinao] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan	Kyushu University; Kyushu University; Kyushu University	Kubo, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan.	mkubo@tumor.med.kyushu-u.ac.jp		Mori, Hitomi/0000-0002-5416-5869	Japan Society for the Promotion of Science, KAKENHI; Ministry of Education, Culture, Sports, Science and Technology, Japan [20591550]; World premier COE	Japan Society for the Promotion of Science, KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); World premier COE	This work was supported by the Japan Society for the Promotion of Science, KAKENHI, and by the budget demand from Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant number 20591550, https://www.jsps.go.jp/j-grantsinaid/ to Makoto Kubo, and by World premier COE (core of excellence) formation for the treatment and research of pancreatic cancer (there is no grant number), http://www.mext.go.jp/en/ to Takao Otsuka. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Conforti R, 2007, ANN ONCOL, V18, P1477, DOI 10.1093/annonc/mdm209; Crown J, 2012, ANN ONCOL, V23, P56, DOI 10.1093/annonc/mds196; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Fostira F, 2012, BREAST CANCER RES TR, V134, P353, DOI 10.1007/s10549-012-2021-9; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gerratana L, 2016, CANCER TREAT REV, V48, P34, DOI 10.1016/j.ctrv.2016.06.004; Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; Isakoff SJ, 2015, J CLIN ONCOL, V33, P1902, DOI 10.1200/JCO.2014.57.6660; Joosse SA, 2009, BREAST CANCER RES TR, V116, P479, DOI 10.1007/s10549-008-0117-z; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144; Lips EH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3049; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Miyoshi Y, 2010, BREAST CANCER-TOKYO, V17, P103, DOI 10.1007/s12282-009-0152-6; Oonk AMM, 2012, ANN ONCOL, V23, P2301, DOI 10.1093/annonc/mdr621; Petrelli F, 2014, BREAST CANCER RES TR, V144, P223, DOI 10.1007/s10549-014-2876-z; Prat A, 2014, BRIT J CANCER, V111, P1532, DOI 10.1038/bjc.2014.444; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Silver DP, 2012, CANCER DISCOV, V2, P679, DOI 10.1158/2159-8290.CD-12-0221; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Telli ML, 2015, J CLIN ONCOL, V33, P1895, DOI 10.1200/JCO.2014.57.0085; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624; Vollebergh MA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3655; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	42	19	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							e0167016	10.1371/journal.pone.0167016	http://dx.doi.org/10.1371/journal.pone.0167016			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7HN	27977696	Green Published, gold, Green Submitted			2023-01-03	WOS:000391217400011
J	de Oliveira, LH; Camacho, LAB; Coutinho, ESF; Martinez-Silveira, MS; Carvalho, AF; Ruiz-Matus, C; Toscano, CM				de Oliveira, Lucia Helena; Camacho, Luiz Antonio B.; Coutinho, Evandro S. F.; Martinez-Silveira, Martha S.; Carvalho, Ana Flavia; Ruiz-Matus, Cuauhtemoc; Toscano, Cristiana M.			Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review	PLOS ONE			English	Review							CHILDHOOD PNEUMONIA HOSPITALIZATIONS; STREPTOCOCCUS-PNEUMONIAE; DISEASE; 10-VALENT; BURDEN; BRAZIL; VACCINATION; MENINGITIS; EFFICACY; YOUNGER	Background Several Latin American and Caribbean (LAC) countries have introduced pneumococcal conjugate vaccine (PCV-10 or PCV-13) in their routine national immunization programs. Objectives We aimed to summarize the evidence of PCV impact and effectiveness in children under 5 years old in the LAC Region. Methods We conducted a systematic review of the literature on impact or effectiveness of PCVs on deaths or hospitalizations due to invasive pneumococcal disease (IPD), pneumonia, meningitis and sepsis. We searched Medline, WoS, Lilacs, Scopus, Central and gray literature published in any language from 2009 to January 2016. We included studies addressing the outcomes of interest in children in the target age group, and with the following designs: randomized trials, cohort or case-control, interrupted time series with at least three data points before and after the intervention, and before-after studies. Screening of citations, data extraction, and risk of bias assessment were conducted in duplicate by independent reviewers, according to the study protocol registered on PROSPERO. Descriptive analysis of the effectiveness measurements and sensitivity analysis were conducted. Effectiveness is reported as 1-OR or 1-RR for case control or cohort/clinical trials, and as percent change of disease incidence rates for before-after studies. Results We identified 1,085 citations, 892 from databases and 193 from other sources. Of these, 22 were further analyzed. Studies were from Brazil, Chile, Uruguay, Argentina, Peru and Nicaragua. Effectiveness ranged from 8.8-37.8% for hospitalizations due to X-ray confirmed pneumonia, 7.4-20.6% for clinical pneumonia, and 13.3-87.7% for meningitis hospitalizations, and 56-83.3% for IPD hospitalization, varying by age, outcome definition, type of vaccine and study design. Conclusions Available evidence to date indicates significant impact of both PCV-10 and PCV-13 in the outcomes studied, with no evidence of the superiority of one vaccine over the other on pneumonia, IPD or meningitis hospitalization reduction in children under 5 years old.	[de Oliveira, Lucia Helena; Ruiz-Matus, Cuauhtemoc] World Hlth Org PAHO, Pan Amer Hlth Org, Immunizat Unit FGL, Washington, DC 20037 USA; [Camacho, Luiz Antonio B.; Coutinho, Evandro S. F.] Oswaldo Cruz Fdn Fiocruz, Natl Publ Hlth Sch ENSP, Dept Epidemiol & Quantitat Methods Hlth, Rio De Janeiro, Brazil; [Martinez-Silveira, Martha S.] Oswaldo Cruz Fdn Fiocruz, Goncalo Moniz Inst, Salvador, BA, Brazil; [Carvalho, Ana Flavia] Sabin Vaccine Inst, Vaccine Advocacy & Educ, Washington, DC USA; [Toscano, Cristiana M.] Fed Univ Goias UFG, Inst Trop Pathol & Publ Hlth IPTSP, Goiania, Go, Brazil	Pan American Health Organization; World Health Organization; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal de Goias	de Oliveira, LH (corresponding author), World Hlth Org PAHO, Pan Amer Hlth Org, Immunizat Unit FGL, Washington, DC 20037 USA.	oliveirl@paho.org	Martinez-Silveira, Martha Silvia/O-7270-2014	Martinez-Silveira, Martha Silvia/0000-0002-1004-1784; Coutinho, Evandro/0000-0002-4649-7353; TOSCANO, CRISTIANA/0000-0002-9453-2643	Pan American Health Organization; Sabin Vaccine Institute	Pan American Health Organization; Sabin Vaccine Institute	The study was funded by the Pan American Health Organization and the Sabin Vaccine Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198; Andrade AL, 2015, 33 ANN EUR SOC PAED, P1101; Andrade AL, 2015, 33 ANN EUR SOC PAED, P250; Andrade AL, 2016, HUM VACC IMMUNOTHER, V12, P285, DOI 10.1080/21645515.2015.1117713; Andrade AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098128; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; Azevedo J, 2015, 115 ANN M AM SOC MIC; Becker-Dreps S, 2013, PNEUM VACC CHILDR AD, P319; Becker-Dreps S, 2014, PEDIATR INFECT DIS J, V33, P637, DOI 10.1097/INF.0000000000000269; Berglund A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112211; Bonner K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135270; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; de Oliveira LH, 2016, EXPERT REV VACCINES, V30, P1; de Oliveira LH, 2013, VACCINE, V31, pC114, DOI 10.1016/j.vaccine.2013.05.032; Deceuninck G, 2015, VACCINE, V33, P2684, DOI 10.1016/j.vaccine.2015.04.005; Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141; Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8; Domingues CMA., 2014, PNEUMONIA, V3, P145; Gabarrot GG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112337; Gentile A, 2015, PED BACT INF IDWEEK, P1234; Gentile A J., 2014, CONTR PNEUM DIS GLOB, V3, P168; Gentile A, 2015, ARCH ARGENT PEDIATR, V113, P502, DOI [10.5546/aap.2015.eng.502, 10.5546/aap.2015.502]; Gladstone RA, 2011, J MED MICROBIOL, V60, P1, DOI 10.1099/jmm.0.020016-0; Grando IM, 2015, CAD SAUDE PUBLICA, V31, P276, DOI 10.1590/0102-311X00169913; Greenberg D, 2015, VACCINE, V33, P4623, DOI 10.1016/j.vaccine.2015.06.062; Guevara M, 2016, EURO SURVEILL, V21; Hanquet G, 2013, VACCINE, V31, P5634, DOI 10.1016/j.vaccine.2013.07.006; Hirose TE, 2015, J PEDIAT-BRAZIL, V91, P130, DOI 10.1016/j.jped.2014.07.002; Hortal M, 2014, 9 INT S PNEUM PNEUM, V3, P142; Hortal M, 2015, WORLD J VACCINES, V5, P37, DOI [10.4236/wjv.2015.51005, DOI 10.4236/WJV.2015.51005]; Hortal M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098567; Instituto de Salud Pu A blica de Chile, 2015, B I SALUD PUBICA CHI, V5, P1; Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center, 2016, STAT PCV US IMP EV S; Lawley CM, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-8; Liphaus B, 2012, 8 INT S PNEUM PNEUM, P619; Loo JD, 2014, PEDIATR INFECT DIS J, V33, pS140, DOI 10.1097/INF.0000000000000082; Lucero MG, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004977.pub2; Minamisava R, 2014, PNEUMONIA, V3, P248; Moreira M, 2016, VACCINE, V34, P2766, DOI 10.1016/j.vaccine.2016.04.006; National Institutes of Health, 2014, QUAL ASS TOOL PREP S; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Palmu AA, 2015, PEDIATRICS, V136, pE22, DOI 10.1542/peds.2015-0458; Pan American Health Organization, 2015, 23 TAG M 2015 1 3 JU; Pan American Health Organization, 2011, 19 TAG M 2011 JUL 6; Pinto L, 2013, PED RESP EP 23 ANN C; Principi N, 2015, EXPERT REV VACCINES, V14, P1359, DOI 10.1586/14760584.2015.1075884; Ramsay CR, 2003, INT J TECHNOL ASSESS, V19, P613, DOI 10.1017/S0266462303000576; Rearte A, 2015, 9 WORLD C WORLD SOC, P73; Rodrigues LC, 1999, EPIDEMIOL REV, V21, P56, DOI 10.1093/oxfordjournals.epirev.a017988; Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401; Russell F, 2012, 8 INT S PNEUM PNEUM, P352; Sagradini S, 2013, REV ARGENT SALUD PUB, V4, P45; Sartori AM, 2015, REV SAUDE PUBLICA, V49; Scotta MC, 2014, VACCINE, V32, P4495, DOI 10.1016/j.vaccine.2014.06.042; Sgambatti S, 2014, 32 ANN EUR SOC PAED; Sgambatti S, 2016, VACCINE, V34, P663, DOI 10.1016/j.vaccine.2015.12.007; Sinha A, 2008, REV PANAM SALUD PUBL, V24, P304, DOI 10.1590/S1020-49892008001100002; Sterne J.A., 2008, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch10, DOI 10.1002/9780470712184.CH10]; Suarez V, 2016, VACCINE, V34, P4738, DOI 10.1016/j.vaccine.2016.07.027; Valenzuela MT, 2009, REV PANAM SALUD PUBL, V25, P270, DOI 10.1590/S1020-49892009000300011; Valenzuela MT, 2014, REV CHIL INFECTOL, V31, P651, DOI 10.4067/S0716-10182014000600002; Verani JR, 2015, VACCINE; Vizzotti C, 2014, GLOB PNEUM DIS POL C, V3, P244; Vizzotti C, 2014, GLOB PNEUM DIS POL C, V3, P243; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1042, DOI 10.1093/oxfordjournals.aje.a116398; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wells GASB, 2008, NEWCASTLEOTTAWA SCAL; Zhou FJ, 2007, ARCH PEDIAT ADOL MED, V161, P1162, DOI 10.1001/archpedi.161.12.1162	69	82	83	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0166736	10.1371/journal.pone.0166736	http://dx.doi.org/10.1371/journal.pone.0166736			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27941979	Green Published, gold, Green Submitted			2023-01-03	WOS:000392745600005
J	Low, LL; Liu, N; Wang, SJ; Thumboo, J; Ong, MEH; Lee, KH				Low, Lian Leng; Liu, Nan; Wang, Sijia; Thumboo, Julian; Ong, Marcus Eng Hock; Lee, Kheng Hock			Predicting 30-Day Readmissions in an Asian Population: Building a Predictive Model by Incorporating Markers of Hospitalization Severity	PLOS ONE			English	Article							RISK-FACTORS; MEDICAL PATIENTS; CARE PROGRAM; INDEX; REHOSPITALIZATION; PERFORMANCE; VALIDATION; DERIVATION; MORTALITY; ICD-9-CM	Background To reduce readmissions, it may be cost-effective to consider risk stratification, with targeting intervention programs to patients at high risk of readmissions. In this study, we aimed to derive and validate a prediction model including several novel markers of hospitalization severity, and compare the model with the LACE index (Length of stay, Acuity of admission, Charlson comorbidity index, Emergency department visits in past 6 months), an established risk stratification tool. Method This was a retrospective cohort study of all patients >= 21 years of age, who were admitted to a tertiary hospital in Singapore from January 1, 2013 through May 31, 2015. Data were extracted from the hospital's electronic health records. The outcome was defined as unplanned readmissions within 30 days of discharge from the index hospitalization. Candidate predictive variables were broadly grouped into five categories: Patient demographics, social determinants of health, past healthcare utilization, medical comorbidities, and markers of hospitalization severity. Multivariable logistic regression was used to predict the outcome, and receiver operating characteristic analysis was performed to compare our model with the LACE index. Results 74,102 cases were enrolled for analysis. Of these, 11,492 patient cases (15.5%) were readmitted within 30 days of discharge. A total of fifteen predictive variables were strongly associated with the risk of 30-day readmissions, including number of emergency department visits in the past 6 months, Charlson Comorbidity Index, markers of hospitalization severity such as 'requiring inpatient dialysis during index admission, and 'treatment with intravenous furosemide 40 milligrams or more' during index admission. Our predictive model outperformed the LACE index by achieving larger area under the curve values: 0.78 (95% confidence interval [CI]: 0.77-0.79) versus 0.70 (95% CI: 0.69-0.71). Conclusion Several factors are important for the risk of 30-day readmissions, including proxy markers of hospitalization severity.	[Low, Lian Leng; Lee, Kheng Hock] Singapore Gen Hosp, Dept Family Med & Continuing Care, Singapore, Singapore; [Low, Lian Leng; Lee, Kheng Hock] Duke NUS Med Sch, Family Med Program, Singapore, Singapore; [Liu, Nan; Thumboo, Julian] Singapore Hlth Serv, Hlth Serv Res Ctr, Singapore, Singapore; [Liu, Nan] Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore; [Wang, Sijia] Integrated Hlth Informat Syst, Singapore, Singapore; [Thumboo, Julian] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore; [Ong, Marcus Eng Hock] Singapore Gen Hosp, Dept Emergency Med, Singapore, Singapore; [Ong, Marcus Eng Hock] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore, Singapore	Singapore General Hospital; National University of Singapore; National University of Singapore; Singapore General Hospital; Singapore General Hospital; National University of Singapore	Low, LL (corresponding author), Singapore Gen Hosp, Dept Family Med & Continuing Care, Singapore, Singapore.; Low, LL (corresponding author), Duke NUS Med Sch, Family Med Program, Singapore, Singapore.; Liu, N (corresponding author), Singapore Hlth Serv, Hlth Serv Res Ctr, Singapore, Singapore.; Liu, N (corresponding author), Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore.	low.lian.leng@singhealth.com.sg; liu.nan@singhealth.com.sg	Liu, Nan/L-9529-2013; Low, Lian Leng/M-2853-2016; Liu, Nan/HCS-2632-2022	Low, Lian Leng/0000-0003-4228-2862; Liu, Nan/0000-0003-3610-4883	Singapore Ministry of Health (MOH) Health Services Research New Investigator Grant [HSRNIG14nov002]; SingHealth Foundation Health Services Research (Ageing) Grant [SHF/HSRAg004/2015]	Singapore Ministry of Health (MOH) Health Services Research New Investigator Grant; SingHealth Foundation Health Services Research (Ageing) Grant	This study was supported by Singapore Ministry of Health (MOH) Health Services Research New Investigator Grant HSRNIG14nov002 and the SingHealth Foundation Health Services Research (Ageing) Grant SHF/HSRAg004/2015. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allaudeen N, 2011, J HOSP MED, V6, P54, DOI 10.1002/jhm.805; Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; Billings J, 2006, BRIT MED J, V333, P327, DOI 10.1136/bmj.38870.657917.AE; Billings J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001667; Bottle A, 2006, J ROY SOC MED, V99, P406, DOI 10.1258/jrsm.99.8.406; Centers for Medicare & Medicaid Services, 2014, READM RED PROGR; Choudhry Shahid A, 2013, Online J Public Health Inform, V5, P219, DOI 10.5210/ojphi.v5i2.4726; Cooksley T, 2015, QJM; Cotter PE, 2012, AGE AGEING, V41, P784, DOI 10.1093/ageing/afs073; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Donze J, 2013, JAMA INTERN MED, V173, P632, DOI 10.1001/jamainternmed.2013.3023; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fiest KM, 2014, BMC PSYCHIATRY, V14, P1; Glasgow JM, 2010, J GEN INTERN MED, V25, P926, DOI 10.1007/s11606-010-1371-4; Graham KL, 2015, ANN INTERN MED, V162, P741, DOI 10.7326/M14-2159; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hasan O, 2010, J GEN INTERN MED, V25, P211, DOI 10.1007/s11606-009-1196-1; Howell S, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-96; Hu JH, 2014, HEALTH AFFAIR, V33, P778, DOI 10.1377/hlthaff.2013.0816; Jasti H, 2008, CLIN INFECT DIS, V46, P550, DOI 10.1086/526526; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Lim E, 2011, BMC HEALTH SERV RES, V2011, P1; Low LL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/169870; Low LL, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0750-2; Luthi JC, 2003, INT J QUAL HEALTH C, V15, P413, DOI 10.1093/intqhc/mzg055; Luthi JC, 2004, QUAL SAF HEALTH CARE, V13, P46, DOI 10.1136/qshc.2003.006999; Ministry of Health, 2010, CHRONIC DIS; Ministry of Health Singapore, 2012, HLTH FACTS SING HEAL; Neupane B, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-22; Onukwugha E, 2011, MED CARE, V49, P215, DOI 10.1097/MLR.0b013e31820192a5; Pederson JL, 2016, J HOSP MED; Peleg AY, 2010, NEW ENGL J MED, V362, P1804, DOI 10.1056/NEJMra0904124; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Shadmi E, 2015, MED CARE, V53, P283, DOI 10.1097/MLR.0000000000000315; Smith DM, 1996, J GEN INTERN MED, V11, P762, DOI 10.1007/BF02598996; Taha M, 2014, INT J QUAL HEALTH C, V26, P271, DOI 10.1093/intqhc/mzu038; Tan SY, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-366; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; Wee SL, 2014, J AM GERIATR SOC, V62, P747, DOI 10.1111/jgs.12750; Zhou HQ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011060	45	30	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0167413	10.1371/journal.pone.0167413	http://dx.doi.org/10.1371/journal.pone.0167413			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE4PU	27936053	Green Published, Green Submitted, gold			2023-01-03	WOS:000389587100093
J	Lee, J; Baek, SH; Ahn, SY; Chin, HJ; Na, KY; Chae, DW; Kim, S				Lee, Jeonghwan; Baek, Seon Ha; Ahn, Shin Young; Chin, Ho Jun; Na, Ki Young; Chae, Dong-Wan; Kim, Sejoong			Pre-Stage Acute Kidney Injury Can Predict Mortality and Medical Costs in Hospitalized Patients	PLOS ONE			English	Article							WORSENING RENAL-FUNCTION; LENGTH-OF-STAY; SERUM CREATININE; MINIMAL CHANGES; DIALYSIS; INCREASES; FAILURE; DISEASE; DEFINITIONS; THERAPY	The significance of minimal increases in serum creatinine below the levels indicative of the acute kidney injury (AKI) stage is not well established. We aimed to investigate the influence of pre-stage AKI (pre-AKI) on clinical outcomes. We enrolled a total of 21,261 patients who were admitted to the Seoul National University Bundang Hospital from January 1, 2013 to December 31, 2013. Pre-AKI was defined as a 25-50% increase in peak serum creatinine levels from baseline levels during the hospital stay. In total, 5.4% of the patients had pre-AKI during admission. The patients with pre-AKI were predominantly female (55.0%) and had a lower body weight and lower baseline levels of serum creatinine (0.63 +/- 0.18 mg/dl) than the patients with AKI and the patients without AKI (P < 0.001). The patients with pre-AKI had a higher prevalence of diabetes mellitus (25.1%) and malignancy (32.6%). The adjusted hazard ratio of in-hospital mortality for pre-AKI was 2.112 [95% confidence interval (CI), 1.143 to 3.903]. In addition, patients with pre-AKI had an increased length of stay (7.7 +/- 9.7 days in patients without AKI, 11.4 +/- 11.4 days in patients with pre-AKI, P < 0.001) and increased medical costs (4,061 +/- 4,318 USD in patients without AKI, 4,966 +/- 5,099 USD in patients with pre-AKI, P < 0.001) during admission. The adjusted hazard ratio of all-cause mortality for pre-AKI during the follow-up period of 2.0 +/- 0.6 years was 1.473 (95% CI, 1.228 to 1.684). Although the adjusted hazard ratio of pre-AKI for overall mortality was not significant among the patients admitted to the surgery department or who underwent surgery, pre-AKI was significantly associated with mortality among the non-surgical patients (adjusted HR 1.542 [95% CI, 1.330 to 1.787]) and the patients admitted to the medical department (adjusted HR 1.384 [95% CI, 1.153 to 1.662]). Pre-AKI is associated with increased mortality, longer hospital stay, and increased medical costs during admission. More attention should be paid to the clinical significance of pre-AKI.	[Lee, Jeonghwan] Hallym Univ, Hangang Sacred Heart Hosp, Dept Internal Med, Seoul, South Korea; [Baek, Seon Ha; Chin, Ho Jun; Na, Ki Young; Chae, Dong-Wan; Kim, Sejoong] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; [Ahn, Shin Young] Korea Univ, Guro Hosp, Med Ctr, Dept Internal Med, Seoul, South Korea	Hallym University; Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine)	Kim, S (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea.	sejoong2@snu.ac.kr	Lee, Jeonghwan/C-5214-2011; Kim, Sejoong/J-5356-2015	Lee, Jeonghwan/0000-0003-3199-635X; Kim, Sejoong/0000-0002-7238-9962	Young Investigator Research Grant from the Korean Society of Nephrology (Kyowa Hakko Kirin) [06-2014-151]; SNUBH Research Fund [02-2014-058]	Young Investigator Research Grant from the Korean Society of Nephrology (Kyowa Hakko Kirin); SNUBH Research Fund	This study was supported by the Young Investigator Research Grant (no 06-2014-151) from the Korean Society of Nephrology (Kyowa Hakko Kirin 2014) and was Supported by grant no 02-2014-058 from the SNUBH Research Fund. The sponsors of this study played no role in its design, or in the collection, analysis, or interpretation of data, or the writing of the report.	Baek SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156444; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Garner AE, 2012, ANN CLIN BIOCHEM, V49, P59, DOI 10.1258/acb.2011.011125; Gottlieb SS, 2002, J CARD FAIL, V8, P136, DOI 10.1054/jcaf.2002.125289; Jin DC, 2015, KIDNEY RES CLIN PRAC, V34, P132, DOI 10.1016/j.krcp.2015.08.004; Jin DC, 2015, KIDNEY INT SUPPL, V5, P8, DOI 10.1038/kisup.2015.3; Jin DC, 2015, KOREAN J INTERN MED, V30, P17, DOI 10.3904/kjim.2015.30.1.17; Kerr M, 2014, NEPHROL DIAL TRANSPL, V29, P1362, DOI 10.1093/ndt/gfu016; Kork F, 2015, ANESTHESIOLOGY, V123, P1301, DOI 10.1097/ALN.0000000000000891; Lafrance JP, 2010, AM J KIDNEY DIS, V56, P651, DOI 10.1053/j.ajkd.2010.05.011; Lafrance JP, 2010, J AM SOC NEPHROL, V21, P345, DOI 10.1681/ASN.2009060636; Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD; Lee CS, 2010, J KOREAN MED SCI, V25, P1616, DOI 10.3346/jkms.2010.25.11.1616; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Liotta M, 2014, AM J CARDIOL, V113, P70, DOI 10.1016/j.amjcard.2013.09.012; Metra M, 2008, EUR J HEART FAIL, V10, P188, DOI 10.1016/j.ejheart.2008.01.011; Newsome BB, 2008, ARCH INTERN MED, V168, P609, DOI 10.1001/archinte.168.6.609; Siew ED, 2013, CLIN J AM SOC NEPHRO, V8, P10, DOI 10.2215/CJN.00200112; Smith GL, 2003, J CARD FAIL, V9, P13, DOI 10.1054/jcaf.2003.3; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Wald R, 2009, JAMA-J AM MED ASSOC, V302, P1179, DOI 10.1001/jama.2009.1322; Weisbord SD, 2006, J AM SOC NEPHROL, V17, P2871, DOI 10.1681/ASN.2006030301; Wu VC, 2011, KIDNEY INT, V80, P1222, DOI 10.1038/ki.2011.259; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668; Zavada J, 2010, NEPHROL DIAL TRANSPL, V25, P3911, DOI 10.1093/ndt/gfp766	27	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167038	10.1371/journal.pone.0167038	http://dx.doi.org/10.1371/journal.pone.0167038			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27907046	Green Submitted, Green Published, gold			2023-01-03	WOS:000389482700069
J	Zang, X; Tang, HL; Min, JE; Gu, DN; Montaner, JSG; Wu, ZY; Nosyk, B				Zang, Xiao; Tang, Houlin; Min, Jeong Eun; Gu, Diane; Montaner, Julio S. G.; Wu, Zunyou; Nosyk, Bohdan			Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REDUCING HETEROSEXUAL TRANSMISSION; ACTIVE ANTIRETROVIRAL THERAPY; PLASMA VIRAL LOAD; QUALITY-OF-LIFE; UNITED-STATES; BRITISH-COLUMBIA; COMBINATION PREVENTION; RANDOMIZED-TRIAL; INFECTION	Background In Guangxi Zhuang Autonomous Region, China, an estimated 80% of newly-identified anti-retroviral therapy (ART)-eligible patients are not engaged in ART. Delayed ART uptake ultimately translates into high rates of HIV morbidity, mortality, and transmission. To enhance HIV testing receipt and subsequent treatment uptake in Guangxi, the Chinese Center for Disease Control and Prevention (CDC) executed a cluster-randomized trial to assess the effectiveness and cost-effectiveness of a streamlined HIV testing algorithm (the One4All intervention) in 12 county-level hospitals. Objective To determine the incremental cost-effectiveness of the One4All intervention delivered at county hospitals in Guangxi, China, compared to the current standard of care (SOC). Perspective Health System. Time Horizon 1-, 5- and 25-years. Methods We adapted a dynamic, compartmental HIV transmission model to simulate HIV transmission and progression in Guangxi, China and identify the economic impact and health benefits of implementing the One4All intervention in all Guangxi hospitals. The One4All intervention algorithm entails rapid point-of-care HIV screening, CD4 and viral load testing of individuals presenting for HIV screening, with same-day results and linkage to counselling. We populated the model with data from the One4All trial (CTN-0056), China CDC HIV registry and published reports. Model outcomes were HIV incidence, mortality, costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) of the One4All intervention compared to SOC. Results The One4All testing intervention was more costly than SOC (CNY 2,182 vs. CNY 846), but facilitated earlier ART access, resulting in delayed disease progression and mortality. Over a 25-year time horizon, we estimated that introducing One4All in Guangxi would result in 802 averted HIV cases and 1629 averted deaths at an ICER of CNY 11,678 per QALY gained. Sensitivity analysis revealed that One4All remained cost-effective at even minimal levels of effectiveness. Results were robust to changes to a range of parameters characterizing the HIV epidemic over time. Conclusions The One4All HIV testing strategy was highly cost-effective by WHO standards, and should be prioritized for widespread implementation in Guangxi, China. Integrating the intervention within a broader combination prevention strategy would enhance the public health response to HIV/AIDS in Guangxi.	[Zang, Xiao; Min, Jeong Eun; Montaner, Julio S. G.; Nosyk, Bohdan] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Zang, Xiao; Nosyk, Bohdan] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Tang, Houlin; Gu, Diane; Wu, Zunyou] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Montaner, Julio S. G.] Univ British Columbia, Div AIDS, Fac Med, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; Simon Fraser University; Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; University of British Columbia	Nosyk, B (corresponding author), British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.; Nosyk, B (corresponding author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada.	bnosyk@cfenet.ubc.ca	tang, houlin/HGA-1502-2022		National Institutes of Health, National Institute on Drug Abuse Clinical Trials Network [CTN-0056 (U10DA013045)]; National Health and Family Planning Commission of the People's Republic of China [131-16-000-105-01]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA036307] Funding Source: NIH RePORTER	National Institutes of Health, National Institute on Drug Abuse Clinical Trials Network; National Health and Family Planning Commission of the People's Republic of China; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was funded by the National Institutes of Health, National Institute on Drug Abuse Clinical Trials Network, study number CTN-0056 (U10DA013045), and by the National Health and Family Planning Commission of the People's Republic of China (131-16-000-105-01). The funder had no direct role in the conduct of the analysis or the decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Abbas UL, 2006, JAIDS-J ACQ IMM DEF, V41, P632, DOI 10.1097/01.qai.0000194234.31078.bf; Anderson SJ, 2014, LANCET, V384, P249, DOI 10.1016/S0140-6736(14)61053-9; [Anonymous], 2016, HIV AIDS DAT HUB AS; Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008; Bove J, 2015, J ACQUIR IMMUNE DEFI; CACERES CF, 1994, AIDS, V8, P1051, DOI 10.1097/00002030-199408000-00004; Cayley WE, 2004, AM FAM PHYSICIAN, V70, P1268; Chaiyachati KH, 2014, AIDS, V28, pS187, DOI 10.1097/QAD.0000000000000252; Chang LW, 2013, LANCET INFECT DIS, V13, P65, DOI 10.1016/S1473-3099(12)70273-6; Chen L, 2014, STUDY HIV AIDS EPIDE; Chen Y, 2012, CHINESE J AIDS STD, V18, P86; Chen Yi, 2013, Disease Surveillance, V28, P643; Cheng Gang, 2009, Beijing Da Xue Xue Bao Yi Xue Ban, V41, P135; Chow EPF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/607261; Ciaranello AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117751; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Davis KR, 1999, FAM PLANN PERSPECT, V31, P272, DOI 10.2307/2991537; Des Jarlais DC, 2010, DRUG ALCOHOL DEPEN, V109, P154, DOI 10.1016/j.drugalcdep.2009.12.028; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; Eaton JW, 2014, P NATL ACAD SCI USA, V111, P16202, DOI 10.1073/pnas.1323007111; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gardner LI, 2014, CLIN INFECT DIS, V59, P725, DOI 10.1093/cid/ciu357; Giannou F.K., 2015, EXPERT REV PHARM OUT, V7167, P1; Guangxi Zhuang Autonomous Region Bureau of Statistics, 2012, TAB 2010 POP CENS GU; HIV Modelling Consortium Treatment, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001259; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Holtgrave DR, 1997, J ACQ IMMUN DEF SYND, V16, P54, DOI 10.1097/00042560-199709010-00009; HOMER JB, 1991, INTERFACES, V21, P26, DOI 10.1287/inte.21.3.26; Honiden S, 2006, QUAL LIFE RES, V15, P69, DOI 10.1007/s11136-005-8485-x; Huang YLA, 2015, APPL HEALTH ECON HEA, V13, P149, DOI 10.1007/s40258-014-0142-5; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Hyle EP, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001725; International Advisory Panel on HIV Care Continuum Optimization, 2015, J Int Assoc Provid AIDS Care, V14 Suppl 1, pS3, DOI 10.1177/2325957415613442; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Jones A, 2014, LANCET, V384, P272, DOI 10.1016/S0140-6736(13)62230-8; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Li JH, 2012, AIDS, V26, P2069, DOI 10.1097/QAD.0b013e3283574e54; Long EF, 2006, AIDS, V20, P2207, DOI 10.1097/QAD.0b013e328010c7d0; Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Ministry of Health in People's Republic of China Joint United Nations Programme on HIV/AIDS World Health Organization, 2011, 2011 EST HIV AIDS EP; Ministry of Health of the People's Republic of China, 2010, CHIN 2010 UNGASS COU; Mo Y, 2010, RES DRUG PROBLEMS GU; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; National Center for AIDS/STD Control and Prevention China CDC, 2012, AN HIV AIDS TEST TRE; NCAIDS N China CDC, 2011, CHINESE J AIDS STD; Nosyk B, 2014, CURR HIV-AIDS REP, V11, P468, DOI 10.1007/s11904-014-0227-7; Nosyk B, 2014, PHARMACOECONOMICS; Nosyk B, 2015, CONT CLIN TRIALS B, V45, P9; Nosyk B, 2015, LANCET HIV, V2, pE393, DOI 10.1016/S2352-3018(15)00127-7; Nosyk B, 2014, LANCET INFECT DIS, V14, P40, DOI 10.1016/S1473-3099(13)70254-8; Nosyk B, 2013, JAIDS-J ACQ IMM DEF, V63, P653, DOI 10.1097/QAI.0b013e3182976891; Nosyk B, 2013, AIDS, V27, P1159, DOI 10.1097/QAD.0b013e32835f1d68; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Pitman R, 2012, VALUE HEALTH, V15, P828, DOI 10.1016/j.jval.2012.06.011; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Region SBoGZA, 2015, GUANGX STAT YB 2015; Rodger ABT., 2014, C RETR OPP INF 2014; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Schackman BR, 2002, MED DECIS MAKING, V22, P27, DOI 10.1177/02729890222062892; Schackman BR, 2013, DRUG ALCOHOL DEPEN, V128, P90, DOI 10.1016/j.drugalcdep.2012.08.009; She Y, 2010, J CHONGQING MED U, V135, P1902; Strathdee SA, 2012, CURR OPIN HIV AIDS, V7, P320, DOI 10.1097/COH.0b013e32835369ad; Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300; UNAIDS, 2014, 90 90 90 AMB TREATM; Vermund SH, 2013, CURR HIV-AIDS REP, V10, P169, DOI 10.1007/s11904-013-0155-y; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; Walensky RP, 2007, CLIN INFECT DIS, V45, pS248, DOI 10.1086/522546; Wang SH, 2011, ASIA-PAC J PUBLIC HE, V23, P620, DOI 10.1177/1010539511412576; Wang X, 2015, J APPL PREV MED, V21, P171; Wang X, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-192; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Wei Liu, 2006, Subst Abus, V27, P53; Wood E., 2009, BMJ-BRIT MED J, V338, P1191; World Health Organization, 2015, CHOOS INT AR COST EF; Wu Z, LANCET UNPUB; Wu ZY, 2013, CLIN INFECT DIS, V57, P298, DOI 10.1093/cid/cit210; Xu Y, 2008, RES PSYCHOL PHYSL CH; Yang Hong-mei, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P393; Zaric GS, 2000, AM J PUBLIC HEALTH, V90, P1100, DOI 10.2105/AJPH.90.7.1100; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	85	16	16	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2016	11	11							e0167308	10.1371/journal.pone.0167308	http://dx.doi.org/10.1371/journal.pone.0167308			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3FE	27893864	Green Published, Green Submitted, gold			2023-01-03	WOS:000389472400111
J	Carson, JL; Guyatt, G; Heddle, NM; Grossman, BJ; Cohn, CS; Fung, MK; Gernsheimer, T; Holcomb, JB; Kaplan, LJ; Katz, LM; Peterson, N; Ramsey, G; Rao, SV; Roback, JD; Shander, A; Tobian, AAR				Carson, Jeffrey L.; Guyatt, Gordon; Heddle, Nancy M.; Grossman, Brenda J.; Cohn, Claudia S.; Fung, Mark K.; Gernsheimer, Terry; Holcomb, John B.; Kaplan, Lewis J.; Katz, Louis M.; Peterson, Nikki; Ramsey, Glenn; Rao, Sunil V.; Roback, John D.; Shander, Aryeh; Tobian, Aaron A. R.			Clinical Practice Guidelines From the AABB Red Blood Cell Transfusion Thresholds and Storage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; ELECTIVE ORTHOPEDIC-SURGERY; RESTRICTIVE TRANSFUSION; HIP FRACTURE; HEMOGLOBIN THRESHOLD; FEASIBILITY TRIAL; ELDERLY-PATIENTS; CARDIAC-SURGERY; ACUTE-LEUKEMIA; PILOT	IMPORTANCE More than 100 million units of blood are collected worldwide each year, yet the indication for red blood cell (RBC) transfusion and the optimal length of RBC storage prior to transfusion are uncertain. OBJECTIVE To provide recommendations for the target hemoglobin level for RBC transfusion among hospitalized adult patients who are hemodynamically stable and the length of time RBCs should be stored prior to transfusion. EVIDENCE REVIEW Reference librarians conducted a literature search for randomized clinical trials (RCTs) evaluating hemoglobin thresholds for RBC transfusion (1950-May 2016) and RBC storage duration (1948-May 2016) without language restrictions. The results were summarized using the Grading of Recommendations Assessment, Development and Evaluation method. For RBC transfusion thresholds, 31 RCTs included 12 587 participants and compared restrictive thresholds (transfusion not indicated until the hemoglobin level is 7-8 g/dL) with liberal thresholds (transfusion not indicated until the hemoglobin level is 9-10 g/dL). The summary estimates across trials demonstrated that restrictive RBC transfusion thresholds were not associated with higher rates of adverse clinical outcomes, including 30-day mortality, myocardial infarction, cerebrovascular accident, rebleeding, pneumonia, or thromboembolism. For RBC storage duration, 13 RCTs included 5515 participants randomly allocated to receive fresher blood or standard-issue blood. These RCTs demonstrated that fresher blood did not improve clinical outcomes. FINDINGS It is good practice to consider the hemoglobin level, the overall clinical context, patient preferences, and alternative therapies when making transfusion decisions regarding an individual patient. Recommendation 1: a restrictive RBC transfusion threshold in which the transfusion is not indicated until the hemoglobin level is 7 g/dL is recommended for hospitalized adult patients who are hemodynamically stable, including critically ill patients, rather than when the hemoglobin level is 10 g/dL (strong recommendation, moderate quality evidence). A restrictive RBC transfusion threshold of 8 g/dL is recommended for patients undergoing orthopedic surgery, cardiac surgery, and those with preexisting cardiovascular disease (strong recommendation, moderate quality evidence). The restrictive transfusion threshold of 7 g/dL is likely comparable with 8 g/dL, but RCT evidence is not available for all patient categories. These recommendations do not apply to patients with acute coronary syndrome, severe thrombocytopenia (patients treated for hematological or oncological reasons who are at risk of bleeding), and chronic transfusion-dependent anemia (not recommended due to insufficient evidence). Recommendation 2: patients, including neonates, should receive RBC units selected at any point within their licensed dating period (standard issue) rather than limiting patients to transfusion of only fresh (storage length: <10 days) RBC units (strong recommendation, moderate quality evidence). CONCLUSIONS AND RELEVANCE Research in RBC transfusion medicine has significantly advanced the science in recent years and provides high-quality evidence to inform guidelines. A restrictive transfusion threshold is safe in most clinical settings and the current blood banking practices of using standard-issue blood should be continued.	[Carson, Jeffrey L.] Rutgers State Univ, Rutgers RobertWood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ USA; [Guyatt, Gordon] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Guyatt, Gordon; Heddle, Nancy M.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Grossman, Brenda J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Cohn, Claudia S.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Fung, Mark K.] Univ Vermont, Med Ctr, Dept Pathol & Lab Med, Burlington, VT USA; [Gernsheimer, Terry] Univ Washington, Div Hematol, Seattle, WA 98195 USA; [Holcomb, John B.] Univ Texas Med Sch, Dept Surg, Galveston, TX USA; [Kaplan, Lewis J.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Katz, Louis M.] Amer Blood Ctr, Washington, DC USA; [Katz, Louis M.] Univ Iowa, Dept Med, Div Infect Dis, Carver Coll Med, Iowa City, IA 52242 USA; [Ramsey, Glenn] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Evanston, IL USA; [Rao, Sunil V.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; [Roback, John D.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Shander, Aryeh] Englewood Hosp & Med Ctr, Dept Anesthesiol, Englewood, NJ USA; [Shander, Aryeh] Englewood Hosp & Med Ctr, Dept Crit Care Med, Englewood, NJ USA; [Shander, Aryeh] Englewood Hosp & Med Ctr, Dept Pain Management, Englewood, NJ USA; [Shander, Aryeh] Englewood Hosp & Med Ctr, Dept Hyperbar Med, Englewood, NJ USA; [Tobian, Aaron A. R.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; McMaster University; McMaster University; Washington University (WUSTL); University of Minnesota System; University of Minnesota Twin Cities; University of Vermont; University of Vermont Medical Center; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health Science Center Houston; University of Texas Medical Branch Galveston; University of Pennsylvania; Pennsylvania Medicine; University of Iowa; Northwestern University; Feinberg School of Medicine; Duke University; Emory University; Englewood Hospital & Medical Center; Englewood Hospital & Medical Center; Englewood Hospital & Medical Center; Englewood Hospital & Medical Center; Johns Hopkins University	Carson, JL (corresponding author), Rutgers State Univ, Rutgers Robert Wood Johnson Med Sch, 125 Paterson St, New Brunswick, NJ 08901 USA.	jeffrey.carson@rutgers.edu		holcomb, john/0000-0001-8312-9157	AABB (previously known as the American Association of Blood Banks)	AABB (previously known as the American Association of Blood Banks)	Support for guideline development was provided by the AABB (previously known as the American Association of Blood Banks).	Alexander PE, 2016, BLOOD, V127, P400, DOI 10.1182/blood-2015-09-670950; Amer Soc Anesthesiologists, 2015, ANESTHESIOLOGY, V122, P241, DOI 10.1097/ALN.0000000000000463; ANDERSON HT, 1978, SURGERY, V84, P8; Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Aubron C, 2012, TRANSFUSION, V52, P1196, DOI 10.1111/j.1537-2995.2011.03437.x; Bennett-Guerrero E, 2010, JAMA-J AM MED ASSOC, V304, P1568, DOI 10.1001/jama.2010.1406; Bennett-Guerrero E, 2009, TRANSFUSION, V49, P1375, DOI 10.1111/j.1537-2995.2009.02152.x; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BLAJCHMAN MA, 1994, BRIT J HAEMATOL, V86, P347, DOI 10.1111/j.1365-2141.1994.tb04737.x; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Bush RL, 1997, AM J SURG, V174, P143, DOI 10.1016/S0002-9610(97)00073-1; Carson JL, 2006, TRANSFUSION, V46, P2192, DOI 10.1111/j.1537-2995.2006.01056.x; Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4; Carson JL, 2015, LANCET, V385, P1183, DOI 10.1016/S0140-6736(14)62286-8; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Clifford L, 2015, ANESTHESIOLOGY, V122, P21, DOI 10.1097/ALN.0000000000000513; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; da Cunha DHF, 2005, TRANSFUSION MED, V15, P467, DOI 10.1111/j.1365-3148.2005.00624.x; de Almeida JP, 2015, ANESTHESIOLOGY, V122, P29, DOI 10.1097/ALN.0000000000000511; de Watering LV, 2006, TRANSFUSION, V46, P1712, DOI 10.1111/j.1537-2995.00958.x; DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DeZern AE, 2016, TRANSFUSION, V56, P1750, DOI 10.1111/trf.13658; Dhabangi A, 2015, JAMA-J AM MED ASSOC, V314, P2514, DOI 10.1001/jama.2015.13977; Dhabangi A, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-55; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Edgren G, 2010, TRANSFUSION, V50, P1185, DOI 10.1111/j.1537-2995.2010.02583.x; ESCOLAR G, 1988, TRANSFUSION, V28, P406, DOI 10.1046/j.1537-2995.1988.28588337325.x; Fan YX, 2014, ARCH GERONTOL GERIAT, V59, P181, DOI 10.1016/j.archger.2014.03.009; Federowicz I, 1996, TRANSFUSION, V36, P21, DOI 10.1046/j.1537-2995.1996.36196190511.x; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; FISHER M R, 1956, Br J Clin Pract, V10, P770; Foss NB, 2009, TRANSFUSION, V49, P227, DOI 10.1111/j.1537-2995.2008.01967.x; Frank SM, 2012, ANESTHESIOLOGY, V117, P99, DOI 10.1097/ALN.0b013e318255e550; Gregersen M, 2015, J AM MED DIR ASSOC, V16, P762, DOI 10.1016/j.jamda.2015.03.022; Gregersen Merete, 2015, Eur J Orthop Surg Traumatol, V25, P1031, DOI 10.1007/s00590-015-1609-2; Gregersen M, 2015, ACTA ORTHOP, V86, P363, DOI 10.3109/17453674.2015.1006980; Grover M, 2006, VOX SANG, V90, P105, DOI 10.1111/j.1423-0410.2006.00730.x; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 2005, ANESTH ANALG, V100, P1433, DOI 10.1213/01.ANE.0000148690.48803.27; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Heddle NM, 2012, TRANSFUSION, V52, P1203, DOI 10.1111/j.1537-2995.2011.03521.x; Hod EA, 2011, BLOOD, V118, P6675, DOI 10.1182/blood-2011-08-371849; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Jairath V, 2015, LANCET, V386, P137, DOI 10.1016/S0140-6736(14)61999-1; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kaukonen KM, 2014, CRIT CARE RESUSC, V16, P255; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Kor DJ, 2012, AM J RESP CRIT CARE, V185, P842, DOI 10.1164/rccm.201107-1332OC; Kwok CS, 2015, JACC-CARDIOVASC INTE, V8, P436, DOI 10.1016/j.jcin.2014.09.026; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Lacroix J, 2015, NEW ENGL J MED, V372, P1410, DOI 10.1056/NEJMoa1500704; Lotke PA, 1999, J ARTHROPLASTY, V14, P647, DOI 10.1016/S0883-5403(99)90216-4; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; Manlhiot C, 2012, ANN THORAC SURG, V93, P1563, DOI 10.1016/j.athoracsur.2011.08.075; Middelburg RA, 2010, TRANSFUSION, V50, P1181, DOI 10.1111/j.1537-2995.2010.02675.x; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; National Blood Authority Australia, 2011, GUID ADM BLOOD PROD; Nielsen K, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-89; Parker MJ, 2013, INJURY, V44, P1916, DOI 10.1016/j.injury.2013.04.033; Popovsky M A, 1996, Immunohematology, V12, P87; Prick BW, 2014, BJOG-INT J OBSTET GY, V121, P1005, DOI 10.1111/1471-0528.12531; Qaseem A, 2013, ANN INTERN MED, V159, P770, DOI 10.7326/0003-4819-159-11-201312030-00009; Rao SV, 2008, AM J CARDIOL, V101, P25, DOI 10.1016/j.amjcard.2007.07.042; Retter A, 2013, BRIT J HAEMATOL, V160, P445, DOI 10.1111/bjh.12143; Roback JD, 2011, TRANSFUSION, V51, P859, DOI 10.1111/j.1537-2995.2011.03094.x; Rogers GM, 2013, NCCN GUIDELINES VERS; Rogers MAM, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-37; Rohde JM, 2014, JAMA-J AM MED ASSOC, V311, P1317, DOI 10.1001/jama.2014.2726; Schulman CI, 2002, J TRAUMA, V52, P1224, DOI 10.1097/00005373-200206000-00036; Shehata N, 2012, TRANSFUSION, V52, P91, DOI 10.1111/j.1537-2995.2011.03236.x; SIRCHIA G, 1994, TRANSFUSION MED, V4, P251; So-Osman C, 2013, BLOOD TRANSFUS-ITALY, V11, P289, DOI 10.2450/2013.0172-12; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; Steiner ME, 2015, NEW ENGL J MED, V372, P1419, DOI 10.1056/NEJMoa1414219; Stramer SL, 2013, TRANSFUSION, V53, P2449, DOI 10.1111/trf.12213; Strauss RG, 1996, TRANSFUSION, V36, P873, DOI 10.1046/j.1537-2995.1996.361097017172.x; Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117; The Cochrane Collaboration, 2011, COCHRANE HDB SYSTEMA; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Valeri CR, 2001, TRANSFUSION, V41, P977, DOI 10.1046/j.1537-2995.2001.41080977.x; VALLES J, 1991, BLOOD, V78, P154; Vamvakas EC, 1999, TRANSFUSION, V39, P701, DOI 10.1046/j.1537-2995.1999.39070701.x; Vamvakas EC, 2000, TRANSFUSION, V40, P101, DOI 10.1046/j.1537-2995.2000.40010101.x; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Vuille-Lessard E, 2010, TRANSFUSION, V50, P2117, DOI 10.1111/j.1537-2995.2010.02697.x; Walsh TS, 2013, CRIT CARE MED, V41, P2354, DOI 10.1097/CCM.0b013e318291cce4; Webert KE, 2008, TRANSFUSION, V48, P81, DOI 10.1111/j.1537-2995.2007.01485.x; Whitaker B. I., 2015, 2013 AABB BLOOD COLL; Whitaker BI, 2011 NATL BLOOD COLL; WILKERSON DK, 1988, SURGERY, V103, P665; Zou SM, 2010, TRANSFUSION, V50, P1495, DOI 10.1111/j.1537-2995.2010.02622.x	103	579	595	4	84	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2016	316	19					2025	2035		10.1001/jama.2016.9185	http://dx.doi.org/10.1001/jama.2016.9185			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB8XC	27732721				2023-01-03	WOS:000387673800020
J	Reck, M; Rodriguez-Abreu, D; Robinson, AG; Hui, RN; Csoszi, T; Fulop, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Leiby, MA; Lubiniecki, GM; Shentu, Y; Rangwala, R; Brahmer, JR				Reck, Martin; Rodriguez-Abreu, Delvys; Robinson, Andrew G.; Hui, Rina; Csoszi, Tibor; Fulop, Andrea; Gottfried, Maya; Peled, Nir; Tafreshi, Ali; Cuffe, Sinead; O'Brien, Mary; Rao, Suman; Hotta, Katsuyuki; Leiby, Melanie A.; Lubiniecki, Gregory M.; Shentu, Yue; Rangwala, Reshma; Brahmer, Julie R.		KEYNOTE-024 Investigators	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KEYNOTE-012; IPILIMUMAB; MELANOMA; TRIAL	BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy.	[Reck, Martin] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany; [Rodriguez-Abreu, Delvys] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain; [Robinson, Andrew G.] Kingston Gen Hosp, Canc Ctr Southeastern Ontario, Kingston, ON, Canada; [Hui, Rina] Westmead Hosp, Sydney, NSW, Australia; [Hui, Rina] Univ Sydney, Sydney, NSW, Australia; [Tafreshi, Ali] Southern Med Day Care Ctr, Wollongong, NSW, Australia; [Csoszi, Tibor] Jasz Nagykun Szolnok Cty Hosp, Szolnok, Hungary; [Fulop, Andrea] Orszagos Koranyi TBC & Pulmonol Int, Budapest, Hungary; [Gottfried, Maya] Meir Med Ctr, Kefar Sava, Israel; [Peled, Nir] Tel Aviv Univ, Davidoff Canc Ctr, Petah Tiqwa, Israel; [Cuffe, Sinead] St James Hosp, Dublin, Ireland; [Cuffe, Sinead] Canc Trials Ireland, Dublin, Ireland; [O'Brien, Mary] Royal Marsden Hosp, Sutton, Surrey, England; [Rao, Suman] MedStar Franklin Sq Hosp, Baltimore, MD USA; [Brahmer, Julie R.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Bunting Blaustein Canc Res Bldg,1650 Orleans St, Baltimore, MD 21287 USA; [Hotta, Katsuyuki] Okayama Univ Hosp, Okayama, Japan; [Leiby, Melanie A.; Lubiniecki, Gregory M.; Shentu, Yue; Rangwala, Reshma] Merck, Kenilworth, NJ USA	Queens University - Canada; University of Sydney; University of Sydney; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Trinity College Dublin; Royal Marsden NHS Foundation Trust; Johns Hopkins University; Johns Hopkins Medicine; Okayama University; Merck & Company	Brahmer, JR (corresponding author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Bunting Blaustein Canc Res Bldg,1650 Orleans St, Baltimore, MD 21287 USA.		Hui, Rina/L-6114-2019; Tiseo, Marcello/K-6119-2016; Reck, Martin/ABF-5721-2020; FELIP, ENRIQUETA/AAG-6316-2019	Tiseo, Marcello/0000-0002-9553-8465; Reck, Martin/0000-0002-5348-4462; Juan, Oscar/0000-0002-7772-9030; Rodriguez-Abreu, Delvys/0000-0003-0506-1366; O'Byrne, Kenneth/0000-0002-6754-5633; Balmana, Judith/0000-0002-0762-6415; FELIP, ENRIQUETA/0000-0002-7620-0098; Peled, Nir/0000-0003-3714-4377; Bennouna, Jaafar/0000-0002-5034-1108	Merck (Kenilworth, NJ)	Merck (Kenilworth, NJ)(Merck & Company)	Supported by Merck (Kenilworth, NJ).	Chatterjee M, 2016, ANN ONCOL, V27, P1291, DOI 10.1093/annonc/mdw174; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Freshwater T, 2015, 6 AM C PHARM ARL VA; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hui R, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9026; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Pilkington G, 2015, THORAX, V70, P359, DOI 10.1136/thoraxjnl-2014-205914; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Tan PS, 2015, EUR J CANCER, V51, P2330, DOI 10.1016/j.ejca.2015.07.007; Xiao HQ, 2016, ONCOTARGETS THER, V9, P1471, DOI 10.2147/OTT.S96160	15	5777	5985	47	433	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2016	375	19					1823	1833		10.1056/NEJMoa1606774	http://dx.doi.org/10.1056/NEJMoa1606774			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB6ZK	27718847	Green Published, Bronze			2023-01-03	WOS:000387534200006
J	Garbati, MA; Fagbo, SF; Fang, VJ; Skakni, L; Joseph, M; Wani, TA; Cowling, BJ; Peiris, M; Hakawi, A				Garbati, Musa A.; Fagbo, Shamsudeen F.; Fang, Vicky J.; Skakni, Leila; Joseph, Mercy; Wani, Tariq A.; Cowling, Benjamin J.; Peiris, Malik; Hakawi, Ahmed			A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes	PLOS ONE			English	Article							SAUDI-ARABIA; INFECTION; OUTBREAK	Middle East Respiratory syndrome (MERS) first emerged in Saudi Arabia in 2012 and remains a global health concern. The objective of this study was to compare the clinical features and risk factors for adverse outcome in patients with RT-PCR confirmed MERS and in those with acute respiratory disease who were MERS-CoV negative, presenting to the King Fahad Medical City (KFMC) in Riyadh between October 2012 and May 2014. The demographics, clinical and laboratory characteristics and clinical outcomes of patients with RT-PCR confirmed MERS-CoV infection was compared with those testing negative MERS-CoV PCR. Health care workers (HCW) with MERS were compared with MERS patients who were not health care workers. One hundred and fifty nine patients were eligible for inclusion. Forty eight tested positive for MERS CoV, 44 (92%) being hospital acquired infections and 23 were HCW. There were 111 MERS-CoV negative patients with acute respiratory illnesses included in this study as "negative controls". Patient with confirmed MERS-CoV infection were not clinically distinguishable from those with negative MERS-CoV RT-PCR results although diarrhoea was commoner in MERS patients. A high level of suspicion in initiating laboratory tests for MERS-CoV is therefore indicated. Variables associated with adverse outcome were older age and diabetes as a co-morbid illness. Interestingly, co-morbid illnesses other than diabetes were not significantly associated with poor outcome. Health care workers with MERS had a markedly better clinical outcome compared to non HCW MERS patients.	[Garbati, Musa A.; Fagbo, Shamsudeen F.; Skakni, Leila; Joseph, Mercy; Wani, Tariq A.; Hakawi, Ahmed] King Fahad Med City, Riyadh, Saudi Arabia; [Fang, Vicky J.; Cowling, Benjamin J.; Peiris, Malik] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Hakawi, A (corresponding author), King Fahad Med City, Riyadh, Saudi Arabia.; Peiris, M (corresponding author), Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China.	malik@hku.hk; ahakawi@kfmc.med.sa	Cowling, Benjamin John/C-4263-2009; Fagbo, Shamsudeen/GYE-1971-2022; Peiris, Joseph Sriyal Malik/C-4380-2009	Cowling, Benjamin John/0000-0002-6297-7154; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Fagbo, Shamsudeen/0000-0003-3448-6136; Garbati, Musa/0000-0003-3438-421X	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272201400006C]	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272201400006C.	Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226; Alraddadi B, 2016, ANN THORAC MED, V11, P128, DOI 10.4103/1817-1737.180027; Alraddadi BM, 2016, EMERG INFECT DIS, V22, P49, DOI 10.3201/eid2201.151340; Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486; Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4; Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505; Fagbo SF, 2015, EMERG INFECT DIS, V21, P1981, DOI 10.3201/eid2111.150944; Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4; Hastings DL, 2016, EMERG INFECT DIS, V22, P794, DOI 10.3201/eid2205.151797; Korea Centers for Disease Control and Prevention, 2015, Osong Public Health Res Perspect, V6, P269, DOI 10.1016/j.phrp.2015.08.006; Memish ZA, 2013, NEW ENGL J MED, V369, P884, DOI 10.1056/NEJMc1308698; Oboho IK, 2015, NEW ENGL J MED, V372, P846, DOI 10.1056/NEJMoa1408636; Peiris JSM, 2007, EMERG INFECT, V7, P23; World Health Organization, MIDDL E RESP SYNDR C; World Health Organization, 2015, LAB TEST MIDDL E SYN; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721	16	73	78	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2016	11	11							e0165978	10.1371/journal.Pone.0165978	http://dx.doi.org/10.1371/journal.Pone.0165978			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA8SX	27812197	Green Published, Green Submitted, gold			2023-01-03	WOS:000386910000088
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: Base care on need, not age	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Age UK, EQ ACT WHAT IT MEANS; Appleby J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1563; Bardsley M, 2013, EVALUATING INTEGRATE; Blumenthal D, 2016, NEW ENGL J MED, V375, P909, DOI 10.1056/NEJMp1608511; British Geriatrics Society College of Emergency Medicine Society of Acute Medicine, 2012, SILV BOOK QUAL CAR O; Centre for Policy on Ageing, 2016, SEL READ AG AG DISCR; Darzi A., 2016, TIMES; Edwards N., 2014, COMMUNITY SERVICES T; McMurdo MET, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f867; National Audit Office, 2000, INP ADM BED MAN NHS; NHS Benchmarking Network, 2015, OLD PEOPL AC SETT BE; NHS Confederation, 2010, DEAL DOWNT; NHS England, 2013, NHS BEL PEOPL CALL A; Oliver D., 2016, WHAT COMMUNITY SERVI; Purdy S, 2012, INTERVENTIONS REDUCE; RAVEN R J, 1988, American Museum Novitates, P1; Trust N. Health Foundation, 2014, QUALITYWATCH FOC A E; Wright O., 2013, INDEPENDENT	18	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2016	355								i5788	10.1136/bmj.i5788	http://dx.doi.org/10.1136/bmj.i5788			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA5LR	27793814	Green Published, Bronze			2023-01-03	WOS:000386662600005
J	Hedberg, AE				Hedberg, Alexandra E.			Do You Dare to Dharma?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIANS; SUICIDE; BURNOUT		[Hedberg, Alexandra E.] Northwestern Feinberg Sch Med, Dept Psychiat, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Hedberg, AE (corresponding author), Northwestern Feinberg Sch Med, Dept Psychiat, Chicago, IL 60611 USA.	aerhedberg@gmail.com						Center C, 2003, JAMA-J AM MED ASSOC, V289, P3161, DOI 10.1001/jama.289.23.3161; Dyrbye LN, 2014, ACAD MED, V89, P443, DOI 10.1097/ACM.0000000000000134; Dyrbye LN, 2011, ACAD MED, V86, P801, DOI 10.1097/ACM.0b013e31821da481; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Epstein RM, 2013, ACAD MED, V88, P301, DOI 10.1097/ACM.0b013e318280cff0; Goenka SN, 2014, VIPASSANA NEWSLETTER; Goenka SN, 2010, DISCOURSE SUMMARIES; Krasner MS, 2009, JAMA-J AM MED ASSOC, V302, P1284, DOI 10.1001/jama.2009.1384; Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295; Shapiro SL, 2000, ACAD MED, V75, P748, DOI 10.1097/00001888-200007000-00023	10	0	0	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2016	316	16					1677	1678		10.1001/jama.2016.8526	http://dx.doi.org/10.1001/jama.2016.8526			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ8GB	27784098				2023-01-03	WOS:000386107800031
J	Zhang, YH; Chu, C; Wang, SP; Chen, L; Lu, J; Kong, XY; Huang, T; Li, HP; Cai, YD				Zhang, Yu-Hang; Chu, Chen; Wang, Shaopeng; Chen, Lei; Lu, Jing; Kong, XiangYin; Huang, Tao; Li, HaiPeng; Cai, Yu-Dong			The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life	PLOS ONE			English	Article							METABOLIZING ENZYME-SYSTEM; AMINO-ACID-COMPOSITION; FUCOSYLATED CHONDROITIN SULFATE; ALBUMIN-BINDING DOMAIN; VOLTAGE-GATED SODIUM; ALPHA-LINOLENIC ACID; IN-VIVO; RECEPTOR AGONIST; STEADY-STATE; PREDICTION	A drug's biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO) terms and biological pathways were highly related to the determination of drug half-life. The investigated drugs, with known half-lives, were analyzed based on their enrichment scores for associated GO terms and KEGG pathways. These scores indicate which GO terms or KEGG pathways the drug targets. The feature selection method, minimum redundancy maximum relevance, was used to analyze these GO terms and KEGG pathways and to identify important GO terms and pathways, such as sodium-independent organic anion transmembrane transporter activity (GO: 0015347), monoamine transmembrane transporter activity (GO: 0008504), negative regulation of synaptic transmission (GO: 0050805), neuroactive ligand-receptor interaction (hsa04080), serotonergic synapse (hsa04726), and linoleic acid metabolism (hsa00591), among others. This analysis confirmed our results and may show evidence for a new method in studying drug half-lives and building effective computational methods for the prediction of drug half-lives.	[Zhang, Yu-Hang; Wang, Shaopeng; Cai, Yu-Dong] Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China; [Zhang, Yu-Hang; Kong, XiangYin; Huang, Tao] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200031, Peoples R China; [Chu, Chen] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; [Chen, Lei] Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China; [Lu, Jing] Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & B, Minist Educ, Sch Pharm,Key Lab Mol Pharmacol & Drug Evaluat, Yantai 264005, Peoples R China; [Li, HaiPeng] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Key Lab Computat Biol, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China	Shanghai University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Maritime University; Yantai University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society	Cai, YD (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200031, Peoples R China.	tohuangtao@l26.com; lihaipeng@picb.ac.cn; cai_yud@126.com	Zhang, Yu-Hang/AAQ-9012-2021; Chen, Lei/A-2275-2011; Chu, Chen/J-6527-2019; Zhang, Yu-Hang/O-9774-2015	Zhang, Yu-Hang/0000-0003-3825-0796; Chen, Lei/0000-0003-3068-1583; Chu, Chen/0000-0001-8084-0867; Zhang, Yu-Hang/0000-0003-3825-0796; cai, yudong/0000-0001-5664-7979	National Natural Science Foundation of China [31371335, 61303099]; Shanghai Sailing Program; Youth Innovation Promotion Association of Chinese Academy of Sciences (CAS) [2016245]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program; Youth Innovation Promotion Association of Chinese Academy of Sciences (CAS)	National Natural Science Foundation of China (31371335, 61303099), Shanghai Sailing Program and The Youth Innovation Promotion Association of Chinese Academy of Sciences (CAS) (2016245). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by the National Natural Science Foundation of China (31371335, 61303099), Shanghai Sailing Program and The Youth Innovation Promotion Association of Chinese Academy of Sciences (CAS) (2016245).	Arnot JA, 2014, ENVIRON SCI TECHNOL, V48, P723, DOI 10.1021/es4029414; BACON E, 1989, DEV BRAIN RES, V47, P293, DOI 10.1016/0165-3806(89)90185-5; Basuli F, 2015, NUCL MED BIOL, V42, P219, DOI 10.1016/j.nucmedbio.2014.11.011; Berezhkovskiy LM, 2013, J PHARM SCI-US, V102, P761, DOI 10.1002/jps.23396; Bhatt DK, 2013, CEPHALALGIA, V33, P87, DOI 10.1177/0333102412466967; BLUSCHKE V, 1976, ARZNEIMITTEL-FORSCH, V26, P591; Bohmer T, 1998, AGE AGEING, V27, P222, DOI 10.1093/ageing/27.2.222; BORELGIRAUD N, 1976, CLIN CHIM ACTA, V71, P117, DOI 10.1016/0009-8981(76)90521-0; BREUER J, 1973, Z KLIN CHEM KLIN BIO, V11, P263; Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Catterall WA, 2015, MOL PHARMACOL, V88, P141, DOI 10.1124/mol.114.097659; Chen D, 2012, J CLIN PHARMACOL, V52, P319, DOI 10.1177/0091270010397049; Chen H, 2015, CLIN DRUG INVEST, V35, P151, DOI 10.1007/s40261-014-0265-3; Chen L, 2016, COMB CHEM HIGH T SCR, V19, P136, DOI 10.2174/1386207319666151110122453; Chen L, 2015, AMINO ACIDS, V47, P1485, DOI 10.1007/s00726-015-1974-5; Chen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107767; Chen L, 2014, MOL BIOSYST, V10, P868, DOI 10.1039/c3mb70490d; Chen L, 2013, CURR BIOINFORM, V8, P545, DOI 10.2174/1574893611308050004; Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035254; Chen L, 2009, J PROTEOME RES, V8, P5212, DOI 10.1021/pr900554a; CONARD GJ, 1984, AM J CARDIOL, V53, pB41, DOI 10.1016/0002-9149(84)90501-0; DEGEN J, 1993, MED KLIN, V88, P129; Diepstraten J, 2015, EUR J CLIN PHARMACOL, V71, P25, DOI 10.1007/s00228-014-1760-4; Ding Chris, 2005, Journal of Bioinformatics and Computational Biology, V3, P185, DOI 10.1142/S0219720005001004; DOWN WH, 1974, ARZNEIMITTELFORSCH, V24, P1986; Elaut G, 2007, J PHARMACOL EXP THER, V321, P400, DOI 10.1124/jpet.106.116202; Evertts AG, 2013, J BIOL CHEM, V288, P12142, DOI 10.1074/jbc.M112.428318; Ferrer I, 1997, J NEUROPATH EXP NEUR, V56, P1; Frampton JE, 2007, CNS DRUGS, V21, P521, DOI 10.2165/00023210-200721060-00007; Gabrielsson J, 2016, AAPS J, V18, P47, DOI 10.1208/s12248-015-9817-6; GEBO H, 1973, DRUG INTEL CLIN PHAR, V7, P357; Gomes CLR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106929; Graham RA, 2011, CLIN CANCER RES, V17, P2512, DOI 10.1158/1078-0432.CCR-10-2736; Gustafsson F, 2014, TOXICOL SCI, V137, P189, DOI 10.1093/toxsci/kft223; Hindmarsh PC, 2015, CLIN ENDOCRINOL, V82, P557, DOI 10.1111/cen.12653; HINO Y, 1974, J BIOCHEM-TOKYO, V76, P735; Hojo R, 2002, ENVIRON HEALTH PERSP, V110, P247, DOI 10.1289/ehp.02110247; Hu LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014556; Hu SW, 2014, J MED FOOD, V17, P749, DOI 10.1089/jmf.2013.2924; Hu SW, 2014, J FOOD SCI, V79, pH1424, DOI 10.1111/1750-3841.12465; Huang T, 2012, BIOCHIMIE, V94, P1017, DOI 10.1016/j.biochi.2011.12.024; Iribarren Carlos, 2013, Pharmacoepidemiol Drug Saf, V22, P1222, DOI 10.1002/pds.3479; Johne A, 2005, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V48, P397, DOI 10.1007/s00103-005-1012-y; Johnson KE, 2016, MOL CELL ENDOCRINOL, V422, P84, DOI 10.1016/j.mce.2015.12.007; Keenan JM, 2013, J CLIN LIPIDOL, V7, P14, DOI 10.1016/j.jacl.2012.10.004; Keller F, 2011, N-S ARCH PHARMACOL, V383, P7; Kietadisorn R, 2011, AM J PHYSIOL-ENDOC M, V300, pE1176, DOI 10.1152/ajpendo.00084.2011; Killen JD, 2010, ADDICTION, V105, P1660, DOI 10.1111/j.1360-0443.2010.03020.x; Kim EJ, 2014, CLIN CANCER RES, V20, P5937, DOI 10.1158/1078-0432.CCR-14-1269; Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Le Noury J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4320; Lee AYY, 2003, J INTERN MED, V254, P313, DOI 10.1046/j.1365-2796.2003.01224.x; LEE EHY, 1985, J PHARMACOL EXP THER, V234, P141; LEVIS S, 1957, ARCH INT PHARMACOD T, V109, P127; Li ZC, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-325; Lim KS, 2008, BRIT J CLIN PHARMACO, V66, P660, DOI 10.1111/j.1365-2125.2008.03267.x; Lindgren J, 2014, BIOPOLYMERS, V102, P252, DOI 10.1002/bip.22474; Liu XP, 2013, BIOINFORMATICS, V29, P1910, DOI 10.1093/bioinformatics/btt303; Liu YN, 2011, ARCH TOXICOL, V85, P1133, DOI 10.1007/s00204-010-0639-0; Lu J, 2016, BBA-GEN SUBJECTS, V1860, P2664, DOI 10.1016/j.bbagen.2016.05.019; Lu J, 2016, J BIOMOL STRUCT DYN, V34, P906, DOI 10.1080/07391102.2015.1060161; Lyseng-Williamson KA, 2014, BIODRUGS, V28, P465, DOI 10.1007/s40259-014-0108-z; Ma TH, 2015, IEICE T INF SYST, VE98D, P902, DOI 10.1587/transinf.2014EDP7283; Mahdi AJ, 2015, BRIT J HAEMATOL, V169, P768, DOI 10.1111/bjh.13360; Malm M, 2014, BIOTECHNOL J, V9, P1215, DOI 10.1002/biot.201400009; Marklund M, 2014, J NUTR, V144, P1674, DOI 10.3945/jn.114.196220; Mathijssen NCJ, 2013, THROMB RES, V132, P256, DOI 10.1016/j.thromres.2013.05.027; Megaraj V, 2014, CHEM RES TOXICOL, V27, P656, DOI 10.1021/tx4004769; MINERS JO, 1986, BRIT J CLIN PHARMACO, V22, P135, DOI 10.1111/j.1365-2125.1986.tb05240.x; Mistraletti G, 2015, MINERVA ANESTESIOL, V81, P1298; Miyasato Katsumasa, 2010, Nihon Rinsho, V68, P1431; MODELL W, 1962, CLIN PHARMACOL THER, V3, P235, DOI 10.1002/cpt196232235; Mohabatkar H, 2013, MED CHEM, V9, P133, DOI 10.2174/157340613804488341; Mohabatkar H, 2011, J THEOR BIOL, V281, P18, DOI 10.1016/j.jtbi.2011.04.017; Montoro JB, 1999, HAEMOPHILIA, V5, P371; Moriyama B, 2011, MYCOSES, V54, pE877, DOI 10.1111/j.1439-0507.2011.02016.x; Mukherjee S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001987; Naziroglu M, 2014, J MEMBRANE BIOL, V247, P253, DOI 10.1007/s00232-014-9630-7; Obach RS, 2008, DRUG METAB DISPOS, V36, P1385, DOI 10.1124/dmd.108.020479; ORTON TC, 1982, DRUG METAB DISPOS, V10, P110; Pawlosky RJ, 2001, J LIPID RES, V42, P1257; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Rahman W, 2013, NEUROSCI LETT, V557, P19, DOI 10.1016/j.neulet.2013.08.004; RASPE HH, 1987, Z RHEUMATOL, V46, P71; Saccenti E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119856; Sagcal-Gironella ACP, 2011, CLIN THER, V33, P1524, DOI 10.1016/j.clinthera.2011.09.015; Sanford M, 2009, DRUGS, V69, P461, DOI 10.2165/00003495-200969040-00006; Schaal W, 2013, BIOINFORMATICS, V29, P2369, DOI 10.1093/bioinformatics/btt390; Shafran Y, 2012, ANAL CHEM, V84, P7315, DOI 10.1021/ac202741z; Sikkel MB, 2013, CARDIOVASC RES, V98, P286, DOI 10.1093/cvr/cvt012; SIMONS FER, 1984, J PEDIATR-US, V104, P123; Sullivan BP, 2013, BLOOD, V121, P1868, DOI 10.1182/blood-2012-09-455436; TRNAVSKY K, 1975, AGENTS ACTIONS, V5, P549, DOI 10.1007/BF01972693; Turner JV, 2003, J PHARM SCI, V92, P552, DOI 10.1002/jps.10314; Vrancken K, 2013, AM J PHYSIOL-REG I, V305, pR1401, DOI 10.1152/ajpregu.00266.2013; Wakao M, 2015, BIOORG MED CHEM LETT, V25, P1407, DOI 10.1016/j.bmcl.2015.02.054; WANG RIH, 1980, JAMA-J AM MED ASSOC, V243, P1901; Wen XZ, 2015, INFORM SCIENCES, V295, P395, DOI 10.1016/j.ins.2014.10.040; Worboys PD, 2015, EUR J CLIN PHARMACOL, V71, P707, DOI 10.1007/s00228-015-1847-6; Xiao YL, 2014, INT J PHARMACEUT, V465, P143, DOI 10.1016/j.ijpharm.2014.02.009; Yan JH, 2014, J CLIN PHARMACOL, V54, P800, DOI 10.1002/jcph.285; Yarwood A, 2013, GENES IMMUN, V14, P325, DOI 10.1038/gene.2013.23; Zeng XX, 2016, BRIEF BIOINFORM, V17, P193, DOI 10.1093/bib/bbv033; Zhang P., 2015, J SENSORS, V2015, P10, DOI DOI 10.1371/J0URNAL.P0NE.0133137; Zhang Y, 2008, BMC GENOMICS, V9, DOI [10.1186/1471-2164-9-S2-S27, 10.1186/1471-2164-9-203]; Zhou K, 2013, BIOCHEM PHARMACOL, V85, P1848, DOI 10.1016/j.bcp.2013.04.014; Zou Q, 2016, BRIEF FUNCT GENOMICS, V15, P55, DOI 10.1093/bfgp/elv024	110	13	13	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0165496	10.1371/journal.pone.0165496	http://dx.doi.org/10.1371/journal.pone.0165496			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED7LQ	27780226	Green Published, Green Submitted, gold			2023-01-03	WOS:000389046900060
J	Roche, R; Bain, R; Cumming, O				Roche, Rachel; Bain, Robert; Cumming, Oliver			A long way to go - Estimates of combined water, sanitation and hygiene coverage for 25 sub-Saharan African countries	PLOS ONE			English	Article							MILLENNIUM DEVELOPMENT GOALS; MIDDLE-INCOME SETTINGS; DRINKING-WATER; DIARRHEA; DISEASE; INTERVENTIONS; RISK; INDICATORS; COMMUNITY; BURDEN	Background Water, sanitation and hygiene (WASH) are essential for a healthy and dignified life. International targets to reduce inadequate WASH coverage were set under the Millennium Development Goals (MDGs, 1990-2015) and now the Sustainable Development Goals (SDGs, 2016-2030). The MDGs called for halving the proportion of the population without access to adequate water and sanitation, whereas the SDGs call for universal access, require the progressive reduction of inequalities, and include hygiene in addition to water and sanitation. Estimating access to complete WASH coverage provides a baseline for monitoring during the SDG period. Sub-Saharan Africa (SSA) has among the lowest rates of WASH coverage globally. Methods The most recent available Demographic Household Survey (DHS) or Multiple Indicator Cluster Survey (MICS) data for 25 countries in SSA were analysed to estimate national and regional coverage for combined water and sanitation (a combined MDG indicator for 'improved' access) and combined water with collection time within 30 minutes plus sanitation and hygiene (a combined SDG indicator for 'basic' access). Coverage rates were estimated separately for urban and rural populations and for wealth quintiles. Frequency ratios and percentage point differences for urban and rural coverage were calculated to give both relative and absolute measures of urban-rural inequality. Wealth inequalities were assessed by visual examination of coverage across wealth quintiles in urban and rural populations and by calculating concentration indices as standard measures of relative wealth related inequality that give an indication of how unevenly a health indicator is distributed across the wealth distribution. Results Combined MDG coverage in SSA was 20%, and combined basic SDG coverage was 4%; an estimated 921 million people lacked basic SDG coverage. Relative measures of inequality were higher for combined basic SDG coverage than combined MDG coverage, but absolute inequality was lower. Rural combined basic SDG coverage was close to zero in many countries. Conclusions Our estimates help to quantify the scale of progress required to achieve universal WASH access in low-income countries, as envisaged under the water and sanitation SDG. Monitoring and reporting changes in the proportion of the national population with access to water, sanitation and hygiene may be useful in focusing WASH policy and investments towards the areas of greatest need.	[Roche, Rachel; Cumming, Oliver] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Dis Control, London, England; [Bain, Robert] UNICEF, Div Data Res & Policy, New York, NY USA	University of London; London School of Hygiene & Tropical Medicine; UNICEF	Roche, R (corresponding author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Dis Control, London, England.	rachel.roche@gmail.com		Cumming, Oliver/0000-0002-5074-8709				Abdelkrim A., 2007, DASP DISTRIBUTIVE AN; Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Bain RES, 2012, B WORLD HEALTH ORGAN, V90, P228, DOI 10.2471/BLT.11.094284; Bain R, 2014, TROP MED INT HEALTH, V19, P917, DOI 10.1111/tmi.12334; Bartram J, 2014, INT J ENV RES PUB HE, V11, P8137, DOI 10.3390/ijerph110808137; Benova L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106738; Biran A, 2008, TROP MED INT HEALTH, V13, P278, DOI 10.1111/j.1365-3156.2007.02001.x; Bradley DJ, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2012.0420; Burt Z, 2016, GENDER EQUITY SANITA; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Checkley W, 2008, INT J EPIDEMIOL, V37, P816, DOI 10.1093/ije/dyn099; Cumming O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114699; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Dar OA, 2011, TROP MED INT HEALTH, V16, P540, DOI 10.1111/j.1365-3156.2011.02736.x; Ejemot-Nwadiaro RI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub3; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Fewtrell L, 2005, WATER SCI TECHNOL, V52, P133, DOI 10.2166/wst.2005.0244; Freeman MC, 2014, TROP MED INT HEALTH, V19, P906, DOI 10.1111/tmi.12339; Graham JP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155981; Grimes JET, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003296; Hunter PR, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000361; Hutton G, 2013, J WATER HEALTH, V11, P1, DOI 10.2166/wh.2012.105; JMP, 2015, JMP GREEN PAP GLOB M; JMP, 2012, PROGR DRINK WAT SAN; JMP, 2015, PROGR SAN DRINK WAT; KAWATA K, 1978, AM J CLIN NUTR, V31, P2114, DOI 10.1093/ajcn/31.11.2114; Kayser GL, 2013, INT J ENV RES PUB HE, V10, P4812, DOI 10.3390/ijerph10104812; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Loughnan L. C., 2015, Waterlines, V34, P296, DOI 10.3362/1756-3488.2015.028; Measure DHS/ICF International, 2008, DHS MOD QUEST PHAS 6; Onda Kyle, 2013, World Health Popul, V14, P32; Pruss-Ustun A, 2014, TROP MED INT HEALTH, V19, P894, DOI 10.1111/tmi.12329; Pruss A, 2002, ENVIRON HEALTH PERSP, V110, P537, DOI 10.1289/ehp.02110537; Rabie T, 2006, TROP MED INT HEALTH, V11, P258, DOI 10.1111/j.1365-3156.2006.01568.x; Rheingans R, 2014, TROP MED INT HEALTH, V19, P2, DOI 10.1111/tmi.12220; Rutstein S. O., 2004, DHS COMP REPORTS, DOI DOI 10.1017/CBO9781107415324.004; Shaheed A, 2014, B WORLD HEALTH ORGAN, V92, P283, DOI 10.2471/BLT.13.119594; STANTON BF, 1987, B WORLD HEALTH ORGAN, V65, P217; StataCorp, 2015, STAT STAT SOFTW REL; Stocks ME, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001605; Strunz EC, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001620; UN, 2015, ARES701 UN, DOI 10.1163/157180910X12665776638740; UNICEF, 2008, MICS 4 HOUS QUEST; United Nations, 2010, RES HUM RIGHT WAT SA; United Nations Economic and Social Council, 2016, STAT COMM 47 SESS RE; United Nations Population Division, 2014, WORLD URB PROSP 2014; Victora CG, 2005, LANCET, V366, P1460, DOI 10.1016/S0140-6736(05)67599-X; WAGNER E G, 1958, Monogr Ser World Health Organ, V39, P1; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; Wagstaff A, 2005, HEALTH ECON, V14, P429, DOI 10.1002/hec.953; Walker CLF, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-70; Wolf J, 2014, TROP MED INT HEALTH, V19, P928, DOI 10.1111/tmi.12331	53	42	42	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2017	12	2							e0171783	10.1371/journal.pone.0171783	http://dx.doi.org/10.1371/journal.pone.0171783			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK9GJ	28182796	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000394231800110
J	McQuade, CN; Mizus, M; Wald, JW; Goldberg, L; Jessup, M; Umscheid, CA				McQuade, Casey N.; Mizus, Marisa; Wald, Joyce W.; Goldberg, Lee; Jessup, Mariell; Umscheid, Craig A.			Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure	ANNALS OF INTERNAL MEDICINE			English	Review							TISSUE DOPPLER-ECHOCARDIOGRAPHY; BLOOD UREA NITROGEN; NT-PROBNP; 6-MONTH MORTALITY; RISK STRATIFICATION; HOSPITAL DISCHARGE; GUIDED TREATMENT; ELDERLY-PATIENTS; PREDISCHARGE; BNP	Background: Acute decompensated heart failure (ADHF) requiring hospitalization is associated with high postdischarge mortality and readmission rates. Purpose: To examine the association between achieving predischarge natriuretic peptide (NP) thresholds and mortality and readmission rates in adults hospitalized for ADHF. Data Sources: Multiple databases from 1947 to October 2016 (English-language studies only). Study Selection: Trials and observational studies that compared mortality and readmission outcomes between patients with ADHF achieving a specific predischarge NP goal and those not achieving the goal. Data Extraction: Two investigators independently extracted study characteristics and assessed study risk of bias. One author graded the overall strength of evidence, with review by a second author. Data Synthesis: One randomized trial, 3 quasi-experimental studies, and 40 observational studies were identified. The most commonly used thresholds were a brain-type NP (BNP) level of 250 pg/mL or less or an amino-terminal pro-brain-type NP (NT-proBNP) decrease of at least 30%. Achievement of absolute BNP thresholds reduced postdischarge all-cause mortality (7 of 8 studies) and the composite outcome of mortality and readmission (12 of 14 studies). Achievement of percentage-change BNP thresholds reduced the composite outcome (5 of 6 studies), and achievement of percentage-change NT-proBNP thresholds reduced all-cause and cardiovascular mortality (2 of 4 studies) and the composite outcome (9 of 9 studies). All findings were low-strength. The randomized trial, assessed as having high risk of bias, suggested that a predischarge decrease in NT-proBNP level was associated with lower risk for the composite outcome. Two quasi-experimental studies and 5 observational studies had low risk of bias. Low-risk-of-bias studies had outcome estimates similar in magnitude and direction to estimates from high-risk-of-bias studies. Limitation: Most studies failed to adjust for critical confounders and had inadequate definition or assessment of exposures and outcomes. Conclusion: Low-strength evidence suggests an association between achieving NP predischarge thresholds and reduced ADHF mortality and readmission.	Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [McQuade, Casey N.; Umscheid, Craig A.] Univ Penn Hlth Syst, Penn Med Ctr Evidence Based Practice, 3535 Market St,Mezzanine 9,Suite 50, Philadelphia, PA 19104 USA; [McQuade, Casey N.] UPMC, Montefiore Hosp, N-715,200 Lothrop St, Pittsburgh, PA 15213 USA; [Mizus, Marisa] Lankenau Med Ctr, 100 East Lancaster Ave, Wynnewood, PA 19096 USA; [Wald, Joyce W.; Goldberg, Lee; Jessup, Mariell] Perelman Ctr Adv Med, 3400 Civ Ctr Blvd,East Pavil,2nd Floor, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Lankenau Medical Center; University of Pennsylvania; Pennsylvania Medicine	Umscheid, CA (corresponding author), Univ Penn Hlth Syst, Penn Med Ctr Evidence Based Practice, 3535 Market St,Mezzanine 9,Suite 50, Philadelphia, PA 19104 USA.	mcquadec@upmc.edu; craig.umscheid@uphs.upenn.edu		Jessup, Mariell/0000-0002-3010-0112; Umscheid, Craig/0000-0003-1853-1013; Goldberg, Lee/0000-0002-7906-9638	Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania; Medtronic	Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania; Medtronic(Medtronic)	Dr. Mizus reports grants from the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania and from the National Institutes of Health during the conduct of the study. Dr. Goldberg reports personal fees from Medtronic and a grant from Respicardia outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-1468.	Aspromonte N, 2007, DIABETIC MED, V24, P124, DOI 10.1111/j.1464-5491.2007.02070.x; Balion C, 2006, Evid Rep Technol Assess (Full Rep), P1; Bettencourt P, 2002, AM J MED, V113, P215, DOI 10.1016/S0002-9343(02)01184-1; Bettencourt P, 2004, CIRCULATION, V110, P2168, DOI 10.1161/01.CIR.0000144310.04433.BE; Bettencourt P, 2007, INT J CARDIOL, V117, P75, DOI 10.1016/j.ijcard.2006.06.004; Carubelli V, 2016, J CARDIOVASC MED, V17, P828, DOI 10.2459/JCM.0000000000000419; Chen CY, 2012, CIRC J, V76, P2372, DOI 10.1253/circj.CJ-12-0040; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; Cournot M, 2008, AM HEART J, V155, P986, DOI 10.1016/j.ahj.2008.01.011; Cournot M, 2007, AM J GERIATR CARDIOL, V16, P8, DOI 10.1111/j.1076-7460.2007.05297.x; De Vecchis R, 2013, MINERVA CARDIOANGIOL, V61, P437; Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435; Di Somma S, 2010, CRIT CARE, V14, DOI 10.1186/cc9067; Dokainish H, 2005, J AM COLL CARDIOL, V45, P1223, DOI 10.1016/j.jacc.2005.01.025; Eurlings LW, 2014, J CARD FAIL, V20, P881, DOI 10.1016/j.cardfail.2014.08.014; Faggiano P, 2010, INT J CARDIOL, V140, P88, DOI 10.1016/j.ijcard.2008.11.020; Feola M, 2008, J CARD FAIL, V14, P420, DOI 10.1016/j.cardfail.2008.01.013; Feola M, 2012, ARCH MED SCI, V8, P462, DOI 10.5114/aoms.2012.29401; Ferreira Susana, 2007, Rev Port Cardiol, V26, P535; Gackowski A, 2004, EUR HEART J, V25, P1788, DOI 10.1016/j.ehj.2004.07.038; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hamada Y, 2005, J CARD FAIL, V11, P43, DOI 10.1016/j.cardfail.2004.05.001; Hartling L, 2015, J CLIN EPIDEMIOL, V68, P1451, DOI 10.1016/j.jclinepi.2015.05.036; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Ho SJ, 2011, ECHOCARDIOGR-J CARD, V28, P303, DOI 10.1111/j.1540-8175.2010.01322.x; Ito K, 2012, EUR HEART J-ACUTE CA, V1, P240, DOI 10.1177/2048872612458580; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kociol RD, 2013, CIRC-HEART FAIL, V6, P240, DOI 10.1161/CIRCHEARTFAILURE.112.969246; Koitabashi T, 2005, INT HEART J, V46, P453, DOI 10.1536/ihj.46.453; Kubler P, 2008, INT J CARDIOL, V129, P373, DOI 10.1016/j.ijcard.2007.07.126; Lindenfeld J, 2010, J CARD FAIL, V16, pe1, DOI DOI 10.1016/J.CARDFAIL.2010.04.004; Logeart D, 2004, J AM COLL CARDIOL, V43, P635, DOI 10.1016/j.jacc.2003.09.044; Lourenco P, 2015, AM J CARDIOL, V116, P744, DOI 10.1016/j.amjcard.2015.05.046; Ludka O, 2013, COR VASA, V55, pE286, DOI 10.1016/j.crvasa.2013.03.007; Metra M, 2007, EUR J HEART FAIL, V9, P776, DOI 10.1016/j.ejheart.2007.05.007; Michtalik HJ, 2011, AM J CARDIOL, V107, P1191, DOI 10.1016/j.amjcard.2010.12.018; Mitchell MD, 2011, INT J TECHNOL ASSESS, V27, P127, DOI 10.1017/S0266462311000031; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Naffaa M, 2014, AM J EMERG MED, V32, P44, DOI 10.1016/j.ajem.2013.10.002; Nakada Y, 2016, AM J PHYSIOL-HEART C, V310, pH813, DOI 10.1152/ajpheart.00602.2015; Noveanu M, 2011, CRIT CARE, V15, DOI 10.1186/cc9398; O'Brien RJ, 2003, EUR J HEART FAIL, V5, P499, DOI 10.1016/S1388-9842(03)00098-9; Omar HR, 2016, INT J CARDIOL, V221, P1116, DOI 10.1016/j.ijcard.2016.07.117; Pimenta JM, 2007, J CARD FAIL, V13, P275, DOI 10.1016/j.cardfail.2007.01.001; Ruocco G, 2016, J CARDIOVASC MED, V17, P818, DOI 10.2459/JCM.0000000000000350; Santaguida PL, 2014, HEART FAIL REV, V19, P453, DOI 10.1007/s10741-014-9442-y; Savarese G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058287; Seo Y, 2008, J CARDIOL, V52, P224, DOI 10.1016/j.jjcc.2008.07.008; Shah MR, 2007, AM J CARDIOL, V100, P1427, DOI 10.1016/j.amjcard.2007.06.035; Siswanto BB, 2006, CRIT CARE SHOCK, V9, P61; Stienen S, 2015, EUR J HEART FAIL, V17, P936, DOI 10.1002/ejhf.320; The Cochrane Collaboration, 2008, COCHR HDB REV INT; Troughton RW, 2014, EUR HEART J, V35, P1559, DOI 10.1093/eurheartj/ehu090; Valle R, 2008, INT J CARDIOL, V126, P400, DOI 10.1016/j.ijcard.2006.03.097; Valle R, 2008, J CARD FAIL, V14, P219, DOI 10.1016/j.cardfail.2007.10.009; Valle Roberto, 2006, Am J Geriatr Cardiol, V15, P202, DOI 10.1111/j.1076-7460.2006.04830.x; Valle R, 2011, HEART FAIL REV, V16, P519, DOI 10.1007/s10741-011-9244-4; Verdiani V, 2005, EUR J HEART FAIL, V7, P566, DOI 10.1016/j.ejheart.2004.12.006; Verdiani V, 2008, J CARDIOVASC MED, V9, P694, DOI 10.2459/JCM.0b013e3282f447ae; Wells G, 2014, NEWCASTLE OTTAWA SCA; Yu CM, 1999, EUR J HEART FAIL, V1, P59, DOI 10.1016/S1388-9842(98)00010-5	61	34	36	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2017	166	3					180	+		10.7326/M16-1468	http://dx.doi.org/10.7326/M16-1468			24	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL7DL	27894126				2023-01-03	WOS:000394781200007
J	Yang, MX; Chen, XZ; Bo, LN; Lao, LX; Chen, J; Yu, SY; Yu, Z; Tang, HZ; Yi, L; Wu, X; Yang, J; Liang, FR				Yang, Mingxiao; Chen, Xiangzhu; Bo, Linna; Lao, Lixing; Chen, Jiao; Yu, Siyi; Yu, Zheng; Tang, Hongzhi; Yi, Ling; Wu, Xi; Yang, Jie; Liang, Fanrong			Moxibustion for pain relief in patients with primary dysmenorrhea: A randomized controlled trial	PLOS ONE			English	Article							MENSTRUAL PAIN; UNIVERSITY-STUDENTS; CLINICAL-TRIALS; ACUPUNCTURE; PREVALENCE; HEAT; ENDOMETRIOSIS; ADOLESCENTS; PREVENTION; MANAGEMENT	Background Though moxibustion is frequently used to treat primary dysmenorrhea in China, relevant evidence supporting its effectiveness is still scanty. Methods This study was a pragmatic randomized, conventional drug controlled, open-labeled clinical trial. After initial screen, 152 eligible participants were averagely randomized to receive two different treatment strategies: Moxibustion and conventional drugs. Participants and practitioners were not blinded in this study. The duration of each treatment was 3 months. The primary outcome was pain relief measured by the Visual Analogue Scale. The menstrual pain severity was recorded in a menstrual pain diary. Results 152 eligible patients were included but only 133 of them eventually completed the whole treatment course. The results showed that the menstrual pain intensity in experimental group and control group was reduced from 6.38 +/- 1.28 and 6.41 +/- 1.29, respectively, at baseline, to 2.54 +/- 1.41 and 2.47 +/- 1.29 after treatment. The pain reduction was not significantly different between these two groups (P = 0.76), however; the pain intensity was significantly reduced relative to baseline for each group (P<0.01). Three months after treatment, the effectiveness of moxibustion sustained and started to be superior to the drug's effect (-0.87, 95% CI -1.32 to -0.42, P<0.01). Secondary outcome analyses showed that moxibustion was as effective as drugs in alleviating menstrual pain-related symptoms. The serum levels of pain mediators, such as PGF(2 alpha), OT, vWF, beta-EP, PGE(2), were significantly improved after treatment in both groups (P<0.05). No adverse events were reported in this trial. Conclusions Both moxibustion and conventional drug showed desirable merits in managing menstrual pain, given their treatment effects and economic costs. This study as a pragmatic trial only demonstrates the effectiveness, not the efficacy, of moxibustion for menstrual pain. It can't rule out the effect of psychological factors during treatment process, because no blind procedure or sham control was used due to availability. In clinical practice, moxibustion should be used at the discretion of patients and their physicians.	[Yang, Mingxiao; Chen, Jiao; Yu, Siyi; Tang, Hongzhi; Wu, Xi; Yang, Jie; Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Sch Acupuncture & Moxibust, Chengdu, Sichuan, Peoples R China; [Chen, Xiangzhu; Yu, Zheng] Pixian Hosp Tradit Chinese Med, Chengdu, Sichuan, Peoples R China; [Bo, Linna] Rentong Clin Tradit Chinese Med, Chengdu, Sichuan, Peoples R China; [Lao, Lixing] Univ Hong Kong, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Yi, Ling] Med Ctr & Hosp Qionglai, Chengdu, Sichuan, Peoples R China	Chengdu University of Traditional Chinese Medicine; University of Hong Kong	Yang, J; Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Acupuncture & Moxibust, Chengdu, Sichuan, Peoples R China.	jenny_yang_jie@126.com; acuresearch@126.com	chen, JJ/HGB-6029-2022; Yang, Mingxiao/ABF-6416-2021; CHEN, JIAO/GZA-5784-2022; Yang, Mingxiao/ABF-7200-2021; Lao, Lixing/P-9107-2019	Yang, Mingxiao/0000-0002-6514-3366; Lao, Lixing/0000-0003-0198-9714; Liang, Fanrong/0000-0003-2210-2027	National Basic Research Program, China 973 program [2012CB518501]; National Natural Science Foundation of China [81590950, 81574089, 81303060]; Chinese Scholarship Council	National Basic Research Program, China 973 program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Scholarship Council(China Scholarship Council)	This study was financially supported by the National Basic Research Program, China 973 program, No. 2012CB518501 and the "2011 Innovation Center" Program from the Education Department of Sichuan province, grants from the National Natural Science Foundation of China (No. 81590950, 81574089, 81303060) and the Chinese Scholarship Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akin MD, 2001, OBSTET GYNECOL, V97, P343, DOI 10.1016/S0029-7844(00)01163-7; Arulkumaran S., 2012, ROLES PROSTANOID EP; Ayan M, 2012, ARCH GYNECOL OBSTET, V286, P403, DOI 10.1007/s00404-012-2316-4; [卜彦青 Bu Yanqing], 2010, [中医杂志, Journal of Traditional Chinese Medicine], V51, P811; Chalkidou K, 2012, CLIN TRIALS, V9, P436, DOI 10.1177/1740774512450097; Chang XR, 2007, WORLD J GASTROENTERO, V13, P4355, DOI 10.3748/wjg.v13.i32.4355; Chiu J-H., 2013, EVIDENCE BASED COMPL, V2013; Cho SH, 2010, BJOG-INT J OBSTET GY, V117, P509, DOI 10.1111/j.1471-0528.2010.02489.x; Chung YC, 2012, COMPLEMENT THER MED, V20, P353, DOI 10.1016/j.ctim.2012.02.008; Dawood MY, 2006, OBSTET GYNECOL, V108, P428, DOI 10.1097/01.AOG.0000230214.26638.0c; Dawood MY, 2007, AM J OBSTET GYNECOL, V196, P35, DOI 10.1016/j.ajog.2006.06.091; DAWOOD MY, 1985, J REPROD MED, V30, P154; Deadman P., 1998, J CHINESE MED PUBLIC; Farquhar C., 2015, NONSTEROIDAL ANTIINF; French L, 2005, AM FAM PHYSICIAN, V71, P285; Gao J, 2015, COMPLEMENT THER MED, V23, P773, DOI 10.1016/j.ctim.2015.08.005; Glickman-Simon R, 2015, EXPLORE-NY, V11, P489, DOI 10.1016/j.explore.2015.08.013; Grandi Giovanni, 2012, J Pain Res, V5, P169, DOI 10.2147/JPR.S30602; Harel Z, 2008, ANN NY ACAD SCI, V1135, P185, DOI 10.1196/annals.1429.007; Harel Z, 2012, EXPERT OPIN PHARMACO, V13, P2157, DOI 10.1517/14656566.2012.725045; Helms PJ, 2002, PEDIAT ALLERG IMM-UK, V13, P4, DOI 10.1034/j.1399-3038.2002.00194.x; Ju H, 2014, EPIDEMIOL REV, V36, P104, DOI 10.1093/epirev/mxt009; Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X; Kennedy S, 1997, LANCET, V349, P1116, DOI 10.1016/S0140-6736(05)63018-8; Kim JI, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-33; Kim Jung Wan, 2015, Journal of Acupuncture Research, V32, P123; KOBAYASHI K, 1995, AM J CHINESE MED, V23, P327, DOI 10.1142/S0192415X95000390; Koga K, 2015, FERTIL STERIL, V104, P793, DOI 10.1016/j.fertnstert.2015.08.026; Langevin HM, 2015, J ALTERN COMPLEM MED, V21, P113, DOI 10.1089/acm.2014.0186; Lee IS, 2015, PHYSIOL BEHAV, V140, P148, DOI 10.1016/j.physbeh.2014.12.030; Lee IS, 2004, J KOREAN PUBLIC HLTH, V18, P39; Lefebvre G, 2005, J OBSTET GYNAECOL CA, V27, P1117; Luce BR, 2009, ANN INTERN MED, V151, P206, DOI 10.7326/0003-4819-151-3-200908040-00126; Ma Y-x, 2015, EVID-BASED COMPL ALT, V501; Ma YX, 2010, PAIN MED, V11, P1564, DOI 10.1111/j.1526-4637.2010.00949.x; Modaress Nejad V, 2006, COMP EFFECTIVENESS F; Okada K, 2009, EVID-BASED COMPL ALT, V6, P11, DOI 10.1093/ecam/nem090; Ortiz MI, 2010, EUR J OBSTET GYN R B, V152, P73, DOI 10.1016/j.ejogrb.2010.04.015; Proctor M, 2001, HERBAL DIETARY THERA; READING AE, 1982, PAIN, V13, P185, DOI 10.1016/0304-3959(82)90028-8; Rigi SN, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-25; Shi GX, 2011, CLIN J PAIN, V27, P258, DOI 10.1097/AJP.0b013e3181fb27ae; Smith CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep239; Steen M, 1998, BRIT J MIDWIFERY, V6, P572; Sun Li-hong, 2009, Zhen Ci Yan Jiu, V34, P398; Tian X, 2014, ALTERN THER HEALTH M, V20, P33; Tu CH, 2010, PAIN, V150, P462, DOI 10.1016/j.pain.2010.05.026; Tu CH, 2009, NEUROIMAGE, V47, P28, DOI 10.1016/j.neuroimage.2009.03.080; Unsal A, 2010, UPSALA J MED SCI, V115, P138, DOI 10.3109/03009730903457218; Wang MC, 2009, J ALTERN COMPLEM MED, V15, P235, DOI 10.1089/acm.2008.0164; Wei SY, 2016, PAIN, V157, P92, DOI 10.1097/j.pain.0000000000000340; Xue Zhe, 2014, Zhongguo Zhen Jiu, V34, P209; Yang J, 2014, EVIDENCE BASED COMPL, V2014; Yang J, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0552-1; Yu S, 2015, EVIDENCE BASED COMPL, V2015; Zahradnik HP, 2010, CONTRACEPTION, V81, P185, DOI 10.1016/j.contraception.2009.09.014; Zhu Ying, 2010, Zhongguo Zhen Jiu, V30, P453; Zorbas KA, 2015, ARCH GYNECOL OBSTET, V292, P37, DOI 10.1007/s00404-015-3641-1	58	42	46	3	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2017	12	2							e0170952	10.1371/journal.pone.0170952	http://dx.doi.org/10.1371/journal.pone.0170952			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK1SG	28170396	Green Published, gold, Green Submitted			2023-01-03	WOS:000393705500014
J	Herold, N; Rudd, SG; Ljungblad, L; Sanjiv, K; Myrberg, IH; Paulin, CBJ; Heshmati, Y; Hagenkort, A; Kutzner, J; Paget, BDG; Calderon-Montano, JM; Loseva, O; Jemth, AS; Bulli, L; Axelsson, H; Tesi, B; Valerie, NCK; Hoglund, A; Bladh, J; Wiita, E; Sundin, M; Uhlin, M; Rassidakis, G; Heyman, M; Tamm, KP; Warpman-Berglund, U; Walfridsson, J; Lehmann, S; Grander, D; Lundback, T; Kogner, P; Henter, JI; Helleday, T; Schaller, T				Herold, Nikolas; Rudd, Sean G.; Ljungblad, Linda; Sanjiv, Kumar; Myrberg, Ida Hed; Paulin, Cynthia B. J.; Heshmati, Yaser; Hagenkort, Anna; Kutzner, Juliane; Paget, Brent D. G.; Calderon-Montano, Jose M.; Loseva, Olga; Jemth, Ann-Sofie; Bulli, Lorenzo; Axelsson, Hanna; Tesi, Bianca; Valerie, Nicholas C. K.; Hoglund, Andreas; Bladh, Julia; Wiita, Elisee; Sundin, Mikael; Uhlin, Michael; Rassidakis, Georgios; Heyman, Mats; Tamm, Katja Pokrovskaja; Warpman-Berglund, Ulrika; Walfridsson, Julian; Lehmann, Soren; Grander, Dan; Lundback, Thomas; Kogner, Per; Henter, Jan-Inge; Helleday, Thomas; Schaller, Torsten			Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ARA-C SENSITIVITY; CYTOSINE-ARABINOSIDE; IN-VITRO; DRUG-RESISTANCE; CELLS; EXPRESSION; MUTATIONS; DNA	The cytostatic deoxycytidine analog cytarabine (ara-C) is the most active agent available against acute myelogenous leukemia (AML). Together with anthracyclines, ara-C forms the backbone of AML treatment for children and adults'. In AML, both the cytotoxicity of ara-C in vitro and the clinical response to ara-C therapy are correlated with the ability of AML blasts to accumulate the active metabolite ara-C triphosphate (ara-CTP)(2-5), which causes DNA damage through perturbation of DNA synthesis(6). Differences in expression levels of known transporters or metabolic enzymes relevant to ara-C only partially account for patient-specific differential ara-CTP accumulation in AML blasts and response to ara-C treatment(7-9). Here we demonstrate that the deoxynucleoside triphosphate (dNTP) triphosphohydrolase SAM domain and HD domain 1 (SAMHD1) promotes the detoxification of intracellular ara-CTP pools. Recombinant SAMHD1 exhibited ara-CTPase activity in vitro, and cells in which SAMHD1 expression was transiently reduced by treatment with the simian immunodeficiency virus (SIV) protein Vpx were dramatically more sensitive to ara-C-induced cytotoxicity. CRISPR-Cas9-mediated disruption of the gene encoding SAMHD1 sensitized cells to ara-C, and this sensitivity could be abrogated by ectopic expression of wild-type (WT), but not dNTPase-deficient, SAMHD1. Mouse models of AML lacking SAMHD1 were hypersensitive to ara-C, and treatment ex vivo with Vpx sensitized primary patient derived AML blasts to ara-C. Finally, we identified SAMHD1 as a risk factor in cohorts of both pediatric and adult patients with de novo AML who received ara-C treatment. Thus, SAMHD1 expression levels dictate patient sensitivity to ara-C, providing proof-of-concept that the targeting of SAMHD1 by Vpx could be an attractive therapeutic strategy for potentiating ara-C efficacy in hematological malignancies.	[Herold, Nikolas; Ljungblad, Linda; Myrberg, Ida Hed; Tesi, Bianca; Bladh, Julia; Heyman, Mats; Kogner, Per; Henter, Jan-Inge] Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden; [Herold, Nikolas; Ljungblad, Linda; Myrberg, Ida Hed; Tesi, Bianca; Bladh, Julia; Heyman, Mats; Kogner, Per; Henter, Jan-Inge] Karolinska Univ Hosp, Stockholm, Sweden; [Rudd, Sean G.; Sanjiv, Kumar; Paulin, Cynthia B. J.; Hagenkort, Anna; Paget, Brent D. G.; Calderon-Montano, Jose M.; Loseva, Olga; Jemth, Ann-Sofie; Axelsson, Hanna; Valerie, Nicholas C. K.; Hoglund, Andreas; Wiita, Elisee; Warpman-Berglund, Ulrika; Lundback, Thomas; Helleday, Thomas] Karolinska Inst, Div Translat Med & Chem Biol, Dept Med Biochem & Biophys, Sci Life Lab, Stockholm, Sweden; [Heshmati, Yaser; Walfridsson, Julian; Lehmann, Soren] Karolinska Hosp, Dept Med, Ctr Hematol & Regenerat Med, Stockholm, Sweden; [Heshmati, Yaser; Walfridsson, Julian; Lehmann, Soren] Karolinska Inst, Stockholm, Sweden; [Kutzner, Juliane; Bulli, Lorenzo; Schaller, Torsten] Univ Heidelberg Hosp, Dept Infect Dis, Virol, Heidelberg, Germany; [Axelsson, Hanna; Lundback, Thomas] Chem Biol Consortium, Stockholm, Sweden; [Sundin, Mikael] Karolinska Inst, Div Pediat, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Sundin, Mikael] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Paediat Blood Disorders Immunodeficiency & Stem C, Stockholm, Sweden; [Uhlin, Michael; Rassidakis, Georgios; Tamm, Katja Pokrovskaja; Grander, Dan] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Uhlin, Michael] Karolinska Univ Hosp, Dept Clin Immunol & Transfus Med, Stockholm, Sweden; [Lehmann, Soren] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Calderon-Montano, Jose M.] Univ Seville, CSIC, Andalusian Mol Biol & Regenerat Med Ctr CABIMER, Seville, Spain; [Lundback, Thomas] AstraZeneca R&D, Molndal, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Ruprecht Karls University Heidelberg; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); AstraZeneca	Herold, N (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden.; Herold, N (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.; Schaller, T (corresponding author), Univ Heidelberg Hosp, Dept Infect Dis, Virol, Heidelberg, Germany.	nikolas.herold@ki.se; torsten.schaller@med.uni-heidelberg.de	Rudd, Sean/AAC-3150-2019; Lundbäck, Thomas/G-8076-2018; Montaño, José Manuel Calderón/AAA-1742-2019; Tesi, Bianca/AAH-6304-2021; Axelsson, Hanna/AGG-7882-2022; Paulin, Cynthia/HGA-1250-2022; Schaller, Torsten/ABC-9153-2020; Höglund, Andreas/AAP-3372-2021; Herold, Nikolas/M-6927-2016; Sundin, Mikael/E-5942-2013	Rudd, Sean/0000-0002-4368-3855; Lundbäck, Thomas/0000-0002-8145-7808; Montaño, José Manuel Calderón/0000-0001-6845-797X; Tesi, Bianca/0000-0002-8253-2507; Axelsson, Hanna/0000-0003-2365-1749; Schaller, Torsten/0000-0001-9597-4112; Herold, Nikolas/0000-0001-9468-4543; Henter, Jan-Inge/0000-0002-0629-2126; Ljungblad, Linda/0000-0002-1428-9090; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Jemth, Ann-Sofie/0000-0002-7550-1833; Sundin, Mikael/0000-0002-9871-0961; Kogner, Per/0000-0002-2202-9694; Valerie, Nicholas/0000-0002-9423-964X; Helleday, Thomas/0000-0002-7384-092X; Warpman Berglund, Ulrika/0000-0002-6372-1396; Hed Myrberg, Ida/0000-0002-8297-2238	Swedish Children's Cancer Foundation [TJ2016-0040, 2015-0005, PR2015-0009, PR2013-0002, PR2014-0048]; Swedish Cancer Society [CAN 2016/837, CAN 2014/814, CAN 2015/768, CAN 2013/396, CAN 2012/770, CAN 2015/255]; Swedish Research Council [2014-1839, 2015-02498, 2012-2037, 2012-5935, 2013-3791]; Radiumhemmet's Research Foundations [154242, 144063]; Knut and Alice Wallenberg Foundation [KAW2014.0273]; Swedish Pain Relief Foundation [SSF/01-05]; Torsten and Ragnar Soderberg Foundation; David and Astrid Hagelen Foundation [C24702193]; Stockholm County Council (ALF project) [20150353, 20150016]; German Research Foundation (DFG) [SCHA1950/1-1]; Federal Ministry of Education and Research of Germany (BMBF) [0316170]; HIVERA: EURECA project [01KI1307B]; EMBO Long-Term Fellowship [ALTF-605-2014]; Swedish Research Council, Science for Life Laboratories and Karolinska Institutet [829-2009-6241]	Swedish Children's Cancer Foundation; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Radiumhemmet's Research Foundations; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Pain Relief Foundation; Torsten and Ragnar Soderberg Foundation; David and Astrid Hagelen Foundation; Stockholm County Council (ALF project)(Stockholm County Council); German Research Foundation (DFG)(German Research Foundation (DFG)); Federal Ministry of Education and Research of Germany (BMBF)(Federal Ministry of Education & Research (BMBF)); HIVERA: EURECA project; EMBO Long-Term Fellowship(European Molecular Biology Organization (EMBO)); Swedish Research Council, Science for Life Laboratories and Karolinska Institutet	We are grateful to M. Wickstrom, N. Eissler and L. Elfman for consulting and assistance with xenotransplantation. We thank S. Olsson and M. Gustafsson for assistance with animal work. We would like to thank I. Bodin for help with paraffin-embedding and processing of tumor tissue and A. Bjorklund for assistance with primary AML samples. We acknowledge M. Nordenskjold and S. Eriksson for laboratory assistance, D. Gavhed and K. Edfeldt for administrative assistance. We thank D. Trono for the gift of the pMD.G plasmid. We would like to thank J. Cinatl for initial discussions. We would like to express our gratitude to NCI's Office of Cancer Genomics (OCG), The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research To Generate Effective Treatments initiative (TARGET) for granting public access to their AML databases, and to the Broad Institute for access to the Cancer Therapeutics Response Portal (CTRP). This work was supported by grants from the Swedish Children's Cancer Foundation (TJ2016-0040 (to N.H.); 2015-0005 (to J.-I.H.); PR2015-0009 (to D.G.); and PR2013-0002 and PR2014-0048 (both to T.H.)), the Swedish Cancer Society (CAN 2016/837 to J.W.; CAN 2014/814 to S.L.; CAN 2015/768 to D.G.; CAN 2013/396 to J.-I.H.; and CAN 2012/770 and CAN 2015/255 to T.H.), the Swedish Research Council (2014-1839 to M.U.; 2015-02498 to S.L.; 2012-2037 to D.G.; and 2012-5935 and 2013-3791 to T.H.), Radiumhemmet's Research Foundations (154242 to G.R. and 144063 to D.G.), the Knut and Alice Wallenberg Foundation (KAW2014.0273 to T.H.), the Swedish Pain Relief Foundation (SSF/01-05 to T.H.), the Torsten and Ragnar Soderberg Foundation (to T.H.), the David and Astrid Hagelen Foundation (C24702193 to B.D.G.P.) and the Stockholm County Council (ALF project) (20150353 to S.L. and 20150016 to J.-I.H.). This work was supported by the German Research Foundation (DFG) (SCHA1950/1-1 to T.S.) and partially through the Federal Ministry of Education and Research of Germany (BMBF)-supported Immunoquant project (0316170 C to T.S.) and HIVERA: EURECA project (01KI1307B to T.S.). S.G.R. is supported by an EMBO Long-Term Fellowship (ALTF-605-2014). Chemical Biology Consortium Sweden is funded by the Swedish Research Council, Science for Life Laboratories and Karolinska Institutet (829-2009-6241 to H.A. and T.L.).	Arnold LH, 2015, ANTIMICROB AGENTS CH, V59, P186, DOI 10.1128/AAC.03903-14; Aye Y, 2011, P NATL ACAD SCI USA, V108, P9815, DOI 10.1073/pnas.1013274108; Bai HT, 2012, J CANCER RES CLIN, V138, P595, DOI 10.1007/s00432-011-1137-3; Bhattacharya A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31353; Clifford R, 2014, BLOOD, V123, P1021, DOI 10.1182/blood-2013-04-490847; de Rooij JDE, 2015, J CLIN MED, V4, P127, DOI 10.3390/jcm4010127; de Silva S, 2014, J INVEST DERMATOL, V134, P562, DOI 10.1038/jid.2013.311; ESTEY E, 1987, LEUKEMIA, V1, P580; Farrar JE, 2016, CANCER RES, V76, P2197, DOI 10.1158/0008-5472.CAN-15-1015; Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544; Fernandez-Calotti P, 2005, LEUKEMIA LYMPHOMA, V46, P335, DOI 10.1080/10428190400015683; Galmarini CM, 2002, LEUKEMIA RES, V26, P621, DOI 10.1016/S0145-2126(01)00184-9; Genini D, 2000, BLOOD, V96, P3537; HEINEMANN V, 1990, LEUKEMIA, V4, P790; Ji XY, 2014, P NATL ACAD SCI USA, V111, pE4305, DOI 10.1073/pnas.1412289111; Jin CZ, 2014, BIOCHEM BIOPH RES CO, V452, P760, DOI 10.1016/j.bbrc.2014.08.151; KESSEL D, 1969, CANCER RES, V29, P459; KUFE D, 1984, BLOOD, V64, P54; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lamba JK, 2009, PHARMACOGENOMICS, V10, P1657, DOI [10.2217/pgs.09.118, 10.2217/PGS.09.118]; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li D, 2015, STEM CELL RES, V15, P271, DOI 10.1016/j.scr.2015.06.012; Li N, 2000, IMMUNOL LETT, V74, P221, DOI 10.1016/S0165-2478(00)00276-5; Majda K, 2010, ANTICANCER RES, V30, P4601; Merati Miesha, 2015, JAAD Case Rep, V1, P227, DOI 10.1016/j.jdcr.2015.05.003; Ossenkoppele G, 2015, BLOOD, V125, P767, DOI 10.1182/blood-2014-08-551499; PLUNKETT W, 1986, SCAND J HAEMATOL, V36, P51; Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/NCHEMBIO.1986, 10.1038/nchembio.1986]; Rentoft M, 2016, P NATL ACAD SCI USA, V113, P4723, DOI 10.1073/pnas.1519128113; Rice GI, 2009, NAT GENET, V41, P829, DOI 10.1038/ng.373; Rowe JM, 2013, BEST PRACT RES CL HA, V26, P241, DOI 10.1016/j.beha.2013.10.002; Schaller T, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-29; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Stam RW, 2003, BLOOD, V101, P1270, DOI 10.1182/blood-2002-05-1600; Styczynski J, 2007, CURR PHARM BIOTECHNO, V8, P59, DOI 10.2174/138920107780487465; Wang JL, 2014, BIOCHEM BIOPH RES CO, V455, P229, DOI 10.1016/j.bbrc.2014.10.153; Weng HY, 2015, CANCER GENET-NY, V208, P225, DOI 10.1016/j.cancergen.2014.12.006; Yamauchi T, 2009, BIOCHEM PHARMACOL, V77, P1780, DOI 10.1016/j.bcp.2009.03.011; Yue LJ, 2003, PHARMACOGENETICS, V13, P29, DOI 10.1097/00008571-200301000-00005; ZITTOUN R, 1987, SEMIN ONCOL, V14, P269	40	79	79	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2017	23	2					256	263		10.1038/nm.4265	http://dx.doi.org/10.1038/nm.4265			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EK2AH	28067901				2023-01-03	WOS:000393729000018
J	Chu, ND; Smith, MB; Perrotta, AR; Kassam, Z; Alm, EJ				Chu, Nathaniel D.; Smith, Mark B.; Perrotta, Allison R.; Kassam, Zain; Alm, Eric J.			Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; CLOSTRIDIUM-DIFFICILE INFECTION; ULCERATIVE-COLITIS; FROZEN INOCULUM; SEQUENCES; SAMPLES; BACTERIOTHERAPY; COMMUNITIES; EFFICACY; TAXONOMY	Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota. But variability in fecal bacterial communities-believed to be the therapeutic agent-can complicate or undermine treatment efficacy. To understand the effects of transplant preparation methods on living fecal microbial communities, we applied a DNA-sequencing method (PMA-seq) that uses propidium monoazide (PMA) to differentiate between living and dead fecal microbes, and we created an analysis pipeline to identify individual bacteria that change in abundance between samples. We found that oxygen exposure degraded fecal bacterial communities, whereas freeze-thaw cycles and lag time between donor defecation and transplant preparation had much smaller effects. Notably, the abundance of Faecalibacterium prausnitzii-an anti-inflammatory commensal bacterium whose absence is linked to inflammatory bowel disease-decreased with oxygen exposure. Our results indicate that some current practices for preparing microbiota transplant material adversely affect living fecal microbial content and highlight PMA-seq as a valuable tool to inform best practices and evaluate the suitability of clinical fecal material.	[Chu, Nathaniel D.] MIT, Microbiol Grad Program, Cambridge, MA 02139 USA; [Chu, Nathaniel D.; Smith, Mark B.; Perrotta, Allison R.; Kassam, Zain; Alm, Eric J.] MIT, Ctr Microbiome Informat & Therapeut, Cambridge, MA 02139 USA; [Smith, Mark B.; Kassam, Zain; Alm, Eric J.] OpenBiome, Medford, MA USA; [Smith, Mark B.; Alm, Eric J.] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; [Perrotta, Allison R.; Alm, Eric J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Alm, EJ (corresponding author), MIT, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ejalm@mit.edu			Center for Microbiome Informatics and Therapeutics at MIT	Center for Microbiome Informatics and Therapeutics at MIT	This project is supported in part by a grant from the Center for Microbiome Informatics and Therapeutics at MIT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen-Vercoe E, 2012, CAN J GASTROENTEROL, V26, P457, DOI 10.1155/2012/213828; Anderson JL, 2012, ALIMENT PHARM THER, V36, P503, DOI 10.1111/j.1365-2036.2012.05220.x; Baughn AD, 2004, NATURE, V427, P441, DOI 10.1038/nature02285; Borody TJ, 2008, GASTROENTEROLOGY, V134, pA361; Borody TJ, 2012, NAT REV GASTRO HEPAT, V9, P88, DOI 10.1038/nrgastro.2011.244; BORODY TJ, 1989, MED J AUSTRALIA, V150, P604, DOI 10.5694/j.1326-5377.1989.tb136704.x; Borody TJ, 2004, J CLIN GASTROENTEROL, V38, P475, DOI 10.1097/01.mcg.0000128988.13808.dc; Borody TJ, 2003, J CLIN GASTROENTEROL, V37, P42, DOI 10.1097/00004836-200307000-00012; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carini P., 2016, BIORXIV; Colman RJ, 2014, J CROHNS COLITIS, V8, P1569, DOI 10.1016/j.crohns.2014.08.006; Cui BT, 2015, J GASTROEN HEPATOL, V30, P51, DOI 10.1111/jgh.12727; David LA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-7-r89; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Exterkate RAM, 2015, CLIN ORAL INVEST, V19, P813, DOI 10.1007/s00784-014-1297-z; Gorzelak MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134802; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Kelly CR, 2015, GASTROENTEROLOGY, V149, P223, DOI 10.1053/j.gastro.2015.05.008; Khoruts A, 2015, CLIN GASTROENTEROL H, V13, P246, DOI 10.1016/j.cgh.2014.11.014; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Miquel S, 2013, CURR OPIN MICROBIOL, V16, P255, DOI 10.1016/j.mib.2013.06.003; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Nocker A, 2010, INT MICROBIOL, V13, P59, DOI 10.2436/20.1501.01.111; Olesen SW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154804; Ott SJ, 2004, DIAGN MICR INFEC DIS, V50, P237, DOI 10.1016/j.diagmicrobio.2004.08.012; Preheim SP, 2013, APPL ENVIRON MICROB, V79, P6593, DOI 10.1128/AEM.00342-13; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; Roesch Luiz F W, 2009, Open Microbiol J, V3, P40, DOI 10.2174/1874285800903010040; Satokari R, 2015, ALIMENT PHARM THER, V41, P46, DOI 10.1111/apt.13009; SHAH HN, 1982, ZBL BAKT MIK HYG I C, V3, P394; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; van Nood E, 2014, CURR OPIN GASTROEN, V30, P34, DOI 10.1097/MOG.0000000000000024; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109; Wu GD, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-206; Youngster I, 2014, CLIN INFECT DIS, V58, P1515, DOI 10.1093/cid/ciu135; Zhang XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071108	48	54	69	3	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2017	12	1							e0170922	10.1371/journal.pone.0170922	http://dx.doi.org/10.1371/journal.pone.0170922			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7IT	28125667	Green Submitted, Green Published, gold			2023-01-03	WOS:000396176100024
J	Avorn, J				Avorn, Jerry			Academic Detailing "Marketing" the Best Evidence to Clinicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROLLED-TRIAL		[Avorn, Jerry] Harvard Med Sch, Boston, MA USA; [Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Avorn, J (corresponding author), Harvard Med Sch, Boston, MA USA.; Avorn, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.	avorn@post.harvard.edu						AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; Avorn J, 2015, NEW ENGL J MED, V373, P967, DOI 10.1056/NEJMhle1506365; Dreischulte T, 2016, NEW ENGL J MED, V374, P1053, DOI 10.1056/NEJMsa1508955; Fischer MA, 2012, HEALTH AFFAIR, V31, P2206, DOI 10.1377/hlthaff.2012.0817; Kesselheim AS, JAMA-J AM MED ASSOC, DOI [10.1001/jama/2016.20640, DOI 10.1001/JAMA/2016.20640]; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; Solomon DH, 2001, ARCH INTERN MED, V161, P1897, DOI 10.1001/archinte.161.15.1897; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003	10	56	58	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2017	317	4					361	362		10.1001/jama.2016.16036	http://dx.doi.org/10.1001/jama.2016.16036			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EI5BW	28118458				2023-01-03	WOS:000392509600015
J	Cottin, V; Schmidt, A; Catella, L; Porte, F; Fernandez-Montoya, C; Le Lay, K; Benard, S				Cottin, Vincent; Schmidt, Aurelie; Catella, Laura; Porte, Fanny; Fernandez-Montoya, Celine; Le Lay, Katell; Benard, Steve			Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; RESPIRATORY-FAILURE; PREVALENCE; MANAGEMENT; GUIDELINES; DIAGNOSIS; PROGNOSIS; COHORT; COSTS	Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with an unpredictable course. An observational study was set up using the French hospital discharge database to describe the reasons, outcomes and costs of hospitalisations related to this disease. Patients newly hospitalised for idiopathic pulmonary fibrosis (ICD-10 code: J84.1) in 2008 were identified and followed for 5 years. As J84.1 includes other fibrotic pulmonary diseases, an algorithm excluding age<50 years and presence of a differential diagnosis in the following year was defined. Overall, 6,476 patients were identified; of whom 30% were admitted through the emergency unit and 12% died during their first hospitalisation. Most of patients were hospitalised at least once for one or several acute events (n = 5,635; 87.0% of patients), of whom 36.5% of patients with an acute respiratory worsening (in-hospital mortality of 17.0% and median cost of 3,224; interquartile range (IQR 889-6,092)), 43.7% of patients with a respiratory infection (in-hospital mortality of 29.5% and median cost of 5,432 (IQR, 3,6209,115)) and 51.7% of patients with a cardiac event (in-hospital mortality of 35.7% and median cost of (sic)4,584 (IQR, (sic)2,803-6,399)); 30.2% of these events occurred during the first hospitalisation. Finally, the 3-year in-hospital mortality crude rate was 36.8%. This study is the first providing extensive data on hospitalisations in patients with pulmonary fibrosis, mostly idiopathic, in France, demonstrating high burden and hospital cost.	[Cottin, Vincent] Univ Claude Bernard Lyon 1, Natl Reference Ctr Rare Pulm Dis, Dept Resp Med, Grp Hosp Est Hop Louis Pradel, Lyon, France; [Schmidt, Aurelie; Catella, Laura; Porte, Fanny; Benard, Steve] Steve Consultants, Oullins, France; [Fernandez-Montoya, Celine; Le Lay, Katell] Boehringer Ingelheim GmbH & Co KG, Paris, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Boehringer Ingelheim	Catella, L (corresponding author), Steve Consultants, Oullins, France.	lcatella@steve-consultants.com		Schmidt, Aurelie/0000-0003-3291-4328	Boehringer Ingelheim France	Boehringer Ingelheim France(Boehringer Ingelheim)	The study was supported by Boehringer Ingelheim France. Celine Fernandez-Montoya and Katell Le Lay are employed by Boehringer Ingelheim. Boehringer Ingelheim was involved in study design, data analysis, decision to publish, and preparation of the manuscript. Aurelie Schmidt, Laura Catella, Fanny Porte and Steve Benard are employed by st[e]ve consultants which is a commercial company providing health economics services. st[e]ve consultants did not fund the study but was in charge of designing and performing the study.	Agabiti N, 2014, SARCOIDOSIS VASC DIF, V31, P191; [Anonymous], NAISSANCES TOUJOURS; [Anonymous], REFERENTIEL COUTS MC; Behr J, 2015, EUR RESPIR J, V46, P186, DOI 10.1183/09031936.00217614; Blivet S, 2001, CHEST, V120, P209, DOI 10.1378/chest.120.1.209; Bossard N., 2012, Bulletin Epidemiologique Hebdomadaire, P77; Brown AW, 2015, CHEST, V147, P173, DOI 10.1378/chest.13-2424; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; Collard HR, 2015, ANN AM THORAC SOC, V12, P981, DOI 10.1513/AnnalsATS.201412-553OC; Cottin V, 2013, REV MAL RESPIR, V30, P879, DOI 10.1016/j.rmr.2013.09.007; Esposito DB, 2015, AM J RESP CRIT CARE, V192, P1200, DOI 10.1164/rccm.201504-0818OC; Gaudry S, 2014, J THORAC CARDIOV SUR, V147, P47, DOI 10.1016/j.jtcvs.2013.06.039; Harari S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147072; Hodgson U, 2002, THORAX, V57, P338, DOI 10.1136/thorax.57.4.338; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4; Kornum Jette B, 2008, BMC Pulm Med, V8, P24, DOI 10.1186/1471-2466-8-24; Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI; Mallick S, 2008, RESP MED, V102, P1355, DOI 10.1016/j.rmed.2008.06.003; Morell F, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0168-6; Moua T, 2016, CHEST, V149, P1205, DOI 10.1016/j.chest.2015.12.026; Nathan SD, 2011, CHEST, V140, P221, DOI 10.1378/chest.10-2572; Navaratnam V, 2013, CHEST, V143, P1078, DOI 10.1378/chest.12-0803; Nunes H, 2011, EUR RESP J S55, V38, P646; Orphanet, 2016, RAR DIS COLL; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Redressements du Programme de me A dicalisation des d'informations (PMSI), SERIE STATISDES AFFA; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Ryerson CJ, 2015, EUR RESPIR J, V46, P512, DOI 10.1183/13993003.00419-2015; Saydain G, 2002, AM J RESP CRIT CARE, V166, P839, DOI 10.1164/rccm.2104038; Stern JB, 2001, CHEST, V120, P213, DOI 10.1378/chest.120.1.213	31	41	43	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2017	12	1							e0166462	10.1371/journal.pone.0166462	http://dx.doi.org/10.1371/journal.pone.0166462			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3HH	28099456	gold, Green Submitted, Green Published			2023-01-03	WOS:000392380100002
J	Fitzgerald, K; White, S; Borodovsky, A; Bettencourt, BR; Strahs, A; Clausen, V; Wijngaard, P; Horton, JD; Taubel, J; Brooks, A; Fernando, C; Kauffman, RS; Kallend, D; Vaishnaw, A; Simon, A				Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Wijngaard, Peter; Horton, Jay D.; Taubel, Jorg; Brooks, Ashley; Fernando, Chamikara; Kauffman, Robert S.; Kallend, David; Vaishnaw, Akshay; Simon, Amy			A Highly Durable RNAi Therapeutic Inhibitor of PCSK9	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBTILISIN/KEXIN TYPE 9; DENSITY-LIPOPROTEIN-CHOLESTEROL; MONOCLONAL-ANTIBODY; LDL CHOLESTEROL; DOUBLE-BLIND; CARDIOVASCULAR EVENTS; HEALTHY-VOLUNTEERS; NONHUMAN-PRIMATES; REDUCING LIPIDS; HYPERCHOLESTEROLEMIA	BACKGROUND Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3: 1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the.-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a least-squares mean reduction of 74.5% from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6% from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8% from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7% from baseline to day 84). CONCLUSIONS In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months. (Funded by Alnylam Pharmaceuticals and the Medicines Company; ClinicalTrials.gov number, NCT02314442.)	[Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna; Bettencourt, Brian R.; Strahs, Andrew; Clausen, Valerie; Kauffman, Robert S.; Vaishnaw, Akshay; Simon, Amy] Alnylam Pharmaceut, 300 Third St, Cambridge, MA 02142 USA; [Wijngaard, Peter; Kallend, David] Medicines Co, Parsippany, NJ USA; [Horton, Jay D.] Univ Texas Southwestern Med Ctr, Dallas, TX USA; [Taubel, Jorg] St Georges Univ London, Richmond Pharmacol, London, England; [Brooks, Ashley; Fernando, Chamikara] Covance Clin Res Unit, Leeds, W Yorkshire, England	University of Texas System; University of Texas Southwestern Medical Center Dallas; St Georges University London	Fitzgerald, K (corresponding author), Alnylam Pharmaceut, 300 Third St, Cambridge, MA 02142 USA.	kfitzgerald@alnylam.com	Taubel, Jorg/I-1286-2019	Taubel, Jorg/0000-0002-0010-207X; Banerjee, Yajnavalka/0000-0002-7546-8893	Alnylam Pharmaceuticals; Medicines Company; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	Alnylam Pharmaceuticals; Medicines Company; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by Alnylam Pharmaceuticals and the Medicines Company.	Ballantyne CM, 2015, AM J CARDIOL, V115, P1212, DOI 10.1016/j.amjcard.2015.02.006; Barkas F, 2015, ANGIOLOGY, V66, P346, DOI 10.1177/0003319714535073; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Dias CS, 2012, J AM COLL CARDIOL, V60, P1888, DOI 10.1016/j.jacc.2012.08.986; Egom EEA, 2016, ADV CLIN CHEM, V73, P127, DOI 10.1016/bs.acc.2015.10.005; Fitzgerald K, 2014, LANCET, V383, P60, DOI 10.1016/S0140-6736(13)61914-5; Frank-Kamenetsky M, 2008, P NATL ACAD SCI USA, V105, P11915, DOI 10.1073/pnas.0805434105; Henne KR, 2015, J PHARMACOL EXP THER, V353, P119, DOI 10.1124/jpet.114.221242; Hooper AJ, 2007, ATHEROSCLEROSIS, V193, P445, DOI 10.1016/j.atherosclerosis.2006.08.039; Hooper AJ, 2013, EXPERT OPIN BIOL TH, V13, P429, DOI 10.1517/14712598.2012.748743; Horton JD, 2009, J LIPID RES, V50, pS172, DOI 10.1194/jlr.R800091-JLR200; Jameson K, 2014, CURR MED RES OPIN, V30, P655, DOI 10.1185/03007995.2014.890926; Jones PH, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.001800; Koren MJ, 2012, LANCET, V380, P1995, DOI 10.1016/S0140-6736(12)61771-1; Lakoski SG, 2009, J CLIN ENDOCR METAB, V94, P2537, DOI 10.1210/jc.2009-0141; Mousavi SA, 2009, J INTERN MED, V266, P507, DOI 10.1111/j.1365-2796.2009.02167.x; Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a; Navarese EP, 2015, ANN INTERN MED, V163, P40, DOI 10.7326/M14-2957; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; Roth EM, 2014, INT J CARDIOL, V176, P55, DOI 10.1016/j.ijcard.2014.06.049; Rouleau J, 2005, AM J MED, V118, p28S, DOI 10.1016/j.amjmed.2005.09.014; Sabatine MS, 2015, NEW ENGL J MED, V372, P1500, DOI 10.1056/NEJMoa1500858; Stein EA, 2012, NEW ENGL J MED, V366, P1108, DOI 10.1056/NEJMoa1105803; Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002; Tabernero J, 2013, CANCER DISCOV, V3, P406, DOI 10.1158/2159-8290.CD-12-0429; Zhang XL, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0358-8; Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488	27	402	419	7	126	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	2017	376	1					41	51		10.1056/NEJMoa1609243	http://dx.doi.org/10.1056/NEJMoa1609243			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG6SS	27959715	Green Accepted			2023-01-03	WOS:000391177100007
J	Mizuno, M; Suzuki, Y; Higashide, K; Sei, Y; Iguchi, D; Sakata, F; Horie, M; Maruyama, S; Matsuo, S; Morgan, BP; Ito, Y				Mizuno, Masashi; Suzuki, Yasuhiro; Higashide, Keiko; Sei, Yumi; Iguchi, Daiki; Sakata, Fumiko; Horie, Masanobu; Maruyama, Shoichi; Matsuo, Seiichi; Morgan, B. Paul; Ito, Yasuhiko			High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients	PLOS ONE			English	Article							MESOTHELIAL CELLS; REGULATORS; ACTIVATION; THERAPY; MODEL; STILL; CD59	Background We searched for indicators to predict the prognosis of infectious peritonitis by measuring levels of complement proteins and activation products in peritoneal dialysis (PD) fluid (PDF) of patients at early stages of peritonitis. We retrospectively analyzed the relationship between the levels of sC5b-9, C3 and C4 in PDF and the subsequent clinical prognosis. Methods We measured levels of sC5b-9, C3 and C4 in PDF on days 1, 2 and 5 post-onset of peritonitis in 104 episodes of infectious peritonitis in PD patients from 2008 and retrospectively compared levels with clinical outcomes. Further analysis for the presence of causative microorganisms or to demonstrate bacterial culture negative peritonitis was performed and correlated with change of levels of sC5b-9 in PDF. Results When PD patients with peritonitis were divided into groups that either failed to recover from peritonitis and were finally withdrawn from PD (group 1; n = 25) or recovered (group 2; n = 79), levels of sC5b-9, C3 and C4 in PDF were significantly higher in group 1 patients compared to those in group 2 on day5. Analysis of microorganisms showed significantly higher sC5b-9 levels in PDF of peritonitis cases caused by culture negative peritonitis in group 1 compared with group 2 when we analyzed for individual microorganisms. Of note, on day5, the sC5b- 9 levels in PDF were similarly high in peritonitis caused by fungi or other organisms. Conclusion Our results suggested that levels of complement markers in PDF, especially sC5b- 9, have potential as surrogate markers to predict prognosis of PD-related peritonitis.	[Mizuno, Masashi; Ito, Yasuhiko] Nagoya Univ, Grad Sch Med, Renal Replacement Therapy, Nagoya, Aichi, Japan; [Mizuno, Masashi; Suzuki, Yasuhiro; Higashide, Keiko; Sei, Yumi; Iguchi, Daiki; Sakata, Fumiko; Maruyama, Shoichi; Matsuo, Seiichi; Ito, Yasuhiko] Nagoya Univ, Grad Sch Med, Div Nephrol, Nagoya, Aichi, Japan; [Horie, Masanobu] Daiyukai Daiichi Hosp, Ichinomiya, Japan; [Morgan, B. Paul] Cardiff Univ, Sch Med, Div Infect & Immun, Complement Biol Grp, Cardiff, S Glam, Wales	Nagoya University; Nagoya University; Cardiff University	Mizuno, M (corresponding author), Nagoya Univ, Grad Sch Med, Renal Replacement Therapy, Nagoya, Aichi, Japan.; Mizuno, M (corresponding author), Nagoya Univ, Grad Sch Med, Div Nephrol, Nagoya, Aichi, Japan.	masashim1jp@yahoo.co.jp	Mizuno, Masashi/I-7347-2014	Morgan, Paul/0000-0003-4075-7676	Ministry of Education, Culture, Sports, Science and Technology in Japan [24591227, 15K09288]; Japanese association for complement research; Japanese association of dialysis physician (JADP) [2012-07, 2014-03]; Ministry of Health, Labour and Welfare of Japan; Great Britain Sasakawa Foundation [B90]; MRC [MC_PC_13060] Funding Source: UKRI; Medical Research Council [MC_PC_13060] Funding Source: researchfish	Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese association for complement research; Japanese association of dialysis physician (JADP); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Great Britain Sasakawa Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was in part supported in part by the Ministry of Education, Culture, Sports, Science and Technology in Japan Grants-in-Aid 24591227 and 15K09288 for Scientific Research, by a research grant of the Japanese association for complement research, by the research grants from Japanese association of dialysis physician (JADP Grants 2012-07 and 2014-03), by a Ministry of Health, Labour and Welfare of Japan grant-in-aid for Progressive Renal Diseases Research, Research on Rare and Intractable Disease, and by the Great Britain Sasakawa Foundation 2015 Butterfield Award for UK-Japan collaboration in Medicine & Health to Mizuno M and Morgan BP (No. B90). Mizuno M, Suzuki Y and Ito Y worked in the Department of Renal Replacement Therapy as positions endowed by Baxter Japan at Nagoya University Graduate School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bunke M, 1994, Adv Perit Dial, V10, P174; Choi P, 2004, AM J KIDNEY DIS, V43, P103, DOI 10.1053/j.ajkd.2003.08.046; Chow KM, 2006, CLIN J AM SOC NEPHRO, V1, P768, DOI 10.2215/CJN.01010306; Davenport A, 2009, PERITON DIALYSIS INT, V29, P297; Kubota K, 2013, MICROBES ENVIRON, V28, P3, DOI 10.1264/jsme2.ME12107; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Lin CY, 2013, J AM SOC NEPHROL; Mactier R, 2009, PERITON DIALYSIS INT, V29, P262; Mizuno M, 2006, CURR MED CHEM, V13, P1707, DOI 10.2174/092986706777441959; Mizuno M., 2004, CURR DRUG TARGETS IN, V3, P85; Mizuno M, 2012, AM J PHYSIOL-RENAL, V302, pF1245, DOI 10.1152/ajprenal.00652.2011; Mizuno M, 2011, CLIN EXP NEPHROL, V15, P727, DOI 10.1007/s10157-011-0471-8; Mizuno M, 2009, J IMMUNOL, V183, P1403, DOI 10.4049/jimmunol.0804245; Mizuno T, 2011, NEPHROL DIAL TRANSPL, V26, P1821, DOI 10.1093/ndt/gfq683; Mizutani M, 2010, AM J PHYSIOL-RENAL, V298, pF721, DOI 10.1152/ajprenal.00368.2009; Mujais S, 2006, KIDNEY INT, V70, pS55, DOI 10.1038/sj.ki.5001916; Sei Y, 2015, MOL IMMUNOL, V65, P302, DOI 10.1016/j.molimm.2015.02.005; Tang S, 2004, CLIN EXP IMMUNOL, V136, P85, DOI 10.1111/j.1365-2249.2004.02407.x; Xu R, 2013, PERITON DIALYSIS INT, V33, P436, DOI 10.3747/pdi.2012.00163; YOUNG GA, 1993, NEPHROL DIAL TRANSPL, V8, P1372; Zweers MM, 1999, J LAB CLIN MED, V134, P124, DOI 10.1016/S0022-2143(99)90116-6	21	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0169111	10.1371/journal.pone.0169111	http://dx.doi.org/10.1371/journal.pone.0169111			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2QJ	28046064	gold, Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000391612300115
J	Busschaert, C; Scherrens, AL; De Bourdeaudhuij, I; Cardon, G; Van Cauwenberg, J; De Cocker, K				Busschaert, Cedric; Scherrens, Anne-Lore; De Bourdeaudhuij, Ilse; Cardon, Greet; Van Cauwenberg, Jelle; De Cocker, Katrien			Socio-Ecological Variables Associated with Context-Specific Sitting Time in Belgian Older Adults: A One-Year Follow-Up Study	PLOS ONE			English	Article							SEDENTARY BEHAVIOR; PHYSICAL-ACTIVITY; DETERMINANTS; RELIABILITY; VALIDITY; FEASIBILITY; ADOLESCENTS; MOTIVATION; BARRIERS; PEOPLE	Introduction Knowledge about variables associated with context-specific sitting time in older adults is limited. Therefore, this study explored cross-sectional and longitudinal associations of sociodemographic, social-cognitive, physical-environmental and health-related variables with sitting during TV viewing, computer use and motorized transport in older adults. Methods A sample of Belgian older adults completed structured interviews on context-specific sitting time and associated variables using a longitudinal study design. Objective measurements of grip strength and physical performance were also completed. Complete baseline data were available of 258 participants (73.98 6.16 years) of which 229 participants remained in the study at one year follow-up (retention rate: 91.60%). Cross-sectional correlates (baseline data) and longitudinal predictors (change-scores in relation with change in sitting time) were explored through multiple linear regression analyses. Results Per context-specific sitting time, most of the cross-sectional correlates differed from the longitudinal predictors. Increases over time in enjoyment of watching TV (+one unit), encouragement of partner to watch less TV (+one unit) and TV time of partner (+30.0 min/day) were associated with respectively 9.1 min/day (p<0.001), 16.0 min/day (p<0.001) and 12.0 min/day (p<0.001) more sitting during TV viewing at follow-up. Increases over time in enjoyment of using a computer (+one unit), the number of smartphones and tablets (+1) and computer use of the partner (+30.0 min/day) were associated with respectively 5.5 min/day (p < .01), 10.4 min/day (p < .05) and 3.0 min/day (p < .05) more sitting during computer use at follow-up. An increase over time in self-efficacy regarding taking a bicycle or walking was associated with 2.9 min/day (p < .05) less sitting during motorized transport at follow-up. Conclusions The results stressed the importance of looking at separate contexts of sitting. Further, the results highlighted the importance of longitudinal research in order to reveal which changes in particular variables predicted changes in context-specific sitting time. Variables at the social-cognitive level were most frequently related to context-specific sitting.	[Busschaert, Cedric; De Bourdeaudhuij, Ilse; Cardon, Greet; De Cocker, Katrien] Univ Ghent, Dept Movement & Sport Sci, Ghent, Belgium; [Busschaert, Cedric; Van Cauwenberg, Jelle; De Cocker, Katrien] Res Fdn Flanders FWO, Brussels, Belgium; [Scherrens, Anne-Lore; Van Cauwenberg, Jelle] Univ Ghent, Dept Publ Hlth, Ghent, Belgium; [Scherrens, Anne-Lore] Vrije Univ Brussel, Dept Primary Care, Brussels, Belgium; [Van Cauwenberg, Jelle] Vrije Univ Brussel, Dept Human Biometry & Biomech, Brussels, Belgium	Ghent University; Ghent University; Vrije Universiteit Brussel; Vrije Universiteit Brussel	De Bourdeaudhuij, I (corresponding author), Univ Ghent, Dept Movement & Sport Sci, Ghent, Belgium.	Ilse.Debourdeaudhuij@UGent.be	De Cocker, Katrien/AAA-5783-2020; De+Bourdeaudhuij, Ilse/AAC-5528-2019; De Cocker, Katrien/AEV-4609-2022	De Cocker, Katrien/0000-0001-7510-4419; De+Bourdeaudhuij, Ilse/0000-0001-9969-7597; Cardon, Greet/0000-0003-4983-6557	Fund for Scientific Research Flanders [B/12530/01]	Fund for Scientific Research Flanders(FWO)	Funded by Fund for Scientific Research Flanders (fund no. B/12530/01): CB IDB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Allison DP, 2012, HANDLING MISSING DAT; [Anonymous], 2005, GUIDELINES DATA PROC; Balboa-Castillo T, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-47; Bann D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116058; Bin Cheung Y, 2002, STAT MED, V21, P1461, DOI 10.1002/sim.1088; Brug J, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0293-2; Busschaert C, 2015, J ADOLESCENT HLTH OF; Busschaert C, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0277-2; Chastin SFM, 2014, BONE, V64, P254, DOI 10.1016/j.bone.2014.04.009; Chastin SFM, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0292-3; Chastin SFM, 2014, INT J ENV RES PUB HE, V11, P773, DOI 10.3390/ijerph110100773; Chastin SFM, 2013, PLOS ONE, V8; De Bourdeaudhuij I, 2005, OBES RES, V13, P1097, DOI 10.1038/oby.2005.128; De Bourdeaudhuij I, 2002, PREV MED, V34, P279, DOI 10.1006/pmed.2001.0979; Deforche B, 2010, PREV MED, V50, pS24, DOI 10.1016/j.ypmed.2009.08.017; Dogra S, 2014, INT J PUBLIC HLTH; Gardiner PA, 2011, AM J PREV MED, V41, P174, DOI 10.1016/j.amepre.2011.03.020; Gardner B, 2014, INT J BEHAV NUTR PHY, V11; Gianoudis J, 2015, OSTEOPOROSIS INT, V26, P571, DOI 10.1007/s00198-014-2895-y; Griffith DM, 2013, AM J MENS HEALTH, V7, P169, DOI 10.1177/1557988312465887; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Hamer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066222; Harvey JA, 2015, J AGING PHYS ACTIV, V23, P471, DOI 10.1123/japa.2014-0164; Haywood KL, 2005, QUAL LIFE RES, V14, P1651, DOI 10.1007/s11136-005-1743-0; Healy GN, 2008, DIABETES CARE, V31, P661, DOI 10.2337/dc07-2046; Healy GN, 2015, EUROPEAN HEART J; Keevil VL, 2015, MED SCI SPORT EXER, V47, P735, DOI 10.1249/MSS.0000000000000453; Kikuchi H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-213; Kolbe-Alexander TL, 2006, J AGING PHYS ACTIV, V14, P98, DOI 10.1123/japa.14.1.98; de Rezende LFM, 2014, BMC PUBLIC HEALTH, V14, DOI [10.1186/1471-2458-14-485, 10.1186/1471-2458-14-333]; Meneguci J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1426-x; Owen N, 2014, BRIT J SPORT MED, V48, P174, DOI 10.1136/bjsports-2013-093107; Owen N, 2011, AM J PREV MED, V41, P189, DOI 10.1016/j.amepre.2011.05.013; Rosenberg DE, 2015, J GERONTOLOGY A; Rovniak LS, 2014, J SCI MED SPORT, V17, P376, DOI 10.1016/j.jsams.2013.07.014; Salmon J, 2003, HEALTH PSYCHOL, V22, P178, DOI 10.1037/0278-6133.22.2.178; Sedentary Behaviour Research Network, 2012, APPL PHYSIOL NUTR ME, V37, P540, DOI [DOI 10.1139/H2012-024, 10.1139/h2012-024]; Stamatakis E, 2012, PREV MED, V54, P82, DOI 10.1016/j.ypmed.2011.10.009; Thogersen-Ntoumani C, 2009, SCAND J MED SCI SPOR, V19, P286, DOI 10.1111/j.1600-0838.2007.00751.x; Tomioka K, 2011, J EPIDEMIOL, V21, P459, DOI 10.2188/jea.JE20110003; Tran DV, 2013, HEALTH PROMOT J AUST, V24, P126, DOI 10.1071/HE13012; Uijtdewilligen L, 2014, SCAND J MED SCI SPOR; Van Cauwenberg J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133175; Van Cauwenberg J, 2014, J AGING PHYS ACTIV, V22, P508, DOI [10.1123/JAPA.2013-0015, 10.1123/japa.2013-0015]; van der Berg JD, 2014, MED SCI SPORT EXER, V46, P1359, DOI 10.1249/MSS.0000000000000246; Van Dyck D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-668; Van Holle V, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0110-3; Walters SJ, 2001, AGE AGEING, V30, P337, DOI 10.1093/ageing/30.4.337; Ware JE., 1994, SF 36 PHYS MENTAL HL; Zhai L, 2015, BRIT J SPORT MED, V49, P705, DOI 10.1136/bjsports-2014-093613	51	7	7	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2016	11	12							e0167881	10.1371/journal.pone.0167881	http://dx.doi.org/10.1371/journal.pone.0167881			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI9QF	27997603	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000392842900016
J	Kirzinger, L; Boy, S; Marienhagen, J; Schuierer, G; Neu, R; Ried, M; Hofmann, HS; Wiebe, K; Strobel, P; May, C; Kleylein-Sohn, J; Baierlein, C; Bogdahn, U; Marx, A; Schalke, B				Kirzinger, Lukas; Boy, Sandra; Marienhagen, Joerg; Schuierer, Gerhard; Neu, Reiner; Ried, Michael; Hofmann, Hans-Stefan; Wiebe, Karsten; Stroebel, Philipp; May, Christoph; Kleylein-Sohn, Julia; Baierlein, Claudia; Bogdahn, Ulrich; Marx, Alexander; Schalke, Berthold			Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study	PLOS ONE			English	Article							SOMATOSTATIN RECEPTOR SCINTIGRAPHY; COOPERATIVE-ONCOLOGY-GROUP; MALIGNANT THYMOMA; MYASTHENIA-GRAVIS; EPITHELIAL TUMORS; LONG-TERM; MANAGEMENT; PROGNOSIS; CARCINOMA; CRITERIA	Therapeutic options to cure advanced, recurrent, and unresectable thymomas are limited. The most important factor for long-term survival of thymoma patients is complete resection (R0) of the tumor. We therefore evaluated the response to and the induction of resectability of primarily or locally recurrent unresectable thymomas and thymic carcinomas by octreotide Long-Acting Release (LAR) plus prednisone therapy in patients with positive octreotide scans. In this open label, single-arm phase II study, 17 patients with thymomas considered unresectable or locally recurrent thymoma (n = 15) and thymic carcinoma (n = 2) at Masaoka stage III were enrolled. Octreotide LAR (30 mg once every 2 weeks) was administered in combination with prednisone (0.6 mg/kg per day) for a maximum of 24 weeks (study design according to Fleming's one sample multiple testing procedure for phase II clinical trials). Tumor size was evaluated by volumetric CT measurements, and a decrease in tumor volume of at least 20% at week 12 compared to baseline was considered as a response. We found that octreotide LAR plus prednisone elicited response in 15 of 17 patients (88%). Median reduction of tumor volume after 12 weeks of treatment was 51% (range 20%-86%). Subsequently, complete surgical resection was achieved in five (29%) and four patients (23%) after 12 and 24 weeks, respectively. Octreotide LAR plus prednisone treatment was discontinued in two patients before week 12 due to unsatisfactory therapeutic effects or adverse events. The most frequent adverse events were gastrointestinal (71%), infectious (65%), and hematological (41%) complications. In conclusion, octreotide LAR plus prednisone is efficacious in patients with primary or recurrent unresectable thymoma with respect to tumor regression. Octreotide LAR plus prednisone was well tolerated and adverse events were in line with the known safety profile of both agents.	[Kirzinger, Lukas; Boy, Sandra; Bogdahn, Ulrich; Schalke, Berthold] Univ Regensburg, Dept Neurol, Regensburg, Germany; [Marienhagen, Joerg] Univ Regensburg, Dept Nucl Med, Regensburg, Germany; [Schuierer, Gerhard] BKR, Inst Neuroradiol, Regensburg, Germany; [Neu, Reiner; Ried, Michael; Hofmann, Hans-Stefan] Univ Regensburg, Dept Thorac Surg, Regensburg, Germany; [Wiebe, Karsten] Univ Munster, Dept Cardiac & Thorac Surg, Munster, Germany; [Stroebel, Philipp] Univ Goettingen, Inst Pathol, Gottingen, Germany; [May, Christoph; Kleylein-Sohn, Julia; Baierlein, Claudia] Novartis Pharma GmbH, Nurnberg, Germany; [Marx, Alexander] Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, Mannheim, Germany; [Boy, Sandra] Asklepios Clin, Bad Toelz, Germany	University of Regensburg; University of Regensburg; University of Regensburg; University of Munster; University of Gottingen; Novartis; Ruprecht Karls University Heidelberg	Kirzinger, L (corresponding author), Univ Regensburg, Dept Neurol, Regensburg, Germany.	lukas.kirzinger@medbo.de	Ried, Michael/AAC-4518-2022	Ried, Michael/0000-0002-2365-4803	Novartis (Novartis Pharma GmbH, Nuremberg, Germany)	Novartis (Novartis Pharma GmbH, Nuremberg, Germany)	Novartis (Novartis Pharma GmbH, Nuremberg, Germany) funded the study, participated in the development of the study design, provided statistical support and the octreotide LAR medication, but did not participate in the collection and interpretation of the data. Novartis participated in the editorial writing and review of the manuscript. The author Dr. Boy became an employee of Asclepios clinic in 2015. Asclepios clinic was not a funder and did not play a role in this study.	Ahmad U, 2015, J THORAC CARDIOV SUR, V149, P95, DOI 10.1016/j.jtcvs.2014.09.124; Barratt S, 2007, EUR J CARDIO-THORAC, V31, P1142, DOI 10.1016/j.ejcts.2007.02.032; Benveniste MF, 2014, J THORAC ONCOL, V9, pS119, DOI 10.1097/JTO.0000000000000296; BESINGER UA, 1983, NEUROLOGY, V33, P1316, DOI 10.1212/WNL.33.10.1316; Bretti S, 2004, LUNG CANCER, V44, P69, DOI 10.1016/j.lungcan.2003.09.022; Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI 10.1056/NEJMoa1316158; Chen G, 2002, CANCER, V95, P420, DOI 10.1002/cncr.10665; DARDENNE M, 1986, CELL IMMUNOL, V100, P112, DOI 10.1016/0008-8749(86)90011-0; Detterbeck FC, 2004, ANN THORAC SURG, V77, P1860, DOI 10.1016/j.athoracsur.2003.10.001; Detterbeck FC, 2011, J THORAC ONCOL, V6, pS1710, DOI 10.1097/JTO.0b013e31821e8cff; Detterbeck FC, 2011, THORAC SURG CLIN, V21, P59, DOI 10.1016/j.thorsurg.2010.08.001; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Engels EA, 2003, INT J CANCER, V105, P546, DOI 10.1002/ijc.11099; FLEMING TR, 1982, BIOMETRICS, V38, P143, DOI 10.2307/2530297; FULLER PJ, 1989, J IMMUNOL, V143, P1015; Geffen DB, 2001, AM J CLIN ONCOL-CANC, V24, P566, DOI 10.1097/00000421-200112000-00007; Giustina A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036411; Harnath T, 2012, J THORAC ONCOL, V7, P1867, DOI 10.1097/JTO.0b013e3182745f73; Holbro A, 2012, HUM IMMUNOL, V73, P287, DOI 10.1016/j.humimm.2011.12.022; HU E, 1986, CANCER, V57, P1101, DOI 10.1002/1097-0142(19860315)57:6<1101::AID-CNCR2820570606>3.0.CO;2-A; Kelly RJ, 2011, J CLIN ONCOL, V29, P4820, DOI 10.1200/JCO.2011.36.0487; Kobayashi Y, 2006, CANCER-AM CANCER SOC, V106, P1901, DOI 10.1002/cncr.21875; Korst RJ, 2014, J THORAC CARDIOV SUR, V147, P36, DOI 10.1016/j.jtcvs.2013.08.061; Lastoria S, 1998, J NUCL MED, V39, P634; Lin K, 1999, CLIN NUCL MED, V24, P24, DOI 10.1097/00003072-199901000-00006; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164, DOI 10.1200/JCO.1994.12.6.1164; Loehrer PJ, 2004, J CLIN ONCOL, V22, P293, DOI 10.1200/JCO.2004.02.047; Marienhagen J, 1999, PATHOL RES PRACT, V195, P575, DOI 10.1016/S0344-0338(99)80008-9; Marx A, 2010, AUTOIMMUNITY, V43, P413, DOI 10.3109/08916930903555935; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; Muller-Hermelink HK., 2004, WHO CLASSIFICATION T, P196; Nicholson, 2015, WHO CLASSIFICATION T, P184; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Palmieri G, 1997, NEW ENGL J MED, V336, P263, DOI 10.1056/NEJM199701233360405; Palmieri G, 2002, CANCER-AM CANCER SOC, V94, P1414, DOI 10.1002/cncr.10374; REUBI JC, 1994, CANCER RES, V54, P3455; Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510; Rosai J., 1999, HISTOLOGICAL TYPING, P5; Scorsetti M, 2016, CRIT REV ONCOL HEMAT, V99, P332, DOI 10.1016/j.critrevonc.2016.01.012; SOFFER LJ, 1952, J CLIN ENDOCR METAB, V12, P690, DOI 10.1210/jcem-12-6-690; Strobel P, 2004, J CLIN ONCOL, V22, P1501, DOI 10.1200/JCO.2004.10.113; Stroebel P, 2010, J THORAC ONCOL, V5, pS286, DOI 10.1097/JTO.0b013e3181f209a8; Weckbecker G, 2003, NAT REV DRUG DISCOV, V2, P999, DOI 10.1038/nrd1255; WECKBECKER G, 1993, PHARMACOL THERAPEUT, V60, P245, DOI 10.1016/0163-7258(93)90009-3; Weis CA, 2015, J THORAC ONCOL, V10, P367, DOI 10.1097/JTO.0000000000000393; WILLCOX N, 1987, AM J PATHOL, V127, P447; Woltering EA, 1997, INVEST NEW DRUG, V15, P77, DOI 10.1023/A:1005774713202	47	5	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2016	11	12							e0168215	10.1371/journal.pone.0168215	http://dx.doi.org/10.1371/journal.pone.0168215			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8LN	27992479	Green Submitted, Green Published, gold			2023-01-03	WOS:000392758000032
J	Smith, AD; Zhang, Y; Barber, RC; Minshall, CT; Huebinger, RM; Allen, MS				Smith, Ashley D.; Zhang, Yan; Barber, Robert C.; Minshall, Christian T.; Huebinger, Ryan M.; Allen, Michael S.			Common Lung Microbiome Identified among Mechanically Ventilated Surgical Patients	PLoS One			English	Article							PNEUMONIA; DIVERSITY; DIAGNOSIS; DISEASE	The examination of the pulmonary microbiome in patients with non-chronic disease states has not been extensively examined. Traditional culture based screening methods are often unable to identify bacteria from bronchoalveolar lavage samples. The advancement of next-generation sequencing technologies allows for a culture-independent molecular based analysis to determine the microbial composition in the lung of this patient population. For this study, the Ion Torrent PGM system was used to assess the microbial complexity of culture negative bronchoalveolar lavage samples. A group of samples were identified that all displayed high diversity and similar relative abundance of bacteria. This group consisted of Hydrogenophaga, unclassified Bacteroidetes, Pedobacter, Thauera, and Acinetobacter. These bacteria may be representative of a common non-pathogenic pulmonary microbiome associated within this population of patients.	[Smith, Ashley D.] Univ North Texas, Hlth Sci Ctr, Dept Cell Biol & Immunol, Ft Worth, TX USA; [Smith, Ashley D.; Zhang, Yan; Allen, Michael S.] Univ North Texas, Hlth Sci Ctr, Ctr Biosafety & Biosecur, Ft Worth, TX 76107 USA; [Zhang, Yan; Barber, Robert C.; Allen, Michael S.] Univ North Texas, Hlth Sci Ctr, Dept Mol & Med Genet, Ft Worth, TX 76107 USA; [Minshall, Christian T.; Huebinger, Ryan M.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA	University of North Texas System; University of North Texas Denton; University of North Texas System; University of North Texas Denton; University of North Texas System; University of North Texas Denton; University of Texas System; University of Texas Southwestern Medical Center Dallas	Allen, MS (corresponding author), Univ North Texas, Hlth Sci Ctr, Ctr Biosafety & Biosecur, Ft Worth, TX 76107 USA.; Allen, MS (corresponding author), Univ North Texas, Hlth Sci Ctr, Dept Mol & Med Genet, Ft Worth, TX 76107 USA.; Huebinger, RM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.	Ryan.Huebinger@UTSouthwestern.edu; Michael.Allen@unthsc.edu	Smith, Ashley/GZB-0298-2022; Zhang, Yan/L-1738-2015	Zhang, Yan/0000-0001-5784-4659; Allen, Michael/0000-0003-2293-8078	UNTHSC	UNTHSC	This work was supported in part by a grant from UNTHSC to MSA.; The authors thank personnel and staff at Parkland Memorial Hospital for samples. Work was supported in part by a grant from UNTHSC to MSA and ADS.	Alain K, 2009, EXTREMOPHILES, V13, P583, DOI 10.1007/s00792-009-0261-3; Alex WI, 2012, AM THOR SOC INT C AM, pA4045; Cabello H, 1997, EUR RESPIR J, V10, P1137, DOI 10.1183/09031936.97.10051137; Cabrera-Rubio R, 2012, J CLIN MICROBIOL, V50, P3562, DOI 10.1128/JCM.00767-12; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Charlson ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015216; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Fittipaldi M, 2012, J MICROBIOL METH, V91, P276, DOI 10.1016/j.mimet.2012.08.007; Gholoobi A, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.8939; Gleeson K, 1997, CHEST, V111, P1266, DOI 10.1378/chest.111.5.1266; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Kelly BJ, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0151-8; Klappenbach JA, 2000, APPL ENVIRON MICROB, V66, P1328, DOI 10.1128/AEM.66.4.1328-1333.2000; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC; Murdoch DR, 2009, J CLIN MICROBIOL, V47, P3405, DOI 10.1128/JCM.01685-09; Musher DM, 2013, J INFECTION, V67, P11, DOI 10.1016/j.jinf.2013.03.003; Nair GB, 2015, INTENS CARE MED, V41, P34, DOI 10.1007/s00134-014-3564-5; Nair GB, 2013, CRIT CARE CLIN, V29, P521, DOI 10.1016/j.ccc.2013.03.007; Nocker A, 2006, J MICROBIOL METH, V67, P310, DOI 10.1016/j.mimet.2006.04.015; Pascual A, 2010, INT J MICROBIOL, V2010; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Scholz CFP, 2012, J CLIN MICROBIOL, V50, P1968, DOI 10.1128/JCM.00365-12; Segal LN, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-19; Smith AD, 2013, BIO SYST, V2, P116; Smith AD, 2013, BIOL SYSTEMS, V2, P5; Venkataraman A, 2015, MBIO, V6, DOI 10.1128/mBio.02284-14; Wang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007401	32	6	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2016	11	11							e0166313	10.1371/journal.pone.0166313	http://dx.doi.org/10.1371/journal.pone.0166313			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FU	27898681	gold, Green Published, Green Submitted			2023-01-03	WOS:000389474000008
J	Lemaire, L; Nel, J; Franconi, F; Bastiat, G; Saulnier, P				Lemaire, Laurent; Nel, Janske; Franconi, Florence; Bastiat, Guillaume; Saulnier, Patrick			Perfluorocarbon-Loaded Lipid Nanocapsules to Assess the Dependence of U87-Human Glioblastoma Tumor pO(2) on In Vitro Expansion Conditions	PLoS One			English	Article							OXYGEN-TENSION; VIVO; HYPOXIA; CELLS; METABOLISM; PHENOTYPE; PERFUSION; OXIMETRY; THERAPY; CULTURE	Growing tumor cell lines, such as U87-MG glioma cells, under mild hypoxia (3% O-2) leads to a ca. 40% reduction in growth rate once implanted in the brain of nude mice, as compared to normoxia (21% O-2) grown cells, wherein the former over-express HIF-1 and VEGF-A. Despite developing differently, the tumors have similar: blood perfusion, oxygen consumption, and vascular surface area parameters, whereas the number of blood vessels is nearly doubled in the tumor arising from normoxia cultured cells. Interestingly, tumor oxygen tension, measured using F-19-oximetry, showed that the normoxia grown cells led to tumors characterized by mild hypoxic environment (approximately 4%) conditions, whilst the hypoxia grown cells led to tumors characterized by physioxic environment (approximately 6%) conditions. This reversal in oxygen concentration may be responsible for the apparent paradoxical growth profiles.	[Lemaire, Laurent; Nel, Janske; Bastiat, Guillaume; Saulnier, Patrick] INSERM, Micro & Nanomed Biomimet MINT U1066, Angers, France; [Lemaire, Laurent; Nel, Janske; Bastiat, Guillaume; Saulnier, Patrick] Univ Angers, UMR S1066, Angers, France; [Franconi, Florence] Univ Angers, PRIMEX IRM, Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Universite d'Angers	Lemaire, L (corresponding author), INSERM, Micro & Nanomed Biomimet MINT U1066, Angers, France.; Lemaire, L (corresponding author), Univ Angers, UMR S1066, Angers, France.	laurent.lemaire@univ-angers.fr	FRANCONI, Florence/K-4258-2015; LEMAIRE, Laurent/A-3100-2011	FRANCONI, Florence/0000-0001-6725-0803; LEMAIRE, Laurent/0000-0002-1308-9345; Bastiat, Guillaume/0000-0001-6495-6747; Saulnier, Patrick/0000-0002-6408-3533	Comite Inter-Regional Grand Ouest de La Ligue Contre le Cancer (CIRGO)	Comite Inter-Regional Grand Ouest de La Ligue Contre le Cancer (CIRGO)	This work was supported by 'Comite Inter-Regional Grand Ouest de La Ligue Contre le Cancer' (CIRGO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert I, 2014, NEUROL RES, V36, P1001, DOI 10.1179/1743132814Y.0000000401; Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Bourke VA, 2007, INT J RADIAT ONCOL, V67, P1179, DOI 10.1016/j.ijrobp.2006.11.037; Bourseau-Guilmain E, 2012, INT J ONCOL, V40, P1220, DOI 10.3892/ijo.2011.1271; Bruning U, 2012, CELL MOL LIFE SCI, V69, P1319, DOI 10.1007/s00018-011-0876-2; Christen T, 2011, NMR BIOMED, V24, P393, DOI 10.1002/nbm.1603; Clavreul A, 2014, J PATHOL, V233, P74, DOI 10.1002/path.4332; Csete M, 2005, ANN NY ACAD SCI, V1049, P1, DOI 10.1196/annals.1334.001; Diepart C, 2011, NMR BIOMED, V24, P458, DOI 10.1002/nbm.1604; Diepart C, 2009, RADIAT RES, V172, P220, DOI 10.1667/RR1448.1; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Franconi F, 2010, MED PHYS, V37, P877, DOI 10.1118/1.3298019; Grimes DR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153692; Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668; Hou HG, 2015, INT J CANCER, V136, P1688, DOI 10.1002/ijc.29132; Hwang SH, 2015, J NUCL MED, V56; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KALLINOWSKI F, 1989, CANCER RES, V49, P3759; Kathagen A, 2013, ACTA NEUROPATHOL, V126, P763, DOI 10.1007/s00401-013-1173-y; Kober F, 2004, MAGN RESON MED, V51, P62, DOI 10.1002/mrm.10676; Kucharzewska P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116740; Lemaire L, 2013, EUR J PHARM BIOPHARM, V84, P479, DOI 10.1016/j.ejpb.2013.01.003; Lemaire L, 2000, NMR BIOMED, V13, P116, DOI 10.1002/1099-1492(200005)13:3<116::AID-NBM616>3.0.CO;2-D; Lemaire L, 2015, TUMOUR BIOL; Lemasson B, 2011, NMR BIOMED, V24, P473, DOI 10.1002/nbm.1611; Mesti T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099198; Platet N, 2007, CANCER LETT, V258, P286, DOI 10.1016/j.canlet.2007.09.012; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sullivan M, 2006, MOL HUM REPROD, V12, P653, DOI 10.1093/molehr/gal081; Wion D, 2009, CELL STEM CELL, V5, P242, DOI 10.1016/j.stem.2009.08.009	31	3	3	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2016	11	10							e0165479	10.1371/journal.pone.0165479	http://dx.doi.org/10.1371/journal.pone.0165479			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4VY	27788227	Green Published, gold			2023-01-03	WOS:000389604900092
J	Silva, CO; Petersen, SB; Reis, CP; Rijo, P; Molpeceres, J; Fernandes, AS; Goncalves, O; Gomes, AC; Correia, I; Vorum, H; Neves-Petersen, MT				Silva, Catarina Oliveira; Petersen, Steffen B.; Reis, Catarina Pinto; Rijo, Patricia; Molpeceres, Jesus; Fernandes, Ana Sofia; Goncalves, Odete; Gomes, Andreia C.; Correia, Isabel; Vorum, Henrik; Neves-Petersen, Maria Teresa			EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; HYALURONIC-ACID; N-FORMYLKYNURENINE; CELL UPTAKE; PROTEIN; FLUORESCENCE; TRYPTOPHAN; DITYROSINE; OXIDATION; IDENTIFICATION	The application of functionalized nanocarriers on photothermal therapy for cancer ablation has wide interest. The success of this application depends on the therapeutic efficiency and biocompatibility of the system, but also on the stability and biorecognition of the conjugated protein. This study aims at investigating the hypothesis that EGF functionalized polymer -coated gold nanoparticles promote EGF photostability and EGFR internalization, making these conjugated particles suitable for photothermal therapy. The conjugated gold nanoparticles (100-200 nm) showed a plasmon absorption band located within the near infrared range (650-900 nm), optimal for photothermal therapy applications. The effects of temperature, of polymer-coated gold nanoparticles and of UVB light (295nm) on the fluorescence properties of EGF have been investigated with steady-state and time-resolved fluorescence spectroscopy. The fluorescence properties of EGF, including the formation of Trp and Tyr photoproducts, is modulated by temperature and by the intensity of the excitation light. The presence of polymeric-coated gold nanoparticles reduced or even avoided the formation of Trp and Tyr photoproducts when EGF is exposed to UVB light, protecting this way the structure and function of EGF. Cytotoxicity studies of conjugated nanoparticles carried out in normal-like human keratinocytes showed small, concentration dependent decreases in cell viability (0-25%). Moreover, conjugated nanoparticles could activate and induce the internalization of overexpressed Epidermal Growth Factor Receptor in human lung carcinoma cells. In conclusion, the gold nanoparticles conjugated with Epidermal Growth Factor and coated with biopolymers developed in this work, show a potential application for near infrared photothermal therapy, which may efficiently destroy solid tumours, reducing the damage of the healthy tissue.	[Silva, Catarina Oliveira; Reis, Catarina Pinto; Rijo, Patricia; Fernandes, Ana Sofia] Univ Lusofona, Res Ctr Biosci & Hlth Technol, Lisbon, Portugal; [Silva, Catarina Oliveira; Molpeceres, Jesus] Univ Alcala, Dept Biomed Sci, Fac Pharm, Alcala De Henares, Spain; [Petersen, Steffen B.; Goncalves, Odete] Aalborg Univ, Dept Hlth Sci & Technol, Med Photon Lab, Fac Med, Aalborg, Denmark; [Reis, Catarina Pinto] Univ Lisbon, IBEB, Biophys & Biomed Engn, Fac Sci, Lisbon, Portugal; [Rijo, Patricia; Fernandes, Ana Sofia] Univ Lisbon, Inst Invest Medicamento, IMed ULisboa, Fac Farm, Lisbon, Portugal; [Goncalves, Odete; Gomes, Andreia C.] Univ Minho, CBMA Ctr Mol & Environm Biol, Campus Gualtar, Braga, Portugal; [Goncalves, Odete] Univ Minho, Dept Phys, CFUM Ctr Phys, Campus Gualtar, Braga, Portugal; [Correia, Isabel] Univ Lisbon, Inst Super Tecn, Ctr Quim Estrutural, Lisbon, Portugal; [Vorum, Henrik] Aalborg Univ Hosp, Dept Ophthalmol, Aalborg, Denmark; [Neves-Petersen, Maria Teresa] Aalborg Univ Hosp, Dept Clin Med, Aalborg, Denmark	Lusofona University; Universidad de Alcala; Aalborg University; Universidade de Lisboa; Universidade de Lisboa; Universidade do Minho; Universidade do Minho; Universidade de Lisboa; Instituto Superior Tecnico; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital	Reis, CP (corresponding author), Univ Lusofona, Res Ctr Biosci & Hlth Technol, Lisbon, Portugal.; Reis, CP (corresponding author), Univ Lisbon, IBEB, Biophys & Biomed Engn, Fac Sci, Lisbon, Portugal.; Neves-Petersen, MT (corresponding author), Aalborg Univ Hosp, Dept Clin Med, Aalborg, Denmark.	catarinapintoreis@ulusofona.pt; nevespetersen@gmail.com	Gomes, Andreia C/B-5905-2009; iMed.ULisboa, NanoBB/B-5393-2014; Rijo, Patrícia/O-2657-2015; /Y-9512-2019; Gomes, Andreia/AAC-9198-2020; Fernandes, Ana S./H-4789-2013; iMed.ULisboa, NatProdChem/B-5387-2014; Correia, Isabel/AAH-6847-2021; Silva, Catarina/AAV-8108-2020; Reis, Catarina/M-8132-2013; Correia, Isabel/H-7772-2012	Gomes, Andreia C/0000-0002-0567-064X; Rijo, Patrícia/0000-0001-7992-8343; /0000-0003-4201-0795; Gomes, Andreia/0000-0002-0567-064X; Fernandes, Ana S./0000-0001-6350-0641; Correia, Isabel/0000-0001-7096-4284; Reis, Catarina/0000-0002-1046-4031; Correia, Isabel/0000-0001-7096-4284; Oliveira Silva, Catarina/0000-0002-5077-5176; Neves-Petersen, Maria Teresa/0000-0003-3178-3709	Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/BBB-BMC/0611/2012]; FCT I.P. [UID/BIA/04050/2013 (POCI-01-0145-FEDER-007569)]; ERDF; European Commission [H2020-644242-SAPHELY, H2020-634013-2-PHOCNOSIS]	Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT I.P.; ERDF(European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre)	Support was provided by: Fundacao para a Ciencia e Tecnologia (FCT) for the financial support under the project reference PTDC/BBB-BMC/0611/2012 [https://www.fct.pt/apoios/projectos)]. The work at CBMA was supported by the strategic programme UID/BIA/04050/2013 (POCI-01-0145-FEDER-007569) funded by national funds through the FCT I.P. and by the ERDF through the COMPETE2020 - Programa Operacional Competitividade e Internacionalizacao (POCI) [https://www.fct.pt/apoios/projectos]; European Commission through the project H2020-644242-SAPHELY (https://saphely.eu/project.php) and the project H2020-634013-2-PHOCNOSIS [http://cordis.europa.eu/project/rcn/193268_en.html].; The authors would like to thank Fundacao para a Ciencia e Tecnologia (FCT) for the financial support under the project reference PTDC/BBB-BMC/0611/2012. The work at CBMA was supported by the strategic programme UID/BIA/04050/2013 (POCI-01-0145-FEDER-007569) funded by national funds through the FCT I.P. and by the ERDF through the COMPETE2020 - Programa Operacional Competitividade e Internacionalizacao (POCI). The authors acknowledge the funding from the European Commission through the project H2020-644242-SAPHELY and the project H2020-634013-2-PHOCNOSIS. Finally, the authors would also like to thank the master student Joao Lopes from Universidade Lusofona (Portugal) for the help with in vitro cytotoxic assays. Isabel Correia acknowledges FCT for Investigator FCT contract.	Antczak C, 2012, ASSAY DRUG DEV TECHN, V10, P24, DOI 10.1089/adt.2011.423; Avanti C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086244; BAYSE GS, 1972, BIOCHIM BIOPHYS ACTA, V284, P34; Bracher A, 2013, J INVEST DERMATOL, V133, P230, DOI 10.1038/jid.2012.272; CHAKRABA.B, 1973, J MOL BIOL, V78, P135, DOI 10.1016/0022-2836(73)90433-6; Chevrier DM, 2012, J NANOPHOTONICS, V6, DOI 10.1117/1.JNP.6.064504; Correia M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116737; Correia M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111617; Correia M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050733; Correia M, 2012, J FLUORESC, V22, P323, DOI 10.1007/s10895-011-0963-7; Creixell M, 2010, J MAGN MAGN MATER, V322, P2244, DOI 10.1016/j.jmmm.2010.02.019; Delehanty JB, 2010, THER DELIV, V1, P411, DOI 10.4155/TDE.10.27; Dreaden TM, 2011, J BIOL CHEM, V286, P22632, DOI 10.1074/jbc.M110.212928; Ferguson EL, 2010, INT J PHARMACEUT, V402, P95, DOI 10.1016/j.ijpharm.2010.09.029; FUKUNAGA Y, 1982, J BIOCHEM-TOKYO, V92, P129, DOI 10.1093/oxfordjournals.jbchem.a133909; Geerlof A, 2006, ACTA CRYSTALLOGR D, V62, P1125, DOI 10.1107/S0907444906030307; Han Q, 2012, BIOCHEM J, V446, P253, DOI 10.1042/BJ20120416; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; Kennedy LC, 2011, SMALL, V7, P169, DOI 10.1002/smll.201000134; Kerwin BA, 2007, J PHARM SCI-US, V96, P1468, DOI 10.1002/jps.20815; Kurnasov O, 2003, CHEM BIOL, V10, P1195, DOI 10.1016/j.chembiol.2003.11.011; Lim J, 2014, ARCH PHARM RES, P1; Liu Y, 2014, MACROMOL RES, V22, P240, DOI 10.1007/s13233-014-2001-5; Lu W, 2009, CLIN CANCER RES, V15, P876, DOI 10.1158/1078-0432.CCR-08-1480; Malencik DA, 2003, AMINO ACIDS, V25, P233, DOI 10.1007/s00726-003-0014-z; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; Master AM, 2012, NANOMEDICINE-UK, V7, P1895, DOI [10.2217/NNM.12.160, 10.2217/nnm.12.160]; MATRISIAN LM, 1984, J BIOL CHEM, V259, P3047; MEHLER AH, 1950, J BIOL CHEM, V187, P431; Merkus HG, PARTICLE SIZE MEASUR; Minati L, 2012, INT J PHARMACEUT, V438, P45, DOI 10.1016/j.ijpharm.2012.08.057; Murphy CJ, 2005, J PHYS CHEM B, V109, P13857, DOI 10.1021/jp0516846; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Neves-Petersen MT, 2010, J FLUORESC, V20, P483, DOI 10.1007/s10895-009-0570-z; Neves-Petersen MT, 2009, BIOPHYS J, V97, P211, DOI 10.1016/j.bpj.2009.01.065; Neves-Petersen MT, 2006, PROTEIN SCI, V15, P343, DOI 10.1110/ps.051885306; Neves-Petersen MT, 2002, PROTEIN SCI, V11, P588, DOI 10.1110/ps.06002; Neves-Petersen MT, UV LIGHT EFFECTS PRO; PIRIE A, 1972, BIOCHEM J, V128, P1365, DOI 10.1042/bj1281365; PRYOR WA, 1993, J BIOL CHEM, V268, P3120; Qhattal HSS, 2011, MOL PHARMACEUT, V8, P1233, DOI 10.1021/mp2000428; Rijo P, 2013, BIOMED BIOPHARM RES, V9, P225; Rijo P, 2014, MEASUREMENT, V58, P249, DOI 10.1016/j.measurement.2014.08.045; Ryu JH, 2013, BIOMATERIALS, V34, P9149, DOI 10.1016/j.biomaterials.2013.08.026; Salminen H, 2009, EFFECT PHENOLIC RICH; Salminen H, 2008, J AGR FOOD CHEM, V56, P11178, DOI 10.1021/jf8022673; Santana H, 2013, INT J PHARMACEUT, V452, P52, DOI 10.1016/j.ijpharm.2013.04.054; Shen LY, 2012, J COLLOID INTERF SCI, V388, P56, DOI 10.1016/j.jcis.2012.06.079; Shimada T, 2009, ANTICANCER RES, V29, P1009; Silva CO, 2016, THER DELIV, V7, P287, DOI 10.4155/tde-2015-0011; Silva CO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144454; Silva CO, 2015, INT J PHARMACEUT, V493, P271, DOI 10.1016/j.ijpharm.2015.07.044; Su ZC, 2014, MAT SCI ENG C-MATER, V44, P440, DOI 10.1016/j.msec.2014.07.039; TAYLOR JM, 1974, J BIOL CHEM, V249, P2188; TEDER P, 1995, CANCER RES, V55, P3908; Wang MJ, 2013, BBA-MOL CELL BIOL L, V1831, P1089, DOI 10.1016/j.bbalip.2013.01.018; Water JJ, 2014, EUR J PHARM BIOPHARM, V88, P325, DOI 10.1016/j.ejpb.2014.09.001; Yang CH, 2004, J BIOMOL STRUCT DYN, V22, P101, DOI 10.1080/07391102.2004.10506985; Yang F, 2006, BBA-PROTEINS PROTEOM, V1764, P1389, DOI 10.1016/j.bbapap.2006.06.012; Zhang SY, 2014, ACS APPL MATER INTER, V6, P21184, DOI 10.1021/am506112u; Zhang ZH, 2010, SMALL, V6, P430, DOI 10.1002/smll.200901515	62	29	30	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2016	11	10							e0165419	10.1371/journal.pone.0165419	http://dx.doi.org/10.1371/journal.pone.0165419			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4VY	27788212	Green Published, gold			2023-01-03	WOS:000389604900079
J	Venables, E; Edwards, JK; Baert, S; Etienne, W; Khabala, K; Bygrave, H				Venables, Emilie; Edwards, Jeffrey K.; Baert, Saar; Etienne, William; Khabala, Kelly; Bygrave, Helen			"They just come, pick and go." The Acceptability of Integrated Medication Adherence Clubs for HIV and Non Communicable Disease (NCD) Patients in Kibera, Kenya	PLOS ONE			English	Article							CARE; PREVALENCE; NAIROBI; PEOPLE	Introduction The number of people on antiretroviral therapy (ART) for the long-term management of HIV in low-and middle-income countries (LMICs) is continuing to increase, along with the prevalence of Non-Communicable Diseases (NCDs). The need to provide large volumes of HIV patients with ART has led to significant adaptations in how medication is delivered, but access to NCD care remains limited in many contexts. Medication Adherence Clubs (MACs) were established in Kibera, Kenya to address the large numbers of patients requiring chronic HIV and/or NCD care. Stable NCD and HIV patients can now collect their chronic medication every three months through a club, rather than through individual clinic appointments. Methodology We conducted a qualitative research study to assess patient and health-care worker perceptions and experiences of MACs in the urban informal settlement of Kibera, Kenya. A total of 106 patients (with HIV and/or other NCDs) and health-care workers were purposively sampled and included in the study. Ten focus groups and 19 in-depth interviews were conducted and 15 sessions of participant observation were carried out at the clinic where the MACs took place. Thematic data analysis was conducted using NVivo software, and coding focussed on people's experiences of MACs, the challenges they faced and their perceptions about models of care for chronic conditions. Results MACs were considered acceptable to patients and health-care workers because they saved time, prevented unnecessary queues in the clinic and provided people with health education and group support whilst they collected their medication. Some patients and health-care workers felt that MACs reduced stigma for HIV positive patients by treating HIV as any other chronic condition. Staff and patients reported challenges recruiting patients into MACs, including patients not fully understanding the eligibility criteria for the clubs. There were also some practical challenges during the implementation of the clubs, but MACs have shown that it is possible to learn from ART provision and enable stable HIV and NCD patients to collect chronic medication together in a group. Conclusions Extending models of care previously only offered to HIV-positive cohorts to NCD patients can help to de-stigmatise HIV, allow for the efficient clinical management of co-morbidities and enable patients to benefit from peer support. Through MACs, we have demonstrated that an integrated approach to providing medication for chronic diseases including HIV can be implemented in resource-poor settings and could thus be rolled out in other similar contexts.	[Venables, Emilie; Baert, Saar; Bygrave, Helen] Med Sans Frontieres, Southern Africa Med Unit, Cape Town, South Africa; [Venables, Emilie] Univ Cape Town, Sch Publ Hlth & Family Med, Div Social & Behav Sci, Cape Town, South Africa; [Edwards, Jeffrey K.; Etienne, William] Med Sans Frontieres Belgium, Operat Ctr Brussels, Dept Med, Brussels, Belgium; [Khabala, Kelly] Med Sans Frontieres, Nairobi, Kenya	University of Cape Town	Venables, E (corresponding author), Med Sans Frontieres, Southern Africa Med Unit, Cape Town, South Africa.; Venables, E (corresponding author), Univ Cape Town, Sch Publ Hlth & Family Med, Div Social & Behav Sci, Cape Town, South Africa.	emilie.venables@brussels.msf.org		Baert, Saar/0000-0002-9822-148X				[Anonymous], 2012, NVIVO COMP PROGR; Ayah R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-371; Belue R, 2009, GLOBALIZATION HEALTH, V5, DOI 10.1186/1744-8603-5-10; Bemelmans M, 2014, TROP MED INT HEALTH, V19, P968, DOI 10.1111/tmi.12332; Council on Foreign Relations, 2014, EM GLOB CRIS NONC DI; Dalal W, 2013, JAIDS-J ACQ IMM DEF, V62, pE47, DOI 10.1097/QAI.0b013e318276bea0; Decroo T, 2011, JAIDS-J ACQ IMM DEF, V56, pE39, DOI 10.1097/QAI.0b013e3182055138; Desgroppes A, 2011, CAHIERS AFRIQUE EST, P23; Duncombe C, 2015, TROP MED INT HEALTH, V20, P430, DOI 10.1111/tmi.12460; Edwards JK, 2015, T ROY SOC TROP MED H, V109, P440, DOI 10.1093/trstmh/trv038; Fedele F, 2011, AIDS REV, V13, P119; Kalra S, 2013, CURR DIABETES REP, V13, P419, DOI 10.1007/s11892-013-0369-9; Kenyan Ministry of Health, 2014, KEN HLTH POL 2014 20; Khabala KB, 2015, TROP MED INT HEALTH, V20, P1265, DOI 10.1111/tmi.12539; Narayan KMV, 2014, JAIDS-J ACQ IMM DEF, V67, pS2, DOI 10.1097/QAI.0000000000000267; National Institute of Allergy and Infectious Diseases (NIAID), 2015, START ANT TREATM EAR; Opwora A, 2015, HEALTH POLICY PLANN, V30, P508, DOI 10.1093/heapol/czu026; Rabkin M, 2011, GLOB PUBLIC HEALTH, V6, P247, DOI 10.1080/17441692.2011.552068; UNAIDS, 2014, 90 90 90 AMB TREATM, P40; UNAIDS and Medecins sans Frontieres, 2015, COMM BAS ANT THER DE; van de Vijver SJM, 2013, J HYPERTENS, V31, P1018, DOI 10.1097/HJH.0b013e32835e3a56; Wilkinson LS, 2013, S AFR J HIV MED, V14, P48, DOI [10.7196/SAJHIVMED.924, 10.7196/sajhivmed.924]; World Health Organization, 2015, GUID START ANT THER	23	55	56	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0164634	10.1371/journal.pone.0164634	http://dx.doi.org/10.1371/journal.pone.0164634			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NZ	27764128	Green Submitted, Green Published, gold			2023-01-03	WOS:000386204500048
J	Iacobucci, G				Iacobucci, Gareth			CCG axes funding for homeopathy	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Dyer C, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4797; Wise J, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3380	2	0	0	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2016	355								i5448	10.1136/bmj.i5448	http://dx.doi.org/10.1136/bmj.i5448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ4UM	27758782				2023-01-03	WOS:000385856000012
J	Wood, G; Miles, CAL; Coyles, G; Alizadehkhaiyat, O; Vine, SJ; Vickers, JN; Wilson, MR				Wood, Greg; Miles, Charlotte A. L.; Coyles, Ginny; Alizadehkhaiyat, Omid; Vine, Samuel J.; Vickers, Joan N.; Wilson, Mark R.			A randomized controlled trial of a group-based gaze training intervention for children with Developmental Coordination Disorder	PLOS ONE			English	Article							PERFORMANCE	The aim of this study was to integrate a gaze training intervention (i.e., quiet eye training; QET) that has been shown to improve the throwing and catching skill of children with Developmental Coordination Disorder (DCD), within an approach (i.e., group therapy) that might alleviate the negative psychosocial impact of these motor skill deficits. Twenty-one children with DCD were split into either QET (8 male 3 female, mean age of 8.6 years (SD = 1.04) or technical training (TT) groups (7 male 3 female, mean age of 8.6 years (SD = 1.84). The TT group were given movement-related instructions via video, relating to the throw and catch phases, while the QET group were also taught to fixate a target location on the wall prior to the throw (QE1) and to track the ball prior to the catch (QE2). Each group partook in a 4 week, group therapy intervention and measurements of QE duration and catching performance were taken before and after training, and at a 6-week delayed retention test. Parental feedback on psychosocial and motor skill outcomes was provided at delayed retention. Children improved their gaze control and catching coordination following QET, compared to TT. Mediation analysis showed that a longer QE aiming duration (QE1) predicted an earlier onset of tracking the ball prior to catching (QE2) which predicted catching success. Parents reported enhanced perceptions of their child's catching ability and general coordination in the QET group compared to the TT group. All parents reported improvements in their child's confidence, social skills and predilection for physical activity following the trial. The findings offer initial support for an intervention that practitioners could apply to address deficits in the motor and psychosocial skills of children with DCD.	[Wood, Greg] Manchester Metropolitan Univ, Ctr Hlth Exercise & Act Living, Crewe, England; [Wood, Greg; Miles, Charlotte A. L.; Coyles, Ginny; Alizadehkhaiyat, Omid] Liverpool Hope Univ, Dept Hlth Sci, Liverpool, Merseyside, England; [Vine, Samuel J.; Wilson, Mark R.] Univ Exeter, Coll Life & Environm Sci, Exeter, Devon, England; [Vickers, Joan N.] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada	Manchester Metropolitan University; Liverpool Hope University; University of Exeter; University of Calgary	Wood, G (corresponding author), Manchester Metropolitan Univ, Ctr Hlth Exercise & Act Living, Crewe, England.; Wood, G (corresponding author), Liverpool Hope Univ, Dept Hlth Sci, Liverpool, Merseyside, England.	greg.wood@mmu.ac.uk	Vickers, Joan/AAW-2815-2020; Vine, Samuel J/AAD-5226-2019	Vine, Samuel J/0000-0001-9329-1262; Wood, Greg/0000-0003-0851-7090	Liverpool Hope University (HEIF5 Programme); Waterloo Foundation [1119/1603]	Liverpool Hope University (HEIF5 Programme); Waterloo Foundation	This research was funded by grants from Liverpool Hope University (HEIF5 Programme 2011-2015) and The Waterloo Foundation (1119/1603). The funders were not involved in the study design, data collection, data analysis, manuscript preparation, nor publication decisions. The authors have stated that they had no interests that might be perceived as posing a conflict or bias.	Alloway TP, 2011, CHILD NEUROPSYCHOL, V17, P483, DOI 10.1080/09297049.2011.553590; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2005, BRIT J OCCUP THER, DOI [10.1177/030802260506800903, DOI 10.1177/030802260506800903]; Bart O, 2010, RES DEV DISABIL, V31, P46, DOI 10.1016/j.ridd.2009.07.021; Biotteau M., 2016, CURR DEV DISORD REP, V3, P152, DOI DOI 10.1007/S40474-016-0084-8; Bunker D, 1994, PRIMARY PHYS ED IMPL; Candler C, 2002, AM J OCCUP THER, V56, P429, DOI 10.5014/ajot.56.4.429; Chen Hsiu-Fen, 2003, Physical & Occupational Therapy in Pediatrics, V23, P61, DOI 10.1300/J006v23n04_05; Cole F L, 1988, Clin Nurse Spec, V2, P53, DOI 10.1097/00002800-198800210-00025; Cummins A, 2005, DEV MED CHILD NEUROL, V47, P437, DOI 10.1017/S001216220500085X; Debrabant J, 2013, RES DEV DISABIL, V34, P1478, DOI 10.1016/j.ridd.2013.02.008; DuPaul GJ, 1998, J PSYCHOPATHOL BEHAV, V20, P83, DOI 10.1023/A:1023087410712; Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028; Henderson S. E., 2007, MOVEMENT ASSESSMENT, DOI 10.1037/t55281-000; Miles CAL, 2015, RES DEV DISABIL, V40, P31, DOI 10.1016/j.ridd.2015.01.005; Miles CA, 2015, EUROPEAN J SPORT SCI, V19, P1; Miles CAL, 2014, PSYCHOL SPORT EXERC, V15, P511, DOI 10.1016/j.psychsport.2014.04.009; Morgan R, 2012, BRIT J OCCUP THER, V75, P10, DOI 10.4276/030802212X13261082051337; Pless M, 2000, ADAPT PHYS ACT Q, V17, P381, DOI 10.1123/apaq.17.4.381; Poulsen AA, 2007, AM J OCCUP THER, V61, P451, DOI 10.5014/ajot.61.4.451; Robert MP, 2014, DEV MED CHILD NEUROL, V56, P595, DOI 10.1111/dmcn.12384; Sugden D., 2006, LEEDS CONSENSUS STAT; Sumner E, 2016, OCULOMOTOR ATYPICALI; Vickers JN, 1996, J EXP PSYCHOL HUMAN, V22, P342, DOI 10.1037/0096-1523.22.2.342; Vine SJ, 2013, INT J SPORT PSYCHOL, V44, P367, DOI 10.7352/IJSP2013.44.367; Wilson MR, 2013, MED SCI SPORT EXER, V45, P1144, DOI 10.1249/MSS.0b013e31828288f1; Wilson MR, 2011, SURG ENDOSC, V25, P2268, DOI 10.1007/s00464-010-1546-4; Wilson MR, 2016, CURRENT ISSUES SPORT, V1, P117, DOI DOI 10.15203/CISS_2016.117; Wilson PH, 2013, DEV MED CHILD NEUROL, V55, P217, DOI 10.1111/j.1469-8749.2012.04436.x	29	21	21	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2017	12	2							e0171782	10.1371/journal.pone.0171782	http://dx.doi.org/10.1371/journal.pone.0171782			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK9KV	28187138	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000394244300043
J	Gueguen, J; Piot, MA; Orri, M; Gutierre, A; Le Moan, J; Berthoz, S; Falissard, B; Godart, N				Gueguen, Juliette; Piot, Marie-Aude; Orri, Massimiliano; Gutierre, Andrea; Le Moan, Jocelyne; Berthoz, Sylvie; Falissard, Bruno; Godart, Nathalie			Group Qigong for Adolescent Inpatients with Anorexia Nervosa: Incentives and Barriers	PLOS ONE			English	Article							EATING-DISORDERS; PHYSICAL-ACTIVITY; BODY; PSYCHOTHERAPY; PERCEPTION; MOTIVATION; ALLIANCE; EXERCISE; ANXIETY; ADULTS	Background Qigong is a mind-body intervention focusing on interoceptive awareness that appears to be a promising approach in anorexia nervosa (AN). In 2008, as part of our multidimensional treatment program for adolescent inpatients with AN, we began a weekly qigong workshop that turned out to be popular among our adolescent patients. Moreover psychiatrists perceived clinical benefits that deserved further exploration. Methods and findings A qualitative study therefore sought to obtain a deeper understanding of how young patients with severe AN experience qigong and to determine the incentives and barriers to adherence to qigong, to understanding its meaning, and to applying it in other contexts. Data were collected through 16 individual semi-structured face-to-face interviews and analyzed with the interpretative phenomenological analysis method. Eleven themes emerged from the analysis, categorized in 3 superordinate themes describing the incentives and barriers related to the patients themselves (individual dimension), to others (relational dimension), and to the setting (organizational dimension). Individual dimensions associated with AN (such as excessive exercise and mind-body cleavage) may curb adherence, whereas relational and organizational dimensions appear to provide incentives to join the activity in the first place but may also limit its post-discharge continuation. Once barriers are overcome, patients reported positive effects: satisfaction associated with relaxation and with the experience of mind-body integration. Conclusions Qigong appears to be an interesting therapeutic tool that may potentiate psychotherapy and contribute to the recovery process of patients with AN. Further analysis of the best time window for initiating qigong and of its place in overall management might help to overcome some of the barriers, limit the risks, and maximize its benefits.	[Gueguen, Juliette; Orri, Massimiliano; Berthoz, Sylvie; Falissard, Bruno; Godart, Nathalie] Univ Paris Sud, Univ Paris Saclay, UVSQ, CESP,INSERM, Paris, France; [Gueguen, Juliette; Piot, Marie-Aude; Orri, Massimiliano; Falissard, Bruno] Univ Paris 05, Paris, France; [Piot, Marie-Aude; Gutierre, Andrea; Le Moan, Jocelyne; Berthoz, Sylvie; Godart, Nathalie] Inst Mutualiste Montsouris, Psychiat Unit, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite	Gueguen, J (corresponding author), Univ Paris Sud, Univ Paris Saclay, UVSQ, CESP,INSERM, Paris, France.; Gueguen, J (corresponding author), Univ Paris 05, Paris, France.	juliette.gueguen@inserm.fr	Berthoz Landron, Sylvie/M-4517-2018; Zamora, Cristina Cuesta/E-2864-2016; PIOT, Marie-Aude/AAO-9051-2021; Orri, Massimiliano/S-9220-2019	Zamora, Cristina Cuesta/0000-0003-1121-9561; Piot, Marie-Aude/0000-0001-6776-1611; Orri, Massimiliano/0000-0003-1389-2610; Berthoz, Sylvie/0000-0002-6862-2362				Ainley V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055568; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, Vfifth, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Andres-Perpina S, 2011, EUR CHILD ADOLES PSY, V20, P541, DOI 10.1007/s00787-011-0216-y; [Anonymous], 1960, CARTESIAN MEDITATION; Arlington Va., 2011, DEV EVIDENCE BASED C; Atkinson MJ, 2015, INT J EAT DISORDER, V48, P1024, DOI 10.1002/eat.22416; Boudette Robin, 2006, Eat Disord, V14, P167, DOI 10.1080/10640260500536334; Carei TR, 2010, J ADOLESCENT HEALTH, V46, P346, DOI 10.1016/j.jadohealth.2009.08.007; Coulon N, 2009, ENCEPHALE, V35, P531, DOI 10.1016/j.encep.2008.09.005; Courty A, 2015, COMPR PSYCHIAT, V56, P217, DOI 10.1016/j.comppsych.2014.09.011; Eklund M, 2016, SCAND J OCCUP THER, V23, P304, DOI 10.3109/11038128.2016.1143529; Ellis DA, 2012, J PEDIATR PSYCHOL, V37, P75, DOI 10.1093/jpepsy/jsr072; Eshkevari E, 2014, EUR EAT DISORD REV, V22, P383, DOI 10.1002/erv.2305; Espindola CR, 2009, ANN CLIN PSYCHIATRY, V21, P38; Farb N, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00763; Fuchs T, 2009, CURR OPIN PSYCHIATR, V22, P570, DOI 10.1097/YCO.0b013e3283318e5c; Fustos J, 2013, SOC COGN AFFECT NEUR, V8, P911, DOI 10.1093/scan/nss089; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; Godart N, 2004, Eat Weight Disord, V9, P224; Godart N, 2005, ARCH PEDIATRIE, V12, P1544, DOI 10.1016/j.arcped.2005.02.030; Godart N.T., 2013, OPEN J EPIDEMIOL, V03, P53, DOI [10.4236/ojepi.2013.32009, DOI 10.4236/0JEPI.2013.32009, DOI 10.4236/OJEPI.2013.32009]; Godart N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028249; Griffiths R, 1998, INT J EAT DISORDER, V23, P443; Halmi KA, 2012, INT J EAT DISORDER, V45, P800, DOI 10.1002/eat.22019; Harrison A, 2009, CLIN PSYCHOL PSYCHOT, V16, P348, DOI 10.1002/cpp.628; Hartmann AS, 2015, BODY IMAGE, V14, P77, DOI 10.1016/j.bodyim.2015.03.013; HAS, 2010, AN MENT PRIS CHARG; Herbert BM, 2012, TOP COGN SCI, V4, P692, DOI 10.1111/j.1756-8765.2012.01189.x; Hillen S, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0516-8; Horndasch S, 2015, EUR ARCH PSY CLIN N, V265, P677, DOI 10.1007/s00406-015-0603-3; Hyland ME, 2005, CLIN MED, V5, P361, DOI 10.7861/clinmedicine.5-4-361; Jeammet P, 1984, PSYCHOL FR, V29, P137; Keski-Rahkonen A, 2014, INT J EAT DISORDER, V47, P117, DOI 10.1002/eat.22168; Keyes A, 2015, INT J EAT DISORDER, V48, P46, DOI 10.1002/eat.22354; Kohl M, 2004, ENCEPHALE, V30, P492; Kolnes LJ, 2012, J BODYW MOV THER, V16, P281, DOI 10.1016/j.jbmt.2011.12.005; Lang K, 2015, PSYCHIAT RES, V225, P387, DOI 10.1016/j.psychres.2014.12.008; Laumer U, 1997, PSYCHOTHER PSYCH MED, V47, P170; Lerner MD, 2011, BEHAV THER, V42, P449, DOI 10.1016/j.beth.2010.11.006; Lloyd S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111697; Mason M, 2010, FORUM QUAL SOZIALFOR, V11, pe8; McIver S, 2009, QUAL HEALTH RES, V19, P1234, DOI 10.1177/1049732309343954; Mehta Neeta, 2011, Mens Sana Monogr, V9, P202, DOI 10.4103/0973-1229.77436; National Collaborating Centre for Mental Health (UK), 2004, EAT DIS COR INT TREA; Nummenmaa L, 2014, P NATL ACAD SCI USA, V111, P646, DOI 10.1073/pnas.1321664111; Patton M. Q., 2001, QUALITATIVE RES EVAL; Pollatos Olga, 2008, Eat Behav, V9, P381, DOI 10.1016/j.eatbeh.2008.02.001; Pollatos O, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00484; Pollatos O, 2016, PSYCHIAT RES, V240, P328, DOI 10.1016/j.psychres.2016.04.072; Posadzki P, 2010, COMPLEMENT THER MED, V18, P87, DOI 10.1016/j.ctim.2009.12.002; Sansone Randy A, 2005, Psychiatry (Edgmont), V2, P40; Schmidt U, 2006, BRIT J CLIN PSYCHOL, V45, P343, DOI 10.1348/014466505X53902; Shapiro JR, 2008, INT J EAT DISORDER, V41, P728, DOI 10.1002/eat.20552; Shelef K, 2005, J CONSULT CLIN PSYCH, V73, P689, DOI 10.1037/0022-006X.73.4.689; Smink FRE, 2014, INT J EAT DISORDER, V47, P610, DOI 10.1002/eat.22316; Smith J., 2008, DOING SOCIAL PSYCHOL, P229; Smith JA, 1996, PSYCHOL HEALTH, V11, P261, DOI 10.1080/08870449608400256; Smith LK, 2005, LANCET, V366, P825, DOI 10.1016/S0140-6736(05)67030-4; Steinglass JE, 2006, J INT NEUROPSYCH SOC, V12, P431, DOI 10.1017/S1355617706060528; Steinhausen HC, 2002, AM J PSYCHIAT, V159, P1284, DOI 10.1176/appi.ajp.159.8.1284; Suri H, 2011, QUAL RES J, V11, P63, DOI 10.3316/QRJ1102063; Swanson SA, 2011, ARCH GEN PSYCHIAT, V68, P714, DOI 10.1001/archgenpsychiatry.2011.22; Tan JOA, 2010, INT J LAW PSYCHIAT, V33, P13, DOI 10.1016/j.ijlp.2009.10.003; Tsang H, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/706892; Vancampfort D, 2014, DISABIL REHABIL, V36, P628, DOI 10.3109/09638288.2013.808271; Vansteelandt K, 2007, BEHAV RES THER, V45, P1717, DOI 10.1016/j.brat.2006.12.005; Vansteenkiste M, 2005, INT J EAT DISORDER, V37, P207, DOI 10.1002/eat.20099; Vocks S, 2007, J PSYCHOSOM RES, V62, P231, DOI 10.1016/j.jpsychores.2006.08.007; Wang CW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-8; Yang Y., 2011, J AGING RES, V2011, DOI [10.4061/2011/650210, DOI 10.4061/2011/650210, 10. 4061/2011/650210]; Yuan CS, 2011, TRADITIONAL CHINESE MEDICINE, P1, DOI 10.3109/9781841848433	71	5	5	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2017	12	2							e0170885	10.1371/journal.pone.0170885	http://dx.doi.org/10.1371/journal.pone.0170885			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7DB	28152083	Green Published, gold, Green Submitted			2023-01-03	WOS:000396161200055
J	Miranda, SP				Miranda, Stephen P.			Learning to Drive - Early Exposure to End-of-Life Conversations in Medical Training	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Miranda, Stephen P.] Univ Rochester, Sch Med & Dent, Rochester, NY 14611 USA	University of Rochester	Miranda, SP (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14611 USA.							Bloom Benjamin, 1956, HDB 1 COGNITIVE DOMA	1	2	2	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2017	376	5					413	415		10.1056/NEJMp1609234	http://dx.doi.org/10.1056/NEJMp1609234			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EJ8WH	28146668				2023-01-03	WOS:000393507200004
J	Haske, D; Beckers, SK; Hofmann, M; Lefering, R; Gliwitzky, B; Wolfl, CC; Grutzner, P; Stockle, U; Dieroff, M; Munzberg, M				Haeske, David; Beckers, Stefan K.; Hofmann, Marzellus; Lefering, Rolf; Gliwitzky, Bernhard; Woelfl, Christoph C.; Gruetzner, Paul; Stoeckle, Ulrich; Dieroff, Marc; Muenzberg, Matthias			Quality of Documentation as a Surrogate Marker for Awareness and Training Effectiveness of PHTLS-Courses. Part of the Prospective Longitudinal Mixed-Methods EPPTC-Trial	PLOS ONE			English	Article							LIFE-SUPPORT PROGRAM; AMBULANCE CAREGIVERS; END-POINTS; TRAUMA; IMPACT; ERROR; PERFORMANCE; MANAGEMENT; INJURY	Objective Care for severely injured patients requires multidisciplinary teamwork. A decrease in the number of accident victims ultimately affects the routine and skills. PHTLS ("Pre-Hospital Trauma Life Support") courses are established two-day courses for medical and non-medical rescue service personnel, aimed at improving the pre-hospital care of trauma patients worldwide. The study aims the examination of the quality of documentation before and after PHTLS courses as a surrogate endpoint of training effectiveness and awareness. Methods This was a prospective pre-post intervention trial and was part of the mixed-method longitudinal EPPTC (Effect of Paramedic Training on Pre-Hospital Trauma Care) study, evaluating subjective and objective changes among participants and real patient care, as a result of PHTLS courses. The courses provide an overview of the SAMPLE approach for interrogation of anamnestic information, which is believed to be responsible for patient safety as relevant, among others, "Allergies," "Medication," and "Patient History" (AMP). The focus of the course is not the documentation. Results In total, 320 protocols were analyzed before and after the training. The PHTLS course led to a significant increase (p < 0.001) in the "AMP" information in the documentation. The subgroups analysis of "allergies" (+47.2%), "drugs" (+38.1%), and "medical history" (+27.8%) before and after the PHTLS course showed a significant increase in the information content. Conclusion In summary, we showed that PHTLS training improves documentation quality, which we used as a surrogate endpoint for learning effectiveness and awareness. In this regard, we demonstrated that participants use certain parts of training in real life, thereby suggesting that the learning methods of PHTLS training are effective. These results, however, do not indicate whether patient care has changed.	[Haeske, David] Eberhard Karls Univ Tubingen, Fac Med, Tubingen, Germany; [Beckers, Stefan K.] Univ Hosp RWTH, Dept Anesthesiol, Aachen, Germany; [Beckers, Stefan K.] Emergency Med Serv, Fire Dept, Aachen, Germany; [Hofmann, Marzellus] Univ Witten Herdecke, Fac Hlth, Witten, Germany; [Lefering, Rolf] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany; [Gliwitzky, Bernhard] Megamed Emergency Management GbR, Annweiler, Germany; [Woelfl, Christoph C.] Hosp Hetzelstift, Dept Orthoped Trauma Surg & Sports Traumatol, Neustadt, Germany; [Gruetzner, Paul; Muenzberg, Matthias] BG Trauma Ctr Ludwigshafen, Dept Trauma & Orthoped Surg, Ludwigshafen, Germany; [Stoeckle, Ulrich] BG Hosp Tuebingen, Dept Traumatol & Reconstruct Surg, Tubingen, Germany; [Dieroff, Marc] Fire Serv Emergency Preparedness & Crisis Managem, Wiesbaden, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Witten Herdecke University; Witten Herdecke University	Munzberg, M (corresponding author), BG Trauma Ctr Ludwigshafen, Dept Trauma & Orthoped Surg, Ludwigshafen, Germany.	matthias.muenzberg@bgu-ludwigshafen.de	Häske, David/B-6250-2017; Beckers, Stefan K./O-2943-2019; Häske, David/O-6358-2019	Häske, David/0000-0001-5190-3937; Beckers, Stefan K./0000-0002-2896-7948; Häske, David/0000-0001-5190-3937; stockle, ulrich/0000-0002-6419-2203	German Association of Emergency Medical Technicians (Deutscher Berufsverband Rettungsdienst e.V. DBRD) [2013-Hae_01]	German Association of Emergency Medical Technicians (Deutscher Berufsverband Rettungsdienst e.V. DBRD)	The German Association of Emergency Medical Technicians (Deutscher Berufsverband Rettungsdienst e.V. DBRD) funded the study in form of research materials (www.dbrd.de) (Funding-Account: 2013-Hae_01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Ali J, 1997, J TRAUMA, V42, P1018, DOI 10.1097/00005373-199706000-00005; Ali J, 1998, WORLD J SURG, V22, P1192, DOI 10.1007/s002689900543; Ali J, 1998, W INDIAN MED J, V47, P102; [Anonymous], 2015, GLOB HLTH OBS IND ES; [Anonymous], 2015, BERICHTE BUNDESANSTA; Arreola-Risa C, 2000, J TRAUMA, V48, P119, DOI 10.1097/00005373-200001000-00020; Bergrath S, 2011, ANAESTHESIST, V60, P221, DOI 10.1007/s00101-010-1790-y; Bernhard M, 2006, ANAESTHESIST, V55, P1157, DOI 10.1007/s00101-006-1106-4; Blomberg H, 2013, J AM COLL SURGEONS, V217, P1010, DOI 10.1016/j.jamcollsurg.2013.08.002; Buyse M, 2010, NAT REV CLIN ONCOL, V7, P309, DOI 10.1038/nrclinonc.2010.43; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; de Haes H, 2009, PATIENT EDUC COUNS, V74, P287, DOI 10.1016/j.pec.2008.12.006; Enke N, 2009, SCHNITTSTELLEN NOTFA; Francis RCE, 2010, EMERG MED J, V27, P350, DOI 10.1136/emj.2008.070284; French SC, 2006, PREHOSP EMERG CARE, V10, P71, DOI 10.1080/10903120500366086; Guldner S, 2011, NOTFALL RETTUNGSMED, V14, P351, DOI 10.1007/s10049-011-1439-7; Haske D, 2014, ANAESTHESIST, V63, P209, DOI 10.1007/s00101-014-2301-3; Haske D, 2013, Z EVIDENZ FORTBILD Q, V107, P484, DOI 10.1016/j.zefq.2013.06.007; Haske D, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-32; Haske D, 2016, J TRAUMA ACUTE CARE; Hohn EA, 2015, J SURG EDUC, V72, P47, DOI 10.1016/j.jsurg.2014.06.005; Jarodzka H, 2015, MED EDUC, V49, P854, DOI 10.1111/medu.12791; Johansson J, 2012, RESUSCITATION, V83, P1259, DOI 10.1016/j.resuscitation.2012.02.018; Kim YS, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-2; Li ZB, 2014, ACCIDENT ANAL PREV, V64, P52, DOI 10.1016/j.aap.2013.11.003; Loftus T, 2015, CUREUS, V7, DOI 10.7759/cureus.283; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; NAEMT, 2011, PRAKL TRAUM PREH TRA; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Peschanski N, 2015, EMERGENCY MED J; Renard D, 2002, BIOMETRICAL J, V44, P921, DOI 10.1002/bimj.200290004; Schiff GD, 2009, ARCH INTERN MED, V169, P1881, DOI 10.1001/archinternmed.2009.333; Schlechtriemen, 2005, NOTFALL RETTUNGSMED, V8, P391, DOI [DOI 10.1007/s10049-005-0756-0, 10.1007/s10049-005-0756-0]; Statistisches Bundesamt, 2015, VERL BEI VERK; Statistisches Bundesamt (Destatis), 2015, VERK; Stewart M, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-19; Ulitsky A, 2012, ANN EMERG MED, V60, pS96, DOI 10.1016/j.annemergmed.2012.06.247; Waydhas C, 2003, NOTFALL RETTUNGSMED, V6, P33, DOI DOI 10.1007/S10049-002-0524-3; Westli HK, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-47	39	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2017	12	1							e0170004	10.1371/journal.pone.0170004	http://dx.doi.org/10.1371/journal.pone.0170004			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3QC	28107394	gold, Green Submitted, Green Published			2023-01-03	WOS:000392405300059
J	Buchbinder, M				Buchbinder, Mara			Extremis A Documentary Look at End-of-Life Decisions in the ICU	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Buchbinder, Mara] Univ N Carolina, Ctr Bioeth, Dept Social Med, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Buchbinder, M (corresponding author), Univ N Carolina, Ctr Bioeth, Dept Social Med, Chapel Hill, NC 27514 USA.	mara_buchbinder@med.unc.edu		Buchbinder, Mara/0000-0002-2319-662X				Chapple H.S., 2010, NO PLACE DYING HOSP; Kaufman Sharon, 2006, TIME DIE AM HOSP SHA	2	0	0	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2017	317	3					240	241		10.1001/jama.2016.20009	http://dx.doi.org/10.1001/jama.2016.20009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9KC	28114529				2023-01-03	WOS:000392089200001
J	Schreiber, S; Parent, EC; Moez, EK; Hedden, DM; Hill, DL; Moreau, M; Lou, E; Watkins, EM; Southon, SC				Schreiber, Sanja; Parent, Eric C.; Moez, Elham Khodayari; Hedden, Douglas M.; Hill, Douglas L.; Moreau, Marc; Lou, Edmond; Watkins, Elise M.; Southon, Sarah C.			Schroth Physiotherapeutic Scoliosis-Specific Exercises Added to the Standard of Care Lead to Better Cobb Angle Outcomes in Adolescents with Idiopathic Scoliosis - an Assessor and Statistician Blinded Randomized Controlled Trial	PLOS ONE			English	Article							REDUCE SPINAL DEFORMITY; ACTIVE SELF-CORRECTION; QUALITY-OF-LIFE; CURVE PROGRESSION; BRACE PRESCRIPTION; MONTICONE M; CAZZANIGA D; AMBROSINI E; BACK-PAIN; ROCCA B	Background The North American non-surgical standard of care for adolescent idiopathic scoliosis (AIS) includes observation and bracing, but not exercises. Schroth physiotherapeutic scoliosis-specific exercises (PSSE) showed promise in several studies of suboptimal methodology. The Scoliosis Research Society calls for rigorous studies supporting the role of exercises before including it as a treatment recommendation for scoliosis. Objectives To determine the effect of a six-month Schroth PSSE intervention added to standard of care (Experimental group) on the Cobb angle compared to standard of care alone (Control group) in patients with AIS. Methods Fifty patients with AIS aged 10-18 years, with curves of 10 degrees-45 degrees and Risser grade 0-5 were recruited from a single pediatric scoliosis clinic and randomized to the Experimental or Control group. Outcomes included the change in the Cobb angles of the Largest Curve and Sum of Curves from baseline to six months. The intervention consisted of a 30-45 minute daily home program and weekly supervised sessions. Intention-to-treat and per protocol linear mixed effects model analyses are reported. Results In the intention-to-treat analysis, after six months, the Schroth group had significantly smaller Largest Curve than controls (-3.5 degrees, 95% CI-1.1 degrees to-5.9 degrees, p = 0.006). Likewise, the between-group difference in the square root of the Sum of Curves was -0.40 degrees, (95% CI -0.03 degrees to -0.8 degrees, p= 0.046), suggesting that an average patient with 51.2 degrees at baseline, will have a 49.3 degrees Sum of Curves at six months in the Schroth group, and 55.1 degrees in the control group with the difference between groups increasing with severity. Per protocol analyses produced similar, but larger differences: Largest Curve = -4.1 degrees (95% CI-1.7 degrees to -6.5 degrees, p= 0.002) and root Sum of Curves = degrees 0.5 (95% CI-0.8 to 0.2, p = 0.006). Conclusion Schroth PSSE added to the standard of care were superior compared to standard of care alone for reducing the curve severity in patients with AIS.	[Schreiber, Sanja; Watkins, Elise M.] Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada; [Parent, Eric C.] Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada; [Moez, Elham Khodayari] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Hedden, Douglas M.; Hill, Douglas L.; Moreau, Marc; Lou, Edmond; Southon, Sarah C.] Univ Alberta, Alberta Hlth Serv, Dept Surg, Edmonton, AB, Canada; [Hedden, Douglas M.; Hill, Douglas L.; Moreau, Marc; Southon, Sarah C.] Alberta Hlth Serv, Edmonton, AB, Canada; [Lou, Edmond] Alberta Hlth Serv, Glenrose Rehabil Res Ctr, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Alberta; Alberta Health Services (AHS); University of Alberta; Alberta Health Services (AHS); Alberta Health Services (AHS)	Schreiber, S (corresponding author), Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada.; Parent, EC (corresponding author), Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada.	sanja.schreiber@ualberta.ca; eparent@ualberta.ca	Schreiber, Sanja/AAQ-2974-2021	Schreiber, Sanja/0000-0002-8231-5131; Parent, Eric/0000-0003-3835-0607	Scoliosis Research Society Small Exploratory Grant; Glenrose Rehabilitation Hospital Foundation; Glenrose Clinical Research Fund; Faculty of Medicine and Dentistry and Faculty of Rehabilitation Medicine	Scoliosis Research Society Small Exploratory Grant; Glenrose Rehabilitation Hospital Foundation; Glenrose Clinical Research Fund; Faculty of Medicine and Dentistry and Faculty of Rehabilitation Medicine	This study was funded by: Scoliosis Research Society 2010 Small Exploratory Grant (US$ 10,000), ECP, EMW, SS, DLH, DMH, MJM, SCS, http://www.srs.org/professionals/research-and-journal/research-grants/grants-awarded; Glenrose Rehabilitation Hospital Foundation, Glenrose Clinical Research Fund (CAD$ 10,000), ECP, EMW, DLH, MJM, http://www.albertahealthservices.ca/Facilities/GRH/page58.asp; Interdepartmental Graduate Studentship jointly awarded by the Faculty of Medicine and Dentistry and Faculty of Rehabilitation Medicine supported PhD work of Sanja Schreiber (CAD$ 23,000/annum for 4 years). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bettany-Saltikov J, 2014, EUR J PHYS REHAB MED, V50, P111; Danielsson AJ, 2003, SPINE, V28, pE373, DOI 10.1097/01.BRS.0000084267.41183.75; Danielsson AJ, 2003, SPINE, V28, P2078; Dishman RK, 2002, PREV MED, V34, P100, DOI 10.1006/pmed.2001.0959; Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN; Fusco C., 2011, Physiotherapy Theory and Practice, V27, P80, DOI 10.3109/09593985.2010.533342; Hennes A, 2011, SCHROTH METHOD; Konieczny MR, 2013, J CHILD ORTHOP, V7, P3, DOI 10.1007/s11832-012-0457-4; Kotwicki Tomasz, 2009, Ortop Traumatol Rehabil, V11, P379; Kuru T, 2016, CLIN REHABIL, V30, P181, DOI 10.1177/0269215515575745; Lenssinck MLB, 2005, PHYS THER, V85, P1329, DOI 10.1093/ptj/85.12.1329; LONSTEIN JE, 1984, J BONE JOINT SURG AM, V66A, P1061, DOI 10.2106/00004623-198466070-00013; Lonstein JE, 1984, J BONE JOINT SURG AM; MACLEAN WE, 1989, J PEDIATR ORTHOPED, V9, P257; Martinez-Llorens J, 2010, EUR RESPIR J, V36, P393, DOI 10.1183/09031936.00025509; Monticone M, 2014, EUR SPINE J, V23, P2221, DOI 10.1007/s00586-014-3465-x; Monticone M, 2014, EUR SPINE J, V23, P1204, DOI 10.1007/s00586-014-3241-y; Mordecai SC, 2012, EUR SPINE J, V21, P382, DOI 10.1007/s00586-011-2063-4; Negrini S, 2005, Eura Medicophys, V41, P183; Negrini S, 2015, SCOLIOSIS, V10, P1, DOI DOI 10.1186/s13013-014-0026-3; Negrini S, 2008, J REHABIL MED, V40, P451, DOI 10.2340/16501977-0195; Negrini S, 2008, DISABIL REHABIL, V30, P731, DOI 10.1080/09638280801889485; Negrini S, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-14; Negrini Stefano, 2003, Pediatr Rehabil, V6, P227; Negrini S, 2012, SCOLIOSIS SPINAL DIS, V7, DOI 10.1186/1748-7161-7-3; Negrini S, 2014, EUR SPINE J, V23, P2218, DOI 10.1007/s00586-014-3464-y; Noh DK, 2014, J BACK MUSCULOSKELET, V27, P331, DOI 10.3233/BMR-130452; Otman S, 2005, SAUDI MED J, V26, P1429; Payne WK, 1997, SPINE, V22, P1380, DOI 10.1097/00007632-199706150-00017; Plaszewski M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110254; R core Team, 2010, R LANG ENV STAT COMP; REFSUM HE, 1990, SPINE, V15, P420, DOI 10.1097/00007632-199005000-00014; Richards BS, 2005, SPINE, V30, P2068, DOI 10.1097/01.brs.0000178819.90239.d0; Rigo M, 2003, Pediatr Rehabil, V6, P209; Romano M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007837.pub2; Roy-Beaudry M, 2010, STUD HEALTH TECHNOL, V158, P152, DOI 10.3233/978-1-60750-573-0-152; Salkind N. J, 2010, ENCY RES DESIGN, V1, DOI 10.4135/9781412961288.n35.SAGEPublicationsInc; Sanders JO, 2007, J BONE JOINT SURG AM, V89A, P64, DOI 10.2106/JBJS.F.00067; Schlosser TPC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097461; Schreiber S, 2015, EFFECT SCHROTH EXERC, V10, P1; Schreiber S, 2012, BIOMED CENTRAL LT S1, V7, pO53; Schreiber Sanja, 2014, J Physiother, V60, P234, DOI 10.1016/j.jphys.2014.08.005; Scoliosis Research Society, AD ID SCOL TREATM; Scoliosis Research Society, 2016, AD ID SCOL, P1; Stokes I. A. F., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P277; Stokes IA, 2006, SCOLIOSIS, V18, P1; Stokes IAF, 2004, SPINE, V29, P2103, DOI 10.1097/01.brs.0000141182.42544.1f; Stokes IAF, 2007, EUR SPINE J, V16, P1621, DOI 10.1007/s00586-007-0442-7; Tan KJ, 2009, SPINE, V34, P697, DOI 10.1097/BRS.0b013e31819c9431; Venables W.N., 2002, MODERN APPL STAT S; Wan L., 2005, ZHONGGUO LINCHUANG K, V9, P82; Watkins EM, 2012, ALGORITHMS PRESCR S1, V7, pP22; Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3; Weinstein SL, 2013, NEW ENGL J MED, V369, P1512, DOI 10.1056/NEJMoa1307337; Weiss Hans-Rudolf, 2003, Pediatr Rehabil, V6, P23, DOI 10.1080/1363849031000095288; Westrick ER, 2011, J PEDIATR ORTHOPED, V31, pS61, DOI 10.1097/BPO.0b013e3181fd87d5; Zhang JH, 2010, J SPINAL DISORD TECH, V23, P383, DOI 10.1097/BSD.0b013e3181bb9a3c	57	44	46	2	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2016	11	12							e0168746	10.1371/journal.pone.0168746	http://dx.doi.org/10.1371/journal.pone.0168746			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7KQ	28033399	Green Published, Green Submitted, gold			2023-01-03	WOS:000391226900042
J	Jobarteh, K; Shiraishi, RW; Malimane, I; Gudo, PS; Decroo, T; Auld, AF; Macome, V; Couto, A				Jobarteh, Kebba; Shiraishi, Ray W.; Malimane, Inacio; Gudo, Paula Samo; Decroo, Tom; Auld, Andrew F.; Macome, Vania; Couto, Aleny			Community ART Support Groups in Mozambique: The Potential of Patients as Partners in Care	PLOS ONE			English	Article							ANTIRETROVIRAL TREATMENT; MORTALITY; ADHERENCE; THERAPY	Background High rates of attrition are stymying Mozambique's national HIV Program's efforts to achieve 80% treatment coverage. In response, Mozambique implemented a national pilot of Community Adherence and Support Groups (CASG). CASG is a model in which antiretroviral therapy (ART) patients form groups of up to six patients. On a rotating basis one CASG group member collects ART medications at the health facility for all group members, and distributes those medications to the other members in the community. Patients also visit their health facility bi-annually to receive clinical services. Methods A matched retrospective cohort study was implemented using routinely collected patient level data in 68 health facilities with electronic data systems and CASG programs. A total of 129,938 adult ART patients were registered in those facilities. Of the 129,938 patients on ART, 6,760 were CASG members. A propensity score matched analysis was performed to assess differences in mortality and loss to follow-up (LTFU) between matched CASG and non-CASG members. Propensity scores were estimated using a random-effects logistic regression model. The following covariates where included in the model: sex, educational status, WHO stage, year of ART initiation, age, CASG eligibility, CD4 cell count category, weight, and employment status. Results Non-CASG participants had higher LTFU rates (HR 2.356; p = 0.04) than matched CASG participants; however, there were no significant mortality differences between CASG and non-CASG participants. Compared with the full cohort of non-CASG members, CASG members were more likely to be female (74% vs. 68%), tended to have a lower median CD4 counts at ART initiation (183 cells/m3 vs. 200cells/m3) and be less likely to have a second ary school education (15% vs. 23%). Conclusion ART patients enrolled in CASG were significantly less likely to be LTFU compared to matched patients who did not join CASG. CASG appears to be an effective strategy to decrease LTFU in Mozambique's national ART program.	[Jobarteh, Kebba; Malimane, Inacio; Gudo, Paula Samo] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Maputo, Mozambique; [Shiraishi, Ray W.; Auld, Andrew F.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA; [Decroo, Tom] Operat Ctr Brussels, Med Sans Frontieres, Dept Med, Brussels, Belgium; [Macome, Vania; Couto, Aleny] Mozamb Minist Hlth, Maputo, Mozambique	Centers for Disease Control & Prevention - USA; Doctors Without Borders	Jobarteh, K (corresponding author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Maputo, Mozambique.	kebba@mac.com	Decroo, Tom/AAV-7208-2020	Decroo, Tom/0000-0002-1205-1484; Shiraishi, Ray/0000-0001-7640-0666; Auld, Andrew/0000-0001-5089-9163				Austin PC, 2008, STAT MED, V27, P2037, DOI 10.1002/sim.3150; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Decroo T, 2013, INT STD RES REV, V12, P49; Decroo T, 2011, JAIDS-J ACQ IMM DEF, V56, pE39, DOI 10.1097/QAI.0b013e3182055138; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Gifford AL, 2002, JAIDS-J ACQ IMM DEF, V31, pS163, DOI 10.1097/00126334-200212153-00016; Joint United Nations Program on HIV/AIDS, 2014, JOINT UN PROGR HIV A, P14; Lawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f; Leuven E, 2014, PSMATCH2 STATA MODUL; Lunt M., 2012, MPBALCHK STATA MODUL; Lunt M., 2012, PBALCHK STATA MODULE; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; MISAU, 2010, INQ NAC PREV RISC CO; Mitra R, 2016, STAT METHODS MED RES, V25, P188, DOI 10.1177/0962280212445945; National Program on HIV AIDS STIs, 2015, NAT PROGR HIV AIDS S; National Program on HIV AIDS STIs, 2011, NAT PROGR HIV AIDS S; Rasschaert F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091544; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; The United National Development Program. Human Development Index Trends, 1980, HUM DEV IND TRENDS 1; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; Wools-Kaloustian KK, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-22; World Health Organization, 2009, WHOHTMNTDWHOPES20094	25	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0166444	10.1371/journal.pone.0166444	http://dx.doi.org/10.1371/journal.pone.0166444			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3JC	27907084	Green Published, gold			2023-01-03	WOS:000389482700027
J	Chen, HM; Lin, HF; Huang, MF; Chang, CW; Yeh, YC; Lo, YC; Yen, CF; Chen, CS				Chen, Hui-Mei; Lin, Hsiu-Fen; Huang, Mei-Feng; Chang, Chun-Wei; Yeh, Yi-Chun; Lo, Yi-Ching; Yen, Cheng-Fang; Chen, Cheng-Sheng			Validation of Taiwan Performance-Based Instrumental Activities of Daily Living (TPIADL), a Performance- Based Measurement of Instrumental Activities of Daily Living for Patients with Vascular Cognitive Impairment	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; OLDER-ADULTS; DEMENTIA	Objective Patients with cerebrovascular diseases often presented both cognitive and physical impairment. Disability in everyday functioning involving cognitive impairment among patients may be hard to completely rely on informants' reports, as their reports may be confounded with physical impairment. The aim of this study was to validate a performance-based measure of functional assessment, the Taiwan Performance-Based Instrumental Activities of Daily Living (TPIADL), for vascular cognitive impairment (VCI) by examining its psychometric properties and diagnostic accuracy. Methods Ninety-seven patients with cerebrovascular diseases, including 30 with vascular dementia (VaD), 28 with mild cognitive impairment and 39 with no cognitive impairment, and 49 healthy control adults were recruited during study period. The TPIADL, as well as the Mini Mental State Examination (MMSE), Lawton-IADL and Barthel Index (BI), were performed. The internal consistency, convergent and criteria validity of the TPIADL were examined. Results Cronbach's alpha of the TPIADL test was 0.84. The TPIADL scores were significantly correlated with the Lawton IADL (r = -0.587, p <0.01). Notably, the TPIADL had a higher correlation coefficient with the cognitive domain of Lawton IADL (r = -0.663) than with physical domain of Lawton IADL (r = -0.541). The area under the relative operating characteristic curve was 0.888 (95% CI = 0.812 -0.965) to differentiate VaD from other groups. The optimal cut-off point of the TPIADL for detecting VaD was 6/7, which gives a sensitivity of 73.3% and a specificity of 84.5%. Conclusion The TPIADL is a brief and sensitive tool for the detection of IADL impairment in patients with VaD.	[Chen, Hui-Mei; Chang, Chun-Wei] Kaohsiung Med Univ, Dept Occupat Therapy, Coll Hlth Sci, Kaohsiung, Taiwan; [Lin, Hsiu-Fen] Kaohsiung Med Univ Hosp, Dept Neurol, Kaohsiung, Taiwan; [Huang, Mei-Feng; Yeh, Yi-Chun; Yen, Cheng-Fang; Chen, Cheng-Sheng] Kaohsiung Med Univ Hosp, Dept Psychiat 3, Kaohsiung, Taiwan; [Chen, Hui-Mei; Huang, Mei-Feng; Yeh, Yi-Chun] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Lin, Hsiu-Fen] Kaohsiung Med Univ, Dept Neurol, Coll Med, Kaohsiung, Taiwan; [Huang, Mei-Feng; Yeh, Yi-Chun; Yen, Cheng-Fang; Chen, Cheng-Sheng] Kaohsiung Med Univ, Dept Psychiat, Coll Med, Kaohsiung, Taiwan; [Lo, Yi-Ching] Kaohsiung Med Univ, Dept Pharmacol, Coll Med, Kaohsiung, Taiwan; [Lo, Yi-Ching] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Yen, CF; Chen, CS (corresponding author), Kaohsiung Med Univ Hosp, Dept Psychiat 3, Kaohsiung, Taiwan.; Yen, CF; Chen, CS (corresponding author), Kaohsiung Med Univ, Dept Psychiat, Coll Med, Kaohsiung, Taiwan.	chfaye@cc.kmu.edu.tw; sheng@kmu.edu.tw		Lin, Hsiu-Fen/0000-0001-6343-826X; Chen, Hui-Mei/0000-0002-3712-5144	Kaohsiung Medical University Hospital [KMUH102-M204]	Kaohsiung Medical University Hospital	This research was supported by grants from the Kaohsiung Medical University Hospital (KMUH102-M204).	Canavan M, 2014, GERONTOLOGY, V60, P212, DOI 10.1159/000356744; Chen HM, 2015, PSYCHOGERIATRICS, V15, P227, DOI 10.1111/psyg.12096; den Ouden MEM, 2014, EXP GERONTOL, V58, P1, DOI 10.1016/j.exger.2014.06.002; Donoghue OA, 2014, ARCH PHYS MED REHAB, V95, P1954, DOI 10.1016/j.apmr.2014.06.008; Gold DA, 2012, J CLIN EXP NEUROPSYC, V34, P11, DOI 10.1080/13803395.2011.614598; Guo NW, 1988, TAIWAN J PHYS MED RE, V16, P52; Gure TR, 2010, J GERONTOL A-BIOL, V65, P434, DOI 10.1093/gerona/glp197; Hachinski V, 2006, STROKE, V37, P2220, DOI 10.1161/01.STR.0000237236.88823.47; Hamel R, 2015, PSYCHOL MED, V45, P1509, DOI 10.1017/S0033291714002645; Hamilton JM, 2014, ALZHEIMERS DEMENT, V10, P171, DOI 10.1016/j.jalz.2013.04.003; Harvey PD, 2007, SCHIZOPHRENIA BULL, V33, P1138, DOI 10.1093/schbul/sbm040; Hosmer D.W., 2000, APPL LOGISTIC REGRES, V2nd; Jekel K, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0099-0; Kalaria RN, 2008, LANCET NEUROL, V7, P812, DOI 10.1016/S1474-4422(08)70169-8; Kim YH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/852784; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MAHONEY F I, 1965, Md State Med J, V14, P61; Middleton L, 2008, J NEUROL SCI, V269, P80, DOI 10.1016/j.jns.2007.04.054; Moore DJ, 2007, J PSYCHIATR RES, V41, P97, DOI 10.1016/j.jpsychires.2005.10.008; Ng TP, 2006, J GERONTOL A-BIOL, V61, P726, DOI 10.1093/gerona/61.7.726; Ni JN, 2015, INT J GERIATR PSYCH, V30, P888, DOI 10.1002/gps.4317; Reppermund S, 2011, INT J GERIATR PSYCH, V26, P843, DOI 10.1002/gps.2612; Rockwood K, 2002, STROKE, V33, P1605, DOI 10.1161/01.STR.0000017878.85274.44; Rockwood K, 2007, J NEUROL SCI, V252, P106, DOI 10.1016/j.jns.2006.10.015; Rodakowski J, 2014, J AM GERIATR SOC, V62, P1347, DOI 10.1111/jgs.12878; Sadek JR, 2011, J INT NEUROPSYCH SOC, V17, P832, DOI 10.1017/S1355617711000841; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Tolea MI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122878; Vasquez BP, 2015, J NEUROPSYCHOL, V9, P109, DOI 10.1111/jnp.12039; Wilms HU, 2007, COMPR PSYCHIAT, V48, P95, DOI 10.1016/j.comppsych.2006.04.001; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	31	2	3	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2016	11	11							e0166546	10.1371/journal.pone.0166546	http://dx.doi.org/10.1371/journal.pone.0166546			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EC1ZU	27851810	Green Published, Green Submitted, gold			2023-01-03	WOS:000387909300064
J	Peng, H; Chen, L; Li, WF; Zhang, Y; Liu, LZ; Tian, L; Lin, AH; Sun, Y; Ma, J				Peng, Hao; Chen, Lei; Li, Wen-Fei; Zhang, Yuan; Liu, Li-Zhi; Tian, Li; Lin, Ai-Hua; Sun, Ying; Ma, Jun			Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; SURVIVAL; RISK; POPULATION; CANCER	Purpose The objective of this study is to assess the prognostic value of ABO blood group in nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). Patients and Methods We retrospectively reviewed the data on 1397 patients with non-metastatic, newly diagnosed NPC treated using IMRT. Patient survival between different ABO blood groups were compared using log-rank test. Cox hazards model was adopted to establish independent prognostic factors. Results In our study, the distribution of the A, B, AB and O blood groups was 26.6% (372/1397), 26.2% (366/1397), 5.2% (73/1397) and 42.0% (586/1397), respectively. The cut-off value of pre-treatment Epstein-Barr virus (EBV) DNA based on disease-free survival (DFS) was 1355 copies/ml (area under curve [AUC], 0.649; sensitivity, 0.76; specificity, 0.496) for the whole cohort. Estimated four-year DFS, overall survival (OS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) rates were 81.7%, 89.2%, 89.4% and 92.3% for blood group A; 82.1%, 89.3%, 89.0% and 92.0% for group B; 83.3%, 88.1%, 86.2% and 95.5% for group AB, 80.9%, 90.7%, 88.4% and 90.2% for group O (P > 0.05 for all rates). Multivariate analysis revealed ABO blood group was not an independent prognostic factor for DFS, OS, DMFS or LRRFS (P > 0.05 for all rates) after adjusting for plasma EBV DNA in either the whole cohort or subgroup analysis by gender. Conclusions The prognostic value of ABO blood group may be limited for patients with NPC in the era of IMRT, and no substantial correlation between ABO blood group and plasma EBV DNA was observed.	[Peng, Hao; Chen, Lei; Li, Wen-Fei; Zhang, Yuan; Sun, Ying; Ma, Jun] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Dept Radiat Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Li-Zhi; Tian, Li] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Imaging Diag & Intervent Ctr,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Lin, Ai-Hua] Sun Yat Sen Univ, Dept Med Stat & Epidemiol, Sch Publ Hlth, Guangzhou 510080, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Ma, J (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Dept Radiat Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	majun2@mail.sysu.edu.cn			Health & Medical Collaborative Innovation Project of Guangzhou City, China [201400000001]; Sun Yat-sen University Clinical Research 5010 Program [2012011]; Science and Technology Project of Guangzhou City, China [14570006]; Planned Science and Technology Project of Guangdong Province [20136020400004]	Health & Medical Collaborative Innovation Project of Guangzhou City, China; Sun Yat-sen University Clinical Research 5010 Program; Science and Technology Project of Guangzhou City, China; Planned Science and Technology Project of Guangdong Province	This work was supported by grants from the Health & Medical Collaborative Innovation Project of Guangzhou City, China (No. 201400000001), the Sun Yat-sen University Clinical Research 5010 Program (No. 2012011), the Science and Technology Project of Guangzhou City, China (No. 14570006), and the Planned Science and Technology Project of Guangdong Province (No. 20136020400004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants from the Health & Medical Collaborative Innovation Project of Guangzhou City, China (No. 201400000001), the Sun Yat-sen University Clinical Research 5010 Program (No. 2012011), the Science and Technology Project of Guangzhou City, China (No. 14570006), and the Planned Science and Technology Project of Guangdong Province (No. 2013B020400004).	Adam SI, 2012, J LARYNGOL OTOL, V126, P180, DOI 10.1017/S0022215111002507; Chan ATC, 2002, JNCI-J NATL CANCER I, V94, P1614, DOI 10.1093/jnci/94.21.1614; Chan KCA, 2014, CHIN J CANCER, V33, P598, DOI 10.5732/cjc.014.10192; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; CHEN CL, 1993, INTERVIROLOGY, V36, P91, DOI 10.1159/000150327; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Engin H, 2012, ASIAN PAC J CANCER P, V13, P131, DOI 10.7314/APJCP.2012.13.1.131; Hou X, 2011, CLIN ONCOL-UK, V23, P128, DOI 10.1016/j.clon.2010.09.001; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260; Lin JC, 2007, INT J RADIAT ONCOL, V68, P1342, DOI 10.1016/j.ijrobp.2007.02.012; Lo YMD, 1999, CANCER RES, V59, P1188; Lo YMD, 1999, CANCER RES, V59, P5452; Lu X, 2013, CHIN J CANCER, V32, P283, DOI 10.5732/cjc.012.10058; Miao SY, 2014, ASIA-PAC J CLIN ONCO, V10, P101, DOI 10.1111/ajco.12083; OuYang PY, 2013, BRIT J CANCER, V109, P2462, DOI 10.1038/bjc.2013.559; Rahbari NN, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-319; Shao JY, 2004, ANTICANCER RES, V24, P4059; Shao JY, 2004, CANCER, V100, P1162, DOI 10.1002/cncr.20099; Sheng LM, 2013, INT J CANCER, V133, P893, DOI 10.1002/ijc.28087; Sun P, 2014, TUMOR BIOL, V35, P7201, DOI 10.1007/s13277-014-1960-7; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Xu LY, 2010, RADIOTHER ONCOL, V96, P94, DOI 10.1016/j.radonc.2010.04.006; Yang X, 2014, INT J CLIN EXP MED, V7, P2214; Yi JL, 2006, INT J RADIAT ONCOL, V65, P161, DOI 10.1016/j.ijrobp.2005.12.003; Zhang YX, 2014, ASIAN PAC J CANCER P, V15, P7459, DOI 10.7314/APJCP.2014.15.17.7459	26	5	6	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2016	11	11							e0166194	10.1371/journal.pone.0166194	http://dx.doi.org/10.1371/journal.pone.0166194			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC0HG	27835689	gold, Green Published, Green Submitted			2023-01-03	WOS:000387779200031
J	Chen, FA; Chien, CC; Chen, YW; Wu, YT; Lin, CC				Chen, Fu-An; Chien, Chih-Chiang; Chen, Yu-Wei; Wu, Yu-Te; Lin, Chih-Ching			Angiotensin Converting-Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers Are Associated with Prolonged Vascular Access Patency in Uremic Patients Undergoing Hemodialysis	PLOS ONE			English	Article							FAILING DIALYSIS-ACCESS; NEOINTIMAL HYPERPLASIA; ARTERIOVENOUS-FISTULA; BALLOON ANGIOPLASTY; GRAFT PATENCY; STENT GRAFT; OUTCOMES; VEIN; SURVIVAL	Background Vascular access failure is a huge burden for patients undergoing hemodialysis. Many efforts have been made to maintain vascular access patency, including pharmacotherapy. Angiotensin converting enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), and calcium channel blocker (CCB) are known for their antihypertensive and cardio-protective effects, however, their effects on long-term vascular access patency are still inconclusive. Design, setting, participants and measurements We retrospectively enrolled patients commencing maintenance hemodialysis between January 1, 2000, and December 31, 2006 by using National Health Insurance Research Database in Taiwan. Primary patency was defined as the date of first arteriovenous fistula (AVF) or arteriovenous graft (AVG) creation to the time of access thrombosis or any intervention aimed to maintain or re-establish vascular access patency. Cox proportional hazards models were used to adjust the influences of patient characteristics, co-morbidities and medications. Results Total 42244 patients were enrolled in this study, 37771 (89.4%) used AVF, 4473 (10.6%) used AVG as their first long term dialysis access. ACE-I, ARB, and CCB use were all associated with prolonged primary patency of AVF [hazard ratio (HR) 0.586, 95% confidence interval (CI) 0.557-0.616 for ACE-I use; HR 0.532, CI 0.508-0.556 for ARB use; HR 0.485, CI 0.470-0.501 for CCB use] and AVG (HR 0.557, CI 0.482-0.643 for ACE-I use, HR 0.536, CI 0.467-0.614 for ARB use, HR 0.482, CI 0.442-0.526 for CCB use). Conclusions In our analysis, ACE-I, ARB, and CCB were strongly associated with prolonged primary patency of both AVF and AVG. Further prospective randomized studies are still warranted to prove the causality.	[Chen, Fu-An; Chen, Yu-Wei; Wu, Yu-Te; Lin, Chih-Ching] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chen, Fu-An] Natl Yang Ming Univ Hosp, Dept Internal Med, Yilan, Taiwan; [Chien, Chih-Chiang] Chi Mei Med Ctr, Dept Nephrol, Tainan, Taiwan; [Chen, Yu-Wei; Wu, Yu-Te; Lin, Chih-Ching] Taipei Vet Gen Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; Chi Mei Hospital; Taipei Veterans General Hospital	Lin, CC (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Lin, CC (corresponding author), Taipei Vet Gen Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan.	lincc2@vghtpe.gov.tw			Taipei Veterans General Hospital [V100C1-050, V101C-188, V102C-060, V102E2-001, V103C-043, V104C-026, V105C-075]; National Science Council [NSC101-2314-B-010-024-MY3]; Ministry of Science and Technology in Taiwan [MOST 104-2314-B-010-032-MY3]	Taipei Veterans General Hospital(Taipei Veterans General Hospital); National Science Council(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by intramural grants (V100C1-050, V101C-188, V102C-060, V102E2-001, V103C-043, V104C-026, V105C-075) from Taipei Veterans General Hospital, and grants from the National Science Council (NSC101-2314-B-010-024-MY3) and the Ministry of Science and Technology (MOST 104-2314-B-010-032-MY3) in Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Astor BC, 2005, J AM SOC NEPHROL, V16, P1449, DOI 10.1681/ASN.2004090748; Bashar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119958; Brauner R, 1997, J THORAC CARDIOV SUR, V114, P53, DOI 10.1016/S0022-5223(97)70117-X; Dixon BS, 2009, NEW ENGL J MED, V360, P2191, DOI 10.1056/NEJMoa0805840; Doi S, 2008, THER APHER DIAL, V12, P232, DOI 10.1111/j.1744-9987.2008.00579.x; Dolmatch BL, 2010, J VASC ACCESS, V11, P89, DOI 10.1177/112972981001100201; Gradzki R, 2001, AM J KIDNEY DIS, V38, P1240, DOI 10.1053/ajkd.2001.29220; Haskal ZJ, 2010, NEW ENGL J MED, V362, P494, DOI 10.1056/NEJMoa0902045; Huang P, 2001, AM J SURG, V181, P492, DOI 10.1016/S0002-9610(01)00615-8; Hung YN, 2010, CLIN J AM SOC NEPHRO, V5, P1029, DOI 10.2215/CJN.08181109; Jackson RS, 2011, J VASC SURG, V54, P1706, DOI 10.1016/j.jvs.2011.06.028; Lin CC, 2007, J AM SOC NEPHROL, V18, P985, DOI 10.1681/ASN.2006050534; Mihmanli I, 2001, J ULTRAS MED, V20, P217; Ng LJ, 2011, NEPHROL DIAL TRANSPL, V26, P3659, DOI 10.1093/ndt/gfr063; Ocak G, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-79; ODONOHOE MK, 1991, ANN SURG, V214, P727, DOI 10.1097/00000658-199112000-00014; Osborn G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002786.pub2; Ravani P, 2013, J AM SOC NEPHROL, V24, P465, DOI 10.1681/ASN.2012070643; Sajgure A, 2007, NEPHROL DIAL TRANSPL, V22, P1390, DOI 10.1093/ndt/gfl821; Saran R, 2002, AM J KIDNEY DIS, V40, P1255, DOI 10.1053/ajkd.2002.36895; Taber T E, 1995, ASAIO J, V41, P842; USRDS, 2014, US REN DAT SYST 2014; Wasse H, 2007, CLIN J AM SOC NEPHRO, V2, P708, DOI 10.2215/CJN.00170107; Yagi S, 2004, HYPERTENS RES, V27, P129, DOI 10.1291/hypres.27.129; Yamada T, 2007, ARTERIOSCL THROM VAS, V27, P2363, DOI 10.1161/ATVBAHA.107.147124	25	18	19	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2016	11	11							e0166362	10.1371/journal.pone.0166362	http://dx.doi.org/10.1371/journal.pone.0166362			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9ON	27832203	Green Published, Green Submitted, gold			2023-01-03	WOS:000387725000110
J	Gong, AGW; Huang, VY; Wang, HY; Lin, HQ; Dong, TTX; Tsim, KWK				Gong, Amy G. W.; Huang, Vincent Y.; Wang, Huai Y.; Lin, Huang Q.; Dong, Tina T. X.; Tsim, Karl W. K.			Ferulic Acid Orchestrates Anti-Oxidative Properties of Danggui Buxue Tang, an Ancient Herbal Decoction: Elucidation by Chemical Knock-Out Approach	PLOS ONE			English	Article							RADIX ANGELICAE SINENSIS; OXIDATIVE STRESS; ASTRAGALI RADIX; CARDIOVASCULAR-DISEASE; SIGNALING PATHWAY; INDUCED APOPTOSIS; ANGIOTENSIN-II; NITRIC-OXIDE; ACTIVATION; CELLS	Ferulic acid, a phenolic acid derived mainly from a Chinese herb Angelica Sinensis Radix (ASR), was reported to reduce the formation of free radicals. Danggui Buxue Tang (DBT), a herbal decoction composing of Astragali Radix (AR) and ASR, has been utilized for more than 800 years in China having known anti-oxidative property. Ferulic acid is a major active ingredient in DBT; however, the role of ferulic acid within the herbal mixture has not been resolved. In order to elucidate the function of ferulic acid within this herbal decoction, a ferulic acid-depleted herbal decoction was created and named as DBT Delta fa. The anti-oxidative properties of chemically modified DBT decoction were systemically compared in cultured H9C2 rat cardiomyoblast cell line. The application of DBT and DBT Delta fa into the cultures showed functions in (i) decreasing the reactive oxygen species (ROS) formation, detected by laser confocal; (ii) increasing of the activation of Akt; (iii) increasing the transcriptional activity of anti-oxidant response element (ARE); and (iv) increasing the expressions of antioxidant enzymes, i.e. NQO1 and GCLM. In all scenario, the aforementioned anti-oxidative properties of DBT Delta fa in H9C2 cells were significantly reduced, as compared to authentic DBT. Thus, ferulic acid could be an indispensable chemical in DBT to orchestrate multicomponents of DBT as to achieve maximal anti-oxidative functions.	[Gong, Amy G. W.; Huang, Vincent Y.; Wang, Huai Y.; Lin, Huang Q.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China; [Gong, Amy G. W.; Huang, Vincent Y.; Wang, Huai Y.; Lin, Huang Q.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Clear Water Bay, Hong Kong, Peoples R China; [Wang, Huai Y.] HKUST Shenzhen Res Inst, Hitech Pk, Shenzhen 518000, Guangdong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.; Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Ctr Chinese Med, Clear Water Bay, Hong Kong, Peoples R China.	botsim@ust.hk		Wang, Huai-You/0000-0003-1407-9912	Hong Kong Research Grants Council Theme-based Research Scheme [T13-607/12R]; ITF [UIM/254]; GRF [663012, 662713, M-HKUST604/13, TUYF15SC01]; Hong Kong Jockey Club Charities Trust [HKJCCT12SC01]; Foundation of The Awareness of Nature [TAON12SC01]	Hong Kong Research Grants Council Theme-based Research Scheme(Hong Kong Research Grants Council); ITF; GRF; Hong Kong Jockey Club Charities Trust; Foundation of The Awareness of Nature	Supported by Hong Kong Research Grants Council Theme-based Research Scheme (T13-607/12R), ITF (UIM/254), GRF (663012, 662713, M-HKUST604/13), TUYF15SC01, The Hong Kong Jockey Club Charities Trust (HKJCCT12SC01) and Foundation of The Awareness of Nature (TAON12SC01) to Karl Tsim.	Alam B, 2013, AVICENNA J PHYTOMEDI, V3, P112; Cai Zhiyou, 2013, J Biochem Pharmacol Res, V1, P15; Carlsen MH, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-37; Chan PH, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/567893; Chen KJ, 1999, CHINESE MED J-PEKING, V112, P934; Cui L, 2015, J CHEM INF MODEL, V55, P2455, DOI 10.1021/acs.jcim.5b00449; Cutler D, 2006, J ECON PERSPECT, V20, P97, DOI 10.1257/jep.20.3.97; Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l; Fang B, 2014, BIOCHEM BIOPH RES CO, V448, P443, DOI 10.1016/j.bbrc.2014.04.123; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Gan XT, 2012, MOL CELL BIOCHEM, V363, P323, DOI 10.1007/s11010-011-1185-7; Giugliano D, 2000, NUTR METAB CARDIOVAS, V10, P38; Gong AGW, 2016, PLANTA MED, V82, P418, DOI 10.1055/s-0035-1558332; Gong AGW, 2015, J ETHNOPHARMACOL, V168, P150, DOI 10.1016/j.jep.2015.03.033; Hou YZ, 2004, EUR J PHARMACOL, V499, P85, DOI 10.1016/j.ejphar.2004.07.107; Huang CY, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-358; Joung EJ, 2007, ANTIOXID REDOX SIGN, V9, P2087, DOI 10.1089/ars.2007.1827; Jun HO, 2011, EXP MOL MED, V43, P53, DOI 10.3858/emm.2011.43.1.006; Kris-Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002-9343(01)00995-0; Kumar SVR, 2014, NAT REV NEPHROL, V10, P545, DOI 10.1038/nrneph.2014.156; Li SM, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/459264; Li XC, 2009, MOLECULES, V14, P5349, DOI 10.3390/molecules14125349; Ma XQ, 2002, J AGR FOOD CHEM, V50, P4861, DOI 10.1021/jf0202279; Maiwulanjiang M, 2014, J ETHNOPHARMACOL, V153, P491, DOI 10.1016/j.jep.2014.03.010; Mak DHF, 2006, PHYTOTHER RES, V20, P561, DOI 10.1002/ptr.1904; Mathew S, 2004, CRIT REV BIOTECHNOL, V24, P59, DOI 10.1080/07388550490491467; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Alok SP, 2007, J MOL CELL CARDIOL, V43, P580, DOI 10.1016/j.yjmcc.2007.08.003; Song ZH, 2004, PLANTA MED, V70, P1222, DOI 10.1055/s-2004-835855; Sugamura K, 2011, FREE RADICAL BIO MED, V51, P978, DOI 10.1016/j.freeradbiomed.2011.05.004; Tan Yong, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1412; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Wang Xiao-ling, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P1093; Wen XD, 2008, J CHROMATOGR B, V865, P99, DOI 10.1016/j.jchromb.2008.02.024; Xin YF, 2007, BASIC CLIN PHARMACOL, V101, P421, DOI 10.1111/j.1742-7843.2007.00144.x; Yu CL, 2016, MOL NEUROBIOL, V53, P6489, DOI 10.1007/s12035-015-9555-x; Zhan JYX, 2013, PLANTA MED, V79, P533, DOI 10.1055/s-0032-1328261; Zhang AH, 2010, PLANTA MED, V76, P2026, DOI 10.1055/s-0030-1250542; Zhang WDL, 2013, PHYTOMEDICINE, V20, P1076, DOI 10.1016/j.phymed.2013.04.016; Zhao KJ, 2003, J AGR FOOD CHEM, V51, P2576, DOI 10.1021/jf026178h	40	12	13	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2016	11	11							e0165486	10.1371/journal.pone.0165486	http://dx.doi.org/10.1371/journal.pone.0165486			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB8BE	27824860	Green Published, gold, Green Submitted			2023-01-03	WOS:000387615200019
J	Van Damme, E; Thys, K; Tuefferd, M; Van Hove, C; Aerssens, J; Van Loock, M				Van Damme, Ellen; Thys, Kim; Tuefferd, Marianne; Van Hove, Carl; Aerssens, Jeroen; Van Loock, Marnix			HCMV Displays a Unique Transcriptome of Immunomodulatory Genes in Primary Monocyte-Derived Cell Types	PLOS ONE			English	Article							HUMAN CYTOMEGALOVIRUS-INFECTION; LATENT HUMAN CYTOMEGALOVIRUS; MHC CLASS-I; HEMATOPOIETIC PROGENITOR CELLS; DENDRITIC CELLS; MACROPHAGE DIFFERENTIATION; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; CD14(+) MONOCYTES; RNA-SYNTHESIS	Human cytomegalovirus (HCMV) is a betaherpesvirus which rarely presents problems in healthy individuals, yet may result in severe morbidity in immunocompromised patients and in immune-naive neonates. HCMV has a large 235 kb genome with a coding capacity of at least 165 open reading frames (ORFs). This large genome allows complex gene regulation resulting in different sets of transcripts during lytic and latent infection. While latent virus mainly resides within monocytes and CD34(+) progenitor cells, reactivation to lytic infection is driven by differentiation towards terminally differentiated myeloid dendritic cells and macrophages. Consequently, it has been suggested that macrophages and dendritic cells contribute to viral spread in vivo. Thus far only limited knowledge is available on the expression of HCMV genes in terminally differentiated myeloid primary cells and whether or not the virus exhibits a different set of lytic genes in primary cells compared with lytic infection in NHDF fibroblasts. To address these questions, we used Illumina next generation sequencing to determine the HCMV transcriptome in macrophages and dendritic cells during lytic infection and compared it to the transcriptome in NHDF fibroblasts. Here, we demonstrate unique expression profiles in macrophages and dendritic cells which significantly differ from the transcriptome in fibroblasts mainly by modulating the expression of viral transcripts involved in immune modulation, cell tropism and viral spread. In a head to head comparison between macrophages and dendritic cells, we observed that factors involved in viral spread and virion composition are differentially regulated suggesting that the plasticity of the virion facilitates the infection of surrounding cells. Taken together, this study provides the full transcript expression analysis of lytic HCMV genes in monocyte-derived type 1 and type 2 macrophages as well as in monocyte-derived dendritic cells. Thereby underlining the potential of HCMV to adapt to or influence different cellular environments to promote its own survival.	[Van Damme, Ellen; Thys, Kim; Tuefferd, Marianne; Aerssens, Jeroen; Van Loock, Marnix] Janssen Pharmaceut NV, Infect Dis, Beerse, Belgium; [Van Hove, Carl] Janssen Pharmaceut NV, Discovery Sci, Beerse, Belgium	Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals	Van Loock, M (corresponding author), Janssen Pharmaceut NV, Infect Dis, Beerse, Belgium.	mvloock@its.jnj.com		Aerssens, Jeroen/0000-0002-9254-4800	Janssen Phamaceutica NV	Janssen Phamaceutica NV	All authors work for Janssen Phamaceutica NV and receive a salary. The work was funded by internal resources without grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Arnolds KL, 2013, VIROLOGY, V439, P122, DOI 10.1016/j.virol.2013.02.006; Arrode G, 2003, CURR TOP MICROBIOL, V276, P277; Avdic S, 2011, J VIROL, V85, P7465, DOI 10.1128/JVI.00088-11; Bayer C, 2013, J VIROL, V87, P67, DOI 10.1128/JVI.01585-12; Bego M, 2005, J VIROL, V79, P11022, DOI 10.1128/JVI.79.17.11022-11034.2005; Bego MG, 2011, ARCH VIROL, V156, P1847, DOI 10.1007/s00705-011-1027-7; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bresnahan WA, 2000, SCIENCE, V288, P2373, DOI 10.1126/science.288.5475.2373; Bullwinkel J, 2011, EPIGENETICS-US, V6, P45, DOI 10.4161/epi.6.1.13314; Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655; Chambers J, 1999, J VIROL, V73, P5757, DOI 10.1128/JVI.73.7.5757-5766.1999; Chan G, 2012, J VIROL, V86, P10714, DOI 10.1128/JVI.07129-11; Cheung AKL, 2006, BLOOD, V108, P3691, DOI 10.1182/blood-2005-12-026682; CHOU SW, 1988, J CLIN MICROBIOL, V26, P504, DOI 10.1128/JCM.26.3.504-507.1988; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Dolken L, 2008, RNA, V14, P1959, DOI 10.1261/rna.1136108; Dolan A, 2004, J GEN VIROL, V85, P1301, DOI 10.1099/vir.0.79888-0; Dugan GE, 2008, J VIROL, V82, P3271, DOI 10.1128/JVI.01705-07; DuRose JB, 2012, J VIROL, V86, P13745, DOI 10.1128/JVI.02244-12; Eligini S, 2015, J PROTEOMICS, V124, P112, DOI 10.1016/j.jprot.2015.03.026; Eligini S, 2013, J CELL PHYSIOL, V228, P1464, DOI 10.1002/jcp.24301; Elkord E, 2005, IMMUNOLOGY, V114, P204, DOI 10.1111/j.1365-2567.2004.02076.x; Furman MH, 2002, J VIROL, V76, P11753, DOI 10.1128/JVI.76.22.11753-11756.2002; Gatherer D, 2011, P NATL ACAD SCI USA, V108, P19755, DOI 10.1073/pnas.1115861108; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gibson W, 2008, CURR TOP MICROBIOL, V325, P187; Goodrum F, 2004, BLOOD, V104, P687, DOI 10.1182/blood-2003-12-4344; Goodrum FD, 2002, P NATL ACAD SCI USA, V99, P16255, DOI 10.1073/pnas.252630899; Goodrum F, 2007, BLOOD, V110, P937, DOI 10.1182/blood-2007-01-070078; Gurczynski SJ, 2014, J VIROL, V88, P2168, DOI 10.1128/JVI.02704-13; Hahn G, 1998, P NATL ACAD SCI USA, V95, P3937, DOI 10.1073/pnas.95.7.3937; Hargett D, 2010, P NATL ACAD SCI USA, V107, P20039, DOI 10.1073/pnas.1014509107; Hesse J, 2013, J GEN VIROL, V94, P376, DOI 10.1099/vir.0.045682-0; Hook L, 2014, CURR OPIN VIROL, V7, P40, DOI 10.1016/j.coviro.2014.03.015; Huang MM, 2012, J VIROL, V86, P8507, DOI 10.1128/JVI.00598-12; Keyes LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052827; Kim ET, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103308; Kim Y, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000123; Kondo K, 1995, SCAND J INFECT DIS, P63; KONDO K, 1994, P NATL ACAD SCI USA, V91, P11879, DOI 10.1073/pnas.91.25.11879; Kreklywich CN, 2014, METHODS MOL BIOL, V1119, P217, DOI 10.1007/978-1-62703-788-4_13; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2007, EUR J IMMUNOL, V37, P14, DOI 10.1002/eji.200636910; Martinez F. O., 2014, F1000PRIME REP, V6, P13; Mezger M, 2009, VIRAL IMMUNOL, V22, P343, DOI 10.1089/vim.2009.0011; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Murphy E, 2008, CURR TOP MICROBIOL, V325, P1; Noriega VM, 2012, MOL IMMUNOL, V51, P245, DOI 10.1016/j.molimm.2012.03.024; O'Connor CM, 2012, J VIROL, V86, P11425, DOI 10.1128/JVI.05900-11; Ohradanova-Repic A, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2015.39; Oresic K, 2008, J GEN VIROL, V89, P1122, DOI 10.1099/vir.0.83516-0; Oresic K, 2006, J BIOL CHEM, V281, P19395, DOI 10.1074/jbc.M601026200; Park B, 2010, J EXP MED, V207, P2033, DOI 10.1084/jem.20091793; Petrucelli A, 2009, J VIROL, V83, P5615, DOI 10.1128/JVI.01989-08; Poole E, 2013, J VIROL, V87, P4261, DOI 10.1128/JVI.03497-12; Raftery MJ, 2009, J GEN VIROL, V90, P2221, DOI 10.1099/vir.0.010538-0; Raghavan N, 2006, J COMPUT BIOL, V13, P798, DOI 10.1089/cmb.2006.13.798; Reeves Matthew, 2005, Discov Med, V5, P170; Reeves MB, 2005, J GEN VIROL, V86, P2949, DOI 10.1099/vir.0.81161-0; Reeves MB, 2005, P NATL ACAD SCI USA, V102, P4140, DOI 10.1073/pnas.0408994102; Renneson J, 2009, EUR J IMMUNOL, V39, P2789, DOI 10.1002/eji.200939414; Riegler S, 2000, J GEN VIROL, V81, P393, DOI 10.1099/0022-1317-81-2-393; Rossetto CC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003366; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schmittel A, 1995, SCAND J IMMUNOL, V42, P701, DOI 10.1111/j.1365-3083.1995.tb03714.x; Seidel E, 2015, CELL REP, V10, P968, DOI 10.1016/j.celrep.2015.01.029; Sinzger C, 1999, J INFECT DIS, V180, P976, DOI 10.1086/315032; Sinzger C, 2008, J GEN VIROL, V89, P359, DOI 10.1099/vir.0.83286-0; Sissons JGP, 2002, J INFECTION, V44, P73, DOI 10.1053/jinf.2001.0948; Slobedman B, 1999, J VIROL, V73, P4806, DOI 10.1128/JVI.73.6.4806-4812.1999; Smith MS, 2004, J LEUKOCYTE BIOL, V76, P65, DOI 10.1189/jlb.1203621; Snaar SP, 1999, J HISTOCHEM CYTOCHEM, V47, P245, DOI 10.1177/002215549904700213; Soderberg-Naucler C, 2001, J VIROL, V75, P7543, DOI 10.1128/JVI.75.16.7543-7554.2001; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; Springer KL, 2004, J ANTIMICROB CHEMOTH, V54, P582, DOI 10.1093/jac/dkh396; Steinbach F, 1998, RES IMMUNOL, V149, P627, DOI 10.1016/S0923-2494(99)80028-5; STENBERG RM, 1985, J VIROL, V56, P665, DOI 10.1128/JVI.56.3.665-675.1985; Stern-Ginossar N, 2012, SCIENCE, V338, P1088, DOI 10.1126/science.1227919; Stevenson EV, 2014, VIRUSES-BASEL, V6, P782, DOI 10.3390/v6020782; STINSKI MF, 1983, J VIROL, V46, P1; Streblow DN, 2007, J VIROL, V81, P3816, DOI 10.1128/JVI.02425-06; Stropes MP, 2009, J VIROL, V83, P10016, DOI 10.1128/JVI.00354-09; Tirabassi R, 2011, J VIROL, V85, P11938, DOI 10.1128/JVI.05443-11; Tirabassi RS, 2002, J VIROL, V76, P6832, DOI 10.1128/JVI.76.13.6832-6835.2002; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; Towler JC, 2012, J GEN VIROL, V93, P1046, DOI 10.1099/vir.0.038083-0; Tugal D, 2013, ARTERIOSCL THROM VAS, V33, P1135, DOI 10.1161/ATVBAHA.113.301453; Van Damme E, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00218; van den Boomen DJH, 2015, MOL IMMUNOL, V68, P106, DOI 10.1016/j.molimm.2015.07.005; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Vogt G, 2011, J CLIN INVEST, V121, P3889, DOI 10.1172/JCI57235; WATHEN MW, 1982, J VIROL, V41, P462, DOI 10.1128/JVI.41.2.462-477.1982; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985; Zhuravskaya T, 1997, BLOOD, V90, P2482, DOI 10.1182/blood.V90.6.2482.2482_2482_2491	99	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2016	11	10							e0164843	10.1371/journal.pone.0164843	http://dx.doi.org/10.1371/journal.pone.0164843			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NW	27760232	Green Published, gold, Green Submitted			2023-01-03	WOS:000386204000060
J	Krumholz, HM; Hsieh, A; Dreyer, RP; Welsh, J; Desai, NR; Dharmarajan, K				Krumholz, Harlan M.; Hsieh, Angela; Dreyer, Rachel P.; Welsh, John; Desai, Nihar R.; Dharmarajan, Kumar			Trajectories of Risk for Specific Readmission Diagnoses after Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia	PLOS ONE			English	Article							RETROSPECTIVE COHORT; PERFORMANCE; RATES; ICD-9-CM; SUPPORT; MODEL	Background The risk of rehospitalization is elevated in the immediate post-discharge period and declines over time. It is not known if the extent and timing of risk vary across readmission diagnoses, suggesting that recovery and vulnerability after discharge differ by physiologic system. Objective We compared risk trajectories for major readmission diagnoses in the year after discharge among all Medicare fee-for-service beneficiaries hospitalized with heart failure (HF), acute myocardial infarction (AMI), or pneumonia from 2008-2010. Methods We estimated the daily risk of rehospitalization for 12 major readmission diagnostic categories after accounting for the competing risk of death after discharge. For each diagnostic category, we identified (1) the time required for readmission risk to peak and then decline 50% from maximum values after discharge; (2) the time required for readmission risk to approach plateau periods of minimal day-to-day change; and (3) the extent to which hospitalization risks are higher among patients recently discharged from the hospital compared with the general elderly population. Results Among > 3,000,000 hospitalizations, the yearly rate of rehospitalization was 67.0%, 49.5%, and 55.3% after hospitalization for HF, AMI, and pneumonia, respectively. The extent and timing of risk varied by readmission diagnosis and initial admitting condition. Risk of readmission for gastrointestinal bleeding/anemia peaked particularly late after hospital discharge, occurring 10, 6, and 7 days after hospitalization for HF, AMI, and pneumonia, respectively. Risk of readmission for trauma/injury declined particularly slowly, requiring 38, 20, and 38 days to decline by 50% after hospitalization for HF, AMI, and pneumonia, respectively. Conclusions Patterns of vulnerability to different conditions that cause rehospitalization vary by time after hospital discharge. This finding suggests that recovery of various physiologic systems occurs at different rates and that post-discharge interventions to minimize vulnerability to specific conditions should be tailored to their underlying risks.	[Krumholz, Harlan M.; Desai, Nihar R.; Dharmarajan, Kumar] Yale Sch Med, Sect Cardiovasc Med, Dept Internal Med, New Haven, CT 06510 USA; [Krumholz, Harlan M.; Hsieh, Angela; Dreyer, Rachel P.; Welsh, John; Desai, Nihar R.; Dharmarajan, Kumar] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Krumholz, Harlan M.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Dept Internal Med, New Haven, CT 06510 USA; [Hsieh, Angela] Genentech Inc, San Francisco, CA USA	Yale University; Yale University; Robert Wood Johnson Foundation (RWJF); Yale University; Roche Holding; Genentech	Krumholz, HM (corresponding author), Yale Sch Med, Sect Cardiovasc Med, Dept Internal Med, New Haven, CT 06510 USA.; Krumholz, HM (corresponding author), Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA.; Krumholz, HM (corresponding author), Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA.; Krumholz, HM (corresponding author), Yale Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Dept Internal Med, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Dreyer, Rachel/0000-0003-2861-1383				Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Dharmarajan K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6571; Dharmarajan K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h411; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Dunlay SM, 2009, J AM COLL CARDIOL, V54, P1695, DOI 10.1016/j.jacc.2009.08.019; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Pope GC, HHSM500200500029 RTI; Pope GC., 2000, DIAGNOSTIC COST GROU; Quan H, 2008, HEALTH SERV RES, V43, P1424, DOI 10.1111/j.1475-6773.2007.00822.x; Ranasinghe I, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001737; Wijeysundera HC, 2013, CIRC-HEART FAIL, V6, P68, DOI 10.1161/CIRCHEARTFAILURE.112.971051	21	37	38	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2016	11	10							e0160492	10.1371/journal.pone.0160492	http://dx.doi.org/10.1371/journal.pone.0160492			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UW	27716841	Green Published, Green Submitted, gold			2023-01-03	WOS:000385698100001
J	Naito, Y; Senchi, A; Sawada, H; Oboshi, M; Horimatsu, T; Okuno, K; Yasumura, S; Ishihara, M; Masuyama, T				Naito, Yoshiro; Senchi, Aya; Sawada, Hisashi; Oboshi, Makiko; Horimatsu, Tetsuo; Okuno, Keisuke; Yasumura, Seiki; Ishihara, Masaharu; Masuyama, Tohru			Iron-restricted pair-feeding affects renal damage in rats with chronic kidney disease	PLOS ONE			English	Article							REMNANT KIDNEY; RAC1 GTPASE; ACCUMULATION; PREVENTS; ANEMIA; GROWTH; MODEL	Background We have previously shown that dietary iron restriction prevents the development of renal damage in a rat model of chronic kidney disease (CKD). However, iron deficiency is associated with appetite loss. In addition, calorie restriction is reported to prevent the development of end-stage renal pathology in CKD rats. Thus, the beneficial effect of iron restriction on renal damage may depend on calorie restriction. Here, we investigate the effect of pair-feeding iron restriction on renal damage in a rat model of CKD. Methods First, to determine the amount of food intake, Sprague-Dawley (SD) rats were randomly given an ad libitum normal diet or an iron-restricted diet, and the food intake was measured. Second, CKD was induced by a 5/6 nephrectomy in SD rats, and CKD rats were given either a pair-feeding normal or iron-restricted diet. Results Food intake was reduced in the iron-restricted diet group compared to the normal diet group of SD rats for 16 weeks (mean food intake; normal diet group and iron-restricted diet group: 25 and 20 g/day, respectively). Based on the initial experiments, CKD rats received either a pair-feeding normal or iron-restricted diet (20 g/day) for 16 weeks. Importantly, pair-feeding iron restriction prevented the development of proteinuria, glomerulosclerosis, and tubulointerstitial damage in CKD rats. Interestingly, pair-feeding iron restriction attenuated renal expression of nuclear mineralocorticoid receptor in CKD rats. Conclusions Pair-feeding iron restriction affected renal damage in a rat model of CKD.	[Naito, Yoshiro; Senchi, Aya; Sawada, Hisashi; Oboshi, Makiko; Horimatsu, Tetsuo; Okuno, Keisuke; Yasumura, Seiki; Masuyama, Tohru] Hyogo Coll Med, Cardiovasc Div, Dept Internal Med, Nishinomiya, Hyogo, Japan; [Ishihara, Masaharu] Hyogo Coll Med, Div Coronary Heart Dis, Dept Internal Med, Nishinomiya, Hyogo, Japan	Hyogo College of Medicine; Hyogo College of Medicine	Naito, Y (corresponding author), Hyogo Coll Med, Cardiovasc Div, Dept Internal Med, Nishinomiya, Hyogo, Japan.	ynaito@hyo-med.ac.jp			JSPS KAKENHI [25460919, 16K09273]; Salt Science Research Foundation [1544, 1641]; Suzuken Memorial Foundation; Takeda Science Foundation; Grants-in-Aid for Scientific Research [16K09273] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Salt Science Research Foundation; Suzuken Memorial Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by a Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI Grant No. 25460919 and 16K09273) and grants from The Salt Science Research Foundation (No. 1544 and 1641), Suzuken Memorial Foundation, and Takeda Science Foundation (to Y. Naito).	Bro S, 2003, J AM SOC NEPHROL, V14, P2466, DOI 10.1097/01.ASN.0000088024.72216.2E; Gay HC, 2016, HYPERTENSION, V67, P733, DOI 10.1161/HYPERTENSIONAHA.115.06853; HARRIS DCH, 1994, CLIN EXP PHARMACOL P, V21, P73, DOI 10.1111/j.1440-1681.1994.tb02472.x; Izuhara Y, 2005, J AM SOC NEPHROL, V16, P3631, DOI 10.1681/ASN.2005050522; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KOBAYASHI S, 1992, KIDNEY INT, V42, P710, DOI 10.1038/ki.1992.338; Naito Y, 2013, J HYPERTENS, V31, P1203, DOI 10.1097/HJH.0b013e328360381d; Naito Y, 2012, J HYPERTENS, V30, P2192, DOI 10.1097/HJH.0b013e3283581a64; Naito Y, 2011, HYPERTENSION, V57, P497, DOI 10.1161/HYPERTENSIONAHA.110.159681; NANKIVELL BJ, 1994, J AM SOC NEPHROL, V4, P1598; NANKIVELL BJ, 1992, AM J KIDNEY DIS, V20, P580, DOI 10.1016/S0272-6386(12)70222-6; Ni ZM, 1997, KIDNEY INT, V52, P195, DOI 10.1038/ki.1997.319; Oboshi M, 2016, HYPERTENS RES, V39, P832, DOI 10.1038/hr.2016.93; Otis L, 1940, SCIENCE, V91, P146, DOI 10.1126/science.91.2354.146; SALMON HA, 1962, J PHYSIOL-LONDON, V164, P17, DOI 10.1113/jphysiol.1962.sp006999; Shibata S, 2011, J CLIN INVEST, V121, P3233, DOI 10.1172/JCI43124; Shibata S, 2008, NAT MED, V14, P1370, DOI 10.1038/nm.1879; Stoltzfus RJ, 2004, J NUTR, V134, P348, DOI 10.1093/jn/134.2.348; TAPP DC, 1989, LAB INVEST, V60, P184; Vassalotti JA, 2016, AM J MED, V129, P153, DOI 10.1016/j.amjmed.2015.08.025	20	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2017	12	2							e0172157	10.1371/journal.pone.0172157	http://dx.doi.org/10.1371/journal.pone.0172157			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2BA	28196143	Green Submitted, Green Published, gold			2023-01-03	WOS:000394423900058
J	Fortuin-de Smidt, M; de Waal, R; Cohen, K; Technau, KG; Stinson, K; Maartens, G; Boulle, A; Igumbor, EU; Davies, MA				Fortuin-de Smidt, Melony; de Waal, Renee; Cohen, Karen; Technau, Karl-Gunter; Stinson, Kathryn; Maartens, Gary; Boulle, Andrew; Igumbor, Ehimario U.; Davies, Mary-Ann			First-line antiretroviral drug discontinuations in children	PLOS ONE			English	Article							HIV-INFECTED CHILDREN; TOLERABILITY; THERAPY; AFRICA; SAFETY; HAART	Introduction There are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for discontinuations in children at two South African ART programmes, where lopinavir/ ritonavir has been recommended for children <3 years old since 2004, and abacavir replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010. Methods We included children (<16 years at ART initiation) who initiated >= 3 antiretrovirals between 2004-2014 with >= 1 follow-up visit on ART. We estimated the incidence of first antiretroviral discontinuation using Kaplan-Meier analysis. We determined the reasons for antiretroviral discontinuations using competing risks analysis. We used Cox regression to identify factors associated with treatment-limiting toxicity. Results We included 3579 children with median follow-up duration of 41 months (IQR 14-72). At ART initiation, median age was 44 months (IQR 13-89) and median CD4 percent was 15% (IQR 9-21%). At three and five years on ART, 72% and 26% of children respectively remained on their initial regimen. By five years on ART, the most common reasons for discontinuations were toxicity (32%), treatment failure (18%), treatment simplification (5%), drug interactions (3%), and other or unspecified reasons (18%). The incidences of treatment limiting toxicity were 50.6 (95% CI 46.2-55.4), 1.6 (0.5-4.8), 2.0 (1.2-3.3), and 1.3 (0.6-2.8) per 1000 patient years for stavudine, abacavir, efavirenz and lopinavir/ritonavir respectively. Conclusions While stavudine was associated with a high risk of treatment-limiting toxicity, abacavir, lopinavir/ ritonavir and efavirenz were well-tolerated. This supports the World Health Organization recommendation to replace stavudine with abacavir or zidovudine in paediatric first-line ART regimens in order to improve paediatric first-line ART durability.	[Fortuin-de Smidt, Melony; Cohen, Karen; Maartens, Gary] Univ Cape Town, Dept Med, Div Clin Pharmacol, Cape Town, South Africa; [de Waal, Renee; Stinson, Kathryn; Boulle, Andrew; Davies, Mary-Ann] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa; [Technau, Karl-Gunter] Univ Witwatersrand, Dept Paediat & Child Hlth, Empilweni Serv & Res Unit, Johannesburg, South Africa; [Stinson, Kathryn] Med Sans Frontieres, Khayelitsha, South Africa; [Igumbor, Ehimario U.] US Ctr Dis Control & Prevent, Pretoria, South Africa	University of Cape Town; University of Cape Town; University of Witwatersrand	Davies, MA (corresponding author), Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa.	karltechnau@gmail.com; andrew.boulle@uct.ac.za; mary-ann.davies@uct.ac.za	Igumbor, Ehimario U/B-2652-2012; Maartens, Gary/S-2788-2019; Boulle, Andrew/C-1413-2008; Cohen, Karen/D-4036-2017	Igumbor, Ehimario U/0000-0002-6313-6031; Maartens, Gary/0000-0003-3080-6606; Boulle, Andrew/0000-0002-7713-8062; Cohen, Karen/0000-0002-1892-4207; de Waal, Renee/0000-0001-6171-2181; Technau, Karl-Gunter/0000-0001-7367-7512	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [GH000371]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069924] Funding Source: NIH RePORTER	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under terms of Cooperative Agreement Number GH000371. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.	[Anonymous], 2004, NAT ANT TREATM GUID; Bracher L, 2007, SCAND J INFECT DIS, V39, P799, DOI 10.1080/00365540701203493; Brennan AT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18794; Green H, 2007, AIDS, V21, P947, DOI 10.1097/QAD.0b013e3280e087e7; Hewitt RG, 2002, CLIN INFECT DIS, V34, P1137, DOI 10.1086/339751; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Kampiire L, 2012, 19 INT AIDS C WASH U; Kline MW, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e47; Kumarasamy N, 2009, J TROP PEDIATRICS, V55, P155, DOI 10.1093/tropej/fmn080; Nahirya-Ntege P, 2011, PEDIATR INFECT DIS J, V30, P535, DOI 10.1097/INF.0b013e3182076864; National Department of Health South Africa, 2005, GUID MAN HIV INF CHI; National Department of Health South Africa and South African National AIDS council, 2010, GUID MAN HIV CHILDR; Palladino C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096307; Palmer M, 2013, AIDS, V27, P781, DOI 10.1097/QAD.0b013e32835c54b8; Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13; South African National Department of Health, 2013, S AFR ANT TREATM GUI; Tukei VJ, 2012, JAIDS-J ACQ IMM DEF, V59, P274, DOI 10.1097/QAI.0b013e3182423668; van Griensven J, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-39; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2010, ANT THER HIV INF INF	22	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0169762	10.1371/journal.pone.0169762	http://dx.doi.org/10.1371/journal.pone.0169762			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192529	gold, Green Published, Green Submitted			2023-01-03	WOS:000394423800006
J	Nagata, Y; Yamamoto, T; Hayashi, M; Hayashi, S; Kadowaki, M				Nagata, Yuka; Yamamoto, Takeshi; Hayashi, Michie; Hayashi, Shusaku; Kadowaki, Makoto			Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model	PLOS ONE			English	Article							RETINOIC-ACID; IMMUNE TOLERANCE; GM-CSF; EPICUTANEOUS IMMUNOTHERAPY; MOUSE MODEL; INDUCTION; CHILDREN; MECHANISMS; INFLAMMATION; PATHOGENESIS	Oral immunotherapy (OIT) has been considered a promising approach for food allergies (FAs). However, the current OIT strategy is limited in terms of the long-term efficacy and safety. We have previously demonstrated that kakkonto, a traditional Japanese herbal medicine, suppresses the occurrence of allergic symptoms in a murine model of ovalbumin (OVA)-induced FA, which is attributed to the induction of the Foxp3(+) CD4(+) regulatory T cells. In this study, we established an OIT model using the FA mice with already established allergic symptoms and determined whether kakkonto could improve the efficacy of OIT. The OIT method consisted of initially administrating a very small amount of OVA and slowly increasing the amount. Allergic symptoms decreased in the OIT-treated FA mice. OIT significantly downregulated Th2 immune response-related gene expression in the FA mouse colon, and decreased the level of mouse mast cell protease-1, a marker of mast cell degranulation in the FA mouse plasma. Moreover, the concomitant use of kakkonto significantly enhanced the effectiveness of OIT on the allergic symptoms, and the combination therapy further suppressed the Th2 immune responses and the mast cell degranulation. In addition, OIT significantly increased the population of Foxp3(+) CD4(+) regulatory T cells in the FA mouse colon, and this population was further increased by OIT in combination with kakkonto. Furthermore, the combined therapy with kakkonto reduced the expression of RA-degrading enzyme CYP26B1 mRNA in the FA mouse colon. These findings indicated that the combination of OIT with kakkonto represents a promising approach for FA treatment.	[Nagata, Yuka; Yamamoto, Takeshi; Hayashi, Michie; Hayashi, Shusaku; Kadowaki, Makoto] Toyama Univ, Inst Nat Med, Div Gastrointestinal Pathophysiol, Toyama, Japan	University of Toyama	Yamamoto, T (corresponding author), Toyama Univ, Inst Nat Med, Div Gastrointestinal Pathophysiol, Toyama, Japan.	ty@inm.u-toyama.ac.jp	Hayashi, Shusaku/AAP-1185-2020	Hayashi, Shusaku/0000-0002-8304-7255; YAMAMOTO, Takeshi/0000-0002-4383-6954	Ministry of Education, Culture, Sports, Science and Technology of Japan [JP16K09234]; Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine) Institute of Natural Medicine, University of Toyama	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine) Institute of Natural Medicine, University of Toyama	This research was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to T. Yamamoto (No. JP16K09234) (https://www.jsps.go.jp/j-grantsinaid/index.html) and by a Grant-in-Aid for the Cooperative Research Project from Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine) Institute of Natural Medicine, University of Toyama in 2015 and 2012 to T. Yamamoto (http://www.inm.u-toyama.ac.jp/jp/collabo/hub_index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akase T., 2002, Journal of Traditional Medicines, V19, P58; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Bailey M, 2005, P NUTR SOC, V64, P451, DOI 10.1079/PNS2005452; Bauer RN, 2015, J ALLERGY CLIN IMMUN, V135, P312, DOI 10.1016/j.jaci.2014.12.1908; Bhattacharya P, 2015, CYTOKINE, V75, P261, DOI 10.1016/j.cyto.2015.05.030; Bhattacharya P, 2015, J INTERF CYTOK RES, V35, P585, DOI 10.1089/jir.2014.0149; Bischoff S, 2004, CURR OPIN GASTROEN, V20, P156, DOI 10.1097/00001574-200403000-00018; Bischoff S, 2005, GASTROENTEROLOGY, V128, P1089, DOI 10.1053/j.gastro.2004.08.015; Bohm L, 2015, J IMMUNOL, V194, P887, DOI 10.4049/jimmunol.1401612; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Casale TB, 2014, J ALLERGY CLIN IMMUN, V133, P612, DOI 10.1016/j.jaci.2014.01.007; Chenery A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072308; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Di Bona D, 2012, J ALLERGY CLIN IMMUN, V130, P1097, DOI 10.1016/j.jaci.2012.08.012; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Egea L, 2010, EXPERT REV GASTROENT, V4, P723, DOI [10.1586/egh.10.73, 10.1586/EGH.10.73]; Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366; Farooq SM, 2014, BRAIN BEHAV IMMUN, V42, P118, DOI 10.1016/j.bbi.2014.06.010; Farooq SM, 2014, J CELL MOL MED, V18, P2512, DOI 10.1111/jcmm.12376; Farooq SM, 2014, BRAIN BEHAV IMMUN, V35, P64, DOI 10.1016/j.bbi.2013.09.016; Farooq SM, 2013, CNS NEUROSCI THER, V19, P503, DOI 10.1111/cns.12087; Farooq SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048635; Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Gathungu G, 2013, INFLAMM BOWEL DIS, V19, P1671, DOI 10.1097/MIB.0b013e318281f506; Gill N, 2010, NAT IMMUNOL, V11, P558, DOI 10.1038/ni0710-558; Haddad CS, 2016, AUTOIMMUNITY, V49, P298, DOI 10.1080/08916934.2016.1183657; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2012, NEW ENGL J MED, V367, P233, DOI [10.1056/NEJMoa1200435, DOI 10.1056/NEJMOA1200435]; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Jutel M, 2013, ALLERGOL INT, V62, P425, DOI 10.2332/allergolint.13-RAI-0608; Kageyama-Yahara N, 2010, FEBS LETT, V584, P111, DOI 10.1016/j.febslet.2009.11.007; Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724; Kerstan A, 2011, J ALLERGY CLIN IMMUN, V127, P495, DOI 10.1016/j.jaci.2010.11.025; Kim SJ, 2016, ARTHRITIS RHEUMATOL, V68, P1099, DOI 10.1002/art.39544; Kim SJ, 2016, ANN RHEUM D IN PRESS; Kurokawa M, 2002, ANTIVIR RES, V56, P183, DOI 10.1016/S0166-3542(02)00104-3; Larange A, 2016, ANNU REV IMMUNOL, V34, P369, DOI 10.1146/annurev-immunol-041015-055427; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Maazi H, 2012, CLIN EXP ALLERGY, V42, P1519, DOI 10.1111/j.1365-2222.2012.04064.x; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Medeiros SR, 2015, NUTRITION, V31, P1260, DOI 10.1016/j.nut.2015.03.004; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Mondoulet L, 2015, J ALLERGY CLIN IMMUN, V135, P1546, DOI 10.1016/j.jaci.2014.11.028; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Nelson CH, 2013, CURR TOP MED CHEM, V13, P1402; Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639; Nowak-Wegrzyn A, 2015, CLIN EXP ALLERGY, V45, P368, DOI 10.1111/cea.12382; Okubo Kimihiro, 2011, Allergology International, V60, P171, DOI [10.2332/allergolint.11-RAI-0334, 10.2332/allergolint. 11-RAI-0334]; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Pastore S, 2006, EUR J DERMATOL, V16, P125; Peric A, 2016, INT ARCH OTORHINOLAR, V20, P364, DOI 10.1055/s-0035-1570746; Pesek RD, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0610-0; Ross AC, 2011, ANNU REV NUTR, V31, P65, DOI 10.1146/annurev-nutr-072610-145127; Rowin J, 2012, MUSCLE NERVE, V46, P449, DOI 10.1002/mus.23488; Rupa P, 2012, ALLERGY, V67, P74, DOI 10.1111/j.1398-9995.2011.02724.x; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P139, DOI 10.1016/j.jaci.2004.11.003; Sato S, 2014, INT ARCH ALLERGY IMM, V164, P1, DOI 10.1159/000361025; Shershakova N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135070; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Siebeneicher S, 2015, ALLERGY, V70, P1559, DOI 10.1111/all.12732; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016089; Terasawa K, 2004, EVID-BASED COMPL ALT, V1, P119, DOI 10.1093/ecam/neh022; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Yamamoto T, 2009, INT ARCH ALLERGY IMM, V148, P175, DOI 10.1159/000161578; Yamamoto T, 2016, INT ARCH ALLERGY IMM, V169, P146, DOI 10.1159/000445433; Yamamoto T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085888; Yamamoto T, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/721085; Yanagida N, 2016, ALLERGOL INT, V65, P135, DOI 10.1016/j.alit.2015.10.010; Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083	76	20	20	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2017	12	1							e0170577	10.1371/journal.pone.0170577	http://dx.doi.org/10.1371/journal.pone.0170577			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3QC	28107533	Green Submitted, gold, Green Published			2023-01-03	WOS:000392405300169
J	Kurien, M; Sleet, S; Sanders, DS; Cave, J				Kurien, Matthew; Sleet, Sarah; Sanders, David S.; Cave, James			Should gluten-free foods be available on prescription?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Kurien, Matthew; Sanders, David S.] Univ Sheffield, Dept Infect & Immun, Academ Unit Gastroenterol, Gastroenterol, Sheffield, S Yorkshire, England; [Kurien, Matthew; Sanders, David S.] Univ Sheffield, Dept Cardiovasc Sci, Academ Unit Gastroenterol, Gastroenterol, Sheffield, S Yorkshire, England; [Kurien, Matthew; Sanders, David S.] Royal Hallamshire Hosp, Dept Gastroenterol, Gastroenterol, Sheffield, S Yorkshire, England; [Sleet, Sarah] Coeliac UK, High Wycombe, Bucks, England	University of Sheffield; University of Sheffield; University of Sheffield	Sanders, DS (corresponding author), Univ Sheffield, Dept Infect & Immun, Academ Unit Gastroenterol, Gastroenterol, Sheffield, S Yorkshire, England.; Sanders, DS (corresponding author), Univ Sheffield, Dept Cardiovasc Sci, Academ Unit Gastroenterol, Gastroenterol, Sheffield, S Yorkshire, England.; Sanders, DS (corresponding author), Royal Hallamshire Hosp, Dept Gastroenterol, Gastroenterol, Sheffield, S Yorkshire, England.	david.sanders@sth.nhs.uk; jamescave@outlook.com		Cave, James/0000-0003-0721-9534; Kurien, Matthew/0000-0002-4227-9500	Dr Schaer (a gluten-free food manufacturer); Tillotts Pharma (producer of a point-of-care test for coeliac disease); National Institute for Health Research [CL-2014-04-501] Funding Source: researchfish	Dr Schaer (a gluten-free food manufacturer); Tillotts Pharma (producer of a point-of-care test for coeliac disease); National Institute for Health Research(National Institute for Health Research (NIHR))	All authors have read and understood BMJ policy on declaration of interests and declare the following interests: SS is the chief executive of Coeliac UK; DSS has received educational research grants from Dr Schaer (a gluten-free food manufacturer) and Tillotts Pharma (producer of a point-of-care test for coeliac disease) for investigator led studies; JC is editor of Drugs and Therapeutics Bulletin.	Burden M, 2015, POSTGRAD MED J, V91, P622, DOI 10.1136/postgradmedj-2015-133395; Coeliac UK, COEL UK LETT DAIL MA; Coeliac UK, 2011, COMM PHARM SUPPL GLU; Coeliac UK, 2016, NHS SUPP PAT COEL DI; Diabetes UK, 2016, DIAB UK POS STAT DIA; Future Foundation, 2007, SHOPP MIL 2007; Gray AM, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-105; Hall NJ, 2013, APPETITE, V68, P56, DOI 10.1016/j.appet.2013.04.016; Health and Social Care Information Centre, 2016, PRESCR DISP COMM STA; Health and Social Care Information Centre, PRESCR COST AN ENGL; King's Fund, 2016, DEF NHS 2016; National Institute for Health and Care Excellence, 2015, COEL DIS REC ASS MAN; National Institute of Health and Care Excellence, 2016, COEL DIS QUAL STAND; NHS Business Services Authority, 2016, DM D BROWS; O'Connor A, 2012, NUTR BULL, V37, P193, DOI 10.1111/j.1467-3010.2012.01975.x; Organisation for Economic Co-operation and Development, HLTH EXP FIN; Tesco, 2016, GEN BROWN SLIC BREAD	17	4	4	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	2017	356								i6810	10.1136/bmj.i6810	http://dx.doi.org/10.1136/bmj.i6810			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9BS	28073799	Green Accepted			2023-01-03	WOS:000392067300006
J	Ding, M; Wang, Y; Chi, JC; Wang, T; Tang, XY; Cui, D; Qian, QJ; Zhai, B				Ding, Min; Wang, Ying; Chi, Jiachang; Wang, Tao; Tang, Xiaoyin; Cui, Dan; Qian, Qijun; Zhai, Bo			Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients	PLOS ONE			English	Article							INDUCED KILLER-CELLS; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; MICROWAVE ABLATION; COMBINATION; THERAPY	Purpose Cellular immunotherapy has appeared to be a promising modality for the treatment of malignant tumor. The objective of this study was to evaluate the efficacy of cellular immunotherapy combined with minimally invasive therapy. Methods We searched PubMed, Web of Science and The Cochrane Library through March 2016 for relevant studies. Short-term efficacy (the disease control rate, the control rate of quality life and the AFP descent rate) and long-term efficacy (overall survival (OS) and progression-free survival (PFS) rate) were compared as the major outcome measures. The meta-analysis was performed using Review Manager 5.3. Results A total of 1174 references in 3 databases were found of which 19 individual studies with 1774 HCC patients enrolled in this meta-analysis. Meta-analysis results showed that cellular immunotherapy combined with minimally-invasive treatment significantly improved the measures of short-term response (the disease control rate (OR = 5.91, P = 0.007), the control rate of quality lift (OR = 3.38, P = 0.003) and the AFP descent rate (OR = 4.48, P = 0.02)). Also higher 6-month PFS (OR = 2.78, P = 0.05), >= 12-month PFS (OR = 3.56, P<0.00001) rate and 6-month OS (OR = 2.81, P = 0.0009), 12-month OS (OR = 3.05, P<0.00001) and 24-month OS (OR = 3.52, P<0.0001) rate were observed in patients undergoing cellular immunotherapy. Conclusions This meta-analysis suggested that cellular immunotherapy is a feasible adjuvant treatment that could be beneficial for the improvement of the clinical outcomes for hepatocellular carcinoma (HCC) patients after minimally invasive treatment, including short-term response and long-term survival.	[Ding, Min; Chi, Jiachang; Wang, Tao; Tang, Xiaoyin; Cui, Dan; Zhai, Bo] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Intervent Oncol, Shanghai, Peoples R China; [Wang, Ying; Qian, Qijun] Second Mil Med Univ, Chinese PLA, Eastern Hepatobiliary Surg Hosp, Lab Gene & Viral Therapy, Shanghai, Peoples R China	Shanghai Jiao Tong University; Naval Medical University	Zhai, B (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Intervent Oncol, Shanghai, Peoples R China.	zhaiboshi@sina.com	Wang, Ying/AAY-4117-2021	Wang, Ying/0000-0002-1819-294X; Zhai, Bo/0000-0003-4337-7126	National Natural Science Fund [81472845]	National Natural Science Fund(National Natural Science Foundation of China (NSFC))	This study was funded by The National Natural Science Fund (No. 81472845).	Aerts M, 2016, WORLD J GASTROENTERO, V22, P253, DOI 10.3748/wjg.v22.i1.253; [Anonymous], 2014, RANDOMIZED CONTROLLE; [Anonymous], 2012, CHINESE J PRIMARY ME, V19, P97; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Cheng XZ P D, 2014, J PRACTICAL MED, V9, P1401; Deng WJ, 2013, LING NAN XIAN DAI LI, V13, P29; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Greten TF, 2008, REV RECENT CLIN TRIA, V3, P31, DOI 10.2174/157488708783330549; Guo Weiwei, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P674; Hao Ming-Zhi, 2010, Chin J Cancer, V29, P172; [郝明志 HAO Mingzhi], 2006, [中国肿瘤生物治疗杂志, Chinese Journal of Cancer Biotherapy], V13, P303; He XBWJ, 2012, SI CHUANXI XUE, V33, P1696; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hong YP, 2015, WORLD J HEPATOL, V7, P980, DOI 10.4254/wjh.v7.i7.980; Huang ZM, 2013, J IMMUNOTHER, V36, P287, DOI 10.1097/CJI.0b013e3182948452; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lencioni R, 2010, HEPATOLOGY, V52, P762, DOI 10.1002/hep.23725; Li XF, 2014, CLIN RES HEPATOL GAS, V38, P583, DOI 10.1016/j.clinre.2014.04.010; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Pan Chang-Chuan, 2010, Chin J Cancer, V29, P596; Poggi G, 2015, WORLD J HEPATOL, V7, P2578, DOI 10.4254/wjh.v7.i25.2578; Poulou LS, 2015, WORLD J HEPATOL, V7, P1054, DOI 10.4254/wjh.v7.i8.1054; Shi Y G C, 2007, J INTERVENT RADIOL, V16, P235; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Su YY, 2016, CLIN LAB, V62, P599, DOI 10.7754/Clin.Lab.2015.150804; Thomas MB, 2010, J CLIN ONCOL, V28, P3994, DOI 10.1200/JCO.2010.28.7805; [佟立权 Tong Liquan], 2013, [中国普通外科杂志, Chinese Journal of General Surgery], V22, P876; Tsurusaki M, 2015, LIVER CANCER, V4, P165, DOI 10.1159/000367739; Vauleon E, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/689171; Waghray A, 2015, WORLD J HEPATOL, V7, P1020, DOI 10.4254/wjh.v7.i8.1020; Wang Jian-peng, 2012, Zhonghua Yi Xue Za Zhi, V92, P3062; Weng DS, 2008, J IMMUNOTHER, V31, P63, DOI 10.1097/CJI.0b013e31815a121b; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Xie F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042879; Xu YM X D, 2013, CHIN J CANC PREV TRE, V24, P1928; Yang K, 2016, WORLD J GASTROENTERO, V22, P4835, DOI 10.3748/wjg.v22.i20.4835; Zhang NZ X Y, 2006, DONG NAN GUO FANG YI, V8, P84; Zhang Q, 2014, ORG LETT, V16, P2014, DOI 10.1021/ol500583d; Zhao M, 2012, EUR J RADIOL, V81, P2717, DOI 10.1016/j.ejrad.2011.10.023; Zhao Ming, 2006, Zhonghua Yi Xue Za Zhi, V86, P1823; 黄丽惜, 2007, [广东医学, Guangdong Medical Journal], V28, P1466	41	12	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2016	11	12							e0168798	10.1371/journal.pone.0168798	http://dx.doi.org/10.1371/journal.pone.0168798			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9QH	28006010	Green Published, gold, Green Submitted			2023-01-03	WOS:000392843200095
J	Milberg, A; Torres, S; Agard, P				Milberg, Anna; Torres, Sandra; Agard, Pernilla			Health Care Professionals' Understandings of Cross- Cultural Interaction in End- of- Life Care: A Focus Group Study	PLOS ONE			English	Article							PALLIATIVE CARE; OF-LIFE; ASIAN PEOPLE; NEW-ZEALAND; EXPERIENCES; IMMIGRANTS; ETHNICITY; CANCER; DEATH	Objective The academic debate on cross-cultural interaction within the context of end-of-life care takes for granted that this interaction is challenging. However, few empirical studies have actually focused on what health care professionals think about this interaction. This study aimed to explore health care professionals' understandings of cross-cultural interaction during end-of-life care. Methods Sixty end-of-life care professionals were recruited from eleven care units in Sweden to take part in focus group interviews. These interviews were analyzed using qualitative content analysis. Results The health care professionals interviewed talked about cross-cultural interaction in end-oflife care as interaction that brings about uncertainty, stress and frustration even though they had limited experience of this type of interaction. The focus group discussions brought attention to four specific challenges that they expected to meet when they care for patients with migrant backgrounds since they took for granted that they would have an ethno-cultural background that is different to their own. These challenges had to do with communication barriers, `unusual' emotional and pain expressions, the expectation that these patients' families would be `different' and the anticipation that these patients and their families lack knowledge. At the core of the challenges in question is the idea that cross-cultural interaction means meeting "the unknown". In addition, the end-of-life care professionals interviewed talked about patients whose backgrounds they did not share in homogenizing terms. It is against this backdrop that they worried about their ability to provide end-of-life care that is individualized enough to meet the needs of these patients. Conclusions The study suggests that end-of-life care professionals who regard cross-cultural interaction in this manner could face actual challenges when caring for patients whose backgrounds they regard as "the unknown" since they anticipate a variety of challenges and do not seem confident enough that they can provide good quality care when cross-cultural interaction is at stake.	[Milberg, Anna] Linkoping Univ, Palliat Educ & Res Ctr, Norrkoping, Sweden; [Milberg, Anna] Linkoping Univ, Dept Adv Home Care, Norrkoping, Sweden; [Milberg, Anna] Linkoping Univ, Dept Social & Welf Studies, Norrkoping, Sweden; [Torres, Sandra; Agard, Pernilla] Uppsala Univ, Dept Sociol, Uppsala, Sweden	Linkoping University; Linkoping University; Linkoping University; Uppsala University	Milberg, A (corresponding author), Linkoping Univ, Palliat Educ & Res Ctr, Norrkoping, Sweden.; Milberg, A (corresponding author), Linkoping Univ, Dept Adv Home Care, Norrkoping, Sweden.; Milberg, A (corresponding author), Linkoping Univ, Dept Social & Welf Studies, Norrkoping, Sweden.	anna.milberg@liu.se		Milberg, Anna/0000-0001-8828-0702	Medical Research Council of Southeast Sweden [FORSS-160161]; Uppsala university; Linkoping university	Medical Research Council of Southeast Sweden(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Uppsala university; Linkoping university	The Medical Research Council of Southeast Sweden (http://www.fou.nu/is/forss) (FORSS-160161; AM), Uppsala university (SE) and Linkoping university (SE) contributed with funding of the Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhui K, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-15; Born Wendi, 2004, J Palliat Med, V7, P247, DOI 10.1089/109662104773709369; Breen RL, 2006, J GEOGR HIGHER EDUC, V30, P463, DOI 10.1080/03098260600927575; Campbell SR, 2014, J PALLIAT MED, V17, P621, DOI 10.1089/jpm.2013.0443; Cang-Wong Celeste, 2009, Perm J, V13, P31; Cort Malcolm A, 2004, J Palliat Med, V7, P63, DOI 10.1089/109662104322737269; Crawley LM, 2005, J PALLIAT MED S1, V8, P58; Creswell JW, 2018, QUAL INQ; Evans N, 2012, J PAIN SYMPTOM MANAG, V43, P261, DOI 10.1016/j.jpainsymman.2011.04.012; Frey R, 2014, HEALTH SOC CARE COMM, V22, P290, DOI 10.1111/hsc.12081; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Gunaratnam Y, 2001, SOCIOL HEALTH ILL, V23, P65, DOI 10.1111/1467-9566.00241; Gunaratnam Y, 2008, ETHNICITY INEQUALITI, V1, P9, DOI DOI 10.1108/17570980200800003; Gunaratnam Y, 2007, INT J PALLIAT NURS, V13, P470, DOI 10.12968/ijpn.2007.13.10.27477; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; Hill S, 2010, CANCER-AM CANCER SOC, V116, P3205, DOI 10.1002/cncr.25127; Horvat L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009405.pub2; Horvath-Lindberg J, 1983, INVANDRARNAS MOTE ME; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jones K, 2005, J RES NURS, V10, P431, DOI 10.1177/174498710501000406; Kai J, 2007, PLOS MED, V4, P1766, DOI 10.1371/journal.pmed.0040323; Kvale S., 1996, INTERVIEWS INTRO QUA; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; McNamara B, 2004, SOC SCI MED, V58, P929, DOI 10.1016/j.socscimed.2003.10.042; Milberg A, 2012, PSYCHO-ONCOLOGY, V21, P886, DOI 10.1002/pon.1982; Mindell JS, 2014, J EPIDEMIOL COMMUN H, V68, P1133, DOI 10.1136/jech-2014-203927; Morgan D. L., 1997, FOCUS GROUPS QUALITA, V16; Owens A, 2004, HEALTH SOC CARE COMM, V12, P414, DOI 10.1111/j.1365-2524.2004.00511.x; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Richardson A, 2006, EUR J ONCOL NURS, V10, P93, DOI 10.1016/j.ejon.2005.05.002; Shahid S, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-26; Torres S., 2013, HLTH AGING SOCIOCULT; Torres S, 2006, J ETHN MIGR STUD, V32, P1341, DOI 10.1080/13691830600928730; Torres S, 2016, J INTERCULT STUD, V37, P103, DOI 10.1080/07256868.2016.1141756; Vaughn Sharon, 1996, FOCUS GROUP INTERVIE; Wang L, 2013, SOC SCI MED, V98, P8, DOI 10.1016/j.socscimed.2013.08.040; who, WHO DEF PALL CAR; Wiking E, 2004, J EPIDEMIOL COMMUN H, V58, P574, DOI 10.1136/jech.2003.011387	38	9	9	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2016	11	11							e0165452	10.1371/journal.pone.0165452	http://dx.doi.org/10.1371/journal.pone.0165452			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ED5KB	27880814	Green Published, Green Submitted, gold			2023-01-03	WOS:000388889500008
J	Foukakis, T; von Minckwitz, G; Bengtsson, NO; Brandberg, Y; Wallberg, B; Fornander, T; Mlineritsch, B; Schmatloch, S; Singer, CF; Steger, G; Egle, D; Karlsson, E; Carlsson, L; Loibl, S; Untch, M; Hellstrom, M; Johansson, H; Anderson, H; Malmstrom, P; Gnant, M; Greil, R; Mobus, V; Bergh, J				Foukakis, Theodoros; von Minckwitz, Gunter; Bengtsson, Nils-Olof; Brandberg, Yvonne; Wallberg, Birgitta; Fornander, Tommy; Mlineritsch, Brigitte; Schmatloch, Sabine; Singer, Christian F.; Steger, Guenther; Egle, Daniel; Karlsson, Eva; Carlsson, Lena; Loibl, Sibylle; Untch, Michael; Hellstrom, Mats; Johansson, Hemming; Anderson, Harald; Malmstrom, Per; Gnant, Michael; Greil, Richard; Mobus, Volker; Bergh, Jonas		Swedish Breast Canc Grp; German Breast Grp; Austrian Breast Colorectal Canc	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUROPEAN-ORGANIZATION; FOLLOW-UP; THERAPY; CMF	IMPORTANCE Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy. Whether tailored dosing can improve outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy. OBJECTIVE To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early breast cancer compared with a standard 3-weekly chemotherapy schedule. DESIGN, SETTING, AND PARTICIPANTS A randomized, open-label, phase 3 trial of women aged 65 years and younger who had surgery for nonmetastatic node-positive or high-risk node-negative breast cancer at 86 sites in Sweden, Germany, and Austria between February 20, 2007, and September 14, 2011. INTERVENTIONS Patients were randomized 1:1 either to 4 cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-interval chemotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks. MAIN OUTCOMES AND MEASURES The primary end point was breast cancer recurrence-free survival (BCRFS). Secondary end points included 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall survival (OS), and rates of grade 3 or 4 toxic effects. RESULTS Among 2017 randomized patients (1006 in the tailored dose-dense group and 1011 in the control group; median [IQR] age, 51 [45-58] years; 80% with hormone receptor-positive tumors; 97% with node-positive disease), 2000 received study treatment (>= 1 cycle of chemotherapy; 1001 in the tailored dose-dense group and 999 in the control group). After a median follow-up of 5.3 years (IQR, 4.5-6.1 years), 269 BCRFS events were reported, 118 in the tailored dose-dense group and 151 in the control group (HR, 0.79; 95% CI, 0.61-1.01; log-rank P=.06; 5-year BCRFS, 88.7% vs 85.0%). The tailored dose-dense group had significantly better EFS than the control group (HR, 0.79; 95% CI, 0.63-0.99; P=.04; 5-year EFS, 86.7% vs 82.1%). The groups did not differ in OS (HR, 0.77; 95% CI, 0.57-1.05; P=.09; 5-year OS, 92.1% vs 90.2%) or DDFS (HR, 0.83; 95% CI, 0.64-1.08; P=.17; 5-year DDFS, 89.4% vs 86.7%). Grade 3 or 4 nonhematologic toxic effects occurred in 527 (52.6%) in the tailored dose-dense group and 366 (36.6%) in the control group. CONCLUSIONS AND RELEVANCE Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival. Nonhematologic toxic effects were more frequent in the tailored dose-dense group.	[Foukakis, Theodoros; Brandberg, Yvonne; Wallberg, Birgitta; Fornander, Tommy; Hellstrom, Mats; Johansson, Hemming; Bergh, Jonas] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden; [Foukakis, Theodoros; Brandberg, Yvonne; Wallberg, Birgitta; Fornander, Tommy; Hellstrom, Mats; Johansson, Hemming; Bergh, Jonas] Univ Hosp, S-17176 Stockholm, Sweden; [von Minckwitz, Gunter; Loibl, Sibylle] German Breast Grp, Neu Isenburg, Germany; [Bengtsson, Nils-Olof] Norrland Univ Hosp, Umea, Sweden; [Mlineritsch, Brigitte; Greil, Richard] Landeskrankenhaus & Paracelsus Med Univ, Salzburg, Austria; [Schmatloch, Sabine] Elisabeth Hosp, Kassel, Germany; [Singer, Christian F.] Med Univ, Dept Gynecol, Ctr Comprehens Canc, Vienna, Austria; [Steger, Guenther] Med Univ, Dept Internal Med, Ctr Comprehens Canc, Vienna, Austria; [Egle, Daniel] Med Univ Innsbruck, Dept Gynecol, Innsbruck, Austria; [Karlsson, Eva] Cent Hosp Karlstad, Karlstad, Sweden; [Carlsson, Lena] Cty Hosp, Sundsvall, Sweden; [Untch, Michael] HELIOS Klin, Berlin, Germany; [Anderson, Harald] Lund Univ, Dept Clin Sci, Canc Epidemiol, Lund, Sweden; [Malmstrom, Per] Skane Univ Hosp, Lund, Sweden; [Gnant, Michael] Med Univ, Dept Surg, Ctr Comprehens Canc, Vienna, Austria; [Mobus, Volker] Klinikum Frankfurt Hochst, Frankfurt, Germany	Karolinska Institutet; German Breast Group; Umea University; Medical University of Innsbruck; Helios Kliniken; Lund University; Lund University; Skane University Hospital	Bergh, J (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden.; Bergh, J (corresponding author), Univ Hosp, S-17176 Stockholm, Sweden.	jonas.bergh@ki.se	Gnant, Michael/AAN-7054-2020; Greil, Richard F/C-7673-2017; Meyer, Anne S/AAN-2157-2020	Gnant, Michael/0000-0003-1002-2118; Greil, Richard F/0000-0002-4462-3694; Meyer, Anne S/0000-0001-8910-9931; Foukakis, Theodoros/0000-0001-8952-9987	Swedish Cancer Society; Radiumhemmet; Amgen; Roche; Sanofi-Aventis; German Breast Group (GBG); Austrian Breast & Colorectal Cancer Study Group (ABCSG)	Swedish Cancer Society(Swedish Cancer Society); Radiumhemmet; Amgen(Amgen); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); German Breast Group (GBG); Austrian Breast & Colorectal Cancer Study Group (ABCSG)	This study was supported by grants from the Swedish Cancer Society to the Karolinska Institutet, from the research funds at Radiumhemmet, and from Amgen, Roche, and Sanofi-Aventis to the Swedish Breast Cancer Group (SweBCG) at Karolinska University Hospital, the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG).	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Baker SD, 2002, JNCI-J NATL CANCER I, V94, P1883, DOI 10.1093/jnci/94.24.1883; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Bonilla L, 2010, JNCI-J NATL CANCER I, V102, P1845, DOI 10.1093/jnci/djq409; Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8; Cameron DA, 2003, BRIT J CANCER, V89, P1837, DOI 10.1038/sj.bjc.6601366; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Colleoni M, 1998, EUR J CANCER, V34, P1693, DOI 10.1016/S0959-8049(98)00209-3; Del Mastro L, 2015, LANCET, V385, P1863, DOI 10.1016/S0140-6736(14)62048-1; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; Margolin S, 2011, ACTA ONCOL, V50, P35, DOI 10.3109/0284186X.2010.535847; Moebus V, 2010, J CLIN ONCOL, V28, P2874, DOI 10.1200/JCO.2009.24.7643; NORTON L, 1988, CANCER RES, V48, P7067; Perez EA, 2011, J CLIN ONCOL, V29, P4491, DOI 10.1200/JCO.2011.36.7045; Saarto T, 1997, BRIT J CANCER, V75, P301, DOI 10.1038/bjc.1997.49; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Sprangers MAG, 1996, J CLIN ONCOL, V14, P2756, DOI 10.1200/JCO.1996.14.10.2756; Wilking N, 2007, ANN ONCOL, V18, P694, DOI 10.1093/annonc/mdl488	21	51	54	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2016	316	18					1888	1896		10.1001/jama.2016.15865	http://dx.doi.org/10.1001/jama.2016.15865			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB1MN	27825007				2023-01-03	WOS:000387116500017
J	Mayor, S				Mayor, Susan			Cranberry capsules do not reduce urinary tract infections in older women, study finds	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Juthani-Mehta M, 2016, JAMA-J AM MED ASSOC, V316, P1879, DOI 10.1001/jama.2016.16141; Nicolle LE, 2016, JAMA-J AM MED ASSOC, V316, P1873, DOI 10.1001/jama.2016.16140	2	0	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	2016	355								i5835	10.1136/bmj.i5835	http://dx.doi.org/10.1136/bmj.i5835			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB4CM	27799145				2023-01-03	WOS:000387316800005
J	Albert, RK; Au, DH; Blackford, AL; Casaburi, R; Cooper, JA; Criner, GJ; Diaz, P; Fuhlbrigge, AL; Gay, SE; Kanner, RE; MacIntyre, N; Martinez, FJ; Panos, RJ; Piantadosi, S; Sciurba, F; Shade, D; Stibolt, T; Stoller, JK; Wise, R; Yusen, RD; Tonascia, J; Sternberg, AL; Bailey, W				Albert, Richard K.; Au, David H.; Blackford, Amanda L.; Casaburi, Richard; Cooper, J. Allen, Jr.; Criner, Gerard J.; Diaz, Philip; Fuhlbrigge, Anne L.; Gay, Steven E.; Kanner, Richard E.; MacIntyre, Neil; Martinez, Fernando J.; Panos, Ralph J.; Piantadosi, Steven; Sciurba, Frank; Shade, David; Stibolt, Thomas; Stoller, James K.; Wise, Robert; Yusen, Roger D.; Tonascia, James; Sternberg, Alice L.; Bailey, William		Long-Term Oxygen Treatment Trial	A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; EXERCISE; THERAPY; SCALE; VALIDITY; QUALITY; DYSPNEA; INDEX	BACKGROUND Long-term treatment with supplemental oxygen has unknown efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced moderate desaturation. METHODS We originally designed the trial to test whether long-term treatment with supplemental oxygen would result in a longer time to death than no use of supplemental oxygen among patients who had stable COPD with moderate resting desaturation (oxyhemoglobin saturation as measured by pulse oximetry [Spo(2)], 89 to 93%). After 7 months and the randomization of 34 patients, the trial was redesigned to also include patients who had stable COPD with moderate exercise-induced desaturation (during the 6-minute walk test, Spo(2) >= 80% for >= 5 minutes and < 90% for >= 10 seconds) and to incorporate the time to the first hospitalization for any cause into the new composite primary outcome. Patients were randomly assigned, in a 1: 1 ratio, to receive long-term supplemental oxygen (supplemental-oxygen group) or no long-term supplemental oxygen (no-supplemental-oxygen group). In the supplemental-oxygen group, patients with resting desaturation were prescribed 24-hour oxygen, and those with desaturation only during exercise were prescribed oxygen during exercise and sleep. The trial-group assignment was not masked. RESULTS A total of 738 patients at 42 centers were followed for 1 to 6 years. In a time-to-event analysis, we found no significant difference between the supplemental-oxygen group and the no-supplemental-oxygen group in the time to death or first hospitalization (hazard ratio, 0.94; 95% confidence interval [CI], 0.79 to 1.12; P = 0.52), nor in the rates of all hospitalizations (rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD exacerbations (rate ratio, 1.08; 95% CI, 0.98 to 1.19), and COPD-related hospitalizations (rate ratio, 0.99; 95% CI, 0.83 to 1.17). We found no consistent between-group differences in measures of quality of life, lung function, and the distance walked in 6 minutes. CONCLUSIONS In patients with stable COPD and resting or exercise-induced moderate desaturation, the prescription of long-term supplemental oxygen did not result in a longer time to death or first hospitalization than no long-term supplemental oxygen, nor did it provide sustained benefit with regard to any of the other measured outcomes. (Funded by the National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services; LOTT ClinicalTrials.gov number, NCT00692198.)	[Albert, Richard K.] Univ Colorado, Denver, CO 80202 USA; [Au, David H.] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA USA; [Au, David H.] Univ Washington, Seattle, WA 98195 USA; [Blackford, Amanda L.; Casaburi, Richard] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Shade, David; Tonascia, James; Sternberg, Alice L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Casaburi, Richard] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA; [Piantadosi, Steven] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Cooper, J. Allen, Jr.] Birmingham VA Med Ctr, Birmingham, AL USA; [Cooper, J. Allen, Jr.; Bailey, William] Univ Alabama Birmingham, Birmingham, AL USA; [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [Sciurba, Frank] Univ Pittsburgh, Pittsburgh, PA USA; [Diaz, Philip] Ohio State Univ, Columbus, OH 43210 USA; [Panos, Ralph J.] Cincinnati VA Med Ctr, Cincinnati, OH USA; [Panos, Ralph J.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Stoller, James K.] Cleveland Clin, Cleveland, OH 44106 USA; [Fuhlbrigge, Anne L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Fuhlbrigge, Anne L.] Harvard Med Sch, Boston, MA USA; [Gay, Steven E.] Univ Michigan, Ann Arbor, MI 48109 USA; [Kanner, Richard E.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [MacIntyre, Neil] Duke Univ, Med Ctr, Durham, NC USA; [Martinez, Fernando J.] Weill Cornell Med Ctr, New York, NY USA; [Stibolt, Thomas] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA; [Yusen, Roger D.] Washington Univ, Sch Med, St Louis, MO 63130 USA	University of Colorado System; University of Colorado Denver; University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Cedars Sinai Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; Utah System of Higher Education; University of Utah; Duke University; Cornell University; Kaiser Permanente; Washington University (WUSTL)	Wise, R (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care, 4B-72,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rwise@jhmi.edu	Sciurba, Frank/AAZ-9339-2021	Wise, Robert/0000-0002-8353-2349; sciurba, frank/0000-0001-7468-2225; Aboussouan, Loutfi/0000-0003-2716-0904; Sriram, P.S/0000-0002-6103-3573	National Heart, Lung, and Blood Institute; Centers for Medicare and Medicaid Services	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Centers for Medicare and Medicaid Services	Funded by the National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services; LOTT ClinicalTrials.gov number, NCT00692198.	Ameer F, 2014, COCHRANE DB SYST REV, V6; [Anonymous], 1980, ANN INTERN MED, V93, P391; [Anonymous], 2013, 2013 CMS STAT CMS PU, V03504; Barr JT, 2000, CLIN THER, V22, P1121, DOI 10.1016/S0149-2918(00)80089-2; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Chaouat A, 1999, EUR RESPIR J, V14, P1002, DOI 10.1183/09031936.99.14510029; COX DR, 1972, J R STAT SOC B, V34, P187; Drummond MB, 2008, CHEST, V134, P497, DOI 10.1378/chest.08-0117; Emtner M, 2003, AM J RESP CRIT CARE, V168, P1034, DOI 10.1164/rccm.200212-1525OC; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1987, CHEST, V92, P604, DOI 10.1378/chest.92.4.604; FLETCHER EC, 1989, AM REV RESPIR DIS, V140, P1237, DOI 10.1164/ajrccm/140.5.1237; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; Hsu J., 1996, MULTIPLE COMP THEORY; Jones Paul W, 2005, COPD, V2, P75; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; Kaplan Robert M, 2005, COPD, V2, P91; O'Donnell DE, 2001, AM J RESP CRIT CARE, V163, P892, DOI 10.1164/ajrccm.163.4.2007026; Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Ringbaek T, 2013, CHRON RESP DIS, V10, P77, DOI 10.1177/1479972312473135; Spira AP, 2012, J GERONTOL A-BIOL, V67, P433, DOI 10.1093/gerona/glr172; Stoller JK, 2010, CHEST, V138, P179, DOI 10.1378/chest.09-2555; TIMMS RM, 1985, AM REV RESPIR DIS, V131, P69; Uronis HE, 2015, THORAX, V70, P492, DOI 10.1136/thoraxjnl-2014-205720; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; Williamson W, 2012, PULM MED, V2012, DOI 10.1155/2012/874020; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	239	246	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2016	375	17					1617	1627		10.1056/NEJMoa1604344	http://dx.doi.org/10.1056/NEJMoa1604344			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB2DX	27783918	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000387168900008
J	Chong, SY; Rohrle, O				Chong, Sook-Yee; Rohrle, Oliver			Exploring the Use of Non-Image-Based Ultrasound to Detect the Position of the Residual Femur within a Stump	PLOS ONE			English	Article							TRANS-FEMORAL SOCKET; PROSTHETIC SOCKET; PTB PROSTHESIS; KNEE AMPUTEES; MOTION; CALIBRATION; MODE; GAIT; LIMB	A satisfactorily fitted socket interacts dynamically with the stump in order to support body weight, transmit load effectively, enhance dynamic stability, and enable the control and stabilization of the residual limb. The internal dynamics occurring within a socket is important in determining optimal fit. Many measurement and imaging techniques, such as X-rays, have been utilized to investigate the movement of the residual femur within the stump during gait. However, due to associated health risks and costs, none of the current techniques have been extended to clinical prosthetics. The use of B-mode ultrasound has been suggested as a safe and cheap alternative, and has been utilized in previous studies to monitor the motion of the femur. However, the need to create a duplicate socket and time-consuming analysis of the images were obstacles to the system being applied clinically. This study aims to gauge the effectiveness of a non-image based ultrasound system. Here, we determined errors expected from the measurements. Accuracy errors of 2.9 mm to 8.4 mm and reproducibility measurements within a standard deviation of 3.9 mm are reported. We also estimated errors up to 14.4 mm in in-vivo measurements. We think there is potential in developing this technique, and we hope to reduce some technical difficulties such that it can, one day, be easily incorporated into prosthetic fitting.	[Chong, Sook-Yee; Rohrle, Oliver] Univ Stuttgart, Inst Appl Mech, Stuttgart, Germany; [Rohrle, Oliver] Fraunhofer IPA, Biomechatron Syst, Stuttgart, Germany	University of Stuttgart	Chong, SY (corresponding author), Univ Stuttgart, Inst Appl Mech, Stuttgart, Germany.	sy.chong@wwu.de	Chong, Sook Yee/T-2947-2018	Chong, Sook Yee/0000-0002-9761-3991; Rohrle, Oliver/0000-0002-1934-6525	European Research Council (ERC) under the European Union's Seventh Framework Program (FP7) [306757]	European Research Council (ERC) under the European Union's Seventh Framework Program (FP7)	Support was provided by the European Research Council (ERC) under the European Union's Seventh Framework Program (FP7/2007-2013) ERC grant agreement no 306757. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boone DA., 2006, J PROSTHET ORTHOT, V18, P68, DOI DOI 10.1097/00008526-200601001-00008; Convery P, 2000, PROSTHET ORTHOT INT, V24, P226, DOI 10.1080/03093640008726552; Douglas TS, 2002, IEEE T NEUR SYS REH, V10, P11, DOI 10.1109/TNSRE.2002.1021582; ERIKSON U, 1973, UPSALA J MED SCI, V78, P203, DOI 10.3109/03009737309178629; ERIKSON U, 1969, ACTA ORTHOP SCAND, V40, P520, DOI 10.3109/17453676909046537; GREVSTEN S, 1975, UPSALA J MED SCI, V80, P49, DOI 10.3109/03009737509178991; He P, 1996, IEEE Trans Rehabil Eng, V4, P114, DOI 10.1109/86.506408; LILJA M, 1993, PROSTHET ORTHOT INT, V17, P21, DOI 10.3109/03093649309164351; Long IA., 1985, CLIN PROSTHET ORTHOT, V9, P9; Mast T. D., 2000, Acoustics Research Letters Online, V1, P37, DOI 10.1121/1.1336896; Mayfield GW, 1977, ORTHOP T, V1, P95; Metwally K, 2016, ULTRASONICS, V65, P10, DOI 10.1016/j.ultras.2015.09.006; Mozes A, 2010, INT J MED ROBOT COMP, V6, P91, DOI 10.1002/rcs.294; Murray KD, 2000, PROSTHET ORTHOT INT, V24, P55, DOI 10.1080/03093640008726522; Oppenheimer A. V., 1999, DISCRETE TIME SIGNAL, V2, P242; Pinkerton JMM., 1949, P PHYS SOC B, V62, P129, DOI [10.1088/0370-1301/62/2/307, DOI 10.1088/0370-1301/62/2/307]; Richards JG, 1999, HUM MOVEMENT SCI, V18, P589, DOI 10.1016/S0167-9457(99)00023-8; Sabolich J., 1985, CLIN PROSTH ORTHOS, V9, P15; SAUNDERS JBDM, 1953, J BONE JOINT SURG AM, V35-A, P543, DOI 10.2106/00004623-195335030-00003; Shen C, 2014, PHYS REV X, V4, DOI 10.1103/PhysRevX.4.041033; Zhang M, 1998, P ANN INT IEEE EMBS, V20, P2741, DOI 10.1109/IEMBS.1998.745244; Zheng YP, 2001, J REHABIL RES DEV, V38, P487	22	1	1	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0164583	10.1371/journal.pone.0164583	http://dx.doi.org/10.1371/journal.pone.0164583			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NZ	27764120	gold, Green Published, Green Submitted			2023-01-03	WOS:000386204500045
J	Sen, CK; Khanna, S; Harris, H; Stewart, R; Balch, M; Heigel, M; Teplitsky, S; Gnyawali, S; Rink, C				Sen, Chandan K.; Khanna, Savita; Harris, Hallie; Stewart, Richard; Balch, Maria; Heigel, Mallory; Teplitsky, Seth; Gnyawali, Surya; Rink, Cameron			Robot-assisted mechanical therapy attenuates strokeinduced limb skeletal muscle injury	FASEB JOURNAL			English	Article						ischemia; rehabilitation; physical therapy; cerebrovascular accident	ACUTE ISCHEMIC-STROKE; MOTOR RECOVERY; BOBATH CONCEPT; BLOOD-FLOW; REHABILITATION; MASSAGE; BDNF; EXPRESSION; OUTCOMES; DIFFERENTIATION	The efficacy and optimization of poststroke physical therapy paradigms is challenged in part by a lack of objective tools available to researchers for systematic preclinical testing. This work represents a maiden effort to develop a robot-assisted mechanical therapy (RAMT) device to objectively address the significance of mechanical physiotherapy on poststroke outcomes. Wistar rats were subjected to right hemisphere middle-cerebral artery occlusion and reperfusion. After 24 h, rats were split into control (RAMT-) or RAMT+ groups (30 min daily RAMT over the stroke-affected gastrocnemius) and were followed up to poststroke d 14. RAMT+ increased perfusion 1.5-fold in stroke-affected gastrocnemius as compared to RAMT- controls. Furthermore, RAMT+ rats demonstrated improved poststroke track width (11% wider), stride length (21% longer), and travel distance (61% greater), as objectively measured using software-automated testing platforms. Stroke injury acutely increased myostatin (3-fold) and lowered brain-derived neurotrophic factor (BDNF) expression (0.6-fold) in the stroke-affected gastrocnemius, as compared to the contralateral one. RAMT attenuated the stroke-induced increase in myostatin and increased BDNF expression in skeletal muscle. Additional RAMT-sensitive myokine targets in skeletal muscle (IL-1ra and IP-10/CXCL10) were identified from a cytokine array. Taken together, outcomes suggest stroke acutely influences signal transduction in hindlimb skeletal muscle. Regimens based on mechanical therapy have the clear potential to protect hindlimb function from such adverse influence.Sen, C. K., Khanna, S., Harris, H., Stewart R., Balch, M., Heigel, M., Teplitsky, S., Gnyawali, S., Rink, C. Robot-assisted mechanical therapy attenuates stroke-induced limb skeletal muscle injury.	[Sen, Chandan K.; Khanna, Savita; Harris, Hallie; Stewart, Richard; Balch, Maria; Heigel, Mallory; Teplitsky, Seth; Gnyawali, Surya; Rink, Cameron] Ohio State Univ, Wexner Med Ctr, Davis Heart & Lung Res Inst, Dept Surg, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Rink, C (corresponding author), Ohio State Univ, Wexner Med Ctr, Davis Heart & Lung Res Inst 505, 473 West 12th Ave, Columbus, OH 43210 USA.	cameron.rink@osumc.edu	Rink, Cameron/AAA-4484-2021; Gnyawali, Surya/AAC-3082-2020; Gnyawali, Surya/AAC-3082-2020	Gnyawali, Surya/0000-0001-8980-4889; Rink, Cameron/0000-0002-3149-3624; Balch, Maria/0000-0003-2011-6345; Gnyawali, Surya/0000-0002-4214-8068; Khanna, Savita/0000-0001-6661-9293; Teplitsky, Seth/0000-0001-9242-1360	U.S.National Institutes of Health,National Institute of Neurological Disorders and Stroke [NS42617, NS085272]; American Heart Association Scientific Development [12SDG11780023]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042617, R01NS085272] Funding Source: NIH RePORTER	U.S.National Institutes of Health,National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); American Heart Association Scientific Development(American Heart Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported in part by U.S.National Institutes of Health, National Institute of Neurological Disorders and Stroke Grants NS42617 (to C.K.S.) and NS085272 (to C.R.,S.K., and A.H.A.), and American Heart Association Scientific Development Grant 12SDG11780023 (to C. R.). The authors declare no conflicts of interest.	Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Ballinger C, 1999, CLIN REHABIL, V13, P301, DOI 10.1191/026921599673198490; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Barrientos RM, 2004, J NEUROIMMUNOL, V155, P119, DOI 10.1016/j.jneuroim.2004.06.009; Barrientos RM, 2003, NEUROSCIENCE, V121, P847, DOI 10.1016/S0306-4522(03)00564-5; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Canu MH, 1996, EUR J APPL PHYSIOL O, V74, P297, DOI 10.1007/s004210050078; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; Choe MA, 2004, NURS RES, V53, P283, DOI 10.1097/00006199-200409000-00001; Clow C, 2010, MOL BIOL CELL, V21, P2182, DOI 10.1091/mbc.E10-02-0154; Coelho HJ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3957958; Crane JD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002882; Crescioli C, 2012, EUR J CELL BIOL, V91, P139, DOI 10.1016/j.ejcb.2011.09.011; DeVries AC, 2001, NEUROSCI BIOBEHAV R, V25, P325, DOI 10.1016/S0149-7634(01)00017-3; Gao L, 2012, GROWTH FACTORS, V30, P167, DOI 10.3109/08977194.2012.678842; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; GOATS GC, 1994, BRIT J SPORT MED, V28, P153, DOI 10.1136/bjsm.28.3.153; Hafer-Macko CE, 2008, J REHABIL RES DEV, V45, P261, DOI 10.1682/JRRD.2007.02.0040; Herson PS, 2011, NEUROMETHODS, V50, P307, DOI 10.1007/978-1-60761-883-6_12; Hiraiwa Y, 2013, CRANIO, V31, P291, DOI 10.1179/crn.2013.31.4.007; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Junhua Z, 2009, STROKE, V40, P2797, DOI 10.1161/STROKEAHA.109.555227; Khanna S, 2005, STROKE, V36, pE144, DOI 10.1161/01.STR.0000181082.70763.22; Khanna S, 2013, J CEREBR BLOOD F MET, V33, P1197, DOI 10.1038/jcbfm.2013.68; Kollen BJ, 2009, STROKE, V40, pE89, DOI 10.1161/STROKEAHA.108.533828; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Kwakkel G, 2002, PHYS THER, V82, P432, DOI 10.1093/ptj/82.5.432; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lennon S, 2001, DISABIL REHABIL, V23, P254; Li L, 2013, BRAIN INJURY, V27, P408, DOI 10.3109/02699052.2012.750750; Liu YH, 2016, INT J NEUROSCI, V126, P168, DOI 10.3109/00207454.2014.998759; Long RP, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8524560; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Manceau M, 2008, GENE DEV, V22, P668, DOI 10.1101/gad.454408; McIlwrath SL, 2005, NEUROSCIENCE, V131, P499, DOI 10.1016/j.neuroscience.2004.11.030; Miller EL, 2010, STROKE, V41, P2402, DOI 10.1161/STR.0b013e3181e7512b; Mori H, 2004, MED SCI MONITOR, V10, pCR173; Pedersen BK, 2012, NAT REV ENDOCRINOL, V8, P457, DOI 10.1038/nrendo.2012.49; Pomeroy VM, 2000, LANCET, V355, P836, DOI 10.1016/S0140-6736(99)08143-X; Rink C, 2011, J CEREBR BLOOD F MET, V31, P2218, DOI 10.1038/jcbfm.2011.85; Rink C, 2010, J CEREBR BLOOD F MET, V30, P1275, DOI 10.1038/jcbfm.2010.7; Ryan A. S., 2011, J AM HEART ASSOC, V42, P416; Salter K, 2006, J REHABIL MED, V38, P113, DOI 10.1080/16501970500314350; Sefton JM, 2010, J ALTERN COMPLEM MED, V16, P723, DOI 10.1089/acm.2009.0441; Shoemaker JK, 1997, MED SCI SPORT EXER, V29, P610, DOI 10.1097/00005768-199705000-00004; Stinear C, 2013, STROKE, V44, P2039, DOI 10.1161/STROKEAHA.113.000968; Trayhurn Paul, 2011, Archives of Physiology and Biochemistry, V117, P47, DOI 10.3109/13813455.2010.535835; Wu JJ, 2014, COMPLEMENT THER MED, V22, P456, DOI 10.1016/j.ctim.2014.04.001; Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343; Zhu CL, 2010, J CEREBR BLOOD F MET, V30, P1017, DOI 10.1038/jcbfm.2009.274	50	11	11	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2017	31	3					927	936		10.1096/fj.201600437R	http://dx.doi.org/10.1096/fj.201600437R			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EM9ZX	27895105	Green Published			2023-01-03	WOS:000395671200010
J	Kapurubandara, S; Melov, SJ; Shalou, ER; Mukerji, M; Yim, S; Rao, U; Battikhi, Z; Karunaratne, N; Nayyar, R; Alahakoon, TI				Kapurubandara, Supuni; Melov, Sarah J.; Shalou, Evangeline R.; Mukerji, Monika; Yim, Stephen; Rao, Ujvala; Battikhi, Zain; Karunaratne, Nirusha; Nayyar, Roshini; Alahakoon, Thushari I.			A perinatal review of singleton stillbirths in an Australian metropolitan tertiary centre	PLOS ONE			English	Review							RISK; PREGNANCY; DEATHS; COHORT; RATES	It is estimated that everyday 7000 women worldwide have their pregnancy end with a stillbirth, however, research and data collection on stillbirth remains underfunded. This stillbirth case series audit investigates an apparent rise in stillbirths at a Sydney tertiary referral hospital in Australia. A retrospective case series of singleton stillbirths from 2005-2010 was conducted at Westmead Hospital. Stillbirth was defined as per the Perinatal Society of Australia and New Zealand classification as a death of a baby before or during birth, from the 20th week of pregnancy onwards, or a birth weight of 400 grams or more if gestational age is unknown. A total of 215 singleton stillbirths were identified in a cohort of 28 109, a rate of 7.6 per 1000 singleton births. There was a significant increase in annual stillbirth rate at our institution; the rate exceeded both Australian national and state singleton stillbirth rates. After pregnancy terminations over 20 weeks were excluded from the data, there was no statistical change in the stillbirth rate over time. Congenital anomalies (27%) and unexplained antepartum death (15%) remained as major causes; fetal growth restriction (17%) was also identified as an increasingly important cause, particularly in preterm gestations. Termination of pregnancy after 20 weeks was found to be the cause of rising stillbirth rate at our institution. Local and national data collection on stillbirth should be standardised and should include differentiation of termination of pregnancy as a separate entity so as to accurately assess stillbirth to target appropriate research and resource allocation.	[Kapurubandara, Supuni; Melov, Sarah J.; Shalou, Evangeline R.; Mukerji, Monika; Yim, Stephen; Rao, Ujvala; Nayyar, Roshini; Alahakoon, Thushari I.] Westmead Hosp, Westmead Inst Maternal & Fetal Med, Sydney, NSW, Australia; [Kapurubandara, Supuni; Alahakoon, Thushari I.] Univ Sydney, Sydney, NSW, Australia; [Battikhi, Zain] Liverpool Hosp, Sydney, NSW, Australia; [Karunaratne, Nirusha] Nepean Hosp, Sydney, NSW, Australia	University of Sydney; University of Sydney; Liverpool Hospital; Nepean Hospital	Melov, SJ (corresponding author), Westmead Hosp, Westmead Inst Maternal & Fetal Med, Sydney, NSW, Australia.	Sarah.Melov@health.nsw.gov.au	Melov, Sarah J/AFK-4262-2022	Melov, Sarah J/0000-0002-7569-1016				Akseer N, 2015, INT J GYNECOL OBSTET, V131, pS43, DOI 10.1016/j.ijgo.2015.03.017; [Anonymous], 2012, PERINATAL STAT SERIE; [Anonymous], CLIN PRACT GUID PER; Australian Institute of Health and Welfare, 2015, PERINATAL STAT SERIE, V31; Bartsch E, 2015, J OBSTET GYNAECOL CA, V37, P314, DOI 10.1016/S1701-2163(15)30281-4; Bhutto ZA, 2011, LANCET, V377, P1523, DOI 10.1016/S0140-6736(10)62269-6; Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2; Bythell M, 2008, BJOG-INT J OBSTET GY, V115, P664, DOI 10.1111/j.1471-0528.2008.01668.x; (CMACE) C. f.M.a.C.E, 2011, PER MORT 2009 UK; Cousens S, 2011, LANCET, V377, P1319, DOI 10.1016/S0140-6736(10)62310-0; Craig ED, 2004, AUST NZ J OBSTET GYN, V44, P441, DOI 10.1111/j.1479-828X.2004.00284.x; de Bernis L, 2016, LANCET, V387, P703, DOI 10.1016/S0140-6736(15)00954-X; Drysdale H, 2012, MED J AUSTRALIA, V197, P278, DOI 10.5694/mja12.10125; Farrant BM, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0904-1; Figueras F, 2011, AM J OBSTET GYNECOL, V204, P288, DOI 10.1016/j.ajog.2010.08.055; Flenady V, 2010, AUST NZ J OBSTET GYN, V50, P138, DOI 10.1111/j.1479-828X.2009.01125.x; Flenady V, 2016, LANCET, V387, P691, DOI 10.1016/S0140-6736(15)01020-X; Flenady V, 2011, LANCET, V377, P1703, DOI 10.1016/S0140-6736(11)60064-0; Froen JF, 2009, BMC PREGNANCY CHILDB, V9, P1; Gardosi J., 2013, BMJ-BRIT MED J, V346, P346; Gynecologists RCOG, 2010, GREEN TOP GUIDELINE, V55, P1; Hamamy H, 2012, J COMMUN GENET, V3, P185, DOI 10.1007/s12687-011-0072-y; Heazell AEP, 2009, J OBSTET GYNAECOL, V29, P225, DOI 10.1080/01443610802716042; Hilder L, 2014, PERINATAL STAT SERIE, V30; Horton R, 2016, LANCET, V387, P418, DOI 10.1016/S0140-6736(16)00159-8; Joseph KS, 2013, CAN MED ASSOC J, V185, pE345, DOI 10.1503/cmaj.121372; Kapurubandara S, 2016, AUST NZ J OBSTET GYN; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; Lawn JE, 2011, LANCET, V377, P1448, DOI 10.1016/S0140-6736(10)62187-3; LEISHER SH, 2016, BMC PREGNANCY CHILDB, V16, DOI DOI 10.1186/S12884-016-; Penn N, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0404-0; Sheridan E, 2013, LANCET, V382, P1350, DOI 10.1016/S0140-6736(13)61132-0; Silver RM, 2007, AM J OBSTET GYNECOL, V196, P433, DOI 10.1016/j.ajog.2006.11.041; Smith GCS, 2007, LANCET, V370, P1715, DOI 10.1016/S0140-6736(07)61723-1; Stacey T, 2012, AUST NZ J OBSTET GYN, V52, P242, DOI 10.1111/j.1479-828X.2011.01406.x; Stoltenberg C, 1999, AM J PUBLIC HEALTH, V89, P517, DOI 10.2105/AJPH.89.4.517; Treacy A, 2006, Ir Med J, V99, P22; Tucker A, 2010, ARCH GYNECOL OBSTET, V281, P613, DOI 10.1007/s00404-009-1152-7; Western Sydney Local Health District (WSLHD), 2013, W SYDN LOC HLTH DIST; WHO, 2014, EV NEWB ACT PLAN END	40	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0171829	10.1371/journal.pone.0171829	http://dx.doi.org/10.1371/journal.pone.0171829			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192505	gold, Green Published, Green Submitted			2023-01-03	WOS:000394423800044
J	Zhao, HL; Li, X; Zhao, TT; Zhang, HJ; Yan, MH; Dong, X; Chen, PM; Ma, L; Li, P				Zhao, Hailing; Li, Xin; Zhao, Tingting; Zhang, Haojun; Yan, Meihua; Dong, Xi; Chen, Pengmin; Ma, Liang; Li, Ping			Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression	PLOS ONE			English	Article							GROWTH; MECHANISMS	The Chinese herbal granule Tangshen Formula (TSF) has been proven to decrease proteinuria and improve estimated glomerular filtration rate (eGFR) in diabetic kidney disease (DKD) patients. However, the underlying mechanism of TSF on treatment of diabetic nephropathy (DN) remains unclear. The present study aimed to identify the therapeutic target of TSF in diabetic renal injuries through microarray-based gene expression profiling and establish its underlying mechanism. TSF treatment significantly attenuated diabetic renal injuries by inhibiting urinary excretion of albumin and renal histological injuries in diabetic (db/db) mice. We found that PLZF might be the molecular target of TSF in DN. In vivo, the db/db mice showed a significant increase in renal protein expression of PLZF and collagen III, and decrease in renal autophagy levels (downregulated LC3 II and upregulated p62/SQSTM1) compared to db/m mice. The application of TSF resulted in the downregulation of PLZF and collagen III and upregulation of autophagy level in the kidneys of db/db mice. In vitro, TSF reduced high glucose (HG)-induced cell proliferation for NRK52E cells. Further studies indicated that the exposure of NRK52E cells to high levels of glucose resulted in the downregulation of cellular autophagy and upregulation of collagen III protein, which was reversed by TSF treatment by decreasing PLZF expression. In conclusion, TSF might have induced cellular autophagy by inhibiting PLZF expression, which in turn resulted in an increase in autophagic degradation of collagen III that attenuated diabetic renal injuries.	[Zhao, Hailing; Li, Xin; Zhao, Tingting; Zhang, Haojun; Yan, Meihua; Dong, Xi; Chen, Pengmin; Ma, Liang; Li, Ping] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China; [Ma, Liang] China Japan Friendship Hosp, Clin Lab, Beijing, Peoples R China	China-Japan Friendship Hospital; China-Japan Friendship Hospital	Li, P (corresponding author), China Japan Friendship Hosp, Inst Clin Med Sci, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China.	lp8675@163.com; lp8675@163.com			International Cooperation and Exchange of the National Natural Science Foundation of China [81620108031]; International Collaboration in Science and Technology Grant, China [2011DFA31860]; National Natural Science Foundation of China [81503418, 81473526]	International Cooperation and Exchange of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Collaboration in Science and Technology Grant, China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from a Project of International Cooperation and Exchange of the National Natural Science Foundation of China (Grant No. 81620108031 to PL), http://www.nsfc.gov.cn/; a Project of International Collaboration in Science and Technology Grant, China (Grant No. 2011DFA31860 to PL), http://www.istcp.org.cn/; and the National Natural Science Foundation of China (Grant No. 81503418 to HLZ, No. 81473526 to TTZ), http://www.nsfc.gov.cn/.	Currie G, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0798-3; Gao JR, 2016, J ETHNOPHARMACOL; Hu C, 2015, CURR MED CHEM, V22, P2858, DOI 10.2174/0929867322666150625095407; Jia X, 2016, J DIABETES; Jones C, 2013, INT J CANCER, V133, P58, DOI 10.1002/ijc.28008; Kong Q, 2016, INT J MOL MED, V38, P1715, DOI 10.3892/ijmm.2016.2799; Li P, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/1802036; Li P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126027; Liu N, 2016, KIDNEY DIS-BASEL, V2, P37, DOI 10.1159/000444841; Liu SL, 2016, ARCH BIOCHEM BIOPHYS, V590, P37, DOI 10.1016/j.abb.2015.11.001; Lu XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117400; Mao AP, 2016, P NATL ACAD SCI USA, V113, P7602, DOI 10.1073/pnas.1601504113; Peng KY, 2011, METABOLISM, V60, P888, DOI 10.1016/j.metabol.2010.08.009; Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214; Pushpakumar SB, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.63; Sun GD, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/5749857; Suzuki H, 2017, CURR OPIN STRUC BIOL, V43, P10, DOI 10.1016/j.sbi.2016.09.010; Vallon V, 2013, AM J PHYSIOL-RENAL, V304, pF156, DOI 10.1152/ajprenal.00409.2012; Wang LL, 2015, MOL BIOSYST, V11, P3033, DOI 10.1039/c5mb00379b; Wang XT, 2013, FASEB J, V27, P4194, DOI 10.1096/fj.13-229070; Xiang L, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/1064924; Xu Y, 2016, PEERJ, V4, DOI 10.7717/peerj.1888; Zhang T, 2015, ELIFE, V4, DOI 10.7554/eLife.06734; Zhao TT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147693	24	13	17	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2017	12	2							e0171475	10.1371/journal.pone.0171475	http://dx.doi.org/10.1371/journal.pone.0171475			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EK9GJ	28182710	Green Published, Green Submitted, gold			2023-01-03	WOS:000394231800063
J	Boerner, B; Tini, GM; Fachinger, P; Graber, SM; Irani, S				Boerner, Bettina; Tini, Gabrielo M.; Fachinger, Patrick; Graber, Sereina M.; Irani, Sarosh			Significant improvement of olfactory performance in sleep apnea patients after three months of nasal CPAP therapy - Observational study and randomized trial	PLOS ONE			English	Article							ODOR DISCRIMINATION; IDENTIFICATION; CONSEQUENCES; DISORDERS	Objectives The olfactory function highly impacts quality of life (QoL). Continuous positive airway pressure is an effective treatment for obstructive sleep apnea (OSA) and is often applied by nasal masks (nCPAP). The influence of nCPAP on the olfactory performance of OSA patients is unknown. The aim of this study was to assess the sense of smell before initiation of nCPAP and after three months treatment, in moderate and severe OSA patients. Methods The sense of smell was assessed in 35 patients suffering from daytime sleepiness and moderate to severe OSA (apnea/hypopnea index >= 15/h), with the aid of a validated test battery (Sniffin' Sticks) before initiation of nCPAP therapy and after three months of treatment. Additionally, adherent subjects were included in a double-blind randomized three weeks CPAP-withdrawal trial (sub-therapeutic CPAP pressure). Results Twenty five of the 35 patients used the nCPAP therapy for more than four hours per night, and for more than 70% of nights (adherent group). The olfactory performance of these patients improved significantly (p = 0.007) after three months of nCPAP therapy. When considering the entire group of patients, olfaction also improved significantly (p = 0.001). In the randomized phase the sense of smell of six patients deteriorated under sub-therapeutic CPAP pressure (p = 0.046) whereas five patients in the maintenance CPAP group showed no significant difference (p = 0.501). Conclusions Olfactory performance improved significantly after three months of nCPAP therapy in patients suffering from moderate and severe OSA. It seems that this effect of nCPAP is reversible under sub-therapeutic CPAP pressure.	[Boerner, Bettina; Tini, Gabrielo M.; Fachinger, Patrick; Irani, Sarosh] Cantonal Hosp Aarau, Clin Pulm & Sleep Med, Aarau, Switzerland; [Graber, Sereina M.] Univ Zurich Irchel, Anthropol Inst & Museum, Zurich, Switzerland	Kantonsspital Aarau AG (KSA); University of Zurich	Irani, S (corresponding author), Cantonal Hosp Aarau, Clin Pulm & Sleep Med, Aarau, Switzerland.	siran@gmx.ch	Irani, Sarosh/AAO-6911-2020	Irani, Sarosh/0000-0002-7667-9748	Research Council of the Cantonal Hospital Aarau, Switzerland	Research Council of the Cantonal Hospital Aarau, Switzerland	The Research Funding from the Research Council of the Cantonal Hospital Aarau, Switzerland provided financial support in the form of funding of the salary of the study nurse (60'000 Euro).	Almendros I, 2008, SLEEP, V31, P127, DOI 10.1093/sleep/31.1.127; Antic NA, 2011, SLEEP, V34, P111, DOI 10.1093/sleep/34.1.111; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; Blomqvist EH, 2004, RHINOLOGY, V42, P189; Campos-Rodriguez F, 2005, CHEST, V128, P624, DOI 10.1378/chest.128.2.624; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Fu D, 2015, EUR ARCH OTO-RHINO-L, V272, P357, DOI 10.1007/s00405-014-3096-1; Geissler K, 2014, EUR ARCH OTO-RHINO-L, V271, P1557, DOI 10.1007/s00405-013-2747-y; Gelardi M, 2012, SLEEP MED, V13, P859, DOI 10.1016/j.sleep.2012.04.004; Giles TL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001106.pub2; Hummel T, 2005, ACTA OTO-LARYNGOL, V125, P116, DOI 10.1080/00016480410022787; Hummel T, 2007, EUR ARCH OTO-RHINO-L, V264, P237, DOI 10.1007/s00405-006-0173-0; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Irani S, 2010, J HEART LUNG TRANSPL, V29, P265, DOI 10.1016/j.healun.2009.07.016; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; LEHR R, 1992, STAT MED, V11, P1099, DOI 10.1002/sim.4780110811; Randhawa PS, 2016, CLIN OTOLARYNGOL, V41, P15, DOI 10.1111/coa.12463; Ruehland WR, 2009, SLEEP, V32, P150, DOI 10.1093/sleep/32.2.150; Salihoglu M, 2014, LARYNGOSCOPE, V124, P2190, DOI 10.1002/lary.24565; Shadan FF, 2008, RHINOLOGY, V46, P347; Verstraeten E, 2007, CURR NEUROL NEUROSCI, V7, P161, DOI 10.1007/s11910-007-0012-8; Weaver TE, 2007, SLEEP, V30, P711, DOI 10.1093/sleep/30.6.711; Wolfensberger M, 2000, ACTA OTO-LARYNGOL, V120, P303, DOI 10.1080/000164800750001134	23	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171087	10.1371/journal.pone.0171087	http://dx.doi.org/10.1371/journal.pone.0171087			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DG	28158212	gold, Green Submitted, Green Published			2023-01-03	WOS:000396161700028
J	Pitcher, B; Khoja, L; Hamilton, RJ; Abdallah, K; Pintilie, M; Joshua, AM				Pitcher, Bethany; Khoja, Leila; Hamilton, Robert J.; Abdallah, Kald; Pintilie, Melania; Joshua, Anthony M.			Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)	PLOS ONE			English	Article							NEUTROPHIL-LYMPHOCYTE RATIO; POPULATION-BASED COHORT; DOWN-REGULATION; SURVIVAL; METFORMIN; CHEMOTHERAPY; TRIALS; CELLS; NOMOGRAM; WARFARIN	Background Prognostic models in metastatic castrate resistant prostate cancer (mCRPC) may have clinical utility. Using data from PDS, we aimed to 1) validate a contemporary prognostic model (Templeton et al., 2014) 2) evaluate prognostic impact of concomitant medications and PSA decrease 3) evaluate factors associated with docetaxel toxicity. Methods We accessed data on 2,449 mCRPC patients in PDS. The existing model was validated with a continuous risk score, time-dependent receiver operating characteristic (ROC) curves, and corresponding time-dependent Area under the Curve (tAUC). The prognostic effects of concomitant medications and PSA response were assessed by Cox proportional hazards models. One year tAUC was calculated for multivariable prognostic model optimized to our data. Conditional logistic regression models were used to assess associations with grade 3/4 adverse events (G3/4 AE) at baseline and after cycle 1 of treatment. Results Despite limitations of the PDS data set, the existing model was validated; one year AUC, was 0.68 (95% CI 95% CI,.66 to.71) to 0.78 (95% CI,.74 to.81) depending on the subset of datasets used. A new model was constructed with an AUC of .74 (.72 to .77). Concomitant medications low molecular weight heparin and warfarin were associated with poorer survival, Metformin and Cox2 inhibitors were associated with better outcome. PSA response was associated with survival, the effect of which was greatest early in follow-up. Age was associated with baseline risk of G3/4 AE. The odds of experiencing G3/4 AE later on in treatment were significantly greater for subjects who experienced a G3/4 AE in their first cycle (OR 3.53, 95% CI 2.53-4.91, p<.0001). Conclusion Despite heterogeneous data collection protocols, PDS provides access to large datasets for novel outcomes analysis. In this paper, we demonstrate its utility for validating existing models and novel model generation including the utility of concomitant medications in outcome analyses, as well as the effect of PSA response on survival and toxicity prediction.	[Pitcher, Bethany; Pintilie, Melania] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada; [Khoja, Leila; Joshua, Anthony M.] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada; [Hamilton, Robert J.] Univ Hlth Network, Dept Urol Oncol, Toronto, ON, Canada; [Abdallah, Kald] Project Data Sphere LLC, Cary, NC USA; [Joshua, Anthony M.] St Vincents Hosp, Kinghorn Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; St Vincents Hospital Sydney	Joshua, AM (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada.	Anthony.joshua@svha.org.au		Khoja, Leila/0000-0002-9111-3080; Joshua, Anthony/0000-0001-5159-4580	Princess Margaret Cancer Foundation Hold'em for Life Prostate Cancer Research Fund; Stanley Tessis Research Fund	Princess Margaret Cancer Foundation Hold'em for Life Prostate Cancer Research Fund; Stanley Tessis Research Fund	Work presented in this manuscript was supported by the Princess Margaret Cancer Foundation Hold'em for Life Prostate Cancer Research Fund and Stanley Tessis Research Fund. LK is an employee of Astrazeneca plc. The specific roles of these authors are articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertsen PC, 2015, CURR OPIN UROL, V25, P232, DOI 10.1097/MOU.0000000000000157; Armstrong AJ, 2007, CLIN CANCER RES, V13, P6396, DOI 10.1158/1078-0432.CCR-07-1036; Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024; Bieniek J, 2014, PROSTATE, V74, P999, DOI 10.1002/pros.22815; Bishoff JT, 2014, J UROLOGY, V192, P409, DOI 10.1016/j.juro.2014.02.003; Briganti A, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2014.11.018; Demir U, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-52; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Francini E, 2014, TUMOR BIOL, V35, P10601, DOI 10.1007/s13277-014-2559-8; Halabi S, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.5002; Halabi S, 2014, J CLIN ONCOL, V32, P671, DOI 10.1200/JCO.2013.52.3696; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Inoue D, 2015, JPN J CLIN ONCOL, V45, P61, DOI 10.1093/jjco/hyu159; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; Jendrossek V, 2013, CANCER LETT, V332, P313, DOI 10.1016/j.canlet.2011.01.012; Kato H, 2015, BIOCHEM BIOPH RES CO, V461, P115, DOI 10.1016/j.bbrc.2015.03.178; Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690; Kumar R, 2015, BRIT J CANCER, V112, P1157, DOI 10.1038/bjc.2015.67; Loubiere C, 2015, ONCOTARGET, V6, P15652, DOI 10.18632/oncotarget.3404; Manzano JGM, 2014, J CLIN ONCOL, V32, P3527, DOI 10.1200/JCO.2014.55.3131; O'Rorke MA, 2015, CANCER CAUSE CONTROL, V26, P355, DOI 10.1007/s10552-014-0511-2; Omlin A, 2013, EUR UROL, V64, P300, DOI 10.1016/j.eururo.2012.12.029; Park JC, 2015, CLIN GENITOURIN CANC, V13, P32, DOI 10.1016/j.clgc.2014.04.008; Patrikidou A, 2014, PROSTATE CANCER P D, V17, P348, DOI 10.1038/pcan.2014.35; Rothermundt C, 2014, EUR UROL, V66, P468, DOI 10.1016/j.eururo.2013.12.057; Seah JA, 2015, CLIN GENITOURIN CANC, DOI [10.1016/j.clgc.2014.04.008, DOI 10.1016/J.CLGC.2014.04.008]; Smaletz O, 2002, J CLIN ONCOL, V20, P3972, DOI 10.1200/JCO.2002.11.021; Sonpavde G, 2014, CLIN GENITOURIN CANC, V12, P317, DOI 10.1016/j.clgc.2014.03.005; Stopsack KH, 2016, WORLD J UROL; Tagalakis V, 2013, CANCER CAUSE CONTROL, V24, P1079, DOI 10.1007/s10552-013-0185-1; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Templeton AJ, 2014, CANCER-AM CANCER SOC, V120, P3346, DOI 10.1002/cncr.28890; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242	33	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2017	12	2							e0170544	10.1371/journal.pone.0170544	http://dx.doi.org/10.1371/journal.pone.0170544			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DB	28151974	gold, Green Published, Green Submitted			2023-01-03	WOS:000396161200026
J	Chiari, P; Forni, C; Guberti, M; Gazineo, D; Ronzoni, S; D'Alessandro, F				Chiari, Paolo; Forni, Cristiana; Guberti, Monica; Gazineo, Domenica; Ronzoni, Sabrina; D'Alessandro, Fabio			Predictive Factors for Pressure Ulcers in an Older Adult Population Hospitalized for Hip Fractures: A Prognostic Cohort Study	PLOS ONE			English	Article							RISK-FACTORS; FUNCTIONAL OUTCOMES; CARE; PREVENTION; MANAGEMENT	Background Older adult patients with fragility hip fractures constitute a population at high risk for complications, in particular pressure ulcers. The aim was to evaluate the incidence of pressure ulcers and potential predictive factors. Methods and Findings A prospective multicentric prognostic cohort study in orthopedic wards in three Italian public hospitals. Participants were all consecutive patients 65 years of age or older diagnosed with a fragility hip fracture. Outcomes were incidence of pressure ulcers. The exposure variables were grouped into three macro areas in order to facilitate reading: "intrinsic" variables, "extrinsic" variables and variables linked to the organization of patient care. One thousand eighty-three older adult patients with fragility hip fractures were enrolled from October 1st, 2013 to January 31st, 2015, and pressure ulcers developed in 22.7%. At multivariate analysis, the following were found to be risk factors: age> 80 years (odds ratio (OR) 1.03; p = 0.015), the length of time a urinary catheter was used (OR 1.013; p<0.001), the length of time pain was present (OR 1.008; p = 0.008), the absence of side rails on the bed (OR 1.668; p = 0.026) and the use of a foam position valve (OR 1.025; p<0.001). Instead, the protective factors were the presence of a caregiver for at least half a day daily (OR 0.994; p = 0.012) and the number of positionings during the postoperative period (OR 0.897; p = 0.008). Conclusions The study allowed the identification of the patients most at risk for developing pressure ulcers, and the construction of a pragmatic predictive model using significant risk or protective factors in order to reduce the number of pressure ulcers.	[Chiari, Paolo] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy; [Forni, Cristiana; D'Alessandro, Fabio] Ist Ortoped Rizzoli, Ctr Ric Professioni Sanit, Bologna, Italy; [Guberti, Monica; Ronzoni, Sabrina] Arcispedale Santa Maria Nuova IRCCS, Ric & EBP, Reggio Emilia, Italy; [Gazineo, Domenica] Univ Bologna, Ctr EBN, Azienda Osped, Bologna, Italy	University of Bologna; IRCCS Istituto Ortopedico Rizzoli; IRCCS Arcispedale S. Maria Nuova; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Chiari, P (corresponding author), Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy.	paolo.chiari@unibo.it	D'Alessandro, Fabio/E-5785-2019	D'Alessandro, Fabio/0000-0002-0867-2819				Baumgarten M, 2003, WOUND REPAIR REGEN, V11, P96, DOI 10.1046/j.1524-475X.2003.11204.x; Baumgarten M, 2012, J AM GERIATR SOC, V60, P277, DOI 10.1111/j.1532-5415.2011.03849.x; Black Joyce, 2007, Urol Nurs, V27, P144; Butler M, 2011, J BONE JOINT SURG AM, V93A, P1104, DOI [10.2106/JBJSJ.00296, 10.2106/JBJS.J.00296]; Chen Q, 2001, J CLIN EPIDEMIOL, V54, P334, DOI 10.1016/S0895-4356(00)00333-4; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; De Brauwer I, 2012, AGING CLIN EXP RES, V24, P62, DOI 10.1007/BF03325355; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Fogerty MD, 2008, WOUND REPAIR REGEN, V16, P11, DOI 10.1111/j.1524-475X.2007.00327.x; Fukui N, 2012, J ORTHOP TRAUMA, V26, P163, DOI 10.1097/BOT.0b013e31821e1261; Gumieiro DN, 2012, NUTRITION, V28, P874, DOI 10.1016/j.nut.2011.11.010; Gunningberg L, 2001, INT J QUAL HEALTH C, V13, P399, DOI 10.1093/intqhc/13.5.399; Haleem S, 2008, INJURY, V39, P219, DOI 10.1016/j.injury.2007.08.030; Houwing RH, 2004, ACTA ORTHOP SCAND, V75, P390, DOI 10.1080/00016470410001132-1; Hung WW, 2012, JAMA-J AM MED ASSOC, V307, P2185, DOI 10.1001/jama.2012.4842; Kim SM, 2012, BONE, V50, P1343, DOI 10.1016/j.bone.2012.02.633; Ksycki MF, 2009, SURG CLIN N AM, V89, P475, DOI 10.1016/j.suc.2008.09.012; Lindholm C, 2008, INT WOUND J, V5, P315, DOI 10.1111/j.1742-481X.2008.00452.x; Lozano-Montoya I, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2015.12.091; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Pancorbo-Hidalgo PL, 2006, J ADV NURS, V54, P94, DOI 10.1111/j.1365-2648.2006.03794.x; Patorno E, 2014, DIABETOLOGIA, V57, P2237, DOI 10.1007/s00125-014-3364-z; Piscitellil P, 2011, CLIN CASES MINER BON, V8, P29; Siu AL, 2006, MED CARE, V44, P862, DOI 10.1097/01.mlr.0000223738.34872.6a; Stansby G, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2592	25	31	33	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2017	12	1							e0169909	10.1371/journal.pone.0169909	http://dx.doi.org/10.1371/journal.pone.0169909			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH5WO	28068425	Green Published, gold, Green Submitted			2023-01-03	WOS:000391843900078
J	Westerlind, E; Persson, HC; Sunnerhagen, KS				Westerlind, Emma; Persson, Hanna C.; Sunnerhagen, Katharina S.			Return to Work after a Stroke in Working Age Persons; A Six-Year Follow Up	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SICK LEAVE; HEALTH; SCALE; DISABILITY; BEHAVIOR; PEOPLE; EQ-5D; CARE	Objectives Stroke is one of the most common and resource intensive diseases for society. Stroke in the working age population is increasing in different parts of the world. An incomplete return to work (RTW) after sick leave post stroke entails negative consequences for the affected person and an economical burden for society. The aim of this study was to explore the RTW rate and factors associated with RTW in a six-year follow up post stroke. Methods Data from 174 persons 63 years or younger, with first ever stroke in 2009-2010 in Gothenburg were analyzed. Baseline characteristics were collected through medical records and the Swedish Health Insurance Office provided information on sick leave up to 6 years post stroke. Time-to-event was presented and cox regression as well as logistic regression were used to analyze risk factors for no-RTW. Results The RTW rate was 74.7%, at the end of follow up. Participants continued to RTW until just over 3 years post stroke. Dependency at discharge (in the modified Rankin Scale) and sick leave prior to the stroke were significant risk factors for no-RTW after 1 year with odds ratio 4.595 and 3.585, respectively. The same factors were significant in time-to-event within six years post stroke with hazard ratio 2.651 and 1.929, respectively. Conclusions RTW after a stroke is incomplete, however RTW is possible over a longer period of time than previously thought. More severe disability at discharge from hospital and sick leave prior to the stroke were shown to be risk factors for no-RTW. This knowledge can contribute to more individualized vocational rehabilitation.	[Westerlind, Emma; Persson, Hanna C.; Sunnerhagen, Katharina S.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden	University of Gothenburg	Westerlind, E (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden.	westerlind.emma@gmail.com	Sunnerhagen, Katharina Stibrant/AAE-2405-2020; Westerlind, Emma/AAN-7227-2021	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400; 	Swedish Heart and Lung Foundation; Swedish Brain Foundation	Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Brain Foundation	This study was funded in part by the Swedish Heart and Lung Foundation and the Swedish Brain Foundation.	Altman DG, 1991, PRACTICAL STAT MED R; Anema JR, 2009, J OCCUP REHABIL, V19, P419, DOI 10.1007/s10926-009-9202-3; Ayis SA, 2013, J NEUROL NEUROSUR PS, V84, P604, DOI 10.1136/jnnp-2012-303525; Bonner B, 2016, EUR J NEUROL, V23, P548, DOI 10.1111/ene.12887; Burstrom K, 2014, QUAL LIFE RES, V23, P431, DOI 10.1007/s11136-013-0496-4; Busch MA, 2009, J NEUROL NEUROSUR PS, V80, P888, DOI 10.1136/jnnp.2008.163295; Chang WH, 2016, J REHABIL MED; Cioncoloni D, 2012, NEUROREHABILITATION, V30, P315, DOI 10.3233/NRE-2012-0761; Clayton S, 2012, EUR J PUBLIC HEALTH, V22, P434, DOI 10.1093/eurpub/ckr101; Cumming TB, 2010, CEREBROVASC DIS, V30, P7, DOI 10.1159/000313438; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Endo M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009682; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Ghatnekar O, 2014, INT J TECHNOL ASSESS, V30, P203, DOI 10.1017/S0266462314000075; Hackett ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041795; Hannerz H, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000180; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Larsen LP, 2016, J REHABIL MED, V48, P339, DOI 10.2340/16501977-2061; Larsson J, 2010, SCAND J PUBLIC HEALT, V38, P541, DOI 10.1177/1403494810371143; Maruthappu M, 2015, INT J STROKE, V10, P364, DOI 10.1111/ijs.12408; Medin J, 2007, BRAIN INJURY, V21, P457, DOI 10.1080/02699050701317643; Mishra NK, 2010, STROKE, V41, P2612, DOI 10.1161/STROKEAHA.110.589317; Nielsen MBD, 2015, EUR J PUBLIC HEALTH, V25, P96, DOI 10.1093/eurpub/cku016; Persson HC, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-162; Peters GO, 2013, DISABIL REHABIL, V35, P455, DOI 10.3109/09638288.2012.697251; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Riks-Stroke (the Swedish Stroke Register), 2015, ETT EFT STROK; Roding J, 2010, J REHABIL MED, V42, P155, DOI 10.2340/16501977-0497; Rosengren A, 2013, STROKE, V44, P2388, DOI 10.1161/STROKEAHA.113.001170; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Stam M, 2013, WORK, V46, P207, DOI 10.3233/WOR-131747; Tanaka H, 2011, ARCH PHYS MED REHAB, V92, P743, DOI 10.1016/j.apmr.2010.12.009; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Vikholmen K, 2015, ACTA NEUROL SCAND, V132, P329, DOI 10.1111/ane.12404; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang YC, 2014, WORK, V47, P553, DOI 10.3233/WOR-131627; Wolfenden B, 2009, INT J REHABIL RES, V32, P93, DOI 10.1097/MRR.0b013e328325a358; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516; Young FB, 2005, STROKE, V36, P2187, DOI 10.1161/01.STR.0000181089.41324.70	42	55	55	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2017	12	1							e0169759	10.1371/journal.pone.0169759	http://dx.doi.org/10.1371/journal.pone.0169759			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH3AX	28061507	Green Published, Green Submitted, gold			2023-01-03	WOS:000391641500135
J	Low, LL; Tan, SY; Ng, MJM; Tay, WY; Ng, LB; Balasubramaniam, K; Towle, RM; Lee, KH				Low, Lian Leng; Tan, Shu Yun; Ng, Matthew Joo Ming; Tay, Wei Yi; Ng, Lee Beng; Balasubramaniam, Kanchana; Towle, Rachel Marie; Lee, Kheng Hock			Applying the Integrated Practice Unit Concept to a Modified Virtual Ward Model of Care for Patients at Highest Risk of Readmission: A Randomized Controlled Trial	PLOS ONE			English	Article							REHOSPITALIZATION; INTERVENTION; TRANSITIONS; PROGRAM	Background Emerging evidence from the virtual ward care model showed that multidisciplinary case management are inadequate to reduce readmissions or death for high risk patients. There is consensus that interventions should encompass both pre-hospital discharge and post-discharge transitional care to be effective. Integrated practice units (IPU) had been proposed as an approach of restructuring the organization and work processes of multidisciplinary teams to achieve value in healthcare. Our primary objective is to evaluate if the novel application of the IPU concept to organize a modified virtual ward model incorporating pre-hospital discharge transitional care can reduce readmissions of patients at highest risk for readmission. Methods We conducted an open label, assessor blinded randomized controlled trial on patients with one or more unscheduled readmissions in the prior 90 days and LACE score >= 10. 840 patients were randomized in 1:1 ratio and blocks of 6 to the intervention program (n = 420) or control (n = 420). Allocation concealment was effected via an off-site telephone service maintained by a hospital administrator. Intervention patients received discharge planning, medication reconciliation, coaching on self-management of chronic diseases using standardized action plans and an individualized care plan complete with written discharge instructions, appointments schedule, medication changes and the contact information of the outpatient VW nurse before discharge. At discharge, care is handed over to the outpatient VW team. Patients were closely monitored in the VW for three months that included a telephone review within 72 hours of discharge, home assessment, regular telephone reviews to identify early complications and early review clinics for patients who destabilize. The VW meet daily to discuss new patients and review care plans for patients. Control patients received standard hospital care that included a standardized patient copy of the hospital discharge summary listing their medical diagnoses and medications; and follow up is arranged with a primary care provider or specialist as considered necessary. The primary outcome was the unplanned readmission rate to any hospital within 30 days of discharge. Secondary outcomes included the unplanned readmission rate, emergency department (ED) attendance rate to any hospital and the probability without readmission or death up to 180 days of discharge. Length of stay and mortality rate at 90-day were compared between the two groups. Outcome data were objectively retrieved from the hospital and National Electronic Health Records by a blinded outcome assessor. Findings All patients' outcomes were included in an intention-to-treat analysis. The characteristics of both study groups were similar. Patients in the intervention group had a significant reduction in the number of 30-day readmissions, IRR 0.67 (95% CI, 0.52 to 0.86, p = 0.001) and the number of 30-day emergency department attendances, IRR 0.60 (95% CI, 0.46 to 0.79, p<0.001) compared to those receiving standard hospital care. The effectiveness was sustained at 90 and 180 days. The intervention group utilized 1164 fewer hospital bed days at 90-day post discharge. No adverse events were reported. Conclusion Applying the integrated practice unit concept to the virtual ward program resulted in reduced readmissions in patients who are at highest risk of readmission.	[Low, Lian Leng; Tan, Shu Yun; Ng, Matthew Joo Ming; Tay, Wei Yi; Ng, Lee Beng; Towle, Rachel Marie; Lee, Kheng Hock] Singapore Gen Hosp, Dept Family Med & Continuing Care, Singapore, Singapore; [Low, Lian Leng; Tan, Shu Yun; Ng, Matthew Joo Ming; Tay, Wei Yi; Ng, Lee Beng; Lee, Kheng Hock] Duke NUS Med Sch, Family Med, Singapore, Singapore; [Balasubramaniam, Kanchana] Singapore Gen Hosp, Med Acad Clin Program, Hlth Serv Res, Singapore, Singapore	Singapore General Hospital; National University of Singapore; Singapore General Hospital	Low, LL; Lee, KH (corresponding author), Singapore Gen Hosp, Dept Family Med & Continuing Care, Singapore, Singapore.; Low, LL; Lee, KH (corresponding author), Duke NUS Med Sch, Family Med, Singapore, Singapore.	low.lian.leng@sgh.com.sg; lee.kheng.hock@singhealth.com.sg	; Low, Lian Leng/M-2853-2016	Tan, Shu Yun/0000-0003-0307-9546; Low, Lian Leng/0000-0003-4228-2862	Agency of Integrated Care Singapore [AIC/RPD/RD-OIC/ICCS/010/05-2011]; SingHealth Regional Health System Office	Agency of Integrated Care Singapore; SingHealth Regional Health System Office(SingHealth)	This project was supported by a project grant from the Agency of Integrated Care Singapore (http://www.aic.sg/) AIC/RPD/RD-OIC/ICCS/010/05-2011 and the SingHealth Regional Health System Office. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, Hosp Peer Rev, V38, P112; [Anonymous], 2007, GUARDIAN; [Anonymous], 2013, AV HOSP INP BILL SIZ; [Anonymous], 2014, SINGAPORE BUDGET 201; Balaban RB, 2015, J GEN INTERN MED, V30, P907, DOI 10.1007/s11606-015-3185-x; Burke RE, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-423; Chan Margaret, 2008, PRIMARY HLTH CARE NO; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Department of Health, 2014, DEL BETT INT CAR; Detsky AS, 2014, JAMA-J AM MED ASSOC, V311, P2160; Dhalla IA, 2014, JAMA-J AM MED ASSOC, V312, P1305, DOI 10.1001/jama.2014.11492; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Health Minister Singapore, 2014, ECONOMIST; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jones CD, 2015, J GEN INTERN MED, V30, P417, DOI 10.1007/s11606-014-3056-x; Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415; Lee KH, 2015, INT J INTEGR CARE, V15; Lee KH, 2011, J HOSP MED, V6, P115, DOI 10.1002/jhm.821; Lewis G, 2013, INT J INTEGR CARE, V13; Lewis GH, 2013, IMPACT VIRTUAL WARDS; Lim E, 2011, BMC HEALTH SERV RES, V2011, P1; Low LL, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0750-2; Mann Cindy, 2012, INTEGRATED CARE MODE; Mitchell SE, 2012, J HEALTH COMMUN, V17, P325, DOI 10.1080/10810730.2012.715233; Mueller SK, 2012, ARCH INTERN MED, V172, P1057, DOI 10.1001/archinternmed.2012.2246; National Committee for Quality Assurance, 2013, INT CAR PEOPL MED ME; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Porter ME, 2006, REDEFINING HLTH CARE; Porter ME, 2013, HEALTH AFFAIR, V32, P516, DOI 10.1377/hlthaff.2012.0961; Singapore Ministry of Health, 2015, MED; Tan SY, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-366	32	35	36	6	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0168757	10.1371/journal.pone.0168757	http://dx.doi.org/10.1371/journal.pone.0168757			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2QJ	28045940	gold, Green Published, Green Submitted			2023-01-03	WOS:000391612300050
J	Carter, L; Rothwell, DG; Mesquita, B; Smowton, C; Leong, HS; Fernandez-Gutierrez, F; Li, YY; Burt, DJ; Antonello, J; Morrow, CJ; Hodgkinson, CL; Morris, K; Priest, L; Carter, M; Miller, C; Hughes, A; Blackhall, F; Dive, C; Brady, G				Carter, Louise; Rothwell, Dominic G.; Mesquita, Barbara; Smowton, Christopher; Leong, Hui Sun; Fernandez-Gutierrez, Fabiola; Li, Yaoyong; Burt, Deborah J.; Antonello, Jenny; Morrow, Christopher J.; Hodgkinson, Cassandra L.; Morris, Karen; Priest, Lynsey; Carter, Mathew; Miller, Crispin; Hughes, Andrew; Blackhall, Fiona; Dive, Caroline; Brady, Ged			Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer	NATURE MEDICINE			English	Article							TOPOTECAN; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; VINCRISTINE	In most patients with small-cell lung cancer (SCLC)-a metastatic, aggressive disease-the condition is initially chemosensitive but then relapses with acquired chemoresistance. In a minority of patients, however, relapse occurs within 3 months of initial treatment; in these cases, disease is defined as chemorefractory. The molecular mechanisms that differentiate chemosensitive from chemorefractory disease are currently unknown. To identify genetic features that distinguish chemosensitive from chemorefractory disease, we examined copy-number aberrations (CNAs) in circulating tumor cells (CTCs) from pretreatment SCLC blood samples. After analysis of 88 CTCs isolated from 13 patients (training set), we generated a CNA-based classifier that we validated in 18 additional patients (testing set, 112 CTC samples) and in six SCLC patient-derived CTC explant tumors(1). The classifier correctly assigned 83.3% of the cases as chemorefractory or chemosensitive. Furthermore, a significant difference was observed in progression-free survival (PFS) (Kaplan-Meier P value = 0.0166) between patients designated as chemorefractory or chemosensitive by using the baseline CNA classifier. Notably, CTC CNA profiles obtained at relapse from five patients with initially chemosensitive disease did not switch to a chemorefractory CNA profile, which suggests that the genetic basis for initial chemoresistance differs from that underlying acquired chemoresistance.	[Carter, Louise; Rothwell, Dominic G.; Mesquita, Barbara; Smowton, Christopher; Fernandez-Gutierrez, Fabiola; Burt, Deborah J.; Antonello, Jenny; Morrow, Christopher J.; Hodgkinson, Cassandra L.; Morris, Karen; Priest, Lynsey; Carter, Mathew; Dive, Caroline; Brady, Ged] Univ Manchester, CRUK Manchester Inst, Clin & Expt Pharmacol Grp, Manchester, Lancs, England; [Leong, Hui Sun; Miller, Crispin] Univ Manchester, CRUK Manchester Inst, Computat Biol Support Grp, Manchester, Lancs, England; [Li, Yaoyong] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Miller, Crispin] Univ Manchester, CRUK Manchester Inst, RNA Biol Grp, Manchester, Lancs, England; [Hughes, Andrew] AstraZeneca, Alderley Pk, Macclesfield, Cheshire, England; [Blackhall, Fiona] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England; [Blackhall, Fiona; Dive, Caroline] Univ Manchester, CRUK Manchester Inst, Cancer Res UK Lung Canc Ctr Excellence, Manchester, Lancs, England	University of Manchester; University of Manchester; University of Manchester; University of Manchester; AstraZeneca; University of Manchester; University of Manchester	Dive, C; Brady, G (corresponding author), Univ Manchester, CRUK Manchester Inst, Clin & Expt Pharmacol Grp, Manchester, Lancs, England.; Dive, C (corresponding author), Univ Manchester, CRUK Manchester Inst, Cancer Res UK Lung Canc Ctr Excellence, Manchester, Lancs, England.	Caroline.Dive@cruk.manchester.ac.uk; Ged.Brady@cruk.manchester.ac.uk	; Blackhall, Fiona/N-2186-2015	Miller, Crispin/0000-0003-4341-1283; Carter, Louise/0000-0002-9854-2304; Blackhall, Fiona/0000-0001-8716-3395; Priest, Lynsey/0000-0003-3780-8508; Dive, Caroline/0000-0002-1726-8850; Rothwell, Dominic/0000-0002-8757-3893	CRUK; AstraZeneca [C147/A12328]; Menarini Biomarkers Singapore PTE Ltd.;  [C5759/A12328];  [A12197]; Cancer Research UK [20465, 15675, 19278] Funding Source: researchfish	CRUK(Cancer Research UK); AstraZeneca(AstraZeneca); Menarini Biomarkers Singapore PTE Ltd.; ; ; Cancer Research UK(Cancer Research UK)	L.C. was funded via a Clinical Pharmacology Fellowship educational grant from CRUK and AstraZeneca (C147/A12328). We would like to acknowledge the help of the CRUK Molecular Biology Core Facilities and members of the CRUK Manchester Institute Clinical and Experimental Pharmacology Group for their support of this study. We also thank the patients and healthy volunteers who provided their blood samples. This work was supported by core funding to CRUK Manchester Institute (C5759/A12328), and via Manchester CRUK Centre Award (A12197) and a research grant from Menarini Biomarkers Singapore PTE Ltd. (funding for all assigned to C.D.)	Chan BA, 2013, J THORAC DIS, V5, pS565, DOI 10.3978/j.issn.2072-1439.2013.07.43; Dowlati A, 2016, ANN ONCOL, V27, P642, DOI 10.1093/annonc/mdw005; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Hagmann R, 2015, J CANCER, V6, P1148, DOI 10.7150/jca.13080; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hou JM, 2009, AM J PATHOL, V175, P808, DOI 10.2353/ajpath.2009.090078; Lally BE, 2007, ONCOLOGIST, V12, P1096, DOI 10.1634/theoncologist.12-9-1096; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; O'Brien MER, 2006, J CLIN ONCOL, V24, P5441, DOI 10.1200/JCO.2006.06.5821; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Polzer B, 2014, EMBO MOL MED, V6, P1371, DOI 10.15252/emmm.201404033; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Semenova EA, 2015, GENE DEV, V29, P1447, DOI 10.1101/gad.263145.115; Smyth G. K., STAT APPL GENET MOL, V3, P1544; Tanaka F, 2009, CLIN CANCER RES, V15, P6980, DOI 10.1158/1078-0432.CCR-09-1095; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; von Pawel J, 1999, J CLIN ONCOL, V17, P658, DOI 10.1200/JCO.1999.17.2.658	18	206	214	2	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2017	23	1					114	119		10.1038/nm.4239	http://dx.doi.org/10.1038/nm.4239			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EH3CN	27869802				2023-01-03	WOS:000391646800020
J	Olanrewaju, O; Kelly, S; Cowan, A; Brayne, C; Lafortune, L				Olanrewaju, Olawale; Kelly, Sarah; Cowan, Andy; Brayne, Carol; Lafortune, Louise			Physical Activity in Community Dwelling Older People: A Systematic Review of Reviews of Interventions and Context	PLOS ONE			English	Review							COGNITIVE FUNCTION; ACTIVITY PROMOTION; ADULTS; EXERCISE; HEALTH; BEHAVIOR; LIFE; PARTICIPATION; IMPAIRMENT; BARRIERS	Background The promotion and maintenance of higher physical activity (PA) levels in the older population is an imperative for cognitive and healthy ageing but it is unclear what approaches are best suited to achieve this for the increasing number of older people living in the community. Effective policies should be informed by robust, multi-disciplinary and multi-dimensional evidence, which not only seeks what works, but in 'what context? In addition to evidence on the efficacy and effectiveness of PA for maintaining cognitive health, social contexts such as `how do we actually get older people to partake in PA?' and 'how do we sustain that activity long-term?' also need highlighting. This review is part of a comprehensive evidence synthesis of preventive interventions in older age, with a focus on healthy behaviours to identify evidence gaps and inform policy relating to ageing well and cognitive health. An overview of systematic reviews of PA was conducted to explore three topics: (1) PA efficacy or effectiveness for primary prevention of cognitive decline in 55+; (2) Interventions efficacious or effective for increasing PA uptake and maintenance in 55+; (3) barriers and facilitators to PA in 55+. Methods Multiple databases were searched for studies in English from OECD countries between 2000 and 2016. Quality of included reviews in questions (1) and (2) were assessed using AMSTAR. Review protocols were registered on PROSPERO (CRD42014015554, 42014015584, CRD42014015557) and reviews follow PRISMA guideline. Findings Overall, 40 systematic reviews were included. Question 1 (n = 14). 8,360 participants. Evidence suggests that PA confer mild positive effects on cognition in older adults with and without previous cognitive impairment. However, there is insufficient evidence of a dose response relationship. Evidence on the effects of PA on delay of dementia onset is inconclusive. Question 2 (n = 17). 79,650 participants. Evidence supports the effectiveness of a variety of interventions, including group delivered, centre-based and cognitive approaches on short-term uptake of PA behaviour. Question 3 (n = 9). 22,413 participants. Barriers include health status, previous PA habits and experiences, and cultural sensitivity, while facilitators include enjoyable activities and convenient scheduling. Conclusion PA can offer small benefits to brain health, but evidence on how much activity is required to produce this effect is lacking. Evidence on the effectiveness of PA for preventing dementia and cognitive decline is lacking. Behavioural (walking, exercise) and cognitive (counselling and motivational interviews) interventions are effective for short-term uptake of physical activity in older people. In order to maintain long-term participation in PA, individualised interventions modelled using behavioural theories may be required. Public health messages should be aimed at promoting acceptable levels of PA above normal daily activities in older people. Policy and strategies aimed at increasing PA in older people should be encouraged while considering barriers and facilitators to behaviour change.	[Olanrewaju, Olawale; Kelly, Sarah; Cowan, Andy; Brayne, Carol; Lafortune, Louise] Cambridge Inst Publ Hlth, Forvie Site,Robinson Way, Cambridge CB2 0SR, England	University of Cambridge	Olanrewaju, O (corresponding author), Cambridge Inst Publ Hlth, Forvie Site,Robinson Way, Cambridge CB2 0SR, England.	oo260@medschl.cam.ac.uk	Brayne, Carol/AAA-4285-2020; Lafortune, Louise/AAJ-9257-2020	Brayne, Carol/0000-0001-5307-663X; Lafortune, Louise/0000-0002-9018-1217; Cowan, Andy/0000-0002-8981-5673; Kelly, Sarah/0000-0002-1114-2456; Olanrewaju, Olawale/0000-0002-0703-1358	National Institute for Health Research (NIHR) School for Public Health Research Ageing Well Programme [RG67185]; NIHR Collaborations for Leadership in Applied Health Research and Care (CLAHRC) East of England; National Institute for Health Research [NF-SI-0611-10084] Funding Source: researchfish	National Institute for Health Research (NIHR) School for Public Health Research Ageing Well Programme(National Institute for Health Research (NIHR)); NIHR Collaborations for Leadership in Applied Health Research and Care (CLAHRC) East of England; National Institute for Health Research(National Institute for Health Research (NIHR))	This review was funded by the National Institute for Health Research (NIHR) School for Public Health Research Ageing Well Programme (RG67185) and the NIHR Collaborations for Leadership in Applied Health Research and Care (CLAHRC) East of England.	Aday L A, 1974, Health Serv Res, V9, P208; ANDERSEN R, 1978, MED CARE, V16, P533, DOI 10.1097/00005650-197807000-00001; Angevaren M, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005381.pub3, 10.1002/14651858.CD005381.pub2]; [Anonymous], 2013, WHAT DOES 2011 CENS; Asikainen TM, 2004, SPORTS MED, V34, P753, DOI 10.2165/00007256-200434110-00004; Balsamo S, 2013, INT J GEN MED, V6, P387, DOI 10.2147/IJGM.S35315; Barnett I, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-97; Bernd R, 2009, CAN HLTH SYSTEMS RES, P1997; Boehm J, 2013, AUST J RURAL HEALTH, V21, P141, DOI 10.1111/ajr.12032; Booth FW, 2012, COMPR PHYSIOL, V2, P1143, DOI 10.1002/cphy.c110025; Bunn F, 2008, AGEING SOC, V28, P449, DOI 10.1017/S0144686X07006861; Cai Y, 2015, QUALITY PRIMARY CARE, V23, P9; Carvalho A, 2014, CLIN INTERV AGING, V9, P661, DOI 10.2147/CIA.S55520; Centers for Disease Control and Prevention, 2009, GLOSS TERMS EX; Chang YK, 2012, J AGING PHYS ACTIV, V20, P497, DOI 10.1123/japa.20.4.497; Chase J-AD, 2014, GERONTOLOGIST; Chase JAD, 2013, RES THEOR NURS PRACT, V27, P53, DOI 10.1891/1541-6577.27.1.53; Child S, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-91; Clegg AP, 2011, AGE AGEING, V40, pII30; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Conn V. S., 2002, Activities, Adaptation & Aging, V27, P39, DOI 10.1300/J016v27n02_04; Conn VS, 2003, J AM GERIATR SOC, V51, P1159, DOI 10.1046/j.1532-5415.2003.51365.x; Conn VS, 2002, ANN BEHAV MED, V24, P190, DOI 10.1207/S15324796ABM2403_04; Corder K, 2009, AM J EPIDEMIOL, V170, P1078, DOI 10.1093/aje/kwp273; Cunningham GO, 2004, AM J HEALTH PROMOT, V18, P435, DOI 10.4278/0890-1171-18.6.435; Cyarto E V, 2004, J Sci Med Sport, V7, P30, DOI 10.1016/S1440-2440(04)80275-5; Coelho FGD, 2013, ARCH GERONTOL GERIAT, V56, P10, DOI 10.1016/j.archger.2012.06.003; de Vries NM, 2012, AGEING RES REV, V11, P136, DOI 10.1016/j.arr.2011.11.002; Devereux-Fitzgerald A, 2016, SOC SCI MED, V158, P14, DOI 10.1016/j.socscimed.2016.04.006; Di Iulio F, 2010, INT PSYCHOGERIATR, V22, P629, DOI 10.1017/S1041610210000281; Dunsky Ayelet, 2012, Curr Aging Sci, V5, P66; Fairhall N, 2011, AGE AGEING, V40, P666, DOI 10.1093/ageing/afr077; Foot J, 2010, GLASS HALF FULL ASSE, P1; Franco MR, 2015, BRIT J SPORT MED, V49, P1268, DOI 10.1136/bjsports-2014-094015; French DP, 2014, ANN BEHAV MED, V48, P225, DOI 10.1007/s12160-014-9593-z; Gates N, 2013, AM J GERIAT PSYCHIAT, V21, P1086, DOI 10.1016/j.jagp.2013.02.018; Geraedts H, 2013, PATIENT EDUC COUNS, V91, P14, DOI 10.1016/j.pec.2012.10.018; Hobbs N, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-75; Horne M, 2012, PREV MED, V55, P276, DOI 10.1016/j.ypmed.2012.07.016; Kasneci D, 2007, EUROPEAN PAPERS NEW, P32; Kelly ME, 2014, AGEING RES REV, V16, P12, DOI 10.1016/j.arr.2014.05.002; Kelly S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145074; Koutsogeorgou E, 2013, HLTH ED J; Lafortune L, 2014, PROSPERO; Lafortune L, 2014, PROSPERO; Lafortune L, 2014, PROSPERO; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Muller AM, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-35; Neidrick TJ, 2012, J AM ACAD NURSE PRAC, V24, P405, DOI 10.1111/j.1745-7599.2012.00703.x; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Nigg CR, 2012, TRANSL BEHAV MED, V2, P163, DOI 10.1007/s13142-012-0130-y; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; O'Brien N, 2015, HEALTH PSYCHOL REV, V9, P417, DOI 10.1080/17437199.2015.1012177; Ohman H, 2014, DEMENT GERIATR COGN, V38, P347, DOI 10.1159/000365388; Paterson DH, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-38; Reis RS, 2016, LANCET, V388, P1337, DOI 10.1016/S0140-6736(16)30728-0; Scherder E, 2014, AM J GERIAT PSYCHIAT, V22, P782, DOI 10.1016/j.jagp.2012.12.026; Soares-Miranda L, 2016, CIRCULATION, V133, P147, DOI 10.1161/CIRCULATIONAHA.115.018323; Stevens Z, 2014, PRIM HEALTH CARE RES, V15, P190, DOI 10.1017/S1463423613000017; Tseng CN, 2011, J NURS RES, V19, P119, DOI 10.1097/JNR.0b013e3182198837; van der Bij AK, 2002, AM J PREV MED, V22, P120, DOI 10.1016/S0749-3797(01)00413-5; van Uffelen JGZ, 2008, CLIN J SPORT MED, V18, P486, DOI 10.1097/JSM.0b013e3181845f0b; Whitty CJM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0544-8; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C	64	87	87	3	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2016	11	12							e0168614	10.1371/journal.pone.0168614	http://dx.doi.org/10.1371/journal.pone.0168614			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI9QF	27997604	Green Submitted, Green Published, gold			2023-01-03	WOS:000392842900062
J	Lee, YH; Lai, YH				Lee, Yu-Hsiang; Lai, Yun-Han			Synthesis, Characterization, and Biological Evaluation of Anti-HER2 Indocyanine Green-Encapsulated PEG-Coated PLGA Nanoparticles for Targeted Phototherapy of Breast Cancer Cells	PLOS ONE			English	Article							PHOTODYNAMIC THERAPY; DRUG-DELIVERY; ABLATION; AMPLIFICATION; NANOMEDICINE; PEGYLATION; RECEPTOR	Human epidermal growth factor receptor 2 (HER2)-overexpressed breast cancer is known to be more aggressive and resistant to medicinal treatment and therefore to whom an alternative therapeutics is needed. Indocyanine green (ICG) has been widely exploited in breast cancer phototherapy. However, drawbacks of accelerated degradation and short half-life (2-4 min) in blood seriously hamper its use in the clinic. To overcome these challenges, an anti-HER2 ICG-encapsulated polyethylene glycol-coated poly(lactic-co-glycolic acid) nanoparticles (HIPPNPs) were developed in this study. Through the analyses of degradation rate coefficients of ICG with and without polymeric encapsulation, the photostability of HIPPNPentrapped ICG significantly enhanced 4 folds (P < 0.05) while its thermal stabilities at 4 and 37 E C significantly enhanced 5 and 3 (P < 0.05 for each) folds, respectively, under equal lighting and/or heating treatment for 48 h. The target specificity of HIPPNPs to HER2-positive cells was demonstrated based on a 6-fold (P < 0.05) enhancement of uptake efficiency of HIPPNPs in MDA-MB-453/HER2(+) cells within 4 h as compared with that in MCF7/HER2 (-) cells. Moreover, the HIPPNPs with <= 25 mu M ICG equivalent were nontoxic to cells in the absence of light illumination, and enabled to generate similar amount of singlet oxygen and hyperthermia effect as compared with that used by free ICG upon NIR irradiation. After 808 nm-laser irradiation with intensity of 6 W/cm(2) for 5 min, the viability of MDA-MB-453 cells pre-treated by HIPPNPs with <= 5 mu M ICG equivalent for 4 h significantly reduced as compared with that treated by equal concentration of free ICG (P < 0.05) and > 90% of the cells were eradicated while the dose of HIPPNPs was increased to 25 mu M ICG equivalent. In summary, the developed HIPPNPs are anticipated as a feasible tool for use in phototherapy of breast cancer cells with HER2 expression.	[Lee, Yu-Hsiang; Lai, Yun-Han] Natl Cent Univ, Dept Biomed Sci & Engn, Taoyuan, Taiwan; [Lee, Yu-Hsiang] Natl Cent Univ, Dept Chem & Mat Engn, Taoyuan, Taiwan	National Central University; National Central University	Lee, YH (corresponding author), Natl Cent Univ, Dept Biomed Sci & Engn, Taoyuan, Taiwan.; Lee, YH (corresponding author), Natl Cent Univ, Dept Chem & Mat Engn, Taoyuan, Taiwan.	yuhsianl@ncu.edu.tw			Ministry of Science and Technology, R.O.C. [MOST 105-2221-E-008-014]	Ministry of Science and Technology, R.O.C.	This work was financially supported by Ministry of Science and Technology, R.O.C. (Grant Number: MOST 105-2221-E-008-014; Y.-H. Lee) Website: https://www.most.gov.tw/en/public. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernardi RJ, 2008, J NEURO-ONCOL, V86, P165, DOI 10.1007/s11060-007-9467-3; BJORNSSON OG, 1983, J CLIN CHEM CLIN BIO, V21, P453; Cheng L, 2014, CHEM REV, V114, P10869, DOI 10.1021/cr400532z; Choudhury A, 2004, Breast Dis, V20, P25; Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Coffey DS, 2006, JAMA-J AM MED ASSOC, V296, P445, DOI 10.1001/jama.296.4.445; Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Fishburn CS, 2008, J PHARM SCI-US, V97, P4167, DOI 10.1002/jps.21278; Fiszman GL, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/352182; Gajendiran M, 2014, J MATER CHEM B, V2, P418, DOI 10.1039/c3tb21113d; Goldberg SN, 1996, ACAD RADIOL, V3, P212, DOI 10.1016/S1076-6332(96)80443-0; Haen SP, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/160250; Harush-Frenkel O, 2007, BIOCHEM BIOPH RES CO, V353, P26, DOI 10.1016/j.bbrc.2006.11.135; Hauck TS, 2008, ADV MATER, V20, P3832, DOI 10.1002/adma.200800921; Hu CMJ, 2010, MOL PHARMACEUT, V7, P914, DOI 10.1021/mp900316a; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Jain KK, 2008, MED PRIN PRACT, V17, P89, DOI 10.1159/000112961; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063; Leonard DS, 2002, BRIT J SURG, V89, P262, DOI 10.1046/j.0007-1323.2001.02022.x; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Mastropasqua R, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/343515; Mordon S, 1998, MICROVASC RES, V55, P146, DOI 10.1006/mvre.1998.2068; Mundra V, 2015, J CONTROL RELEASE, V220, P130, DOI 10.1016/j.jconrel.2015.10.029; Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017; Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x; Ogris M, 2001, AAPS PHARMSCI, V3, part. no.; Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1200/JCO.2002.09.094; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Saxena V, 2004, J PHOTOCH PHOTOBIO B, V74, P29, DOI 10.1016/j.jphotobiol.2004.01.002; Saxena V, 2003, J PHARM SCI, V92, P2090, DOI 10.1002/jps.10470; Schaafsma BE, 2011, J SURG ONCOL, V104, P323, DOI 10.1002/jso.21943; Shemesh CS, 2015, PHARM RES-DORDR, V32, P1604, DOI 10.1007/s11095-014-1560-7; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sun C, 2006, J BIOMED MATER RES A, V78A, P550, DOI 10.1002/jbm.a.30781; THOMSEN S, 1991, PHOTOCHEM PHOTOBIOL, V53, P825, DOI 10.1111/j.1751-1097.1991.tb09897.x; Tinoco G, 2013, J CANCER, V4, P117, DOI 10.7150/jca.4925; Yang J, 2007, J MATER CHEM, V17, P2695, DOI 10.1039/b702538f; Zelken JA, 2015, ANN SURG ONCOL, V22, pS1271, DOI 10.1245/s10434-015-4743-5	43	12	12	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2016	11	12							e0168192	10.1371/journal.pone.0168192	http://dx.doi.org/10.1371/journal.pone.0168192			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8HA	27942034	Green Published, gold, Green Submitted			2023-01-03	WOS:000392745600058
J	Couzin-Frankel, J				Couzin-Frankel, Jennifer			CANCER IMMUNOTHERAPY Worries, confusion after cancer trial deaths	SCIENCE			English	News Item																			0	4	4	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2016	354	6317					1211	1211		10.1126/science.354.6317.1211	http://dx.doi.org/10.1126/science.354.6317.1211			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4TS	27940822				2023-01-03	WOS:000389598800009
J	Sung, YY; Yoon, T; Jang, S; Kim, HK				Sung, Yoon-Young; Yoon, Taesook; Jang, Seol; Kim, Ho Kyoung			Forsythia suspensa Suppresses House Dust Mite Extract-Induced Atopic Dermatitis in NC/Nga Mice	PLOS ONE			English	Article							NF-KAPPA-B; INFLAMMATORY RESPONSES; TACROLIMUS OINTMENT; ACTIVATION; CHEMOKINE; BLOCKADE; FRUCTUS; KERATINOCYTES; PATHOGENESIS; SEVERITY	Forsythia suspensa (F. suspensa) is a traditional medicine for treatment of inflammation. In this study, we evaluated the therapeutic effects of an ethanol extract from F. suspensa fruits on atopic dermatitis both in vivo and in vitro. We investigated the inhibitory effects of F. suspensa extract on the development of atopic dermatitis-like skin lesions in an NC/Nga mouse model exposed to Dermatophagoides farinae crude extract. Topical application of F. suspensa extract to the mice attenuated the atopic dermatitis symptoms, including increased dermatitis severity score, ear thickness, infiltration of inflammatory cells in the skin lesions, serum levels of IgE, TNF-alpha, and histamine, and expression of chemokines, cytokines, and adhesion molecules in ear tissue. In addition, F. suspensa extract inhibited the production of chemokines in TNF-alpha/IFN-gamma-activated human keratinocytes. High-performance liquid chromatography analysis of FSE revealed the presence of four chemical constituents (forsythiaside, phillyrin, pinoresinol, and phylligenin). These compounds inhibited the production of chemokines in TNF-alpha/IFN-gamma-activated human keratinocytes. These results suggest that the F. suspensa might be a useful candidate for treating allergic skin inflammatory disorders.	[Sung, Yoon-Young; Jang, Seol; Kim, Ho Kyoung] Korea Inst Oriental Med, Mibyeong Res Ctr, Daejeon, South Korea; [Yoon, Taesook] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Coll Pharm, Seoul, South Korea	Korea Institute of Oriental Medicine (KIOM); Ewha Womans University	Kim, HK (corresponding author), Korea Inst Oriental Med, Mibyeong Res Ctr, Daejeon, South Korea.	hkkim@kiom.re.kr			Korea Research Council of Fundamental Science and Technology [G10102]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government, MSIP [NRF-2015M3A9E3052336]	Korea Research Council of Fundamental Science and Technology; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government, MSIP(Ministry of Food & Drug Safety (MFDS), Republic of Korea)	This research was supported by project (G10102) "Development of herbal materials for treatment and prevention of allergic disease," which was funded by the Korea Research Council of Fundamental Science and Technology. This research was also supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government, MSIP (NRF-2015M3A9E3052336).	Albanesi Cristina, 2005, Current Drug Targets - Inflammation and Allergy, V4, P329, DOI 10.2174/1568010054022033; Bardana EJ, 2004, ALLERGY, V59, P25, DOI 10.1111/j.1398-9995.2004.00565.x; Bulfone-Paus S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00394; Carroll CL, 2006, DRUG TODAY, V42, P431, DOI 10.1358/dot.2006.42.7.1003316; Chen L, 2010, IMMUNOL CELL BIOL, V88, P334, DOI 10.1038/icb.2009.107; Cheng GD, 2014, EXP THER MED, V7, P179, DOI 10.3892/etm.2013.1378; Choi JK, 2014, AM J CHINESE MED, V42, P967, DOI 10.1142/S0192415X1450061X; Dilshara MG, 2015, BMB REP, V48, P559, DOI 10.5483/BMBRep.2015.48.10.003; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Hanifin JM, 2005, J AM ACAD DERMATOL, V53, pS186, DOI 10.1016/j.jaad.2005.04.062; Horikawa T, 2002, INT IMMUNOL, V14, P767, DOI 10.1093/intimm/dxf044; Inagaki N, 2006, EUR J PHARMACOL, V546, P189, DOI 10.1016/j.ejphar.2006.07.019; Jahnz-Rozyk K, 2005, ALLERGY, V60, P685, DOI 10.1111/j.1398-9995.2005.00774.x; Je IG, 2015, TOXICOL APPL PHARM, V287, P119, DOI 10.1016/j.taap.2015.05.006; Jeong YI, 2015, ALLERGY ASTHMA IMMUN, V7, P557, DOI 10.4168/aair.2015.7.6.557; Jung HW, 2010, NEUROSCI LETT, V480, P215, DOI 10.1016/j.neulet.2010.06.043; Kanda N, 2006, BIOCHEM PHARMACOL, V72, P463, DOI 10.1016/j.bcp.2006.05.001; Kim MS, 2003, INFLAMMATION, V27, P129, DOI 10.1023/A:1023865727780; KRUTMANN J, 1990, J INVEST DERMATOL, V95, P127, DOI 10.1111/1523-1747.ep12477839; Kwon DJ, 2012, BIOCHEM BIOPH RES CO, V417, P1254, DOI 10.1016/j.bbrc.2011.12.119; Kwon TR, 2014, PHOTOCHEM PHOTOBIOL, V90, P1160, DOI 10.1111/php.12284; Lee H, 2014, BIOMOL THER, V22, P438, DOI 10.4062/biomolther.2014.023; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lim H, 2008, J ETHNOPHARMACOL, V118, P113, DOI 10.1016/j.jep.2008.03.016; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nedoszytko B, 2014, POSTEP DERM ALERGOL, V31, P84, DOI 10.5114/pdia.2014.40920; NISHIBE S, 1982, CHEM PHARM BULL, V30, P4548; Otsuka A, 2015, ALLERGY, V70, P131, DOI 10.1111/all.12526; Ozaki Y, 1997, BIOL PHARM BULL, V20, P861, DOI 10.1248/bpb.20.861; Park JH, 2015, J ETHNOPHARMACOL, V171, P85, DOI 10.1016/j.jep.2015.05.039; Pastore Saveria, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P497; Pivarcsi A, 2005, CURR ALLERGY ASTHM R, V5, P284, DOI 10.1007/s11882-005-0068-y; Prieto JM, 2003, J PHARM PHARMACOL, V55, P1275, DOI 10.1211/0022357021620; Qu HH, 2012, BIOORG CHEM, V40, P87, DOI 10.1016/j.bioorg.2011.09.005; Sasakawa T, 2004, INT ARCH ALLERGY IMM, V133, P55, DOI 10.1159/000076128; Seo WY, 2015, BMB REP, V48, P495, DOI 10.5483/BMBRep.2015.48.9.259; Simpson D, 2005, DRUGS, V65, P827, DOI 10.2165/00003495-200565060-00011; Suto H, 1999, INT ARCH ALLERGY IMM, V120, P70, DOI 10.1159/000053599; Sykes L, 2012, MEDIAT INFLAMM, V2012, DOI [10.1155/2012/416739, DOI 10.1155/2012/416739]; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Yamamoto Mina, 2007, Allergol Int, V56, P139, DOI 10.2332/allergolint.O-06-458; Zhong WT, 2013, FITOTERAPIA, V90, P132, DOI 10.1016/j.fitote.2013.06.003	43	20	22	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0167687	10.1371/journal.pone.0167687	http://dx.doi.org/10.1371/journal.pone.0167687			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4PU	27936051	Green Published, gold, Green Submitted			2023-01-03	WOS:000389587100151
J	Park, SY; Choi, CH; Park, JM; Chun, M; Han, JH; Kim, JI				Park, So-Yeon; Choi, Chang Heon; Park, Jong Min; Chun, MinSoo; Han, Ji Hye; Kim, Jung-in			A Patient-Specific Polylactic Acid Bolus Made by a 3D Printer for Breast Cancer Radiation Therapy	PLOS ONE			English	Article							ELECTRON BOLUS; RADIOTHERAPY; PHOTON; BEAMS; CT	Purpose The aim of this study was to assess the feasibility and advantages of a patient-specific breast bolus made using a 3D printer technique. Methods We used the anthropomorphic female phantom with breast attachments, which volumes are 200, 300, 400, 500 and 650 cc. We simulated the treatment for a right breast patient using parallel opposed tangential fields. Treatment plans were used to investigate the effect of unwanted air gaps under bolus on the dose distribution of the whole breast. The commercial Super-Flex bolus and 3D-printed polylactic acid (PLA) bolus were applied to investigate the skin dose of the breast with the MOSFET measurement. Two boluses of 3 and 5 mm thicknesses were selected. Results There was a good agreement between the dose distribution for a virtual bolus generated by the TPS and PLA bolus. The difference in dose distribution between the virtual bolus and Super-Flex bolus was significant within the bolus and breast due to unwanted air gaps. The average differences between calculated and measured doses in a 200 and 300 cc with PLA bolus were not significant, which were -0.7% and -0.6% for 3mm, and -1.1% and -1.1% for 5 mm, respectively. With the Super-Flex bolus, however, significant dose differences were observed (-5.1% and -3.2% for 3mm, and -6.3% and -4.2% for 5 mm). Conclusion The 3D-printed solid bolus can reduce the uncertainty of the daily setup and help to overcome the dose discrepancy by unwanted air gaps in the breast cancer radiation therapy.	[Park, So-Yeon; Choi, Chang Heon; Park, Jong Min; Chun, MinSoo; Han, Ji Hye; Kim, Jung-in] Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; [Park, So-Yeon; Choi, Chang Heon; Park, Jong Min; Chun, MinSoo; Kim, Jung-in] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea; [Park, So-Yeon; Choi, Chang Heon; Park, Jong Min; Chun, MinSoo; Han, Ji Hye; Kim, Jung-in] Seoul Natl Univ, Coll Med, Biomed Res Inst, Seoul, South Korea; [Park, Jong Min] Adv Inst Convergence Technol, Ctr Convergence Res Robot, Suwon, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Kim, JI (corresponding author), Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea.; Kim, JI (corresponding author), Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea.; Kim, JI (corresponding author), Seoul Natl Univ, Coll Med, Biomed Res Inst, Seoul, South Korea.	madangin@gmail.com	Chun, Minsoo/C-4493-2014	Chun, Minsoo/0000-0001-8578-9976	SNUH Research Fund [04-2015-0890]; Seoul National University Hospital Research Fund [04-2015-0890]	SNUH Research Fund; Seoul National University Hospital Research Fund	This research was supported by a grant of the SNUH Research Fund (grant number: 04-2015-0890). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported by grant no. 04-2015-0890 from the Seoul National University Hospital Research Fund.	Andic F, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-41; Arac M, 2003, RADIOLOGY, V229, P195, DOI 10.1148/radiol.2291020642; Blitzblau RC, 2013, PRACT RADIAT ONCOL, V3, P241, DOI 10.1016/j.prro.2012.09.004; Burleson S, 2015, J APPL CLIN MED PHYS, V16, P166, DOI 10.1120/jacmp.v16i3.5247; Butson MJ, 2000, RADIAT MEAS, V32, P201, DOI 10.1016/S1350-4487(99)00276-0; Cho JH, 2003, J KOREAN SOC THER RA, V21, P82; Gupta T, 2011, CLIN ONCOL-UK, V23, P86, DOI 10.1016/j.clon.2010.08.029; Hsu SH, 2008, PHYS MED BIOL, V53, P2593, DOI 10.1088/0031-9155/53/10/010; Khan Y., 2013, J CANC THERAPY, V04, P1251, DOI DOI 10.4236/JCT.2013.47147; Klein Eric E, 2003, J Appl Clin Med Phys, V4, P1, DOI 10.1120/1.1520113; Kudchadker R, 2002, MED PHYS, V29, P1337; Kudchadker R J, 2003, J Appl Clin Med Phys, V4, P321, DOI 10.1120/1.1621494; Lamb A, 1998, PHYS MED BIOL, V43, P1133, DOI 10.1088/0031-9155/43/5/006; LOEVINGER R, 1981, MED PHYS, V8, P1, DOI 10.1118/1.594901; Low DA, 1995, INT J RADIAT ONCOL, V33, P1127, DOI 10.1016/0360-3016(95)00257-X; Mihaylov IB, 2009, RADIOTHER ONCOL, V93, P147, DOI 10.1016/j.radonc.2009.05.008; Park JM, 2014, BR J RADIOL, V87; Park K, 2016, ONCOTARGET, P1; Perkins GH, 2001, INT J RADIAT ONCOL, V51, P1142, DOI 10.1016/S0360-3016(01)01744-8; Su S., 2014, J APPL CLIN MED PHYS, V15, P4831, DOI [DOI 10.1120/JACMP.V15I4.4831, 10.1120/jacmp.v15i4.4831]; Sung W, 2012, RADIAT ONCOL J, V30, P27, DOI 10.3857/roj.2012.30.1.27; TARVER RD, 1988, AM J ROENTGENOL, V151, P1117, DOI 10.2214/ajr.151.6.1117; Turner JY, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160060; Vyas V, 2013, MED DOSIM, V38, P268, DOI 10.1016/j.meddos.2013.02.007; Yoon Mee Sun, 2012, [PROGRESS in MEDICAL PHYSICS, 의학물리], V23, P219; Zou W, 2015, J APPL CLIN MED PHYS, V16, P90, DOI 10.1120/jacmp.v16i1.5090	26	34	37	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2016	11	12							e0168063	10.1371/journal.pone.0168063	http://dx.doi.org/10.1371/journal.pone.0168063			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4OA	27930717	Green Published, Green Submitted, gold			2023-01-03	WOS:000389580900077
J	Jin, HJ; Fang, W; Zhu, ML; Yu, ZZ; Fang, Y; Yan, H; Zhang, MF; Wang, Q; Che, XJ; Xie, YY; Huang, JY; Hu, CH; Zhang, HF; Mou, S; Ni, ZH				Jin, Haijiao; Fang, Wei; Zhu, Mingli; Yu, Zanzhe; Fang, Yan; Yan, Hao; Zhang, Minfang; Wang, Qin; Che, Xiajing; Xie, Yuanyuan; Huang, Jiaying; Hu, Chunhua; Zhang, Haifen; Mou, Shan; Ni, Zhaohui			Urgent-Start Peritoneal Dialysis and Hemodialysis in ESRD Patients: Complications and Outcomes	PLOS ONE			English	Article							BREAK-IN PERIOD; ACCESS; ASSOCIATIONS; MORTALITY; OPTION	Background Several studies have suggested that urgent-start peritoneal dialysis (PD) is a feasible alternative to hemodialysis (HD) in patients with end-stage renal disease (ESRD), but the impact of the dialysis modality on outcome, especially on short-term complications, in urgent-start dialysis has not been directly evaluated. The aim of the current study was to compare the complications and outcomes of PD and HD in urgent-start dialysis ESRD patients. Methods In this retrospective study, ESRD patients who initiated dialysis urgently without a preestablished functional vascular access or PD catheter at a single center from January 2013 to December 2014 were included. Patients were grouped according to their dialysis modality (PD and HD). Each patient was followed for at least 30 days after catheter insertion (until January 2016). Dialysis-related complications and patient survival were compared between the two groups. Results Our study enrolled 178 patients (56.2% male), of whom 96 and 82 patients were in the PD and HD groups, respectively. Compared with HD patients, PD patients had more cardiovascular disease, less heart failure, higher levels of serum potassium, hemoglobin, serum albumin, serum pre-albumin, and lower levels of brain natriuretic peptide. There were no significant differences in gender, age, use of steroids, early referral to a nephrologist, prevalence of primary renal diseases, prevalence of co-morbidities, and other laboratory characteristics between the groups. The incidence of dialysis-related complications during the first 30 days was significantly higher in HD than PD patients. HD patients had a significantly higher probability of bacteremia compared to PD patients. HD was an independent predictor of short-term (30-day) dialysis-related complications. There was no significant difference between PD and HD patients with respect to patient survival rate. Conclusion In an experienced center, PD is a safe and feasible dialysis alternative to HD for ESRD patients with an urgent need for dialysis.	[Jin, Haijiao; Fang, Wei; Zhu, Mingli; Yu, Zanzhe; Fang, Yan; Yan, Hao; Zhang, Minfang; Wang, Qin; Che, Xiajing; Xie, Yuanyuan; Huang, Jiaying; Hu, Chunhua; Zhang, Haifen; Mou, Shan; Ni, Zhaohui] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Nephrol, Shanghai, Peoples R China	Shanghai Jiao Tong University	Ni, ZH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Nephrol, Shanghai, Peoples R China.	profnizh@126.com		mou, shan/0000-0003-4160-1681	National Natural Science Foundation of China [81370794]; National "Twelfth Five-Year" Plan for Science and Technology [2011BAI10B08]; Research Project of Health Public Welfare Industry in China [201502023]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National "Twelfth Five-Year" Plan for Science and Technology; Research Project of Health Public Welfare Industry in China	This work was supported by the National Natural Science Foundation of China (81370794, http://www.nsfc.gov.cn) and the National "Twelfth Five-Year" Plan for Science and Technology (2011BAI10B08, http://prograrm.most.gov.cn) to Dr Ni, as well as the Research Project of Health Public Welfare Industry in China (201502023, http://www.moh.gov.cn) to Dr Lin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the National Natural Science Foundation of China (grant No. 81370794), the National "Twelfth Five-Year" Plan for Science & Technology (grant No. 2011BAI10B08), and the Research Project of Health Public Welfare Industry in China (grant No. 201502023).	Alkatheeri AMA, 2016, PERITON DIALYSIS INT, V36, P171, DOI 10.3747/pdi.2014.00148; [Anonymous], 2001, AM J KIDNEY DIS, V37, p137 ; Dean D, 2016, SEMIN DIAL; Dias DB, 2016, INT UROL NEPHROL, V48, P901, DOI 10.1007/s11255-016-1243-x; Dombros N., 2005, NEPHROL DIAL TRANSPL, V20, pix8, DOI DOI 10.1093/NDT/GFI1117; Figueiredo A, 2010, PERITON DIALYSIS INT, V30, P424, DOI 10.3747/pdi.2010.00087; Ghaffari A, 2012, AM J KIDNEY DIS, V59, P400, DOI 10.1053/j.ajkd.2011.08.034; Johnson DW, 2009, AM J KIDNEY DIS, V53, P290, DOI 10.1053/j.ajkd.2008.06.032; Koch M, 2012, NEPHROL DIAL TRANSPL, V27, P375, DOI 10.1093/ndt/gfr262; Lee T, 2005, AM J KIDNEY DIS, V46, P501, DOI 10.1053/j.ajkd.2005.05.024; Liangos O, 2006, SEMIN DIALYSIS, V19, P158, DOI 10.1111/j.1525-139X.2006.00143.x; Liu FX, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000293; Liu YR, 2014, PERITON DIALYSIS INT, V34, P49, DOI 10.3747/pdi.2012.00293; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Lobbedez T, 2008, NEPHROL DIAL TRANSPL, V23, P3290, DOI 10.1093/ndt/gfn213; Lok CE, 2013, CLIN J AM SOC NEPHRO, V8, P1213, DOI 10.2215/CJN.01690213; Lorenzo V, 2004, AM J KIDNEY DIS, V43, P999, DOI 10.1053/j.ajkd.2004.02.012; Povlsen JV, 2006, NEPHROL DIAL TRANSPL, V21, DOI 10.1093/ndt/gfl192; Ravani P, 2013, J AM SOC NEPHROL, V24, P465, DOI 10.1681/ASN.2012070643; Rehman R, 2009, CLIN J AM SOC NEPHRO, V4, P456, DOI 10.2215/CJN.03840808; Sharma AP, 2008, NEPHROLOGY, V13, P672, DOI 10.1111/j.1440-1797.2008.01000.x; United States Renal Data System, 2014, USRDS 2014 ANN DAT R, V2; United States Renal Data System, 2015, USRDS 2015 ANN DAT R, V2; United States Renal Data System, 2014, USRDS 2014 ANN DAT R, V1; US Renal Data System, 2011, AM J KIDNEY DIS, V57, P1, DOI [10.1053/j.ajkd.2010.11.005, DOI 10.1053/J.AJKD.2010.11.005]	25	45	49	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2016	11	11							e0166181	10.1371/journal.pone.0166181	http://dx.doi.org/10.1371/journal.pone.0166181			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB8BE	27824950	Green Published, gold, Green Submitted			2023-01-03	WOS:000387615200067
J	Kessel, KA; Lettner, S; Kessel, C; Bier, H; Biedermann, T; Friess, H; Herrschbach, P; Gschwend, JE; Meyer, B; Peschel, C; Schmid, R; Schwaiger, M; Wolff, KD; Combs, SE				Kessel, Kerstin A.; Lettner, Sabrina; Kessel, Carmen; Bier, Henning; Biedermann, Tilo; Friess, Helmut; Herrschbach, Peter; Gschwend, Juergen E.; Meyer, Bernhard; Peschel, Christian; Schmid, Roland; Schwaiger, Markus; Wolff, Klaus-Dietrich; Combs, Stephanie E.			Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients' Attitude towards CAM in a University-Based Oncology Center in Germany	PLOS ONE			English	Article							COMPREHENSIVE CANCER CENTER; RADIATION-THERAPY; DIETARY ANTIOXIDANTS; INCREASE SURVIVAL; CHEMOTHERAPY; ACUPUNCTURE; RADIOTHERAPY; AUSTRALIA; NUTRIENTS; WOMEN	Introduction To understand if and which patients would be open-minded to Complementary and Alternative Medicine (CAM) use parallel to their oncological treatment. Moreover, we sought to determine which methods are most accepted and which are the primary motivators to use CAM. Methods We developed and anonymously conducted a questionnaire for patients in the oncology center (TU Munich). Questions focus on different CAM methods, previous experiences, and willingness to apply or use CAM when offered in a university-based setting. Results A total of 171 of 376 patients (37.4% women, 62.0% men, 0.6% unknown) participated. This corresponds to a return rate of 45%. Median age was 64 years (17-87 years). Of all participants, 15.2% used CAM during their oncological therapy; 32.7% have used it in the past. The majority (81.9%) was not using CAM during therapy; 55.5% have not used CAM in the past respectively. The analysis revealed a significant correlation between education and CAM use during therapy (r = 0.18; p = 0.02), and CAM use in the past (r = 0.17; p = 0.04). Of all patients using CAM during therapy, favored methods were food supplements (42.3%), vitamins/minerals (42.3%), massage (34.6%). Motivations are especially the reduction of side effect and stress, the positive effect of certain CAM-treatments on the immune system and tumor therapy. Results showed no difference between women and men. Most patients not having had any experience with CAM complain about the deficiency of information by their treating oncologist (31.4%) as well as missing treatment possibilities (54.3%). Conclusion Since many patients believe in study results demonstrating the efficacy of CAM, it stresses our task to develop innovative study protocols to investigate the outcomes of certain CAM on symptom reduction or other endpoints. Thus, prospective trials and innovative evidence-based treatment concepts to include CAM into high-end oncology is what patients demand and what a modern oncology center should offer.	[Kessel, Kerstin A.; Lettner, Sabrina; Kessel, Carmen; Combs, Stephanie E.] TUM, Dept Radiat Oncol, Ismaninger Str 22, Munich, Germany; [Kessel, Kerstin A.; Combs, Stephanie E.] Helmholtz Zentrum Munchen, Inst Innovat Radiotherapy IRT, Ingolstadter Landstr 1, Neuherberg, Germany; [Kessel, Carmen; Combs, Stephanie E.] TUM, Onkol Zentrum, RHCCC, Klinikum Rechts Isar, Ismaninger Str 22, Munich, Germany; [Bier, Henning] TUM, Dept Otorhinolaryngol, Ismaninger Str 22, Munich, Germany; [Biedermann, Tilo] TUM, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, Munich, Germany; [Friess, Helmut] TUM, Dept Surg, Ismaninger Str 22, Munich, Germany; [Herrschbach, Peter] TUM, Roman Herzog Krebszentrum Comprehens Canc Ctr RHC, Trogerstr 26, Munich, Germany; [Gschwend, Juergen E.] TUM, Dept Urol, Ismaninger Str 22, Munich, Germany; [Meyer, Bernhard] TUM, Dept Neurosurg, Ismaninger Str 22, Munich, Germany; [Peschel, Christian] TUM, Dept Internal Med 3, Ismaninger Str 22, Munich, Germany; [Schmid, Roland] TUM, Dept Internal Med 2, Ismaninger Str 22, Munich, Germany; [Schwaiger, Markus] TUM, Dept Nucl Med, Ismaninger Str 22, Munich, Germany; [Wolff, Klaus-Dietrich] TUM, Dept Oral & Maxillofacial Surg, Ismaninger Str 22, Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; University of Munich; Technical University of Munich; Technical University of Munich; University of Munich; Technical University of Munich	Kessel, KA (corresponding author), TUM, Dept Radiat Oncol, Ismaninger Str 22, Munich, Germany.; Kessel, KA (corresponding author), Helmholtz Zentrum Munchen, Inst Innovat Radiotherapy IRT, Ingolstadter Landstr 1, Neuherberg, Germany.	Kerstin.Kessel@tum.de		Kessel, Carmen/0000-0002-3791-0206; Biedermann, Tilo/0000-0002-5352-5105				Abdallah R, 2015, INT J GYNECOL CANCER, V25, P1724, DOI 10.1097/IGC.0000000000000549; Adams J, 2015, INTEGR CANCER THER, V14, P359, DOI 10.1177/1534735415583555; Akpunar Dercan, 2015, Asian Pac J Cancer Prev, V16, P7847; AlBedah Abdullah M, 2015, Asian Pac J Cancer Prev, V16, P6799; Asadpour R, 2016, ADV RAD ONCOLOGY; Barnes P., 2007, COMPLEMENTARY ALTERN; Begbie SD, 1996, MED J AUSTRALIA, V165, P545, DOI 10.5694/j.1326-5377.1996.tb138639.x; Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; Cassileth BR, 2001, CANCER, V91, P1390, DOI 10.1002/1097-0142(20010401)91:7<1390::AID-CNCR1143>3.0.CO;2-C; Correa-Velez I, 2003, PALLIATIVE MED, V17, P695, DOI 10.1191/0269216303pm834oa; D'Andrea GM, 2005, CA-CANCER J CLIN, V55, P319, DOI 10.3322/canjclin.55.5.319; Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402; Endres HG, 2005, SCHMERZ, V19, P201, DOI 10.1007/s00482-004-0345-z; Endres HG, 2007, AKUPUNKTUR BEI CHRON; Gunawan S, 2016, PEDIATR BLOOD CANCER, V63, P118, DOI 10.1002/pbc.25689; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920; Huebner J, 2009, ONKOLOGE, DOI [10.1007/s00761-009-1764-3, DOI 10.1007/S00761-009-1764-3]; Huebner J, 2014, ONCOL RES TREAT, V37, DOI 10.1159/000362616; Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126; Knight Aishah, 2015, Asian Pac J Cancer Prev, V16, P3125; Labriola D, 1999, ONCOLOGY-NY, V13, P1003; Lawenda BD, 2008, JNCI-J NATL CANCER I, V100, P773, DOI 10.1093/jnci/djn148; Magi T, 2015, USE COMPLEMENTARY AL, V10, DOI [10.1371/journal.pone.0145787, DOI 10.1371/JOURNAL.PONE.0145787]; Mani J, 2015, USE COMPLEMENTARY AL, P1407, DOI [10.2147/PPA.S90061, DOI 10.2147/PPA.S90061]; Micke O, 2009, EUR J INTEGR MED, V1, P19, DOI 10.1016/j.eujim.2009.02.001; Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110; Molassiotis A, 2006, EUROPEAN J, DOI [10.1111/j.1365-2354.2005.00615.x/pdf, DOI 10.1111/J.1365-2354.2005.00615.X/PDF]; Montazeri A, 2007, EUR J CANCER CARE, V16, P144, DOI 10.1111/j.1365-2354.2006.00722.x; Montazeri A, 2005, SUPPORT CARE CANCER, V13, P339, DOI 10.1007/s00520-004-0709-z; Naja F, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0969-9; Nakayama A, 2011, CANCER INVEST, V29, P655, DOI 10.3109/07357907.2011.626479; National Institutes of Health Bethesda MD (US), 2002, ACT HUM GEN NOM COMM, DOI [10.2172/804185, DOI 10.2172/804185]; Nazik E, 2012, ASIAN PAC J CANCER P, V13, P21, DOI 10.7314/APJCP.2012.13.1.021; Nissen N, 2012, FORSCH KOMPLEMENTMED, V19, P9, DOI 10.1159/000342710; Ojukwu M, 2015, INTEGR CANCER THER, V14, P503, DOI 10.1177/1534735415589347; Paul M, 2013, J CANCER RES CLIN, V139, P1515, DOI 10.1007/s00432-013-1460-y; Rausch SM, 2011, SUPPORT CARE CANCER, V19, P521, DOI 10.1007/s00520-010-0846-5; Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505; Risberg T, 2003, QUAL LIFE RES, V12, P539, DOI 10.1023/A:1025063705413; Robotin M, 2012, COMPLEMENT THER MED, V20, P345, DOI 10.1016/j.ctim.2012.04.001; Shumer G, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-360; Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515; Simone CB, 2007, ALTERN THER HEALTH M, V13, P40; Simone CB, 2007, ALTERN THER HEALTH M, V13, P22; Sullivan A, 2015, INTEGR CANCER THER, V14, P350, DOI 10.1177/1534735415580679; Ustundag S, 2015, HOLIST NURS PRACT, V29, P357, DOI 10.1097/HNP.0000000000000113; Vickers A, 2004, HEALTH TECHNOL ASSES, V8, DOI [10.3310/hta8480, DOI 10.3310/HTA8480]; Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102; Yates JS, 2005, SUPPORT CARE CANCER, V13, P806, DOI 10.1007/s00520-004-0770-7; Yeung K Simon, 2007, J Soc Integr Oncol, V5, P113, DOI 10.2310/7200.2007.008; Yidirim Y, 2006, EUR J GYNAECOL ONCOL, V27, P81	52	33	34	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2016	11	11							e0165801	10.1371/journal.pone.0165801	http://dx.doi.org/10.1371/journal.pone.0165801			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA8SX	27812163	Green Published, gold, Green Submitted			2023-01-03	WOS:000386910000059
J	Fonsah, JY; Njamnshi, AK; Kouanfack, C; Qiu, F; Njamnshi, DM; Tagny, CT; Nchindap, E; Kenmogne, L; Mbanya, D; Heaton, R; Kanmogne, GD				Fonsah, Julius Y.; Njamnshi, Alfred K.; Kouanfack, Charles; Qiu, Fang; Njamnshi, Dora M.; Tagny, Claude T.; Nchindap, Emilienne; Kenmogne, Leopoldine; Mbanya, Dora; Heaton, Robert; Kanmogne, Georgette D.			Adherence to Antiretroviral Therapy (ART) in Yaounde-Cameroon: Association with Opportunistic Infections, Depression, ART Regimen and Side Effects	PLOS ONE			English	Article							ANRS 12110/ESTHER TRIAL; NONADHERENCE; PATTERNS; AFRICA; IMPACT; ADULTS; TIME	Following global efforts to increase antiretroviral therapy (ART) access in Sub-Saharan Africa, ART coverage among HIV-infected Cameroonians increased from 0% in 2003 to 22% in 2014. However, the success of current HIV treatment programs depends not only on access to ART, but also on retention in care and good treatment adherence. This is necessary to achieve viral suppression, prevent virologic failure, and reduce viral transmission and HIV/AIDS-related deaths. Previous studies in Cameroon showed poor adherence, treatment interruption, and loss to follow-up among HIV+ subjects on ART, but the factors that influence ART adherence are not well known. In the current cross-sectional study, patient/self-reported questionnaires and pharmacy medication refill data were used to quantify ART adherence and determine the factors associated with increased risk of non-adherence among HIV-infected Cameroonians. We demonstrated that drug side-effects, low CD4 cell counts and higher viral loads are associated with increased risk of non-adherence, and compared to females, males were more likely to forego ART because of side effects (p< 0.05). Univariate logistic regression analysis demonstrated that subjects with opportunistic infections (on antibiotics) had 2.42-times higher odds of having been non-adherent (p< 0.001). Multivariable analysis controlling for ART regimen, age, gender, and education showed that subjects with opportunistic infections had 3.1-times higher odds of having been non-adherent (p< 0.0003), with significantly longer periods of non-adherence, compared to subjects without opportunistic infections (p = 0.02). We further showed that compared to younger subjects (<= 40 years), older subjects (>40 years) were less likely to be non-adherent (p< 0.01) and had shorter non-adherent periods (p< 0.0001). The presence of depression symptoms correlated with non-adherence to ART during antibiotic treatment (r = 0.53, p = 0.04), and was associated with lower CD4 cell counts (p = 0.04) and longer non-adherent periods (p = 0.04). Change in ART regimen was significantly associated with increased likelihood of non-adherence and increased duration of the non-adherence period. Addressing these underlying risk factors could improve ART adherence, retention in care and treatment outcomes for HIV/AIDS patients in Cameroon.	[Fonsah, Julius Y.; Njamnshi, Alfred K.] Yaounde Cent Hosp, Dept Neurol, Yaounde, Cameroon; [Fonsah, Julius Y.; Njamnshi, Alfred K.; Kouanfack, Charles; Tagny, Claude T.; Mbanya, Dora] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon; [Kouanfack, Charles; Njamnshi, Dora M.] Yaounde Cent Hosp, HIV Day Care Serv, Yaounde, Cameroon; [Qiu, Fang] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA; [Tagny, Claude T.; Nchindap, Emilienne; Kenmogne, Leopoldine; Mbanya, Dora] Univ Yaounde, Teaching Hosp, Yaounde, Cameroon; [Heaton, Robert] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Kanmogne, Georgette D.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA	University of Yaounde I; University of Nebraska System; University of Nebraska Medical Center; University of Yaounde I; University of California System; University of California San Diego; University of Nebraska System; University of Nebraska Medical Center	Kanmogne, GD (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	gkanmogne@unmc.edu			NIMH [RO1 MH094160]; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062512, R01MH094160] Funding Source: NIH RePORTER	NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by NIMH RO1 MH094160.	Abah Isaac Okoh, 2016, J Int Assoc Provid AIDS Care, V15, P77, DOI 10.1177/2325957414539197; Al-Dakkak I, 2013, AIDS CARE, V25, P400, DOI 10.1080/09540121.2012.712667; [Anonymous], 2015, GLOB HLTH OBS IND ES; Badiee J, 2012, AIDS PATIENT CARE ST, V26, P388, DOI 10.1089/apc.2011.0447; Bank W, 2016, ANT THER COV PEOPL A; Barroso J, 2001, QUAL HEALTH RES, V11, P491, DOI 10.1177/104973201129119271; Beck A.T., 1996, PSYCHOL CORP; Bor J, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001905; Boulle C, 2015, JAIDS-J ACQ IMM DEF, V69, P355, DOI 10.1097/QAI.0000000000000604; Bragard I, 2013, CANCER RADIOTHER, V17, P731, DOI 10.1016/j.canrad.2013.05.014; Cauldbeck MB, 2009, AIDS RES THER, V6, P7, DOI DOI 10.1186/1742-6405-6-7; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Chkhartishvili Nikoloz, 2014, J Int AIDS Soc, V17, P18885, DOI 10.7448/IAS.17.1.18885; Corbiere M, 2011, CLIN J PAIN, V27, P62, DOI 10.1097/AJP.0b013e3181eef903; Cornell M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001304; Cunningham S, 2008, J CAN ACAD CHILD ADO, V17, P137; Denison JA, 2015, AIDS, V29, P361, DOI 10.1097/QAD.0000000000000543; Duran S, 2001, HIV Clin Trials, V2, P38; Ehlers Valerie J., 2015, Curationis, V38, P1, DOI [10.4102/curationis.v38i1.1255, 10.4102/CURATIONIS.V38I1.1255]; Ekouevi DK, 2010, TROP MED INT HEALTH, V15, P34, DOI 10.1111/j.1365-3156.2010.02505.x; Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1; Fokam J, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0129210, 10.137]; Gaynes BN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140001; Gonzalez-Serna A, 2014, J ANTIMICROB CHEMOTH, V69, P2202, DOI 10.1093/jac/dku112; Gordon LL, 2015, AIDS PATIENT CARE ST, V29, P384, DOI 10.1089/apc.2014.0165; Grimwade K, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003508.pub2; Hsu J., 1996, MULTIPLE COMP THEORY; Johnson MO, 2009, J GEN INTERN MED, V24, P247, DOI 10.1007/s11606-008-0854-z; Kanmogne GD, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-60; Kaplan JE, 1996, AM J TROP MED HYG, V55, P1; Kindzeka ME., 2013, SHORTAGE ARVS HITS C; Kouanfack C, 2008, JAIDS-J ACQ IMM DEF, V48, P216, DOI 10.1097/QAI.0b013e3181743955; Kunutsor S, 2010, AIDS RES TREAT, V2010, DOI 10.1155/2010/872396; Lahlou-Laforet K, 2015, J AFFECT DISORDERS, V184, P256, DOI 10.1016/j.jad.2015.05.056; Lamb MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038443; Langebeek N, 2014, BMC MED, V12, DOI [10.1186/s12916-014-0142-1, 10.1186/PREACCEPT-1453408941291432]; Legrand F, 2007, J SPORT EXERCISE PSY, V29, P348, DOI 10.1123/jsep.29.3.348; Marcotte D, 2014, CIENC SAUDE COLETIVA, V19, P785, DOI 10.1590/1413-81232014193.16072013; Mbuagbaw L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046909; Meloni ST, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu055; Meresse M, 2014, HIV MED, V15, P478, DOI 10.1111/hiv.12140; Meresse M, 2013, ANTIVIR THER, V18, P29, DOI 10.3851/IMP2535; Muula AS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-63; Muya Aisa N, 2015, J Int Assoc Provid AIDS Care, V14, P163, DOI 10.1177/2325957414539193; NACC, 2010, IMP HIV AIDS CAM 202; NACC, 2014, RAPP NAT SUIV DECL P; Newman J, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/725713; Pefura-Yone EW, 2013, J INFECT PUBLIC HEAL, V6, P307, DOI 10.1016/j.jiph.2013.02.003; Perrine R, 2011, JAIDS-J ACQ IMM DEF, V57, pS40, DOI 10.1097/QAI.0b013e318222b5c2; Protopopescu C, 2009, J ANTIMICROB CHEMOTH, V64, P599, DOI 10.1093/jac/dkp232; Reynolds NR, 2007, JAIDS-J ACQ IMM DEF, V46, P402, DOI 10.1097/QAI.0b013e318158a44f; Rougemont Mathieu, 2009, AIDS Res Ther, V6, P21, DOI 10.1186/1742-6405-6-21; Saberi P, 2015, AIDS PATIENT CARE ST, V29, P111, DOI 10.1089/apc.2014.0255; Safren SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104178; Sangeda RZ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1035; Takarinda KC, 2015, INT J INFECT DIS, V30, P98, DOI 10.1016/j.ijid.2014.11.009; UNAIDS, 2014, 2014 PROGR REP GLOB; UNAIDS, 2013, ACC ANT THER AFR STA; UNAIDS, 2015, FACT SHEET 2015 GLOB; Uthman OA, 2014, CURR HIV-AIDS REP, V11, P291, DOI 10.1007/s11904-014-0220-1; World Health Organization, 2015, CONGUID UANT DRU	61	54	54	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2017	12	1							e0170893	10.1371/journal.pone.0170893	http://dx.doi.org/10.1371/journal.pone.0170893			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN6QW	28141867	Green Published, Green Submitted, gold			2023-01-03	WOS:000396129500024
J	Ullenhag, GJ; Mozaffari, F; Broberg, M; Mellstedt, H; Liljefors, M				Ullenhag, Gustav J.; Mozaffari, Fariba; Broberg, Mats; Mellstedt, Hakan; Liljefors, Maria			Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer	PLOS ONE			English	Article							REGULATORY T-CELLS; PHASE-I; IMMUNOMODULATORY DRUGS; ADJUVANT CHEMOTHERAPY; THALIDOMIDE ANALOG; SUPPRESSOR-CELLS; PLUS GEMCITABINE; DENDRITIC CELLS; SOLID TUMORS; TRIAL	Purpose To assess the immunomodulatory and clinical effects of lenalidomide with standard treatment of gemcitabine in patients with advanced pancreatic cancer. Patients and Methods Patients with advanced pancreatic cancer were treated in first line with lenalidomide orally for 21 days of a 28 days cycle and the standard regimen for gemcitabine. In Part I, which we previously have reported, the dose of lenalidomide was defined (n = 12). In Part II, every other consecutive patient was treated with either lenalidomide (Group A, n = 11) or gemcitabine (Group B, n = 10) during cycle 1. From cycle 2 on, all Part II patients received the combination. Results A significant decrease in the proliferative response of peripheral blood mononuclear cells and the frequency of DCs were noted in patients at baseline compared to healthy control donors while the frequencies of CD4+ and CD8+ T cells, NK-cells and MDSCs were significantly higher in patients compared to controls. In Group A, a significant increase in the absolute numbers of activated (HLA-DR+) CD4 and CD8 T cells and CD8 effector memory T cells (p<0.01) was noted during treatment. A statistical increment in the absolute numbers of Tregs were seen after cycle 1 (p<0.05). The addition of gemcitabine, reduced most lymphocyte subsets (p<0.05). In Group B, the proportion of lymphocytes remained unchanged during the study period. There was no difference in overall survival, progression free survival and survival rate at one year comparing the two groups. Discussion Patients with advanced pancreatic carcinoma had impaired immune functions. Lenalido-mide augmented T cell reactivities, which were abrogated by gemcitabine. However, addition of lenalidomide to gemcitabine seemed to have no therapeutic impact compared to gemcitabine alone in this non-randomized study.	[Ullenhag, Gustav J.] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Ullenhag, Gustav J.] Univ Uppsala Hosp, Dept Oncol, Entrance 78, Uppsala, Sweden; [Mozaffari, Fariba; Mellstedt, Hakan; Liljefors, Maria] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden; [Broberg, Mats] Danderyd Hosp, Dept Oncol, Stockholm, Sweden; [Liljefors, Maria] Karolinska Univ Hosp Solna, Dept Oncol, Stockholm, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Karolinska University Hospital	Liljefors, M (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden.; Liljefors, M (corresponding author), Karolinska Univ Hosp Solna, Dept Oncol, Stockholm, Sweden.	maria.gustafsson-liljefors@karolinska.se			Swedish Cancer Society [110711]; Karolinska Institute Foundation; Stockholm County Council [20150070]; Research Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond; Lion's Cancer Fund; Celgene Corporation, Summit, NJ, USA	Swedish Cancer Society(Swedish Cancer Society); Karolinska Institute Foundation(Karolinska Institutet); Stockholm County Council(Stockholm County Council); Research Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond; Lion's Cancer Fund; Celgene Corporation, Summit, NJ, USA	This investigator-initiated study was supported by the Swedish Cancer Society (Grant no. 110711, URL: www.cancerfonden.se); The Karolinska Institute Foundation (URL: https://fonder.ki.se/) and the Stockholm County Council (ALF) (Grant nr. 20150070, URL: https://forskningsstod.vmi.se/Ansokan/start.asp); the Research Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond; Lion's Cancer Fund and in part by a grant from Celgene Corporation, Summit, NJ, USA which provided the lenalidomide. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexakis N, 2004, BRIT J SURG, V91, P1410, DOI 10.1002/bjs.4794; Amato RJ, 2008, AM J CLIN ONCOL-CANC, V31, P244, DOI [10.1097/COC.0b013e31815e45H, 10.1097/COC.0b013e31815e451f]; Bartlett JB, 2004, BRIT J CANCER, V90, P955, DOI 10.1038/sj.bjc.6601579; Bazhin AV, 2014, CANCER IMMUNOL IMMUN, V63, P59, DOI 10.1007/s00262-013-1485-8; Bergmann-Leitner ES, 2001, CANCER IMMUNOL IMMUN, V50, P445, DOI 10.1007/s002620100229; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Corral LG, 1999, J IMMUNOL, V163, P380; Crane E, 2005, CANCER INVEST, V23, P625, DOI 10.1080/07357900500283101; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Dredge K, 2005, MICROVASC RES, V69, P56, DOI 10.1016/j.mvr.2005.01.002; European Medicine Agency (EMA) Science Medicine Health, 2013, SPC LEN PDF; Freelove R, 2006, AM FAM PHYSICIAN, V73, P485; Fritz S, 2015, DIGEST DIS, V33, P99, DOI 10.1159/000368448; Fryer RA, 2011, ANTICANCER RES, V31, P3747; Galustian C, 2009, CANCER IMMUNOL IMMUN, V58, P1033, DOI 10.1007/s00262-008-0620-4; Hayashi T, 2005, BRIT J HAEMATOL, V128, P192, DOI 10.1111/j.1365-2141.2004.05286.x; Homma Y, 2014, CLIN TRANSL ONCOL, V16, P330, DOI 10.1007/s12094-013-1079-0; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Infante JR, 2013, CANCER BIOL THER, V14, P340, DOI 10.4161/cbt.23625; Infante JR, 2011, EUR J CANCER, V47, P199, DOI 10.1016/j.ejca.2010.09.002; LeBlanc R, 2004, BLOOD, V103, P1787, DOI 10.1182/blood-2003-02-0361; Lee BN, 2011, CANCER-AM CANCER SOC, V117, P3999, DOI 10.1002/cncr.25983; Lindemalm C, 2008, SUPPORT CARE CANCER, V16, P57, DOI 10.1007/s00520-007-0275-2; Lioznov M, 2010, BONE MARROW TRANSPL, V45, P349, DOI 10.1038/bmt.2009.155; Maraveyas A, 2012, EUR J CANCER, V48, P1283, DOI 10.1016/j.ejca.2011.10.017; Miller AA, 2007, J THORAC ONCOL, V2, P445, DOI 10.1097/01.JTO.0000268679.33238.67; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mozaffari F, 2009, CANCER IMMUNOL IMMUN, V58, P111, DOI 10.1007/s00262-008-0530-5; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; PITUCHNOWOROLSKA A, 1981, ARCH IMMUNOL THER EX, V29, P161; Plate JMD, 2005, CANCER IMMUNOL IMMUN, V54, P915, DOI 10.1007/s00262-004-0638-1; Sanborn SL, 2009, INVEST NEW DRUG, V27, P453, DOI 10.1007/s10637-008-9200-x; Schmitz-Winnenthal FH, 2005, CANCER RES, V65, P10079, DOI 10.1158/0008-5472.CAN-05-1098; Sharma RA, 2006, EUR J CANCER, V42, P2318, DOI 10.1016/j.ejca.2006.05.018; Soeda A, 2009, JPN J CLIN ONCOL, V39, P797, DOI 10.1093/jjco/hyp112; Srivastava MK, 2010, CANCER RES, V70, P68, DOI 10.1158/0008-5472.CAN-09-2587; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Suzuki E, 2007, CANCER BIOL THER, V6, P880, DOI 10.4161/cbt.6.6.4090; Teo SK, 2005, AAPS J, V7, pE14, DOI 10.1208/aapsj070103; Ullenhag GJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121197; Vizio B, 2012, EXP THER MED, V4, P70, DOI 10.3892/etm.2012.553; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wolf AM, 2003, CLIN CANCER RES, V9, P606; Wu L, 2011, CANCER IMMUNOL IMMUN, V60, P61, DOI 10.1007/s00262-010-0919-9; Yamamoto T, 2012, PANCREAS, V41, P409, DOI 10.1097/MPA.0b013e3182373a66; Yanagimoto H, 2005, CLIN IMMUNOL, V114, P52, DOI 10.1016/j.clim.2004.09.007	48	10	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2017	12	1							e0169736	10.1371/journal.pone.0169736	http://dx.doi.org/10.1371/journal.pone.0169736			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3HH	28099502	Green Published, Green Submitted, gold			2023-01-03	WOS:000392380100031
J	Block, GA; Bushinsky, DA; Cheng, SF; Cunningham, J; Dehmel, B; Drueke, TB; Ketteler, M; Kewalramani, R; Martin, KJ; Moe, SM; Patel, UD; Silver, J; Sun, Y; Wang, H; Chertow, GM				Block, Geoffrey A.; Bushinsky, David A.; Cheng, Sunfa; Cunningham, John; Dehmel, Bastian; Drueke, Tilman B.; Ketteler, Markus; Kewalramani, Reshma; Martin, Kevin J.; Moe, Sharon M.; Patel, Uptal D.; Silver, Justin; Sun, Yan; Wang, Hao; Chertow, Glenn M.			Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALCIUM-SENSING RECEPTOR; CHRONIC KIDNEY-DISEASE; AMG 416 VELCALCETIDE; PEPTIDE AGONIST; CARDIOVASCULAR-DISEASE; MINERAL METABOLISM; EVOLVE TRIAL; DIALYSIS; FGF23; BONE	IMPORTANCE Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is suboptimal in the majority of patients receiving hemodialysis. An intravenously (IV) administered calcimimetic could improve adherence and reduce adverse gastrointestinal effects. OBJECTIVE To evaluate the relative efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet. DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind, double-dummy active clinical trial was conducted comparing IV etelcalcetide vs oral placebo and oral cinacalcet vs IV placebo in 683 patients receiving hemodialysis with serum parathyroid hormone (PTH) concentrations higher than 500 pg/mL on active therapy at 164 sites in the United States, Canada, Europe, Russia, and New Zealand. Patients were enrolled from August 2013 to May 2014, with end of follow-up in January 2015. INTERVENTIONS Etelcalcetide intravenously and oral placebo (n = 340) or oral cinacalcet and IV placebo (n = 343) for 26 weeks. The IV study drug was administered 3 times weekly with hemodialysis; the oral study drug was administered daily. MAIN OUTCOMES AND MEASURES The primary efficacy end pointwas noninferiority of etelcalcetide at achieving more than a 30% reduction from baseline in mean predialysis PTH concentrations during weeks 20-27 (noninferiority margin, 12.0%). Secondary end points included superiority in achieving biochemical end points (> 50% and > 30% reduction in PTH) and self-reported nausea or vomiting. RESULTS The mean (SD) age of the trial participants was 54.7 (14.1) years and 56.2% were men. Etelcalcetide was noninferior to cinacalcet on the primary end point. The estimated difference in proportions of patients achieving reduction in PTH concentrations of more than 30% between the 198 of 343 patients (57.7%) randomized to receive cinacalcet and the 232 of 340 patients (68.2%) randomized to receive etelcalcetide was -10.5%(95% CI, -17.5% to -3.5%, P for noninferiority, <. 001; P for superiority,.004). One hundred seventy-eight patients (52.4%) to randomized etelcalcetide achieved more than 50% reduction in PTH concentrations compared with 138 patients (40.2%) randomized to cinacalcet (P =.001; difference in proportions, 12.2%; 95% CI, 4.7% to 19.5%). The most common adverse effect was decreased blood calcium (68.9% vs 59.8%). CONCLUSIONS AND RELEVANCE Among patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism, the use of etelcalcetide was not inferior to cinacalcet in reducing serum PTH concentrations over 26 weeks; it also met superiority criteria. Further studies are needed to assess clinical outcomes as well as longer-term efficacy and safety. Copyright 2016 American Medical Association. All rights reserved.	[Block, Geoffrey A.] Denver Nephrol, Denver, CO USA; [Bushinsky, David A.] Univ Rochester, Rochester, NY USA; [Cheng, Sunfa; Dehmel, Bastian; Kewalramani, Reshma; Sun, Yan; Wang, Hao] Amgen Inc, Thousand Oaks, CA 91320 USA; [Cunningham, John] UCL, London, England; [Drueke, Tilman B.] Univ Picardie, INSERM, Amiens, France; [Ketteler, Markus] Klinikum Coburg GmbH, Coburg, Germany; [Martin, Kevin J.] St Louis Univ, St Louis, MO 63103 USA; [Moe, Sharon M.] Indiana Univ, Indianapolis, IN USA; [Patel, Uptal D.] Duke Univ, Durham, NC USA; [Silver, Justin] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel; [Chertow, Glenn M.] Stanford Univ, Stanford, CA 94305 USA	University of Rochester; Amgen; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); Klinikum Coburg; Saint Louis University; Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; Hebrew University of Jerusalem; Hadassah University Medical Center; Stanford University	Chertow, GM (corresponding author), Stanford Univ, Sch Med, 1070 Arastradero Rd,Ste 313, Palo Alto, CA 94034 USA.	gchertow@stanford.edu	DRUEKE, Tilman B./B-4958-2010; Centeno, Patricia Pacios/O-8368-2016; Block, Geoffrey/AAV-8070-2021	DRUEKE, Tilman B./0000-0002-0700-7681; Block, Geoffrey/0000-0002-4646-7074; Chertow, Glenn/0000-0002-7599-0534	Amgen	Amgen(Amgen)	The trial was sponsored by Amgen. An academically led trial steering committee-supervised trial design and operation; Amgen employees were nonvoting members of the trial steering committee.	Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Block GA, 2017, JAMA-J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456; Bushinsky DA, 2015, AM J NEPHROL, V42, P379, DOI 10.1159/000442754; Chen P, 2015, J CLIN PHARMACOL, V55, P620, DOI 10.1002/jcph.460; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Cozzolino M, 2014, BLOOD PURIFICAT, V38, P37, DOI 10.1159/000365386; Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47; Koch GG, 2008, STAT MED, V27, P333, DOI 10.1002/sim.2923; Levin A, 2014, NEPHROL DIAL TRANSPL, V29, P1037, DOI 10.1093/ndt/gft479; Fernandez-Martin JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099; Martin KJ, 2014, NEPHROL DIAL TRANSPL, V29, P385, DOI 10.1093/ndt/gft417; Martin KJ, 2014, KIDNEY INT, V85, P191, DOI 10.1038/ki.2013.289; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876; Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414; Poelzl G, 2014, EUR J CLIN INVEST, V44, P1150, DOI 10.1111/eci.12349; Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213; Walter S, 2013, J PHARMACOL EXP THER, V346, P229, DOI 10.1124/jpet.113.204834; Wheeler DC, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001363; Yusuf AA, 2014, AM J KIDNEY DIS, V64, P770, DOI 10.1053/j.ajkd.2014.04.014	22	131	145	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2017	317	2					156	164		10.1001/jama.2016.19468	http://dx.doi.org/10.1001/jama.2016.19468			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH5PV	28097356	Green Published, Bronze			2023-01-03	WOS:000391826200018
J	Kho, ME; Molloy, AJ; Clarke, FJ; Ajami, D; McCaughan, M; Obrovac, K; Murphy, C; Camposilvan, L; Herridge, MS; Koo, KKY; Rudkowski, J; Seely, AJE; Zanni, JM; Mourtzakis, M; Piraino, T; Cook, DJ				Kho, Michelle E.; Molloy, Alexander J.; Clarke, France J.; Ajami, Daana; McCaughan, Magda; Obrovac, Kristy; Murphy, Christina; Camposilvan, Laura; Herridge, Margaret S.; Koo, Karen K. Y.; Rudkowski, Jill; Seely, Andrew J. E.; Zanni, Jennifer M.; Mourtzakis, Marina; Piraino, Thomas; Cook, Deborah J.		Canadian Critical Care Trials Grp	TryCYCLE: A Prospective Study of the Safety and Feasibility of Early In-Bed Cycling in Mechanically Ventilated Patients	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; NEUROMUSCULAR ELECTRICAL-STIMULATION; PHYSICAL FUNCTION; INTEROBSERVER AGREEMENT; FUNCTIONAL DISABILITY; HANDGRIP STRENGTH; ACQUIRED WEAKNESS; ICU SURVIVORS; MUSCLE MASS	Introduction The objective of this study was to assess the safety and feasibility of in-bed cycling started within the first 4 days of mechanical ventilation (MV) to inform a future randomized clinical trial. Methods We conducted a 33-patient prospective cohort study in a 21-bed adult academic medical-surgical intensive care unit (ICU) in Hamilton, ON, Canada. We included adult patients (>= 18 years) receiving MV who walked independently pre-ICU. Our intervention was 30 minutes of in-bed supine cycling 6 days/week in the ICU. Our primary outcome was Safety (termination), measured as events prompting cycling termination; secondary Safety (disconnection or dislodgement) outcomes included catheter/tube dislodgements. Feasibility was measured as consent rate and fidelity to intervention. For our primary outcome, we calculated the binary proportion and 95% confidence interval (CI). Results From 10/2013-8/2014, we obtained consent from 34 of 37 patients approached (91.9%), 33 of whom received in-bed cycling. Of those who cycled, 16(48.4%) were female, the mean (SD) age was 65.8(12.2) years, and APACHE II score was 24.3(6.7); 29(87.9%) had medical admitting diagnoses. Cycling termination was infrequent (2.0%, 95% CI: 0.8%-4.9%) and no device dislodgements occurred. Cycling began a median [IQR] of 3 [2, 4] days after ICU admission; patients received 5 [3, 8] cycling sessions with a median duration of 30.7 [21.6, 30.8] minutes per session. During 205 total cycling sessions, patients were receiving invasive MV (150 [73.1%]), vasopressors (6 [2.9%]), sedative or analgesic infusions (77 [37.6%]) and dialysis (4 [2.0%]). Conclusions Early cycling within the first 4 days of MV among hemodynamically stable patients is safe and feasible. Research to evaluate the effect of early cycling on patient function is warranted.	[Kho, Michelle E.] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [Kho, Michelle E.; Molloy, Alexander J.; Ajami, Daana; McCaughan, Magda; Obrovac, Kristy; Murphy, Christina; Camposilvan, Laura] St Josephs Healthcare, Dept Physiotherapy, Hamilton, ON, Canada; [Kho, Michelle E.; Zanni, Jennifer M.; Cook, Deborah J.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA; [Clarke, France J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Herridge, Margaret S.] Univ Toronto, Dept Med, Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada; [Koo, Karen K. Y.] Swedish Early Mobil Program Crit Care, Swedish Med Grp, First Hill Campus, Seattle, WA USA; [Koo, Karen K. Y.] Western Univ, Dept Med, London, ON, Canada; [Rudkowski, Jill] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Seely, Andrew J. E.] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Mourtzakis, Marina] Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada; [Piraino, Thomas] St Josephs Healthcare, Resp Therapy Serv, Hamilton, ON, Canada	McMaster University; Johns Hopkins University; McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Swedish Medical Center; Western University (University of Western Ontario); McMaster University; University of Ottawa; Ottawa Hospital Research Institute; University of Waterloo	Kho, ME (corresponding author), McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada.; Kho, ME (corresponding author), St Josephs Healthcare, Dept Physiotherapy, Hamilton, ON, Canada.; Kho, ME (corresponding author), Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA.	khome@mcmaster.ca	Piraino, Thomas/AAB-8938-2019; , Michelle/W-7414-2019	Herridge, Margaret/0000-0002-2903-1631; Kho, Michelle/0000-0003-3170-031X; Piraino, Thomas/0000-0002-4887-8686	Canadian Institutes of Health Research; Institute of Musculoskeletal Health and Arthritis Operating grant [131584]; Canada Research Chairs MEK DJC; Canadian Institutes of Health Research; Institute of Musculoskeletal Health and Arthritis Operating grant [131584]; Canada Research Chairs MEK DJC	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Institute of Musculoskeletal Health and Arthritis Operating grant; Canada Research Chairs MEK DJC; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Institute of Musculoskeletal Health and Arthritis Operating grant; Canada Research Chairs MEK DJC	This work was supported by: Canadian Institutes of Health Research (www.cihr-irsc.gc.ca.), Institute of Musculoskeletal Health and Arthritis Operating grant Priority Announcement: IMHA New investigators - Bridge Funding (131584) MEK DJC MSH KK MM JR AS; Canada Research Chairs MEK DJC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler Joseph, 2012, Cardiopulm Phys Ther J, V23, P5; Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; [Anonymous], 2002, CRIT CARE MED, V166, P111, DOI [10.1164/rccm.166/1/111, DOI 10.1164/RCCM.166/1/111]; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Brummel NE, 2014, INTENS CARE MED, V40, P370, DOI 10.1007/s00134-013-3136-0; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Calvo-Ayala E, 2013, CHEST, V144, P1469, DOI 10.1378/chest.13-0779; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Damluji A, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.01.006; Dantas Camila Moura, 2012, Rev. bras. ter. intensiva, V24, P173, DOI 10.1590/S0103-507X2012000200013; Daugherty EL, 2009, CRIT CARE MED, V37, P1210, DOI [10.1097/CCM.0b013e3181b6fa29, 10.1097/CCM.0b013e31819d67b5]; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Denehy L, 2013, PHYS THER, V93, P1636, DOI 10.2522/ptj.20120310; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Fan E, 2010, INTENS CARE MED, V36, P1038, DOI 10.1007/s00134-010-1796-6; Gerovasili V, 2009, CRIT CARE, V13, DOI 10.1186/cc8123; Groll DL, 2005, J CLIN EPIDEMIOL, V58, P595, DOI 10.1016/j.jclinepi.2004.10.018; Hermans G, 2012, MUSCLE NERVE, V45, P18, DOI 10.1002/mus.22219; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hickmann CE, 2014, INTENS CARE MED, V40, P548, DOI 10.1007/s00134-014-3218-7; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kayambu G, 2015, INTENS CARE MED, V41, P865, DOI 10.1007/s00134-015-3763-8; Kho ME, 2015, J CRIT CARE, V30, pe1, DOI DOI 10.1016/J.JCRC.2015.07.025; Kho ME, 2015, J CRIT CARE, V30, P32, DOI 10.1016/j.jcrc.2014.09.014; Kho ME, 2012, PHYS THER, V92, P1564, DOI 10.2522/ptj.20110437; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Korupolu R, 2009, CONT CRIT CARE, V6, P1; LEBLANC AD, 1992, J APPL PHYSIOL, V73, P2172, DOI 10.1152/jappl.1992.73.5.2172; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Needham DM, 2005, CRIT CARE MED, V33, P574, DOI [10.1097/01.CCM.0000155992.21174.31, 10.1097/01.ccm.0000155992.21174.31]; Parry SM, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2014.03.017; Pires-Neto RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074182; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Segers J, 2014, J CRIT CARE; Skinner EH, 2009, CRIT CARE RESUSC, V11, P110; Sricharoenchai T, 2014, J CRIT CARE, V29, P395, DOI 10.1016/j.jcrc.2013.12.012; TEAM Study Investigators, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0765-4; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Vanpee G, 2011, CRIT CARE MED, V39, P1929, DOI 10.1097/CCM.0b013e31821f050b; Vivodtzev I, 2014, CRIT CARE, V18, DOI 10.1186/cc13888; Zanni JM, 2010, J CRIT CARE, V25, P254, DOI 10.1016/j.jcrc.2009.10.010	48	32	35	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2016	11	12							e0167561	10.1371/journal.pone.0167561	http://dx.doi.org/10.1371/journal.pone.0167561			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7JB	28030555	Green Published, gold			2023-01-03	WOS:000391222000010
J	Hetland, G; Eide, DM; Tangen, JM; Haugen, MH; Mirlashari, MR; Paulsen, JE				Hetland, Geir; Eide, Dag M.; Tangen, Jon M.; Haugen, Mads H.; Mirlashari, Mohammad R.; Paulsen, Jan E.			The Agaricus blazei-Based Mushroom Extract, Andosan (TM), Protects against Intestinal Tumorigenesis in the A/J Min/ plus Mouse	PLOS ONE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; BLOOD EX-VIVO; MEDICINAL MUSHROOM; COLORECTAL-CANCER; LEGUMAIN EXPRESSION; ANTITUMOR-ACTIVITY; GRIFOLA-FRONDOSA; FRUITING BODIES; GENE-EXPRESSION; BREAST-CANCER	Background The novel A/J Min/+ mouse, which is a model for human Familial Adenomatous Polyposis (FAP), develops spontaneously multiple adenocarcinomas in the colon as well as in the small intestine. Agaricus blazei Murill (AbM) is an edible Basidiomycetes mushroom that has been used in traditional medicine against cancer and other diseases. The mushroom contains immunomodulating 8-glucans and is shown to have antitumor effects in murine cancer models. Andosan (TM) is a water extract based on AbM (82%), but it also contains the medicinal Basidiomycetes mushrooms Hericeum erinaceus and Grifola frondosa. Methods and findings Tap water with 10% Andosan (TM) was provided as the only drinking water for 15 or 22 weeks to AM Min/+ mice and A/J wild-type mice (one single-nucleotide polymorphism (SNP) difference), which then were exsanguinated and their intestines preserved in formaldehyde and the serum frozen. The intestines were examined blindly by microscopy and also stained for the tumor-associated protease, legumain. Serum cytokines (pro- and anti-inflammatory, Th1-, Th2 -and Th17 type) were measured by Luminex multiplex analysis. Andosan (TM) treated AM Min/+ mice had a significantly lower number of adenocarcinomas in the intestines, as well as a 60% significantly reduced intestinal tumor load (number of tumors x size) compared to control. There was also reduced legumain expression in intestines from Andosan (TM) treated animals. Moreover, Andosan (TM) had a significant cytotoxic effect correlating with apoptosis on the human cancer colon cell line, Caco-2, in vitro. When examining serum from both AM Min/+ and wild type mice, there was a significant increase in anti-tumor Th1 type and pro-inflammatory cytokines in the Andosan (TM) treated mice. Conclusions The results from this mouse model for colorectal cancer shows significant protection of orally administered Andosan (TM) against development of intestinal cancer. This is supported by the finding of less legumain in intestines of Andosan (TM) treated mice and increased systemic Th1 cytokine response. The mechanism is probably both immuno-modulatory and growth inhibition of tumor cells by induction of apoptosis.	[Hetland, Geir; Mirlashari, Mohammad R.] Oslo Univ Hosp, Dept Immunol, Oslo, Norway; [Hetland, Geir; Tangen, Jon M.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Eide, Dag M.] Norwegian Inst Publ Hlth, Dept Chem & Radiat, Oslo, Norway; [Tangen, Jon M.] Oslo Univ Hosp, Dept Acute Med, Oslo, Norway; [Tangen, Jon M.] Oslo Univ Hosp, Natl CBRNE Med & Advisory Ctr Norway, Oslo, Norway; [Haugen, Mads H.] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Tumor Biol, Inst Canc Res, Oslo, Norway; [Paulsen, Jan E.] Norwegian Univ Life Sci, Dept Food Safety & Infect Biol, Oslo, Norway	University of Oslo; University of Oslo; Norwegian Institute of Public Health (NIPH); University of Oslo; University of Oslo; University of Oslo; Norwegian University of Life Sciences	Hetland, G (corresponding author), Oslo Univ Hosp, Dept Immunol, Oslo, Norway.; Hetland, G (corresponding author), Univ Oslo, Inst Clin Med, Oslo, Norway.	geir.hetland@medisin.uio.no			Norwegian company Immunopharma	Norwegian company Immunopharma	The authors received no specific funding for this work, except for Andosan (TM) that was provided free of charge for the study from the Norwegian company Immunopharma.	Bernardshaw S, 2006, SHOCK, V25, P420, DOI 10.1097/01.shk.0000209526.58614.92; Bernardshaw S, 2007, APMIS, V115, P719, DOI 10.1111/j.1600-0463.2007.apm_619.x; Berven L, 2015, J MED FOOD, V18, P429, DOI 10.1089/jmf.2014.0018; Chan CB, 2009, P NATL ACAD SCI USA, V106, P468, DOI 10.1073/pnas.0809824105; De Jesus M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091002; Ellertsen Linda K, 2009, Clin Mol Allergy, V7, P6, DOI 10.1186/1476-7961-7-6; Ellertsen LK, 2006, INT IMMUNOPHARMACOL, V6, P133, DOI 10.1016/j.intimp.2005.07.007; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Forland DT, 2011, SCAND J IMMUNOL, V73, P66, DOI 10.1111/j.1365-3083.2010.02477.x; Forland DT, 2010, CYTOKINE, V49, P245, DOI 10.1016/j.cyto.2009.09.002; Gao L, 2007, BRAZ J MED BIOL RES, V40, P1545, DOI 10.1590/S0100-879X2007001100015; Gatner BN, 2003, J EXP MED, V197, P1107, DOI [10.1084/jem.20021787, DOI 10.1084/JEM.20021787]; Gawenda J, 2007, BREAST CANCER RES TR, V102, P1, DOI 10.1007/s10549-006-9311-z; Grinde B, 2006, INT IMMUNOPHARMACOL, V6, P1311, DOI 10.1016/j.intimp.2006.04.005; Half E, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-22; Haugen MH, 2015, EUR J CANCER, V51, P9, DOI 10.1016/j.ejca.2014.10.020; Hetland G, 2008, SCAND J IMMUNOL, V68, P363, DOI 10.1111/j.1365-3083.2008.02156.x; Hetland G, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/157015; Holson RR, 2008, NEUROTOXICOL TERATOL, V30, P326, DOI 10.1016/j.ntt.2007.06.001; Hopkins MH, 2012, BIOMARK INSIGHTS, V7, P143, DOI 10.4137/BMI.S10092; IKUZAWA M, 1988, INT J IMMUNOPHARMACO, V10, P415; ITOH H, 1994, JPN J PHARMACOL, V66, P265, DOI 10.1254/jjp.66.265; Johnson E, 2009, SCAND J IMMUNOL, V69, P242, DOI 10.1111/j.1365-3083.2008.02218.x; KAWAGISHI H, 1989, CARBOHYD RES, V186, P267, DOI 10.1016/0008-6215(89)84040-6; Kerrigan RW, 2005, MYCOLOGIA, V97, P12, DOI 10.3852/mycologia.97.1.12; Kim SP, 2013, J AGR FOOD CHEM, V61, P4898, DOI 10.1021/jf400916c; Lin YY, 2013, CANCER SCI, V104, P1217, DOI 10.1111/cas.12202; Liu C, 2003, CANCER RES, V63, P2957; Liu Y, 2012, MOL PHARMACEUT, V9, P168, DOI 10.1021/mp200434n; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Masuda Y, 2013, INT J CANCER, V133, P108, DOI 10.1002/ijc.27999; Metzler-Zebeli BU, 2011, FEMS MICROBIOL ECOL, V75, P402, DOI 10.1111/j.1574-6941.2010.01017.x; Miller G, 2011, FASEB J, V25, P1606, DOI 10.1096/fj.10-172312; Morita Y, 2007, FEBS LETT, V581, P1417, DOI 10.1016/j.febslet.2007.02.064; Murthy RV, 2005, CLIN CANCER RES, V11, P2293, DOI 10.1158/1078-0432.CCR-04-1642; Paulsen JE, 1997, CARCINOGENESIS, V18, P1905, DOI 10.1093/carcin/18.10.1905; Paulsen JE, 2000, TOXICOL LETT, V112, P403, DOI 10.1016/S0378-4274(99)00262-3; Pinheiro F, 2003, FOOD CHEM TOXICOL, V41, P1543, DOI 10.1016/S0278-6915(03)00171-6; Sodring M, 2016, INT J CANCER, V138, P1936, DOI 10.1002/ijc.29928; Sorimachi K, 2001, CELL STRUCT FUNCT, V26, P103, DOI 10.1247/csf.26.103; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUZUKI I, 1984, J PHARMACOBIO-DYNAM, V7, P492; Takaku T, 2001, J NUTR, V131, P1409, DOI 10.1093/jn/131.5.1409; Takimoto H, 2008, IMMUNOPHARM IMMUNOT, V30, P747, DOI [10.1080/08923970802279092, 10.1080/08923970802279092 ]; Tangen J. M., 2014, APPL SCI REPORTS, V1, P1, DOI DOI 10.7243/2054-9903-1-1; Tangen JM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/718539; Therkelsen SP, 2016, PLOS ONE; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; Yoo JY, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030173; Ziliotto L, 2009, NUTR CANCER, V61, P245, DOI 10.1080/01635580802395717	53	7	8	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2016	11	12							e0167754	10.1371/journal.pone.0167754	http://dx.doi.org/10.1371/journal.pone.0167754			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI9TW	28002446	gold, Green Published, Green Accepted			2023-01-03	WOS:000392853100021
J	Teerlink, JR; Felker, GM; McMurray, JJV; Solomon, SD; Adams, KF; Cleland, JGF; Ezekowitz, JA; Goudev, A; Macdonald, P; Metra, M; Mitrovic, V; Ponikowski, P; Serpytis, P; Spinar, J; Tomcsanyi, J; Vandekerckhove, HJ; Voors, AA; Monsalvo, ML; Johnston, J; Malik, FI; Honarpour, N				Teerlink, John R.; Felker, G. Michael; McMurray, John J. V.; Solomon, Scott D.; Adams, Kirkwood F., Jr.; Cleland, John G. F.; Ezekowitz, Justin A.; Goudev, Assen; Macdonald, Peter; Metra, Marco; Mitrovic, Veselin; Ponikowski, Piotr; Serpytis, Pranas; Spinar, Jindrich; Tomcsanyi, Janos; Vandekerckhove, Hans J.; Voors, Adriaan A.; Monsalvo, Maria Laura; Johnston, James; Malik, Fady I.; Honarpour, Narimon		COSMIC-HFf Investigators	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial	LANCET			English	Article							CARDIAC RESYNCHRONIZATION THERAPY; OMECAMTIV MECARBIL; TIME; MECHANISMS; PREDICTION; MORTALITY; EXERCISE; SAFETY	Background Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and eff ects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. Methods In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials. gov, number NCT01786512. Findings From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fi xed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fi xed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean diff erences were as follows: systolic ejection time 25 ms (95% CI 18-32, p< 0.0001), stroke volume 3.6 mL (0.5-6.7, p= 0.0217), left ventricular end-systolic diameter -1.8 mm (-2.9 to -0.6, p= 0.0027), left ventricular end-diastolic diameter -1.3 mm, (-2.3 to 0.3, p= 0.0128), heart rate -3.0 beats per min (-5.1 to -0.8, p= 0.0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p= 0.0069). The frequency of adverse clinical events did not diff er between groups. Interpretation Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter.	[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA; [Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA; [McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA; [Solomon, Scott D.] Harvard Med Sch, Boston, MA USA; [Adams, Kirkwood F., Jr.] Univ North Carolina Chapel Hill, Div Cardiol, Chapel Hill, NC USA; [Cleland, John G. F.] Imperial Coll, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England; [Cleland, John G. F.] Imperial Coll, Harefield Hosp, London, England; [Cleland, John G. F.] Univ Glasgow, Robertson Ctr Biostat & Clin Trials, Glasgow, Lanark, Scotland; [Ezekowitz, Justin A.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Goudev, Assen] Queen Giovanna Univ Hosp, Dept Cardiol, Sofia, Bulgaria; [Goudev, Assen] Med Univ Sofia, Sofia, Bulgaria; [Macdonald, Peter] St Vincents Hosp, Heart Transplant Unit, Sydney, NSW, Australia; [Macdonald, Peter] Victor Chang Cardiac Res Inst, Transplantat Res Lab, Sydney, NSW, Australia; [Macdonald, Peter] Univ New South Wales, Sydney, NSW, Australia; [Metra, Marco] Univ Brescia, Div Cardiol, Brescia, Italy; [Mitrovic, Veselin] Kerckhoff Klin Forsch Gesell, Frankfurt, Germany; [Mitrovic, Veselin] Goethe Univ Frankfurt, Mainz, Germany; [Ponikowski, Piotr] Med Univ, Dept Heart Dis, Wroclaw, Poland; [Ponikowski, Piotr] Mil Hosp, Ctr Heart Dis, Wroclaw, Poland; [Serpytis, Pranas] Vilnius Univ Hosp Santariskiu Klin, Emergency Ctr, Vilnius, Lithuania; [Serpytis, Pranas] Vilnius Univ, Vilnius, Lithuania; [Spinar, Jindrich] Univ Hosp Brno, Brno, Czech Republic; [Spinar, Jindrich] Masaryk Univ, Fac Med, Brno, Czech Republic; [Tomcsanyi, Janos] St John God Hosp, Dept Cardiol, Budapest, Hungary; [Vandekerckhove, Hans J.] AZ St Lucas, Dept Cardiol, Ghent, Belgium; [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Monsalvo, Maria Laura; Johnston, James; Honarpour, Narimon] Amgen Inc, Thousand Oaks, CA USA; [Malik, Fady I.] Cytokinetics, San Francisco, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Duke University; University of Glasgow; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Imperial College London; Royal Brompton Hospital; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of Glasgow; University of Alberta; Medical University Sofia; Medical University Sofia; St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of New South Wales Sydney; University of Brescia; Goethe University Frankfurt; Wroclaw Medical University; Vilnius University Hospital Santariskiu Klinikos; Vilnius University; University Hospital Brno; Masaryk University Brno; University of Groningen; Amgen	Teerlink, JR (corresponding author), San Francisco VA Med Ctr, Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA.	john.teerlink@ucsf.edu	Metra, marco/E-7101-2010; mcmurray, John/B-2467-2013; Macdonald, Peter/Q-3188-2019; Felker, Michael/AAX-2288-2021; Voors, Adriaan/ABE-6784-2020; Teerlink, John R/D-2986-2012; Cleland, John G./AAZ-4185-2020; Ponikowski, Piotr/O-6454-2015; Ezekowitz, Justin/C-4579-2013	mcmurray, John/0000-0002-6317-3975; Cleland, John G./0000-0002-1471-7016; Ponikowski, Piotr/0000-0002-3391-7064; Ezekowitz, Justin/0000-0002-2724-4086	Amgen; Cytokinetics; National Institute for Health Research [NF-SI-0611-10227] Funding Source: researchfish	Amgen(Amgen); Cytokinetics; National Institute for Health Research(National Institute for Health Research (NIHR))	Amgen.; The COSMIC-HF study was funded and done by Amgen in collaboration with Cytokinetics.	Apple FS, 2009, CLIN CHEM, V55, P1303, DOI 10.1373/clinchem.2009.128363; Biering-Sorensen T, 2015, J CARD FAIL, V21, pS84, DOI 10.1016/j.cardfail.2015.06.254; BRAUWNAL.E, 1967, NEW ENGL J MED, V277, P1012, DOI 10.1056/NEJM196711092771907; Cleland J, 2008, J AM COLL CARDIOL, V52, P438, DOI 10.1016/j.jacc.2008.04.036; Cleland JGF, 2011, LANCET, V378, P676, DOI 10.1016/S0140-6736(11)61126-4; Cleland JGF, 2009, J AM COLL CARDIOL, V54, P1850, DOI 10.1016/j.jacc.2009.06.041; Greenberg BH, 2015, JACC-HEART FAIL, V3, P22, DOI 10.1016/j.jchf.2014.07.009; Hasenfuss G, 2011, EUR HEART J, V32, P1838, DOI 10.1093/eurheartj/ehr026; Klinkenberg LJJ, 2014, J AM COLL CARDIOL, V63, P1788, DOI 10.1016/j.jacc.2014.01.040; Kramer DG, 2010, J AM COLL CARDIOL, V56, P392, DOI 10.1016/j.jacc.2010.05.011; Malik FI, 2011, SCIENCE, V331, P1439, DOI 10.1126/science.1200113; PACKER M, 1993, NEW ENGL J MED, V329, P201, DOI 10.1056/NEJM199307153290310; Palaparthy R, 2016, INT J CLIN PHARM TH, V54, P217, DOI 10.5414/CP202458; Rahimi K, 2014, JACC-HEART FAIL, V2, P440, DOI 10.1016/j.jchf.2014.04.008; Shave R, 2010, J AM COLL CARDIOL, V56, P169, DOI 10.1016/j.jacc.2010.03.037; Shen YT, 2010, CIRC-HEART FAIL, V3, P522, DOI 10.1161/CIRCHEARTFAILURE.109.930321; Solomon SD, 2010, CIRCULATION, V122, P985, DOI 10.1161/CIRCULATIONAHA.110.955039; Teerlink JR, 2016, J AM COLL CARDIOL, V67, P1444, DOI 10.1016/j.jacc.2016.01.031; Teerlink JR, 2011, LANCET, V378, P667, DOI 10.1016/S0140-6736(11)61219-1; Vu T, 2015, J CLIN PHARMACOL, V55, P1236, DOI 10.1002/jcph.538; Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001; Waldenstrom A, 2014, CIRC RES, V114, P315, DOI 10.1161/CIRCRESAHA.114.300584; WEISSLER AM, 1968, CIRCULATION, V37, P149, DOI 10.1161/01.CIR.37.2.149	23	172	176	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 10	2016	388	10062					2895	2903		10.1016/S0140-6736(16)32049-9	http://dx.doi.org/10.1016/S0140-6736(16)32049-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EE5FU	27914656	Green Submitted, Green Accepted			2023-01-03	WOS:000389631700034
J	Marzotto, M; Bonafini, C; Olioso, D; Baruzzi, A; Bettinetti, L; Di Leva, F; Galbiati, E; Bellavite, P				Marzotto, Marta; Bonafini, Clara; Olioso, Debora; Baruzzi, Anna; Bettinetti, Laura; Di Leva, Francesca; Galbiati, Elisabetta; Bellavite, Paolo			Arnica montana Stimulates Extracellular Matrix Gene Expression in a Macrophage Cell Line Differentiated to Wound-Healing Phenotype	PLOS ONE			English	Article							RECEPTOR-RELATED PROTEIN-1; IN-VITRO; SESQUITERPENE LACTONES; QUANTITATIVE-ANALYSIS; L.; FIBRONECTIN; PLANT; SENSITIVITY; ACTIVATION; REGULATOR	Arnica montana (Arnica m.) is used for its purported anti-inflammatory and tissue healing actions after trauma, bruises, or tissue injuries, but its cellular and molecular mechanisms are largely unknown. This work tested Arnica m. effects on gene expression using an in vitro model of macrophages polarized towards a "wound-healing" phenotype. The monocyte-macrophage human THP-1 cell line was cultured and differentiated with phorbol-myristate acetate and Interleukin-4, then exposed for 24h to Arnica m. centesimal (c) dilutions 2c, 3c, 5c, 9c, 15c or Control. Total RNA was isolated and cDNA libraries were sequenced with a NextSeq500 sequencer. Genes with significantly positive (up-regulated) or negative (downregulated) fold changes were defined as differentially expressed genes (DEGs). A total of 20 DEGs were identified in Arnica m. 2c treated cells. Of these, 7 genes were up-regulated and 13 were down-regulated. The most significantly up-regulated function concerned 4 genes with a conserved site of epidermal growth factor-like region (p<0.001) and three genes of proteinaceous extracellular matrix, including heparin sulphate proteoglycan 2 (HSPG2), fibrillin 2 (FBN2), and fibronectin (FN1) (p<0.01). Protein assay confirmed a statistically significant increase of fibronectin production (p<0.05). The down-regulated transcripts derived from mitochondrial genes coding for some components of electron transport chain. The same groups of genes were also regulated by increasing dilutions of Arnica m. (3c, 5c, 9c, 15c), although with a lower effect size. We further tested the healing potential of Arnica m. 2c in a scratch model of wound closure based on the motility of bone marrow-derived macrophages and found evidence of an accelerating effect on cell migration in this system. The results of this work, taken together, provide new insights into the action of Arnica m. in tissue healing and repair, and identify extracellular matrix regulation by macrophages as a therapeutic target.	[Marzotto, Marta; Bonafini, Clara; Olioso, Debora; Baruzzi, Anna; Bellavite, Paolo] Univ Verona, Dept Med, Str Le Grazie 8, I-37134 Verona, Italy; [Bettinetti, Laura; Di Leva, Francesca] Univ Verona, Dept Biotechnol, Str Le Grazie 15, I-37134 Verona, Italy; [Galbiati, Elisabetta] Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 3, I-20126 Milan, Italy	University of Verona; University of Verona; University of Milano-Bicocca	Bellavite, P (corresponding author), Univ Verona, Dept Med, Str Le Grazie 8, I-37134 Verona, Italy.	paola.bellavite@univr.it			Boiron Laboratoires Lyon	Boiron Laboratoires Lyon	This work was supported by Boiron Laboratoires Lyon, www.boiron.fr. The funder had no role in data collection and analysis, interpretation, decision to publish, or writing the manuscript.	Alonso D, 2002, DERMATOL SURG, V28, P686, DOI 10.1046/j.1524-4725.2002.02011.x; Babot M, 2014, BBA-BIOENERGETICS, V1837, P1083, DOI 10.1016/j.bbabio.2014.02.018; Balleza E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002456; Baruzzi A, 2015, J IMMUNOL, V195, P4900, DOI 10.4049/jimmunol.1500579; Bell IR, 2015, HOMEOPATHY, V104, P123, DOI 10.1016/j.homp.2014.11.003; Bell IR, 2014, DOSE-RESPONSE, V12, P202, DOI 10.2203/dose-response.13-025.Bell; Bell Iris R, 2013, Front Biosci (Schol Ed), V5, P685; Bellavite P, 2015, HOMEOPATHY, V104, P139, DOI 10.1016/j.homp.2015.02.002; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Bhattacharyya SS, 2008, EXP BIOL MED, V233, P1591, DOI 10.3181/0805-RM-181; Bigagli E, 2016, DOSE-RESPONSE, V14, DOI 10.1177/1559325815626685; Bresler A, 2007, IND J RES HOM, V2, P7; Brinkhaus B, 2006, COMPLEMENT THER MED, V14, P237, DOI 10.1016/j.ctim.2006.04.004; Budovsky A, 2015, WOUND REPAIR REGEN, V23, P171, DOI 10.1111/wrr.12274; Castro FCB, 2012, HOMEOPATHY, V101, P147, DOI 10.1016/j.homp.2012.05.006; Chanput W, 2012, FOOD FUNCT; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; Chikramane PS, 2010, HOMEOPATHY, V99, P231, DOI 10.1016/j.homp.2010.05.006; Conforti Anita, 2007, BMC Complement Altern Med, V7, P1, DOI 10.1186/1472-6882-7-1; Craciunescu O, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-97; Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001; Das Durba, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P752; Das Sreemanti, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P337, DOI 10.3736/jcim20120314; De Arnab, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P210; de Camargo RA, 2013, HOMEOPATHY, V102, P49, DOI 10.1016/j.homp.2012.11.001; Douglas JA, 2004, PLANTA MED, V70, P166, DOI 10.1055/s-2004-815495; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fleck D, 2013, J NEUROSCI, V33, P7856, DOI 10.1523/JNEUROSCI.3372-12.2013; Ganzera M, 2008, ANAL CHIM ACTA, V614, P196, DOI 10.1016/j.aca.2008.03.023; Gaultier A, 2010, MATRIX BIOL, V29, P22, DOI 10.1016/j.matbio.2009.08.003; GELBERMAN RH, 1991, J HAND SURG-AM, V16A, P686, DOI 10.1016/0363-5023(91)90195-H; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Gonias SL, 2014, AM J PATHOL, V184, P18, DOI 10.1016/j.ajpath.2013.08.029; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gratchev A, 2001, SCAND J IMMUNOL, V53, P386, DOI 10.1046/j.1365-3083.2001.00885.x; Hirst J, 2013, ANNU REV BIOCHEM, V82, P551, DOI 10.1146/annurev-biochem-070511-103700; Hostanska K, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-100; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iannitti T, 2016, AM J THER, V23, pE184, DOI 10.1097/MJT.0000000000000036; Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620; Juneja SC, 2013, CONNECT TISSUE RES, V54, P218, DOI 10.3109/03008207.2013.787418; Karow JH, 2008, J ALTERN COMPLEM MED, V14, P17, DOI 10.1089/acm.2007.0560; Kawakami AP, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/917541; Kennedy JM, 2014, J EXP MED, V211, P2519, DOI 10.1084/jem.20140455; Khuda-Bukhsh A., 1997, COMPLEMENT THER MED, V5, P43; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Klaas CA, 2002, PLANTA MED, V68, P385, DOI 10.1055/s-2002-32067; Lawrence WT, 2003, PLAST RECONSTR SURG, V112, P1164, DOI 10.1097/01.PRS.0000075161.89940.81; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lussignoli S, 1999, Complement Ther Med, V7, P225, DOI 10.1016/S0965-2299(99)80006-5; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Macedo S B, 2004, Homeopathy, V93, P84, DOI 10.1016/j.homp.2004.02.006; Mantle David, 2001, Adverse Drug Reactions and Toxicological Reviews, V20, P89; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Marzotto M, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-104; Maurer E, 2015, THROMB HAEMOSTASIS, V114, P1175, DOI 10.1160/TH14-11-0958; Maver T, 2015, INT J DERMATOL, V54, P740, DOI 10.1111/ijd.12766; May P, 2013, CURR OPIN LIPIDOL, V24, P134, DOI 10.1097/MOL.0b013e32835e809c; Meldolesi J, 2016, PHARMACOL RES, V107, P430, DOI 10.1016/j.phrs.2015.10.019; Mu JY, 2014, MOL NUTR FOOD RES, V58, P1561, DOI 10.1002/mnfr.201300729; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Olioso D, 2016, HOMEOPATHY, V105, P131, DOI 10.1016/j.homp.2016.02.001; Olioso D, 2014, J ETHNOPHARMACOL, V153, P535, DOI 10.1016/j.jep.2014.02.048; Qin LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-5; Ramo P, 2006, J THEOR BIOL, V242, P164, DOI 10.1016/j.jtbi.2006.02.011; Reddy KK, 2013, J AM ACAD DERMATOL, V68, pE127, DOI 10.1016/j.jaad.2011.06.030; Sharma S, 2016, J SCI FOOD AGR, V96, P1500, DOI 10.1002/jsfa.7252; Staneva J, 2011, J PHARMACEUT BIOMED, V54, P94, DOI 10.1016/j.jpba.2010.08.018; Strickland DK, 2014, ARTERIOSCL THROM VAS, V34, P487, DOI 10.1161/ATVBAHA.113.301924; Suen PW, 1999, J CELL SCI, V112, P4067; Sutovska M, 2014, INT J BIOL MACROMOL, V69, P214, DOI 10.1016/j.ijbiomac.2014.05.051; Theocharis AD, 2015, ADV DRUG DELIV REV; To WS, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-21; Verma N, 2010, MOL CELL BIOCHEM, V336, P127, DOI 10.1007/s11010-009-0263-6; Widrig R, 2007, RHEUMATOL INT, V27, P585, DOI 10.1007/s00296-007-0304-y; Wijeratne SS, 2016, MATRIX BIOL, V50, P27, DOI 10.1016/j.matbio.2015.11.001; Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045; Yamamoto K, 2013, FASEB J, V27, P511, DOI 10.1096/fj.12-216671	80	28	28	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2016	11	11							e0166340	10.1371/journal.pone.0166340	http://dx.doi.org/10.1371/journal.pone.0166340			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9ON	27832158	Green Published, gold			2023-01-03	WOS:000387725000102
J	Butt, CA				Butt, Carrie A.			Art in My Veins A Medical Self-portrait	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Butt, Carrie A.] JAMA Network, Digital Content Operat, Chicago, IL 60654 USA		Butt, CA (corresponding author), JAMA Network, Digital Content Operat, Chicago, IL 60654 USA.	carri.butt@jamanetwork.org							0	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2016	316	16					1628	1629		10.1001/jama.2016.15507	http://dx.doi.org/10.1001/jama.2016.15507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ8GB	27784076				2023-01-03	WOS:000386107800001
J	Huang, CY; Lee, SY; Yang, CW; Hung, SC; Chiang, CK; Huang, JW; Hung, KY				Huang, Chiung-Ying; Lee, Szu-Ying; Yang, Chung-Wei; Hung, Szu-Chun; Chiang, Chih-Kang; Huang, Jenq-Wen; Hung, Kuan-Yu			A Simpler Creatinine Index Can Predict Long-Term Survival in Chinese Hemodialysis Patients	PLOS ONE			English	Article							STAGE RENAL-DISEASE; LEAN BODY-MASS; NUTRITIONAL-STATUS; MORTALITY; ASSOCIATION; OUTCOMES; HEMO	Background Low lean body mass (LBM) is an indicator of malnutrition inflammation syndrome, which is common in hemodialysis (HD) patients. The creatinine index (CI) has been validated as a reliable method to estimate LBM and evaluate the protein-energy status of HD patients. However, the traditional creatinine index formula was complex. We sought to investigate the impact of CI derived from a new simple formula on Chinese HD patient outcomes. Methods In this retrospective cohort study, we enrolled 1269 patients who initiated HD between February 1981 and February 2012 and followed them until the end of February 2013. CI was calculated using the simple creatinine kinetic model (CKM) formula. Multiple linear regression analysis and Cox regression proportional hazard analysis were used to define independent variables and compare survival between groups. Results The 1269 HD patients were categorized into 3 groups according to the tertiles of calculated CI between men and women. Each group consisted of 423 patients (50.6% men, 49.4% women). Patients in the highest sex-specific tertile of CI had longer overall survival (HR, 0.46; P 0.002). BMI did not significantly associate with survival after adjustment (HR, 0.99; P 0.613). Conclusions CI derived from the simple CKM formula serves as a good parameter than BMI to predict the survival of HD patients. The formula could extend its convenient use in clinical practice for HD patients.	[Chiang, Chih-Kang; Huang, Jenq-Wen; Hung, Kuan-Yu] Natl Taiwan Univ, Coll Med & Hosp, Dept Internal Med, Taipei, Taiwan; [Huang, Chiung-Ying; Lee, Szu-Ying] Natl Taiwan Univ, Coll Med & Hosp, Dept Internal Med, Yun Lin Branch, Huwei, Yun Lin County, Taiwan; [Yang, Chung-Wei] Natl Taiwan Univ, Coll Med & Hosp, Hsin Chu Branch, Dept Internal Med, Hsinchu, Taiwan; [Hung, Szu-Chun] Taipei Tzu Chi Hosp, Div Nephrol, New Taipei, Taiwan	National Taiwan University; National Taiwan University; Buddhist Tzu Chi General Hospital; Taipei Tzu Chi Hospital	Huang, JW (corresponding author), Natl Taiwan Univ, Coll Med & Hosp, Dept Internal Med, Taipei, Taiwan.	jenqwen@ntuh.gov.tw		Huang, Chiung-Ying/0000-0003-1285-089X; CHIANG, CHIH-KANG/0000-0001-9021-4616; YANG, CHUNG-WEI/0000-0002-8613-3597; HUNG, KUAN-YU/0000-0003-3472-5512; HUANG, JENQ-WEN/0000-0001-8011-2317				Canaud B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093286; Combe C, 2001, AM J KIDNEY DIS, V37, pS81, DOI 10.1053/ajkd.2001.20756; de Mutsert R, 2009, J RENAL NUTR, V19, P127, DOI 10.1053/j.jrn.2008.08.003; Desmeules S, 2004, NEPHROL DIAL TRANSPL, V19, P1182, DOI 10.1093/ndt/gfh016; Dong J, 2011, NEPHROL DIAL TRANSPL, V26, P3715, DOI 10.1093/ndt/gfr142; Dwyer JT, 2005, KIDNEY INT, V68, P1766, DOI 10.1111/j.1523-1755.2005.00593.x; Gallar-Ruiz P, 2012, NEFROLOGIA, V32, P467, DOI 10.3265/Nefrologia.pre2012.Mar.11219; Huang C, 2010, J DEV ORIG HLTH DIS, V1, P412, DOI 10.1017/S2040174410000504; Huang JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054976; Johansen KL, 2004, AM J CLIN NUTR, V80, P324, DOI 10.1093/ajcn/80.2.324; K/ DOQI National Kidney Foundation, 2000, AM J KIDNEY DIS, V35, pS1, DOI DOI 10.1053/AJKD.2000.V35.AAJKD03517; Kalantar-Zadeh K, 2003, J RENAL NUTR, V13, P15, DOI 10.1053/jren.2003.50005; Kamimura MA, 2003, NEPHROL DIAL TRANSPL, V18, P101, DOI 10.1093/ndt/18.1.101; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; Leavey SF, 2001, NEPHROL DIAL TRANSPL, V16, P2386, DOI 10.1093/ndt/16.12.2386; Pupim LB, 2004, J RENAL NUTR, V14, P6, DOI 10.1053/j.jrn.2003.10.001; Rambod M, 2009, AM J KIDNEY DIS, V53, P298, DOI 10.1053/j.ajkd.2008.09.018; Rocco MV, 2002, AM J KIDNEY DIS, V39, P245, DOI 10.1053/ajkd.2002.30543; Wong JS, 1999, KIDNEY INT, V55, P2515, DOI 10.1046/j.1523-1755.1999.00464.x; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406	20	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0165164	10.1371/journal.pone.0165164	http://dx.doi.org/10.1371/journal.pone.0165164			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED7LQ	27780214	Green Published, Green Submitted, gold			2023-01-03	WOS:000389046900031
J	Broring, T; Oostrom, KJ; Lafeber, HN; Jansma, EP; Oosterlaan, J				Broering, Tinka; Oostrom, Kim J.; Lafeber, Harrie N.; Jansma, Elise P.; Oosterlaan, Jaap			Sensory modulation in preterm children: Theoretical perspective and systematic review	PLOS ONE			English	Review							NEONATAL INTENSIVE-CARE; BIRTH-WEIGHT CHILDREN; BRAIN-DEVELOPMENT; PROCESSING DISORDER; BEHAVIORAL OUTCOMES; DEVELOPMENTAL CARE; EVERYDAY LIFE; INFANTS; BORN; AGE	Background Neurodevelopmental sequelae in preterm born children are generally considered to result from cerebral white matter damage and noxious effects of environmental factors in the neonatal intensive care unit (NICU). Cerebral white matter damage is associated with sensory processing problems in terms of registration, integration and modulation. However, research into sensory processing problems and, in particular, sensory modulation problems, is scarce in preterm children. Aim This review aims to integrate available evidence on sensory modulation problems in preterm infants and children (<37 weeks of gestation) and their association with neurocognitive and behavioral problems. Method Relevant studies were extracted from PubMed, EMBASE.com and PsycINFO following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Selection criteria included assessment of sensory modulation in preterm born children (<37 weeks of gestation) or with prematurity as a risk factor. Results Eighteen studies were included. Results of this review support the presence of sensory modulation problems in preterm children. Although prematurity may distort various aspects of sensory modulation, the nature and severity of sensory modulation problems differ widely between studies. Conclusions Sensory modulation problems may play a key role in understanding neurocognitive and behavioral sequelae in preterm children. Some support is found for a dose-response relationship between both white matter brain injury and length of NICU stay and sensory modulation problems.	[Broering, Tinka; Oostrom, Kim J.] Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, Amsterdam, Netherlands; [Lafeber, Harrie N.] Vrije Univ Amsterdam, Med Ctr, Dept Neonatol, Amsterdam, Netherlands; [Jansma, Elise P.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Jansma, Elise P.] Vrije Univ Amsterdam, Med Ctr, Med Lib, Amsterdam, Netherlands; [Oosterlaan, Jaap] Vrije Univ Amsterdam, Dept Clin Neuropsychol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Broring, T (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, Amsterdam, Netherlands.	t.broring@vumc.nl	Jansma, Elise/AAG-7983-2020; Jansma, Elise P/E-8358-2016	Jansma, Elise P/0000-0002-1516-2171				Aarnoudse-Moens CSH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055994; Aarnoudse-Moens CSH, 2009, PEDIATRICS, V124, P717, DOI 10.1542/peds.2008-2816; Adams JN, 2015, EARLY HUM DEV, V91, P227, DOI 10.1016/j.earlhumdev.2015.01.013; Als H, 1997, SEMIN PERINATOL, V21, P178, DOI 10.1016/S0146-0005(97)80062-6; Als H, 2004, PEDIATRICS, V113, P846, DOI 10.1542/peds.113.4.846; ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; ALS H, 1986, PEDIATRICS, V78, P1123; Als H., 1986, PHYS OCCUP THER PEDI, V6, P3, DOI DOI 10.1080/J006V06N03_02; Anand KJS, 2000, BIOL NEONATE, V77, P69, DOI 10.1159/000014197; Anderson PJ, 2014, SEMIN FETAL NEONAT M, V19, P90, DOI 10.1016/j.siny.2013.11.012; Aucott S, 2002, MENT RETARD DEV D R, V8, P298, DOI 10.1002/mrdd.10040; Bart O, 2011, RES DEV DISABIL, V32, P2732, DOI 10.1016/j.ridd.2011.05.037; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Ben-Sasson A, 2009, J AUTISM DEV DISORD, V39, P1, DOI 10.1007/s10803-008-0593-3; Bhutta AT, 2002, CLIN PERINATOL, V29, P357, DOI 10.1016/S0095-5108(02)00011-8; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Bisiacchi PS, 2009, BIOL PSYCHOL; Cabral TI, 2016, EARLY HUM DEV; Cascio CJ, 2010, J NEURODEV DISORD, V2, P62, DOI 10.1007/s11689-010-9046-3; Case-Smith J, 1998, AM J OCCUP THER, V52, P547, DOI 10.5014/ajot.52.7.547; Chorna O, 2014, ARCH DIS CHILD-FETAL, V99, pF475, DOI 10.1136/archdischild-2014-306486; Christou Helen, 2005, J Intensive Care Med, V20, P76, DOI 10.1177/0885066604273494; Crepeau-Hobson MF, 2009, J DEV PHYS DISABIL, V21, P315, DOI 10.1007/s10882-009-9144-x; Crozier SC, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.018747; de Kieviet JF, 2012, DEV MED CHILD NEUROL, V54, P313, DOI 10.1111/j.1469-8749.2011.04216.x; de Kieviet JF, 2009, JAMA-J AM MED ASSOC, V302, P2235, DOI 10.1001/jama.2009.1708; DeGangi GA., 1989, TEST SENSORY FUNCTIO; Dubois J, 2008, BRAIN; Dubois J, 2008, CEREB CORTEX; Dudova I, 2014, NEUROPSYCH DIS TREAT, V10, P277, DOI 10.2147/NDT.S57057; Dunn W, 1997, INFANT YOUNG CHILD, V9, P23, DOI 10.1097/00001163-199704000-00005; Dunn W, 2002, J EARLY INTERVENTION, V25, P27, DOI 10.1177/105381510202500104; Dunn W, 2001, AM J OCCUP THER, V55, P608, DOI 10.5014/ajot.55.6.608; Dunn W., 1999, SENSORY PROFILE USER, DOI DOI 10.1037/T15155-000; Dunn W., 2002, INFANT TODDLER SENSO; Dunn W, 2007, INFANT YOUNG CHILD, V20, P84, DOI 10.1097/01.IYC.0000264477.05076.5d; Ecevit A, 2012, TURKISH J PEDIATR, V54, P509; Eeles AL, 2013, EARLY HUM DEV, V89, P1075, DOI 10.1016/j.earlhumdev.2013.07.027; Eeles AL, 2013, EARLY HUM DEV, V89, P727, DOI 10.1016/j.earlhumdev.2013.05.005; Eeles AL, 2013, DEV MED CHILD NEUROL, V55, P314, DOI 10.1111/j.1469-8749.2012.04434.x; Geldof CJA, 2012, RES DEV DISABIL, V33, P726, DOI 10.1016/j.ridd.2011.08.025; Geldof CJA, 2014, DEV MED CHILD NEUROL, V56, P862, DOI 10.1111/dmcn.12404; Gioia GA, 2003, BRIEF P BEHAV RATING; Goldsmith HH, 1996, CHILD DEV, V67, P218, DOI 10.1111/j.1467-8624.1996.tb01730.x; Gomot M, 2007, INT J PSYCHOPHYSIOL, V64, P123, DOI 10.1016/j.ijpsycho.2007.01.003; Hille ETM, 2007, PEDIATRICS, V120, pE587, DOI 10.1542/peds.2006-2407; Janssens A, 2009, ACTA PAEDIATR, V98, P1988, DOI 10.1111/j.1651-2227.2009.01488.x; Jiang ZD, 2013, EUR J PEDIATR, V172, P1033, DOI 10.1007/s00431-013-1989-4; Johnson S, 2007, SEMIN FETAL NEONAT M, V12, P363, DOI 10.1016/j.siny.2007.05.004; Kaindl AN, 2009, J CHILD NEUROL, V24, P1112, DOI 10.1177/0883073809337920; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Koziol LF, 2011, CEREBELLUM, V10, P770, DOI 10.1007/s12311-011-0288-8; Lane AE, 2010, J AUTISM DEV DISORD, V40, P112, DOI 10.1007/s10803-009-0840-2; Lemons JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e1; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lickliter R, 2011, CLIN PERINATOL, V38, P591, DOI 10.1016/j.clp.2011.08.007; Limperopoulos C, 2008, PEDIATRICS, V121, P758, DOI 10.1542/peds.2007-2158; Lin PW, 2006, LANCET, V368, P1271, DOI 10.1016/S0140-6736(06)69525-1; Mangeot SD, 2001, DEV MED CHILD NEUROL, V43, P399, DOI 10.1017/S0012162201000743; Maroney Dianne I, 2003, J Perinatol, V23, P679, DOI 10.1038/sj.jp.7211010; May-Benson TA, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.031.2009; McIntosh D. N., 1999, OVERVIEW SHORT SENSO; Ment LR, 2009, LANCET NEUROL, V8, P1042, DOI 10.1016/S1474-4422(09)70257-1; Mento G, 2012, NEUROSCIENCE BIOBEHA; Mento G, 2010, EUR J NEUROSCI; Milgrom J, 2010, PEDIAT RES; Miller LJ, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.022.2009; Miller LJ, 2007, AM J OCCUP THER, V61, P135, DOI 10.5014/ajot.61.2.135; Miller LJ, 2012, RES DEV DISABIL, V33, P804, DOI 10.1016/j.ridd.2011.12.005; Mitchell A, 2015, AM J OCCUP THER, V1-11; Mitha A, 2013, PEDIATRICS, V132, pE372, DOI 10.1542/peds.2012-3979; National Center for Infants Toddlers and Families, 1994, ZER TOT 3 DIAGN CLAS; Nevalainen P, 2008, INT J PSYCHOPHYSIOL, V68, P85, DOI 10.1016/j.ijpsycho.2007.10.014; Ortibus EL, 2011, PEDIATR NEUROL, V45, P1, DOI 10.1016/j.pediatrneurol.2011.02.008; Owen JP, 2013, NEUROIMAGE-CLIN, V2, P844, DOI 10.1016/j.nicl.2013.06.009; Pekcetin S, 2016, PERCEPT MOTOR SKILL, V123, P411, DOI 10.1177/0031512516662895; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Provost B, 1994, SENSORY RATING SCALE, V13, P15; Rahkonen P, 2015, ACTA PAEDIATR, V104, P522, DOI 10.1111/apa.12911; Roofthooft DWE, 2014, NEONATOLOGY, V105, P218, DOI 10.1159/000357207; Schendel D, 2008, PEDIATRICS, V121, P1155, DOI 10.1542/peds.2007-1049; Scher MS, 2009, CLIN NEUROPHYSIOL; Scherder EJA, 2008, EUR J PAEDIATR NEURO, V12, P461, DOI 10.1016/j.ejpn.2007.11.004; Shea B., 2011, NEW CASTLE OTTAWA SC; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; Smith GC, 2011, ANN NEUROL, V70, P541, DOI 10.1002/ana.22545; Symington A, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001814.pub2; Treyvaud K, 2013, J CHILD PSYCHOL PSYC, V54, P772, DOI 10.1111/jcpp.12040; Van Hulle C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129968; van Noort-van der Spek IL, 2012, PEDIATRICS, V129, P745, DOI 10.1542/peds.2011-1728; Verkerk G, 2011, J PEDIATR-US, V159, P933, DOI 10.1016/j.jpeds.2011.05.035; Volpe JJ, 2008, NEUROLOGY NEWBORN, V5th; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Walker SM, 2009, PAIN, V141, P79, DOI 10.1016/j.pain.2008.10.012; Weisglas-Kuperus N, 2009, ARCH DIS CHILD-FETAL, V94, pF196, DOI 10.1136/adc.2007.135095; Wickremasinghe AC, 2013, J PERINATOL, V33, P631, DOI 10.1038/jp.2013.12; Wiener Andrea Santman, 1996, Physical and Occupational Therapy in Pediatrics, V16, P1, DOI 10.1300/J006v16n04_01; World Health Organization, 1992, INT CLASS DIS REL HL	99	26	26	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2017	12	2							e0170828	10.1371/journal.pone.0170828	http://dx.doi.org/10.1371/journal.pone.0170828			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK9GJ	28182680	Green Published, gold, Green Submitted			2023-01-03	WOS:000394231800020
J	Liu, XY; Behrman, JR; Stein, AD; Adair, LS; Bhargava, SK; Borja, JB; da Silveira, MF; Horta, BL; Martorell, R; Norris, SA; Richter, LM; Sachdev, HS				Liu, Xiaoying; Behrman, Jere R.; Stein, Aryeh D.; Adair, Linda S.; Bhargava, Santosh K.; Borja, Judith B.; da Silveira, Mariangela Freitas; Horta, Bernardo L.; Martorell, Reynaldo; Norris, Shane A.; Richter, Linda M.; Sachdev, Harshpal S.			Prenatal care and child growth and schooling in four low- and medium-income countries	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIALS; BIRTH-WEIGHT; COHORT PROFILE; ANTENATAL CARE; NUTRITION; OUTCOMES; HEALTH; PATTERNS; IMPACT; MORTALITY	Background The effectiveness of prenatal care for improving birth and subsequent child outcomes in low-income countries remains controversial, with much of the evidence to date coming from high-income countries and focused on early-life outcomes. We examined associations between prenatal care visits and birth weight, height-for-age at 24 months and attained schooling in four low- and middle-income countries. Methods We pooled data from prospective birth-cohort studies from Brazil, Guatemala, Philippines and South Africa. We created a prenatal care utilization index based on the number and timing of prenatal visits. Associations were examined between this index and birth weight, height-for-age at 24 months, and highest attained schooling grade until adulthood. Results Among 7203 individuals in the analysis, 68.9% (Philippines) to 96.7% (South Africa) had at least one prenatal care visit, with most having at least four visits. Over 40% of Brazilians and Guatemalans had their first prenatal visit in the first trimester, but fewer Filipinos (13.9%) and South Africans (19.8%) did so. Prenatal care utilization was not significantly associated with birth weight (p>0.05 in pooled data). Each unit increase in the prenatal care utilization index was associated with 0.09 (95% CI 0.04 to 0.15) higher height-for-age z-score at 24 months and with 0.26 (95% CI 0.17 to 0.35) higher schooling grades attained. Although there was some heterogeneity and greater imprecision across sites, the results were qualitatively similar among the four different populations. Conclusions While not related to birth weight, prenatal care utilization was associated with important outcomes later in life, specifically higher height-for-age at 24 months and higher attained school grades. These results suggest the relevance of prenatal care visits for human capital outcomes important over the lifecycle.	[Liu, Xiaoying; Behrman, Jere R.] Univ Penn, Ctr Populat Studies, Philadelphia, PA 19104 USA; [Stein, Aryeh D.; Martorell, Reynaldo] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA; [Stein, Aryeh D.; Norris, Shane A.; Richter, Linda M.] Univ Witwatersrand, Med Res Council Dev Pathways Hlth Res Unit, Johannesburg, South Africa; [Adair, Linda S.] Univ North Carolina Chapel Hill, Dept Nutr, Chapel Hill, NC USA; [Bhargava, Santosh K.] SL Jain Hosp, Dept Pediat, Delhi, India; [Borja, Judith B.] Univ San Carlos, USC Off Populat Studies Fdn Inc, Cebu, Philippines; [Borja, Judith B.] Univ San Carlos, Dept Nutr & Dietet, Cebu, Philippines; [da Silveira, Mariangela Freitas; Horta, Bernardo L.] Univ Fed Pelotas, Fac Med, Postgrad Program Epidemiol, Pelotas, RS, Brazil; [Richter, Linda M.] Univ Witwatersrand, DST NRF Ctr Excellence Human Dev, Johannesburg, South Africa; [Sachdev, Harshpal S.] Sitaram Bhartia Inst Sci & Res, Dept Pediat & Clin Epidemiol, New Delhi, India	University of Pennsylvania; Emory University; Rollins School Public Health; University of Witwatersrand; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of San Carlos; University of San Carlos; Universidade Federal de Pelotas; University of Witwatersrand; Sitaram Bhartia Institute of Science & Research	Liu, XY (corresponding author), Univ Penn, Ctr Populat Studies, Philadelphia, PA 19104 USA.	xiaoyliu@sas.upenn.edu	Horta, Bernardo/A-7604-2008; Silveira, Mariangela F/L-6868-2013; Norris, Shane/C-4664-2014; Martorell, Reynaldo/I-2539-2012; Behrman, Jere R/A-9734-2009; Stein, Aryeh D/J-9831-2012	Horta, Bernardo/0000-0001-9843-412X; Silveira, Mariangela F/0000-0002-3551-9713; Norris, Shane/0000-0001-7124-3788; Stein, Aryeh/0000-0003-1138-6458; Liu, Xiaoying/0000-0001-9897-1291; Sachdev, Harshpal Singh/0000-0002-4956-9391	Grand Challenges Canada Grant [0072-03]; Bill & Melinda Gates Foundation Global Health Grant [OPP1032713]; Eunice Shriver Kennedy National Institute of Child Health and Development [R01 HD070993, HD070993]; Wellcome Trust (UK); Bill & Melinda Gates Foundation [OPP1032713]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P2CHD050924, R01HD070993] Funding Source: NIH RePORTER	Grand Challenges Canada Grant; Bill & Melinda Gates Foundation Global Health Grant; Eunice Shriver Kennedy National Institute of Child Health and Development; Wellcome Trust (UK)(Wellcome Trust); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by grants from Grand Challenges Canada Grant 0072-03 (http://www.grandchallenges ca/), Bill & Melinda Gates Foundation Global Health Grant OPP1032713 (http://www.gatesfoundaton org/) and Eunice Shriver Kennedy National Institute of Child Health and Development Grant R01 HD070993 (https://www.nichd.nih.gov/Pages/index.aspx). COHORTS has received support from the Wellcome Trust (UK), the Bill & Melinda Gates Foundation. Funding for the individual cohorts was as follows: Guatemala (US National Institutes of Health; US National Science Foundation); Pelotas (Wellcome Trust); Birth To Twenty (Wellcome Trust, Human Sciences Research Council, South African Medical Research Council, Mellon Foundation, Anglo American Chairman's Fund, University of the Witwatersrand); Cebu (US National Institutes of Health). These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Grant sponsors: Grand Challenges Canada Grant 0072-03, Bill & Melinda Gates Foundation Global Health Grant OPP1032713 and Eunice Shriver Kennedy National Institute of Child Health and Development Grant R01 HD070993. COHORTS has received supports from the Wellcome Trust (UK), the Bill & Melinda Gates Foundation. Funding for the individual cohorts was as follows: Guatemala (US National Institutes of Health; US National Science Foundation); Pelotas (Wellcome Trust); Birth To Twenty (Wellcome Trust, Human Sciences Research Council, South African Medical Research Council, Mellon Foundation, Anglo American Chairman's Fund, University of the Witwatersrand); Cebu (US National Institutes of Health).	Abou-Zahr CL, 2003, ANTENATAL CARE DEV C; Adair LS, 2011, INT J EPIDEMIOL, V40, P619, DOI 10.1093/ije/dyq085; Alderman H, 2006, WORLD BANK RES OBSER, V21, P25, DOI 10.1093/wbro/lkj001; Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 2001, PUBLIC HEALTH REP, V116, P306; [Anonymous], 1988, HDB DEV EC, DOI DOI 10.1016/S1573-4471(88)01016-2; Antonisamy B, 2009, INT J EPIDEMIOL, V38, P663, DOI 10.1093/ije/dyn159; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; Becker G. S., 2009, TREATISE FAMILY; Behrman JR, 2010, HBK ECON, V5, P4883, DOI 10.1016/B978-0-444-52944-2.00011-2; Behrman JR, 2009, AM J CLIN NUTR, V90, P1372, DOI 10.3945/ajcn.2009.27524; Behrman JR, 2004, REV ECON STAT, V86, P586, DOI 10.1162/003465304323031139; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Chamberlain C, 2013, COCHRANE DB SYST REV, P10; Christian P, 2012, J NUTR, V142, p173S, DOI 10.3945/jn.111.149898; Conley D, 2001, J HEALTH SOC BEHAV, V42, P450, DOI 10.2307/3090189; Conley D, 2006, ECON HUM BIOL, V4, P151, DOI 10.1016/j.ehb.2005.12.001; Conway KS, 2005, J HEALTH ECON, V24, P489, DOI 10.1016/j.jhealeco.2004.09.012; Doyle O, 2009, ECON HUM BIOL, V7, P1, DOI 10.1016/j.ehb.2009.01.002; Eyles D, 2003, NEUROSCIENCE, V118, P641, DOI 10.1016/S0306-4522(03)00040-X; Fall CHD, 2011, INT J EPIDEMIOL, V40, P47, DOI 10.1093/ije/dyq155; Gajate-Garrido G, 2013, ECON DEV CULT CHANGE, V62, P95, DOI 10.1086/671716; Glei DA, 2003, SOC SCI MED, V57, P2447, DOI 10.1016/S0277-9536(03)00140-0; Glewwe P., 2006, HDB EC ED, V2, P945, DOI [10.1016/S1574-0692(06)02016-2, DOI 10.1016/S1574-0692(06)02016-2]; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; GROSSMAN M, 1990, J POLIT ECON, V98, P983, DOI 10.1086/261716; GUILKEY DK, 1989, J DEV EC, V30; Haas JD, 1996, NUTR REV, V54, pS41, DOI 10.1111/j.1753-4887.1996.tb03869.x; Habibov NN, 2011, ECON HUM BIOL, V9, P56, DOI 10.1016/j.ehb.2010.08.003; Haider BA, 2013, BMJ-BRIT MED J, P346; Hanushek EA, 2008, J ECON LIT, V46, P607, DOI 10.1257/jel.46.3.607; Hoddinott J, 2013, AM J CLIN NUTR; Hoddinott J, 2008, LANCET, V371, P411, DOI 10.1016/S0140-6736(08)60205-6; Hoddinott J, 2013, MATERN CHILD NUTR, V9, P69, DOI 10.1111/mcn.12080; Hollowell J, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-13; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; Jewell RT, 2006, HEALTH ECON, V15, P1245, DOI 10.1002/hec.1121; Kirkham C, 2005, AM FAM PHYSICIAN, V71, P1307; Krueger Paul M., 2000, Journal of the American Osteopathic Association, V100, P485; Kuzawa CW, 2012, AM J HUM BIOL, V24, P5, DOI 10.1002/ajhb.21227; Lu M C, 2003, J Matern Fetal Neonatal Med, V13, P362, DOI 10.1080/713605924; Maluccio JA, 2009, ECON J, V119, P734, DOI 10.1111/j.1468-0297.2009.02220.x; MARTORELL R, 1994, EUR J CLIN NUTR, V48, pS45; Noonan K, 2013, MATERN CHILD HLTH J, V17, P189, DOI 10.1007/s10995-012-0966-2; Psacharopoulos G, 2004, EDUC ECON, V12, P111, DOI [10.1080/0964529042000239140, DOI 10.1080/0964529042000239140]; Ramakrishna T, 1999, PHYSIOL RES, V48, P175; Ramakrishnan U, 2014, MATERNAL NUTR INTERV; REYNES JF, 1985, J SOUTHE ASIAN STUD, V16, P292, DOI 10.1017/S0022463400008468; Richter L, 2007, INT J EPIDEMIOL, V36, P504, DOI 10.1093/ije/dym016; ROSENZWEIG MR, 1983, J POLIT ECON, V91, P723, DOI 10.1086/261179; SCHULTZ TW, 1961, AM ECON REV, V51, P1; Shankar AH, 2008, LANCET, V371, P215, DOI 10.1016/S0140-6736(08)60133-6; SHWARTZ S, 1962, AM J OBSTET GYNECOL, V83, P591, DOI 10.1016/S0002-9378(16)35888-4; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Stein AD, 2008, INT J EPIDEMIOL, V37, P716, DOI 10.1093/ije/dyn028; Stein AD, 2013, J PEDIATR-US, V163, P1740, DOI 10.1016/j.jpeds.2013.08.012; Stein AD, 2010, AM J HUM BIOL, V22, P353, DOI 10.1002/ajhb.20998; United Nations Department of Economic, 2008, MILL DEV GOALS REP 2; VanderWeele TJ, 2012, SOC SCI MED, V74, P196, DOI 10.1016/j.socscimed.2011.10.031; Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4; Victora CG, 2006, INT J EPIDEMIOL, V35, P237, DOI 10.1093/ije/dyi290; Victora CG, 2010, PEDIATRICS; von Hippel PT, 2009, SOCIOL METHODOL, V39, P265, DOI 10.1111/j.1467-9531.2009.01215.x; Wehby GL, 2009, ECON HUM BIOL, V7, P84, DOI 10.1016/j.ehb.2008.10.001; WHO, 2014, TRENDS MAT MORT 1990; WONG EL, 1987, SOC SCI MED, V24, P927, DOI 10.1016/0277-9536(87)90286-3; Woodhouse C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091292	69	11	11	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171299	10.1371/journal.pone.0171299	http://dx.doi.org/10.1371/journal.pone.0171299			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7DG	28158229	Green Published, gold, Green Submitted			2023-01-03	WOS:000396161700055
J	Jeong, S; Oh, JM; Oh, KH; Kim, IW				Jeong, Sohyun; Oh, Jung Mi; Oh, Kook-Hwan; Kim, In-Wha			Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; BONE-MINERAL DENSITY; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; ADYNAMIC BONE; HIP FRACTURE; INCREASED RISK; PTH; OSTEODYSTROPHY; OSTEOPOROSIS	Mineral and bone disorder (MBD) is observed universally in patients with chronic kidney disease (CKD). Detrimental MBD-related skeletal changes include increased prevalence of fracture, cardiovascular disease, and mortality. MicroRNAs (miRNAs) have been identified as useful biomarkers in various diseases, and the aim of this study was to identify miRNAs associated with parathyroid hormone level in peritoneal dialysis (PD) patients. Fifty-two PD patients were enrolled and grouped by their intact parathyroid hormone (iPTH) level; 11 patients had low iPTH (<150 pg/mL) and 41 patients had high iPTH (>= 150 pg/mL). Total RNA was extracted from whole blood samples. Total RNA from 15 patients (7 and 8 patients in the low and high iPTH groups, respectively) underwent miRNA microarray analysis, and three differentially upregulated (>2-fold change) miRNAs previously associated with human disease were selected for real-time quantitative PCR (qPCR) analysis. Interaction analyses between miRNAs and genes were performed by using TargetScan and the KEGG pathway database. Microarray results revealed 165 miRNAs were differentially expressed between patients with high iPTH levels and low iPTH levels. Of those miRNAs, 81 were upregulated and 84 were downregulated in patients with high iPTH levels. Expression levels of miR-1299, miR-3680-5p, and miR-548b-5p (previously associated with human disease) in 52 patients were analyzed by using qPCR. MiR-3680-5p was differentially expressed in low and high iPTH patients (P < 0.05). The predicted target genes of miR-3680-5p were USP6, USP32, USP46, and DLT, which are involved in the ubiquitin proteolysis pathway. This pathway has roles in PTH and parathyroid hormone related protein degradation and proteolysis. The mechanisms involved in the associations among low PTH, adynamic bone disease, miR-3680-5p, and the target genes should be explored further in order to elucidate their roles in CKD-MBD development.	[Jeong, Sohyun; Oh, Jung Mi; Kim, In-Wha] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Jeong, Sohyun; Oh, Jung Mi; Kim, In-Wha] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea; [Oh, Kook-Hwan] Seoul Natl Univ Hosp, Dept Internal Med, Div Nephrol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Kim, IW (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Div Nephrol, Seoul, South Korea.	khoh@snu.ac.kr; iwkim2@hanmail.net	Jeong, Sohyun/ABC-4625-2020	Jeong, Sohyun/0000-0003-3805-4349	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2014R1A1A2055734]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2055734). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523-1755.2000.00178.x; Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Andress DL, 2008, KIDNEY INT, V73, P1345, DOI 10.1038/ki.2008.60; ANDRESS DL, 1989, KIDNEY INT, V36, P471, DOI 10.1038/ki.1989.219; Atsumi K, 1999, AM J KIDNEY DIS, V33, P287, DOI 10.1016/S0272-6386(99)70302-1; Barreto FC, 2008, KIDNEY INT, V73, P771, DOI 10.1038/sj.ki.5002769; Barreto FC, 2006, KIDNEY INT, V69, P1852, DOI 10.1038/sj.ki.5000311; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Brandenburg VM, 2008, CLIN KIDNEY J, V1, P135, DOI 10.1093/ndtplus/sfn040; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Callis TE, 2008, TRENDS MOL MED, V14, P254, DOI 10.1016/j.molmed.2008.03.006; Cannata-Andia JB, 2013, J NEPHROL, V26, P73, DOI 10.5301/jn.5000212; Coco M, 2000, AM J KIDNEY DIS, V36, P1115, DOI 10.1053/ajkd.2000.19812; Coen G, 1996, NEPHROL DIAL TRANSPL, V11, P813, DOI 10.1093/oxfordjournals.ndt.a027404; Dooley AC, 2008, AM J KIDNEY DIS, V51, P38, DOI 10.1053/j.ajkd.2007.08.019; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; Fazi F, 2008, CARDIOVASC RES, V79, P553, DOI 10.1093/cvr/cvn151; Ferreira A, 2008, J AM SOC NEPHROL, V19, P405, DOI 10.1681/ASN.2006101089; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Frazao JM, 2009, CURR OPIN NEPHROL HY, V18, P303, DOI 10.1097/MNH.0b013e32832c4df0; Garrett G, 2013, CLIN J AM SOC NEPHRO, V8, P299, DOI 10.2215/CJN.09580911; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hackl M, 2016, MOL CELL ENDOCRINOL, V432, P93, DOI 10.1016/j.mce.2015.10.015; Holmes David, 2015, Nat Rev Endocrinol, V11, P445, DOI 10.1038/nrendo.2015.104; Hutchison A J, 1996, Perit Dial Int, V16 Suppl 1, pS295; Ingsathit A, 2010, NEPHROL DIAL TRANSPL, V25, P1567, DOI 10.1093/ndt/gfp669; Jamal SA, 2007, AM J KIDNEY DIS, V49, P674, DOI 10.1053/j.ajkd.2007.02.264; Jean G, 2013, NEPHROL THER, V9, P154, DOI 10.1016/j.nephro.2013.02.006; Kalantar-Zadeh K, 2010, KIDNEY INT, V78, pS10, DOI 10.1038/ki.2010.189; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Li N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/524519; LLACH F, 2000, KIDNEY, P2103; Lobao R, 2004, CLIN NEPHROL, V62, P432; London G, 2010, CLIN NEPHROL, V74, P423, DOI 10.2379/CN106512; Malluche HH, 2006, CLIN NEPHROL, V65, P235; Malluche HH, 2004, NEPHROL DIAL TRANSPL, V19, pI9, DOI 10.1093/ndt/gfh1002; Meng QL, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-37; Nickolas TL, 2006, J AM SOC NEPHROL, V17, P3223, DOI 10.1681/ASN.2005111194; Oliveira RB, 2010, CLIN J AM SOC NEPHRO, V5, P286, DOI 10.2215/CJN.05420709; Parfitt AM, 2003, CURR OPIN NEPHROL HY, V12, P387, DOI 10.1097/00041552-200307000-00007; Picton ML, 2000, KIDNEY INT, V58, P1440, DOI 10.1046/j.1523-1755.2000.00306.x; SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64; Shilo V, 2016, CURR OPIN NEPHROL HY, V25, P271, DOI 10.1097/MNH.0000000000000227; Souberbielle JCP, 2010, KIDNEY INT, V77, P93, DOI 10.1038/ki.2009.374; Sprague SM, 2000, SEMIN DIALYSIS, V13, P152, DOI 10.1046/j.1525-139x.2000.00042.x; Stehman-Breen CO, 1999, AM J KIDNEY DIS, V33, P941, DOI 10.1016/S0272-6386(99)70430-0; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; United States Renal Data System, 2014, DIS NIOHNIODADAK; Warnes G.R., 2006, R NEWS, V6, P64; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006; Zhu HQ, 2016, BIOMED PHARMACOTHER, V83, P792, DOI 10.1016/j.biopha.2016.07.037	56	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2017	12	2							e0170535	10.1371/journal.pone.0170535	http://dx.doi.org/10.1371/journal.pone.0170535			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DB	28152049	Green Submitted, Green Published, gold			2023-01-03	WOS:000396161200025
J	Gubensek, J; Orsag, A; Ponikvar, R; Buturovic-Ponikvar, J				Gubensek, Jakob; Orsag, Alesa; Ponikvar, Rafael; Buturovic-Ponikvar, Jadranka			Calcium Mass Balance during Citrate Hemodialysis: A Randomized Controlled Trial Comparing Normal and Low Ionized Calcium Target Ranges	PLOS ONE			English	Article							DIALYSATE CALCIUM; PARATHYROID-HORMONE; MINERAL METABOLISM; ANTICOAGULATION; MORTALITY; DEGRANULATION; DISORDERS; DISEASE	Background Regional citrate anticoagulation (RCA) during hemodialysis interferes with calcium homeostasis. Optimal ionized calcium (iCa) target range during RCA and consequent calcium balance are unknown. Methods In a randomized controlled trial (ACTRN12613001029785) 30 chronic hemodialysis patients were assigned to normal (1.1-1.2 mmol/) or low (0.95-1.05 mmol/I) iCa target range during a single hemodialysis with RCA. The primary outcome was calcium mass balance during the procedure, using a partial spent dialysate collection method; magnesium mass balance was also measured. Intact parathormone (iPTH), total calcium (tCa) and magnesium were measured before and after procedures. Results Mean iCa during procedures was significantly different in the two groups (1.12 +/- 0.06 in normal and 1.06 +/- 0.07 mmol/1 in low iCa group, p <0.001), resulting in different tCa (2.18 +/- 0.22 vs. 1.95 +/- 0.17, p = 0.003) after the procedure. Mean delivered calcium during the procedure was 58.3 +/- 4.8 mmol in the normal and 51.5 +/- 8.2 mmol in the low iCa group (p = 0.010), which resulted in a significantly higher mean positive calcium mass balance of 14.6 +/- 8.3 mmol (584 +/- 333 mg) per procedure in normal as compared to 7.2 +/- 8.5 mmol (290 +/- 341 mg) in low iCa group (p = 0.024). Linear mixed effects model showed a significant interaction effect of time and iCa target range group on iPTH, i.e. a significant increase in iPTH in the low as compared to normal iCa target group (p = 0.008). Magnesium mass balance was mildly negative and comparable in both groups. Conclusions Low iCa target range resulted in a significantly less positive calcium mass balance, but in a significant increase in iPTH. To achieve a more neutral calcium balance, we recommend allowing a mild hypocalcemia during hemodialysis with RCA, especially when it is used for prolonged periods.	[Gubensek, Jakob; Orsag, Alesa; Ponikvar, Rafael; Buturovic-Ponikvar, Jadranka] Univ Med Ctr Ljubljana, Dept Nephrol, Ljubljana, Slovenia; [Gubensek, Jakob; Ponikvar, Rafael; Buturovic-Ponikvar, Jadranka] Univ Ljubljana, Fac Med, Ljubljana, Slovenia	University Medical Centre Ljubljana; University of Ljubljana	Gubensek, J (corresponding author), Univ Med Ctr Ljubljana, Dept Nephrol, Ljubljana, Slovenia.; Gubensek, J (corresponding author), Univ Ljubljana, Fac Med, Ljubljana, Slovenia.	jakob.gubensek@kclj.si	Gubensek, Jakob/A-5077-2010	Gubensek, Jakob/0000-0002-5394-3729; Buturovic-Ponikvar, Jadranka/0000-0001-7473-3731	University Medical Centre Ljubljana [20140029]	University Medical Centre Ljubljana	The study was funded by Research & Development Grant No. 20140029 from the University Medical Centre Ljubljana (Improvements of regional citrate anticoagulation during hemodialysis). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Alhosaini M, 2015, AM J KIDNEY DIS, V66, P523, DOI 10.1053/j.ajkd.2015.01.029; Apsner R, 2005, AM J KIDNEY DIS, V45, P557, DOI 10.1053/j.ajkd.2004.12.002; Apsner R, 2004, ANESTH ANALG, V99, P1199, DOI 10.1213/01.ANE.0000132780.87036.F5; Argiles A, 1997, KIDNEY INT, V52, P530, DOI 10.1038/ki.1997.364; Bai M, 2015, INTENS CARE MED, V41, P2098, DOI 10.1007/s00134-015-4099-0; Basile C, 2011, INT J NEPHROL, V2011, DOI 10.4061/2011/540592; Basile C, 2012, AM J KIDNEY DIS, V59, P92, DOI 10.1053/j.ajkd.2011.08.033; Bolan CD, 2001, TRANSFUSION, V41, P1165, DOI 10.1046/j.1537-2995.2001.41091165.x; Bos JC, 1997, NEPHROL DIAL TRANSPL, V12, P1387, DOI 10.1093/ndt/12.7.1387; Bosticardo G, 2012, NEPHROL DIAL TRANSPL, V27, P2489, DOI 10.1093/ndt/gfr733; Buturovic J, 2008, ARTIF ORGANS, V32, P77, DOI 10.1111/j.1525-1594.2007.00459.x; Buturovic-Ponikvar J, 2005, THER APHER DIAL, V9, P237, DOI 10.1111/j.1774-9987.2005.00262.x; Buturovic-Ponikvar J, 2016, THER APHER DIAL, V20, P234, DOI 10.1111/1744-9987.12429; Drueke TB, 2009, NEPHROL DIAL TRANSPL, V24, P2990, DOI 10.1093/ndt/gfp365; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; GAWOSKI JM, 1989, CLIN CHEM, V35, P2140; Gotch FA, 2009, NEPHROL DIAL TRANSPL, V24, P2994, DOI 10.1093/ndt/gfp360; Gritters M, 2006, NEPHROL DIAL TRANSPL, V21, P153, DOI 10.1093/ndt/gfi069; Gubensek J, 2011, THER APHER DIAL, V15, P278, DOI 10.1111/j.1744-9987.2011.00951.x; Haris A, 2006, KIDNEY INT, V70, P931, DOI 10.1038/sj.ki.5001666; Hofbauer R, 1999, KIDNEY INT, V56, P1578, DOI 10.1046/j.1523-1755.1999.00671.x; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Kozik-Jaromin J, 2009, NEPHROL DIAL TRANSPL, V24, P2244, DOI 10.1093/ndt/gfp017; Langote A, 2015, AM J KIDNEY DIS, V66, P348, DOI 10.1053/j.ajkd.2015.02.336; Meier-Kriesche HU, 2001, CRIT CARE MED, V29, P748, DOI 10.1097/00003246-200104000-00010; Messa P, 2014, SEMIN DIALYSIS, V27, P4, DOI 10.1111/sdi.12150; Moe SM, 2010, SEMIN DIALYSIS, V23, P492, DOI 10.1111/j.1525-139X.2010.00771.x; Noordzij M, 2011, NEPHROL DIAL TRANSPL, V26, P1662, DOI 10.1093/ndt/gfq582; OMOKAWA S, 1990, INT J ARTIF ORGANS, V13, P768, DOI 10.1177/039139889001301110; Pirklbauer M, 2011, NEPHROL DIAL TRANSPL, V26, P2438, DOI 10.1093/ndt/gfr207; Rodriguez-Garcia M, 2009, NEPHROL DIAL TRANSPL, V24, P239, DOI 10.1093/ndt/gfn466; Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327; Sigrist M, 2006, J RENAL NUTR, V16, P41, DOI 10.1053/j.jrn.2005.10.006; Singer Richard F, 2016, Can J Kidney Health Dis, V3, P22, DOI 10.1186/s40697-016-0113-x; Strobl K, 2013, BLOOD PURIFICAT, V36, P136, DOI 10.1159/000355012; Szamosfalvi B, 2010, BLOOD PURIFICAT, V29, P204, DOI 10.1159/000245648; Unver B, 2002, ACTA MED AUST, V29, P146, DOI 10.1046/j.1563-2571.2002.02019.x	37	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2016	11	12							e0168593	10.1371/journal.pone.0168593	http://dx.doi.org/10.1371/journal.pone.0168593			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7JB	28030601	Green Submitted, gold, Green Published			2023-01-03	WOS:000391222000060
J	Ghebrehewet, S; MacPherson, P; Ho, A				Ghebrehewet, Sam; MacPherson, Peter; Ho, Antonia			Influenza	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEMAGGLUTININ-STEM; VACCINE CANDIDATE; VIRUS-INFECTION; PHASE-III; SAFETY; ADULTS; IMMUNOGENICITY; QUADRIVALENT; TRIVALENT; CHILDREN		[Ghebrehewet, Sam; MacPherson, Peter] Publ Hlth England North West, Cheshire & Merseyside Hlth Protect Team, Liverpool, Merseyside, England; [MacPherson, Peter] Univ Liverpool, Farr Inst HeRC, Dept Publ Hlth & Policy, Liverpool, Merseyside, England; [MacPherson, Peter] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Res, Liverpool, Merseyside, England; [Ho, Antonia] Queen Elizabeth Univ Hosp, Dept Infect Dis, Glasgow, Lanark, Scotland; [Ho, Antonia] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England	Public Health England; University of Liverpool; Liverpool School of Tropical Medicine; Queen Elizabeth University Hospital (QEUH); University of Liverpool	Ghebrehewet, S (corresponding author), Publ Hlth England North West, Cheshire & Merseyside Hlth Protect Team, Liverpool, Merseyside, England.	sam.ghebrehewet@phe.gov.uk	Ho, Antonia/X-1751-2019	Ho, Antonia/0000-0003-1465-3785; MacPherson, Peter/0000-0002-0329-9613	MRC [MC_UU_12014/9] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ambrose CS, 2008, INFLUENZA OTHER RESP, V2, P193, DOI 10.1111/j.1750-2659.2008.00056.x; [Anonymous], 1980, B WORLD HEALTH ORGAN, V58, P585; [Anonymous], 2010, WHO GUID PHARM MAN P; Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Beran J, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-224; Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013; Demicheli V, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub5; Department of Health, 2016, CHIEF MED OFF CHIEF; Department of Health, 2011, ROUT TRANSM INFL VIR; Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1; ENGLUND JA, 1993, J INFECT DIS, V168, P647, DOI 10.1093/infdis/168.3.647; European Centre for Disease Prevention and Control (ECDC), 2014, TECHN DOC SAF US PER; Ferguson L, 2015, VIROLOGY, V486, P28, DOI 10.1016/j.virol.2015.08.030; Fleming DM, 2006, PEDIATR INFECT DIS J, V25, P860, DOI 10.1097/01.inf.0000237797.14283.cf; Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015; Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0; Hause BM, 2014, MBIO, V5, DOI 10.1128/mBio.00031-14; Health and Safety Executive, 2016, PAND FLU WORKPL GUID; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Jefferson T, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008965.pub4, 10.1002/14651858.CD008965.pub3]; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Kawai S, 2011, CLIN INFECT DIS, V53, P130, DOI 10.1093/cid/cir336; Kieninger D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-343; Killingley B, 2016, J INFECT PUBLIC HEAL, V9, P278, DOI 10.1016/j.jiph.2015.10.009; Kliner M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012149; Lam PP, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1966-4; Lau LLH, 2010, J INFECT DIS, V201, P1509, DOI 10.1086/652241; Leneva IA, 2009, ANTIVIR RES, V81, P132, DOI 10.1016/j.antiviral.2008.10.009; Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6; Loeb M, 2010, JAMA-J AM MED ASSOC, V303, P943, DOI 10.1001/jama.2010.250; Matsuzaki Y, 2016, J VIROL, V90, P8251, DOI 10.1128/JVI.00969-16; Minodier L, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0448-4; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; Moura FEA, 2010, CURR OPIN INFECT DIS, V23, P415, DOI 10.1097/QCO.0b013e32833cc955; Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4; Naleway AL, 2014, VACCINE, V32, P3122, DOI 10.1016/j.vaccine.2014.04.021; National Institute for Health and Care Excellence, 2015, CLIN KNOWL SUMM INFL; National Institute for Health and Care Excellence, 2008, OS AM ZAN PROPH INFL; National Institute for Health and Care Excellence, 2009, AM OS ZAN TREATM INF; Ohmit SE, 2006, CLIN INFECT DIS, V43, P564, DOI 10.1086/506352; Olson DR, 2007, PLOS MED, V4, P1349, DOI 10.1371/journal.pmed.0040247; Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15; Pepin S, 2013, VACCINE, V31, P5572, DOI 10.1016/j.vaccine.2013.08.069; Public Health England, 2016, PHE GUID US ANT AG T; Public Health England, 2012, MAN OUTBR AC RESP DI; Public Health England, 2014, INF CONTR PREC MIN T; Public Health England, 2016, PHE GUID MAN OUTBR I; Public Health England, 2013, IMMUNISATION INFECT; Rossignol JF, 2009, J BIOL CHEM, V284, P29798, DOI 10.1074/jbc.M109.029470; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Tamma PD, 2009, AM J OBSTET GYNECOL, V201, P547, DOI 10.1016/j.ajog.2009.09.034; Tinoco JC, 2014, VACCINE, V32, P1480, DOI 10.1016/j.vaccine.2014.01.022; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; World Health Organization, 2010, PAND INFL PREP RESP; World Health Organization, 2016, GLOB INFL SURV RESP; World Health Organization, 2016, INFL VACC VIR REAG; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630; Zambon M, 2014, CURR OPIN INFECT DIS, V27, P560, DOI 10.1097/QCO.0000000000000113	61	65	70	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	2016	355								i6258	10.1136/bmj.i6258	http://dx.doi.org/10.1136/bmj.i6258			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF0SX	27927672	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000390037400006
J	Bhavan, KP; Agrawal, D; Cerise, F				Bhavan, Kavita P.; Agrawal, Deepak; Cerise, Frederick			Achieving the Triple Aim Through Disruptive Innovations in Self-care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THERAPY		[Bhavan, Kavita P.; Agrawal, Deepak] Univ Texas Southwestern Med Ctr Dallas, Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Cerise, Frederick] Parkland Hlth & Hosp Syst, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Bhavan, KP (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	kavita.bhavan@utsouthwestern.edu	Agrawal, Deepak/L-6592-2019	Agrawal, Deepak/0000-0001-7224-6921				ANTONISKIS A, 1978, WESTERN J MED, V128, P203; Bhavan KP, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001922; Christensen CM, 2016, HARVARD BUS REV; KIND AC, 1979, ARCH INTERN MED, V139, P413, DOI 10.1001/archinte.139.4.413; Paladino JA, 2010, CLIN INFECT DIS, V51, pS198, DOI 10.1086/653520	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2016	316	20					2081	2082		10.1001/jama.2016.15391	http://dx.doi.org/10.1001/jama.2016.15391			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ED1XD	27893138				2023-01-03	WOS:000388637300010
J	Jonard, M; Ducloy-Bouthors, AS; Fourrieri, F				Jonard, Marie; Ducloy-Bouthors, Anne Sophie; Fourrieri, Francois			Comparison of Two Diagnostic Scores of Disseminated Intravascular Coagulation in Pregnant Women Admitted to the ICU	PLOS ONE			English	Article							INTERNATIONAL SOCIETY; SCORING SYSTEM; POSTPARTUM HEMORRHAGE; HEMOSTASIS; THROMBOSIS	Objective To compare the validity of two previously published diagnostic scores of disseminated intravascular coagulation (DIC) in pregnant women admitted to ICU for an acute thrombotic or hemorrhagic complication of delivery and postpartum. Methods This was a population based retrospective study of 154 patients admitted to ICU for severe delivery and postpartum complications in a University Hospital. A recently published score (adapted to physiological changes of pregnancy and based on three components: platelet count, prothrombin time difference and fibrinogen) was compared to the International Society for Thrombosis and Hemostasis (ISTH) score (based on four components: platelet count, fibrinogen, prothrombin time, and fibrin related marker). Both scores were calculated at delivery, ICU admission (day 0), day 1 and day 2 during the postpartum ICU stay. The validity of both scores was assessed by comparison with the consensual and blinded analysis of two experts. The sensitivity, specificity, and area under the curve (AUC) of each score were calculated at each time and overall by generalized linear mixed model. The agreement between the two scores was evaluated by the Kappa coefficient. Results The new score had a sensitivity of 0.78, a specificity of 0.97 (p < 0.01) and a global AUC of 96% while the ISTH score had a sensitivity of 0.31, a specificity of 0.99 and an AUC of 94% (p < 0.01). The Kappa coefficient of correlation between both scores was 0.35. The lower sensitivity of the ISTH score was mainly explained by the lack of fibrinogen and fibrin-related peptides thresholds adapted to the physiological changes of coagulation induced by pregnancy. Conclusion The new DIC score seem highly discriminant in the subset of patients admitted to the ICU after delivery for an acute specific complication. The ISTH score is not recommended in pregnant women because of its poor sensitivity.	[Jonard, Marie] Ctr Hosp Reg Univ, Lens & Ctr Hosp Roger Salengro, Ctr Hosp Dr Schaffner, Dept Intens Care Unit, Lille, France; [Ducloy-Bouthors, Anne Sophie] Ctr Hosp Reg Univ, Dept Obstet Anesthesia, Lille, France; [Fourrieri, Francois] Ctr Hosp Reg Univ, Ctr Hosp Roger Salengro, Dept Intens Care Unit, Lille, France	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille	Jonard, M (corresponding author), Ctr Hosp Reg Univ, Lens & Ctr Hosp Roger Salengro, Ctr Hosp Dr Schaffner, Dept Intens Care Unit, Lille, France.	marie.jonard@wanadoo.fr	Ducloy-Bouthors, Anne-Sophie/N-4891-2016					Angstwurm MWA, 2006, CRIT CARE MED, V34, P314, DOI 10.1097/01.CCM.0000196832.27501.B2; Bakhtiari K, 2004, CRIT CARE MED, V32, P2416, DOI 10.1097/01.CCM.0000147769.07699.E3; Brenner B, 2004, THROMB RES, V114, P409, DOI 10.1016/j.thromres.2004.08.004; Charbit B, 2007, J THROMB HAEMOST, V5, P266, DOI 10.1111/j.1538-7836.2007.02297.x; Collins PW, 2014, BLOOD, V124, P1727, DOI 10.1182/blood-2014-04-567891; Collis RE, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12913; Ducloy-Bouthors A-S, 2010, Ann Fr Anesth Reanim, V29, pe121, DOI 10.1016/j.annfar.2010.03.012; Erez O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093240; Fourrier F, 2002, REANIMATION, V11, P341; Francalanci I, 1997, INT J CLIN LAB RES, V27, P65, DOI 10.1007/BF02827245; Levi M, 2011, BLOOD REV, V25, P33, DOI 10.1016/j.blre.2010.09.002; O'Riordan MN, 2003, BEST PRACT RES CL OB, V17, P385, DOI 10.1016/S1521-6934(03)00019-1; Rattray DD, 2012, J OBSTET GYNAECOL CA, V34, P341, DOI 10.1016/S1701-2163(16)35214-8; Szecsi PB, 2010, THROMB HAEMOSTASIS, V103, P718, DOI [10.1160/TH09-10-0704, DOI 10.1160/TH09-10-07074]; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; Terao T, 1987, Asia Oceania J Obstet Gynaecol, V13, P1; Thachil J, 2009, BLOOD REV, V23, P167, DOI 10.1016/j.blre.2009.04.002; Toh CH, 2007, J THROMB HAEMOST, V5, P604, DOI 10.1111/j.1538-7836.2007.02313.x; VANWERSCH JWJ, 1991, EUR J CLIN CHEM CLIN, V29, P45; Windsperger K, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.025	20	14	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2016	11	11							e0166471	10.1371/journal.pone.0166471	http://dx.doi.org/10.1371/journal.pone.0166471			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC7WC	27861597	Green Published, gold, Green Submitted			2023-01-03	WOS:000388350300061
J	Liou, JM; Fang, YJ; Chen, CC; Bair, MJ; Chang, CY; Lee, YC; Chen, MJ; Chen, CC; Tseng, CH; Hsu, YC; Lee, JY; Yang, TH; Luo, JC; Chang, CC; Chen, CY; Chen, PY; Shun, CT; Hsu, WF; Hu, WH; Chen, YN; Sheu, BS; Lin, JT; Wu, JY; El-Omar, EM; Wu, MS				Liou, Jyh-Ming; Fang, Yu-Jen; Chen, Chieh-Chang; Bair, Ming-Jong; Chang, Chi-Yang; Lee, Yi-Chia; Chen, Mei-Jyh; Chen, Chien-Chuan; Tseng, Cheng-Hao; Hsu, Yao-Chun; Lee, Ji-Yuh; Yang, Tsung-Hua; Luo, Jiing-Chyuan; Chang, Chun-Chao; Chen, Chi-Yi; Chen, Po-Yueh; Shun, Chia-Tung; Hsu, Wen-Feng; Hu, Wen-Hao; Chen, Yen-Nien; Sheu, Bor-Shyang; Lin, Jaw-Town; Wu, Jeng-Yih; El-Omar, Emad M.; Wu, Ming-Shiang		Taiwan Gastrointestinal Dis	Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial	LANCET			English	Article							GASTRIC-CANCER; SEQUENTIAL THERAPY; INFECTION; ERADICATION; METAANALYSIS; CLARITHROMYCIN; RESISTANCE; EFFICACY; METRONIDAZOLE; ESOMEPRAZOLE	Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. Methods In this multicentre, open-label, randomised trial, we recruited adult patients (aged > 20 years) with H pylori infection from nine medical centres in Taiwan. Patients who had at least two positive tests from the rapid urease test, histology, culture, or serology or who had a single positive 1 3 C-urea breath test for gastric cancer screening were eligible for enrolment. Patients were randomly assigned (1: 1: 1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. A computer-generated permuted block randomisation sequence with a block size of 6 was used for randomisation, and the sequence was concealed in an opaque envelope until the intervention was assigned. Investigators were masked to treatment allocation. The primary outcome was the eradication frequency of H pylori with first-line therapy assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01906879. Findings Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90.4% (488/540 [95% CI 87.6-92.6]) for 10-day bismuth quadruple therapy, 85.9% (464/540 [82.7-88.6]) for 10-day concomitant therapy, and 83.7% (452/540 [80.4-86.6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6.7% [95% CI 2.7-10.7], p=0.001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67% (358/533) in patients treated with 10-day bismuth quadruple therapy, 58% (309/535) in patients treated with 10-day concomitant therapy, and 47% (252/535) in patients treated with 14-day triple therapy. Interpretation Bismuth quadruple therapy is preferable to 14-day triple therapy in the first-line treatment in the face of rising prevalence of clarithromycin resistance. Concomitant therapy given for 10 days might not be optimum and a longer treatment length should be considered.	[Liou, Jyh-Ming; Chen, Chieh-Chang; Lee, Yi-Chia; Chen, Mei-Jyh; Chen, Chien-Chuan; Lin, Jaw-Town; Wu, Ming-Shiang] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Shun, Chia-Tung] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Fang, Yu-Jen; Lee, Ji-Yuh; Yang, Tsung-Hua] Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp,Yun Lin Branch, Yunlin, Taiwan; [Bair, Ming-Jong] Mackay Mem Hosp, Taitung Branch, Div Gastroenterol, Dept Internal Med, Taitung, Taiwan; [Bair, Ming-Jong] Meiho Univ, Dept Nursing, Pingtung, Taiwan; [Chang, Chi-Yang; Tseng, Cheng-Hao; Hsu, Yao-Chun] E DA Hosp, Dept Internal Med, Kaohsiung, Kaohsiung Count, Taiwan; [Chang, Chi-Yang; Tseng, Cheng-Hao; Hsu, Yao-Chun] I Shou Univ, Kaohsiung, Kaohsiung Count, Taiwan; [Luo, Jiing-Chyuan] Natl Yang Ming Univ, Dept Med, Sch Med, Taipei, Taiwan; [Luo, Jiing-Chyuan] Taipei Vet Gen Hosp, Taipei, Taiwan; [Chang, Chun-Chao] Taipei Med Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taipei, Taiwan; [Chang, Chun-Chao] Taipei Med Univ, Coll Med, Sch Med, Taipei, Taiwan; [Chen, Chi-Yi; Chen, Po-Yueh] Chia Yi Christian Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Chiayi, Taiwan; [Hsu, Wen-Feng; Hu, Wen-Hao; Chen, Yen-Nien] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsinchu, Taiwan; [Sheu, Bor-Shyang] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Sheu, Bor-Shyang] Natl Cheng Kung Univ, Med Ctr, Tainan, Taiwan; [Lin, Jaw-Town] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan; [Wu, Jeng-Yih] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung Municipal Hsiao Kang Hosp, Dept Internal Med, Kaohsiung, Taiwan; [El-Omar, Emad M.] Univ New South Wales, Dept Med, St George & Sutherland Clin Sch, Sydney, NSW, Australia	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Mackay Memorial Hospital; E-Da Hospital; I Shou University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; National Taiwan University; National Taiwan University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; Fu Jen Catholic University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Municipal Siao-Gang Hospital; University of New South Wales Sydney	Wu, MS (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med & Primary Care Med, Taipei, Taiwan.	mingshiang@ntu.edu.tw	Shun, Chia-Tung/M-1400-2019; El-Omar, Emad/AAT-7780-2021; Chen, Chieh-Chang/ABD-3228-2021	LIOU, JYH-MING/0000-0002-7945-5408; HU, WEN-HAO/0000-0001-5486-8591; El-Omar, Emad/0000-0002-0011-3924; LEE, YI-CHIA/0000-0002-8160-1216; HSU, WEN-FENG/0000-0001-7138-2614; Wu, Ming-Shiang/0000-0002-1940-6428; Chen, Mei-Jyh/0000-0003-3284-004X; SHUN, CHIA-TUNG/0000-0002-0468-4468; Chen, Chieh-Chang/0000-0003-2953-210X	National Taiwan University Hospital; Ministry of Science and Technology of Taiwan	National Taiwan University Hospital(National Taiwan University); Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.	Chey WD, 2007, AM J GASTROENTEROL, V102, P1808, DOI 10.1111/j.1572-0241.2007.01393.x; Dore MP, 2016, GUT, V65, P870, DOI 10.1136/gutjnl-2015-311019; Fallone CA, 2016, GASTROENTEROLOGY, V151, P51, DOI 10.1053/j.gastro.2016.04.006; Ford AC, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3174; Gatta L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4587; Georgopoulos SD, 2013, HELICOBACTER, V18, P459, DOI 10.1111/hel.12062; Gisbert JP, 2011, ALIMENT PHARM THER, V34, P604, DOI 10.1111/j.1365-2036.2011.04770.x; Graham DY, 2007, HELICOBACTER, V12, P275, DOI 10.1111/j.1523-5378.2007.00518.x; Graham DY, 2016, HELICOBACTER, V21, P85, DOI 10.1111/hel.12287; Graham DY, 2015, GASTROENTEROL CLIN N, V44, P537, DOI 10.1016/j.gtc.2015.05.003; Graham DY, 2010, GUT, V59, P1143, DOI 10.1136/gut.2009.192757; Greenberg ER, 2011, LANCET, V378, P507, DOI 10.1016/S0140-6736(11)60825-8; Kitahara F, 1999, GUT, V44, P693, DOI 10.1136/gut.44.5.693; Lee YC, 2016, GASTROENTEROLOGY, V150, P1113, DOI 10.1053/j.gastro.2016.01.028; Lee YC, 2013, GUT, V62, P676, DOI 10.1136/gutjnl-2012-302240; Li BZ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4052; Liou JM, 2016, GUT, V65, P1784, DOI 10.1136/gutjnl-2015-310142; Liou JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124199; Liou JM, 2013, J ANTIMICROB CHEMOTH, V68, P450, DOI 10.1093/jac/dks407; Liou JM, 2013, LANCET, V381, P205, DOI 10.1016/S0140-6736(12)61579-7; Liou JM, 2011, J ANTIMICROB CHEMOTH, V66, P1847, DOI 10.1093/jac/dkr217; Liou JM, 2011, ANTIMICROB AGENTS CH, V55, P1123, DOI 10.1128/AAC.01131-10; Liu KSH, 2014, GUT, V63, P1410, DOI 10.1136/gutjnl-2013-306120; Luther J, 2010, AM J GASTROENTEROL, V105, P65, DOI 10.1038/ajg.2009.508; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; Malfertheiner P, 2011, LANCET, V377, P905, DOI 10.1016/S0140-6736(11)60020-2; Megraud F, 2013, GUT, V62, P34, DOI 10.1136/gutjnl-2012-302254; Molina-Infante J, 2015, ALIMENT PHARM THER, V41, P581, DOI 10.1111/apt.13069; Molina-Infante J, 2013, GASTROENTEROLOGY, V145, P121, DOI 10.1053/j.gastro.2013.03.050; Songur Y, 2009, AM J MED SCI, V338, P50, DOI 10.1097/MAJ.0b013e31819c7320; Uygun A, 2007, J DIGEST DIS, V8, P211, DOI 10.1111/j.1751-2980.2007.00308.x; Venerito M, 2013, DIGESTION, V88, P33, DOI 10.1159/000350719; Wu DC, 2010, CLIN GASTROENTEROL H, V8, P36, DOI 10.1016/j.cgh.2009.09.030; Wu JY, 2014, EXPERT REV GASTROENT, V8, P21, DOI 10.1586/17474124.2014.859522; Yang JC, 2015, CLIN GASTROENTEROL H, V13, P895, DOI 10.1016/j.cgh.2014.10.036; Yuan YH, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008337.pub2; Zhang W, 2015, GUT, V64, P1715, DOI 10.1136/gutjnl-2015-309900	37	87	91	0	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2016	388	10058					2355	2365		10.1016/S0140-6736(16)31409-X	http://dx.doi.org/10.1016/S0140-6736(16)31409-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB5RB	27769562				2023-01-03	WOS:000387436900024
J	Ushie, BA; Ugal, DB; Ingwu, JA				Ushie, Boniface Ayanbekongshie; Ugal, David Betelwhobel; Ingwu, Justin Agorye			Overdependence on For-Profit Pharmacies: A Descriptive Survey of User Evaluation of Medicines Availability in Public Hospitals in Selected Nigerian States	PLOS ONE			English	Article							HEALTH-CARE; AFFORDABILITY; VENDORS; ACCESS; INCOME; DRUGS; URBAN	Objective Lower availability of medicines in Nigerian public health facilities D the most affordable option for the masses D undermines global health reforms to improve access to health for all, especially the chronically ill and poor. Thus, a sizeable proportion of healthcare users, irrespective of purchasing power, buy medicines at higher costs from for-profit pharmacies. We examined user evaluation of medicine availability in public facilities and how this influences their choice of where to buy medicines in selected states D Cross River, Enugu and Oyo D in Nigeria. Methods We approached and interviewed 1711 healthcare users using a semi-structured, interviewer-administered questionnaire as they exited for-profit pharmacies after purchasing medicines. This ensured that both clients who had presented at health facilities (private/public) and those who did not were included. Information was collected on why respondents could not buy medicines at the hospitals they attended, their views of medicine availability and whether their choice of where to buy medicines is influenced by non-availability. Principal Findings Respondents' mean age was 37.7 +/- 14.4 years; 52% were males, 59% were married, 82% earned >= NGN18, 000 (US$57.19) per month, and 72% were not insured. Majority (66%) had prescriptions; of this, 70% were from public facilities. Eighteen percent of all respondents indicated that all their medicines were usually available at the public facilities, most (29%), some (44%) and not always available (10%). Reasons for using for-profit pharmacies included: health workers attitudes (43%), referral by providers (43%); inadequate money to purchase all prescribed drugs (42%) and cumbersome processes for obtaining medicines. Conclusions Lower availability of medicines has serious implications for healthcare behavior, especially because of poverty. It is crucial for government to fulfill its mandate of equitable access to care for all by making medicines available and cheap through reviving and sustaining the drug revolving fund scheme and encouraging the prescription of generic drugs in all public health facilities.	[Ushie, Boniface Ayanbekongshie] Univ Ibadan, Inst Child Hlth, Coll Med, Ibadan, Nigeria; [Ugal, David Betelwhobel] Fed Univ Lafia, Dept Sociol, Lafia, Nigeria; [Ingwu, Justin Agorye] Univ Nigeria, Dept Nursing Sci, Nsukka, Nigeria	University of Ibadan; University of Nigeria	Ushie, BA (corresponding author), Univ Ibadan, Inst Child Hlth, Coll Med, Ibadan, Nigeria.	boniface.ushie@gmail.com		Ushie, Boniface Ayanbekongshie/0000-0001-6579-6327	Tertiary Education Trust Fund; Federal Government of Nigeria	Tertiary Education Trust Fund; Federal Government of Nigeria	The authors received funding for this work from the Tertiary Education Trust Fund, which is provided by the Federal Government of Nigeria; http://www.tetfund.gov.ng/.	Abegunde K. A., 2013, J COMMUNITY MED PRIM, V26, P1; Adesina, 2002, CURRENTS PERSPECTIVE, P212; Alubo O, 2001, HEALTH POLICY PLANN, V16, P313, DOI 10.1093/heapol/16.3.313; Alubo S. O., 1999, SOC SCI MED, V38, P97; Babar ZUD, 2013, PHARMACOECONOMICS, V31, P1063, DOI 10.1007/s40273-013-0095-9; Bigdeli M, 2013, HEALTH POLICY PLANN, V28, P692, DOI 10.1093/heapol/czs108; Brieger WR, 2004, HEALTH POLICY PLANN, V19, P177, DOI 10.1093/heapol/czh021; Brinda EM, 2014, BMC INT HEALTH HUM R, V14, DOI 10.1186/1472-698X-14-5; BROCK DW, 1987, J MED PHILOS, V12, P1; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chandler CIR, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-13; Eke Christopher Bismarck, 2014, BMC Res Notes, V7, P800, DOI 10.1186/1756-0500-7-800; Fadare J. O., 2015, EXPERT REV PHARM OUT, P1; FMOH, 2005, INV HLTH FAC NIG; Foster S.D., 1990, IMPROVING SUPPLY USE; Garg CC, 2009, HEALTH POLICY PLANN, V24, P116, DOI 10.1093/heapol/czn046; Iloh GUP, 2012, NIGER J CLIN PRACT, V15, P469, DOI 10.4103/1119-3077.104529; Iyioha IO, 2016, COMP HLTH LAW POLICY; Jitta J, 2003, HEALTH POLICY, V65, P167, DOI 10.1016/S0168-8510(03)00003-4; Johnson O. E., 2015, J COMMUNITY MED PRIM, V27, P73; Kotwani A, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-285; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Muhammed KA, 2013, J PUBLIC HEALTH AFR, V4, P64, DOI 10.4081/jphia.2013.e13; NHA, 2006, NAT HLTH ACC NHA 200; Niens LM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000333; Odusanya O. O., 1999, NIGERIAN Q J HOSP ME, V9, DOI [10.4314/nqjhm.v9i4.12397, DOI 10.4314/NQJHM.V9I4.12397]; Odusanya OO, 2004, J COMMUNITY MED PRIM, V16, P21; Okafor C., 2015, AFRICAN RES REV, V9, P333; Oparah C. A., 2001, INT J PHARM PRACT, V9, P191; Orem JN, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-175; OSHINAME FO, 1992, SOC SCI MED, V35, P1477, DOI 10.1016/0277-9536(92)90050-Z; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Sado E, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0572-3; Salako L. A., 2004, J CLIN EPIDEMIOL, V45, P15; Shabangu K, 2015, AFR J PRIM HEALTH CA, V7, DOI [10.4102/phcfm.v7i1.829, 10.4102/PHCFM.V7I1.829]; Uche I., 2014, ACAD J INTERDISCIPLI, V3, P501; Umoru A, 2016, VALUE HEALTH, V19, pA35, DOI 10.1016/j.jval.2016.03.380; UNDP, 2007, HUMAN DEV REPORT; Uzochukwu B, 2005, HEALTH POLICY, V75, P1, DOI 10.1016/j.healthpol.2005.01.019; Wang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116897; WHO, 2004, WORLD MED SITUATION; Wirtz VJ, 2012, VALUE HEALTH, V15, P593, DOI 10.1016/j.jval.2012.01.006; World Health Organization, 2004, EQ ACC ESS MED FRAM	43	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2016	11	11							e0165707	10.1371/journal.pone.0165707	http://dx.doi.org/10.1371/journal.pone.0165707			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EA8SX	27812177	Green Published, gold, Green Submitted			2023-01-03	WOS:000386910000049
J	Faust, JJ; Doudrick, K; Yang, Y; Capco, DG; Westerhoff, P				Faust, James J.; Doudrick, Kyle; Yang, Yu; Capco, David G.; Westerhoff, Paul			A Facile Method for Separating and Enriching Nano and Submicron Particles from Titanium Dioxide Found in Food and Pharmaceutical Products	PLOS ONE			English	Article							IN-VITRO; ENGINEERED NANOMATERIALS; NANOPARTICLES; CENTRIFUGATION; SEDIMENTATION; TOXICITY; ENVIRONMENT; CHALLENGES; EXPOSURE; GRADIENT	Recent studies indicate the presence of nano-scale titanium dioxide (TiO2) as an additive in human foodstuffs, but a practical protocol to isolate and separate nano-fractions from soluble foodstuffs as a source of material remains elusive. As such, we developed a method for separating the nano and submicron fractions found in commercial-grade TiO2 (E171) and E171 extracted from soluble foodstuffs and pharmaceutical products (e.g., chewing gum, pain reliever, and allergy medicine). Primary particle analysis of commercial-grade E171 indicated that 54% of particles were nano-sized (i.e., < 100 nm). Isolation and primary particle analysis of five consumer goods intended to be ingested revealed differences in the percent of nano-sized particles from 32%-58%. Separation and enrichment of nano- and submicron-sized particles from commercial-grade E171 and E171 isolated from foodstuffs and pharmaceuticals was accomplished using rate-zonal centrifugation. Commercial-grade E171 was separated into nano-and submicron-enriched fractions consisting of a nano: submicron fraction of approximately 0.45:1 and 3.2:1, respectively. E171 extracted from gum had nano: submicron fractions of 1.4:1 and 0.19:1 for nano- and submicron-enriched, respectively. We show a difference in particle adhesion to the cell surface, which was found to be dependent on particle size and epithelial orientation. Finally, we provide evidence that E171 particles are not immediately cytotoxic to the Caco-2 human intestinal epithelium model. These data suggest that this separation method is appropriate for studies interested in isolating the nano-sized particle fraction taken directly from consumer products, in order to study separately the effects of nano and submicron particles.	[Faust, James J.; Capco, David G.] Arizona State Univ, Sch Life Sci, Mol & Cellular Biosci, Tempe, AZ 85287 USA; [Doudrick, Kyle] Dept Civil & Environm Engn & Earth Sci, 156 Fitzpatrick Hall, Notre Dame, IN 46556 USA; [Yang, Yu; Westerhoff, Paul] Arizona State Univ, Sch Sustainable Engn & Built Environm, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Doudrick, K (corresponding author), Dept Civil & Environm Engn & Earth Sci, 156 Fitzpatrick Hall, Notre Dame, IN 46556 USA.	kdoudrick@nd.edu	Westerhoff, Paul/AAF-1850-2019; Doudrick, Kyle/J-4683-2014	Westerhoff, Paul/0000-0002-9241-8759; Doudrick, Kyle/0000-0003-1912-9819	US Environmental Protection Agency [RD83558001]; National Science Foundation Nanosystems Engineering Research Center for Nanotechnology Enabled Water Treatment (NEWT) [1449500]; NSF/ASEE Small Business Postdoctoral Research Diversity Fellowship; Notre Dame; Maher Alumni Award	US Environmental Protection Agency(United States Environmental Protection Agency); National Science Foundation Nanosystems Engineering Research Center for Nanotechnology Enabled Water Treatment (NEWT); NSF/ASEE Small Business Postdoctoral Research Diversity Fellowship; Notre Dame; Maher Alumni Award	This research was supported by US Environmental Protection Agency (RD83558001) and the National Science Foundation (EEC 1449500) Nanosystems Engineering Research Center for Nanotechnology Enabled Water Treatment (NEWT). KD recognizes funding from NSF/ASEE Small Business Postdoctoral Research Diversity Fellowship and startup funding from Notre Dame. JF was supported in part by the Maher Alumni Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbulut O, 2012, NANO LETT, V12, P4060, DOI 10.1021/nl301452x; Appendix Asadi M., 2005, BEET SUGAR HDB, P769; Auffan M, 2009, NAT NANOTECHNOL, V4, P634, DOI 10.1038/nnano.2009.242; Bae TH, 2005, J MEMBRANE SCI, V249, P1, DOI 10.1016/j.memsci.2004.09.008; Brun E, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-13; Cho EC, 2011, NAT NANOTECHNOL, V6, P385, DOI [10.1038/nnano.2011.58, 10.1038/NNANO.2011.58]; Dorier M, 2015, NANOSCALE, V7, P7352, DOI 10.1039/c5nr00505a; Dudkiewicz A, 2011, TRAC-TREND ANAL CHEM, V30, P28, DOI 10.1016/j.trac.2010.10.007; Faust JJ, 2014, CELL BIOL TOXICOL, V30, P169, DOI 10.1007/s10565-014-9278-1; Faust JJ, 2014, CELL BIOL TOXICOL, V30, P31, DOI 10.1007/s10565-013-9267-9; Fisichella M, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-18; Hotze EM, 2010, J ENVIRON QUAL, V39, P1909, DOI 10.2134/jeq2009.0462; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Koeneman BA, 2010, CELL BIOL TOXICOL, V26, P225, DOI 10.1007/s10565-009-9132-z; Kreyling WG, 2010, NANO TODAY, V5, P165, DOI 10.1016/j.nantod.2010.03.004; Kruger K, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2402-6; Lomer MCE, 2000, ANALYST, V125, P2339, DOI 10.1039/b006285p; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Maynard AD, 2014, NAT NANOTECHNOL, V9, P658, DOI 10.1038/nnano.2014.196; McCracken C, 2016, ENVIRON SCI-NANO, V3, P256, DOI [10.1039/c5en00242g, 10.1039/C5EN00242G]; McCracken C, 2013, CHEM RES TOXICOL, V26, P1514, DOI 10.1021/tx400231u; Mihail CR, 2007, ELECT ENG HDB; MOOSEKER MS, 1976, J CELL BIOL, V71, P417, DOI 10.1083/jcb.71.2.417; Pele LC, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0101-9; Qiu PH, 2011, ADV MATER, V23, P4880, DOI 10.1002/adma.201102636; Reed RB, 2014, ACS SUSTAIN CHEM ENG, V2, P1616, DOI 10.1021/sc500108m; Rice J, 1997, SUBCELLULAR FRACTION; Singh G, 2014, COMPR REV FOOD SCI F, V13, P693, DOI 10.1111/1541-4337.12078; Song ZM, 2015, J APPL TOXICOL, V35, P1169, DOI 10.1002/jat.3171; Stanley WM, 1944, J EXP MED, V79, P267, DOI 10.1084/jem.79.3.267; Swindells J. F., 1958, VISCOSITIES SUCROSE; Tarantini A, 2015, TOXICOL IN VITRO, V29, P398, DOI 10.1016/j.tiv.2014.10.023; von der Kammer F, 2012, ENVIRON TOXICOL CHEM, V31, P32, DOI 10.1002/etc.723; Weir A, 2012, ENVIRON SCI TECHNOL, V46, P2242, DOI 10.1021/es204168d; Xiu ZM, 2012, NANO LETT, V12, P4271, DOI 10.1021/nl301934w; Yang Y, 2016, SCI TOTAL ENVIRON, V565, P902, DOI 10.1016/j.scitotenv.2016.01.165; Yang Y, 2014, ENVIRON SCI TECHNOL, V48, P6391, DOI 10.1021/es500436x; Zhang Z, 2012, J AGR FOOD CHEM, V60, P10762, DOI 10.1021/jf303423q	38	16	17	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2016	11	10							e0164712	10.1371/journal.pone.0164712	http://dx.doi.org/10.1371/journal.pone.0164712			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA6BX	27798677	Green Published, gold, Green Submitted			2023-01-03	WOS:000386711100012
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Margaret McCartney: Long live generics!	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material													mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Adams S., 2012, DAILY TELEGRAPH; [Anonymous], 2016, GUARDIAN; Bradshaw J., 2016, TELEGRAPH; Hire Carly, 2013, Inform Prim Care, V21, P1, DOI 10.14236/jhi.v21i1.6; KIRKNESS CM, 1995, EYE, V9, pR7, DOI 10.1038/eye.1995.97; NHS Greater Glasgow and Clyde, 2010, CAS STUD SCRIPTSWITC	6	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	2016	355								i5808	10.1136/bmj.i5808	http://dx.doi.org/10.1136/bmj.i5808			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB4CM	27799144	Bronze, Green Published			2023-01-03	WOS:000387316800003
J	Eisenstein, M				Eisenstein, Michael			Shock value	NATURE			English	Editorial Material							DEEP-BRAIN-STIMULATION; PARKINSONS-DISEASE											Charles D, 2014, PARKINSONISM RELAT D, V20, P731, DOI 10.1016/j.parkreldis.2014.03.019; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Li Q, 2012, NEURON, V76, P1030, DOI 10.1016/j.neuron.2012.09.032; Li S, 2007, J NEUROPHYSIOL, V98, P3525, DOI 10.1152/jn.00808.2007; Little S, 2013, ANN NEUROL, V74, P449, DOI 10.1002/ana.23951; Malekmohammadi M, 2016, MOVEMENT DISORD, V31, P426, DOI 10.1002/mds.26482; POLLAK P, 1993, REV NEUROL, V149, P175; Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158; Swann NC, 2016, J NEUROSCI, V36, P6445, DOI 10.1523/JNEUROSCI.1128-16.2016	9	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2016	538	7626					S10	S12		10.1038/538S10a	http://dx.doi.org/10.1038/538S10a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EA5IY	27783575	Bronze			2023-01-03	WOS:000386654400008
J	Canaud, B; Hegbrant, J; Nissenson, AR; Barth, C; Maddux, F; Etter, M; Krishnan, M				Canaud, Bernard; Hegbrant, Jorgen; Nissenson, Allen R.; Barth, Claudia; Maddux, Franklin; Etter, Michael; Krishnan, Mahesh			Improving outcomes of dialysis patients by population health management-the Global Chief Medical Officer Initiative	LANCET			English	Editorial Material							STAGE KIDNEY-DISEASE; RENAL REGISTRIES; CARE; QUALITY; ACCESS		[Canaud, Bernard] Fresenius Med Care Europe Middle East Afr, D-61352 Bad Homburg, Germany; [Hegbrant, Jorgen] Diaverum Renal Serv Grp, Lund, Sweden; [Nissenson, Allen R.; Krishnan, Mahesh] DaVita HealthCare Partners Inc, Denver, CO USA; [Barth, Claudia] BBraun Avitum AG, Melsungen, Germany; [Maddux, Franklin] Fresenius Med Care North Amer, Waltham, MA USA; [Etter, Michael] Fresenius Med Care Asia Pacific, Hong Kong, Hong Kong, Peoples R China	Diaverum; DaVita	Canaud, B (corresponding author), Fresenius Med Care Europe Middle East Afr, D-61352 Bad Homburg, Germany.	bernard.canaud@fmc-ag.com		Maddux, Franklin/0000-0003-1395-2011				Breckenridge K, 2015, NEPHROL DIAL TRANSPL, V30, P1605, DOI 10.1093/ndt/gfv209; Claudia B., 2010, DIALYSIS TRANSPLANT, V39, P404; Hodach R., 2012, POPULATION HLTH MANA; Krishnan M, 2014, CLIN J AM SOC NEPHRO, V9, P1124, DOI 10.2215/CJN.11061013; Krishnan M, 2012, CLIN J AM SOC NEPHRO, V7, P1891, DOI 10.2215/CJN.03220312; Liu FX, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0028-2; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; National Institute for Health and Care Excellence, 2011, QS5 NICE; Parker T, 2011, CLIN J AM SOC NEPHRO, V6, P457, DOI 10.2215/CJN.08450910; Porter ME, 2016, JAMA-J AM MED ASSOC, V316, P1047, DOI 10.1001/jama.2016.11698; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; Robinson BM, 2016, LANCET, V388, P294, DOI 10.1016/S0140-6736(16)30448-2; US Food and Drug Administration. National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions, 2015, FED REG; van der Veer SN, 2014, NEPHROL DIAL TRANSPL, V29, P1460, DOI 10.1093/ndt/gft473; van der Veer SN, 2011, KIDNEY INT, V80, P1021, DOI 10.1038/ki.2011.222; Wetmore JB, 2016, CLIN J AM SOC NEPHRO, V11, P1297, DOI 10.2215/CJN.12981215	16	6	6	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2016	388	10055					1966	1967		10.1016/S0140-6736(16)31894-3	http://dx.doi.org/10.1016/S0140-6736(16)31894-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DZ6EQ	27789006				2023-01-03	WOS:000385954800009
J	Kratochwill, K; Boehm, M; Herzog, R; Gruber, K; Lichtenauer, AM; Kuster, L; Csaicsich, D; Gleiss, A; Alper, SL; Aufricht, C; Vychytil, A				Kratochwill, Klaus; Boehm, Michael; Herzog, Rebecca; Gruber, Katharina; Lichtenauer, Anton Michael; Kuster, Lilian; Csaicsich, Dagmar; Gleiss, Andreas; Alper, Seth L.; Aufricht, Christoph; Vychytil, Andreas			Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial	PLOS ONE			English	Article							HUMAN MESOTHELIAL CELLS; STAPHYLOCOCCUS-EPIDERMIDIS CHALLENGE; BLOOD MONONUCLEAR-CELLS; HUMAN MONOCYTIC CELLS; HEAT-SHOCK RESPONSE; RENAL-FAILURE MICE; NF-KAPPA-B; CYTOKINE PRODUCTION; IN-VITRO; BIOCOMPATIBILITY	Background Peritonitis and ultrafiltration failure remain serious complications of chronic peritoneal dialysis (PD). Dysfunctional cellular stress responses aggravate peritoneal injury associated with PD fluid exposure, potentially due to peritoneal glutamine depletion. In this randomized cross-over phase I/II trial we investigated cytoprotective effects of alanyl-glutamine (AlaGln) addition to glucose-based PDF. Methods In a prospective randomized cross-over design, 20 stable PD outpatients underwent paired peritoneal equilibration tests 4 weeks apart, using conventional acidic, single chamber 3.86% glucose PD fluid, with and without 8 mM supplemental AlaGln. Heat-shock protein 72 expression was assessed in peritoneal effluent cells as surrogate parameter of cellular stress responses, complemented by metabolomics and functional immunocompetence assays. Results AlaGln restored peritoneal glutamine levels and increased the primary outcome heat-shock protein expression (effect 1.51-fold, CI 1.07-2.14; p = 0.022), without changes in peritoneal ultrafiltration, small solute transport, or biomarkers reflecting cell mass and inflammation. Further effects were glutamine-like metabolomic changes and increased ex-vivo LPS-stimulated cytokine release from healthy donor peripheral blood monocytes. In patients with a history of peritonitis (5 of 20), AlaGln supplementation decreased dialysate interleukin-8 levels. Supplemented PD fluid also attenuated inflammation and enhanced stimulated cytokine release in a mouse model of PD-associated peritonitis. Conclusion We conclude that AlaGln-supplemented, glucose-based PD fluid can restore peritoneal cellular stress responses with attenuation of sterile inflammation, and may improve peritoneal host-defense in the setting of PD.	[Kratochwill, Klaus; Boehm, Michael; Herzog, Rebecca; Gruber, Katharina; Lichtenauer, Anton Michael; Kuster, Lilian; Csaicsich, Dagmar; Aufricht, Christoph] Med Univ Vienna, Dept Pediat & Adolescent Med, Div Pediat Nephrol & Gastroenterol, Vienna, Austria; [Kratochwill, Klaus; Herzog, Rebecca] Med Univ Vienna, Christian Doppler Lab Mol Stress Res Peritoneal D, Dept Pediat & Adolescent Med, Vienna, Austria; [Kratochwill, Klaus; Herzog, Rebecca; Lichtenauer, Anton Michael; Kuster, Lilian] Zytoprotec GmbH, Vienna, Austria; [Gleiss, Andreas] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria; [Alper, Seth L.] Harvard Med Sch, Div Nephrol, Boston, MA USA; [Alper, Seth L.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA USA; [Vychytil, Andreas] Med Univ Vienna, Div Nephrol & Dialysis, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Medical University of Vienna	Vychytil, A (corresponding author), Med Univ Vienna, Div Nephrol & Dialysis, Vienna, Austria.	andreas.vychytil@meduniwien.ac.at		Herzog, Rebecca/0000-0003-1946-7770; Kratochwill, Klaus/0000-0003-0803-614X	ZIT Technology Agency of the City of Vienna [701333]; FFG - the Austrian Research Promotion Agency [823972, 839912]; European Union within the Marie Curie scheme	ZIT Technology Agency of the City of Vienna; FFG - the Austrian Research Promotion Agency; European Union within the Marie Curie scheme	This study was funded by ZIT Technology Agency of the City of Vienna (ID 701333) and FFG - the Austrian Research Promotion Agency (IDs 823972 and 839912). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; KK and CA were part of the European Training and Research in Peritoneal Dialysis (EuTRiPD) program, a project funded by the European Union within the Marie Curie scheme. We are specifically grateful for the fruitful discussions and support by the group leaders of EuTRiPD. We also thank the team of the clinical studies coordination center (Koordinationszentrum fur Klinische Studien, KKS) of the Medical University of Vienna, the staff of the dialysis ward at the Vienna General Hospital, Konstantin Bergmeister and Markus Sass for assistance with the mouse experiments, David Kasper for support regarding the metabolomics analysis, Anja Wagner and Silvia Tarantino for assistance with the proteomics analysis, Isabel Sobieszek and Katarzyna Bialas for assistance with analyses and Axana Hellmann and Markus Unterwurzacher for technical support in manuscript preparation.	[Anonymous], 2014, ESRD PAT 2013 GLOB P; Arbeiter K, 2001, KIDNEY INT, V60, P1930, DOI 10.1046/j.1523-1755.2001.00004.x; Aufricht C, 2001, PERITON DIALYSIS INT, V21, P85; Aufricht C, 2007, PERITON DIALYSIS INT, V27, P258; Bacharaki D, 2009, NEPHRON CLIN PRACT, V113, pC321, DOI 10.1159/000235951; Bender TO, 2010, PERITON DIALYSIS INT, V30, P294, DOI 10.3747/pdi.2009.00024; Bidmon B, 2004, KIDNEY INT, V66, P2300, DOI 10.1111/j.1523-1755.2004.66040.x; Boehm M, 2010, PEDIATR NEPHROL, V25, P169, DOI 10.1007/s00467-009-1284-9; Boldyrev Alexander, 2013, Curr Aging Sci, V6, P29; Brulez HFH, 1999, J CLIN PATHOL, V52, P901, DOI 10.1136/jcp.52.12.901; Cendoroglo M, 1998, AM J KIDNEY DIS, V31, P273, DOI 10.1053/ajkd.1998.v31.pm9469498; Chen Yu, 2007, Inflammation & Allergy Drug Targets, V6, P91; Cho Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007554.pub2; Cho Y, 2013, KIDNEY INT, V84, P969, DOI 10.1038/ki.2013.190; Coeffier M, 2010, INFLAMM BOWEL DIS, V16, P518, DOI 10.1002/ibd.21017; Csaicsich D, 2015, PERITON DIALYSIS INT, V35, P590, DOI 10.3747/pdi.2014.00118; Davies SJ, 1998, KIDNEY INT, V54, P2207, DOI 10.1046/j.1523-1755.1998.00180.x; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Devuyst O, 2002, NEPHROL DIAL TRANSPL, V17, P12, DOI 10.1093/ndt/17.suppl_3.12; Eliasen MM, 2006, J MOL MED, V84, P147, DOI 10.1007/s00109-005-0004-6; Endemann M, 2007, AM J PHYSIOL-RENAL, V292, pF47, DOI 10.1152/ajprenal.00503.2005; Evans DW, 2010, NEPHROL DIAL TRANSPL, V25, P2315, DOI 10.1093/ndt/gfq003; Exner R, 2003, ANN SURG, V237, P110, DOI 10.1097/00000658-200301000-00015; Exner R, 2002, SURGERY, V131, P75, DOI 10.1067/msy.2002.118318; Ferrantelli E, 2016, KIDNEY INT, V89, P625, DOI 10.1016/j.kint.2015.12.005; Flessner MF, 2007, CLIN NEPHROL, V68, P341; Fusshoeller A, 2004, NEPHROL DIAL TRANSPL, V19, P2101, DOI 10.1093/ndt/gfh326; GALLIMORE B, 1989, AM J KIDNEY DIS, V14, P184, DOI 10.1016/S0272-6386(89)80069-1; GALLIMORE B, 1987, KIDNEY INT, V32, P678, DOI 10.1038/ki.1987.260; Garcia-Lopez E, 2012, NAT REV NEPHROL, V8, P224, DOI 10.1038/nrneph.2012.13; Haas S, 2003, J AM SOC NEPHROL, V14, P2632, DOI 10.1097/01.ASN.0000086475.83211.DF; Herzog R, 2014, J AM SOC NEPHROL, V25, P2778, DOI 10.1681/ASN.2013101128; JORRES A, 1992, INT J ARTIF ORGANS, V15, P79; Kratochwill K, 2012, NEPHROL DIAL TRANSPL, V27, P937, DOI 10.1093/ndt/gfr459; Kratochwill K, 2011, AM J PATHOL, V178, P1544, DOI 10.1016/j.ajpath.2010.12.034; Kratochwill K, 2009, J PROTEOME RES, V8, P1731, DOI 10.1021/pr800916s; Lichtenauer AM, 2014, ELECTROPHORESIS, V35, P1387, DOI 10.1002/elps.201300499; Mackenzie R, 2003, KIDNEY INT, V64, pS84, DOI 10.1046/j.1523-1755.2003.08809.x; Gomes AM, 2009, NEPHROL DIAL TRANSPL, V24, P3513, DOI 10.1093/ndt/gfp319; Marzec L, 2007, PERITON DIALYSIS INT, V27, P288; Mbodji K, 2011, CLIN NUTR, V30, P672, DOI 10.1016/j.clnu.2011.04.002; McIntyre CW, 2007, KIDNEY INT, V71, P486, DOI 10.1038/sj.ki.5002109; Mehrotra R, 2016, J AM SOC NEPHROL; Melis GC, 2005, BRIT J NUTR, V94, P19, DOI 10.1079/BJN20051463; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Morimoto RI, 2011, COLD SH Q B, V76, P91, DOI 10.1101/sqb.2012.76.010637; Morinaga H, 2012, PERITON DIALYSIS INT, V32, P453, DOI 10.3747/pdi.2011.00032; Morrison AL, 2006, AM J PHYSIOL-CELL PH, V290, pC1625, DOI 10.1152/ajpcell.00635.2005; Mujais S, 2000, PERITON DIALYSIS INT, V20, pS5; Naka S, 1996, JPEN-PARENTER ENTER, V20, P417, DOI 10.1177/0148607196020006417; Nakao T, 1996, Perit Dial Int, V16 Suppl 1, pS88; Newsholme P, 2001, J NUTR, V131, p2515S, DOI 10.1093/jn/131.9.2515S; Ni J, 2003, J AM SOC NEPHROL, V14, P3205, DOI 10.1097/01.ASN.0000099382.18284.57; Pecoits-Filho R, 2004, PERITON DIALYSIS INT, V24, P327; Pippias M, 2016, NEPHROL DIAL TRANSPL, V31, P831, DOI 10.1093/ndt/gfv327; Richter K, 2010, MOL CELL, V40, P253, DOI 10.1016/j.molcel.2010.10.006; Riesenhuber A, 2007, PEDIATR NEPHROL, V22, P1205, DOI 10.1007/s00467-007-0484-4; Roth E, 2008, J NUTR, V138, p2025S, DOI 10.1093/jn/138.10.2025S; Schilte MN, 2009, PERITON DIALYSIS INT, V29, P605; Singleton KD, 2005, SHOCK, V24, P583, DOI 10.1097/01.shk.0000185795.96964.71; Spittler A, 1997, CLIN NUTR, V16, P97, DOI 10.1016/S0261-5614(97)80031-3; SPITTLER A, 1995, BLOOD, V86, P1564, DOI 10.1182/blood.V86.4.1564.bloodjournal8641564; Spittler A, 2001, CLIN NUTR, V20, P37, DOI 10.1054/clnu.2000.0153; Tao KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010050.pub2; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; van Diepen AT, 2014, PERIT DIAL INT; van Esch S, 2014, PERIT DIAL INT; Weitzel LRB, 2010, CRIT CARE CLIN, V26, P515, DOI 10.1016/j.ccc.2010.04.006; Wernerman J, 2008, J NUTR, V138, p2040S, DOI 10.1093/jn/138.10.2040S; Wischmeyer PE, 2001, J APPL PHYSIOL, V90, P2403, DOI 10.1152/jappl.2001.90.6.2403	70	24	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2016	11	10							e0165045	10.1371/journal.pone.0165045	http://dx.doi.org/10.1371/journal.pone.0165045			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9OE	27768727	Green Published, Green Submitted, gold			2023-01-03	WOS:000386205400046
J	Dolgin, E				Dolgin, Elie			CANCER Using DNA, radiation therapy gets personal	SCIENCE			English	News Item																			0	11	11	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	2016	353	6306					1348	1349		10.1126/science.353.6306.1348	http://dx.doi.org/10.1126/science.353.6306.1348			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DW5TB	27708015				2023-01-03	WOS:000383708700011
J	Zandvakili, I; Lin, Y; Morris, JC; Zheng, Y				Zandvakili, I.; Lin, Y.; Morris, J. C.; Zheng, Y.			Rho GTPases: Anti- or pro-neoplastic targets?	ONCOGENE			English	Review							CANCER-CELL MOTILITY; DRIVER MUTATIONS; RATIONAL DESIGN; TUMOR-FORMATION; PROTEIN-KINASE; BREAST-CANCER; LUNG-CANCER; PERINEURAL INVASION; PROTEOMIC ANALYSIS; SIGNALING AXIS	Rho GTPases are critical signal transducers of multiple pathways. They have been proposed to be useful anti-neoplastic targets for over two decades, especially in Ras-driven cancers. Until recently, however, few in vivo studies had been carried out to test this premise. Several recent mouse model studies have verified that Rac1, RhoA, and some of their effector proteins such as PAK and ROCK, are likely anti-cancer targets for treating K-Ras-driven tumours. Other seemingly contradictory studies have suggested that at least in certain instances inhibition of individual Rho GTPases may paradoxically result in pro-neoplastic effects. Significantly, both RhoA GTPase gain-and loss-of-function mutations have been discovered in primary leukemia/lymphoma and gastric cancer by human cancer genome sequencing efforts, suggesting both pro-and anti-neoplastic roles. In this review we summarize and integrate these unexpected findings and discuss the mechanistic implications in the design and application of Rho GTPase targeting strategies in future cancer therapies.	[Zandvakili, I.; Lin, Y.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Zandvakili, I.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Mol & Dev Biol Grad Program, Cincinnati, OH 45229 USA; [Zandvakili, I.; Zheng, Y.] Univ Cincinnati, Coll Med, Med Scientist Training Program, Cincinnati, OH USA; [Morris, J. C.] Univ Cincinnati, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@cchmc.org	Zandvakili, Inuk/P-7241-2019	Zandvakili, Inuk/0000-0003-3409-0019	University of Cincinnati Medical Scientist Training Program; Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center; NIH [R01 CA193350, R01 DK104814, R01 HL134617]; NATIONAL CANCER INSTITUTE [R01CA193350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL134617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK104814, P30DK090971] Funding Source: NIH RePORTER	University of Cincinnati Medical Scientist Training Program; Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge support from the University of Cincinnati Medical Scientist Training Program and the Molecular and Developmental Biology Graduate Program at Cincinnati Children's Hospital Medical Center. The work in the Yi Zheng lab is partly supported by NIH grants R01 CA193350, R01 DK104814 and R01 HL134617.	Abiatari I, 2009, MOL CANCER THER, V8, P1494, DOI 10.1158/1535-7163.MCT-08-0755; Alan Jamie K, 2013, Small GTPases, V4, P159, DOI 10.4161/sgtp.26530; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becker MS, 2016, ONCOTARGET, V7, P51908, DOI 10.18632/oncotarget.10188; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Biro M, 2014, BRIT J PHARMACOL, V171, P5491, DOI 10.1111/bph.12658; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Bosco EE, 2012, CHEM BIOL, V19, P228, DOI 10.1016/j.chembiol.2011.12.017; Boulter Etienne, 2010, Small GTPases, V1, P65; Bousquet E, 2009, CANCER RES, V69, P6092, DOI 10.1158/0008-5472.CAN-08-4147; Braun AC, 2015, CELL SIGNAL, V27, P1643, DOI 10.1016/j.cellsig.2015.04.003; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Chew TW, 2014, ONCOGENE, V33, P2717, DOI 10.1038/onc.2013.240; Chiba Shigeru, 2015, Small GTPases, V6, P100, DOI 10.4161/21541248.2014.988088; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; Croise P, 2016, ENDOCR-RELAT CANCER, V23, P281, DOI 10.1530/ERC-15-0502; Cullis J, 2014, CANCER CELL, V25, P181, DOI 10.1016/j.ccr.2014.01.025; Deribe YL, 2016, P NATL ACAD SCI USA, V113, pE1296, DOI 10.1073/pnas.1513801113; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evelyn CR, 2009, J BIOMOL SCREEN, V14, P161, DOI 10.1177/1087057108328761; Feng YB, 2016, J MED CHEM, V59, P2269, DOI 10.1021/acs.jmedchem.5b00683; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Forti FL, 2007, ENDOCR-RELAT CANCER, V14, P1117, DOI 10.1677/ERC-07-0154; Frances D, 2015, ONCOGENE, V34, P5505, DOI 10.1038/onc.2014.471; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fukumoto Y, 2007, J CARDIOVASC PHARM, V49, P117, DOI 10.1097/FJC.0b013e31802ef532; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Gilbert-Ross M, 2015, GENES DIS, V2, P2, DOI 10.1016/j.gendis.2014.10.001; Grogg MW, 2010, RHO GTPASES IN CANCER, P93, DOI 10.1007/978-1-4419-1111-7_6; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heckman-Stoddard BM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2352; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Holderfield M, 2014, BRIT J CANCER, V111, P640, DOI 10.1038/bjc.2014.139; Hu LD, 2007, ONCOL REP, V17, P1383; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ishikawa S, 2016, BLOOD, V127, P524, DOI 10.1182/blood-2015-12-683458; Jiang WG, 2003, CLIN CANCER RES, V9, P6432; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Koide N, 2006, CLIN CANCER RES, V12, P2419, DOI 10.1158/1078-0432.CCR-05-1852; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kumper S, 2016, ELIFE, V5, DOI 10.7554/eLife.12203; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kumar RD, 2016, NAT GENET, V48, P1288, DOI 10.1038/ng.3658; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2016, CANCER RES, V76, P3826, DOI 10.1158/0008-5472.CAN-15-2923; Li H, 2014, BIOFACTORS, V40, P226, DOI 10.1002/biof.1155; Lin M, 2004, BREAST CANCER RES TR, V84, P49, DOI 10.1023/B:BREA.0000018424.43445.f3; Lin Y, 2015, EXPERT OPIN DRUG DIS, V10, P991, DOI 10.1517/17460441.2015.1058775; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu N, 2007, J MOL MED-JMM, V85, P1149, DOI 10.1007/s00109-007-0217-y; Maeda M, 2016, GASTRIC CANCER, V19, P326, DOI 10.1007/s10120-015-0525-9; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Manso R, 2014, BLOOD, V123, P2893, DOI 10.1182/blood-2014-02-555946; Rojas AM, 2012, J CELL BIOL, V196, P189, DOI 10.1083/jcb.201103008; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; McHenry PR, 2010, CURR DRUG TARGETS, V11, P1043, DOI 10.2174/138945010792006852; Melendez J, 2013, GASTROENTEROLOGY, V145, P808, DOI 10.1053/j.gastro.2013.06.021; Meyer N, 2014, J INVEST DERMATOL, V134, P203, DOI 10.1038/jid.2013.278; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Mizukawa B, 2011, BLOOD, V118, P5235, DOI 10.1182/blood-2011-04-351817; Morgan-Fisher M, 2013, J HISTOCHEM CYTOCHEM, V61, P185, DOI 10.1369/0022155412470834; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Huynh N, 2015, RES REP BIOCHEM, V5, P119, DOI 10.2147/RRBC.S57278; Nohata N, 2016, DEV BIOL, V411, P183, DOI 10.1016/j.ydbio.2016.02.005; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Orgaz Jose L, 2014, Small GTPases, V5, pe29019, DOI 10.4161/sgtp.29019; Pajic Marina, 2015, Small GTPases, V6, P123, DOI 10.4161/21541248.2014.973749; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Pranatharthi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5785786; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riou P, 2010, BIOESSAYS, V32, P986, DOI 10.1002/bies.201000060; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Rocken C, 2016, J CLIN PATHOL, V69, P70, DOI 10.1136/jclinpath-2015-202980; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sakamori R, 2014, CANCER RES, V74, P5480, DOI 10.1158/0008-5472.CAN-14-0267; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Samuel MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017143; Sato N, 2007, INT J CANCER, V120, P543, DOI 10.1002/ijc.22328; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shang X, 2013, P NATL ACAD SCI USA, V110, P3155, DOI 10.1073/pnas.1212324110; Shang X, 2012, CHEM BIOL, V19, P699, DOI 10.1016/j.chembiol.2012.05.009; Shimokawa H, 2002, J CARDIOVASC PHARM, V40, P749; Silva AL, 2013, EUR J ENDOCRINOL, V168, P795, DOI 10.1530/EJE-12-0960; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Skalnikova H, 2011, J PROTEOME RES, V10, P404, DOI 10.1021/pr100468w; Smithers CC, 2016, CELLS, P5; Stengel KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037317; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Hengel J, 2008, GASTROENTEROLOGY, V134, P781, DOI 10.1053/j.gastro.2008.01.002; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicari RM, 2005, J AM COLL CARDIOL, V46, P1803, DOI 10.1016/j.jacc.2005.07.047; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Vogel CJ, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12364; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Wang DS, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15017453; Wang J., 2016, SHOCK VIB, V2016, P1, DOI DOI 10.1155/2016/9371563; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Watson IR, 2014, CANCER RES, V74, P4845, DOI 10.1158/0008-5472.CAN-14-1232-T; Wei L, 2016, ARCH IMMUNOL THER EX, V64, P259, DOI 10.1007/s00005-015-0382-6; Welch Heidi C E, 2015, Small GTPases, V6, P49, DOI 10.4161/21541248.2014.973770; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wu CYC, 2014, GASTROENTEROLOGY, V147, P1405, DOI 10.1053/j.gastro.2014.08.032; Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007; Yang L, 2007, BLOOD, V110, P3853, DOI 10.1182/blood-2007-03-079582; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916; Zandvakili I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127923; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; Zhang SY, 2009, MOL CANCER RES, V7, P570, DOI 10.1158/1541-7786.MCR-08-0248; Zhao L, 2008, J PROTEOME RES, V7, P3994, DOI 10.1021/pr800271b; Zhao LA, 2010, FEBS J, V277, P4195, DOI 10.1111/j.1742-4658.2010.07808.x; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99; Zhou J, 2014, CANCER CELL, V26, P9, DOI 10.1016/j.ccr.2014.06.022; Zhou W, 2014, J PATHOL, V234, P502, DOI 10.1002/path.4412; Zhou X, 2013, J BIOL CHEM, V288, P36179, DOI 10.1074/jbc.R113.515486	161	60	63	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3213	3222		10.1038/onc.2016.473	http://dx.doi.org/10.1038/onc.2016.473			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991930	Green Accepted			2023-01-03	WOS:000402869800001
J	Wasfy, JH; Zigler, CM; Choirat, C; Wang, Y; Dominici, F; Yeh, RW				Wasfy, Jason H.; Zigler, Corwin Matthew; Choirat, Christine; Wang, Yun; Dominici, Francesca; Yeh, Robert W.			Readmission Rates After Passage of the Hospital Readmissions Reduction Program	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; 30-DAY MORTALITY-RATES; MEDICARE BENEFICIARIES; HEART-FAILURE; PERFORMANCE; OUTCOMES; ENGLAND; PAY	Background: Whether hospitals with the highest riskstandardized readmission rates (RSRRs) subsequently experienced the greatest improvement after passage of the Medicare Hospital Readmissions Reduction Program (HRRP) is unknown. Objective: To evaluate whether passage of the HRRP was followed by acceleration in improvement in 30-day RSRRs after hospitalizations for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether the lowestperforming hospitals had faster acceleration in improvement after passage of the law than hospitals that were already performing well. Design: Pre-post analysis stratified by hospital performance groups. Setting: U.S. acute care hospitals. Patients: 15 170 008 Medicare patients discharged alive from 2000 to 2013. Intervention: Passage of the HRRP. Measurements: 30-day readmission rates after hospitalization for AMI, CHF, or pneumonia for hospitals in the highestperformance (0% penalty), average-performance (>0% and <0.50% penalty), low-performance (>= 0.50% and <0.99% penalty), and lowest-performance (>= 0.99% penalty) groups. Results: Of 2868 hospitals serving 1 109 530 Medicare discharges annually, 30.1% were highest performers, 44.0% were average performers, 16.8% were low performers, and 9.0% were lowest performers. After controlling for prelaw trends, an additional 67.6 (95% CI, 66.6 to 68.4), 74.8 (CI, 74.0 to 75.4), 85.4 (CI, 84.0 to 86.8), and 95.1 (CI, 92.6 to 97.5) readmissions per 10 000 discharges were found to have been averted per year in the highest-, average-, low-, and lowest-performance groups, respectively, after passage of the law. Limitation: Inability to distinguish between improvement caused by the magnitude of the penalty or by different levels of health improvement in different patient populations. Conclusion: After passage of the HRRP, 30-day RSRRs for myocardial infarction, heart failure, and pneumonia decreased more rapidly than before the law's passage. Improvement was most marked for hospitals with the lowest prelaw performance.	[Wasfy, Jason H.] Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA USA; [Dominici, Francesca] Harvard TH Chan Sch Publ Hlth, Off Dean, 655 Huntington Ave, Boston, MA 02115 USA; [Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave, Boston, MA 02215 USA; [Zigler, Corwin Matthew; Choirat, Christine; Wang, Yun; Dominici, Francesca] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Dominici, F (corresponding author), Harvard TH Chan Sch Publ Hlth, Off Dean, 655 Huntington Ave, Boston, MA 02115 USA.; Yeh, RW (corresponding author), Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave, Boston, MA 02215 USA.; Dominici, F (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.	jwasfy@mgh.harvard.edu	Yeh, Robert/AAJ-3463-2020; Hug, Balthasar L./G-1568-2010	Choirat, Christine/0000-0002-3745-9718	National Institutes of Health; NATIONAL CANCER INSTITUTE [R35CA197449, P01CA134294] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001100] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL118138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012054, R01ES024332, R21ES022585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111339] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	National Institutes of Health.	Barnett ML, 2015, JAMA INTERN MED, V175, P1803, DOI 10.1001/jamainternmed.2015.4660; Barr CD, 2012, AM J EPIDEMIOL, V176, P642, DOI 10.1093/aje/kws267; Berenson RA, 2012, NEW ENGL J MED, V366, P1364, DOI 10.1056/NEJMp1201268; Berkowitz SA, 2013, J HOSP MED, V8, P639, DOI 10.1002/jhm.2074; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Centers for Medicare Medicaid Services, 2016, READM RED PROGR; Cuellar AE, 2003, HEALTH AFFAIR, V22, P77, DOI 10.1377/hlthaff.22.6.77; Department of Health and Human Services, 2014, HHS DAT SHOWS MAJ ST; French B, 2008, STAT MED, V27, P5005, DOI 10.1002/sim.3340; Himmelstein D., 2015, HLTH AFFAIRS BLOG; James J., 2013, HLTH AFFAIRS BLOG; Jha AK, 2012, NEW ENGL J MED, V366, P1606, DOI 10.1056/NEJMsa1112351; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Khullar D, 2015, NEW ENGL J MED, V372, P2281, DOI 10.1056/NEJMp1502312; Kristensen SR, 2014, NEW ENGL J MED, V371, P540, DOI 10.1056/NEJMoa1400962; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Pope GC., 2000, DIAGNOSTIC COST GROU; Rathore SS, 2006, AM HEART J, V152, P371, DOI 10.1016/j.ahj.2005.12.002; Rosetta L, 2009, SALT LAKE TRIBU 0709; Soumerai SB, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/pcd12.150187; Sutton M, 2012, NEW ENGL J MED, V367, P1821, DOI 10.1056/NEJMsa1114951; Zigler CM, 2014, AM J EPIDEMIOL, V180, P1133, DOI 10.1093/aje/kwu263; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	25	124	124	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2017	166	5					324	+		10.7326/M16-0185	http://dx.doi.org/10.7326/M16-0185			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO1BO	28024302	Green Accepted			2023-01-03	WOS:000396432800005
J	Abbasi, J				Abbasi, Jennifer			Amid Reports of Infant Deaths, FTC Cracks Down on Homeopathy While FDA Investigates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	8	8	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	2017	317	8					793	795		10.1001/jama.2016.19090	http://dx.doi.org/10.1001/jama.2016.19090			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM7PW	28196192				2023-01-03	WOS:000395505600002
J	Burci, GL; Gostin, LO				Burci, Gian Luca; Gostin, Lawrence O.			Privatized Pharmaceutical Innovation vs Access to Essential Medicines A Global Framework for Equitable Sharing of Benefits	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Burci, Gian Luca] Grad Inst Int & Dev Studies, Geneva, Switzerland; [Gostin, Lawrence O.] Georgetown Univ, ONeill Inst Natl & Global Hlth Law, Washington, DC USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Burci, Gian Luca/0000-0002-7650-2192				Gostin LO, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002042	1	4	4	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2017	317	5					473	474		10.1001/jama.2016.17994	http://dx.doi.org/10.1001/jama.2016.17994			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ9RN	28170485				2023-01-03	WOS:000393564200012
J	Nlooto, M				Nlooto, Manimbulu			Comorbidities of HIV infection and health care seeking behavior among HIV infected patients attending public sector healthcare facilities in KwaZulu-Natal: A cross sectional study	PLOS ONE			English	Article							AGE-RELATED COMORBIDITIES; SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; ALTERNATIVE MEDICINE; DRUG INTERACTIONS; COMPLEMENTARY; POPULATION; DISEASE; PEOPLE	Background HIV-infected people may present with co-infections, comorbidities, and side effects associated with antiretroviral therapy. This study explored the prevalence of comorbid health problems and determined the extent of the use of traditional medicine for treatment of coinfections, comorbidities of HIV infection and side effects. Methods A cross sectional study, using researcher-administered questionnaires, was carried out among HIV-infected patients in eight public sector healthcare facilities in KwaZulu-Natal between April and October 1024. Self-reports of comorbidities, co-infections and side effects were analyzed with respect to factors such as age, gender, race, and health care seeking behavior including the use of traditional medicine. Cross-tabulations were conducted to test the association between factors and the use of traditional medicine, using Pearson chi-squared (chi(2)) test. Simple and multiple logistic regression models tested the association of the use of traditional medicine with age, gender, race, side effects and comorbidities. Odds ratios with 95% confidence intervals were estimated. Missing values were handled, defined and treated as missing values in the final analysis. Results Overall, 29.5% (n = 516) of the survey participants reported having other comorbidities and or co-infections besides their HIV condition. Same participants reported two or more comorbidities. Almost forty percent of participants (208/531, 39.17%) reported having hypertension as the most noninfectious comorbidity while 21.65% of participants (115/531) had tuberculosis accounting for the most infectious comorbidity. Almost eight percent of participants (142/1748, 8.12%) reported using traditional medicine after starting with cART. Sixty out of 142 participants (60/142, 42.25%) on cART resorted to the use of traditional medicine for the management of comorbidities and or co-infections of their HIV infection. Overall, 311 out of 1748 participants (17.80%) complained of ARVs related side-effects. Forty-five percent of those with side-effects (141/311, 45.34%) reported taking various types of medicines for treating side-effects, with 90.07% of them (127/141) using medicines prescribed by bio-medically trained doctors or by pharmacy personnel as over-the -counter medicines, p<0. 001. Very few participants (14/141, 9.93%) resorted to the use of traditional medicine for treating side effects associated with antiretroviral therapy with no significant difference (p=0.293). In a multiple logistic regression, after adjusting for age, gender, race and side-effects due to antiretroviral therapy, odds for using traditional medicine were almost two times higher [odds ratio = 1.884, 95% Confidence Interval 1.317-2.695] with those participants having comorbidities and co-infections, with a significant difference p-value<0.001. Conclusions Comorbidities, co-infections and side effects are prevalent among HIV-infected patients attending public sector healthcare facilities. Odds of using traditional medicine were almost two times higher and significantly associated with the presence of comorbidities and co-infections than for other factors. The presence of such comorbid health problems does not explain the increased use of traditional medicine among HIV-infected patients on antiretroviral therapy. Findings from this study should be interpreted cautiously as they cannot be generalized to the entire population of HIV-infected patients in KwaZulu-Natal. Studies on safety and efficacy of herbal traditional medicines are needed for beneficiation of the minority of patients who still resort to them for co-treatment with combination antiretroviral therapy.	[Nlooto, Manimbulu] Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, Durban, South Africa	University of Kwazulu Natal	Nlooto, M (corresponding author), Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, Durban, South Africa.	Nlooto@ukzn.ac.za			DST-NRF-Excellence Centre Indigenous Knowledge Systems, University of KwaZulu-Natal; Victor Daitz Information Gateway; Victor Daitz Foundation; University of KwaZulu-Natal	DST-NRF-Excellence Centre Indigenous Knowledge Systems, University of KwaZulu-Natal; Victor Daitz Information Gateway; Victor Daitz Foundation; University of KwaZulu-Natal	The author received running expenses from the College of Health Sciences and a stipend from the DST-NRF-Excellence Centre Indigenous Knowledge Systems, University of KwaZulu-Natal, during the time this study was conducted. Open access publication of this article has been made possible through support from the Victor Daitz Information Gateway, an initiative of Victor Daitz Foundation and the University of KwaZulu-Natal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Audet CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070326; Bajunirwe F, 2013, ANTIRETROVIRAL TREAT, P39; Bessong PO, 2008, T ROY SOC TROP MED H, V102, P209, DOI 10.1016/j.trstmh.2007.11.009; Boyer S, 2011, HLTH POLICY PLANNING; Capeau J, 2011, CLIN INFECT DIS, V53, P1127, DOI 10.1093/cid/cir628; Chinggwaru W, 2006, EUR J INTEGR MED; Cichello S., 2014, AUSTR J HERBAL MED, V26, P100; Deebii N, 2015, J BIOSCIENCES MED, V4, P54; Fasinu PS, 2016, CURR DRUG METAB, V17, P52, DOI 10.2174/1389200216666151103115053; Fasinu PS, 2013, PHARM BIOL, V51, P1499, DOI 10.3109/13880209.2013.796393; Grundy C., 2005, WHO GLOBAL ATLAS TRA; Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627; Gustafsson M, 2010, COSTS ILLITERACY S A; Hamza Omar J M, 2006, BMC Oral Health, V6, P12; Hasan SS, 2011, MED PRIN PRACT, V20, P265, DOI 10.1159/000321274; Kendall CE, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-161; Levin Kate Ann, 2006, Evid Based Dent, V7, P24, DOI 10.1038/sj.ebd.6400375; Littlewood RA, 2008, AIDS CARE, V20, P1002, DOI 10.1080/09540120701767216; Machin D, 2011, SAMPLE SIZE TABLES C; Mbatha N, 2012, SAMJ S AFR MED J, V102, P129, DOI 10.7196/SAMJ.5295; McInerney PA, 2008, NURS HEALTH SCI, V10, P266, DOI 10.1111/j.1442-2018.2008.00410.x; Mosha F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-38; National Department of Health Republic of South Africa, 2014, NAT CONS GUID PREV M; Nlooto M, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1101-5; PageShafer K, 1996, ANN EPIDEMIOL, V6, P420, DOI 10.1016/S1047-2797(96)00064-6; Peltzer K, 2009, AFR J TRADIT COMPLEM, V6, P175; Peltzer K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-255; Reed R., 2012, HORIZ ENFERM, V1, P81; Simbayi L, 2014, S AFRICAN NATL HIV P; Souhami RL, 1997, LANCET, V350, P911, DOI 10.1016/S0140-6736(97)02307-6; UNAIDS, 2014, HIV AIDS EST; Venter F, 2012, S AFRICAN HLTH REV, V2012, P37; WHO (The World Health Organization), 2008, TRADITIONAL MED; Young F, 2009, GLOBALIZATION HEALTH, V5, DOI 10.1186/1744-8603-5-9	34	12	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2017	12	2							e0170983	10.1371/journal.pone.0170983	http://dx.doi.org/10.1371/journal.pone.0170983			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DB	28151951	gold, Green Published			2023-01-03	WOS:000396161200065
J	McDougal, L; Atmavilas, Y; Hay, K; Silverman, JG; Tarigopula, UK; Raj, A				McDougal, Lotus; Atmavilas, Yamini; Hay, Katherine; Silverman, Jay G.; Tarigopula, Usha K.; Raj, Anita			Making the continuum of care work for mothers and infants: Does gender equity matter? Findings from a quasi-experimental study in Bihar, India	PLOS ONE			English	Article							COMMUNITY-HEALTH WORKERS; MIDDLE-INCOME COUNTRIES; QUALITY-OF-CARE; NEONATAL-MORTALITY; PREVENTIVE INTERVENTIONS; REPRODUCTIVE HEALTH; CHILD MARRIAGE; NEWBORN HEALTH; UTTAR-PRADESH; IMPACT	Background Improvements in continuum of care (CoC) utilization are needed to address inadequate reductions in neonatal and infant mortality in India and elsewhere. This study examines the effect of Ananya, a health system training and community outreach intervention, on reproductive, maternal and newborn health continuum of care (RMNH CoC) utilization in Bihar, India, and explores whether that effect is moderated by gender equity factors (child marriage, restricted mobility and low decision-making control). Methods A two-armed quasi-experimental design compared districts in Bihar that did/did not implement Ananya. Cross-sections of married women aged 15-49 with a 0-5 month old child were surveyed at baseline and two year follow-up (baseline n = 7191 and follow-up n = 6143; response rates 88.9% and 90.7%, respectively). Difference-in-difference analyses assessed program impact on RMNH CoC co-coverage, defined by 9 health services/behaviors for the index pregnancy (e.g.,antenatal care, skin-to-skin care). Three-way interactions assessed gender equity as a moderator of Ananya's impact. Findings Participants reported low RMNH CoC co-coverage at baseline (on average 3.2 and 3.0 of the 9 RMNH services/behaviors for Ananya and control groups, respectively). The Ananya group showed a significantly greater increase in RMNH CoC co-coverage (. 41 services) compared with the control group over time (p< 0.001), with the primary drivers being increases in clean cord care, skin-to-skin care and postpartum contraceptive use. Gender equity interaction analyses revealed diminished intervention effects on antenatal care, skilled birth attendance and exclusive breastfeeding for women married as minors. Conclusion Ananya improved RMNH CoC co-coverage among these recent mothers, largely through positive health behavior changes. Child marriage attenuated Ananya's impact on utilization of key health services and behaviors. Supporting the health system with training and community outreach can be beneficial to RMNH CoC utilization; additional support is needed to adequately address the unique issues faced by women married as minors.	[McDougal, Lotus; Silverman, Jay G.; Raj, Anita] Univ Calif San Diego, Dept Med, Ctr Gender Equ & Hlth, Div Global Publ Hlth,Sch Med, San Diego, CA 92103 USA; [Atmavilas, Yamini; Hay, Katherine; Tarigopula, Usha K.] Bill & Melinda Gates Fdn, New Delhi, India	University of California System; University of California San Diego	McDougal, L (corresponding author), Univ Calif San Diego, Dept Med, Ctr Gender Equ & Hlth, Div Global Publ Hlth,Sch Med, San Diego, CA 92103 USA.	lmcdouga@ucsd.edu	Hay, Katherine/ABB-7795-2021		Bill and Melinda Gates Foundation (BMGF); BMGF [OPP1163682]; Sambodhi Research and Communications Private Limited [UCSD 2016-3182]	Bill and Melinda Gates Foundation (BMGF)(Bill & Melinda Gates Foundation); BMGF; Sambodhi Research and Communications Private Limited	This manuscript and the Ananya Program and data collection were supported by the Bill and Melinda Gates Foundation (BMGF www.gatesfoundation.org). LM, JGS and AR received funding from BMGF directly [OPP1163682] and via Sambodhi Research and Communications Private Limited [UCSD 2016-3182]. KH, YA and UKT are BMGF staff who participated in the development of this study and the generation of this manuscript, and are recognized as coauthors. In their roles with BMGF, they were involved with the design and conduct of the Ananya Program and evaluation study design from which data for this study were obtained. They provided some oversight of data collection and management, and gave input into analyses included in this manuscript. They assisted with the interpretation of this paper and reviewed and approved this final manuscript.	Agrawal PK, 2012, J EPIDEMIOL COMMUN H, V66, P755, DOI 10.1136/jech-2011-200362; Anand S, 2010, INT J HEALTH CARE Q, V23, P718, DOI 10.1108/09526861011081859; Arregoces L, 2015, LANCET GLOB HEALTH, V3, pE410, DOI 10.1016/S2214-109X(15)00057-1; Baqui AH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2826; Baqui AH, 2009, PEDIATR INFECT DIS J, V28, P304, DOI 10.1097/INF.0b013e31819069e8; Barros AJD, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001390; Barros AJD, 2012, LANCET, V379, P1225, DOI 10.1016/S0140-6736(12)60113-5; Bhutta ZA, 2010, SEMIN PERINATOL, V34, P434, DOI 10.1053/j.semperi.2010.09.002; Black R., 2013, LANCET; Borkum E, 2014, MIDLINE FINDINGS EVA; Countdown to 2015, 2015, 9789280648140 WHO; Darmstadt GL, 2008, HEALTH POLICY PLANN, V23, P101, DOI 10.1093/heapol/czn001; Gilmore B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-847; Glenton C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010414.pub2; Graham WJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001368; IIPS and Macro International, 2007, NATL FAMILY HLTH SUR, V1; IIPS and MoHFW, 2016, NATL FAMILY HLTH SUR; Jejeebhoy SJ, 2014, STUD FAMILY PLANN, V45, P183, DOI 10.1111/j.1728-4465.2014.00384.x; Kamiya Y, 2013, SOC SCI MED, V83, P34, DOI 10.1016/j.socscimed.2013.01.035; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Kraft JM, 2014, J HEALTH COMMUN, V19, P122, DOI 10.1080/10810730.2014.918216; Kumar GA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-357; Lassi ZS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub3; Lassi ZS, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S1-S5; Lassi ZS, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S2-S2; Lassi ZS, 2013, J MATERN-FETAL NEO M, V26, P3, DOI 10.3109/14767058.2013.784737; Lassi ZS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub2; Lawn JE, 2011, INT J EPIDEMIOL, V40, P525, DOI 10.1093/ije/dyq172; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS5, DOI 10.1016/j.ijgo.2009.07.016; McCurdy RJ, 2011, ACTA OBSTET GYN SCAN, V90, P779, DOI 10.1111/j.1600-0412.2011.01133.x; Moran AC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001415; National Family Health Survey (NFHS-3), 2007, NAT FAM HLTH SURV NF, VI; National Health Mission MoHFW Government of India, 2015, STAT WIS INF; Pervin J, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-111; Peterman A., 2015, IFPRI - Discussion Papers; Raj A, 2014, INT J GYNECOL OBSTET, V124, P86, DOI 10.1016/j.ijgo.2013.07.027; Raj A, 2010, ARCH DIS CHILD, V95, P931, DOI 10.1136/adc.2009.178707; Raj A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4258; Randive B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067452; Scott VK, 2015, STUD FAMILY PLANN, V46, P241, DOI 10.1111/j.1728-4465.2015.00028.x; Shengelia B, 2005, SOC SCI MED, V61, P97, DOI 10.1016/j.socscimed.2004.11.055; Singh A, 2013, MATERN CHILD HLTH J, V17, P493, DOI 10.1007/s10995-012-1023-x; Singh K, 2015, HEALTH CARE WOMEN IN, V36, P57, DOI 10.1080/07399332.2013.824971; Singh S, 2012, ADDING IT COSTS BENE; Smith K, 2011, MEASUREMENT LEARNING; Sudhinaraset M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0942-8; UNICEF WHO & World Bank Group., 2021, LEVELS TRENDS CHILD; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; Victora C, 2015, LANCET; Victora CG, 2005, LANCET, V366, P1460, DOI 10.1016/S0140-6736(05)67599-X; Wall SN, 2010, SEMIN PERINATOL, V34, P395, DOI 10.1053/j.semperi.2010.09.009; Wendt A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120404; WHO, 2009, WHO UNICEF JOINT STA; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World Health Organization, 2010, NEWBORN CHILD HLTH; Yakoob MY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S7; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	58	14	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2017	12	2							e0171002	10.1371/journal.pone.0171002	http://dx.doi.org/10.1371/journal.pone.0171002			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN6RS	28146586	Green Published, Green Submitted, gold			2023-01-03	WOS:000396131700025
J	Ramzan, M; Bilal, M; Chung, JD				Ramzan, Muhammad; Bilal, Muhammad; Chung, Jae Dong			Radiative Flow of Powell-Eyring MagnetoNanofluid over a Stretching Cylinder with Chemical Reaction and Double Stratification near a Stagnation Point	PLOS ONE			English	Article							CONVECTIVE BOUNDARY-CONDITION; POROUS-MEDIUM; THERMAL-RADIATION; FLUID-FLOW; LAYER-FLOW; MHD FLOW; NANOFLUID; SORET; PLATE; SHEET	This exploration addresses MHD stagnation point Powell Eyring nanofluid flow with double stratification. The effects of thermal radiation and chemical reaction are added in temperature and nanoparticle concentration fields respectively. Furthermore, appropriate transformations are betrothed to obtain nonlinear differential equations from the system of partial differential equations and an analytical solution of system of coupled differential equations is obtained by means of the renowned Homotopy Analysis method. Through graphical illustrations, momentum, energy and concentration distributions are conversed for different prominent parameters. Comparison in limiting case is also part of present study to validate the obtained results. It is witnessed that nanoparticle concentration is diminishing function of chemical reaction parameter. Moreover, mounting values of thermal and solutal stratification lowers the temperature and concentration fields respectively.	[Ramzan, Muhammad] Bahria Univ, Dept Comp Sci, Islamabad Campus, Islamabad 44000, Pakistan; [Bilal, Muhammad] Capital Univ Sci & Technol, Fac Comp, Dept Math, Islamabad, Pakistan; [Chung, Jae Dong] Sejong Univ, Dept Mech Engn, Seoul 143747, South Korea	Capital University of Science & Technology; Sejong University	Ramzan, M (corresponding author), Bahria Univ, Dept Comp Sci, Islamabad Campus, Islamabad 44000, Pakistan.	mramzan@bahria.edu.pk	Ramzan, M./AAH-9959-2020	Ramzan, M./0000-0002-9523-5800	World Class 300 Project of the SMBA (Korea) [S2367878]	World Class 300 Project of the SMBA (Korea)	This work was supported by the World Class 300 Project (No. S2367878) of the SMBA (Korea).	Abbas Z, 2016, ENERGY, V95, P12, DOI 10.1016/j.energy.2015.11.039; Abbasi FM, 2016, J MAGN MAGN MATER, V404, P159, DOI 10.1016/j.jmmm.2015.11.090; Akbar NS, 2015, J MAGN MAGN MATER, V382, P355, DOI 10.1016/j.jmmm.2015.01.088; Dogonchi AS, 2016, J MOL LIQ, V220, P592, DOI 10.1016/j.molliq.2016.05.022; Hayat T, 2016, APPL MATH MECH-ENGL, V37, P919, DOI 10.1007/s10483-016-2093-9; Hayat T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156955; Hayat T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152555; Hayat T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133831; Hayat T, 2016, J AEROSPACE ENG, V29, DOI 10.1061/(ASCE)AS.1943-5525.0000501; Hayat T., 2016, THERMAL SCI; Hayat T, 2017, J AEROSPACE ENG, V30, DOI 10.1061/(ASCE)AS.1943-5525.0000674; Hayat T, 2017, THERM SCI, V21, P849, DOI 10.2298/TSCI141106052H; Hayat T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145332; Hayat T, 2016, INT J HEAT MASS TRAN, V92, P100, DOI 10.1016/j.ijheatmasstransfer.2015.08.013; Hayat T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127646; Hussain T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103719; Hussanan A, 2016, J TEKNOL, V78, P121; Hussanan A, 2015, MAEJO INT J SCI TECH, V9, P224; Hussanan A, 2014, EUR PHYS J PLUS, V129, DOI 10.1140/epjp/i2014-14046-x; Kaladhar K, 2017, COMPUT APPL MATH, V36, P611, DOI 10.1007/s40314-015-0248-x; Khan NA, 2015, INT J CHEM REACT ENG, V13, DOI 10.1515/ijcre-2014-0090; Liao S, 2004, APPL MATH COMPUT, V147, P499, DOI [10.1016/S0096-3003(02)00790-7, 10.1016/50096-3003(02)00790-7]; Powell RE, 1944, NATURE, V154, P427, DOI 10.1038/154427a0; Qasim M, 2014, EUR PHYS J PLUS, V129, DOI 10.1140/epjp/i2014-14024-4; Qasim M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083930; Ramzan M, 2016, J MOL LIQ, V221, P394, DOI 10.1016/j.molliq.2016.05.091; Ramzan M, 2016, ALEX ENG J, V55, P311, DOI 10.1016/j.aej.2015.09.012; Ramzan M, 2016, J MOL LIQ, V215, P212, DOI 10.1016/j.molliq.2015.12.036; Ramzan M, 2015, AIP ADV, V5, DOI 10.1063/1.4921312; Ramzan M, 2015, J CENT SOUTH UNIV, V22, P707, DOI 10.1007/s11771-015-2574-y; Ramzan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124699; Shehzad SA, 2015, J CENT SOUTH UNIV, V22, P360, DOI 10.1007/s11771-015-2530-x; Sk MT, 2016, APPL THERM ENG, V104, P758, DOI 10.1016/j.applthermaleng.2016.05.129	33	49	51	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2017	12	1							e0170790	10.1371/journal.pone.0170790	http://dx.doi.org/10.1371/journal.pone.0170790			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7VX	28129356	Green Published, Green Submitted, gold			2023-01-03	WOS:000396211400034
J	Crossland, RF; Balasa, A; Ramakrishnan, R; Mahadevan, SK; Fiorotto, ML; Van den Veyver, IB				Crossland, Randy F.; Balasa, Alfred; Ramakrishnan, Rajesh; Mahadevan, Sangeetha K.; Fiorotto, Marta L.; Van den Veyver, Ignatia B.			Chronic Maternal Low-Protein Diet in Mice Affects Anxiety, Night-Time Energy Expenditure and Sleep Patterns, but Not Circadian Rhythm in Male Offspring	PLOS ONE			English	Article							OBSESSIVE-COMPULSIVE DISORDER; PRENATAL MALNUTRITION; TRYPTOPHAN DEPLETION; GENE-EXPRESSION; PHYSICAL GROWTH; BEHAVIOR; RESTRICTION; NUTRITION; DISEASE; MODEL	Offspring of murine dams chronically fed a protein-restricted diet have an increased risk for metabolic and neurobehavioral disorders. Previously we showed that adult offspring, developmentally exposed to a chronic maternal low-protein (MLP) diet, had lower body and hind leg muscle weights and decreased liver enzyme serum levels. We conducted energy expenditure, neurobehavioral and circadian rhythm assays in male offspring to examine mechanisms for the body-weight phenotype and assess neurodevelopmental implications of MLP exposure. C57BL/6J dams were fed a protein restricted (8%protein, MLP) or a control protein (20% protein, C) diet from four weeks before mating until weaning of offspring. Male offspring were weaned to standard rodent diet (20% protein) and single-housed until 8-12 weeks of age. We examined body composition, food intake, energy expenditure, spontaneous rearing activity and sleep patterns and performed behavioral assays for anxiety (open field activity, elevated plus maze [EPM], light/dark exploration), depression (tail suspension and forced swim test), sociability (three-chamber), repetitive (marble burying), learning and memory (fear conditioning), and circadian behavior (wheel-running activity during light-dark and constant dark cycles). We also measured circadian gene expression in hypothalamus and liver at different Zeitgeber times (ZT). Male offspring from separate MLP exposed dams had significantly greater body fat (P = 0.03), less energy expenditure (P = 0.004), less rearing activity (P = 0.04) and a greater number of night-time rest/sleep bouts (P = 0.03) compared to control. MLP offspring displayed greater anxiety-like behavior in the EPM (P<0.01) but had no learning and memory deficit in fear-conditioning assay (P = 0.02). There was an effect of time on Pen, Per 2 and C/ockcircadian gene expression in the hypothalamus but not on circadian behavior. Thus, transplacental and early developmental exposure of dams to chronic MLP reduces food intake and energy expenditure, increases anxiety like behavior and disturbs sleep patterns but not circadian rhythm in adult male offspring.	[Crossland, Randy F.; Balasa, Alfred; Ramakrishnan, Rajesh; Mahadevan, Sangeetha K.; Van den Veyver, Ignatia B.] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; [Crossland, Randy F.; Balasa, Alfred; Ramakrishnan, Rajesh; Mahadevan, Sangeetha K.; Van den Veyver, Ignatia B.] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA; [Mahadevan, Sangeetha K.; Van den Veyver, Ignatia B.] Baylor Coll Med, Interdept Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Fiorotto, Marta L.] ARS, USDA, Childrens Nutr Res Ctr, Houston, TX USA; [Van den Veyver, Ignatia B.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Crossland, Randy F.] Henry M Jackson Fdn Adv Mil Med Expeditionary & T, Combat Casualty Care, Naval Med Res Unit San Antonio NAMRU SA, 3650 Chambers Pass, San Antonio, TX USA; [Balasa, Alfred] Baylor Coll Med, Dept Pediat, Child Neurol Neurodev Disabil Residency Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; Naval Medical Research Center (NMRC); Naval Medical Research Unit San Antonio (NAMRU-SA); Baylor College of Medicine	Van den Veyver, IB (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.; Van den Veyver, IB (corresponding author), Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA.; Van den Veyver, IB (corresponding author), Baylor Coll Med, Interdept Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA.; Van den Veyver, IB (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	iveyver@bcm.edu	Van den Veyver, Ignatia B/AAF-4510-2021	Van den Veyver, Ignatia B/0000-0002-0651-5924; Ramakrishnan, Rajesh/0000-0001-8841-570X	US Department of Agriculture/Agricultural Research Service [6250-51000-055, 3092-51000-056-00D]; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR46308]; Intellectual and Developmental Disabilities Research Center (IDDRC) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development [1U54 HD083092]; National Center For Research Resources [C06RR029965]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046308] Funding Source: NIH RePORTER	US Department of Agriculture/Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service); NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intellectual and Developmental Disabilities Research Center (IDDRC) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development; National Center For Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by: 1)6250-51000-055; US Department of Agriculture/Agricultural Research Service; http://www.ars.usda.gov/main/main.htm; I.B.VdV, 2) 3092-51000-056-00D; US Department of Agriculture/Agricultural Research Service; http://www.ars.usda.gov/main/main.htm; M.L.F., 3) AR46308; The NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases; http://www.niams.nih.gov/; M.L.F., 4) 1U54 HD083092; Intellectual and Developmental Disabilities Research Center (IDDRC) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development; https://www.bcm.edu/research/centers/intellectual-developmental-disabilities, and 5) C06RR029965; The National Center For Research Resources; https://www.nih.gov/research-training/research-resources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akitake Y, 2015, NUTR RES, V35, P76, DOI 10.1016/j.nutres.2014.10.014; Alamy M, 2012, NEUROSCI BIOBEHAV R, V36, P1463, DOI 10.1016/j.neubiorev.2012.03.009; Asher G, 2015, CELL, V161, P84, DOI 10.1016/j.cell.2015.03.015; Balasa A, 2011, J NUTR, V141, P2106, DOI 10.3945/jn.111.146597; Bale TL, 2010, BIOL PSYCHIAT, V68, P314, DOI 10.1016/j.biopsych.2010.05.028; Barker DJP, 1997, NUTRITION, V13, P807, DOI 10.1016/S0899-9007(97)00193-7; BARR LC, 1994, ARCH GEN PSYCHIAT, V51, P309; Bedi KS, 2003, NUTR NEUROSCI, V6, P141, DOI 10.1080/1028415031000098549; Belluscio LM, 2014, PHYSIOL BEHAV, V129, P237, DOI 10.1016/j.physbeh.2014.02.051; Carter RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085508; Chun LE, 2015, J BIOL RHYTHM, V30, P417, DOI 10.1177/0748730415598608; Crowley JJ, 2004, PHARMACOL BIOCHEM BE, V78, P269, DOI 10.1016/j.pbb.2004.03.014; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Datta S, 2000, J SLEEP RES, V9, P71, DOI 10.1046/j.1365-2869.2000.00179.x; Desai M, 1996, BRIT J NUTR, V76, P591, DOI 10.1079/BJN19960065; Duran P, 2005, NUTR NEUROSCI, V8, P167, DOI 10.1080/10284150400026117; Duran P, 2006, PHYSIOL BEHAV, V89, P156, DOI 10.1016/j.physbeh.2006.05.045; Eckel-Mahan KL, 2013, CELL, V155, P1464, DOI 10.1016/j.cell.2013.11.034; Fall CHD, 2003, J NUTR, V133, p1747S, DOI 10.1093/jn/133.5.1747S; Febinger HY, 2014, J AM ASSOC LAB ANIM, V53, P29; Fernandez-Twinn DS, 2005, AM J PHYSIOL-REG I, V288, pR368, DOI 10.1152/ajpregu.00206.2004; Gonzalez PN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152227; He JY, 2015, J MOL NEUROSCI, V55, P644, DOI 10.1007/s12031-014-0403-7; Heinonen K, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-91; Karatsoreos IN, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00162; Kulz AK, 2007, NEUROPSYCHOBIOLOGY, V56, P127, DOI 10.1159/000115778; Kulesskaya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024755; Lacaria M, 2012, HUM MOL GENET, V21, P3083, DOI 10.1093/hmg/dds124; Lecarpentier Y, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00429; Lister JP, 2006, HIPPOCAMPUS, V16, P946, DOI 10.1002/hipo.20221; Lister JP, 2005, HIPPOCAMPUS, V15, P393, DOI 10.1002/hipo.20065; Ma XJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016391; MATHIS C, 1994, BEHAV GENET, V24, P171, DOI 10.1007/BF01067821; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Morgane PJ, 2005, PROG NEUROBIOL, V75, P143, DOI 10.1016/j.pneurobio.2005.01.001; Morgane PJ, 2002, NEUROSCI BIOBEHAV R, V26, P471, DOI 10.1016/S0149-7634(02)00012-X; Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030; Nascimento Elizabeth, 2013, PLoS One, V8, pe56231, DOI 10.1371/journal.pone.0056231; O'Neil D, 2013, MOL GENET METAB, V110, P378, DOI 10.1016/j.ymgme.2013.08.015; Orozco-Solis R, 2011, INT J OBESITY, V35, P990, DOI 10.1038/ijo.2010.223; Ozanne SE, 2005, MECH AGEING DEV, V126, P852, DOI 10.1016/j.mad.2005.03.005; Pack AI, 2007, PHYSIOL GENOMICS, V28, P232, DOI 10.1152/physiolgenomics.00139.2006; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Ramamoorthy TG, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00126; Ramos A, 2008, TRENDS PHARMACOL SCI, V29, P493, DOI 10.1016/j.tips.2008.07.005; Ranade SC, 2012, BRIT J NUTR, V107, P1167, DOI 10.1017/S0007114511004119; Rando OJ, 2015, CELL, V161, P93, DOI 10.1016/j.cell.2015.02.021; Reyes-Castro LA, 2011, INT J DEV NEUROSCI, V29, P177, DOI 10.1016/j.ijdevneu.2010.11.002; Rodgers RJ, 1997, NEUROSCI BIOBEHAV R, V21, P801, DOI 10.1016/S0149-7634(96)00058-9; Roseboom TJ, 2011, MATURITAS, V70, P141, DOI 10.1016/j.maturitas.2011.06.017; Seidell JC, 2000, BRIT J NUTR, V83, pS5, DOI 10.1017/S000711450000088X; Spencer CA, 2008, BEHAV NEUROSCI, V122, P710, DOI 10.1037/0735-7044.122.3.710; Strata F, 2015, REPROD SCI, V22, P23, DOI 10.1177/1933719114557900; Suter M, 2011, FASEB J, V25, P714, DOI 10.1096/fj.10-172080; Sutton GM, 2010, ENDOCRINOLOGY, V151, P1570, DOI 10.1210/en.2009-1133; Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y; Verwey Michael, 2013, J Vis Exp, DOI 10.3791/50186; Voikar V, 2005, GENES BRAIN BEHAV, V4, P240, DOI 10.1111/j.1601-183X.2004.00103.x; Walz K, 2004, HUM MOL GENET, V13, P367, DOI 10.1093/hmg/ddh044; Watkins AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028745; Zadik Z, 2003, J ENDOCRINOL INVEST, V26, P941, DOI 10.1007/BF03345248; Zohdi V, 2015, NUTRIENTS, V7, P119, DOI 10.3390/nu7010119	62	13	13	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2017	12	1							e0170127	10.1371/journal.pone.0170127	http://dx.doi.org/10.1371/journal.pone.0170127			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI3HH	28099477	gold, Green Published, Green Submitted			2023-01-03	WOS:000392380100057
J	Wolfe, MK; Wells, E; Mitro, B; Desmarais, AM; Scheinman, P; Lantagne, D				Wolfe, Marlene K.; Wells, Emma; Mitro, Brittany; Desmarais, Anne Marie; Scheinman, Pamela; Lantagne, Daniele			Seeking Clearer Recommendations for Hand Hygiene in Communities Facing Ebola: A Randomized Trial Investigating the Impact of Six Handwashing Methods on Skin Irritation and Dermatitis	PLOS ONE			English	Article							HEALTH-CARE WORKERS; SODIUM-HYPOCHLORITE; CONTACT-DERMATITIS; BARRIER FUNCTION; ATOPIC-DERMATITIS; ECZEMA; DISINFECTION; SENSITIVITY; POPULATION; PHYSIOLOGY	To prevent disease transmission, 0.05% chlorine solution is commonly recommended for handwashing in Ebola Treatment Units. In the 2014 West Africa outbreak this recommendation was widely extended to community settings, although many organizations recommend soap and hand sanitizer over chlorine. To evaluate skin irritation caused by frequent handwashing that may increase transmission risk in Ebola-affected communities, we conducted a randomized trial with 91 subjects who washed their hands 10 times a day for 28 days. Subjects used soap and water, sanitizer, or one of four chlorine solutions used by Ebola responders (calcium hypochlorite (HTH), sodium dichloroisocyanurate (NaDCC), and generated or pH-stabilized sodium hypochlorite (NaOCl)). Outcomes were self-reported hand feel, irritation as measured by the Hand Eczema Score Index (HECSI) (range 0-360), signs of transmission risk (e.g., cracking), and dermatitis diagnosis. All groups experienced statistically significant increases in HECSI score. Subjects using sanitizer had the smallest increases, followed by higher pH chlorine solutions (HTH and stabilized NaOCl), and soap and water. The greatest increases were among neutral pH chlorine solutions (NaDCC and generated NaOCl). Signs of irritation related to higher transmission risk were observed most frequently in subjects using soap and least frequently by those using sanitizer or HTH. Despite these irritation increases, all methods represented minor changes in HECSI score. Average HECSI score was only 9.10 at endline (range 1-33) and 4% (4/91) of subjects were diagnosed with dermatitis, one each in four groups. Each handwashing method has benefits and drawbacks: soap is widely available and inexpensive, but requires water and does not inactivate the virus; sanitizer is easy-to use and effective but expensive and unacceptable to many communities, and chlorine is easy-to-use but difficult to produce properly and distribute. Overall, we recommend Ebola responders and communities use whichever handwashing method(s) are most acceptable, available, and sustainable for community handwashing.	[Wolfe, Marlene K.; Wells, Emma; Mitro, Brittany; Desmarais, Anne Marie; Lantagne, Daniele] Tuft Univ, Dept Civil & Environm Engn, Medford, MA 02155 USA; [Scheinman, Pamela] Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Wolfe, MK (corresponding author), Tuft Univ, Dept Civil & Environm Engn, Medford, MA 02155 USA.	marlene.wolfe@tufts.edu			United States Agency for International Development, Office of Foreign Disaster Assistance [AID-OFDA-A-15-00026]; National Science Foundation [0966093]	United States Agency for International Development, Office of Foreign Disaster Assistance(United States Agency for International Development (USAID)); National Science Foundation(National Science Foundation (NSF))	This study was funded by a grant from the United States Agency for International Development, Office of Foreign Disaster Assistance (AID-OFDA-A-15-00026). MW was supported by the National Science Foundation (grant 0966093). The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript. The funders did have a small role in study design - in that the initial design we proposed was 15 participants per study arm, and the funders came back to us in the proposal stage and suggested increasing the funding to support 18 participants per study arm, which was done. The funders had no input into study design after the grant was awarded. The funders were provided a final version of the manuscript before submission, and had only minor grammatical comments.	Allegranzi B, 2009, AM J INFECT CONTROL, V37, P28, DOI 10.1016/j.ajic.2008.01.014; Angelova-Fischer I, 2014, ACTA DERM-VENEREOL, V94, P640, DOI 10.2340/00015555-1815; [Anonymous], HAND HYG W AFR GEN N; [Anonymous], 2014, IF USING CHLORINE HA; [Anonymous], 1988, DERMATOS BER UMWELT, V37, P96; [Anonymous], EB EB VIR DIS SIGNS; Antonov D, 2015, AM J CLIN DERMATOL; Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x; Callahan A, 2013, DERMATITIS, V24, P170, DOI 10.1097/DER.0b013e318290c57f; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; Darlenski R, 2012, CLIN DERMATOL, V30, P269, DOI 10.1016/j.clindermatol.2011.08.013; Emmanuel J, 2015, REPORT WHO ASSESSMEN; English JSC, 2004, OCCUP ENVIRON MED, V61, P722, DOI 10.1136/oem.2003.010710; ESCOFFIER C, 1989, J INVEST DERMATOL, V93, P353, DOI 10.1111/1523-1747.ep12280259; Eun HC, 1984, CONTACT DERMATITIS, P11; Feldmann H., FILOVIRIDAE MARBURG; Florentin A, 2011, INT J HYG ENVIR HEAL, V214, P461, DOI 10.1016/j.ijheh.2011.07.012; Gatherer D, 2014, J GEN VIROL, V95, P1619, DOI 10.1099/vir.0.067199-0; Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082; Gire SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/science.1259657; HABETS JMW, 1986, CONTACT DERMATITIS, V15, P140, DOI 10.1111/j.1600-0536.1986.tb01314.x; HANSEN KS, 1983, CONTACT DERMATITIS, V9, P343, DOI 10.1111/j.1600-0536.1983.tb04426.x; Held E, 2005, BRIT J DERMATOL, V152, P302, DOI 10.1111/J.1365-2133.2004.06305.X; HOSTYNEK JJ, 1990, CONTACT DERMATITIS, V23, P316, DOI 10.1111/j.1600-0536.1990.tb05165.x; HOSTYNEK JJ, 1989, CONTACT DERMATITIS, V20, P32, DOI 10.1111/j.1600-0536.1989.tb03092.x; Houben E, 2006, CONTACT DERMATITIS, V54, P261, DOI 10.1111/j.0105-1873.2006.00817.x; Ibler KS, 2012, CONTACT DERMATITIS, V66, P247, DOI 10.1111/j.1600-0536.2011.02027.x; JM Boyce, 2002, GUIDELINE HAND HYGIE, V51; Jungbauer FHW, 2004, CONTACT DERMATITIS, V51, P135, DOI 10.1111/j.0105-1873.2004.00422.x; Kortepeter MG, 2011, J INFECT DIS, V204, pS810, DOI 10.1093/infdis/jir299; Luther N, 2012, SKIN PHARMACOL PHYS, V25, P182, DOI 10.1159/000337933; Organization WH, 2009, WHO GUID HAND HYG HL; OSMUNDSEN PE, 1978, CONTACT DERMATITIS, V4, P177, DOI 10.1111/j.1600-0536.1978.tb03779.x; PATTYN S, 1977, LANCET, V1, P573; Pedersen LK, 2005, BRIT J DERMATOL, V153, P1142, DOI 10.1111/j.1365-2133.2005.06875.x; REED JT, 1995, ARCH DERMATOL, V131, P1134, DOI 10.1001/archderm.131.10.1134; Robinson MK, 1999, CONTACT DERMATITIS, V41, P65; Salphale PS, 2003, CONTACT DERMATITIS, V48, P162, DOI 10.1034/j.1600-0536.2003.00001.x; Schmid-Wendtner MH, 2006, SKIN PHARMACOL PHYS, V19, P296, DOI 10.1159/000094670; SHUSTER S, 1975, BRIT J DERMATOL, V93, P639, DOI 10.1111/j.1365-2133.1975.tb05113.x; Staff MC, 2015, DIS COND DERM 2015; Sterk E., 2008, MED SANS FILOVIRUS H; Thyssen JP, 2010, CONTACT DERMATITIS, V62, P75, DOI 10.1111/j.1600-0536.2009.01669.x; Visser MJ, 2014, CONTACT DERMATITIS, V70, P139, DOI 10.1111/cod.12139; Wahlberg JE, 2001, TXB CONTACT DERMAT, P435; Wesley NO, 2003, AM J CLIN DERMATOL, V4, P843, DOI 10.2165/00128071-200304120-00004; WHO CDC, 1998, INF CONTR VIR HAEM F; World Health Organisation, 2016, EB SIT REP 30 MARCH; World Health Organization, 2014, REP EB VIR DIS EVD K; World Health Organization, 2009, WHO GUID HAND HYG HL, V30; WORLD HEALTHY ORGANIZATION, 2009, WHO REC HANDR FORM; Zaki SR, 1999, CURR TOP MICROBIOL, V235, P97	52	11	11	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2016	11	12							e0167378	10.1371/journal.pone.0167378	http://dx.doi.org/10.1371/journal.pone.0167378			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7JB	28030544	gold, Green Published, Green Submitted			2023-01-03	WOS:000391222000007
J	Levac, DE; Glegg, SMN; Sveistrup, H; Colquhoun, H; Miller, P; Finestone, H; DePaul, V; Harris, JE; Velikonja, D				Levac, Danielle E.; Glegg, Stephanie M. N.; Sveistrup, Heidi; Colquhoun, Heather; Miller, Patricia; Finestone, Hillel; DePaul, Vincent; Harris, Jocelyn E.; Velikonja, Diana			Promoting Therapists' Use of Motor Learning Strategies within Virtual Reality-Based Stroke Rehabilitation	PLOS ONE			English	Article							PHYSICAL-THERAPY; CHILDREN; INTERVENTIONS; RELIABILITY; INSTRUMENT	Purpose Therapists use motor learning strategies (MLSs) to structure practice conditions within stroke rehabilitation. Virtual reality (VR)-based rehabilitation is an MLS-oriented stroke intervention, yet little support exists to assist therapists in integrating MLSs with VR system use. Method A pre-post design evaluated a knowledge translation (KT) intervention incorporating interactive e-learning and practice, in which 11 therapists learned how to integrate MLSs within VR-based therapy. Self-report and observer-rated outcome measures evaluated therapists' confidence, clinical reasoning and behaviour with respect to MLS use. A focus group captured therapists' perspectives on MLS use during VR-based therapy provision. Results The intervention improved self-reported confidence about MLS use as measured by confidence ratings (p <0.001). Chart-Stimulated Recall indicated a moderate level of competency in therapists' clinical reasoning about MLSs following the intervention, with no changes following additional opportunities to use VR (p =.944). On the Motor Learning Strategy Rating Instrument, no behaviour change with respect to MLS use was noted (p = 0.092). Therapists favoured the strategy of transferring skills from VR to real-life tasks over employing a more comprehensive MLS approach. Conclusion The KT intervention improved therapists' confidence but did not have an effect on clinical reasoning or behaviour with regard to MLS use during VR-based therapy.	[Levac, Danielle E.] Northwestern Univ, Bouve Coll Hlth Sci, Dept Phys Therapy Movement Sci & Rehabil, Boston, MA 60208 USA; [Glegg, Stephanie M. N.] Sunny Hill Hlth Ctr Children, Therapy Dept, Vancouver, BC, Canada; [Sveistrup, Heidi; Harris, Jocelyn E.] Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON, Canada; [Colquhoun, Heather] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Miller, Patricia] McMaster Univ, Fac Hlth Sci, Sch Rehabil Sci, Hamilton, ON, Canada; [Finestone, Hillel] Eiisabeth Bruyere Hosp & Bruyere Continuing Care, Physiat, Ottawa, ON, Canada; [DePaul, Vincent] Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada; [Velikonja, Diana] Hamilton Hlth Sci, Reg Rehabil Ctr, Hamilton, ON, Canada	Northeastern University; Northwestern University; University of Ottawa; University of Toronto; McMaster University; Queens University - Canada; McMaster University	Levac, DE (corresponding author), Northwestern Univ, Bouve Coll Hlth Sci, Dept Phys Therapy Movement Sci & Rehabil, Boston, MA 60208 USA.	d.levac@northeastern.edu	Harris, Jocelyn Ellen/ABE-7420-2021; Levac, Danielle/O-9008-2015	Harris, Jocelyn Ellen/0000-0002-3293-1833; Levac, Danielle/0000-0001-7356-9335; Glegg, Stephanie/0000-0002-8164-6983	Ontario Ministry of Health and Long-Term Care; Ontario Stroke Network; Canadian Institutes of Health Research; Canadian Child Health Clinician Scientist Program; NeuroDevNet	Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Ontario Stroke Network; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Child Health Clinician Scientist Program; NeuroDevNet	This project has been generously funded, by a grant from the Ontario Ministry of Health and Long-Term Care, administered and supported by the Ontario Stroke Network (www.ontariostrokenetwork.ca), to DEL, SMNG, HS, HC, PM, HF, VD, and JEH. The views expressed do not necessarily reflect those of the Ministry or the Ontario Stroke Network. Dr. Levac's postdoctoral fellowship was supported by the Canadian Institutes of Health Research, the Canadian Child Health Clinician Scientist Program and NeuroDevNet.	Baker R, 2015, COCHRANE DB SYST REV, V29; Barker M, 2015, KNOWLEDGE PRAC UNPUB; Darekar A, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0035-3; Fisher BE, 2014, J NEUROL PHYS THER, V38, P149, DOI 10.1097/NPT.0000000000000043; Glegg SMN, DISABI REHA IN PRESS; Glegg SMN, 2012, J CYBERTHER REHABIL, V5; Glegg SMN, 2014, NEUROREHABILITATION, V35, P563, DOI 10.3233/NRE-141152; Glegg SMN, 2014, DISABIL REHABIL-ASSI, V9, P89, DOI 10.3109/17483107.2013.799236; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jones CA, 2015, PHYS THER, V95, P663, DOI 10.2522/ptj.20130512; Kamath T, 2012, PHYS OCCUP THER PEDI, V32, P288, DOI 10.3109/01942638.2012.672551; Kaminker MK, 2004, PHYS THER, V84, P919, DOI 10.1093/ptj/84.10.919; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kleynen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135522; Krakauer JW, 2006, CURR OPIN NEUROL, V19, P84, DOI 10.1097/01.wco.0000200544.29915.cc; Laver K, 2012, EUR J PHYS REHAB MED, V48, P523; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Levac D, 2015, PHYS THER, V95, P648, DOI 10.2522/ptj.20130500; Levac D, 2013, PEDIATR PHYS THER, V25, P53, DOI 10.1097/PEP.0b013e3182750c28; Levac D, 2012, PHYS OCCUP THER PEDI, V32, P180, DOI 10.3109/01942638.2011.616266; Levac D, 2012, RES DEV DISABIL, V33, P214, DOI 10.1016/j.ridd.2011.09.007; Levac D, 2011, PHYS THER, V91, P689, DOI 10.2522/ptj.20100415; Levac DE, 2013, PHYSIOTHER THEOR PR, V29, P504, DOI 10.3109/09593985.2012.762078; Levac DE, BMC HLTH SE IN PRESS; Levac DE, 2012, ARCH PHY MEDREHABIL; Levin MF, 2008, P 8 INT C VIRT REH; Levin MF, 2015, PHYS THER, V95, P415, DOI 10.2522/ptj.20130579; Levin MF, 2012, NEUROL THER, V1, DOI 10.1007/s40120-012-0003-9; Levin MF, 2011, EXPERT REV NEUROTHER, V11, P153, DOI 10.1586/ERN.10.201; MacDermid JC, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-14; Mathur S, 2005, PHYS THER, V85, P226, DOI 10.1093/ptj/85.3.226; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; Salvatori P, 2000, Can J Occup Ther, V67, P51; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Schmidt R. A, 2011, MOTOR CONTROL LEARNI; Schmidt RA., 1991, CONT MANAGEMENT MOTO, P49; Schoemaker M. M., 2013, THESIS; Scott SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-70; Squires JE, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0152-6; Subramanian SK, 2010, NEUROREHAB NEURAL RE, V24, P113, DOI 10.1177/1545968309349941; Sveistrup Heidi, 2004, J Neuroeng Rehabil, V1, P10, DOI 10.1186/1743-0003-1-10; Tatla SK, 2015, JMIR SERIOUS GAMES, V3, DOI 10.2196/games.3401; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; Winstein C, 2014, J NEUROL PHYS THER, V38, P190, DOI 10.1097/NPT.0000000000000046	45	24	26	3	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2016	11	12							e0168311	10.1371/journal.pone.0168311	http://dx.doi.org/10.1371/journal.pone.0168311			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI9QC	27992492	gold, Green Submitted, Green Published			2023-01-03	WOS:000392842600047
J	Shah, SN; Gelderman, MP; Lewis, EMA; Farrel, J; Wood, F; Strader, MB; Alayash, AI; Vostal, JG				Shah, Sandeep N.; Gelderman, Monique P.; Lewis, Emily M. A.; Farrel, John; Wood, Francine; Strader, Michael Brad; Alayash, Abdu I.; Vostal, Jaroslav G.			Evaluation of Stem Cell-Derived Red Blood Cells as a Transfusion Product Using a Novel Animal Model	PLOS ONE			English	Article							HUMAN ERYTHROID PROGENITORS; EX-VIVO GENERATION; HEMATOPOIETIC STEM; FETAL-HEMOGLOBIN; IN-VITRO; HEREDITARY PERSISTENCE; GENE-EXPRESSION; CORD BLOOD; ENUCLEATION; MICE	Reliance on volunteer blood donors can lead to transfusion product shortages, and current liquid storage of red blood cells (RBCs) is associated with biochemical changes over time, known as 'the storage lesion'. Thus, there is a need for alternative sources of transfusable RBCs to supplement conventional blood donations. Extracorporeal production of stem cellderived RBCs (stemRBCs) is a potential and yet untapped source of fresh, transfusable RBCs. A number of groups have attempted RBC differentiation from CD34(+) cells. However, it is still unclear whether these stemRBCs could eventually be effective substitutes for traditional RBCs due to potential differences in oxygen carrying capacity, viability, deformability, and other critical parameters. We have generated ex vivo stemRBCs from primary human cord blood CD34(+) cells and compared them to donor-derived RBCs based on a number of in vitro parameters. In vivo, we assessed stemRBC circulation kinetics in an animal model of transfusion and oxygen delivery in a mouse model of exercise performance. Our novel, chronically anemic, SCID mouse model can evaluate the potential of stemRBCs to deliver oxygen to tissues (muscle) under resting and exercise-induced hypoxic conditions. Based on our data, stem cell-derived RBCs have a similar biochemical profile compared to donor-derived RBCs. While certain key differences remain between donor-derived RBCs and stemRBCs, the ability of stemRBCs to deliver oxygen in a living organism provides support for further development as a transfusion product.	[Shah, Sandeep N.; Gelderman, Monique P.; Lewis, Emily M. A.; Farrel, John; Vostal, Jaroslav G.] US FDA, Lab Cellular Hematol, Div Hematol Res & Review, Off Blood Res & Review,Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA; [Wood, Francine; Strader, Michael Brad; Alayash, Abdu I.] US FDA, Lab Biochem & Vasc Biol, Div Hematol Res & Review, Off Blood Res & Review,Ctr Biol Evaluat & Res, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Vostal, JG (corresponding author), US FDA, Lab Cellular Hematol, Div Hematol Res & Review, Off Blood Res & Review,Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	Jaroslav.Vostal@fda.hhs.gov			FDA Critical Path research funding	FDA Critical Path research funding	Funding for this project came through FDA Critical Path research funding.	Akinsheye I, 2011, BLOOD, V118, P19, DOI 10.1182/blood-2011-03-325258; [Anonymous], 2013, 2011 NATL BLOOD COLL; Anstee DJ, 2012, CURR OPIN HEMATOL, V19, P163, DOI 10.1097/MOH.0b013e328352240a; Baek EJ, 2009, TRANSFUSION, V49, P2285, DOI 10.1111/j.1537-2995.2009.02303.x; Berg J.M., 2002, BIOCHEMISTRY-US; Betz T, 2009, P NATL ACAD SCI USA, V106, P15320, DOI 10.1073/pnas.0904614106; Beutler E., 1995, OSMOTIC FRAGILITY; Beutler E, 1983, OSMOTIC FRAGILITY; Buehler PW, 2004, TRANSFUSION, V44, P1516, DOI 10.1111/j.1537-2995.2004.04081.x; Can A, 2012, JOVE-J VIS EXP, V59, P3638, DOI DOI 10.3791/3638; CONLEY CL, 1963, BLOOD, V21, P261, DOI 10.1182/blood.V21.3.261.261; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Darling RC, 1941, J CLIN INVEST, V20, P739, DOI 10.1172/JCI101267; Dhabangi A, 2015, JAMA-J AM MED ASSOC, V314, P2514, DOI 10.1001/jama.2015.13977; di Prampero PE, 1999, RESP PHYSIOL, V118, P103, DOI 10.1016/S0034-5687(99)00083-3; Fujimi A, 2008, INT J HEMATOL, V87, P339, DOI 10.1007/s12185-008-0062-y; Gelderman MP, 2010, TRANSFUSION MED, V20, P341, DOI 10.1111/j.1365-3148.2010.01016.x; Gelderman MP, 2015, HAEMATOLOGICA, V100, P611, DOI 10.3324/haematol.2014.117325; Gelderman MP, 2011, TRANSFUSION, V51, P1096, DOI 10.1111/j.1537-2995.2010.02972.x; Giarratana MC, 2011, BLOOD, V118, P5071, DOI 10.1182/blood-2011-06-362038; Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047; Goo YK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097390; Griffiths RE, 2012, BLOOD, V119, P6296, DOI 10.1182/blood-2011-09-376475; GUEST GM, 1948, BLOOD, V3, P541, DOI 10.1182/blood.V3.5.541.541; Heaven MR, 2016, J MASS SPECTROM, V51, P1, DOI 10.1002/jms.3716; Jin H, 2014, BIOMED RES INT, V2014; Jin HM, 2011, INT J MOL SCI, V12, P4770, DOI 10.3390/ijms12084770; Jung K, 2004, J ETHNOPHARMACOL, V93, P75, DOI 10.1016/j.jep.2004.03.022; Khodabux CM, 2013, TRANSFUSION, V53, P3230, DOI 10.1111/trf.12169; Kirby BS, 2014, AM J PHYSIOL-HEART C, V307, pH1737, DOI 10.1152/ajpheart.00542.2014; Kuphal KE, 2007, J PAIN, V8, P989, DOI 10.1016/j.jpain.2007.08.001; Lapillonne H, 2010, HAEMATOL-HEMATOL J, V95, P1651, DOI 10.3324/haematol.2010.023556; Leberbauer C, 2005, BLOOD, V105, P85, DOI 10.1182/blood-2004-03-1002; Leparc GF, 2015, CANCER CONTROL, V22, P6; Lu SJ, 2008, BLOOD, V112, P4475, DOI 10.1182/blood-2008-05-157198; McGrath KE, 2008, BLOOD, V111, P2409, DOI 10.1182/blood-2007-08-107581; Migliaccio AR, 2012, CELL STEM CELL, V10, P115, DOI 10.1016/j.stem.2012.01.001; Miharada K, 2006, NAT BIOTECHNOL, V24, P1255, DOI 10.1038/nbt1245; Mountford J, 2010, BRIT J HAEMATOL, V149, P22, DOI 10.1111/j.1365-2141.2010.08079.x; Ngo DA, 2012, BRIT J HAEMATOL, V156, P259, DOI 10.1111/j.1365-2141.2011.08916.x; Park YK, 2010, P NATL ACAD SCI USA, V107, P1289, DOI 10.1073/pnas.0910785107; Patel S, 2015, J CLIN DIAGN RES, V9, pOD9, DOI 10.7860/JCDR/2015/12878.6548; Rousseau GF, 2014, BIOTECHNOL J, V9, P28, DOI 10.1002/biot.201200368; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Singh VK, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00026; Strader MB, 2014, J BIOL CHEM, V289, P22342, DOI 10.1074/jbc.M114.568980; Tao ZY, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-251; Timmins NE, 2011, TISSUE ENG PART C-ME, V17, P1131, DOI [10.1089/ten.tec.2011.0207, 10.1089/ten.TEC.2011.0207]; Zhang X, 2007, BIOL RES, V40, P41, DOI 10.4067/S0716-97602007000100005; Zimring JC, 2011, TRANSFUSION, V51, P435, DOI 10.1111/j.1537-2995.2010.03024.x	50	11	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2016	11	12							e0166657	10.1371/journal.pone.0166657	http://dx.doi.org/10.1371/journal.pone.0166657			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8JY	27959920	Green Published, gold, Green Submitted			2023-01-03	WOS:000392753900004
J	Storch, K; Dickreuter, E; Artati, A; Adamski, J; Cordes, N				Storch, Katja; Dickreuter, Ellen; Artati, Anna; Adamski, Jerzy; Cordes, Nils			BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage	PLOS ONE			English	Article							DOUBLE-STRAND BREAKS; MAGNETIC-FIELDS; NEUROBLASTOMA-CELLS; TUMOR-GROWTH; RESISTANCE; EXPOSURE; PROLIFERATION; MECHANISMS; APOPTOSIS; LEVEL	Each year more than 450,000 Germans are expected to be diagnosed with cancer subsequently receiving standard multimodal therapies including surgery, chemotherapy and radiotherapy. On top, molecular-targeted agents are increasingly administered. Owing to intrinsic and acquired resistance to these therapeutic approaches, both the better molecular understanding of tumor biology and the consideration of alternative and complementary therapeutic support are warranted and open up broader and novel possibilities for therapy personalization. Particularly the latter is underpinned by the increasing utilization of noninvasive complementary and alternative medicine by the population. One investigated approach is the application of low-dose electromagnetic fields (EMF) to modulate cellular processes. A particular system is the BEMER therapy as a Physical Vascular Therapy for which a normalization of the microcirculation has been demonstrated by a low-frequency, pulsed EMF pattern. Open remains whether this EMF pattern impacts on cancer cell survival upon treatment with radiotherapy, chemotherapy and the molecular-targeted agent Cetuximab inhibiting the epidermal growth factor receptor. Using more physiological, three-dimensional, matrix-based cell culture models and cancer cell lines originating from lung, head and neck, colorectal and pancreas, we show significant changes in distinct intermediates of the glycolysis and tricarboxylic acid cycle pathways and enhanced cancer cell radiosensitization associated with increased DNA double strand break numbers and higher levels of reactive oxygen species upon BEMER treatment relative to controls. Intriguingly, exposure of cells to the BEMER EMF pattern failed to result in sensitization to chemotherapy and Cetuximab. Further studies are necessary to better understand the mechanisms underlying the cellular alterations induced by the BEMER EMF pattern and to clarify the application areas for human disease.	[Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany; [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Storch, Katja; Dickreuter, Ellen; Cordes, Nils] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, Dresden, Germany; [Artati, Anna; Adamski, Jerzy] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany; [Adamski, Jerzy] Tech Univ Munich, Lehrstuhl Expt Genet, Freising Weihenstephan, Germany; [Adamski, Jerzy] German Ctr Diabet Res DZD eV, Munich, Germany; [Cordes, Nils] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Radiat Oncol, Dresden, Germany; [Cordes, Nils] German Canc Consortium DKTK, Dresden, Germany; [Cordes, Nils] German Canc Res Ctr, Heidelberg, Germany	Technische Universitat Dresden; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Cordes, N (corresponding author), Tech Univ Dresden, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany.; Cordes, N (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.; Cordes, N (corresponding author), Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, Dresden, Germany.; Cordes, N (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Radiat Oncol, Dresden, Germany.; Cordes, N (corresponding author), German Canc Consortium DKTK, Dresden, Germany.; Cordes, N (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	Nils.Cordes@OncoRay.de		Adamski, Jerzy/0000-0001-9259-0199; Cordes, Nils/0000-0001-5684-629X	BEMER Int. AG (Liechtenstein); Deutsche Krebshilfe [108976]; European Union (RADIATE) [642623]; EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen [100066308]; German Federal Ministry of Education and Research (BMBF)	BEMER Int. AG (Liechtenstein); Deutsche Krebshilfe(Deutsche Krebshilfe); European Union (RADIATE); EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The research and authors were in part supported by the BEMER Int. AG (Liechtenstein) and grants from the Deutsche Krebshilfe (108976 to N.C.), the European Union (RADIATE; GA No. 642623 to N.C.) and the EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen (100066308). This work was also supported in part by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The research and authors were in part supported by the BEMER Int. AG (Liechtenstein) and grants from the Deutsche Krebshilfe (108976 to N.C.), the European Union (RADIATE; GA No.642623 to N.C.) and the EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen (100066308). This work was also supported in part by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.). We are grateful to R. Grenman for providing UTSCC15 cell line.	Al-Dimassi S, 2014, CLIN TRANSL ONCOL, V16, P511, DOI 10.1007/s12094-014-1162-1; Baharara J, 2015, CYTOTECHNOLOGY; Bohn Wolfgang, 2013, J Complement Integr Med, V10, pS1, DOI 10.1515/jcim-2013-0036; Bohn Wolfgang, 2013, J Complement Integr Med, V10, pS5, DOI 10.1515/jcim-2013-0037; Buckner CA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124136; Cameron IL, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-23; Cameron IL, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0125-5; Crocetti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072944; Delle Monache S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061484; Destefanis M, 2015, INT J RADIAT BIOL, V91, P964, DOI 10.3109/09553002.2015.1101648; Duan YQ, 2014, FOOD FUNCT, V5, P2289, DOI [10.1039/c4fo00250d, 10.1039/C4FO00250D]; Eke I., 2015, J BIOL METHODS, V2, P31, DOI [DOI 10.14440/JBM.2015.96, 10.14440/jbm.2015.96]; Eke I, 2016, INT J ONCOL, V48, P313, DOI 10.3892/ijo.2015.3230; Eke I, 2015, SEMIN CANCER BIOL, V31, P65, DOI 10.1016/j.semcancer.2014.07.009; Eke I, 2013, CANCER RES, V73, P297, DOI 10.1158/0008-5472.CAN-12-2021; Eke I, 2012, J CLIN INVEST, V122, P1529, DOI 10.1172/JCI61350; Elson E, 2009, ELECTROMAGN BIOL MED, V28, P275, DOI [10.1080/15368370903114271, 10.3109/15368370903114271]; Falone S, 2007, INT J BIOCHEM CELL B, V39, P2093, DOI 10.1016/j.biocel.2007.06.001; Francisco AC, 2013, INT J MOL SCI, V14, P14974, DOI 10.3390/ijms140714974; GORCZYNSKA E, 1991, ENVIRON RES, V55, P188, DOI 10.1016/S0013-9351(05)80175-6; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jiang Y, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/4927035; Karagiannis TC, 2004, CELL MOL LIFE SCI, V61, P2137, DOI 10.1007/s00018-004-4174-0; Kim J, 2010, BIOCHEM BIOPH RES CO, V400, P739, DOI 10.1016/j.bbrc.2010.08.140; Kirson ED, 2004, CANCER RES, V64, P3288, DOI 10.1158/0008-5472.CAN-04-0083; Marchesi N, 2014, J CELL PHYSIOL, V229, P1776, DOI 10.1002/jcp.24631; Miao XD, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0247-z; Patruno A, 2012, J CELL PHYSIOL, V227, P2767, DOI 10.1002/jcp.23024; Phillips J L, 2009, Pathophysiology, V16, P79, DOI 10.1016/j.pathophys.2008.11.005; Piatkowski J, 2009, MULT SCLER, V15, pS255; Piatkowski J, 2011, ALTERN THER HEALTH M, V17, P22; Reubold TF, 2012, CELL SIGNAL, V24, P1420, DOI 10.1016/j.cellsig.2012.03.007; Rihova B, 2011, J DRUG TARGET, V19, P890, DOI 10.3109/1061186X.2011.622403; Ruiz-Gomez MJ, 2009, ELECTROMAGN BIOL MED, V28, P201, DOI 10.1080/15368370802608696; Ruiz-Gomez MJ, 2002, BIOELECTROMAGNETICS, V23, P578, DOI 10.1002/bem.10054; Storch K, 2010, CANCER RES, V70, P3925, DOI 10.1158/0008-5472.CAN-09-3848; Tannock IF, 2001, CANCER METAST REV, V20, P123, DOI 10.1023/A:1013125027697; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tofani S, 2001, BIOELECTROMAGNETICS, V22, P419, DOI 10.1002/bem.69; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Walther M, 2007, ELECTROMAGN BIOL MED, V26, P179, DOI 10.1080/15368370701580814; Wen JA, 2011, BIOELECTROMAGNETICS, V32, P322, DOI 10.1002/bem.20646; Winker R, 2005, MUTAT RES-GEN TOX EN, V585, P43, DOI 10.1016/j.mrgentox.2005.04.013; Wolf FI, 2005, BBA-MOL CELL RES, V1743, P120, DOI 10.1016/j.bbamcr.2004.09.005; Yao CG, 2008, IEEE ENG MED BIO, P1044, DOI 10.1109/IEMBS.2008.4649338	45	30	33	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2016	11	12							e0167931	10.1371/journal.pone.0167931	http://dx.doi.org/10.1371/journal.pone.0167931			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8JY	27959944	Green Published, gold, Green Submitted			2023-01-03	WOS:000392753900024
J	Kaul, SC; Ishida, Y; Tamura, K; Wada, T; Iitsuka, T; Garg, S; Kim, M; Gao, R; Nakai, S; Okamoto, Y; Terao, K; Wadhwa, R				Kaul, Sunil C.; Ishida, Yoshiyuki; Tamura, Kazuya; Wada, Teruo; Iitsuka, Tomoko; Garg, Sukant; Kim, Mijung; Gao, Ran; Nakai, Shoichi; Okamoto, Youji; Terao, Keiji; Wadhwa, Renu			Novel Methods to Generate Active Ingredients-Enriched Ashwagandha Leaves and Extracts	PLOS ONE			English	Article							STUDYING CHEMOTYPE VARIATIONS; NF-KAPPA-B; WITHANIA-SOMNIFERA; NMR-SPECTROSCOPY; CANCER-CELLS; GAMMA-CYCLODEXTRIN; ALCOHOLIC EXTRACT; LEAF EXTRACT; WITHAFERIN; APOPTOSIS	Ashwagandha (Withania somnifera) is an Ayurvedic herb commonly used in world-renowned traditional Indian home medicine system. Roots of Ashwagandha have been traditionally known to possess a variety of therapeutic and health promoting potentials that have not been sufficiently supported by laboratory studies. Nevertheless, most, if not all, of the preventive and therapeutic potentials have been assigned to its bioactive components, steroidal alkaloids and lactones. In contrast to the traditional use of roots, we have been exploring bioactivities in leaves of Ashwagandha. Here, we report that the leaves possess higher content of active Withanolides, Withaferin-A (Wi-A) and Withanone (Wi-N), as compared to the roots. We also established, for the first time, hydroponic cultivation of Ashwagandha and investigated the effect of various cultivation conditions on the content of Wi-A and Wi-N by chemical analysis and bioassays. We report that the Withanone/Withaferin Arich leaves could be obtained by manipulating light condition during hydroponic cultivation. Furthermore, we recruited cyclodextrins to prepare extracts with desired ratio of Wi-N and Wi-A. Hydroponically grown Ashwagandha and its extracts with high ratio of withanolides are valuable for cancer treatment.	[Kaul, Sunil C.; Iitsuka, Tomoko; Garg, Sukant; Kim, Mijung; Gao, Ran; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, Drug Discovery & Assets Innovat Lab, DBT AIST Int Lab Adv Biomed DAILAB, Tsukuba, Ibaraki, Japan; [Ishida, Yoshiyuki; Terao, Keiji] CycloChem Co Ltd, Chuo Ku, 7-4-5 Minatojima Minamimachi, Kobe, Hyogo, Japan; [Tamura, Kazuya; Nakai, Shoichi] DAI DAN Co Ltd, 390 Kitanagai, Miyoshi, Saitama, Japan; [Wada, Teruo] Osaka Prefecture Univ, 1-1 Nakakugakuencho, Sakai, Osaka, Japan; [Garg, Sukant; Wadhwa, Renu] Univ Tsukuba, Sch Integrat & Global Majors, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan; [Okamoto, Youji] Zuiron Private Ltd, 2-3-1 Nakajyosanjimacho, Tokushima, Tokushima, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Osaka Metropolitan University; University of Tsukuba	Wadhwa, R (corresponding author), Natl Inst Adv Ind Sci & Technol, Drug Discovery & Assets Innovat Lab, DBT AIST Int Lab Adv Biomed DAILAB, Tsukuba, Ibaraki, Japan.; Wadhwa, R (corresponding author), Univ Tsukuba, Sch Integrat & Global Majors, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.	renu-wadhwa@aist.go.jp	Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192	AIST-Industrial Collaboration Funds	AIST-Industrial Collaboration Funds	The study was partly supported by AIST-Industrial Collaboration Funds. Dr. Yoshiyuki Ishida and Dr. Keiji Terao are research employees of CycloChem Co., Ltd. Mr. Kazuya Tamura and Mr. Shoichi Nakai are employees of DAI-DAN Co., Ltd. Dr. Youji Okamoto is an employee of Zuiron Private Ltd. These three commercial companies significantly contributed in the present study starting from conceptualization, investigation, analyses of the data to supervision. The specific roles of these authors are articulated in the 'author contributions' section.	Akihisa T, 2009, REGULATION OF PLANT, V44, P177; Bharti SK, 2011, MAGN RESON CHEM, V49, P659, DOI 10.1002/mrc.2817; Bhatia A, 2013, PHYTOCHEMISTRY, V93, P105, DOI 10.1016/j.phytochem.2013.03.013; Bhattacharya S K, 1997, Indian J Exp Biol, V35, P236; Dar PA, 2016, CURR PHARM DESIGN, V22, P535, DOI 10.2174/1381612822666151125001751; Das T, 2014, BIOCHEM PHARMACOL, V91, P31, DOI 10.1016/j.bcp.2014.06.022; Deocaris CC, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-14; Devi P. Uma, 1996, Indian Journal of Experimental Biology, V34, P927; Devi PU, 1996, INT J RADIAT BIOL, V69, P193, DOI 10.1080/095530096146020; Gao R, 2014, MOL CANCER THER, V13, P2930, DOI 10.1158/1535-7163.MCT-14-0324; Gautam A, 2016, MOL NEUROBIOL, V53, P1760, DOI 10.1007/s12035-015-9117-2; Gautam A, 2013, NEUROBIOL LEARN MEM, V106, P177, DOI 10.1016/j.nlm.2013.08.009; Grin B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039065; Ichikawa H, 2006, MOL CANCER THER, V5, P1434, DOI 10.1158/1535-7163.MCT-06-0096; Kalani A, 2012, BMJ CASE REP, V2012; Kamigauchi M, 2007, CHEM PHARM BULL, V55, P729, DOI 10.1248/cpb.55.729; Kataria H, 2016, MOL NEUROBIOL, V53, P4143, DOI 10.1007/s12035-015-9320-1; Kataria H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055316; Kataria H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037080; Kataria H, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep188; Khanna D, 2007, CURR OPIN PHARMACOL, V7, P344, DOI 10.1016/j.coph.2007.03.002; Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294; Konar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027265; Kuboyama T, 2014, BIOL PHARM BULL, V37, P892, DOI 10.1248/bpb.b14-00022; Lee J, 2015, MOL CARCINOGEN, V54, P417, DOI 10.1002/mc.22110; Lopez-Miranda S, 2016, FOOD CHEM, V203, P379, DOI 10.1016/j.foodchem.2016.02.100; Mandal C, 2008, APOPTOSIS, V13, P1450, DOI 10.1007/s10495-008-0271-0; Mantegna S, 2012, FOOD CHEM, V130, P746, DOI 10.1016/j.foodchem.2011.07.038; Miyoshi N, 2011, J NUTR BIOCHEM, V22, P1121, DOI 10.1016/j.jnutbio.2010.09.011; Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3; Murthy M. R. Ven, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P238; Namdeo AG, 2011, PLANTA MED, V77, P1958, DOI 10.1055/s-0031-1279997; Raghavan A, 2015, MOL NEUROBIOL, V52, P1093, DOI 10.1007/s12035-014-8907-2; Sangwan Neelam S, 2014, Recent Pat Biotechnol, V8, P25, DOI 10.2174/1872208307666131218125300; Shah N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120554; Shah N, 2009, CANCER SCI, V100, P1740, DOI 10.1111/j.1349-7006.2009.01236.x; Sidhu OP, 2011, PHYTOCHEM ANALYSIS, V22, P492, DOI 10.1002/pca.1307; Singh D, 2007, PHYTOTHER RES, V21, P905, DOI 10.1002/ptr.2180; Singh N, 2011, AFR J TRADIT COMPLEM, V8, P208, DOI 10.4314/ajtcam.v8i5S.9; Singh P, 2015, MOL BIOL INT, V2015, P1, DOI DOI 10.1080/02648725.2015.1020467; Sinha P, 2013, CANCER IMMUNOL IMMUN, V62, P1663, DOI 10.1007/s00262-013-1470-2; Stan SD, 2008, NUTR CANCER, V60, P51, DOI 10.1080/01635580802381477; Terao K, 2006, NUTR RES, V26, P503, DOI 10.1016/j.nutres.2006.08.004; Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938; Tohda C, 2000, NEUROREPORT, V11, P1981, DOI 10.1097/00001756-200006260-00035; Uchida R, 2015, INT J MOL SCI, V16, P10105, DOI 10.3390/ijms160510105; Vaishnavi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044419; Vyas AR, 2014, AAPS J, V16, P1, DOI 10.1208/s12248-013-9531-1; Wadhwa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077189; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Widodo N, 2007, CLIN CANCER RES, V13, P2298, DOI 10.1158/1078-0432.CCR-06-0948; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; Widodo N, 2009, J GERONTOL A-BIOL, V64, P1031, DOI 10.1093/gerona/glp088; Zhao J, 2002, CHEM PHARM BULL, V50, P760, DOI 10.1248/cpb.50.760	54	14	14	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0166945	10.1371/journal.pone.0166945	http://dx.doi.org/10.1371/journal.pone.0166945			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4PU	27936030	Green Submitted, Green Published, gold			2023-01-03	WOS:000389587100050
J	Akhter, S; Anwar, I; Akter, R; Kumkum, FA; Nisha, MK; Ashraf, F; Islam, F; Begum, N; Chowdhury, ME; Austin, A; Islam, SS; Rahman, A				Akhter, Sadika; Anwar, Iqbal; Akter, Rashida; Kumkum, Feroza Akhter; Nisha, Monjura Khatun; Ashraf, Fatema; Islam, Ferdousi; Begum, Nazneen; Chowdhury, Mahbub Elahi; Austin, Anne; Islam, Syed Shariful; Rahman, Aminur			Barriers to Timely and Safe Blood Transfusion for PPH Patients: Evidence from a Qualitative Study in Dhaka, Bangladesh	PLOS ONE			English	Article								Background and Objectives In Bangladesh, postpartum hemorrhage (PPH) is the leading cause of maternal mortality accounting for 31% of all blood transfusions in the country. Although safe blood transfusion is one of the 8 signal functions of Comprehensive Emergency Obstetric Care (CEmOC) strategy, most of the designated public sector CEmOC facilities do not have on-site blood storage system. Emergent blood is mainly available from external blood banks. As a result, emergent patients are to rely on an unregulated network of brokers for blood which may raise question about blood safety. This study explored lived experiences of patients' attendants, managers, providers, and blood brokers before and after the implementation of an on-line Blood Information and Management Application (BIMA) in regards to barriers and facilitators of blood transfusion for emergent patients. Methods Data were collected at Dhaka Medical College Hospital (DMCH), a tertiary-level teaching hospital before (January 2014) and after (March 2015) the introduction of an online BIMA system. Data collection methods included 24 key informant interviews (KIIs) and 40 in-depth interviews (IDIs). KIIs were conducted with formal health service providers, health managers and unlicensed blood brokers. IDIs were conducted with the relatives and husbands of women who suffered PPH, and needed emergency blood. Results Patients' attendants were unaware of patients' blood type and availability of blood in emergency situation. Newly introduced online BIMA system could facilitate blood transfusion process for poor patients at lower cost and during any time of day and night. However, service providers and service recipients were heavily dependent on a network of unlicensed blood brokers for required blood for emergent PPH patients. Blood collected through unlicensed blood brokers is un-screened, unregulated and probably unsafe. Blood brokers feel that they are providing a needed service, acknowledged a financial incentive and unaware about safety of blood that they supply. Conclusions Ensuring safe and timely blood transfusion is necessary to end preventable maternal mortality. In a context where facilities have no on-site blood, and both providers and patient attendants are heavily dependent on an unregulated cadre of unlicensed blood brokers, access to timely safe blood transfusion is seriously threatened. BIMA is a promising intervention to reduce inefficiencies in obtaining blood, but steps must be taken to ensure buy-in from current purveyors of blood, and to increase the acceptance of the intervention.	[Akhter, Sadika; Anwar, Iqbal; Akter, Rashida; Kumkum, Feroza Akhter; Chowdhury, Mahbub Elahi; Rahman, Aminur] Int Ctr Diarrhoeal & Dis Res Bangladesh Icddr B, Dhaka, Bangladesh; [Akhter, Sadika] Griffith Univ, Ctr Environm & Populat Hlth, Griffith, NSW, Australia; [Nisha, Monjura Khatun] Sydney Med Sch, Sch Publ Hlth, Sydney, NSW, Australia; [Ashraf, Fatema] Shaheed Suhrawardi Med Coll & Hosp, Dhaka, Bangladesh; [Islam, Ferdousi; Begum, Nazneen] Dhaka Med Coll & Hosp, Dhaka, Bangladesh; [Austin, Anne] JSI Res & Training Inst Inc, Boston, MA USA; [Islam, Syed Shariful] Bangabandhu Sheikh Mujib Med Univ, Dept Publ Hlth & Informat, Dhaka, Bangladesh; [Rahman, Aminur] Chulalongkorn Univ, Coll Publ Hlth Sci, Bangkok, Thailand	International Centre for Diarrhoeal Disease Research (ICDDR); Griffith University; University of Sydney; Dhaka Medical College; Bangabandhu Sheikh Mujib Medical University (BSMMU); Chulalongkorn University	Akhter, S (corresponding author), Int Ctr Diarrhoeal & Dis Res Bangladesh Icddr B, Dhaka, Bangladesh.; Akhter, S (corresponding author), Griffith Univ, Ctr Environm & Populat Hlth, Griffith, NSW, Australia.	sadika@icddrb.org	Rahman, Aminur/AAG-5391-2020	Rahman, Aminur/0000-0003-1434-3883	Maternal Health Task Force at the Harvard T. H. Chan School of Public Health from the Bill & Melinda Gates Foundation [01065000621]	Maternal Health Task Force at the Harvard T. H. Chan School of Public Health from the Bill & Melinda Gates Foundation	This project was made possible with support from the Maternal Health Task Force at the Harvard T. H. Chan School of Public Health through Grant# 01065000621 from the Bill & Melinda Gates Foundation.	Alam B, 2015, INT J GYNECOL OBSTET, V131, P63, DOI 10.1016/j.ijgo.2015.04.041; Alkema L, 2015, LANCET; Balki M, 2008, J OBSTET GYNAECOL CA, V30, P1002, DOI 10.1016/S1701-2163(16)32994-2; Bangladesh. Bangladesh Planning Commission. General Economics Division, 2014, MILL DEV GOALS PROGR; Bhuiya I, 1995, SITUATION BLOOD TEST; Boyatzis Richard E., 1998, TRANSFORMING QUALITA, DOI 10.1191/1478088706qp063oa; Hossain M, 1994, SOUV 13 SANDH CENTR; Miles M., 1984, ANAL DONNEES QUALITA; National Institute of Population Research and Training, 2012, BANGL MAT MORT HLTH; Rahman A, 2016, DIGITAL BLOOD MANAGE; Ryan G. W., 2003, FIELD METHOD, V15, P85, DOI DOI 10.1177/1525822X02239569; United Nations, 2016, 17 GOALS TRANSF WORL; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT	13	7	7	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2016	11	12							e0167399	10.1371/journal.pone.0167399	http://dx.doi.org/10.1371/journal.pone.0167399			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3TF	27911959	Green Submitted, gold, Green Published			2023-01-03	WOS:000389520600033
J	Sherr, CJ				Sherr, Charles J.			FOCUS ON RESEARCH A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sherr, Charles J.] St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA; [Sherr, Charles J.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Sherr, CJ (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.; Sherr, CJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206				Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293	5	23	23	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2016	375	20					1920	1923		10.1056/NEJMp1612343	http://dx.doi.org/10.1056/NEJMp1612343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EC1HS	27959598				2023-01-03	WOS:000387856100004
J	Li, J; Wu, MF; Lu, HW; Zhang, BZ; Wang, LJ; Lin, ZQ				Li, Jing; Wu, Miao-fang; Lu, Huai-wu; Zhang, Bing-zhong; Wang, Li-juan; Lin, Zhong-qiu			Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer	PLOS ONE			English	Article							FASTING BLOOD-GLUCOSE; BREAST-CANCER; DIABETES-MELLITUS; PATHOLOGICAL-RESPONSE; RADICAL HYSTERECTOMY; INSULIN-RECEPTORS; SURVIVAL; PROGNOSIS; CARCINOMA; TRANSPORTERS	Background The impact of hyperglycemia on survival of patients undergoing neoadjuvant chemotherapy (NACT) for bulky early stage cervical cancer (BESCC) has not been explored. Method Records of patients who received NACT and radical hysterectomy in our institution between January 2005 and June 2010 were reviewed. Results In total, 347 patients were included. The median follow-up time was 37 months (range: 4-65). Patients with hyperglycemia (fasting blood glucose >= 100 mg/dl) had shorter recurrence-free survival (RFS) (univariate hazard ratio [HR] = 1.95, 95% confidence interval [CI] [1.16, 3.28], P = 0.010) and cancer-specific survival (CSS) (univariate HR = 2.24, 95% CI [1.33, 3.78], P = 0.002) compared with those with euglycemia (fasting blood glucose < 100 mg/dl). In multivariate analysis, positive surgical margins, parametrium invasion, node metastasis, hyperglycemia and complete response to NACT independently predicted recurrence and cancer-specific death. To further validate the prognostic value of hyperglycemia, we conducted a subgroup analysis based on patient baseline characteristics and prognostic effect of hyperglycemia remained significant in all subgroups. On multivariable logistic regression analysis, euglycemia before NACT, squamous cell tumor and pre-treatment squamous cell carcinoma antigen levels < 3.5ng/ml were identified as independent predictors of complete response after NACT. Conclusions FBG >= 100 mg/dl is a negative prognostic predictor for cervical cancer patients receiving NACT for BESCC. Patients with hyperglycemia are less likely to achieve complete response after NACT. Our findings underscore the clinical utility of hyperglycemia screening of for cervical cancer patients.	[Li, Jing; Wu, Miao-fang; Lu, Huai-wu; Zhang, Bing-zhong; Wang, Li-juan; Lin, Zhong-qiu] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Gynecol Oncol, Guangzhou, Guangdong, Peoples R China; [Li, Jing] Sun Yat Sen Univ, Team Based Learning Grp Clin Study, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Wang, LJ; Lin, ZQ (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Gynecol Oncol, Guangzhou, Guangdong, Peoples R China.	wanglijuan_sysu@sina.com; zhongqiu_lin@163.com		Li, Jing/0000-0002-9609-5846; Li, Jing/0000-0003-1361-7790				Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS55, DOI 10.2337/dc08-S055; Anonymous, 2007, Zhonghua Xinxueguanbing Zazhi, V35, P390; Belfiore A, 1996, ANN NY ACAD SCI, V784, P173, DOI 10.1111/j.1749-6632.1996.tb16235.x; Boronow RC, 2000, GYNECOL ONCOL, V78, P313, DOI 10.1006/gyno.2000.5911; Brunello A, 2011, AM J CLIN ONCOL-CANC, V34, P292, DOI 10.1097/COC.0b013e3181e1d0c0; Buda A, 2015, INT J GYNECOL CANCER, V25, P1468, DOI 10.1097/IGC.0000000000000515; Cai Q, 2013, BRIT J CANCER, V108, P380, DOI 10.1038/bjc.2012.566; Choi JI, 2015, GYNECOL ONCOL, V139, P319, DOI 10.1016/j.ygyno.2015.09.004; Chu CK, 2010, ANN SURG ONCOL, V17, P502, DOI 10.1245/s10434-009-0789-6; Coyle C, 2016, ANN ONCOL, V27, P2184, DOI 10.1093/annonc/mdw410; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Erickson K, 2011, J CLIN ONCOL, V29, P54, DOI 10.1200/JCO.2010.29.3183; Frumovitz M, 2005, J CLIN ONCOL, V23, P7428, DOI 10.1200/JCO.2004.00.3996; Gadducci A, 2013, GYNECOL ONCOL, V131, P640, DOI 10.1016/j.ygyno.2013.09.029; Gadducci A, 2016, CRIT REV ONCOL HEMAT, V105, P73, DOI 10.1016/j.critrevonc.2016.06.006; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Goss PE, 2014, LANCET ONCOL, V15, P489, DOI 10.1016/S1470-2045(14)70029-4; HACKER NF, 1995, INT J GYNECOL CANCER, V5, P250, DOI 10.1046/j.1525-1438.1995.05040250.x; Hu T, 2012, EUR J CANCER, V48, P2353, DOI 10.1016/j.ejca.2012.03.015; Kiderlen M, 2013, ANN ONCOL, V24, P3011, DOI 10.1093/annonc/mdt367; Koh WJ, 2015, J NATL COMPR CANC NE, V13, P395, DOI 10.6004/jnccn.2015.0055; Kupets R, 2002, GYNECOL ONCOL, V87, P163, DOI 10.1006/gyno.2002.6815; Lamkin DM, 2009, CANCER-AM CANCER SOC, V115, P1021, DOI 10.1002/cncr.24126; Lee YY, 2010, GYNECOL ONCOL, V116, P459, DOI 10.1016/j.ygyno.2009.11.016; Li X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122361; Luo JH, 2012, LUNG CANCER, V76, P242, DOI 10.1016/j.lungcan.2011.10.019; Mathieu MC, 1997, P ASSOC AM PHYSICIAN, V109, P565; Medina RA, 2002, BIOL RES, V35, P9, DOI 10.4067/S0716-97602002000100004; Meyerkardt JA, 2003, J CLIN ONCOL, V21, P433, DOI 10.1200/JCO.2003.07.125; Tieu MT, 2015, J NEURO-ONCOL, V124, P119, DOI 10.1007/s11060-015-1815-0; Mueckler M, 2013, MOL ASPECTS MED, V34, P121, DOI 10.1016/j.mam.2012.07.001; Papa V, 1996, J ENDOCRINOL INVEST, V19, P324, DOI 10.1007/BF03347871; Ryu HS, 2007, INT J GYNECOL CANCER, V17, P132, DOI 10.1111/j.1525-1438.2007.00803.x; Ryu TY, 2014, DIABETES METAB J, V38, P330, DOI 10.4093/dmj.2014.38.5.330; Satariano WA, 1992, J GERONTOLOGY, V47; Nomelini RS, 2011, CLIN MED INSIGHTS-ON, V5, P77, DOI 10.4137/CMO.S6916; Sonabend RY, 2009, J PEDIATR-US, V155, P73, DOI 10.1016/j.jpeds.2009.01.072; Srokowski TP, 2009, J CLIN ONCOL, V27, P2170, DOI 10.1200/JCO.2008.17.5935; Takatori E, 2015, INT J CLIN ONCOL, V20, P345, DOI 10.1007/s10147-014-0702-6; Tseng CH, 2016, ONCOTARGET, DOI 10.18632/oncotarget.8399; Tseng CH, 2015, DIABETES-METAB RES, V31, P619, DOI 10.1002/dmrr.2649; Uma S, 2013, J OBSTET GYN INDIA, V63, P273, DOI 10.1007/s13224-012-0342-6; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ye Q, 2013, J CANCER RES CLIN, V139, P1887, DOI 10.1007/s00432-013-1509-y; Zhao YB, 2012, ASIAN PAC J CANCER P, V13, P1487, DOI 10.7314/APJCP.2012.13.4.1487	45	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2016	11	11							e0166612	10.1371/journal.pone.0166612	http://dx.doi.org/10.1371/journal.pone.0166612			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC1ZU	27851819	Green Submitted, Green Published, gold			2023-01-03	WOS:000387909300073
J	Gupta, S; Chaudhary, K; Dhanda, SK; Kumar, R; Kumar, S; Sehgal, M; Nagpal, G; Raghava, GPS				Gupta, Sudheer; Chaudhary, Kumardeep; Dhanda, Sandeep Kumar; Kumar, Rahul; Kumar, Shailesh; Sehgal, Manika; Nagpal, Gandharva; Raghava, Gajendra P. S.			A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer	PLOS ONE			English	Article							T-CELL EPITOPES; IN-SILICO PREDICTION; HLA-DR; C-KIT; IDENTIFICATION; PEPTIDES; ANTIGENS; MELANOMA; LIGANDS; MOUSE	Due to advancement in sequencing technology, genomes of thousands of cancer tissues or cell-lines have been sequenced. Identification of cancer-specific epitopes or neoepitopes from cancer genomes is one of the major challenges in the field of immunotherapy or vaccine development. This paper describes a platform Cancertope, developed for designing genome-based immunotherapy or vaccine against a cancer cell. Broadly, the integrated resources on this platform are apportioned into three precise sections. First section explains a cancer-specific database of neoepitopes generated from genome of 905 cancer cell lines. This database harbors wide range of epitopes (e.g., B-cell, CD8(+) T-cell, HLA class I, HLA class II) against 60 cancer-specific vaccine antigens. Second section describes a partially personalized module developed for predicting potential neoepitopes against a user-specific cancer genome. Finally, we describe a fully personalized module developed for identification of neoepitopes from genomes of cancerous and healthy cells of a cancer-patient. In order to assist the scientific community, wide range of tools are incorporated in this platform that includes screening of epitopes against human reference proteome (http://vvvvw.imtech. res.inkaghavaibancertope/).	[Gupta, Sudheer; Chaudhary, Kumardeep; Dhanda, Sandeep Kumar; Kumar, Rahul; Kumar, Shailesh; Sehgal, Manika; Nagpal, Gandharva; Raghava, Gajendra P. S.] CSIR Inst Microbial Technol, Bioinformat Ctr, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Raghava, GPS (corresponding author), CSIR Inst Microbial Technol, Bioinformat Ctr, Chandigarh 160036, India.	raghava@imtech.res.in	kumar, rahul/GZG-2171-2022; Raghava, Gajendra/B-1717-2009; Kumar, Rahul/ABB-3530-2020; Raghava, Gajendra P.S./AAA-2413-2022; Dhanda, Sandeep Kumar/J-8471-2016; Chaudhary, Kumardeep/Q-9740-2018	Raghava, Gajendra P.S./0000-0002-8902-2876; Dhanda, Sandeep Kumar/0000-0003-1381-7434; Chaudhary, Kumardeep/0000-0002-4117-6403; Kumar, Rahul/0000-0002-6927-5390; Kumar, Shailesh/0000-0002-1872-9903; Gupta, Sudheer/0000-0002-6836-6696	project Open Source Drug Discovery (OSDD); GENESIS [BSC0121]	project Open Source Drug Discovery (OSDD); GENESIS	Authors are thankful to project Open Source Drug Discovery (OSDD) and GENESIS BSC0121.	Ansari Hifzur Rahman, 2010, Immunome Res, V6, P6, DOI 10.1186/1745-7580-6-6; Ashman LK, 2013, EXPERT OPIN INV DRUG, V22, P103, DOI 10.1517/13543784.2013.740010; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bergot Anne-Sophie, 2011, Cancers (Basel), V3, P3461, DOI 10.3390/cancers3033461; Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005; Bhasin M, 2007, J BIOSCIENCES, V32, P31, DOI 10.1007/s12038-007-0004-5; Bodey B, 2000, ANTICANCER RES, V20, P2665; Brossart P, 1999, BLOOD, V93, P4309, DOI 10.1182/blood.V93.12.4309.412k19_4309_4317; Brown SD, 2014, GENOME RES, V24, P743, DOI 10.1101/gr.165985.113; Cai A, 2012, CLIN CANCER RES, V18, P5761, DOI 10.1158/1078-0432.CCR-12-1182; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Dhanda SK, 2016, BRIEF BIOINFORM; Emens LA, 2008, EXPERT OPIN EMERG DR, V13, P295, DOI [10.1517/14728214.13.2.295, 10.1517/14728214.13.2.295 ]; Fidler IJ, 2012, HUM VACC IMMUNOTHER, V8, P1141, DOI 10.4161/hv.19643; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Fisk B, 1997, INT J ONCOL, V10, P159; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y; Kato M, 2004, CANCER RES, V64, P801, DOI 10.1158/0008-5472.CAN-03-2532; Khalili JS, 2012, ONCOIMMUNOLOGY, V1, P1281, DOI 10.4161/onci.21511; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Kwak LW, 2011, CANCER PREV RES, V4, P954, DOI 10.1158/1940-6207.CAPR-11-0236; Lata Sneh, 2009, BMC Res Notes, V2, P61, DOI 10.1186/1756-0500-2-61; Li J, 2010, HUM MUTAT, V31, P219, DOI 10.1002/humu.21176; Lin HH, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S12-S22; Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202; Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092; Morrow MP, 2013, EXPERT REV VACCINES, V12, P271, DOI [10.1586/ERV.13.23, 10.1586/erv.13.23]; Mustafa AS, 2011, CLIN VACCINE IMMUNOL, V18, P1752, DOI 10.1128/CVI.05260-11; Mustafa AS, 2006, TUBERCULOSIS, V86, P115, DOI 10.1016/j.tube.2005.05.001; Nielsen M, 2010, IMMUNOLOGY, V130, P319, DOI 10.1111/j.1365-2567.2010.03268.x; Rajasagi M, 2014, BLOOD, V124, P453, DOI 10.1182/blood-2014-04-567933; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Roider J, 2014, IMMUNOLOGY, V143, P193, DOI 10.1111/imm.12301; Saha S, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-79; Saha Sudipto, 2007, V409, P387, DOI 10.1007/978-1-60327-118-9_29; Schirle M, 2000, EUR J IMMUNOL, V30, P2216, DOI 10.1002/1521-4141(2000)30:18<2216::AID-IMMU2216>3.3.CO;2-F; Schuler Mathias M., 2007, V409, P75; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108; Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236; Somasundaram R, 2006, CANCER RES, V66, P3287, DOI 10.1158/0008-5472.CAN-05-1932; Sweredoski MJ, 2009, PROTEIN ENG DES SEL, V22, P113, DOI 10.1093/protein/gzn075; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Warren RL, 2010, HUM IMMUNOL, V71, P245, DOI 10.1016/j.humimm.2009.12.007; Yamada T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078389; Zhang LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030483; Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254	50	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2016	11	11							e0166372	10.1371/journal.pone.0166372	http://dx.doi.org/10.1371/journal.pone.0166372			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9ON	27832200	Green Submitted, Green Published, gold			2023-01-03	WOS:000387725000113
J	Perez, LM; Inzitari, M; Quinn, TJ; Montaner, J; Gavalda, R; Duarte, E; Coll-Planas, L; Cerda, M; Santaeugenia, S; Closa, C; Gallofre, M				Perez, Laura M.; Inzitari, Marco; Quinn, Terence J.; Montaner, Joan; Gavalda, Ricard; Duarte, Esther; Coll-Planas, Laura; Cerda, Merce; Santaeugenia, Sebastia; Closa, Conxita; Gallofre, Miguel			Rehabilitation Profiles of Older Adult Stroke Survivors Admitted to Intermediate Care Units: A Multi-Centre Study	PLOS ONE			English	Article							FUNCTIONAL OUTCOMES; DISCHARGE; PREDICTOR; RECOVERY; SCALE; DESTINATION; POPULATION; VALIDATION; DISABILITY; ADMISSION	Background Stroke is a major cause of disability in older adults, but the evidence around post-acute treatment is limited and heterogeneous. We aimed to identify profiles of older adult stroke survivors admitted to intermediate care geriatric rehabilitation units. Methods We performed a cohort study, enrolling stroke survivors aged 65 years or older, admitted to 9 intermediate care units in Catalonia-Spain. To identify potential profiles, we included age, caregiver presence, comorbidity, pre-stroke and post-stroke disability, cognitive impairment and stroke severity in a cluster analysis. We also proposed a practical decision tree for patient's classification in clinical practice. We analyzed differences between profiles in functional improvement (Barthel index), relative functional gain (Montebello index), length of hospital stay (LOS), rehabilitation efficiency (functional improvement by LOS), and new institutionalization using multivariable regression models (for continuous and dichotomous outcomes). Results Among 384 patients (79.1 +/- 7.9 years, 50.8% women), we identified 3 complexity profiles: a) Lower Complexity with Caregiver (LCC), b) Moderate Complexity without Caregiver (MCN), and c) Higher Complexity with Caregiver (HCC). The decision tree showed high agreement with cluster analysis (96.6%). Using either linear (continuous outcomes) or logistic regression, both LCC and MCN, compared to HCC, showed statistically significant higher chances of functional improvement (OR = 4.68, 95% Cl= 2.54-8.63 and OR = 3.0, 95%Cl = 1.52-5.87, respectively, for Barthel index improvement >= 20), relative functional gain (OR = 4.41, 95%Cl = 1.81-10.75 and OR = 3.45, 95%Cl= 1.31-9.04, respectively, for top Vs lower tertiles), and rehabilitation efficiency (OR = 7.88, 95%Cl= 3.65-17.03 and OR = 3.87, 95%Cl= 1.69-8.89, respectively, for top Vs lower tertiles). In relation to LOS, MCN cluster had lower chance of shorter LOS than LCC (OR = 0.41, 95%Cl= 0.23-0.75) and HCC (OR = 0.37, 95)%Cl= 0.19-0.73), for LOS lower Vs higher tertiles. Conclusion Our data suggest that post-stroke rehabilitation profiles could be identified using routine assessment tools and showed differential recovery. If confirmed, these findings might help to develop tailored interventions to optimize recovery of older stroke patients.	[Perez, Laura M.; Inzitari, Marco] Hosp Parc Sanitari Pere Virgili, Convalescence & Rehabil Unit, Barcelona, Spain; [Perez, Laura M.; Inzitari, Marco; Santaeugenia, Sebastia] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain; [Quinn, Terence J.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Montaner, Joan] Vall DHebron Hosp, Dept Neurol, Neurovasc Res Lab VHIR, Barcelona, Spain; [Gavalda, Ricard] Univ Politecn Cataluna, Dept Comp Sci, Barcelona, Spain; [Duarte, Esther] Parc Salut Mar, Phys Med & Rehabil Dept, Barcelona, Spain; [Coll-Planas, Laura] Univ Autonoma Barcelona, Fundacio Salut & Envillement, Barcelona, Spain; [Cerda, Merce] Govt Catalonia, Catalan Healthcare Serv, Barcelona, Spain; [Santaeugenia, Sebastia] Badalona Serv Assistencials, Dept Geriatr Med & Palliat Care, Badalona, Spain; [Closa, Conxita] Corp Fisiogest, Rehabil Dept, Barcelona, Spain; [Gallofre, Miguel] Govt Catalonia, Dept Hlth, Malaltia Vasc Cerebral, Barcelona, Spain	Autonomous University of Barcelona; University of Glasgow; Hospital Universitari Vall d'Hebron; Universitat Politecnica de Catalunya; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona	Perez, LM (corresponding author), Hosp Parc Sanitari Pere Virgili, Convalescence & Rehabil Unit, Barcelona, Spain.; Perez, LM (corresponding author), Univ Autonoma Barcelona, Dept Med, Barcelona, Spain.	lperez@perevirgili.catsalut.net	Duarte, Esther/L-9771-2017; Montaner, Joan/D-3063-2015; Inzitari, Marco/ABC-1529-2021; Quinn, Terence Joseph/H-7000-2019; coll planas, laura/ABC-4362-2021	Duarte, Esther/0000-0002-4058-1802; Montaner, Joan/0000-0003-4845-2279; Quinn, Terence Joseph/0000-0003-1401-0181; Inzitari, Marco/0000-0002-3796-0625; Santaeugenia Gonzalez, Sebastia J/0000-0002-2725-4065; Perez, Laura Monica/0000-0003-3152-9882; Coll-Planas, Laura/0000-0001-5204-8717; Gavalda, Ricard/0000-0003-4736-7179	Generalitat de Catalunya; Stroke Association/Chief Scientist Office Senior Clinical Lecturer Fellowship; AGAUR (Agenda de Gestio d'Ajuts Universitaris i de Recerca) [SGR2014-890]; MINECO (Ministry of Economy and Competitiveness) project APCOM	Generalitat de Catalunya(Generalitat de Catalunya); Stroke Association/Chief Scientist Office Senior Clinical Lecturer Fellowship; AGAUR (Agenda de Gestio d'Ajuts Universitaris i de Recerca); MINECO (Ministry of Economy and Competitiveness) project APCOM	This study was partially funded by the Generalitat de Catalunya.-Dr. Quinn is supported by a joint Stroke Association/Chief Scientist Office Senior Clinical Lecturer Fellowship. The mathematical analysis was supported by the projects SGR2014-890 (MACDA) of AGAUR (Agenda de Gestio d'Ajuts Universitaris i de Recerca) and by MINECO (Ministry of Economy and Competitiveness) project APCOM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Rahim AH, 2015, STROKE, V46, P395, DOI 10.1161/STROKEAHA.114.006837; Armstrong JJ, 2012, ARCH PHYS MED REHAB, V93, P2198, DOI 10.1016/j.apmr.2012.05.026; Baztan JJ, 2009, GERONTOLOGY, V55, P269, DOI 10.1159/000193068; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brown AW, 2015, STROKE, V46, P1038, DOI 10.1161/STROKEAHA.114.007392; Buijck BI, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-443; Catalan Department of Health, 2006, PLA DIR SOC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Denti L, 2015, J STROKE CEREBROVASC, V24, P330, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.034; Dominguez R, 2006, MAYO CLIN PROC, V81, P476, DOI 10.4065/81.4.476; Drubach DA, 1994, J NEUROL REHABIL, V8, P92; Duarte E, 2010, REHAB, V44, P60, DOI [10.1016/j.rh.2009.10.001, DOI 10.1016/J.RH.2009.10.001]; Gagnon P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123626; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hall M., 2009, SIGKDD EXPLORATIONS, V11, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]; Heruti RJ, 2002, ARCH PHYS MED REHAB, V83, P742, DOI 10.1053/apmr.2002.32739; Koh GCH, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003483; Kwakkel G, 2011, STROKE, V42, P342, DOI 10.1161/STROKEAHA.110.599035; Langhorne P, 2001, STROKE, V32, P268, DOI 10.1161/01.STR.32.1.268; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Louie SWS, 2009, NEUROREHABILITATION, V25, P129, DOI 10.3233/NRE-2009-0508; Luengo-Fernandez R, 2013, STROKE, V44, P2854, DOI 10.1161/STROKEAHA.113.001584; Mahoney FI, 1965, MD STATE MED J, V14, P61; McLachlan G J, 1992, Stat Methods Med Res, V1, P27, DOI 10.1177/096228029200100103; Meyer MJ, 2015, DISABIL REHABIL, V37, P1316, DOI 10.3109/09638288.2014.963706; Perez LM, 2015, NEUROL SCI, V36, P1875, DOI 10.1007/s10072-015-2273-3; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Pinedo S, 2014, EUR J PHYS REHAB MED, V50, P323; Quinn TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; Sucharew H, 2013, STROKE, V44, P2182, DOI 10.1161/STROKEAHA.113.001255; Tanwir S, 2014, EUR J PHYS REHAB MED, V50, P355; Tinetti ME, 2014, MED CARE, V52, pS3, DOI 10.1097/MLR.0000000000000093; van Almenkerk S, 2013, DISABIL REHABIL, V35, P1774, DOI 10.3109/09638288.2012.756941; Young J, 2007, BMJ-BRIT MED J, V334, P86, DOI 10.1136/bmj.39059.456794.68	34	10	10	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2016	11	11							e0166304	10.1371/journal.pone.0166304	http://dx.doi.org/10.1371/journal.pone.0166304			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EB9OG	27829011	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000387724300105
J	Choo, EK; Feldstein, SW; Lovejoy, TI				Choo, Esther K.; Feldstein, Sarah W.; Lovejoy, Travis I.			Opioids Out, Cannabis In Negotiating the Unknowns in Patient Care for Chronic Pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Choo, Esther K.] Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, 3181 SW Sam Jackson Pk Rd,HRC 11D47, Portland, OR 97239 USA; [Feldstein, Sarah W.; Lovejoy, Travis I.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Lovejoy, Travis I.] VA Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	Choo, EK (corresponding author), Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, 3181 SW Sam Jackson Pk Rd,HRC 11D47, Portland, OR 97239 USA.	chooe@ohsu.edu		Choo, Esther/0000-0001-8847-5745	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA023658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K23DA031881] Funding Source: NIH RePORTER; Veterans Affairs [IK2HX001516] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA023658] Funding Source: Medline; NIDA NIH HHS [K23 DA031881] Funding Source: Medline; HSRD VA [IK2 HX001516] Funding Source: Medline; 3R01AA023658-02S1 Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Veterans Affairs(US Department of Veterans Affairs); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); HSRD VA; 3R01AA023658-02S1		[Anonymous], 2016, COMMUNICATION; Department of Health and Human Services, 2016, OP EP NUMB; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Hayes MJ, 2014, JAMA INTERN MED, V174, P1673, DOI 10.1001/jamainternmed.2014.2716; Powell D, 2015, DO MED MARIJUANA LAW; Rahn B, QUALIFYING CONDITION; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Ziemianski D, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0335-0	8	35	35	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2016	316	17					1763	1764		10.1001/jama.2016.13677	http://dx.doi.org/10.1001/jama.2016.13677			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EA4GP	27802551	Green Accepted			2023-01-03	WOS:000386569300011
J	Johansen, KL; Stistrup, RD; Schjott, CS; Madsen, J; Vinther, A				Johansen, Katrine Lyders; Stistrup, Rikke Derby; Schjott, Camilla Skibdal; Madsen, Jacqueline; Vinther, Anders			Absolute and Relative Reliability of the Timed 'Up & Go' Test and '30second Chair-Stand' Test in Hospitalised Patients with Stroke	PLOS ONE			English	Article							FUNCTIONAL MOBILITY; PERFORMANCE TESTS; MUSCLE STRENGTH; HIP FRACTURE; OLDER-PEOPLE; OSTEOARTHRITIS; ADULTS	Objective The timed 'Up & Go' test and '30second Chair-Stand' test are simple clinical outcome measures widely used to assess functional performance. The reliability of both tests in hospitalised stroke patients is unknown. The purpose was to investigate the relative and absolute reliability of both tests in patients admitted to an acute stroke unit. Methods Sixty-two patients (men, n = 41) attended two test sessions separated by a one hours rest. Intraclass correlation coefficients (ICC2,1) were calculated to assess relative reliability. Absolute reliability was expressed as Standard Error of Measurement (with 95% certainty-SEM95) and Smallest Real Difference (SRD) and as percentage of their respective means if heteroscedasticity was observed in Bland Altman plots (SEM95% and SRD%). Results ICC values for interrater reliability were 0.97 and 0.99 for the timed 'Up & Go' test and 0.88 and 0.94 for '30second Chair-Stand' test, respectively. ICC values for intrarater reliability were 0.95 and 0.96 for the timed 'Up & Go' test and 0.87 and 0.91 for '30second ChairStand' test, respectively. Heteroscedasticity was observed in the timed 'Up & Go' test. Interrater SEM95% ranged from 9.8% to 14.2% with corresponding SRD% of 13.9-20.1%. Intrarater SEM95% ranged from 15.8% to 18.7% with corresponding SRD% of 22.3-26.5%. For '30second Chair-Stand' test interrater SEM95 ranged between 1.5 and 1.9 repetitions with corresponding SRD of 2 and 3 and intrarater SEM95 ranged between 1.8 and 2.0 repetitions with corresponding SRD values of 3. Conclusion Excellent reliability was observed for the timed 'Up & Go' test and the '30second ChairStand' test in hospitalised stroke patients. The thresholds to detect a real change in performance were 18.7% for the timed 'Up & Go' test and 2.0 repetitions for the '30second Chair-Stand' in groups of patients and 26.5% and 3 repetitions in individual patients, respectively.	[Johansen, Katrine Lyders; Stistrup, Rikke Derby; Schjott, Camilla Skibdal; Madsen, Jacqueline; Vinther, Anders] Herlev Gentofte Hosp, Copenhagen Univ Hosp, Dept Rehabil, Herlev, Denmark	University of Copenhagen	Johansen, KL (corresponding author), Herlev Gentofte Hosp, Copenhagen Univ Hosp, Dept Rehabil, Herlev, Denmark.	katrine.lyders.johansen@regionh.dk			Danish Association of Physical Therapists	Danish Association of Physical Therapists	This work was supported by the Danish Association of Physical Therapists with a grant for AV [https://fysio.dk/fafo/fonde/danske-fysioterapeuters-fond-for-forskning-uddannelse-og-praksisudvikling/]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandre TS, 2012, BRAZ J PHYS THER, V16, P381, DOI 10.1590/S1413-35552012000500008; Blankevoort CG, 2013, PHYS THER, V93, P69, DOI 10.2522/ptj.20110164; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; Dobson F, 2012, OSTEOARTHR CARTILAGE, V20, P1548, DOI 10.1016/j.joca.2012.08.015; Faria CDCM, 2013, DISABIL REHABIL, V35, P146, DOI 10.3109/09638288.2012.690497; Faria CDCM, 2012, CLIN REHABIL, V26, P460, DOI 10.1177/0269215511423849; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Gill S, 2008, PHYSIOTHER RES INT, V13, P141, DOI 10.1002/pri.411; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hafsteinsdottir TB, 2014, TOP STROKE REHABIL, V21, P197, DOI 10.1310/tsr2103-197; Hesseberg K, 2015, PHYSIOTHER RES INT, V20, P37, DOI 10.1002/pri.1594; Hiengkaew V, 2012, ARCH PHYS MED REHAB, V93, P1201, DOI 10.1016/j.apmr.2012.01.014; Holm B, 2011, PM&R, V3, P117, DOI 10.1016/j.pmrj.2010.10.019; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028; Jorgensen MG, 2013, J GERONTOL A-BIOL, V68, P845, DOI 10.1093/gerona/gls222; Kottner J, 2011, J CLIN EPIDEMIOL, V64, P96, DOI 10.1016/j.jclinepi.2010.03.002; Kristensen MT, 2010, ARCH PHYS MED REHAB, V91, P885, DOI 10.1016/j.apmr.2010.01.021; Kristensen MT, 2008, J REHABIL MED, V40, P589, DOI 10.2340/16501977-0217; Kristensen MT, 2011, J AM GERIATR SOC, V59, P565, DOI 10.1111/j.1532-5415.2010.03293.x; Ng SSM, 2010, AM J PHYS MED REHAB, V89, P497, DOI 10.1097/PHM.0b013e3181d3e90a; Ng SS, 2005, ARCH PHYS MED REHAB, V86, P1641, DOI 10.1016/j.apmr.2005.01.011; Paquet N, 2009, DISABIL REHABIL, V31, P1267, DOI 10.1080/09638280802621374; Persson CU, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-83; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Portney LG., 2000, FDN CLIN RES APPL PR, V2, DOI DOI 10.1016/S0039-6257(02)00362-4; Rikli RE, 2001, HUMAN KINETICS; Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967; Silva PFS, 2014, BRAZ J PHYS THER, V18, P99, DOI 10.1590/S1413-35552012005000155; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5; Wright AA, 2011, J ORTHOP SPORT PHYS, V41, P319, DOI 10.2519/jospt.2011.3515	31	24	24	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2016	11	10							e0165663	10.1371/journal.pone.0165663	http://dx.doi.org/10.1371/journal.pone.0165663			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EA6BX	27798686	Green Published, gold, Green Submitted			2023-01-03	WOS:000386711100053
J	Nair, NP; Chalmers, L; Connolly, M; Bereznicki, BJ; Peterson, GM; Curtain, C; Castelino, RL; Bereznicki, LR				Nair, Nibu Parameswaran; Chalmers, Leanne; Connolly, Michael; Bereznicki, Bonnie J.; Peterson, Gregory M.; Curtain, Colin; Castelino, Ronald L.; Bereznicki, Luke R.			Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score)	PLOS ONE			English	Article							OLDER PATIENTS; ORTHOSTATIC HYPOTENSION; EMERGENCY-DEPARTMENT; MANAGING HYPERTENSION; COMBINATION THERAPY; RISK-FACTORS; ADMISSION; EVENTS; PREVALENCE; VALIDATION	Background Adverse drug reactions (ADRs) are the major cause of medication-related hospital admissions in older patients living in the community. This study aimed to develop and validate a score to predict ADR-related hospitalization in people aged >= 65 years. Methods ADR-related hospitalization and its risk factors were determined using a prospective, cross-sectional study in patients aged >= 65 years admitted to two hospitals. A predictive model was developed in the derivation cohort (n = 768) and the model was applied in the validation cohort (n = 240). ADR-related hospital admission was determined through expert consensus from comprehensive reviews of medical records and patient interviews. The causality and preventability of the ADR were assessed based on the Naranjo algorithm and modified Schumock and Thornton criteria, respectively. Results In the derivation sample (mean [+/-SD] age, 80.1+/-7.7 years), 115 (15%) patients were admitted due to a definite or probable ADR; 92.2% of these admissions were deemed preventable. The number of antihypertensives was the strongest predictor of an ADR followed by presence of dementia, renal failure, drug changes in the preceding 3 months and use of anticholinergic medications; these variables were used to derive the ADR prediction score. The predictive ability of the score, assessed from calculation of the area under the receiver operator characteristic (ROC) curve, was 0.70 (95% confidence interval (CI) 0.65-0.75). In the validation sample (mean [+/-SD] age, 79.6+/-7.6 years), 30 (12.5%) patients' admissions were related to definite or probable ADRs; 80% of these admissions were deemed preventable. The area under the ROC curve in this sample was 0.67 (95% CI 0.56-0.78). Conclusions This study proposes a practical and simple tool to identify elderly patients who are at an increased risk of preventable ADR-related hospital admission. Further refinement and testing of this tool is necessary to implement the score in clinical practice.	[Nair, Nibu Parameswaran; Chalmers, Leanne; Connolly, Michael; Bereznicki, Bonnie J.; Peterson, Gregory M.; Curtain, Colin; Castelino, Ronald L.; Bereznicki, Luke R.] Univ Tasmania, Sch Med, Fac Hlth, Unit Medicat Outcomes Res & Educ,Div Pharm, Hobart, Tas, Australia; [Connolly, Michael] Royal Hobart Hosp, Hobart, Tas, Australia	University of Tasmania; Royal Hobart Hospital	Nair, NP (corresponding author), Univ Tasmania, Sch Med, Fac Hlth, Unit Medicat Outcomes Res & Educ,Div Pharm, Hobart, Tas, Australia.		Nair, Nibu Parameswaran/F-3317-2017; Nair, Nibu Parameswaran/B-6347-2014	Nair, Nibu Parameswaran/0000-0002-0202-6453; Nair, Nibu Parameswaran/0000-0003-3503-8503; Chalmers, Leanne/0000-0002-2477-2190; Bereznicki, Bonnie/0000-0001-8463-4817				[Anonymous], 1968, TECHNICAL REPORT SER; [Anonymous], 2015, AUSTR MED HDB; Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Butt TF, 2010, J HUM HYPERTENS, V24, P514, DOI 10.1038/jhh.2009.116; Calderon-Ospina Carlos, 2010, Int J Pharm Pract, V18, P230, DOI 10.1111/j.2042-7174.2010.00039.x; Chan M, 2001, INTERN MED J, V31, P199, DOI 10.1046/j.1445-5994.2001.00044.x; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chen YC, 2014, EUR J INTERN MED, V25, P49, DOI 10.1016/j.ejim.2013.10.006; COCHRANE RA, 1992, BRIT MED J, V305, P694, DOI 10.1136/bmj.305.6855.694; Conforti A, 2012, DRUG HEALTHC PATIENT, V4, P75, DOI 10.2147/DHPS.S29287; Corsonello A, 2005, ARCH INTERN MED, V165, P790, DOI 10.1001/archinte.165.7.790; Cutler DM, 2010, NEW ENGL J MED, V362, P1553, DOI 10.1056/NEJMp1002305; Everett BM, 2008, CLIN THER, V30, P661, DOI 10.1016/j.clinthera.2008.04.013; FEINBERG M, 1993, DRUG AGING, V3, P335, DOI 10.2165/00002512-199303040-00004; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Franceschi M, 2008, DRUG SAFETY, V31, P545, DOI 10.2165/00002018-200831060-00009; Frank J, 2008, AM FAM PHYSICIAN, V77, P1279; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Gustafsson M, 2016, EUR J CLIN PHARM; Gustafsson M, 2016, EUR J CLIN PHARMACOL, V72, P1143, DOI 10.1007/s00228-016-2084-3; Hajjar Emily R, 2003, Am J Geriatr Pharmacother, V1, P82; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Hellden A, 2009, DRUG AGING, V26, P595, DOI 10.2165/11315790-000000000-00000; Hippisley-Cox J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003482; Jatau Abubakar Ibrahim, 2015, Drugs Real World Outcomes, V2, P387; Kaufmann CP, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006376; Laroche ML, 2013, PHARMACOEPIDEM DR S, V22, P952, DOI 10.1002/pds.3471; Lavan AH, 2016, THER ADV DRUG SAF, V7, P11, DOI 10.1177/2042098615615472; Lee KI, 1997, COMMUN STAT-SIMUL C, V26, P559, DOI 10.1080/03610919708813397; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lyon D, 2007, FAM PRACT, V24, P158, DOI 10.1093/fampra/cml069; MAHONEY F I, 1965, Md State Med J, V14, P61; Mannesse CK, 2000, AGE AGEING, V29, P35, DOI 10.1093/ageing/29.1.35; Marcum ZA, 2012, J AM GERIATR SOC, V60, P34, DOI 10.1111/j.1532-5415.2011.03772.x; May S, 2008, J MAN MANIP THER, V16, P155, DOI 10.1179/jmt.2008.16.3.155; METS TF, 1995, DRUG AGING, V6, P219, DOI 10.2165/00002512-199506030-00005; Min SY, 2010, CIRC-CARDIOVASC INTE, V3, P127, DOI 10.1161/CIRCINTERVENTIONS.109.890053; Muir SW, 2010, PHYS THER, V90, P338, DOI 10.2522/ptj.20090163; Mussi C, 2009, J GERONTOL A-BIOL, V64, P801, DOI 10.1093/gerona/glp028; Nair NP, 2016, CLIN INTERV AGING, V11, P497, DOI 10.2147/CIA.S99097; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Ness Jose, 2006, Am J Geriatr Pharmacother, V4, P42, DOI 10.1016/j.amjopharm.2006.03.008; O'Connor MN, 2012, AGE AGEING, V41, P771, DOI 10.1093/ageing/afs046; Olsen H, 1999, BLOOD PRESSURE, V8, P94; Onder G, 2002, J AM GERIATR SOC, V50, P1962, DOI 10.1046/j.1532-5415.2002.50607.x; Onder G, 2013, AGE AGEING, V42, P284, DOI 10.1093/ageing/aft038; Onder G, 2010, ARCH INTERN MED, V170, P1142, DOI 10.1001/archinternmed.2010.153; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Poon IO, 2005, J CLIN PHARM THER, V30, P173, DOI 10.1111/j.1365-2710.2005.00629.x; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; Reeve E, 2015, BRIT J CLIN PHARMACO, V80, P1254, DOI 10.1111/bcp.12732; Rende P, 2013, J PHARMACOL PHARMACO, V4, pS47, DOI 10.4103/0976-500X.120954; Salahudeen MS, 2015, J AM GERIATR SOC, V63, P85, DOI 10.1111/jgs.13206; Schumock G T, 1992, Hosp Pharm, V27, P538; Shelton P, 2000, AM J MANAG CARE, V6, P925; Tangiisuran B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111254; The Society of Hospital Pharmacists of Australia (SHPA), 2005, J PHARM PRACT RES, V35, P122; Tune LE, 2001, J CLIN PSYCHIAT, V62, P11; UpToDate, COMPR CLIN DAT; Wawruch M, 2009, ARCH GERONTOL GERIAT, V48, P186, DOI 10.1016/j.archger.2008.01.004; *WICC, 1998, ICPC 2 INT CLASS PRI; World Health Organization, 1969, TECHNICAL REPORT SER, V425; Wu C, 2012, DRUG SAFETY, V35, P769, DOI 10.2165/11599540-000000000-00000	67	38	38	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2016	11	10							e0165757	10.1371/journal.pone.0165757	http://dx.doi.org/10.1371/journal.pone.0165757			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EA6BX	27798708	Green Published, gold, Green Submitted			2023-01-03	WOS:000386711100062
J	Poder, TG; Pruneau, D; Dorval, J; Thibault, L; Fisette, JF; Bedard, SK; Jacques, A; Beauregard, P				Poder, Thomas G.; Pruneau, Denise; Dorval, Josee; Thibault, Louis; Fisette, Jean-Francois; Bedard, Suzanne K.; Jacques, Annie; Beauregard, Patrice			Pressure Infusion Cuff and Blood Warmer during Massive Transfusion: An Experimental Study About Hemolysis and Hypothermia	PLOS ONE			English	Article							MANAGEMENT; TEMPERATURE; HEMORRHAGE	Background Blood warmers were developed to reduce the risk of hypothermia associated with the infusion of cold blood products. During massive transfusion, these devices are used with compression sleeve, which induce a major stress to red blood cells. In this setting, the combination of blood warmer and compression sleeve could generate hemolysis and harm the patient. We conducted this study to compare the impact of different pressure rates on the hemolysis of packed red blood cells and on the outlet temperature when a blood warmer set at 41.5 degrees C is used. Methods Pressure rates tested were 150 and 300 mmHg. Ten packed red blood cells units were provided by He A ma-Que A bec and each unit was sequentially tested. Results We found no increase in hemolysis either at 150 or 300 mmHg. By cons, we found that the blood warmer was not effective at warming the red blood cells at the specified temperature. At 150 mmHg, the outlet temperature reached 37.1 degrees C and at 300 mmHg, the temperature was 33.7 degrees C. Conclusion To use a blood warmer set at 41.5 degrees C in conjunction with a compression sleeve at 150 or 300 mmHg does not generate hemolysis. At 300 mmHg a blood warmer set at 41.5 degrees C does not totally avoid a risk of hypothermia.	[Poder, Thomas G.; Fisette, Jean-Francois; Bedard, Suzanne K.] CIUSSS Estrie CHUS, UETMIS, Sherbrooke, PQ J1G 2E8, Canada; [Poder, Thomas G.] CIUSSS Estrie CHUS, CRCHUS, Sherbrooke, PQ J1H 5N4, Canada; [Pruneau, Denise; Dorval, Josee; Beauregard, Patrice] CIUSSS Estrie CHUS, Blood Bank, Sherbrooke, PQ J1H 5N4, Canada; [Thibault, Louis; Jacques, Annie] Hema Quebec, Div Res & Dev, Quebec City, PQ G1V 5C3, Canada; [Beauregard, Patrice] CIUSSS Estrie CHUS, Div Hematol Oncol, Sherbrooke, PQ J1H 5N4, Canada	Hema-Quebec	Poder, TG (corresponding author), CIUSSS Estrie CHUS, UETMIS, Sherbrooke, PQ J1G 2E8, Canada.; Poder, TG (corresponding author), CIUSSS Estrie CHUS, CRCHUS, Sherbrooke, PQ J1H 5N4, Canada.	tpoder.chus@sss.gouv.qc.ca		Poder, Thomas/0000-0001-7017-096X	operating budgets of the health technology assessment unit of the CHUS; Blood Bank of the CHUS; Hema-Quebec; FRQS	operating budgets of the health technology assessment unit of the CHUS; Blood Bank of the CHUS; Hema-Quebec; FRQS	This project was funded from the operating budgets of the health technology assessment unit of the CHUS, the Blood Bank of the CHUS and Hema-Quebec.; We acknowledge Flavien Nicolas Andrianary, Christian Bellemare, Sylvie Bergeron, Valerie Bertelle, Line Bilodeau, Lise L. Blais, Martine Comtois, Stephanie Dion, Renee Lafreniere, Helene Levesque, Genevieve Paquette, Monique Robillard, Daniel Sale Menard and Sylvie Thibault for their support and advice. We also acknowledge the personnel of the Blood Bank of the CHUS for their cooperation during the study. TGP is a member of the FRQS-funded Centre de recherche du CHUS (CRCHUS).	AABB, 2002, GUID US BLOOD WARM D; AABB, 2014, STANDARDS BLOOD BANK, p[215, 111], DOI [10.1016/s0887-7963(88)70036-x, DOI 10.1016/S0887-7963(88)70036-X]; Aslam AF, 2006, AM J MED, V119, P297, DOI 10.1016/j.amjmed.2005.09.062; BEAUREGARD P, 1994, TRANSFUS MED REV, V8, P184, DOI 10.1016/S0887-7963(94)70110-3; Ciavarella D, 1988, Transfus Med Rev, V2, P95, DOI 10.1016/S0887-7963(88)70036-X; Du Plessis J M, 1966, S Afr Med J, V40, P479; Hardy JF, 2004, CAN J ANAESTH, V51, P293, DOI 10.1007/BF03018233; Hayter MA, 2012, CAN J ANESTH, V59, P1130, DOI 10.1007/s12630-012-9795-4; Hess JR, 2009, TRANSFUSION, V49, P2599, DOI 10.1111/j.1537-2995.2009.02275.x; Kim HJ, 2016, CLIN HEMORHEOL MICRO, V62, P13, DOI 10.3233/CH-151926; Kim P, 2004, CAN J SURG, V47, P295; Lacroix J, 2011, TRANSFUS CLIN BIOL, V18, P97, DOI 10.1016/j.tracli.2011.02.020; LINKO K, 1979, ACTA ANAESTH SCAND, V23, P46, DOI 10.1111/j.1399-6576.1979.tb01420.x; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; MATEER JR, 1985, ANN EMERG MED, V14, P966, DOI 10.1016/S0196-0644(85)80238-9; Miller TE, 2013, PERIOPER MED, V2, DOI 10.1186/2047-0525-2-13; PAPPAS CG, 1995, CRIT CARE MED, V23, P1243, DOI 10.1097/00003246-199507000-00015; Perlman R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1271-z; Pisciotto PT., 2004, HDB PEDIAT TRANSFUSI, pP. 121, DOI [10.1016/B978-012348776-6/50014-5, DOI 10.1016/B978-012348776-6/50014-5]; Poder TG, 2015, TRANSFUS MED REV, V29, P172, DOI 10.1016/j.tmrv.2015.03.002; Ramakrishnan VT, 2014, INDIAN J ANAESTH, V58, P609, DOI 10.4103/0019-5049.144668; Refaai MA, 2013, BEST PRACT RES-CLIN, V27, P17, DOI 10.1016/j.bpa.2012.12.006; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Savage SA, 2015, J TRAUMA ACUTE CARE, V78, P224, DOI 10.1097/TA.0000000000000502; Smith CE, 2008, INT TRAUMACARE, V18, P71; Spinella PC, 2008, CRIT CARE MED, V36, pS340, DOI 10.1097/CCM.0b013e31817e2ef9; Unite d'evaluation des technologies et des modes d'intervention en sante du Centre hospitalier universitaire de Sherbrooke (UETMIS-CHUS), 2013, UN EV TECHN MOD INT, VXIV; VANDERWALT JH, 1978, BRIT J ANAESTH, V50, P815, DOI 10.1093/bja/50.8.815; WILLIAMSON JR, 1975, BLOOD, V46, P611	29	6	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2016	11	10							e0163429	10.1371/journal.pone.0163429	http://dx.doi.org/10.1371/journal.pone.0163429			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UR	27711116	Green Published, gold, Green Submitted			2023-01-03	WOS:000385697600024
J	Yang, YT; Tai, CJ; Chen, CF; Wu, HC; Mikhaylichenko, N; Chiu, HT; Chen, YY; Hsu, YHE				Yang, Ya-Ting; Tai, Cheng-Jeng; Chen, Chiehfeng; Wu, Hong-Cheng; Mikhaylichenko, Natalia; Chiu, Hsien-Tsai; Chen, Yun-Yi; Hsu, Yi-Hsin Elsa			Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review	PLOS ONE			English	Review							PHASE-II TRIAL; MATCHED-PAIR ANALYSIS; SINGLE-AGENT; OPEN-LABEL; CHEMOTHERAPY; SURVIVAL; GEMCITABINE	Background The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. Method The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL. Results Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia. Conclusion The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.	[Yang, Ya-Ting; Chen, Yun-Yi] Natl Taiwan Univ, Inst Hlth Policy & Management, 17 Xu Zhou Rd, Taipei 100, Taiwan; [Yang, Ya-Ting; Chiu, Hsien-Tsai; Chen, Yun-Yi; Hsu, Yi-Hsin Elsa] Golden Dream Think Tank & Res Ctr, 17 Songjiang Rd, Taipei 104, Taiwan; [Yang, Ya-Ting; Hsu, Yi-Hsin Elsa] Taipei Med Univ, Sch Hlth Care Adm, 250 Wuxing St, Taipei, Taiwan; [Tai, Cheng-Jeng; Wu, Hong-Cheng] Taipei Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, 252 Wuxing St, Taipei 110, Taiwan; [Tai, Cheng-Jeng] Taipei Med Univ, Sch Med, Dept Internal Med, Coll Med, 250 Wuxing St, Taipei 110, Taiwan; [Chen, Chiehfeng] Taipei Med Univ, Ctr Evidence Based Med, 250 Wuxing St, Taipei 110, Taiwan; [Chen, Chiehfeng] Taipei Med Univ, Sch Med, Dept Publ Hlth, Coll Med, 250 Wuxing St, Taipei 110, Taiwan; [Chen, Chiehfeng] Taipei Med Univ, Wan Fang Hosp, Div Plast Surg, Dept Surg, 111,Sect 3,Hsing Long Rd, Taipei 116, Taiwan; [Chen, Chiehfeng] Taipei Med Univ, Wan Fang Hosp, Evidence Based Med Ctr, 111,Sect 3,Hsing Long Rd, Taipei 116, Taiwan; [Mikhaylichenko, Natalia] Nevron, Int Med Ctr, Vladivostok, Russia; [Chiu, Hsien-Tsai] China Med Univ, Dept Publ Hlth, 91 Hsueh Shih Rd, Taichung 404, Taiwan	National Taiwan University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital; China Medical University Taiwan	Hsu, YHE (corresponding author), Golden Dream Think Tank & Res Ctr, 17 Songjiang Rd, Taipei 104, Taiwan.; Hsu, YHE (corresponding author), Taipei Med Univ, Sch Hlth Care Adm, 250 Wuxing St, Taipei, Taiwan.	elsahsu@tmu.edu.tw		Chen, Chiehfeng/0000-0002-1595-6553; Chen, Yun-Yi/0000-0002-5343-4887	"Golden Dream Project" launched by TaiShang Resources International Group in Taiwan	"Golden Dream Project" launched by TaiShang Resources International Group in Taiwan	This study was supported by grants from "Golden Dream Project" launched by TaiShang Resources International Group in Taiwan. The funding body does not play roles in study design, interpretation of data and the manuscript drafting.	Abouyabis AN, 2011, ISRN HEMATOL, V2011, P623924; Bachy E, 2014, BLOOD, V123, P3059, DOI 10.1182/blood-2014-04-565267; Chan WC, 1997, BLOOD, V89, P3909; Cheah Chan Yoon, 2015, Am Soc Clin Oncol Educ Book, pe468, DOI 10.14694/EdBook_AM.2015.35.e468; Coiffier B, 2014, CANCER TREAT REV, V40, P1080, DOI 10.1016/j.ctrv.2014.08.001; Coiffier B, 2012, J CLIN ONCOL, V30, P631, DOI 10.1200/JCO.2011.37.4223; d'Amore F, 2010, BRIT J HAEMATOL, V150, P565, DOI 10.1111/j.1365-2141.2010.08298.x; Damaj G, 2013, J CLIN ONCOL, V31, P104, DOI 10.1200/JCO.2012.43.7285; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Enblad G, 2004, BLOOD, V103, P2920, DOI 10.1182/blood-2003-10-3389; Foerster R, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-335; Foss F, 2015, BRIT J HAEMATOL, V168, P811, DOI 10.1111/bjh.13222; Foss F, 2011, NAT REV CLIN ONCOL, V8, P321, DOI 10.1038/nrclinonc.2011.51; Goldberg JD, 2012, LEUKEMIA LYMPHOMA, V53, P1124, DOI 10.3109/10428194.2011.645818; HARRIS NL, 1994, BLOOD, V84, P1361; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Horwitz SM, 2014, BLOOD, V123, P3095, DOI 10.1182/blood-2013-12-542142; Huang CL, 2002, LEUKEMIA LYMPHOMA, V43, P1415, DOI 10.1080/1042819022386806; Karlin L, 2014, SEMIN HEMATOL, V51, P25, DOI 10.1053/j.seminhematol.2013.11.001; Kim SJ, 2012, INVEST NEW DRUG, V30, P368, DOI 10.1007/s10637-010-9523-2; Koch E, 2013, LEUKEMIA LYMPHOMA, V54, P2448, DOI 10.3109/10428194.2013.779688; Lunning MA, 2013, CURR TREAT OPTION ON, V14, P212, DOI 10.1007/s11864-013-0232-x; Mak V, 2013, J CLIN ONCOL, V31, P1970, DOI 10.1200/JCO.2012.44.7524; Moga C., 2012, IHE PUBL; Morgensztern D, 2011, LEUKEMIA LYMPHOMA, V52, P194, DOI 10.3109/10428194.2010.542596; Morschhauser F, 2013, EUR J CANCER, V49, P2869, DOI 10.1016/j.ejca.2013.04.029; NCCN, 2020, ANT; O'Connor OA, 2011, J CLIN ONCOL, V29, P1182, DOI 10.1200/JCO.2010.29.9024; Pro B, 2012, J CLIN ONCOL, V30, P2190, DOI 10.1200/JCO.2011.38.0402; Rades D, 2010, J CLIN ONCOL, V28, P3597, DOI 10.1200/JCO.2010.28.5635; Raghupathi W, 2014, HEALTH INF SCI SYST, V2, DOI 10.1186/2047-2501-2-3; Reddy NM, 2014, SEMIN HEMATOL, V51, P17, DOI 10.1053/j.seminhematol.2013.11.006; Sterne JAC., 2014, COCHRANE RISK BIAS A; VELASQUEZ WS, 1994, J CLIN ONCOL, V12, P1169, DOI 10.1200/JCO.1994.12.6.1169; VELASQUEZ WS, 1988, BLOOD, V71, P117; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Vose JM, 2008, HEMATOL ONCOL CLIN N, V22, P997, DOI 10.1016/j.hoc.2008.07.010; Zelenetz AD, 2003, ANN ONCOL, V14, P5, DOI 10.1093/annonc/mdg702; Zinzani PL, 2010, ANN ONCOL, V21, P860, DOI 10.1093/annonc/mdp508; Zinzani PL, 2000, J CLIN ONCOL, V18, P2603, DOI 10.1200/JCO.2000.18.13.2603	40	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2016	11	10							e0161811	10.1371/journal.pone.0161811	http://dx.doi.org/10.1371/journal.pone.0161811			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UR	27711130	Green Published, gold, Green Submitted			2023-01-03	WOS:000385697600004
J	Kepreotes, E; Whitehead, B; Attia, J; Oldmeadow, C; Collison, A; Searles, A; Goddard, B; Hilton, J; Lee, M; Mattes, J				Kepreotes, Elizabeth; Whitehead, Bruce; Attia, John; Oldmeadow, Christopher; Collison, Adam; Searles, Andrew; Goddard, Bernadette; Hilton, Jodi; Lee, Mark; Mattes, Joerg			High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial	LANCET			English	Article							POSITIVE AIRWAY PRESSURE; PRETERM INFANTS; THERAPY	Background Bronchiolitis is the most common lung infection in infants and treatment focuses on management of respiratory distress and hypoxia. High-flow warm humidified oxygen (HFWHO) is increasingly used, but has not been rigorously studied in randomised trials. We aimed to examine whether HFWHO provided enhanced respiratory support, thereby shortening time to weaning off oxygen. Methods In this open, phase 4, randomised controlled trial, we recruited children aged less than 24 months with moderate bronchiolitis attending the emergency department of the John Hunter Hospital or the medical unit of the John Hunter Children's Hospital in New South Wales, Australia. Patients were randomly allocated (1:1) via opaque sealed envelopes to HFWHO (maximum flow of 1 L/kg per min to a limit of 20 L/min using 1:1 air-oxygen ratio, resulting in a maximum FiO(2) of 0.6) or standard therapy (cold wall oxygen 100% via infant nasal cannulae at low flow to a maximum of 2 L/min) using a block size of four and stratifying for gestational age at birth. The primary outcome was time from randomisation to last use of oxygen therapy. All randomised children were included in the primary and secondary safety analyses. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12612000685819. Findings From July 16, 2012, to May 1, 2015, we randomly assigned 202 children to either HFWHO (101 children) or standard therapy (101 children). Median time to weaning was 24 h (95% CI 18-28) for standard therapy and 20 h (95% CI 17-34) for HFWHO (hazard ratio [HR] for difference in survival distributions 0.9 [95% CI 0.7-1.2]; log rank p=0.61). Fewer children experienced treatment failure on HFWHO (14 [14%]) compared with standard therapy (33 [33%]; p=0.0016); of these children, those on HFWHO were supported for longer than were those on standard therapy before treatment failure (HR 0.3; 95% CI 0.2-0.6; p<0.0001). 20 (61%) of 33 children who experienced treatment failure on standard therapy were rescued with HFWHO. 12 (12%) of children on standard therapy required transfer to the intensive care unit compared with 14 (14%) of those on HFWHO (difference -1%; 95% CI-7 to 16; p=0.41). Four adverse events occurred (oxygen desaturation and condensation inhalation in the HFWHO group, and two incidences of oxygen tubing disconnection in the standard therapy group); none resulted in withdrawal from the trial. No oxygen-related serious adverse events occurred. Secondary effectiveness outcomes are reported in the Results section. Interpretation HFWHO did not significantly reduce time on oxygen compared with standard therapy, suggesting that early use of HFWHO does not modify the underlying disease process in moderately severe bronchiolitis. HFWHO might have a role as a rescue therapy to reduce the proportion of children requiring high-cost intensive care.	[Kepreotes, Elizabeth; Whitehead, Bruce; Goddard, Bernadette; Hilton, Jodi; Lee, Mark; Mattes, Joerg] John Hunter Childrens Hosp, Newcastle, NSW 2310, Australia; [Kepreotes, Elizabeth; Collison, Adam; Mattes, Joerg] Univ Newcastle, Prior Res Ctr GrowUpWell, Newcastle, NSW, Australia; [Kepreotes, Elizabeth; Whitehead, Bruce; Attia, John] Univ Newcastle, Fac Hlth, Newcastle, NSW, Australia; [Attia, John; Oldmeadow, Christopher; Lee, Mark] John Hunter Hosp, Newcastle, NSW, Australia; [Kepreotes, Elizabeth; Attia, John; Oldmeadow, Christopher; Collison, Adam; Searles, Andrew; Mattes, Joerg] Hunter Med Res Inst, Newcastle, NSW, Australia	University of Newcastle; University of Newcastle; John Hunter Hospital; Hunter Medical Research Institute; University of Newcastle	Kepreotes, E (corresponding author), John Hunter Childrens Hosp, Newcastle, NSW 2310, Australia.	Elizabeth.Kepreotes@hnehealth.nsw.gov.au	MATTES, JOERG/M-5179-2019; Attia, John R/F-5376-2013; Collison, Adam/G-7718-2013	Attia, John R/0000-0001-9800-1308; Collison, Adam/0000-0002-3074-3046; Oldmeadow, Christopher/0000-0001-6104-1322; Searles, Andrew/0000-0002-9452-9735	Hunter Children's Research Foundation; John Hunter Hospital Charitable Trust; University of Newcastle Priority Research Centre GrowUpWell	Hunter Children's Research Foundation; John Hunter Hospital Charitable Trust; University of Newcastle Priority Research Centre GrowUpWell	Hunter Children's Research Foundation, John Hunter Hospital Charitable Trust, and the University of Newcastle Priority Research Centre GrowUpWell.	Beggs S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009609.pub2; Chisti MJ, 2015, LANCET, V386, P1057, DOI 10.1016/S0140-6736(15)60249-5; Clinical Excellence Commission, 2011, FLAGS KEEP PAT SAF; Collins CL, 2013, J PEDIATR-US, V162, P949, DOI 10.1016/j.jpeds.2012.11.016; Cunningham S, 2016, THORAX, V71, P679, DOI 10.1136/thoraxjnl-2016-209012; Cunningham S, 2015, LANCET, V386, P1041, DOI 10.1016/S0140-6736(15)00163-4; Duarte-Dorado DM, 2013, J ASTHMA, V50, P1056, DOI 10.3109/02770903.2013.834504; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Haq I, 2014, PAEDIATR RESPIR REV, V15, P124, DOI 10.1016/j.prrv.2013.12.002; Hough JL, 2012, J PAEDIATR CHILD H, V48, P106, DOI 10.1111/j.1440-1754.2011.02070.x; Independent Hospital Pricing Authority, 2015, NAT EFF PRIC DET 201; Jubran A, 1999, CRIT CARE, V3, pR11, DOI 10.1186/cc341; Manley BJ, 2013, NEW ENGL J MED, V369, P1425, DOI 10.1056/NEJMoa1300071; Manley BJ, 2012, NEONATOLOGY, V102, P300, DOI 10.1159/000341754; Mayfield S, 2014, J PAEDIATR CHILD H, V50, P373, DOI 10.1111/jpc.12509; Mayfield S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009850.pub2; McKiernan C, 2010, J PEDIATR-US, V156, P634, DOI 10.1016/j.jpeds.2009.10.039; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; NSW Health, 2011, PD2011077 NSW HLTH; NSW Health, 2012, PD2012004 NSW HLTH; Piedra P, 2016, BRONCHIOLITIS INFANT; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Schibler A, 2011, INTENS CARE MED, V37, P847, DOI 10.1007/s00134-011-2177-5; Schuh S, EFFECT OXIMETRY HOSP; SIGN, BRONCH CHILDR NAT CL; STEPHAN F, 2015, JAMA-J AM MED ASSOC, V313, P2331, DOI [DOI 10.1001/JAMA.2015.5213, 10.1001/jama.2015.5213]; Suiter DM, 2007, ARCH PHYS MED REHAB, V88, P1681, DOI 10.1016/j.apmr.2007.07.042; Welliver RC, 2003, J PEDIATR-US, V143, pS112, DOI 10.1067/S0022-3476(03)00508-0; Wettstein Richard B, 2005, Respir Care, V50, P604; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	30	154	157	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2017	389	10072					930	939		10.1016/S0140-6736(17)30061-2	http://dx.doi.org/10.1016/S0140-6736(17)30061-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM4DL	28161016				2023-01-03	WOS:000395263400032
J	Lee, J; Shin, JS; Lee, YJ; Kim, MR; Choi, A; Lee, JH; Shin, KM; Shin, BC; Cho, JH; Ha, IH				Lee, Jinho; Shin, Joon-Shik; Lee, Yoon Jae; Kim, Me-riong; Choi, Areum; Lee, Jun-Hwan; Shin, Kyung-Min; Shin, Byung-Cheul; Cho, Jae-Heung; Ha, In-Hyuk			Long-Term Course of Failed Back Surgery Syndrome (FBSS) Patients Receiving Integrative Korean Medicine Treatment: A 1 Year Prospective Observational Multicenter Study	PLOS ONE			English	Article							SPINAL-CORD STIMULATION; RANDOMIZED CONTROLLED-TRIAL; NEUROPATHIC PAIN; TRADITIONAL MEDICINE; HEALTH SURVEY; MANAGEMENT; QUALITY; COMPLEMENTARY; ACUPUNCTURE; HERNIATION	Background With increase of spine surgeries, failed back surgery syndrome (FBSS) prevalence is also rising. While complementary and alternative medicine (CAM) is commonly used for low back pain (LBP), there are no studies reporting use of integrative Korean medicine in FBSS patients. Methods Patients with pain continuing after back surgery or recurring within 1 year and visual analogue scale (VAS) of LBP or leg pain of >= 6 (total n = 120) were recruited at 2 hospital sites from November 2011 to September 2014. Weekly sessions of integrative Korean medicine treatment were conducted for 16 weeks (herbal medicine, acupuncture/electroacupuncture, pharmacopuncture/bee venom pharmacopuncture, and Chuna manual therapy) with additional follow-ups at 24 weeks and 1 year. Outcome measures included VAS of LBP and leg pain (primary outcome), Oswestry Disability Index (ODI), Short-Form 36 (SF-36), medical use, and patient global impression of change (PGIC). Results VAS of LBP and leg pain improved at 6 months (LBP from 6.1 +/- 2.0 at baseline to 2.9 +/- 2.3; and leg pain from 5.4 +/- 2.6 to 2.4 +/- 2.5, respectively). Eighty patients (66.7%) showed improvement of 50% or more in main pain of LBP or leg pain from baseline. Disability and quality of life also improved at 6 months (ODI from 41.3 +/- 12.3 at baseline to 23.6 +/- 13.6; and SF-36 from 42.8 +/- 14.5 to 62.7 +/- 16.8). At 1 year follow-up, conventional medical management use decreased, improvement in pain and disability was maintained, and 79.2% reported improvement of PGIC. Conclusions Despite limitations as an observational study, integrative Korean medicine treatment showed positive results in pain, function, and quality of life of FBSS patients.	[Lee, Jinho; Shin, Joon-Shik; Lee, Yoon Jae; Kim, Me-riong; Choi, Areum; Ha, In-Hyuk] Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul, South Korea; [Lee, Jun-Hwan; Shin, Kyung-Min] Korea Inst Oriental Med, Div Clin Res, Daejeon, South Korea; [Lee, Jun-Hwan] Univ Sci & Technol, Korean Med Life Sci, Campus Korea Inst Oriental Med, Daejeon, South Korea; [Shin, Kyung-Min] Pusan Natl Univ, Sch Korean Med, Div Clin Med, Yangsan, South Korea; [Cho, Jae-Heung] Kyung Hee Univ, Dept Korean Rehabil Med, Seoul, South Korea	Korea Institute of Oriental Medicine (KIOM); Korea Institute of Oriental Medicine (KIOM); University of Science & Technology (UST); Pusan National University; Kyung Hee University	Ha, IH (corresponding author), Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul, South Korea.	hanihata@gmail.com	Shin, Kyung-Min/AAO-9382-2020; Lee, Yoon Jae/ABA-8808-2020	Lee, Yoon Jae/0000-0002-1532-0942; HA, IN-HYUK/0000-0002-5020-6723; Lee, Jinho/0000-0003-0672-6892; Shin, Joon-Shik/0000-0001-5488-3273	Korea Institute of Oriental Medicine [K16123]	Korea Institute of Oriental Medicine	This study was supported by a grant from the Korea Institute of Oriental Medicine (K16123). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by a grant from the Korea Institute of Oriental Medicine (K16123). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Ki Byung Park for his help in statistical analysis.	[Anonymous], 1991, GUIDE CLIN TRIALS, P565; Brox JI, 2006, PAIN, V122, P145, DOI 10.1016/j.pain.2006.01.027; Brunelli B, 2004, J NEUROL SCI, V218, P59, DOI 10.1016/j.jns.2003.10.013; Chung HJ, 2010, J ETHNOPHARMACOL, V130, P450, DOI 10.1016/j.jep.2010.05.020; Deyo RA, 2006, CLIN ORTHOP RELAT R, P139, DOI 10.1097/01.blo.0000198726.62514.75; Deyo RA, 2009, EUR SPINE J, V18, pS331, DOI 10.1007/s00586-009-0908-x; Doth AH, 2010, PAIN, V149, P338, DOI 10.1016/j.pain.2010.02.034; Eldabe S, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-189; Evidence-based Korean Medicine Clinical Practice Guideline Development Committee for Lumbar Herniated Intervertebral Disc(Korea Institute of Oriental Medicine and the Society of Korean Medicine Rehabilitation), 2014, KOREAN MEDICINE CLIN; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fritzell P, 2003, EUR SPINE J, V12, P178, DOI 10.1007/s00586-002-0493-8; Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01; Han CW, 2004, TOHOKU J EXP MED, V203, P189, DOI 10.1620/tjem.203.189; Hussain A, 2014, PAIN PRACT, V14, P64, DOI 10.1111/papr.12035; Jeon CH, 2006, J KOREAN MED SCI, V21, P1092, DOI 10.3346/jkms.2006.21.6.1092; Kim JK, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/730907; Kim Tae, 2011, Open Neuroimag J, V5, P136, DOI 10.2174/1874440001105010136; Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028; Kvachadze I, 2015, Georgian Med News, P102; Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012; Manca A, 2008, EUR J PAIN, V12, P1047, DOI 10.1016/j.ejpain.2008.01.014; Moon TW, 2013, CHIN J INTEGR MED, V19, P228, DOI 10.1007/s11655-012-1238-0; National Center for Health Statistics, 1997, NAT HOSP DISCH SURV, V13; NORTH RB, 1991, NEUROSURGERY, V28, P685, DOI 10.1227/00006123-199105000-00008; Park JJ, 2010, COMPLEMENT THER MED, V18, P78, DOI 10.1016/j.ctim.2010.02.003; Park YG, 2013, J ETHNOPHARMACOL, V149, P816, DOI 10.1016/j.jep.2013.08.008; Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039; Rahimzadeh P, 2014, PAIN PHYSICIAN, V17, pE75; Rigoard P, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-376; Robinson N, 2012, EUR J INTEGR MED, V4, pE363, DOI 10.1016/j.eujim.2012.10.001; Rubinstein SM, 2010, EUR SPINE J, V19, P1213, DOI 10.1007/s00586-010-1356-3; Shin JS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005801; Shin JS, 2016, SPINE PHILA PA 1976; Shin YS, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0956-1; Stevens L, 2007, J ALTERN COMPLEM MED, V13, P481, DOI 10.1089/acm.2007.6263; Taylor RS, 2012, BRIT J PAIN, V6, P174, DOI 10.1177/2049463712470887; TURK DC, 1993, PAIN, V53, P3, DOI 10.1016/0304-3959(93)90049-U; VANTULDER MW, 1995, PAIN, V62, P233, DOI 10.1016/0304-3959(94)00272-G; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; Wilkinson HA., 1991, FAILED BACK SYNDROME; World Health Organization, 2005, US WHO UMC SYST STAN	43	14	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2017	12	1							e0170972	10.1371/journal.pone.0170972	http://dx.doi.org/10.1371/journal.pone.0170972			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7VX	28129399	Green Submitted, gold, Green Published			2023-01-03	WOS:000396211400015
J	Tung, YC; Chang, GM; Chang, HY; Yu, TH				Tung, Yu-Chi; Chang, Guann-Ming; Chang, Hsien-Yen; Yu, Tsung-Hsien			Relationship between Early Physician Follow-Up and 30-Day Readmission after Acute Myocardial Infarction and Heart Failure	PLOS ONE			English	Article							PRIMARY-CARE PHYSICIAN; EMERGENCY-DEPARTMENT; CHEST-PAIN; OUTCOMES; RISK; ASSOCIATION; TAIWAN; CONTINUITY; ADMISSIONS; MANAGEMENT	Background Thirty-day readmission rates after acute myocardial infarction (AMI) and heart failure are important patient outcome metrics. Early post-discharge physician follow-up has been promoted as a method of reducing 30-day readmission rates. However, the relationships between early post-discharge follow-up and 30-day readmission for AMI and heart failure are inconclusive. We used nationwide population-based data to examine associations between 7-day physician follow-up and 30-day readmission, and further associations of 7-day same physician (during the index hospitalization and at follow-up) and cardiologist follow- up with 30-day readmission for non-ST-segment-elevation myocardial infarction (NSTEMI) or heart failure. Methods We analyzed all patients 18 years or older with NSTEMI and heart failure and discharged from hospitals in 2010 in Taiwan through Taiwan's National Health Insurance Research Database. Cox proportional hazard models with robust sandwich variance estimates and propensity score weighting were performed after adjustment for patient and hospital characteristics to test associations between 7-day physician follow-up and 30-day readmission. Results The study population for NSTEMI and heart failure included 5,008 and 13,577 patients, respectively. Early physician follow-up was associated with a lower hazard ratio of readmission compared with no early physician follow-up for patients with NSTEMI (hazard ratio [HR], 0.47; 95% confidence interval [CI], 0.39-0.57), and for patients with heart failure (HR, 0.54; 95% CI, 0.48-0.60). Same physician follow-up was associated with a reduced hazard ratio of readmission compared with different physician follow-up for patients with NSTEMI (HR, 0.56; 95% CI, 0.48-0.65), and for patients with heart failure (HR, 0.69; 95% CI, 0.62-0.76). Conclusions For each condition, patients who have an outpatient visit with a physician within 7 days of discharge have a lower risk of 30- day readmission. Moreover, patients who have an outpatient visit with the same physician within 7 days of discharge have a much lower risk of 30-day readmission.	[Tung, Yu-Chi] Natl Taiwan Univ, Inst Hlth Policy & Management, Taipei, Taiwan; [Chang, Guann-Ming] Cardinal Tien Hosp, Dept Family Med, New Taipei, Taiwan; [Chang, Guann-Ming] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan; [Chang, Hsien-Yen] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Drug Safety & Effectiveness, Baltimore, MD USA; [Yu, Tsung-Hsien] Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan	National Taiwan University; Fu Jen Catholic University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Taipei University of Nursing & Health Science (NTUNHS)	Yu, TH (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan.	ericthyu@ntu.edu.tw	Chang, Hsien-Yen/E-4627-2014; Tung, Yu-Chi/V-1036-2019	Chang, Hsien-Yen/0000-0002-7997-4822; Tung, Yu-Chi/0000-0001-9031-8749; Yu, Tsung-Hsien/0000-0002-6874-989X; CHANG, HAO-YUAN/0000-0001-5810-7562	Taiwan Ministry of Science and Technology [MOST 103-2410-H-002-209-MY2, MOST 105-2410-H-002-220-MY2]	Taiwan Ministry of Science and Technology	Taiwan Ministry of Science and Technology provides the financial support (MOST 103-2410-H-002-209-MY2 and MOST 105-2410-H-002-220-MY2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.016, 10.1016/j.jacc.2014.09.017]; Andersson C, 2014, J AM COLL CARDIOL, V64, P247, DOI 10.1016/j.jacc.2014.04.042; Centers for Medicare and Medicaid Services, 2015, OUTC MEAS 2015; Centers for Medicare & Medicaid Services, 2014, READM RED PROGR; Chang HY, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1585; Chang HY, 2015, ASIA-PAC J PUBLIC HE, V27, pNP958, DOI 10.1177/1010539512471073; Chiu HY, 2016, TAIWAN J PUBLIC HLTH, V35, P66; Ciccone MM, 2010, VASC HEALTH RISK MAN, V6, P297; Coleman EA, 2007, J HOSP MED, V2, P287, DOI 10.1002/jhm.276; Czarnecki A, 2014, AM HEART J, V168, P289, DOI 10.1016/j.ahj.2014.05.016; Czarnecki A, 2013, CIRCULATION, V127, P1386, DOI 10.1161/CIRCULATIONAHA.112.000737; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ezekowitz JA, 2005, CAN MED ASSOC J, V172, P189, DOI 10.1503/cmaj.1032017; Field TS, 2015, J GEN INTERN MED, V30, P565, DOI 10.1007/s11606-014-3106-4; Geronimus AT, 1996, J AM STAT ASSOC, V91, P529, DOI 10.2307/2291645; Glickman SW, 2012, AM HEART J, V163, P372, DOI 10.1016/j.ahj.2011.10.021; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hess CN, 2013, CIRCULATION, V128, P1206, DOI 10.1161/CIRCULATIONAHA.113.004569; Hirano K, 2003, ECONOMETRICA, V71, P1161, DOI 10.1111/1468-0262.00442; Huang IC, 2005, HEALTH SERV RES, V40, P253, DOI 10.1111/j.1475-6773.2005.00352.x; Institute of Medicine, 2007, REW PROV PERF AL INC; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Lee KK, 2016, MED CARE, V54, P365, DOI 10.1097/MLR.0000000000000492; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Lin YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062492; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; McAlister FA, 2013, CAN MED ASSOC J, V185, pE681, DOI 10.1503/cmaj.130048; Medicare Payment Advisory Commission, 2007, PROM GREAT EFF MED R; O'Gara PT, 2013, CIRCULATION, V127, P529, DOI 10.1161/CIR.0b013e3182742c84; Roux AVD, 2004, EPIDEMIOL REV, V26, P104, DOI 10.1093/epirev/mxh006; Ryan J, 2013, AM J MED, V126, P989, DOI 10.1016/j.amjmed.2013.06.027; SCHWARTZ S, 1994, AM J PUBLIC HEALTH, V84, P819, DOI 10.2105/AJPH.84.5.819; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; Tung YC, 2015, CIRC-CARDIOVASC QUAL, V8, P30, DOI 10.1161/CIRCOUTCOMES.114.001086; Tung YC, 2014, MED CARE, V52, P519, DOI 10.1097/MLR.0000000000000132; Tung YC, 2009, MED CARE, V47, P1018, DOI 10.1097/MLR.0b013e3181a81144; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Yang G, 2015, REV PROPENSITY SCORE; Yeung DF, 2012, CAN MED ASSOC J, V184, pE765, DOI 10.1503/cmaj.111958; Yu TH, 2015, INT J QUAL HEALTH C, V27, P361, DOI 10.1093/intqhc/mzv050; Zhang YT, 2014, AM J MANAG CARE, V20, pE498	45	46	48	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2017	12	1							e0170061	10.1371/journal.pone.0170061	http://dx.doi.org/10.1371/journal.pone.0170061			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EN7VX	28129332	Green Published, Green Submitted, gold			2023-01-03	WOS:000396211400064
J	Liu, YC; Lee, YD; Wang, HL; Liao, KH; Chen, KB; Poon, KS; Pan, YL; Lai, TWT				Liu, Yu-Cheng; Lee, Yu-Da; Wang, Hwai-Lee; Liao, Kate Hsiurong; Chen, Kuen-Bao; Poon, Kin-Shing; Pan, Yu-Ling; Lai, Ted Weita			Anesthesia-Induced Hypothermia Attenuates Early-Phase Blood-Brain Barrier Disruption but Not Infarct Volume following Cerebral Ischemia	PLOS ONE			English	Article							TRANSIENT FOCAL ISCHEMIA; ARTERY OCCLUSION; THERAPEUTIC HYPOTHERMIA; NEURONAL INJURIES; STROKE RESEARCH; PERMEABILITY; RAT; ISOFLURANE; NEUROPROTECTION; EXPRESSION	Blood-brain barrier (BBB) disruption is thought to facilitate the development of cerebral infarction after a stroke. In a typical stroke model (such as the one used in this study), the early phase of BBB disruption reaches a peak 6 h post-ischemia and largely recovers after 8-24 h, whereas the late phase of BBB disruption begins 48-58 h post-ischemia. Because cerebral infarct develops within 24 h after the onset of ischemia, and several therapeutic agents have been shown to reduce the infarct volume when administered at 6 h post-ischemia, we hypothesized that attenuating BBB disruption at its peak (6 h post-ischemia) can also decrease the infarct volume measured at 24 h. We used a mouse stroke model obtained by combining 120 min of distal middle cerebral arterial occlusion (dMCAo) with ipsilateral common carotid arterial occlusion (CCAo). This model produced the most reliable BBB disruption and cerebral infarction compared to other models characterized by a shorter duration of ischemia or obtained with dMCAO or CCAo alone. The BBB permeability was measured by quantifying Evans blue dye (EBD) extravasation, as this tracer has been shown to be more sensitive for the detection of early-phase BBB disruption compared to other intravascular tracers that are more appropriate for detecting late-phase BBB disruption. We showed that a 1 h-long treatment with isoflurane-anesthesia induced marked hypothermia and attenuated the peak of BBB disruption when administered 6 h after the onset of dMCAo/CCAo-induced ischemia. We also demonstrated that the inhibitory effect of isoflurane was hypothermia-dependent because the same treatment had no effect on ischemic BBB disruption when the mouse body temperature was maintained at 37 degrees C. Importantly, inhibiting the peak of BBB disruption by hypothermia had no effect on the volume of brain infarct 24 h post-ischemia. In conclusion, inhibiting the peak of BBB disruption is not an effective neuroprotective strategy, especially in comparison to the inhibitors of the neuronal death signaling cascade; these, in fact, can attenuate the infarct volume measured at 24 h post-ischemia when administered at 6 h in our same stroke model.	[Liu, Yu-Cheng; Lee, Yu-Da; Wang, Hwai-Lee; Liao, Kate Hsiurong; Chen, Kuen-Bao; Poon, Kin-Shing; Pan, Yu-Ling; Lai, Ted Weita] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Liu, Yu-Cheng; Liao, Kate Hsiurong; Chen, Kuen-Bao; Poon, Kin-Shing] China Med Univ Hosp, Dept Anesthesiol, Taichung, Taiwan; [Lai, Ted Weita] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Lai, Ted Weita] China Med Univ Hosp, Translat Med Res Ctr, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lai, TWT (corresponding author), China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.; Lai, TWT (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Lai, TWT (corresponding author), China Med Univ Hosp, Translat Med Res Ctr, Taichung, Taiwan.	ted.weita@me.com	Lai, Ted Weita/E-9392-2016	Lai, Ted Weita/0000-0002-6229-4134	China Medical University Hospital [DMR-102-062]; Taiwan Ministry of Science and Technology [MOST105-2320-B-039-007]; National Health Research Institutes [NHRI-EX105-10412NC]	China Medical University Hospital; Taiwan Ministry of Science and Technology; National Health Research Institutes(National Health Research Institutes, JapanNational Health Research Institutes - Taiwan)	This study was supported by research grants from the China Medical University Hospital (DMR-102-062), the Taiwan Ministry of Science and Technology (MOST105-2320-B-039-007), and the National Health Research Institutes (NHRI-EX105-10412NC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albayrak S, 1997, ACTA NEUROPATHOL, V94, P158, DOI 10.1007/s004010050688; Altay O, 2012, STROKE, V43, P2513, DOI 10.1161/STROKEAHA.112.661728; Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Broderick JP, 2002, CIRCULATION, V106, P1736, DOI 10.1161/01.CIR.0000030407.10591.35; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; Cheng CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23882; CHI OZ, 1992, ANESTH ANALG, V75, P31; CHI OZ, 1992, ANESTHESIOLOGY, V76, P426, DOI 10.1097/00000542-199203000-00016; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dirnagl U, 2013, STROKE, V44, P1754, DOI 10.1161/STROKEAHA.113.000734; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; FISCHER S, 1995, ANESTHESIOLOGY, V82, P451, DOI 10.1097/00000542-199502000-00015; Haley M. J., 2016, J CEREB BLOOD FLOW M; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; Hemmen TM, 2009, J NEUROTRAUM, V26, P387, DOI 10.1089/neu.2008.0574; Jackman K, 2013, J NEUROSCI, V33, P19579, DOI 10.1523/JNEUROSCI.4318-13.2013; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krueger M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056419; Kuntz M, 2014, J CEREBR BLOOD F MET, V34, P95, DOI 10.1038/jcbfm.2013.169; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Liu YT, 2000, BRAIN RES, V862, P111, DOI 10.1016/S0006-8993(00)02078-3; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; OLSSON Y, 1971, ACTA NEUROPATHOL, V18, P89, DOI 10.1007/BF00687597; Redel A, 2009, EXP BIOL MED, V234, P1186, DOI 10.3181/0902-RM-58; SAIJA A, 1989, NEUROPHARMACOLOGY, V28, P997, DOI 10.1016/0028-3908(89)90202-5; Schindler S., 2016, MED RES ARCH, V4, P1; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Shi YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10523; Shi YJ, 2016, TRANSL STROKE RES, V7, P89, DOI 10.1007/s12975-016-0447-9; STEWART PA, 1988, BRAIN RES, V443, P12, DOI 10.1016/0006-8993(88)91593-4; Taghibiglou C, 2009, NAT MED, V15, P1399, DOI 10.1038/nm.2064; Tetrault S, 2008, EUR J NEUROSCI, V28, P1330, DOI 10.1111/j.1460-9568.2008.06443.x; Wang HL, 2014, SCI REP-UK, V4, DOI 10.1038/srep06588; Whittington RA, 2013, SCI REP-UK, V3, DOI 10.1038/srep01388; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Xie ZC, 2008, ANN NEUROL, V64, P618, DOI 10.1002/ana.21548; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang S, 2013, J NEUROSCI, V33, P7997, DOI 10.1523/JNEUROSCI.5661-12.2013; Zhou Y, 2014, PHYTOMEDICINE, V21, P998, DOI 10.1016/j.phymed.2013.12.005	45	18	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2017	12	1							e0170682	10.1371/journal.pone.0170682	http://dx.doi.org/10.1371/journal.pone.0170682			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7CU	28118390	Green Published, Green Submitted, gold			2023-01-03	WOS:000396160500015
J	Webster, PC				Webster, Paul C.			Calls for medically safe heroin mount in Canada	LANCET			English	Editorial Material								Canada is rapidly scaling up supervised injection facilities to tackle a surge in heroin overdoses. The move is welcomed by experts but several are calling for further measures. Paul C Webster reports.											0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2017	389	10066					239	239		10.1016/S0140-6736(17)30135-6	http://dx.doi.org/10.1016/S0140-6736(17)30135-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EI9BC	28118904				2023-01-03	WOS:000392801200012
J	Song, Y; Kim, HD; Lee, MK; Hong, IH; Won, CK; Bai, HW; Lee, SS; Lee, S; Chung, BY; Cho, JH				Song, Yuno; Kim, Hong-Duck; Lee, Min-Kwon; Hong, Il-Hwa; Won, Chung-Kil; Bai, Hyoung-Woo; Lee, Seung Sik; Lee, SungBeom; Chung, Byung Yeoup; Cho, Jae-Hyeon			Maysin and Its Flavonoid Derivative from Centipedegrass Attenuates Amyloid Plaques by Inducting Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APPswe, PS1dE9) Alzheimer's Mouse Model	PLOS ONE			English	Article							CORN-EARWORM LEPIDOPTERA; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; DISEASE; BETA; RISK; SILK; ANTIOXIDANT; ACTIVATION; INHIBITION	Alzheimer's disease (AD) is a slow, progressive neurodegenerative disease and the most common type of dementia in the elderly. The etiology of AD and its underlying mechanism are still not clear. In a previous study, we found that an ethyl acetate extract of Centipedegrass (CG) (i.e., EA-CG) contained 4 types of Maysin derivatives, including Luteolin, Isoorientin, Rhamnosylisoorientin, and Derhamnosylmaysin, and showed protective effects against Amyloid beta (A beta) by inhibiting oligomeric A beta in cellular and in vitro models. Here, we examined the preventative effects of EA-CG treatment on the A beta burden in the Tg (MoHu APPswe PS1dE9) AD mouse model. We have investigated the EA-CG efficacy as novel anti-AD likely preventing amyloid plaques using immunofluorescence staining to visually analyze A beta 40/42 and fibril formation with Thioflavin-S or 6E10 which are the profile of immunoreactivity against epitope A beta 1-16 or neuritic plaque, the quantitation of humoral immune response against A beta, and the inflammatory cytokine responses (Th1 and Th2) using ELISA and QRT-PCR. To minimize the toxicity of the extracted CG, we addressed the liver toxicity in response to the CG extract treatment in Tg mice using relevant markers, such as aspartate aminotransferase (AST)/alanine aminotransferase (ALT) measurements in serum. The EA-CG extract significantly reduced the A beta burden, the concentration of soluble A beta 40/42 protein, and fibril formation in the hippocampus and cortex of the Tg mice treated with EA-CG (50 mg/kg BW/day) for 6 months compared with the Tg mice treated with a normal diet. Additionally, the profile of anti-inflammatory cytokines revealed that the levels of Th2 (interleukin-4 (IL-4) and interleukin-10 (IL-10)) cytokines are more significantly increased than Th1 (interferon-gamma (IFN-gamma), interleukin-2(IL-2)) in the sera. These results suggest that the EA-CG fraction induces IL-4/IL-10-dependent anti-inflammatory cytokines (Th2) rather than pro-inflammatory cytokines (Th1), which are driven by IL-2/IFN-gamma. With regard to the immune response, EA-CG induced an immunoglobulin IgG and IgM response against the EA-CG treatment in the Tg mice. Furthermore, EA-CG significantly ameliorated the level of soluble A beta 42 and A beta 40. Similarly, we observed that the fibril formation was also decreased by EA-CG treatment in the hippocampus and cortex after quantitative analysis with Thioflavin-S staining in the Tg brain tissues. Taken together, our findings suggested that Maysin and its derivative flavonoid compounds in the EA-CG fraction might be beneficial therapeutic treatments or alternative preventative measures to adjuvant for boosting humoral and cellular include immune response and anti-inflammation which may lead to amyloid plaque accumulation in Alzheimer's patients' brains.	[Song, Yuno; Lee, Min-Kwon; Hong, Il-Hwa; Won, Chung-Kil; Cho, Jae-Hyeon] Gyeongsang Natl Univ, Inst Anim Med, Coll Vet Med, Jinju, South Korea; [Kim, Hong-Duck] New York Med Coll, Dept Environm Hlth Sci, Valhalla, NY 10595 USA; [Bai, Hyoung-Woo; Lee, Seung Sik; Lee, SungBeom; Chung, Byung Yeoup] Korea Atom Energy Inst, Adv Radiat Technol Inst, Jeongeup, South Korea	Gyeongsang National University; New York Medical College; Korea Atomic Energy Research Institute (KAERI)	Cho, JH (corresponding author), Korea Atom Energy Inst, Adv Radiat Technol Inst, Jeongeup, South Korea.	bychung@kaeri.re.kr; jaehcho@gnu.ac.kr			Nuclear R & D Program of the Ministry of Science and Technology; Ministry of Education, National Research Foundation, Korea [2013066165]	Nuclear R & D Program of the Ministry of Science and Technology; Ministry of Education, National Research Foundation, Korea	This project was supported in part by the Nuclear R & D Program of the Ministry of Science and Technology and by the Ministry of Education, National Research Foundation, Korea (No. 2013066165).	Barnes LL, 2015, J INFECT DIS, V211, P230, DOI 10.1093/infdis/jiu437; Butterfield DA, 2002, J ALZHEIMERS DIS, V4, P193, DOI 10.3233/JAD-2002-4309; Caldeira GL, 2013, J ALZHEIMERS DIS, V34, P115, DOI 10.3233/JAD-121444; Cecchi C, 2002, FREE RADICAL BIO MED, V33, P1372, DOI 10.1016/S0891-5849(02)01049-3; Cheng HY, 2010, PHYTOTHER RES, V24, pS102, DOI 10.1002/ptr.2940; Choi JS, 2014, ARCH PHARM RES, V37, P1354, DOI 10.1007/s12272-014-0351-3; Chouraki V, 2014, ADV GENET, V87, P245, DOI 10.1016/B978-0-12-800149-3.00005-6; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cornejo A, 2011, J ALZHEIMERS DIS, V27, P143, DOI 10.3233/JAD-2011-110623; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; Eckert A, 2001, J NEUROSCI RES, V64, P183, DOI 10.1002/jnr.1064; Farsi DA, 2008, PHYTOTHER RES, V22, P108, DOI 10.1002/ptr.2275; Frydman-Marom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016564; Giovagnoli AR, 2006, DEMENT GERIATR COGN, V22, P238, DOI 10.1159/000094972; Godbolt AK, 2004, NEUROLOGY, V63, P1702, DOI 10.1212/01.WNL.0000143060.98164.1A; Goldman JS, 2002, INT J GERIATR PSYCH, V17, P649, DOI 10.1002/gps.657; Grossi C, 2014, NEURODEGENER DIS, V13, P131, DOI 10.1159/000355461; Guo BZ, 2001, J ECON ENTOMOL, V94, P564, DOI 10.1603/0022-0493-94.2.564; Hamaguchi T, 2009, AM J PATHOL, V175, P2557, DOI 10.2353/ajpath.2009.090417; Hamidpour Rafie, 2014, J Tradit Complement Med, V4, P140, DOI 10.4103/2225-4110.136540; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Holtzman JL, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00059; KARLINSKY H, 1992, AM J MED GENET, V44, P591, DOI 10.1002/ajmg.1320440512; Kim HD, 2007, IMMUNOL LETT, V112, P30, DOI 10.1016/j.imlet.2007.06.006; Kim HD, 2007, J GENE MED, V9, P88, DOI 10.1002/jgm.993; Kountouras J, 2010, COGN BEHAV NEUROL, V23, P199, DOI 10.1097/WNN.0b013e3181df3034; LaFontaine MA, 2002, NEUROCHEM RES, V27, P417, DOI 10.1023/A:1015560116208; Lee J, 2014, BMB REP, V47, P382, DOI 10.5483/BMBRep.2014.47.7.191; Lee Jung-Eun, 2013, Exp Neurobiol, V22, P84, DOI 10.5607/en.2013.22.2.84; Lesne SE, 2013, BRAIN, V136, P1383, DOI 10.1093/brain/awt062; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Liu R, 2009, NEUROSCIENCE, V162, P1232, DOI 10.1016/j.neuroscience.2009.05.009; Longpre F, 2006, FREE RADICAL BIO MED, V41, P1781, DOI 10.1016/j.freeradbiomed.2006.08.015; Luck T, 2015, NEUROPSYCHOLOGY, V29, P382, DOI 10.1037/neu0000147; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Mattson MP, 1997, BRAIN RES, V771, P147, DOI 10.1016/S0006-8993(97)00824-X; Myhrer T, 1998, NEUROSCI BIOBEHAV R, V23, P131, DOI 10.1016/S0149-7634(98)00039-6; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Panza F, 2016, EXPERT OPIN EMERG DR, V6, P1; Panza F, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3245935; Pasinetti GM, 1996, NEUROBIOL AGING, V17, P707, DOI 10.1016/0197-4580(96)00113-3; Piscopo P, 2006, NEUROSCI LETT, V398, P124, DOI 10.1016/j.neulet.2005.12.063; Rector BG, 2002, J ECON ENTOMOL, V95, P1303, DOI 10.1603/0022-0493-95.6.1303; Reddy PH, 2008, TRENDS MOL MED, V14, P45, DOI 10.1016/j.molmed.2007.12.002; Reddy PVB, 2010, NEUROCHEM INT, V56, P780, DOI 10.1016/j.neuint.2010.02.017; Rezai-Zadeh K, 2008, BRAIN RES, V1214, P177, DOI 10.1016/j.brainres.2008.02.107; Rojanathammanee L, 2013, J NUTR, V143, P597, DOI 10.3945/jn.112.169516; Serretti A, 2007, J ALZHEIMERS DIS, V12, P73; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; Song Y, 2015, PHARM BIOL, P8, DOI DOI 10.1016/1MARP0LBUL.2015.01.015; St George-Hyslop PH, 2000, ANN NY ACAD SCI, V924, P1; Wang J, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00042; WISEMAN BR, 1990, J CHEM ECOL, V16, P2677, DOI 10.1007/BF00988078; Yegambaram M, 2015, CURR ALZHEIMER RES, V12, P116, DOI 10.2174/1567205012666150204121719; Yin F, 2011, NEUROCHEM INT, V58, P399, DOI 10.1016/j.neuint.2010.12.017	55	11	12	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2017	12	1							e0169509	10.1371/journal.pone.0169509	http://dx.doi.org/10.1371/journal.pone.0169509			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH5WR	28072821	Green Published, Green Submitted, gold			2023-01-03	WOS:000391844200023
J	Seidemann, T; Spies, C; Morgenstern, R; Wernecke, KD; Netzhammer, N				Seidemann, Thomas; Spies, Claudia; Morgenstern, Rudolf; Wernecke, Klaus-Dieter; Netzhammer, Nicolai			Influence of Volatile Anesthesia on the Release of Glutamate and other Amino Acids in the Nucleus Accumbens in a Rat Model of Alcohol Withdrawal: A Pilot Study	PLOS ONE			English	Article							D-ASPARTATE RECEPTORS; PROTEIN-KINASE-C; TRANSPORTER TYPE-3; ETHANOL WITHDRAWAL; EXTRACELLULAR GLUTAMATE; DELIRIUM-TREMENS; INDUCED INCREASE; ANIMAL-MODELS; WISTAR RATS; IN-VIVO	Background Alcohol withdrawal syndrome is a potentially life-threatening condition, which can occur when patients with alcohol use disorders undergo general anesthesia. Excitatory amino acids, such as glutamate, act as neurotransmitters and are known to play a key role in alcohol withdrawal syndrome. To understand this process better, we investigated the influence of isoflurane, sevoflurane, and desflurane anesthesia on the profile of excitatory and inhibitory amino acids in the nucleus accumbens (NAcc) of alcohol-withdrawn rats (AWR). Methods Eighty Wistar rats were randomized into two groups of 40, pair-fed with alcoholic or nonalcoholic nutrition. Nutrition was withdrawn and microdialysis was performed to measure the activity of amino acids in the NAcc. The onset time of the withdrawal syndrome was first determined in an experiment with 20 rats. Sixty rats then received isoflurane, sevoflurane, or desflurane anesthesia for three hours during the withdrawal period, followed by one hour of elimination. Amino acid concentrations were measured using chromatography and results were compared to baseline levels measured prior to induction of anesthesia. Results Glutamate release increased in the alcohol group at five hours after the last alcohol intake (p = 0.002). After 140 min, desflurane anesthesia led to a lower release of glutamate (p < 0.001) and aspartate (p = 0.0007) in AWR compared to controls. GABA release under and after desflurane anesthesia was also significantly lower in AWR than controls (p = 0.023). Over the course of isoflurane anesthesia, arginine release decreased in AWR compared to controls (p < 0.001), and aspartate release increased after induction relative to controls (P-20min = 0.015 and P-40min = 0.006). However, amino acid levels did not differ between the groups as a result of sevoflurane anesthesia. Conclusions Each of three volatile anesthetics we studied showed different effects on excitatory and inhibitory amino acid concentrations. Under desflurane anesthesia, both glutamate and aspartate showed a tendency to be lower in AWR than controls over the whole timecourse. The inhibitory amino acid arginine increased in AWR compared to controls, whereas GABA levels decreased. However, there were no significant differences in amino acid concentrations under or after sevoflurane anesthesia. Under isoflurane, aspartate release increased in AWR following induction, and from 40 min to 140 min arginine release in controls was elevated. The precise mechanisms through which each of the volatile anesthetics affected amino acid concentrations are still unclear and further experimental research is required to draw reliable conclusions.	[Seidemann, Thomas; Spies, Claudia; Netzhammer, Nicolai] Charite, Dept Anesthesiol & Intens Care Med, Campus Charite Mitte, Berlin, Germany; [Seidemann, Thomas; Spies, Claudia; Netzhammer, Nicolai] Charite, Campus Virchow Klinikum, Berlin, Germany; [Morgenstern, Rudolf] Charite, Inst Pharmacol, Campus Charite Mitte, Berlin, Germany; [Wernecke, Klaus-Dieter] SOSTANA, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Spies, C (corresponding author), Charite, Dept Anesthesiol & Intens Care Med, Campus Charite Mitte, Berlin, Germany.; Spies, C (corresponding author), Charite, Campus Virchow Klinikum, Berlin, Germany.	claudia.spies@charite.de	Spies, Claudia/AAJ-5412-2020	Spies, Claudia/0000-0002-1062-0495				Awissi DK, 2013, INTENS CARE MED, V39, P16, DOI 10.1007/s00134-012-2758-y; Baum SS, 2006, ALCOHOL CLIN EXP RES, V30, P1414, DOI 10.1111/j.1530-0277.2006.00169.x; Chen G, 2011, ALCOHOL CLIN EXP RES, V35, P1739, DOI 10.1111/j.1530-0277.2011.01520.x; Chen PE, 2005, MOL PHARMACOL, V67, P1470, DOI 10.1124/mol.104.008185; Christian DT, 2013, NEUROPHARMACOLOGY, V65, P134, DOI 10.1016/j.neuropharm.2012.09.004; Cippitelli A, 2012, PHARMACOL BIOCHEM BE, V100, P522, DOI 10.1016/j.pbb.2011.10.016; Dahchour A, 2003, EUR J PHARMACOL, V459, P171, DOI 10.1016/S0014-2999(02)02851-0; Dahchour A, 2000, PHARMACOL BIOCHEM BE, V65, P345, DOI 10.1016/S0091-3057(99)00197-5; Do SH, 2002, ANESTHESIOLOGY, V96, P1492, DOI 10.1097/00000542-200206000-00032; Eyer F, 2011, ALCOHOL ALCOHOLISM, V46, P427, DOI 10.1093/alcalc/agr053; Fliegel Sarah, 2013, In Silico Pharmacology, V1, P7, DOI 10.1186/2193-9616-1-7; Hapfelmeier G, 2001, EUR J ANAESTH, V18, P377, DOI 10.1046/j.0265-0215.2001.00848.x; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Hendricson AW, 2007, J PHARMACOL EXP THER, V321, P60, DOI 10.1124/jpet.106.111419; Hollmann MW, 2001, ANESTH ANALG, V92, P1182; Huang YM, 2006, J BIOL CHEM, V281, P38133, DOI 10.1074/jbc.M603885200; Kim JH, 2005, ALCOHOL CLIN EXP RES, V29, P2046, DOI 10.1097/01.alc.0000187594.92476.07; Larsen M, 1997, BRIT J ANAESTH, V78, P55, DOI 10.1093/bja/78.1.55; Larsen M, 1998, TOXICOL LETT, V101, P59, DOI 10.1016/S0378-4274(98)00165-9; Lee SN, 2010, NEUROSCIENCE, V171, P788, DOI 10.1016/j.neuroscience.2010.09.044; Lee SA, 2009, ANESTH ANALG, V109, P1506, DOI 10.1213/ANE.0b013e3181b6709a; LIEBER CS, 1989, ALCOHOL ALCOHOLISM, V24, P197; Mathews GC, 2003, J NEUROSCI, V23, P2040; Mawhinney LJ, 2012, BRAIN RES, V1431, P23, DOI 10.1016/j.brainres.2011.11.004; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; Mehta Ashish Jitendra, 2016, World J Crit Care Med, V5, P27, DOI 10.5492/wjccm.v5.i1.27; Moe MC, 2002, J NEUROSURG ANESTH, V14, P180, DOI 10.1097/00008506-200207000-00002; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MUCHA RF, 1975, PHARMACOL BIOCHEM BE, V3, P765, DOI 10.1016/0091-3057(75)90104-5; Nadler JV, 2011, NEUROCHEM RES, V36, P668, DOI 10.1007/s11064-010-0291-3; Nath V, 2012, ALCOHOL, V46, P3, DOI 10.1016/j.alcohol.2011.08.003; Ouyang W, 2005, J PHARMACOL EXP THER, V312, P801, DOI 10.1124/jpet.104.074609; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Quintero GC, 2013, NEUROPSYCH DIS TREAT, V9, P1499, DOI 10.2147/NDT.S45963; Rossetti ZL, 1999, NEUROSCIENCE, V93, P1135, DOI 10.1016/S0306-4522(99)00250-X; Sancho-Tello M, 2008, ALCOHOL ALCOHOLISM, V43, P254, DOI 10.1093/alcalc/agn006; Simms JA, 2008, ALCOHOL CLIN EXP RES, V32, P1816, DOI 10.1111/j.1530-0277.2008.00753.x; Spies CD, 1996, INTENS CARE MED, V22, P286, DOI 10.1007/BF01700448; Trevisan LA, 1998, ALCOHOL HEALTH RES W, V22, P61; Yan JZ, 2011, J BIOL CHEM, V286, P25187, DOI 10.1074/jbc.M110.192708	40	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0169017	10.1371/journal.pone.0169017	http://dx.doi.org/10.1371/journal.pone.0169017			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2QJ	28045949	Green Published, Green Submitted, gold			2023-01-03	WOS:000391612300091
J	Iwanicki, JL; Severtson, SG; McDaniel, H; Rosenblum, A; Fong, C; Cicero, TJ; Ellis, MS; Kurtz, SP; Buttram, ME; Dart, RC				Iwanicki, Janetta L.; Severtson, S. Geoff; McDaniel, Heather; Rosenblum, Andrew; Fong, Chunki; Cicero, Theodore J.; Ellis, Matthew S.; Kurtz, Steven P.; Buttram, Mance E.; Dart, Richard C.			Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States	PLOS ONE			English	Article							DETERRENT FORMULATIONS; MISUSE; MODEL	Background Therapeutic use and abuse of prescription opioids in the United States increased substantially between 1990 and 2010. The Centers for Disease Control estimated deaths related to pharmaceutical opioids reached nearly 19,000 in 2014. Of prescription opioids sold, 10% are extended release (ER) and 90% immediate release (IR). However, most regulations and interventions have focused on decreasing ER abuse. Our objective was to compare rates of abuse and diversion of ER and IR opioid analgesics over time using multiple surveillance programs. Methods Rates of abuse and diversion of ER and IR opioid formulations were compared using data from four surveillance programs in the Researched Abuse, Diversion and Addiction Related Surveillance (RADARS (R)) System. Data were evaluated from 2009 through 2015, and Poisson regression used to compare IR and ER opioid cases over time. Results From 2009 to 2015, IR opioids were prescribed at a rate 12 to 16 times higher than ER. In the Poison Center Program, population-adjusted rates of Intentional Abuse for IR were 4.6 fold higher than ER opioids (p<0.001). In the Drug Diversion Program, population-adjusted rates of diversion were 6.1 fold higher for IR than ER opioids (p<0.001). In the Opioid Treatment Program, population-adjusted rates of endorsements for abuse were 1.6 fold higher for IR opioids than ER (p = 0.002). In the Survey of Key Informants' Patients Program, population-adjusted rates of endorsements for abuse were 1.5 fold higher for IR opioids than ER (p<0.001). Conclusions Between 2009 and 2015, IR opioids were prescribed at a much higher rate than ER opioids. Results from four surveillance programs show population-adjusted rates of prescription opioid abuse were markedly higher for IR than ER medications. For the greatest public health benefit, future interventions to decrease prescription opioid abuse should focus on both IR and ER formulations.	[Iwanicki, Janetta L.; Severtson, S. Geoff; McDaniel, Heather; Dart, Richard C.] Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO 80204 USA; [Rosenblum, Andrew; Fong, Chunki] Natl Dev & Res Inst Inc, New York, NY USA; [Cicero, Theodore J.; Ellis, Matthew S.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Kurtz, Steven P.; Buttram, Mance E.] Nova Southeastern Univ, Ctr Appl Res Subst Use & Hlth Dispar, Ft Lauderdale, FL 33314 USA	Denver Health Medical Center; National Development & Research Institutes, Inc; Washington University (WUSTL); Nova Southeastern University	Iwanicki, JL (corresponding author), Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO 80204 USA.	Janetta.iwanicki@rmpdc.org		Dart, Richard/0000-0001-5989-9354; Iwanicki, Janetta/0000-0001-9608-391X; Ellis, Matthew/0000-0003-3753-9651	pharmaceutical manufacturers for surveillance, research and reporting services	pharmaceutical manufacturers for surveillance, research and reporting services	The RADARS System is supported by subscriptions from pharmaceutical manufacturers for surveillance, research and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases and systems. Subscribers do not participate in in data collection or analysis, nor do they have access to the raw data. This study was not sponsored or funded by any subscriber. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Budman SH, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-8; Butler SF, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-29; Califf RM, 2016, NEJM; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Cicero TJ, 2015, JAMA PSYCHIAT, V72, P424, DOI 10.1001/jamapsychiatry.2014.3043; Cleland CM, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-11; Comer SD, 2012, PAIN, V153, P2315, DOI 10.1016/j.pain.2012.07.035; Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443; Coplan PM, 2013, PHARMACOEPIDEM DR S, V22, P1274, DOI 10.1002/pds.3522; Dart RC, 2015, NEJM S, V372, P1; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMsa1406143, 10.1056/NEJMc1501822]; Dasgupta N, 2006, DRUG ALCOHOL DEPEN, V82, P135, DOI 10.1016/j.drugalcdep.2005.08.019; Dasgupta N, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2810; Davis JM, 2014, PHARMACOEPIDEM DR S, V23, P18, DOI 10.1002/pds.3533; FDA Guidance for Industry, AB DET OP EV LAB; Food and Drug Administration, 2015, 3837517 ID FDA; Franklin G, 2015, AM J PUBLIC HEALTH, V105, P463, DOI 10.2105/AJPH.2014.302367; Harney, 2015, 2015Q3 RADARS; Hwang CS, 2015, PHARMACOEPIDEM DR S, V24, P197, DOI 10.1002/pds.3723; IMS Government Solutions Inc, 2012, NAT PRESCR AUD NPA; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Paone D, 2015, MMWR-MORBID MORTAL W, V64, P491; Severtson SG, 2016, DRUG ALCOHOL DEPEND; Smith MY, 2008, PHARMACOEPIDEM DR S, V17, P1050, DOI 10.1002/pds.1658; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, DAWN REP HIGHL 2011; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401; Wakeland W, 2015, AM J DRUG ALCOHOL AB, V41, P508, DOI 10.3109/00952990.2015.1043435	30	29	29	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0167499	10.1371/journal.pone.0167499	http://dx.doi.org/10.1371/journal.pone.0167499			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE4PU	27936038	gold, Green Published, Green Submitted			2023-01-03	WOS:000389587100111
J	Vella, S; Tavanti, E; Hattinger, CM; Fanelli, M; Versteeg, R; Koster, J; Picci, P; Serra, M				Vella, Serena; Tavanti, Elisa; Hattinger, Claudia Maria; Fanelli, Marilu; Versteeg, Rogier; Koster, Jan; Picci, Piero; Serra, Massimo			Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells	PLoS One			English	Article							CYCLIN-DEPENDENT KINASES; IN-VITRO; EMERGING DRUGS; R-ROSCOVITINE; CANCER CELLS; HIGH-GRADE; INHIBITOR; RESISTANCE; APOPTOSIS; LINES	Cyclin-dependent kinase 2 (CDK2) has been reported to be essential for cell proliferation in several human tumours and it has been suggested as an appropriate target to be considered in order to enhance the efficacy of treatment regimens based on the use of DNA damaging drugs. We evaluated the clinical impact of CDK2 overexpression on a series of 21 high-grade osteosarcoma (OS) samples profiled by using cDNA microarrays. We also assessed the in vitro efficacy of the CDKs inhibitor roscovitine in a panel of drug-sensitive and drug-resistant human OS cell lines. OS tumour samples showed an inherent overexpression of CDK2, and high expression levels at diagnosis of this kinase appeared to negatively impact on clinical outcome. CDK2 expression also proved to be relevant for in vitro OS cells growth. These findings indicated CDK2 as a promising candidate therapeutic marker for OS and therefore we assessed the efficacy of the CDKs-inhibitor roscovitine in both drug-sensitive and -resistant OS cell lines. All cell lines resulted to be responsive to roscovitine, which was also able to increase the activity of cisplatin and doxorubicin, the two most active DNA damaging drugs used in OS chemotherapy. Our results indicated that combined treatment with conventional OS chemotherapeutic drugs and roscovitine may represent a new candidate intervention approach, which may be considered to enhance tumour cell sensitivity to DNA damaging drugs.	[Vella, Serena; Tavanti, Elisa; Hattinger, Claudia Maria; Fanelli, Marilu; Picci, Piero; Serra, Massimo] Orthopaed Rizzoli Inst, Expt Oncol Lab, Bologna, Italy; [Versteeg, Rogier] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, Amsterdam, Netherlands; [Koster, Jan] Univ Amsterdam, Acad Med Ctr, Dept Oncogen, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Serra, M (corresponding author), Orthopaed Rizzoli Inst, Expt Oncol Lab, Bologna, Italy.	massimo.serra@ior.it	Versteeg, Rogier/AAQ-1765-2020; Serra, Massimo/J-4878-2016; Koster, Jan/C-5934-2008; Hattinger, Claudia/Q-1212-2016	Serra, Massimo/0000-0003-0742-1177; Koster, Jan/0000-0002-0890-7585; Versteeg, Rogier/0000-0001-7172-0388; Hattinger, Claudia/0000-0002-9316-5095	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) [IG2014 I.d.15851]; Istituto Ortopedico Rizzoli	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.)(Fondazione AIRC per la ricerca sul cancro); Istituto Ortopedico Rizzoli	This study was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C. www.airc.it; grant to MS, IG2014 I.d.15851) and the Istituto Ortopedico Rizzoli (www.ior.it; 5 parts per thousand contributions to Rizzoli Institute). Dr. ET received a fellowship from the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) to perform the research project "Pre-clinical validation of approaches targeting protein kinases in osteosarcoma". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abaza MSI, 2008, WORLD J GASTROENTERO, V14, P5162, DOI 10.3748/wjg.14.5162; Abbotts R, 2014, CANCER MANAG RES, V6, P77, DOI 10.2147/CMAR.S50497; Achille C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052356; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood-2004-07-2713; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO;2-F; Bruyere C, 2013, CURR OPIN CELL BIOL, V25, P772, DOI 10.1016/j.ceb.2013.08.004; Cicenas J, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.61; Coley HM, 2007, GYNECOL ONCOL, V105, P462, DOI 10.1016/j.ygyno.2007.01.004; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226; Fischer PM, 2003, EXPERT OPIN INV DRUG, V12, P955, DOI 10.1517/eoid.12.6.955.21792; Fu W, 2011, MOL CANCER THER, V10, P1018, DOI 10.1158/1535-7163.MCT-11-0167; Han XF, 2014, CYTOTECHNOLOGY, V66, P567, DOI 10.1007/s10616-013-9604-0; Hattinger CM, 2015, EXPERT OPIN EMERG DR, V20, P495, DOI 10.1517/14728214.2015.1051965; Hattinger CM, 2015, HISTOPATHOLOGY, V67, P338, DOI 10.1111/his.12653; Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603; Johnson N, 2010, EXPERT OPIN THER TAR, V14, P1199, DOI 10.1517/14728222.2010.525221; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Khalil HS, 2015, J BIOTECHNOL, V202, P40, DOI 10.1016/j.jbiotec.2015.02.032; Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Le Tourneau C, 2010, EUR J CANCER, V46, P3243, DOI 10.1016/j.ejca.2010.08.001; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; McInnes C, 2008, DRUG DISCOV TODAY, V13, P875, DOI 10.1016/j.drudis.2008.06.012; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Messerschmitt PJ, 2008, CLIN ORTHOP RELAT R, V466, P2168, DOI 10.1007/s11999-008-0338-9; Mohapatra S, 2005, CANCER RES, V65, P7717, DOI 10.1158/0008-5472.CAN-05-0347; Mohapatra S, 2007, MOL CANCER RES, V5, P145, DOI 10.1158/1541-7786.MCR-06-0300; Molenaar JJ, 2012, GENE CHROMOSOME CANC, V51, P10, DOI 10.1002/gcc.20926; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Pasello M, 2008, CANCER RES, V68, P6661, DOI 10.1158/0008-5472.CAN-07-5840; Pepper C, 2003, CELL CYCLE, V2, P53, DOI 10.4161/cc.2.1.249; Pitts TM, 2014, PHARMACOL THERAPEUT, V142, P258, DOI 10.1016/j.pharmthera.2013.12.010; Raynaud FI, 2005, CLIN CANCER RES, V11, P4875, DOI 10.1158/1078-0432.CCR-04-2264; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Senderowicz AM, 2003, CANCER BIOL THER, V2, pS84; Sero V, 2014, INVEST NEW DRUG, V32, P1167, DOI 10.1007/s10637-014-0158-6; SERRA M, 1993, ANTICANCER RES, V13, P323; Serra M, 2004, ANN ONCOL, V15, P151, DOI 10.1093/annonc/mdh004; Siemeister G, 2012, MOL CANCER THER, V11, P2265, DOI 10.1158/1535-7163.MCT-12-0286; Sorensen CS, 2012, NUCLEIC ACIDS RES, V40, P477, DOI 10.1093/nar/gkr697; Tavanti E, 2013, BRIT J CANCER, V109, P2607, DOI 10.1038/bjc.2013.643; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wesierska-Gadek J, 2009, ANN NY ACAD SCI, V1171, P228, DOI 10.1111/j.1749-6632.2009.04726.x; Yata K, 2009, DNA REPAIR, V8, P6, DOI 10.1016/j.dnarep.2008.09.002	49	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2016	11	11							e0166233	10.1371/journal.pone.0166233	http://dx.doi.org/10.1371/journal.pone.0166233			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FU	27898692	Green Submitted, gold, Green Published			2023-01-03	WOS:000389474000006
J	Hamza, AA; Ahmed, MM; Elwey, HM; Amin, A				Hamza, Alaaeldin Ahmed; Ahmed, Mahguob Mohamed; Elwey, Hanan Mohamed; Amin, Amr			Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells	PLOS ONE			English	Article							BREAST-CANCER; OXIDATIVE STRESS; IN-VITRO; MAMMALIAN-CELLS; APOPTOSIS; ANTIOXIDANT; ASSAY; SUPPRESSION; PREVENTION; MECHANISM	Cardiotoxicity is a limiting factor of doxorubicin (DOX)-based anticancer therapy. Due to its beneficial effects, we investigated whether standardized extract of Melissa officinalis (MO) can attenuate doxorubicin-induced cardiotoxicity and can potentiate the efficacy of DOX against human breast cancer cells. MO was administered orally to male albino rats once daily for 10 consecutive days at doses of 250, 500 and 750 mg/kg b.wt. DOX (15 mg/kg b.wt. i.p.) was administered on the 8th day. MO protected against DOX-induced leakage of cardiac enzymes and histopathological changes. MO ameliorated DOX-induced oxidative stress as evidenced by decreasing lipid peroxidation, protein oxidation and total oxidant capacity depletion and by increasing antioxidant capacity. Additionally, MO pretreatment inhibited inflammatory responses to DOX by decreasing the expressions of nuclear factor kappa-B, tumor necrosis factor-alpha and cyclooxygenase-2 and the activity of myeloperoxidase. MO ameliorated DOX-induced apoptotic tissue damage in heart of rats. In vitro study showed that MO augmented the anticancer efficacy of DOX in human breast cancer cells (MCF-7) and potentiated oxidative damage and apoptosis. Thus, combination of DOX and MO may prove future cancer treatment protocols safer and more efficient.	[Hamza, Alaaeldin Ahmed] Natl Org Drug Control & Res NODCAR, Hormone Evaluat Dept, Giza, Egypt; [Ahmed, Mahguob Mohamed] NODCAR, Mol Drug Evaluat Dept, Giza, Egypt; [Elwey, Hanan Mohamed] NODCAR, Dept Analyt Chem, Giza, Egypt; [Amin, Amr] UAE Univ, Dept Biol, Al Ain, U Arab Emirates; [Amin, Amr] Cairo Univ, Dept Zool, Giza, Egypt	National Organization for Drug Control & Research (NODCAR); National Organization for Drug Control & Research (NODCAR); National Organization for Drug Control & Research (NODCAR); United Arab Emirates University; Egyptian Knowledge Bank (EKB); Cairo University	Amin, A (corresponding author), Natl Org Drug Control & Res NODCAR, Hormone Evaluat Dept, Giza, Egypt.	alaa17mm@gmail.com; a.amin@uaeu.ac.ae	Mustafa, Mahgoub/ABG-7779-2021; Hamza, Alaaeldin Ahmed/O-9035-2017; Amin, Amr/I-2137-2019	Mustafa, Mahgoub/0000-0001-8452-8651; Hamza, Alaaeldin Ahmed/0000-0001-5450-1116; Amin, Amr/0000-0001-8888-1102	Terry Fox Foundation [21S088]	Terry Fox Foundation	This work was supported by the Terry Fox Foundation, grant# 21S088. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AEBI H, 1984, METHOD ENZYMOL, V105, P121; Ahmed AS, 2012, J ETHNOPHARMACOL, V143, P826, DOI 10.1016/j.jep.2012.08.004; Arceusz A, 2013, J PHARMACEUT BIOMED, V83, P215, DOI 10.1016/j.jpba.2013.05.020; Arrigo AP, 2005, METHODS, V35, P126, DOI 10.1016/j.ymeth.2004.08.003; Barros L, 2013, FOOD CHEM, V136, P1, DOI 10.1016/j.foodchem.2012.07.107; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bjelogrlic SK, 2005, ARCH BIOCHEM BIOPHYS, V97, P311; Block KI, 2015, SEMIN CANCER BIOL, V35, pS276, DOI 10.1016/j.semcancer.2015.09.007; Bolkent S, 2005, J ETHNOPHARMACOL, P99; Cummings J, 2004, BBA-REV CANCER, V1705, P53, DOI 10.1016/j.bbcan.2004.09.005; Dalloz F, 1999, FREE RADICAL BIO MED, V26, P785, DOI 10.1016/S0891-5849(98)00259-7; Dastmalchi K, 2008, LWT-FOOD SCI TECHNOL, V41, P391, DOI 10.1016/j.lwt.2007.03.007; de Sousa AC, 2004, J PHARM PHARMACOL, V56, P677, DOI 10.1211/0022357023321; De U, 2014, INT J ONCOL, V44, P167, DOI 10.3892/ijo.2013.2160; Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; Gille L, 1997, FREE RADICAL BIO MED, V23, P775, DOI 10.1016/S0891-5849(97)00025-7; Hamza A, 2008, CELL BIOL TOXICOL, V24, P63, DOI 10.1007/s10565-007-9016-z; Hasinoff BB, 2003, FREE RADICAL BIO MED, V35, P1469, DOI 10.1016/j.freeradbiomed.2003.08.005; Herodez SS, 2003, FOOD CHEM, V80, P275, DOI 10.1016/S0308-8146(02)00382-5; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Khan HY, 2014, MOL NUTR FOOD RES, V58, P437, DOI 10.1002/mnfr.201300417; Khan N, 2008, BIOCHEM PHARMACOL, V76, P1333, DOI 10.1016/j.bcp.2008.07.015; Li W, 2009, BASIC CLIN PHARMACOL, V104, P192, DOI 10.1111/j.1742-7843.2008.00358.x; Lin JT, 2012, LWT-FOOD SCI TECHNOL, V49, P1, DOI 10.1016/j.lwt.2012.04.009; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majors BS, 2007, METAB ENG, V9, P317, DOI 10.1016/j.ymben.2007.05.003; Mantawy EM, 2014, EUR J PHARMACOL, V728, P107, DOI 10.1016/j.ejphar.2014.01.065; Mencherini T, 2007, J NAT PROD, V70, P1889, DOI 10.1021/np070351s; Michael J Morgan, 2011, Cell Research, V21, P103; Muanda F, 2009, ECAM ADV ACCESS, P1; Nagai K, 2015, FOOD CHEM TOXICOL, V78, P147, DOI 10.1016/j.fct.2015.02.009; NANDI A, 1988, J BIOSCIENCE, V13, P305, DOI 10.1007/BF02712155; Nichenametla SN, 2006, CRIT REV FOOD SCI, V46, P161, DOI 10.1080/10408390591000541; Park SJ, 2004, ANTICANCER RES, V24, P123; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Saeed NM, 2015, BIOCHEM PHARMACOL, V95, P145, DOI [10.1016/j.bcp.2015.02.006, 10.1016/j.bcp.2015.02.00]; Saraydin SU, 2012, ASIAN PAC J CANCER P, V13, P2765, DOI 10.7314/APJCP.2012.13.6.2765; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Tonomura Y, 2012, TOXICOLOGY, V302, P179, DOI 10.1016/j.tox.2012.07.012; Trivedi PP, 2011, CARDIOVASC TOXICOL, V11, P215, DOI 10.1007/s12012-011-9114-2; Weidner C, 2015, PHYTOMEDICINE, V22, P262, DOI 10.1016/j.phymed.2014.12.008; Wouters KA, 2005, BRIT J HAEMATOL, V131, P561, DOI 10.1111/j.1365-2141.2005.05759.x; Yagmurca M, 2003, PHARMACOL RES, V48, P377, DOI 10.1016/S1043-6618(03)00185-3; Yilmaz S, 2006, TOXICOLOGY, V218, P164, DOI 10.1016/j.tox.2005.10.015	49	59	59	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2016	11	11							e0167049	10.1371/journal.pone.0167049	http://dx.doi.org/10.1371/journal.pone.0167049			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED5KB	27880817	Green Submitted, Green Published, gold			2023-01-03	WOS:000388889500060
J	Wyss-Coray, T				Wyss-Coray, Tony			Ageing, neurodegeneration and brain rejuvenation	NATURE			English	Review							MILD COGNITIVE IMPAIRMENT; ANTIINFLAMMATORY DRUG-USE; ALZHEIMERS-DISEASE; DNA METHYLATION; COMMON VARIANTS; GROWTH-HORMONE; OLDER-ADULTS; AGE; YOUNG; BETA	Although systemic diseases take the biggest toll on human health and well-being, increasingly, a failing brain is the arbiter of a death preceded by a gradual loss of the essence of being. Ageing, which is fundamental to neurodegeneration and dementia, affects every organ in the body and seems to be encoded partly in a blood-based signature. Indeed, factors in the circulation have been shown to modulate ageing and to rejuvenate numerous organs, including the brain. The discovery of such factors, the identification of their origins and a deeper understanding of their functions is ushering in a new era in ageing and dementia research.	[Wyss-Coray, Tony] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; [Wyss-Coray, Tony] VA Palo Alto Hlth Care Syst, Ctr Tissue Regenerat Repair & Restorat, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Wyss-Coray, T (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA.; Wyss-Coray, T (corresponding author), VA Palo Alto Hlth Care Syst, Ctr Tissue Regenerat Repair & Restorat, Palo Alto, CA 94304 USA.	twc@stanford.edu	Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831	US Department of Veterans Affairs; US National Institute on Aging [AG045034]; NATIONAL INSTITUTE ON AGING [P50AG047366, R01AG045034] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	I would like to thank T. Montine at Stanford University for his critical reading of the manuscript. This work was supported by the US Department of Veterans Affairs and the US National Institute on Aging (AG045034).	Ash PEA, 2014, BRAIN RES, V1584, P52, DOI 10.1016/j.brainres.2014.05.052; Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131; Baird GS, 2012, AM J PATHOL, V180, P446, DOI 10.1016/j.ajpath.2011.10.024; Baker LD, 2012, ARCH NEUROL-CHICAGO, V69, P1420, DOI 10.1001/archneurol.2012.1970; Baruch K, 2013, P NATL ACAD SCI USA, V110, P2264, DOI 10.1073/pnas.1211270110; Britschgi M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.008862; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Caccamo A, 2013, AGING CELL, V12, P370, DOI 10.1111/acel.12057; Castellano JM, 2015, JAMA NEUROL, V72, P1191, DOI 10.1001/jamaneurol.2015.1616; Choi KM, 2007, EUR J ENDOCRINOL, V157, P437, DOI 10.1530/EJE-07-0127; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy MJ, 2013, AGING CELL, V12, P525, DOI 10.1111/acel.12065; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Cote S, 2012, ALZHEIMERS DEMENT, V8, P219, DOI 10.1016/j.jalz.2011.03.012; De Jager PL, 2014, NAT NEUROSCI, V17, P1156, DOI 10.1038/nn.3786; Dubois B, 2016, ALZHEIMERS DEMENT, V12, P292, DOI 10.1016/j.jalz.2016.02.002; Elobeid A, 2016, J NEUROPATH EXP NEUR, V75, P316, DOI 10.1093/jnen/nlw002; Erikson GA, 2016, CELL, V165, P1002, DOI 10.1016/j.cell.2016.03.022; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Friedlander AL, 2001, J CLIN ENDOCR METAB, V86, P1496, DOI 10.1210/jc.86.4.1496; Gjoneska E, 2015, NATURE, V518, P365, DOI 10.1038/nature14252; Grabert K, 2016, NAT NEUROSCI, V19, P504, DOI 10.1038/nn.4222; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hernandez DG, 2011, HUM MOL GENET, V20, P1164, DOI 10.1093/hmg/ddq561; Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/BF02185763; Hjelmborg JV, 2006, HUM GENET, V119, P312, DOI 10.1007/s00439-006-0144-y; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Holmes C, 2011, NEUROLOGY, V77, P212, DOI 10.1212/WNL.0b013e318225ae07; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859; Horvath S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0649-6; Hu WT, 2012, NEUROLOGY, V79, P897, DOI 10.1212/WNL.0b013e318266fa70; Hye A, 2014, ALZHEIMERS DEMENT, V10, P799, DOI 10.1016/j.jalz.2014.05.1749; Jack CR, 2016, NAT REV NEUROL, V12, P117, DOI 10.1038/nrneurol.2015.251; Jaeger PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0095-2; Johnstone D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034341; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Kawas CH, 2015, NEUROLOGY, V85, P535, DOI 10.1212/WNL.0000000000001831; Kiddle SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044260; Kim MJ, 2015, J IMMUNOL, V194, P4784, DOI 10.4049/jimmunol.1403158; Lalli MA, 2015, MOL PSYCHIATR, V20, P1294, DOI 10.1038/mp.2015.131; Lambert J. C., NATURE GENET, V45, P1452; Landau SM, 2016, NEUROLOGY, V86, P1377, DOI 10.1212/WNL.0000000000002576; Linnartz B, 2013, GLIA, V61, P37, DOI 10.1002/glia.22359; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Lord J, 2014, NAT NEUROSCI, V17, P1138, DOI 10.1038/nn.3792; Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039; Lunnon K, 2014, NAT NEUROSCI, V17, P1164, DOI 10.1038/nn.3782; Manthripragada AD, 2011, NEUROEPIDEMIOLOGY, V36, P155, DOI 10.1159/000325653; Matteini AM, 2016, AGING CELL, V15, P792, DOI 10.1111/acel.12468; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; Menni C, 2015, J GERONTOL A-BIOL, V70, P809, DOI 10.1093/gerona/glu121; Menzies FM, 2015, NAT REV NEUROSCI, V16, P345, DOI 10.1038/nrn3961; Middeldorp J., 2016, JAMA NEUROL; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Mrak RE, 1997, J NEUROPATH EXP NEUR, V56, P1269, DOI 10.1097/00005072-199712000-00001; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Newman AB, 2013, EPIDEMIOL REV, V35, P181, DOI 10.1093/epirev/mxs013; Nilsson P, 2013, CELL REP, V5, P61, DOI 10.1016/j.celrep.2013.08.042; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Pilling LC, 2016, AGING-US, V8, P547, DOI 10.18632/aging.100930; Podtelezhnikov AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029610; Putin E, 2016, AGING-US, V8, P1021, DOI 10.18632/aging.100968; Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Salpeter SJ, 2013, DIABETES, V62, P2843, DOI 10.2337/db13-0160; Satoh J, 2014, GENE REGUL SYST BIO, V8, P127, DOI 10.4137/GRSB.S19711; Sattlecker M, 2014, ALZHEIMERS DEMENT, V10, P724, DOI 10.1016/j.jalz.2013.09.016; Schafer MJ, 2016, CELL METAB, V23, P1207, DOI 10.1016/j.cmet.2016.05.023; Sebastiani P, 2013, AGING-US, V5, P653, DOI 10.18632/aging.100594; Shadyab AH, 2015, AGEING RES REV, V19, P1, DOI 10.1016/j.arr.2014.10.005; Shatz CJ, 2009, NEURON, V64, P40, DOI 10.1016/j.neuron.2009.09.044; Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Soares HD, 2012, ARCH NEUROL-CHICAGO, V69, P1310, DOI 10.1001/archneurol.2012.1070; Sonntag WE, 2005, AGEING RES REV, V4, P195, DOI 10.1016/j.arr.2005.02.001; Spencer B, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00114; Stern SA, 2014, NEUROPSYCHOPHARMACOL, V39, P2179, DOI 10.1038/npp.2014.69; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; United Nations Department of Economic and Social Affairs Population Division, 2015, STESASERA390 POP DIV; Vanderweyde T, 2012, J NEUROSCI, V32, P8270, DOI 10.1523/JNEUROSCI.1592-12.2012; Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Walker RG, 2016, CIRC RES, V118, P1125, DOI 10.1161/CIRCRESAHA.116.308391; Zeng Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21243; Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030; Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143	97	495	516	14	172	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2016	539	7628					180	186		10.1038/nature20411	http://dx.doi.org/10.1038/nature20411			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB4CZ	27830812	Green Accepted			2023-01-03	WOS:000387318500028
J	Jouglar, E; Wagner, A; Delpon, G; Campion, L; Meingan, P; Bernier, V; Demoor-Goldschmidt, C; Mahe, MA; Lacornerie, T; Supiot, S				Jouglar, Emmanuel; Wagner, Antoine; Delpon, Gregory; Campion, Loic; Meingan, Philippe; Bernier, Valerie; Demoor-Goldschmidt, Charlotte; Mahe, Marc-Andre; Lacornerie, Thomas; Supiot, Stephane			Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation	PLOS ONE			English	Article							MODULATED RADIATION-THERAPY; COMPUTED-TOMOGRAPHY; DIABETES-MELLITUS; CANCER; SURVIVORS; CHILDREN; RESPIRATION; MOVEMENT; TUMORS	Objectives Late abdominal irradiation toxicity during childhood included renal damage, hepatic toxicity and secondary diabetes mellitus. We compared the potential of conformal radiotherapy (CRT), helical tomotherapy (HT) and proton beam therapy (PBT) to spare the abdominal organs at risk (pancreas, kidneys and liver-OAR) in children undergoing abdominal irradiation. Methods We selected children with abdominal tumors who received more than 10 Gy to the abdomen. Treatment plans were calculated in order to keep the dose to abdominal OAR as low as possible while maintaining the same planned target volume (PTV) coverage. Dosimetric values were compared using the Wilcoxon signed-rank test. Results The dose distribution of 20 clinical cases with a median age of 8 years (range 1-14) were calculated with different doses to the PTV: 5 medulloblastomas (36 Gy), 3 left-sided and 2 right-sided nephroblastomas (14.4 Gy to the tumor + 10.8 Gy boost to para-aortic lymphnodes), 1 left-sided and 4 right-sided or midline neuroblastomas (21 Gy) and 5 Hodgkin lymphomas (19.8 Gy to the para-aortic lymphnodes and spleen). HT significantly reduced the mean dose to the whole pancreas (WP), the pancreatic tail (PT) and to the ipsilateral kidney compared to CRT. PBT reduced the mean dose to the WP and PT compared to both CRT and HT especially in midline and right-sided tumors. PBT decreased the mean dose to the ispilateral kidney but also to the contralateral kidney and the liver compared to CRT. Low dose to normal tissue was similar or increased with HT whereas integral dose and the volume of normal tissue receiving at least 5 and 10 Gy were reduced with PBT compared to CRT and HT. Conclusion In children undergoing abdominal irradiation therapy, proton beam therapy reduces the dose to abdominal OAR while sparing normal tissue by limiting low dose irradiation.	[Jouglar, Emmanuel; Demoor-Goldschmidt, Charlotte; Mahe, Marc-Andre; Supiot, Stephane] Inst Cancerol Ouest, Dept Radiat Oncol, Blvd Jacques Monod, F-44800 St Herblain, France; [Wagner, Antoine; Lacornerie, Thomas] Ctr Oscar Lambret, Dept Med Phys, 3 Rue Frederic Combemale, F-59000 Lille, France; [Delpon, Gregory] Inst Cancerol Ouest, Dept Med Phys, Blvd Jacques Monod, F-44800 St Herblain, France; [Campion, Loic] Inst Cancerol Ouest, Dept Stat, Blvd Jacques Monod, F-44800 St Herblain, France; [Meingan, Philippe] Inst Cancerol Ouest, Dept Radiol, Blvd Jacques Monod, F-44800 St Herblain, France; [Bernier, Valerie] Inst Cancerol Lorraine, Dept Radiat Oncol, 6 Ave Bourgogne, F-54519 Vandoeuvre Les Nancy, France	UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Oscar Lambret; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut de cancerologie de Lorraine (ICL)	Supiot, S (corresponding author), Inst Cancerol Ouest, Dept Radiat Oncol, Blvd Jacques Monod, F-44800 St Herblain, France.	Stephane.supiot@ico.unicancer.fr	Supiot, Stéphane/M-1586-2015; Campion, Loic/K-4726-2015	Supiot, Stéphane/0000-0003-2094-1708; Campion, Loic/0000-0003-4903-0908; , charlotte/0000-0002-1236-9089; Lacornerie, Thomas/0000-0001-8994-5999				[Anonymous], 2010, J APPL CLIN MED PHYS, DOI DOI 10.1120/JACMP.V11I1.3042; [Anonymous], 2014, SEER TRAIN MOD PANCR; [Anonymous], 2014, AUTOMATED CHILDHOOD; Beneyton Violaine, 2012, BMC Med Phys, V12, P2, DOI 10.1186/1756-6649-12-2; Bolling T, 2010, ANTICANCER RES, V30, P227; Brower JV, 2015, ACTA ONCOL, V54, P562, DOI 10.3109/0284186X.2014.978368; BRYAN PJ, 1984, J ULTRAS MED, V3, P317; Bussels B, 2003, RADIOTHER ONCOL, V68, P69, DOI 10.1016/S0167-8140(03)00133-6; Claude L, 2011, B CANCER, V98, P571, DOI 10.1684/bdc.2011.1350; Curry HL, 2006, EUR J CANCER, V42, P501, DOI 10.1016/j.ejca.2005.11.003; D'Souza WD, 2003, MED PHYS, V30, P2065, DOI 10.1118/1.1591991; de Vathaire F, 2012, LANCET ONCOL, V13, P1002, DOI 10.1016/S1470-2045(12)70323-6; Diallo I, 2009, INT J RADIAT ONCOL, V74, P876, DOI 10.1016/j.ijrobp.2009.01.040; Hall EJ, 2006, INT J RADIAT ONCOL, V65, P1, DOI 10.1016/j.ijrobp.2006.01.027; Hilbrand M, 2008, RADIOTHER ONCOL, V89, P141, DOI 10.1016/j.radonc.2008.06.012; KIVISAARI L, 1982, J COMPUT ASSIST TOMO, V6, P854, DOI 10.1097/00004728-198208000-00044; Laprie A, 2016, Cancer Radiother, V20 Suppl, pS216, DOI 10.1016/j.canrad.2016.07.021; Leseur J, 2009, CANCER RADIOTHER, V13, P536, DOI 10.1016/j.canrad.2009.07.006; Lisbona A, 2010, CANCER RADIOTHER, V14, P563, DOI 10.1016/j.canrad.2010.07.227; Merchant TE, 2013, SEMIN RADIAT ONCOL, V23, P97, DOI 10.1016/j.semradonc.2012.11.008; Newhauser WD, 2011, NAT REV CANCER, V11, P438, DOI 10.1038/nrc3069; Nguyen F, 2008, INT J RADIAT ONCOL, V70, P908, DOI 10.1016/j.ijrobp.2007.10.034; Nievelstein RAJ, 2011, PEDIATR RADIOL, V41, P55, DOI 10.1007/s00247-010-1858-5; Panandiker ASP, 2013, PRACT RADIAT ONCOL, V3, P107, DOI 10.1016/j.prro.2012.04.002; Panandiker ASP, 2013, PEDIATR BLOOD CANCER, V60, P761, DOI 10.1002/pbc.24350; Panandiker ASP, 2012, INT J RADIAT ONCOL, V82, P1771, DOI 10.1016/j.ijrobp.2011.03.046; Penagaricano JA, 2007, TECHNOL CANCER RES T, V6, P355, DOI 10.1177/153303460700600413; Rembielak A, 2005, NAT CLIN PRACT ONCOL, V2, P211, DOI 10.1038/ncponc0139; Shaffer R, 2011, PEDIATR BLOOD CANCER, V56, P16, DOI 10.1002/pbc.22649; SURAMO I, 1984, ACTA RADIOL DIAGN, V25, P129, DOI 10.1177/028418518402500208; van Nimwegen FA, 2014, J CLIN ONCOL, V32, P3257, DOI 10.1200/JCO.2013.54.4379	31	13	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0164643	10.1371/journal.pone.0164643	http://dx.doi.org/10.1371/journal.pone.0164643			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ9NZ	27764132	Green Published, gold, Green Submitted			2023-01-03	WOS:000386204500049
J	Gupta, A; Juneja, S; Vitoria, M; Habiyambere, V; Nguimfack, BD; Doherty, M; Low-Beer, D				Gupta, Aastha; Juneja, Sandeep; Vitoria, Marco; Habiyambere, Vincent; Nguimfack, Boniface Dongmo; Doherty, Meg; Low-Beer, Daniel			Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025	PLOS ONE			English	Article							HIV-1 INFECTION; TREATMENT-NAIVE; LOPINAVIR/RITONAVIR; TENOFOVIR; EFFICACY; ZIDOVUDINE/LAMIVUDINE; EMTRICITABINE; SAFETY; TRIAL	With anti-retroviral treatment (ART) scale-up set to continue over the next few years it is of key importance that manufacturers and planners in low- and middle-income countries (LMICs) hardest hit by the HIV/AIDS pandemic are able to anticipate and respond to future changes to treatment regimens, generics pipeline and demand, in order to secure continued access to all ARV medicines required. We did a forecast analysis, using secondary WHO and UNAIDS data sources, to estimate the number of people living with HIV (PLHIV) and the market share and demand for a range of new and existing ARV drugs in LMICs up to 2025. UNAIDS estimates 24.7 million person-years of ART in 2020 and 28.5 million person-years of ART in 2025 (24.3 million on first-line treatment, 3.5 million on second-line treatment, and 0.6 million on third-line treatment). Our analysis showed that TAF and DTG will be major players in the ART regimen by 2025, with 8 million and 15 million patients using these ARVs respectively. However, as safety and efficacy of dolutegravir (DTG) and tenofovir alafenamide (TAF) during pregnancy and among TB/HIV co-infected patients using rifampicin is still under debate, and ART scale-up is predicted to increase considerably, there also remains a clear need for continuous supplies of existing ARVs including TDF and EFV, which 16 million and 10 million patients-respectively-are predicted to be using in 2025. It will be important to ensure that the existing capacities of generics manufacturers, which are geared towards ARVs of higher doses (such as TDF 300mg and EFV 600mg), will not be adversely impacted due to the introduction of lower dose ARVs such as TAF 25mg and DTG 50mg. With increased access to viral load testing, more patients would be using protease inhibitors containing regimens in second-line, with 1 million patients on LPV/r and 2.3 million on ATV/r by 2025. However, it will remain important to continue monitoring the evolution of ARV market in LMICs to guarantee the availability of these medicines.	[Gupta, Aastha; Juneja, Sandeep] Med Patent Pool, Geneva, Switzerland; [Vitoria, Marco; Habiyambere, Vincent; Nguimfack, Boniface Dongmo; Doherty, Meg; Low-Beer, Daniel] WHO, Dept HIV AIDS, Geneva, Switzerland	World Health Organization	Gupta, A (corresponding author), Med Patent Pool, Geneva, Switzerland.	agupta@medicinespatentpool.org	juneja, sandeep/AAP-3404-2020	Gupta, Aastha/0000-0002-3278-4351	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Boender TS, 2016, J INFECT DIS, V214, P873, DOI 10.1093/infdis/jiw219; Bygrave H, 2011, JAIDS-J ACQ IMM DEF, V56, pE75, DOI 10.1097/QAI.0b013e3182097505; Fisher M, 2009, JAIDS-J ACQ IMM DEF, V51, P562, DOI 10.1097/QAI.0b013e3181ae2eb9; Greig SL, 2015, DRUGS, V75, P503, DOI 10.1007/s40265-015-0361-6; Habiyambere V, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002088; HIV-iBase/TAG, 2016, ANT TREATM OPT; Lecher S, 2015, MMWR-MORBID MORTAL W, V64, P1287, DOI 10.15585/mmwr.mm6446a3; Lennox JL, 2014, ANN INTERN MED, V161, P461, DOI 10.7326/M14-1084; Medicines Patent Pool, SUB LICENSEES WORKIN; Mills AM, 2009, AIDS, V23, P1679, DOI 10.1097/QAD.0b013e32832d7350; Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf; Nishijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077268; Orkin C, 2013, HIV MED, V14, P49, DOI 10.1111/j.1468-1293.2012.01060.x; Patel DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105653; Pinheiro ED, 2008, ANTIVIR RES, V79, P143, DOI 10.1016/j.antiviral.2008.05.001; Ribera E, 2013, HIV MED, V14, P327, DOI 10.1111/hiv.12011; Sax Paul E, 2014, J Acquir Immune Defic Syndr, V67, P52, DOI 10.1097/QAI.0000000000000225; Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140-6736(15)60616-X; Stover J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154893; The World Bank, DATA LOW MIDDLE INCO; UNAIDS, 2015, UNDERSTANDING FAST T; UNAIDS, 2016, GLOBAL STATISTICS 20; UNAIDS, 2014, FAST TRACK ENDING TH; UNAIDS, DATABASE AIDSINFO ON; UNAIDS, 2015, HOW AIDS CHANGED EVE; US NIH, DAT CLIN TRIALS GOV; Walmsley S, 2014, TOPICS ANTIVIRAL MED, V22, P261; Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541; WHO, 2015, CONSOLIDATED GUIDELI; World Health Organization, 2009, ANNUAL 2010 SURVEY O; World Health Organization, 2006, ANTIRETROVIRAL THERA; World Health Organization, 2016, CONSOLIDATED GUIDELI; World Health Organization, DATABASE GLOBAL PRIC; World Health Organization, 2012, WHO SURVEY ON ARV AN; World Health Organization, 2014, WHO GLOBAL ARVS AND; World Health Organization, 2013, WHO GLOBAL SURVEY ON; World Health Organization, 2010, WHO SURVEY ON ARV US; World Health Organization, 2011, WHO SURVEY ON ARV AN	38	30	29	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2016	11	10							e0164619	10.1371/journal.pone.0164619	http://dx.doi.org/10.1371/journal.pone.0164619			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0CV	27736953	gold, Green Published, Green Submitted			2023-01-03	WOS:000385505800098
J	Turner, NC; Neven, P; Loibl, S; Andre, F				Turner, Nicholas C.; Neven, Patrick; Loibl, Sibylle; Andre, Fabrice			Advances in the treatment of advanced oestrogen-receptor-positive breast cancer	LANCET			English	Article							RANDOMIZED PHASE-II; KINASE 4/6 INHIBITOR; FULVESTRANT 500 MG; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; MEDIATE RESISTANCE; GENE AMPLIFICATION; 1ST-LINE TREATMENT; ENDOCRINE THERAPY; ESR1 MUTATIONS	Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development of resistance to therapy is inevitable in advanced cancer. Major progress has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve progression-free survival. A new wave of targeted therapies is being developed, including inhibitors of PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders. Considerable challenges remain in patient selection, deciding on the most appropriate order in which to administer therapies, and establishing whether cross-resistance occurs between therapies.	[Turner, Nicholas C.] Royal Marsden Hosp, London, England; [Turner, Nicholas C.] Inst Canc Res, London, England; [Neven, Patrick] Univ Hosp Leuven, Dept Oncol, Multidisciplinary Breast Ctr, Leuven, Belgium; [Neven, Patrick] Univ Hosp Leuven, Dept Oncol, Dept Gynaecol Oncol, Leuven, Belgium; [Loibl, Sibylle] GBG Forsch GmbH, GBG, D-63263 Neu Isenburg, Germany; [Loibl, Sibylle] Bethanien, Ctr Haematol & Oncol, Frankfurt, Germany; [Andre, Fabrice] Univ Paris Sud, Gustave Roussy Canc Ctr, INSERM U981, Villejuif, France	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; German Breast Group; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Loibl, S (corresponding author), GBG Forsch GmbH, GBG, D-63263 Neu Isenburg, Germany.	sibylle.loibl@GBG.de	ANDRE, Fabrice/AAL-2683-2020	ANDRE, Fabrice/0000-0001-5795-8357; Turner, Nicholas/0000-0001-8937-0873	Pfizer; Roche/Genentech; AstraZeneca; Clovis; Servier; Novartis; Biomarin; Lilly; Synthon; Astellas; NHS	Pfizer(Pfizer); Roche/Genentech(Roche HoldingGenentech); AstraZeneca(AstraZeneca); Clovis; Servier(Servier); Novartis(Novartis); Biomarin; Lilly(Eli Lilly); Synthon; Astellas(Astellas Pharmaceuticals); NHS	NCT has received research grants from Pfizer, Roche/Genentech, AstraZeneca, Clovis, and Servier; personal fees from Novartis, Biomarin, Lilly, Synthon, Astellas; and acknowledges NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research. PN has served on international advisory boards for Lilly, Novartis, Pfizer, and Puma. SL's institution has received grants from Pfizer, Novartis, and AstraZeneca. FA has received research grants from Pfizer, AstraZeneca, Novartis, and Lilly.	Akcakanat A, 2008, CANCER-AM CANCER SOC, V112, P2352, DOI 10.1002/cncr.23456; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-88; Andre F, 2014, LANCET ONCOL, V15, P267, DOI 10.1016/S1470-2045(13)70611-9; Arnedos M, 2016, AACR 107 ANN M NEW O; Awada A, 2008, EUR J CANCER, V44, P84, DOI 10.1016/j.ejca.2007.10.003; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Baselga J, 2015, SAN ANT BREAST CANC; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Beagle B, 2011, CANCER CELL, V19, P693, DOI 10.1016/j.ccr.2011.05.020; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Bowles DW, 2013, BRIT J CANCER, V109, P1085, DOI 10.1038/bjc.2013.474; Cardoso F, 2014, ANN ONCOL, V25, P1871, DOI 10.1093/annonc/mdu385; Carlson RW, 2012, J NATL COMPR CANC NE, V10, P821, DOI 10.6004/jnccn.2012.0086; Carpenter JT, 2005, J CLIN ONCOL, V23, p19S; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Chandarlapaty S SP, 2015, SAN ANT BREAST CANC; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Di Cosimo S, 2015, CLIN CANCER RES, V21, P49, DOI 10.1158/1078-0432.CCR-14-0940; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Dickler M, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT231; Dickler MN, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.510; Dickson MA, 2009, CURR ONCOL, V16, P120; Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033; Ellis MJ, 2015, J CLIN ONCOL, V33, P3781, DOI 10.1200/JCO.2015.61.5831; Ellis MJ, 2016, EUR SOC MED ONC 2016; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Finn RS, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.507; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fleming GF, 2012, BREAST CANCER RES TR, V136, P355, DOI 10.1007/s10549-011-1910-7; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Harper Jane V., 2004, V296, P113; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Hirsch E, PI3K CANC STROMA INT; Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Hortobagyi GN, 2016, J CLIN ONCOL, V34, P419, DOI 10.1200/JCO.2014.60.1971; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hu WY, 2016, CLIN CANCER RES, V22, P2000, DOI 10.1158/1078-0432.CCR-15-1421; Hyman D, 2015, AACR NCI EORTC INT C; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Janku F, 2014, SAN ANT BREAST CANC; Juric D, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-PD1-3; Juric D, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.568; King TA, 2016, J CLIN ONCOL, V34, P2359, DOI 10.1200/JCO.2015.63.1960; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krop I, 2015, SAN ANT BREAST CAN 1; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lehmann BD, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0406-x; Loi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053292; Ma CX, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.516; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Markman B, 2012, ANN ONCOL, V23, P2399, DOI 10.1093/annonc/mds011; Mehta RS, 2012, NEW ENGL J MED, V367, P435, DOI 10.1056/NEJMoa1201622; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Piccart M, 2014, ANN ONCOL, V25, P2357, DOI 10.1093/annonc/mdu456; Robertson JFR, 2013, LANCET ONCOL, V14, P228, DOI 10.1016/S1470-2045(13)70026-3; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Ross JS, 2016, CANCER-AM CANCER SOC, V122, P2654, DOI 10.1002/cncr.30102; Rugo H, 2015, SAN ANT BREAST CANC; Rugo HS, 2014, ANN ONCOL, V25, P808, DOI 10.1093/annonc/mdu009; Rugo HS, 2014, J CLIN ONCOL S, V32, p5s; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Serra V, 2013, J CLIN INVEST, V123, P2551, DOI 10.1172/JCI66343; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Soler A, 2013, J EXP MED, V210, P1937, DOI 10.1084/jem.20121571; Soria JC, 2014, ANN ONCOL, V25, P2244, DOI 10.1093/annonc/mdu390; Swanton C, 2016, ANN ONCOL, V27, P1443, DOI 10.1093/annonc/mdw192; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Treilleux I, 2015, ANN ONCOL, V26, P120, DOI 10.1093/annonc/mdu497; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Warenius HM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-72; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wolff AC, 2013, J CLIN ONCOL, V31, P195, DOI 10.1200/JCO.2011.38.3331; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251	103	105	110	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2017	389	10087					2403	2414		10.1016/S0140-6736(16)32419-9	http://dx.doi.org/10.1016/S0140-6736(16)32419-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX6ED	27939057				2023-01-03	WOS:000403334400026
J	Fischer, S; Rose, A				Fischer, Shira; Rose, Adam			Responsible e-Prescribing Needs e-Discontinuation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Fischer, Shira; Rose, Adam] RAND Corp, 20 Pk Plaza,Ste 920, Boston, MA 02116 USA	RAND Corporation	Fischer, S (corresponding author), RAND Corp, 20 Pk Plaza,Ste 920, Boston, MA 02116 USA.	sfischer@rand.org	Rose, Adam/HHY-9078-2022; Fischer, Shira/ABC-4293-2021	Fischer, Shira/0000-0002-1124-4962; Rose, Adam/0000-0001-8681-6155				Allen AS, 2012, ANN INTERN MED, V157, P700, DOI 10.7326/0003-4819-157-10-201211200-00006; Department of Health and Human Services-Office of the National Coordinator for Health Information Technology, 2015, 2015 ED HLTH INF TEC; Kaushal R, 2010, J GEN INTERN MED, V25, P530, DOI 10.1007/s11606-009-1238-8; Lourenco LM, 2016, J GEN INTERN MED, V31, P808, DOI 10.1007/s11606-016-3606-5	4	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2017	317	5					469	470		10.1001/jama.2016.19908	http://dx.doi.org/10.1001/jama.2016.19908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ9RN	28170486				2023-01-03	WOS:000393564200010
J	Das, P; Horton, R				Das, Pamela; Horton, Richard			Essential medicines for universal health coverage	LANCET			English	Editorial Material									[Das, Pamela; Horton, Richard] The Lancet, London EC2Y 5AS, England		Das, P (corresponding author), The Lancet, London EC2Y 5AS, England.				Bill & Melinda Gates Foundation; WHO; University Medical Centre Groningen; Boston University	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); WHO(World Health Organization); University Medical Centre Groningen; Boston University	We thank Veronika Wirtz, Hans Hogerzeil, and Andy Gray for their leadership of the Lancet Commission on Essential Medicines Policies, and commissioners for their contributions to this report. We also thank the Bill & Melinda Gates Foundation, WHO, University Medical Centre Groningen, and Boston University for their financial support, together with the academic and other institutions that have generously allowed colleagues to devote time to the work of the Commission.	[Anonymous], 2015, LANCET, V386, P220; Rubin R, 2016, LANCET, V388, P1266, DOI 10.1016/S0140-6736(16)31708-1; UN Secretary-General and Co-Chairs of the High-Level Panel, 2016, UN SECR GEN HIGH LEV; United Nations, 2015, SUSTAINABLE DEV GOAL; Wirtz VJ, 2016, LANCET; Witty A, 2016, LANCET; World Health Organization, 2015, GLOBAL ACTION PLAN A	7	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2017	389	10067					337	339		10.1016/S0140-6736(16)31907-9	http://dx.doi.org/10.1016/S0140-6736(16)31907-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EI9CK	27832878				2023-01-03	WOS:000392804700007
J	Beaudart, C; Zaaria, M; Pasleau, FEO; Reginster, JY; Bruyere, O				Beaudart, Charlotte; Zaaria, Myriam; Pasleau, Francoise; Reginster, Jean-Yves; Bruyere, Olivier			Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							QUALITY-OF-LIFE; WORKING GROUP; OLDER-ADULTS; RISK-FACTOR; MORTALITY; ASSOCIATION; DEFINITION; CONSENSUS; DYNAPENIA; REHABILITATION	Objective The purpose of this study was to perform a systematic review to assess the short-, middle and long-term consequences of sarcopenia. Methods Prospective studies assessing the consequences of sarcopenia were searched across different electronic databases (MEDLINE, EMBASE, EBM Reviews, Cochrane Database of Systematic Reviews, EBM Reviews ACP Journal Club, EBM Reviews DARE and AMED). Only studies that used the definition of the European Working Group on Sarcopenia in Older People to diagnose sarcopenia were included. Study selection and data extraction were performed by two independent reviewers. For outcomes reported by three or more studies, a meta-analysis was performed. The study results are expressed as odds ratios (OR) with 95% Cl. Results Of the 772 references identified through the database search, 17 were included in this systematic review. The number of participants in the included studies ranged from 99 to 6658, and the duration of follow-up varied from 3 months to 9.8 years. Eleven out of 12 studies assessed the impact of sarcopenia on mortality. The results showed a higher rate of mortality among sarcopenic subjects (pooled OR of 3.596 (95% CI 2.96-4.37)). The effect was higher in people aged 79 years or older compared with younger subjects (p = 0.02). Sarcopenia is also associated with functional decline (pooled OR of 6 studies 3.03 (95% CI 1.80-5.12)), a higher rate of falls (2/2 studies found a significant association) and a higher incidence of hospitalizations (1/1 study). The impact of sarcopenia on the incidence of fractures and the length of hospital stay was less clear (only 1/2 studies showed an association for both outcomes). Conclusion Sarcopenia is associated with several harmful outcomes, making this geriatric syndrome a real public health burden.	[Beaudart, Charlotte; Reginster, Jean-Yves; Bruyere, Olivier] Univ Liege, Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium; [Zaaria, Myriam] Aix Marseille Univ, Sch Med, Marseille, France; [Pasleau, Francoise] Univ Liege, Life Sci Lib, Liege, Belgium	University of Liege; UDICE-French Research Universities; Aix-Marseille Universite; Universite de Franche-Comte; University of Liege	Beaudart, C (corresponding author), Univ Liege, Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium.	c.beaudart@ulg.ac.be	Beaudart, Charlotte/AAL-3044-2020; Bruyere, Olivier/H-8302-2019	Bruyere, Olivier/0000-0003-4269-9393	FNRS (Fonds National de la Recherche Scientifique de Belgique-FRS-FNRS)	FNRS (Fonds National de la Recherche Scientifique de Belgique-FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS)	C.B. is supported by a fellowship from the FNRS (Fonds National de la Recherche Scientifique de Belgique-FRS-FNRS-www.frs-fnrs.be).	Alexandre TD, 2014, J NUTR HEALTH AGING, V18, P547, DOI [10.1007/s12603-014-0465-9, 10.1007/s12603-013-0424-x]; Arango-Lopera VE, 2013, J NUTR HEALTH AGING, V17, P259, DOI 10.1007/s12603-012-0434-0; Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520; Beaudart C, 2015, EXP GERONTOL, V61, P31, DOI 10.1016/j.exger.2014.11.014; Beaudart C, 2015, AGE AGEING, V44, P960, DOI 10.1093/ageing/afv133; Beaudart C, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-45; Bianchi L, 2016, J GERONTOL A-BIOL, V71, P259, DOI 10.1093/gerona/glv129; Bijlsma AY, 2013, OSTEOPOROSIS INT, V24, P2681, DOI 10.1007/s00198-013-2376-8; Bischoff-Ferrari HA, 2015, OSTEOPOROS INT; Cao L, 2016, J AM MED DIR ASSOC, V17, P675, DOI 10.1016/j.jamda.2016.06.001; Cawthon PM, 2015, J AM GERIATR SOC, V63, P2247, DOI 10.1111/jgs.13788; Cerri AP, 2015, CLIN NUTR, V34, P745, DOI 10.1016/j.clnu.2014.08.015; Chalhoub D, 2015, J AM GERIATR SOC, V63, P1733, DOI 10.1111/jgs.13605; Chang S-F, 2016, WORLDVIEWS EVID BASE; Chen LK, 2014, J AM MED DIR ASSOC, V15, P95, DOI 10.1016/j.jamda.2013.11.025; Clark BC, 2010, CURR OPIN CLIN NUTR, V13, P271, DOI 10.1097/MCO.0b013e328337819e; Cooper C, 2012, OSTEOPOROSIS INT, V23, P1839, DOI 10.1007/s00198-012-1913-1; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Alexandre TD, 2014, J NUTR HEALTH AGING, V18, P751, DOI [10.1007/s12603-014-0450-3, 10.1007/s12603-014-0540-2]; Dam TT, 2014, J GERONTOL A-BIOL, V69, P584, DOI 10.1093/gerona/glu013; Delmonico MJ, 2009, AM J CLIN NUTR, V90, P1579, DOI 10.3945/ajcn.2009.28047; Deschenes MR, 2004, SPORTS MED, V34, P809, DOI 10.2165/00007256-200434120-00002; Dupuy C, 2015, J CACHEXIA SARCOPENI, V6, P144, DOI 10.1002/jcsm.12021; Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003; Go SW, 2013, KOREAN J FAM MED, V34, P281, DOI 10.4082/kjfm.2013.34.4.281; Kim JH, 2014, J GERONTOL A-BIOL, V69, P1244, DOI 10.1093/gerona/glu050; Landi F, 2013, AGE AGEING, V42, P203, DOI 10.1093/ageing/afs194; Landi F, 2012, CLIN NUTR, V31, P652, DOI 10.1016/j.clnu.2012.02.007; Landi F, 2012, J AM MED DIR ASSOC, V13, P121, DOI 10.1016/j.jamda.2011.07.004; Manini TM, 2012, J GERONTOL A-BIOL, V67, P28, DOI 10.1093/gerona/glr010; Mitchell WK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00260; Morishita S, 2012, SUPPORT CARE CANCER, V20, P821, DOI 10.1007/s00520-011-1156-2; Morley JE, 2011, J AM MED DIR ASSOC, V12, P403, DOI 10.1016/j.jamda.2011.04.014; Muscaritoli M, 2010, CLIN NUTR, V29, P154, DOI 10.1016/j.clnu.2009.12.004; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; Saka B, 2016, EUR GERIATR MED, V7, P232, DOI 10.1016/j.eurger.2015.12.010; Sanchez-Rodriguez D, 2015, ARCH GERONTOL GERIAT, V61, P176, DOI 10.1016/j.archger.2015.05.008; Sanchez-Rodriguez D, 2014, ARCH GERONTOL GERIAT, V59, P39, DOI 10.1016/j.archger.2014.02.009; Neto LSS, 2012, BRAZ J PHYS THER, V16, P360; Studenski SA, 2014, J GERONTOL A-BIOL, V69, P547, DOI 10.1093/gerona/glu010; Tanimoto Y, 2013, GERIATR GERONTOL INT; Vetrano DL, 2014, J GERONTOL A-BIOL, V69, P1154, DOI 10.1093/gerona/glu034; Woo J, 2015, J AM MED DIR ASSOC, V16, P247, DOI 10.1016/j.jamda.2014.11.013; Yadav A, 2015, CLIN TRANSPLANT, V29, P134, DOI 10.1111/ctr.12493	44	468	490	5	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2017	12	1							e0169548	10.1371/journal.pone.0169548	http://dx.doi.org/10.1371/journal.pone.0169548			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI3EK	28095426	Green Submitted, Green Published, gold			2023-01-03	WOS:000392372300023
J	Yang, WL; Zhu, XY; Zhu, N; Su, CY; Han, QF; Wang, T; Zhang, AH				Yang, Wen-Ling; Zhu, Xue-Yan; Zhu, Ning; Su, Chun-Yan; Han, Qing-Feng; Wang, Tao; Zhang, Ai-Hua			What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital	PLOS ONE			English	Article							ATHEROSCLEROTIC CARDIOVASCULAR EVENTS; DENSITY-LIPOPROTEIN CHOLESTEROL; CHRONIC KIDNEY-DISEASE; MANAGING DYSLIPIDEMIA; NON-HDL; HEMODIALYSIS; ABNORMALITIES; POPULATION; GUIDELINES	Background With lipid level being a major contributing factor for cardiovascular health, the high cardiovascular mortality among dialysis patients has raised substantial concerns in regard to the optimal lipid level in these patient population. Objective To explore the optimal lipid level for the survival of dialysis patients. Methods The lipid profile was measured for each patient. All participants were followed throughout the course of the study. Cox proportional hazards analysis was performed to analyze the prognostic value of lipid level on the survival of these patients. Results In our study that included 311 stable maintenance dialysis patients, 54.98% of the participants had LDL-C level >= 100 mg/dl and 82.91% of the patients with triglycerides >= 200 mg/dl had non-HDL level >= 130 mg/dl. During the follow-up period of 48.0 (18.0, 55.5) months, 149 (47.91%) participants died. Among those who died, 59 patients died of cardiovascular disease (CVD) and 33 patients died of ischemic CVD (12.0, 4.7, and 2.7 events per 100 patient-years, respectively). Patients with LDL-C 100-130 mg/dl or non-HDL 130-160 mg/dl had a lower all-cause mortality rate than those who did not meet these criteria. After adjusting for the traditional and ESRD-related risk factors, non-HDL was found to be the independent risk factor for the all-cause mortality. Compared to those patients with non-HDL 130-160 mg/dl, patients with non-HDL < 100 mg/dl, 100-130 mg/dl, 160-190 mg/dl, or >= 190 mg/dl all had higher all-cause mortality: HR (95% CI) 3.207 (1.801, 5.713), 2.493 (1.485, 4.184), 2.476 (1.423, 4.307), and 1.917 (1.099, 3.345), respectively. There were no differences in nutrition, comorbidity, and inflammation indices among the patients with different non-HDL groups. However, patients with non-HDL of 130-160 mg/dl had the lowest corrected calcium and calcium phosphate product values as compared with other non-HDL groups. Conclusion Our study demonstrated that non-HDL 130-160 mg/dl might be the most appropriate lipid level in our dialysis patients. Our follow-up data also showed that patients with higher lipid level had poorer prognosis, just as in the general population.	[Yang, Wen-Ling; Zhu, Ning; Su, Chun-Yan; Han, Qing-Feng; Wang, Tao; Zhang, Ai-Hua] Peking Univ, Hosp 3, Dept Nephrol, Beijing, Peoples R China; [Zhu, Xue-Yan] Jilin Med Univ, Dept Nephrol, Changchun, Jilin Province, Peoples R China	Peking University; Jilin Medical University	Zhang, AH (corresponding author), Peking Univ, Hosp 3, Dept Nephrol, Beijing, Peoples R China.	hanqingfeng@sina.com; zgbjrose9985@yahoo.com			peking university third hospital; Atherosclerosis Clinical medical research special funds projects by Chinese Medical Association [09010030158]	peking university third hospital; Atherosclerosis Clinical medical research special funds projects by Chinese Medical Association	Funded by the seed money of the peking university third hospital and Atherosclerosis Clinical medical research special funds projects by Chinese Medical Association (grant number: 09010030158) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Chae JW, 2011, NEPHRON CLIN PRACT, V117, pC379, DOI 10.1159/000321525; Chan DT, 2008, ATHEROSCLEROSIS, V196, P823, DOI 10.1016/j.atherosclerosis.2007.01.023; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chawla V, 2010, CLIN J AM SOC NEPHRO, V5, P1582, DOI 10.2215/CJN.01450210; Collins AJ, 2003, AM J KIDNEY DIS, V41, pV, DOI 10.1016/S0272-6386(03)80001-X; Echida Y, 2012, CLIN EXP NEPHROL, V16, P767, DOI 10.1007/s10157-012-0615-5; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Keane WF, 2005, CARDIOL CLIN, V23, P363, DOI 10.1016/j.ccl.2005.03.004; Kim C-G, 2014, ELECTRON J DIFFER EQ, V2014, P38, DOI DOI 10.1159/000367803; Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E; Lupton JR, 2016, J CLIN LIPIDOL, V10, P72, DOI 10.1016/j.jacl.2015.09.006; Marz W, 2011, CLIN J AM SOC NEPHRO, V6, P1316, DOI 10.2215/CJN.09121010; Navaneethan SD, 2009, COCHRANE DATABASE SY, VD4289; Nogueira J, 2007, CLIN J AM SOC NEPHRO, V2, P766, DOI 10.2215/CJN.04131206; Patwardhan VG, 2015, J CLIN LIPIDOL, V9, P652, DOI 10.1016/j.jacl.2015.05.007; Pennell P, 2006, CLIN NEPHROL, V66, P336; Quaschning T, 2001, AM J KIDNEY DIS, V38, pS14, DOI 10.1053/ajkd.2001.27384; Reiner Z, 2011, EUR HEART J, V32, P1769, DOI [10.1093/eurheartj/ehr158, 10.1016/j.atherosclerosis.2011.06.012]; Shoji T, 2006, THER APHER DIAL, V10, P305, DOI 10.1111/j.1744-9987.2006.00382.x; Shoji T, 2014, CLIN EXP NEPHROL, V18, P257, DOI 10.1007/s10157-013-0871-z; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; Sidhu Manavjot S, 2010, Adv Perit Dial, V26, P47; Snyder JJ, 2009, AM J NEPHROL, V30, P44, DOI 10.1159/000201014; Stone NJ, 2014, ANN INTERN MED, V160, P339, DOI 10.7326/M14-0126; Tonelli M, 2014, ANN INTERN MED, V160, P182, DOI 10.7326/M13-2453; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Weiner DE, 2004, J GEN INTERN MED, V19, P1045, DOI 10.1111/j.1525-1497.2004.40049.x; Zoppellaro G, 2012, AM J KIDNEY DIS, V59, P135, DOI 10.1053/j.ajkd.2011.07.027	31	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2016	11	12							e0167258	10.1371/journal.pone.0167258	http://dx.doi.org/10.1371/journal.pone.0167258			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8LN	27992532	Green Published, Green Submitted, gold			2023-01-03	WOS:000392758000012
J	Wang, J; Krejci, R; Giangrandel, S; Kuang, C; Barbosa, HMJ; Brito, J; Carbone, S; Chi, XG; Comstock, J; Ditas, F; Lavric, J; Manninen, HE; Mei, F; Moran-Zuloaga, D; Pohlker, C; Pohlker, ML; Saturno, J; Schmid, B; Souza, RAF; Springston, SR; Tomlinson, JM; Toto, T; Walter, D; Wimmer, D; Smith, JN; Kulmala, M; Machado, LAT; Artaxo, P; Andreae, MO; Petaja, T; Martin, ST				Wang, Jian; Krejci, Radovan; Giangrandel, Scott; Kuang, Chongai; Barbosa, Henrique M. J.; Brito, Joel; Carbone, Samara; Chi, Xuguang; Comstock, Jennifer; Ditas, Florian; Lavric, Jost; Manninen, Hanna E.; Mei, Fan; Moran-Zuloaga, Daniel; Poehlker, Christopher; Poehlker, Mira L.; Saturno, Jorge; Schmid, Beat; Souza, Rodrigo A. F.; Springston, Stephen R.; Tomlinson, Jason M.; Toto, Tami; Walter, David; Wimmer, Daniela; Smith, James N.; Kulmala, Markku; Machado, Luiz A. T.; Artaxo, Paulo; Andreae, Meinrat O.; Petaja, Tuukka; Martin, Scot T.			Amazon boundary layer aerosol concentration sustained by vertical transport during rainfall	NATURE			English	Article							ATMOSPHERIC AEROSOLS; FREE TROPOSPHERE; WET SEASON; TALL TOWER; NUCLEATION; FOREST; NUCLEI; CCN	The nucleation of atmospheric vapours is an important source of new aerosol particles that can subsequently grow to form cloud condensation nuclei in the atmosphere(1). Most field studies of atmospheric aerosols over continents are influenced by atmospheric vapours of anthropogenic origin (for example, ref. 2) and, in consequence, aerosol processes in pristine, terrestrial environments remain poorly understood. The Amazon rainforest is one of the few continental regions where aerosol particles and their precursors can be studied under near-natural conditions(3-5), but the origin of small aerosol particles that grow into cloud condensation nuclei in the Amazon boundary layer remains unclear(6-8). Here we present aircraft- and ground-based measurements under clean conditions during the wet season in the central Amazon basin. We find that high concentrations of small aerosol particles (with diameters of less than 50 nanometres) in the lower free troposphere are transported from the free troposphere into the boundary layer during precipitation events by strong convective downdrafts and weaker downward motions in the trailing stratiform region. This rapid vertical transport can help to maintain the population of particles in the pristine Amazon boundary layer, and may therefore influence cloud properties and climate under natural conditions.	[Wang, Jian; Giangrandel, Scott; Kuang, Chongai; Springston, Stephen R.; Toto, Tami] Brookhaven Natl Lab, Environm & Climate Sci Dept, Upton, NY 11973 USA; [Krejci, Radovan] Stockholm Univ, Dept Appl Environm Sci & Analyt Chem, S-10691 Stockholm, Sweden; [Barbosa, Henrique M. J.; Brito, Joel; Carbone, Samara; Artaxo, Paulo] Univ Sao Paulo, BR-05508900 Sao Paulo, Brazil; [Chi, Xuguang; Ditas, Florian; Moran-Zuloaga, Daniel; Poehlker, Christopher; Poehlker, Mira L.; Saturno, Jorge; Walter, David; Andreae, Meinrat O.] Max Planck Inst Chem, Biogeochem & Multiphase Chem Dept, D-55128 Mainz, Germany; [Chi, Xuguang] Nanjing Univ, Sch Atmospher Sci, Nanjing 210023, Jiangsu, Peoples R China; [Chi, Xuguang] Collaborat Innovat Ctr Climate Change, Nanjing 210023, Jiangsu, Peoples R China; [Comstock, Jennifer; Mei, Fan; Schmid, Beat; Tomlinson, Jason M.] Pacific Northwest Natl Lab, Atmospher Sci & Global Change Div, Richland, WA 99352 USA; [Lavric, Jost] Max Planck Inst Biogeochem, Dept Biogeochem Syst, D-07745 Jena, Germany; [Manninen, Hanna E.; Wimmer, Daniela; Kulmala, Markku; Petaja, Tuukka] Univ Helsinki, Dept Phys, POB 64, FI-00014 Helsinki, Finland; [Souza, Rodrigo A. F.] Amazonas State Univ, BR-69050020 Manaus, Amazonas, Brazil; [Smith, James N.] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; [Machado, Luiz A. T.] Natl Inst Space Res, BR-12227010 Sao Jose Dos Campos, SP, Brazil; [Andreae, Meinrat O.] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; [Martin, Scot T.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Martin, Scot T.] Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Stockholm University; Universidade de Sao Paulo; Max Planck Society; Nanjing University; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Max Planck Society; University of Helsinki; Universidade do Estado do Amazonas; University of California System; University of California Irvine; Instituto Nacional de Pesquisas Espaciais (INPE); University of California System; University of California San Diego; Scripps Institution of Oceanography; Harvard University; Harvard University	Wang, J (corresponding author), Brookhaven Natl Lab, Environm & Climate Sci Dept, Upton, NY 11973 USA.	jian@bnl.gov	Ferreira de Souza, Rodrigo/B-8453-2013; Springston, Stephen R/P-5237-2018; Pöhlker, Christopher/S-5207-2016; Machado, Luiz/C-4314-2012; Petäjä, Tuukka/A-8009-2008; Martin, Scot/G-1094-2015; Lavric, Jost/H-4487-2011; Moran, Daniel/Q-9227-2019; Mei, Fan/D-9953-2013; Kulmala, Markku T/I-7671-2016; Andreae, Meinrat O./B-1068-2008; Smith, James/C-5614-2008; Wang, Jian/G-9344-2011; Barbosa, H. M. J./F-3499-2012; Giangrande, Scott/I-4089-2016; Pöhlker, Mira L/N-2835-2017; Saturno, Jorge/AAA-5529-2020; Tomlinson, Jason M/C-6566-2009; Artaxo, Paulo/E-8874-2010; Kuang, Chongai/E-4446-2013; Krejci, Radovan/L-3257-2013; Brito, Joel/B-6181-2013	Ferreira de Souza, Rodrigo/0000-0003-0838-3723; Springston, Stephen R/0000-0003-0159-4931; Pöhlker, Christopher/0000-0001-6958-425X; Machado, Luiz/0000-0002-8243-1706; Petäjä, Tuukka/0000-0002-1881-9044; Martin, Scot/0000-0002-8996-7554; Lavric, Jost/0000-0003-3610-9078; Moran, Daniel/0000-0002-1517-2732; Mei, Fan/0000-0003-4285-2749; Kulmala, Markku T/0000-0003-3464-7825; Andreae, Meinrat O./0000-0003-1968-7925; Smith, James/0000-0003-4677-8224; Barbosa, H. M. J./0000-0002-4027-1855; Giangrande, Scott/0000-0002-8119-8199; Pöhlker, Mira L/0000-0001-6852-0756; Saturno, Jorge/0000-0002-3761-3957; Tomlinson, Jason M/0000-0002-0734-3298; Artaxo, Paulo/0000-0001-7754-3036; Krejci, Radovan/0000-0002-9384-9702; Brito, Joel/0000-0002-4420-9442; Ditas, Florian/0000-0003-3824-9373; Comstock, Jennifer/0000-0002-4183-7355; Schmid, Beat/0000-0002-4705-8715	Office of Biological and Environmental Research; Atmospheric System Research (ASR) programme (Office of Biological and Environmental Research of US DOE) [DE-AC02-98CH10886]; Amazonas State Research Foundation (FAPEAM-GoAmazon); Sao Paulo Research Foundation (FAPESP) [2013/50510-5, 2013/05014-0, CHUVA 2009/15235-8]; Brazil Scientific Mobility Program (CsF/CAPES-CNPq); Brazilian Ministry of Science, Technology, and Innovation (MCTI/FINEP) [01.11.01248.00]; German Max Planck Society (MPG); German Federal Ministry of Education and Research (BMBF) [01LB1001A]	Office of Biological and Environmental Research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Atmospheric System Research (ASR) programme (Office of Biological and Environmental Research of US DOE); Amazonas State Research Foundation (FAPEAM-GoAmazon); Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazil Scientific Mobility Program (CsF/CAPES-CNPq); Brazilian Ministry of Science, Technology, and Innovation (MCTI/FINEP); German Max Planck Society (MPG); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	Institutional support was provided by the Central Office of the Brazilian Large Scale Biosphere Atmosphere Experiment in Amazonia (LBA), the Brazilian National Institute of Amazonian Research (INPA), the Brazilian National Institute for Space Research (INPE), Amazonas State University (UEA) and Amazonas State (SDS/CEUC/RDS-Uatuma). We acknowledge the Atmospheric Radiation Measurement (ARM) Climate Research Facility, a user facility of the United States Department of Energy (US DOE), Office of Science, sponsored by the Office of Biological and Environmental Research. Funding was obtained from the Atmospheric System Research (ASR) programme (Office of Biological and Environmental Research of US DOE, under contract DE-AC02-98CH10886), the Amazonas State Research Foundation (FAPEAM-GoAmazon), the Sao Paulo Research Foundation (FAPESP, project numbers 2013/50510-5, 2013/05014-0 and CHUVA 2009/15235-8), the Brazil Scientific Mobility Program (CsF/CAPES-CNPq), the Brazilian Ministry of Science, Technology, and Innovation (MCTI/FINEP contract 01.11.01248.00), the German Max Planck Society (MPG) and the German Federal Ministry of Education and Research (BMBF contract 01LB1001A). This work contains results of research conducted under the Technical/Scientific Cooperation Agreement between the National Institute for Amazonian Research, Amazonas State University, and the Max Planck Society. The work was conducted under scientific licenses 001030/2012-4, 001262/2012-2 and 00254/2013-9 of the Brazilian National Council for Scientific and Technological Development (CNPq). The opinions expressed herein are the entire responsibility of the authors and not of the participating institutions.	Andreae MO, 2015, ATMOS CHEM PHYS, V15, P10723, DOI 10.5194/acp-15-10723-2015; Andreae MO, 2007, SCIENCE, V315, P50, DOI 10.1126/science.1136529; Artaxo P, 2013, FARADAY DISCUSS, V165, P203, DOI 10.1039/c3fd00052d; Carslaw KS, 2013, NATURE, V503, P67, DOI 10.1038/nature12674; Chen Q, 2015, ATMOS CHEM PHYS, V15, P3687, DOI 10.5194/acp-15-3687-2015; Chen Q, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039880; Chi X, 2013, ATMOS CHEM PHYS, V13, P12271, DOI 10.5194/acp-13-12271-2013; Claeys M, 2004, SCIENCE, V303, P1173, DOI 10.1126/science.1092805; Clarke AD, 2013, ATMOS CHEM PHYS, V13, P7511, DOI 10.5194/acp-13-7511-2013; Clarke AD, 1999, J GEOPHYS RES-ATMOS, V104, P5735, DOI 10.1029/98JD02303; Clarke AD, 1998, J GEOPHYS RES-ATMOS, V103, P16397, DOI 10.1029/97JD02987; Ekman AML, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034970; Katoshevski D, 1999, J AEROSOL SCI, V30, P503, DOI 10.1016/S0021-8502(98)00740-X; Kirkby J, 2011, NATURE, V476, P429, DOI 10.1038/nature10343; Krejci R, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD001375; Krejci R, 2005, ATMOS CHEM PHYS, V5, P1527, DOI 10.5194/acp-5-1527-2005; Kulmala M, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006963; Kulmala M, 2013, SCIENCE, V339, P943, DOI 10.1126/science.1227385; Lee SH, 2003, SCIENCE, V301, P1886, DOI 10.1126/science.1087236; Machado LAT, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000338; Martin ST, 2016, ATMOS CHEM PHYS, V16, P4785, DOI 10.5194/acp-16-4785-2016; Martin ST, 2010, ATMOS CHEM PHYS, V10, P11415, DOI 10.5194/acp-10-11415-2010; Martin ST, 2010, REV GEOPHYS, V48, DOI 10.1029/2008RG000280; Merikanto J, 2009, ATMOS CHEM PHYS, V9, P8601, DOI 10.5194/acp-9-8601-2009; Pohlker C, 2012, SCIENCE, V337, P1075, DOI 10.1126/science.1223264; Poschl U, 2010, SCIENCE, V329, P1513, DOI 10.1126/science.1191056; RAES F, 1995, J GEOPHYS RES-ATMOS, V100, P2893, DOI 10.1029/94JD02832; Spracklen DV, 2006, ATMOS CHEM PHYS, V6, P5631, DOI 10.5194/acp-6-5631-2006; Williams E, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000380; Zhou JC, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000203	30	74	76	5	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2016	539	7629					416	419		10.1038/nature19819	http://dx.doi.org/10.1038/nature19819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EC5GP	27776357	Green Submitted			2023-01-03	WOS:000388161700051
J	Morzelle, MC; Salgado, JM; Telles, M; Mourelle, D; Bachiega, P; Buck, HS; Viel, TA				Morzelle, Maressa Caldeira; Salgado, Jocelem Mastrodi; Telles, Milena; Mourelle, Danilo; Bachiega, Patricia; Buck, Hudson Sousa; Viel, Tania Araujo			Neuroprotective Effects of Pomegranate Peel Extract after Chronic Infusion with Amyloid-beta Peptide in Mice	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; IN-VITRO; COGNITIVE IMPAIRMENT; RAT-BRAIN; ANTIBACTERIAL ACTIVITY; SUPEROXIDE-DISMUTASE; NEUROTROPHIC FACTOR; TRANSGENIC MOUSE; OXIDATIVE DAMAGE; FREE-RADICALS	Alzheimer's disease is a chronic and degenerative condition that had no treatment until recently. The current therapeutic strategies reduce progression of the disease but are expensive and commonly cause side effects that are uncomfortable for treated patients. Functional foods to prevent and/or treat many conditions, including neurodegenerative diseases, represent a promising field of study currently gaining attention. To this end, here we demonstrate the effects of pomegranate (Punica granatum) peel extract (PPE) regarding spatial memory, biomarkers of neuroplasticity, oxidative stress and inflammation in a mouse model of neurodegeneration. Male C57Bl/6 mice were chronically infused for 35 days with amyloid-beta peptide 1-42 (A beta) or vehicle (control) using mini-osmotic pumps. Another group, also infused with A beta, was treated with PPE (p.o. -beta A+PPE, 800 mg/kg/day). Spatial memory was evaluated in the Barnes maze. Animals treated with PPE and in the control group exhibited a reduction in failure to find the escape box, a finding that was not observed in the A beta group. The consumption of PPE reduced amyloid plaque density, increased the expression of neurotrophin BDNF and reduced the activity of acetylcholinesterase enzyme. A reduction in lipid peroxidation and in the concentration of the pro-inflammatory cytokine TNF-alpha was also observed in the PPE group. No hepatic lesions were observed in animals treated with PPE. In conclusion, administration of pomegranate peel extract has neuroprotective effects involving multiple mechanisms to prevent establishment and progression of the neurodegenerative process induced by infusion with amyloid-beta peptide in mice.	[Morzelle, Maressa Caldeira; Salgado, Jocelem Mastrodi; Bachiega, Patricia] Univ Sao Paulo, Dept Agrifood Ind Food & Nutr, Luiz de Queiroz Coll Agr, Padua Dias Ave,POB 9, BR-13418900 Piracicaba, SP, Brazil; [Telles, Milena; Mourelle, Danilo; Viel, Tania Araujo] Univ Sao Paulo, Inst Biomed Sci, Grad Course Pharmacol, Ave Prof Lineu Prestes 1524, BR-05508900 Sao Paulo, Brazil; [Buck, Hudson Sousa] Santa Casa Sao Paulo Sch Med Sci, Dept Physiol Sci, R Dr Cesario Motta Jr 61,111 Andar, BR-01221020 Sao Paulo, SP, Brazil; [Viel, Tania Araujo] Univ Sao Paulo, Sch Arts Sci & Humanities, Av Arlindo Bettio 1000, BR-03828080 Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Viel, TA (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Grad Course Pharmacol, Ave Prof Lineu Prestes 1524, BR-05508900 Sao Paulo, Brazil.; Viel, TA (corresponding author), Univ Sao Paulo, Sch Arts Sci & Humanities, Av Arlindo Bettio 1000, BR-03828080 Sao Paulo, SP, Brazil.	taniaviel@usp.br	Morzelle, Maressa C/N-4461-2015; Buck, Hudson/E-7664-2013; Viel, Tania/K-2909-2016	Buck, Hudson/0000-0002-1867-2441; Viel, Tania/0000-0002-4015-785X; Bachiega, Patricia/0000-0002-6517-5464	Sao Paulo Research Foundation [2013/0898-1, 2013/13656-1, 2012/12917-3]	Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Sao Paulo Research Foundation 2013/0898-1, 2013/13656-1 and 2012/12917-3 (www.fapesp.br). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ademosun AO, 2012, J MED FOOD, V15, P428, DOI 10.1089/jmf.2011.0226; Ahmed S, 2005, J NUTR, V135, P2096, DOI 10.1093/jn/135.9.2096; Ahmed T, 2014, PHYTOTHER RES, V28, P517, DOI 10.1002/ptr.5030; Akhtar S, 2015, FOOD CHEM, V174, P417, DOI 10.1016/j.foodchem.2014.11.035; ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; Allen SJ, 2011, CURR NEUROPHARMACOL, V9, P559, DOI 10.2174/157015911798376190; Amaral FA, 2010, NEUROPEPTIDES, V44, P93, DOI 10.1016/j.npep.2009.10.006; BALAZS L, 1994, NEUROCHEM RES, V19, P1131, DOI 10.1007/BF00965146; Baraldi T, 2013, EXP GERONTOL, V48, P831, DOI 10.1016/j.exger.2013.05.055; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Benamar H, 2010, J BIOL SCI, V10, P100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang L, 2015, SCI REP-UK, V5, DOI 10.1038/srep10256; Choi SJ, 2011, J MED FOOD, V14, P695, DOI 10.1089/jmf.2010.1452; Ennaceur A, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.223; Essa MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120964; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Franklin K.B.J., 2007, MOUSE BRAIN STEREOTA; Frautschy SA, 1998, J NEUROSCI, V18, P8311; Gao YL, 2012, ENVIRON TOXICOL PHAR, V33, P304, DOI 10.1016/j.etap.2011.12.022; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Gomez-Pinilla F, 2012, NUTR NEUROSCI, V15, P127, DOI 10.1179/1476830511Y.0000000035; Gullon B, 2016, FOOD CONTROL, V59, P94, DOI 10.1016/j.foodcont.2015.05.025; Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006; Hu SQ, 2015, J MOL NEUROSCI, V55, P1014, DOI 10.1007/s12031-014-0458-5; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Iores-Marcal LM, 2006, PEPTIDES, V27, P3363, DOI 10.1016/j.peptides.2006.08.012; Johanningsmeier SD, 2011, ANNU REV FOOD SCI T, V2, P181, DOI 10.1146/annurev-food-030810-153709; Kreutz F, 2013, NEUROCHEM RES, V38, P2342, DOI 10.1007/s11064-013-1145-6; Kwak HM, 2005, ARCH PHARM RES, V28, P1328, DOI 10.1007/BF02977896; LEVIMONTALCINI R, 1987, BIOSCIENCE REP, V7, P681, DOI 10.1007/BF01116861; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Luque-Rodriguez JM, 2007, BIORESOURCE TECHNOL, V98, P2705, DOI 10.1016/j.biortech.2006.09.019; Lyras L, 1997, J NEUROCHEM, V68, P2061; Mahboubi A, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0887-x; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Morris MC, 2005, AM J CLIN NUTR, V81, P508; Nunes MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142267; Oh MH, 2004, PHYTOMEDICINE, V11, P544, DOI 10.1016/j.phymed.2004.03.001; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ono K, 2004, BBA-MOL BASIS DIS, V1690, P193, DOI 10.1016/j.bbadis.2004.06.008; Ozcankaya R, 2002, CROAT MED J, V43, P28; Pervin M, 2014, MOLECULES, V19, P9403, DOI 10.3390/molecules19079403; Qu W, 2009, T ASABE, V52, P1997, DOI 10.13031/2013.29196; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; RICHARDSON JS, 1993, ANN NY ACAD SCI, V695, P73, DOI 10.1111/j.1749-6632.1993.tb23031.x; Rojanathammanee L, 2013, J NUTR, V143, P597, DOI 10.3945/jn.112.169516; Ryu HW, 2012, FOOD CHEM, V132, P1244, DOI 10.1016/j.foodchem.2011.11.093; Salgado JM, 2012, PLANT FOOD HUM NUTR, V67, P39, DOI 10.1007/s11130-011-0264-y; Schrag M, 2013, NEUROBIOL DIS, V59, P100, DOI 10.1016/j.nbd.2013.07.005; Schubert SY, 1999, J ETHNOPHARMACOL, V66, P11, DOI 10.1016/S0378-8741(98)00222-0; Schulz V, 2003, PHYTOMEDICINE, V10, P74, DOI 10.1078/1433-187X-00302; Seeram N, 2005, SEP PURIF TECHNOL, V41, P49, DOI 10.1016/j.seppur.2004.04.003; Small SA, 2000, MICROSC RES TECHNIQ, V51, P101, DOI 10.1002/1097-0029(20001001)51:1<101::AID-JEMT11>3.0.CO;2-H; Sorensen G, 1996, Z LEBENSM UNTERS FOR, V202, P205, DOI 10.1007/BF01263541; Spencer JPE, 2009, ARCH BIOCHEM BIOPHYS, V492, P1, DOI 10.1016/j.abb.2009.10.003; Subash S, 2015, NUTRITION, V31, P223, DOI 10.1016/j.nut.2014.06.004; Szwajgier D, 2014, POL J FOOD NUTR SCI, V64, P59, DOI 10.2478/v10222-012-0089-x; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vardin H, 2012, INT J FOOD SCI TECH, V47, P167, DOI 10.1111/j.1365-2621.2011.02823.x; Venkatesan R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/814068; Viel TA, 2012, CURR ALZHEIMER RES, V2011; Viel TA, 2008, NEUROBIOL AGING, V29, P1805, DOI 10.1016/j.neurobiolaging.2007.04.019; Wang DL, 2012, BIOL PHARM BULL, V35, P2128, DOI 10.1248/bpb.b12-00238; Xu BJ, 2007, J FOOD SCI, V72, pS159, DOI 10.1111/j.1750-3841.2006.00260.x; Yang JP, 2016, FOOD CHEM, V194, P1300, DOI 10.1016/j.foodchem.2015.08.099; Yu TX, 2015, INT J CLIN EXP PATHO, V8, P6740; ZEMLAN FP, 1989, BRAIN RES, V476, P160, DOI 10.1016/0006-8993(89)91550-3; Zhang JS, 2016, NEUROSCIENCE, V325, P1, DOI 10.1016/j.neuroscience.2016.03.024	72	45	47	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2016	11	11							e0166123	10.1371/journal.pone.0166123	http://dx.doi.org/10.1371/journal.pone.0166123			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9OG	27829013	gold, Green Published, Green Submitted			2023-01-03	WOS:000387724300084
J	Juthani-Mehta, M; Van Ness, PH; Bianco, L; Rink, A; Rubeck, S; Ginter, S; Argraves, S; Charpentier, P; Acampora, D; Trentalange, M; Quagliarello, V; Peduzzi, P				Juthani-Mehta, Manisha; Van Ness, Peter H.; Bianco, Luann; Rink, Andrea; Rubeck, Sabina; Ginter, Sandra; Argraves, Stephanie; Charpentier, Peter; Acampora, Denise; Trentalange, Mark; Quagliarello, Vincent; Peduzzi, Peter			Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT-INFECTIONS; ASYMPTOMATIC BACTERIURIA; ESCHERICHIA-COLI; DOUBLE-BLIND; PREVENTION; REDUCTION; INGESTION; DIAGNOSIS; PRODUCTS; JUICE	IMPORTANCE Bacteriuria plus pyuria is highly prevalent among older women living in nursing homes. Cranberry capsules are an understudied, nonantimicrobial prevention strategy used in this population. OBJECTIVE To test the effect of 2 oral cranberry capsules once a day on presence of bacteriuria plus pyuria among women residing in nursing homes. DESIGN, SETTING, AND PARTICIPANTS Double-blind, randomized, placebo-controlled efficacy trial with stratification by nursing home and involving 185 English-speaking women aged 65 years or older, with or without bacteriuria plus pyuria at baseline, residing in 21 nursing homes located within 50 miles (80 km) of New Haven, Connecticut (August 24, 2012-October 26, 2015). INTERVENTIONS Two oral cranberry capsules, each capsule containing 36 mg of the active ingredient proanthocyanidin (ie, 72 mg total, equivalent to 20 ounces of cranberry juice) vs placebo administered once a day in 92 treatment and 93 control group participants. MAIN OUTCOMES AND MEASURES Presence of bacteriuria (ie, at least 105 colony-forming units [CFUs] per milliliter of 1 or 2 microorganisms in urine culture) plus pyuria (ie, any number of white blood cells on urinalysis) assessed every 2 months over the 1-year study surveillance; any positive finding was considered to meet the primary outcome. Secondary outcomes were symptomatic urinary tract infection (UTI), all-cause death, all-cause hospitalization, all multidrug antibiotic-resistant organisms, antibiotics administered for suspected UTI, and total antimicrobial administration. RESULTS Of the 185 randomized study participants (mean age, 86.4 years [SD, 8.2], 90.3% white, 31.4% with bacteriuria plus pyuria at baseline), 147 completed the study. Overall adherence was 80.1%. Unadjusted results showed the presence of bacteriuria plus pyuria in 25.5%(95% CI, 18.6%-33.9%) of the treatment group and in 29.5%(95% CI, 22.2%-37.9%) of the control group. The adjusted generalized estimating equations model that accounted for missing data and covariates showed no significant difference in the presence of bacteriuria plus pyuria between the treatment group vs the control group (29.1% vs 29.0%; OR, 1.01; 95% CI, 0.61-1.66; P=.98). There were no significant differences in number of symptomatic UTIs (10 episodes in the treatment group vs 12 in the control group), rates of death (17 vs 16 deaths; 20.4 vs 19.1 deaths/100 person-years; rate ratio [RR], 1.07; 95% CI, 0.54-2.12), hospitalization (33 vs 50 admissions; 39.7 vs 59.6 hospitalizations/100 person-years; RR, 0.67; 95% CI, 0.32-1.40), bacteriuria associated with multidrug-resistant gram-negative bacilli (9 vs 24 episodes; 10.8 vs 28.6 episodes/100 person-years; RR, 0.38; 95% CI, 0.10-1.46), antibiotics administered for suspected UTIs (692 vs 909 antibiotic days; 8.3 vs 10.8 antibiotic days/person-year; RR, 0.77; 95% CI, 0.44-1.33), or total antimicrobial utilization (1415 vs 1883 antimicrobial days; 17.0 vs 22.4 antimicrobial days/person-year; RR, 0.76; 95% CI, 0.46-1.25). CONCLUSIONS AND RELEVANCE Among older women residing in nursing homes, administration of cranberry capsules vs placebo resulted in no significant difference in presence of bacteriuria plus pyuria over 1 year.	[Juthani-Mehta, Manisha; Quagliarello, Vincent] Yale Sch Med, Infect Dis Sect, Dept Internal Med, New Haven, CT USA; [Van Ness, Peter H.; Bianco, Luann; Rink, Andrea; Rubeck, Sabina; Ginter, Sandra; Argraves, Stephanie; Charpentier, Peter; Acampora, Denise; Trentalange, Mark] Yale Sch Med, Sect Geriatr, Dept Internal Med, New Haven, CT USA; [Peduzzi, Peter] Yale Sch Publ Hlth, Yale Ctr Analyt Sci, Dept Biostat, New Haven, CT USA	Yale University; Yale University; Yale University	Juthani-Mehta, M (corresponding author), Yale Univ, Infect Dis Sect, Dept Internal Med, Sch Med, POB 208022, New Haven, CT 06520 USA.	manisha.juthani@yale.edu			Claude D. Pepper Older Americans Independence Center [P30 AG021342]; National Institute on Aging, National Institutes of Health [R01 AG041153, K07 AG030093]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041153, K07AG030093, P30AG021342] Funding Source: NIH RePORTER	Claude D. Pepper Older Americans Independence Center; National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants P30 AG021342 Claude D. Pepper Older Americans Independence Center, R01 AG041153, and K07 AG030093 all from the National Institute on Aging, National Institutes of Health. Cranberry and placebo capsules used in this study were manufactured and donated by Pharmatoka.	ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; AVORN J, 1994, JAMA-J AM MED ASSOC, V271, P751, DOI 10.1001/jama.271.10.751; Bianco L, 2012, J AM GERIATR SOC, V60, P1180, DOI 10.1111/j.1532-5415.2012.03976.x; Caljouw MAA, 2014, J AM GERIATR SOC, V62, P103, DOI 10.1111/jgs.12593; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Foxman B, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.04.003; HAVERKORN MJ, 1994, JAMA-J AM MED ASSOC, V272, P590; HOPKINS WJ, 1994, JAMA-J AM MED ASSOC, V272, P588, DOI 10.1001/jama.1994.03520080030023; Howell AB, 1998, NEW ENGL J MED, V339, P1085, DOI 10.1056/NEJM199810083391516; Jepson R, 2013, JAMA-J AM MED ASSOC, V310, P1395, DOI 10.1001/jama.2013.277509; Jepson RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001321.pub5; Juthani-Mehta M, 2015, CLIN INFECT DIS, V60, P849, DOI 10.1093/cid/ciu935; Juthani-Mehta M, 2014, JAMA-J AM MED ASSOC, V312, P1687, DOI 10.1001/jama.2014.13554; Juthani-Mehta M, 2010, J AM GERIATR SOC, V58, P2028, DOI 10.1111/j.1532-5415.2010.03080.x; Juthani-Mehta M, 2009, J AM GERIATR SOC, V57, P963, DOI 10.1111/j.1532-5415.2009.02227.x; Lavigne JP, 2008, CLIN MICROBIOL INFEC, V14, P350, DOI 10.1111/j.1469-0691.2007.01917.x; McMurdo MET, 2005, AGE AGEING, V34, P256, DOI 10.1093/ageing/afi101; Mody L, 2014, JAMA-J AM MED ASSOC, V311, P844, DOI 10.1001/jama.2014.303; Nicolle LE, 2005, CLIN INFECT DIS, V40, P643, DOI 10.1086/427507; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; Pop-Vicas A, 2009, INFECT CONT HOSP EP, V30, P325, DOI 10.1086/596608; Prior RL, 2010, J SCI FOOD AGR, V90, P1473, DOI 10.1002/jsfa.3966; Rowe TA, 2014, INFECT DIS CLIN N AM, V28, P75, DOI 10.1016/j.idc.2013.10.004; SAS, 2015, SAS QUAL TOOLS US GU; Stone ND, 2012, INFECT CONT HOSP EP, V33, P965, DOI 10.1086/667743; Terris MK, 2001, UROLOGY, V57, P26, DOI 10.1016/S0090-4295(00)00884-0; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; van den Hout WB, 2014, J AM GERIATR SOC, V62, P111, DOI 10.1111/jgs.12595; Wang CH, 2012, ARCH INTERN MED, V172, P988, DOI 10.1001/archinternmed.2012.3004; Wing DA, 2008, J UROLOGY, V180, P1367, DOI 10.1016/j.juro.2008.06.016; Wotton K, 2008, CONTEMP NURSE, V31, P44, DOI 10.5172/conu.673.31.1.44	31	48	48	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2016	316	18					1879	1887		10.1001/jama.2016.16141	http://dx.doi.org/10.1001/jama.2016.16141			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB1MN	27787564	Green Accepted, Bronze			2023-01-03	WOS:000387116500016
J	Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; Kostaras, E; Nathan, MR; Wotherspoon, A; Gao, ZH; Shi, Y; Van den Eynden, G; Daley, F; Peckitt, C; Tan, X; Salman, A; Lazaris, A; Gazinska, P; Berg, TJ; Eltahir, Z; Ritsma, L; van Rheenen, J; Khashper, A; Brown, G; Nystrom, H; Sund, M; Van Laere, S; Loyer, E; Dirix, L; Cunningham, D; Metrakos, P; Reynolds, AR				Frentzas, Sophia; Simoneau, Eve; Bridgeman, Victoria L.; Vermeulen, Peter B.; Foo, Shane; Kostaras, Eleftherios; Nathan, Mark R.; Wotherspoon, Andrew; Gao, Zu-Hua; Shi, Yu; Van den Eynden, Gert; Daley, Frances; Peckitt, Clare; Tan, Xianming; Salman, Ayat; Lazaris, Anthoula; Gazinska, Patrycja; Berg, Tracy J.; Eltahir, Zak; Ritsma, Laila; van Rheenen, Jacco; Khashper, Alla; Brown, Gina; Nystrom, Hanna; Sund, Malin; Van Laere, Steven; Loyer, Evelyne; Dirix, Luc; Cunningham, David; Metrakos, Peter; Reynolds, Andrew R.			Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases	NATURE MEDICINE			English	Article							BEVACIZUMAB PLUS CAPECITABINE; PHASE-III TRIAL; ANTIANGIOGENIC THERAPY; TUMOR INVASION; EXPERT CONSENSUS; VEGF ANTIBODY; CANCER; GROWTH; PROGRESSION; CHEMOTHERAPY	The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the nonangiogenic mechanism of vessel co-option. Here we show that vessel co-option is associated with a poor response to the anti-angiogenic agent bevacizumab in patients with colorectal cancer liver metastases. Moreover, we find that vessel co-option is also prevalent in human breast cancer liver metastases, a setting in which results with anti-angiogenic therapy have been disappointing. In preclinical mechanistic studies, we found that cancer cell motility mediated by the actin-related protein 2/3 complex (Arp2/3) is required for vessel co-option in liver metastases in vivo and that, in this setting, combined inhibition of angiogenesis and vessel co-option is more effective than the inhibition of angiogenesis alone. Vessel co-option is therefore a clinically relevant mechanism of resistance to anti-angiogenic therapy and combined inhibition of angiogenesis and vessel co-option might be a warranted therapeutic strategy.	[Frentzas, Sophia; Bridgeman, Victoria L.; Vermeulen, Peter B.; Foo, Shane; Kostaras, Eleftherios; Nathan, Mark R.; Berg, Tracy J.; Reynolds, Andrew R.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Tumour Biol Team, London, England; [Frentzas, Sophia; Wotherspoon, Andrew; Peckitt, Clare; Eltahir, Zak; Brown, Gina; Cunningham, David] Royal Marsden Hosp, London, England; [Simoneau, Eve; Gao, Zu-Hua; Shi, Yu; Salman, Ayat; Lazaris, Anthoula; Khashper, Alla; Metrakos, Peter] McGill Univ, Ctr Hlth, Royal Victoria Hosp Glen Site, Montreal, PQ, Canada; [Vermeulen, Peter B.; Van den Eynden, Gert; Nystrom, Hanna; Van Laere, Steven; Dirix, Luc] Gasthuiszusters Antwerpen Hosp St Augustinus, Translat Canc Res Unit, Antwerp, Belgium; [Daley, Frances] Royal Marsden Hosp, Breast Canc Now Histopathol Core Facil, London, England; [Tan, Xianming] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Gazinska, Patrycja] Kings Coll London, Sch Med, Guys Hosp, Breast Canc Now Unit, London, England; [Ritsma, Laila; van Rheenen, Jacco] Netherlands Hubrecht Inst Royal Netherlands Acad, Canc Genom Ctr, Utrecht, Netherlands; [Ritsma, Laila; van Rheenen, Jacco] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Nystrom, Hanna; Sund, Malin] Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden; [Loyer, Evelyne] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; McGill University; Royal Marsden NHS Foundation Trust; University of North Carolina; University of North Carolina Chapel Hill; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Utrecht University; Utrecht University; Utrecht University Medical Center; Umea University; University of Texas System; UTMD Anderson Cancer Center	Reynolds, AR (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Tumour Biol Team, London, England.; Cunningham, D (corresponding author), Royal Marsden Hosp, London, England.; Metrakos, P (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp Glen Site, Montreal, PQ, Canada.	David.Cunningham@rmh.nhs.uk; peter.metrakos@mcgill.ca; andrew.reynolds@icr.ac.uk	Eltahir, Zakaria/AAG-9869-2020; metrakos, peter/D-3726-2013; Nystrom, Hanna/AAK-4743-2021; Van Laere, Steven/GQA-8872-2022; Eltahir, Zakaria/AGW-7511-2022; Dirix, Luc/AAI-8880-2020; Ritsma, Laila/AAZ-6620-2020	Eltahir, Zakaria/0000-0001-6815-4100; Van Laere, Steven/0000-0002-2640-0040; Eltahir, Zakaria/0000-0001-6815-4100; Ritsma, Laila/0000-0002-0214-2008; Cunningham, David/0000-0001-5158-1069; Brown, Gina/0000-0002-2336-622X	Breakthrough Breast Cancer; NHS; Liver Disease Biobank (Montreal); De Stichting tegen Kanker (Antwerp); Breast Cancer Now; National Institute for Health Research [NF-SI-0515-10045] Funding Source: researchfish	Breakthrough Breast Cancer; NHS; Liver Disease Biobank (Montreal); De Stichting tegen Kanker (Antwerp); Breast Cancer Now; National Institute for Health Research(National Institute for Health Research (NIHR))	The study was supported by Breakthrough Breast Cancer (which recently merged with the Breast Cancer Campaign to form Breast Cancer Now), NHS funding to the NIHR Biomedical Research Centre at RM/ICR (London), the Liver Disease Biobank (Montreal) and De Stichting tegen Kanker (Antwerp). We thank I. Hart, K. Hodivala-Dilke, C. Isacke, R. Kerbel, A. Tutt and the members of the Liver Metastasis Research Network for their critical comments on the work. We thank Genentech for providing B20-4.1.1, S. Petrillo for assistance with the Liver Disease Biobank, J. Campbell for advice on statistical analysis and M. Balazsi for assistance with digital pathology. For their technical assistance, we thank the staff of the ICR Biological Services Unit and the staff of the Breast Cancer Now Histopathology Core Facility.	Adams RB, 2013, HPB, V15, P91, DOI 10.1111/j.1477-2574.2012.00557.x; Boonsirikamchai P, 2011, AM J ROENTGENOL, V197, pW1060, DOI 10.2214/AJR.11.6459; Brufsky AM, 2011, J CLIN ONCOL, V29, P4286, DOI 10.1200/JCO.2010.34.1255; Bugyik E, 2011, J NEUROPATH EXP NEUR, V70, P979, DOI 10.1097/NEN.0b013e318233afd7; Carbonell WS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005857; Chaudhury P, 2010, HPB, V12, P37, DOI 10.1111/j.1477-2574.2009.00119.x; Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755; Colpaert CG, 2003, HISTOPATHOLOGY, V42, P530, DOI 10.1046/j.1365-2559.2003.01629.x; Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2; de Groot JF, 2010, NEURO-ONCOLOGY, V12, P233, DOI 10.1093/neuonc/nop027; Depner C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12329; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; Donnem T, 2013, CANCER MED-US, V2, P427, DOI 10.1002/cam4.105; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gray MJ, 2008, ONCOGENE, V27, P7192, DOI 10.1038/onc.2008.356; Gruenberger B, 2008, J CLIN ONCOL, V26, P1830, DOI 10.1200/JCO.2007.13.7679; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Iwaya K, 2007, CANCER SCI, V98, P992, DOI 10.1111/j.1349-7006.2007.00488.x; Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Jeong HS, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv155; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kopetz S, 2009, CANCER RES, V69, P3842, DOI 10.1158/0008-5472.CAN-08-2246; Kuczynski EA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw030; Kusters B, 2002, CANCER RES, V62, P341; Leenders WPJ, 2004, CLIN CANCER RES, V10, P6222, DOI 10.1158/1078-0432.CCR-04-0823; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Naresh KN, 2001, HISTOPATHOLOGY, V38, P466, DOI 10.1046/j.1365-2559.2001.01061.x; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Nyati MK, 2002, GENE THER, V9, P844, DOI 10.1038/sj.gt.3301706; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pezzella F, 1996, EUR J CANCER, V32A, P2494, DOI 10.1016/S0959-8049(96)00377-2; Pezzella F, 2000, LANCET, V355, P1787; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102; Semelka RC, 2000, RADIOLOGY, V215, P89, DOI 10.1148/radiology.215.1.r00mr2989; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Shindoh J, 2012, J CLIN ONCOL, V30, P4566, DOI 10.1200/JCO.2012.45.2854; Stessels F, 2004, BRIT J CANCER, V90, P1429, DOI 10.1038/sj.bjc.6601727; Szabo V, 2015, J PATHOL, V235, P384, DOI 10.1002/path.4464; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Van den Eynden GG, 2013, CANCER RES, V73, P2031, DOI 10.1158/0008-5472.CAN-12-3931; Van den Eynden GG, 2012, CLIN EXP METASTAS, V29, P541, DOI 10.1007/s10585-012-9469-1; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Wong R, 2011, ANN ONCOL, V22, P2042, DOI 10.1093/annonc/mdq714	53	240	245	4	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2016	22	11					1294	1302		10.1038/nm.4197	http://dx.doi.org/10.1038/nm.4197			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EB3XK	27748747	Green Accepted, Green Submitted			2023-01-03	WOS:000387302300022
J	Jeon, WY; Shin, IS; Shin, HK; Jin, SE; Lee, MY				Jeon, Woo-Young; Shin, In-Sik; Shin, Hyeun-Kyoo; Jin, Seong Eun; Lee, Mee-Young			Aqueous Extract of Gumiganghwal-tang, a Traditional Herbal Medicine, Reduces Pulmonary Fibrosis by Transforming Growth Factor-beta 1/Smad Signaling Pathway in Murine Model of Chronic Asthma	PLOS ONE			English	Article							ALLERGIC AIRWAY INFLAMMATION; FACTOR-BETA; T-CELLS; PATHOGENESIS; INHIBITION; SMAD3; MICE; MONTELUKAST; EOSINOPHILS; SUPPRESSION	Gumiganghwal-tang is a traditional herbal prescription that is used widely for the treatment of the common cold and inflammatory diseases in Korea and other Asian countries. In this study, we investigated the protective effects of a Gumiganghwal-tang aqueous extract (GGTA) against airway inflammation and pulmonary fibrosis using a mouse model of chronic asthma. Chronic asthma was modeled in BALB/c mice via sensitization/challenge with an intraperitoneal injection of 1% ovalbumin (OVA) and inhalation of nebulized 1% OVA for 4 weeks. GGTA (100 mg/kg or 200 mg/kg) was also administered by oral gavage once a day for 4 weeks. We investigated the number of inflammatory cells, production of T-helper type 2 (Th2) cytokines, chemokine and the total transforming growth factor-beta 1 (TGF-beta 1) in bronchoalveolar lavage fluid (BALF); the levels of immunoglobulin E (lgE) in the plasma; the infiltration of inflammatory cells in lung tissue; and the expression of TGF-beta 1, Smad-3, and collagen in lung tissue. Our results revealed that GGTA lowered the recruitment of inflammatory cells (particularly, lymphocyte); and decreased the production of Th2 cytokines, chemokine and total TGF-beta 1; and attenuated the levels of total and OVA-specific IgE; and decreased the infiltration of inflammatory cells. Moreover, GGTA significantly reduced the expression of TGF-beta 1 and Smad-3, and lowered collagen deposition. These results indicate that GGTA reduces airway inflammation and pulmonary fibrosis by regulating Th2 cytokines production and the TGF-beta 1/Smad-3 pathway, thus providing a potential treatment for chronic asthma.	[Jeon, Woo-Young; Shin, Hyeun-Kyoo; Jin, Seong Eun; Lee, Mee-Young] Korea Inst Oriental Med, Kherb Res Ctr, Daejeon, South Korea; [Shin, In-Sik] Chonnam Natl Univ, Coll Vet Med, Gwangju, South Korea	Korea Institute of Oriental Medicine (KIOM); Chonnam National University	Lee, MY (corresponding author), Korea Inst Oriental Med, Kherb Res Ctr, Daejeon, South Korea.	cozy11@kiom.re.kr		Jin, Seong Eun/0000-0002-9224-0735	Korea Institute of Oriental Medicine [K15251]	Korea Institute of Oriental Medicine	This research was supported by a Grant for "Construction of Scientific Evidences for Herbal Medicine Formulas (K15251)" from the Korea Institute of Oriental Medicine.; This research was supported by a Grant for "Construction of Scientific Evidences for Herbal Medicine Formulas (K16251)" from the Korea Institute of Oriental Medicine.	Al-Alawi M, 2014, RESP MED, V108, P1409, DOI 10.1016/j.rmed.2014.08.008; Bensky D., 1990, CHINESE HERBAL MED F; Chen LJ, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/790739; Chen M, 2011, IMMUNOLOGY, V132, P376, DOI 10.1111/j.1365-2567.2010.03392.x; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Isohama Y, 1997, Nihon Yakurigaku Zasshi, V110 Suppl 1, p120P; Jeon CM, 2014, INT IMMUNOPHARMACOL, V22, P414, DOI 10.1016/j.intimp.2014.07.013; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Jung HW, 2011, ASIAN PAC J ALLERGY, V29, P338; Kay AB, 2005, TRENDS MOL MED, V11, P148, DOI 10.1016/j.molmed.2005.02.002; Ki KD, 2009, J GYNECOL ONCOL, V20, P117, DOI 10.3802/jgo.2009.20.2.117; Kim MC, 2013, J ACUPUNCT MERIDIAN, V6, P98, DOI 10.1016/j.jams.2012.10.007; Kim SJ, 2005, BIOL PHARM BULL, V28, P233, DOI 10.1248/bpb.28.233; Kowalewski R, 2010, PATHOBIOLOGY, V77, P1, DOI 10.1159/000272948; Lee H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/743075; Lee MY, 2014, INT J MOL MED, V33, P978, DOI 10.3892/ijmm.2014.1654; Lee SH, 2014, EUR REV MED PHARMACO, V18, P1806; Lin RJ, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0017-0; Lynch KR, 1999, NATURE, V399, P789; Moustakas A, 2001, J CELL SCI, V114, P4359; Nam KS, 2015, ONCOL LETT, V9, P483, DOI 10.3892/ol.2014.2660; Oh SM, 2013, ONCOL LETT, V5, P305, DOI 10.3892/ol.2012.1012; Qu ZH, 2012, INT J MOL MED, V29, P564, DOI 10.3892/ijmm.2011.868; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Rogerio AP, 2010, PHARMACOL RES, V61, P288, DOI 10.1016/j.phrs.2009.10.005; Royce SG, 2014, LAB INVEST, V94, P1326, DOI 10.1038/labinvest.2014.119; Salib RJ, 2009, CLIN EXP ALLERGY, V39, P1128, DOI 10.1111/j.1365-2222.2009.03239.x; Shimbori C, 2011, EUR J PHARMACOL, V650, P424, DOI 10.1016/j.ejphar.2010.09.084; Shin IS, 2013, INT IMMUNOPHARMACOL, V17, P867, DOI 10.1016/j.intimp.2013.09.017; Shin Y. O., 2015, EVID-BASED COMPL ALT, V2015, DOI DOI 10.1155/2015/456846; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Uitto J, 2000, J DERMATOL SCI, V24, pS60, DOI 10.1016/S0923-1811(00)00143-2; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; Wan Yisong Y, 2007, Proc Am Thorac Soc, V4, P271, DOI 10.1513/pats.200701-020AW; Wang WS, 2006, CIRC RES, V98, P1032, DOI 10.1161/01.RES.0000218782.52610.dc; Wu TY, 2011, AAPS J, V13, P1, DOI 10.1208/s12248-010-9239-4; Yu X, 2015, PHYTOMEDICINE, V22, P1150, DOI 10.1016/j.phymed.2015.09.002; Yun BR, 2014, J BIOSCI BIOENG, V118, P235, DOI 10.1016/j.jbiosc.2014.01.004; Zhang YF, 2015, INT J CLIN EXP PATHO, V8, P8983; Zhou ES, 2014, FITOTERAPIA, V96, P131, DOI 10.1016/j.fitote.2014.04.016	42	10	11	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2016	11	10							e164833	10.1371/journal.pone.0164833	http://dx.doi.org/10.1371/journal.pone.0164833			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0DG	27741312	Green Published, gold			2023-01-03	WOS:000385507000073
J	Hohl, CM; Partovi, N; Ghement, I; Wickham, ME; McGrail, K; Reddekopp, LN; Sobolev, B				Hohl, Corinne M.; Partovi, Nilu; Ghement, Isabella; Wickham, Maeve E.; McGrail, Kimberlyn; Reddekopp, Lisa N.; Sobolev, Boris			Impact of early in-hospital medication review by clinical pharmacists on health services utilization	PLOS ONE			English	Review							ADVERSE DRUG EVENTS; RANDOMIZED-CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; ELDERLY-PATIENTS; RECOGNITION; PREVENTABILITY; INTERVENTION; INPATIENTS; CRITERIA; CARE	Background Adverse drug events are a leading cause of emergency department visits and unplanned admissions, and prolong hospital stays. Medication review interventions aim to identify adverse drug events and optimize medication use. Previous evaluations of in-hospital medication reviews have focused on interventions at discharge, with an unclear effect on health outcomes. We assessed the effect of early in-hospital pharmacist-led medication review on the health outcomes of high-risk patients. Methods We used a quasi-randomized design to evaluate a quality improvement project in three hospitals in British Columbia, Canada. We incorporated a clinical decision rule into emergency department triage pathways, allowing nurses to identify patients at high-risk for adverse drug events. After randomly selecting the first eligible patient for participation, clinical pharmacists systematically allocated subsequent high-risk patients to medication review or usual care. Medication review included obtaining a best possible medication history and reviewing the patient's medications for appropriateness and adverse drug events. The primary outcome was the number of days spent in-hospital over 30 days, and was ascertained using administrative data. We used median and inverse propensity score weighted logistic regression modeling to determine the effect of pharmacist-led medication review on downstream health services use. Results Of 10,807 high-risk patients, 6,416 received early pharmacist-led medication review and 4,391 usual care. Their baseline characteristics were balanced. The median number of hospital days was reduced by 0.48 days (95% confidence intervals [CI] = 0.00 to 0.96; p = 0.058) in the medication review group compared to usual care, representing an 8% reduction in the median length of stay. Among patients under 80 years of age, the median number of hospital days was reduced by 0.60 days (95% CI = 0.06 to 1.17; p = 0.03), representing 11% reduction in the median length of stay. There was no significant effect on emergency department revisits, admissions, readmissions, or mortality. Limitations We were limited by our inability to conduct a randomized controlled trial, but used quasi-random patient allocation methods and propensity score modeling to ensure balance between treatment groups, and administrative data to ensure blinded outcomes ascertainment. We were unable to account for alternate level of care days, and therefore, may have underestimated the treatment effect in frail elderly patients who are likely to remain in hospital while awaiting long-term care. Conclusions Early pharmacist-led medication review was associated with reduced hospital-bed utilization compared to usual care among high-risk patients under 80 years of age, but not among those who were older. The results of our evaluation suggest that medication review by pharmacists in the emergency department may impact the length of hospital stay in select patient populations.	[Hohl, Corinne M.; Wickham, Maeve E.; Sobolev, Boris] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada; [Hohl, Corinne M.; Wickham, Maeve E.; Sobolev, Boris] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada; [Hohl, Corinne M.] Vancouver Gen Hosp, Emergency Dept, Vancouver, BC, Canada; [Partovi, Nilu] Univ British Columbia, Dept Pharmaceut Sci, Vancouver, BC, Canada; [Partovi, Nilu] Vancouver Gen Hosp, Clin Pharm Serv, Vancouver, BC, Canada; [Ghement, Isabella] Ghement Stat Consulting Co Ltd, Richmond, ON, Canada; [McGrail, Kimberlyn; Sobolev, Boris] Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Reddekopp, Lisa N.] Vancouver Coastal Hlth, Vancouver, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Hohl, CM (corresponding author), Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada.; Hohl, CM (corresponding author), Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada.; Hohl, CM (corresponding author), Vancouver Gen Hosp, Emergency Dept, Vancouver, BC, Canada.	chohl@mail.ubc.ca	Hohl, Corinne M/AAY-3325-2021	Hohl, Corinne M/0000-0002-9210-7838	British Columbia Ministry of Health; Vancouver Coastal Health; Canadian Institutes of Health Research; Ghement Statistical Consulting Company Ltd	British Columbia Ministry of Health; Vancouver Coastal Health; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ghement Statistical Consulting Company Ltd	The British Columbia Ministry of Health and Vancouver Coastal Health funded this quality improvement program. None of the sponsors had any role in the evaluation design, data collection or processing, statistical analysis or preparation of the manuscript. Dr. Hohl is supported by a New Investigator grant from the Canadian Institutes of Health Research. Isabella Ghement is affiliated to Ghement Statistical Consulting Company Ltd. Ghement Statistical Consulting Company Ltd provided support in the form of salary for author IG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Bladh L, 2011, BMJ QUAL SAF, V20, P738, DOI 10.1136/bmjqs.2009.039693; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Christensen M, 2013, COCHRANE DB SYST REV, P2; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Curtis LH, 2007, MED CARE, V45, pS103, DOI 10.1097/MLR.0b013e31806518ac; Dalleur O, 2014, DRUG AGING, V31, P291, DOI 10.1007/s40266-014-0157-5; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Farris KB, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-406; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HEPLER CD, 1990, AM J HOSP PHARM, V47, P533, DOI 10.1093/ajhp/47.3.533; Hohl CM, 2005, ACAD EMERG MED, V12, P197, DOI 10.1197/j.aem.2004.08.056; Hohl CM, 2009, CJEM, V11, P274; Hohl CM, 2015, BRIT J CLIN PHARMACO, V80, P51, DOI 10.1111/bcp.12585; Hohl Corinne M, 2015, CMAJ Open, V3, pE103, DOI 10.9778/cmajo.20140010; Hohl CM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-473; Hohl CM, 2012, ACAD EMERG MED, V19, P640, DOI 10.1111/j.1553-2712.2012.01379.x; Hohl CM, 2011, ANN EMERG MED, V58, P270, DOI 10.1016/j.annemergmed.2011.01.003; Hohl CM, 2010, ANN EMERG MED, V55, P493, DOI 10.1016/j.annemergmed.2009.10.008; Klopotowska JE, 2013, EUR J CLIN PHARMACOL, V69, P75, DOI 10.1007/s00228-012-1316-4; Lisby M, 2015, J PATIENT SAF; Lisby M, 2010, BASIC CLIN PHARMACOL, V106, P422, DOI 10.1111/j.1742-7843.2009.00511.x; Makowsky Mark J, 2009, Med Care, V47, P642, DOI 10.1097/MLR.0b013e3181926032; Manos Daria, 2002, CJEM, V4, P16; PATEL H., 2007, BMC CLIN PHARM, V7, P1; Rodriguez-Monguio R, 2003, PHARMACOECONOMICS, V21, P623, DOI 10.2165/00019053-200321090-00002; Roulet L, 2014, J EMERG MED, V46, P857, DOI 10.1016/j.jemermed.2013.11.124; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Scullin C, 2007, J EVAL CLIN PRACT, V13, P781, DOI 10.1111/j.1365-2753.2006.00753.x; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Tegeder I, 1999, BRIT J CLIN PHARMACO, V47, P557; World Health Organization, 2008, GLOB PRIOR RES PAT S; Zed PJ, 2008, CAN MED ASSOC J, V178, P1563, DOI 10.1503/cmaj.071594	35	33	34	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							0170495	10.1371/journal.pone.0170495	http://dx.doi.org/10.1371/journal.pone.0170495			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192477	Green Published, Green Submitted, gold			2023-01-03	WOS:000394423800010
J	Yurgelun, MB; Chenevix-Trench, G; Lippman, SM				Yurgelun, Matthew B.; Chenevix-Trench, Georgia; Lippman, Scott M.			Translating Germline Cancer Risk into Precision Prevention	CELL			English	Editorial Material							PANCREATIC-CANCER; BREAST; CARRIERS	Study of the biology of tumors caused by germline mutations has led to recent paradigm-changing therapy and is driving precision prevention efforts, including immune oncology and early detection research. Here, we explore recent biologic advances that are redefining the spectrum of cancers linked to various hereditary predisposition syndromes and can be leveraged to improve personalized risk assessment and develop novel interventions to prevent or intercept cancer.	[Yurgelun, Matthew B.] Dana Farber Canc Inst, Boston, MA 02215 USA; [Yurgelun, Matthew B.] Harvard Med Sch, Boston, MA 02215 USA; [Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Brisbane, Qld 4029, Australia; [Lippman, Scott M.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; QIMR Berghofer Medical Research Institute; University of California System; University of California San Diego	Lippman, SM (corresponding author), Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.	slippman@ucsd.edu	Chenevix-Trench, Georgia/AAV-2014-2020	Chenevix-Trench, Georgia/0000-0002-1878-2587				Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051; Communal L, 2016, ONCOTARGET, V7, P45317, DOI 10.18632/oncotarget.9638; Connor AA, 2016, JAMA ONCOL; Dunning AM, 2016, NAT GENET, V48, P374, DOI 10.1038/ng.3521; Kotsopoulos J, 2016, J NATL CANC I; Kuchenbaecker K.B., J NATL CANC I; Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563; Milne RL, 2016, ENDOCR-RELAT CANCER, V23, pT69, DOI 10.1530/ERC-16-0277; Montrose DC, 2016, CANCER PREV RES, V9, P721, DOI 10.1158/1940-6207.CAPR-16-0095; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; Salo-Mullen EE, 2015, CANCER-AM CANCER SOC, V121, P4382, DOI 10.1002/cncr.29664; Spira A, 2016, P NATL ACAD SCI USA, V113, P10750, DOI 10.1073/pnas.1608077113; Vasen H, 2016, J CLIN ONCOL, V34, P2010, DOI 10.1200/JCO.2015.64.0730; Yurgelun M.B., 2017, J CLIN ONCOL	15	15	15	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	2017	168	4					566	570		10.1016/j.cell.2017.01.031	http://dx.doi.org/10.1016/j.cell.2017.01.031			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN8VJ	28187278	Bronze			2023-01-03	WOS:000396277600007
J	Luthy, C; Gerstel, PF; Pugliesi, A; Piguet, V; Allaz, AF; Cedraschi, C				Luthy, Christophe; Gerstel, Patricia Francis; Pugliesi, Angela; Piguet, Valerie; Allaz, Anne-Francoise; Cedraschi, Christine			Bedside or not bedside: Evaluation of patient satisfaction in intensive medical rehabilitation wards	PLOS ONE			English	Article							CASE PRESENTATIONS; EXAMINATION ROOM; WORK-ROUNDS; CARE; PERSPECTIVES; PERCEPTIONS; VALIDATION; IMPACT; TRIAL	Background Concerns that bedside presentation (BsP) rounds could make patients uncomfortable led many residency programs to move daily rounds outside the patients' room (OsPR). We performed a prospective quasi-experimental controlled study measuring the effect of these two approaches on patient satisfaction. Methods Patient satisfaction was measured using the Picker questionnaire (PiQ). Results are expressed in problematic percentage scores scaled from 0 = best-100 = worst. During three months, 3 wards of a 6 ward medical rehabilitation division implemented BsP and 3 control wards kept their usual organization of rounds. In total, 90 patients of each group were included in the study and completed the PiQ. Results Socio-clinical characteristics were similar in both groups: mean age = 67 years (SD = 13), mean Charlson comorbidity index = 8.6 (2.4); mean length of stay = 22 days (12). During their stay, patients in the BsP units had a mean of 14.3 (8) BsP rounds and 0.5 (0.8) OsPR; control patients had a mean of 0.9 (0.7) BsP and 14.8 (7.3) OsPR (p< 0.0001). Patients in BsP units reported lower problematic scores regarding coordination of care (39% vs 45%, p = 0.029), involvement of family/friends (29 vs 41%, p = 0.006) and continuity/transition (44% vs 54%, p = 0.020); two questions of the PiQ had worse scores in the BsP: trust in nurses (46.7% vs 30 %, p = 0.021) and recommendation of the institution (61.1% vs 44.4%. p = 0.025). No worsening in dimensions such as respect for patient preferences was seen. Conclusions BsP rounds influenced the patient-healthcare professionals' encounter. These rounds were associated with improved patient satisfaction with care, particularly regarding interprofessional collaboration and discharge planning.	[Luthy, Christophe; Allaz, Anne-Francoise; Cedraschi, Christine] Univ Hosp Geneva, Div Gen Med Rehabil, Geneva, Switzerland; [Luthy, Christophe; Piguet, Valerie; Allaz, Anne-Francoise; Cedraschi, Christine] Univ Geneva, Geneva, Switzerland; [Gerstel, Patricia Francis] Univ Hosp Geneva, Div Qual Care, Geneva, Switzerland; [Pugliesi, Angela] Univ Hosp Geneva, Div Oncol, Geneva, Switzerland; [Piguet, Valerie] Univ Hosp Geneva, Div Clin Pharmacol & Toxicol, Geneva, Switzerland; [Gerstel, Patricia Francis] Clin Colline, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Luthy, C (corresponding author), Univ Hosp Geneva, Div Gen Med Rehabil, Geneva, Switzerland.; Luthy, C (corresponding author), Univ Geneva, Geneva, Switzerland.	Christophe.luthy@hcuge.ch						Anderson RJ, 2002, AM J MED, V113, P657, DOI 10.1016/S0002-9343(02)01320-7; ASHTON CM, 1994, J GEN INTERN MED, V9, P208, DOI 10.1007/BF02600126; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chauke HL, 2006, SAMJ S AFR MED J, V96, P398; Conroy KM, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0060-1; Doyle C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001570; Gonzalo JD, 2014, J GEN INTERN MED, V29, P1040, DOI 10.1007/s11606-014-2817-x; Gonzalo JD, 2014, ACAD MED, V89, P326, DOI 10.1097/ACM.0000000000000100; Gonzalo JD, 2010, J GEN INTERN MED, V25, P792, DOI 10.1007/s11606-010-1344-7; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Jenkinson C, 2002, INT J QUAL HEALTH C, V14, P353, DOI 10.1093/intqhc/14.5.353; Kianmehr N, 2010, SAUDI MED J, V31, P565; Kim MM, 2010, ARCH INTERN MED, V170, P369, DOI 10.1001/archinternmed.2009.521; Kirthi V, 2012, OYAL COLL PHYS ROYAL, DOI [10.1136/bmiqs-2013-002436, DOI 10.1136/BMIQS-2013-002436]; KROENKE K, 1990, J GEN INTERN MED, V5, P229, DOI 10.1007/BF02600540; Kutney-Lee A, 2009, HEALTH AFFAIR, V28, pW669, DOI 10.1377/hlthaff.28.4.w669; Landry MA, 2007, PEDIATRICS, V120, P275, DOI 10.1542/peds.2007-0107; Lehmann LS, 1997, NEW ENGL J MED, V336, P1150, DOI 10.1056/NEJM199704173361606; LEWIS C, 1988, J PEDIATR-US, V112, P378, DOI 10.1016/S0022-3476(88)80316-0; LINFORS EW, 1980, NEW ENGL J MED, V303, P1230, DOI 10.1056/NEJM198011203032110; Luthy C, 2005, SWISS MED WKLY, V135, P82; Muller-Juge V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057570; New PW, 2008, J REHABIL MED, V40, P678, DOI 10.2340/16501977-0224; Norgaard K, 2004, MED EDUC, V38, P700, DOI 10.1111/j.1365-2929.2004.01840.x; Paice E, 2002, BMJ-BRIT MED J, V325, P707, DOI 10.1136/bmj.325.7366.707; Pannick S, 2015, JAMA INTERN MED, V175, P1288, DOI 10.1001/jamainternmed.2015.2421; Papastavrou E, 2014, BMC NURS, V13, DOI 10.1186/1472-6955-13-26; Perneger TV, 2003, MED CARE, V41, P1343, DOI 10.1097/01.MLR.0000100580.94559.AD; Ramani S, 2003, ACAD MED, V78, P384, DOI 10.1097/00001888-200304000-00014; Rogers HD, 2003, ACAD MED, V78, P945, DOI 10.1097/00001888-200309000-00023; Seo M, 2000, MED EDUC, V34, P409, DOI 10.1046/j.1365-2923.2000.00516.x; Sox HC, 2016, JAMA-J AM MED ASSOC, V316, P1205, DOI 10.1001/jama.2016.11409; Tariq M, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-53; Taylor SP, 2014, BMJ QUAL SAF, V23, P584, DOI 10.1136/bmjqs-2013-002436; WANGCHENG RM, 1989, J GEN INTERN MED, V4, P284, DOI 10.1007/BF02597397; Ward DR, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-37; WRAY NP, 1986, J MED EDUC, V61, P893; Wright SM, 1998, NEW ENGL J MED, V339, P1986, DOI 10.1056/NEJM199812313392706; Zwarentein M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000072.pub2	39	8	8	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2017	12	2							e0170474	10.1371/journal.pone.0170474	http://dx.doi.org/10.1371/journal.pone.0170474			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK1SG	28170431	Green Published, gold, Green Submitted			2023-01-03	WOS:000393705500006
J	Huang, KS; Wang, SH; Chuah, SK; Rau, KM; Lin, YH; Hsieh, MC; Shih, LH; Chen, YH				Huang, Kun-Siang; Wang, Shih-Ho; Chuah, Seng-Kee; Rau, Kun-Ming; Lin, Yu-Hung; Hsieh, Meng-Che; Shih, Li-Hsueh; Chen, Yen-Hao			The effects of hospice-shared care for gastric cancer patients	PLOS ONE			English	Article							LYMPH-NODE METASTASIS; PALLIATIVE CARE; LIFE; END; TAIWAN; IMPACT; EXPENDITURE; OUTCOMES; JAPAN	Background Hospice care has been proved to result in changes to the medical behaviors of terminally ill patients. The aim of this study was to evaluate the effects and medical behavior changes of hospice-shared care intervention among terminally ill gastric cancer patients. Methods A total of 174 patients who died of gastric cancer between 2012 and 2014 were identified. These patients were divided into two groups: a hospice-shared care group (n = 93) and a control group (n = 81). Results Among the 174 patients, 84% had advanced stage (stage III or stage IV) cancer. The females and the patients cared by medical oncologists had a higher percentage of hospice-shared care than the males (71% vs 44%, p = 0.001) and those cared by other physicians (63% vs 41%, p = 0.004). Compared to the control group, the hospice-shared care group underwent lower incidence of life sustaining or aggressive medical treatments, including intensive care unit admission (2% vs 26%, p<0.001), intubation (1% vs 27%, p<0.001), cardiopulmonary- cerebral resuscitation (0% vs 11%, p = 0.001), ventilator use (1% vs 27%, p< 0.001), inotropic agent use (8% vs 46%, p< 0.001), total or partial parenteral nutrition use (38% vs. 58%, p = 0.029), and blood transfusion (45% vs 74%, p< 0.001). Besides, the hospice- shared care group had a higher percentage of palliative treatments than the control group, including signed Do-Not-Resuscitate (DNR) orders (95% vs 37%, p< 0.001), receiving home hospice care (16% vs 1%, p< 0.001), and indicating home as the realistically preferred place of death (41% vs 19%, p = 0.001). The hospice ward admission rate in the hospice-shared care group increased from 30% to 53% from 2012 to 2014. Conclusion The use of hospice-shared care for gastric cancer patients could increase the rate of signed DNR orders, decrease the use of life sustaining and aggressive/palliative treatments, and improve quality of life.	[Huang, Kun-Siang] Kaohsiung Chang Gung Mem Hosp, Dept Family Med, Kaohsiung, Taiwan; [Huang, Kun-Siang; Wang, Shih-Ho; Chuah, Seng-Kee; Rau, Kun-Ming; Lin, Yu-Hung; Hsieh, Meng-Che; Chen, Yen-Hao] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Wang, Shih-Ho; Lin, Yu-Hung] Kaohsiung Chang Gung Mem Hosp, Div Gen Surg, Dept Surg, Kaohsiung, Taiwan; [Wang, Shih-Ho; Chuah, Seng-Kee; Rau, Kun-Ming; Lin, Yu-Hung; Hsieh, Meng-Che; Shih, Li-Hsueh; Chen, Yen-Hao] Kaohsiung Chang Gung Mem Hosp, Gastr Canc Team, Kaohsiung, Taiwan; [Chuah, Seng-Kee] Kaohsiung Chang Gung Mem Hosp, Div Hepatogastroenterol, Dept Internal Med, Kaohsiung, Taiwan; [Rau, Kun-Ming; Hsieh, Meng-Che; Chen, Yen-Hao] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Kaohsiung, Taiwan; [Shih, Li-Hsueh] Kaohsiung Chang Gung Mem Hosp, Dept Nursing, Kaohsiung, Taiwan; [Chen, Yen-Hao] Kaohsiung Chang Gung Mem Hosp, Hosp Care Team, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Chen, YH (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Chen, YH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Gastr Canc Team, Kaohsiung, Taiwan.; Chen, YH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Kaohsiung, Taiwan.; Chen, YH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Hosp Care Team, Kaohsiung, Taiwan.	alex8701125@gmail.com						Bai Yana, 2016, Zhonghua Liu Xing Bing Xue Za Zhi, V37, P306, DOI 10.3760/cma.j.issn.0254-6450.2016.03.002; Chuang R-B, 2005, TAIWAN J HOSPICE PAL, V10, P5; Donohoe CL, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/601434; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; Everett SM, 1997, GUT, V41, P142, DOI 10.1136/gut.41.2.142; Gwilliam B, 2001, Int J Palliat Nurs, V7, P474; Hong JH, 2013, CANCER RES TREAT, V45, P270, DOI 10.4143/crt.2013.45.4.270; Izadi Azar, 2016, Asian Pac J Cancer Prev, V17, P3007; Kang SC, 2012, J CHIN MED ASSOC, V75, P221, DOI 10.1016/j.jcma.2012.04.005; Lai YL, 1997, SUPPORT CARE CANCER, V5, P348, DOI 10.1007/s005200050090; Lin WY, 2014, SUPPORT CARE CANCER, V22, P1907, DOI 10.1007/s00520-014-2168-5; Liu CN, 2002, J FORMOS MED ASSOC, V101, P552; Loke SS, 2011, J PALLIAT MED, V14, P683, DOI 10.1089/jpm.2010.0331; Loke SS, 2011, CANCER NURS, V34, pE21, DOI 10.1097/NCC.0b013e3181ff78b6; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; MAEHARA Y, 1992, BRIT J SURG, V79, P245, DOI 10.1002/bjs.1800790320; Masuda Y, 2006, J PALLIAT MED, V9, P152, DOI 10.1089/jpm.2006.9.152; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Obermeyer Z, 2015, HEALTH AFFAIR, V34, P993, DOI 10.1377/hlthaff.2014.1055; Okada K, 2012, ENDOSCOPY, V44, P122, DOI 10.1055/s-0031-1291486; Rosania R, 2015, GASTROINTEST TUMORS, V2, P178, DOI 10.1159/000445188; Sato K, 2008, SUPPORT CARE CANCER, V16, P113, DOI 10.1007/s00520-007-0332-x; Torelli GF, 1999, NUTRITION, V15, P665, DOI 10.1016/S0899-9007(99)00118-5; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tse DMW, 2007, PALLIATIVE MED, V21, P425, DOI 10.1177/0269216307079825; Wang HM, 2011, J PAIN SYMPTOM MANAG, V42, P400, DOI 10.1016/j.jpainsymman.2010.12.011; Wu LF, 2016, SUPPORT CARE CANCER, V24, P53, DOI 10.1007/s00520-015-2741-6; Yasuda K, 1999, CANCER, V85, P2119, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2119::AID-CNCR4>3.0.CO;2-M	28	17	18	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171365	10.1371/journal.pone.0171365	http://dx.doi.org/10.1371/journal.pone.0171365			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DG	28158232	Green Submitted, Green Published, gold			2023-01-03	WOS:000396161700065
J	Adams, AJ; Banister, SD; Irizarry, L; Trecki, J; Schwartz, M; Gerona, R				Adams, Axel J.; Banister, Samuel D.; Irizarry, Lisandro; Trecki, Jordan; Schwartz, Michael; Gerona, Roy			"Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AB-FUBINACA; DESIGNER DRUGS; PINACA; 5F-AB-PINACA; PHARMACOLOGY; 5F-AMB	BACKGROUND New psychoactive substances constitute a growing and dynamic class of abused drugs in the United States. On July 12, 2016, a synthetic cannabinoid caused mass intoxication of 33 persons in one New York City neighborhood, in an event described in the popular press as a "zombie" outbreak because of the appearance of the intoxicated persons. METHODS We obtained and tested serum, whole blood, and urine samples from 8 patients among the 18 who were transported to local hospitals; we also tested a sample of the herbal "incense" product "AK-47 24 Karat Gold,"which was implicated in the outbreak. Samples were analyzed by means of liquid chromatography-quadrupole time-of-flight mass spectrometry. RESULTS The synthetic cannabinoid methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (AMB-FUBINACA, also known as MMB-FUBINACA or FUB-AMB) was identified in AK-47 24 Karat Gold at a mean (+/- SD) concentration of 16.0 +/- 3.9 mg per gram. The de-esterified acid metabolite was found in the serum or whole blood of all eight patients, with concentrations ranging from 77 to 636 ng per milliliter. CONCLUSIONS The potency of the synthetic cannabinoid identified in these analyses is consistent with strong depressant effects that account for the "zombielike" behavior reported in this mass intoxication. AMB-FUBINACA is an example of the emerging class of "ultrapotent" synthetic cannabinoids and poses a public health concern. Collaboration among clinical laboratory staff, health professionals, and law enforcement agencies facilitated the timely identification of the compound and allowed health authorities to take appropriate action.	[Adams, Axel J.; Gerona, Roy] Univ Calif San Francisco, Clin Toxicol & Environm Biomonitoring Lab, San Francisco, CA 94143 USA; [Adams, Axel J.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Banister, Samuel D.] Stanford Univ, Sch Med, Dept Radiat Oncol, Palo Alto, CA 94304 USA; [Irizarry, Lisandro] Wyckoff Hts Med Ctr, Dept Emergency Med, New York, NY USA; [Trecki, Jordan] Drug Enforcement Adm, Drug & Chem Evaluat Sect, Off Divers Control, Springfield, VA USA; [Schwartz, Michael] Dept Homeland Secur, Off Hlth Affairs, Chem Def Program, Washington, DC USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Gerona, R (corresponding author), Univ Calif San Francisco, Clin Toxicol & Environm Biomonitoring Lab, San Francisco, CA 94143 USA.	roy.gerona@ucsf.edu	Banister, Samuel/G-8501-2012	Banister, Samuel/0000-0002-4690-4318				Akamatsu S, 2016, J MASS SPECTROM, V51, P28, DOI 10.1002/jms.3722; Andersson M, 2016, RAPID COMMUN MASS SP, V30, P1067, DOI 10.1002/rcm.7538; [Anonymous], 2014, DHH ADDS 2 NEW SYNTH; [Anonymous], 2016, LOOK SO FAR MY US FU; Auwarter V, 2013, NOVEL PSYCHOACTIVE SUBSTANCES: CLASSIFICATION, PHARMACOLOGY AND TOXICOLOGY, P317, DOI 10.1016/B978-0-12-415816-0.00013-4; Auwarter V, 2009, J MASS SPECTROM, V44, P832, DOI 10.1002/jms.1558; Banister SD, 2016, ACS CHEM NEUROSCI, V7, P1241, DOI 10.1021/acschemneuro.6b00137; Banister SD, 2015, ACS CHEM NEUROSCI, V6, P1546, DOI 10.1021/acschemneuro.5b00112; Banister SD, 2015, ACS CHEM NEUROSCI, V6, P1445, DOI 10.1021/acschemneuro.5b00107; Barratt MJ, 2013, DRUG ALCOHOL REV, V32, P141, DOI 10.1111/j.1465-3362.2012.00519.x; Buser GL, 2014, CLIN TOXICOL, V52, P664, DOI 10.3109/15563650.2014.932365; Drug Enforcement Administration, 2011, CHEM US SPIC K2 TYP; Drug Enforcement Administration Department of Justice, 2016, Fed Regist, V81, P6175; Egde SG, 2009, Intl patent, Patent No. [PCT/IB2009/000432, 2009000432]; European Monitoring Centre for Drugs and Drug Addiction & Eurojust, 2016, NEW PSYCH SUBST EUR; Holpuch A., 2016, GUARDIAN; Longworth M, 2016, FORENSIC TOXICOL, V34, P286, DOI 10.1007/s11419-016-0316-y; MECHOULA.R, 1965, J AM CHEM SOC, V87, P3273, DOI 10.1021/ja01092a065; Nichols D, 2011, NATURE, V469, P7, DOI 10.1038/469007a; Rominger A, 2013, EUR NEUROPSYCHOPHARM, V23, P1606, DOI 10.1016/j.euroneuro.2013.01.009; Rosenberg Eli, 2016, NY TIMES; Schwartz MD, 2015, J EMERG MED, V48, P573, DOI 10.1016/j.jemermed.2014.12.038; Shanks KG, 2016, FORENSIC SCI INT, V262, pE21, DOI 10.1016/j.forsciint.2016.03.004; Trecki J, 2015, NEW ENGL J MED, V373, P103, DOI 10.1056/NEJMp1505328; Tyndall JA, 2015, CLIN TOXICOL, V53, P950, DOI 10.3109/15563650.2015.1100306; Uchiyama N, 2013, FORENSIC TOXICOL, V31, P93, DOI 10.1007/s11419-012-0171-4; United Nations Office on Drugs and Crime, 2015, WORLD DRUG REP 2015; Vandrey R, 2012, DRUG ALCOHOL DEPEN, V120, P238, DOI 10.1016/j.drugalcdep.2011.07.011; Wiley JL, 2016, NEUROPHARMACOLOGY, V110, P143, DOI 10.1016/j.neuropharm.2016.07.016; Winstock AR, 2016, GLOBAL DRUG SURVEY 2	30	179	184	8	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2017	376	3					235	242		10.1056/NEJMoa1610300	http://dx.doi.org/10.1056/NEJMoa1610300			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EI0XO	27973993	Bronze			2023-01-03	WOS:000392199100007
J	Volkow, ND; Compton, WM; Wargo, EM				Volkow, Nora D.; Compton, Wilson M.; Wargo, Eric M.			The Risks of Marijuana Use During Pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Volkow, Nora D.; Compton, Wilson M.; Wargo, Eric M.] NIDA, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Wargo, EM (corresponding author), NIDA, Off Sci Policy & Commun, Sci Policy Branch, 6001 Execut Blvd,Room 5235, Bethesda, MD 20892 USA.	wargoem@nida.nih.gov			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		El Marroun H, 2016, BIOL PSYCHIAT, V79, P971, DOI 10.1016/j.biopsych.2015.08.024; Gunn JKL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009986; Roberson Emily K, 2014, Hawaii J Med Public Health, V73, P283; Sulik KK, NEUROTOXICOL TERATOL, DOI [10.1016/j.ntt.2015.12.004, DOI 10.1016/J.NTT.2015]; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Wu CS, 2011, FUTUR NEUROL, V6, P459, DOI 10.2217/FNL.11.27	6	77	77	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2017	317	2					129	130		10.1001/jama.2016.18612	http://dx.doi.org/10.1001/jama.2016.18612			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH5PV	27992628				2023-01-03	WOS:000391826200009
J	Konigsbrugge, O; Posch, F; Antlanger, M; Kovarik, J; Klauser-Braun, R; Kletzmayr, J; Schmaldienst, S; Auinger, M; Zuntner, G; Lorenz, M; Grilz, E; Stampfel, G; Steiner, S; Pabinger, I; Saemann, M; Ay, C				Koenigsbruegge, Oliver; Posch, Florian; Antlanger, Marlies; Kovarik, Josef; Klauser-Braun, Renate; Kletzmayr, Josef; Schmaldienst, Sabine; Auinger, Martin; Zuntner, Guenther; Lorenz, Matthias; Grilz, Ella; Stampfel, Gerald; Steiner, Stefan; Pabinger, Ingrid; Saeemann, Marcus; Ay, Cihan			Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolismin Patients on HemoDIalysis (VIVALDI)	PLOS ONE			English	Article							WARFARIN INITIATION; ISCHEMIC-STROKE; RISK-FACTORS; MORTALITY; MORBIDITY; OUTCOMES; DISEASE; COHORT; DEATH	Background Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for stroke prevention in AF. Methods The Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemodialysis (VIVALDI), an ongoing prospective observational cohort study, investigates the prevalence of AF and the risk of thromboembolic events in HD patients in Vienna, Austria. We analyzed cross-sectional data of 626 patients (63.4% men, median age 66 years, approx. 73% of HD patients in Vienna), who provided informed consent. A structured interview with each patient was performed, recent and archived ECGs were viewed and medical histories were verified with electronic records. Results The overall prevalence of AF was 26.5% (166 patients, 71.1% men, median age 72 years) of which 57.8% had paroxysmal AF, 3.0% persistent AF, 32.5% permanent AF, and 6.6% of patients had newly diagnosed AF. The median CHA(2)DS(2)-VASc Score was 4 [25th-75th percentile 3-5]. In multivariable analysis, AF was independently associated with age (odds ratio: 1.05 per year increase, 95% confidence interval: 1.03-1.07), male sex (1.7, 1.1-2.6), history of venous thromboembolism (2.0, 1.1-3.6), congestive heart failure (1.7, 1.1-2.5), history of or active cancer (1.5, 1.0-2.4) and time on HD (1.08 per year on HD, 1.03-1.13). Antithrombotic treatment was applied in 84.4% of AF patients (anticoagulant agents in 29.5%, antiplatelet agents in 33.7%, and both in 21.1%). In AF patients, vitamin-K-antagonists were used more often than low-molecular-weight heparins (30.1% and 19.9%). Conclusions The prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF.	[Koenigsbruegge, Oliver; Posch, Florian; Grilz, Ella; Stampfel, Gerald; Steiner, Stefan; Pabinger, Ingrid; Ay, Cihan] Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna, Austria; [Posch, Florian] Med Univ Graz, Dept Med, Div Clin Oncol, Graz, Austria; [Antlanger, Marlies; Saeemann, Marcus] Med Univ Vienna, Clin Div Nephrol, Dept Med 3, Vienna, Austria; [Kovarik, Josef] Wilhelminenspital Stadt Wien, Dept Med 6, Vienna, Austria; [Klauser-Braun, Renate; Kletzmayr, Josef] Donauspital, Dept Med 3, Vienna, Austria; [Schmaldienst, Sabine] Kaiser Franz Josef Spital, Dept Med 1, Vienna, Austria; [Auinger, Martin] Hietzing Hosp, Dept Med 3, Vienna, Austria; [Zuntner, Guenther] Rudolfstiftung Hosp, Dept Med 1, Vienna, Austria; [Lorenz, Matthias] Vienna Dialysis Ctr, Vienna, Austria; [Ay, Cihan] Univ North Carolina Chapel Hill, McAllister Heart Inst, Dept Med, Thrombosis & Hemostasis Program, Chapel Hill, NC USA	Medical University of Vienna; Medical University of Graz; Medical University of Vienna; Wilhelminenspital; Donauspital; Kaiser-Franz-Josef Hospital; Hietzing Hospital; Rudolfstiftung Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Ay, C (corresponding author), Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna, Austria.; Ay, C (corresponding author), Univ North Carolina Chapel Hill, McAllister Heart Inst, Dept Med, Thrombosis & Hemostasis Program, Chapel Hill, NC USA.	cihan.ay@meduniwen.ac.at		Konigsbrugge, Oliver/0000-0002-6183-3685; Posch, Florian/0000-0002-0448-6314; Ay, Cihan/0000-0003-2607-9717	Osterreichische Nationalbank Jubilaumsfond (Austrian Nationbank Anniversary fund) [16433]; Osterreichische Gesellschaft fur Innere Medizin (Austrian Society for Internal Medicine) Joseph-Skoda-Prize	Osterreichische Nationalbank Jubilaumsfond (Austrian Nationbank Anniversary fund); Osterreichische Gesellschaft fur Innere Medizin (Austrian Society for Internal Medicine) Joseph-Skoda-Prize	Support was provided by Osterreichische Nationalbank Jubilaumsfond (Austrian Nationbank Anniversary fund) grant number 16433 awarded to IP [https://www.oenb.at/Ueber-Uns/Forschungsfoerderung/Jubilaeumsfonds.html] and Osterreichische Gesellschaft fur Innere Medizin (Austrian Society for Internal Medicine) Joseph-Skoda-Prize 2014 awarded to CA [http://www.oegim.at/aktuell/preise/josef-skoda-projektfoerderungspreis.html]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atar I, 2006, INT J CARDIOL, V106, P47, DOI 10.1016/j.ijcard.2004.12.048; Buiten MS, 2014, HEART, V100, P685, DOI 10.1136/heartjnl-2013-305417; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Carrero JJ, 2014, JAMA-J AM MED ASSOC, V311, P919, DOI 10.1001/jama.2014.1334; Chan KE, 2009, J AM SOC NEPHROL, V20, P2223, DOI 10.1681/ASN.2009030319; Chao TF, 2014, HEART RHYTHM, V11, P1752, DOI [10.1016/j.hrthm.20l4.06.021, 10.1016/j.hrthm.2014.06.021]; Friberg L, 2015, EUR HEART J, V36, P297, DOI 10.1093/eurheartj/ehu139; Gage BF, 2015, VALIDATION CLIN CLAS, V285, P2864; Genovesi S, 2005, AM J KIDNEY DIS, V46, P897, DOI 10.1053/j.ajkd.2005.07.044; Genovesi S, 2008, AM J KIDNEY DIS, V51, P255, DOI 10.1053/j.ajkd.2007.10.034; Genovesi S, 2015, NEPHROL DIAL TRANSPL, V30, P491, DOI 10.1093/ndt/gfu334; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hart RG, 1999, ANN INTERN MED, V131, P688, DOI 10.7326/0003-4819-131-9-199911020-00010; January CT, 2014, CIRCULATION, V130, pE199, DOI [10.1161/CIR.0000000000000041, 10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.021, 10.1016/j.jacc.2014.03.022]; Knoll F, 2012, NEPHROL DIAL TRANSPL, V27, P332, DOI 10.1093/ndt/gfr341; Kramar R, 2015, JAHRESBERICHT 2013; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Molnar AO, 2016, J AM SOC NEPHROL, V27, P2825, DOI 10.1681/ASN.2015050535; Nagge J, 2002, ARCH INTERN MED, V162, P2605, DOI 10.1001/archinte.162.22.2605; Ohsawa M, 2016, J EPIDEMIOL, V26, P272, DOI 10.2188/jea.JE20150077; Olesen JB, 2012, NEW ENGL J MED, V367, P625, DOI 10.1056/NEJMoa1105594; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134; Schnabel RB, 2015, LANCET, V386, P154, DOI 10.1016/S0140-6736(14)61774-8; Seliger SL, 2003, KIDNEY INT, V64, P603, DOI 10.1046/j.1523-1755.2003.00101.x; Shah M, 2014, CIRCULATION, V129, P1196, DOI 10.1161/CIRCULATIONAHA.113.004777; Shen JI, 2015, AM J KIDNEY DIS, V66, P677, DOI 10.1053/j.ajkd.2015.05.019; Shih CJ, 2016, CIRCULATION, V133, P265, DOI 10.1161/CIRCULATIONAHA.115.018294; Stel VS, 2005, NEPHROL DIAL TRANSPL, V20, P2803, DOI 10.1093/ndt/gfi099; Vazquez E, 2009, KIDNEY INT, V76, P324, DOI 10.1038/ki.2009.185; Wang HH, 2014, AM J KIDNEY DIS, V63, P604, DOI 10.1053/j.ajkd.2013.10.013; Wetmore JB, 2013, J AM SOC NEPHROL, V24, P2053, DOI 10.1681/ASN.2012111077; Wetmore JB, 2011, AM J KIDNEY DIS, V58, P73, DOI 10.1053/j.ajkd.2011.02.387; Wiesholzer M, 2001, AM J NEPHROL, V21, P35, DOI 10.1159/000046216; Winkelmayer WC, 2011, CLIN J AM SOC NEPHRO, V6, P2662, DOI 10.2215/CJN.04550511; Winkelmayer WC, 2011, J AM SOC NEPHROL, V22, P349, DOI 10.1681/ASN.2010050459; Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477; Yang H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154627	39	38	39	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2017	12	1							e0169400	10.1371/journal.pone.0169400	http://dx.doi.org/10.1371/journal.pone.0169400			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2TP	28052124	Green Submitted, Green Published, gold			2023-01-03	WOS:000391621500058
J	Comber, H; Cancela, MD; Haase, T; Johnson, H; Sharp, L; Pratschke, J				Comber, Harry; Cancela, Marianna De Camargo; Haase, Trutz; Johnson, Howard; Sharp, Linda; Pratschke, Jonathan			Affluence and Private Health Insurance Influence Treatment and Survival in Non-Hodgkin's Lymphoma	PLOS ONE			English	Article							CANCER SURVIVAL; ELDERLY-PATIENTS; COMMON CANCERS; SOCIOECONOMIC INEQUALITIES; MARITAL-STATUS; BREAST-CANCER; RARER CANCERS; AGE; DISPARITIES; DIAGNOSIS	Background The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), distinguishing between direct and indirect effects of patient, social and process-of care factors. Methods All cases of NHL diagnosed in Ireland in 2004-2008 were included. Variables describing patient, cancer, stage and process of care were included in a discrete-time model of survival using Structural Equation Modelling software. Results Emergency admissions were more common in patients with co-morbid conditions or with more aggressive cancers, and less frequent for patients from more affluent areas. Aggressive morphology, female sex, emergency admission, increasing age, comorbidity, treatment in a high caseload hospital and late stage were associated with increased hazard of mortality. Private patients had a reduced hazard of mortality, mediated by systemic therapy, admission to high caseload hospitals and fewer emergency admissions. Discussion The higher rate of emergency presentation, and consequent poorer survival, of uninsured patients, suggests they face barriers to early presentation. Social, educational and cultural factors may also discourage disadvantaged patients from consulting with early symptoms of NHL. Non-insured patients, who present later and have more emergency admissions would benefit from better access to diagnostic services. Older patients remain disadvantaged by sub-optimal treatment, treatment in non-specialist centres and emergency admission.	[Comber, Harry] Natl Canc Registry, Cork, Ireland; [Cancela, Marianna De Camargo] Brazilian Natl Canc Inst, Div Epidemiol, Rio De Janeiro, Brazil; [Johnson, Howard] Hlth Serv Execut, Hlth & Wellbeing Directorate, Hlth Intelligence Unit, Dublin, Ireland; [Sharp, Linda] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Pratschke, Jonathan] Univ Salerno, Dept Econ & Stat, Salerno, Italy	National Cancer Institute (Inca); Newcastle University - UK; University of Salerno	Comber, H (corresponding author), Natl Canc Registry, Cork, Ireland.	hcomber1@gmail.com	de Camargo Cancela, Marianna/F-7309-2017; De Camargo Cancela, Marianna/D-4053-2015	de Camargo Cancela, Marianna/0000-0002-8169-8054; De Camargo Cancela, Marianna/0000-0002-8169-8054	Department of Health; Irish Cancer Society [H1COM12]	Department of Health; Irish Cancer Society	The National Cancer Registry is funded by the Department of Health. Additional funding for this study was provided by Irish Cancer Society grant H1COM12. There was no additional external source of funding for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel GA, 2015, BRIT J CANCER, V112, pS129, DOI 10.1038/bjc.2015.52; Aizer AA, 2013, J CLIN ONCOL, V31, P3869, DOI 10.1200/JCO.2013.49.6489; Al-Hamadani M, 2015, AM J HEMATOL, V90, P790, DOI 10.1002/ajh.24086; Alberto Q, 2013, CRIT REV ONCOL HEMAT, V85, P266, DOI 10.1016/j.critrevonc.2012.08.007; Bonnet C, 2007, J CLIN ONCOL, V25, P787, DOI 10.1200/JCO.2006.07.0722; Braga IC, 2015, J CANC ED; Bray C, 2008, LEUKEMIA LYMPHOMA, V49, P917, DOI 10.1080/10428190801933377; Brown LM, 2015, INT J CANC; Burns RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106456; Cancela MDC, 2015, CANCER EPIDEMIOL, V39, P778, DOI 10.1016/j.canep.2015.08.006; Chang CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044325; Charlson M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112479; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Cox B, 2014, J CANCER EPIDEMIOL, V2014, DOI 10.1155/2014/315378; Crozier JA, 2015, CL LYMPH MYELOM LEUK, V15, P578, DOI 10.1016/j.clml.2015.06.005; De Angelis R, 2015, EUR J CANCER, V51, P2254, DOI 10.1016/j.ejca.2015.08.003; De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1; deRijke JM, 1996, ANN ONCOL, V7, P677; Economic and Social Research Institute Department of Health Health Service Executive, 2013, ACT AC PUBL HOSP IR; Ewing J C, 2003, Hematology, V8, P211, DOI 10.1080/1024533031000135685; Firat S, 2006, AM J CLIN ONCOL-CANC, V29, P252, DOI 10.1097/01.coc.0000217824.20290.ab; Forbes LJL, 2011, BRIT J CANCER, V105, P1474, DOI 10.1038/bjc.2011.406; Frederiksen BL, 2012, BRIT J CANCER, V106, P988, DOI 10.1038/bjc.2012.3; Frederiksen BL, 2011, EUR J CANCER, V47, P910, DOI 10.1016/j.ejca.2010.11.014; Haase T, 2012, POBAL HP DEPRIVATION; Hastert TA, 2016, SOC SCI MED, V148, P52, DOI 10.1016/j.socscimed.2015.11.023; Health Service Executive, 2014, HLTH SERV PERF ASS R; Inverso G, 2015, CANCER-AM CANCER SOC, V121, P1273, DOI 10.1002/cncr.29171; Irish Health, 2011, ALL HAIL MIGHT WAIT; Issa DE, 2015, HAEMATOLOGICA, V100, P528, DOI 10.3324/haematol.2014.107300; Jansen L, 2015, INT J CANCER, V136, P2649, DOI 10.1002/ijc.29316; Kato Ikuko, 2012, J Registry Manag, V39, P158; Kent EE, 2015, CANCER CAUSE CONTROL, V26, P1153, DOI 10.1007/s10552-015-0609-1; Kogevinas M, 1997, IARC Sci Publ, P177; Luddy G, 2007, Ir Med J, V100, P71; Lyratzopoulos G, 2015, BRIT J CANCER, V112, pS35, DOI 10.1038/bjc.2015.40; Lyratzopoulos G, 2015, CANCER EPIDEM BIOMAR, V24, P720, DOI 10.1158/1055-9965.EPI-14-0969; Macleod U, 2009, BRIT J CANCER, V101, pS92, DOI 10.1038/sj.bjc.6605398; Marlow LAV, 2014, PSYCHO-ONCOLOGY, V23, P749, DOI 10.1002/pon.3464; Muthen L., 2007, MPLUS USERS GUIDE; O'Brien K, 2014, IRISH J MED SCI, V183, P219, DOI 10.1007/s11845-013-0993-z; Olszewski AJ, 2015, ONCOLOGIST, V20, P1223, DOI 10.1634/theoncologist.2015-0228; Ozturk C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141244; Pratschke J, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0130-6; Pulte D, 2008, ARCH INTERN MED, V168, P469, DOI 10.1001/archinternmed.2007.125; Quaglia A, 2005, CRIT REV ONCOL HEMAT, V54, P117, DOI 10.1016/j.critrevonc.2004.12.001; Roswall N, 2008, EUR J CANCER, V44, P2058, DOI 10.1016/j.ejca.2008.06.011; Sant M, 2014, LANCET ONCOL, V15, P931, DOI 10.1016/S1470-2045(14)70282-7; Scottish Cancer Intelligence Unit, 2000, TRENDS CANC SURV SCO; Sharp L, 2014, J URBAN HEALTH, V91, P510, DOI 10.1007/s11524-013-9846-3; Shephard EA, 2015, BRIT J GEN PRACT, V65, pE289, DOI 10.3399/bjgp15X684805; Shiels MS, 2013, CANCER EPIDEM BIOMAR, V22, P1069, DOI 10.1158/1055-9965.EPI-13-0040; Smith A, 2015, CANC EPIDEMIOL; Tang SY, 2015, SOCIOL HEALTH ILL, V37, P698, DOI 10.1111/1467-9566.12236; The Health Insurance Authority, 2014, ANN REP ACC 2013; Thompson AS, 2016, J MULTILING MULTICUL, V37, P115, DOI 10.1080/01434632.2015.1031136; Vasudev NS, 2004, BRIT J GEN PRACT, V54, P595; Vedsted P, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X588484; Vulto AJCM, 2006, CANCER-AM CANCER SOC, V106, P2734, DOI 10.1002/cncr.21934; Wang M, 2008, CANCER-AM CANCER SOC, V113, P3231, DOI 10.1002/cncr.23914; Woods LM, 2006, ANN ONCOL, V17, P5, DOI 10.1093/annonc/mdj007; Zhang Amy Y, 2003, Oncol Nurs Forum, V30, P1022; Zhou R, 2015, J GASTROENTEROL HEPA	63	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2016	11	12							e0168684	10.1371/journal.pone.0168684	http://dx.doi.org/10.1371/journal.pone.0168684			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EI9QC	27992551	Green Submitted, Green Published, gold			2023-01-03	WOS:000392842600087
J	Dalzon, B; Lebas, C; Jimenez, G; Gutjahr, A; Terrat, C; Exposito, JY; Verrier, B; Lethias, C				Dalzon, Bastien; Lebas, Celia; Jimenez, Gina; Gutjahr, Alice; Terrat, Celine; Exposito, Jean-Yves; Verrier, Bernard; Lethias, Claire			Poly(Lactic Acid) Nanoparticles Targeting alpha 5 beta 1 Integrin as Vaccine Delivery Vehicle, a Prospective Study	PLOS ONE			English	Article							HUMAN FIBRONECTIN; CELL-ADHESION; RGD; SURFACE; SITES; FORMULATION; RESPONSES; THERAPY	Biodegradable polymeric nanoparticles are vehicles of choice for drug delivery and have the ability to encapsulate and present at their surface different molecules of interest. Among these bio-nanocarriers, poly(lactic acid) (PLA) nanoparticles have been used as adjuvant and vehicle for enhanced vaccine efficacy. In order to develop an approach to efficient vaccine delivery, we developed nanoparticles to target alpha 5 beta 1 positive cells. We first overproduced, in bacteria, human fibronectin FNIII9/10 recombinant proteins possessing an integrin alpha 5 beta 1 binding site, the RGDS sequence, or a mutated form of this site. After having confirmed the integrin binding properties of these recombinant proteins in cell culture assays, we were able to formulate PLA nanoparticles with these FNIII9/10 proteins at their surface. We then confirmed, by fluorescence and confocal microscopy, an enhanced cellular uptake by alpha 5 beta 1(+) cells of RGDS-FNIII9/10 coated PLA nanoparticles, in comparison to KGES-FNIII9/10 coated or non-coated controls. As a first vaccination approach, we prepared PLA nanoparticles co-coated with p24 (an HIV antigen), and RGDS-or KGES-FNIII9/10 proteins, followed by subcutaneous vaccine administration, in mice. Although we did not detect improvements in the apparent humoral response to p24 antigen in the serum of RGDS/p24 nanoparticle-treated mice, the presence of the FNIII proteins increased significantly the avidity index of anti-p24 antibodies compared to p24-nanoparticle-injected control mice. Future developments of this innovative targeted vaccine are discussed.	[Dalzon, Bastien; Lebas, Celia; Jimenez, Gina; Gutjahr, Alice; Terrat, Celine; Exposito, Jean-Yves; Verrier, Bernard; Lethias, Claire] Univ Lyon 1, Inst Biol & Chim Prot, Federat Rech,Gerland Lyon Sud, SFR BioSci Unite Mixte Serv 3444 US8, Lyon, France; [Dalzon, Bastien; Lebas, Celia; Jimenez, Gina; Gutjahr, Alice; Terrat, Celine; Exposito, Jean-Yves; Verrier, Bernard; Lethias, Claire] CNRS, Lab Biol Tissulaire & Ingn Therapeut, Unite Mixte Rech, Lyon, France; [Jimenez, Gina] Univ Lyon 1, CNRS, INSERM, UMR 5310,U1217,Inst NeuroMyogene, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Exposito, JY (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, Federat Rech,Gerland Lyon Sud, SFR BioSci Unite Mixte Serv 3444 US8, Lyon, France.	jy.exposito@ibcp.fr	Dalzon, Bastien/GPP-4184-2022; verrier, bernard/J-4094-2017	verrier, bernard/0000-0002-8478-7095	AFM doctoral fellowship; ANRT PhD fellowship; Fondation Pierre Berge - Sidaction; FP7 European grants [241904, 280873]; HIVERA; InvivoGen	AFM doctoral fellowship; ANRT PhD fellowship(French National Research Agency (ANR)); Fondation Pierre Berge - Sidaction; FP7 European grants; HIVERA; InvivoGen	GJ is supported by an AFM doctoral fellowship, AG by an ANRT PhD fellowship in collaboration with InvivoGen, whereas JYE and BV are supported by grants from the Fondation Pierre Berge - Sidaction, two FP7 European grants CUT'HIVAC (No. 241904) and ADITEC (No. 280873) and HIVERA support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen CAS, 2006, INT IMMUNOL, V18, P1295, DOI 10.1093/intimm/dxl062; AOTA S, 1994, J BIOL CHEM, V269, P24756; Bobbala S, 2016, PHARM RES-DORDR, V33, P2078, DOI 10.1007/s11095-016-1979-0; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Elefteriou F, 1999, EUR J BIOCHEM, V263, P840, DOI 10.1046/j.1432-1327.1999.00563.x; Feng YZ, 2004, BIOCHEMISTRY-US, V43, P15811, DOI 10.1021/bi049174+; FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0; Garg A, 2009, INT J PHARMACEUT, V366, P201, DOI 10.1016/j.ijpharm.2008.09.016; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GOODWIN AE, 1995, J IMMUNOL METHODS, V187, P213, DOI 10.1016/0022-1759(95)00187-6; GRENZ H, 1993, J CELL SCI, V105, P739; Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060; Hussein HAM, 2015, ARCH VIROL, V160, P2669, DOI 10.1007/s00705-015-2579-8; Jancic C, 1998, IMMUNOLOGY, V95, P283; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; Kankaanpaa P, 2015, NANOSCALE, V7, P17889, DOI 10.1039/c5nr06218g; Kenny FN, 2015, CELL TISSUE RES, V360, P571, DOI 10.1007/s00441-014-2064-9; Khanbeigi RA, 2012, J CONTROL RELEASE, V162, P259, DOI 10.1016/j.jconrel.2012.07.019; Kim H, 2016, J BIOMED NANOTECHNOL, V12, P536, DOI 10.1166/jbn.2016.2189; Legaz S, 2016, NANOTOXICOLOGY, V16, P1; Legaz S, 2015, PROTEIN EXPRES PURIF, V113, P94, DOI 10.1016/j.pep.2015.05.009; Li B, 2011, MOL CANCER RES, V9, P702, DOI 10.1158/1541-7786.MCR-10-0484; Liard C, 2012, J INVEST DERMATOL, V132, P615, DOI 10.1038/jid.2011.346; Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080; Mann JFS, 2014, J VIROL, V88, P6959, DOI 10.1128/JVI.00183-14; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mittal A, 2013, DEV BIOL, V381, P73, DOI 10.1016/j.ydbio.2013.06.010; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Pavot V, 2014, NANOMEDICINE-UK, V9, P2703, DOI [10.2217/NNM.14.156, 10.2217/nnm.14.156]; Pavot V, 2014, J IMMUNOL, V193, P5781, DOI 10.4049/jimmunol.1402184; Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015; Pereira M, 2007, TISSUE ENG, V13, P567, DOI 10.1089/ten.2006.0228; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Pike DB, 2010, ADV DRUG DELIVER REV, V62, P167, DOI 10.1016/j.addr.2009.11.027; Primard C, 2010, BIOMATERIALS, V31, P6060, DOI 10.1016/j.biomaterials.2010.04.021; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Saini V, 2010, J DRUG TARGET, V18, P212, DOI 10.3109/10611860903386920; Shi F, 2008, J CELL SCI, V121, P2360, DOI 10.1242/jcs.014977; Stolzoff M, 2015, BIOMACROMOLECULES, V16, P1958, DOI 10.1021/acs.biomac.5b00336; Thomas C, 2011, MOL PHARMACEUT, V8, P405, DOI 10.1021/mp100255c; Torrano AA, 2013, NANOMEDICINE-UK, V8, P1815, DOI 10.2217/nnm.12.178; Vakonakis I, 2007, EMBO J, V26, P2575, DOI 10.1038/sj.emboj.7601694; Waithman J, 2016, EUR J IMMUNOL, V46, P543, DOI 10.1002/eji.201646293; Wang F, 2013, INT J MOL SCI, V14, P13447, DOI 10.3390/ijms140713447	45	9	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2016	11	12							e0167663	10.1371/journal.pone.0167663	http://dx.doi.org/10.1371/journal.pone.0167663			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EI8KC	27973577	Green Published, Green Submitted, gold			2023-01-03	WOS:000392754300037
J	Bruckner, S; Kammer, T				Brueckner, Sabrina; Kammer, Thomas			No Modulation of Visual Cortex Excitability by Transcranial Direct Current Stimulation	PLOS ONE			English	Article							THETA-BURST STIMULATION; HUMAN MOTOR CORTEX; MAGNETIC STIMULATION; CORTICAL EXCITABILITY; PHOSPHENE THRESHOLDS; LOW-FREQUENCY; LIGHT DEPRIVATION; MOVING PHOSPHENE; TDCS; PERCEPTION	Measuring phosphene thresholds (PTs) is often used to investigate changes in the excitability of the human visual cortex through different brain stimulation methods like repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation (tDCS). In several studies, PT increase or decrease has been shown after rTMS or tDCS application. Recently, using PT measurements we showed that the state of the neurons in the visual cortex after rTMS might have an influence on the modulatory effects of stimulation. In the present study we aimed to investigate whether visual cortex activity following stimulation influences the modulatory effects of tDCS as well. In a between-group design, anodal or cathodal tDCS was applied to the visual cortex twice per subject, with either high or low visual demand following stimulation. We observed no modulation of PT neither directly following both anodal and cathodal tDCS nor following the visual demand periods. We rather found high inter-individual variability in the response to tDCS, and intra-individual reliability in the direction of modulation was observed for cathodal tDCS only. Thus, our results do not confirm the modulatory effects of tDCS on visual cortex excitability published previously. Moreover, they support the confirmation that tDCS effects have little reliability on varied TMS outcome measurements.	[Brueckner, Sabrina; Kammer, Thomas] Univ Ulm, Sect Neurostimulat, Dept Psychiat, Ulm, Germany	Ulm University	Bruckner, S (corresponding author), Univ Ulm, Sect Neurostimulat, Dept Psychiat, Ulm, Germany.	sabrina.brueckner@uni-ulm.de	Kammer, Thomas/K-2168-2012	Kammer, Thomas/0000-0002-2769-5645; Lorenz, Sabrina/0000-0001-5798-4838				Antal A, 2003, EXP BRAIN RES, V150, P375, DOI 10.1007/s00221-003-1459-8; Antal A, 2004, NEUROREPORT, V15, P297, DOI 10.1097/00001756-200402090-00017; Antal A, 2004, NEUROREPORT, V15, P1307, DOI 10.1097/01.wnr.0000127460.08361.84; Antal A, 2004, INVEST OPHTH VIS SCI, V45, P702, DOI 10.1167/iovs.03-0688; Antal A, 2003, NEUROPSYCHOLOGIA, V41, P1802, DOI 10.1016/S0028-3932(03)00181-7; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; Antal A, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00642; Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008; BARKER AT, 1985, J PHYSIOL-LONDON, V369, pP3; Bocci T, 2014, J NEURAL TRANSM, V121, P221, DOI 10.1007/s00702-013-1104-z; Boroojerdi B, 2000, CEREB CORTEX, V10, P529, DOI 10.1093/cercor/10.5.529; Boroojerdi B, 2000, NEUROLOGY, V54, P1529, DOI 10.1212/WNL.54.7.1529; Brighina F, 2002, EXP BRAIN RES, V145, P177, DOI 10.1007/s00221-002-1096-7; Bruckner S, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00591; Bruckner S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159743; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Dundas JE, 2007, CLIN NEUROPHYSIOL, V118, P1166, DOI 10.1016/j.clinph.2007.01.010; Fierro B, 2005, J PHYSIOL-LONDON, V565, P659, DOI 10.1113/jphysiol.2004.080184; Franca M, 2006, CLIN NEUROPHYSIOL, V117, P1808, DOI 10.1016/j.clinph.2006.03.019; Furubayashi T, 2008, EXP BRAIN RES, V185, P279, DOI 10.1007/s00221-007-1149-z; Gangitano M, 2002, CLIN NEUROPHYSIOL, V113, P1249, DOI 10.1016/S1388-2457(02)00109-8; Gratton C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101430; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; Horvath JC, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00002; Horvath JC, 2015, NEUROPSYCHOLOGIA, V66, P213, DOI 10.1016/j.neuropsychologia.2014.11.021; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Kammer T, 2007, NEUROIMAGE, V36, P313, DOI 10.1016/j.neuroimage.2007.03.001; Lang N, 2004, EXP BRAIN RES, V156, P439, DOI 10.1007/s00221-003-1800-2; Lang N, 2007, INVEST OPHTH VIS SCI, V48, P5782, DOI 10.1167/iovs.07-0706; Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432; Muellbacher W, 2000, CLIN NEUROPHYSIOL, V111, P1002, DOI 10.1016/S1388-2457(00)00284-4; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nozari N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084338; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Pirulli C, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00226; Pirulli C, 2013, BRAIN STIMUL, V6, P683, DOI 10.1016/j.brs.2012.12.005; Rauschecker AM, 2004, EXP BRAIN RES, V157, P124, DOI 10.1007/s00221-004-1910-5; Simis M, 2013, NEUROREPORT, V24, P973, DOI 10.1097/WNR.0000000000000021; Siniatchkin M, 2011, CLIN NEUROPHYSIOL, V122, P2475, DOI 10.1016/j.clinph.2011.05.003; Stagg CJ, 2009, EUR J NEUROSCI, V30, P1412, DOI 10.1111/j.1460-9568.2009.06937.x; Stewart LM, 2001, NEUROPSYCHOLOGIA, V39, P415, DOI 10.1016/S0028-3932(00)00130-5; Wichmann FA, 2001, PERCEPT PSYCHOPHYS, V63, P1293, DOI 10.3758/BF03194544; Wiethoff S, 2014, BRAIN STIMUL, V7, P468, DOI 10.1016/j.brs.2014.02.003	44	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2016	11	12							e0167697	10.1371/journal.pone.0167697	http://dx.doi.org/10.1371/journal.pone.0167697			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE4PU	27936117	gold, Green Published, Green Submitted			2023-01-03	WOS:000389587100155
J	Urfer, M; Elzi, L; Dell-Kuster, S; Bassetti, S				Urfer, Milena; Elzi, Luigia; Dell-Kuster, Salome; Bassetti, Stefano			Intervention to Improve Appropriate Prescribing and Reduce Polypharmacy in Elderly Patients Admitted to an Internal Medicine Unit	PLOS ONE			English	Article							POTENTIALLY INAPPROPRIATE MEDICATION; STOPP SCREENING TOOL; BEERS CRITERIA; OLDER PERSONS; COMMON OUTCOMES; RISK; PRESCRIPTIONS; PEOPLE; ADULTS; HOSPITALIZATION	Background Polypharmacy and inappropriate medication prescriptions are associated with increased morbidity and mortality. Most interventions proposed to improve appropriate prescribing are time and resource intensive and therefore hardly applicable in daily clinical practice. Objective To test the efficacy of an easy-to-use checklist aimed at supporting the therapeutic reasoning of physicians in order to reduce inappropriate prescribing and polypharmacy. Methods We assessed the efficacy and safety of a 5-point checklist to be used by all physicians on the internal medicine wards of a Swiss hospital by comparing outcomes in 450 consecutive patients aged >= 65 years hospitalized after the introduction of the checklist, and in 450 consecutive patients >= 65 years hospitalized before the introduction of the checklist. The main measures were the proportion of patients with prescription of potentially inappropriate medications (PIMs) at discharge, according to STOPP criteria, and the number of prescribed medications at discharge, before and after the introduction of the checklist. Secondary outcomes were the prevalence of polypharmacy (>= 5 drugs) and hyperpolypharmacy (>= 10 drugs), and the prevalence of potentially inappropriate prescribing omissions (PPOs) according to START criteria. Results At admission 59% of the 900 patients were taking >5 drugs, 13% >= 10 drugs, 37% had >= 1 PIM and 25% >= 1 PPO. The introduction of the checklist was associated with a significant reduction by 22% of the risk of being prescribed >= 1 PIM at discharge (adjusted risk ratios [RR] 0.78; 95% CI: 0.68-0.94), but not with a reduction of at least 20% of the number of drugs prescribed at discharge, nor with a reduction of the risk of PPOs at discharge. Conclusions The introduction of an easy-to-use 5-point checklist aimed at supporting therapeutic reasoning of physicians on internal medicine wards significantly reduced the risk of prescriptions of inappropriate medications at discharge.	[Urfer, Milena] Kantonsspital Olten, Div Internal Med, Olten, Switzerland; [Elzi, Luigia] Reg Hosp San Giovanni, Div Infect Dis, Bellinzona, Switzerland; [Dell-Kuster, Salome] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, Basel, Switzerland; [Bassetti, Stefano] Univ Basel Hosp, Div Internal Med, Basel, Switzerland; [Bassetti, Stefano] Univ Basel Hosp, Dept Clin Res, Basel, Switzerland	Kantonsspital Olten; Regional Hospital of Bellinzona & Valleys, San Giovanni; University of Basel; University of Basel; University of Basel	Bassetti, S (corresponding author), Univ Basel Hosp, Div Internal Med, Basel, Switzerland.; Bassetti, S (corresponding author), Univ Basel Hosp, Dept Clin Res, Basel, Switzerland.	stefano.bassetti@usb.ch	Dell-Kuster, Salome/H-4259-2017; Dell-Kuster, Salome/P-2653-2019	Dell-Kuster, Salome/0000-0001-7219-7138; Dell-Kuster, Salome/0000-0001-7219-7138				Bayoumi I, 2009, ANN PHARMACOTHER, V43, P1667, DOI 10.1345/aph.1M059; Blozik E, 2013, DRUG AGING, V30, P561, DOI 10.1007/s40266-013-0073-0; Carey EC, 2008, J AM GERIATR SOC, V56, P68, DOI 10.1111/j.1532-5415.2007.01496.x; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; Cook TD, 2002, ACAD EMERG MED, V9, P1430; Dalleur O, 2014, DRUG AGING, V31, P291, DOI 10.1007/s40266-014-0157-5; Dalleur O, 2012, DRUG AGING, V29, P829, DOI 10.1007/s40266-012-0016-1; Dovjak P, 2012, Z GERONTOL GERIATR, V45, P468, DOI 10.1007/s00391-012-0362-y; Egger SS, 2006, DRUG AGING, V23, P823, DOI 10.2165/00002512-200623100-00005; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2008, AGE AGEING, V37, P673, DOI 10.1093/ageing/afn197; Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Health FOoP, 2015, EV KVG REV BER SPIT, V13; Hubbard RE, 2015, MED J AUSTRALIA, V202, P373, DOI 10.5694/mja13.00172; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Onder G, 2010, ARCH INTERN MED, V170, P1142, DOI 10.1001/archinternmed.2010.153; Patterson SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008165.pub3, 10.1002/14651858.CD008165.pub4]; Price SD, 2014, ANN PHARMACOTHER, V48, P6, DOI 10.1177/1060028013504904; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Scott IA, 2012, AM J MED, V125, P529, DOI 10.1016/j.amjmed.2011.09.021; Sganga F, 2015, GERIATR GERONTOL INT; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Steinman MA, 2014, J GEN INTERN MED, V29, P1379, DOI 10.1007/s11606-014-2924-8; Topinkova E, 2012, DRUG AGING, V29, P477, DOI 10.2165/11632400-000000000-00000; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	33	35	35	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2016	11	11							e0166359	10.1371/journal.pone.0166359	http://dx.doi.org/10.1371/journal.pone.0166359			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE3FV	27902720	Green Submitted, Green Published, gold			2023-01-03	WOS:000389474100021
J	Arepally, S; Blanchard, AR				Arepally, Sandeep; Blanchard, Amy R.			In CVD with moderate-to-severe obstructive sleep apnea, adding CPAP to usual care did not reduce major CV events	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE		[Arepally, Sandeep; Blanchard, Amy R.] Augusta Univ, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Arepally, S (corresponding author), Augusta Univ, Augusta, GA 30912 USA.		Mukherjee, Sutapa/U-7262-2017	Mukherjee, Sutapa/0000-0001-5021-1648; Heeley, Emma/0000-0001-9190-2832				Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Peker Y, 2016, AM J RESP CRIT CARE, V194, P613, DOI 10.1164/rccm.201601-0088OC	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2016	165	10					JC59	JC59		10.7326/ACPJC-2016-165-10-059	http://dx.doi.org/10.7326/ACPJC-2016-165-10-059			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EC2RB	27842396				2023-01-03	WOS:000387970500010
J	Lopez-Liria, R; Vega-Ramirez, FA; Rocamora-Perez, P; Aguilar-Parra, JM; Padilla-Gongora, D				Lopez-Liria, Remedios; Antonio Vega-Ramirez, Francisco; Rocamora-Perez, Patricia; Manuel Aguilar-Parra, Jose; Padilla-Gongora, David			Comparison of Two Post-Stroke Rehabilitation Programs: A Follow-Up Study among Primary versus Specialized Health Care	PLOS ONE			English	Article							QUALITY-OF-LIFE; STROKE PATIENTS; HOME; VALIDATION; DISABILITY; DISCHARGE; SURVIVORS; PEOPLE; COSTS; INDEX	Objective To compare home-based rehabilitation (RITH) and standard outpatient rehabilitation in a hospital setting, in terms of improving the functional recovery and quality of life of stroke patients. Study Design and Setting This was a prospective cohort study in Andalusia (Spain). Participants One hundred and forty-five patients completed the outcome data. Measures Daily activities were measured by the Barthel index, Canadian Neurological Scale (to assess mental state), Tinetti scale (balance and gait), and Short Form Health Survey-36 (SF-36 to compare the quality of life). Results No statistically significant differences were found between the two groups regarding the clinical characteristics of patients in the initial measurement, except for age and mental state (younger and with greater neurological impairment in the hospital group). After physical therapy, both groups showed statistically significant improvements from baseline in each of the measures. These improvements were better in RITH patients than in the hospital patients on all functionality scales with a smaller number of sessions. Conclusions Home rehabilitation is at least as effective as the outpatient rehabilitation programs in a hospital setting, in terms of recovery of functionality in post-stroke patients. Overall quality of life is severely impaired in both groups, as stroke is a very disabling disease that radically affects patients' lives.	[Lopez-Liria, Remedios; Rocamora-Perez, Patricia] Univ Almeria, Dept Nursing Physiotherapy & Med, Almeria, Spain; [Antonio Vega-Ramirez, Francisco] Complejo Hosp Torrecardenas, Serv Andaluz Salud, Almeria, Spain; [Manuel Aguilar-Parra, Jose; Padilla-Gongora, David] Univ Almeria, Dept Psychol, Almeria, Spain; [Lopez-Liria, Remedios; Rocamora-Perez, Patricia; Manuel Aguilar-Parra, Jose; Padilla-Gongora, David] Univ Almeria, Carretera Sacramento S-N, La Canada De San Urbano 04120, Almeria, Spain	Universidad de Almeria; Hospital Torrecardenas; Universidad de Almeria; Universidad de Almeria	Lopez-Liria, R (corresponding author), Univ Almeria, Dept Nursing Physiotherapy & Med, Almeria, Spain.; Lopez-Liria, R (corresponding author), Univ Almeria, Carretera Sacramento S-N, La Canada De San Urbano 04120, Almeria, Spain.	rll040@ual.es	López-Liria, Remedios/V-3851-2019; Rocamora-Perez, Patricia/AAW-3775-2021; PARRA, JOSE MANUEL AGUILAR/AAD-6978-2019	López-Liria, Remedios/0000-0002-3416-2791; PARRA, JOSE MANUEL AGUILAR/0000-0002-6703-0680	Ministry of Health of the Government of Andalusia [PI 0449/2008]	Ministry of Health of the Government of Andalusia	The authors would like to acknowledge the Andalusian Regional Government for funding this investigation. Research Project PI 0449/2008 issued by the Ministry of Health of the Government of Andalusia, through the General Secretariat of Quality and Modernization, within the Biomedical and Health Sciences Research frame in Andalusia (resolution of 26th December, 2008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agencia de Evaluacion de Tecnologia e Investigacion Medicas, 2005, PLAN DIR ENF VASC CE; Aprile I, 2006, NEUROL SCI, V27, P40, DOI 10.1007/s10072-006-0563-5; Arias-Cuadrado A., 2009, GALICIA CLIN, V70, P25; Aziz NA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005952.pub2; Bobath B., 1982, HEMIPLEJIA ADULTO EV; Chaiyawat P, 2012, CLIN NEUROL NEUROSUR, V114, P866, DOI 10.1016/j.clineuro.2012.01.018; Chaiyawat Pakaratee, 2009, Neurol Int, V1, pe10, DOI 10.4081/ni.2009.e10; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; Direccion General de Asistencia Sanitaria, 2002, EQUIPOS MOVILES; Doig E, 2010, DISABIL REHABIL, V32, P2061, DOI 10.3109/09638281003797356; Eng XW, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/626538; Jimenez-Caballero PE, 2012, REV NEUROLOGIA, V55, P337, DOI 10.33588/rn.5506.2012307; Graessel E, 2014, INT J REHABIL RES, V37, P212, DOI 10.1097/MRR.0000000000000060; Gustafsson L, 2013, DISABIL REHABIL, V35, P1380, DOI 10.3109/09638288.2012.740134; Hamza AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/350281; Hervas-Angulo A, 2006, REV NEUROLOGIA, V43, P518, DOI 10.33588/rn.4309.2005830; Hillier S, 2010, INT J STROKE, V5, P178, DOI 10.1111/j.1747-4949.2010.00427.x; Hole E, 2014, SCI WORLD J, DOI 10.1155/2014/349151; Janssen H, 2014, DISABIL REHABIL, V36, P255, DOI 10.3109/09638288.2013.788218; Lopez-Liria R, 2013, REV NEUROLOGIA, V56, P601, DOI 10.33588/rn.5612.2013098; Lopez-Liria R, 2012, GAC SANIT, V26, P284, DOI 10.1016/j.gaceta.2011.09.017; Lopez-Liria R, 2010, ATEN PRIM, V42, P278, DOI 10.1016/j.aprim.2009.10.005; Mar J, 2013, NEUROLOGIA, V28, P332, DOI 10.1016/j.nrl.2012.07.004; Markle-Reid M, 2011, CAN J NEUROL SCI, V38, P317, DOI 10.1017/S0317167100011537; Montagut F, 2014, REHABILITACION DOMIC; Morone G, 2014, BIOMED RES INT; Musicco M, 2003, ARCH PHYS MED REHAB, V84, P551, DOI 10.1053/apmr.2003.50084; Paolucci S, 2015, EUR J PHYS REHAB MED, V51, P233; Rasmussen RS, 2016, CLIN REHABIL, V30, P225, DOI 10.1177/0269215515575165; Rodrigo-Gil J, 2012, REV NEUROLOGIA, V54, P151, DOI 10.33588/rn.5403.2011189; Rodriguez-Yanez M, 2013, NEUROLOGIA, V28, P236, DOI 10.1016/j.nrl.2011.03.010; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Stineman MG, 2014, AM J PHYS MED REHAB, V93, P217, DOI 10.1097/PHM.0b013e3182a92bfb; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ytterberg C, 2010, J NEUROL SCI, V294, P86, DOI 10.1016/j.jns.2010.03.027	36	9	10	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2016	11	11							e0166242	10.1371/journal.pone.0166242	http://dx.doi.org/10.1371/journal.pone.0166242			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EC0HG	27835673	Green Published, Green Submitted, gold			2023-01-03	WOS:000387779200033
J	Kunisawa, S; Fushimi, K; Imanaka, Y				Kunisawa, Susumu; Fushimi, Kiyohide; Imanaka, Yuichi			Reducing Length of Hospital Stay Does Not Increase Readmission Rates in Early-Stage Gastric, Colon, and Lung Cancer Surgical Cases in Japanese Acute Care Hospitals	PLOS ONE			English	Article							COLORECTAL RESECTION; EARLY DISCHARGE	Background The Japanese government has worked to reduce the length of hospital stay by introducing a per-diem hospital payment system that financially incentivizes the timely discharge of patients. However, there are concerns that excessively reducing length of stay may reduce healthcare quality, such as increasing readmission rates. The objective of this study was to investigate the temporal changes in length of stay and readmission rates as quality indicators in Japanese acute care hospitals. Methods We used an administrative claims database under the Diagnosis Procedure Combination Per-Diem Payment System for Japanese hospitals. Using this database, we selected hospitals that provided data continuously from July 2010 to March 2014 to enable analyses of temporal changes in length of stay and readmission rates. We selected stage I (T1N0M0) gastric, colon, and lung cancer surgical patients who had been discharged alive from the index hospitalization. The outcome measures were length of stay during the index hospitalization and unplanned emergency readmissions within 30 days after discharge. Results From among 804 hospitals, we analyzed 42,585, 15,467, and 40,156 surgical patients for gastric, colon, and lung cancer, respectively. Length of stay was reduced by approximately 0.5 days per year. In contrast, readmission rates were generally stable at approximately 2% or had decreased slightly over the 4-year period. Conclusions In early-stage gastric, colon, and lung cancer surgical patients in Japan, reductions in length of stay did not result in increased readmission rates.	[Kunisawa, Susumu; Imanaka, Yuichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan; [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Dept Hlth Policy & Informat, Tokyo, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU)	Imanaka, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan.	imanaka-y@umin.net	Yuichi, Imanaka/GYR-2098-2022; KUNISAWA, Susumu/HCH-1094-2022	Yuichi, Imanaka/0000-0003-4613-2159; 	Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan [H28-seisaku-shitei-009]; Japan Society for the Promotion of Science [16H02634]	Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported in part by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan (H28-seisaku-shitei-009), http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/, and a Grant-in-aid for Scientific Research from the Japan Society for the Promotion of Science (16H02634), https://www.jsps.go.jp/i-grantsinaid/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brooke BS, 2013, J VASC SURG, V57, P734, DOI 10.1016/j.jvs.2012.07.055; Gash KJ, 2012, COLORECTAL DIS, V14, P1287, DOI 10.1111/j.1463-1318.2012.02969.x; Hamada H, 2012, HEALTH POLICY, V107, P194, DOI 10.1016/j.healthpol.2012.01.002; Hoffman RL, 2014, J SURG RES, V190, P579, DOI 10.1016/j.jss.2014.02.006; Mackenzie SJ, 2016, J HEALTHC QUAL, V38, P187, DOI 10.1111/jhq.12080; Ministry of Health Labour and Welfare, HEIS 26 NEND BYOSH K, V26; Ministry of Health Labour and Welfare, 2014, HEIS 25 NEN IN PRESS; Ministry of Health Labour and Welfare, 2015, YOK SAIN KEIN; OECD Indicators, 2015, HLTH GLANC 2015; Otsubo T, 2012, READMISSION RATE HLT, V67, P62	10	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2016	11	11							e0166269	10.1371/journal.pone.0166269	http://dx.doi.org/10.1371/journal.pone.0166269			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB9ON	27832182	gold, Green Published, Green Submitted			2023-01-03	WOS:000387725000086
J	Bell, K; Fleckenstein, J; Nuesken, F; Licht, N; Rube, C; Dzierma, Y				Bell, Katharina; Fleckenstein, Jochen; Nuesken, Frank; Licht, Norbert; Ruebe, Christian; Dzierma, Yvonne			mARC Treatment of Hypopharynx Carcinoma with Flat and Flattening-Filter-Free Beam Energies - A Planning Study	PLOS ONE			English	Article							MODULATED ARC THERAPY; LINEAR-ACCELERATOR; CELL-SURVIVAL; NECK-CANCER; DOSE-RATE; IMRT; PROSTATE; VMAT; RADIOTHERAPY; DELIVERY	Background The recently implemented mARC-rotation-technique is capable to deliver high dose rate bursts. For the case of hypopharynx cancer plans we evaluate whether the mARC can achieve an advantage in treatment time in comparison to IMRT. These plans consider two arcs with flat and flattening filter free (FFF) beam energies. Materials and Methods For 8 hypopharynx-cancer patients step-and-shoot-IMRT and mARC plans were created retrospectively using flat and FFF beam energy. The comparison of the plan scenarios considered measures of quality for PTV coverage and sparing of organs at risk. All plans were irradiated on an anthromorphic phantom equipped with thermoluminescent dosimeters to measure scattered dose and treatment times. Results A visual comparison of the dose distribution did not show a marked preference for either technique or energy. The statistical evaluation yielded significant differences in favor of the mARC technique and the FFF energy. Scattered dose could be decreased markedly by the use of the mARC technique. Treatment times could be reduced up to 3 minutes with the use of mARC in comparison to IMRT. The high dose rate energy results in another time advantage of about 1 minute. Conclusions All four plan scenarios yielded equally good quality plans. A combination of the mARC technique with FFF 7 MV high dose rate resulted in a decrease of treatment times from about 9 minutes to 5-6 minutes in comparison to 6 MV IMRT.	[Bell, Katharina; Fleckenstein, Jochen; Nuesken, Frank; Licht, Norbert; Ruebe, Christian; Dzierma, Yvonne] Univ Saarland, Med Ctr, Dept Radiotherapy & Radiat Oncol, Kirrberger Str Geb 6-5, D-66421 Homburg, Germany	Saarland University	Bell, K (corresponding author), Univ Saarland, Med Ctr, Dept Radiotherapy & Radiat Oncol, Kirrberger Str Geb 6-5, D-66421 Homburg, Germany.	katharina.bell@uks.eu						Alvarez-Moret J, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-110; Bell K, 2016, PHYS MEDICA, V32, P474, DOI 10.1016/j.ejmp.2016.02.011; Cashmore J, 2011, INT J RADIAT ONCOL, V80, P1220, DOI 10.1016/j.ijrobp.2010.10.002; Dogan N, 2003, INT J RADIAT ONCOL, V57, P1480, DOI 10.1016/S0360-3016(03)01569-4; Dzierma Y, 2016, Z MED PHYS IN PRESS, DOI [10.1016/j, DOI 10.1016/J]; Dzierma Y, 2015, STRAHLENTHER ONKOL, V191, P961, DOI 10.1007/s00066-015-0889-0; Dzierma Y, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0250-2; Dzierma Y, 2014, STRAHLENTHER ONKOL, V190, P1046, DOI 10.1007/s00066-014-0662-9; Dzierma Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094371; Dzierma Y, 2014, PRACT RADIAT ONCOL, V4, pE109, DOI 10.1016/j.prro.2013.04.004; Dzierma Y, 2012, MED PHYS, V39, P2595, DOI 10.1118/1.3703835; Guckenberger M, 2009, RADIOTHER ONCOL, V93, P259, DOI 10.1016/j.radonc.2009.08.015; Kainz K, 2011, MED PHYS, V38, P5104, DOI 10.1118/1.3622612; King RB, 2013, PHYS MED BIOL, V58, pN83, DOI 10.1088/0031-9155/58/5/N83; Kragl G, 2011, Z MED PHYS, V21, P91, DOI 10.1016/j.zemedi.2010.07.003; Kry SF, 2010, PHYS MED BIOL, V55, P2155, DOI 10.1088/0031-9155/55/8/003; Lechner W, 2013, RADIOTHER ONCOL, V109, P437, DOI 10.1016/j.radonc.2013.09.020; Lohse I, 2011, RADIOTHER ONCOL, V101, P226, DOI 10.1016/j.radonc.2011.05.072; Murray LJ, 2015, PHYS MED BIOL, V60, P1237, DOI 10.1088/0031-9155/60/3/1237; Mynampati DK, 2012, J APPL CLIN MED PHYS, V13, P108, DOI 10.1120/jacmp.v13i5.3382; Salter BJ, 2011, PHYS MED BIOL, V56, P1931, DOI 10.1088/0031-9155/56/7/002; Sarkar V, 2015, J APPL CLIN MED PHYS, V16, P458, DOI 10.1120/jacmp.v16i2.5351; Sorensen BS, 2011, RADIOTHER ONCOL, V101, P223, DOI 10.1016/j.radonc.2011.06.018; Spahn U, 2013, STRAHLENTHER ONKOL, V189, P62; Stromberger C, 2016, STRAHLENTHER ONKOL, V192, P17, DOI 10.1007/s00066-015-0913-4; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; Vanetti E, 2009, RADIOTHER ONCOL, V92, P111, DOI 10.1016/j.radonc.2008.12.008; vantRiet A, 1997, INT J RADIAT ONCOL, V37, P731, DOI 10.1016/S0360-3016(96)00601-3; Verbakel WFAR, 2013, ACTA ONCOL, V52, P652, DOI 10.3109/0284186X.2012.737021	29	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2016	11	10							e0164616	10.1371/journal.pone.0164616	http://dx.doi.org/10.1371/journal.pone.0164616			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ0DG	27741272	Green Published, gold, Green Submitted			2023-01-03	WOS:000385507000046
J	Niedrig, DF; Hoppe, L; Machler, S; Russmann, H; Russmann, S				Niedrig, David Franklin; Hoppe, Liesa; Machler, Sarah; Russmann, Heike; Russmann, Stefan			Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events	PLOS ONE			English	Article							DRUG-INTERACTIONS; RISK; PHARMACOKINETICS; PHARMACODYNAMICS; MIDAZOLAM; PRESCRIPTIONS; FLUNITRAZEPAM; ITRACONAZOLE; POPULATION; INHIBITION	Objective Benzodiazepines and "Z-drug" GABA-receptor modulators (BDZ) are among the most frequently used drugs in hospitals. Adverse drug events (ADE) associated with BDZ can be the result of preventable medication errors (ME) related to dosing, drug interactions and comorbidities. The present study evaluated inpatient use of BDZ and related ME and ADE. Methods We conducted an observational study within a pharmacoepidemiological database derived from the clinical information system of a tertiary care hospital. We developed algorithms that identified dosing errors and interacting comedication for all administered BDZ. Associated ADE and risk factors were validated in medical records. Results Among 53,081 patients contributing 495,813 patient-days BDZ were administered to 25,626 patients (48.3%) on 115,150 patient-days (23.2%). We identified 3,372 patient-days (2.9%) with comedication that inhibits BDZ metabolism, and 1,197 (1.0%) with lorazepam administration in severe renal impairment. After validation we classified 134, 56, 12, and 3 cases involving lorazepam, zolpidem, midazolam and triazolam, respectively, as clinically relevant ME. Among those there were 23 cases with associated adverse drug events, including severe CNS-depression, falls with subsequent injuries and severe dyspnea. Causality for BDZ was formally assessed as 'possible' or 'probable' in 20 of those cases. Four cases with ME and associated severe ADE required administration of the BDZ antagonist flumazenil. Conclusions BDZ use was remarkably high in the studied setting, frequently involved potential ME related to dosing, co-medication and comorbidities, and rarely cases with associated ADE. We propose the implementation of automated ME screening and validation for the prevention of BDZ-related ADE.	[Niedrig, David Franklin; Hoppe, Liesa; Russmann, Stefan] Univ Zurich Hosp, Dept Clin Pharmacol & Toxicol, Zurich Zh, Switzerland; [Niedrig, David Franklin; Russmann, Stefan] ETHZ, Swiss Fed Inst Technol Zurich, Zurich, ZH, Switzerland; [Machler, Sarah; Russmann, Stefan] Drugsafety Ch, Kusnacht Zh, Switzerland; [Russmann, Heike] Neurol See, Kusnacht Zh, Switzerland	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich	Russmann, S (corresponding author), Univ Zurich Hosp, Dept Clin Pharmacol & Toxicol, Zurich Zh, Switzerland.; Russmann, S (corresponding author), ETHZ, Swiss Fed Inst Technol Zurich, Zurich, ZH, Switzerland.; Russmann, S (corresponding author), Drugsafety Ch, Kusnacht Zh, Switzerland.	rustefan@ethz.ch			Swiss National Science Foundation [320030_143867]; ID Suisse AG	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); ID Suisse AG	This work was supported by Swiss National Science Foundation, grant #320030_143867 to Stefan Russmann, and an unrestricted research grant from ID Suisse AG to Stefan Russmann. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altamura AC, 2013, EXPERT OPIN DRUG MET, V9, P423, DOI 10.1517/17425255.2013.759209; [Anonymous], 2015, GOOD PRACTICE GUIDE, pPP. 9; Backman JT, 1998, EUR J CLIN PHARMACOL, V54, P53, DOI 10.1007/s002280050420; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bramness JG, 2006, FORENSIC SCI INT, V159, P83, DOI 10.1016/j.forsciint.2005.06.009; Brunero S, 2016, INT PSYCHOGERIATR, V28, P967, DOI 10.1017/S104161021500232X; Carli-Ghabarou D, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13894; Chen SJ, 2015, SLEEP, V38, P1045, DOI 10.5665/sleep.4808; Dionne PA, 2013, PSYCHIAT SERV, V64, P331, DOI 10.1176/appi.ps.201200089; Donoghue J, 2010, INT J PSYCHIAT CLIN, V14, P78, DOI 10.3109/13651500903447810; Ekstrom MP, 2014, BMJ-BRIT MED J, V348, pg445, DOI DOI 10.1136/BMJ.G445; Fritz D, 2012, EUR J CLIN PHARMACOL, V68, P1209, DOI 10.1007/s00228-012-1241-6; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Greenblatt DJ, 2004, CLIN PHARMACOL THER, V76, P467, DOI 10.1016/j.clpt.2004.07.009; Gudin JA, 2013, POSTGRAD MED, V125, P115, DOI 10.3810/pgm.2013.07.2684; Gustavsen I, 2008, SLEEP MED, V9, P818, DOI 10.1016/j.sleep.2007.11.011; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Huerta C, 2016, PHARMACOEPIDEM DR S, V25, P56, DOI 10.1002/pds.3825; Kamel Amin, 2013, Drug Discov Today Technol, V10, pe177, DOI 10.1016/j.ddtec.2012.09.011; Kawano Daniel Fabio, 2009, J Patient Saf, V5, P69, DOI 10.1097/PTS.0b013e3181a5dafa; Khawaja Muhammad Rizwamillah, 2005, JPMA Journal of the Pakistan Medical Association, V55, P259; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Lader M, 2011, ADDICTION, V106, P2086, DOI 10.1111/j.1360-0443.2011.03563.x; Lagnaoui R, 2001, PHARMACOEPIDEM DR S, V10, P531, DOI 10.1002/pds.621; Lin FY, 2014, SLEEP, V37, P673, DOI 10.5665/sleep.3566; Nakafero G, 2015, PHARMACOEPIDEM DR S, V24, P793, DOI 10.1002/pds.3799; Niedrig DF, 2016, INT CLIN PSYCHOPHARM, V31, P42, DOI 10.1097/YIC.0000000000000103; Onder G, 2012, J GERONTOL A-BIOL, V67, P698, DOI 10.1093/gerona/glr233; Petitjean S, 2007, INT CLIN PSYCHOPHARM, V22, P292, DOI 10.1097/YIC.0b013e328105e0f2; Popovic B, 2014, EUR J CLIN PHARMACOL, V70, P737, DOI 10.1007/s00228-014-1667-0; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Requena G, 2016, PHARMACOEPIDEM DR S, V25, P66, DOI 10.1002/pds.3816; Robin Christian, 2002, Anesth Prog, V49, P128; Saari TI, 2006, CLIN PHARMACOL THER, V79, P362, DOI 10.1016/j.clpt.2005.12.305; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Starcevic V, 2014, EXPERT REV NEUROTHER, V14, P1275, DOI 10.1586/14737175.2014.963057; Tae CH, 2014, DIGEST LIVER DIS, V46, P710, DOI 10.1016/j.dld.2014.04.007; Taegtmeyer AB, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13615; Tapper EB, 2015, CLIN GASTROENTEROL H, V13, P1670, DOI 10.1016/j.cgh.2015.03.019; Templeton I, 2010, CLIN PHARMACOL THER, V88, P499, DOI 10.1038/clpt.2010.119; VERBEECK RK, 1981, BRIT J CLIN PHARMACO, V12, P749, DOI 10.1111/j.1365-2125.1981.tb01300.x; Vozoris NT, 2014, EUR RESPIR J, V44, P332, DOI 10.1183/09031936.00008014; Webster LR, 2015, POSTGRAD MED, V127, P27, DOI 10.1080/00325481.2015.993276; Zhou SF, 2007, THER DRUG MONIT, V29, P687, DOI 10.1097/FTD.0b013e31815c16f5; Zint K, 2010, PHARMACOEPIDEM DR S, V19, P1248, DOI 10.1002/pds.2031	45	5	6	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2016	11	10							e0163224	10.1371/journal.pone.0163224	http://dx.doi.org/10.1371/journal.pone.0163224			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DZ2UR	27711224	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000385697600017
J	Jhan, JR; Andrechek, ER				Jhan, J-R; Andrechek, E. R.			Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis	ONCOGENE			English	Article							TRASTUZUMAB RESISTANCE; TRANSCRIPTION FACTORS; ADJUVANT BEVACIZUMAB; MOLECULAR PORTRAITS; TARGETED THERAPIES; LUNG-CANCER; IN-VITRO; INHIBITION; MODELS; CONTRIBUTES	Current therapeutic outcomes for breast cancer underscore the complexity of treating a heterogeneous disease. Indeed, studies have shown that differences in gene expression among patients with the same subtype of breast cancer are correlated with the response to treatment. This strongly suggests that there is an urgent need to treat breast cancer with a personalized approach. Here we employed cell signaling pathway signatures to predict pathway activity in subtypes of MMTV-Myc mammary tumors. We then split tumors into subsets and developed individualized combinatorial treatments for two subtypes with distinct pathway activation patterns. Elevation of the EGFR, RAS and TGF beta pathways was observed in one subtype whereas these pathways were not predicted to be active in the other subtype that had high predicted activity of the Myc, Stat3 and Akt pathways. In a proof-of-principle experiment, treatment of these two subtypes with targeted therapies inhibited tumor growth only in the subtype of tumor where the therapy was designed to be active. We then analyzed gene expression profiles of human breast cancer patients and patientderived xenograft (PDX) samples to predict pathway activity, and validated our approach of developing individualized treatments in mice with PDX tumors. Importantly, our combinatorial therapy resulted in tumor regression, including regression in PDX samples from triple-negative breast cancer. Together our data is a proof-of-principle experiment that demonstrates that cell signaling pathway signature-guided treatment for breast cancer is viable.	[Jhan, J-R; Andrechek, E. R.] Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA.	andrech1@msu.edu			Susan Komen Career Catalyst [KG110510]; NIH [R011CA160514]	Susan Komen Career Catalyst; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the members of the Andrechek laboratory for helpful discussions. Funding for this project was provided by grants from Susan Komen Career Catalyst (KG110510) and NIH R011CA160514 to ERA.	Alok J., 2004, BIOINFORMATICS, V20, P3246; Andrechek ER, 2015, ONCOGENE, V34, P217, DOI 10.1038/onc.2013.540; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bear HD, 2015, LANCET ONCOL, V16, P1037, DOI 10.1016/S1470-2045(15)00041-8; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Carvalho CM, 2008, J AM STAT ASSOC, V103, P1438, DOI 10.1198/016214508000000869; Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; DaCosta BS, 2004, MOL PHARM, V65, P744, DOI DOI 10.1124/M0L.65.3.744; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Eo HS, 2012, MOL CELLS, V34, P393, DOI 10.1007/s10059-012-0177-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560; Hoefflin R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11845; Hollern DP, 2013, ONCOGENE, V32, P1296, DOI 10.1038/onc.2012.142; Hollern DP, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3672; Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127; Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; 2007, CLIN CANCER RES, V13, P4429, DOI DOI 10.1158/1078-0432.CCR-06-3045	56	10	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3553	3561		10.1038/onc.2016.503	http://dx.doi.org/10.1038/onc.2016.503			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28135251				2023-01-03	WOS:000403878600005
J	Cunningham, S; Fernandes, RM				Cunningham, Steve; Fernandes, Ricardo M.			High-flow oxygen therapy in acute bronchiolitis	LANCET			English	Editorial Material							INFANTS; SATURATION; CHILDREN		[Cunningham, Steve] Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland; [Cunningham, Steve] Royal Hosp Sick Children, Dept Resp & Sleep Med, Edinburgh EH9 1LF, Midlothian, Scotland; [Fernandes, Ricardo M.] Hosp Santa Maria, Ctr Hosp, Dept Pediat, Lisbon, Portugal; [Fernandes, Ricardo M.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal	University of Edinburgh; Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa	Cunningham, S (corresponding author), Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland.; Cunningham, S (corresponding author), Royal Hosp Sick Children, Dept Resp & Sleep Med, Edinburgh EH9 1LF, Midlothian, Scotland.	steve.cunningham@nhs.net	Fernandes, Ricardo M/C-7501-2015	Fernandes, Ricardo M/0000-0002-7253-6475; Cunningham, Steve/0000-0001-7342-251X	LFB Paris; Ablynx [ALX-0171]	LFB Paris; Ablynx(Ablynx)	SC reports consultancy fees paid to NHS Lothian from Ablynx for development of the phase I/IIa trial of ALX-0171 in bronchiolitis and personal fees from LFB Paris outside the submitted work. RMF was a member of the Independent Data Monitoring Committee for the Ablynx phase I/IIa trial of ALX-0171 in bronchiolitis.	Alam N, 2014, RESUSCITATION, V85, P587, DOI 10.1016/j.resuscitation.2014.01.013; Beggs S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009609.pub2; Cunningham S, 2015, JAMA PEDIATR, V169, P891, DOI 10.1001/jamapediatrics.2015.1971; Cunningham S, 2015, LANCET, V386, P1041, DOI 10.1016/S0140-6736(15)00163-4; Dumas O, 2016, THORAX, V71, P712, DOI 10.1136/thoraxjnl-2016-208535; Franklin D, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0501-x; Kepreotes E, 2016, LANCET; Mason BW, 2016, ARCH DIS CHILD, V101, P552, DOI 10.1136/archdischild-2015-308465; Milesi C, 2013, INTENS CARE MED, V39, P1088, DOI 10.1007/s00134-013-2879-y; Ricci V, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2305; Sinha IP, 2015, CHEST, V148, P810, DOI 10.1378/chest.14-1589; Unger S, 2008, PEDIATRICS, V121, P470, DOI 10.1542/peds.2007-1135	12	5	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2017	389	10072					886	887		10.1016/S0140-6736(17)30192-7	http://dx.doi.org/10.1016/S0140-6736(17)30192-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EM4DL	28161017	Green Submitted			2023-01-03	WOS:000395263400007
J	Keum, J; Nam, H				Keum, Jongsoo; Nam, Hojung			SELF-BLM: Prediction of drug-target interactions via self-training SVM	PLOS ONE			English	Article							WEB SERVER; MI-DRAGON; PROTEIN; INHIBITORS; IDENTIFICATION; INFORMATION; ALGORITHM; DATABASE; NETWORK; KERNELS	Predicting drug-target interactions is important for the development of novel drugs and the repositioning of drugs. To predict such interactions, there are a number of methods based on drug and target protein similarity. Although these methods, such as the bipartite local model (BLM), show promise, they often categorize unknown interactions as negative interaction. Therefore, these methods are not ideal for finding potential drug-target interactions that have not yet been validated as positive interactions. Thus, here we propose a method that integrates machine learning techniques, such as self-training support vector machine (SVM) and BLM, to develop a self-training bipartite local model (SELF-BLM) that facilitates the identification of potential interactions. The method first categorizes unlabeled interactions and negative interactions among unknown interactions using a clustering method. Then, using the BLM method and self-training SVM, the unlabeled interactions are self-trained and final local classification models are constructed. When applied to four classes of proteins that include enzymes, G-protein coupled receptors (GPCRs), ion channels, and nuclear receptors, SELF-BLM showed the best performance for predicting not only known interactions but also potential interactions in three protein classes compare to other related studies. The implemented software and supporting data are available at https://github.com/GIST-CSBL/SELF-BLM.	[Keum, Jongsoo; Nam, Hojung] Gwangju Inst Sci & Technol, Sch Elect Engn & Comp Sci, 123 Cheomdangwgi Ro, Gwangju, South Korea	Gwangju Institute of Science & Technology (GIST)	Nam, H (corresponding author), Gwangju Inst Sci & Technol, Sch Elect Engn & Comp Sci, 123 Cheomdangwgi Ro, Gwangju, South Korea.	hjnam@gist.ac.kr	Nam, Hojung/AAR-4065-2020	Nam, Hojung/0000-0002-5109-9114	Bio-Synergy Research Project of the Ministry of Science, ICT and Future Planning through the National Research Foundation [NRF-2014M3A9C4066449]; National Research Foundation of Korea grant - the Korea government (MSIP) [NRF-2015R1C1A1A01051578]	Bio-Synergy Research Project of the Ministry of Science, ICT and Future Planning through the National Research Foundation(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); National Research Foundation of Korea grant - the Korea government (MSIP)(National Research Foundation of Korea)	This work was supported by the Bio-Synergy Research Project (NRF-2014M3A9C4066449, http://nrf.re.kr/) of the Ministry of Science, ICT and Future Planning through the National Research Foundation, and supported by the National Research Foundation of Korea grant funded by the Korea government (MSIP) (NRF-2015R1C1A1A01051578, http://nrf.re.kr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bleakley K, 2009, BIOINFORMATICS, V25, P2397, DOI 10.1093/bioinformatics/btp433; Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chen X, 2016, BRIEF BIOINFORM, V17, P696, DOI 10.1093/bib/bbv066; Chen X, 2012, MOL BIOSYST, V8, P1970, DOI 10.1039/c2mb00002d; Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273; Ding H, 2014, BRIEF BIOINFORM, V15, P734, DOI 10.1093/bib/bbt056; Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293; Gonen M, 2012, BIOINFORMATICS, V28, P2304, DOI 10.1093/bioinformatics/bts360; Gonzalez-Diaz H, 2011, J PROTEOME RES, V10, P1698, DOI 10.1021/pr101009e; Gonzalez-Diaz H, 2011, J THEOR BIOL, V276, P229, DOI 10.1016/j.jtbi.2011.01.010; Gunther S, 2008, NUCLEIC ACIDS RES, V36, pD919, DOI 10.1093/nar/gkm862; Hattori M, 2003, J AM CHEM SOC, V125, P11853, DOI 10.1021/ja036030u; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kaufman L, 2009, FINDING GROUPS DATA, V344; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Li YQ, 2008, PATTERN RECOGN LETT, V29, P1285, DOI 10.1016/j.patrec.2008.01.030; Mei JP, 2013, BIOINFORMATICS, V29, P238, DOI 10.1093/bioinformatics/bts670; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nickel J, 2014, NUCLEIC ACIDS RES, V42, pW26, DOI 10.1093/nar/gku477; Perlman L, 2011, J COMPUT BIOL, V18, P133, DOI 10.1089/cmb.2010.0213; Prado-Prado F, 2012, CURR TOP MED CHEM, V12, P1843; Prado-Prado F, 2011, EUR J MED CHEM, V46, P5838, DOI 10.1016/j.ejmech.2011.09.045; Romero-Duran FJ, 2016, NEUROPHARMACOLOGY, V103, P270, DOI 10.1016/j.neuropharm.2015.12.019; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; van Laarhoven T, 2011, BIOINFORMATICS, V27, P3036, DOI 10.1093/bioinformatics/btr500; Wang YC, 2016, BIOINFORMATICS, V32, P226, DOI 10.1093/bioinformatics/btv528; Wang YC, 2011, COMPUT BIOL CHEM, V35, P353, DOI 10.1016/j.compbiolchem.2011.10.003; Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; Yoo M, 2015, BIOINFORMATICS, V31, P3069, DOI 10.1093/bioinformatics/btv313; Zhao XM, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-57	33	43	43	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2017	12	2							e0171839	10.1371/journal.pone.0171839	http://dx.doi.org/10.1371/journal.pone.0171839			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EL2AZ	28192537	gold, Green Published			2023-01-03	WOS:000394423800045
J	Tian, HL; Ge, XL; Nie, YZ; Yang, LF; Ding, C; McFarland, LV; Zhang, XY; Chen, QY; Gong, JF; Li, N				Tian, Hongliang; Ge, Xiaolong; Nie, Yongzhan; Yang, Linfeng; Ding, Chao; McFarland, Lynne V.; Zhang, Xueying; Chen, Qiyi; Gong, Jianfeng; Li, Ning			Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial	PLOS ONE			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; COLONIC TRANSIT; METAANALYSIS; CHILDHOOD; SYMPTOMS; ADULTS	Fecal microbiota transplantation has been proposed as a therapeutic approach for chronic constipation. This randomized, controlled trial aimed to compare the effects of conventional treatment alone (control) with additional treatment with FMT (intervention) in patients with slow -transit constipation (STC). Adults with STC were randomized to receive intervention or control treatment. The control group received education, behavioral strategies, and oral laxatives. The intervention group was additionally provided 6 days of FMT. The primary endpoint was the clinical cure rate (proportion of patients achieving a mean of > three complete spontaneous bowel movements [CSBMs] per week]. Secondary outcomes and safety parameters were assessed throughout the study. Sixty patients were randomized to either conventional treatment alone (n = 30) or FMT (n = 30) through a nasointestinal tube. There were significant differences between the intervention group and control group in the clinical improvement rate (intention -to -treat [ITT]: 53.3% vs. 20.0%, P= 0.009), clinical cure rate (ITT: 36.7% vs. 13.3%, P= 0.04), mean number of CSBMs per week (ITT: 3.2 1.4 vs. 2.1 1.2, P = 0.001), and the Wexner constipation score (ITT: 8.6 1.5 vs. 12.7 2.5, P< 0.00001). Compared with the control group, the intervention group showed better results in the stool consistency score (ITT: 3.9 vs. 2.4, P< 0.00001) and colonic transit time (ITT: 58.5 vs. 73.6 h, P< 0.00001). The intervention group had more treatment-related adverse events than did the control group (50 vs. 4 cases). FMT was significantly more effective (30% higher cure rate) for treatment of STC than conventional treatment. No serious adverse events were observed.	[Tian, Hongliang; Ge, Xiaolong; Ding, Chao; Zhang, Xueying; Chen, Qiyi; Gong, Jianfeng; Li, Ning] Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China; [Nie, Yongzhan] Fourth Mil Med Univ, Xi Jing Hosp, Inst Digest Dis, Xian, Peoples R China; [Yang, Linfeng] BGI Shenzhen, Shenzhen, Peoples R China; [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; [Li, Ning] Tongji Univ, Shanghai Peoples Hosp 10, Peoples Hosp 10, Shanghai, Peoples R China	Nanjing University; Air Force Military Medical University; Beijing Genomics Institute (BGI); University of Washington; University of Washington Seattle; Tongji University	Gong, JF; Li, N (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China.; Li, N (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Peoples Hosp 10, Shanghai, Peoples R China.	gongjianfeng@aliyun.com; liningrigsnju@163.com	Yang, Linfeng/AAZ-8792-2020		National Nature Science Foundation of China [81670493]; National Gastroenterology Research Project [2015BAI131307]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Gastroenterology Research Project	This study was supported by the National Nature Science Foundation of China (no. 81670493) (http://www.nsfc.gov.cn/publish/portal1/) and by the National Gastroenterology Research Project (2015BAI131307). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agachan F, 1996, DIS COLON RECTUM, V39, P681, DOI 10.1007/BF02056950; ANDREWS P, 1995, GASTROENTEROLOGY, V108, pA563; Benninga MA, 2004, J PEDIATR GASTR NUTR, V39, P448, DOI 10.1097/00005176-200411000-00002; Bharucha Adil E., 2001, Curr Treat Options Gastroenterol, V4, P309, DOI 10.1007/s11938-001-0056-9; Colman RJ, 2014, J CROHNS COLITIS, V8, P1569, DOI 10.1016/j.crohns.2014.08.006; Crouzet L, 2013, NEUROGASTROENT MOTIL, V25, pe272, DOI 10.1111/nmo.12103; Emmanuel A, 2014, AM J GASTROENTEROL, V109, P887, DOI 10.1038/ajg.2014.74; Kang DW, 2015, ANAEROBE, V33, P33, DOI 10.1016/j.anaerobe.2015.01.005; Kassam Z, 2013, AM J GASTROENTEROL, V108, P500, DOI 10.1038/ajg.2013.59; Kelly CR, 2015, GASTROENTEROLOGY, V149, P223, DOI 10.1053/j.gastro.2015.05.008; Khalif IL, 2005, DIGEST LIVER DIS, V37, P838, DOI 10.1016/j.dld.2005.06.008; McFarland LV, 2016, WORLD J GASTROENTERO, V22, P3078, DOI 10.3748/wjg.v22.i11.3078; Metcalf AM, 1987, GASTROENTEROLOGY, V92, P40, DOI 10.1016/0016-5085(87)90837-7; Mugie SM, 2011, NAT REV GASTRO HEPAT, V8, P502, DOI 10.1038/nrgastro.2011.130; Parthasarathy G, 2016, GASTROENTEROLOGY, V150, P367, DOI 10.1053/j.gastro.2015.10.005; Simren M, 2013, GUT, V62, P159, DOI 10.1136/gutjnl-2012-302167; Southwell BR, 2009, PEDIATR SURG INT, V25, P559, DOI 10.1007/s00383-009-2387-x; Tian HL, 2016, J CLIN GASTROENTEROL, V50, P865, DOI 10.1097/MCG.0000000000000472; Tian HL, 2015, J CLIN GASTROENTEROL, V49, P537, DOI 10.1097/MCG.0000000000000330; Turan I, 2014, TURK J GASTROENTEROL, V25, P650, DOI 10.5152/tjg.2014.6990; Vandeputte D, 2016, GUT, V65, P57, DOI 10.1136/gutjnl-2015-309618; Voderholzer WA, 1997, AM J GASTROENTEROL, V92, P95; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875; Zhu LX, 2014, PHYSIOL GENOMICS, V46, P679, DOI 10.1152/physiolgenomics.00082.2014; Zoppi G, 1998, ACTA PAEDIATR, V87, P836, DOI 10.1080/080352598750013590	25	74	80	4	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2017	12	2							e0171308	10.1371/journal.pone.0171308	http://dx.doi.org/10.1371/journal.pone.0171308			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN7DG	28158276	Green Submitted, Green Published, gold			2023-01-03	WOS:000396161700058
J	Butt, CA				Butt, Carrie A.			"Move Your Arm Like a Swan" Dance for PD Demedicalizes Parkinson Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Butt, Carrie A.] JAMA Network, Digital Content Operat, Chicago, IL 60654 USA		Butt, CA (corresponding author), JAMA Network, Digital Content Operat, Chicago, IL 60654 USA.	carrie.butt@jamanetwork.org							0	9	9	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2017	317	4					342	343		10.1001/jama.2016.21033	http://dx.doi.org/10.1001/jama.2016.21033			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EI5BW	28118430				2023-01-03	WOS:000392509600001
J	Roehr, B				Roehr, Bob			Henry Heimlich Creator of the eponymous manoeuvre OBITUARY	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item																		HEIMLICH H, PUBLICATION LIST	1	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	2017	356								j118	10.1136/bmj.j118	http://dx.doi.org/10.1136/bmj.j118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EH9BN	28069709				2023-01-03	WOS:000392066800004
J	Czerwinski, M; Spence, JR				Czerwinski, Michael; Spence, Jason R.			Hacking the Matrix	CELL STEM CELL			English	Editorial Material							STEM-CELLS; ORGANOIDS; INDUCTION; YAP/TAZ		[Czerwinski, Michael; Spence, Jason R.] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA; [Spence, Jason R.] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Spence, Jason R.] Univ Michigan, Sch Med, Ctr Organogenesis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Spence, JR (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA.; Spence, JR (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.; Spence, JR (corresponding author), Univ Michigan, Sch Med, Ctr Organogenesis, Ann Arbor, MI 48109 USA.	spencejr@umich.edu		Czerwinski, Michael/0000-0003-1965-2191	NIAID NIH HHS [U19 AI116482] Funding Source: Medline; NICHD NIH HHS [T32 HD007505] Funding Source: Medline; NIDDK NIH HHS [U01 DK085532, U01 DK103141, P30 DK034933] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI116482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, U01DK103141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Caiazzo M, 2016, NAT MATER, V15, P344, DOI [10.1038/nmat4536, 10.1038/NMAT4536]; Enemchukwu NO, 2016, J CELL BIOL, V212, P113, DOI 10.1083/jcb.201506055; Gjorevski N, 2016, NATURE, V539, P359, DOI 10.1038/nature20168; Gregorieff A, 2015, NATURE, V526, P715, DOI 10.1038/nature15382; Kretzschmar K, 2016, DEV CELL, V38, P590, DOI 10.1016/j.devcel.2016.08.014; Panciera T, 2016, CELL STEM CELL, V19, P725, DOI 10.1016/j.stem.2016.08.009; St Johnston D, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002149; Turner DA, 2016, BIOESSAYS, V38, P181, DOI 10.1002/bies.201500111	10	16	16	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JAN 5	2017	20	1					9	10		10.1016/j.stem.2016.12.010	http://dx.doi.org/10.1016/j.stem.2016.12.010			2	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	EO0FR	28061355	Bronze, Green Accepted			2023-01-03	WOS:000396374200005
J	Hamza, F; Abd Ei-Latief, A; Khatan, W				Hamza, F.; Abd EI-Latief, A.; Khatan, W.			Thermomechanical Fractional Model of TEMHD Rotational Flow	PLOS ONE			English	Article							ORDER THEORY; 2ND-GRADE FLUID; COUETTE-FLOW; THERMOELASTICITY; CYLINDER; BEHAVIOR; ANNULUS; SPACE	In this work, the fractional mathematical model of an unsteady rotational flow of Xanthan gum (XG) between two cylinders in the presence of a transverse magnetic field has been studied. This model consists of two fractional parameters alpha and beta representing thermomechanical effects. The Laplace transform is used to obtain the numerical solutions. The fractional parameter influence has been discussed graphically for the functions field distribution (temperature, velocity, stress and electric current distributions). The relationship between the rotation of both cylinders and the fractional parameters has been discussed on the functions field distribution for small and large values of time.	[Hamza, F.; Abd EI-Latief, A.] Univ Alexandria, Dept Math, Fac Sci, Alexandria, Egypt; [Khatan, W.] Univ Damanhour, Dept Math, Fac Sci, Damanhour, Egypt	Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Damanhour University	Abd Ei-Latief, A (corresponding author), Univ Alexandria, Dept Math, Fac Sci, Alexandria, Egypt.	naladellatief@yahoo.com			Alexandria University	Alexandria University(Alexandria University)	Alexandria University is the only funder of this research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abd El-Latief AM, 2015, ZAMM-Z ANGEW MATH ME, V95, P511, DOI 10.1002/zamm.201300174; Ali F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065223; Ali F, 2012, J PHYS SOC JPN, V81, DOI 10.1143/JPSJ.81.064402; [Anonymous], ADV OPER RES, DOI DOI 10.1371/J0URNAL.P0NE.0090280; [Anonymous], 1998, FRACTIONAL DIFFERENT; Anwar MI, 2014, INDIAN J CHEM TECHN, V21, P199; Asghar S, 2005, INT J HEAT MASS TRAN, V48, P599, DOI 10.1016/j.ijheatmasstransfer.2004.08.023; Athar M, 2011, NONLINEAR ANAL-MODEL, V16, P135, DOI 10.15388/NA.16.2.14101; Ezzat MA, 2012, HEAT MASS TRANSFER, V48, P71, DOI 10.1007/s00231-011-0830-8; Ezzat MA, 2010, PHYSICA B, V405, P4188, DOI 10.1016/j.physb.2010.07.009; Fetecau C, 2010, COMPUT MATH APPL, V59, P2836, DOI 10.1016/j.camwa.2010.02.002; Gul T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103843; Hamza F, 2015, ADV MATER SCI ENG, V2015, DOI 10.1155/2015/391454; Hamza F, 2014, J THERM STRESSES, V37, P1080, DOI 10.1080/01495739.2014.936196; Hemeda A. A., 2013, ABSTR APPL ANAL, V2013, P1, DOI DOI 10.1155/2013/717540; HONIG G, 1984, J COMPUT APPL MATH, V10, P113, DOI 10.1016/0377-0427(84)90075-X; Hussanan A, 2014, EUR PHYS J PLUS, V129, DOI 10.1140/epjp/i2014-14046-x; Imran M, 2011, NONLINEAR ANAL-MODEL, V16, P47, DOI 10.15388/NA.16.1.14114; Jamil M., 2012, ISRN MATH PHYS, P1, DOI [10.5402/2012/908386, DOI 10.5402/2012/908386]; Jumarie G, 2010, COMPUT MATH APPL, V59, P1142, DOI 10.1016/j.camwa.2009.05.015; Khajohnsaksumeth N, 2013, ABSTR APPL ANAL, DOI 10.1155/2013/858597; Khalid A., 2015, ENG SCI TECHNOL, V80, P1; Khalid A, 2015, EUR PHYS J PLUS, V130, DOI 10.1140/epjp/i2015-15057-9; Mahmood A, 2011, ACTA MECH SINICA-PRC, V27, P222, DOI 10.1007/s10409-011-0443-y; Mohyuddin MR, 2005, INT J NUMER METH FL, V49, P837, DOI 10.1002/fld.1026; Navarrete R., 2000, SPE PERM BAS OIL GAS; Nemir D, 2010, J ELECTRON MATER, V39, P1897, DOI 10.1007/s11664-009-1060-4; Orczykowska M, 2012, CHEM PROCESS ENG-INZ, V33, P141, DOI 10.2478/v10176-012-0013-2; Owen JM, 2012, J TURBOMACH, V134, DOI 10.1115/1.4003071; Pereira FAR, 2010, LAT AM APPL RES, V40, P53; Ruzic DN, 2011, NUCL FUSION, V51, DOI 10.1088/0029-5515/51/10/102002; Samiulhaq, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088766; Shah SHAM, 2010, MECCANICA, V45, P143, DOI 10.1007/s11012-009-9233-z; Sharma R., 2011, J PURE APPL SCI TECH, V1, P36; SHERCLIFF JA, 1979, J FLUID MECH, V91, P231, DOI 10.1017/S0022112079000136; Sherief H, 2013, INT J MECH SCI, V74, P185, DOI 10.1016/j.ijmecsci.2013.05.016; Sherief HH, 2014, APPL MATH COMPUT, V248, P584, DOI 10.1016/j.amc.2014.10.019; Sherief HH, 2014, ZAMM-Z ANGEW MATH ME, V94, P509, DOI 10.1002/zamm.201200173; Sherief HH, 2010, INT J SOLIDS STRUCT, V47, P269, DOI 10.1016/j.ijsolstr.2009.09.034; Sherief HH, 2004, J THERM STRESSES, V27, P885, DOI 10.1080/01495730490498331; SHERIEF HH, 1988, INT J ENG SCI, V26, P301, DOI 10.1016/0020-7225(88)90079-1; Sukumar A., 2010, 2010 2 INT C COMPUTI, P1, DOI DOI 10.1109/ICCCNT.2010.5591733; Tan WC, 2004, ACTA MECH SINICA-PRC, V20, P471, DOI 10.1007/BF02484269; Tan WC, 2003, INT J NONLINEAR MECH, V38, P645, DOI 10.1016/S0020-7462(01)00121-4; Tong DK, 2005, SCI CHINA SER G, V48, P485, DOI 10.1360/04yw0105; Neto JLV, 2014, BRAZ J CHEM ENG, V31, P829, DOI 10.1590/0104-6632.20140314s00002871; Xu MY, 2001, SCI CHINA SER A, V44, P1387, DOI 10.1007/BF02877067	47	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2017	12	1							e0168530	10.1371/journal.pone.0168530	http://dx.doi.org/10.1371/journal.pone.0168530			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EH2QJ	28045941	Green Published, Green Submitted, gold			2023-01-03	WOS:000391612300028
J	Hunter, BR				Hunter, Benton R.			Therapeutic hypothermia during CPR did not improve survival to discharge in out-of-hospital cardiac arrest	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hunter, Benton R.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Hunter, BR (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46202 USA.							Heard KJ, 2010, RESUSCITATION, V81, P9, DOI 10.1016/j.resuscitation.2009.09.015; Nie CR, 2016, AM J EMERG MED, V34, P2209, DOI 10.1016/j.ajem.2016.09.007; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 20	2016	165	12					JC70	JC70		10.7326/ACPJC-2016-165-12-070	http://dx.doi.org/10.7326/ACPJC-2016-165-12-070			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EG7OJ	27992926				2023-01-03	WOS:000391236900009
J	Gao, XY; Zhao, YX; Su, YS; Liu, K; Yu, XC; Cui, CX; Yang, ZK; Shi, H; Jing, XH; Zhu, B				Gao, Xinyan; Zhao, Yuxue; Su, Yangshuai; Liu, Kun; Yu, Xiaochun; Cui, Changxiang; Yang, Zhaokun; Shi, Hong; Jing, Xianghong; Zhu, Bing			beta(1/2) or M-2/3 Receptors Are Required for Different Gastrointestinal Motility Responses Induced by Acupuncture at Heterotopic or Homotopic Acupoints	PLOS ONE			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; GASTRIC-ACID-SECRETION; SMOOTH-MUSCLE; ELECTRICAL-STIMULATION; NEURAL MECHANISM; URINARY-BLADDER; M-3; CONTRACTIONS; ANTAGONISTS; SUBTYPES	Acupuncture at homotopic acupoints or heterotopic acupoints is known to either inhibit or facilitate gastrointestinal motility, depending on the acupoint location. However, little effort has been made to investigate the roles of specific receptors (such as adrenergic and muscarinic acetylcholine receptors) in mediating the effects of acupuncture at heterotopic and homotopic acupoints. Different adrenergic receptor subtypes or cholinergic receptor subtypes are predominantly expressed in various sections of the gut, resulting in variations between the effects of acupuncture at heterotopic or homotopic acupoints on gastrointestinal motility. Here, we investigated the role of beta(1)/beta(2) receptors and M-2/M-3 receptors in gastrointestinal motility regulated by acupuncture at ST37, a heterotopic acupoint, and ST25, a homotopic acupoint, by simultaneously recording intraluminal pressures in the distal colon and stomach or jejunum and examining fecal phenol red excretion in beta(1/2) receptor-knockout mice and M-2/3 receptor-knockout mice. We found that knockout of the M-2/3 receptor significantly inhibited ST37 acupuncture-induced enhancement of gastric motility, jejunal motility, and colonic motility. Additionally, knocking out of the beta(1/2) receptor significantly diminished the ST25 acupuncture-induced inhibition of gastric motility and jejunal motility without significantly altering the enhancement of colonic motility induced by acupuncture at ST25. Acupuncture at ST37 significantly accelerated gastrointestinal transition in beta(1/2) receptorknockout mice and their wild-type littermates. However, this acceleration of gastrointestinal transition was markedly diminished in M-2/3 receptor-knockout mice relative to their wild-type littermates. Acupuncture at ST25 significantly increased gastrointestinal transition in beta(1/2) receptor-knockout mice and significantly decreased gastrointestinal transition in M-2/3 receptor- knockout mice without altering gastrointestinal transition in wild-type littermates of either. Our study revealed that M-2/3 receptors are required for the gastrointestinal motility associated with whole gastrointestinal transition enhanced by acupuncture at heterotopic acupoints, whereas beta(1/2) receptors are required for the same gastrointestinal motility processes inhibited by acupuncture at homotopic acupoints. Therefore, our findings reveal important biological mechanisms underlying acupuncture treatment of disorders involving gastrointestinal motility dysfunction.	[Gao, Xinyan; Zhao, Yuxue; Su, Yangshuai; Liu, Kun; Yu, Xiaochun; Cui, Changxiang; Yang, Zhaokun; Shi, Hong; Jing, Xianghong; Zhu, Bing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Cui, Changxiang] Peoples Hosp Ri Zhao, Rizhao, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS	Jing, XH; Zhu, B (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China.	jxhtjb@263.net; zhubing@mail.cintcm.ac.cn	Jing, Xianghong/HHS-4003-2022; Gao, Xinyan/HHN-8438-2022	Liu, Kun/0000-0002-1388-3514	National Basic Research Program of China [2011CB505201, 2014CB543103]; National Natural Science Foundation of China [81173345, 81130063]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Basic Research Program of China granted to BZ (No.2011CB505201) and to XG (No. 2014CB543103), and by National Natural Science Foundation of China granted to XG (No. 81173345) and to BZ (No. 81130063). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAHAMSSON H, 1983, DIGEST DIS SCI, V28, P590, DOI 10.1007/BF01299918; AHLUWALIA NK, 1994, GUT, V35, P1356, DOI 10.1136/gut.35.10.1356; Ahluwalia NK, 1993, J GASTROINTEST MOTIL, V5, P177; Aihara T, 2005, AM J PHYSIOL-GASTR L, V288, pG1199, DOI 10.1152/ajpgi.00514.2004; Broccardo A, 2005, PEPTIDES, V26, P1590, DOI 10.1016/j.peptides.2005.02.018; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chang CS, 2001, DIGESTION, V64, P184, DOI 10.1159/000048860; Chiba T, 2002, NEUROGASTROENT MOTIL, V14, P535, DOI 10.1046/j.1365-2982.2002.00357.x; DePonti F, 1996, PHARMACOL THERAPEUT, V69, P59, DOI 10.1016/0163-7258(95)02031-4; Eglen RM, 1996, PHARMACOL REV, V48, P531; Ehlert FJ, 2003, LIFE SCI, V74, P355, DOI 10.1016/j.lfs.2003.09.023; Ehlert FJ, 1997, LIFE SCI, V61, P1729, DOI 10.1016/S0024-3205(97)00433-5; Ehlert FJ, 1997, MUSCARINIC RECEPTOR, P87; Ehlert Frederick J, 2012, Handb Exp Pharmacol, P343, DOI 10.1007/978-3-642-23274-9_15; Gao X, 2015, NEUROGASTROENT MOTIL, V27, P1817, DOI 10.1111/nmo.12694; Goyal RK, 1996, NEW ENGL J MED, V334, P1106, DOI 10.1056/NEJM199604253341707; HEDGES A, 1969, BRIT J PHARMACOL, V37, pP547; Hutchinson DS, 2001, BRIT J PHARMACOL, V132, P433, DOI 10.1038/sj.bjp.0703828; Kaan SK, 1996, EUR J PHARMACOL, V317, P115, DOI 10.1016/S0014-2999(96)00705-4; KOIZUMI K, 1980, BRAIN RES, V182, P85, DOI 10.1016/0006-8993(80)90832-X; Li YQ, 2007, WORLD J GASTROENTERO, V13, P709, DOI 10.3748/wjg.v13.i5.709; Li YQ, 2006, WORLD J GASTROENTERO, V12, P7642, DOI 10.3748/wjg.v12.i47.7642; LI YY, 1992, AM J GASTROENTEROL, V87, P1372; Lin XM, 1997, AM J GASTROENTEROL, V92, P1527; Lomasney KW, 2014, AM J PHYSIOL-GASTR L, V307, pG241, DOI 10.1152/ajpgi.00401.2013; Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7; LUX G, 1994, GUT, V35, P1026, DOI 10.1136/gut.35.8.1026; Matsui M, 2000, P NATL ACAD SCI USA, V97, P9579, DOI 10.1073/pnas.97.17.9579; Matsui M, 2002, J NEUROSCI, V22, P10627; MCINTYRE AS, 1992, ALIMENT PHARM THERAP, V6, P125; Mule F, 2010, J PHYSIOL SCI, V60, P75, DOI 10.1007/s12576-009-0060-8; Ouyang H, 2004, ALIMENT PHARM THER, V20, P831, DOI 10.1111/j.1365-2036.2004.02196.x; Qin QG, 2014, WORLD J GASTROENTERO, V20, P18271, DOI 10.3748/wjg.v20.i48.18271; SATO A, 1993, NEUROSCI RES, V18, P53, DOI 10.1016/0168-0102(93)90105-Y; SATO A, 1992, J MANIP PHYSIOL THER, V15, P57; Stengel PW, 2003, J PHARMACOL EXP THER, V304, P675, DOI 10.1124/jpet.102.042283; Stengel PW, 2002, AM J PHYSIOL-REG I, V282, pR1443, DOI 10.1152/ajpregu.00486.2001; Stengel PW, 2000, J PHARMACOL EXP THER, V292, P877; Tache Y, 2002, HDB AUTONOMIC NERVOU, P474; Tada H, 2003, DIGEST DIS SCI, V48, P59, DOI 10.1023/A:1021730314068; Takahashi T, 2011, NEUROMODULATION, V14, P8, DOI 10.1111/j.1525-1403.2010.00295.x; Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6; Tobin G, 1995, J AUTON PHARMACOL, V15, P451, DOI 10.1111/j.1474-8673.1995.tb00410.x; Unno T, 2005, BRIT J PHARMACOL, V146, P98, DOI 10.1038/sj.bjp.0706300; Unno T, 2006, BRIT J PHARMACOL, V149, P1022, DOI 10.1038/sj.bjp.0706955; Wallis RM, 1999, LIFE SCI, V64, P395, DOI 10.1016/S0024-3205(98)00585-2; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Yang B, 2015, MOL MED REP, V11, P2735, DOI 10.3892/mmr.2014.3039; Yin JY, 2010, AUTON NEUROSCI-BASIC, V157, P31, DOI 10.1016/j.autneu.2010.03.007; Yoshimoto S, 2012, DIGEST DIS SCI, V57, P1213, DOI 10.1007/s10620-012-2040-8; Yu O, 1997, DIGEST DIS SCI, V42, P1146, DOI 10.1023/A:1018877318101; Zhao YX, 2015, J TRADIT CHIN MED, V35, P227, DOI 10.1016/S0254-6272(15)30033-9	52	13	16	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2016	11	12							e0168200	10.1371/journal.pone.0168200	http://dx.doi.org/10.1371/journal.pone.0168200			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EG7HN	27978539	gold, Green Submitted, Green Published			2023-01-03	WOS:000391217400075
J	Rose, NS; LaRocque, JJ; Riggall, AC; Gosseries, O; Starrett, MJ; Meyering, EE; Postle, BR				Rose, Nathan S.; LaRocque, Joshua J.; Riggall, Adam C.; Gosseries, Olivia; Starrett, Michael J.; Meyering, Emma E.; Postle, Bradley R.			Reactivation of latent working memories with transcranial magnetic stimulation	SCIENCE			English	Article							SHORT-TERM-MEMORY; PREFRONTAL CORTEX; PARIETAL CORTEX; ATTENTION	The ability to hold information in working memory is fundamental for cognition. Contrary to the long-standing view that working memory depends on sustained, elevated activity, we present evidence suggesting that humans can hold information in working memory via "activity-silent" synaptic mechanisms. Using multivariate pattern analyses to decode brain activity patterns, we found that the active representation of an item in working memory drops to baseline when attention shifts away. A targeted pulse of transcranial magnetic stimulation produced a brief reemergence of the item in concurrently measured brain activity. This reactivation effect occurred and influenced memory performance only when the item was potentially relevant later in the trial, which suggests that the representation is dynamic and modifiable via cognitive control. The results support a synaptic theory of working memory.	[Rose, Nathan S.; LaRocque, Joshua J.; Riggall, Adam C.; Gosseries, Olivia; Starrett, Michael J.; Meyering, Emma E.; Postle, Bradley R.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA; [Rose, Nathan S.] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA; [LaRocque, Joshua J.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; [Gosseries, Olivia] Univ Liege, Coma Sci Grp, B-4000 Liege, Belgium; [Riggall, Adam C.; Postle, Bradley R.] Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Notre Dame; University of Wisconsin System; University of Wisconsin Madison; University of Liege; University of Wisconsin System; University of Wisconsin Madison	Rose, NS; Postle, BR (corresponding author), Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA.; Rose, NS (corresponding author), Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA.; Postle, BR (corresponding author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA.	nrose1@nd.edu; postle@wisc.edu	Gosseries, Olivia/AAB-6469-2020; Starrett, Michael J./AAD-5077-2021	Gosseries, Olivia/0000-0001-9011-7496; Starrett, Michael J./0000-0002-1746-2688; Rose, Nathan/0000-0002-7619-4441	NIH [MH095984]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH095984] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank J. Samaha, A. Sheldon, B. Kundu, J. Lewis-Peacock, and J. Johnson for assistance and helpful discussions. Supported by NIH grant MH095984 (B.R.P.). The data are stored at curate.nd.edu. Author contributions: N.S.R., B.R.P., J.J.L., and A.C.R. designed the research; N.S.R., O.G., M.J.S., and E.M.M. conducted the research; N.S.R., J.J.L., and A.C.R. analyzed the data; and N.S.R., B.R.P., and J.J.L. wrote the manuscript. The authors declare no conflict of interest.	Baddeley A, 2012, ANNU REV PSYCHOL, V63, P1, DOI 10.1146/annurev-psych-120710-100422; Beck DM, 2006, CEREB CORTEX, V16, P712, DOI 10.1093/cercor/bhj017; Christophel TB, 2012, J NEUROSCI, V32, P12983, DOI 10.1523/JNEUROSCI.0184-12.2012; Cowan N., 1999, MODELS WORKING MEMOR, P62; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Ester EF, 2013, J COGNITIVE NEUROSCI, V25, P754, DOI 10.1162/jocn_a_00357; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Hayden BY, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00018; Itskov V, 2011, FRONT COMPUT NEUROSC, V5, DOI 10.3389/fncom.2011.00040; Kundu B, 2015, NEUROIMAGE, V114, P320, DOI 10.1016/j.neuroimage.2015.04.001; LaRocque JJ, 2017, CEREB CORTEX, V27, P4881, DOI 10.1093/cercor/bhw283; LaRocque JJ, 2013, J COGNITIVE NEUROSCI, V25, P127, DOI 10.1162/jocn_a_00305; Lee TG, 2012, J NEUROSCI, V32, P15458, DOI 10.1523/JNEUROSCI.0627-12.2012; Lewis-Peacock JA, 2012, J COGNITIVE NEUROSCI, V24, P61, DOI 10.1162/jocn_a_00140; McElree B, 2006, PSYCHOL LEARN MOTIV, V46, P155, DOI 10.1016/S0079-7421(06)46005-9; Mongillo G, 2008, SCIENCE, V319, P1543, DOI 10.1126/science.1150769; MONSELL S, 1978, COGNITIVE PSYCHOL, V10, P465, DOI 10.1016/0010-0285(78)90008-7; Myers N. E., ELIFE, V4; Oberauer K, 2009, PSYCHOL LEARN MOTIV, V51, P45, DOI 10.1016/S0079-7421(09)51002-X; Polyn SM, 2005, SCIENCE, V310, P1963, DOI 10.1126/science.1117645; Riggall AC, 2012, J NEUROSCI, V32, P12990, DOI 10.1523/JNEUROSCI.1892-12.2012; Stokes MG, 2015, TRENDS COGN SCI, V19, P394, DOI 10.1016/j.tics.2015.05.004; Sugase-Miyamoto Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000073; Wolff MJ, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00123	25	225	226	11	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	2016	354	6316					1136	1139		10.1126/science.aah7011	http://dx.doi.org/10.1126/science.aah7011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED5TY	27934762	Green Accepted, Green Submitted			2023-01-03	WOS:000388916400039
J	Antwi, GD; Bates, LA; King, R; Mahama, PR; Tagbor, H; Cairns, M; Newell, JN				Antwi, Gifty D.; Bates, Laura A.; King, Rebecca; Mahama, Princess R.; Tagbor, Harry; Cairns, Matt; Newell, James N.			Facilitators and Barriers to Uptake of an Extended Seasonal Malaria Chemoprevention Programme in Ghana: A Qualitative Study of Caregivers and Community Health Workers	PLOS ONE			English	Article							INTERMITTENT PREVENTIVE TREATMENT; KNOWLEDGE-BEHAVIOR GAP; SHARED DECISION-MAKING; SULFADOXINE-PYRIMETHAMINE; SENEGALESE CHILDREN; TRIAL; EFFICACY; IMPACT	Background Seasonal Malaria Chemoprevention (SMC) is currently recommended for children under five in areas where malaria transmission is highly seasonal. We explored children's caregivers' and community health workers' (CHWs) responses to an extended 5-month SMC programme. Methods Thirteen in-depth interviews and eight focus group discussions explored optimal and suboptimal 'uptake' of SMC to examine facilitators and barriers to caregivers' uptake. Results There did not appear to be major differences between caregivers of children with optimal and sub-optimal SMC uptake in terms of their knowledge of malaria, their perceptions of the effect of SMC on a child's health, nor their understanding of chemoprevention. Caregivers experienced difficulty in prioritising SMC for well children, perceiving medication being for treatment rather than prevention. Prior to the study, caregivers had become accustomed to rapid diagnostic testing (RDT) for malaria, and therefore blood testing for malaria during the baseline survey at the start of the SMC programme may have positively influenced uptake. Facilitators of uptake included caregivers' trust in and respect for administrators of SMC (including CHWs), access to medication and supportive (family) networks. Barriers to uptake related to poor communication of timings of community gatherings, travel distances, absence during SMC home deliveries, and limited demand for SMC due to lack of previous experience. Future delivery of SMC by trained CHWs would be acceptable to caregivers. Conclusion A combination of caregivers' physical access to SMC medication, the drug regimen, trust in the medical profession and perceived norms around malaria prevention all likely influenced caregivers' level of uptake. SMC programmes need to consider: 1) developing supportive, accessible and flexible modes of drug administration including home delivery and village community kiosks; 2) improving demand for preventive medication including the harnessing of learnt trust; and 3) developing community-based networks for users to support optimal uptake of SMC.	[Antwi, Gifty D.; Tagbor, Harry] Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi, Ghana; [Bates, Laura A.; King, Rebecca; Newell, James N.] Univ Leeds, Leeds Inst Hlth Sci, Nuffield Ctr Int Hlth & Dev, Leeds, W Yorkshire, England; [Mahama, Princess R.] KNUST, Ctr Global Hlth Res, Kumasi, Ghana; [Cairns, Matt] London Sch Hyg & Trop Med, Trop Epidemiol Grp, London, England	Kwame Nkrumah University Science & Technology; University of Leeds; Kwame Nkrumah University Science & Technology; University of London; London School of Hygiene & Tropical Medicine	Bates, LA (corresponding author), Univ Leeds, Leeds Inst Hlth Sci, Nuffield Ctr Int Hlth & Dev, Leeds, W Yorkshire, England.	L.A.Bates@leeds.ac.uk	Tagbor, Harry/B-9312-2018	Tagbor, Harry/0000-0002-9300-665X; Acheampong, Princess Ruhama/0000-0002-3161-6487	Department for International Development [5245]; COMDIS-HSD; Medical Research Council [MR/K012126/1, MR/J012394/1] Funding Source: researchfish; Department for International Development (DFID) [201025] Funding Source: researchfish; MRC [MR/J012394/1] Funding Source: UKRI	Department for International Development; COMDIS-HSD; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Department for International Development (DFID); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Th grant number with Department for International Development is 5245 - 'Delivering effective health services'. Their websites can be found here: www.dfid.gov.uk http://r4d.dfid.gov.uk/. COMDIS-HSD received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, T3 TEST TREAT TRACK; Bojang KA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000409; Cairns M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1879; Cantey PT, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000728; Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0; Cisse B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007164; Coulter A, 1997, J Health Serv Res Policy, V2, P112; Dial NJ, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-47; Dicko A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000407; Edwards A, 2005, BRIT J GEN PRACT, V55, P6; Elkington H, 2004, RESP MED, V98, P439, DOI 10.1016/j.rmed.2003.11.006; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Ghana Statistical Service (GSS) GHSG and ICF International, 2015, GHAN DEM HLTH SURV 2; Gopichandran V, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-004115; Konate AT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000408; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080051; Lin GA, 2014, CIRC-CARDIOVASC QUAL, V7, P328, DOI 10.1161/CIRCOUTCOMES.113.000322; Menaca A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109707; Orish VN, 2016, TROPICAL DOCTOR, P1; Peters D, INT J HLTH PLANN MGM, V31, P227; Pitt C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032900; Rimal RN, 2000, HEALTH COMMUN, V12, P219, DOI 10.1207/S15327027HC1203_01; Sangare LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039712; Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471; Tagbor H, 2015, TROPICAL MED INT HLT; Wegwarth O, 2014, VACCINE, V32, P1388, DOI 10.1016/j.vaccine.2013.12.038; Wilson AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016976; Woolf SH, 2005, ANN INTERN MED, V143, P293, DOI 10.7326/0003-4819-143-4-200508160-00010; World Health Organisation, 2015, WORLD MAL PROGR; World Health Organisation, 2012, GLOB MAL PROGR WHO P	30	12	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2016	11	11							e0166951	10.1371/journal.pone.0166951	http://dx.doi.org/10.1371/journal.pone.0166951			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FU	27898699	Green Published, Green Accepted, gold			2023-01-03	WOS:000389474000027
J	Barth, SM; Schreitmuller, CM; Proehl, F; Oehl, K; Lumpp, LM; Kowalewski, DJ; Di Marco, M; Sturm, T; Backert, L; Schuster, H; Stevanovic, S; Rammensee, HG; Planz, O				Barth, Sharon M.; Schreitmueller, Christian M.; Proehl, Franziska; Oehl, Kathrin; Lumpp, Leonie M.; Kowalewski, Daniel J.; Di Marco, Moreno; Sturm, Theo; Backert, Linus; Schuster, Heiko; Stevanovic, Stefan; Rammensee, Hans-Georg; Planz, Oliver			Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy	PLOS ONE			English	Article							PET DOGS; NEURAL-NETWORKS; MATRIX PEPTIDE; VIRAL PEPTIDES; CANCER-THERAPY; DOMESTIC DOGS; ANIMAL-MODEL; ANTIGEN; MOLECULES; HLA-A2	There are limitations in pre-clinical settings using mice as a basis for clinical development in humans. In cancer, similarities exist between humans and dogs; thus, the dog patient can be a link in the transition from laboratory research on mouse models to clinical trials in humans. Knowledge of the peptides presented on MHC molecules is fundamental for the development of highly specific T cell-based immunotherapies. This information is available for human MHC molecules but is absent for the canine MHC. In the present study, we characterized the binding motif of dog leukocyte antigen (DLA) class I allele DLA-88*50101, using human C1R and K562 transfected cells expressing the DLA-88*50101 heavy chain. MHC class I immunoaffinity-purification revealed 3720 DLA-88*50101 derived peptides, which enabled the determination of major anchor positions. The characterized binding motif of DLA-88*50101 was similar to HLA-A*02:01. Peptide binding analyses on HLA-A*02:01 and DLA-88*50101 via flow cytometry showed weak binding of DLA-88*50101 derived peptides to HLA-A*02:01, and vice versa. Our results present for the first time a detailed peptide binding motif of the canine MHC class I allelic product DLA-88*50101. These data support the goal of establishing dogs as a suitable animal model for the evaluation and development of T cell-based cancer immunotherapies, benefiting both dog and human patients.	[Barth, Sharon M.; Schreitmueller, Christian M.; Proehl, Franziska; Oehl, Kathrin; Lumpp, Leonie M.; Kowalewski, Daniel J.; Di Marco, Moreno; Backert, Linus; Schuster, Heiko; Stevanovic, Stefan; Rammensee, Hans-Georg; Planz, Oliver] Univ Tubingen, Inst Cell Biol, Dept Immunol, Tubingen, Germany; [Oehl, Kathrin; Schuster, Heiko] Univ Zurich Hosp, Inst Surg Pathol, Zurich, Switzerland; [Kowalewski, Daniel J.] Immat Biotechnol GmbH, Tubingen, Germany; [Sturm, Theo] ETH, Inst Mol Syst Biol, Dept Biol, Zurich, Switzerland; [Sturm, Theo] Univ Utrecht, Biomol Mass Spectrometry & Prote, Bijvoet Ctr Biomol Res, Utrecht, Netherlands; [Sturm, Theo] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands; [Backert, Linus] Univ Tubingen, Appl Bioinformat, Ctr Bioinformat, Tubingen, Germany; [Backert, Linus] Univ Tubingen, Dept Comp Sci, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Zurich; University Zurich Hospital; Immatics Biotechnologies GmbH; Swiss Federal Institutes of Technology Domain; ETH Zurich; Utrecht University; Utrecht University; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Planz, O (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Tubingen, Germany.	oliver.planz@uni-tuebingen.de						Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; BAROUCH D, 1995, J EXP MED, V182, P1847, DOI 10.1084/jem.182.6.1847; Berlin C, 2016, LEUKEMIA, V30, P1003, DOI 10.1038/leu.2016.1; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Bukowski JA, 1998, J TOXICOL ENV HEAL A, V54, P579, DOI 10.1080/009841098158719; Burnett RC, 1997, TISSUE ANTIGENS, V49, P484, DOI 10.1111/j.1399-0039.1997.tb02783.x; BURNETT RC, 1995, J IMMUNOL, V155, P4278; Du JM, 2009, J MOL RECOGNIT, V22, P465, DOI 10.1002/jmr.964; Dutra AS, 1996, CYTOGENET CELL GENET, V74, P113, DOI 10.1159/000134395; EDWARDS PAW, 1982, EUR J IMMUNOL, V12, P641, DOI 10.1002/eji.1830120804; FALK K, 1993, P NATL ACAD SCI USA, V90, P12005, DOI 10.1073/pnas.90.24.12005; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Frantz LAF, 2016, SCIENCE, V352, P1228, DOI 10.1126/science.aaf3161; Graumann MB, 1998, TISSUE ANTIGENS, V51, P374, DOI 10.1111/j.1399-0039.1998.tb02976.x; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Hardt C, 2006, TISSUE ANTIGENS, V67, P163, DOI 10.1111/j.1399-0039.2006.00497.x; HAYES HM, 1981, AM J EPIDEMIOL, V114, P229, DOI 10.1093/oxfordjournals.aje.a113186; Jensen PE, 2007, NAT IMMUNOL, V8, P1041, DOI 10.1038/ni1516; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kennedy LJ, 2001, TISSUE ANTIGENS, V58, P55, DOI 10.1034/j.1399-0039.2001.580111.x; Kowalewski DJ, 2015, P NATL ACAD SCI USA, V112, pE166, DOI 10.1073/pnas.1416389112; Kowalewski Daniel J, 2013, Methods Mol Biol, V960, P145, DOI 10.1007/978-1-62703-218-6_12; Leone P, 2013, JNCI-J NATL CANCER I, V105, P1172, DOI 10.1093/jnci/djt184; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; Marchetti S, 2007, BRIT J CANCER, V97, P577, DOI 10.1038/sj.bjc.6603925; Marconato L, 2013, HEMATOL ONCOL, V31, P1, DOI 10.1002/hon.2017; MATSUI M, 1993, P NATL ACAD SCI USA, V90, P674, DOI 10.1073/pnas.90.2.674; MATSUI M, 1994, HUM IMMUNOL, V41, P160, DOI 10.1016/0198-8859(94)90010-8; Momburg F, 1996, J IMMUNOL, V156, P1756; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; OBST R, 1995, EUR J IMMUNOL, V25, P2170, DOI 10.1002/eji.1830250808; Paoloni M, 2008, NAT REV CANCER, V8, P147, DOI 10.1038/nrc2273; Parmiani G, 2014, HUM VACC IMMUNOTHER, V10, P3175, DOI 10.4161/hv.29418; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pinho SS, 2012, TRANSL RES, V159, P165, DOI 10.1016/j.trsl.2011.11.005; Rammensee HG, 2013, EXPERT REV VACCINES, V12, P1211, DOI 10.1586/14760584.2013.836911; Reif JS, 1998, AM J EPIDEMIOL, V147, P488, DOI 10.1093/oxfordjournals.aje.a009475; Ross P, 2012, TISSUE ANTIGENS, V80, P175, DOI 10.1111/j.1399-0039.2012.01889.x; Ross P, 2012, VET IMMUNOL IMMUNOP, V150, P206, DOI 10.1016/j.vetimm.2012.08.012; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004; Sant A, 2003, CURR OPIN IMMUNOL, V15, P66, DOI 10.1016/S0952-7915(02)00020-1; Scheidt WM, 2003, EVOLUTION COGNITION, V9, P57; Singh-Jasuja H, 2004, CANCER IMMUNOL IMMUN, V53, P187, DOI 10.1007/s00262-003-0480-x; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TENG JMC, 1994, MOL IMMUNOL, V31, P459, DOI 10.1016/0161-5890(94)90065-5; TERHORST C, 1976, P NATL ACAD SCI USA, V73, P910, DOI 10.1073/pnas.73.3.910; Thalmann O, 2013, SCIENCE, V342, P871, DOI 10.1126/science.1243650; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Tsai KL, 2013, IMMUNOGENETICS, V65, P501, DOI 10.1007/s00251-013-0704-y; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; Venkataraman GM, 2007, TISSUE ANTIGENS, V70, P53, DOI 10.1111/j.1399-0039.2007.00839.x; Wagner JL, 2000, TISSUE ANTIGENS, V55, P564, DOI 10.1034/j.1399-0039.2000.550607.x; Xiao J, 2016, J IMMUNOL, P50801; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	58	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2016	11	11							e0167017	10.1371/journal.pone.0167017	http://dx.doi.org/10.1371/journal.pone.0167017			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EE3FE	27893789	Green Published, gold, Green Submitted			2023-01-03	WOS:000389472400070
J	Finn, RS; Martin, M; Rugo, HS; Jones, S; Im, SA; Gelmon, K; Harbeck, N; Lipatov, ON; Walshe, JM; Moulder, S; Gauthier, E; Lu, DRR; Randolph, S; Dieras, V; Slamon, DJ				Finn, Richard S.; Martin, Miguel; Rugo, Hope S.; Jones, Stephen; Im, Seock-Ah; Gelmon, Karen; Harbeck, Nadia; Lipatov, Oleg N.; Walshe, Janice M.; Moulder, Stacy; Gauthier, Eric; Lu, Dongrui R.; Randolph, Sophia; Dieras, Veronique; Slamon, Dennis J.			Palbociclib and Letrozole in Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT KINASE 4/6; ENDOCRINE THERAPY; 1ST-LINE TREATMENT; TRIAL; BEVACIZUMAB; INHIBITOR	BACKGROUND A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS In this double-blind study, we randomly assigned, in a 2: 1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclibletrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.govnumber, NCT01740427.)	[Finn, Richard S.; Slamon, Dennis J.] Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, David Geffen Sch Med, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA; [Rugo, Hope S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Gauthier, Eric; Lu, Dongrui R.; Randolph, Sophia] Pfizer, La Jolla, CA USA; [Martin, Miguel] Univ Complutense, Hosp Gregorio Maranon, Madrid, Spain; [Jones, Stephen] US Oncol Res, The Woodlands, TX USA; [Im, Seock-Ah] Seoul Natl Univ, Canc Res Inst, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea; [Gelmon, Karen] British Columbia Canc Agcy, Vancouver, BC, Canada; [Harbeck, Nadia] Univ Munchen LMU, Brustzentrum, Munich, Germany; [Lipatov, Oleg N.] State Budget Med Inst Republican Clin Oncol, Ufa, Russia; [Walshe, Janice M.] All Ireland Cooperat Oncol Res Grp, Dublin, Ireland; [Moulder, Stacy] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Dieras, Veronique] Inst Curie, Paris, France	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Pfizer; Complutense University of Madrid; General University Gregorio Maranon Hospital; US Oncology Network; Seoul National University (SNU); Seoul National University Hospital; British Columbia Cancer Agency; University of Munich; All-Ireland Cooperative Oncology Research Group; University of Texas System; UTMD Anderson Cancer Center; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Finn, RS (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, David Geffen Sch Med, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA.	rfinn@mednet.ucla.edu	Perren, Timothy J/D-5387-2013; Martin, Miguel/AAJ-9242-2020	Perren, Timothy J/0000-0001-8472-8856; Martin, Miguel/0000-0001-9237-3231	Pfizer	Pfizer(Pfizer)	Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427.	Beaver JA, 2015, CLIN CANCER RES, V21, P4760, DOI 10.1158/1078-0432.CCR-15-1185; Chlebowski RT, 2013, CLIN BREAST CANCER, V13, P159, DOI 10.1016/j.clbc.2012.11.002; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Dickler MN, 2016, J CLIN ONCOL, V34, P2602, DOI 10.1200/JCO.2015.66.1595; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Finn RS, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0661-5; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fry DW, 2004, MOL CANCER THER, V3, P1427; Johnston SRD, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv212; Martin M, 2015, J CLIN ONCOL, V33, P1045, DOI 10.1200/JCO.2014.57.2388; Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006	12	1345	1415	4	98	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2016	375	20					1925	1936		10.1056/NEJMoa1607303	http://dx.doi.org/10.1056/NEJMoa1607303			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EC1HS	27959613	Bronze			2023-01-03	WOS:000387856100005
J	Park, YB; Ha, CW; Kim, JA; Rhim, JH; Park, YG; Chung, JY; Lee, HJ				Park, Yong-Beom; Ha, Chul-Won; Kim, Jin-A; Rhim, Ji-Heon; Park, Yong-Geun; Chung, Jun Young; Lee, Han-Jun			Effect of Transplanting Various Concentrations of a Composite of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronic Acid Hydrogel on Articular Cartilage Repair in a Rabbit Model	PLOS ONE			English	Article							HUMAN BONE-MARROW; CHONDROGENIC DIFFERENTIATION; STROMAL CELLS; CLINICAL-USE; IN-VITRO; DEFECTS; CHONDROCYTES; THERAPY; TISSUE; COCULTURE	Background Mesenchymal stem cells (MSCs) are known to have therapeutic potential for cartilage repair. However, the optimal concentration of MSCs for cartilage repair remains unclear. Therefore, we aimed to explore the feasibility of cartilage repair by human umbilical cord blood-derived MSCs (hUCB-MSCs) and to determine the optimal concentrations of the MSCs in a rabbit model. Methods Osteochondral defects were created in the trochlear groove of femur in 55 rabbits. Four experimental groups (11 rabbits/group) were treated by transplanting the composite of hUCB-MSCs and HA with various MSCs concentrations (0.1, 0.5, 1.0, and 1.5 x 10(7) cells/ ml). One control group was left untreated. At 4, 8, and 16 weeks post-transplantation, the degree of cartilage repair was evaluated grossly and histologically. Findings Overall, transplanting hUCB-MSCs and HA hydrogel resulted in cartilage repair tissue with better quality than the control without transplantation (P = 0.015 in 0.1, P = 0.004 in 0.5, P = 0.004 in 1.0, P = 0.132 in 1.5 x 10(7) cells/ml). Interestingly, high cell concentration of hUCB-MSCs (1.5x10(7) cells/ml) was inferior to low cell concentrations (0.1, 0.5, and 1.0 x 10(7) cells/ml) in cartilage repair (P = 0.394, P = 0.041, P = 0.699, respectively). The 0.5 x 10(7) cells/ml group showed the highest cartilage repair score at 4, 8 and 16 weeks post transplantation, and followed by 0.1x10(7) cells/ml group or 1.0 x 10(7) cell/ml group. Conclusions The results of this study suggest that transplantation of the composite of hUCB-MSCs and HA is beneficial for cartilage repair. In addition, this study shows that optimal MSC concentration needs to be determined for better cartilage repair.	[Park, Yong-Beom; Lee, Han-Jun] Chung Ang Univ, Coll Med, Chung Ang Univ Hosp, Dept Orthoped Surg, 102 Heukseok Ro, Seoul 06973, South Korea; [Ha, Chul-Won; Kim, Jin-A; Rhim, Ji-Heon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthopaed Surg, 81 Irwon Ro, Seoul 06351, South Korea; [Ha, Chul-Won; Kim, Jin-A; Rhim, Ji-Heon] Samsung Med Ctr, Stem Cell & Regenerat Med Res Inst, 81 Irwon Ro, Seoul 06351, South Korea; [Ha, Chul-Won] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea; [Park, Yong-Geun] Jeju Natl Univ, Sch Med, Jeju Natl Univ Hosp, Dept Orthoped Surg, 15 Aran 13 Gil, Jeju Si 63241, South Korea; [Chung, Jun Young] Ajou Univ, Sch Med, Ajou Univ Hosp, Dept Orthopaed Surg, 164 World Cup Ro, Suwon 16499, South Korea	Chung Ang University; Chung Ang University Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Jeju National University; Ajou University; Ajou University Hospital	Ha, CW (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthopaed Surg, 81 Irwon Ro, Seoul 06351, South Korea.; Ha, CW (corresponding author), Samsung Med Ctr, Stem Cell & Regenerat Med Res Inst, 81 Irwon Ro, Seoul 06351, South Korea.; Ha, CW (corresponding author), Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea.	chulwon.ha@gmail.com	Ha, C/GZL-9046-2022	Park, Yong-Beom/0000-0002-3741-2311; CHUNG, JUN YOUNG/0000-0002-6944-5812	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C3484]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant (HI14C3484) of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea. The funding sources had no involvement in the study design, collection, data analysis, data interpretation, writing of the manuscript, or the decision to submit the manuscript for publication.	Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22-4-625; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Choi YS, 2008, CYTOTHERAPY, V10, P165, DOI 10.1080/14653240701817002; Chung JY, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt427; De Bari C, 2003, J CELL BIOL, V160, P909, DOI 10.1083/jcb.200212064; Fischer J, 2010, ARTHRITIS RHEUM-US, V62, P2696, DOI 10.1002/art.27565; Fisher MB, 2015, TISSUE ENG PT A, V21, P850, DOI [10.1089/ten.tea.2014.0384, 10.1089/ten.TEA.2014.0384]; Flynn A, 2007, CYTOTHERAPY, V9, P717, DOI 10.1080/14653240701584578; Giovannini S, 2010, EUR CELLS MATER, V20, P245; GUERNE PA, 1995, ARTHRITIS RHEUM-US, V38, P960, DOI 10.1002/art.1780380712; Ha CW, 2015, STEM CELL TRANSL MED, V4, P1044, DOI 10.5966/sctm.2014-0264; Haleem AM, 2010, CARTILAGE, V1, P253, DOI 10.1177/1947603510366027; Ibrahim AM, 2015, MICROSC RES TECHNIQ, V78, P667, DOI 10.1002/jemt.22520; Isakova IA, 2007, STEM CELLS, V25, P3261, DOI 10.1634/stemcells.2007-0543; Jeong SY, 2013, STEM CELLS, V31, P2136, DOI 10.1002/stem.1471; Kao IT, 2008, CHINESE J PHYSIOL, V51, P252; Kim SM, 2008, CANCER RES, V68, P9614, DOI 10.1158/0008-5472.CAN-08-0451; Koga H, 2008, CELL TISSUE RES, V333, P207, DOI 10.1007/s00441-008-0633-5; Lee KBL, 2007, STEM CELLS, V25, P2964, DOI 10.1634/stemcells.2006-0311; Lee M, 2014, BIOCHEM BIOPH RES CO, V446, P983, DOI 10.1016/j.bbrc.2014.03.051; Li YY, 2014, ACTA BIOMATER, V10, P1919, DOI 10.1016/j.actbio.2014.01.002; Martin JA, 2003, J BONE JOINT SURG AM, V85A, P106, DOI 10.2106/00004623-200300002-00014; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; ODRISCOLL SW, 1986, J BONE JOINT SURG AM, V68A, P1017, DOI 10.2106/00004623-198668070-00008; Osiecka-Iwan A, 2003, CELL TRANSPLANT, V12, P389, DOI 10.3727/000000003108746939; Park YB, 2015, J ORTHOP RES, V33, P1580, DOI 10.1002/jor.22950; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Seo Seung-Suk, 2011, Knee Surg Relat Res, V23, P185, DOI 10.5792/ksrr.2011.23.4.185; Smith GD, 2005, ARTHROSCOPY, V21, P1462, DOI 10.1016/j.arthro.2005.09.007; Steck E, 2009, STEM CELLS DEV, V18, P969, DOI 10.1089/scd.2008.0213; Tipnis S, 2010, IMMUNOL CELL BIOL, V88, P795, DOI 10.1038/icb.2010.47; Veronesi F, 2013, STEM CELLS DEV, V22, P181, DOI 10.1089/scd.2012.0373; Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003; Wakitani S, 2002, OSTEOARTHR CARTILAGE, V10, P199, DOI 10.1053/joca.2001.0504; Wakitani S, 2011, J TISSUE ENG REGEN M, V5, P146, DOI 10.1002/term.299; Wang M, 2009, IMMUNOLOGY, V126, P220, DOI 10.1111/j.1365-2567.2008.02891.x; Wong KL, 2013, ARTHROSCOPY, V29, P2020, DOI 10.1016/j.arthro.2013.09.074; Yang SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041; Yang SH, 2008, SPINE, V33, P1951, DOI 10.1097/BRS.0b013e31817e6974; Zhang X, 2011, J CELL BIOCHEM, V112, P1206, DOI 10.1002/jcb.23042; Zhao QJ, 2009, CYTOTHERAPY, V11, P414, DOI 10.1080/14653240902849754	43	24	25	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2016	11	11							e0165446	10.1371/journal.pone.0165446	http://dx.doi.org/10.1371/journal.pone.0165446			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EB8BE	27824874	Green Published, gold, Green Submitted			2023-01-03	WOS:000387615200018
J	Choi, H; Schoeni, RF; Martin, LG				Choi, HwaJung; Schoeni, Robert F.; Martin, Linda G.			Are Functional and Activity Limitations Becoming More Prevalent among 55 to 69-Year-Olds in the United States?	PLOS ONE			English	Article							DISABILITY; TRENDS; ADULTS; HEALTH	Objectives This study examines changes in functional and activity limitations 1998-2012 for individuals 55-69. Methods Logistic models are used to estimate trends in limitations in vision, hearing, physical and cognitive functioning, IADLs, and ADLs. Additional models assess the extent to which trends are associated with and differ by education, smoking, and BMI. Results Changes in prevalence of limitations in vision, hearing, cognitive functioning, and ADLs are not statistically significant. Limitations in physical functioning declined by 0.37% per year. IADL limitations increased by 1.33% per year, but most of the increase occurred between 2008 and 2010/2012, and are associated with economic hardship during the Great Recession. Increases in education are especially beneficially associated with trends in limitations, but reductions in smoking also appear to be advantageous for some outcomes. Increases in BMI are associated with trends in physical functioning, IADL, and ADL limitation. Discussion For Americans 55-69, functional and activity limitations were largely unchanged 1998-2012. Our results suggest that if educational attainment had not increased, most functional and activity limitations potentially could have worsened substantially. Future change in educational attainment is not expected to be so positive. Continued monitoring of trends in activity limitations might well include greater focus on the explanatory roles of environmental factors, including economic circumstances.	[Choi, HwaJung] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Schoeni, Robert F.] Univ Michigan, Dept Econ, Ann Arbor, MI USA; [Schoeni, Robert F.] Univ Michigan, G Ford Sch Publ Policy, Ann Arbor, MI USA; [Schoeni, Robert F.] Univ Michigan, Survey Res Ctr, Ann Arbor, MI USA; [Martin, Linda G.] RAND Corp, Arlington, VA USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; RAND Corporation	Choi, H (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.	hwajungc@umich.edu		Choi, Hwajung/0000-0001-6497-7679	Alfred P. Sloan Foundation [G-2014-13748]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P2CHD041028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG012846] Funding Source: NIH RePORTER	Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	H. Choi, R. Schoeni, and L. Martin were supported by a grant (G-2014-13748) from the Alfred P. Sloan Foundation (http://www.sloan.org/) for their work on this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bound J, 2015, HEALTH AFFAIR, V34, P2167, DOI 10.1377/hlthaff.2015.0481; Bricker J., 2014, FEDERAL RESERVE B, V100; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Crimmins E., 2008, HRS DOC REP DR 011, V14, P47, DOI DOI 10.7826/ISR-UM.06.585031.001.05.0014.2008; Crimmins EM, 2011, J GERONTOL B-PSYCHOL, V66, P162, DOI 10.1093/geronb/gbr048; Denavas-Walt C, 2015, INCOME POVERTY US 20; Freedman VA, 2004, DEMOGRAPHY, V41, P417, DOI 10.1353/dem.2004.0022; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Freedman VA, 2013, DEMOGRAPHY, V50, P661, DOI 10.1007/s13524-012-0167-z; HRS, 2011, SAMPL SIZ RESP RAT; HRS, 2008, SAMPL EV 1992 1998; Hummer Robert A, 2013, Popul Bull, V68, P1; Kaye HS, 2013, HEALTH AFFAIR, V32, P127, DOI 10.1377/hlthaff.2012.0533; Langa K, 2010, REPORT RACE COGNITIV, V12; Martin LG, 2014, DISABIL HEALTH J, V7, pS4, DOI 10.1016/j.dhjo.2013.06.007; Martin LG, 2010, DEMOGRAPHY, V47, pS17, DOI 10.1353/dem.2010.0003; Martin LG, 2010, HEALTH AFFAIR, V29, P725, DOI 10.1377/hlthaff.2008.0746; National Academies of Sciences E and Medicine, 2015, GROW GAP LIF EXP INC; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; Ofstedal MB, 2005, DR006 HRS U MICH SUR; Schoeni R. F., 2009, HLTH OLDER AGES CAUS, P75; Schoeni RF, 2005, AM J PUBLIC HEALTH, V95, P2065, DOI 10.2105/AJPH.2004.048744; Schoeni RF, 2008, MILBANK Q, V86, P47, DOI 10.1111/j.1468-0009.2007.00513.x; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Weir D., 2007, REDEFINING RETIREMEN, P95, DOI DOI 10.1093/ACPROF:OSO/9780199230778.003.0005	25	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2016	11	10							e0164565	10.1371/journal.pone.0164565	http://dx.doi.org/10.1371/journal.pone.0164565			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EE4VE	27783638	gold, Green Published, Green Submitted			2023-01-03	WOS:000389602800044
J	Gao, W; Crosby, V; Wilcock, A; Burman, R; Silber, E; Hepgul, N; Chaudhuri, KR; Higginson, IJ				Gao, Wei; Crosby, Vincent; Wilcock, Andrew; Burman, Rachael; Silber, Eli; Hepgul, Nilay; Chaudhuri, K. Ray; Higginson, Irene J.		OPTCARE Neuro Trier	Psychometric Properties of a Generic, Patient-Centred Palliative Care Outcome Measure of Symptom Burden for People with Progressive Long Term Neurological Conditions	PLOS ONE			English	Article							QUALITY-OF-LIFE; IMPACT SCALE MSIS-29; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; HEALTH-STATUS; NONMOTOR SYMPTOMS; VALIDATION; QUESTIONNAIRE; CRITERIA; EUROQOL	Background There is no standard palliative care outcome measure for people with progressive long term neurological conditions (LTNC). This study aims to determine the psychometric properties of a new 8-item palliative care outcome scale of symptom burden (IPOS Neuro-S8) in this population. Data and Methods Data were merged from a Phase II palliative care intervention study in multiple sclerosis (MS) and a longitudinal observational study in idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). The IPOS Neuro-S8 was assessed for its data quality, score distribution, ceiling and floor effects, reliability, factor structure, convergent and discriminant validity, concurrent validity with generic (Palliative care Outcome Scale) and condition specific measures (Multiple Sclerosis Impact Scale; Non-motor Symptoms Questionnaire; Parkinson's Disease Questionnaire), responsiveness and minimally clinically important difference. Results Of the 134 participants, MS patients had a mean Extended Disability Status Scale score 7.8 (SD = 1.0), patients with an IPD, MSA or PSP were in Hoehn & Yahr stage 3-5. The IPOS Neuro-S8 had high data quality (2% missing), mean score 8 (SD = 5; range 0-32), no ceiling effects, borderline floor effects, good internal consistency (Cronbach's alpha = 0.7) and moderate test-retest reliability (intraclass coefficient = 0.6). The results supported a moderately correlated two-factor structure (Pearson's r = 0.5). It was moderately correlated with generic and condition specific measures (Pearson's r: 0.5-0.6). There was some evidence for discriminant validity in IPD, MSA and PSP (p = 0.020), and for good responsiveness and longitudinal construct validity. Conclusions IPOS Neuro-S8 shows acceptable to promising psychometric properties in common forms of progressive LTNCs. Future work needs to confirm these findings with larger samples and its usefulness in wider disease groups.	[Gao, Wei; Burman, Rachael; Hepgul, Nilay; Higginson, Irene J.] Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, London, England; [Crosby, Vincent] Nottingham Univ Hosp NHS Trust, Palliat Med, Nottingham, England; [Wilcock, Andrew] Univ Nottingham, Sch Med, Palliat Med & Med Oncol, Nottingham, England; [Silber, Eli] Kings Coll Hosp London, Dept Neurol, London, England; [Chaudhuri, K. Ray] Kings Coll Hosp London, Natl Parkinson Fdn Ctr Excellence, London, England; [Chaudhuri, K. Ray] Kings Coll London, London, England	University of London; King's College London; Nottingham University Hospital NHS Trust; University of Nottingham; King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Gao, W (corresponding author), Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, London, England.	wei.gao@kcl.ac.uk	; Higginson, Irene Julie/C-7309-2012	/0000-0001-8298-3415; Ray Chaudhuri, K/0000-0003-2815-0505; Higginson, Irene Julie/0000-0002-3687-1313; Wilcock, Andrew/0000-0002-3214-1188	National Institute for Health Research, Health Services and Delivery Research Programme [12/130/47]; Collaboration for Leadership in Applied Health Research and Care South London; National Institute for Health Research; King's Health Partners; St. George's, University London; St George's Healthcare NHS Trust; National Institute for Health Research [12/130/47, NF-SI-0611-10209] Funding Source: researchfish	National Institute for Health Research, Health Services and Delivery Research Programme; Collaboration for Leadership in Applied Health Research and Care South London; National Institute for Health Research(National Institute for Health Research (NIHR)); King's Health Partners; St. George's, University London; St George's Healthcare NHS Trust; National Institute for Health Research(National Institute for Health Research (NIHR))	Funding received by WG, VC, AW, RB, ES, KRC, IJH from the National Institute for Health Research, Health Services and Delivery Research Programme (12/130/47) http://www.nets.nihr.ac.uk/programmes/hsdr. Funding received by WG and IJH from the Collaboration for Leadership in Applied Health Research and Care South London, National Institute for Health Research which is a partnership between King's Health Partners, St. George's, University London, and St George's Healthcare NHS Trust. http://www.clahrc-southlondon.nihr.ac.uk/palliative-and-end-life-care. IJH is a National Institute for Health Research senior investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson N, 2002, QUAL LIFE RES, V11, P193; Bausewein C, 2011, PALLIATIVE MED, V25, P304, DOI 10.1177/0269216310395984; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Chahine LM, 2008, EUR J NEUROL, V15, P1265, DOI 10.1111/j.1468-1331.2008.02319.x; Chaudhuri KR, 2015, PARKINSONISM RELAT D, V21, P287, DOI 10.1016/j.parkreldis.2014.12.031; Chaudhuri KR, 2006, MOVEMENT DISORD, V21, P916, DOI 10.1002/mds.20844; Cleeland CS, 2007, J NATL CANC I MONOGR, V2007, P16; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98; Costello AB., 2005, PRACT ASSESS RES EVA, V10, P7; Curie Marie, 2015, REPORT; Department of Health, 2005, THE NATIONAL SERVICE; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Edmonds P, 2010, MULT SCLER J, V16, P627, DOI 10.1177/1352458510364632; Evans CJ, 2013, PALLIATIVE MED, V27, P885, DOI 10.1177/0269216312467489; Gao W, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0050710, 10.1371/journal.pone.0046327]; Hannan EL, 2008, JACC-CARDIOVASC INTE, V1, P211, DOI 10.1016/j.jcin.2008.01.008; Hearn J, 1999, QUAL HEALTH CARE, V8, P219, DOI 10.1136/qshc.8.4.219; Higginson IJ, 2011, POSTGRAD MED J, V87, P769, DOI 10.1136/postgradmedj-2011-130290; Higginson IJ, 2009, J PAIN SYMPTOM MANAG, V38, P816, DOI 10.1016/j.jpainsymman.2009.07.002; Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jenkinson C, 1997, AGE AGEING, V26, P353, DOI 10.1093/ageing/26.5.353; Jenkinson C, 1997, PSYCHOL HEALTH, V12, P805, DOI 10.1080/08870449708406741; Jordhoy MS, 1999, PALLIATIVE MED, V13, P299, DOI 10.1191/026921699668963873; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; NEoLCP NCPC, 2011, END OF LIFE CARE IN; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Riazi A, 2002, J NEUROL NEUROSUR PS, V73, P701, DOI 10.1136/jnnp.73.6.701; Saleem T, 2007, J PALLIAT CARE, V23, P291, DOI 10.1177/082585970702300408; Saleem TZ, 2013, PALLIATIVE MED, V27, P722, DOI 10.1177/0269216312465783; Selby JV, 2012, JAMA-J AM MED ASSOC, V307, P1583, DOI 10.1001/jama.2012.500; Siegert RJ, 2010, J PAIN SYMPTOM MANAG, V40, P67, DOI 10.1016/j.jpainsymman.2009.11.326; Sleeman KE, 2013, J PAIN SYMPTOM MANAG, V46, P406, DOI 10.1016/j.jpainsymman.2012.08.007; STAGE FK, 2006, THE JOURNAL OF EDUCA, V99, P15; Tavakol M, 2011, INT J MED EDUC, V2, P1, DOI 10.5116/ijme.4d27.32ff; TAYLOR R, 1990, J DIAGN MED SONOG, V6, P35, DOI 10.1177/875647939000600106; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Turner-Stokes L, 2008, REPORT; Turner-Stokes L, 2008, CLIN MED, V8, P186, DOI 10.7861/clinmedicine.8-2-186; Wright A, 2012, J MAN MANIP THER, V20, P160, DOI 10.1179/2042618612Y.0000000001; Wyrwich KW, 2000, J EVAL CLIN PRACT, V6, P39, DOI 10.1046/j.1365-2753.2000.00238.x	45	11	11	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0165379	10.1371/journal.pone.0165379	http://dx.doi.org/10.1371/journal.pone.0165379			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ED7LQ	27780237	Green Published, gold			2023-01-03	WOS:000389046900051
